gene.clinical,entrez_id.clinical,variant.clinical,disease,doid,phenotypes,drugs,drug_interaction_type,evidence_type,evidence_direction,evidence_level,clinical_significance,evidence_statement,citation_id,source_type,asco_abstract_id,citation,nct_ids,rating,evidence_status,evidence_id,gene_id,chromosome.clinical,start.clinical,stop.clinical,reference_bases.clinical,variant_bases.clinical,representative_transcript.clinical,chromosome2.clinical,start2.clinical,stop2.clinical,representative_transcript2.clinical,ensembl_version.clinical,reference_build.clinical,variant_summary,variant_origin,last_review_date.clinical,evidence_civic_url,variant_civic_url.clinical,gene_civic_url,summary,variant_groups,variant_types,hgvs_expressions,civic_actionability_score,drug1,drug2,drug3,drug4,drug5,gFormat,cFormat,pFormat
ABL1,25,BCR-ABL,Acute_Myeloid_Leukemia,9119,,Imatinib,,Predictive,Supports,D,Resistance,BCR-ABL_fusions_have_been_found_to_contribute_to_imatinib_resistance_in_AML_cell_lines.,12476305,PubMed,,"Nimmanapalli_et_al.,_2002,_Oncogene",,3,accepted,232,4,22,23522397,23632600,,,ENST00000305877.8,9,133729451,133763063,ENST00000318560.5,75,GRCh37,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/232,https://civic.genome.wustl.edu/links/variants/1,https://civic.genome.wustl.edu/links/genes/4,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",,transcript_fusion,,238,Imatinib,,,,,,,
ABL1,25,BCR-ABL,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,A,Sensitivity/Response,"BCR-ABL_inhibitors_such_as_imatinib_have_lead_to_significantly_improved_prognosis,_response_rate,_overall_survival,_and_patient_outcome_in_CML_patients_compared_to_previous_therapeutic_regimens.",20537386,PubMed,,"An_et_al.,_2010,_Leuk._Res.",,5,accepted,344,4,22,23522397,23632600,,,ENST00000305877.8,9,133729451,133763063,ENST00000318560.5,75,GRCh37,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",Somatic_Mutation,2016-10-04_08:14:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/344,https://civic.genome.wustl.edu/links/variants/1,https://civic.genome.wustl.edu/links/genes/4,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",,transcript_fusion,,238,Imatinib,,,,,,,
ABL1,25,BCR-ABL,Acute_Myeloid_Leukemia,9119,,Imatinib,,Predictive,Supports,A,Sensitivity/Response,Treatment_of_Philadelphia_chromosome_positive_leukemias_with_imatinib_results_in_high_rates_of_complete_remission_in_patients_with_CML.,12476305,PubMed,,"Nimmanapalli_et_al.,_2002,_Oncogene",,5,accepted,259,4,22,23522397,23632600,,,ENST00000305877.8,9,133729451,133763063,ENST00000318560.5,75,GRCh37,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",Somatic_Mutation,2016-03-03_00:09:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/259,https://civic.genome.wustl.edu/links/variants/1,https://civic.genome.wustl.edu/links/genes/4,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",,transcript_fusion,,238,Imatinib,,,,,,,
ABL1,25,BCR-ABL,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,A,Sensitivity/Response,The_clinical_use_of_imatinib_in_patients_with_BCR-ABL_fusion_has_resulted_in_drastic_prognostic_improvements_in_patients_with_CML.,20537386,PubMed,,"An_et_al.,_2010,_Leuk._Res.",,5,accepted,260,4,22,23522397,23632600,,,ENST00000305877.8,9,133729451,133763063,ENST00000318560.5,75,GRCh37,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",Somatic_Mutation,2015-07-07_22:48:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/260,https://civic.genome.wustl.edu/links/variants/1,https://civic.genome.wustl.edu/links/genes/4,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",,transcript_fusion,,238,Imatinib,,,,,,,
ABL1,25,BCR-ABL,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Dasatinib",Substitutes,Predictive,Supports,A,Sensitivity/Response,"The_use_of_nilotinib_and_dasatinib,_second-generation_BCR-ABL_targeted_therapies,_has_been_effective_in_patients_resistant_to_imatinib,_leading_to_their_FDA-approval.",20537386,PubMed,,"An_et_al.,_2010,_Leuk._Res.",,4,accepted,261,4,22,23522397,23632600,,,ENST00000305877.8,9,133729451,133763063,ENST00000318560.5,75,GRCh37,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",Somatic_Mutation,2017-05-31_00:51:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/261,https://civic.genome.wustl.edu/links/variants/1,https://civic.genome.wustl.edu/links/genes/4,"The_BCR-ABL_fusion_protein,_commonly_referred_to_as_the_Philadelphia_chromosome,_is_one_of_the_most_studied_fusion_genes_in_cancer._It_has_widely_been_considered_the_initiating_event_in_chronic_myelogenous_leukemia_(CML)._However,_despite_its_ability_to_initiate_disease_in_mice,_its_status_as_an_initiating_mutation_is_in_dispute._In_what_is_commonly_used_as_the_poster-child_for_targeted_therapeutics,_the_development_and_use_of_imatinib_in_the_clinic_has_led_to_profound_improvements_in_the_prognosis_of_the_disease._However,_imatinib_resistance_is_still_seen_in_patients_with_mutations_in_the_ABL_kinase_domain_of_the_fusion,_most_notably_the_T315I_variant._In_patients_resistant_to_imatinib,_either_acquired_or_otherwise,_second_generation_BCR-ABL_TKI's_(dasatinib_and_nilotinib)_have_seen_some_success_in_delivering_a_tumor_response._Third_generation_ABL1_inhibitor_ponatinib_is_the_only_FDA_approved_drug_with_activity_against_T315I_._However_due_to_risk_of_life-threatening_blood_clots_and_severe_narrowing_of_blood_vessels_ponatinib_is_ONLY_approved_for_T315I-positive_CML_or_T315I-positive_Ph+_ALL_or_in_cases_of_CML,_Ph+_ALL_with_resistance_or_intolerance_to_other_approved_ABL1_inhibitors.",,transcript_fusion,,238,Nilotinib,Dasatinib,,,,,,
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_T315I,_2/7_had_a_CHR_and_0/6_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,2,accepted,4362,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-12-21_19:58:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/4362,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Bosutinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_T315I_was_seen_in_7_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,6990,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2019-01-14_20:37:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/6990,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib_Mesylate,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate,Dasatinib",Substitutes,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_T315I_mutation_was_associated_with_resistance_in_16_μM_imatinib_(_15_clones,_45%_of_viable_clones_in_this_treatment),_5000_nM_nilotinib_(10_clones,_100%),_and_25_nM_dasatinib_(32_clones,_100%)_which_were_the_highest_concentrations_used._T315I_resistant_clones_were_also_found_at_all_lower_concentrations_tested.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,3,accepted,6285,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-10-08_21:57:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/6285,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Nilotinib,Imatinib_Mesylate,Dasatinib,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,"Dasatinib,Imatinib_Mesylate",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_the_p210_BCR-ABL_fusion_were_generated_and_stably_expressed_in_Ba/F3_cell_lines_from_mutagenized_libraries._Combination_therapy_with_10﻿_μM_imatinib_and_50_nM_dasatinib_resulted_in_a_single_clone_with_the_T315I_variant._Combination_therapy_with_25_nM_dasatinib_resulted_in_11_clones,_6_of_which_had_the_T315I_variant.",15705718,PubMed,,"Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,6192,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-06-20_00:51:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/6192,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Dasatinib,Imatinib_Mesylate,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_T315I_evaluated,_1/2_had_a_complete_hematologic_response_and_0/3_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,2,accepted,4364,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-07-12_21:49:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4364,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Bosutinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,"Dasatinib,Nilotinib",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_T315I_mutation_was_associated_with_resistance_in_50_nM_nilotinib_+_10_nM_dasatinib_(7_clones,_100%_of_viable_clones_in_this_treatment),_1_μM_nilotinib_+_50_nM_dasatinib_(9_clones,_100%),_and_2_μM_nilotinib_+_100_nM_dasatinib_(2_clones,_100%)_combination_treatments.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,3,accepted,6235,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-10-08_22:34:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/6235,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Dasatinib,Nilotinib,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Resistance,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_T315I_mutation_was__resistant_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2669,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2017-05-19_16:51:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/2669,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3__cell_line_stably_expressing_the_T315I_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_nilotinib_treatment_(IC50:_39.41-fold),_as_compared_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,4,accepted,2670,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2017-07-25_16:39:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/2670,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Nilotinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,B,Resistance,"In_chronic_myeloid_leukemia_patients_with_the_ABL_T315I_mutation,_tumors_have_shown_to_be_resistant_to_imatinib_treatment.",20537386,PubMed,,"An_et_al.,_2010,_Leuk._Res.",,4,accepted,234,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2015-06-21_16:49:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/234,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Acute_Lymphocytic_Leukemia,9952,,Dasatinib,,Predictive,Supports,C,Resistance,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_T315I,_0/5_had_MaHRs_and_0/5_had_MCyRs_which_were_lower_than_response_rates_among_wild_type_patients.",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,2,accepted,4376,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2019-01-31_09:58:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/4376,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Dasatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,"Imatinib_Mesylate,Nilotinib",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._The_T315I_mutation_was_associated_with_resistance_in_400_nM_imatinib_+_50_nM_nilotinib_(3_clones,_~16%),_2_μM_imatinib_+_1_μM_nilotinib_(8_clones,_100%),_and_4_μM_imatinib_+_2_μM_nilotinib_(2_clones,_100%)_combination_treatments.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6196,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-10-08_21:47:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/6196,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib_Mesylate,Nilotinib,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,COS7_cell_lines_transfected_with_BCR-ABL_constructs_harboring_T315I_mutations_were_shown_to_be_resistant_to_imatinib_and_exhibited_increased_kinase_activity.,15194504,PubMed,,"Yamamoto_et_al.,_2004,_Biochem._Biophys._Res._Commun.",,4,accepted,235,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/235,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,"Dasatinib,Imatinib_Mesylate",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_T315I_mutation_was_associated_with_resistance_in_400_nM_imatinib_+_10_nM_dasatinib_(10_clones,_~91%),_2_μM_imatinib_+_50_nM_dasatinib_(8_clones,_100%),_and_4_μM_imatinib_+_100_nM_dasatinib_(8_clones,_100%)_combination_treatments.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,3,accepted,6234,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-10-08_22:35:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/6234,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Dasatinib,Imatinib_Mesylate,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_T315I_mutation_was_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,4,accepted,2667,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2017-07-25_16:33:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2667,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Ponatinib,,Predictive,Supports,B,Sensitivity/Response,"Study_describes_a_phase_1_clinical_trial_of_ponatinib_in_treatment_of_81_refractory_Philadelphia_chromosome-positive_leukemias._43_of_these_patients_were_considered_to_have_chronic-phase_CML._All_12_chronic-phase_CML_patients_with_a_T315I_mutation_showed_a_complete_hematologic_response._Furthermore,_91%_of_these_patients_were_estimated_to__remain_in_response_at_1_year_(95%_CI,_Kaplan-Meier_analysis).",23190221,PubMed,,"Cortes_et_al.,_2012,_N._Engl._J._Med.",,4,accepted,1390,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2016-07-05_16:04:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1390,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Ponatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_5_had_T315I_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7038,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2019-01-31_10:20:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/7038,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Imatinib_Mesylate,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_T315I,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_21_patients_with_T315I_mutations,_0,_2,_and_6_achieved_CCyR,_MCyR,_and_CHR_to_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations._Of_the_63_variants_considered,_the_authors_associate_T315I,_F317L,_and_V299L_with_resistance_to_dasatinib_or_lower_levels_of_response_due_to_clinical_resistance_and_low_in_vitro_sensitivity._They_suggest_considering_alternative_treatment_options_for_patients_with_these_variants.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4365,4,9,133748283,133748283,C,T,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-07-19_21:50:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/4365,https://civic.genome.wustl.edu/links/variants/2,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_T315I_(aka_T334I)_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_ponatinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T",105,Dasatinib,,,,,chr9_g.133748283C~T,ABL1_c.1001C~T,ABL1_T315I
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_E255K_mutation_was_associated_with_resistance_in_16_μM_imatinib_(_1_clone_recovered,_~3%)_and_all_lower_concentrations_as_well_as_in_50_nM_nilotinib_(5_clones,_~11%)_and_5_nM_dasatinib_(2_clones,_~6%),_the_lowest_concentrations_tested_for_these_two_drugs._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6282,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-10-08_21:26:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/6282,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib_Mesylate,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_E255K_evaluated,_2/2_had_complete_hematologic_responses_and_1/2_had_a_major_cytogenetic_response.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,1,accepted,4348,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-07-12_21:42:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/4348,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Bosutinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_E255K_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,6991,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2019-01-14_20:38:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/6991,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib_Mesylate,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,"Dasatinib,Imatinib_Mesylate",Substitutes,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_were_generated_in_Ba/F3_cell_lines_from_five_independently_derived,_mutagenized_libraries._Dasatinib_resistant_subclones_were_identified_using_﻿50_nM_dasatinib_in_liquid_culture._201_individual_clones_were_identified_representing_10_different_mutations_at_6_different_residues._4_of_these_clones_had_E255K_mutations._To_validate_resistance_to_dasatinib,_a_Ba/F3_cell_line_stably_expressing_the_E255K_mutation_in_the_ABL1_region_of_the_BCR-ABL_fusion_was_generated._The_E255K_variants_was_associated_with_higher_dasatinib_IC50_of_13_nM_vs_1.34_nM_in_wildtype_and_higher_imatinib_IC50_of_8,400_nM_vs_323_nM_in_wildtype_as_determined_by_dose_response_curves.",15705718,PubMed,,"Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,6214,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-06-20_01:41:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/6214,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Dasatinib,Imatinib_Mesylate,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._The_E255V_mutation_was_associated_with_resistance_in_4_μM_imatinib_(_1_clone,_0.43%)_and_500_nM_nilotinib_(1_clone,_1.25%)_tyrosine_kinase_inhibitors.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6194,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-10-08_21:24:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/6194,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Nilotinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,COS7_cell_lines_transfected_with_BCR-ABL_constructs_harboring_E255K_mutations_were_shown_to_be_resistant_to_imatinib_and_exhibited_increased_kinase_activity.,15194504,PubMed,,"Yamamoto_et_al.,_2004,_Biochem._Biophys._Res._Commun.",,4,accepted,233,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/233,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Reduced_Sensitivity,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_E255K,_4/6_had_MaHRs_which_was_comparable_to_response_rates_among_wild_type_patients,_and_0/6_had_MCyRs_which_was_lower_than_response_rates_among_wild_type_patients.",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,4352,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2019-01-31_10:00:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4352,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Dasatinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_E255K,_0/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,4347,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-12-21_19:43:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/4347,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Bosutinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_E255K_mutation_was_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,2659,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2017-07-25_16:32:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/2659,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_16_patients_with_E255K_mutations,_6,_9,_and_14_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4350,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-07-19_21:24:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/4350,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Dasatinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,A_panel_of_16_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_evaluated_for_anti-proliferative_activity_and_substrate_or_auto-phosphorylation_assays._The_E255K_mutation_was_resistant_to_imatinib_(20-fold_IC50_increase_for_the_proliferation_assay).,15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,3,accepted,2661,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2017-07-25_16:32:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/2661,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,"Imatinib_Mesylate,Dasatinib",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_the_p210_BCR-ABL_fusion_were_generated_and_stably_expressed_in_Ba/F3_cell_lines_from_mutagenized_libraries._Combination_therapy_with_10﻿_μM_imatinib_and_50_nM_Dasatinib_resulted_in_11_clones,_5_of_which_had_the_E255K_variant.",15705718,PubMed,,"Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,6193,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-06-20_00:55:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/6193,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib_Mesylate,Dasatinib,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_Ba/F3_cell_line_stably_expressing_the_E255K_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_nilotinib_treatment_(IC50:_6.69-fold),_as_compared_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2662,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2017-07-25_16:31:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/2662,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Nilotinib,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_6_had_E255K_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7039,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2019-01-31_10:27:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/7039,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib_Mesylate,,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
ABL1,25,BCR-ABL_E255K,Chronic_Myeloid_Leukemia,8552,,"Imatinib_Mesylate,Nilotinib",Substitutes,Predictive,Supports,C,Resistance,"In_this_open-label,_phase_II_registration_trial,_patients_that_were_imatinib_resistant_or_intolerant_underwent_nilotinib_monotherapy._Within_12_months_of_nilotinib_therapy,_there_was_no_significant_difference_in_response_to_nilotinib_treatment_between_patients_with_mutations_in_the_Abl1_kinase_domain_versus_without._However,_the_authors_identify_Y253H,_E255K/V,_and_F359C/V_variants_as_resistant_as_they_had_an_IC50_greater_than_150_nM._In_patients_with_E255K_and/or_E255V_mutations_prior_to_nilotinib_treatment,_complete_hematological_responses_were_achieved_in_5_of_7_patients,_major_cytogenetic_responses_in_3_of_7_patients,_complete_cytogenetic_responses_in_0_of_7_patients,_and_a_major_molecular_response_in_1_of_7_patients._After_a_median_follow-up_of_15.5_months,_6_of_7_patients_with_this_mutation_progressed_or_died._The_E255K_mutation_was_present_in_6_patients_at_baseline_and_newly_emerged_in_4_patients_at_progression._The_E255V_mutation_was_present_in_0_patients_at_baseline_and_newly_emerged_in_3_patients_at_progression.",19652056,PubMed,,"Hughes_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,6232,4,9,133738363,133738363,G,A,ENST00000318560.5,,,,,75,GRCh37,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Somatic_Mutation,2018-11-05_22:45:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/6232,https://civic.genome.wustl.edu/links/variants/3,https://civic.genome.wustl.edu/links/genes/4,"While_the_efficacy_of_imatinib_has_revolutionized_chronic_myelogenous_leukemia_(CML)_treatment,_it_is_still_not_a_cure-all._Both_initial_resistance_and_acquired_resistance_as_a_result_of_selection_have_been_seen_in_a_small_subset_of_CML_patients._The_ABL_kinase_domain_mutation_E255K_has_been_shown_to_be_one_such_mutation_that_confers_resistance_to_imatinib._Second_generation_TKI's_(dasatinib_and_nilotinib)_specific_to_BCR-ABL_have_shown_efficacy_in_treating_resistant_cases.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A",56,Imatinib_Mesylate,Nilotinib,,,,chr9_g.133738363G~A,ABL1_c.763G~A,ABL1_E255K
AKT1,207,E17K,Breast_Cancer,1612,,MK-2206,,Predictive,Does_Not_Support,D,Sensitivity/Response,"Breast_cancer_cell_lines_with_the_AKT1_E17K_mutation_did_not_show_sensitivity_to_AKT_inhibitor_MK-2206,_unlike_cell_lines_with_PIK3CA_mutations.",23888070,PubMed,,"Beaver_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,231,2,14,105246551,105246551,C,T,ENST00000407796.2,,,,,75,GRCh37,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/231,https://civic.genome.wustl.edu/links/variants/4,https://civic.genome.wustl.edu/links/genes/2,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",,missense_variant,"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A",32.5,MK-2206,,,,,chr14_g.105246551C~T,AKT1_c.49G~A,AKT1_E17K
AKT1,207,E17K,Cancer,162,,AZD-5363,,Predictive,Supports,B,Sensitivity/Response,"AKT1_E17K_mutations_are_oncogenic_and_occur_in_many_cancers_at_a_low_prevalence._We_performed_a_multihistology_basket_study_of_AZD5363._58_patients_with_advanced_solid_tumors_were_treated._In_patients_with_AKT1_E17K-mutant_tumors_(n_=_52)_and_a_median_of_5_lines_of_prior_therapy,_the_median_PFS_was_5.5_months_,_6.6_months_and_4.2_months_in_patients_with_ER+_breast,_gynecologic,_and_other_solid_tumors,_respectively._In_an_exploratory_biomarker_analysis,_imbalance_of_the_AKT1_E17K-mutant_allele,_most_frequently_caused_by_copy-neutral_loss-of-heterozygosity_targeting_the_wild-type_allele,_was_associated_with_longer_PFS_as_was_the_presence_of_coincident_PI3K_pathway_hotspot_mutations._Persistent_declines_in_AKT1_E17K_in_cfDNA_were_associated_with_improved_PFS_and_response._Responses_were_not_restricted_to_patients_with_detectable_AKT1_E17K_in_pretreatment_cfDNA.",28489509,PubMed,,"Hyman_et_al.,_2017,_J._Clin._Oncol.",,4,accepted,3039,2,14,105246551,105246551,C,T,ENST00000407796.2,,,,,75,GRCh37,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",Somatic_Mutation,2017-06-09_18:44:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/3039,https://civic.genome.wustl.edu/links/variants/4,https://civic.genome.wustl.edu/links/genes/2,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",,missense_variant,"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A",32.5,AZD-5363,,,,,chr14_g.105246551C~T,AKT1_c.49G~A,AKT1_E17K
AKT1,207,E17K,Melanoma,1909,,GSK2141795,,Predictive,Supports,D,Sensitivity/Response,A_cell_line_with_AKT_E17K_mutation_was_found_to_be_sensitive_to_AKT_inhibition_with_GSK2141795B__in_this_study.,24735930,PubMed,,"Lassen_et_al.,_2014,_Mol._Cancer",,2,accepted,707,2,14,105246551,105246551,C,T,ENST00000407796.2,,,,,75,GRCh37,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/707,https://civic.genome.wustl.edu/links/variants/4,https://civic.genome.wustl.edu/links/genes/2,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",,missense_variant,"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A",32.5,GSK2141795,,,,,chr14_g.105246551C~T,AKT1_c.49G~A,AKT1_E17K
AKT1,207,E17K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_M229_cell_line_endogenously_expressing_BRAF_V600E_mutation_(a_known_vemurafenib_sensitizing_mutation)_and_overexpressing_AKT1_E17K_mutation_was_associated_with_resistance_to_vemurafenib_treatment,_as_compared_to_cells_expressing_BRAF_V600E_mutation_and_wildtype_AKT1._Resistance_was_determined_by_assessing_cell_survival.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,,accepted,4029,2,14,105246551,105246551,C,T,ENST00000407796.2,,,,,75,GRCh37,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",Somatic_Mutation,2017-06-09_19:14:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4029,https://civic.genome.wustl.edu/links/variants/4,https://civic.genome.wustl.edu/links/genes/2,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",,missense_variant,"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A",32.5,Vemurafenib,,,,,chr14_g.105246551C~T,AKT1_c.49G~A,AKT1_E17K
AKT1,207,E17K,Breast_Cancer,1612,,AZD5363,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase-I_study_of_AZD5363,_partial_response_was_observed_in_2_patients_with_breast_and_ovarian_carcinoma,_respectively,_and_AKT1_E17K_mutations._While_full_study_results_have_not_yet_been_published,_this_paper_highlights_in_vitro_results_that_further_confirm_the_role_of_AKT_E17K_mutation.",26351323,PubMed,,"Davies_et_al.,_2015,_Mol._Cancer_Ther.",,3,accepted,709,2,14,105246551,105246551,C,T,ENST00000407796.2,,,,,75,GRCh37,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/709,https://civic.genome.wustl.edu/links/variants/4,https://civic.genome.wustl.edu/links/genes/2,"AKT1_E17K_is_a_recurrent_mutation_that_has_been_observed_in_breast,_colorectal,_lung,_and_ovarian_cancer._It_has_been_convincingly_shown_to_be_an_activating_mutation_resulting_in_PI3K/AKT/mTOR_pathway_activity._It_has_been_suggested_that_this_mutation_decreases_the_cell's_sensitivity_to_AKT1_allosteric_kinase_inhibitors._This,_and_other_AKT1_mutations,_are_the_subject_of_much_research_and_development_for_therapeutics.",,missense_variant,"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A",32.5,AZD5363,,,,,chr14_g.105246551C~T,AKT1_c.49G~A,AKT1_E17K
ALK,238,EML4-ALK,Non-small_Cell_Lung_Carcinoma,3908,,WHI-P154,,Predictive,Supports,D,Sensitivity/Response,"A_retroviral_cDNA_expression_library_was_constructed_using_a_lung_adenocarcinoma_specimen_from_a_67_year_old_NSCLC_patient,_and_transfected_into_mouse_3T3_fibroblasts_which_were_assessed_for_transformed_foci.__Analysis_of_clones_from_one_transformed_focus_yielded_a_novel_fusion._This_fusion_generated_a_protein_with_N-terminal_consisting_of_EML4_exons_1-13_and_C-terminal_consisting_of_ALK_exons_20-29,_which_comprise_the_intracellular_kinase_domain_of_ALK._In_subsequent_experiments_using_EML4-ALK_or_altered_versions,_the_transforming_potential_of_EML4-ALK_was_found_to_be_dependent_on_a_functional_ALK_kinase_activity_as_well_as_the_EML4_basic_domain,_which_was_shown_to_have_an_important_role_in_EML4-ALK_dimer_formation.__BA/F3_cells_expressing_EML4-ALK_were_able_to_grow_independently_of_IL3_addition,_but_addition_of_ALK_inhibitor_WHI-P154_induced_cell_death_and_inhibited_tyrosine_phosphorylation_of_EML4-ALK._These_results_indicated_that_EML4-ALK_may_be_a_driver_mutation_in_NSCLC,__and_a_target_for_ALK_inhibitor_treatment.",17625570,PubMed,,"Soda_et_al.,_2007,_Nature",,5,accepted,1188,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2016-04-04_22:58:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1188,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,WHI-P154,,,,,,,
ALK,238,EML4-ALK,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,IPI-504",Combination,Predictive,Supports,D,Sensitivity/Response,"In_preclinical_work_using_H3122_NSCLC_cells_which_contain_the_EML4-ALK_variant_1,_administration_of_the_Hsp90_inhibitor_IPI-504_caused_marked_decrease_of_EML4-ALK_protein_levels_at_concentrations_lower_than_those_used_to_knock_down_protein_levels_of_drivers_such_as_HER2_or_EGFR_in_other_cell_lines,_making_it_the_most_sensitive_Hsp90_client_protein_the_authors_had_encountered.__IPI-504_treatment_caused_regression_of_H3122_tumors_in_nude_mice,_whereas_Hsp90_inhibitors_usually_only_cause_growth_inhibition_in_these_models.__Combined_treatment_of_these_mice_with_IPI-504_and_crizotinib_caused_an_even_stronger_tumor_regression.",21258415,PubMed,,"Normant_et_al.,_2011,_Oncogene",,4,accepted,1203,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2016-06-27_21:07:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1203,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,Crizotinib,IPI-504,,,,,,
ALK,238,EML4-ALK,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"In_patients_with_non-small_cell_lung_cancer_harboring_the_EML4-ALK_fusion,_treatment_with_crizotinib_has_shown_to_be_effective_in_acheiving_stable_disease.",20979473,PubMed,,"Choi_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,262,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2015-06-21_16:49:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/262,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,Crizotinib,,,,,,,
ALK,238,EML4-ALK,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,17-DMAG",Combination,Predictive,Supports,D,Sensitivity/Response,"Transduction_of_Ba/F3_cells_with_EML4-ALK_variant_1_causes_IL3_independent_growth._Incubation_of_EML4-ALK_variant_1_transduced_Ba/F3_cells_with_Hsp90_inhibitor_17-DMAG_caused_cell_death_that_was_reversible_with_IL3_addition,_suggesting_that_17-DMAG_was_effecting_the_EML4-ALK_driver_of_IL3-independant_proliferation,_and_that_EML4-ALK_variant_1_is_a_client_protein_of_Hsp90._The_degree_of_Hsp90_dependence,_and_targetability_of_EML4-ALK_for_Hsp90_inhibition,_may_vary_among_ALK_fusion_variants.__Addition_of_crizotinib_to_17-DMAG_caused_synergistic_death_effects,_suggesting_potential_clinical_benefit_for_this_inhibitor_combination_in_targeting_EML4-ALK_variant_1.",22912387,PubMed,,"Heuckmann_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,1206,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2016-07-01_16:15:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1206,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,Crizotinib,17-DMAG,,,,,,
ALK,238,EML4-ALK,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"In_the_PROFILE_1001_study_of_crizotinib_in_82_patients_with_ALK-rearranged_NSCLC,_31_patients_with_sufficient_tumor_material_were_tested_using_RT-PCR_for_the_presence_of_certain_EML4-ALK_variants.__13/31_tested_patients_had_the_EML4-ALK_variant_1._Of_these,_12/13_had_a_partial_response,_and_1_had_stable_disease._This_response_rate_of_92%_is_in_contrast_to_the_57%_response_rate_in_the_overall_patient_population,_but_the_numbers_of_patients_with_specific_EML4-ALK_breakpoints_were_insufficient_to_correlate_with_patient_response_rate.",20979469,PubMed,,"Kwak_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,1207,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2016-04-04_22:55:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1207,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,Crizotinib,,,,,,,
ALK,238,EML4-ALK,Non-small_Cell_Lung_Carcinoma,3908,,Lorlatinib,,Predictive,Supports,D,Sensitivity/Response,"EML4-ALK_variant_1_containing_H-3122_NSCLC_cells_were_treated_with_second_generation_ALK_inhibitor_PF-06463922._PF-06463922_was_125x_more_potent_at_reducing_cell_viability_than_crizotinib._Control_neuroblastoma_cell_lines_with_wild-type_ALK_did_not_show_inhibition_below_3800_nM_with_either_drug._At_values_of_10_and_100_nM,_PF-06463922_showed_increased_ability_to_inhibit_ALK_1278_tyrosine_phosphorylation_in_H3122_cells.",26554404,PubMed,,"Infarinato_et_al.,_2016,_Cancer_Discov",,2,accepted,1332,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2016-07-11_04:10:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1332,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,Lorlatinib,,,,,,,
ALK,238,EML4-ALK,Lung_Acinar_Adenocarcinoma,6482,,Erlotinib,,Predictive,Supports,C,Resistance,"A_39-year-old_man_presented_was_observed_to_have_lung_acinar_adenocarcinoma._Treatment_with_chemotherapy_produced_no_remarkable_response._A_EGFR_L858R_point_mutation_was_observed;_the_patient_was_therefore_treated_with_erlotinib,_but_the_disease_progressed_after_30_days._A_second_biopsy_identified_a_EML4-ALK_fusion,_which_may_explain_the_therapeutic_resistance.",23181703,PubMed,,"Tanaka_et_al.,_2012,_BMC_Cancer",,2,accepted,1121,1,2,42396490,42522656,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",Somatic_Mutation,2016-02-26_14:58:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1121,https://civic.genome.wustl.edu/links/variants/5,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_fusion_variant_1_consisting_of_ALK_kinase_domain_(exons_20-29)_fused_to_EML4_exons_1-13_is_the_most_common_EML4-ALK_variant,_and_was_discovered_in_non-small_cell_lung_cancer._Multiple_EML4_breakpoint_shave_been_described_with_differential_sensitivity_to_inhibitors_with_variant_1_showing_greater_sensitivity_than_3a_in_cell_lines._EML4-ALK_is_crizotinib_sensitive;_however,_several_mutations_that_confer_resistance_mutations_have_been_described_in_case_studies._In_the_only_clinical_trial_for_crizotinib_that_included_determination_of_EML4-ALK_variant_type_in_a_subset_of_its_participants,_a_very_high_response_rate_was_observed,_although_the_numbers_were_insufficient_to_validate_correlation_of_variant_type_to_outcome._Preclinical_studies_with_this_variant_have_indicated_sensitivity_to_Hsp90_inhibitors.",ALK_Fusions,transcript_fusion,,48,Erlotinib,,,,,,,
ALK,238,EML4-ALK_C1156Y,Non-small_Cell_Lung_Carcinoma,3908,,Lorlatinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_metastatic_ALK-rearranged_NSCLC_after_progression_under_sequential_crizotinib,_ceritinib,_HSP90_inhibitor_AUY922_and_chemotherapy_followed_by_crizotinib_again._Third_generation_ALK_inhibitor_lorlatinib_led_to_a_partial_response_that_lasted_for_8_months._The_C1156Y_mutation_was_confirmed_in_a_sample_prior_to_initial_crizotinib_(<7%_of_cells),_following_crizotinib_treatment_(~50%_of_cells)_and_following_lorlatinib_resistance_(100%_of_cells)._However,_a_second_ALK_mutation_(C1156Y_&_L1198F)_was_detected_in_the_lorlatinib_resistant_tumor.",26698910,PubMed,,"Shaw_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,842,1,2,29445258,29445258,C,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_C1156Y_has_been_shown_to_confer_resistance_to_crizotinib._Case_reports_indicate_that_secondary_mutations_can_modulate_drug_sensitivity._EML4-ALK_C1156Y/L1196M_maintained_crizotinib_resistance_while_the_lorlatinib_resistant_combination_EML4-ALK_C1156Y/L1198F_re-sensitized_the_tumor_to_crizotinib_treatment.",Somatic_Mutation,2016-02-18_18:44:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/842,https://civic.genome.wustl.edu/links/variants/6,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_C1156Y_has_been_shown_to_confer_resistance_to_crizotinib._Case_reports_indicate_that_secondary_mutations_can_modulate_drug_sensitivity._EML4-ALK_C1156Y/L1196M_maintained_crizotinib_resistance_while_the_lorlatinib_resistant_combination_EML4-ALK_C1156Y/L1198F_re-sensitized_the_tumor_to_crizotinib_treatment.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3467G>A,NC_000002.11:g.29445258C>T,NM_004304.4:c.3467G>A,NP_004295.2:p.Cys1156Tyr",19,Lorlatinib,,,,,chr2_g.29445258C~T,ALK_c.3467G~A,ALK_C1156Y
ALK,238,EML4-ALK_C1156Y,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,"EML4-ALK_variant_3_containing_NSCLC_cell_line_H2228_xenografts_in_SCID_beige_mice_were_treated_with_increasing_doses_of_crizotinib_up_to_100_mg/kg_per_day_by_oral_gavage._At_approximately_40_days_tumors_progressed._80_progressed_tumors_were_tested_for_ALK_mutations,_and_6_mutant_ALK_variants_were_found._Two_of_the_mutations_were_at_ALK_C1156Y._In_Ba/F3_cells,_EML4-ALK_variant_3_with_C1156Y_was_introduced_and_tested_for_crizotinib_sensitivity._Survival_IC50_value_of_177_nM_was_reported,_which_is_9.3_times_the_IC50_reported_for_crizotinib_in_EML4-ALK_wild-type_Ba/F3_cells.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,4,accepted,1346,1,2,29445258,29445258,C,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_C1156Y_has_been_shown_to_confer_resistance_to_crizotinib._Case_reports_indicate_that_secondary_mutations_can_modulate_drug_sensitivity._EML4-ALK_C1156Y/L1196M_maintained_crizotinib_resistance_while_the_lorlatinib_resistant_combination_EML4-ALK_C1156Y/L1198F_re-sensitized_the_tumor_to_crizotinib_treatment.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1346,https://civic.genome.wustl.edu/links/variants/6,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_C1156Y_has_been_shown_to_confer_resistance_to_crizotinib._Case_reports_indicate_that_secondary_mutations_can_modulate_drug_sensitivity._EML4-ALK_C1156Y/L1196M_maintained_crizotinib_resistance_while_the_lorlatinib_resistant_combination_EML4-ALK_C1156Y/L1198F_re-sensitized_the_tumor_to_crizotinib_treatment.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3467G>A,NC_000002.11:g.29445258C>T,NM_004304.4:c.3467G>A,NP_004295.2:p.Cys1156Tyr",19,Crizotinib,,,,,chr2_g.29445258C~T,ALK_c.3467G~A,ALK_C1156Y
ALK,238,EML4-ALK_C1156Y,Non-small_Cell_Lung_Carcinoma,3908,,"AUY922,Ceritinib,Crizotinib",Sequential,Predictive,Supports,C,Resistance,"In_this_case_report,_a_patient_with_metastatic,_ALK-rearranged_NSCLC_with_C1156Y_mutation_had_tumor_progression_under_sequential_treatment_with_first_crizotinib,_then_ceritinib_and_finally_AUY922._Subsequent_chemotherapy_(carboplatin–pemetrexed)_was_administered_and_the_patient_had_a_response_for_6_months_before_progression._Exome_sequencing_revealed_the_C1156Y_mutation_was_present_in_<7%_of_the_pretreatment_tumor_and_in_~50%_of_the_crizotinib_tumor_prior_to_ceritinib_therapy.",26698910,PubMed,,"Shaw_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,841,1,2,29445258,29445258,C,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_C1156Y_has_been_shown_to_confer_resistance_to_crizotinib._Case_reports_indicate_that_secondary_mutations_can_modulate_drug_sensitivity._EML4-ALK_C1156Y/L1196M_maintained_crizotinib_resistance_while_the_lorlatinib_resistant_combination_EML4-ALK_C1156Y/L1198F_re-sensitized_the_tumor_to_crizotinib_treatment.",Somatic_Mutation,2016-02-18_18:45:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/841,https://civic.genome.wustl.edu/links/variants/6,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_C1156Y_has_been_shown_to_confer_resistance_to_crizotinib._Case_reports_indicate_that_secondary_mutations_can_modulate_drug_sensitivity._EML4-ALK_C1156Y/L1196M_maintained_crizotinib_resistance_while_the_lorlatinib_resistant_combination_EML4-ALK_C1156Y/L1198F_re-sensitized_the_tumor_to_crizotinib_treatment.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3467G>A,NC_000002.11:g.29445258C>T,NM_004304.4:c.3467G>A,NP_004295.2:p.Cys1156Tyr",19,AUY922,Ceritinib,Crizotinib,,,chr2_g.29445258C~T,ALK_c.3467G~A,ALK_C1156Y
ALK,238,EML4-ALK_L1196M,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,B,Resistance,"In_patients_with_non-small_cell_lung_cancer_harboring_EML4-ALK_fusion,_the_L1196M_variant_has_been_shown_to_confer_resistance_to_crizotinib.",20979473,PubMed,,"Choi_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,237,1,2,29443631,29443631,G,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.",Somatic_Mutation,2015-06-21_16:49:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/237,https://civic.genome.wustl.edu/links/variants/7,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3586C>A,NC_000002.11:g.29443631G>T,NM_004304.4:c.3586C>A,NP_004295.2:p.Leu1196Met",31,Crizotinib,,,,,chr2_g.29443631G~T,ALK_c.3586C~A,ALK_L1196M
ALK,238,EML4-ALK_L1196M,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"The_crizotinib-resistant_MGH045_cell_line_with_EML4-ALK_L1196M_was_treated_with_crizotinib_or_ceritinib._In_nude_mice_with_MGH045_xenografts,_tumor_response_to_crizotinib_did_not_differ_appreciably_from_vehicle,_while_ceritinib_controlled_tumor_growth._Ceritinib_inhibited_Ba/F3_cells_expressing_EML4-ALK_L1196M_slightly_stronger_than_ALK_wild-type,_but_approximately_double_the_potency_as_crizotinib,_indicating_ceritinib_sensitivity_in_Ba/F3_EML4-ALK_L1196M_cells.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,4,accepted,1341,1,2,29443631,29443631,G,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.",Somatic_Mutation,2016-07-26_16:04:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1341,https://civic.genome.wustl.edu/links/variants/7,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3586C>A,NC_000002.11:g.29443631G>T,NM_004304.4:c.3586C>A,NP_004295.2:p.Leu1196Met",31,Ceritinib,,,,,chr2_g.29443631G~T,ALK_c.3586C~A,ALK_L1196M
ALK,238,EML4-ALK_L1196M,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,The_L1196M_mutation_in_the_EML4-ALK_fusion_was_found_to_confer_resistance_to_crizotinib_in_Ba/F3_cells.,22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,4,accepted,442,1,2,29443631,29443631,G,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/442,https://civic.genome.wustl.edu/links/variants/7,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3586C>A,NC_000002.11:g.29443631G>T,NM_004304.4:c.3586C>A,NP_004295.2:p.Leu1196Met",31,Crizotinib,,,,,chr2_g.29443631G~T,ALK_c.3586C~A,ALK_L1196M
ALK,238,EML4-ALK_L1196M,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,D,Sensitivity/Response,CH5424802_treatment_resulted_in_significant_tumor_regression_in_xenograft_models_produced_from_Ba/F3_cells_expressing_EML4-ALK_or_EML4-ALK_with_the_L1196M_mutation.,21575866,PubMed,,"Sakamoto_et_al.,_2011,_Cancer_Cell",,3,accepted,141,1,2,29443631,29443631,G,T,ENST00000389048.3,,,,,75,GRCh37,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.",Somatic_Mutation,2016-06-29_21:04:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/141,https://civic.genome.wustl.edu/links/variants/7,https://civic.genome.wustl.edu/links/genes/1,"In_patients_with_non-small_cell_lung_cancer_exhibiting_EML4-ALK_fusion,_L1196M_has_been_shown_to_confer_resistance_to_crizotinib._This_was_also_true_in_a_patient_with_both_EML4-ALK_C1156Y_&_L1196M.","ALK_Fusions,Crizotinib_Resistance","transcript_fusion,missense_variant","ENST00000389048.3:c.3586C>A,NC_000002.11:g.29443631G>T,NM_004304.4:c.3586C>A,NP_004295.2:p.Leu1196Met",31,Alectinib_(CH5424802),,,,,chr2_g.29443631G~T,ALK_c.3586C~A,ALK_L1196M
ALK,238,F1174L,Inflammatory_Myofibroblastic_Tumor,50905,,Crizotinib,,Predictive,Supports,D,Resistance,Ba/F3_cells_expressing_the_RANBP2-ALK_fusion_containing_an_F1174L_mutation_were_more_resistant_to_crizotinib_treatment_than_Ba/F3_cells_expressing_RANBP2-ALK_without_this_mutation.,21030459,PubMed,,"Sasaki_et_al.,_2010,_Cancer_Res.",,3,accepted,32,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/32,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Crizotinib,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,High_levels_of_crizotinib_can_overcome_drug_resistance_of_Ba/F3_cells_expressing_the_EML4-ALK_fusion_containing_the_F1174L_mutation.,21948233,PubMed,,"Heuckmann_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,38,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/38,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Crizotinib,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,Crizotinib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"In_a_Phase_I_trial_(NCT00939770)_of_the_drug_crizotinib_in_pediatric_patients,_a_subset_of_11_neuroblastoma_patients_were_characterized_for_mutations_in_ALK._Of_these_11_patients,_4_had_the_F1174L_mutation._Among_these_4_patients,_stable_disease_(SD)_was_observed_in_one,_and_progressive_disease_(PD)_was_observed_in_3_others_after_administration_of_crizotinib._In_contrast,_in_the_remaining_7_patients_with_mutations_different_than_F1174L,_4_had_PD,_2_had_SD_and_one_had_complete_response_as_best_response_after_initiation_of_crizotinib.",23598171,PubMed,,"Mossé_et_al.,_2013,_Lancet_Oncol.",,3,accepted,1271,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2017-10-19_15:57:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1271,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Crizotinib,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,Lorlatinib,,Predictive,Supports,D,Sensitivity/Response,"Efficacy_of_the_second_generation_ALK_inhibitor_PF-06463922_was_tested_on_ALK_mutation_F1174L_containing_neuroblastoma-derived_cells.__COG-N-453x_and_SH-SY5Y_xenografts_showed_some_inhibition_when_treated_with_crizotinib,_but_showed_complete_growth_inhibition_with_PF-06463922_treatment.__This_corresponded_to_0%_event_free_survival_(EFS)_in_these_mice_by_6_weeks_with_crizotinib_treatment,_but_100%_EFS_with_PF-06463922_treatment._Comparison_of_crizotinib_and_PF-06463922_growth_inhibition_in_F1174L_cells_SH-SY5Y,_NBSD_415-IMDM_and_KELLY_showed_increased_sensitivity_to_PF-06463922,_as_compared_to_crizotinib._Inhibition_effects_were_not_seen_on_neuroblastoma_cells_with_wild_type_ALK_(NB-EBc1,_SK-N-BE(2)C)._Decreased_phosphorylation_on_ALK_tyrosine_1278_was_seen_with_PF-06463922_over_crizotinib_at_10_and_100_nM_concentrations_in_SH-SY5Y_cells._PF-06463922_was_well_tolerated_in_the_in-vivo_models.",26554404,PubMed,,"Infarinato_et_al.,_2016,_Cancer_Discov",,4,accepted,1329,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-06-28_03:03:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1329,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Lorlatinib,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,TAE684,,Predictive,Supports,D,Sensitivity/Response,SH-SY5Y_and_Kelly_cells_with_mutant_ALK_(F1174L)_and_Ba/F3_cells_overexpressing_ALK_harboring_the_F1174L_mutation_are_sensitive_to_TAE684-mediated_growth_inhibition.,18923525,PubMed,,"George_et_al.,_2008,_Nature",,4,accepted,142,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/142,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,TAE684,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,Ba/F3_cells_expressing_the_EML4-ALK_fusion_containing_an_F1174L_mutation_were_more_resistant_to_crizotinib_treatment_than_Ba/F3_cells_expressing_EML4-ALK_without_this_mutation.,21030459,PubMed,,"Sasaki_et_al.,_2010,_Cancer_Res.",,3,accepted,33,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/33,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Crizotinib,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,Alectinib_(CH5424802),,Predictive,Supports,D,Sensitivity/Response,CH5424802_is_effective_in_inhibiting_the_activity_of_the_F1174L_ALK_mutant_in_a_kinase_activity_assay_and_proliferation_assay_using_neuroblastoma_KELLY_cells.,21575866,PubMed,,"Sakamoto_et_al.,_2011,_Cancer_Cell",,3,accepted,37,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/37,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Alectinib_(CH5424802),,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,AZD3463,,Predictive,Supports,D,Sensitivity/Response,"The_SH-SY5Y_neuroblastoma_cell_line_containing_the_F1174L_ALK_mutation_was_found_to_undergo_cell_death_when_treated_with_the_ALK/IGF1R_inhibitor_AZD3463._These_cells_were_more_sensitive_than_other_neuroblastoma_cell_lines_containing_wild-type_ALK._Marked_inhibition_of_soft_agar_colony_formation_of_SH-SY5Y_cells_was_also_observed_with_drug_treatment._AZD3463_inhibited_Akt_signaling_in_these_cells_within_two_hours_of_treatment,_and_activated_apoptosis_and_autophagy_pathways._Treatment_of_SH-SY5Y_cells_implanted_into_left_kidneys_of_nude_mice_resulted_in_almost_complete_tumor_regression.",26786851,PubMed,,"Wang_et_al.,_2016,_Sci_Rep",,3,accepted,1327,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2016-07-02_15:53:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1327,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,AZD3463,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,F1174L,Neuroblastoma,769,,Crizotinib,,Predictive,Supports,D,Resistance,Cells_lines_expressing_ALK_harboring_the_F1174L_mutation_are_less_sensitive_to_growth_inhibition_by_crizotinib_than_cells_expressing_the_R1275Q_mutation._The_authors_conclude_that_this_effect_should_be_surmountable_with_higher_doses_of_crizotinib_and/or_with_higher-affinity_inhibitors.,22072639,PubMed,,"Bresler_et_al.,_2011,_Sci_Transl_Med",,3,accepted,125,1,2,29443695,29443695,G,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Somatic_Mutation,2017-10-19_15:58:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/125,https://civic.genome.wustl.edu/links/variants/8,https://civic.genome.wustl.edu/links/genes/1,"ALK_F1174L_has_been_observed_as_recurrent_in_neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_and_other_cancer_types._Neuroblastoma_cells_containing_this_mutation_have_shown_resistance_to_low_doses_of_criztonib._However,_increased_dosage_can_overcome_this_resistance_in_cell_lines_studies._TAE684_has_also_proven_effective_in_both_NSCLC_and_neuroblastoma_F1174L_containing_cells.",Crizotinib_Resistance,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",33.5,Crizotinib,,,,,chr2_g.29443695G~T,ALK_c.3522C~A,ALK_F1174L
ALK,238,R1275Q,Neuroblastoma,769,,Lorlatinib,,Predictive,Supports,D,Sensitivity/Response,"In_NB-1643_and_LAN-5_neuroblastoma_cell_lines_containing_R1275Q_mutation,_PF-06463922_showed_51_and_19_fold_greater_effect_on_cell_viability_over_crizotinib_treatment_respectively._ALK_wild-type_neuroblastoma_cell_lines_did_not_show_differential_sensitivity_to_the_treatments_within_the_sensitivity_range_of_R1275Q_cells,_and_had_IC50_values_above_3800_nM_to_the_inhibitors._NB-1653_cells_induced_tumors_in_CB17_SCID_mice_and_crizotinib_treatment_inhibited_tumor_growth_over_vehicle_treatment,_but_PF-06463922_induced_complete_tumor_regression.",26554404,PubMed,,"Infarinato_et_al.,_2016,_Cancer_Discov",,4,accepted,1331,1,2,29432664,29432664,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",Somatic_Mutation,2016-06-28_00:29:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1331,https://civic.genome.wustl.edu/links/variants/9,https://civic.genome.wustl.edu/links/genes/1,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",23,Lorlatinib,,,,,chr2_g.29432664C~T,ALK_c.3824G~A,ALK_R1275Q
ALK,238,R1275Q,Neuroblastoma,769,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,Cells_lines_expressing_ALK_harboring_the_F1174L_mutation_are_less_sensitive_to_growth_inhibition_by_crizotinib_than_cells_expressing_the_R1275Q_mutation.,22072639,PubMed,,"Bresler_et_al.,_2011,_Sci_Transl_Med",,3,accepted,143,1,2,29432664,29432664,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/143,https://civic.genome.wustl.edu/links/variants/9,https://civic.genome.wustl.edu/links/genes/1,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",23,Crizotinib,,,,,chr2_g.29432664C~T,ALK_c.3824G~A,ALK_R1275Q
ALK,238,R1275Q,Neuroblastoma,769,,TAE684,,Predictive,Supports,D,Resistance,The_SMS-KCNR_cell_line_harboring_the_R1275Q_mutation_was_resistant_to_TAE684.,18923525,PubMed,,"George_et_al.,_2008,_Nature",,3,accepted,48,1,2,29432664,29432664,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/48,https://civic.genome.wustl.edu/links/variants/9,https://civic.genome.wustl.edu/links/genes/1,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",23,TAE684,,,,,chr2_g.29432664C~T,ALK_c.3824G~A,ALK_R1275Q
ALK,238,R1275Q,Neuroblastoma,769,,TAE684,,Predictive,Supports,D,Sensitivity/Response,"TAE684_inhibits_growth_of_Ba/F3_cells_expressing_ALK_mutations;_however,_cells_with_the_R1275Q_mutation_were_inhibited_at_a_higher_IC50_than_those_expressing_F1174L.",18923525,PubMed,,"George_et_al.,_2008,_Nature",,3,accepted,39,1,2,29432664,29432664,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/39,https://civic.genome.wustl.edu/links/variants/9,https://civic.genome.wustl.edu/links/genes/1,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",23,TAE684,,,,,chr2_g.29432664C~T,ALK_c.3824G~A,ALK_R1275Q
ALK,238,R1275Q,Neuroblastoma,769,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"This_Phase_I_study_of_crizotinib_involved_a_cohort_of_pediatric_neuroblastoma_patients_between_ages_12_months_and_22_years._In_11_patients_with_characterized_ALK_mutations,_4_had_R1275Q_mutations,_and_two_of_these_were_germline_mutations.__Of_these_2_germline_patients,_1_showed_stable_disease_(SD)_and_1_complete_response_(CR)._In_contrast,_in_the_7_characterized_patients_with_ALK_mutations_that_were_not_R1275Q,_6_showed_PD_and_1_SD._The_authors_conclude_this_finding_is_promising_and_merits_further_study.",23598171,PubMed,,"Mossé_et_al.,_2013,_Lancet_Oncol.",,2,accepted,1269,1,2,29432664,29432664,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",Germline_Mutation,2016-06-28_00:35:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1269,https://civic.genome.wustl.edu/links/variants/9,https://civic.genome.wustl.edu/links/genes/1,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",23,Crizotinib,,,,,chr2_g.29432664C~T,ALK_c.3824G~A,ALK_R1275Q
ALK,238,R1275Q,Neuroblastoma,769,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"A_cohort_of_pediatric_neuroblastoma_patients_ages_12_months_to_22_years_were_assessed_for_response_to_crizotinib_in_a_Phase_I_study.__11_patients_in_this_cohort_had_characterized_ALK_mutations,_4_of_which_were_R1275Q_mutation._Two_of_these_R1275Q_mutations_were_germline_and_two_were_somatic._Of_these_2_somatic_R1275Q_patients,_1_showed_progressive_disease_(PD)_and_1_showed_stable_disease_(SD)._In_contrast,_of_the_7_characterized_patients_with_ALK_mutations_that_were_not_R1275Q,_6_showed_PD_and_1_SD._The_stable_disease_patient_had_an_R1275L_mutation_in_ALK._In_general,_patients_with_germline_or_somatic_R1275Q_mutations_or_R1275L_mutations_had_1_complete_response,_3_SD_and_one_PD,_while_patients_with_other_ALK_mutations_had_6_PD.",23598171,PubMed,,"Mossé_et_al.,_2013,_Lancet_Oncol.",,2,accepted,1270,1,2,29432664,29432664,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",Somatic_Mutation,2016-06-28_00:30:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1270,https://civic.genome.wustl.edu/links/variants/9,https://civic.genome.wustl.edu/links/genes/1,"ALK_R1275Q_has_been_observed_as_a_recurrent_mutation_in__neuroblastoma,_non-small_cell_lung_cancer_(NSCLC),_as_well_as_other_cancer_types._Neuroblastoma_cells_with_this_mutation_have_shown_sensitivity_to_the_ALK-inhibitor_TAE684._This_and_the_geldanamycin_deriviative_17-DMAG_have_been_shown_to_be_effective_in_NSCLC_cell_lines.",,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",23,Crizotinib,,,,,chr2_g.29432664C~T,ALK_c.3824G~A,ALK_R1275Q
ARAF,369,S214C,Non-small_Cell_Lung_Carcinoma,3908,,Trametinib,,Predictive,Supports,D,Sensitivity/Response,Trametinib_can_inhibit_ARF-mediated_ERK_phosphorylation_and_soft_agar_colony_formation_of_AALE_cells_expressing_ARAF_S214C_in_vitro.,24569458,PubMed,,"Imielinski_et_al.,_2014,_J._Clin._Invest.",,3,accepted,41,3,X,47426121,47426121,C,G,ENST00000377045.4,,,,,75,GRCh37,"ARAF_S214C_has_been_found_to_be_a_recurrent_oncogenic_mutation_in_non-small_cell_lung_cancer._It_has_been_shown_to_confer_sensitivity_to_sorafenib_and_trametenib_in_cell_lines._In_a_case_study_of_advanced_stage_lung_adenocarcinoma_harboring_this_mutation,_sorafenib_also_acheived_near-complete_clinical_remission._This_case_has_brought_more_interest_to_the_variant_from_a_research_and_clinical_perspective.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/41,https://civic.genome.wustl.edu/links/variants/10,https://civic.genome.wustl.edu/links/genes/3,"ARAF_S214C_has_been_found_to_be_a_recurrent_oncogenic_mutation_in_non-small_cell_lung_cancer._It_has_been_shown_to_confer_sensitivity_to_sorafenib_and_trametenib_in_cell_lines._In_a_case_study_of_advanced_stage_lung_adenocarcinoma_harboring_this_mutation,_sorafenib_also_acheived_near-complete_clinical_remission._This_case_has_brought_more_interest_to_the_variant_from_a_research_and_clinical_perspective.",,missense_variant,"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G",11,Trametinib,,,,,chrX_g.47426121C~G,ARAF_c.641C~G,ARAF_S214C
ARAF,369,S214C,Non-small_Cell_Lung_Carcinoma,3908,,Sorafenib,,Predictive,Supports,C,Sensitivity/Response,"In_one_patient_with_S214C_mutation,_the_use_of_sorafenib_has_led_to_more_than_5_years_of_survival_and_near_remission.",24569458,PubMed,,"Imielinski_et_al.,_2014,_J._Clin._Invest.",,2,accepted,17,3,X,47426121,47426121,C,G,ENST00000377045.4,,,,,75,GRCh37,"ARAF_S214C_has_been_found_to_be_a_recurrent_oncogenic_mutation_in_non-small_cell_lung_cancer._It_has_been_shown_to_confer_sensitivity_to_sorafenib_and_trametenib_in_cell_lines._In_a_case_study_of_advanced_stage_lung_adenocarcinoma_harboring_this_mutation,_sorafenib_also_acheived_near-complete_clinical_remission._This_case_has_brought_more_interest_to_the_variant_from_a_research_and_clinical_perspective.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/17,https://civic.genome.wustl.edu/links/variants/10,https://civic.genome.wustl.edu/links/genes/3,"ARAF_S214C_has_been_found_to_be_a_recurrent_oncogenic_mutation_in_non-small_cell_lung_cancer._It_has_been_shown_to_confer_sensitivity_to_sorafenib_and_trametenib_in_cell_lines._In_a_case_study_of_advanced_stage_lung_adenocarcinoma_harboring_this_mutation,_sorafenib_also_acheived_near-complete_clinical_remission._This_case_has_brought_more_interest_to_the_variant_from_a_research_and_clinical_perspective.",,missense_variant,"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G",11,Sorafenib,,,,,chrX_g.47426121C~G,ARAF_c.641C~G,ARAF_S214C
ARAF,369,S214C,Non-small_Cell_Lung_Carcinoma,3908,,Sorafenib,,Predictive,Supports,D,Sensitivity/Response,Sorafenib_can_inhibit_ARF-mediated_MEK_phosphorylation_and_soft_agar_colony_formation_of_AALE_cells_expressing_ARAF_S214C_in_vitro.,24569458,PubMed,,"Imielinski_et_al.,_2014,_J._Clin._Invest.",,3,accepted,40,3,X,47426121,47426121,C,G,ENST00000377045.4,,,,,75,GRCh37,"ARAF_S214C_has_been_found_to_be_a_recurrent_oncogenic_mutation_in_non-small_cell_lung_cancer._It_has_been_shown_to_confer_sensitivity_to_sorafenib_and_trametenib_in_cell_lines._In_a_case_study_of_advanced_stage_lung_adenocarcinoma_harboring_this_mutation,_sorafenib_also_acheived_near-complete_clinical_remission._This_case_has_brought_more_interest_to_the_variant_from_a_research_and_clinical_perspective.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/40,https://civic.genome.wustl.edu/links/variants/10,https://civic.genome.wustl.edu/links/genes/3,"ARAF_S214C_has_been_found_to_be_a_recurrent_oncogenic_mutation_in_non-small_cell_lung_cancer._It_has_been_shown_to_confer_sensitivity_to_sorafenib_and_trametenib_in_cell_lines._In_a_case_study_of_advanced_stage_lung_adenocarcinoma_harboring_this_mutation,_sorafenib_also_acheived_near-complete_clinical_remission._This_case_has_brought_more_interest_to_the_variant_from_a_research_and_clinical_perspective.",,missense_variant,"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G",11,Sorafenib,,,,,chrX_g.47426121C~G,ARAF_c.641C~G,ARAF_S214C
BRAF,673,V600D,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_the_WM2664_and_WM239A_cell_lines_expressing_BRAF_V600D_were_associated_with_increased_sensitivity_to_vemurafenib_treatment,_as_compared_to_cell_lines_expressing_BRAF_wild-type._Sensitivity_was_determined_by_proliferation_assay.",20551065,PubMed,,"Yang_et_al.,_2010,_Cancer_Res.",,,accepted,4489,5,7,140453135,140453136,CA,AT,ENST00000288602.6,,,,,75,GRCh37,"Patients_harboring_mutations_in_valine_600_residue_of_BRAF_have_been_shown_to_be_sensitive_to_dabrafenib._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Somatic_Mutation,2018-03-20_15:50:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/4489,https://civic.genome.wustl.edu/links/variants/11,https://civic.genome.wustl.edu/links/genes/5,"Patients_harboring_mutations_in_valine_600_residue_of_BRAF_have_been_shown_to_be_sensitive_to_dabrafenib._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Other_V600's,missense_variant,"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT",25,Vemurafenib,,,,,chr7_g.140453135_140453136delinsAT,BRAF_c.1799_1800delTGinsAT,BRAF_V600D
BRAF,673,V600D,Melanoma,1909,,Dabrafenib,,Predictive,Supports,B,Sensitivity/Response,Patients_with_other_BRAF_V600_mutations_also_respond_well_to_the_V600E_drug_dabrafenib.,23463675,PubMed,,"Ponti_et_al.,_2013,_J._Clin._Pathol.",,5,accepted,94,5,7,140453135,140453136,CA,AT,ENST00000288602.6,,,,,75,GRCh37,"Patients_harboring_mutations_in_valine_600_residue_of_BRAF_have_been_shown_to_be_sensitive_to_dabrafenib._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Somatic_Mutation,2015-06-21_16:49:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/94,https://civic.genome.wustl.edu/links/variants/11,https://civic.genome.wustl.edu/links/genes/5,"Patients_harboring_mutations_in_valine_600_residue_of_BRAF_have_been_shown_to_be_sensitive_to_dabrafenib._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Other_V600's,missense_variant,"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT",25,Dabrafenib,,,,,chr7_g.140453135_140453136delinsAT,BRAF_c.1799_1800delTGinsAT,BRAF_V600D
BRAF,673,V600D,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_WM2664,_a_BRAF_V600D_expressing_cell_line,_demonstrated_improved_sensitivity_to_vemurafenib_treatment,_compared_to_BRAF_wild-type_expressing_cells._Sensitivity_was_determined_by_assessing_cell_proliferation_(WM2664,_GI50:_1.5uM;_vs._BRAF_expressing_cells_(n=9)_GI50:_10-41uM).",18287029,PubMed,,"Tsai_et_al.,_2008,_Proc._Natl._Acad._Sci._U.S.A.",,,accepted,4488,5,7,140453135,140453136,CA,AT,ENST00000288602.6,,,,,75,GRCh37,"Patients_harboring_mutations_in_valine_600_residue_of_BRAF_have_been_shown_to_be_sensitive_to_dabrafenib._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Somatic_Mutation,2018-07-06_14:04:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/4488,https://civic.genome.wustl.edu/links/variants/11,https://civic.genome.wustl.edu/links/genes/5,"Patients_harboring_mutations_in_valine_600_residue_of_BRAF_have_been_shown_to_be_sensitive_to_dabrafenib._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Other_V600's,missense_variant,"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT",25,Vemurafenib,,,,,chr7_g.140453135_140453136delinsAT,BRAF_c.1799_1800delTGinsAT,BRAF_V600D
BRAF,673,V600E,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,Chemotherapy-refractory_patients_with_colorectal_cancer_harboring_BRAF_mutations_had_lower_response_and_disease_control_rates_as_well_as_shorter_progression_free_and_overall_survival_following_cetuximab_plus_chemotherapy_than_those_with_wildtype_BRAF.,20619739,PubMed,,"De_Roock_et_al.,_2010,_Lancet_Oncol.",,3,accepted,126,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/126,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Cetuximab,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Papillary_Thyroid_Carcinoma,3969,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Open-label_non-randomised_phase_2_trial_in_patients_with_recurrent_or_metastatic_BRAF_V600E_mutant_papillary_thyroid_cancer_refractory_to_radioactive_iodine._Patients_had_(cohort_2)_or_had_not_(cohort_1)_previously_been_treated_with_VEGFR_inhibitors._51_patients_were_enrolled_(26_cohort_1,_25_cohort_2)._In_cohort_1,_partial_response_was_achieved_in_ten_(38.5%)_patients._Nine_patients_achieved_stable_disease_for_at_least_6_months_(35%)._Median_PFS_was_18.2_months_and_median_OS_not_reached_after_a_median_follow-up_pf_18.8_months._In_cohort_2,_six_patients_(27.3%)_achieved_a_partial_response_and_another_six_patients_achieved_stable_disease_for_at_least_six_months._Median_PFS_was_8.9_months_and_median_OS_was_14.4._months.",27460442,PubMed,,"Brose_et_al.,_2016,_Lancet_Oncol.",,3,accepted,1591,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-08-16_07:40:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1591,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Supports,B,Resistance,"The_presence_of_BRAF_V600E_or_D594K_was_associated_with_reduced_progression-free_survival_in_5_patients_with_metastatic_colorectal_cancer_treated_with_irinotecan-based_first_line_therapy_(3.5mo_vs._12.8mo,_HR:4.1,_95%CI:1.5-11.3,_P=0.006)_when_compared_to_39_patients_with_wildtype_BRAF.",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,2118,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-07-19_22:53:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/2118,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Irinotecan,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Trametinib,PD0325901",Substitutes,Predictive,Does_Not_Support,D,Resistance,"In_the_setting_of_BRAF(V600E),_NF1_loss_resulted_in_elevated_activation_of_RAS-GTP_but_does_not_show_resistance_to_MEK_inhibitors.",24576830,PubMed,,"Nissan_et_al.,_2014,_Cancer_Res.",,3,accepted,86,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-02-18_18:20:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/86,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib,PD0325901,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_III_trial_(NCT01584648_COMBI-d),_previously_untreated_patients_with_unresectable_stage_IIIC_or_IV_melanoma_with_BRAF_V600E_(359_patients)_or_V600K_(61_patients)_received_dabrafenib_and_trametinib_or_dabrafenib_alone_with_primary_endpoint_of_progression_free_survival_and_secondary_endpoints_including_disease_response._The_hazard_ratio_for_progression_or_death_in_the_V600E_group_was_0.81_for_dabrafenib-trametinib_vs_dabrafenib-alone._Of_179_V600E_patients_in_the_dabrafenib-trametinib_group,_68%_of_patients_had_a_response,_which_was_15_percentage_points_higher_than_in_the_dabrafenib-alone_group_(95%_CI,_4_to_24;_P=0.006).",25265492,PubMed,,"Long_et_al.,_2014,_N._Engl._J._Med.",NCT01584648,5,accepted,6938,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-11-08_17:54:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/6938,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib,Dabrafenib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,A,Sensitivity/Response,"Phase_3_randomized_clinical_trial_comparing_vemurafenib_with_dacarbazine_in_675_patients_with_previously_untreated,_metastatic_melanoma_with_the_BRAF_V600E_mutation._At_6_months,_overall_survival_was_84%_(95%_confidence_interval_[CI],_78_to_89)_in_the_vemurafenib_group_and_64%_(95%_CI,_56_to_73)_in_the_dacarbazine_group._A_relative_reduction_of_63%_in_the_risk_of_death_and_of_74%_in_the_risk_of_either_death_or_disease_progression_was_observed_with_vemurafenib_as_compared_with_dacarbazine_(P<0.001_for_both_comparisons).",21639808,PubMed,,"Chapman_et_al.,_2011,_N._Engl._J._Med.",,5,accepted,1409,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-27_15:39:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1409,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Selumetinib_(AZD6244),BEZ235_(NVP-BEZ235,_Dactolisib)",Combination,Predictive,Supports,D,Sensitivity/Response,"49_BRAF-mutant_melanoma_cell_lines_from_patients_not_previously_treated_with_BRAF_inhibition_were_analyzed._21_exhibited_primary_resistance_to_BRAF_inhibition_using_PLX4720._Inhibition_of_MEK1/2_(BEZ235)_and_PI3K/mTOR_(AZD6244_[selumetinib])_was_the_most_effective_approach_to_counteract_resistance_in_comparison_to_inhibition_with_the_PLX4720-BEZ235_(where_response_was_assessed_by_apoptosis,_viability,_p-ERK,_p-Akt_inhibition).",26678033,PubMed,,"Penna_et_al.,_2016,_Oncotarget",,2,accepted,1005,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-07-13_23:47:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1005,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Selumetinib_(AZD6244),BEZ235_(NVP-BEZ235,_Dactolisib),,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Multiple_Myeloma,9538,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,A_54-year-old_man_presented_with_stage_II_myeloma.__He_was_initially_treated_with_chemotherapy_and_received_an_autologous_stem_cell_transplant.__Genomic_profiling_of_the_bone_biopsy_revealed_BRAF_V600E_activating_mutation_and_the_patient_was_treated_with_vemurafenib.__At_4-months_post_treatment_(time_of_case_study_report)_the_patient_maintains_near-resolution_of_hypermetabolic_lesions.,24997557,PubMed,,"Sharman_et_al.,_2014,_Clin_Lymphoma_Myeloma_Leuk",,2,accepted,1699,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-11-05_22:24:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1699,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Laryngeal_Squamous_Cell_Carcinoma,2876,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._One_patient_with_BRAF_V600E_mutant_laryngeal_cancer_had_a_partial_response_with_vemurafenib.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,3,accepted,5962,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-16_11:26:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/5962,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Gastrointestinal_Neuroendocrine_Tumor,50626,,"Dabrafenib,Trametinib,Vemurafenib",Combination,Predictive,Supports,C,Sensitivity/Response,"BRAF_mutations_were_identified_in_9%_of_108_cases_of_high-grade_colorectal_neuroendocrine_tumors_(80%_V600E)._Two_patients_were_treated_with_a_combination_of_BRAF_and_MEK_inhibition_and_exhibited_durable_response_(beyond_7_and_9_months,_respectively)._Urinary_BRAF_V600E_tumor_DNA_correlated_with_disease_response_in_one_of_the_patients._BRAF_and_MEK_inhibition_was_either_dabrafenib+trametinib_(case_1)_or_vemurafenib+trametinib_(case_2).",27048246,PubMed,,"Klempner_et_al.,_2016,_Cancer_Discov",,3,accepted,1430,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-07-01_16:10:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1430,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,Trametinib,Vemurafenib,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Dacarbazine,Temozolomide",Substitutes,Predictive,Does_Not_Support,B,,BRAF_status_does_not_predict_outcome_in_patients_treated_with_dacarbazine_or_temozolomide.,24586605,PubMed,,"Meckbach_et_al.,_2014,_PLoS_ONE",,2,accepted,82,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-05-31_02:12:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/82,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dacarbazine,Temozolomide,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Cholangiocarcinoma,4947,,"Panitumumab,Irinotecan,Vemurafenib",Combination,Predictive,Supports,C,Sensitivity/Response,"Patients_with_metastatic_cholangiocarcinoma_havoring_with_BRAF_V600E_was_treated_with_vemurafenib,_panitumumab_and_irinotecan_triplet_therapy._Multiple_lung_metastasis_was_dramatically_regressed_and_this_treatment_was_continued.",26687137,PubMed,,"Silkin_et_al.,_2016,_J_Gastrointest_Cancer",,3,accepted,5906,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-15_15:54:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/5906,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Panitumumab,Irinotecan,Vemurafenib,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Vemurafenib,Panitumumab",Combination,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_BRAF_V600E_mutant_metastatic_colorectal_cancer._Combined_EGFR_and_BRAF_inhibition_(panitumumab_and_vemurafenib)_showed_an_initial_partial_response_for_4_months_with_subsequent_disease_progression.,27325282,PubMed,,"Pietrantonio_et_al.,_2016,_Cancer_Discov",,2,accepted,1589,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-08-04_14:55:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1589,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,Panitumumab,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Vemurafenib,Cobimetinib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_III_trial_(coBRIM,_NCT01689519)_of_495_V600_mutant_melanoma_patients,_344_had_V600E_mutation._174_patients_were_treated_with_vemurafenib_and_placebo,_and_170_were_treated_with_vemurafenib_and_cobimetinib_and_tested_for_progression_free_survival._88_of_174_monotherapy_group_patients_had_an_event_with_median_progression_free_survival_of_6.5_months._In_the_combination_group_58_of_174_patients_had_an_event_with_median_progression-free_survival_not_met,_however,_when_in_combination_with_other_V600_mutations_median_progression-free_survival_was_9.9_months_with_combination_treatment._Median_time_to_followup_for_the_whole_cohort_was_7.3_months._Hazard_Ratio_for_progression_or_death_was_0.57_(0.41-0.80).",25265494,PubMed,,"Larkin_et_al.,_2014,_N._Engl._J._Med.",,4,accepted,1421,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-11-08_16:29:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1421,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,Cobimetinib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Adenocarcinoma,50861,,"Panitumumab,Trametinib",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_trial,_142_patients_with_metastatic,_BRAF_V600E_mutant_colorectal_cancer_were_randomized_to_receive_either_BRAF_inhibitor_dabrafenib_(D)_+_EGFR_inhibitor_panitumumab_(P);_or_a_triple_therapy_of_D_+_P_and_MEK_inhibition_with_trametinib_(T)_or_T_+_P._Confirmed_response_rates_for_D+P_(n=20),_D+T+P_(n=91),_and_T+P_(n=31)_were_10%,_21%,_and_0%,_respectively.",29431699,PubMed,,"Corcoran_et_al.,_2018,_Cancer_Discov",,3,accepted,6124,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-05-23_18:47:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/6124,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Panitumumab,Trametinib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"In_a_retrospective_study_of_300_stage_IV_melanoma_patients,_patients_with_BRAF_V600E_mutation_(n=175)_were_associated_with_a_4.8%_(8/167)_complete_response,_a_58.1%_(97/167)_partial_response_and_stable_disease_in_22.2%_(37/167)_of_cases;_however,_15%_(25/167)_of_patients_harboring_BRAF_V600E_experienced_progressive_disease.",25524477,PubMed,,"Ugurel_et_al.,_2015,_Ann._Oncol.",,,accepted,3757,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-15_14:33:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/3757,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Vemurafenib,,Predictive,Supports,D,Sensitivity/Response,Cell_lines_expressing_the_BRAF_V600E_mutation_responded_better_to_vemurafenib_treatment_than_cells_wildtype_for_BRAF_as_measured_by_reduced_cellular_proliferation_and_inhibition_of_MET_and_ERK_phosphorylation.,22180495,PubMed,,"Yang_et_al.,_2012,_Cancer_Res.",,2,accepted,99,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/99,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_I_and_II_study_(NCT01072175)_patients_with_metastatic_melanoma_were_given_dabrafenib_and_trametinib_combination_therapy_vs._dabrafenib_monotherapy._From_V600E_patients,_45_received_monotherapy_and_92_received_combination_therapy._Hazard_ratio_for_progression_or_death_was_0.43_(95%_CI,_0.27-0.71)._Both_patients_with_the_BRAF_V600E_and_V600K_mutation_showed_significant_improvement_in_progression-free_survival.",23020132,PubMed,,"Flaherty_et_al.,_2012,_N._Engl._J._Med.",,4,accepted,6940,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-11-08_17:18:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/6940,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib,Dabrafenib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"BEZ235_(NVP-BEZ235,_Dactolisib),GDC-0879",Combination,Predictive,Supports,D,Sensitivity/Response,"In_a_mouse_model_of_BRAF_V600E_colorectal_cancer,_western_blots_from_tumors_in_mice_treated_with_BRAF_inhibitor_GDC-0879_and_PI3K/mTOR_inhibitor_BEZ235_showed_stronger_reduction_in_phospho-Akt_and_phospho-S6_than_PI3K/mTOR_inhibitor_alone,_and_combination_inhibition_also_resulted_in_stronger_phospho-ERK_inhibition_in_tumors_than_did_BRAF_inhibition_alone._Increased_apoptosis_in_tumors_was_seen_in_dual_treatment_conditions_with_increased_TUNEL-positive_cells._In_vehicle_treated_mice,_area_of_colon_covered_by_tumor_increased,_while_treatment_with_single_agent_inhibitors_caused_growth_inhibition_resulting_in_no_change_in_colon_area_covered_by_tumors._Administration_of_dual_inhibitors_induced_tumor_regression_apparent_in_a_decrease_of_colonic_area_covered_by_tumors_over_the_course_of_treatment.",23549875,PubMed,,"Coffee_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1428,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-07-08_18:00:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1428,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,BEZ235_(NVP-BEZ235,_Dactolisib),GDC-0879,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"In_the_setting_of_BRAF(V600E),_NF1_loss_resulted_in_elevated_activation_of_RAS-GTP_and_resistance_to_RAF_inhibitors.",24576830,PubMed,,"Nissan_et_al.,_2014,_Cancer_Res.",,3,accepted,90,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/90,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Cancer,162,,Cobimetinib,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_analyzing_the_differential_response_to_MEK_inhibitors_in_KRAS_and_BRAF_mutant_cancer_cell_lines_and_mouse_xenografts._Inhibition_of_active,_phosphorylated_MEK_by_GDC-0973_(cobimetinib)_is_required_for_strong_inhibition_of_the_MAPK_pathway_in_BRAF-mutant_tumours._This_study_provides_mechanistic_rationale_for_improved_efficacy_of_cobimetinib_in_BRAF-mutant_models_compared_to_MEK_inhibitors_acting_through_an_alternative_mechanism_(GDC-0623_and_G-573).",23934108,PubMed,,"Hatzivassiliou_et_al.,_2013,_Nature",,3,accepted,1141,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-29_21:04:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1141,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Cobimetinib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Bevacizumab,,Predictive,Supports,B,Resistance,"In_a_study_of_metastatic_colorectal_cancer_patients_treated_with_capecitabine,_oxaliplatin,_and_bevacizumab,_those_with_BRAF_V600E_mutations_had_reduced_progression-free_survival_(5.9mo_vs._12.2mo,_P=0.003)_and_reduced_overall_survival_(15.0mo_vs._24.6mo,_P=0.002)_compared_to_those_with_wildtype_BRAF.",19571295,PubMed,,"Tol_et_al.,_2009,_N._Engl._J._Med.",,,accepted,2121,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-07-06_14:22:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/2121,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Bevacizumab,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Vemurafenib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_Phase_II_pilot_study_(NCT00405587)_of_BRAF_V600_inhibitor_vemurafenib_in_21_metastatic_colorectal_cancer_(CRC)_patients_with_BRAF_V600E,_one_patient_had_a_durable_21_week_partial_response,_and_seven_patients_had_8_week_stable_disease_as_best_response._Median_progression_free_survival_was_2.1_months_and_median_overall_survival_was_7.7_months._The_authors_conclude_that_single_agent_vemurafenib_did_not_show_meaningful_activity_in_V600E_CRC,_in_contrast_to_the_significant_vemurafenib_activity_against_V600_in_melanoma.",26460303,PubMed,,"Kopetz_et_al.,_2015,_J._Clin._Oncol.",,4,accepted,1405,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-27_23:41:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1405,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Dabrafenib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_trial_NCT00880321,_dabrafenib_was_tested_in_various_solid_tumor_types_harboring_mutant_BRAF_after_establishing_dosage_of_150_mg_twice_daily._In_nine_colorectal_cancer_patients_with_established_V600E_mutation,_1_confirmed_response,_7_instances_of_stable_disease,_and_1_case_of_progressive_disease_was_seen,_which_contrasted_strongly_with_a_56%_confirmed_response_rate_seen_in_metastatic_V600E_melanoma_patients_similarly_treated_in_the_same_study.",22608338,PubMed,,"Falchook_et_al.,_2012,_Lancet",,3,accepted,1406,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-27_23:30:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1406,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_clinical_trial_(NCT00949702)_of_132_BRAF_mutation_positive_metastatic_melanoma_patients_treated_with_vemurafenib_monotherapy,_patients_harboring_BRAF_V600E_(n=123)_or_V600K_(n=9)_mutations_were_associated_with_a_favorable_objective_response_rate_(53%_per_RECIST_v1.1_criteria,_70/132),_with_6%_(8/132)_and_47%_(62/132)_of_patients_achieving_complete_response_and_partial_response,_respectively.",23569304,PubMed,,"Trunzer_et_al.,_2013,_J._Clin._Oncol.",,,accepted,3750,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-15_14:25:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/3750,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"PLX4720,Nutlin-3",Combination,Predictive,Supports,D,Sensitivity/Response,Combined_nutlin-3_and_PLX4720_administration_to_athymic_nude_mice_subcutanousely_injected_with_the_A357_colorectal_cell_line_with_a_BRAF_V600E_mutation_effectively_inhibited_tumor_growth_significantly_more_than_single_agent_therapy.,23812671,PubMed,,"Ji_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,97,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-05-31_00:11:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/97,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,PLX4720,Nutlin-3,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Anaplastic_Thyroid_Carcinoma,,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Interim_analysis_of_a_basket_trial_evaluating_the_combination_of_dabrafenib_(BRAF_inhibitor)_and_trametinib_(MEK_inhibitor)_in_previously_treated_V600E-mutated_patients_showed_11/16_patients_with_anaplastic_thyroid_carcinoma_responded_to_treatment_(overall_response_rate_69%;_95%_CI,_41%_to_89%)._Seven_patients_had_ongoing_responses.",29072975,PubMed,,"Subbiah_et_al.,_2018,_J._Clin._Oncol.",,4,accepted,6975,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2019-02-09_22:12:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/6975,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib,Dabrafenib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Multicenter,_phase_1,_dose-escalation_trial_of_PLX4032_(Vemurafenib)._Treatment_of_metastatic_melanoma_with_PLX4032_in_patients_with_tumors_that_carry_the_V600E_BRAF_mutation_resulted_in_complete_or_partial_tumor_regression_in_the_majority_of_patients._Patients_without_the_V600E_mutation_had_evidence_of_tumor_regression.",20818844,PubMed,,"Flaherty_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,1749,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-01-05_19:08:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/1749,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,The_BRIM-3_Phase_III_trial_NCT01006980_assessed_BRAF_inhibitor_vemurafenib_versus_dacarbazine_in_598_patients_with_treatment_naive_metastatic_melanoma_and_confirmed_V600E_mutation._Significant_differences_were_seen_in_overall_survival_(13.3_months_with_vemurafenib_vs._10.0_months_with_dacarbazine)_and_median_progression_free_survival_(6.9_months__with_vemurafenib_vs._1.6_months_with_dacarbazine),24508103,PubMed,,"McArthur_et_al.,_2014,_Lancet_Oncol.",,5,accepted,1398,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-27_15:42:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1398,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Among_2_patients_with_BRAF_V600E_mutant_colorectal_cancer,_1_had_a_partial_response.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5960,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-16_11:12:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/5960,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Anaplastic_Thyroid_Carcinoma,,,"Pertuzumab,Vemurafenib",Combination,Predictive,Supports,C,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._One_patient_with_BRAF_V600E_mutant_anaplastic_thyroid_cancer_had_a_complete_response.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,3,accepted,5961,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-10-24_16:08:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/5961,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Pertuzumab,Vemurafenib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Non-small_Cell_Lung_Carcinoma,3908,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,A,Sensitivity/Response,"Patients_with_BRAF_V600E-mutant_NSCLC_(n=57)_were_enrolled_into_a_phase_2,_multicentre,_non-randomised,_open-label_study,_administering_dabrafenib_plus_trametinib._The_overall_response_rate_was_36/57_(63.2%,_[95%_CI_49.3-75.6])_and_the_median_progression-free_survival_was_9.7_months_(95%_CI_6.9-19.6)._At_data_cutoff_(11.6_months_of_follow-up),_18/36__(50%)_confirmed_responses_were_ongoing_and_23/57_(40%)_of_patients_had_died.",27283860,PubMed,,"Planchard_et_al.,_2016,_Lancet_Oncol.",,4,accepted,3017,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-06-29_14:37:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/3017,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,Trametinib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Cholangiocarcinoma,4947,,"Dabrafenib,Trametinib_DMSO",Combination,Predictive,Supports,C,Sensitivity/Response,"Chemotherapy-refractory,_metastatic_cholangiocarcinoma_with_BRAF_V600E_showed_dramatically_response_for_Dabrafenib_and_Trametinib_combination.",28480077,PubMed,,"Kocsis_et_al.,_2017,_J_Gastrointest_Oncol",,3,accepted,5902,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-01-04_16:22:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/5902,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,Trametinib_DMSO,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Non-small_Cell_Lung_Carcinoma,3908,,Dabrafenib,,Predictive,Supports,C,Resistance,"In_a_patient_with_V600E-positive_NSCLC,_KRAS_G12D_seemed_to_confer_resistance_to_dabrafenib.",23524406,PubMed,,"Rudin_et_al.,_2013,_J_Thorac_Oncol",,2,accepted,91,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/91,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Cholangiocarcinoma,4947,,"Dabrafenib,Trametinib_DMSO",Combination,Predictive,Supports,C,Sensitivity/Response,Dabrafenib_and_trametinib_combination_showed_durable_response_for_patients_with_standard_chemotherapy_refractory_cholangiocarcinoma_havoring_BRAF_V600E.,25435907,PubMed,,"Loaiza-Bonilla_et_al.,_2014,_Ecancermedicalscience",,3,accepted,5904,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-01-04_16:31:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/5904,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,Trametinib_DMSO,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Cetuximab,Irinotecan,Vemurafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Phase_1b_study_of_vemurafenib,_cetuximab_and_irinotecan_in_19_patients_with_colorectal_cancer_(1_with_appendiceal_cancer)._Six_of_17_evaluable_patients_achieved_an_objective_response,_15_patients_total_had_either_stable_disease_or_radiographic_response_(the_patient_with_appendiceal_cancer_had_disease_progression)._Estimated_median_PFS_was_7.7_months._Effect_of_the_combined_treatment_was_also_observed_in_xenograft_and_cell_line_studies.",27729313,PubMed,,"Hong_et_al.,_2016,_Cancer_Discov",,4,accepted,1902,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-02-14_21:10:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1902,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Cetuximab,Irinotecan,Vemurafenib,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Capecitabine,Vemurafenib,Bevacizumab",Combination,Predictive,Supports,D,Sensitivity/Response,"Mouse_xenografts_using_HT29_cells_harboring_the_BRAF_V600E_mutation_treated_with_combination_therapy_(capecitabine,_vemurafenib,_bevacizumab)_showed_increased_survival_and_reduced_tumor_burden_compared_to_single_and_double_agent_therapies.",22180495,PubMed,,"Yang_et_al.,_2012,_Cancer_Res.",,2,accepted,98,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-05-31_15:36:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/98,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Capecitabine,Vemurafenib,Bevacizumab,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Panitumumab,Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_trial,_142_patients_with_metastatic,_BRAF_V600E_mutant_colorectal_cancer_were_randomized_to_receive_either_BRAF_inhibitor_dabrafenib_(D)_+_EGFR_inhibitor_panitumumab_(P);_or_a_triple_therapy_of_D_+_P_and_MEK_inhibition_with_trametinib_(T)_or_T_+_P._Confirmed_response_rates_for_D+P_(n=20),_D+T+P_(n=91),_and_T+P_(n=31)_were_10%,_21%,_and_0%,_respectively.",29431699,PubMed,,"Corcoran_et_al.,_2018,_Cancer_Discov",,4,accepted,6123,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-05-23_18:47:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/6123,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Panitumumab,Trametinib,Dabrafenib,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Vemurafenib,Gefitinib,Cetuximab",Combination,Predictive,Supports,D,Sensitivity/Response,"5_of_7_colorectal_cancer_(CRC)_cell_lines_with_BRAF_V600E_mutation_were_resistant_to_treatment_with_the_BRAF_inhibitor_vemurafenib._An_RNAi_screen_in_the_WiDr_cell_line_(a_V600E_CRC_line)_identified_EGFR_as_an_enhancer_for_survival_when_exposed_to_vemurafenib.__Treatment_with_vemurafenib_and_EGFR_inhibitor_(cetuximab_or_gefitinib)_in_V600E_CRC_cells_(WiDr,_VACO432_and_KM20)_showed_inhibited_growth_as_well_as_induction_of_the_cleaved_PARP_apoptotic_marker._WiDr_and_VACO432_cells_were_injected_into_immunodeficient_mice._Modest_response_was_seen_with_vemurafenib_treatment,_while_combination_treatment_showed_considerable_tumor_growth_inhibition_as_compared_to_control.",22281684,PubMed,,"Prahallad_et_al.,_2012,_Nature",,3,accepted,1408,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-29_20:22:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1408,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,Gefitinib,Cetuximab,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Skin_Melanoma,8923,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_clinical_trial_(NCT01597908)_of_704_metastatic_melanoma_patients,_patients_harboring_a_BRAF_V600E_mutation_and_treated_with_vemurafenib_(n=317)_were_associated_with_a_51%_response_rate,_as_compared_to_a_64%_response_rate_(p<0.001)_in_V600E_mutation_positive_patients_treated_with_dabrafenib_and_trametinib_combination_therapy_(n=312)._Median_progression-free_survival_was_11.4_months_in_the_combination-therapy_group_and_7.3_months_in_the_vemurafenib_group_(hazard_ratio,_0.56;_95%_CI,_0.46_to_0.69;_P<0.001).",25399551,PubMed,,"Robert_et_al.,_2015,_N._Engl._J._Med.",NCT01597908,4,accepted,3758,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-11-08_18:02:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/3758,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib,Dabrafenib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Ganglioglioma,5078,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"In_a_case_report,_a_cervicomedullary_ganglioglioma_patient_harboring_BRAF_V600E_mutation_was_associated_with_radiological_and_clinical_response_to_vemurafenib_monotherapy_after_3_months_of_treatment,_which_was_sustained_after_6_months_of_therapy._Prior_to_vemurafenib_treatment,_the_patient_had_undergone_tracheotomy,_was_treated_with_standard_chemotherapy_and_underwent_another_surgery,_but_had_developed_progressive_disease.",25524464,PubMed,,"del_Bufalo_et_al.,_2014,_J_Transl_Med",,,accepted,3777,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-04-19_20:36:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/3777,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Sorafenib,Panitumumab",Combination,Predictive,Supports,D,Sensitivity/Response,Cetuximab_or_panitumumab_may_be_ineffective_in_patients_with_BRAF_mutation_unless_BRAF_inhibitor_such_as_Sorafenib_is_introduced.,19001320,PubMed,,"Di_Nicolantonio_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,89,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-09-16_01:20:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/89,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Sorafenib,Panitumumab,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Pictilisib,,Predictive,Supports,C,Sensitivity/Response,"One_patient_with_BRAF_V600E_mutated_melanoma_(with_no_detected_PI3K_pathway_deregulation)_had_a_partial_response_on_treatment_with_pictilisib,_a_PI3K_inhibitor,_for_9.5_months._Study_was_a_phase-1_with_60_patients_enrolled.",25370471,PubMed,,"Sarker_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,757,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/757,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Pictilisib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,B,Sensitivity/Response,"Adjuvant_dual_treatment_with_BRAF_inhibitor_dabrafenib_and_MEK_inhibitor_trametinib_was_administered_to_patients_with_stage_III_resected_melenoma_with_V600E_or_V600K_mutation_in_this_stage_III_trial_(COMBO-AD,_NCT01682083)._792_(91%)_patients_had_V600E,_and_were_administered_dabrafenib_and_trametinib_or_placebo_for_12_months._In_subsequent_analysis,_relapse_or_death_occurred_in_150/397_patients_(38%)_in_the_treatment_group_and_229/395_patients_(58%)_in_the_placebo_group_for_a_95%_CI_Hazard_Ratio_of_0.48_(0.39-0.58).",28891408,PubMed,,"Long_et_al.,_2017,_N._Engl._J._Med.",NCT01682083,5,accepted,6178,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-05-23_17:55:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/6178,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,Trametinib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Oxaliplatin,,Predictive,Supports,B,Resistance,"Of_100_metastatic_colorectal_cancer_patients_treated_with_oxaliplatin-based_first-line_therapy,_the_6_patients_with_either_BRAF_V600E_or_D594K_had_reduced_progression-free_survival_compared_to_94_patients_with_wildtype_BRAF_(5.0mo_vs._11.7mo,_HR:6.4,_95%CI:2.6-15.6,_P<0.0001).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,2117,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-07-19_23:02:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/2117,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Oxaliplatin,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Trametinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_322_advanced_melanoma_patients_with_BRAF-V600E_or_BRAF-V600K_mutations,_treatment_with_trametinib_was_associated_with_improved_progression-free_survival_(4.8mo_vs._1.5mo,_<0.001)_compared_to_chemotherapy_control_group._Additionally,_treatment_with_trametinib_was_associated_with_increased_6-month_overall_survival_(HR:0.54,_95%_CI:0.32-0.92,_P=0.01).",22663011,PubMed,,"Flaherty_et_al.,_2012,_N._Engl._J._Med.",,,accepted,2135,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-07-06_14:21:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/2135,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Multiple_Myeloma,9538,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"A_65-year-old_man_presented_with_stage_II_myeloma.__He_was_initially_treated_with_chemotherapy_and_he_received_an_autologous_stem_cell_transplant._Sequencing_of_the_recurrent_tumor_harbored_BRAF_V600E_mutation_and_he_was_treated_with_vemurafenib.__After_7_weeks_of_treatment,_the_patient_relapsed_and_died.",24997557,PubMed,,"Sharman_et_al.,_2014,_Clin_Lymphoma_Myeloma_Leuk",,3,accepted,1698,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-11-05_22:24:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1698,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,B,Sensitivity/Response,Dabrafenib_with_trametinib_provides_higher_response_rate_and_lower_toxicity_(as_compared_to_chemotherapy)_in_patients_with_melanoma.,24583796,PubMed,,"Menzies_et_al.,_2014,_Clin._Cancer_Res.",,5,accepted,95,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-02-18_21:13:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/95,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Dabrafenib,Trametinib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Ovarian_Cystadenocarcinoma,3605,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"A_stage_4B,_low-grade_papillary_serous_ovarian_adenocarcinoma_patient,_harboring_a_BRAF_V600E_mutation_was_associated_with_response_to_vemurafenib_monotherapy._The_patient_was_treated_with_standard_chemotherapy,_hormone_therapy_and_bevacizumab_prior_to_the_identification_of_the_BRAF_V600E_mutation;_next,_the_patient_was_treated_with_paclitaxel_and_an_anti-HER3_antibody_and_finally_with_vemurafenib,_obtaining_a_partial_response_of_greater_than_1_year.",26490654,PubMed,,"Combe_et_al.,_2015,_Invest_New_Drugs",,,accepted,3787,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-07-06_20:28:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/3787,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"PLX4720,GDC0941",Combination,Predictive,Supports,D,Sensitivity/Response,Combined_MEK_inhibitor_GDC0941_and_BRAF_inhibitor_PLX4720_administration_to_NSG_mice_subcutanousely_injected_with_colorectal_cell_lines_with_a_BRAF_V600E_mutation_effectively_inhibited_tumor_growth_and_reduced_cellular_proliferation.,23845441,PubMed,,"Rad_et_al.,_2013,_Cancer_Cell",,3,accepted,96,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-05-31_15:38:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/96,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,PLX4720,GDC0941,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Ovarian_Cancer,2394,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Among_4_patients_with_BRAF_V600E_mutant_ovarian_cancer,_2_had_a_partial_response_and_one_had_stable_disease_>_120days.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,3,accepted,5959,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-15_21:52:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/5959,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"In_a__clinical_study_of_Polish,_stage_IIIC/IV,_melanoma_patients_with_metastases_(n=75)_harboring_BRAF_V600_mutation_(as_detected_by_cobas_4800_BRAF_V600_Mutation_Test),_patients_were_associated_with_a_61.9%_(95%_CI:_50.1-73.6)_median_overall_survival,_a_7.4_months_(95%_CI:_5.5-9.2)_median_progression_free_survival;_a_median_duration_response_of_7.4_months_was_reported,_with_3%_(2/75)_and_43%_(29/75)_of_patients_achieving_a_complete_and_partial_response,_respectively.",26557775,PubMed,,"Rutkowski_et_al.,_2015,_Contemp_Oncol_(Pozn)",,,accepted,3755,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-15_14:26:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/3755,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Hairy_Cell_Leukemia,285,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Two_clinical_trials_evaluated_the_effects_of_vemurafenib_in_54_patients_with_BRAF_(V600E)_positive_hairy-cell_leukemia.__The_overall_response_rate_was_98%_with_19/54_having_a_complete_response_and_34/54_having_a_partial_response.__In_the_Italian_study_(n=25),_the_median_relapse-free_survival_was_9_months_and_in_the_U.S._study_(n=24),_rate_of_progression-free_survival_was_73%_with_overall_survival_rate_of_91%.",26352686,PubMed,,"Tiacci_et_al.,_2015,_N._Engl._J._Med.",,2,accepted,1579,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-08-15_19:25:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1579,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,B,Resistance,"In_metastatic_colorectal_cancer_patients_with_wildtype_KRAS_status,_those_with_a_BRAF_V600E_mutation_were_less_likely_to_respond_to_treatment_with_cetuximab_or_panitumumab_than__those_with_wildtype_BRAF_(0%__vs._32%_,_P=0.029)._Regardless_of_KRAS_status,_patients_with_BRAF_mutations_had_reduced_progression-free_and_overall_survival_(P=0.0107_and_P_<0.0001,_respectively)._Transfection_of_the_colorectal_cancer_cell_line_DiFi_with_a_BRAF_V600E_expression_vector_conferred_decreased_sensitivity_to_cetuximab_and_panitumumab_in_comparison_to_cells_transfected_with_empty_vector.",19001320,PubMed,,"Di_Nicolantonio_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,2115,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-05-12_03:37:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/2115,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Cetuximab,Panitumumab,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Cholangiocarcinoma,4947,,"Trametinib_DMSO,Dabrafenib",Combination,Predictive,Supports,C,Sensitivity/Response,Two_cases_of_patients_with_BRAF_V600E_positive_cholangiocarcinoma_showed_excellent_response_for_Dabrafenib_and_Trametinib.,28078132,PubMed,,"Lavingia_et_al.,_2016,_J_Gastrointest_Oncol",,3,accepted,5903,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-01-04_16:16:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/5903,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Trametinib_DMSO,Dabrafenib,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Anaplastic_Thyroid_Carcinoma,,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_“basket”_study_of_vemurafenib_in_BRAF_V600-positive_non-melanoma_cancers,_seven_patients_with_anaplastic_thyroid_cancer_were_enrolled._All_7_patients_had_V600E_mutations._One_complete_response_and_one_partial_response_was_observed,_for_a_response_rate_of_29%.",26287849,PubMed,,"Hyman_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,6045,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2019-01-29_21:59:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/6045,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Vemurafenib,Panitumumab",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"Treatment_response_to_mutant_BRAF_inhibitor_vemurafenib_and_EGFR_inhibitor_panitumumab_was_assayed_in_12_patients_with_metastatic_colorectal_cancer_(CRC)_who_had_progressed_on_chemotherapy._Two_patients_had_confirmed_partial_responses,_and_2_showed_stable_disease_over_6_months._The_authors_conclude_that_although_some_efficacy_is_seen,_only_a_small_subset_of_patients_respond_to_this_treatment_and_the_responses_are_not_durable.",25589621,PubMed,,"Yaeger_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,1413,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-28_20:20:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1413,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,Panitumumab,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Does_Not_Support,B,Resistance,"This_meta-analysis_of_7_randomized_control_trials_evaluating_overall_survival_(OS)_(8_for_progression_free_survival)_could_not_definitely_state_that_survival_benefit_of_anti-EGFR_monoclonal_antibodies_is_limited_to_patients_with_wild_type_BRAF._In_other_words,_the_authors_believe_that_there_is_insufficient_data_to_justify_the_exclusion_of_anti-EGFR_monoclonal_antibody_therapy_for_patients_with_mutant_BRAF._In_these_studies,_mutant_BRAF_specifically_meant_the_V600E_mutation.",25989278,PubMed,,"Rowland_et_al.,_2015,_Br._J._Cancer",,4,accepted,816,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-02-18_19:56:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/816,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Cetuximab,Panitumumab,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Papillary_Thyroid_Carcinoma,3969,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"A_73_year_old_patient_with_prior_history_of_breast_cancer_presented_with_metastatic_papillary_thyroid_carcinoma._After_two_treatments_of_I-131_a_comprehensive_tumor_profile_revealed_BRAF_V600E_as_the_only_genetic_alteration_on_a_near_diploid_genome_with_trisomy_1q._Vemurafenib_treatment_resulted_in_improvement_of_symptoms_and_considerable_reductions_in_tumor_mass,_and_after_23_months_the_patient_remained_on_therapy_with_well_controlled_disease.",24987354,PubMed,,"Ali_et_al.,_2014,_Case_Rep_Oncol",,4,accepted,1414,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-28_19:21:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/1414,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_148_treatment_naive_metastatic_colorectal_cancer_patients,_patients_with_BRAF_V600E_(n=14)_mutation_treated_with_FOLFOX4_plus_cetuximab_were_associated_with_a_decreased_progression_free_survival_(7.2mo_vs._9.7mo,_HR:0.39,_95%_CI:0.21-0.72,_P=0.0017),_and_decreased_overall_survival_(11.7mo_vs._28.5mo,_HR:0.23,_95%_CI:0.12-0.41,_P<0.0001),_as_compared_to_patients_with_wildtype_BRAF.",25666295,PubMed,,"Kaczirek_et_al.,_2015,_Clin_Colorectal_Cancer",,,accepted,3739,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2017-07-20_16:14:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/3739,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Cetuximab,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Phase_2_trial_in_132_patients_with_previously_treated_metastatic_melanoma_with_BRAF_V600E_mutation.__Confirmed_overall_response_rate_was_53%_(95%_confidence_interval_[CI],_44_to_62;_6%_with_a_complete_response_and_47%_with_a_partial_response),_median_duration_of_response_was_6.7_months_(95%_CI,_5.6_to_8.6),_and_median_progression-free_survival_was_6.8_months_(95%_CI,_5.6_to_8.1)._Median_overall_survival_was_15.9_months_(95%_CI,_11.6_to_18.3).",22356324,PubMed,,"Sosman_et_al.,_2012,_N._Engl._J._Med.",,3,accepted,1410,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2016-06-27_18:13:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1410,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E,Non-small_Cell_Lung_Carcinoma,3908,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Within_the_BRAF_mutant_group,_fourteen_patients_had_refractory_BRAF_V600E-mutated_NSCLC_(adenocarcinoma,_n_=_13;_sarcomatoid,_n_=_1)._Six_patients_(43%;_95%_CI,_18%_to_71%)_had_objective_responses_(one_CR,_five_PR),_and_two_additional_patients_had_SD_>_120_days._The_median_DOR_was_5_months_(range,_4_to_14_months).",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,4,accepted,5958,5,7,140453136,140453136,A,T,ENST00000288602.6,,,,,75,GRCh37,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",Somatic_Mutation,2018-02-15_21:50:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/5958,https://civic.genome.wustl.edu/links/variants/12,https://civic.genome.wustl.edu/links/genes/5,"BRAF_V600E_has_been_shown_to_be_recurrent_in_many_cancer_types._It_is_one_of_the_most_widely_studied_variants_in_cancer._This_variant_is_correlated_with_poor_prognosis_in_certain_cancer_types,_including_colorectal_cancer_and_papillary_thyroid_cancer._The_targeted_therapeutic_dabrafenib_has_been_shown_to_be_effective_in_clinical_trials_with_an_array_of_BRAF_mutations_and_cancer_types._Dabrafenib_has_also_shown_to_be_effective_when_combined_with_the_MEK_inhibitor_trametinib_in_colorectal_cancer_and_melanoma._However,_in_patients_with_TP53,_CDKN2A_and_KRAS_mutations,_dabrafenib_resistance_has_been_reported._Ipilimumab,_regorafenib,_vemurafenib,_and_a_number_of_combination_therapies_have_been_successful_in_treating_V600E_mutations._However,_cetuximab_and_panitumumab_have_been_largely_shown_to_be_ineffective_without_supplementary_treatment.",,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",979,Vemurafenib,,,,,chr7_g.140453136A~T,BRAF_c.1799T~A,BRAF_V600E
BRAF,673,V600E+V600M,Melanoma,1909,,Dabrafenib,,Predictive,Supports,C,Sensitivity/Response,A_single_patient_with_BRAF_V600E/V600M_bi-allelic_mutation_responded_to_the_V600E_drug_dabrafenib.,23031422,PubMed,,"Ponti_et_al.,_2012,_J_Hematol_Oncol",,3,accepted,73,5,7,140453135,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"A_case_study_of_a_single_patient_harboring_both_a_V600E_and_a_V600M_mutation,_dabrafenib_was_shown_to_acheive_clinical_response.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/73,https://civic.genome.wustl.edu/links/variants/13,https://civic.genome.wustl.edu/links/genes/5,"A_case_study_of_a_single_patient_harboring_both_a_V600E_and_a_V600M_mutation,_dabrafenib_was_shown_to_acheive_clinical_response.",Other_V600's,missense_variant,,7.5,Dabrafenib,,,,,,,
BRAF,673,V600E_AMPLIFICATION,Colorectal_Cancer,9256,,Selumetinib_(AZD6244),,Predictive,Supports,E,Resistance,COLO201_and_COLO206F_cells_harboring_BRAF_V600E_mutations_were_cloned_to_be_MEK_inhibitor_(AZD6244_[selumetinib])_resistant._The_mechanism_of_this_resistance_was_shown_to_be_amplification_of_the_BRAF_V600E_gene.,21098728,PubMed,,"Corcoran_et_al.,_2010,_Sci_Signal",,4,accepted,92,5,7,140434279,140624564,,,ENST00000288602.6,,,,,75,GRCh37,"Amplification_of_BRAF_V600E_has_been_shown_to_confer_resistance_to_MEK_inhibitors._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",Somatic_Mutation,2016-07-13_23:41:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/92,https://civic.genome.wustl.edu/links/variants/14,https://civic.genome.wustl.edu/links/genes/5,"Amplification_of_BRAF_V600E_has_been_shown_to_confer_resistance_to_MEK_inhibitors._For_more_information_on_the_V600_locus,_see_the_V600E_entry.",,"transcript_amplification,missense_variant",,1,Selumetinib_(AZD6244),,,,,,,
BRAF,673,V600,Melanoma,1909,,RO4987655,,Predictive,Supports,B,Sensitivity/Response,Phase_I_expansion_and_pharmacodynamic_study_of_oral_MEK_inhibitor_RO4987655._Partial_response_was_observed_in_4_of_17_patients_with_BRAF_V600_mutated_melanoma._2_patients_with_prior_vemurafenib_treatment_progressed_under_treatment.,24947927,PubMed,,"Zimmer_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,994,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-02-12_23:16:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/994,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,RO4987655,,,,,,,
BRAF,673,V600,Cholangiocarcinoma,4947,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Eight_patients_with_BRAF_V600_(7_with_V600E,_1_with_V600_unknown)_mutated_cholangiocarcinoma_received_vemurafenib._Only_one_patients_showed_partial_response_and_duration_of_response_of_this_patient_was_longer_than_12_months.",26287849,PubMed,,"Hyman_et_al.,_2015,_N._Engl._J._Med.",,4,accepted,5905,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-02-13_20:04:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/5905,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Vemurafenib,,,,,,,
BRAF,673,V600,Melanoma,1909,,"Cobimetinib,Vemurafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_1b_study,_129_patients_with_unresectable_or_metastatic_melanoma_were_verified_for_BRAF_V600_mutation_using_the_cobas_4800_mutation_test_were_selected_who_had_progressed_on_vemurafenib_(66_patients)_or_never_received_BRAF_inhibitor_(63_patients)._The_combination_of_vemurafenib_and_cobimetinib_was_deemed_safe_and_tolerable._Confirmed_objective_responses_were_seen_in_15%_of_vemurafenib_progressed_patients_and_median_progression-free_survival_was_2.8_months_(95%_CI_2·6–3·4)._Confirmed_objective_responses_were_seen_in_87%_of_patients_who_had_never_received_BRAF_inhibitor,_including_10%_with_complete_response._Median_progression-free_survival_was_13.7_months_(95%_CI_10·1–17·5)._The_majority_of_patients_had_BRAF_V600E_mutation._Post-hoc_sequencing_of_94_tumor_samples_indicated_seven_tumors_with_a_mutation_other_than_BRAF_V600E.",25037139,PubMed,,"Ribas_et_al.,_2014,_Lancet_Oncol.",NCT01271803,3,accepted,6966,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-11-08_16:33:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/6966,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Cobimetinib,Vemurafenib,,,,,,
BRAF,673,V600,Melanoma,1909,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Combination_Dabrafenib_and_Trametinib_treatment_was_assessed_for_adjuvant_treatment_of_stage_III_resected_BRAF_V600_mutant_melanoma_in_the_COMBI-AD_trial_NCT01682083._Patients_were_treated_with_combination_therapy_or_placebo_for_12_months._The_estimated_3-year_rate_of_relapse-free_survival_was_58%_in_the_treated_group_and_39%_in_the_placebo_group__with_hazard_ratio_for_relapse_or_death_of_0.47_(95%_CI,_0.39_to_0.58;_P<0.001)._3-year_overall_survival_rate_for_treated_group_was_86%,_and_77%_in_the_placebo_group_(hazard_ratio_for_death,_0.57;_95%_CI,_0.42-0.79;_P=0.0006)._The_level_of_improvement_observed_did_not_cross_the_prespecified_interim_analysis_boundary_of_P=0.000019._Distant_metastasis-free_survival_and_freedom_from_relapse_was_higher_in_the_combination-treated_group.",28891408,PubMed,,"Long_et_al.,_2017,_N._Engl._J._Med.",NCT01682083,5,accepted,6180,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-07-06_13:59:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/6180,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Trametinib,Dabrafenib,,,,,,
BRAF,673,V600,Melanoma,1909,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_III_trial_(NCT01584648_COMBI-d),_423_previously_untreated_patients_with_unrescectable_stage_IIIC_or_IV_BRAF_V600E_or_V600K_melanoma_received_dabrafenib_and_trametinib_or_dabrafenib_alone_with_primary_endpoint_of_progression_free_survival_with_secondary_endpoints_including_disease_response.___Hazard_ratio_for_progression_or_death_in_the_dabrafenib–trametinib_group,_0.75;_(95%_confidence_interval,_0.57_to_0.99;_P=0.03)._Of_210_patients_in_the_dabrafenib_+_trametinib_group,_67%_of_patients_had_a_response,_which_was_16_percentage_points_higher_than_in_the_dabrafenib_group._(95%_CI,_6_to_25;_P=0.002)",25265492,PubMed,,"Long_et_al.,_2014,_N._Engl._J._Med.",NCT01584648,5,accepted,6937,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-11-08_17:32:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/6937,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Trametinib,Dabrafenib,,,,,,
BRAF,673,V600,Melanoma,1909,,"Vemurafenib,Cobimetinib",Combination,Predictive,Supports,A,Sensitivity/Response,"In_this_double-blind,_randomized,_placebo-controlled,_multicentre_study,_adult_patients_with_histologically_confirmed_BRAF(V600)_mutation-positive_unresectable_stage_IIIC_or_stage_IV_melanoma_were_randomly_assigned_(1:1)_to_receive_cobimetinib_or_placebo,_in_combination_with_oral_vemurafenib._Progression-free_survival_was_the_primary_endpoint._Between_Jan_8,_2013,_and_Jan_31,_2014,_495_eligible_adult_patients_were_enrolled_and_randomly_assigned_to_the_cobimetinib_plus_vemurafenib_group_(n=247)_or_placebo_plus_vemurafenib_group_(n=248)._Investigator-assessed_median_progression-free_survival_was_12.3_months_for_cobimetinib_and_vemurafenib_versus_7.2_months_for_placebo_and_vemurafenib_(HR_0.58_[95%_CI_0.46-0.72],_p<0.0001)._Median_overall_survival_was_22.3_months_for_cobimetinib_and_vemurafenib_versus_17.4_months_for_placebo_and_vemurafenib_(HR_0.70,_95%_CI_0.55-0.90;_p=0.005)._The_safety_profile_for_cobimetinib_and_vemurafenib_was_tolerable_and_manageable,_and_no_new_safety_signals_were_observed_with_longer_follow-up.",27480103,PubMed,,"Ascierto_et_al.,_2016,_Lancet_Oncol.",NCT01689519,5,accepted,6044,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-11-08_15:34:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/6044,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Vemurafenib,Cobimetinib,,,,,,
BRAF,673,V600,Non-small_Cell_Lung_Carcinoma,3908,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_BRAF-V600_mutated_cancers_were_identified_(n=122)_and_clinical_response_to_vemurafenib_was_evaluated._Of_the_20_patients_with_non-small-cell-lung_cancer_(17_with_BRAF_V600E,_one_with_BRAF_V600G_and_one_with_BRAF_V600_unknown_status),_19_were_evaluable_and_the_response_rate_to_vemurafenib_was_42%,_tumor_regression_was_observed_in_14/19_patients,_progression-free_survival_was_7.3_months,_and_12-month_overall_survival_was_66%.",26287849,PubMed,,"Hyman_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,1574,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-08-22_22:35:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1574,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Vemurafenib,,,,,,,
BRAF,673,V600,Melanoma,1909,,Trametinib,,Predictive,Supports,B,Sensitivity/Response,"Patients_who_had_histologically_confirmed,_unresectable_stage_IIIC_or_IV_cutaneous_melanoma_with_a_V600E_or_V600K_BRAF_mutation_were_eligible_for_the_study._322_eligible_patients_(281_with_the_V600E_mutation,_40_with_the_V600K_mutation,_and_1_with_both_mutations)_in_a_2:1_ratio_to_receive_oral_trametinib_(2_mg_once_daily)_or_intravenous_chemotherapy_consisting_of_either_dacarbazine_(1000_mg_per_square_meter_of_body-surface_area)_or_paclitaxel_(175_mg_per_square_meter),_at_the_discretion_of_the_investigator,_every_3_weeks._The_primary_end_point_was_progression-free_survival;_secondary_end_points_included_overall_survival,_overall_response_rate,_duration_of_response,_and_safety._Treatment_continued_until_disease_progression,_death,_or_withdrawal_from_the_study._In_the_intention-to-treat_population,_the_median_duration_of_progression-free_survival_was_4.8_months_in_the_trametinib_group_as_compared_with_1.5_months_in_the_chemotherapy_group_(hazard_ratio_for_progression,_0.45;_95%_confidence_interval_[CI],_0.33_to_0.63;_P<0.001).__The_6-month_overall_survival_rate_in_the_intention-to-treat_population_was_81%_in_the_trametinib_group_and_67%_in_the_chemotherapy_group.",22663011,PubMed,,"Flaherty_et_al.,_2012,_N._Engl._J._Med.",,3,accepted,1750,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2017-02-14_21:48:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/1750,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Trametinib,,,,,,,
BRAF,673,V600,Colorectal_Cancer,9256,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_clinical_trial_NCT01072175,_43_patients_with_BRAF_V600_metastatic_colorectal_cancer_(CRC)_received_mutant_BRAF_inhibitor_dabrafenib_and_MEK_inhibitor_trametinib._Only_12%_of_patients_showed__partial_response_or_better,_with_one_complete_response_lasting_36_months_and_ongoing_after_data_cutoff._56%_of_patients_achieved_stable_disease._The_median_progression_free_survival_(PFS)_was_3.5_months,_longer_than_the_median_PFS_(2.5_months)_reported_for_metastatic_CRC_treated_with_standard_chemotherapy._The_authors_conclude_that_MAPK_targeting_in_CRC_is_a_valid_approach_that_can_produce_meaningful_responses_but_additional_work_is_required_to_more_effectively_inhibit_the_pathway.",26392102,PubMed,,"Corcoran_et_al.,_2015,_J._Clin._Oncol.",,2,accepted,1415,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-06-28_20:12:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1415,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Dabrafenib,Trametinib,,,,,,
BRAF,673,V600,Skin_Melanoma,8923,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,A,Sensitivity/Response,"The_Combi-v_(NCT01597908)_open-label,_randomized_phase_3_trial_had_704_patients_with_metastatic_melanoma_with_a_BRAF_V600_mutation._Patients_were_randomized_to_receive_either_a_combination_of_dabrafenib_and_trametinib_or_vemurafenib_orally_as_first-line_therapy._At_preplanned_interim_analysis_the_overall_survival_rate_at_12_months_was_72%_(95%_confidence_interval_[CI],_67_to_77)_in_the_combination-therapy_group_and_65%_(95%_CI,_59_to_70)_in_the_vemurafenib_group_(hazard_ratio_for_death_in_the_combination-therapy_group,_0.69;_95%_CI,_0.53_to_0.89;_P=0.005)._Median_progression-free_survival_was_11.4_months_in_the_combination-therapy_group_and_7.3_months_in_the_vemurafenib_group_(hazard_ratio,_0.56;_95%_CI,_0.46_to_0.69;_P<0.001)._Cutaneous_squamous-cell_carcinoma_and_keratoacanthoma_occurred_at_1%_with_combination-therapy_and_18%_in_the_vemurafenib_group.",25399551,PubMed,,"Robert_et_al.,_2015,_N._Engl._J._Med.",NCT01597908,5,accepted,1411,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-11-01_14:55:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1411,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Trametinib,Dabrafenib,,,,,,
BRAF,673,V600,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,B,Resistance,"In_metastatic_colorectal_cancer_patients_with_wildtype_KRAS,_BRAF_mutations_were_associated_with_poor_progression_free_survival_regardless_of_treatment_(panitumumab_with_best_supportive_care_or_best_supportive_care_alone).",23325582,PubMed,,"Peeters_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,88,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/88,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Panitumumab,,,,,,,
BRAF,673,V600,Melanoma,1909,,BAY_86-9766,,Predictive,Supports,C,Resistance,Phase_I_trial_of_the_mitogen-activated_protein_kinase_1/2_inhibitor_BAY_86-9766._2_of_2_patients_with_BRAF_mutant_melanoma_had_moderate_progressive_disease_(despite_receiving_the_highest_doses_administered_in_the_study).,23434733,PubMed,,"Weekes_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1000,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1000,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,BAY_86-9766,,,,,,,
BRAF,673,V600,Colorectal_Cancer,9256,,"Cetuximab,Vemurafenib",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"Patients_with_BRAF-V600_mutated_cancers_were_identified_(n=122)_and_subsequently_underwent_targeted_therapy._27_patients_with_colorectal_cancer_were_treated_with_vemurafenib_and_cetuximab_(N=24_with_BRAF_V600E_mutation,_N=3_with_V600_unknown_status)._One_response_was_observed;_however,_approximately_half_the_patients_had_tumor_regression_that_did_not_meet_the_standard_criteria_for_a_partial_response._Median_progression-free_survival_and_overall_survival_for_patients_receiving_combination_therapy_were_3.7_months_(95%_CI,_1.8_to_5.1)_and_7.1_months_(95%_CI,_4.4_to_not_reached),_respectively._Patients_were_heavily_pretreated,_with_a_median_of_two_lines_of_previous_therapy_(range,_one_to_six).",26287849,PubMed,,"Hyman_et_al.,_2015,_N._Engl._J._Med.",,2,accepted,1598,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-09-11_13:14:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1598,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Cetuximab,Vemurafenib,,,,,,
BRAF,673,V600,Colorectal_Cancer,9256,,"Cetuximab,Alpelisib,Encorafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_Phase_Ib_Dose-Escalation_Study_of_Encorafenib,_Cetuximab_and_Alpelisib,_Twenty-eight_patients_with_refractory_BRAFV600_mutant_metastatic_CRC_(mCRC)_were_treated_with_a_selective_RAF_kinase_inhibitor_(encorafenib)_plus_a_monoclonal_antibody_targeting_EGFR_(cetuximab)_with_a_PI3Kα_inhibitor_(alpelisib).__Confirmed_overall_response_rates_of_18%_were_observed_and_median_progression-free_survival_was_4.2_months",28363909,PubMed,,"van_Geel_et_al.,_2017,_Cancer_Discov",,3,accepted,6047,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-07-06_14:02:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/6047,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Cetuximab,Alpelisib,Encorafenib,,,,,
BRAF,673,V600,Melanoma,1909,Brain_neoplasm,Dabrafenib,,Predictive,Supports,B,Sensitivity/Response,"In_the_NCT00880321_trial_using_mutant_BRAF_inhibitor_dabrafenib_in_solid_tumors,_10_cases_of_melanoma_brain_metastases_were_assessed_for_dabrafenib_response._In_nine_patients_a_decrease_in_size_of_metastases_was_seen,_and_in_four_cases_a_complete_resolution_of_brain_lesions_was_observed._This_subset_of_patients_had_median_progression_free_survival_of_4.2_months.",22608338,PubMed,,"Falchook_et_al.,_2012,_Lancet",,4,accepted,1407,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-06-27_15:47:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1407,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Dabrafenib,,,,,,,
BRAF,673,V600,Langerhans-Cell_Histiocytosis,2571,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_BRAF-V600_mutated_cancers_were_identified_(n=122)_and_clinical_response_to_vemurafenib_was_evaluated.__Of_the_14_patients_with_Langerhans’-cell_histiocytosis,_43%_of_patients_had_a_response_to_vemurafenib_(1_complete_and_5_partial_responses),_disease_regression_was_observed_in_12/14_patients,_all_patients_detailed_improvement_in_disease-related_symptoms,_0_patients_had_progressive_disease_during_treatment,_12-month_progression_free_survival_was_91%,_and_overall_survival_rate_was_100%._Among_all_18_patients_with_Erdheim-Chester_disease_or_Langerhans_histiocytosis,_94%_had_BRAF_V600E_mutations_and_the_remaining_6_percent_(1_patient)_had_an_unknown_V600_mutation.",26287849,PubMed,,"Hyman_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,1575,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-08-22_22:35:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1575,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Vemurafenib,,,,,,,
BRAF,673,V600,Colorectal_Cancer,9256,,"Encorafenib,Cetuximab",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_Phase_Ib_Dose-Escalation_Study_of_Encorafenib_and_Cetuximab,_Twenty-six_patients_with_refractory_BRAF_V600_mutant_metastatic_CRC_(mCRC)_were_treated_with_a_selective_RAF_kinase_inhibitor_(encorafenib)_plus_a_monoclonal_antibody_targeting_EGFR_(cetuximab).__Confirmed_overall_response_rates_of_19%_were_observed_and_median_progression-free_survival_was_3.7_months.",28363909,PubMed,,"van_Geel_et_al.,_2017,_Cancer_Discov",,4,accepted,6046,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-07-06_14:00:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/6046,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Encorafenib,Cetuximab,,,,,,
BRAF,673,V600,Colorectal_Cancer,9256,,Vemurafenib,,Predictive,Supports,B,Resistance,"Patients_with_BRAF-V600_mutated_cancers_were_identified_(n=122)_and_clinical_response_to_vemurafenib_was_evaluated.__Of_the_10_patients_with_colorectal_cancer_(80%_BRAF_V600E,_20%_V600_unknown_status),_no_responses_were_observed_and_overall_survival_was_9.3_months_with_a_median_progression-free_survival_of_4.5_months.",26287849,PubMed,,"Hyman_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,1576,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2016-08-22_22:33:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1576,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Vemurafenib,,,,,,,
BRAF,673,V600,Melanoma,1909,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,B,Sensitivity/Response,"This_was_a_Phase_I_and_II_study_(NCT01072175)_of_dabrafenib_and_trametinib_combination_therapy_vs._dabrafenib_monotherapy_in_patients_with_metastatic_melanoma.____Cutaneous_squamous-cell_carcinoma_was_seen_in_7%_of_patients_receiving_combination_therapy_in_contrast_to_19%_in_those_receiving_monotherapy_(P_=_0.09).__Of_162_patients_with_V600E_or_V600K_mutation,_108_were_given_combination_therapy_and_54_monotherapy.__After_1_year,_41%_of_patients_in_the_combination_group_were_alive_and_progression_free_whereas_this_was_9%_in_the_monotherapy_group_(P<0.001).___Median_progression-free_survival_was_9.4_months_with_combination_and_5.8_months_with_monotherapy._Hazard_ratio_for_progression_or_death_was_0.39_(95%_CI,_0.25_to_0.62;_P<0.001).",23020132,PubMed,,"Flaherty_et_al.,_2012,_N._Engl._J._Med.",,3,accepted,93,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-11-08_17:21:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/93,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Dabrafenib,Trametinib,,,,,,
BRAF,673,V600,Melanoma,1909,,"Vemurafenib,Cobimetinib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_randomized_phase_3_study,_previously_untreated_advanced_or_metastatic_BRAF_V600_mutation-positive_melanoma_patients_treated_with_combination_vemurafenib_and_cobimetinib_showed_improved_progression_free_survival_(9.9_vs_6.2_months),_increased_rate_of_complete_or_partial_response_(68%_vs_45%),_and_improved_overall_survival_at_9_months_(_81%_vs_73%)_compared_to_the_vemurafenib_and_placebo_control_group.",25265494,PubMed,,"Larkin_et_al.,_2014,_N._Engl._J._Med.",,4,accepted,1422,5,7,140453136,140453137,,,ENST00000288602.6,,,,,75,GRCh37,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Somatic_Mutation,2018-11-01_18:31:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1422,https://civic.genome.wustl.edu/links/variants/17,https://civic.genome.wustl.edu/links/genes/5,"BRAF_mutations_of_the_valine_600_residue_have_been_shown_to_be_recurrent_in_many_cancer_types._Of_the_V600_mutations,_V600E_is_the_most_widely_researched._V600_mutations_as_a_whole_have_been_correlated_to_poorer_prognosis_in_colorectal_and_papilarry_thyroid_cancers._V600_mutations_have_also_been_shown_to_confer_sensitivity_to_the_BRAF_inhibitor_dabrafenib._For_a_more_detailed_summary,_click_the_individual_mutations.",Other_V600's,protein_altering_variant,,405,Vemurafenib,Cobimetinib,,,,,,
CCND1,595,AMPLIFICATION,Ovarian_Cancer,2394,,Palbociclib_(PD0332991),,Predictive,Does_Not_Support,D,Sensitivity/Response,A_panel_of_40_ovarian_cancer_cell_lines_with_varied_mutation_profiles_was_assayed_for_sensitivity_to_the_cdk4/6_inhibitor_palbociclib_(PD0332991)_via_measurement_of_IC50_values_for_inhibition_of_proliferation._Large_variation_in_palbociclib_sensitivity_was_observed_and_cell_lines_(N=40)_were_classified_as_above_(resistant)_or_below_(sensitive)_the_mean_log_of_all_IC50_values._6/18_(33%)_of_the_resistant_lines_and_in_only_1/22_(5%)_of_the_sensitive_lines_(P_=_0.017)_had_CCND1_copy_number_gain._Increased_CCND1_expression_was_not_correlated_with_sensitivity_to_palbociclib_(p=0.671).,21278246,PubMed,,"Konecny_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,1599,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,Somatic_Mutation,2016-11-07_18:53:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1599,https://civic.genome.wustl.edu/links/variants/18,https://civic.genome.wustl.edu/links/genes/8,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,,transcript_amplification,,47,Palbociclib_(PD0332991),,,,,,,
CCND1,595,AMPLIFICATION,Renal_Cell_Carcinoma,4450,,Palbociclib_(PD0332991),,Predictive,Does_Not_Support,D,Sensitivity/Response,"28_renal_cell_carcinoma_cell_lines_were_tested_for_sensitivity_to_CDK4/6_inhibitor_Palbociclib_(PD0332991)._19_were_reported_sensitive,_and_9_resistant._15_of_the_28_cell_lines_had_high_levels_of_Cyclin_D1_(CCND1)_expression_which_did_not_correlate_significantly_with_palbociclib_sensitivity_(p=0.348).",23898052,PubMed,,"Logan_et_al.,_2013,_Anticancer_Res.",,2,accepted,1560,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,Somatic_Mutation,2016-10-11_17:32:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/1560,https://civic.genome.wustl.edu/links/variants/18,https://civic.genome.wustl.edu/links/genes/8,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,,transcript_amplification,,47,Palbociclib_(PD0332991),,,,,,,
CCND1,595,AMPLIFICATION,Skin_Melanoma,8923,,"Carboplatin,Paclitaxel,Sorafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Retrospective_analysis_of_somatic_mutations_and_copy_number_changes_in_119_patient_treated_with_carboplatin,_paclitaxel,_±_sorafenib_(CPS)_in_the_E2603_trial._CPS_therapy_was_associated_with_improved_progression-free_survival_(PFS)_compared_with_CP_in_patients_with_tumors_with_CCND1_gene_copy_gains_(HR,_0.45;_P_=_0.035).",26307133,PubMed,,"Wilson_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1495,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,Somatic_Mutation,2016-07-06_05:05:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/1495,https://civic.genome.wustl.edu/links/variants/18,https://civic.genome.wustl.edu/links/genes/8,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,,transcript_amplification,,47,Carboplatin,Paclitaxel,Sorafenib,,,,,
CCND1,595,AMPLIFICATION,Breast_Cancer,1612,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"A_panel_of_47_breast_cancer_cell_lines_was_tested_for_sensitivty/resistance_to_CDK4/6_inhibitor_Palbociclib_(PD0332991),__where_IC50_below_150nM_was_sensitive,_and_above_1000nM_resistant._Cyclin_D1_had_higher_expression_levels_in_sensitive_cell_lines.",19874578,PubMed,,"Finn_et_al.,_2009,_Breast_Cancer_Res.",,2,accepted,1562,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,Somatic_Mutation,2016-11-07_18:54:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1562,https://civic.genome.wustl.edu/links/variants/18,https://civic.genome.wustl.edu/links/genes/8,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,,transcript_amplification,,47,Palbociclib_(PD0332991),,,,,,,
CCND1,595,AMPLIFICATION,Breast_Cancer,1612,,Tamoxifen,,Predictive,Does_Not_Support,B,Resistance,"In_this_retrospective_analysis,_CCND1_amplification_was_analyzed_in_442_patients._No_interaction_with_treatment_was_observed.",24367492,PubMed,,"Keilty_et_al.,_2013,_PLoS_ONE",,3,accepted,858,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,Somatic_Mutation,2016-02-10_16:39:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/858,https://civic.genome.wustl.edu/links/variants/18,https://civic.genome.wustl.edu/links/genes/8,CCND1_amplification_has_been_implicated_in_poorer_prognosis_in_non-small_cell_lung_cancer.,,transcript_amplification,,47,Tamoxifen,,,,,,,
CCND1,595,OVEREXPRESSION,Mantle_Cell_Lymphoma,50746,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"In_Mantle_Cell_Lymphoma_(MCL),_t(11:14)-induced_overexpression_of_cyclin_D1_was_targeted_by_CDK4/6_inhibitor_Palbociclib_(PD0332991)._Palbociclib_caused_Rb_dephosphorylation_in_MCL_cell_lines_and_patient_derived_tumor_cells._MCL_cell_lines_overexpressing_cyclin_D1_showed_growth_inhibition_with_Palbociclib._The_VAL_DLBCL_cell_line_was_used_as_control_to_verify_cyclin_D1_overexpression_but_was_not_used_as_a_control_in_Palbociclib_inhibitor_experiments._Instead,_the_investigators_report_that_other_publications_report_cell_lines_without_cyclin_D1_overexpression_had_higher_IC50_values_for_palbociclib,_suggesting_overexpresssed_cyclin_D1_targetability_in_MCL.",16690963,PubMed,,"Marzec_et_al.,_2006,_Blood",,1,accepted,1563,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_misregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._While_Cyclin_D2_has_only_been_found_to_be_significantly_misregulated_in_glioma,_Cyclin_D1_in_particular_seems_to_be_a_pan-cancer_actor._Cyclin_D_misregulation_has_been_shown_to_lead_to_poorer_outcomes_in_a_number_of_studies,_and_currently_there_are_no_FDA-approved_targeted_therapies.",Somatic_Mutation,2017-04-21_18:58:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1563,https://civic.genome.wustl.edu/links/variants/20,https://civic.genome.wustl.edu/links/genes/8,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_misregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._While_Cyclin_D2_has_only_been_found_to_be_significantly_misregulated_in_glioma,_Cyclin_D1_in_particular_seems_to_be_a_pan-cancer_actor._Cyclin_D_misregulation_has_been_shown_to_lead_to_poorer_outcomes_in_a_number_of_studies,_and_currently_there_are_no_FDA-approved_targeted_therapies.",,,,106,Palbociclib_(PD0332991),,,,,,,
CCND1,595,OVEREXPRESSION,Estrogen-receptor_Positive_Breast_Cancer,60075,,Tamoxifen,,Predictive,Supports,B,Resistance,The_authors_performed_a_tissue_microarray_analysis_of_167_postmenopausal_breast_cancers_that_had_been_randomized_to_treatment_with_or_without_tamoxifen.__ER_+ve_patients_with_high_CCND1_tumor_expression_did_not_show_any_difference_in_survival_between_tamoxifen_and_no_treatment.,15138475,PubMed,,"Stendahl_et_al.,_2004,_Br._J._Cancer",,3,accepted,856,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_misregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._While_Cyclin_D2_has_only_been_found_to_be_significantly_misregulated_in_glioma,_Cyclin_D1_in_particular_seems_to_be_a_pan-cancer_actor._Cyclin_D_misregulation_has_been_shown_to_lead_to_poorer_outcomes_in_a_number_of_studies,_and_currently_there_are_no_FDA-approved_targeted_therapies.",,2016-02-18_18:33:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/856,https://civic.genome.wustl.edu/links/variants/20,https://civic.genome.wustl.edu/links/genes/8,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_misregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._While_Cyclin_D2_has_only_been_found_to_be_significantly_misregulated_in_glioma,_Cyclin_D1_in_particular_seems_to_be_a_pan-cancer_actor._Cyclin_D_misregulation_has_been_shown_to_lead_to_poorer_outcomes_in_a_number_of_studies,_and_currently_there_are_no_FDA-approved_targeted_therapies.",,,,106,Tamoxifen,,,,,,,
CCND1,595,OVEREXPRESSION,Mantle_Cell_Lymphoma,50746,,Palbociclib_(PD0332991),,Predictive,Does_Not_Support,B,Sensitivity/Response,"A_pharmacodynamic_study_(NCT00420056)_of_17_mantle_cell_lymphoma_MCL_patients_was_performed_using_the_CDK4/6_inhibitor_palbociclib_(PD0332991)._Patients_were_verified_by_IHC,_FISH_or_molecular_testing_for_the_t(11:14)_rearrangement__causing_Cyclin_D_overexpression_in_MCL._1_patient_demonstrated_complete_response,_and_2_showed_partial_response_for_an_18%_overall_response_rate._7_patients_showed_stable_disease._Patient_population_was_heavily_pretreated.",22383795,PubMed,,"Leonard_et_al.,_2012,_Blood",,2,accepted,1536,8,11,69455855,69469242,,,ENST00000227507.2,,,,,75,GRCh37,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_misregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._While_Cyclin_D2_has_only_been_found_to_be_significantly_misregulated_in_glioma,_Cyclin_D1_in_particular_seems_to_be_a_pan-cancer_actor._Cyclin_D_misregulation_has_been_shown_to_lead_to_poorer_outcomes_in_a_number_of_studies,_and_currently_there_are_no_FDA-approved_targeted_therapies.",Somatic_Mutation,2017-04-21_18:58:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1536,https://civic.genome.wustl.edu/links/variants/20,https://civic.genome.wustl.edu/links/genes/8,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_misregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._While_Cyclin_D2_has_only_been_found_to_be_significantly_misregulated_in_glioma,_Cyclin_D1_in_particular_seems_to_be_a_pan-cancer_actor._Cyclin_D_misregulation_has_been_shown_to_lead_to_poorer_outcomes_in_a_number_of_studies,_and_currently_there_are_no_FDA-approved_targeted_therapies.",,,,106,Palbociclib_(PD0332991),,,,,,,
CCND3,896,LOSS,T-cell_Leukemia,715,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,Treatment_of_Notch-driven_T-cell_leukemia_in_Ccnd3_knockout_mice_with_Palbociclib_(PD-0332991)_significantly_increased_median_survival.,23079656,PubMed,,"Sawai_et_al.,_2012,_Cancer_Cell",,3,accepted,263,10,6,41902671,41909586,,,ENST00000372991.4,,,,,75,GRCh37,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_deregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._Cyclin_D3_loss_has_been_reported_in_T-cell_acute_lymphoblastic_leukemia_(T-ALL),_a_seemingly_unique_trend_when_compared_to_the_amplifcations_and_overexpressions_of_the_other_cyclin_D's._Treating_cyclin_D3_knockout_mice_with_the_targeted_therapeutic_palbociclib_significantly_increased_the_median_survival_of_a_Notch-driven_model_of_T-ALL.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/263,https://civic.genome.wustl.edu/links/variants/23,https://civic.genome.wustl.edu/links/genes/10,"Cyclin_D_has_been_shown_in_many_cancer_types_to_be_misregulated._Well_established_for_their_oncogenic_properties,_the_cyclins_and_the_cyclin-dependent_kinases_(CDK's)_they_activate_have_been_the_focus_of_major_research_and_development_efforts_over_the_past_decade._The_methods_by_which_the_cyclins_are_deregulated_are_widely_variable,_and_range_from_genomic_amplification_to_promoter_methylation_changes._Cyclin_D3_loss_has_been_reported_in_T-cell_acute_lymphoblastic_leukemia_(T-ALL),_a_seemingly_unique_trend_when_compared_to_the_amplifcations_and_overexpressions_of_the_other_cyclin_D's._Treating_cyclin_D3_knockout_mice_with_the_targeted_therapeutic_palbociclib_significantly_increased_the_median_survival_of_a_Notch-driven_model_of_T-ALL.",,loss_of_function_variant,,3,Palbociclib_(PD0332991),,,,,,,
CCNE1,898,OVEREXPRESSION,Ovarian_Cancer,2394,,BMS-387032_(SNS-032),,Predictive,Supports,D,Sensitivity/Response,Four_ovarian_cancer_cell_lines_with_elevated_CCNE1_expression_were_40x_more_sensitive_to_Cdk2_inhibitor_SNS-032_than_four_cell_lines_without_CCNE1_overexpression._SNS-032_greatly_prolonged_the_survival_of_mice_with_CCNE1_overexpressing_xenografts.,26204491,PubMed,,"Yang_et_al.,_2015,_Oncotarget",,2,accepted,1734,11,19,30302805,30315215,,,ENST00000262643.3,,,,,75,GRCh37,"Cyclin_E,_while_currenly_not_as_widely_implicated_as_its_counterpart,_cyclin_D,_has_been_implicated_in_various_carcinomas,_including_breast,_gastric,_stomach_and_colorectal._High_levels_of_cyclin_E,_either_by_gene_amplification_or_overexpression,_are_correlated_with_later_stage_disease_and_have_been_shown_to_lead_to_poorer_prognosis_in_gastic_carcinoma._It_has_also_been_shown,_in_lung_cancer_specifically,_that_neoplastic_cells_with_higher_levels_of_the_cyclin_E/CDK2_complex_are_more_radiosensitive_than_their_lowly_expressed_counterparts.",,2016-11-12_15:50:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1734,https://civic.genome.wustl.edu/links/variants/24,https://civic.genome.wustl.edu/links/genes/11,"Cyclin_E,_while_currenly_not_as_widely_implicated_as_its_counterpart,_cyclin_D,_has_been_implicated_in_various_carcinomas,_including_breast,_gastric,_stomach_and_colorectal._High_levels_of_cyclin_E,_either_by_gene_amplification_or_overexpression,_are_correlated_with_later_stage_disease_and_have_been_shown_to_lead_to_poorer_prognosis_in_gastic_carcinoma._It_has_also_been_shown,_in_lung_cancer_specifically,_that_neoplastic_cells_with_higher_levels_of_the_cyclin_E/CDK2_complex_are_more_radiosensitive_than_their_lowly_expressed_counterparts.",,,,62,BMS-387032_(SNS-032),,,,,,,
CDK4,1019,EXPRESSION,Estrogen-receptor_Positive_Breast_Cancer,60075,,BYL719_(Alpelisib),,Predictive,Supports,D,Sensitivity/Response,"In_mouse_xenograft_studies_of_PIK3CA_mutant_breast_cancers,_the_combination_of_PI3K_and_CDK4/6_inhibitors_overcomes_intrinsic_and_adaptive_resistance_leading_to_tumor_regressions.",25002028,PubMed,,"Vora_et_al.,_2014,_Cancer_Cell",,4,accepted,264,13,12,58141510,58146304,,,ENST00000257904.6,,,,,75,GRCh37,"CDK4,_along_with_its_partner_CDK6,_are_key_players_in_cell_cycle_progression._The_complex_has_been_implicated_in_a_number_of_cancer_types,_and_is_the_focus_of_therapeutic_research_and_development._One_targeted_therapy_for_CDK_inhibition_is_palbociclib,_which_may_slow_the_growth_of_advanced_stage_breast_cancers._It_has_also_been_shown,_in_mouse,_that_CDK_inhibition_may_sensitize_mutant_PIK3CA_tumors_to_PI3K_inhibitors.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/264,https://civic.genome.wustl.edu/links/variants/25,https://civic.genome.wustl.edu/links/genes/13,"CDK4,_along_with_its_partner_CDK6,_are_key_players_in_cell_cycle_progression._The_complex_has_been_implicated_in_a_number_of_cancer_types,_and_is_the_focus_of_therapeutic_research_and_development._One_targeted_therapy_for_CDK_inhibition_is_palbociclib,_which_may_slow_the_growth_of_advanced_stage_breast_cancers._It_has_also_been_shown,_in_mouse,_that_CDK_inhibition_may_sensitize_mutant_PIK3CA_tumors_to_PI3K_inhibitors.",,,,8,BYL719_(Alpelisib),,,,,,,
CDK4,1019,EXPRESSION,Sarcoma,1115,,Palbociclib,,Predictive,Supports,D,Sensitivity/Response,"A_preclinical_study_to_explore_the_efficacy_of_CDK4/6_inhibition_with_palbociclib,_in_a_panel_of_sarcoma_cell_lines_and_sarcoma_tumor_xenografts_(PDXs)._The_responsiveness_of_these_cell_lines_correlated_with_their_levels_of_CDK4_mRNA_as_well_as_in_vivo_PDX,_but_not_against_sarcomas_displaying_low_levels_of_CDK4_and_high_levels_of_p16ink4a_(CDKN2A).",26528855,PubMed,,"Perez_et_al.,_2015,_Oncotarget",,4,accepted,4872,13,12,58141510,58146304,,,ENST00000257904.6,,,,,75,GRCh37,"CDK4,_along_with_its_partner_CDK6,_are_key_players_in_cell_cycle_progression._The_complex_has_been_implicated_in_a_number_of_cancer_types,_and_is_the_focus_of_therapeutic_research_and_development._One_targeted_therapy_for_CDK_inhibition_is_palbociclib,_which_may_slow_the_growth_of_advanced_stage_breast_cancers._It_has_also_been_shown,_in_mouse,_that_CDK_inhibition_may_sensitize_mutant_PIK3CA_tumors_to_PI3K_inhibitors.",,2017-07-27_14:50:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/4872,https://civic.genome.wustl.edu/links/variants/25,https://civic.genome.wustl.edu/links/genes/13,"CDK4,_along_with_its_partner_CDK6,_are_key_players_in_cell_cycle_progression._The_complex_has_been_implicated_in_a_number_of_cancer_types,_and_is_the_focus_of_therapeutic_research_and_development._One_targeted_therapy_for_CDK_inhibition_is_palbociclib,_which_may_slow_the_growth_of_advanced_stage_breast_cancers._It_has_also_been_shown,_in_mouse,_that_CDK_inhibition_may_sensitize_mutant_PIK3CA_tumors_to_PI3K_inhibitors.",,,,8,Palbociclib,,,,,,,
CEBPA,1050,N-TERMINAL_FRAME_SHIFT,Acute_Myeloid_Leukemia,9119,,OICR-9429,,Predictive,Supports,D,Sensitivity/Response,"This_preclinical_study_establishes_that_the_p30_isoform_of_CEBPA_expressed_as_a_result_of_N-terminal_truncating_mutations_preferentially_interacts_with_WRD5,_a_component_of_the_SET/MLL_complex._Knockdown_of_WRD5_in_32D_cells_(mouse_hematopoietic_cell_line)_or_transplanted_primary_mouse_bone_marrow_expressing_the_p30_isoform_restored_myeloid_differentiation_in_these_cells._OICR-9429,_a_small_molecule_inhibitor_of_WRD5,_and_anti-WRD5_siRNAs_selectively_inhibited_colony_formation_of_mouse_fetal_liver_cells_homozygous_for_N-terminal_CEBPA_mutations_but_not_wildtype_colony_formation._Finally,_OICR-9429_reduced_viability_of_primary_human_AML_blasts_harboring_N-terminal_domain_CEBPA_mutations_in_culture_but_not_AML_blasts_with_other_mutations._Taken_together,_WRD5_inhibition_is_a_potential_therapeutic_method_for_patients_harboring_N-terminal_CEBPA_mutations.",26167872,PubMed,,"Grebien_et_al.,_2015,_Nat._Chem._Biol.",,3,accepted,1103,15,19,33792961,33793470,,,ENST00000498907.2,,,,,75,GRCh37,"CEBPA_N-terminal_frame_shift_mutations_that_result_in_a_premature_stop_codon_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)._CEBPA_mutations_are_associated_with_a_favorable_prognosis;_however,_NPM1_and_FLT3_mutations_should_also_be_assessed_in_CN-AML_patients_as_concurrent_mutations_may_have_prognostic_implications._N-terminal_frame_shift_mutations_within_amino_acids_1-120_have_been_shown_to_disrupt_expression_of_the_full-length_42kDa_isoform_while_maintaining_expression_of_a_30kDa_isoform_(translated_from_the_AUG_at_full-length_protein_isoform_amino_acid_M120)._This_30kDa_isoform_exhibits_dominant_negative_activity.",Somatic_Mutation,2016-02-24_21:16:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1103,https://civic.genome.wustl.edu/links/variants/28,https://civic.genome.wustl.edu/links/genes/15,"CEBPA_N-terminal_frame_shift_mutations_that_result_in_a_premature_stop_codon_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)._CEBPA_mutations_are_associated_with_a_favorable_prognosis;_however,_NPM1_and_FLT3_mutations_should_also_be_assessed_in_CN-AML_patients_as_concurrent_mutations_may_have_prognostic_implications._N-terminal_frame_shift_mutations_within_amino_acids_1-120_have_been_shown_to_disrupt_expression_of_the_full-length_42kDa_isoform_while_maintaining_expression_of_a_30kDa_isoform_(translated_from_the_AUG_at_full-length_protein_isoform_amino_acid_M120)._This_30kDa_isoform_exhibits_dominant_negative_activity.",,"dominant_negative_variant,frameshift_truncation",,3,OICR-9429,,,,,,,
CEBPA,1050,MUTATION,Acute_Myeloid_Leukemia,9119,,All-trans_Retinoic_Acid,,Predictive,Does_Not_Support,B,Sensitivity/Response,In_a_randomized_trial_of_previously_untreated_younger_(<60)_patients_with_acute_myeloid_leukemia_(excluding_acute_promyelocytic_leukemia)_and_high-risk_myelodysplastic_syndrome_CEBPA_mutation_status_had_no_significant_impact_on_patient_response_to_ATRA_(N=20)_compared_to_randomized_control_(N=15).,19965647,PubMed,,"Burnett_et_al.,_2010,_Blood",,3,accepted,122,15,19,33790840,33793470,,,ENST00000498907.2,,,,,75,GRCh37,"CEBPA_mutations_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)_and_a_favorable_prognosis._However,_NPM1_and_FLT3_mutations_should_also_be_assessed_in_CN-AML_patients_as_concurrent_mutations_may_have_prognostic_implications.",Somatic_Mutation,2016-02-25_20:53:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/122,https://civic.genome.wustl.edu/links/variants/29,https://civic.genome.wustl.edu/links/genes/15,"CEBPA_mutations_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)_and_a_favorable_prognosis._However,_NPM1_and_FLT3_mutations_should_also_be_assessed_in_CN-AML_patients_as_concurrent_mutations_may_have_prognostic_implications.",,"loss_of_function_variant,transcript_variant",,105,All-trans_Retinoic_Acid,,,,,,,
CSF1R,1436,MEF2D-CSF1R,Acute_Lymphocytic_Leukemia,9952,,"Imatinib,GW-2580",Substitutes,Predictive,Supports,D,Sensitivity/Response,Cell_lines_with_MEF2D-CSF1R_fusion_show_sensitivity_to_the_tyrosine_kinase_inhibitors_Imatinib_and_GW-2580.,24186003,PubMed,,"Lilljebjörn_et_al.,_2014,_Leukemia",,3,accepted,403,33,1,156446804,156470620,,,ENST00000348159.4,5,149433787,149441412,ENST00000286301.3,75,GRCh37,"MEF2D-CSF1R_is_a_fusion_that_has_been_observed_in_acute_lymphocytic_leukemia._In_cell_lines_harboring_this_event,_treatment_with_imatinib_has_shown_notable_sensitivity.",Somatic_Mutation,2017-05-31_15:35:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/403,https://civic.genome.wustl.edu/links/variants/30,https://civic.genome.wustl.edu/links/genes/33,"MEF2D-CSF1R_is_a_fusion_that_has_been_observed_in_acute_lymphocytic_leukemia._In_cell_lines_harboring_this_event,_treatment_with_imatinib_has_shown_notable_sensitivity.",,transcript_fusion,,3,Imatinib,GW-2580,,,,,,
DNMT3A,1788,R882,Acute_Myeloid_Leukemia,9119,,Idarubicin,,Predictive,Supports,B,Sensitivity/Response,Idarubicin_increases_the_overall_survival_and_disease_free_survival_in_de_novo_AML_patients_with_DNMT3A_R882_mutation_compared_to_those_who_do_not_harbor_this_mutation.,22081665,PubMed,,"LaRochelle_et_al.,_2011,_Oncotarget",,4,accepted,18,18,2,25457241,25457243,,,ENST00000264709.3,,,,,75,GRCh37,"DNMT3A_R882_mutations_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)_with_R882H_as_the_most_common_form._Mutations_in_DNMT3A_have_largely_been_associated_with_poorer_prognosis,_however_this_is_not_consistent_across_all_studies._This_may_be_a_result_of_patient_age_or_combining_R882_and_non-R882_mutations_during_analysis_as_studies_have_indicated_independent_mechanisms_of_action_and_differential_prognostic_implications_for_these_mutation_types._One_study_that_independently_analyzed_R882_and_non-R882_mutations_showed_R882_mutations_were_associated_with_poorer_prognosis_than_patients_with_wildtype_and_non-R882_mutations,_but_only_in_older_patients_with_AML.",Somatic_Mutation,2015-06-21_16:49:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/18,https://civic.genome.wustl.edu/links/variants/32,https://civic.genome.wustl.edu/links/genes/18,"DNMT3A_R882_mutations_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)_with_R882H_as_the_most_common_form._Mutations_in_DNMT3A_have_largely_been_associated_with_poorer_prognosis,_however_this_is_not_consistent_across_all_studies._This_may_be_a_result_of_patient_age_or_combining_R882_and_non-R882_mutations_during_analysis_as_studies_have_indicated_independent_mechanisms_of_action_and_differential_prognostic_implications_for_these_mutation_types._One_study_that_independently_analyzed_R882_and_non-R882_mutations_showed_R882_mutations_were_associated_with_poorer_prognosis_than_patients_with_wildtype_and_non-R882_mutations,_but_only_in_older_patients_with_AML.",,missense_variant,,525,Idarubicin,,,,,,,
DNMT3A,1788,R882,Acute_Myeloid_Leukemia,9119,,Daunorubicin,,Predictive,Does_Not_Support,B,Resistance,Daunorubicin_treatment_resulted_in_similar_overall_survival_and_disease_free_survival_in_de_novo_AML_patients_with_DNMT3A_R882_mutation_compared_to_those_who_do_not_harbor_this_mutation.,22081665,PubMed,,"LaRochelle_et_al.,_2011,_Oncotarget",,4,accepted,11,18,2,25457241,25457243,,,ENST00000264709.3,,,,,75,GRCh37,"DNMT3A_R882_mutations_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)_with_R882H_as_the_most_common_form._Mutations_in_DNMT3A_have_largely_been_associated_with_poorer_prognosis,_however_this_is_not_consistent_across_all_studies._This_may_be_a_result_of_patient_age_or_combining_R882_and_non-R882_mutations_during_analysis_as_studies_have_indicated_independent_mechanisms_of_action_and_differential_prognostic_implications_for_these_mutation_types._One_study_that_independently_analyzed_R882_and_non-R882_mutations_showed_R882_mutations_were_associated_with_poorer_prognosis_than_patients_with_wildtype_and_non-R882_mutations,_but_only_in_older_patients_with_AML.",Somatic_Mutation,2015-06-21_16:49:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/11,https://civic.genome.wustl.edu/links/variants/32,https://civic.genome.wustl.edu/links/genes/18,"DNMT3A_R882_mutations_are_associated_with_cytogenetically_normal_acute_myeloid_leukemia_(CN-AML)_with_R882H_as_the_most_common_form._Mutations_in_DNMT3A_have_largely_been_associated_with_poorer_prognosis,_however_this_is_not_consistent_across_all_studies._This_may_be_a_result_of_patient_age_or_combining_R882_and_non-R882_mutations_during_analysis_as_studies_have_indicated_independent_mechanisms_of_action_and_differential_prognostic_implications_for_these_mutation_types._One_study_that_independently_analyzed_R882_and_non-R882_mutations_showed_R882_mutations_were_associated_with_poorer_prognosis_than_patients_with_wildtype_and_non-R882_mutations,_but_only_in_older_patients_with_AML.",,missense_variant,,525,Daunorubicin,,,,,,,
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,PF_00299804,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H322_cells_(wildtype_EGFR)_and_NCI-H3255_cells_(EGFR-L858R),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_irreversible_tyrosine_kinase_inhibitor_(TKI)_drugs._Cells_with_an_EGFR_L858R_mutation_demonstrated_an_improved_response_to_PF_00299804__(IC50:_0.007umol/L_vs._>10umol/L)_compared_to_wildtype_EGFR_cells_or_compared_to_reversible_TKI_drug_gefitinib_(IC50:_0.075umol/L_vs._wild-type_>10umol/L).",18089823,PubMed,,"Engelman_et_al.,_2007,_Cancer_Res.",,,accepted,2627,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/2627,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,PF_00299804,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_Ba/F3_cell_line_expressing_EGFR_L858R_was_associated_with_sensitivity_to_erlotinib_treatment._Sensitivity_was_determined_by_assessing_cell_viability,_AKT_and_ERK_phosphorylation,_and_EGFR_auto-phosphorylation.",27102076,PubMed,,"Konduri_et_al.,_2016,_Cancer_Discov",,,accepted,4291,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/4291,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Cancer,162,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"MCF-7_cells_were_transduced_with_YFP_tagged_EGFR_with_E746_A750delELREA_mutation,_or_YFP_EGFR_wildtype,_and_stained_for_ectopic_YFP_EGFR_and_phospho-Akt_as_a_readout_for_EGFR_pathway_activity._Increased_p-Akt_stain_was_seen_with_ectopic_mutant_EGFR_over_wildtype_cells._Parallel_erlotinib_incubations_of_cells_with_wildtype_EGFR_induced_recompartmentalization_of_ectopic_EGFR_protien_only_at_high_concentration_(10uM)._Addition_of_erlotinib_to_mutant_EGFR_cell_incubations_reduced_p-Akt_signal_and_induced_recompartmentalization_of_ectopic_EGFR_protien_at_considerably_lower_conecntration_(100_nM)_erlotinib.__These_results_indicate_the_EGFR_L858R_variant_as_a_growth_pathway_driver_targetable_by_erlotinib.",17877814,PubMed,,"de_Gunst_et_al.,_2007,_Mol._Cancer",,3,accepted,4265,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-09-08_20:57:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/4265,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H3255_cells_(EGFR-L858R),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_reversible_tyrosine_kinase_inhibitor_drugs._Cells_with_an_EGFR_L858R_mutation_demonstrated_an_improved_response_to_lapatinib_(IC50:_63nM_vs._534nM)_compared_to_wildtype_EGFR_cells.",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,,accepted,2626,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/2626,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Lapatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,"In_a_non-small_cell_lung_cancer_patient_with_an_EGFR_L858R_mutation,_EGFR_L858R_was_reported_to_be_refractory_to_61-day_crizotinib_treatment.",22235099,PubMed,,"Doebele_et_al.,_2012,_Clin._Cancer_Res.",,,accepted,4288,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/4288,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Crizotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,Cells_harboring_L858R_were_sensitive_to_afatinib._This_study_performed_drug_response_assays_using_five_human_NSCLC_cell_lines_with_various_combinations_of_EGFR_mutations._In_order_to_directly_compare_the_sensitivity_of_multiple_EGFR_mutations_to_EGFR-TKIs_the_authors_also_generated_multiple_EGFR_transduced_Ba/F3_stable_cell_lines_and_evaluated_sensitivity_to_EGFR-TKIs_by_MTS_assay.,26515464,PubMed,,"Hirano_et_al.,_2015,_Oncotarget",,2,accepted,968,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/968,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Afatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,"Mutational_profiling_was_performed_on_EGFR_exons_18-24_from_a_group_of_10_retrospectively_chosen_patients_who_had_shown_partial_response_or_clinical_improvement_in_response_to_gefitinib._Of_7_tumors_with_EGFR_mutations,_1_was_L858R._The_patient_was_a_female_former_smoker_who_had_lung_adenocarcinoma_histology,_and_demonstrated_response_for_5_months,_with_overall_survival_8_months.",15329413,PubMed,,"Pao_et_al.,_2004,_Proc._Natl._Acad._Sci._U.S.A.",,1,accepted,2624,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-09-08_20:52:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2624,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Canertinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H3255_cells_(EGFR-L858R),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_irreversible_tyrosine_kinase_inhibitor_(TKI)_drugs._Cells_with_an_EGFR_L858R_mutation_demonstrated_an_improved_response_to_canertinib_(IC50:_1nM_vs._198nM)_compared_to_wildtype_EGFR_cells.",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,,accepted,2631,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/2631,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Canertinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_retrospective_study_of_46_Caucasian,_advanced_lung_adenocarcinoma_patients,_a_patient_harboring_EGFR_L858R_mutation_was_associated_with_resistance_to_erlotinib_treatment;_the_patient_survived_3.9_months,_as_compared_to_the_overall_24_months_median_overall_survival_of_the_other_patients_who_were_not_resistant_to_erlotinib_treatment.",27032107,PubMed,,"De_Grève_et_al.,_2016,_PLoS_ONE",,,accepted,4290,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-09-16_05:19:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/4290,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Does_Not_Support,B,Reduced_Sensitivity,"In_a_Japanese_Phase_III_clinical_trial,_noninferiority_of_Gefitinib_as_compared_to_Erlotinib_was_assessed_in_561_postoperative_recurrent_or_stage_IIIb/VI_patients_who_had_undergone_prior_chemotherapy_treatment_but_no_tyrosine_kinase_inhibitor_therapy._In_a_subset_of_patients_with_sole_EGFR_L858R,_there_was_an_insignificant_difference_between_the_objective_response_and_disease_control_rates_for_patients_treated_with_erlotinib_(N=67)_and_gefitinib_(N=78)._Progression_free_survival_was_also_not_significantly_different_and_did_not_meet_the_noninferiority_endpoint_with_Gefitinib_and_Erlotinib_arms_at_8.1_and_8.5_months,_respectively_(HR,_0.938;_95%_CI,_0.675_to_1.304;_P_=_.704).",27022112,PubMed,,"Urata_et_al.,_2016,_J._Clin._Oncol.",,2,accepted,6183,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-06-04_15:38:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/6183,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Sensitivity/Response,Gefinitib_has_been_shown_to_be_effective_in_treating_cell_lines_with_L858R_missense_mutations.,15118125,PubMed,,"Paez_et_al.,_2004,_Science",,4,accepted,276,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/276,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_II_trial_for_bronchioloalveolar_carcinoma_(BAC,_or_in_situ_pulmonary_adenocarcinoma),_EGFR_exons_18-24_were_analyzed_in_7_patients_who_had_shown_a_partial_response_to_erlotinib._Two_patients_had_the_del_L858R_mutation._One_patient_was_a_male_former_smoker_who_demonstrated_response_for_3_months_with_overall_survival_of_3.5_months,_and_the_other_patient_was_a_female_never_smoker_who_had_response_for_6_months_and_overall_survival_of_17+_months_as_the_patient_was_alive_at_study_end.",15329413,PubMed,,"Pao_et_al.,_2004,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,2632,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-09-08_20:54:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/2632,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Cetuximab,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_Ba/F3_cell_line_expressing_EGFR_L858R_was_associated_with_sensitivity_to_cetuximab_treatment._Sensitivity_was_determined_by_assessing_cell_viability,_AKT_and_ERK_phosphorylation_and_EGFR_auto-phosphorylation.",27102076,PubMed,,"Konduri_et_al.,_2016,_Cancer_Discov",,,accepted,4292,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/4292,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Cetuximab,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_3_clinical_trial_of_non-small_cell_lung_cancer_(NSCLC)_patients,_a_subset_of_patients_with_EGFR_mutations_(n=44)_treated_with_gefitinib_were_associated_with_improved_progression_free_survival_(HR:_0.16,_95%_CI:_0.05-0.49,_P=0.001),_and_a_higher_objective_response_rate_(ORR:_42.1%_vs_21.1%,_p=0.04)_compared_to_patients_treated_with_docetaxel._Of_the_44_patients,_22_had_an_exon_19_deletion,_16_had_an_L858R_mutation,_one_patient_had_an_exon_20_T790M_mutation,_two_had_an_exon_G719A_mutation_and_four_had_other_mutations.",20038723,PubMed,,"Douillard_et_al.,_2010,_J._Clin._Oncol.",,4,accepted,2621,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-10-21_23:33:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/2621,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H3255_cells_(EGFR-L858R),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_reversible_tyrosine_kinase_inhibitor_drugs._Cells_with_an_EGFR_L858R_mutation_demonstrated_an_improved_response_to_erlotinib_(IC50:_40nM_vs._110nM)_compared_to_EGFR_wild_type_cells.",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,,accepted,4284,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/4284,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"90_NSCLC_patients_with_stage_IIIB/IV_chemotherapy-resistant_tumors_were__treated_with_gefitinib,_and_the_L858R_EGFR_mutation_was_associated_with_longer_time_to_treatment_failure_than_those_with_wild-type_EGFR(median_9.1_versus_2.1)._In_multivariate_analysis,_L858R_mutations_plus_adenocarcinoma_was_a_significant_predictive_factor_for_TTF_(HR_=_0.1030;_P_=_.0004).",18509184,PubMed,,"Yang_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,1665,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-09-15_16:46:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1665,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Small_Cell_Carcinoma,5409,,Erlotinib,,Predictive,,D,,"In_an_in_vitro_study_using_NCI-H3255_cells_(EGFR_L858R_mutation),_inhibition_of_EGFR_phosphorylation_was_used_as_an_assay_to_determine_sensitivity_to_EGFR_tyrosine_kinase_inhibitors._NCI-H3255_cells_demonstrated_an_sensitivity_to_erlotinib_(IC50:_8.0-11.0_nmol/L_vs_108.0_nmol/L)_compared_to_NCI-H2073_cells_(EGFR_wild_type).",24893891,PubMed,,"Cross_et_al.,_2014,_Cancer_Discov",,,accepted,4293,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/4293,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,MEDI4736,,Predictive,,D,,"EGFR_L858R_mutation_has_been_associated_with_increased_sensitivity_to_first_generation_EGFR_tyrosine_kinase_inhibitors,_including_erlotinib_and_gefitinib.In_an_in_vitro_study_using_PC9_cells_(EGFR_L858R_mutation),_inhibition_of_EGFR_phosphorylation_was_used_as_an_assay_to_determine_sensitivity_to_EGFR_tyrosine_kinase_inhibitors._PC9_cells_demonstrated_an_increased_sensitivity_to_gefitinib__(IC50:_11.0-12.0_nmol/L_vs_61.0_nmol/L)_compared_to_NCI-H2073_cells_(EGFR_wild_type).",24893891,PubMed,,"Cross_et_al.,_2014,_Cancer_Discov",,,accepted,2633,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/2633,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,MEDI4736,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"A_phase_III_clinical_trial_(NCT00949650)_found_that_median_progression_free_survival_among_patients_with_exon_19_deletions_or_L858R_EGFR_mutations_(n_=_308)_was_13.6_months_for_afatinib_and_6.9_months_for_chemotherapy_(HR,_0.47;_95%_CI,_0.34_to_0.65;_P_=_0.001).",23816960,PubMed,,"Sequist_et_al.,_2013,_J._Clin._Oncol.",,4,accepted,879,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-13_03:54:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/879,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Afatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_study_of_patients_with_lung_adenocarcinoma_(stage_IIIb_with_pleural_effusion_or_stage_IV)_and_EGFR_mutations,_treated_with_afatinib_were_assessed_by_objective_response._129_patients_were_treated_with_afatinib._66%_of_the_106_patients_with_two_common_activating_EGFR_mutations_(deletion_19_or_L858R)_had_an_objective_response_compared_to_39%_of_23_patients_with_less_common_mutations.",22452895,PubMed,,"Yang_et_al.,_2012,_Lancet_Oncol.",,3,accepted,883,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-03_23:36:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/883,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Afatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,B,Sensitivity/Response,"A_randomized_phase_3_trial_(NCT00446225)_involving_173_NSCLC_patients_with_EGFR_mutations_(exon_19_deletion_or_L858R_mutation_in_exon_21)_with_no_history_of_chemotherapy_for_metastatic_disease._Patients_were_randomly_allocated_(1:1)_to_receive_either_erlotinib_or_standard_chemotherapy._The_primary_endpoint_was_progression-free_survival_(PFS)._Median_PFS_was_9.7_months_in_the_erlotinib_group,_compared_with_5.2_months_in_the_standard_chemotherapy_group.",22285168,PubMed,,"Rosell_et_al.,_2012,_Lancet_Oncol.",,3,accepted,885,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-18_18:40:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/885,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_MCF-7_cell_line_expressing_EGFR_L858R_mutation_demonstrated_sensitivity_to_erlotinib_treatment,_compared_to_MCF-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_YFP_signal-EGFR_relocation.",21132006,PubMed,,"Harada_et_al.,_2011,_Oncogene",,,accepted,4285,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4285,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_Ba/F3_and_NCI-H3255_cell_lines_expressing_EGFR_L858R_demonstrated_increased_sensitivity_to_erlotinib_treatment_(IC50=0.006�M)._Sensitivity_was_determined_by_assessing_cell_proliferation,_EGFR,_AKT_and_ERK_phosphorylation,_levels_of_BIM_(a_marker_of_EGFR_TKI-induced_cell_killing)_and_cell_viability.",24353160,PubMed,,"Yasuda_et_al.,_2013,_Sci_Transl_Med",,,accepted,4286,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/4286,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,There_is_no_statistical_difference_in_progression_free_survival_between_lung_cancer_patients_treated_with_gefitinib_or_erlotinib_with_EGFR_L858R_mutations_(N=72/242;_univariate:_P=0.283;_multivariate:_P=0.250)_compared_to_patients_with_Exon_19_mutations_(N=170).,24736073,PubMed,,"Lim_et_al.,_2014,_J_Thorac_Oncol",,3,accepted,229,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-24_00:12:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/229,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,Erlotinib,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,Afatinib_is_an_irreversible_covalent_inhibitor_of_EGFR_(second_generation)._This_Phase_III_clinical_trial_(LUX-Lung_6;_NCT01121393)_was_performed_in_Asian_patients_with_EGFR_mutant_advanced_NSCLC._364_eligible_patients_with_EGFR_mutations_were_assigned_to_afatinib_(n=242)_or_gemcitabine_and_cisplatin_(n=122)_treatment._The_trial_observed_significantly_longer_median_progression-free_survival_with_afatinib_vs._gemcitabine_and_cisplatin_treatment_(11.0_vs._5.6_months)._Afatinib/Chemotherapy_group_compositions:_51.2/50.8_%_del_19;_38/37.7_%_Leu858Arg;_10.8/11.5_%_Uncommon.,24439929,PubMed,,"Wu_et_al.,_2014,_Lancet_Oncol.",,4,accepted,982,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-13_05:52:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/982,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Afatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,A,Sensitivity/Response,"On_May_14,_2013,_the_U.S._Food_and_Drug_Administration_approved_erlotinib_(Tarceva)_for_the_first-line_treatment_of_patients_with_metastatic_non-small_cell_lung_cancer_(NSCLC)_whose_tumors_have_epidermal_growth_factor_receptor_(EGFR)_exon_19_deletions_or_exon_21_(L858R)_substitution_mutations.",24868098,PubMed,,"Khozin_et_al.,_2014,_Oncologist",,5,accepted,2994,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-05-18_20:18:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2994,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H3255_cells_(EGFR-L858R),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_irreversible_tyrosine_kinase_inhibitor_(TKI)_drugs._Cells_with_an_EGFR_L858R_mutation_demonstrated_an_improved_response_to_afatinib_(IC50:_0.7nM_vs._60nM)_compared_to_wildtype_EGFR_cells.",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,2,accepted,2629,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-04-18_20:58:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/2629,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Afatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Cancer,162,,"Gefitinib,Erlotinib,AEE788",Substitutes,Predictive,Supports,D,Sensitivity/Response,"EGFR_L858R_was_expressed_in_Ba/F3_cells_which_do_not_contain_endogenous_EGFR,_and_conferred_growth_factor_independance_to_the_cells._Cells_were_plated_and_treated_with_1st_generation_EGFR_inhibitors_Gefitinib,_Erlotinib,_or_the_the_tool_compound_AEE788,_and_IC50_values_were_measured._L858R_EGFR_cells_had_very_low_IC50_nmol/L_values_for_all_three_inhibitors_in_comparison_to_other_constructs_(Gefitinib=12,_Erlotinib=6,_AEE788=6),_indicating_sensitivity_to_all_three_constructs.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,3,accepted,3811,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-09-16_05:19:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/3811,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,Erlotinib,AEE788,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_3_clinical_trial_of_Korean,_never-smoker,_lung_adenocarcinoma_patients,_a_subset_of_patients_with_EGFR_mutations_(n=42)_treated_with_gefitinib_were_associated_with_improved_overall_response_rate_compared_to_gemcitabine_plus_cisplatin_treatment_(84.6%,_22/26,_vs._37.5%,_6/16,_P=0.002)._By_contrast,_in_EGFR_mutation_negative_cases,_the_response_rate_was_much_lower_(25.9%,_7/27)._The_frequency_of_mutation_in_exon_19_deletion_and_L858R_was_64.3%_(27/42)_and_36.4%_(16/42),_respectively._Exon_19_and_L858R_mutations_were_mutually_exclusive_in_this_cohort.",22370314,PubMed,,"Han_et_al.,_2012,_J._Clin._Oncol.",,3,accepted,2634,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-06-15_18:57:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/2634,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_CHO_and_NCI-H3255_cells_expressing_EGFR_L858R_mutation_were_associated_with_sensitivity_to_erlotinib_treatment._Sensitivity_was_determined_by_assessing_cell_density.",27612423,PubMed,,"Ray_et_al.,_2016,_Oncotarget",,,accepted,4287,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/4287,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_PC9_cells_(EGFR_exon_19_deletion),_inhibition_of_cell_viability_was_used_as_an_assay_to_determine_sensitivity_to_EGFR_tyrosine_kinase_inhibitors._PC9_cells_demonstrated_an_increased_sensitivity_to_gefitinib__(IC50:_23.0_nmol/L_vs_200.0_nmol/L)_compared_to_NCI-H2073_cells_(EGFR_wild_type).",24893891,PubMed,,"Cross_et_al.,_2014,_Cancer_Discov",,,accepted,2625,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/2625,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,A,Sensitivity/Response,"Afatinib,_an_irreversible_inhibitor_of_the_ErbB_family_of_tyrosine_kinases_has_been_approved_in_the_US_for_the_first-line_treatment_of_patients_with_metastatic_non-small-cell_lung_cancer_(NSCLC)_who_have_tumours_with_EGFR_exon_19_deletions_or_exon_21_(L858R)_substitution_mutations_as_detected_by_a_US_FDA-approved_test",23982599,PubMed,,"Dungo_et_al.,_2013,_Drugs",,5,accepted,2997,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-05-18_20:22:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2997,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Afatinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Dacomitinib,,Predictive,Supports,B,Sensitivity/Response,"The_authors_pooled_patients_with_exon_19_deletion_and_L858R_EGFR_(Exon_21)_mutations_from_both_studies_(The_ARCHER_1009_(NCT01360554)_and_A7471028_(NCT00769067))_to_compare_the_efficacy_of_dacomitinib_to_erlotinib._121_patients_with_any_EGFR_mutation_were_enrolled,_101_had_activating_mutations_in_exon_19_or_21._For_those_(exon19/21),_the_median_PFS_was_14.6_months_with_dacomitinib_and_9.6_months_with_erlotinib_The_median_survival_was_26.6_months_with_dacomitinib_versus_23.2_months_with_erlotinib.",26768165,PubMed,,"Ramalingam_et_al.,_2016,_Ann._Oncol.",,5,accepted,4860,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-05-23_12:46:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/4860,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Dacomitinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Malignant_Glioma,3070,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_L858R_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",17177598,PubMed,,"Lee_et_al.,_2006,_PLoS_Med.",,,accepted,4295,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2017-06-15_22:25:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/4295,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Erlotinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Hematologic_Cancer,2531,,Cetuximab,,Predictive,,D,,"EGFR_L858R_mutation_has_been_associated_with_increased_sensitivity_to_first_generation_EGFR_tyrosine_kinase_inhibitors,_including_erlotinib_and_gefitinib._In_an_in_vitro_study_using_NCI-H3255_cells_(EGFR_L858R_mutation),_inhibition_of_EGFR_phosphorylation_was_used_as_an_assay_to_determine_sensitivity_to_EGFR_tyrosine_kinase_inhibitors._NCI-H3255_cells_demonstrated_increased_sensitivity_to_erlotinib_(IC50:_8.0-11.0_nmol/L_vs_108.0_nmol/L)_compared_to_NCI-H2073_cells_(EGFR_wild_type).",24893891,PubMed,,"Cross_et_al.,_2014,_Cancer_Discov",,,accepted,4294,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:46:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/4294,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Cetuximab,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1781_cells_(EGFR_wild-type)_and_NCI-H3255_cells_(EGFR_L858R),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_irreversible_tyrosine_kinase_inhibitor_(TKI)_drugs._Cells_with_an_EGFR_L858R_mutation_demonstrated_an_improved_response_to_neratinib_(IC50:_0.0049umol/L_vs._0.085umol/L)_compared_to_wildtype_EGFR_cells_or_compared_to_reversible_TKI_drug_erlotinib_(IC50:_0.031umol/L_vs._wildtype_>1umol/L).",16818618,PubMed,,"Shimamura_et_al.,_2006,_Cancer_Res.",,,accepted,2628,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2018-02-13_19:45:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/2628,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Neratinib,,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,L858R,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_NSCLC_patients_treated_with_EGFR_tyrosine_kinase_inhibitors,_the_presence_of_L858R_mutation_is_prognostic_for_better_progression_free_survival.",24457318,PubMed,,"Fukihara_et_al.,_2014,_Oncology",,4,accepted,275,19,7,55259515,55259515,T,G,ENST00000275493.2,,,,,75,GRCh37,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",Somatic_Mutation,2016-02-18_18:39:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/275,https://civic.genome.wustl.edu/links/variants/33,https://civic.genome.wustl.edu/links/genes/19,"EGFR_L858R_has_long_been_recognized_as_a_functionally_significant_mutation_in_cancer,_and_is_one_of_the_most_prevalent_single_mutations_in_lung_cancer._Best_described_in_non-small_cell_lung_cancer_(NSCLC),_the_mutation_seems_to_confer_sensitivity_to_first_and_second_generation_TKI's_like_gefitinib_and_neratinib._NSCLC_patients_with_this_mutation_treated_with_TKI's_show_increased_overall_and_progression-free_survival,_as_compared_to_chemotherapy_alone._Third_generation_TKI's_are_currently_in_clinical_trials_that_specifically_focus_on_mutant_forms_of_EGFR,_a_few_of_which_have_shown_efficacy_in_treating_patients_that_failed_to_respond_to_earlier_generation_TKI_therapies.",,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",326.5,Gefitinib,Erlotinib,,,,chr7_g.55259515T~G,EGFR_c.2573T~G,EGFR_L858R
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Dacomitinib,,Predictive,Supports,B,Resistance,"In_Lung_Cancer_patients_with_acquired_resistance_to_Dacomitinib_(PF00299804),_MET_amplification_and_EGFR_T790M_were_found_to_be_the_primary_drivers_of_resistance.",21430269,PubMed,,"Sequist_et_al.,_2011,_Sci_Transl_Med",,4,accepted,240,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2015-06-21_16:49:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/240,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Dacomitinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Osimertinib,,Predictive,Supports,B,Sensitivity/Response,"This_study_summarized_9_EGFR-mutant_patients_from_two_clinical_trials_involving_rociletinib_(NCT01526928)_and_subsequent_osimertinib_(NCT01802632)._8_were_T790M-positive_prior_to_treatment_with_osimertinib._6_transitioned_directly_from_rociletinib_to_osimertinib._3_patients_achieved_PR_and_4_achieved_SD._The_median_PFS_was_208_days_(95%_CI,_41-208_days)._Among_6_patients_who_transitioned_directly_from_rociletinib_to_osimertinib_all_derived_clinical_benefit_from_osimertinib_with_either_prolonged_SD_or_PR.",26720284,PubMed,,"Sequist_et_al.,_2016,_JAMA_Oncol",,3,accepted,966,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-02-11_21:39:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/966,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,B,Resistance,"Patients_with_advanced_NSCLC_and_acquired_resistance_to_EGFR_TKI_(gefitinib_or_erlotinib)_were_analyzed_for_T790M_mutations.__Of_the_70_patients_analyzed,_36_(51%)_had_the_T790M_mutation_and_34_(49%)_were_T790M-negative.__There_was_no_significant_difference_in_the_median_post-progression_or_overall_survival_between_patients_with_T790M_mutation_and_without_T790M_mutation_for_initial_TKI_treatment.__However,_subsequent_treatment_with_afatinib_showed_partial_response_in_six_patients_where_1/21(5%)_were_in_the_T790M-positive_group_and_5/13_(38%)_were_in_the_T790M-negative_group_(P=0.01).",24035188,PubMed,,"Sun_et_al.,_2013,_Lung_Cancer",,4,accepted,1863,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-01-01_21:00:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1863,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Afatinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Resistance,"In_non-small_cell_lung_cancer,_the_appearance_of_T790M_mutation_leads_to_resistance_to_gefitinib.",15728811,PubMed,,"Kobayashi_et_al.,_2005,_N._Engl._J._Med.",,3,accepted,239,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2015-06-21_16:49:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/239,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Gefitinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,A,Resistance,"The_T790M_mutation_in_EGFR_has_been_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_erlotinib,_and_patients_harboring_this_mutation_that_are_placed_on_the_drug_are_likely_to_relapse.",25668228,PubMed,,"Denis_et_al.,_2015,_Clin._Chim._Acta",,5,accepted,238,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2015-08-05_18:28:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/238,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Erlotinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Resistance,"In_a_study_of_6_patients_with_progressive_non-small_cell_lung_cancer_during_gefitinib_or_erlotinib_therapy,__comparison_of_DNA_sequences_from_the_original_diagnostic_biopsy_specimen_and_the_second_biopsy_specimen_demonstrated_that_2_patients_acquired_a_new_EGFR-T790M_mutation.",15737014,PubMed,,"Pao_et_al.,_2005,_PLoS_Med.",,,accepted,2158,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-04-12_08:55:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/2158,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Gefitinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Osimertinib,,Predictive,Supports,A,Sensitivity/Response,Osimertinib_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC.,26729184,PubMed,,"Greig,_2016,_Drugs",,5,accepted,1592,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-08-17_16:58:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1592,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Osimertinib,,Predictive,Supports,B,Sensitivity/Response,"This_phase_I/II_trial_(NCT01802632)_involved_253_non-small_cell_lung_cancer_patients_with_activating_EGFR_mutations,_who_had_progressed_on_first_generation_tyrosine_kinase_inhibitor_treatment,_and_were_subsequently_treated_with_Osimertinib_(AZD9291)._The_overall_objective_tumor_response_rate_was_51%._Among_127_patients_with_EGFR_T790M_who_could_be_evaluated_for_response,_the_response_rate_was_61%_(95%_CI,_52_to_70)._In_contrast,_among_61_patients_without_EGFR_T790M,_the_response_rate_was_21%_(95%_CI,_12_to_34)._The_median_progression-free_survival_was_9.6_months_in_EGFR_T790M-positive_patients_and_2.8_months_in_EGFR_T790M-negative_patients.",25923549,PubMed,,"Jänne_et_al.,_2015,_N._Engl._J._Med.",,4,accepted,965,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:35:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/965,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Osimertinib,,Predictive,Supports,A,Sensitivity/Response,"Randomized,_international,_open-label,_phase_3_trial_(NCT02151981)_in_419_patients_with_T790M-positive_advanced_NSCLC_and_disease_progression_after_first-line_EGFR-TKI_therapy._Patients_were_randomized,_in_a_2:1_ratio,_to_oral_osimertinib_or_chemotherapy_(pemetrexed_plus_either_carboplatin_or_cisplatin_every_3_weeks_for_up_to_six_cycles,_maintenance_pemetrexed_was_allowed)._Primary_end_point_was_PFS,_which_was_significantly_longer_with_osimertinib_than_with_chemotherapy_(10.1_months_vs._4.4_months;_HR_0.30;_95%_CI:_0.23_to_0.41;_P<0.001)._Objective_response_rate_was_significantly_better_with_osimertinib_(71%;_95%_CI,_65_to_76)_than_with_chemotherapy_(31%;_95%_CI,_24_to_40)_(odds_ratio_for_objective_response,_5.39;_95%_CI,_3.47_to_8.48;_P<0.001).",27959700,PubMed,,"Mok_et_al.,_2016,_N._Engl._J._Med.",,5,accepted,1867,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-01-19_19:59:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1867,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Lung_Adenocarcinoma,3910,,Osimertinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_lung_adenocarcinoma_patient_harboring_an_EGFR_E746_A750_mutation_and_an_acquired_EGFR_T790M_co-mutation,_EGFR_T790M_was_associated_with_sensitivity_to_osimertinib_monotherapy._Prior_to_the_development_of_the_EGFR_T790M_mutation,_the_patient_was_treated_with_gefitinib_and_achieved_a_partial_response,_but_subsequently_tumor_progression_occurred;_however,_osimertinib_treatment_resulted_a_favorable_tumor_response_with_the_extinguishment_of_the_EGFR_T790M_mutation._In_a_stage_IV_lung_adenocarcinoma_patient_harboring_an_EGFR_L858R_mutation_and_an_acquired_EGFR_T790M_co-mutation,_EGFR_T790M_was_associated_with_sensitivity_to_osimertinib_monotherapy._Prior_to_the_development_of_the_EGFR_T790M_mutation,_the_patient_was_treated_with_erlotinib,_followed_by_gefitinib_for_12_months_and_achieved_stable_disease,_but_subsequently_metastasis_occurred;_the_EGFR_T790M_was_then_identified_and_subsequent_10_month_treatment_with_osimertinib_monotherapy_resulted_in_a_45%_disease_regression.",26269204,PubMed,,"Planchard_et_al.,_2015,_Ann._Oncol.",,2,accepted,2157,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:36:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/2157,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Rociletinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase1-2_study,_patients_with_the_T790M_mutation_were_more_sensitive_to_rocelitinib_in_comparison_to_patients_with_T790M-negative_NSCLC.",25923550,PubMed,,"Sequist_et_al.,_2015,_N._Engl._J._Med.",,4,accepted,646,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2015-11-09_20:33:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/646,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Rociletinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Lung_Cancer,1324,,"Gefitinib,AEE788",Sequential,Predictive,Supports,D,Resistance,"Lung_cancers_can_accumulate_activating_mutations_in_oncogenes_such_as_EGFR._The_common_L858R_EGFR_mutation_has_been_shown_previously_to_be_sensitive_to_small_molecular_tyrosine_kinase_inhibitors_(ie._erlotinib)._In_response,_tumors_may_accumulate_an_additional_'gatekeeper'_mutation_in_EGFR,_T790M._Authors_show_that_T790M_retain_low_affinity_for_gefitinib_and_that_introduction_of_T790M_in_the_presence_of_L858R_mutant_increases_the_ATP_affinity_of_L858R_and_activates_wild-type_EGFR,_thus_showing_that_increased_ATP_affinity_is_the_primary_mode_of_resistance_in_tumors_with_T790M,_though_irreversible_ATP_inhibitors_(ie._HKI-272)_are_able_to_overcome_this_resistance_via_covalent_bonding.",18227510,PubMed,,"Yun_et_al.,_2008,_Proc._Natl._Acad._Sci._U.S.A.",,5,accepted,642,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/642,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Gefitinib,AEE788,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Canertinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H1975_cells_(EGFR-L858R/T790M),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_tyrosine_kinase_inhibitor_(TKI)_drugs._Cells_with_an_EGFR_L858R/T790M_mutation_demonstrated_an_improved_response_to_canertinib_(IC50:_101nM_vs._>4000nM)_compared_to_the_same_cells_treated_with_erlotinib._IC50_values_of_canertinib_were_comparable_to_afatinib.",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,2,accepted,2165,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:36:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2165,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Canertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Lung_Adenocarcinoma,3910,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Resistance,"155_patients_with_lung_adenocarcinomas_underwent_rebiopsy_and_genotyping_(EGFR,_AKT1,_BRAF,_ERBB2,_KRAS,_MEK1,_NRAS,_PIK3CA_and_FISH_for_MET_and_HER2)_after_the_development_of_acquired_resistance_to_EGFR_inhibitors_(gefitinib_or_erlotinib)._98_patients_were_found_to_have_developed_EGFR_T790M_mutations.",23470965,PubMed,,"Yu_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1391,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-06-27_15:49:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1391,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Gefitinib,Erlotinib,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Lung_Adenocarcinoma,3910,,Osimertinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_stage_IV_lung_adenocarcinoma_and_a_15–base_pair_deletion_in_EGFR_exon_19._Partial_response_with_erlotinib_was_achieved_for_15_months_after_initial_chemotherapy._After_further_progression,_rebiopsy_additionally_identified_the_EGFR_T790M_mutation_and_the_patient_received_several_cycles_of_chemotherapy_and_targeted_therapy_including_afatinib,_cetuximab,_erlotinib,_AZD9291._She_was_treated_with_AZD9291_for_9_months_until_disease_progression.",26181354,PubMed,,"Yu_et_al.,_2015,_JAMA_Oncol",,1,accepted,1397,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-07-08_00:00:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1397,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,"Osimertinib,Rociletinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"For_cell_harboring_EGFR_T790M_mutation,_osimertinib_and_rociletinib_showed_potent_inhibition_compared_to_erlotinib_or_afatinib._This_study_performed_drug_response_assays_using_five_human_NSCLC_cell_lines_with_various_combinations_of_EGFR_mutations._In_order_to_directly_compare_the_sensitivity_of_multiple_EGFR_mutations_to_EGFR-TKIs_the_authors_also_generated_multiple_EGFR_transduced_Ba/F3_stable_cell_lines_and_evaluated_sensitivity_to_EGFR-TKIs_by_MTS_assay.",26515464,PubMed,,"Hirano_et_al.,_2015,_Oncotarget",,2,accepted,967,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/967,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,Rociletinib,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Rociletinib,,Predictive,Supports,D,Sensitivity/Response,CO-1686_(Rociletinib)_more_effectively_induced_apoptosis_in_EGFR_mutated_(T790M_and_others)_NSCLC_cell_lines_than_those_harboring_wildtype_EGFR._CO-1686_also_more_effectively_reduced_tumor_volume_of_mouse_xenografts_harboring_the_T790M_than_those_with_wildtype_EGFR.,24065731,PubMed,,"Walter_et_al.,_2013,_Cancer_Discov",,3,accepted,762,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/762,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Rociletinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,"Afatinib,Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Resistance,"48_tumor_samples_from_41_patients_with_EGFR_mutant_lung_adenocarcinoma_that_were_resistant_to_tyrosine_kinase_inhibition_underwent_next_generation_sequencing_(NGS_failed_in_5_samples_leading_to_a_remaining_43_specimens_from_39_patients)._The_prevalence_of_various_mutations_post-treatment_was_analyzed._79%,_or_31_out_of_the_39_patients,__had_the_T790M_EGFR_mutation_present,_indicating_its_importance_in_the_development_of_resistance.",27304188,PubMed,,"Belchis_et_al.,_2016,_Oncotarget",,3,accepted,1667,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-10-06_05:41:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/1667,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Afatinib,Gefitinib,Erlotinib,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"The_NSCLC_cell_line_NCI-H1975_carrying_the_EGFR_T790M_mutation_was_resistant_to_erlotinib_but_showed_increased_sensitivity_to_HKI-272_(neratinib,_IC50:_0.29_μmol/L)._In_an_in_vitro_study_Ba/F3_cells_transfected_with_either_EGFR-L858R_or_EGFR-L858R/T790M_were_used_to_assay_cell_growth._Ba/F3_cells_require_IL-3_in_order_to_proliferate,_but_cells_transfected_with_an_activated_oncogene_are_IL-3_independent._Cells_with_an_EGFR_L858R/T790M_mutation_demonstrated_an_improved_response_to_neratinib_(IC50:_0.185umol/L_vs._>10umol/L)_compared_to_the_same_cells_treated_with_erlotinib.",16818618,PubMed,,"Shimamura_et_al.,_2006,_Cancer_Res.",,2,accepted,2162,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:38:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2162,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Neratinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,"Pemetrexed,Erlotinib",Combination,Predictive,Supports,C,Sensitivity/Response,"In_an_NSCLC_patient_initially_with_L858R_mutation,_pemetrexed_and_cisplatin_combination_treatment_was_followed_by_erlotinib_treatment._A_slow_progression_developed_which_was_found_to_be_positive_for_L858R_as_well_as_T790M_mutation_which_confers_resistance_to_tyrosine_kinase_inhibitors._Due_to_slow_tumor_growth_erlotinib_was_continued_despite_T790M,_with_re-addition_of_premetrexed,_and_this_reduced_tumor_size_and_resulted_in_stable_disease.",24636847,PubMed,,"Li_et_al.,_2014,_Lung_Cancer",,3,accepted,277,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-05-31_02:19:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/277,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Pemetrexed,Erlotinib,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Staurosporine,,Predictive,Supports,E,Sensitivity/Response,"In_NSCLC_containing_a_T790M_mutation,_staurosporine_may_be_inhibitive_of_EGFR,_especially_when_an_L858R_mutation_is_also_present.",24658966,PubMed,,"Ai_et_al.,_2014,_Amino_Acids",,1,accepted,278,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2015-06-21_16:49:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/278,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Staurosporine,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,PF_00299804,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H322_cells_(wildtype_EGFR)_and_NCI-H1975_cells_(EGFR-L858R/T790M),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_irreversible_tyrosine_kinase_inhibitor_(TKI)_drugs._PF00299804_inhibited_the_growth_of_Ba/F3_cell_lines_containing_the_EFGR_T790M_resistance_mutation_as_well_as_H1975_and_H3255_cell_lines_that_contain_both_EGFR_L858R_and_T790M_mutations_and_H820_containing_an_EGFR_exon_19_deletion_(Del_747_L751,_Ins_S)_and_a_T790M_mutation._All_three_cell_lines_were_resistant_to_gefitinib_in_vitro,_but_sensitive_to_PF00299804_(IC50_<1_μmol/L_for_all_three_cell_lines).",18089823,PubMed,,"Engelman_et_al.,_2007,_Cancer_Res.",,3,accepted,2161,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:38:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/2161,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,PF_00299804,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Cancer,162,,Erlotinib,,Predictive,Supports,D,,"Experimental_-_EGFR_T790M_mutation_has_been_associated_with_resistance_to_first_generation_EGFR_tyrosine_kinase_inhibitors,_including_erlotinib_and_gefitinib._In_an_in_vitro_study,_Ba/F3_cells_stably_expressing_EGFR_T790M_demonstrated__resistance_to_gefitinib_and_erlotinib_and_the_tool_construct_AEE788._These_cells_had_very_high_IC50_nmol/L_values_for_all_three_inhibitors_in_comparison_to_other_constructs_(Gefitinib>2000,_Erlotinib>2000,_AEE788>2000),_indicating_resitance_to_all_three_inhibitors.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,3,accepted,3810,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2018-08-23_17:05:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/3810,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Erlotinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Osimertinib,,Predictive,Supports,D,Sensitivity/Response,"Cell_line,_xenograft,_and_transgenic_models_were_used_to_establish_Osimertinib_as_an_inhibitor_of_both_EGFR_mutation_sensitizing_(L858M,_del_exon_19)_and_T790M_resistance_mutants._Preclinically,_the_drug_inhibits_signaling_pathways_and_cellular_growth_in_both_EGFRm(+)_and_EGFRm(+)/T790M(+)_mutant_cell_lines_in_vitro,_with_lower_activity_against_wild-type_EGFR_lines._Sustained_tumor_regression_was_observed_in_EGFR-mutant_tumor_xenograft_and_transgenic_models._Treatment_of_2_patients_with_advanced_EGFRm(+)_T790M(+)_NSCLC_was_reported_as_proof_of_principle.",24893891,PubMed,,"Cross_et_al.,_2014,_Cancer_Discov",,3,accepted,963,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/963,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Osimertinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_purified_EGFR_protein,_kinase_activity_was_assayed_and_compared_for_wildtype_EGFR,_EGFR-T790M_and_EGFR-T790M/L858R_using_both_reversible_and_irreversible_TKI_drugs._EFGR_proteins_with_T790M_or_T790M/L858R_mutations_were_more_sensitive_to_afatinib_treatment_(IC50:_9.8nM_and_24nM,_respectively_vs._IC50:_>1000nM_and_>1000nM,_respectively)_compared_to_treatment_with_erlotinib_or_lapatinib_treatment._In_an_in_vitro_study_using_NCI-H358_cells_(wildtype_EGFR)_and_NCI-H1975_cells_(EGFR-L858R/T790M),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_tyrosine_kinase_inhibitor_drugs._Cells_with_an_EGFR_L858R/T790M_mutation_demonstrated_an_improved_response_to_afatinib_(GI50:_42.0nM_vs._>1000nM)_compared_to_the_same_cells_treated_with_erlotinib._However,_IC50s_were_intermediate_compared_to_a_more_potent_pan-HER_inhibitor.",21732342,PubMed,,"Cha_et_al.,_2012,_Int._J._Cancer",,2,accepted,2164,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:37:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/2164,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Afatinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Resistance,"In_a_study_of_14_patients_with_progressive_non-small_cell_lung_cancer_during_gefitinib,__comparison_of_DNA_sequences_from_the_original_diagnostic_biopsy_specimen_and_the_second_biopsy_specimen_demonstrated_that_7_patients_acquired_a_new_EGFR-T790M_mutation.",17020982,PubMed,,"Kosaka_et_al.,_2006,_Clin._Cancer_Res.",,,accepted,2159,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-04-12_08:56:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/2159,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Gefitinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H1975_cells_(EGFR-L858R/T790M),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_tyrosine_kinase_inhibitor_(TKI)_drugs._Cells_with_an_EGFR_L858R/T790M_mutation_demonstrated_an_improved_response_to_afatinib_(IC50:_99nM_vs._>4000nM)_compared_to_the_same_cells_treated_with_erlotinib._In_an_in_vivo_mouse_xenograft_study,_the_growth_of_cells_with_an_EGFR-L858R/T790M_mutation_were_more_sensitive_to_treatment_of_afatinib_(concentration:_15-20mg/kg)_(median_tumor_volume_=_75-150mm^3_vs._1000mm^3),_compared_to_reversible_TKI_lapatinib-treated_xenografts._However,_no_complete_responses_were_observed_with_afatinib_alone.",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,2,accepted,2163,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:37:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/2163,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Afatinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
EGFR,1956,T790M,Non-small_Cell_Lung_Carcinoma,3908,,Lapatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study_using_NCI-H1666_cells_(wildtype_EGFR)_and_NCI-H1975_cells_(EGFR-L858R/T790M),_inhibition_of_cell_growth_was_used_as_an_assay_to_determine_sensitivity_to_reversible_tyrosine_kinase_inhibitor_drugs._Cells_with_an_EGFR_L858R/T790M_mutation_demonstrated_a_reduced_response_to_lapatinib_(IC50:_>4000nM_vs._534nM)_compared_to_wildtype_EGFR_cells._Similarly,_NIH-3T3_ectopically_expression_EGFR-L858R/T790M_showed_reduced_sensistivity_to_lapatinib_compared_to_EGFR_wt_or_L585R_mutant_cells._These_results_were_further_confirmed_in_a_Ba/F3_cell_line_model",18408761,PubMed,,"Li_et_al.,_2008,_Oncogene",,4,accepted,2160,19,7,55249071,55249071,C,T,ENST00000275493.2,,,,,75,GRCh37,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",Somatic_Mutation,2017-07-27_15:36:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/2160,https://civic.genome.wustl.edu/links/variants/34,https://civic.genome.wustl.edu/links/genes/19,"EGFR_T790M_was_one_of_the_very_first_mutations_recognized_to_confer_resistance_to_targeted_therapies_in_non-small_cell_lung_cancer._While_successful_in_amplified_EGFR,_the_efficacy_of_the_first_and_second_generation_TKI's_(erlotinib,_gefitinib,_neratinib)_in_treating_patients_harboring_this_mutation_before_treatment_is_notably_lower._This_lack_of_efficacy_can_likely_be_to_blame_for_the_poorer_prognosis_for_patients_with_this_mutation_as_compared_to_patients_with_wildtype_EGFR_or_other_types_of_EGFR_mutations._Approximately_half_of_EGFR_mutant_tumors_with_acquired_resistance_to_TKI_inhibition_have_been_shown_to_harbor_this_mutation,_implicating_it_as_a_mechanism_of_acquired_therapy_resistence._A_third_generation_TKI_(osimertinib)_has_been_approved_for_the_treatment_of_EGFR_T790M_mutant_NSCLC._Patients_positive_for_T790M_in_a_plasma-based_test_have_similar_outcomes_like_those_with_tumor_biopsy_testing.",EGFR_TKI_Resistance,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",376.25,Lapatinib,,,,,chr7_g.55249071C~T,EGFR_c.2369C~T,EGFR_T790M
ERBB2,2064,D769H,Breast_Cancer,1612,,"Lapatinib,Neratinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_D769H_mutation_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,4,accepted,279,20,17,37880261,37880261,G,C,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_D769H_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_were_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_activating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2017-10-21_23:12:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/279,https://civic.genome.wustl.edu/links/variants/35,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_D769H_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_were_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_activating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"NM_001289937.1:c.2305G>C,NP_001276866.1:p.Asp769His,ENST00000269571.5:c.2305G>C,NC_000017.10:g.37880261G>C",4,Lapatinib,Neratinib,,,,chr17_g.37880261G~C,ERBB2_c.2305G~C,ERBB2_D769H
ERBB2,2064,D769Y,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_D769Y_mutation_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,4,accepted,280,20,17,37880261,37880261,G,T,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_D769Y_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al.,_2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/280,https://civic.genome.wustl.edu/links/variants/36,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_D769Y_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al.,_2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"ENST00000269571.5:c.2305G>T,NC_000017.10:g.37880261G>T,NM_004448.3:c.2305G>T,NP_004439.2:p.Asp769Tyr",4,Neratinib,,,,,chr17_g.37880261G~T,ERBB2_c.2305G~T,ERBB2_D769Y
ERBB2,2064,DEL_755-759,Breast_Cancer,1612,,"Lapatinib,Neratinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines_retrovirally_transduced_with_wildtype_or_mutant_ERBB2,_cells_expressing_the_in-frame_deletion_of_amino_acids_755-759_were_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,281,20,17,37880219,37880233,TTGAGGGAAAACACA,,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_in-frame_deletion_of_755-759_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2017-10-21_23:13:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/281,https://civic.genome.wustl.edu/links/variants/37,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_in-frame_deletion_of_755-759_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",,inframe_deletion,"ENST00000269571.5:c.2263_2277del,NC_000017.10:g.37880219_37880233del,NP_004439.2:p.Leu755_Thr759del,NM_004448.3:c.2263_2277delTTGAGGGAAAACACA",5,Lapatinib,Neratinib,,,,chr17_g.37880219_37880233del,ERBB2_c.2263_2277delTTGAGGGAAAACACA,p.leu755_thr759del
ERBB2,2064,G309A,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_G309A_mutation_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,282,20,17,37868205,37868205,G,C,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_G309A_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/282,https://civic.genome.wustl.edu/links/variants/38,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_G309A_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"ENST00000269571.5:c.926G>C,NC_000017.10:g.37868205G>C,NM_004448.3:c.926G>C,NP_004439.2:p.Gly309Ala",5,Neratinib,,,,,chr17_g.37868205G~C,ERBB2_c.926G~C,ERBB2_G309A
ERBB2,2064,L755S,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,The_L755S_mutation_showed_mild_response_to_neratinib_in_MCF10A_cell_lines_retrovirally_transduced_with_wildtype_or_mutant_ERBB2.,23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,283,20,17,37880220,37880220,T,C,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_L755S_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_not_shown_to_be_an_activating_mutation,_unlike_many_of_the_other_variants_queried._This_mutation_was_also_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_lapatinib_in_MCF10A_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/283,https://civic.genome.wustl.edu/links/variants/39,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_L755S_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_not_shown_to_be_an_activating_mutation,_unlike_many_of_the_other_variants_queried._This_mutation_was_also_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_lapatinib_in_MCF10A_cell_lines.",,missense_variant,"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser",14,Neratinib,,,,,chr17_g.37880220T~C,ERBB2_c.2264T~C,ERBB2_L755S
ERBB2,2064,L755S,Colon_Cancer,219,,"Trastuzumab,Neratinib,Lapatinib",Combination,Predictive,Supports,D,Sensitivity/Response,Colon_cancer_patient_derived_xenografts_with_HER2_mutations_are_sensitive_to_HER2_targeted_drugs_and_the_greatest_tumor_reduction_was_seen_with_the_combination_of_a_tyrosine_kinase_inhibitor_with_trastuzumab.,26243863,PubMed,,"Kavuri_et_al.,_2015,_Cancer_Discov",,4,accepted,1176,20,17,37880220,37880220,T,C,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_L755S_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_not_shown_to_be_an_activating_mutation,_unlike_many_of_the_other_variants_queried._This_mutation_was_also_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_lapatinib_in_MCF10A_cell_lines.",Somatic_Mutation,2016-03-17_22:21:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1176,https://civic.genome.wustl.edu/links/variants/39,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_L755S_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_not_shown_to_be_an_activating_mutation,_unlike_many_of_the_other_variants_queried._This_mutation_was_also_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_lapatinib_in_MCF10A_cell_lines.",,missense_variant,"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser",14,Trastuzumab,Neratinib,Lapatinib,,,chr17_g.37880220T~C,ERBB2_c.2264T~C,ERBB2_L755S
ERBB2,2064,L755S,Breast_Cancer,1612,,Lapatinib,,Predictive,Supports,D,Resistance,The_L755S_mutation_was_shown_to_confer_resistance_to_lapatinib_in_MCF10A_cell_lines_retrovirally_transduced_with_wildtype_or_mutant_ERBB2.,23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,241,20,17,37880220,37880220,T,C,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_L755S_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_not_shown_to_be_an_activating_mutation,_unlike_many_of_the_other_variants_queried._This_mutation_was_also_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_lapatinib_in_MCF10A_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/241,https://civic.genome.wustl.edu/links/variants/39,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_L755S_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_not_shown_to_be_an_activating_mutation,_unlike_many_of_the_other_variants_queried._This_mutation_was_also_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_lapatinib_in_MCF10A_cell_lines.",,missense_variant,"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser",14,Lapatinib,,,,,chr17_g.37880220T~C,ERBB2_c.2264T~C,ERBB2_L755S
ERBB2,2064,L755W,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,MCF10A_cells_transduced_with_ERBB2_harboring_an_L755W_mutation_were_sensitive_to_the_irreversible_kinase_inhibitor_neratinib_in_an_matrigel_colony_forming_assay.,23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,284,20,17,37880220,37880220,T,G,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_L755W_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al.,_2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/284,https://civic.genome.wustl.edu/links/variants/40,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_L755W_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al.,_2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",,missense_variant,"ENST00000269571.5:c.2264T>G,NC_000017.10:g.37880220T>G,NM_004448.3:c.2264T>G,NP_004439.2:p.Leu755Trp",5,Neratinib,,,,,chr17_g.37880220T~G,ERBB2_c.2264T~G,ERBB2_L755W
ERBB2,2064,P780INS,Lung_Adenocarcinoma,3910,,Dacomitinib,,Predictive,Supports,C,Sensitivity/Response,"In_this_phase_II_study_(NCT00818441)_of_dacomitinib_in_HER2_amplified_or_mutant_NSCLC_tumors,_three_of_26_patients_with_HER2_p.P780_Y781insGSP_or_p.M774delinsWLV_showed_partial_responses_of_duration_between_3_and_14_months,_while_13_patients_with_the_more_common_HER2_p._A775_G776insYVMA_showed_no_partial_responses.__The_authors_conclude_that_in_the_set_of_activating_HER2_mutations,_benefits_of_an_individual_agent_may_be_specific_to_certain_mutations,_and_that_""HER2-positive_lung_cancers""_is_not_an_adequate_term_to_describe_this_group_of_distinguishable_illnesses.",25899785,PubMed,,"Kris_et_al.,_2015,_Ann._Oncol.",,3,accepted,1048,20,17,37881011,37881012,,GGCTCCCCA,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_P780_insertion_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_activating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-22_23:43:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1048,https://civic.genome.wustl.edu/links/variants/41,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_P780_insertion_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_activating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,inframe_insertion,"ENST00000269571.5:c.2340_2341insGGCTCCCCA,NC_000017.10:g.37881011_37881012insGGCTCCCCA",12.5,Dacomitinib,,,,,chr17_g.37881011_37881012insGGCTCCCCA,ERBB2_c.2340_2341insGGCTCCCCA,
ERBB2,2064,P780INS,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_in-frame_insertion_of_a_single_amino_acid_at_position_780_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,285,20,17,37881011,37881012,,GGCTCCCCA,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_P780_insertion_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_activating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/285,https://civic.genome.wustl.edu/links/variants/41,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_P780_insertion_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_activating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,inframe_insertion,"ENST00000269571.5:c.2340_2341insGGCTCCCCA,NC_000017.10:g.37881011_37881012insGGCTCCCCA",12.5,Neratinib,,,,,chr17_g.37881011_37881012insGGCTCCCCA,ERBB2_c.2340_2341insGGCTCCCCA,
ERBB2,2064,R678Q,Breast_Cancer,1612,,"Neratinib,Lapatinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,MCF10A_cells_transduced_with_ERBB2_harboring_an_R678Q_mutation_were_sensitive_to_lapatinib_and_the_irreversible_kinase_inhibitor_neratinib_in_an_matrigel_colony_forming_assay.,23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,286,20,17,37879658,37879658,G,A,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_R678Q_was_shown_to_have_NO_functional_effect_in_tissue_culture_assay_(Bose_et_al_2013)._This_conclusion_was_confirmed_by_a_second,_independent_lab.",Somatic_Mutation,2017-05-31_15:40:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/286,https://civic.genome.wustl.edu/links/variants/42,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_R678Q_was_shown_to_have_NO_functional_effect_in_tissue_culture_assay_(Bose_et_al_2013)._This_conclusion_was_confirmed_by_a_second,_independent_lab.",,missense_variant,"ENST00000269571.5:c.2033G>A,NC_000017.10:g.37879658G>A,NM_004448.3:c.2033G>A,NP_004439.2:p.Arg678Gln",5,Neratinib,Lapatinib,,,,chr17_g.37879658G~A,ERBB2_c.2033G~A,ERBB2_R678Q
ERBB2,2064,R896C,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_R896C_mutation_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,287,20,17,37881616,37881616,C,T,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_R896C_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/287,https://civic.genome.wustl.edu/links/variants/43,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_R896C_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"ENST00000269571.5:c.2686C>T,NC_000017.10:g.37881616C>T,NM_004448.3:c.2686C>T,NP_004439.2:p.Arg896Cys",5,Neratinib,,,,,chr17_g.37881616C~T,ERBB2_c.2686C~T,ERBB2_R896C
ERBB2,2064,V777L,Colon_Cancer,219,,"Neratinib,Lapatinib,Trastuzumab",Combination,Predictive,Supports,D,Sensitivity/Response,Colon_cancer_patient_derived_xenografts_with_HER2_mutations_are_sensitive_to_HER2_targeted_drugs_and_the_greatest_tumor_reduction_was_seen_with_the_combination_of_a_tyrosine_kinase_inhibitor_with_trastuzumab.,26243863,PubMed,,"Kavuri_et_al.,_2015,_Cancer_Discov",,4,accepted,1177,20,17,37881000,37881000,G,T,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_V777L_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-03-17_22:20:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1177,https://civic.genome.wustl.edu/links/variants/44,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_V777L_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T,NC_000017.10:g.37881000G>T",9,Neratinib,Lapatinib,Trastuzumab,,,chr17_g.37881000G~T,ERBB2_c.2329G~T,ERBB2_V777L
ERBB2,2064,V777L,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_V777L_mutation_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,288,20,17,37881000,37881000,G,T,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_V777L_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/288,https://civic.genome.wustl.edu/links/variants/44,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_V777L_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T,NC_000017.10:g.37881000G>T",9,Neratinib,,,,,chr17_g.37881000G~T,ERBB2_c.2329G~T,ERBB2_V777L
ERBB2,2064,V842I,Colon_Cancer,219,,"Neratinib,Lapatinib,Trastuzumab",Combination,Predictive,Supports,D,Sensitivity/Response,Colon_cancer_patient_derived_xenografts_with_HER2_mutations_are_sensitive_to_HER2_targeted_drugs_and_the_greatest_tumor_reduction_was_seen_with_the_combination_of_a_tyrosine_kinase_inhibitor_with_trastuzumab.,26243863,PubMed,,"Kavuri_et_al.,_2015,_Cancer_Discov",,4,accepted,1174,20,17,37881332,37881332,G,A,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_V842I_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-03-17_20:41:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/1174,https://civic.genome.wustl.edu/links/variants/45,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_V842I_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"ENST00000269571.5:c.2524G>A,NM_004448.3:c.2524G>A,NP_004439.2:p.Val842Ile,NC_000017.10:g.37881332G>A",9,Neratinib,Lapatinib,Trastuzumab,,,chr17_g.37881332G~A,ERBB2_c.2524G~A,ERBB2_V842I
ERBB2,2064,V842I,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,D,Sensitivity/Response,"In_MCF10A_cell_lines,_the_V842I_mutation_was_shown_to_be_sensitive_to_neratinib.",23220880,PubMed,,"Bose_et_al.,_2013,_Cancer_Discov",,5,accepted,289,20,17,37881332,37881332,G,A,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_V842I_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/289,https://civic.genome.wustl.edu/links/variants/45,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_V842I_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Bose_et_al._2013)._This_mutation_was_shown_to_be_an_activating_mutation_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_MCF10A_breast_cancer_cell_lines_have_been_shown_to_be_sensitive_to_the_kinase_inhibitor_neratinib._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",HER2_Activating,missense_variant,"ENST00000269571.5:c.2524G>A,NM_004448.3:c.2524G>A,NP_004439.2:p.Val842Ile,NC_000017.10:g.37881332G>A",9,Neratinib,,,,,chr17_g.37881332G~A,ERBB2_c.2524G~A,ERBB2_V842I
ESR1,2099,L536Q,Breast_Cancer,1612,,Hormone_Therapy,,Predictive,Supports,D,Resistance,MCF7_cell_lines_harboring_the_L536Q_mutation_in_the_ligand-binding_domain_of_ESR1_have_shown_resistance_to_hormone_therapy.,24185512,PubMed,,"Toy_et_al.,_2013,_Nat._Genet.",,3,accepted,242,21,6,152419920,152419921,TC,AG,ENST00000440973.1,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y536Q_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/242,https://civic.genome.wustl.edu/links/variants/46,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y536Q_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,NC_000006.11:g.152419920_152419921delinsAG,8,Hormone_Therapy,,,,,chr6_g.152419920_152419921delinsAG,,
ESR1,2099,L536Q,Breast_Cancer,1612,,"Tamoxifen,Fulvestrant",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Using_an_estrogen_response_element_(ERE)-luciferase_reporter_system_co-transfected_with_one_of_five_ESR1_mutants,_the_L536Q_ligand_binding_domain_mutation_was_shown_to_result_in_constitutive_activity_(response_in_the_absence_of_beta-estradiol_ligand)_and_continued_responsiveness_(inhibition_of_downstream_target_activation)_to_anti-estrogen_therapies_(tamoxifen_or_fulvestrant)_in_HEK293T_cell_lines.",24185510,PubMed,,"Robinson_et_al.,_2013,_Nat._Genet.",,5,accepted,290,21,6,152419920,152419921,TC,AG,ENST00000440973.1,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y536Q_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-05-31_01:23:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/290,https://civic.genome.wustl.edu/links/variants/46,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y536Q_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,NC_000006.11:g.152419920_152419921delinsAG,8,Tamoxifen,Fulvestrant,,,,chr6_g.152419920_152419921delinsAG,,
ESR1,2099,D538G,Breast_Cancer,1612,,"Tamoxifen,Fulvestrant",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Using_an_estrogen_response_element_(ERE)-luciferase_reporter_system_co-transfected_with_one_of_five_ESR1_mutants,_the_N538G_ligand_binding_domain_mutation_was_shown_to_result_in_constitutive_activity_(response_in_the_absence_of_beta-estradiol_ligand)_and_continued_responsiveness_(inhibition_of_downstream_target_activation)_to_anti-estrogen_therapies_(tamoxifen_or_fulvestrant)_in_HEK293T_cell_lines.",24185510,PubMed,,"Robinson_et_al.,_2013,_Nat._Genet.",,5,accepted,291,21,6,152419926,152419926,A,G,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._D538G_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-05-31_01:24:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/291,https://civic.genome.wustl.edu/links/variants/47,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._D538G_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G",18,Tamoxifen,Fulvestrant,,,,chr6_g.152419926A~G,ESR1_c.1613A~G,
ESR1,2099,D538G,Breast_Cancer,1612,,Hormone_Therapy,,Predictive,Supports,D,Resistance,MCF7_cell_lines_harboring_the_D538G_mutation_in_the_ligand-binding_domain_of_ESR1_have_shown_resistance_to_hormone_therapy.,24185512,PubMed,,"Toy_et_al.,_2013,_Nat._Genet.",,3,accepted,243,21,6,152419926,152419926,A,G,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._D538G_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-04-13_16:33:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/243,https://civic.genome.wustl.edu/links/variants/47,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._D538G_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G",18,Hormone_Therapy,,,,,chr6_g.152419926A~G,ESR1_c.1613A~G,
ESR1,2099,D538G,Breast_Cancer,1612,,"Letrozole,Palbociclib",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_a_study_of_16_patients_with_metastatic_breast_cancer_(NCT02142868)_treated_with_palbociclib_in_combination_with_letrozole,_patients_with_ESR1_mutations_(5/16),_including_ESR1_D538G_(n=2),_detected_at_any_time_or_at_initial_blood_draw,_were_associated_with_reduced_progression_free_survival_(HR=0.31,_95%_CI:_0.05-0.95,_P=0.047),_as_compared_with_patients_with_wildtype_ESR1_(n=11)._There_was_no_significant_difference_in_overall_survival_(median;_14.1_versus_12.8_months,_HR=0.40;_95%_CI:_0.06-2.0,_P-value=0.24).",27556863,PubMed,,"Gyanchandani_et_al.,_2016,_Oncotarget",,2,accepted,4814,21,6,152419926,152419926,A,G,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._D538G_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-07-25_22:25:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/4814,https://civic.genome.wustl.edu/links/variants/47,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._D538G_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G",18,Letrozole,Palbociclib,,,,chr6_g.152419926A~G,ESR1_c.1613A~G,
ESR1,2099,Y537C,Breast_Cancer,1612,,"Tamoxifen,Fulvestrant",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Using_an_estrogen_response_element_(ERE)-luciferase_reporter_system_co-transfected_with_one_of_five_ESR1_mutants,_the_Y537C_ligand_binding_domain_mutation_was_shown_to_result_in_constitutive_activity_(response_in_the_absence_of_beta-estradiol_ligand)_and_continued_responsiveness_(inhibition_of_downstream_target_activation)_to_anti-estrogen_therapies_(tamoxifen_or_fulvestrant)_in_HEK293T_cell_lines.",24185510,PubMed,,"Robinson_et_al.,_2013,_Nat._Genet.",,5,accepted,292,21,6,152419923,152419923,A,G,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537C_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-05-31_01:24:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/292,https://civic.genome.wustl.edu/links/variants/48,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537C_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1610A>G,NC_000006.11:g.152419923A>G",8,Tamoxifen,Fulvestrant,,,,chr6_g.152419923A~G,ESR1_c.1610A~G,
ESR1,2099,Y537C,Breast_Cancer,1612,,Hormone_Therapy,,Predictive,Supports,D,Resistance,MCF7_cell_lines_harboring_the_Y537C_mutation_in_the_ligand-binding_domain_of_ESR1_have_shown_resistance_to_hormone_therapy.,24185512,PubMed,,"Toy_et_al.,_2013,_Nat._Genet.",,3,accepted,244,21,6,152419923,152419923,A,G,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537C_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/244,https://civic.genome.wustl.edu/links/variants/48,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537C_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1610A>G,NC_000006.11:g.152419923A>G",8,Hormone_Therapy,,,,,chr6_g.152419923A~G,ESR1_c.1610A~G,
ESR1,2099,Y537N,Breast_Cancer,1612,,Hormone_Therapy,,Predictive,Supports,D,Resistance,MCF7_cell_lines_harboring_the_Y537N_mutation_in_the_ligand-binding_domain_of_ESR1_have_shown_resistance_to_hormone_therapy.,24185512,PubMed,,"Toy_et_al.,_2013,_Nat._Genet.",,3,accepted,245,21,6,152419922,152419922,T,A,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537N_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/245,https://civic.genome.wustl.edu/links/variants/49,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537N_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1609T>A,NC_000006.11:g.152419922T>A",8,Hormone_Therapy,,,,,chr6_g.152419922T~A,ESR1_c.1609T~A,
ESR1,2099,Y537N,Breast_Cancer,1612,,"Tamoxifen,Fulvestrant",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Using_an_estrogen_response_element_(ERE)-luciferase_reporter_system_co-transfected_with_one_of_five_ESR1_mutants,_the_Y537N_ligand_binding_domain_mutation_was_shown_to_result_in_constitutive_activity_(response_in_the_absence_of_beta-estradiol_ligand)_and_continued_responsiveness_(inhibition_of_downstream_target_activation)_to_anti-estrogen_therapies_(tamoxifen_or_fulvestrant)_in_HEK293T_cell_lines.",24185510,PubMed,,"Robinson_et_al.,_2013,_Nat._Genet.",,5,accepted,293,21,6,152419922,152419922,T,A,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537N_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-05-31_01:25:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/293,https://civic.genome.wustl.edu/links/variants/49,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537N_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1609T>A,NC_000006.11:g.152419922T>A",8,Tamoxifen,Fulvestrant,,,,chr6_g.152419922T~A,ESR1_c.1609T~A,
ESR1,2099,Y537S,Breast_Cancer,1612,,Hormone_Therapy,,Predictive,Supports,D,Resistance,MCF7_cell_lines_harboring_the_L537S_mutation_in_the_ligand-binding_domain_of_ESR1_have_shown_resistance_to_hormone_therapy.,24185512,PubMed,,"Toy_et_al.,_2013,_Nat._Genet.",,3,accepted,246,21,6,152419923,152419923,A,C,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537S_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/246,https://civic.genome.wustl.edu/links/variants/50,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537S_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1610A>C,NC_000006.11:g.152419923A>C",8,Hormone_Therapy,,,,,chr6_g.152419923A~C,ESR1_c.1610A~C,
ESR1,2099,Y537S,Breast_Cancer,1612,,"Tamoxifen,Fulvestrant",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Using_an_estrogen_response_element_(ERE)-luciferase_reporter_system_co-transfected_with_one_of_five_ESR1_mutants,_the_Y537S_ligand_binding_domain_mutation_was_shown_to_result_in_constitutive_activity_(response_in_the_absence_of_beta-estradiol_ligand)_and_continued_responsiveness_(inhibition_of_downstream_target_activation)_to_anti-estrogen_therapies_(tamoxifen_or_fulvestrant)_in_HEK293T_cell_lines.",24185510,PubMed,,"Robinson_et_al.,_2013,_Nat._Genet.",,5,accepted,294,21,6,152419923,152419923,A,C,ENST00000206249.3,,,,,75,GRCh37,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537S_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",Somatic_Mutation,2017-05-31_01:18:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/294,https://civic.genome.wustl.edu/links/variants/50,https://civic.genome.wustl.edu/links/genes/21,"ESR1_biology_has_become_a_central_focus_in_breast_cancer_therapy._In_ER+_tumors,_mutations_in_the_ESR1_ligand_binding_domain_have_been_shown_to_confer_resistance_to_hormone_therapy._This_evidence_has_led_to_an_increased_use_of_targeted_sequencing_of_the_estrogen_receptor_in_breast_and_ovarian_cancer._Y537S_is_one_of_these_ligand_binding_domain_mutations,_and_is_commonly_implicated_in_this_hormone_resistance._Preliminary_data_suggests_ER-degrading_agents,_such_as_fulvestrant,_may_be_beneficial_in_treating_ESR1_mutant,_hormone_resistant_breast_cancers.",ESR1_Ligand-Binding_Domain,missense_variant,"ENST00000206249.3:c.1610A>C,NC_000006.11:g.152419923A>C",8,Tamoxifen,Fulvestrant,,,,chr6_g.152419923A~C,ESR1_c.1610A~C,
FGFR2,2263,FGFR2-MGEA5,Cholangiocarcinoma,4947,,Ponatinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_single_patient_with_this_fusion_in_intrahepatic_cholangiocarcinoma._Ponatinib_treatment_resulted_in_necrosis_and_shrinkage_of_the_primary_and_metastatic_sites_and_overall_stable_disease._However,_this_response_did_not_meet_criteria_for_RECIST_partial_response.",24550739,PubMed,,"Borad_et_al.,_2014,_PLoS_Genet.",,2,accepted,295,22,10,123243212,123357917,,,ENST00000457416.2,10,103544209,103552700,ENST00000361464.3,75,GRCh37,"In_a_clinical_sequencing_program_for_advanced_stage_cancers,_Wu_et_al_(2013,_Cancer_Discovery)_has_idenified_a_number_of_FGFR_fusions_in_patients_with_many_different_cancer_types._These_fusions_were_also_found_to_retain_oligomerization_capability,_and_result_in_enhanced_cell_proliferation._Cell_lines_harboring_these_fusions_were_shown_to_respond_to_pazopanib._Additionally,_tumor_size_reduction_was_achieved_by_both_ponatinib_and_pazopanib_treatments_administered_separately_in_a_single_patient_with_intrahepatic_cholangiocarcinoma_and_this_fusion._The_authors_use_these_cases_to_highlight_the_need_for_enhanced_clinical_sequencing_efforts.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/295,https://civic.genome.wustl.edu/links/variants/52,https://civic.genome.wustl.edu/links/genes/22,"In_a_clinical_sequencing_program_for_advanced_stage_cancers,_Wu_et_al_(2013,_Cancer_Discovery)_has_idenified_a_number_of_FGFR_fusions_in_patients_with_many_different_cancer_types._These_fusions_were_also_found_to_retain_oligomerization_capability,_and_result_in_enhanced_cell_proliferation._Cell_lines_harboring_these_fusions_were_shown_to_respond_to_pazopanib._Additionally,_tumor_size_reduction_was_achieved_by_both_ponatinib_and_pazopanib_treatments_administered_separately_in_a_single_patient_with_intrahepatic_cholangiocarcinoma_and_this_fusion._The_authors_use_these_cases_to_highlight_the_need_for_enhanced_clinical_sequencing_efforts.",FGFR_fusions,transcript_fusion,,5,Ponatinib,,,,,,,
FGFR3,2261,FGFR3-BAIAP2L1,Bladder_Carcinoma,4007,,PD173074,,Predictive,Supports,D,Sensitivity/Response,"Following_identification_of_this_fusion_in_a_patient,_this_fusion_was_expressed_in_HEK_293T_cells_leading_to_oligomerization_in_the_absence_of_ligand,_induced_morphologic_changes_in_the_cell_and_increased_cellular_proliferation_consistent_with_FGFR_activation._Mouse_xenografts_using_the_bladder_cell_line_SW780_which_harbors_an_FGFR3-BAIAP2L1_fusion_showed_reduced_tumor_burden_when_treated_with_the_FGFR_inhibitor_PD173074.",23558953,PubMed,,"Wu_et_al.,_2013,_Cancer_Discov",,3,accepted,144,23,4,1795039,1810599,,,ENST00000340107.4,7,97991744,97920963,ENST00000005260.8,75,GRCh37,"In_a_clinical_sequencing_program_for_advanced_stage_cancers,_Wu_et_al_(2013,_Cancer_Discovery)_has_identified_a_number_of_FGFR_fusions_in_patients_with_many_different_cancer_types._These_fusions_were_also_found_to_retain_oligomerization_capability,_and_result_in_enhanced_cell_proliferation._These_fusions_were_shown_to_respond_to_pazopanib._The_authors_use_these_cases_to_highlight_the_need_for_enhanced_clinical_sequencing_efforts.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/144,https://civic.genome.wustl.edu/links/variants/53,https://civic.genome.wustl.edu/links/genes/23,"In_a_clinical_sequencing_program_for_advanced_stage_cancers,_Wu_et_al_(2013,_Cancer_Discovery)_has_identified_a_number_of_FGFR_fusions_in_patients_with_many_different_cancer_types._These_fusions_were_also_found_to_retain_oligomerization_capability,_and_result_in_enhanced_cell_proliferation._These_fusions_were_shown_to_respond_to_pazopanib._The_authors_use_these_cases_to_highlight_the_need_for_enhanced_clinical_sequencing_efforts.",FGFR_fusions,transcript_fusion,,3,PD173074,,,,,,,
FGFR2,2263,FGFR2-TACC3,Cholangiocarcinoma,4947,,"Pazopanib,Ponatinib",Sequential,Predictive,Supports,C,Sensitivity/Response,In_a_43_year_old_female_patient_with_this_fusion_in_intrahepatic_cholangiocarcinoma._Both_pazopanib_and_ponatinib_separately_resulted_in_minor_tumor_shrinkage._This_fusion_is_also_shown_to_be_recurrent_in_multiple_other_cancer_types.,24550739,PubMed,,"Borad_et_al.,_2014,_PLoS_Genet.",,3,accepted,296,22,4,123243212,123357598,,,ENST00000358487.5,4,1723266,1741505,ENST00000313288.4,75,GRCh37,"In_a_clinical_sequencing_program_for_advanced_stage_cancers,_Wu_et_al_has_identified_a_number_of_FGFR_fusions_in_patients_with_many_different_cancer_types._These_fusions_were_also_found_to_retain_oligomerization_capability,_and_result_in_enhanced_cell_proliferation._These_fusions_were_shown_to_respond_to_pazopanib._The_authors_use_these_cases_to_highlight_the_need_for_enhanced_clinical_sequencing_efforts.",Somatic_Mutation,2017-05-31_00:16:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/296,https://civic.genome.wustl.edu/links/variants/54,https://civic.genome.wustl.edu/links/genes/22,"In_a_clinical_sequencing_program_for_advanced_stage_cancers,_Wu_et_al_has_identified_a_number_of_FGFR_fusions_in_patients_with_many_different_cancer_types._These_fusions_were_also_found_to_retain_oligomerization_capability,_and_result_in_enhanced_cell_proliferation._These_fusions_were_shown_to_respond_to_pazopanib._The_authors_use_these_cases_to_highlight_the_need_for_enhanced_clinical_sequencing_efforts.",FGFR_fusions,transcript_fusion,,7.5,Pazopanib,Ponatinib,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,AG1296,,Predictive,Supports,D,Sensitivity/Response,AG1296_is_effective_in_triggering_apoptosis_in_Ba/F3_and_primary_AML_cells_with_FLT3_internal_tandem_repeat.,12357354,PubMed,,"Tse_et_al.,_2002,_Leukemia",,4,accepted,299,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/299,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,AG1296,,,,,,,
FLT3,2322,ITD,Acute_Promyelocytic_Leukemia,60318,,"Anthracycline,All-trans_Retinoic_Acid",Combination,Predictive,Supports,B,Resistance,"In_a_study_of_171_APL_patients_treated_with_combination_ATRA/anthracycline_chemotherapy,_FLT3_ITD_mutations_(n=35)_were_associated_with_lower_3-year_OS_compared_to_the_FLT3_ITD-negative_group_(62%_vs._82%),_as_well_as_higher_CR_achievement_failure_and_early_death.",24981688,PubMed,,"Lucena-Araujo_et_al.,_2014,_Ann._Hematol.",,4,accepted,1112,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-02-25_18:37:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1112,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Anthracycline,All-trans_Retinoic_Acid,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,Selumetinib_(AZD6244),,Predictive,Supports,B,Resistance,"Forty-seven_patients_with_relapsed/refractory_AML_or_60+_years_old_with_untreated_AML_were_enrolled_on_a_phase_II_study._In_FLT3_wild-type_patients,_six_out_of_36_(17%)_had_a_response_(1_PR,_3_MR,_2_uMR)_that_lasted_a_median_of_58_days_(range,_33–273_days)._No_patient_with_FLT3-ITD_(n_=_10)_responded._One_patient_with_unknown_FLT3_status_also_had_no_response._Of_note,_this_study_did_not_meet_its_primary_endpoint_of_6_responses_(CR,_CRi,_PR_or_MR)_in_the_first_35_patients_enrolled.",24178622,PubMed,,"Jain_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,1137,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-03-14_14:16:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1137,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Selumetinib_(AZD6244),,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,Daunorubicin,,Predictive,Supports,D,Resistance,Ba/F3_cells_with_both_FLT3-ITD_and_TKD_mutations_on_the_same_allele_have_more_resistance_to_daunorubicin_than_cells_with_FLT3-ITD_alone.,15626738,PubMed,,"Bagrintseva_et_al.,_2005,_Blood",,3,accepted,130,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/130,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Daunorubicin,,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,SU5614,,Predictive,Supports,D,Resistance,Ba/F3_cells_with_both_FLT3-ITD_and_TKD_mutations_on_the_same_allele_have_more_resistance_to_the_protein_tyrosine_kinase_(PTK)_inhibitor_SU5614_than_cells_with_FLT3-ITD_alone_or_FLT3_ITD_and_TKD_mutations_on_opposing_alleles.,15626738,PubMed,,"Bagrintseva_et_al.,_2005,_Blood",,3,accepted,131,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/131,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,SU5614,,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,B,Sensitivity/Response,"Sorafenib_is_effective_in_patients_with_FLT3_internal_tandem_repeats,_but_not_in_wild_type_or_D835_mutation.",18230792,PubMed,,"Zhang_et_al.,_2008,_J._Natl._Cancer_Inst.",,4,accepted,298,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2015-06-21_16:49:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/298,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Sorafenib,,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,B,Sensitivity/Response,13_patients_with_relapsed_or_chemo-refractory_FLT3-ITD+_AML_were_treated_with_sorafenib_(200-400_mg_twice_daily)._12_patients_showed_clearance_or_near_clearance_of_bone_marrow_myeloblasts_after_27_(range_21-84)_days_with_evidence_of_differentiation_of_leukemia_cells._Sorafenib_response_was_lost_in_most_patients_after_72_(range_54-287)_days.,22368270,PubMed,,"Man_et_al.,_2012,_Blood",,2,accepted,1040,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-02-19_23:30:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1040,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Sorafenib,,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,Lestaurtinib_(CEP-701),,Predictive,Supports,B,Sensitivity/Response,CEP701_was_effective_in_reducing_blast_counts_of_5/14_heavily_pre-treated_AML_patients_with_FLT3_mutations.,14726387,PubMed,,"Smith_et_al.,_2004,_Blood",,4,accepted,297,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/297,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Lestaurtinib_(CEP-701),,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,All-trans_Retinoic_Acid,,Predictive,Supports,B,Resistance,ATRA_treatment_did_not_effect_overall_survival_in_patients_<60_years_old_with_FLT3-ITD_mutation.,19965647,PubMed,,"Burnett_et_al.,_2010,_Blood",,3,accepted,127,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/127,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,All-trans_Retinoic_Acid,,,,,,,
FLT3,2322,ITD,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,C,Sensitivity/Response,"Six_children_with_relapsed_or_refractory_FLT3-ITD-positive_AML_received_initial_therapy_with_sorafenib_(alone_or_in_combination_with_clofarabine_and_cytarabine).__Four_of_the_patients_initially_achieved_morphological_complete_remission_(bone_marrow_blasts_<5%),_however,_3_patients_developed_resistance_within_14-37_weeks_and_and_1_required_a_bone_marrow_transplant.__Two_patients_did_not_have_any_clinical_response_to_sorafenib_upon_initial_treatment.",23969938,PubMed,,"Baker_et_al.,_2013,_Clin._Cancer_Res.",,1,accepted,1555,24,13,28608219,28608351,,,ENST00000241453.7,,,,,75,GRCh37,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",Somatic_Mutation,2016-08-28_22:03:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1555,https://civic.genome.wustl.edu/links/variants/55,https://civic.genome.wustl.edu/links/genes/24,"FLT3-ITD_(internal_tandem_duplications)_frequently_occur_in_patients_with_hematologic_malignancies_such_as_chronic_myelogenous_leukemia,_acute_myeloid_leukemia_(AML)_and_myelodysplastic_syndrome,_but_particularly_in_cytogenetically_normal_AML_(CN-AML)._These_duplication_events_disrupt_the_juxtamembrane_domain_of_FLT3_and_can_be_the_result_of_a_duplication_of_internal_FLT3_sequence_or_other_unrelated_sequence_resulting_in_an_in-frame_duplication_event._The_length_of_these_duplications_can_vary_widely_which_may_have_prognostic_consequences,_but_this_has_not_been_conclusively_determined._FLT3-ITD_mutations_overall_have_generally_been_associated_with_poor_prognosis._Additional_genes_associated_with_CN-AML_such_as_NPM1_may_modulate_the_prognosis_associated_with_this_variant.",,inframe_insertion,,432.5,Sorafenib,,,,,,,
FLT3,2322,TKD_MUTATION,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,B,Resistance,"Sorafenib_is_effective_in_patients_with_FLT3_internal_tandem_repeat_mutations,_but_not_in_patients_with_wild_type_or_D835_mutation.",18230792,PubMed,,"Zhang_et_al.,_2008,_J._Natl._Cancer_Inst.",,4,accepted,248,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,"FLT3_tyrosine_kinase_domain_mutations_(FLT3-TKD)_are_much_less_common_than_FLT3-ITD_(internal_tandem_duplication)_mutations_and_may_not_confer_the_same_prognostic_impact._Although_the_majority_of_mutations_are_point_mutations_effecting_D835_(most_frequently_D835Y),_a_small_proportion_involve_an_in-frame_deletion_of_I836._These_mutations_are_within_the_activation_loop_of_the_second_tyrosine_kinase_domain_of_FLT3_and_thought_to_result_in_constitutive_activation_of_the_receptor.",Somatic_Mutation,2015-06-21_16:49:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/248,https://civic.genome.wustl.edu/links/variants/56,https://civic.genome.wustl.edu/links/genes/24,"FLT3_tyrosine_kinase_domain_mutations_(FLT3-TKD)_are_much_less_common_than_FLT3-ITD_(internal_tandem_duplication)_mutations_and_may_not_confer_the_same_prognostic_impact._Although_the_majority_of_mutations_are_point_mutations_effecting_D835_(most_frequently_D835Y),_a_small_proportion_involve_an_in-frame_deletion_of_I836._These_mutations_are_within_the_activation_loop_of_the_second_tyrosine_kinase_domain_of_FLT3_and_thought_to_result_in_constitutive_activation_of_the_receptor.",,nonsynonymous_variant,NC_000013.10:g.28592642C>A,120,Sorafenib,,,,,chr13_g.28592642C~A,,
FLT3,2322,TKD_MUTATION,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,B,Resistance,Emergence_of_D835_mutation_in_AML_patients_with_FLT3_tandem_repeat_is_associated_with_sorafenib_resistance.,22368270,PubMed,,"Man_et_al.,_2012,_Blood",,4,accepted,247,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,"FLT3_tyrosine_kinase_domain_mutations_(FLT3-TKD)_are_much_less_common_than_FLT3-ITD_(internal_tandem_duplication)_mutations_and_may_not_confer_the_same_prognostic_impact._Although_the_majority_of_mutations_are_point_mutations_effecting_D835_(most_frequently_D835Y),_a_small_proportion_involve_an_in-frame_deletion_of_I836._These_mutations_are_within_the_activation_loop_of_the_second_tyrosine_kinase_domain_of_FLT3_and_thought_to_result_in_constitutive_activation_of_the_receptor.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/247,https://civic.genome.wustl.edu/links/variants/56,https://civic.genome.wustl.edu/links/genes/24,"FLT3_tyrosine_kinase_domain_mutations_(FLT3-TKD)_are_much_less_common_than_FLT3-ITD_(internal_tandem_duplication)_mutations_and_may_not_confer_the_same_prognostic_impact._Although_the_majority_of_mutations_are_point_mutations_effecting_D835_(most_frequently_D835Y),_a_small_proportion_involve_an_in-frame_deletion_of_I836._These_mutations_are_within_the_activation_loop_of_the_second_tyrosine_kinase_domain_of_FLT3_and_thought_to_result_in_constitutive_activation_of_the_receptor.",,nonsynonymous_variant,NC_000013.10:g.28592642C>A,120,Sorafenib,,,,,chr13_g.28592642C~A,,
FLT3,2322,TKD_MUTATION,Acute_Myeloid_Leukemia,9119,,Midostaurin,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_clinical_study_of_95_AML/high-risk_MDS_patients_treated_with_either_50_or_100_mg_midostaurin,_35_harbored_FLT3_mutations_(26_had_FLT3_ITD,_9_had_FLT3_D835Y_mutations)._A_higher_percentage_of_patients_saw_blast_reductions_in_the_FLT3_mutant_group_than_in_the_FLT3_wild_type_group_(71_vs_42%)._Only_one_permanent_response_occurred_in_a_FLT3_mutant_patient_receiving_the_100_mg_dose._No_differences_were_observed_in_toxicity_or_response_rate_between_the_two_doses_of_midostaurin.",20733134,PubMed,,"Fischer_et_al.,_2010,_J._Clin._Oncol.",,3,accepted,1295,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,"FLT3_tyrosine_kinase_domain_mutations_(FLT3-TKD)_are_much_less_common_than_FLT3-ITD_(internal_tandem_duplication)_mutations_and_may_not_confer_the_same_prognostic_impact._Although_the_majority_of_mutations_are_point_mutations_effecting_D835_(most_frequently_D835Y),_a_small_proportion_involve_an_in-frame_deletion_of_I836._These_mutations_are_within_the_activation_loop_of_the_second_tyrosine_kinase_domain_of_FLT3_and_thought_to_result_in_constitutive_activation_of_the_receptor.",Somatic_Mutation,2016-10-25_04:27:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1295,https://civic.genome.wustl.edu/links/variants/56,https://civic.genome.wustl.edu/links/genes/24,"FLT3_tyrosine_kinase_domain_mutations_(FLT3-TKD)_are_much_less_common_than_FLT3-ITD_(internal_tandem_duplication)_mutations_and_may_not_confer_the_same_prognostic_impact._Although_the_majority_of_mutations_are_point_mutations_effecting_D835_(most_frequently_D835Y),_a_small_proportion_involve_an_in-frame_deletion_of_I836._These_mutations_are_within_the_activation_loop_of_the_second_tyrosine_kinase_domain_of_FLT3_and_thought_to_result_in_constitutive_activation_of_the_receptor.",,nonsynonymous_variant,NC_000013.10:g.28592642C>A,120,Midostaurin,,,,,chr13_g.28592642C~A,,
GATA2,2624,EXPRESSION,Lung_Adenocarcinoma,3910,,"Bortezomib,Fasudil",Combination,Predictive,Supports,D,Sensitivity/Response,Targeting_overactive_GATA2-mediated_pathways_with_inhibitors_bortezomib_and_fasudil_led_to_dramatic_tumor_regression.,22541434,PubMed,,"Kumar_et_al.,_2012,_Cell",,4,accepted,301,25,3,128198270,128212028,,,ENST00000341105.2,,,,,75,GRCh37,"GATA2_misregulation_has_been_observed_in_a_number_of_hematologic_malignancies,_as_well_as_non-small_cell_lung_cancer._Treatment_of_over-active_GATA2_pathways_using_the_proteasome_inhibitor_bortezomib_has_shown_dramatic_tumor_regression_in_lung_cancer.",Somatic_Mutation,2016-11-03_19:01:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/301,https://civic.genome.wustl.edu/links/variants/57,https://civic.genome.wustl.edu/links/genes/25,"GATA2_misregulation_has_been_observed_in_a_number_of_hematologic_malignancies,_as_well_as_non-small_cell_lung_cancer._Treatment_of_over-active_GATA2_pathways_using_the_proteasome_inhibitor_bortezomib_has_shown_dramatic_tumor_regression_in_lung_cancer.",,,,4,Bortezomib,Fasudil,,,,,,
IDH1,3417,R132C,Acute_Myeloid_Leukemia,9119,,AG-120,,Predictive,Supports,B,Sensitivity/Response,"In_a_clinical_study_of_17_relapsed_or_refractory_AML_patients_harboring_IDH1_mutations,_these_patients_were_associated_with_response_to_AG-120_monotherapy;_4/7_patients_who_achieved_a_response_experienced_complete_remission.",25583779,PubMed,,"2015,_Cancer_Discov",,2,accepted,2331,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2017-07-25_19:50:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2331,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,AG-120,,,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
IDH1,3417,R132C,Acute_Myeloid_Leukemia,9119,,"Bis-2-[5-(phenylacetamide)-1,3,4-thiadiazol-2-yl]ethyl_Sulfide",,Predictive,Supports,D,Sensitivity/Response,"In_an_experimental_study_of_acute_myeloid_leukemia_(AML)_cell_lines_expressing_IDH1_R132C,_IDH1_R132G,_or_IDH1_R132H_mutations_were_associated_with_increased_sensitivity_to_small_molecule_glutaminase_inhibitor,_bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl_sulfide_(BPTES)_as_compared_to_AML_cell_lines_expressing_wild-type_IDH1._Sensitivity_was_determined_by_assessing_cell_growth.",24333121,PubMed,,"Emadi_et_al.,_2014,_Exp._Hematol.",,3,accepted,2332,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2017-07-25_19:50:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2332,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,Bis-2-[5-(phenylacetamide)-1,3,4-thiadiazol-2-yl]ethyl_Sulfide,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
IDH1,3417,R132C,Malignant_Glioma,3070,,Bevacizumab,,Predictive,Supports,B,Sensitivity/Response,"In_a_clinical_study_of_63_recurrent_glioma_patients,_patients_treated_with_bevacizumab_monotherapy_(n=11)_and_harboring_IDH1_codon_132_mutation_were_associated_with_improved_progression_free_survival_(3.23_months_vs._1.37_months,_P=0.05),_as_compared_to_patients_with_wild-type_IDH1.",22199315,PubMed,,"Lv_et_al.,_2011,_Anticancer_Res.",,2,accepted,2330,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2017-07-25_19:50:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/2330,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,Bevacizumab,,,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
IDH1,3417,R132C,Acute_Myeloid_Leukemia,9119,,GSK321,,Predictive,Supports,D,Sensitivity/Response,Newly_developed_allosteric_inhibitors_(GSK321)_of_IDH1_led_to_granulocytic_differentiation_in-vitro_and_in-vivo.,26436839,PubMed,,"Okoye-Okafor_et_al.,_2015,_Nat._Chem._Biol.",,3,accepted,732,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/732,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,GSK321,,,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
IDH1,3417,R132C,Glioblastoma_Multiforme,3068,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,"In_a__clinical_study_of_63_recurrent_glioma_patients,_de_novo_glioblastoma_patients_treated_with_cetuximab_monotherapy_(n=27)_and_harboring_IDH1_codon_132_mutation_were_associated_with_improved_overall_survival_(5.13_months_vs._0.90_months,_95%_CI:_1.8,_P=0.035),_as_compared_to_patients_with_wild-type_IDH1.",22199315,PubMed,,"Lv_et_al.,_2011,_Anticancer_Res.",,,accepted,4032,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2017-07-25_19:51:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/4032,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,Cetuximab,,,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
IDH1,3417,R132C,Brain_Glioma,60108,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_189_low-grade_gliomas,_IDH_(IDH1_or_IDH2)_mutations_were_found_in_132_patients_(70%)._IDH_mutations_were_associated_with_improved_rate_of_response_to_temozolomide_as_compared_to_patients_with_wildtype_IDH_(61%__vs._17%_,_P=0.01).",20975057,PubMed,,"Houillier_et_al.,_2010,_Neurology",,2,accepted,2327,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2017-07-25_19:50:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/2327,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,Temozolomide,,,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
IDH1,3417,R132C,Malignant_Glioma,3070,,AGI-5198,,Predictive,Supports,D,Sensitivity/Response,"In_an_experimental_in_vitro_study,_glioma_cells_expressing_IDH1_R132C_were_associated_with_sensitivity_to_AGI-5198_(IC50:_0.16M_vs._IC50_>_100.00M),_as_compared_to_cells_expressing_wild-type_IDH1._Sensitivity_was_determined_by_assessing_cell_growth.",23558169,PubMed,,"Rohle_et_al.,_2013,_Science",,2,accepted,2329,26,2,209113113,209113113,G,A,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2017-07-10_21:43:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/2329,https://civic.genome.wustl.edu/links/variants/59,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",63,AGI-5198,,,,,chr2_g.209113113G~A,IDH1_c.394C~T,IDH1_R132C
JAK2,3717,V617F,Polycythemia_Vera,8997,,Pegylated_IFN-alpha-2a,,Predictive,Supports,B,Sensitivity/Response,"In_patients_with_JAK2_V617F,_the_use_of_pegylated_IFN-alpha-2a_leads_to_reduction_in_the_percentage_of_cells_harboring_JAK2_V617F.",16709929,PubMed,,"Kiladjian_et_al.,_2006,_Blood",,4,accepted,19,28,9,5073770,5073770,G,T,ENST00000381652.3,,,,,75,GRCh37,"JAK2_V617F_is_a_highly_recurrent_mutation_in_myeloproliferative_diseases._It_is_found_in_around_98%_of_patients_with_polycythemia_vera,_and_just_over_half_of_the_patients_with_essential_thrombocythemia_and_primary_myelofibrosis._While_less_associated_with_cancer,_when_it_is_seen,_it_is_more_likely_to_be_in_myeloid_leukemias_than_lymphoid_leukemias._The_V617F_mutation_is_an_activating_mutation,_resulting_in_increased_kinase_activity._The_mutation_seems_to_be_restricted_to_hematologic_malignancies._Treatment_of_JAK_mutant_diseases_with_ruxolitinib_has_seen_some_clinical_success.",Somatic_Mutation,2015-06-21_16:49:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/19,https://civic.genome.wustl.edu/links/variants/64,https://civic.genome.wustl.edu/links/genes/28,"JAK2_V617F_is_a_highly_recurrent_mutation_in_myeloproliferative_diseases._It_is_found_in_around_98%_of_patients_with_polycythemia_vera,_and_just_over_half_of_the_patients_with_essential_thrombocythemia_and_primary_myelofibrosis._While_less_associated_with_cancer,_when_it_is_seen,_it_is_more_likely_to_be_in_myeloid_leukemias_than_lymphoid_leukemias._The_V617F_mutation_is_an_activating_mutation,_resulting_in_increased_kinase_activity._The_mutation_seems_to_be_restricted_to_hematologic_malignancies._Treatment_of_JAK_mutant_diseases_with_ruxolitinib_has_seen_some_clinical_success.",,"gain_of_function_variant,missense_variant","NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T",83,Pegylated_IFN-alpha-2a,,,,,chr9_g.5073770G~T,JAK2_c.1849G~T,JAK2_V617F
JAK2,3717,V617F,Polycythemia_Vera,8997,,TG101348,,Predictive,Supports,D,Sensitivity/Response,TG101348_effectively_inhibits_STAT5_signaling_in_JAK2_V617F_cells.,18394554,PubMed,,"Wernig_et_al.,_2008,_Cancer_Cell",,3,accepted,20,28,9,5073770,5073770,G,T,ENST00000381652.3,,,,,75,GRCh37,"JAK2_V617F_is_a_highly_recurrent_mutation_in_myeloproliferative_diseases._It_is_found_in_around_98%_of_patients_with_polycythemia_vera,_and_just_over_half_of_the_patients_with_essential_thrombocythemia_and_primary_myelofibrosis._While_less_associated_with_cancer,_when_it_is_seen,_it_is_more_likely_to_be_in_myeloid_leukemias_than_lymphoid_leukemias._The_V617F_mutation_is_an_activating_mutation,_resulting_in_increased_kinase_activity._The_mutation_seems_to_be_restricted_to_hematologic_malignancies._Treatment_of_JAK_mutant_diseases_with_ruxolitinib_has_seen_some_clinical_success.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/20,https://civic.genome.wustl.edu/links/variants/64,https://civic.genome.wustl.edu/links/genes/28,"JAK2_V617F_is_a_highly_recurrent_mutation_in_myeloproliferative_diseases._It_is_found_in_around_98%_of_patients_with_polycythemia_vera,_and_just_over_half_of_the_patients_with_essential_thrombocythemia_and_primary_myelofibrosis._While_less_associated_with_cancer,_when_it_is_seen,_it_is_more_likely_to_be_in_myeloid_leukemias_than_lymphoid_leukemias._The_V617F_mutation_is_an_activating_mutation,_resulting_in_increased_kinase_activity._The_mutation_seems_to_be_restricted_to_hematologic_malignancies._Treatment_of_JAK_mutant_diseases_with_ruxolitinib_has_seen_some_clinical_success.",,"gain_of_function_variant,missense_variant","NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T",83,TG101348,,,,,chr9_g.5073770G~T,JAK2_c.1849G~T,JAK2_V617F
KIT,3815,D816V,Systemic_Mastocytosis,349,,Midostaurin,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_II_clinical_trial,_60%_of_patients_(N=89)_with_advanced_systemic_mastocytosis_responded_to_treatment_with_midostaurin.",27355533,PubMed,,"Gotlib_et_al.,_2016,_N._Engl._J._Med.",,4,accepted,1725,29,4,55599321,55599321,A,T,ENST00000288135.5,,,,,75,GRCh37,KIT_D816V_is_a_mutation_observed_in_acute_myeloid_leukemia_(AML)._This_variant_has_been_linked_to_poorer_prognosis_and_worse_outcome_in_AML_patients.,Somatic_Mutation,2016-11-04_23:12:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1725,https://civic.genome.wustl.edu/links/variants/65,https://civic.genome.wustl.edu/links/genes/29,KIT_D816V_is_a_mutation_observed_in_acute_myeloid_leukemia_(AML)._This_variant_has_been_linked_to_poorer_prognosis_and_worse_outcome_in_AML_patients.,KIT_Exon_17,missense_variant,"NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T",60,Midostaurin,,,,,chr4_g.55599321A~T,KIT_c.2447A~T,KIT_D816V
KIT,3815,EXON_11_MUTATION,Melanoma,1909,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,Melanoma_patients_with_KIT_mutation_but_not_KIT_amplification_showed_response_to_imatinib_treatment_in_a_small_cohort_of_patients.,23775962,PubMed,,"Hodi_et_al.,_2013,_J._Clin._Oncol.",,3,accepted,58,29,4,55593582,55593708,,,ENST00000288135.5,,,,,75,GRCh37,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",Somatic_Mutation,2016-10-02_15:11:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/58,https://civic.genome.wustl.edu/links/variants/66,https://civic.genome.wustl.edu/links/genes/29,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",KIT_Exon_11,coding_sequence_variant,,127.5,Imatinib,,,,,,,
KIT,3815,EXON_11_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,"This_prospective_study_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_examined_the_relationship_between_KIT_genotype_and_treatment_outcome_for_patients_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105_who_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._The_study_found_that_patients_whose_tumors_harbored_mutations_in_KIT_exon_11_had_signficantly_superior_responses_to_imatinib,_regardless_of_dose,__than_those_whose_tumors_harbored_wildtype_KIT_or_KIT_exon_9_mutations._This_is_evidenced_by_the_findings_that_imatinib-treated_patients_whose_tumors_contained_KIT_exon_11_mutations_had_longer_overall_survival_compared_to_those_with_exon_9_mutations_(60.0mo_vs.38.4mo,_P=0.011)_or_wildtype_KIT_(60mo_vs._49.0mo,_P=0.049)._Patients_with_exon_11_mutations_had_improved_progression-free_survival_in_comparison_to_those_with_exon_9_mutations_(24.7mo_vs._16.7mo,_P=0.0013)_or_wildtype_KIT_(24.7mo_vs._12.8mo,_P=0.005).",18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,4,accepted,2471,29,4,55593582,55593708,,,ENST00000288135.5,,,,,75,GRCh37,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",Somatic_Mutation,2019-02-08_17:24:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/2471,https://civic.genome.wustl.edu/links/variants/66,https://civic.genome.wustl.edu/links/genes/29,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",KIT_Exon_11,coding_sequence_variant,,127.5,Imatinib,,,,,,,
KIT,3815,EXON_11_MUTATION,Melanoma,1909,,Sunitinib,,Predictive,Supports,C,Sensitivity/Response,"10_melanoma_patients_were_evaluated_after_sunitinib_treatment,_among_which_3_out_of_the_4_patients_with_KIT_exon_11_mutations_showed_either_complete_or_partial_response.",22261812,PubMed,,"Minor_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,1224,29,4,55593582,55593708,,,ENST00000288135.5,,,,,75,GRCh37,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",Somatic_Mutation,2016-06-28_00:08:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1224,https://civic.genome.wustl.edu/links/variants/66,https://civic.genome.wustl.edu/links/genes/29,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",KIT_Exon_11,coding_sequence_variant,,127.5,Sunitinib,,,,,,,
KIT,3815,EXON_11_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_Phase_II_trial_for_the_treatment_of_GIST_patients_with_imatinib,_patients_with_Exon_11_Kit_mutations_(N=85)_had_significantly_better_event-free_and_overall_survival_than_patients_with_Exon_9_Kit_mutations_(N=23)_or_no_Kit_mutations_(N=9).",14645423,PubMed,,"Heinrich_et_al.,_2003,_J._Clin._Oncol.",,4,accepted,654,29,4,55593582,55593708,,,ENST00000288135.5,,,,,75,GRCh37,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",Somatic_Mutation,2015-11-17_01:26:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/654,https://civic.genome.wustl.edu/links/variants/66,https://civic.genome.wustl.edu/links/genes/29,"c-KIT_mutations_in_exon_11_lie_within_the_juxtamembrane_domain,_and_are_very_recurrent_in_gastrointestinal_stromal_tumors,_often_bearing_a_poorer_prognosis_than_other_KIT_mutations._Cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year._Small_cohorts_of_melanoma_patients_harboring_exon_11_KIT_mutations_have_shown_response_to_imatinib_and_sunitinib.",KIT_Exon_11,coding_sequence_variant,,127.5,Imatinib,,,,,,,
KIT,3815,INTERNAL_DUPLICATION,Malignant_Anus_Melanoma,14145,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_case_study,_a_patient_with_anal_melanoma_harboring_a_7_codon_duplication_in_the_juxtamambrane_region_(exon_11)_of_KIT_showed_marked_response_4_months_after_imatinib_treatment.",18421059,PubMed,,"Hodi_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,302,29,4,55593582,55593708,,,ENST00000288135.5,,,,,75,GRCh37,"c-KIT_internal_duplications_have_been_observed_in_exon_11,_within_the_juxtamembrane_domain._In_a_case_study_of_an_anal_melanoma_patient_harboring_this_event,_imatinib_confered_marked_response._Also,_cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year.",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/302,https://civic.genome.wustl.edu/links/variants/67,https://civic.genome.wustl.edu/links/genes/29,"c-KIT_internal_duplications_have_been_observed_in_exon_11,_within_the_juxtamembrane_domain._In_a_case_study_of_an_anal_melanoma_patient_harboring_this_event,_imatinib_confered_marked_response._Also,_cells_harboring_exon_11_mutations_have_shown_sensitivity_to_the_tyrosine_kinase_inhibitor_imatinib,_offering_a_better_prognosis_to_patients_treated_with_the_drug_in_the_first_year.",KIT_Exon_11,inframe_insertion,,7.5,Imatinib,,,,,,,
KIT,3815,L576P,Melanoma,1909,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,"The_melanoma_cell_line_WM3211,_which_harbors_the_L576P_mutation,_is_sensitive_to_dasatinib._Molecular_modeling_indicated_the_L576P_mutation_alters_the_conformation_of_KIT_but_did_not_alter_the_binding_affinity_of_dasatinib.",19671763,PubMed,,"Woodman_et_al.,_2009,_Mol._Cancer_Ther.",,3,accepted,42,29,4,55593661,55593661,T,C,ENST00000288135.5,,,,,75,GRCh37,"KIT_L576P_is_an_exon_11_mutation_that_lies_within_the_juxtamembrane_domain._It_is_one_of_the_most_recurrent_KIT_mutations_in_melanoma,_and_both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_imatinib.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/42,https://civic.genome.wustl.edu/links/variants/72,https://civic.genome.wustl.edu/links/genes/29,"KIT_L576P_is_an_exon_11_mutation_that_lies_within_the_juxtamembrane_domain._It_is_one_of_the_most_recurrent_KIT_mutations_in_melanoma,_and_both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_imatinib.",KIT_Exon_11,missense_variant,"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C",9,Dasatinib,,,,,chr4_g.55593661T~C,KIT_c.1727T~C,KIT_L576P
KIT,3815,L576P,Non-small_Cell_Lung_Carcinoma,3908,,"Dasatinib,Imatinib,Nilotinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_harboring_the_KIT_L576P_mutation_were_sensitive_to_dasatinib,_nilotinib_and_imatinib._In_these_assays,_dasatinib_was_more_efficacious_than_nilotinib_or_imatinib,_showing_results_most_similar_to_the_known_sensitive_KIT_mutation_V559D.",17372901,PubMed,,"Antonescu_et_al.,_2007,_Int._J._Cancer",,3,accepted,303,29,4,55593661,55593661,T,C,ENST00000288135.5,,,,,75,GRCh37,"KIT_L576P_is_an_exon_11_mutation_that_lies_within_the_juxtamembrane_domain._It_is_one_of_the_most_recurrent_KIT_mutations_in_melanoma,_and_both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_imatinib.",Somatic_Mutation,2017-05-31_15:41:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/303,https://civic.genome.wustl.edu/links/variants/72,https://civic.genome.wustl.edu/links/genes/29,"KIT_L576P_is_an_exon_11_mutation_that_lies_within_the_juxtamembrane_domain._It_is_one_of_the_most_recurrent_KIT_mutations_in_melanoma,_and_both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_imatinib.",KIT_Exon_11,missense_variant,"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C",9,Dasatinib,Imatinib,Nilotinib,,,chr4_g.55593661T~C,KIT_c.1727T~C,KIT_L576P
KIT,3815,L576P,Melanoma,1909,,"Imatinib,Nilotinib,Sorafenib",Substitutes,Predictive,Supports,D,Resistance,"The_melanoma_cell_line_WM3211,_which_harbors_the_L576P_mutation,_is_not_sensitive_to_imatinib,_nilotinib,_and_sorafenib._Molecular_modeling_indicated_the_L576P_mutation_alters_the_conformation_of_KIT_and_reduces_the_binding_affinity_of_imatinib.",19671763,PubMed,,"Woodman_et_al.,_2009,_Mol._Cancer_Ther.",,3,accepted,34,29,4,55593661,55593661,T,C,ENST00000288135.5,,,,,75,GRCh37,"KIT_L576P_is_an_exon_11_mutation_that_lies_within_the_juxtamembrane_domain._It_is_one_of_the_most_recurrent_KIT_mutations_in_melanoma,_and_both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_imatinib.",Somatic_Mutation,2017-05-31_00:09:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/34,https://civic.genome.wustl.edu/links/variants/72,https://civic.genome.wustl.edu/links/genes/29,"KIT_L576P_is_an_exon_11_mutation_that_lies_within_the_juxtamembrane_domain._It_is_one_of_the_most_recurrent_KIT_mutations_in_melanoma,_and_both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_imatinib.",KIT_Exon_11,missense_variant,"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C",9,Imatinib,Nilotinib,Sorafenib,,,chr4_g.55593661T~C,KIT_c.1727T~C,KIT_L576P
KIT,3815,V654A,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,D,Resistance,KIT_V654A_results_in_imatinib_resistance_in_GIST_patient-derived_cell_lines.,16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,249,29,4,55594258,55594258,T,C,ENST00000288135.5,,,,,75,GRCh37,"KIT_V654A_is_an_exon_13_mutation_that_lies_within_the_tyrosine_kinase_1_domain_of_the_protein._It_has_been_shown_to_be_an_activating_mutation_by_in_vitro_studies._This_mutation_is_associated_with_imatinib_resistance_in_melanoma_patients._However,_second_generation_TKI's_such_as_sunitinib_and_midostaurin_(PKC_412)_have_seen_success_in_acheiving_tumor_response.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/249,https://civic.genome.wustl.edu/links/variants/73,https://civic.genome.wustl.edu/links/genes/29,"KIT_V654A_is_an_exon_13_mutation_that_lies_within_the_tyrosine_kinase_1_domain_of_the_protein._It_has_been_shown_to_be_an_activating_mutation_by_in_vitro_studies._This_mutation_is_associated_with_imatinib_resistance_in_melanoma_patients._However,_second_generation_TKI's_such_as_sunitinib_and_midostaurin_(PKC_412)_have_seen_success_in_acheiving_tumor_response.",KIT_Exon_11,missense_variant,"NM_000222.2:c.1961T>C,NP_000213.1:p.Val654Ala,ENST00000288135.5:c.1961T>C,NC_000004.11:g.55594258T>C",18,Imatinib,,,,,chr4_g.55594258T~C,KIT_c.1961T~C,KIT_V654A
KIT,3815,V654A,Gastrointestinal_Stromal_Tumor,9253,,Sunitinib,,Predictive,Supports,B,Sensitivity/Response,"In_GIST_tumor_cells_and_patients_harboring_KIT_V654A_mutation,_SU11248_is_effective_for_those_that_are_refractory_to_imatinib.",16638875,PubMed,,"Prenen_et_al.,_2006,_Clin._Cancer_Res.",,3,accepted,304,29,4,55594258,55594258,T,C,ENST00000288135.5,,,,,75,GRCh37,"KIT_V654A_is_an_exon_13_mutation_that_lies_within_the_tyrosine_kinase_1_domain_of_the_protein._It_has_been_shown_to_be_an_activating_mutation_by_in_vitro_studies._This_mutation_is_associated_with_imatinib_resistance_in_melanoma_patients._However,_second_generation_TKI's_such_as_sunitinib_and_midostaurin_(PKC_412)_have_seen_success_in_acheiving_tumor_response.",Somatic_Mutation,2015-08-05_18:28:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/304,https://civic.genome.wustl.edu/links/variants/73,https://civic.genome.wustl.edu/links/genes/29,"KIT_V654A_is_an_exon_13_mutation_that_lies_within_the_tyrosine_kinase_1_domain_of_the_protein._It_has_been_shown_to_be_an_activating_mutation_by_in_vitro_studies._This_mutation_is_associated_with_imatinib_resistance_in_melanoma_patients._However,_second_generation_TKI's_such_as_sunitinib_and_midostaurin_(PKC_412)_have_seen_success_in_acheiving_tumor_response.",KIT_Exon_11,missense_variant,"NM_000222.2:c.1961T>C,NP_000213.1:p.Val654Ala,ENST00000288135.5:c.1961T>C,NC_000004.11:g.55594258T>C",18,Sunitinib,,,,,chr4_g.55594258T~C,KIT_c.1961T~C,KIT_V654A
KRAS,3845,EXON_2_MUTATION,Pancreatic_Carcinoma,4905,,Erlotinib,,Predictive,Does_Not_Support,B,Resistance,KRAS_exon_2_was_mutated_in_121_of_173_(70%)_patients_with_advanced_pancreatic_cancer_and_did_not_show_an_association_with_response_to_erlotinib_treatment.,23435671,PubMed,,"Boeck_et_al.,_2013,_J._Gastroenterol.",,3,accepted,916,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-02-13_04:06:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/916,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,Erlotinib,,,,,,,
KRAS,3845,EXON_2_MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,A,Resistance,"KRAS_mutation_status_was_assessed_in_394_tumor_samples_from_colorectal_cancer_patients_who_were_randomly_assigned_to_receive_cetuximab_plus_best_supportive_care_or_best_supportive_care_alone.___42%_of_the_tumors_evaluated_had_at_least_one_mutation_in_exon_2._Patients_with_a_colorectal_tumor_bearing_mutated_K-ras_did_not_benefit_from_cetuximab,_whereas_patients_with_a_tumor_bearing_wild-type_K-ras_did_benefit_from_cetuximab._The_effectiveness_of_cetuximab_was_significantly_associated_with_K-ras_mutation_status_(P=0.01_for_overall_survival_and_P<0.001_for_progression-free_survival)._In_patients_with_wild-type_K-ras_tumors,_treatment_with_cetuximab_as_compared_with_supportive_care_alone_significantly_improved_overall_survival._The_related_clinical_trial_ID_is_NCT00079066.",18946061,PubMed,,"Karapetis_et_al.,_2008,_N._Engl._J._Med.",,5,accepted,993,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-02-10_20:24:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/993,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,Cetuximab,,,,,,,
KRAS,3845,EXON_2_MUTATION,Colorectal_Cancer,9256,,EGFR_Inhibitor,,Predictive,Supports,B,Resistance,"102_mCRC_patients_treated_with_anti-EGFR_therapy_were_analyzed_for_34_hotspot_mutations_in_KRAS,_NRAS_and_BRAF_with_nanofluidic_digital_PCR_and_quantitative_PCR._dPCR_and_qPCR_results_were_correlated_to_PFS_and_OS._Analysis_of_only_KRAS_exon_2_hotspot_mutations_showed_that_patients_with_more_than_1%_mutant_allele_fraction_(n_=_19/83)_had_a_hazard_ratio_of_3.43_for_PFS_(95%_CI,_1.67–7.02;_P=0.002)_and_2.72_for_OS_(95%_CI,_1.52–4.88;_P=0.002)_compared_to_wild-type_patients_or_patients_with_less_than_1%_mutant_allele_fraction._Considering_all_RAS_and_BRAF_mutations,_the_patients_with_more_than_1%_mutant_allele_fraction_(n_=_37/65)_had_a_hazard_ratio_of_4.52_for_PFS_(95%_CI,_2.25–9.07;_P<0.001)_and_2.5_for_OS_(95%_CI,_1.57–4.02;_P<0.001)._ROC_analysis_showed_that_a_cut-off_of_1%_for_any_mutated_allele_offered_the_best_predictive_value.",27037411,PubMed,,"Azuara_et_al.,_2016,_Mol._Cancer_Ther.",,3,accepted,1208,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-10-10_22:54:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1208,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,EGFR_Inhibitor,,,,,,,
KRAS,3845,EXON_2_MUTATION,Colorectal_Cancer,9256,,"Irinotecan,Selumetinib_(AZD6244)",Combination,Predictive,Supports,B,Sensitivity/Response,"31_patients_with_KRAS_exon_2_mutation_(codons_12_and_13)_were_treated_with_selumetinib_and_irinotecan._All_patients_had_ECOG_status_0_or_1_and_confirmed_progression_after_first_line_therapy_with_oxaliplatin-based_chemotherapy_and_bevacizumab._Patients_with_more_than_one_line_of_therapy,_MEK_or_B-RAF_inhibitor_treatment_or_prior_irinotecan_treatment_were_excluded._The_study_was_terminated_before_full_accrual_due_to_non-protocol_considerations._Three_patients_had_a_PR,_16_patients_had_SD_>=_4_weeks._Median_PFS_for_all_patients_was_105_days,_median_OS_was_267_days.",25322874,PubMed,,"Hochster_et_al.,_2015,_Cancer_Chemother._Pharmacol.",,1,accepted,1326,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-06-28_15:28:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1326,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,Irinotecan,Selumetinib_(AZD6244),,,,,,
KRAS,3845,EXON_2_MUTATION,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Does_Not_Support,B,Sensitivity/Response,KRAS_mutation_status_was_not_predictive_of_response_to_regorafenib_treatment_in_patients_that_had_received_standard_therapy_and_progressed_within_3_months_of_their_last_treatment.,24559322,PubMed,,"Sartore-Bianchi_et_al.,_2014,_Expert_Rev_Anticancer_Ther",,4,accepted,87,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/87,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,Regorafenib,,,,,,,
KRAS,3845,EXON_2_MUTATION,Pancreatic_Cancer,1793,,"Gemcitabine,Erlotinib",Combination,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_136_pancreatic_cancer_patients,_point_mutations_in_KRAS_exon_2_were_associated_with_worse_overall_survival_compared_to_that_of_wild-type_KRAS_(5.8_vs_8.0_months;_P_=_0.001;_multivariate_analysis)._This_difference_was_largely_driven_by_the_subgroup_of_patients_with_reduced_response_to_gemcitabine-erlotinib_combination_therapy_(7.5%_vs_23.3%)_with_overall_survival_of_5.2_vs_9.7_months_(N=40_vs_30)_compared_to_those_that_received_other_therapies_with_an_overall_survival_of_7.0_months_for_both_KRAS_mutated_(N=31)_and_KRAS_wildtype_(N=35)_patients.",21862683,PubMed,,"Kim_et_al.,_2011,_Mol._Cancer_Ther.",,4,accepted,1219,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-08-15_19:58:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1219,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,Gemcitabine,Erlotinib,,,,,,
KRAS,3845,EXON_2_MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,Patients_with_colorectal_cancer_who_harbor_KRAS_mutation_have_low_response_rate_to_cetuximab.,16618717,PubMed,,"Lièvre_et_al.,_2006,_Cancer_Res.",,3,accepted,250,30,12,25398208,25398329,,,ENST00000256078.4,,,,,75,GRCh37,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/250,https://civic.genome.wustl.edu/links/variants/75,https://civic.genome.wustl.edu/links/genes/30,Exon_2_mutations_have_been_associated_with_reduced_response_rates_or_resistance_to_EGFR_inhibitors_in_non-small_cell_lung_and_colorectal_cancer._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS.,,missense_variant,,170,Cetuximab,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"This_was_a_retrospective_clinical_study_of_92_metastatic_colorectal_cancer_patients_who_received_cetuximab_in_conjunction_with_salvage_chemotherapy_(refractory_to_at_least_one_line_of_treatment)._Salvage_chemotherapy_was_composed_of_5-fluorouracil_(5-FU)_only,_5-FU_+_oxaliplatin,_5-FU_+_irinotecan,_or_5-FU_+_oxaliplatin_+_irinotecan._The_study_assessed_the_relationship_between_KRAS_mutation_status_in_primary_tumors_and_response_to_cetuximab-containing_salvage_chemotherapy,_as_measured_by_PFS._Of_the_92_patients,_60_had_wildtype_KRAS_and_32_had_mutations_in_KRAS—including_G12A,_G12C,_G12D,_G12R,_G12S,_G12V,_and_G13D._The_study_found_that_patients_harboring_a_KRAS_mutation_were_trending_toward_resistance_to_cetuximab-containing_salvage_chemotherapy_as_compared_to_patients_with_wildtype_KRAS_(p=0.094)._Note:_while_differences_in_PFS_were_nonsignificant_between_patients_with_wildtype_or_mutant_KRAS,_differences_in_objective_response_(defined_as_reduction_by_at_least_30%_in_the_sum_of_the_longest_diameters_of_target_lesions_compared_to_baseline)_were_significantly_different._Of_the_32_patients_with_mutant_KRAS,_none_responded_to_cetuximab-containing_salvage_therapy,_while_14/60_of_the_patients_with_wildtype_KRAS_(23%)_responded_(p=.002).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6296,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2018-07-12_20:11:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/6296,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Cetuximab,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,KRAS_mutations_were_significantly_associated_with_lack_of_response_to_cetuximab_in_patients_with_advanced_colorectal_cancer.,18202412,PubMed,,"Lièvre_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,135,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/135,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Cetuximab,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,Chemotherapy-refractory_patients_with_colorectal_cancer_harboring_KRAS_mutations_(primarily_G12/G13)_had_lower_response_and_disease_control_rates_and_shorter_progression_free_and_overall_survival_following_cetuximab_plus_chemotherapy_than_those_with_wildtype_KRAS.,20619739,PubMed,,"De_Roock_et_al.,_2010,_Lancet_Oncol.",,3,accepted,134,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/134,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Cetuximab,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_clinical_study_of_44_metastatic_colorectal_cancer_patients_who_recieved_FOLFIRI_(5-Fluorouacil_+_Folinic_acid_+_irinotecan)_first-line_therapy_alone_or_with_bevacizumab._It_assessed_the_relationship_between_KRAS_mutation_status_in_primary_tumors_and_response_to_irinotecan-based_first_line_therapy,_as_measured_by_PFS._Of_the_44_patients,_26_had_wildtype_KRAS_and_18_had_mutations_in_KRAS—including_G12A,_G12C,_G12D,_G12R,_G12S,_G12V,_and_G13D._The_study_found_that_patients_harboring_a_KRAS_mutation_were_not_significantly_more_resistant_to_irinotecan-based_first-line_therapy_than_patients_with_wildtype_KRAS._The_difference_in_PFS_between_patients_with_KRAS-mutated_tumors_and_the_patients_with_wtKRAS_tumors_was_nonsignificant_(PFS:_13.7_and_12.0_months;_p=_0.074).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6294,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2018-07-12_20:22:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/6294,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Irinotecan,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,Bevacizumab,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_clinical_study_of_97_metastatic_colorectal_cancer_patients_who_received_bevacizumab_in_conjunction_with_first-line_chemotherapy_(composed_of_5-fluorouracil_(5-FU)_only,_5-FU_+_oxaliplatin,_5-FU_+_irinotecan,_or_5-FU_+_oxaliplatin_+_irinotecan)._It_assessed_the_relationship_between_KRAS_mutation_status_in_primary_tumors_and_response_to_bevacizumab-containing_first_line_chemotherapy,_as_measured_by_PFS._Of_the_97_patients,_58_had_wildtype_KRAS_and_39_had_mutations_in_KRAS—including_G12A,_G12C,_G12D,_G12R,_G12S,_G12V,_and_G13D._The_study_found_that_patients_with_KRAS-mutated_tumors_were_not_significantly_more_resistant_to_bevacizumab-containing_first-line_chemotherapy_than_patients_with_wildtype_KRAS,_as_evidenced_by_a_non-significant_difference_in_PFS_between_the_two_groups_(12.1_and_11.7_months,_respectively).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6295,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2018-07-12_20:15:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/6295,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Bevacizumab,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,Oxaliplatin,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_clinical_study_of_100_metastatic_colorectal_cancer_patients_who_received_FOLFOX_(oxaliplatin_+_5-fluorouracil_+_folinic_acid)_first-line_therapy_alone_or_with_monoclonal_antibodies_(bevacizumab_or_cetuximab)._It_assessed_the_relationship_between_KRAS_mutation_status_in_primary_tumors_and_response_to_oxaliplatin-based_first-line_therapy,_as_measured_by_post_treatment_PFS._Of_100_patients,_61_had_wildtype_KRAS_and_39_had_mutations_in_KRAS—including_G12A,_G12C,_G12D,_G12R,_G12S,_G12V,_and_G13D._The_study_found_that_patients_with_KRAS-mutated_tumors_were_not_significantly_more_resistant_to_oxaliplatin-based_first-line_therapy_than_patients_with_wildtype_KRAS,_as_evidenced_by_a_nonsignificant_difference_in_PFS_(11.7_and_11.4_months,_respectively).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6293,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2018-07-12_20:24:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/6293,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Oxaliplatin,,,,,,,
KRAS,3845,G12/G13,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,B,Resistance,"Mutational_analysis_of_109_metastatic_colorectal_cancer_patients_was_used_to_examine_objective_tumor_response,_progression_free_survival_(PFS),_and_overall_survival_(OS)_following_treatment_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._In_univariate_analysis,_KRAS_mutations_(G12V,_G12S,_G12D,_G12A,_G13V,_G13D)_were_significantly_associated_with_lack_of_response_to_panitumumab_or_cetuximab_(objective_response_rate:_2/32_vs_20/77_for_patients_harboring_KRAS_mutated_or_wildtype_tumors,_respectively;_P_=_0.019)._Multivariate_logistic_regression_of_KRAS_mutations,_PIK3CA_mutations_and_PTEN_protein_expression_also_confirmed_an_independent_effect_of_KRAS_mutations_on_objective_response_(p_=_0.0029)._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_(32/108)_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,3,accepted,6363,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2018-10-09_21:44:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/6363,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Panitumumab,Cetuximab,,,,,,
KRAS,3845,G12/G13,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Resistance,"In_60_patients_with_NSCLC,_Exon_2_KRAS_mutations_were_associated_with_resistance_to_the_EGFR_kinase_inhibitors_gefitinib_or_erlotinib_(9/38_refractory_vs_0/21_sensitive_patients;_P=0.0201).",15696205,PubMed,,"Pao_et_al.,_2005,_PLoS_Med.",,3,accepted,35,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2018-07-25_16:35:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/35,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Gefitinib,Erlotinib,,,,,,
KRAS,3845,G12/G13,Pancreatic_Adenocarcinoma,4074,,Trametinib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"KRAS_G12/G13_status_was_evaluated_in_cell-free_DNA_(cfDNA)_of_patients_with_untreated_metastatic_adenocarcinoma_of_the_pancreas_that_were_randomised_(1:1)_to_receive_gemcitabine_plus_trametinib_or_placebo._KRAS_mutations_were_identified_in_103_patients_using_cfDNA._There_was_no_difference_betweeen_overall_survival_of_KRAS_Mutation-positive_and_-negative_patients._Of_note,_evaluation_of_KRAS_mutations_from_archival_tissue_from_71/143_patients_identified_8_patients_with_mutant_KRAS_(wildtype_by_cfDNA)_and_3_patients_with_wildtype_KRAS_(mutant_by_cfDNA).",24915778,PubMed,,"Infante_et_al.,_2014,_Eur._J._Cancer",,3,accepted,990,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2016-02-11_23:19:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/990,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Trametinib,,,,,,,
KRAS,3845,G12/G13,Pancreatic_Adenocarcinoma,4074,,"Gemcitabine,Trametinib",Combination,Predictive,Supports,B,Resistance,"Adding_trametinib_to_gemcitabine_does_not_improve_overall_survival_(OS),_progression-free_survival_(PFS),_overall_response_rate_(ORR)_or_duration_of_response_(DOR)_in_patients_with_untreated_metastatic_adenocarcinoma_of_the_pancreas.",24915778,PubMed,,"Infante_et_al.,_2014,_Eur._J._Cancer",,4,accepted,622,30,12,25398280,25398285,,,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2015-10-09_13:28:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/622,https://civic.genome.wustl.edu/links/variants/77,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",,protein_altering_variant,,161,Gemcitabine,Trametinib,,,,,,
KRAS,3845,G12C,Colorectal_Cancer,9256,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Resistance,"In_a_study_of_448_metastatic_colorectal_cancer_patients_treated_with_EGFR-TKIs_and_tested_for_EGFR_and_KRAS_mutations,_69_tested_positive_for_KRAS_mutations._In_38_EGFR_wildtype_patients_treated_with_erlotinib_or_gefitinib,_those_with_KRAS_G12C_mutations_(n=24)_had_shorter_progression_free_survival_rates_compared_to_patients_with_non-G12C_KRAS_mutations_(n=14;_4.3_vs_9_weeks;_P_=_0.009;_HR=2.7)._This_was_true_when_restricted_to_patients_with_an_adenocarcinoma_subtype_only_(n=18_vs_12;_4.1_vs_9_weeks;_P_=_0.007;_HR=3.1)._Overall_survival_was_not_different_between_groups.",23313110,PubMed,,"Fiala_et_al.,_Cancer_Genet",,3,accepted,1216,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2016-10-10_22:52:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1216,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Gefitinib,Erlotinib,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),BEZ235",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_harboring_BRAF,_KRAS,_NRAS_or_PIK3CA_mutations_and_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._32/40_tumors_harbored_KRAS_mutations_including_4_G12C_mutations_where_disease_stabilization_occurred_in_3/4_treated_with_BEZ235_or_doublet_therapy_and_2/4_treated_with_AZD6244_only.",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,2212,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-07-21_16:31:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/2212,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Selumetinib_(AZD6244),BEZ235,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,B,Resistance,"In_a_study_of_patients_receiving_melphalan-based_therapy,_those_with_KRAS_codon_12_mutations_were_less_likely_to_have_a_positive_response_than_those_with_wildtype_KRAS_(26.9%_vs._58.3%,_P=0.015).",19284554,PubMed,,"Greco_et_al.,_2009,_J._Exp._Clin._Cancer_Res.",,,accepted,2258,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-03-31_02:50:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/2258,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Melphalan,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2253,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-03-31_02:22:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/2253,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Panitumumab,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",16497971,PubMed,,"Hoang_et_al.,_2006,_Blood",,2,accepted,2263,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-07-21_11:24:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/2263,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Melphalan,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Cancer,162,,"EGFR_Inhibitor,ARS-853",Combination,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_to_investigate_mechanisms_of_KRAS_G12C_activity_and_inhibition_with_ARS-853,_a_covalent_(irreversible)_inhibitor_which_binds_KRAS_G12C_in_the_GDP-bound_state_to_prevent_activation._Results_from_a_mass_spectrometry-based_assay_to_evaluate_KRAS_activity_suggests_that_G12C_mutant_KRAS_is_in_a_“hyperexcitable”_rather_than_a_“statically_active”_state._ARS-853_targets_the_inactive_state_and_inhibited_proliferation_in_a_subset__(3/11)_of_KRAS_G12C_mutant_cell_lines_in_2-D_growth_assays_and_11/11_cell_lines_in_soft-agar_colony_formation_and_3-D_assays._This_effect_was_specific_for_KRAS_G12C_as_12/12_cell_lines_with_other_KRAS_mutations_(including_other_G12_mutations_V,_D_and_A)_were_not_inhibited_in_either_soft-agar_assay.__Relative_resistance_to_ARS-853_developed_after_epidermal_growth_factor_(50_ng/mL)_administration_and_the_combination_of_erlotinib_or_afatinib_(EGFR-inhibitors)_with_ARS-853_greatly_potentiated_growth_arrest,_apoptosis_and_decrease_of_PI3K_and_MAPK-signaling_over_single-agent_ARS-853_treatment,_even_in_the_presence_of_added_EGF.",26739882,PubMed,,"Patricelli_et_al.,_2016,_Cancer_Discov",,3,accepted,1173,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2016-10-10_22:44:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1173,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,EGFR_Inhibitor,ARS-853,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Non-small_Cell_Lung_Carcinoma,3908,,"Docetaxel,Selumetinib_(AZD6244)",Combination,Predictive,Supports,B,Sensitivity/Response,"83_patients_from_a_phase_II_trial_(docetaxel_+_placebo_or_MEK1/2_inhibitor_selumetinib)_with_KRAS_mutant_tumors_were_retrospectively_assessed_for_differences_in_OS,_PFS,_ORR_and_change_in_tumor_size_at_week_6_according_to_type_of_KRAS_mutation._G12C,_G12D_and_G12V_were_the_most_common_mutations_(46%,_22%,_11%,_respectively)._Patients_with_G12C_or_G12V_mutations_had_a_trend_towards_longer_OS,_PFS_and_ORR_compared_to_other_KRAS_mutations._Changes_in_tumor_size_were_similar_between_groups_with_the_best_responses_in_tumors_with_G12V_mutations._Few_differences_were_observed_between_groups_when_treated_with_docetaxel_+_placebo.",26125448,PubMed,,"Jänne_et_al.,_2015,_Br._J._Cancer",,3,accepted,1142,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-05-31_00:04:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1142,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Docetaxel,Selumetinib_(AZD6244),,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",12483530,PubMed,,"Rowley_et_al.,_2002,_Oncogene",,,accepted,2262,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-03-31_02:27:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/2262,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Melphalan,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",11050000,PubMed,,"Rowley_et_al.,_2000,_Blood",,2,accepted,2261,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-07-21_11:23:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/2261,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Melphalan,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Lung_Cancer,1324,,Gefitinib,,Predictive,Supports,B,Resistance,"In_recurrent_lung_cancer_patients_treated_with_the_epidermal_growth_factor_receptor_tyrosine_kinase_inhibitor_gefitinib,_patients_with_KRAS_mutations_had_a_lower_frequency_of_partial_response_(PR)_and_stable_disease_(SD)_and_a_higher_rate_of_progressive_disease_(PD)_(PR:0,_SD:1,_PD:15_vs._PR:24,_SD:8,_PD:14;_P=0.0274)_compared_to_wildtype_KRAS_patients._Patients_with_KRAS_mutations_also_had_a_shorter_overall_survival_compared_to_wildtype_KRAS_patients_(HR:2.542,_95%_CI:1.048-6.168,_P=0.0390).",17409929,PubMed,,"Endoh_et_al.,_2006,_J_Thorac_Oncol",,2,accepted,2257,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-04-11_19:49:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2257,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Gefitinib,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12C,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_SW48_cell_line_expressing_KRAS_G12C_mutation_demonstrated_decreased_sensitivity__to_regorafenib_treatment_(IC50:_386.22_nmol_vs._114.28_nmol,_P<0.01)_compared_to_SW48_cells_expressing_KRAS_wild-type._Resistance_was_determined_by_assessing_cell_viability.",26161928,PubMed,,"Camaj_et_al.,_2015,_Future_Oncol",,,accepted,3973,30,12,25398285,25398285,C,A,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",Somatic_Mutation,2017-07-21_19:12:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/3973,https://civic.genome.wustl.edu/links/variants/78,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_cohort_of_colorectal_patients.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",74,Regorafenib,,,,,chr12_g.25398285C~A,KRAS_c.34G~T,KRAS_G12C
KRAS,3845,G12D,Ovarian_Cancer,2394,,Cetuximab,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_MCAS_cell_line_expressing_KRAS_G12D_mutation_was_associated_with_reduced_sensitivity_to_cetuximab_treatment_as_compared_to_RMUG-L_and_OMC-1_cells_expressing_wild-type_KRAS._Resistance_was_determined_by_assessing_cell_growth._Further,_in_an_in_vivo_experiment,_KRAS_G12D_expressing_MCAS_xenografts_in_nude_mice_had_reduced_response_to_cetuximab,_as_compared_to_KRAS_wild-type_expressing_RMUG-L_xenografts._Resistance_was_determined_by_assessing_tumor_growth.",22246397,PubMed,,"Sato_et_al.,_2012,_Oncol._Rep.",,,accepted,3958,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2018-07-06_21:24:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/3958,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Cetuximab,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Lung_Cancer,1324,,Gefitinib,,Predictive,Supports,B,Resistance,"In_recurrent_lung_cancer_patients_treated_with_the_epidermal_growth_factor_receptor_tyrosine_kinase_inhibitor_gefitinib,_patients_with_KRAS_mutations_had_a_lower_frequency_of_partial_response_(PR)_and_stable_disease_(SD)_and_a_higher_rate_of_progressive_disease_(PD)_(PR:0,_SD:1,_PD:15_vs._PR:24,_SD:8,_PD:14;_P=0.0274)_compared_to_wildtype_KRAS_patients._Patients_with_KRAS_mutations_also_had_a_shorter_overall_survival_compared_to_wildtype_KRAS_patients_(HR:2.542,_95%_CI:1.048-6.168,_P=0.0390).",17409929,PubMed,,"Endoh_et_al.,_2006,_J_Thorac_Oncol",,2,accepted,2240,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-04-11_19:52:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/2240,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Gefitinib,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",11050000,PubMed,,"Rowley_et_al.,_2000,_Blood",,2,accepted,2250,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-07-21_11:23:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/2250,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Melphalan,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Hairy_Cell_Leukemia,285,,Vemurafenib,,Predictive,Supports,C,Resistance,"One_patient_enrolled_in_a_clinical_study_to_evaluate_vemurafenib_treatment_of_BRAF_V600E_mutant_hairy-cell_leukemia_developed_resistance_to_vemurafenib_retreatment._300-gene_targeted_sequencing_of_the_patient’s_genome_revealed_activating_subclonal_KRAS_mutations_(KRAS_G12D,_15.2%_allele_frequency;_KRAS_K117N,_1.2%),_as_well_as_a_RUNX1_A55E_mutation_(5.9%)_that_had_not_been_seen_prior_to_vemurafenib_treatment_or_at_remission._BRAF_V600E_allele_frequency_was_detectable_(2.4%)_at_the_time_of_remission_but_dramatically_increased_at_relapse_(64.9%).",26352686,PubMed,,"Tiacci_et_al.,_2015,_N._Engl._J._Med.",,2,accepted,1580,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2016-09-04_22:34:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1580,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Vemurafenib,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,In_vitro_studies_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_KRAS_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_virally_induced_to_stably_over-express_KRAS4a_G12D_or_KRAS4b_G12D__were_more_resistant_to_vemurafenib_(a_BRAF_inhibitor)_than_cells_transduced_with_empty_vectors_(90%_vs_10%_survival).,24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,3957,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2018-07-19_20:19:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/3957,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Vemurafenib,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),BEZ235",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_harboring_KRAS,_NRAS,_BRAF_or_PIK3CA_mutations_and_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._32/40_tumors_studied_had_KRAS_mutations_with_9_G12D_(2_with_PIK3CA_H1047R)_and_13_other_G12_mutations.",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,2218,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-07-20_22:35:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/2218,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Selumetinib_(AZD6244),BEZ235,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Pancreatic_Carcinoma,4905,,MK-2206,,Predictive,Supports,C,Sensitivity/Response,"Among_33_patients_treated_with_pan-AKT_inhibitor_MK-2206_in_this_phase_1_study,_one_patient_with_pancreatic_adenocarcinoma_and_PTEN_loss_and_a_KRAS_G12D_mutation_experienced_a_decrease_of_approximately_60%_in_cancer_antigen_19-9_levels_and_23%_shrinkage_in_tumor_measurements.",22025163,PubMed,,"Yap_et_al.,_2011,_J._Clin._Oncol.",,2,accepted,937,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2016-02-20_23:19:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/937,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,MK-2206,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,B,Resistance,"In_a_study_of_patients_receiving_melphalan-based_therapy,_those_with_KRAS_codon_12_mutations_were_less_likely_to_have_a_positive_response_than_those_with_wildtype_KRAS_(26.9%_vs._58.3%,_P=0.015).",19284554,PubMed,,"Greco_et_al.,_2009,_J._Exp._Clin._Cancer_Res.",,,accepted,2247,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-03-31_02:50:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/2247,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Melphalan,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",12483530,PubMed,,"Rowley_et_al.,_2002,_Oncogene",,,accepted,2251,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-03-31_02:28:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/2251,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Melphalan,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_SW48_cell_line_expressing_KRAS_G12D_mutation_demonstrated_decreased_sensitivity__to_regorafenib_treatment_(IC50:_195.01nmol_vs._114.28_nmol_P<0.01)_compared_to_SW48_cells_expressing_KRAS_wild-type._Resistance_was_determined_by_assessing_cell_viability.",26161928,PubMed,,"Camaj_et_al.,_2015,_Future_Oncol",,,accepted,3946,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-07-21_19:17:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/3946,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Regorafenib,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2236,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-03-31_02:21:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/2236,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Panitumumab,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Non-small_Cell_Lung_Carcinoma,3908,,"BEZ235_(NVP-BEZ235,_Dactolisib),ARRY-142886",Combination,Predictive,Supports,D,Sensitivity/Response,"The_use_of_NVP-BEZ235_in_conjunction_with_ARRY-142886,_but_not_as_monotherapy,_in_a_lung_cancer_model_with_KRAS_G12D_mutation_led_to_marked_tumor_regression.",19029981,PubMed,,"Engelman_et_al.,_2008,_Nat._Med.",,4,accepted,305,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-05-30_23:57:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/305,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,BEZ235_(NVP-BEZ235,_Dactolisib),ARRY-142886,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",16497971,PubMed,,"Hoang_et_al.,_2006,_Blood",,2,accepted,2252,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-07-21_11:24:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/2252,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Melphalan,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Colorectal_Cancer,9256,,Adoptive_T-cell_Transfer,,Predictive,Supports,C,Sensitivity/Response,"A_patient_with_metastatic_colorectal_cancer_was_enrolled_in_a_phase_2_clinical_trial_(NCT01174121)._24_cultures_of_tumor-infiltrating_lymphocytes_were_expanded_from_3_lung_metastasis_resections._After_cultures_were_tested_for_reactivity,_the_patient_was_infused_with_1.48_x_10^11_tumor-infiltrating_lymphocytes_(75%_CD8+_T_cells)_that_were_specifically_reactive_to_KRAS_G12D._All_7_metastatic_lung_lesions_regressed_40_days_after_therapy,_and_the_patient_had_a_9-month_partial_response.",27959684,PubMed,,"Tran_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,1898,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2017-01-31_17:24:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1898,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Adoptive_T-cell_Transfer,,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G12D,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS,_PIK3CA,_and_PTEN_were_tested_for_mutation;_KRAS_G12D_was_the_only_variant_noted_in_the_primary_tumor_of_two_patients_who_experienced_stable_disease__following_treatment_(Patients_22_and_36;_colon_and_rectum_tumors;_Supplemental_Table_1)._In_the_larger_cohort,_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,6316,30,12,25398284,25398284,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",Somatic_Mutation,2018-11-02_22:11:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/6316,https://civic.genome.wustl.edu/links/variants/79,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_actively_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort_in_patients_with_colorectal_and_pancreatic_cancer,_however_this_hypothesis_is_in_need_of_further_validation._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G13_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._The_NCCN_guidelines_for_colorectal_cancer_contain_recommendations_that_the_targeted_therapies_cetuximab_and_panitumumab_should_only_be_used_in_the_context_of_wild_type_KRAS._However,_cetuximab_treatment_was_shown_to_extend_survival_in_a_single_cohort_of_colorectal_patients_with_G12D_mutations._Overall,_the_interpretation_for_KRAS_mutations_in_most_clinical_scenarios_is_still_undecided.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A",125.5,Panitumumab,Cetuximab,,,,chr12_g.25398284C~T,KRAS_c.35G~A,KRAS_G12D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"12_patients_with_KRAS_G13D_mutant,_metastatic_colorectal_cancer_were_treated_with_single_agent_cetuximab_in_a_prospective_phase_II_study._The_primary_endpoint_of_the_trial_was_4-month_progression-free_survival,_with_a_benefit_to_treatment_evaluated_to_be_50%_of_patients_were_progression_free_at_this_point._None_of_12_patients_achieved_response_by_RECIST_1.1_criteria_and_three_patients_(25%)_were_progression-free_at_4_months,_with_disease_control_rate_at_6_months_reaching_0%._Median_PFS_and_OS_were_1.9_(95%_CI_1.7–3.8)_and_7.2_months_(95%_CI_5.7–9.7).",26371285,PubMed,,"Schirripa_et_al.,_2015,_Ann._Oncol.",,3,accepted,1180,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2016-03-23_22:01:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1180,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS_G13D_was_the_only_variant_noted_in_the_primary_rectal_tumor_of_one_patient_who_experienced_disease_progression_following_treatment_(Patient_45;_Supplemental_Table_1)._This_is_response_is_consistent_with_observations_made_of_the_larger_cohort,_where_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant._However,_two_other_patients_(37_and_47;_Table_S1)_had_G13D_as_their_only_noted_variant,_but_experienced_partial_response.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,6322,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2018-11-02_22:33:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/6322,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Panitumumab,Cetuximab,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_analysis_of_98_patients_with_metastatic_colorectal_cancer_and_KRAS_mutations._23_(23.5%)_had_KRAS_p.G13D-mutated_tumors._Of_the_98_patients,_31_patients_received_cetuximab,_of_these,_9_(29.0%)_had_KRAS_p.G13D_mutations._Univariate_analysis_did_not_show_any_differences_between_these_groups._Multivariate_analysis_showed_a_trend_towards_better_PFS_among_patients_with_a_G13D_mutation_(PFS:_HR=0.29;_95%_CI:_0.08-1.10;_P=0.07;_OS:_HR=0.23;_95%_CI:_0.04-1.54;_P=0.13).",26623049,PubMed,,"Osumi_et_al.,_2015,_Mol_Clin_Oncol",,2,accepted,806,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/806,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Sensitivity/Response,Cells_harboring_KRAS_G13D_mutation_were_sensitive_to_cetuximab_treatment_in_isogenic_SW48_cells_and_in_a_mouse_xenograft_model.,20978259,PubMed,,"De_Roock_et_al.,_2010,_JAMA",,4,accepted,145,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/145,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),BEZ235",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_harboring_KRAS,_NRAS,_PIK3CA_or_BRAF_mutations_and_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._32/40_mice_harbored_KRAS_mutations_including_5_G13D_mutations_where_disease_stabilization_was_achieved_in_2/5_mice_treated_with_AZD6244_or_combination_therapy_and_0/5_mice_treated_with_BEZ235_alone.",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,2183,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2017-07-21_16:29:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/2183,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Selumetinib_(AZD6244),BEZ235,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Lim1215_colorectal_cancer_cell_line_endogenously_expressing_KRAS_G13D_mutation_demonstrated_resistance_to_cetuximab_treatment,_compared_to_Lim1215_parental_cells_expressing_wild-type_KRAS._Resistance_was_determined_by_assessing_cell_viability.",22722830,PubMed,,"Misale_et_al.,_2012,_Nature",,,accepted,3878,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2017-07-21_17:03:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/3878,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Does_Not_Support,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS,_PIK3CA,_and_PTEN_were_tested_for_mutation;_KRAS_G13D_was_the_only_variant_noted_in_the_primary_colon_tumors_of_two_patients_who_experienced_partial_response_following_treatment_(Patients_37,_47;_Supplemental_Table_1)._In_the_larger_cohort,_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,6320,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2018-11-02_22:26:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/6320,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Panitumumab,Cetuximab,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_148_treatment_naive_metastatic_colorectal_cancer_patients,_patients_with_RAS_mutations_(n=10),_including_KRAS_A146T,_KRAS_G13D,_NRAS_G12D_and_NRAS_Q179*,_treated_with_FOLFOX4_plus_cetuximab_were_associated_with_decreased_overall_survival_(16.3mo_vs._28.5mo,_HR:0.43,_95%_CI:0.20-0.89,_P=0.020)_and_decreased_progression_free_survival_(7.2mo_vs._9.7mo,_HR:0.56,_95%_CI:0.27-1.16,_P=0.11),_as_compared_to_patients_with_wild-type_KRAS_and_NRAS.",25666295,PubMed,,"Kaczirek_et_al.,_2015,_Clin_Colorectal_Cancer",,,accepted,3882,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2017-07-20_16:08:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/3882,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,KRAS_G13D_mutation_is_associated_with_better_response_to_Cetuximab_with_longer_progression-free_and_overall_survival_in_colorectal_patients_compared_to_other_KRAS.,20978259,PubMed,,"De_Roock_et_al.,_2010,_JAMA",,4,accepted,306,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/306,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2231,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2017-03-31_02:20:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/2231,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Panitumumab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
KRAS,3845,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"Meta-analysis_encompassing_eight_randomized_controlled_trials_(n_=_5967)_for_assessment_of_both_overall_survival_(OS)_and_progression-free_survival_(PFS)_of_patients_with_KRAS_mutant_metastatic_colorectal_cancer._For_other_KRAS_MT_the_hazard_ratio_for_OS_benefit_with_addition_of_anti-EGFR_mAb_therapy_was_1.06_(95%_confidence_interval_[CI];_0.96,_1.17),_compared_to_1.08_(95%_CI;_0.73,_1.60)_for_KRAS_G13D_[test_for_interaction_p=0.99]._In_contrast,_the_hazard_ratio_for_KRAS_wild-type_(WT)_tumours_was_0.85_(95%_CI;_0.76,_0.95)._Regarding_PFS_benefit_with_anti-EGFR_mAbs,_the_hazard_ratio_was_1.07_(95%_CI;_0.92,_1.26)_for_other_KRAS_MT,_0.96_(95%_CI;_0.73,_1.27)_for_KRAS_G13D,_and_0.68_(95%_CI;_0.54,_0.85)_for_KRAS_wild-type._Again,_the_test_for_interaction_(p=0.46)_demonstrated_no_significant_difference_in_PFS_benefit_for_anti-EGFR_mAb_therapy_between_KRAS_G13D_and_other_KRAS_MT.",26812186,PubMed,,"Rowland_et_al.,_2016,_Eur._J._Cancer",,4,accepted,1181,30,12,25398281,25398281,C,T,ENST00000256078.4,,,,,75,GRCh37,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",Somatic_Mutation,2016-07-13_18:40:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1181,https://civic.genome.wustl.edu/links/variants/81,https://civic.genome.wustl.edu/links/genes/30,"While_the_KRAS_G13_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated._Often_associated_with_tumors_that_are_wild-type_for_other_drivers_(EGFR_and_ALK_specifically),_the_prognosis_for_patients_with_this_mutation_seems_to_be_worse_than_the_KRAS_wild-type_cohort._This_mutation,_along_with_the_mutations_affecting_the_neighboring_G12_position,_may_result_in_a_less_responsive_tumor_when_treated_with_first-generation_TKI's_like_gefitinib._However,_results_are_conflicting_with_retrospective_analyses_suggesting_a_better_response_to_EGFR-Inhibition._A_recent_prospective_phase-II_study_(12_patients,_Schirripa_et._al._2015)_could_not_reproduce_this_finding_and_another_prospective_phase_II_trial_is_currently_ongoing.",,missense_variant,"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A",81,Cetuximab,,,,,chr12_g.25398281C~T,KRAS_c.38G~A,KRAS_G13D
MAP2K1,5604,P124S,Melanoma,1909,,Selumetinib_(AZD6244),,Predictive,Supports,D,Resistance,"A375_cells_expressing_MAP2K1_P124S_mutation_conferred_an_approximately_5-fold_increased_resistance_to_selumetinib_(AZD6244)_induced_growth_inhibition_when_compared_to_untransduced_cells,_cells_expressing_wild-type_MAP2K1_or_cells_expressing_a_constitutively_active_form._This_mutation_also_attenuated_pERK_inhibition_by_selumetinib_in_these_cells.",19915144,PubMed,,"Emery_et_al.,_2009,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,12,31,15,66729162,66729162,C,T,ENST00000307102.5,,,,,75,GRCh37,"MAP2K1_P124S_is_a_recurrent_mutation_in_melanoma,_and_is_seen_in_bladder_and_colon_cancer_to_a_lesser_degree._The_P124S_mutation_has_been_shown_to_contribute_to_AZD6244_resistance_in_melanoma_cell_lines,_but_considerably_less_so_than_its_Q56P_counterpart.",Somatic_Mutation,2016-08-19_18:23:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/12,https://civic.genome.wustl.edu/links/variants/82,https://civic.genome.wustl.edu/links/genes/31,"MAP2K1_P124S_is_a_recurrent_mutation_in_melanoma,_and_is_seen_in_bladder_and_colon_cancer_to_a_lesser_degree._The_P124S_mutation_has_been_shown_to_contribute_to_AZD6244_resistance_in_melanoma_cell_lines,_but_considerably_less_so_than_its_Q56P_counterpart.",,missense_variant,"ENST00000307102.5:c.370C>T,NC_000015.9:g.66729162C>T,NM_002755.3:c.370C>T,NP_002746.1:p.Pro124Ser",3,Selumetinib_(AZD6244),,,,,chr15_g.66729162C~T,MAP2K1_c.370C~T,MAP2K1_P124S
MAP2K1,5604,Q56P,Melanoma,1909,,Selumetinib_(AZD6244),,Predictive,Supports,D,Resistance,"A375_cells_expressing_MAP2K1_Q56P_mutation_conferred_an_approximately_100-fold_increased_resistance_to_selumetinib_(AZD6244)_induced_growth_inhibition_when_compared_to_untransduced_cells,_cells_expressing_wild-type_MAP2K1,_or_cells_expressing_a_constitutively_active_form._This_mutation_also_attenuated_pERK_inhibition_by_selumetinib_in_these_cells.",19915144,PubMed,,"Emery_et_al.,_2009,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,13,31,15,66727451,66727451,A,C,ENST00000307102.5,,,,,75,GRCh37,MAP2K1_Q56P_is_a_recurrent_mutation_in_melanoma_and_gastric_cancer._This_mutation_has_been_shown_to_confer_considerable_resistance_to_AZD6244_treatment_of_melanoma_cell_lines.,Somatic_Mutation,2016-11-07_18:43:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/13,https://civic.genome.wustl.edu/links/variants/83,https://civic.genome.wustl.edu/links/genes/31,MAP2K1_Q56P_is_a_recurrent_mutation_in_melanoma_and_gastric_cancer._This_mutation_has_been_shown_to_confer_considerable_resistance_to_AZD6244_treatment_of_melanoma_cell_lines.,,missense_variant,"ENST00000307102.5:c.167A>C,NC_000015.9:g.66727451A>C,NM_002755.3:c.167A>C,NP_002746.1:p.Gln56Pro",3,Selumetinib_(AZD6244),,,,,chr15_g.66727451A~C,MAP2K1_c.167A~C,MAP2K1_Q56P
MGMT,4255,PROMOTER_METHYLATION,Glioblastoma_Multiforme,3068,,Temozolomide,,Predictive,Supports,A,Sensitivity/Response,"In_a_randomized_clinical_trial,_patients_with_MGMT_promoter_methyaltion_benefitted_from_temozolomide._This_benefit_was_also_methylation_status_dependent,_as_those_without_methylation_did_not_see_increased_survival.",15758010,PubMed,,"Hegi_et_al.,_2005,_N._Engl._J._Med.",,5,accepted,307,34,10,131264495,131265656,,,ENST00000306010.7,,,,,75,GRCh37,"MGMT_promoter_methylation_has_been_observed_to_impact_tumor_progression_in_glioblastoma_multiforme._In_patients_exhibiting_promoter_methylation,_the_akylating_agent_carmustine_has_shown_efficacy._In_patients_lacking_methylation,_combining_carmustine_with_the_MGMT_inhibitor_O(6)-benzylguanine_may_be_effective,_but_more_experiments_are_required._Clinical_trials_have_also_shown_selective_sensitivity_of_promoter_methylation-positive_patients_to_temozolomide,_making_a_case_for_wider_methylation_screening_in_GBM_patients.",Somatic_Mutation,2015-06-21_16:49:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/307,https://civic.genome.wustl.edu/links/variants/85,https://civic.genome.wustl.edu/links/genes/34,"MGMT_promoter_methylation_has_been_observed_to_impact_tumor_progression_in_glioblastoma_multiforme._In_patients_exhibiting_promoter_methylation,_the_akylating_agent_carmustine_has_shown_efficacy._In_patients_lacking_methylation,_combining_carmustine_with_the_MGMT_inhibitor_O(6)-benzylguanine_may_be_effective,_but_more_experiments_are_required._Clinical_trials_have_also_shown_selective_sensitivity_of_promoter_methylation-positive_patients_to_temozolomide,_making_a_case_for_wider_methylation_screening_in_GBM_patients.",,,,136,Temozolomide,,,,,,,
MGMT,4255,PROMOTER_METHYLATION,Glioblastoma_Multiforme,3068,,O(6)-benzylguanine,,Predictive,Supports,E,Sensitivity/Response,"In_patients_lacking_MGMT_promoter_methylation,_the_use_of_an_MGMT_inhibitor,_such_as_O(6)-benzylguanine,_in_combination_with_alkylating_agents_(Carmustine)_may_be_useful_in_treating_patients_with_initial_resistance_to_alkylating_agents.",11070098,PubMed,,"Esteller_et_al.,_2000,_N._Engl._J._Med.",,4,accepted,309,34,10,131264495,131265656,,,ENST00000306010.7,,,,,75,GRCh37,"MGMT_promoter_methylation_has_been_observed_to_impact_tumor_progression_in_glioblastoma_multiforme._In_patients_exhibiting_promoter_methylation,_the_akylating_agent_carmustine_has_shown_efficacy._In_patients_lacking_methylation,_combining_carmustine_with_the_MGMT_inhibitor_O(6)-benzylguanine_may_be_effective,_but_more_experiments_are_required._Clinical_trials_have_also_shown_selective_sensitivity_of_promoter_methylation-positive_patients_to_temozolomide,_making_a_case_for_wider_methylation_screening_in_GBM_patients.",Somatic_Mutation,2015-06-21_16:49:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/309,https://civic.genome.wustl.edu/links/variants/85,https://civic.genome.wustl.edu/links/genes/34,"MGMT_promoter_methylation_has_been_observed_to_impact_tumor_progression_in_glioblastoma_multiforme._In_patients_exhibiting_promoter_methylation,_the_akylating_agent_carmustine_has_shown_efficacy._In_patients_lacking_methylation,_combining_carmustine_with_the_MGMT_inhibitor_O(6)-benzylguanine_may_be_effective,_but_more_experiments_are_required._Clinical_trials_have_also_shown_selective_sensitivity_of_promoter_methylation-positive_patients_to_temozolomide,_making_a_case_for_wider_methylation_screening_in_GBM_patients.",,,,136,O(6)-benzylguanine,,,,,,,
MGMT,4255,PROMOTER_METHYLATION,Glioblastoma_Multiforme,3068,,Carmustine,,Predictive,Supports,B,Sensitivity/Response,"MGMT_promoter_methylation_has_been_shown_to_confer_sensitivity_to_alkylating_agents,_such_as_carmustine,_in_glioblastoma_cells.",11070098,PubMed,,"Esteller_et_al.,_2000,_N._Engl._J._Med.",,4,accepted,308,34,10,131264495,131265656,,,ENST00000306010.7,,,,,75,GRCh37,"MGMT_promoter_methylation_has_been_observed_to_impact_tumor_progression_in_glioblastoma_multiforme._In_patients_exhibiting_promoter_methylation,_the_akylating_agent_carmustine_has_shown_efficacy._In_patients_lacking_methylation,_combining_carmustine_with_the_MGMT_inhibitor_O(6)-benzylguanine_may_be_effective,_but_more_experiments_are_required._Clinical_trials_have_also_shown_selective_sensitivity_of_promoter_methylation-positive_patients_to_temozolomide,_making_a_case_for_wider_methylation_screening_in_GBM_patients.",Somatic_Mutation,2015-06-21_16:49:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/308,https://civic.genome.wustl.edu/links/variants/85,https://civic.genome.wustl.edu/links/genes/34,"MGMT_promoter_methylation_has_been_observed_to_impact_tumor_progression_in_glioblastoma_multiforme._In_patients_exhibiting_promoter_methylation,_the_akylating_agent_carmustine_has_shown_efficacy._In_patients_lacking_methylation,_combining_carmustine_with_the_MGMT_inhibitor_O(6)-benzylguanine_may_be_effective,_but_more_experiments_are_required._Clinical_trials_have_also_shown_selective_sensitivity_of_promoter_methylation-positive_patients_to_temozolomide,_making_a_case_for_wider_methylation_screening_in_GBM_patients.",,,,136,Carmustine,,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,Valproic_Acid,,Predictive,Supports,B,Sensitivity/Response,"For_patients_with_NPM1_mutation_that_achieved_CR_following_induction_therapy,_relapse-free_survival_was_improved_following_treatment_with_valproic_acid.",24797300,PubMed,,"Tassara_et_al.,_2014,_Blood",,2,accepted,148,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/148,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,Valproic_Acid,,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,Anti-CD33,,Predictive,Supports,E,Sensitivity/Response,"CD33_expression_was_significantly_increased_in_patients_with_NPM1_mutation_with_or_without_FLT3-ITD,_indicating_these_patients_may_respond_to_anti-CD33_therapy.",24927407,PubMed,,"Ehninger_et_al.,_2014,_Blood_Cancer_J",,2,accepted,151,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/151,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,Anti-CD33,,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,All-trans_Retinoic_Acid,,Predictive,Supports,B,Resistance,ATRA_treatment_did_not_effect_overall_survival_in_patients_<60_years_old_with_NPM1_mutation_regardless_of_FLT3-ITD_status.,19965647,PubMed,,"Burnett_et_al.,_2010,_Blood",,3,accepted,137,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/137,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,All-trans_Retinoic_Acid,,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,Daunorubicin,,Predictive,Supports,B,Sensitivity/Response,"Young_patients_(18-60)_with_NPM1_mutations_had_improved_overall_survival_following_high-dose_versus_standard_dose_daunorubicin_(p=0.01)_in_univariate_analysis._However,_the_adjusted_p-value_for_multiple_testing_is_0.11.",22417203,PubMed,,"Patel_et_al.,_2012,_N._Engl._J._Med.",,2,accepted,147,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2015-06-21_16:49:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/147,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,Daunorubicin,,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,"All-trans_Retinoic_Acid,NSC348884",Combination,Predictive,Supports,D,Sensitivity/Response,NSC348884_combined_with_ATRA_treatment_induces_apoptosis_in_primary_AML_cells_harboring_mutant_NPM1_but_not_in_cells_with_wildtype_NPM1_or_both_mutant_NPM1_and_FLT3-ITD.,21719597,PubMed,,"Balusu_et_al.,_2011,_Blood",,3,accepted,149,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2017-05-31_15:38:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/149,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,All-trans_Retinoic_Acid,NSC348884,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,All-trans_Retinoic_Acid,,Predictive,Supports,B,Sensitivity/Response,ATRA_treatment_improved_overall_and_relapse-free_survival_in_older_(>60)_patients_with_mutant_NPM1_and_without_FLT3-ITD.,19059939,PubMed,,"Schlenk_et_al.,_2009,_Haematologica",,2,accepted,146,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/146,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,All-trans_Retinoic_Acid,,,,,,,
NPM1,4869,EXON_12_MUTATION,Acute_Myeloid_Leukemia,9119,,"Anti-CD33,Anti-CD123",Combination,Predictive,Supports,E,Sensitivity/Response,"CD33_and_CD123_expression_was_significantly_increased_in_patients_with_NPM1_mutation_with_FLT3-ITD,_indicating_these_patients_may_respond_to_combined_anti-CD33_and_anti-CD123_therapy.",24927407,PubMed,,"Ehninger_et_al.,_2014,_Blood_Cancer_J",,2,accepted,150,35,5,170837531,170837569,,,ENST00000517671.1,,,,,75,GRCh37,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",Somatic_Mutation,2016-03-16_22:09:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/150,https://civic.genome.wustl.edu/links/variants/86,https://civic.genome.wustl.edu/links/genes/35,"NPM1_exon_12_mutations_are_frequently_identified_in_patients_with_cytogenetically_normal_acute_myeloid_leukemia_(AML)_and_often_co-occur_with_FLT3-ITD._FLT3_status_should_also_be_evaluated_as_co-occurence_with_FLT3-ITD_may_impact_prognosis._Exon_12_mutations_have_been_identified_as_a_predictor_of_good_prognostic_outcomes_in_the_absence_of_FLT3-ITD._Due_to_their_high_frequency,_NPM1_mutations_have_been_retrospectively_analyzed_in_the_context_of_a_number_of_therapies_including_variable_results_following_ATRA_treatment_as_well_as_improved_response_to_high-dose_daunorubicin_or_valproic_acid._Additionally,_multiple_groups_have_shown_increased_surface_expression_of_CD33_associated_with_NPM1_mutation,_suggesting_these_patients_may_respond_to_anti-CD33_therapy._Cytoplasmic_sequestration_of_NPM1_(NPM1c)_is_associated_with_a_good_response_to_induction_therapy.",NPM1_Exon_12,exon_variant,,454,Anti-CD33,Anti-CD123,,,,,,
NPM1,4869,W288FS,Acute_Myeloid_Leukemia,9119,,NSC348884,,Predictive,Supports,D,Sensitivity/Response,NSC348884_induced_apoptosis_in_OPI-AML3_cells_harboring_an_NPM1_mutation.,21719597,PubMed,,"Balusu_et_al.,_2011,_Blood",,3,accepted,152,35,5,170837547,170837548,,TCTG,ENST00000517671.1,,,,,75,GRCh37,"NPM1_W288fs_(aka_NPM1-A)_is_located_in_exon_12_of_NPM1_and_is_the_most_common_NPM1_mutation_identified_in_acute_myeloid_leukemia._This_mutation_results_in_cytoplasmic_localization_of_NPM1_(NPM1c)_which_is_associated_with_a_good_response_to_induction_therapy._Although_it_is_the_most_extensively_studied_NPM1_exon_12_mutation,_it_is_generally_grouped_with_other_exon_12_mutations_for_patient_analysis_(see_NPM1_Exon_12_variants_for_more_information).",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/152,https://civic.genome.wustl.edu/links/variants/87,https://civic.genome.wustl.edu/links/genes/35,"NPM1_W288fs_(aka_NPM1-A)_is_located_in_exon_12_of_NPM1_and_is_the_most_common_NPM1_mutation_identified_in_acute_myeloid_leukemia._This_mutation_results_in_cytoplasmic_localization_of_NPM1_(NPM1c)_which_is_associated_with_a_good_response_to_induction_therapy._Although_it_is_the_most_extensively_studied_NPM1_exon_12_mutation,_it_is_generally_grouped_with_other_exon_12_mutations_for_patient_analysis_(see_NPM1_Exon_12_variants_for_more_information).",NPM1_Exon_12,frameshift_elongation,"NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1c.860_863dupTCTG",43.75,NSC348884,,,,,chr5_g.170837544_170837547dupTCTG,NPM1_p.Trp288Cysfs,p.trp288cysfs
NPM1,4869,W288FS,Acute_Myeloid_Leukemia,9119,,Induction_Therapy,,Predictive,Supports,E,Sensitivity/Response,"NPM1_mutation_(Type_A,_W288fs)_causes_cytoplasmic_localization_of_NPM_when_transfected_into_a_non-hematopoietic_cell_line_(293T_cells)._Cytoplasmic_localization_of_NPM_in_AML_patients_was_associated_with_good_response_to_induction_therapy.",15659725,PubMed,,"Falini_et_al.,_2005,_N._Engl._J._Med.",,3,accepted,153,35,5,170837547,170837548,,TCTG,ENST00000517671.1,,,,,75,GRCh37,"NPM1_W288fs_(aka_NPM1-A)_is_located_in_exon_12_of_NPM1_and_is_the_most_common_NPM1_mutation_identified_in_acute_myeloid_leukemia._This_mutation_results_in_cytoplasmic_localization_of_NPM1_(NPM1c)_which_is_associated_with_a_good_response_to_induction_therapy._Although_it_is_the_most_extensively_studied_NPM1_exon_12_mutation,_it_is_generally_grouped_with_other_exon_12_mutations_for_patient_analysis_(see_NPM1_Exon_12_variants_for_more_information).",Somatic_Mutation,2015-06-21_16:49:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/153,https://civic.genome.wustl.edu/links/variants/87,https://civic.genome.wustl.edu/links/genes/35,"NPM1_W288fs_(aka_NPM1-A)_is_located_in_exon_12_of_NPM1_and_is_the_most_common_NPM1_mutation_identified_in_acute_myeloid_leukemia._This_mutation_results_in_cytoplasmic_localization_of_NPM1_(NPM1c)_which_is_associated_with_a_good_response_to_induction_therapy._Although_it_is_the_most_extensively_studied_NPM1_exon_12_mutation,_it_is_generally_grouped_with_other_exon_12_mutations_for_patient_analysis_(see_NPM1_Exon_12_variants_for_more_information).",NPM1_Exon_12,frameshift_elongation,"NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1c.860_863dupTCTG",43.75,Induction_Therapy,,,,,chr5_g.170837544_170837547dupTCTG,NPM1_p.Trp288Cysfs,p.trp288cysfs
NRAS,4893,G13D,Melanoma,1909,,17-AAG,,Predictive,Supports,C,Sensitivity/Response,"Likely_due_to_increased_reliance_of_mutant_NRAS_on_HSP90_for_stabilization,_inhibition_of_HSP90_by_17-AAG_was_shown_to_be_effective_in_a_patient_with_metastatic_malignant_melanoma_with_an_NRAS_G13D_mutation.",18375819,PubMed,,"Banerji_et_al.,_2008,_Mol._Cancer_Ther.",,2,accepted,21,36,1,115258744,115258744,C,T,ENST00000369535.4,,,,,75,GRCh37,"While_the_NRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/21,https://civic.genome.wustl.edu/links/variants/93,https://civic.genome.wustl.edu/links/genes/36,"While_the_NRAS_G12_region_is_a_widely_studied_recurrent_region_in_cancer,_its_impact_on_clinical_action_is_still_debated.",,missense_variant,"NM_002524.4:c.38G>A,NP_002515.1:p.Gly13Asp,NC_000001.10:g.115258744C>T,ENST00000369535.4:c.38G>A",5,17-AAG,,,,,chr1_g.115258744C~T,NRAS_c.38G~A,NRAS_G13D
NRAS,4893,Q61,Skin_Melanoma,8923,,Selumetinib_(AZD6244),,Predictive,Supports,C,Sensitivity/Response,Phase_1_trial_in_57_patients_with_advanced_cancers_treated_with_selumetinib._4_melanoma_patients_had_NRAS_Q61_mutations._One_patient_with_NRAS_mutation_had_70%_tumor_shrinkage_after_three_cycles_of_selumetinib_(AZD6244)_but_developed_symptomatic_brain_metastases_before_confirmatory_scans_could_be_performed.,18390968,PubMed,,"Adjei_et_al.,_2008,_J._Clin._Oncol.",,2,accepted,1473,36,1,115256528,115256530,,,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2016-07-19_19:43:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1473,https://civic.genome.wustl.edu/links/variants/94,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,,105,Selumetinib_(AZD6244),,,,,,,
NRAS,4893,Q61,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Does_Not_Support,B,Resistance,"In_chemotherapy-refractory_patients_with_colorectal_cancer,_NRAS_mutation_status_(primarily_Q61)_was_not_informative_for_disease_control_rate,_progression_free_survival_or_overall_survival_following_cetuximab_plus_chemotherapy.",20619739,PubMed,,"De_Roock_et_al.,_2010,_Lancet_Oncol.",,3,accepted,124,36,1,115256528,115256530,,,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2015-06-21_16:49:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/124,https://civic.genome.wustl.edu/links/variants/94,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,,105,Cetuximab,,,,,,,
NRAS,4893,Q61,Skin_Melanoma,8923,,Binimetinib_(MEK162),,Predictive,Supports,B,Sensitivity/Response,"Phase_2_study_of_MEK162_in_patients_with_advanced_melanoma_and_NRAS_or_BRAF_mutation._71_patients_were_enrolled,_6/30_patients_with_NRAS_mutation_had_a_partial_response_(Gln61Leu_1_Patient,_Gln61Lys_9_Patients,_Gln61Arg_15_Patients)._Another_13_patients_had_stable_disease_(63%_disease_control_rate).",23414587,PubMed,,"Ascierto_et_al.,_2013,_Lancet_Oncol.",,2,accepted,1226,36,1,115256528,115256530,,,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2016-06-21_18:50:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1226,https://civic.genome.wustl.edu/links/variants/94,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,,105,Binimetinib_(MEK162),,,,,,,
NRAS,4893,Q61,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Resistance,Vemurafenib_resistance_is_associated_with_gain_of_Q61_mutation_in_NRAS.,23569304,PubMed,,"Trunzer_et_al.,_2013,_J._Clin._Oncol.",,4,accepted,14,36,1,115256528,115256530,,,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2015-06-21_16:49:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/14,https://civic.genome.wustl.edu/links/variants/94,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,,105,Vemurafenib,,,,,,,
NRAS,4893,Q61,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,Chemotherapy-refractory_patients_with_colorectal_cancer_harboring_NRAS_mutation_(primarily_Q61)_have_a_significantly_lower_response_rate_to_cetuximab_than_patients_wildtype_for_NRAS.,20619739,PubMed,,"De_Roock_et_al.,_2010,_Lancet_Oncol.",,3,accepted,36,36,1,115256528,115256530,,,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2015-06-21_16:49:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/36,https://civic.genome.wustl.edu/links/variants/94,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._Two_melanoma_patients,_each_harboring_mutations_at_this_locus_(Q61L_and_Q61R),_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,,105,Cetuximab,,,,,,,
NRAS,4893,Q61L,Melanoma,1909,,Temozolomide,,Predictive,Supports,C,Sensitivity/Response,"In_a_melanoma_patient_with_NRAS_Q61L_mutation,_treatment_with_temozolomide_resulted_in_disease_free_survival_of_14_months.",21576590,PubMed,,"Soon_et_al.,_2011,_Arch_Dermatol",,2,accepted,22,36,1,115256529,115256529,T,A,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._A_melanoma_patient_harboring_a_mutation_at_this_locus_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/22,https://civic.genome.wustl.edu/links/variants/95,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._A_melanoma_patient_harboring_a_mutation_at_this_locus_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,"NP_002515.1:p.Gln61Leu,NC_000001.10:g.115256529T>A,NM_002524.4:c.182A>T,ENST00000369535.4:c.182A>T",5,Temozolomide,,,,,chr1_g.115256529T~A,NRAS_c.182A~T,NRAS_Q61L
NRAS,4893,Q61R,Melanoma,1909,,Temozolomide,,Predictive,Supports,C,Sensitivity/Response,"In_a_melanoma_patient_with_Q61R_mutation,_treatment_with_temozolomide_resulted_in_overall_survival_of_16_months.",21576590,PubMed,,"Soon_et_al.,_2011,_Arch_Dermatol",,2,accepted,23,36,1,115256529,115256529,T,C,ENST00000369535.4,,,,,75,GRCh37,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._A_melanoma_patient_harboring_a_mutation_at_this_locus_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/23,https://civic.genome.wustl.edu/links/variants/96,https://civic.genome.wustl.edu/links/genes/36,"NRAS_Q61_mutations_have_been_found_in_multiple_myeloma,_gastrointestinal_stromal_tumors,_melanoma,_and_others._A_melanoma_patient_harboring_a_mutation_at_this_locus_responded_to_treatment_with_the_akylating_agent_temozolomide._However,_in_colorectal_cancer_patients,_mutations_at_this_locus_have_been_shown_to_confer_resistance_to_cetuximab._The_prognostic_impact_of_mutations_at_this_locus_is_currently_under_study.",,missense_variant,"NM_002524.4:c.182A>G,NP_002515.1:p.Gln61Arg,NC_000001.10:g.115256529T>C,ENST00000369535.4:c.182A>G",5,Temozolomide,,,,,chr1_g.115256529T~C,NRAS_c.182A~G,NRAS_Q61R
PDGFRA,5156,D842I,Gastrointestinal_Stromal_Tumor,9253,,Crenolanib,,Predictive,Supports,D,Sensitivity/Response,"In_CHO_cells_with_PDGFRA_D842I_mutation_that_have_shown_imatinib_resistance,_crenolanib_was_significantly_more_potent_at_inhibiting_kinase_activity_than_imatinib.",22745105,PubMed,,"Heinrich_et_al.,_2012,_Clin._Cancer_Res.",,4,accepted,43,38,4,55152092,55152093,GA,AT,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/43,https://civic.genome.wustl.edu/links/variants/98,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"ENST00000257290.5:c.2524_2525delinsAT,NC_000004.11:g.55152092_55152093delinsAT,NP_006197.1:p.Asp842Ile,NM_006206.5:c.2524_2525delGAinsAT",4,Crenolanib,,,,,chr4_g.55152092_55152093delinsAT,PDGFRA_c.2524_2525delGAinsAT,PDGFRA_D842I
PDGFRA,5156,D842V,Gastrointestinal_Stromal_Tumor,9253,,Sunitinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_Chinese_hamster_ovary_cells_expressing_PDGFRA_D842V_mutation_demonstrated_reduced_sensitivity_to_sunitinib_treatment_(IC50>1000_vs._IC50<100),_compared_to_Chinese_hamster_ovary_cells_expressing_wild-type_PDGFRA._Sensitivity_was_determined_by_assessing_PDGFRA_auto-phosphorylation.",18955458,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,2,accepted,4060,38,4,55152093,55152093,A,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2017-07-25_21:33:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/4060,https://civic.genome.wustl.edu/links/variants/99,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",84,Sunitinib,,,,,chr4_g.55152093A~T,PDGFRA_c.2525A~T,PDGFRA_D842V
PDGFRA,5156,D842V,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,D,Resistance,"When_293T_cells_stably_transduced_with_PDGFRA_A842V_were_treated_with_imatinib,_tyrosine_phosphorylation_was_maintained_at_1_and_10umol/L_concentrations_that_inhibited_phosphorylation_of_wildtype_PDGFRA,_consistent_with_resistance_to_this_inhibitor.",12949711,PubMed,,"Hirota_et_al.,_2003,_Gastroenterology",,3,accepted,651,38,4,55152093,55152093,A,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/651,https://civic.genome.wustl.edu/links/variants/99,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",84,Imatinib,,,,,chr4_g.55152093A~T,PDGFRA_c.2525A~T,PDGFRA_D842V
PDGFRA,5156,D842V,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Resistance,GIST_cancer_with_D842V_mutation_is_resistant_to_imatinib.,15928335,PubMed,,"Corless_et_al.,_2005,_J._Clin._Oncol.",,4,accepted,15,38,4,55152093,55152093,A,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2015-06-21_16:49:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/15,https://civic.genome.wustl.edu/links/variants/99,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",84,Imatinib,,,,,chr4_g.55152093A~T,PDGFRA_c.2525A~T,PDGFRA_D842V
PDGFRA,5156,D842V,Gastrointestinal_Stromal_Tumor,9253,,Crenolanib,,Predictive,Supports,D,Sensitivity/Response,"In_CHO_cells_with_PDGFRA_D842V_mutation_that_have_shown_imatinib_resistance,_crenolanib_was_significantly_more_potent_at_inhibiting_kinase_activity_than_imatinib.",22745105,PubMed,,"Heinrich_et_al.,_2012,_Clin._Cancer_Res.",,4,accepted,44,38,4,55152093,55152093,A,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/44,https://civic.genome.wustl.edu/links/variants/99,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",84,Crenolanib,,,,,chr4_g.55152093A~T,PDGFRA_c.2525A~T,PDGFRA_D842V
PDGFRA,5156,D842V,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Resistance,"While_cancer_with_PDGFRA_V561D_mutation_is_known_to_be_sensitive_to_Imatinib,_double_mutation_of_V561D_and_D842V_mutants_are_resistant_to_imatinib.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,4,accepted,16,38,4,55152093,55152093,A,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-12-01_15:26:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/16,https://civic.genome.wustl.edu/links/variants/99,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",84,Imatinib,,,,,chr4_g.55152093A~T,PDGFRA_c.2525A~T,PDGFRA_D842V
PDGFRA,5156,D842V,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Resistance,"823_patients_with_GIST_under_therapy_with_imatinib_were_genotyped_for_this_study._18_patients_(2%)_with_PDGFRA_mutations_were_identified._In_D842V-mutant_GISTs,_PFS_(median_3.8_months)_and_OS_(median_25.2_months)_were_significantly_poorer_than_Non-D842V_mutated_(PFS_median_29.5_months_OS_median_59.8_months).",26130666,PubMed,,"Yoo_et_al.,_2016,_Cancer_Res_Treat",,4,accepted,738,38,4,55152093,55152093,A,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2015-12-27_21:28:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/738,https://civic.genome.wustl.edu/links/variants/99,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._Exogenous_expression_of_the_A842V_mutation_resulted_in_constitutive_tyrosine_phosphorylation_of_PDGFRA_in_the_absence_of_ligand_in_293T_cells_and_cytokine-independent_proliferation_of_the_IL-3-dependent_Ba/F3_cell_line,_both_evidence_that_this_is_an_activating_mutation._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",84,Imatinib,,,,,chr4_g.55152093A~T,PDGFRA_c.2525A~T,PDGFRA_D842V
PDGFRA,5156,D842Y,Gastrointestinal_Stromal_Tumor,9253,,Crenolanib,,Predictive,Supports,D,Sensitivity/Response,"In_CHO_cells_with_PDGFRA_D842Y_mutation_that_have_shown_imatinib_resistance,_crenolanib_was_significantly_more_potent_at_inhibiting_kinase_activity_than_imatinib.",22745105,PubMed,,"Heinrich_et_al.,_2012,_Clin._Cancer_Res.",,4,accepted,45,38,4,55152092,55152092,G,T,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/45,https://civic.genome.wustl.edu/links/variants/100,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,"ENST00000257290.5:c.2524G>T,NC_000004.11:g.55152092G>T,NM_006206.5:c.2524G>T,NP_006197.1:p.Asp842Tyr",4,Crenolanib,,,,,chr4_g.55152092G~T,PDGFRA_c.2524G~T,PDGFRA_D842Y
PDGFRA,5156,I843DEL,Gastrointestinal_Stromal_Tumor,9253,,Crenolanib,,Predictive,Supports,D,Sensitivity/Response,"In_CHO_cells_with_the_PDGFRA_deletion_I843_mutation_that_have_shown_imatinib_sensitivity,_crenolanib_showed_no_significant_difference_from_imatinib_in_kinase_activity_inhibition.",22745105,PubMed,,"Heinrich_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,46,38,4,55152095,55152097,ATC,,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-11-04_16:27:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/46,https://civic.genome.wustl.edu/links/variants/101,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,inframe_deletion,"ENST00000257290.5:c.2527_2529delATC,NC_000004.11:g.55152095_55152097del",6,Crenolanib,,,,,chr4_g.55152095_55152097del,PDGFRA_c.2527_2529delATC,
PDGFRA,5156,I843DEL,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,D,Sensitivity/Response,15/127_patients_with_metastatic_gastrointestinal_stromal_tumors_were_tested_for_PDGFRA_mutations._1_patient_had_a_deletion_of_I843._CHO_cells_expressing_this_variant_showed_similar_sensitivity_to_imatinib_as_cells_expressing_wildtype_PDGFRA._2/3_patients_with_a_mutation_determined_to_be_sensitive_in_vitro_(del_I843_included)_achieved_partial_response_on_imatinib_treatment.,14645423,PubMed,,"Heinrich_et_al.,_2003,_J._Clin._Oncol.",,3,accepted,1309,38,4,55152095,55152097,ATC,,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-07-02_02:56:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/1309,https://civic.genome.wustl.edu/links/variants/101,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,inframe_deletion,"ENST00000257290.5:c.2527_2529delATC,NC_000004.11:g.55152095_55152097del",6,Imatinib,,,,,chr4_g.55152095_55152097del,PDGFRA_c.2527_2529delATC,
PDGFRA,5156,DI842-843VM,Gastrointestinal_Stromal_Tumor,9253,,Crenolanib,,Predictive,Supports,D,Sensitivity/Response,"In_CHO_cells_with_PDGFRA_DI842-843VM_mutation_that_have_shown_imatinib_resistance,_crenolanib_was_significantly_more_potent_at_inhibiting_kinase_activity_than_imatinib.",22745105,PubMed,,"Heinrich_et_al.,_2012,_Clin._Cancer_Res.",,4,accepted,47,38,4,55152093,55152097,ACATC,TCATG,ENST00000257290.5,,,,,75,GRCh37,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._The_DI842-843VM_variant_is_the_result_of_a_double_point_mutation._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Somatic_Mutation,2016-02-18_18:22:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/47,https://civic.genome.wustl.edu/links/variants/102,https://civic.genome.wustl.edu/links/genes/38,"PDGFRA_D842_mutations_are_characterized_broadly_as_imatinib_resistance_mutations._The_DI842-843VM_variant_is_the_result_of_a_double_point_mutation._This_is_most_well_characterized_in_gastrointestinal_stromal_tumors,_but_other_cell_lines_containing_these_mutations_have_been_shown_to_be_resistant_as_well._In_imatinib_resistant_cell_lines,_a_number_of_other_therapeutics_have_demonstrated_efficacy._These_include;_crenolanib,_sirolimus,_and_midostaurin_(PKC412).",Imatinib_Resistance,missense_variant,NC_000004.11:g.55152093_55152097delinsTCATG,4,Crenolanib,,,,,chr4_g.55152093_55152097delinsTCATG,,
PIK3CA,5290,E542K,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Apitolisib,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_with_the_dual_PI3K/mTOR_inhibitor_apitolisib._120_patients_were_treated_at_doses_between_2_and_70mg._Of_the_14_evaluable_patients_with_PIK3CA_mutations_total,_there_were_3_PRs_(1_confirmed),_8_SD,_and_3_PD_as_best_radiological_responses._One_of_the_partial_responses_harbored_a_PIK3CA_E542K_mutation.",26787751,PubMed,,"Dolly_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1549,37,3,178936082,178936082,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-08-05_06:54:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1549,https://civic.genome.wustl.edu/links/variants/103,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",65.5,Apitolisib,,,,,chr3_g.178936082G~A,PIK3CA_c.1624G~A,PIK3CA_E542K
PIK3CA,5290,E542K,Breast_Cancer,1612,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,Rapamycin_inhibits_transformation_induced_by_mutation_in_PIK3CA.,15647370,PubMed,,"Kang_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,311,37,3,178936082,178936082,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/311,https://civic.genome.wustl.edu/links/variants/103,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",65.5,Rapamycin_(Sirolimus),,,,,chr3_g.178936082G~A,PIK3CA_c.1624G~A,PIK3CA_E542K
PIK3CA,5290,E542K,Thyroid_Cancer,1781,,"Perifosine,Temsirolimus",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_thyroid_cancer_cell_lines._6_cell_lines_with_alterations_of_the_PI3K/Akt_pathway_were_more_sensitive_to_Akt_inhibitor_perifosine_or_MTOR_inhibitor_temsirolimus_than_5_cell_lines_without_genetic_alterations_in_the_PI3K/Akt_pathway._Among_the_alterations,_One_cell_line_harbored_a_PIK3CA_E542K_mutation._Transfection_of_another_cell_line_with_this_mutation_led_to_lower_IC50_values_to_perifosine_and_temsirolimus_than_in_a_cell_line_transfected_with_a_control_vector",19706758,PubMed,,"Liu_et_al.,_2009,_Cancer_Res.",,3,accepted,1626,37,3,178936082,178936082,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-11-05_23:25:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1626,https://civic.genome.wustl.edu/links/variants/103,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",65.5,Perifosine,Temsirolimus,,,,chr3_g.178936082G~A,PIK3CA_c.1624G~A,PIK3CA_E542K
PIK3CA,5290,E542K,Breast_Cancer,1612,,CH5132799,,Predictive,Supports,D,Sensitivity/Response,Breast_cancer_cell_lines_with_E542K/E545K_mutations_showed_increased_sensitivity_to_CH5132799_than_cells_with_wild-type_PIK3CA_gene.,21558396,PubMed,,"Tanaka_et_al.,_2011,_Clin._Cancer_Res.",,4,accepted,310,37,3,178936082,178936082,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/310,https://civic.genome.wustl.edu/links/variants/103,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",65.5,CH5132799,,,,,chr3_g.178936082G~A,PIK3CA_c.1624G~A,PIK3CA_E542K
PIK3CA,5290,E542K,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Does_Not_Support,B,,PIK3CA_mutation_status_was_not_predictive_of_response_to_regorafenib_treatment_in_patients_that_had_received_standard_therapy_and_progressed_within_3_months_of_their_last_treatment.,24559322,PubMed,,"Sartore-Bianchi_et_al.,_2014,_Expert_Rev_Anticancer_Ther",,4,accepted,83,37,3,178936082,178936082,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/83,https://civic.genome.wustl.edu/links/variants/103,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",65.5,Regorafenib,,,,,chr3_g.178936082G~A,PIK3CA_c.1624G~A,PIK3CA_E542K
PIK3CA,5290,E542K,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,B,Resistance,The_presence_of_a_PIK3CA_mutation_in_exon_9_(such_as_E542K)_or_exon_20_were_associated_with_lack_of_panitumumab_or_cetuximab_response.,19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,3,accepted,256,37,3,178936082,178936082,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-05-31_15:25:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/256,https://civic.genome.wustl.edu/links/variants/103,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_other_PIK3CA_variants_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",65.5,Cetuximab,Panitumumab,,,,chr3_g.178936082G~A,PIK3CA_c.1624G~A,PIK3CA_E542K
PIK3CA,5290,E545K,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,D,Resistance,"PI3K_mutant_E545K_was_overexpressed_in_the_trastuzumab_sensitive_HER2_BT474_breast_cancer_cell_line,_and_significant_resistance_to_trastuzumab_was_induced_in_comparison_to_control_cells.",18829560,PubMed,,"Serra_et_al.,_2008,_Cancer_Res.",,2,accepted,1453,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-07-21_17:22:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1453,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Trastuzumab,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Breast_Cancer,1612,,Ado-trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_3_clinical_trial_(NCT00829166),_metastatic_breast_cancer_patients_with_PIK3CA_mutation_(n=40),_including_patients_with_PIK3CA_E545K,_treated_with_ado-trastuzumab_were_associated_with_improved_median_progression_free_survival_(10.9_vs._9.8_months),_as_compared_to_patients_with_wild-type_PIK3CA_(n=93)._Further,_the_patients_harboring_PIK3CA_mutations_(n=79)_were_associated_with_a_decrease_in_disease_progression_(ado-trastuzumab_relative_to_standard_chemotherapy;_HR:0.45;_95%_CI:0.25-0.82),_as_compared_to_patients_with_wild-type_PIK3CA_(n=180;_HR:0.74;_95%_CI:0.50-1.10)._In_an_in_vitro_study,_MCF7_cell_lines_expressing_PIK3CA_E545K_mutation_was_associated_with_increased_sensitivity_to_ado-trastuzumab_emtansine_treatment_compared_to_trastuzumab_treated_MCF7_cells._Sensitivity_was_determined_by_assessing_cell_viability._Further,_in_an_in_vivo_study,_MCF7_xenografts_expressing_PIK3CA_E545K_were_reportedly_sensitive_to_ado-trastuzumab_emtansine,_as_assessed_by_tumor_growth.",26920887,PubMed,,"Baselga_et_al.,_2016,_Clin._Cancer_Res.",,,accepted,2036,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-03-31_16:54:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/2036,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Ado-trastuzumab_Emtansine,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Breast_Cancer,1612,,Pictilisib,,Predictive,Supports,D,Sensitivity/Response,"Breast_cancer_cell_lines_with_oncogenic_PIK3CA_mutations_had_an_increased_sensitivity_to_treatment_with_class_I_PI3K_inhibitor_GDC-0941_compared_to_wildtype_PIK3CA_cell_lines_(n=54,_P=0.005).",20453058,PubMed,,"O'Brien_et_al.,_2010,_Clin._Cancer_Res.",,,accepted,2034,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-03-31_17:18:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/2034,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Pictilisib,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Does_Not_Support,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._PIK3CA_E545K_was_the_only_variant_noted_in_the_primary_tumor_(found_in_the_sigma-rectum_junction)_of_one_patient_who_experienced_partial_response_following_treatment._In_the_larger_cohort,_patients_with_tumors_harboring_any_PIK3CA_mutation_had_significantly_shorter_progression_free_survival_and_decreased_incidence_of_objective_response_than_patients_with_wtPIK3CA_tumors._See_Patient_55_from_Supplemental_Table_1_for_more_information_on_this_patient.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,2037,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2018-10-23_21:47:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/2037,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Panitumumab,Cetuximab,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Lung_Adenocarcinoma,3910,,"Gefitinib,Erlotinib,Afatinib",Substitutes,Predictive,Supports,B,Resistance,"48_tumor_samples_from_41_patients_with_EGFR_mutant_lung_adenocarcinoma_that_were_resistant_to_tyrosine_kinase_inhibition_underwent_next_generation_sequencing_(AmpliSeq_Cancer_Hotspot_Panel_(v2)_failed_in_5_samples_leading_to_a_remaining_43_specimens_from_39_patients)._The_prevalence_of_various_mutations_post-treatment_was_analyzed._2_out_of_the_39_patients_had_the_E545K_PIK3CA_mutation_in_the_absence_of_EGFR_T790M,_indicating_that_E545K_may_be_an_alternative_mutation_contributing_to_resistance.",27304188,PubMed,,"Belchis_et_al.,_2016,_Oncotarget",,2,accepted,1670,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-10-22_14:40:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1670,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Gefitinib,Erlotinib,Afatinib,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Supports,D,Resistance,"HCC827_cell_lines_harboring_activated_PI3K_(HCC827_p110α_E545K_cells)_were_more_resistant_to_gefitinib_in_vitro_(IC50,_1_μM)_compared_with_those_harboring_GFP_alone_(IC50,_0.01_μM)._The_presence_of_p110α_E545K_also_protected_HCC827_cells_from_gefitinib-mediated_apoptosis.",16906227,PubMed,,"Engelman_et_al.,_2006,_J._Clin._Invest.",,2,accepted,1171,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-03-14_03:13:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1171,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Gefitinib,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS_PIK3CA_and_PTEN_were_tested_for_mutation,_and_1_patient_(patient_95,_see_supplemental_table_1)_had_PIK3CA_E545K_in_the_primary_tumor_without_co-occurring_mutations_in_the_other_tested_genes._This_response_was_consistent_with_observations_made_of_the_larger_cohort,_where_patients_with_tumors_harboring_any_PIK3CA_mutation_had_significantly_shorter_progression_free_survival_and_decreased_incidence_of_objective_response_than_patients_with_wtPIK3CA_tumors._However,_there_was_one_patient_(Patient_55,_Table_S1)_who_had_E545K_as_the_only_noted_variant,_but_experienced_partial_response.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,3,accepted,387,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2018-10-23_22:28:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/387,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Cetuximab,Panitumumab,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_PIK3CA_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_used_PIK3CA_E545K_as_a_positive_control_for_testing_resistance_to_BRAF_inhibition_by_vemurafenib._M229_cells_virally_transduced_with_PIK3CA_E545K_were_significantly_more_resistant_to_vemurafenib-mediated_growth_suppression_than_cells_transduced_with_empty_vectors_(50%_vs_20%_survival_at_the_highest_concentration,_p_<.0001)._Furthermore,_E545K_appears_to_confer_more_resistance_to_vemurafenib_than_PIK3CA_D350G_and_similar_levels_of_resistance_as_E545G._Resistance_was_determined_by_assessing_cell_survival.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,3722,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2018-07-19_20:25:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/3722,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Vemurafenib,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Cancer,162,,Apitolisib,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_with_the_dual_PI3K/mTOR_inhibitor_apitolisib._120_patients_were_treated_at_doses_between_2_and_70mg._Of_45_evaluable_patients_receiving_40mg,_two_patients_with_E545K_PIK3CA_mutation_(one_head_and_neck_squamous_cell_carcinoma_patient_and_a_patient_with_ovarian_cancer)_had_unconfirmed_partial_responses._Of_the_14_evaluable_patients_with_PIK3CA_mutations_total,_there_were_3_PRs_(1_confirmed),_8_SD,_and_3_PD_as_best_radiological_responses.",26787751,PubMed,,"Dolly_et_al.,_2016,_Clin._Cancer_Res.",,1,accepted,1550,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-11-09_20:09:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1550,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,Apitolisib,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Breast_Cancer,1612,,"MK-2206,Pictilisib",Substitutes,Predictive,Supports,D,Sensitivity/Response,PIK3CA_E545K_mutation_increased_sensitivity_to_AKT_inhibitor_MK-2206_and_PI3K_inhibitor_GDC-0941_in_a_breast_cancer_cell_line_model.,23888070,PubMed,,"Beaver_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,710,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/710,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,MK-2206,Pictilisib,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,E545K,Non-small_Cell_Lung_Carcinoma,3908,,PI103,,Predictive,Supports,D,Sensitivity/Response,"H460,_a_gefitinib-resistant_NSCLC_cell_line_harboring_PIK3CA_E545K_(a_PIK3CA_activating_mutation),_was_used_to_test_the_anti-tumor_effects_of_PI103._Without_treatment,_H460_cells_expressed_high_levels_of_phosphorylated_AKT._Following_treatment,_p-AKT_decreased_which_correlated_with_cell_senescence._PI103_treatment_resulted_in_greater_cell_senescence_in_the_PIK3CA_E545K_cell_line_than_in_A549,_a_wildtype_PIK3CA_gefinitib-resistant_NSCLC_cell_line.",19513541,PubMed,,"Zou_et_al.,_2009,_Int._J._Mol._Med.",,2,accepted,2040,37,3,178936091,178936091,G,A,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2019-01-20_00:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2040,https://civic.genome.wustl.edu/links/variants/104,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_E545K/E542K_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_are_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_E545/542_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",46,PI103,,,,,chr3_g.178936091G~A,PIK3CA_c.1633G~A,PIK3CA_E545K
PIK3CA,5290,EXON_21_MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,Chemotherapy-refractory_patients_with_colorectal_cancer_harboring_Exon_20_PIK3CA_mutations_had_lower_response_and_disease_control_rates_as_well_as_shorter_progression_free_and_overall_survival_following_cetuximab_plus_chemotherapy_than_those_with_wildtype_PIK3CA.,20619739,PubMed,,"De_Roock_et_al.,_2010,_Lancet_Oncol.",,3,accepted,138,37,3,178951882,178952495,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_Exon_21_Mutations_(e.g.,_H1047R;_often_referred_to_as_Exon_20_mutations_if_counting_only_coding_exons)_are_among_the_most_recurrent_mutations_in_cancer,_especially_breast_cancer._Of_PIK3CA_mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_Exon_21_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-03-16_22:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/138,https://civic.genome.wustl.edu/links/variants/105,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_Exon_21_Mutations_(e.g.,_H1047R;_often_referred_to_as_Exon_20_mutations_if_counting_only_coding_exons)_are_among_the_most_recurrent_mutations_in_cancer,_especially_breast_cancer._Of_PIK3CA_mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_Exon_21_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,exon_variant,,15,Cetuximab,,,,,,,
PIK3CA,5290,EXON_10_MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Does_Not_Support,B,,"In_chemotherapy-refractory_patients_with_colorectal_cancer,_Exon_9_PIK3CA_mutations_(Exon_9)_had_no_significant_impact_on_response_rate,_disease_control_rate,_progression_free_surivival_or_overall_survival_following_cetuximab_plus_chemotherapy_than_those_with_wildtype_PIK3CA.",20619739,PubMed,,"De_Roock_et_al.,_2010,_Lancet_Oncol.",,3,accepted,123,37,3,178935998,178936122,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_Exon_10_Mutations_(e.g._E545K/E542K;_often_referred_to_as_Exon_9_mutations_if_counting_only_coding_exons)_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_exon_10_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2015-08-14_16:03:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/123,https://civic.genome.wustl.edu/links/variants/106,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_Exon_10_Mutations_(e.g._E545K/E542K;_often_referred_to_as_Exon_9_mutations_if_counting_only_coding_exons)_are_the_second_most_recurrent_PIK3CA_mutations_in_breast_cancer,_and_highly_recurrent_mutations_in_many_other_cancer_types._E545K,_and_possibly_the_other_mutations_in_the_E545_region,_may_present_patients_with_a_poorer_prognosis_than_patients_with_either_patients_with_other_PIK3CA_variant_or_wild-type_PIK3CA._There_is_also_data_to_suggest_that_exon_10_mutations_may_confer_resistance_to_EGFR_inhibitors_like_cetuximab._While_very_prevalent,_targeted_therapies_for_variants_in_PIK3CA_are_still_in_early_clinical_trial_phases.",,exon_variant,,15,Cetuximab,,,,,,,
PIK3CA,5290,H1047R,Head_And_Neck_Cancer,11934,,BYL719_(Alpelisib),,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_head_and_neck_cancer_cell_lines,_2_lines_containing_the_PIK3CA_mutation_H1047R_(Detroit562_and_SNU-1076)_were_more_sensitive_to_growth_inhibition_(IC50_1.10_and_6.82)_by_the_PI3Kalpha_specific_inhibitor_BYL719_(Alepelisib)_than_3_of_4_lines_with_wild_type_PI3K_(SNU-1066_IC50_1.13_μM;_SNU-1041,_20.65_μM;_FaDu,_19.67_μM;_SCC25,_49.30_μM)._In_the_H1047R_mutant_cell_lines_and_the_wildtype_cell_line_tested,_phospho-Akt_and_phospho-S6_levels_were_diminished_with_increasing_BYL719_levels.",25550549,PubMed,,"Keam_et_al.,_2015,_Anticancer_Res.",,1,accepted,1401,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-06-28_22:10:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1401,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,BYL719_(Alpelisib),,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Her2-receptor_Positive_Breast_Cancer,60079,,"AZD5363,Trastuzumab",Combination,Predictive,Supports,D,Sensitivity/Response,"Tumor_xenografts_in_mice_were_established_with_the_KPL4_HER2_positive_breast_cancer_cell_line_with_PIK3CA_H1047R_mutation._KPL4_has_suboptimal_responses_to_trastuzumab_and_lapatinib._Xengraft_treatment_with_trastuzumab_and_AZD5363_monotherapy_induced_moderate_growth_inhibition_which_was_significant_for_AZD5363,_but_co-treatment_with_trastuzumab_and_AZD5363_induced_significant_tumor_regression_and_enhanced_growth_delay_upon_removal_of_treatment.",22294718,PubMed,,"Davies_et_al.,_2012,_Mol._Cancer_Ther.",,3,accepted,1505,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-07-06_19:35:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1505,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,AZD5363,Trastuzumab,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Breast_Cancer,1612,,CH5132799,,Predictive,Supports,D,Sensitivity/Response,Breast_cancer_cell_lines_with_H1047R_mutation_showed_increased_sensitivity_to_CH5132799_than_cells_with_wild-type_PIK3CA_gene.,21558396,PubMed,,"Tanaka_et_al.,_2011,_Clin._Cancer_Res.",,4,accepted,314,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/314,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,CH5132799,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Her2-receptor_Positive_Breast_Cancer,60079,,"AZD5363,Lapatinib",Combination,Predictive,Supports,D,Sensitivity/Response,"The_HER2_breast_cancer_cell_line_KPL4_with_PIK3CA_H1047R_shows_sub-optimal_responses_to_trastuzumab_and_lapatinib,_and_was_used_to_establish_mouse_xenografts._Treatment_of_mice_with_monotherapy_of_AZD5363_or_lapatinib_alone_induced_growth_inhibition_(37%,_not_significant;_65%,_P_=_0.004),_but_treatment_with_AZD5363_and_lapatinib_together_induced_significant_tumor_regression_(109%,_P_<_0.0001)_as_well_as_delayed_tumor_regrowth_after_removal_of_therapy.",22294718,PubMed,,"Davies_et_al.,_2012,_Mol._Cancer_Ther.",,3,accepted,1506,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-11-05_23:21:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1506,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,AZD5363,Lapatinib,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,B,Resistance,"Rectal_cancer_patients_with_PIK3CA_mutations_showed_a_higher_risk_of_local_recurrence_(HR:3.5;_95%_CI:1.3-9.3,_P=0.013,_univariate_analysis;_HR:3.4,_95%_CI:1.2-9.2,_P=0.017,_multivariate_analysis)_compared_to_wildtype_PIK3CA_patients.",19903786,PubMed,,"He_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,2106,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-03-31_20:50:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/2106,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Panitumumab,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Breast_Cancer,1612,,Ado-trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_3_clinical_trial_(NCT00829166),_metastatic_breast_cancer_patients_with_PIK3CA_mutation_(n=40),_including_patients_with_PIK3CA_H1047R,_treated_with_ado-trastuzumab_were_associated_with_improved_median_progression_free_survival_(10.9_vs._9.8_months),_as_compared_to_patients_with_wild-type_PIK3CA_(n=93)._Further,_the_patients_harboring_PIK3CA_mutations_(n=79)_were_associated_with_a_decrease_in_disease_progression_(ado-trastuzumab_relative_to_standard_chemotherapy;_HR:0.45;_95%_CI:0.25-0.82),_as_compared_to_patients_with_wild-type_PIK3CA_(n=180;_HR:0.74;_95%_CI:0.50-1.10)._In_an_in_vitro_study,_HCC1954_and_KPL-4_cell_lines_expressing_PIK3CA_H1047R_mutation_was_associated_with_increased_sensitivity_to_ado-trastuzumab_emtansine_treatment_compared_to_trastuzumab_treated_HCC1954_and_KPL-4_cells._Sensitivity_was_determined_by_assessing_cell_viability._Further,_in_an_in_vivo_study,_KPL-4_xenografts_expressing_PIK3CA_H1047R_were_reportedly_sensitive_to_ado-trastuzumab_emtansine,_as_assessed_by_tumor_growth.",26920887,PubMed,,"Baselga_et_al.,_2016,_Clin._Cancer_Res.",,,accepted,2103,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-03-31_19:38:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2103,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Ado-trastuzumab_Emtansine,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,D,Resistance,"Breast_cancer_cell_lines_with_oncogenic_PIK3CA_mutations_had_an_increased_sensitivity_to_treatment_with_class_I_PI3K_inhibitor,_GDC-0941_(pictilisib),_as_compared_to_wildtype_PIK3CA_cell_lines.",20453058,PubMed,,"O'Brien_et_al.,_2010,_Clin._Cancer_Res.",,3,accepted,2102,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-07-25_19:17:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/2102,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Trastuzumab,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Taselisib_(GDC-0032),,Predictive,Supports,D,Sensitivity/Response,"The_Cal-33_HNSCC_cell_line_with_H1047R_mutation_was_found_to_have_a_low_antiproliferative_IC50_value_for_the_alpha,_gamma_and_delta_isoform-specific_PI3K_inhibitor_taselisib._Increasing_taselisib_concentration_induced_reduction_of_phospho-Akt_levels_in_Call-33_cells,_while_upregulating_the_cleaved_PARP_apoptotic_marker._Among_a_panel_of_26_HNSCC_cell_lines,_activating_PI3K_mutations_were_associated_with_taselisib_sensitivity_in_comparison_to_wild-type_PI3K_or_PTEN_mutant_cell_lines.",26589432,PubMed,,"Zumsteg_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1465,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-07-21_20:54:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1465,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Taselisib_(GDC-0032),,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Non-small_Cell_Lung_Carcinoma,3908,,PI103,,Predictive,Supports,D,Sensitivity/Response,"In_H460,_a_gefitinib-resistant_NSCLC_cell_line_that_harbors_PIK3CA_mutations,_the_dual_PI3Kalpha/mTOR_inhibitor_PI103_reduced_cell_growth_and_increased_the_expression_of_the_tumor_suppressor_p53_compared_to_the_wildtype_PIK3CA_cell_line_A549.",19513541,PubMed,,"Zou_et_al.,_2009,_Int._J._Mol._Med.",,2,accepted,2110,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-07-25_19:17:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/2110,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,PI103,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Head_And_Neck_Cancer,11934,,"Cetuximab,BEZ235_(NVP-BEZ235,_Dactolisib)",Combination,Predictive,Supports,D,Sensitivity/Response,"Xenografts_from_one_head_and_neck_cancer_cell_line_(CAL-33)_with_a_PIK3CA_H1047R_mutation_were_more_sensitive_to_the_combined_inhibition_of_PI3K/mTOR_and_EGFR_with_BEZ-235_and_cetuximab_(N=9)_than_cetuximab_(N=9,_P=0.0039)_or_BEZ-235_alone_(N=9,_P=0.0002)_in-vivo.",23619167,PubMed,,"Lui_et_al.,_2013,_Cancer_Discov",,2,accepted,1363,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-06-08_21:29:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1363,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Cetuximab,BEZ235_(NVP-BEZ235,_Dactolisib),,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Lung_Adenocarcinoma,3910,,"BEZ235_(NVP-BEZ235,_Dactolisib)",,Predictive,Supports,D,Sensitivity/Response,"Doxycycline_dependent_expression_of_the_PIK3CA_H1047R_mutation_in_mouse_type_II_alveolar_epithelial_cells_drove_lung_cancer_in_a_reversible_fashion,_indicating_the_driver_properties_of_this_p110alpha_catalytic_domain_mutation._Administration_of_pan-p110_isoform_and_mTOR_inhibitor_BEZ235_to_H1047R_mice_with_established_tumors_resulted_in_reduced_tumor_phospho-Akt_and_phosoho-S6_levels,_and_significant_regression_of_tumor_volume.",19029981,PubMed,,"Engelman_et_al.,_2008,_Nat._Med.",,3,accepted,1447,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-11-05_23:21:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1447,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,BEZ235_(NVP-BEZ235,_Dactolisib),,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Does_Not_Support,B,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS_PIK3CA_and_PTEN_were_tested_for_mutation;_PIK3CA_H1047R_was_the_only_variant_noted_in_the_primary_tumor_(located_in_rectum)_of_one_patient_who_experienced_partial_response_(patient_38;_Supplemental_Table_1),_following_treatment._In_the_larger_cohort,_patients_with_tumors_harboring_any_PIK3CA_mutation_had_significantly_shorter_progression_free_survival_and_decreased_incidence_of_objective_response_than_patients_with_wtPIK3CA_tumors.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,258,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2018-11-02_21:51:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/258,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Cetuximab,Panitumumab,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,B,Resistance,"In_Japanese_invasive_breast_cancer_patients,_PIK3CA_mutation_was_associated_with_improved_relapse-free_survival.",17202311,PubMed,,"Maruyama_et_al.,_2007,_Clin._Cancer_Res.",,,accepted,2100,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-03-31_18:13:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2100,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Trastuzumab,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS_PIK3CA_and_PTEN_were_tested_for_mutation;_PIK3CA_H1047R_was_the_only_variant_noted_in_the_primary_tumors_of_four_patients_(Patient_Ids:_7,_42,_52,_64;_Table_S1)_and_the_metastatic_tumor_of_one_patient_(11;_Table_S1),_who_experienced_disease_progression_following_treatment._It_was_also_noted_in_the_primary_tumors_of_3_patients_(25,_48,_88;_Table_S1)_who_experienced_stable_disease_following_treatment.This_response_was_consistent_with_observations_made_of_the_larger_cohort,_where_patients_with_tumors_harboring_any_PIK3CA_mutation_had_significantly_shorter_progression_free_survival_and_decreased_incidence_of_objective_response_than_patients_with_wtPIK3CA_tumors._However,_one_patient_(38,_Table_S1)_had_PIK3CA_H1047R_as_the_only_noted_variant,_but_experienced_partial_response.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,388,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2018-11-02_21:41:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/388,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Panitumumab,Cetuximab,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Her2-receptor_Positive_Breast_Cancer,60079,,"Everolimus,Fulvestrant",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_44-year-old_patient_with_recurrent_HER2-positive_breast_cancer._The_primary_tumor_was_HR_positive;_however,_the_metastatic_tumor_was_HR_negative._The_patient_was_resistant_to_classical_chemotherapeutic_agents_and_anti-HER2_treatment._Thus,_the_combination_of_everolimus_and_fulvestrant_was_administered._The_patient_experienced_stable_disease_and_PFS_of_10_months._Genetic_testing_of_pleural_effusion_after_disease_progression_revealed_a_PIK3CA_H1047R_gene_mutation_but_was_positive_for_PTEN_expression_(IHC).",27445490,PubMed,,"Sun_et_al.,_2016,_Onco_Targets_Ther",,2,accepted,1623,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-11-05_23:21:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1623,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Everolimus,Fulvestrant,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Thyroid_Cancer,1781,,"Perifosine,Temsirolimus",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_thyroid_cancer_cell_lines._6_cell_lines_with_alterations_of_the_PI3K/Akt_pathway_were_more_sensitive_to_Akt_inhibitor_perifosine_or_MTOR_inhibitor_temsirolimus_than_5_cell_lines_without_genetic_alterations_in_the_PI3K/Akt_pathway._Among_the_alterations,_One_cell_line_harbored_a_PIK3CA_H1047R_mutation._Transfection_of_another_cell_line_with_this_mutation_led_to_lower_IC50_values_to_perifosine_and_temsirolimus_than_in_a_cell_line_transfected_with_a_control_vector._Perifosine_treatment_also_increased_apoptosis_of_a_thyroid_tumor_xenograft_with_PIK3CA_H1047R_mutation.",19706758,PubMed,,"Liu_et_al.,_2009,_Cancer_Res.",,3,accepted,1625,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-11-05_23:23:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1625,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Perifosine,Temsirolimus,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,B,Resistance,"In_colorectal_cancer,_PIK3CA_mutations_were_associated_with_reduced_relapse-free_survival_in_stage_II/III_patients_(HR:2.587,_95%_CI:1.108-6.039,_P=0.0280,_univariate_analysis;_HR:2.478,_95%_CI:1.028-5.973,_P=0.0433,_multivariate_analysis)_and_reduced_disease-specific_survival_in_patients_of_any_stage_(n=18_vs._n=140,_P=0.0357)_compared_to_wildtype_PIK3CA.",17590872,PubMed,,"Kato_et_al.,_2007,_Int._J._Cancer",,,accepted,2105,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2017-03-31_20:32:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2105,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,Panitumumab,,,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Head_And_Neck_Cancer,11934,,"BEZ235_(NVP-BEZ235,_Dactolisib)",,Predictive,Supports,D,Sensitivity/Response,"Two_head_and_neck_cancer_cell_lines_with_PIK3CA_H1047R_mutation_were_more_sensitive_to_PI3K/mTOR_inhibition_with_BEZ-235_(NVP-BEZ235,_Dactolisib)_than_two_wild_type_cell_lines_in_vitro._One_cell_line_with_H1047R_mutation_was_also_found_to_be_sensitive_to_BEZ-235_in_vivo._PIK3CA_(H1047R)_mutation_positive_cell_lines_used_were_""CAL-33""_and_""Detroit_562""._Wild_type_cell_lines_used_here_were_""SCC-9""_and_""PE/CA-PJ34(clone_C12)"".",23619167,PubMed,,"Lui_et_al.,_2013,_Cancer_Discov",,2,accepted,1362,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-06-22_19:27:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1362,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,BEZ235_(NVP-BEZ235,_Dactolisib),,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PIK3CA,5290,H1047R,Head_And_Neck_Cancer,11934,,"BEZ235_(NVP-BEZ235,_Dactolisib)",,Predictive,Supports,D,Sensitivity/Response,Lentiviral_transduction_of_PIK3CA_H1047R_mutation_into_head_and_neck_cancer_cell_line_SCC25_led_to_increased_sensitivity_to_PI3K/mTOR_inhibition_with_BEZ235_compared_to_unmanipulated_cells_(IC50_values_6_nM_and_31_nM).,25855885,PubMed,,"Wirtz_et_al.,_2015,_JAMA_Otolaryngol_Head_Neck_Surg",,1,accepted,1361,37,3,178952085,178952085,A,G,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",Somatic_Mutation,2016-06-22_19:27:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1361,https://civic.genome.wustl.edu/links/variants/107,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_H1047R_is_one_of_the_most_recurrent_single_nucleotide_variants_in_cancer,_especially_breast_cancer._Of_PIK3CA-mutant_breast_cancers,_over_half_harbor_this_mutation._Meta-analyses_have_shown_that_patients_harboring_this_mutation_may_have_worse_overall_survival,_but_other_studies_have_shown_no_difference_between_H1047R_and_other_PIK3CA_mutants_from_a_prognostic_standpoint._While_very_prevalent,_targeted_therapies_for_this_particular_mutation_are_still_in_early_clinical_trial_phases.",,missense_variant,"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G",64,BEZ235_(NVP-BEZ235,_Dactolisib),,,,chr3_g.178952085A~G,PIK3CA_c.3140A~G,PIK3CA_H1047R
PML,5371,PML-RARA,Acute_Promyelocytic_Leukemia,60318,,All-trans_Retinoic_Acid,,Predictive,Supports,C,Sensitivity/Response,"A_39-year_old_woman_who_presented_with_acute_myeloid_leukemia_revealed_a_complicated_genetic_profile_using_conventional_metaphase_cytogenetics_and_FISH_analysis.__Whole_genome_sequencing_elucidated_a_PML-RARA_fusion,_which_can_be_successfully_treated_with_ATRA._Uncovering_this_mutation_prevented_an_unnecessary_allogeneic_transplant_and_the_patient_remained_in_remission_15_months_post-treatment_(date_of_publication).",21505136,PubMed,,"Welch_et_al.,_2011,_JAMA",,3,accepted,1519,39,15,74287058,74325755,,,ENST00000268058.3,17,38504568,38513048,ENST00000254066.5,75,GRCh37,"The_PML-RARA_fusion_is_seen_as_a_diagnostic_event_in_acute_promyelocytic_leukemia_(APL)._Both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_ATRA_in_APL_patients_harboring_the_PML-RARa_fusion._Recent_interest_has_been_shown_in_combining_ATRA_and_arsenic_trioxide_for_treating_these_patients,_and_early_results_seem_promising.",Somatic_Mutation,2016-09-15_16:53:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1519,https://civic.genome.wustl.edu/links/variants/108,https://civic.genome.wustl.edu/links/genes/39,"The_PML-RARA_fusion_is_seen_as_a_diagnostic_event_in_acute_promyelocytic_leukemia_(APL)._Both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_ATRA_in_APL_patients_harboring_the_PML-RARa_fusion._Recent_interest_has_been_shown_in_combining_ATRA_and_arsenic_trioxide_for_treating_these_patients,_and_early_results_seem_promising.",,transcript_fusion,,132.5,All-trans_Retinoic_Acid,,,,,,,
PML,5371,PML-RARA,Acute_Promyelocytic_Leukemia,60318,,"All-trans_Retinoic_Acid,Arsenic_Trioxide",Combination,Predictive,Supports,A,Sensitivity/Response,ATRA/Arsenic_combined_with_standard_chemotherapy_has_been_shown_to_induce_a_complete_remission_rate_of_greater_than_75%_of_patients_with_acute_promyelocytic_leukemia_harboring_the_PML-RARa_fusion.,11704842,PubMed,,"Degos_et_al.,_2001,_Oncogene",,5,accepted,1091,39,15,74287058,74325755,,,ENST00000268058.3,17,38504568,38513048,ENST00000254066.5,75,GRCh37,"The_PML-RARA_fusion_is_seen_as_a_diagnostic_event_in_acute_promyelocytic_leukemia_(APL)._Both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_ATRA_in_APL_patients_harboring_the_PML-RARa_fusion._Recent_interest_has_been_shown_in_combining_ATRA_and_arsenic_trioxide_for_treating_these_patients,_and_early_results_seem_promising.",Somatic_Mutation,2016-02-25_18:43:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1091,https://civic.genome.wustl.edu/links/variants/108,https://civic.genome.wustl.edu/links/genes/39,"The_PML-RARA_fusion_is_seen_as_a_diagnostic_event_in_acute_promyelocytic_leukemia_(APL)._Both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_ATRA_in_APL_patients_harboring_the_PML-RARa_fusion._Recent_interest_has_been_shown_in_combining_ATRA_and_arsenic_trioxide_for_treating_these_patients,_and_early_results_seem_promising.",,transcript_fusion,,132.5,All-trans_Retinoic_Acid,Arsenic_Trioxide,,,,,,
PML,5371,PML-RARA,Acute_Promyelocytic_Leukemia,60318,,All-trans_Retinoic_Acid,,Predictive,Supports,B,Sensitivity/Response,Fusion_protein_degradation_is_accelerated_upon_ATRA_treatment_of_acute_promyelocytic_cells_at_pharmalogical_concentrations.,8674046,PubMed,,"Yoshida_et_al.,_1996,_Cancer_Res.",,5,accepted,316,39,15,74287058,74325755,,,ENST00000268058.3,17,38504568,38513048,ENST00000254066.5,75,GRCh37,"The_PML-RARA_fusion_is_seen_as_a_diagnostic_event_in_acute_promyelocytic_leukemia_(APL)._Both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_ATRA_in_APL_patients_harboring_the_PML-RARa_fusion._Recent_interest_has_been_shown_in_combining_ATRA_and_arsenic_trioxide_for_treating_these_patients,_and_early_results_seem_promising.",Somatic_Mutation,2016-02-25_18:44:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/316,https://civic.genome.wustl.edu/links/variants/108,https://civic.genome.wustl.edu/links/genes/39,"The_PML-RARA_fusion_is_seen_as_a_diagnostic_event_in_acute_promyelocytic_leukemia_(APL)._Both_in_vitro_and_in_vivo_studies_have_shown_sensitivity_to_ATRA_in_APL_patients_harboring_the_PML-RARa_fusion._Recent_interest_has_been_shown_in_combining_ATRA_and_arsenic_trioxide_for_treating_these_patients,_and_early_results_seem_promising.",,transcript_fusion,,132.5,All-trans_Retinoic_Acid,,,,,,,
PTEN,5728,R233*,Breast_Cancer,1612,,MTOR_Inhibitors,,Predictive,Supports,D,Sensitivity/Response,Cells_with_PTEN_deficiency_have_been_shown_to_exhibit_slowed_growth_in_reponse_to_PI3K-mTOR_inhibitors.,20085938,PubMed,,"Courtney_et_al.,_2010,_J._Clin._Oncol.",,4,accepted,317,41,10,89717672,89717672,C,T,ENST00000371953.3,,,,,75,GRCh37,"PTEN_R233*_has_been_shown_to_be_a_loss_of_function_mutation,_and_PTEN_loss_has_been_the_subject_of_considerable_research_in_breast_cancer._PTEN_loss_may_sensitize_cells_to_PI3K-mTOR_inhibition._While_still_being_debated,_there_is_data_to_support_that_PTEN_loss_is_both_associated_with_poorer_prognosis,_and_no_change_in_prognosis.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/317,https://civic.genome.wustl.edu/links/variants/110,https://civic.genome.wustl.edu/links/genes/41,"PTEN_R233*_has_been_shown_to_be_a_loss_of_function_mutation,_and_PTEN_loss_has_been_the_subject_of_considerable_research_in_breast_cancer._PTEN_loss_may_sensitize_cells_to_PI3K-mTOR_inhibition._While_still_being_debated,_there_is_data_to_support_that_PTEN_loss_is_both_associated_with_poorer_prognosis,_and_no_change_in_prognosis.",PTEN_Loss-of-Function,"stop_gained,loss_of_function_variant","NM_000314.6:c.697C>T,NP_000305.3:p.Arg233Ter,ENST00000371953.3:c.697C>T,NC_000010.10:g.89717672C>T",19,MTOR_Inhibitors,,,,,chr10_g.89717672C~T,PTEN_c.697C~T,p.arg233ter
RET,5979,C634W,Thyroid_Medullary_Carcinoma,3973,,Motesanib,,Predictive,Supports,D,Resistance,"Medullary_thyroid_cancer_cells_with_RET_C634W_mutation_are_insensitive_to_motesanib,_compared_to_wild-type_RET.",21422803,PubMed,,"Coxon_et_al.,_2012,_J._Endocrinol._Invest.",,3,accepted,75,42,10,43609950,43609950,C,G,ENST00000355710.3,,,,,75,GRCh37,"RET_C634W_has_been_implicated_as_an_alternate_mechanism_of_activating_RET_in_medullary_thyroid_cancer._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_C634W_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/75,https://civic.genome.wustl.edu/links/variants/112,https://civic.genome.wustl.edu/links/genes/42,"RET_C634W_has_been_implicated_as_an_alternate_mechanism_of_activating_RET_in_medullary_thyroid_cancer._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_C634W_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib.",Motesanib_Resistance,missense_variant,"NM_020975.4:c.1902C>G,NP_065681.1:p.Cys634Trp,ENST00000355710.3:c.1902C>G,NC_000010.10:g.43609950C>G",3,Motesanib,,,,,chr10_g.43609950C~G,RET_c.1902C~G,RET_C634W
RET,5979,M918T,Thyroid_Medullary_Carcinoma,3973,,AZD1480,,Predictive,Supports,D,Sensitivity/Response,The_use_of_AZD1480_on_RET-mutated/rearranged_cell_lines_in_vitro_led_to_strong_repression_of_tyroid_cancer_cell_growth.,23056499,PubMed,,"Couto_et_al.,_2012,_PLoS_ONE",,3,accepted,77,42,10,43617416,43617416,T,C,ENST00000355710.3,,,,,75,GRCh37,"RET_M819T_is_the_most_common_somatically_acquired_mutation_in_medullary_thyroid_cancer_(MTC)._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_M918T_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib._It_has_also_been_suggested_that_RET_M819T_leads_to_more_aggressive_MTC_with_a_poorer_prognosis.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/77,https://civic.genome.wustl.edu/links/variants/113,https://civic.genome.wustl.edu/links/genes/42,"RET_M819T_is_the_most_common_somatically_acquired_mutation_in_medullary_thyroid_cancer_(MTC)._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_M918T_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib._It_has_also_been_suggested_that_RET_M819T_leads_to_more_aggressive_MTC_with_a_poorer_prognosis.",Motesanib_Resistance,missense_variant,"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C",66,AZD1480,,,,,chr10_g.43617416T~C,RET_c.2753T~C,RET_M918T
RET,5979,M918T,Thyroid_Medullary_Carcinoma,3973,,Sorafenib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_clinical_trial_of_sorafenib_in_patients_with_hereditary_or_sporadic_advanced_medullary_thyroid_cancer,_10_out_of_12_patients_genotyped_in_arm_B_(sporadic_MTC)_tested_positive_for_RET_mutations._In_response_to_sorafenib,_8_patients_with_RET_M918T_mutations_had_stable_disease,_1_RET_M918T_mutant_had_partial_response,_and_1_patient_with_a_RET_C634R_mutation_had_stable_disease._Prior_to_study_entry,_all_patients_with_RET_M918T_mutations_had_progressive_disease_or_were_newly_diagnosed.",20368568,PubMed,,"Lam_et_al.,_2010,_J._Clin._Oncol.",,3,accepted,1365,42,10,43617416,43617416,T,C,ENST00000355710.3,,,,,75,GRCh37,"RET_M819T_is_the_most_common_somatically_acquired_mutation_in_medullary_thyroid_cancer_(MTC)._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_M918T_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib._It_has_also_been_suggested_that_RET_M819T_leads_to_more_aggressive_MTC_with_a_poorer_prognosis.",Somatic_Mutation,2016-06-28_00:12:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1365,https://civic.genome.wustl.edu/links/variants/113,https://civic.genome.wustl.edu/links/genes/42,"RET_M819T_is_the_most_common_somatically_acquired_mutation_in_medullary_thyroid_cancer_(MTC)._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_M918T_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib._It_has_also_been_suggested_that_RET_M819T_leads_to_more_aggressive_MTC_with_a_poorer_prognosis.",Motesanib_Resistance,missense_variant,"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C",66,Sorafenib,,,,,chr10_g.43617416T~C,RET_c.2753T~C,RET_M918T
RET,5979,M918T,Thyroid_Medullary_Carcinoma,3973,,Motesanib,,Predictive,Supports,D,Resistance,"Medullary_thyroid_cancer_cells_with_RET_M918T_mutation_are_insensitive_to_motesanib,_compared_to_wild-type_RET.",21422803,PubMed,,"Coxon_et_al.,_2012,_J._Endocrinol._Invest.",,3,accepted,76,42,10,43617416,43617416,T,C,ENST00000355710.3,,,,,75,GRCh37,"RET_M819T_is_the_most_common_somatically_acquired_mutation_in_medullary_thyroid_cancer_(MTC)._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_M918T_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib._It_has_also_been_suggested_that_RET_M819T_leads_to_more_aggressive_MTC_with_a_poorer_prognosis.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/76,https://civic.genome.wustl.edu/links/variants/113,https://civic.genome.wustl.edu/links/genes/42,"RET_M819T_is_the_most_common_somatically_acquired_mutation_in_medullary_thyroid_cancer_(MTC)._While_there_currently_are_no_RET-specific_inhibiting_agents,_promiscuous_kinase_inhibitors_have_seen_some_success_in_treating_RET_overactivity._Data_suggests_however,_that_the_M918T_mutation_may_lead_to_drug_resistance,_especially_against_the_VEGFR-inhibitor_motesanib._It_has_also_been_suggested_that_RET_M819T_leads_to_more_aggressive_MTC_with_a_poorer_prognosis.",Motesanib_Resistance,missense_variant,"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C",66,Motesanib,,,,,chr10_g.43617416T~C,RET_c.2753T~C,RET_M918T
SF3B1,23451,K666N,Breast_Cancer,1612,,Spliceostatin_A,,Predictive,Supports,D,Sensitivity/Response,"Mutations_in_SF3B1_were_identified_in_21/936_ER_positive_vs._1/289_ER_negative_breast_cancers._Mutation_was_recurrent_(K700E_in_74%_or_K666Q_or_K666E_in_another_9%_of_tumors)._Treatment_of_two_SF3B1_mutant_cell_lines_(pancreatic_and_endometrial_with_K700_and_K666_mutation,_respectively)_and_six_wild-type_controls_showed_that_mutant_cell_lines_were_significantly_more_sensitive_to_spliceostatin_A_(SF3b_complex_inhibitor).",25424858,PubMed,,"Maguire_et_al.,_2015,_J._Pathol.",,2,accepted,1418,44,2,198267359,198267359,C,A,ENST00000335508.6,,,,,75,GRCh37,"SF3B1_K666N_is_a_variant_found_in_myelodysplastic_syndromes,_chronic_leukemias,_and_more_recently,_breast_cancer._This_somatic_mutation_has_been_linked_to_better_overall_outcome_and_event-free_survival_in_MDS_patients.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1418,https://civic.genome.wustl.edu/links/variants/114,https://civic.genome.wustl.edu/links/genes/44,"SF3B1_K666N_is_a_variant_found_in_myelodysplastic_syndromes,_chronic_leukemias,_and_more_recently,_breast_cancer._This_somatic_mutation_has_been_linked_to_better_overall_outcome_and_event-free_survival_in_MDS_patients.",HEAT_domain_mutation,missense_variant,"NM_012433.3:c.1998G>T,NP_036565.2:p.Lys666Asn,ENST00000335508.6:c.1998G>T,NC_000002.11:g.198267359C>A",2,Spliceostatin_A,,,,,chr2_g.198267359C~A,SF3B1_c.1998G~T,SF3B1_K666N
TP53,7157,R175H,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R175H_loss_of_function_mutation_is_present_in_4_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,4880,45,17,7578406,7578406,C,T,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R175H_variant_seems_not_only_to_result_in_loss_of_tumor-suppression,_but_also_acts_as_a_gain-of-function_mutation_that_promotes_tumorigenesis_in_mouse_models._Cell_lines_harboring_this_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_shown_that_the_R175H_mutation_is_correlated_with_worse_overall_survival_than_wild-type_TP53,_but_is_not_as_detrimental_as_the_R248W_variant.",Somatic_Mutation,2018-04-30_23:46:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/4880,https://civic.genome.wustl.edu/links/variants/116,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R175H_variant_seems_not_only_to_result_in_loss_of_tumor-suppression,_but_also_acts_as_a_gain-of-function_mutation_that_promotes_tumorigenesis_in_mouse_models._Cell_lines_harboring_this_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_shown_that_the_R175H_mutation_is_correlated_with_worse_overall_survival_than_wild-type_TP53,_but_is_not_as_detrimental_as_the_R248W_variant.",,missense_variant,"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T",22,AMGMDS3,,,,,chr17_g.7578406C~T,TP53_c.524G~A,TP53_R175H
TP53,7157,R175H,Stomach_Carcinoma,5517,,EAP_Protocol,,Predictive,Supports,C,Sensitivity/Response,"In_a_study_of_25_patients_with_advanced_gastric_cancer,_mutations_in_TP53_were_identified_in_32%_of_primary_tumors._TP53_mutations_were_associated_with_an_improved_response_to_preoperative_treatment_of_a_modified_EAP_protocol_(combination_of_doxorubicin,_etoposide_and_cisplatin)._Patients_with_mutations_in_TP53_had_an_increased_median_survival_compared_to_patients_with_wildtype_TP53_(18.5mo_vs._10.2mo,_P=0.044).",14514923,PubMed,,"Bataille_et_al.,_2003,_MP,_Mol._Pathol.",,,accepted,2310,45,17,7578406,7578406,C,T,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R175H_variant_seems_not_only_to_result_in_loss_of_tumor-suppression,_but_also_acts_as_a_gain-of-function_mutation_that_promotes_tumorigenesis_in_mouse_models._Cell_lines_harboring_this_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_shown_that_the_R175H_mutation_is_correlated_with_worse_overall_survival_than_wild-type_TP53,_but_is_not_as_detrimental_as_the_R248W_variant.",Somatic_Mutation,2017-05-15_07:25:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/2310,https://civic.genome.wustl.edu/links/variants/116,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R175H_variant_seems_not_only_to_result_in_loss_of_tumor-suppression,_but_also_acts_as_a_gain-of-function_mutation_that_promotes_tumorigenesis_in_mouse_models._Cell_lines_harboring_this_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_shown_that_the_R175H_mutation_is_correlated_with_worse_overall_survival_than_wild-type_TP53,_but_is_not_as_detrimental_as_the_R248W_variant.",,missense_variant,"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T",22,EAP_Protocol,,,,,chr17_g.7578406C~T,TP53_c.524G~A,TP53_R175H
TP53,7157,R175H,Breast_Cancer,1612,,Doxorubicin,,Predictive,Supports,D,Sensitivity/Response,Breast_tumors_in_a_mouse_model_with_R172H_mutation_(homologous_to_human_R175H)_are_more_responsive_to_doxorubicin_than_breast_tumors_with_wild_type_TP53.,22698404,PubMed,,"Jackson_et_al.,_2012,_Cancer_Cell",,3,accepted,319,45,17,7578406,7578406,C,T,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R175H_variant_seems_not_only_to_result_in_loss_of_tumor-suppression,_but_also_acts_as_a_gain-of-function_mutation_that_promotes_tumorigenesis_in_mouse_models._Cell_lines_harboring_this_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_shown_that_the_R175H_mutation_is_correlated_with_worse_overall_survival_than_wild-type_TP53,_but_is_not_as_detrimental_as_the_R248W_variant.",Somatic_Mutation,2018-05-23_18:10:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/319,https://civic.genome.wustl.edu/links/variants/116,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R175H_variant_seems_not_only_to_result_in_loss_of_tumor-suppression,_but_also_acts_as_a_gain-of-function_mutation_that_promotes_tumorigenesis_in_mouse_models._Cell_lines_harboring_this_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_shown_that_the_R175H_mutation_is_correlated_with_worse_overall_survival_than_wild-type_TP53,_but_is_not_as_detrimental_as_the_R248W_variant.",,missense_variant,"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T",22,Doxorubicin,,,,,chr17_g.7578406C~T,TP53_c.524G~A,TP53_R175H
TP53,7157,R248Q,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R248Q_loss_of_function_mutation_is_present_in_5_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,3042,45,17,7577538,7577538,C,T,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R248_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_R248_mutations_have_been_shown_to_confer_worse_overall_survival._The_R248Q_mutation_has_also_shown_an_increased_invasive_behavior_in_cell_lines._This_is_specific_to_the_248Q_variant.",Somatic_Mutation,2017-06-15_15:37:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/3042,https://civic.genome.wustl.edu/links/variants/117,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R248_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_R248_mutations_have_been_shown_to_confer_worse_overall_survival._The_R248Q_mutation_has_also_shown_an_increased_invasive_behavior_in_cell_lines._This_is_specific_to_the_248Q_variant.",,missense_variant,"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A",34,AMGMDS3,,,,,chr17_g.7577538C~T,TP53_c.743G~A,TP53_R248Q
TP53,7157,R248W,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R248W_loss_of_function_mutation_is_present_in_4_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,4879,45,17,7577539,7577539,G,A,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R248_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_R248_mutations_have_been_shown_to_confer_worse_overall_survival.",Somatic_Mutation,2018-04-30_23:49:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/4879,https://civic.genome.wustl.edu/links/variants/118,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R248_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_R248_mutations_have_been_shown_to_confer_worse_overall_survival.",,missense_variant,"NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp,NC_000017.10:g.7577539G>A",19,AMGMDS3,,,,,chr17_g.7577539G~A,TP53_c.742C~T,TP53_R248W
TP53,7157,R249,Breast_Cancer,1612,,Doxorubicin,,Predictive,Supports,B,Sensitivity/Response,Breast_tumors_with_R175H_or_R249_mutations_are_more_responsive_to_doxorubicin_than_breast_tumors_with_wild_type_TP53.,9569050,PubMed,,"Berns_et_al.,_1998,_Br._J._Cancer",,3,accepted,399,45,17,7577535,7577535,C,G,ENST00000269305.4,,,,,75,GRCh37,"This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R249_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",Somatic_Mutation,2015-11-26_21:20:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/399,https://civic.genome.wustl.edu/links/variants/119,https://civic.genome.wustl.edu/links/genes/45,"This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R249_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",,protein_altering_variant,NC_000017.10:g.7577535C>G,30,Doxorubicin,,,,,chr17_g.7577535C~G,,
TP53,7157,R273C,Stomach_Carcinoma,5517,,"Etoposide,Cisplatin,Mitomycin",Combination,Predictive,Does_Not_Support,C,Sensitivity/Response,"A_female_patient_taking_part_in_a_25_patient_gastric_cancer_trial_was_diagnosed_at_age_46,_and_received_preoperative_high_dose_chemotherapy_(HDCT)._Japanese_Society_for_Gastric_Cancer_Response_Score_was_0._Resection_was_performed_on_patients_with_greater_than_50%_size_reduction_of_the_lesion._This_patient_did_not_undergo_resection,_and_had_on_overall_survival_of_7.4_months.",14514923,PubMed,,"Bataille_et_al.,_2003,_MP,_Mol._Pathol.",,3,accepted,2292,45,17,7577121,7577121,G,A,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R273_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R273_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",Somatic_Mutation,2018-12-18_22:59:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2292,https://civic.genome.wustl.edu/links/variants/121,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R273_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R273_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",,missense_variant,"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A",41.5,Etoposide,Cisplatin,Mitomycin,,,chr17_g.7577121G~A,TP53_c.817C~T,TP53_R273C
TP53,7157,R273C,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R273C_loss_of_function_mutation_is_present_in_2_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,4881,45,17,7577121,7577121,G,A,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R273_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R273_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",Somatic_Mutation,2018-04-30_23:44:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/4881,https://civic.genome.wustl.edu/links/variants/121,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R273_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R273_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",,missense_variant,"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A",41.5,AMGMDS3,,,,,chr17_g.7577121G~A,TP53_c.817C~T,TP53_R273C
TP53,7157,R273H,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R273H_loss_of_function_mutation_is_present_in_7_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,4882,45,17,7577120,7577120,C,T,ENST00000269305.4,,,,,75,GRCh37,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R273_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R273_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",Somatic_Mutation,2018-04-30_23:43:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/4882,https://civic.genome.wustl.edu/links/variants/122,https://civic.genome.wustl.edu/links/genes/45,"While_loss-of-function_events_in_TP53_are_very_common_in_cancer,_the_R273_variants_seem_not_only_to_result_in_loss_of_tumor-suppression,_but_also_act_as_a_gain-of-function_mutation_that_can_promote_tumorigenesis_in_mouse_models._This_mutant_is_also_more_responsive_to_treatment_with_doxorubicin_than_its_wild-type_counterparts._While_the_prognostic_impact_of_individual_TP53_mutations_is_influenced_by_the_cohort_being_studied,_it_has_been_suggested_that_the_R273_mutants_have_been_correlated_with_worse_overall_survival_in_breast_cancer_patients_when_compared_to_wild-type.",,missense_variant,"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T",34,AMGMDS3,,,,,chr17_g.7577120C~T,TP53_c.818G~A,TP53_R273H
TSC1,7248,FRAMESHIFT_TRUNCATION,Non-small_Cell_Lung_Carcinoma,3908,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,"Following_rapamycin_treatment_of_mice_with_KrasG12D-induced_lung_tumors,_mice_with_Tsc1_deletion_(exon17/18_deletion_resulting_in_frameshift)_in_the_lung_exhibit_increased_overall_survival,_increased_apoptosis,_reduced_proliferation_and_reduced_tumor_burden_compared_to_Tsc1_wildtype_mice.",19966866,PubMed,,"Liang_et_al.,_2010,_Oncogene",,3,accepted,154,46,9,135766735,135820008,,,ENST00000298552.3,,,,,75,GRCh37,"In_a_small_cohort_study_of_bladder_cancer,_patients_with_TSC1_mutations_showed_better_responses_to_and_increased_treatment_duration_tolerance_with_the_mTOR_inhibitor_everolimus._Additionally,_patient-derived_bladder_cancer_cell_lines_with_TSC1_or_TSC2_mutations_are_much_more_sensitive_to_everolimus_treatment_than_TSC1/TSC2_wildtype_cells.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/154,https://civic.genome.wustl.edu/links/variants/124,https://civic.genome.wustl.edu/links/genes/46,"In_a_small_cohort_study_of_bladder_cancer,_patients_with_TSC1_mutations_showed_better_responses_to_and_increased_treatment_duration_tolerance_with_the_mTOR_inhibitor_everolimus._Additionally,_patient-derived_bladder_cancer_cell_lines_with_TSC1_or_TSC2_mutations_are_much_more_sensitive_to_everolimus_treatment_than_TSC1/TSC2_wildtype_cells.",TSC_Loss,frameshift_truncation,,18,Rapamycin_(Sirolimus),,,,,,,
TSC1,7248,FRAMESHIFT_TRUNCATION,Invasive_Bladder_Transitional_Cell_Carcinoma,6477,,Everolimus,,Predictive,Supports,B,Sensitivity/Response,"A_patient_with_metastatic_bladder_cancer_that_responded_well_to_the_mTOR_inhibitor_everolimus_was_shown_to_harbor_a_TSC1_frameshift_truncation_mutation_(c.1907_1908del,_p.Glu636fs)_and_a_nonsense_NF2_mutation._2/3_additional_patients_with_TSC1_mutations_also_had_mild_responses_to_everolimus.",22923433,PubMed,,"Iyer_et_al.,_2012,_Science",,3,accepted,320,46,9,135766735,135820008,,,ENST00000298552.3,,,,,75,GRCh37,"In_a_small_cohort_study_of_bladder_cancer,_patients_with_TSC1_mutations_showed_better_responses_to_and_increased_treatment_duration_tolerance_with_the_mTOR_inhibitor_everolimus._Additionally,_patient-derived_bladder_cancer_cell_lines_with_TSC1_or_TSC2_mutations_are_much_more_sensitive_to_everolimus_treatment_than_TSC1/TSC2_wildtype_cells.",Somatic_Mutation,2015-12-24_22:51:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/320,https://civic.genome.wustl.edu/links/variants/124,https://civic.genome.wustl.edu/links/genes/46,"In_a_small_cohort_study_of_bladder_cancer,_patients_with_TSC1_mutations_showed_better_responses_to_and_increased_treatment_duration_tolerance_with_the_mTOR_inhibitor_everolimus._Additionally,_patient-derived_bladder_cancer_cell_lines_with_TSC1_or_TSC2_mutations_are_much_more_sensitive_to_everolimus_treatment_than_TSC1/TSC2_wildtype_cells.",TSC_Loss,frameshift_truncation,,18,Everolimus,,,,,,,
TSC1,7248,LOSS-OF-FUNCTION,Bladder_Carcinoma,4007,,Everolimus,,Predictive,Supports,B,Sensitivity/Response,Tumors_expressing_TSC1_or_TSC2_mutations_show_notably_more_sensitivity_to_everolimus_than_their_wild-type_counterparts.,22923433,PubMed,,"Iyer_et_al.,_2012,_Science",,3,accepted,155,46,9,135766735,135820008,,,ENST00000298552.3,,,,,75,GRCh37,"In_a_small_cohort_study_of_bladder_cancer,_patients_with_TSC1_mutations_showed_better_responses_to_and_increased_treatment_duration_tolerance_with_the_mTOR_inhibitor_everolimus._Additionally,_patient-derived_bladder_cancer_cell_lines_with_TSC1_or_TSC2_mutations_are_much_more_sensitive_to_everolimus_treatment_than_TSC1/TSC2_wildtype_cells.",Somatic_Mutation,2015-06-21_16:49:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/155,https://civic.genome.wustl.edu/links/variants/125,https://civic.genome.wustl.edu/links/genes/46,"In_a_small_cohort_study_of_bladder_cancer,_patients_with_TSC1_mutations_showed_better_responses_to_and_increased_treatment_duration_tolerance_with_the_mTOR_inhibitor_everolimus._Additionally,_patient-derived_bladder_cancer_cell_lines_with_TSC1_or_TSC2_mutations_are_much_more_sensitive_to_everolimus_treatment_than_TSC1/TSC2_wildtype_cells.",TSC_Loss,loss_of_function_variant,,15,Everolimus,,,,,,,
WT1,7490,EXON_7_MUTATION,Acute_Myeloid_Leukemia,9119,,"Daunorubicin,Cytarabine",Combination,Predictive,Supports,B,Resistance,"WT1_mutations_were_associated_with_an_inferior_response_to_induction_chemotherapy_with_a_higher_rate_of_resistant_disease_in_young_(15-60+,_median_45)_patients_with_cytogenetically_normal_AML.",18591546,PubMed,,"Virappane_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,139,49,11,32417803,32417953,,,ENST00000332351.3,,,,,75,GRCh37,"WT1_exon_7_mutations_have_been_shown_to_be_recurrent_in_acute_myeloid_leukemia._Many_sources_have_examined_the_prognostic_impact_of_these,_agreeing_that_the_mutant_exon_7_cohort_is_correlated_with_worse_overall_survival_and_a_number_of_poor_prognistic_outcomes._This_may_be_the_result_of_an_overall_poor_response_to_chemotherapy_from_WT1_mutant_tumors.",Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/139,https://civic.genome.wustl.edu/links/variants/129,https://civic.genome.wustl.edu/links/genes/49,"WT1_exon_7_mutations_have_been_shown_to_be_recurrent_in_acute_myeloid_leukemia._Many_sources_have_examined_the_prognostic_impact_of_these,_agreeing_that_the_mutant_exon_7_cohort_is_correlated_with_worse_overall_survival_and_a_number_of_poor_prognistic_outcomes._This_may_be_the_result_of_an_overall_poor_response_to_chemotherapy_from_WT1_mutant_tumors.",,exon_variant,,130,Daunorubicin,Cytarabine,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Pancreatic_Cancer,1793,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,In_multicenter_phase_II_study_included_individuals_with_a_germline_BRCA1/2_mutation_and_pancreatic_cancer_after_gemcitabine_treatment._Olaparib_was_administered_at_400_mg_twice_per_day.__Tumor_response_rate_was_21.7%_(five_of_23_patients).Stable_disease_more_than_8_weeks_was_observed_in_35%_of_patients.,25366685,PubMed,,"Kaufman_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,6075,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2018-07-06_14:40:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/6075,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,Olaparib,,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Ovarian_Cancer,2394,,Talazoparib,,Predictive,Supports,B,Sensitivity/Response,"In_part_2_of_a_two-part_dose-escalation_phase_I_trial_(NCT01286987),_71_patients_with_Ewings_sarcoma,_breast,_ovarian,_small_cell_lung,_or_pancreatic_cancers_received_1.0_mg/day_talazoparib_treatment._Of_patients_with_BRCA_mutation-associated_breast_and_ovarian_cancers,_confirmed_responses_were_observed_in_7_of_14_(50%)_and_5_of_12_(42%)_patients,_respectively.",28242752,PubMed,,"de_Bono_et_al.,_2017,_Cancer_Discov",,3,accepted,4876,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2017-06-15_16:39:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/4876,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,Talazoparib,,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Her2-receptor_Negative_Breast_Cancer,60080,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"302_patients_(234_with_progression_events)_with_HER2-negative_metastatic_breast_cancer_and_with_a_confirmed_deleterious_or_suspected_deleterious_germline_BRCA_mutation_(164_BRCA1,_129_BRCA2)_had_significantly_improved_progression-free_survival_and_better_response_rate_to_olaparib_(PARP_inhibitor)_than_standard_therapy_(7.0_mo_vs_4.2_mo,_hazard_ratio_0.58,_95%_CI_0.43-0.8)_in_this_randomized_phase_3_trial_(NCT02000622)._For_BRCA1_patients_specifically,_the_hazard_ratio_was_0.54,_95%_CI_0.37-0.79).",28578601,PubMed,,"Robson_et_al.,_2017,_N._Engl._J._Med.",NCT02000622,5,accepted,5815,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2017-10-21_23:06:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/5815,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,Olaparib,,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Breast_Cancer,1612,,"CX-3543,CX-5461",Substitutes,Predictive,Supports,D,Sensitivity/Response,"The_authors_show_that_in_the_CX-5461_and_CX-3543,_G-quadruplex_stabilizing_agents,_demonstrate_specific_toxicity_against_BRCA_deficient_breast_cancer_derived_cells_and_polyclonal_patient-derived_xenograft_models._Xenografts_harbored_both_a_germline_BRCA_and_a_somatic_BRCA_mutation_leading_to_disruption_of_both._The_BRCA_and_NHEJ_pathways_are_required_for_the_repair_of_CX-5461_and_CX-3543-induced_DNA_damage_and_failure_to_do_so_leads_to_lethality.",28211448,PubMed,,"Xu_et_al.,_2017,_Nat_Commun",,4,accepted,1924,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Unknown,2017-10-21_23:07:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1924,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,CX-3543,CX-5461,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Prostate_Cancer,10283,,Olaparib,,Predictive,Supports,C,Sensitivity/Response,1/1_patients_with_BRCA1_homozygous_deletion_had_a_response_to_olaparib_in_this_phase_2_study.,26510020,PubMed,,"Mateo_et_al.,_2015,_N._Engl._J._Med.",,2,accepted,845,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Somatic_Mutation,2016-09-06_02:00:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/845,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,Olaparib,,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Breast_Cancer,1612,,Talazoparib,,Predictive,Supports,B,Sensitivity/Response,"In_part_2_of_a_two-part_dose-escalation_phase_I_trial_(NCT01286987),_71_patients_with_Ewings_sarcoma,_breast,_ovarian,_small_cell_lung,_or_pancreatic_cancers_received_1.0_mg/day_talazoparib_treatment._Of_patients_with_BRCA_mutation-associated_breast_and_ovarian_cancers,_confirmed_responses_were_observed_in_7_of_14_(50%)_and_5_of_12_(42%)_patients,_respectively.",28242752,PubMed,,"de_Bono_et_al.,_2017,_Cancer_Discov",,4,accepted,4838,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2017-06-15_16:35:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/4838,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,Talazoparib,,,,,,,
BRCA1,672,LOSS-OF-FUNCTION,Ovarian_Cancer,2394,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,The_combination_of_PARP_inhibition_(Olaparib)_with_BRCA_mutation_results_in_irreparable_and_lethal_DNA_damage._Response_rates_are_higher_in_BRCA1_mutation_positive_women_with_high_grade_serous_or_undifferentiated_ovarian_cancer.,23346317,PubMed,,"Goff,_2013,_J_Gynecol_Oncol",,4,accepted,211,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2015-06-21_16:49:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/211,https://civic.genome.wustl.edu/links/variants/131,https://civic.genome.wustl.edu/links/genes/6,BRCA1_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,"loss_of_heterozygosity,loss_of_function_variant",,119,Olaparib,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Prostate_Cancer,10283,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_trial_of_patients_with_metastatic,_castration-resistant_prostate_cancer,_treated_with_olaparib_tablets_at_a_dose_of_400_mg_twice_a_day,_all_7_patients_harbouring_BRCA2_loss_of_function_alleles_(biallelic_somatic_loss_or_germline_mutations_in_combination_with_somatic_copy_loss_or_copy_neutral_LOH)_demonstrated_a_clinical_response.",26510020,PubMed,,"Mateo_et_al.,_2015,_N._Engl._J._Med.",,4,accepted,650,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Somatic_Mutation,2015-11-20_22:33:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/650,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Olaparib,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Pancreatic_Cancer,1793,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,In_multicenter_phase_II_study_included_individuals_with_a_germline_BRCA1/2_mutation_and_pancreatic_cancer_after_gemcitabine_treatment._Olaparib_was_administered_at_400_mg_twice_per_day.__Tumor_response_rate_was_21.7%_(five_of_23_patients).Stable_disease_more_than_8_weeks_was_observed_in_35%_of_patients.,25366685,PubMed,,"Kaufman_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,6076,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,,2018-07-12_18:17:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/6076,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Olaparib,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Her2-receptor_Negative_Breast_Cancer,60080,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"302_patients_(234_with_progression_events)_with_HER2-negative_metastatic_breast_cancer_and_with_a_confirmed_deleterious_or_suspected_deleterious_germline_BRCA_mutation_(164_BRCA1,_129_BRCA2)_had_significantly_improved_progression-free_survival_and_better_response_rate_to_olaparib_(PARP_inhibitor)_than_standard_therapy_(7.0_mo_vs_4.2_mo,_hazard_ratio_0.58,_95%_CI_0.43-0.8)_in_this_randomized_phase_3_trial_(NCT02000622)._For_BRCA2_patients_specifically,_the_hazard_ratio_was_0.68,_95%_CI_0.45-0.1.07.",28578601,PubMed,,"Robson_et_al.,_2017,_N._Engl._J._Med.",NCT02000622,3,accepted,5816,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2018-07-12_18:17:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/5816,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Olaparib,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Ovarian_Cancer,2394,,Talazoparib,,Predictive,Supports,B,Sensitivity/Response,"In_part_2_of_a_two-part_dose-escalation_phase_I_trial_(NCT01286987),_71_patients_with_Ewings_sarcoma,_breast,_ovarian,_small_cell_lung,_or_pancreatic_cancers_received_1.0_mg/day_talazoparib_treatment._Of_patients_with_BRCA_mutation-associated_breast_and_ovarian_cancers,_confirmed_responses_were_observed_in_7_of_14_(50%)_and_5_of_12_(42%)_patients,_respectively.",28242752,PubMed,,"de_Bono_et_al.,_2017,_Cancer_Discov",,3,accepted,4875,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2017-06-15_16:39:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/4875,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Talazoparib,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Pancreatic_Cancer,1793,,Mitomycin_C,,Predictive,Supports,D,Sensitivity/Response,"In_pancreatic_cell_lines_PL11_(FANCC-deficient)_and_CAPAN1_(BRCA2-mutated),_sensitivity_to_DNA_cross-linking_agents_was_observed_compared_to_FANCC/BRCA2_wildtype_cell_lines_(Su86.86,_CFPAC,_AsPc1,_and_MiaPaCa2)._Mitomycin_C_specifically_led_to_regression_in_8/11_xenografts_of_the_CAPAN1_cell_line_compared_to_2/9_in_the_CFPAC_(BRCA2_wildtype)_cell_line.",16243825,PubMed,,"van_der_Heijden_et_al.,_2005,_Clin._Cancer_Res.",,2,accepted,1308,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2016-06-27_15:34:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1308,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Mitomycin_C,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Breast_Cancer,1612,,"CX-5461,CX-3543",Substitutes,Predictive,Supports,D,Sensitivity/Response,"The_authors_show_that_in_the_CX-5461_and_CX-3543,_G-quadruplex_stabilizing_agents,_demonstrate_specific_toxicity_against_BRCA_deficient_breast_cancer_derived_cells_and_polyclonal_patient-derived_xenograft_models._The_BRCA_and_NHE_J_pathways_are_required_for_the_repair_of_CX-5461_and_CX-3543-induced_DNA_damage_and_failure_to_do_so_leads_to_lethality.",28211448,PubMed,,"Xu_et_al.,_2017,_Nat_Commun",,4,accepted,1925,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Unknown,2018-07-12_18:17:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1925,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,CX-5461,CX-3543,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Breast_Cancer,1612,,Talazoparib,,Predictive,Supports,B,Sensitivity/Response,"In_part_2_of_a_two-part_dose-escalation_phase_I_trial_(NCT01286987),_71_patients_with_Ewings_sarcoma,_breast,_ovarian,_small_cell_lung,_or_pancreatic_cancers_received_1.0_mg/day_talazoparib_treatment._Of_patients_with_BRCA_mutation-associated_breast_and_ovarian_cancers,_confirmed_responses_were_observed_in_7_of_14_(50%)_and_5_of_12_(42%)_patients,_respectively.",28242752,PubMed,,"de_Bono_et_al.,_2017,_Cancer_Discov",,4,accepted,4839,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2017-06-15_16:35:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/4839,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Talazoparib,,,,,,,
BRCA2,675,LOSS-OF-FUNCTION,Ovarian_Cancer,2394,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,The_combination_of_PARP_inhibition_(Olaparib)_with_BRCA_mutation_results_in_irreparable_and_lethal_DNA_damage._Response_rates_are_higher_in_BRCA2_mutation_positive_women_with_high_grade_serous_or_undifferentiated_ovarian_cancer.,23346317,PubMed,,"Goff,_2013,_J_Gynecol_Oncol",,4,accepted,212,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,Germline_Mutation,2015-06-21_16:49:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/212,https://civic.genome.wustl.edu/links/variants/132,https://civic.genome.wustl.edu/links/genes/7,BRCA2_loss_of_function_mutations_have_been_shown_to_increase_risk_of_breast_and_ovarian_cancer_in_those_carrying_the_allele_in_their_germline._Treating_BRCA_mutant_patients_with_PARP_inhibitors_such_as_Olaparib_has_led_to_significant_response.,BRCA_Germline_Variants,loss_of_function_variant,,126,Olaparib,,,,,,,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_study_(NCT00525148),_patients_with_lung_adenocarcinoma_(stage_IIIb_with_pleural_effusion_or_stage_IV)_and_EGFR_mutations,_treated_with_afatinib,_were_assessed_by_objective_response._In_total,_129_patients_were_treated_with_afatinib._66%_of_the_106_patients_with_two_common_activating_EGFR_mutations_(exon_19_deletion_or_L858R)_had_an_objective_response_compared_to_39%_of_23_patients_with_less_common_EGFR_mutations.",22452895,PubMed,,"Yang_et_al.,_2012,_Lancet_Oncol.",,3,accepted,882,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-18_19:39:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/882,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,B,Sensitivity/Response,"A_randomized_phase_3_trial_involving_173_NSCLC_patients_with_EGFR_mutations_(exon_19_deletion_or_L858R_mutation_in_exon_21)_with_no_history_of_chemotherapy_for_metastatic_disease._Patients_were_randomly_allocated_(1:1)_to_receive_either_erlotinib_or_standard_chemotherapy._The_primary_endpoint_was_progression-free_survival_(PFS)._Median_PFS_was_9.7_months_in_the_erlotinib_group,_compared_with_5.2_months_in_the_standard_chemotherapy_group.",22285168,PubMed,,"Rosell_et_al.,_2012,_Lancet_Oncol.",,3,accepted,884,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-10_23:14:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/884,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Erlotinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Sensitivity/Response,Exon_19_deletion_has_been_shown_to_be_correlated_with_gefitinib_response.,16730237,PubMed,,"Ji_et_al.,_2006,_Cancer_Cell",,4,accepted,273,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/273,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Gefitinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_3_clinical_trial_of_Korean,_never-smoker,_lung_adenocarcinoma_patients,_a_subset_of_patients_with_EGFR_mutations_(n=42)_treated_with_gefitinib_were_associated_with_improved_overall_response_rate_compared_to_gemcitabine_plus_cisplatin_treatment_(84.6%,_22/26,_vs._37.5%,_6/16,_P=0.002)._By_contrast,_in_EGFR_mutation_negative_cases,_the_response_rate_was_much_lower_(25.9%,_7/27)._The_frequency_of_mutation_in_exon_19_deletion_and_L858R_was_64.3%_(27/42)_and_36.4%_(16/42),_respectively._Exon_19_and_L858R_mutations_were_mutually_exclusive_in_this_cohort.",22370314,PubMed,,"Han_et_al.,_2012,_J._Clin._Oncol.",,3,accepted,2519,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2017-06-15_18:56:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/2519,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Gefitinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,Afatinib_is_an_irreversible_covalent_inhibitor_of_EGFR_(second_generation)._This_Phase_III_clinical_trial_(LUX-Lung_6;_NCT01121393)_was_performed_in_Asian_patients_with_EGFR_mutant_advanced_NSCLC._364_eligible_patients_with_EGFR_mutations_were_assigned_to_afatinib_(n=242)_or_gemcitabine_and_cisplatin_(n=122)_treatment._The_trial_observed_significantly_longer_median_progression-free_survival_with_afatinib_vs._gemcitabine_and_cisplatin_treatment_(11.0_vs._5.6_months)._Afatinib/Chemotherapy_group_compositions:_51.2/50.8_%_del_19;_38/37.7_%_Leu858Arg;_10.8/11.5_%_Uncommon.,24439929,PubMed,,"Wu_et_al.,_2014,_Lancet_Oncol.",,4,accepted,981,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-13_05:36:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/981,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,NSCLC_patients_with_exon_19_deletions_in_EGFR_had_longer_overall_survival_than_patients_with_an_L858R_mutation_when_treated_with_gefitinib_or_erlotinib_(38_versus_17_months;_P_=_0.04).,16818686,PubMed,,"Jackman_et_al.,_2006,_Clin._Cancer_Res.",,4,accepted,413,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2017-07-06_19:58:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/413,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Gefitinib,Erlotinib,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"A_phase_III_clinical_trial_(NCT00949650)_found_that_median_progression_free_survival_among_patients_with_EGFR_exon_19_deletion_was_13.6_months_for_afatinib_and_6.9_months_for_chemotherapy_(HR,_0.47;_95%_CI,_0.34_to_0.65;_P_=_.001)._308_patients_had_either_exon_19_or_L858_mutations.",23816960,PubMed,,"Sequist_et_al.,_2013,_J._Clin._Oncol.",,4,accepted,880,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-10_21:31:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/880,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_stage_IV_lung_adenocarcinoma_patient_harboring_EGFR_exon_19_deletion,_EGFR_exon_19_deletion_was_associated_with_sensitivity_to_erlotinib_monotherapy._Prior_to_identification_of_the_EGFR_exon_19_deletion,_the_patient_was_underwent_complex_treatments_with_standard_chemotherapy_and_experienced_disease_progression;_upon_identification_of_EGFR_exon_19_deletion_and_treatment_with_erlotinib,_the_patient_achieved_a_clinical_response.",27566387,PubMed,,"Kanemaru_et_al.,_2016,_Respir_Investig",,,accepted,4766,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2017-06-15_20:09:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/4766,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Erlotinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,"Erlotinib,Dacomitinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"Non-small_cell_cancer_patients_from_two_studies_[The_ARCHER_1009_(NCT01360554)_and_A7471028_(NCT00769067)]_with_exon_19_deletion_and_L858R_EGFR_(Exon_21)_mutations_were_pooled_to_compare_the_efficacy_of_dacomitinib_to_erlotinib._121_patients_with_any_EGFR_mutation_were_enrolled,_101_had_activating_mutations_in_exon_19_or_21._Median_progression-free_survival_and_median_survival_were_better_following_dacomitinib_treatment_(14.6_and_26.6_months,_N=53)_than_erlotinib_(9.6_and_23.2,_P_=_0.146_and_P_=_0.265,_N=48)._In_exon_19_mutated_patients_(N=32_and_36)_PFS_was_better_for_dacomitinib_treated_patients_(HR_of_0.585_[95%_CI_0.335–1.024],_two-sided_log-rank,_P_=_0.058)_but_did_not_reach_significance.",26768165,PubMed,,"Ramalingam_et_al.,_2016,_Ann._Oncol.",,3,accepted,4859,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2017-07-27_21:58:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/4859,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Erlotinib,Dacomitinib,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Does_Not_Support,B,Reduced_Sensitivity,"A_Japanese_Phase_III_clinical_study_assessed_the_noninferiority_of_gefitinib_in_comparison_to_erlotinib_in_561_patients_with_postoperative_or_recurrent_stage_IIIB/IV_lung_adenocarcinoma._Patients_were_pretreated_with_at_least_one_chemotherapy_regimen,_but_no_tyrosine_kinase_inhibitors._In_the_subgroup_of_156_patients_with_exon_19_deletions_as_their_sole_EGFR_mutation,_83_and_78_were_treated_with_erlotinib_and_gefitinib,_respectively._Objective_response_(defined_as_complete_+_partial_response)_was_approximately_65_percent_for_both_erlotinib_gefitinib_and_non_significantly_different__(p=_.965)._Disease_control_rate_(defined_as_complete_response_+_partial_response_+_stable_disease)_was_91.6_and_83.3_percent_for_erlotinib_and_gefitinib,_respectively_(p=.113)._The_study_was_unable_to_demonstrate_statistical_noninferiority_via_the_planned_end_point;_however,_the_lack_of_statistically_significant_differences_between_erlotinib_and_gefitinib_responses,_and_the_milder_adverse_effects_experienced_by_gefitinib_treated_patients,_led_the_authors_to_conclude_that_gefitinib_is_a_feasible_alternative_to_erlotinib_in_treating_patients_with_ex19del_EGFR_positive,_advanced_lung_adenocarcinoma.",27022112,PubMed,,"Urata_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,6184,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2019-02-04_14:30:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/6184,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Gefitinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"90_NSCLC_patients_with_stage_IIIB/IV_chemotherapy-resistant_tumors_were_treated_with_gefitinib,_and_exon_19_deletion_of_EGFR_was_associated_with_longer_time_to_treatment_failure_than_those_with_wild-type_EGFR_(median_8.9_versus_2.1)._In_multivariate_analysis,_exon_19_deletion_was_a_significant_predictive_factor_for_TTF_(HR_=_0.0320;_P_<_.0001).",18509184,PubMed,,"Yang_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,1666,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-09-15_16:44:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1666,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Gefitinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,Cells_harboring_an_exon_19_deletion_were_sensitive_to_afatinib._This_study_performed_drug_response_assays_using_five_human_NSCLC_cell_lines_with_various_combinations_of_EGFR_mutations._In_order_to_directly_compare_the_sensitivity_of_multiple_EGFR_mutations_to_EGFR-TKIs_the_authors_also_generated_multiple_EGFR_transduced_Ba/F3_stable_cell_lines_and_evaluated_sensitivity_to_EGFR-TKIs_by_MTS_assay.,26515464,PubMed,,"Hirano_et_al.,_2015,_Oncotarget",,2,accepted,969,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/969,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,Stable_HEK293_cell_lines_expressing_mutant_EGFR_cDNAs_were_created_(using_a_pQCLIN_retroviral_vector)_and_their_drug_sensitivities_to_afatinib_were_examined_by_MTT_assay._Phorphorylation_of_EGFR_was_assayed_by_Western_blot._The_50%_inhibitory_concentration_(IC50)_of_afatinib_was_significantly_lower_in_cells_harboring_EGFR_exon_19_deletion_than_in_cells_harboring_EGFR_L858R.,25862853,PubMed,,"Banno_et_al.,_2015,_Anticancer_Res.",,2,accepted,881,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/881,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,A,Sensitivity/Response,"Afatinib,_an_irreversible_inhibitor_of_the_ErbB_family_of_tyrosine_kinases_has_been_approved_in_the_US_for_the_first-line_treatment_of_patients_with_metastatic_non-small-cell_lung_cancer_(NSCLC)_who_have_tumours_with_EGFR_exon_19_deletions_or_exon_21_(L858R)_substitution_mutations_as_detected_by_a_US_FDA-approved_test",23982599,PubMed,,"Dungo_et_al.,_2013,_Drugs",,5,accepted,2996,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2017-05-18_19:40:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/2996,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,A,Sensitivity/Response,"On_May_14,_2013,_the_U.S._Food_and_Drug_Administration_approved_erlotinib_(Tarceva)_for_the_first-line_treatment_of_patients_with_metastatic_non-small_cell_lung_cancer_(NSCLC)_whose_tumors_have_epidermal_growth_factor_receptor_(EGFR)_exon_19_deletions_or_exon_21_(L858R)_substitution_mutations.",24868098,PubMed,,"Khozin_et_al.,_2014,_Oncologist",,5,accepted,2995,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2017-05-11_21:11:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/2995,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Erlotinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,EXON_19_DELETION,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_analysis_of_LUX-Lung_3_and_LUX-Lung_6_trials_(NCT00949650_and_NCT01121393),_of_EGFR_mutant_NSCLC,_median_overall_survival_with_afatinib_treatment_was_seen_to_be_significantly_improved_over_chemotherapy_(33.3_vs_21.1_and_31.4_vs_18.4_months_in_LUX-Lung_3_and_LUX-Lung_6_respectively).__This_effect_was_observed_in_the_EGFR_exon_19_deletion_subgroup,_but_not_in_the_L858R_mutant_subgroup.",25589191,PubMed,,"Yang_et_al.,_2015,_Lancet_Oncol.",,4,accepted,983,19,7,55242415,55242513,,,ENST00000275493.2,,,,,75,GRCh37,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",Somatic_Mutation,2016-02-18_14:43:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/983,https://civic.genome.wustl.edu/links/variants/133,https://civic.genome.wustl.edu/links/genes/19,"Deletions_within_exon_19_of_EGFR_are_most_common_in_lung_cancer._These_deletions,_in_non-small_cell_lung_cancer,_have_been_shown_to_be_sensitive_to_the_EGFR_tyrosine_kinase_inhibitors_gefitinib,_afatinib,_and_erlotinib._There_is_also_data_to_suggest_that_this_event_is_a_good_prognostic_marker_in_lung_adenocarcinoma.",,inframe_deletion,ENST00000275493.2:c.2185_2283del,278,Afatinib,,,,,,EGFR_c.2185_2283del,
EGFR,1956,G719S,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_G719S_demonstrated_increased_sensitivity_to_erlotinib_treatment_comparable_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_G719S_and_EGFR_L858R_expressing_cells_were_16_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4190,19,7,55241707,55241707,G,A,ENST00000275493.2,,,,,75,GRCh37,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",Somatic_Mutation,2017-09-16_11:44:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/4190,https://civic.genome.wustl.edu/links/variants/134,https://civic.genome.wustl.edu/links/genes/19,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",,missense_variant,"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser",23,Erlotinib,,,,,chr7_g.55241707G~A,EGFR_c.2155G~A,EGFR_G719S
EGFR,1956,G719S,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Sensitivity/Response,Gefinitib_has_been_shown_to_be_effective_in_treating_cell_lines_with_G719S_missense_mutations.,15118125,PubMed,,"Paez_et_al.,_2004,_Science",,4,accepted,274,19,7,55241707,55241707,G,A,ENST00000275493.2,,,,,75,GRCh37,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/274,https://civic.genome.wustl.edu/links/variants/134,https://civic.genome.wustl.edu/links/genes/19,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",,missense_variant,"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser",23,Gefitinib,,,,,chr7_g.55241707G~A,EGFR_c.2155G~A,EGFR_G719S
EGFR,1956,G719S,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Sensitivity/Response,"Whole_genome_sequencing_of_a_case_of_colon_carcinoma_revealed_a_G724S_mutation_in_the_EGFR_gene._In-vitro,_this_mutation_was_shown_to_be_oncogenic_and_sensitive_to_Cetuximab,_yet_relatively_insensitive_towards_small_molecules._The_same_in-vitro_results_could_be_reproduced_for_the_G719S_mutation.",24894453,PubMed,,"Cho_et_al.,_2014,_Mol._Cancer",,4,accepted,787,19,7,55241707,55241707,G,A,ENST00000275493.2,,,,,75,GRCh37,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/787,https://civic.genome.wustl.edu/links/variants/134,https://civic.genome.wustl.edu/links/genes/19,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",,missense_variant,"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser",23,Cetuximab,,,,,chr7_g.55241707G~A,EGFR_c.2155G~A,EGFR_G719S
EGFR,1956,G719S,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"This_small_clinical_(n=56)_study_suggests_that_patients_with_minor_mutations_of_EGFR,_like_G719S,_are_likely_to_have_a_moderate_response_to_Tyrosine_kinase_inhibitors_like_Gefitinib_and_Erlotinib._In_this_study_44_of_56_patients_were_treated_with_either_gefitinib_or_erlotinib._35_patients_had_a_G719_mutation_but_the_majority_of_these_were_G719S_(20_with_G719S,_9_with_G719A,_3_with_G719C).",26124334,PubMed,,"Otsuka_et_al.,_2015,_Anticancer_Res.",,3,accepted,1736,19,7,55241707,55241707,G,A,ENST00000275493.2,,,,,75,GRCh37,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",Somatic_Mutation,2018-01-30_17:20:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1736,https://civic.genome.wustl.edu/links/variants/134,https://civic.genome.wustl.edu/links/genes/19,"While_not_as_recurrent_as_the_L858R_mutation,_EGFR_G719S_has_also_been_shown_to_be_an_activating_mutation._In_lung_cancer_cell_lines,_it_also_confers_sensitivity_to_the_tyrosine_kinase_inhibitors_gefitinib_and_erlotinib.",,missense_variant,"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser",23,Gefitinib,Erlotinib,,,,chr7_g.55241707G~A,EGFR_c.2155G~A,EGFR_G719S
DDR2,4921,L63V,Non-small_Cell_Lung_Carcinoma,3908,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,In_3T3_fibroblasts_expressing_the_L63V_mutation_have_to_be_sensitive_to_the_tyrosine_kinase_inhibitor_dasatinib.,22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,4,accepted,271,51,1,162724415,162724415,C,G,ENST00000367922.3,,,,,75,GRCh37,"Activating_mutations_in_DDR2,_including_L63V,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/271,https://civic.genome.wustl.edu/links/variants/139,https://civic.genome.wustl.edu/links/genes/51,"Activating_mutations_in_DDR2,_including_L63V,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",,missense_variant,"NM_006182.2:c.187C>G,NP_006173.2:p.Leu63Val,ENST00000367922.3:c.187C>G,NC_000001.10:g.162724415C>G",4,Dasatinib,,,,,chr1_g.162724415C~G,DDR2_c.187C~G,DDR2_L63V
DDR2,4921,L239R,Non-small_Cell_Lung_Carcinoma,3908,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,In_3T3_fibroblasts_expressing_the_L239R_mutation_have_to_be_sensitive_to_the_tyrosine_kinase_inhibitor_dasatinib.,22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,4,accepted,270,51,1,162729630,162729630,T,G,ENST00000367922.3,,,,,75,GRCh37,"Activating_mutations_in_DDR2,_including_L239R,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/270,https://civic.genome.wustl.edu/links/variants/140,https://civic.genome.wustl.edu/links/genes/51,"Activating_mutations_in_DDR2,_including_L239R,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",,missense_variant,"ENST00000367922.3:c.716T>G,NC_000001.10:g.162729630T>G",4,Dasatinib,,,,,chr1_g.162729630T~G,DDR2_c.716T~G,
DDR2,4921,G253C,Non-small_Cell_Lung_Carcinoma,3908,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,In_3T3_fibroblasts_expressing_the_G253C_mutation_have_to_be_sensitive_to_the_tyrosine_kinase_inhibitor_dasatinib.,22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,4,accepted,266,51,1,162729671,162729671,G,T,ENST00000367922.3,,,,,75,GRCh37,"Activating_mutations_in_DDR2,_including_G253C,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/266,https://civic.genome.wustl.edu/links/variants/141,https://civic.genome.wustl.edu/links/genes/51,"Activating_mutations_in_DDR2,_including_G253C,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",,missense_variant,"ENST00000367922.3:c.757G>T,NC_000001.10:g.162729671G>T",4,Dasatinib,,,,,chr1_g.162729671G~T,DDR2_c.757G~T,
DDR2,4921,G505S,Non-small_Cell_Lung_Carcinoma,3908,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,In_3T3_fibroblasts_expressing_the_G505S_mutation_have_to_be_sensitive_to_the_tyrosine_kinase_inhibitor_dasatinib.,22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,4,accepted,267,51,1,162741822,162741822,G,A,ENST00000367922.3,,,,,75,GRCh37,"Activating_mutations_in_DDR2,_including_G505S,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/267,https://civic.genome.wustl.edu/links/variants/142,https://civic.genome.wustl.edu/links/genes/51,"Activating_mutations_in_DDR2,_including_G505S,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",,missense_variant,"NM_006182.2:c.1513G>A,NP_006173.2:p.Gly505Ser,ENST00000367922.3:c.1513G>A,NC_000001.10:g.162741822G>A",4,Dasatinib,,,,,chr1_g.162741822G~A,DDR2_c.1513G~A,DDR2_G505S
DDR2,4921,I638F,Non-small_Cell_Lung_Carcinoma,3908,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,In_3T3_fibroblasts_expressing_the_I638F_mutation_have_to_be_sensitive_to_the_tyrosine_kinase_inhibitor_dasatinib.,22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,4,accepted,269,51,1,162745497,162745497,A,T,ENST00000367922.3,,,,,75,GRCh37,"DDR2_I638F_has_been_shown_to_be_a_loss_of_function_mutation,_but_also_confers_sensitivity_to_dasatinib_in_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/269,https://civic.genome.wustl.edu/links/variants/143,https://civic.genome.wustl.edu/links/genes/51,"DDR2_I638F_has_been_shown_to_be_a_loss_of_function_mutation,_but_also_confers_sensitivity_to_dasatinib_in_cell_lines.",,missense_variant,"ENST00000367922.3:c.1912A>T,NC_000001.10:g.162745497A>T",4,Dasatinib,,,,,chr1_g.162745497A~T,DDR2_c.1912A~T,
DDR2,4921,G774V,Non-small_Cell_Lung_Carcinoma,3908,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,In_3T3_fibroblasts_expressing_the_G774V_mutation_have_to_be_sensitive_to_the_tyrosine_kinase_inhibitor_dasatinib.,22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,4,accepted,268,51,1,162748407,162748407,G,T,ENST00000367922.3,,,,,75,GRCh37,"Activating_mutations_in_DDR2,_including_G774V,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/268,https://civic.genome.wustl.edu/links/variants/144,https://civic.genome.wustl.edu/links/genes/51,"Activating_mutations_in_DDR2,_including_G774V,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",,missense_variant,"ENST00000367922.3:c.2321G>T,NC_000001.10:g.162748407G>T",4,Dasatinib,,,,,chr1_g.162748407G~T,DDR2_c.2321G~T,
DDR2,4921,S768R,Non-small_Cell_Lung_Carcinoma,3908,,"Dasatinib,Erlotinib",Combination,Predictive,Supports,C,Sensitivity/Response,"In_a_patient_expressing_a_DDR2_S768R_mutation,_treatment_with_dasatinib_plus_erlotinib_acheived_a_partial_response.",22328973,PubMed,,"Hammerman_et_al.,_2011,_Cancer_Discov",,3,accepted,272,51,1,162748390,162748390,T,A,ENST00000367922.3,,,,,75,GRCh37,"Activating_mutations_in_DDR2,_including_S768R,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",Somatic_Mutation,2017-05-31_00:13:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/272,https://civic.genome.wustl.edu/links/variants/145,https://civic.genome.wustl.edu/links/genes/51,"Activating_mutations_in_DDR2,_including_S768R,_has_been_shown_to_be_sensitive_to_dasatinib_in_cell_lines.",,missense_variant,"ENST00000367922.3:c.2304T>A,NC_000001.10:g.162748390T>A",7.5,Dasatinib,Erlotinib,,,,chr1_g.162748390T~A,DDR2_c.2304T~A,
KRAS,3845,G12A,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2004,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2017-03-31_02:19:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/2004,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Panitumumab,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,B,Resistance,"In_a_study_of_patients_receiving_melphalan-based_therapy,_those_with_KRAS_codon_12_mutations_were_less_likely_to_have_a_positive_response_than_those_with_wildtype_KRAS_(26.9%_vs._58.3%,_P=0.015).",19284554,PubMed,,"Greco_et_al.,_2009,_J._Exp._Clin._Cancer_Res.",,2,accepted,2009,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2018-07-18_15:21:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/2009,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Melphalan,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Lung_Adenocarcinoma,3910,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Resistance,"KRAS_mutations_(N=29_G12,_N=1_G13)_were_the_primary_predictor_of_EGFR_TKI_resistance_in_patients_with_lung_adenocarcinoma_(N=83)._Overall_survival_(P=0.001)_and_progression-free_survival_(P=0.005)_were_significantly_shorter_in_mutated_patients.",19794967,PubMed,,"Marchetti_et_al.,_2009,_Neoplasia",,3,accepted,251,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2018-07-18_15:21:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/251,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Gefitinib,Erlotinib,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Lung_Cancer,1324,,Gefitinib,,Predictive,Supports,B,Resistance,"In_recurrent_lung_cancer_patients_treated_with_the_epidermal_growth_factor_receptor_tyrosine_kinase_inhibitor_gefitinib,_patients_with_KRAS_mutations_had_a_lower_frequency_of_partial_response_(PR)_and_stable_disease_(SD)_and_a_higher_rate_of_progressive_disease_(PD)_(PR:0,_SD:1,_PD:15_vs._PR:24,_SD:8,_PD:14;_P=0.0274)_compared_to_wildtype_KRAS_patients._Patients_with_KRAS_mutations_also_had_a_shorter_overall_survival_compared_to_wildtype_KRAS_patients_(HR:2.542,_95%_CI:1.048-6.168,_P=0.0390).",17409929,PubMed,,"Endoh_et_al.,_2006,_J_Thorac_Oncol",,2,accepted,2008,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2017-04-11_19:51:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/2008,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Gefitinib,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_SW48_cell_line_expressing_KRAS_G12A_mutation_demonstrated_decreased_sensitivity__to_regorafenib_treatment_(IC50:_330.13_nmol_vs._114.28_nmol,_P<0.01)_compared_to_SW48_cells_expressing_KRAS_wild-type._Resistance_was_determined_by_assessing_cell_viability.",26161928,PubMed,,"Camaj_et_al.,_2015,_Future_Oncol",,2,accepted,3710,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2018-07-18_15:22:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/3710,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Regorafenib,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",12483530,PubMed,,"Rowley_et_al.,_2002,_Oncogene",,2,accepted,2013,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2017-07-21_11:25:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/2013,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Melphalan,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS,_PIK3CA,_and_PTEN_were_tested_for_mutation;_KRAS_G12A_was_the_only_variant_noted_in_the_both_the_primary_and_metastatic_colon_tumors_of_one_patient_(Patient_29;_Supplemental_table_1)_,_and_the_primary_colon_tumor_of_another_patient_(104;_Table_S1),__who_both_experienced_stable_disease_following_treatment._In_the_larger_cohort,_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,6319,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2018-11-02_22:23:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/6319,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Panitumumab,Cetuximab,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",11050000,PubMed,,"Rowley_et_al.,_2000,_Blood",,2,accepted,2012,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2017-07-21_11:22:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/2012,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Melphalan,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
KRAS,3845,G12A,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",16497971,PubMed,,"Hoang_et_al.,_2006,_Blood",,2,accepted,2014,30,12,25398284,25398284,C,G,ENST00000256078.4,,,,,75,GRCh37,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",Somatic_Mutation,2017-07-21_11:25:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/2014,https://civic.genome.wustl.edu/links/variants/148,https://civic.genome.wustl.edu/links/genes/30,"KRAS_G12A,_like_EGFR_T790M,_has_been_shown_to_be_capable_of_driving_acquired_resistance_to_tyrosine_kinase_inhibitors_in_lung_adenocarcinoma.",EGFR_TKI_Resistance,missense_variant,"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C",48,Melphalan,,,,,chr12_g.25398284C~G,KRAS_c.35G~C,KRAS_G12A
RUNX1,861,MUTATION,Acute_Myeloid_Leukemia,9119,,Cytarabine,,Predictive,Supports,B,Resistance,"In_non-APL_patients_with_AML_(age_18-60),_those_who_had_mutations_in_RUNX1_had_significantly_shorter_relapse-free_survival_following_conventional_post-remission_treatment_(repetitive_cycles_of_high-dose_cytarabine)_than_those_treated_with_an_allogeneic_hematopoietic_stem-cell_transplantation_(N=32)_at_first_remission_(4-year_RFS;_0%_vs_52%;_P<0.0001).",21343560,PubMed,,"Gaidzik_et_al.,_2011,_J._Clin._Oncol.",,4,accepted,411,43,21,36160098,36421641,,,ENST00000300305.3,,,,,75,GRCh37,"RUNX1_mutations_are_associated_with_poor_prognosis_in_patients_with_acute_myeloid_leukemia_or_adult_T-cell_acute_lymphocytic_leukemia._In_younger_(<60_years_old)_AML_patients,_allogeneic_stem_cell_transplant_at_complete_remission_led_to_much_better_relapse-free_survival_than_repetitive_cycles_of_high-dose_cytarabine.",Somatic_Mutation,2016-11-03_21:50:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/411,https://civic.genome.wustl.edu/links/variants/155,https://civic.genome.wustl.edu/links/genes/43,"RUNX1_mutations_are_associated_with_poor_prognosis_in_patients_with_acute_myeloid_leukemia_or_adult_T-cell_acute_lymphocytic_leukemia._In_younger_(<60_years_old)_AML_patients,_allogeneic_stem_cell_transplant_at_complete_remission_led_to_much_better_relapse-free_survival_than_repetitive_cycles_of_high-dose_cytarabine.",,"loss_of_function_variant,transcript_variant",,110,Cytarabine,,,,,,,
IGF2,3481,OVEREXPRESSION,Prostate_Cancer,10283,,OSI-906_(Linsitinib),,Predictive,Supports,D,,"OSI-906,_an_IGF1R/INSR_inhibitor,_does_not_have_a_significant_effect_on_chemotherapy_resistant_castration-resistant_prostate_cancer_cell_lines.",25670080,PubMed,,"Vidal_et_al.,_2015,_Cancer_Cell",,3,accepted,412,60,11,2150348,2170833,,,ENST00000300632.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/412,https://civic.genome.wustl.edu/links/variants/156,https://civic.genome.wustl.edu/links/genes/60,,,,,6,OSI-906_(Linsitinib),,,,,,,
IGF2,3481,OVEREXPRESSION,Prostate_Cancer,10283,,"OSI-906_(Linsitinib),Docetaxel,Cabazitaxel",Substitutes,Predictive,Supports,D,Sensitivity/Response,"OSI-906,_an_IGF1R/INSR_inhibitor,_sensitizes_cell_lines_to_docetaxel_and_cabazitaxel,_resulting_in_better_overall_survival_in_mouse_xenografts_of_patient_derived_chemotherapy_resistant_castration-resistant_prostate_cancer_cell_lines.",25670080,PubMed,,"Vidal_et_al.,_2015,_Cancer_Cell",,3,accepted,414,60,11,2150348,2170833,,,ENST00000300632.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-31_15:45:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/414,https://civic.genome.wustl.edu/links/variants/156,https://civic.genome.wustl.edu/links/genes/60,,,,,6,OSI-906_(Linsitinib),Docetaxel,Cabazitaxel,,,,,
AURKA,6790,EXPRESSION,Esophagus_Squamous_Cell_Carcinoma,3748,,"Cisplatin,5-fluorouracil",Combination,Predictive,Supports,B,Sensitivity/Response,"A_retrospective_study_examining_the_expression_of_AURKA_in_tumor_samples_of_78_esophageal_squamous_cell_carcinoma_patients_found_that_positive_expression_of_AURKA_(>10%_of_cells_by_IHC)_was_correlated_with_increased_clinical_response_to_chemoradiation_therapy_consisting_of_cisplatin,_5-fluorouracil,_and_40_gy_radiation_(P_=_0.0003).",25924824,PubMed,,"Tamotsu_et_al.,_2015,_BMC_Cancer",,3,accepted,1653,61,20,54944446,54967393,,,ENST00000395913.3,,,,,75,GRCh37,,,2016-09-23_20:20:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1653,https://civic.genome.wustl.edu/links/variants/158,https://civic.genome.wustl.edu/links/genes/61,,,,,30,Cisplatin,5-fluorouracil,,,,,,
VHL,7428,MUTATION,Renal_Cell_Carcinoma,4450,,VEGF_Inhibition,,Predictive,Supports,B,Resistance,"A_meta-analysis_to_evaluate_the_association_between_the_VHL_alteration_and_clinical_outcomes_in_patients_with_RCC._There_were_six_studies_including_a_total_of_633_patients:_244_patients_who_received_anti-VEGF_therapy_in_the_predictive_value_analysis_and_419_in_the_prognostic_value_analysis._410_(61.8%)_had_VHL_alteration._The_meta-analysis_showed_no_association_between_the_VHL_gene_alteration_and_ORR_or_PFS,_as_well_as_no_correlation_to_OS._VEGFR_inhibition_included:_Sunitinib,_Sorafenib,_Axitinib,_Pazopanib,_Bevacizumab.",28103578,PubMed,,"Kim_et_al.,_2017,_Oncotarget",,4,accepted,4832,58,3,10182692,10193904,,,ENST00000256474.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_18:43:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/4832,https://civic.genome.wustl.edu/links/variants/160,https://civic.genome.wustl.edu/links/genes/58,,,"gene_variant,loss_of_function_variant",,85,VEGF_Inhibition,,,,,,,
VHL,7428,MUTATION,Renal_Cell_Carcinoma,4450,,Pazopanib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"VHL_mutations_were_evaluated_in_78_tumors_samples_of_patients_with_metastatic_RCC_treated_with_pazopanib_as_part_of_a_clinical_trial._Overall,_87%_had_one_VHL_mutation,_12%_showed_promoter_hypermethylation,_and_6_patients_had_both._8_patients_exhibited_neither_mutation_nor_methylation_of_VHL._There_was_no_correlation_between_VHL_status_and_overall_response_rate_or_progression_free_survival_under_pazopanib_therapy.",23881929,PubMed,,"Choueiri_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1672,58,3,10182692,10193904,,,ENST00000256474.2,,,,,75,GRCh37,,Somatic_Mutation,2016-10-15_16:29:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1672,https://civic.genome.wustl.edu/links/variants/160,https://civic.genome.wustl.edu/links/genes/58,,,"gene_variant,loss_of_function_variant",,85,Pazopanib,,,,,,,
VHL,7428,MUTATION,Renal_Cell_Carcinoma,4450,,Everolimus,,Predictive,Supports,B,Sensitivity/Response,"A_randomized,_open-label_phase_2_study,_encompassing_85_patients,_to_compare_the_efficacy_of_dual_PIK3/mTOR_Inhibitor_Apitolisib_and_mTORC1_inhibitor_Everolimus_in_patients_who_progressed_on_or_after_antiangiogenetic_therapy_(VEGFR)._There_was_a_trend_towards_association_between_deleterious_VHL_alterations_and_progression-free-survival_in_the_Everolimus_arm_only.",26951309,PubMed,,"Powles_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,5323,58,3,10182692,10193904,,,ENST00000256474.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_18:42:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/5323,https://civic.genome.wustl.edu/links/variants/160,https://civic.genome.wustl.edu/links/genes/58,,,"gene_variant,loss_of_function_variant",,85,Everolimus,,,,,,,
EZH2,2146,Y646,Skin_Melanoma,8923,,GSK126,,Predictive,Supports,D,Sensitivity/Response,Preclinical_study_in_melanoma_cell_lines._EZH2_expression_was_higher_in_EZH2_mutant_(N=3)_and_wild-type_melanoma_cell_lines_(N=12)_than_untransformed_cells_(human_epithelial_melanocytes_and_human_dermal_fibroblasts)._EZH2_mutant_cell_lines_were_the_most_sensitive_to_GSK126_compared_to_wild-type_and_untransformed.,26304929,PubMed,,"Tiffen_et_al.,_2015,_Oncotarget",,2,accepted,1494,63,7,148508726,148508728,,,ENST00000320356.2,,,,,75,GRCh37,"Mutations_of_Y646_are_associated_with_a_diagnosis_of_Germinal_Center_B_type_DLBCL_and_Follicular_non-Hodgkin_Lymphoma._In_vitro_experimental_findings_suggest_that_this_may_be_due_to_reduced_methyltransferase_activity_of_EZH2_on_protein_H3K27_(Morin_et_al.,_2010).",Somatic_Mutation,2016-11-03_19:21:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/1494,https://civic.genome.wustl.edu/links/variants/165,https://civic.genome.wustl.edu/links/genes/63,"Mutations_of_Y646_are_associated_with_a_diagnosis_of_Germinal_Center_B_type_DLBCL_and_Follicular_non-Hodgkin_Lymphoma._In_vitro_experimental_findings_suggest_that_this_may_be_due_to_reduced_methyltransferase_activity_of_EZH2_on_protein_H3K27_(Morin_et_al.,_2010).",,protein_altering_variant,,42,GSK126,,,,,,,
BTK,695,C481S,Chronic_Lymphocytic_Leukemia,1040,,Ibrutinib,,Predictive,Supports,B,Resistance,"In_a_trial_of_308_patients_with_chronic_lymphocytic_leukemia_treated_with_ibrutinib,_31_discontinued_treatment_due_to_disease_progression_(13_CLL_progression,_18_Richter’s_transformation)._11/13_patients_were_deep_sequenced_for_BTK_and_PLCG2._9_patients_were_identified_with_BTK_mutations_(C481S_in_8_patients)._In_5_patients,_C481S_was_the_sole_abnormality.",26182309,PubMed,,"Maddocks_et_al.,_2015,_JAMA_Oncol",,4,accepted,1770,65,X,100611165,100611165,A,T,ENST00000308731.7,,,,,75,GRCh37,,Somatic_Mutation,2017-01-23_14:42:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1770,https://civic.genome.wustl.edu/links/variants/168,https://civic.genome.wustl.edu/links/genes/65,,,missense_variant,"ENST00000308731.7:c.1441T>A,NC_000023.10:g.100611165A>T,NM_000061.2:c.1441T>A,NP_000052.1:p.Cys481Ser",40,Ibrutinib,,,,,chrX_g.100611165A~T,BTK_c.1441T~A,BTK_C481S
BTK,695,C481S,Chronic_Lymphocytic_Leukemia,1040,,Ibrutinib,,Predictive,Supports,B,Resistance,Whole_exome_sequencing_of_6_chronic_lymphocytic_leukemia_patients_with_acquired_resistance_to_ibrutinib_determined_5/6_patients_harbored_a_C481S_mutation_in_BTK.,24869598,PubMed,,"Woyach_et_al.,_2014,_N._Engl._J._Med.",,4,accepted,436,65,X,100611165,100611165,A,T,ENST00000308731.7,,,,,75,GRCh37,,Somatic_Mutation,2015-07-24_22:41:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/436,https://civic.genome.wustl.edu/links/variants/168,https://civic.genome.wustl.edu/links/genes/65,,,missense_variant,"ENST00000308731.7:c.1441T>A,NC_000023.10:g.100611165A>T,NM_000061.2:c.1441T>A,NP_000052.1:p.Cys481Ser",40,Ibrutinib,,,,,chrX_g.100611165A~T,BTK_c.1441T~A,BTK_C481S
AKT1,207,Q79K,Melanoma,1909,,Dabrafenib,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_44_relapsed_melanoma_patients_with_BRAF_V600E/K_(known_BRAF_inhibitor_sensitizing_mutations),_AKT1_Q79K_was_associated_with_acquired_resistance_to_BRAF_inhibitor_(dabrafenib)_monotherapy_in_one_patient._This_patient_was_a_38_year_old_female_with_stage_IV_M1a_melanoma_who_took_dabrafenib_(35_mg_twice_daily_to_100_mg_three_times_a_day)._The_best_overall_response_was_a_100%_reduction_in_the_sum_of_target_lesions,_and_progression_free_survival_lasted_119_days._Prior_to_dabrafenib_monotherapy,_this_patient's_baseline_tumor_harbored_BRAF_V600K—no_other_somatic_alterations_were_noted._Following_relapse,_the_patient_gained_AKT1_Q79K_in_one_of_two_disease_progressive_tumors._Whole_exome_sequencing_and_Sanger_re-sequencing_were_used_for_all_tumors._The_authors_hypothesized_that_disruptions_in_the_PI3K-PTEN-AKT_pathway_represent_a_core_mechanism_of_acquired_resistance_to_BRAF_inhibitor_therapy.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,4,accepted,6260,2,14,105243048,105243048,G,T,ENST00000407796.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_20:04:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/6260,https://civic.genome.wustl.edu/links/variants/169,https://civic.genome.wustl.edu/links/genes/2,,,missense_variant,"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A",14,Dabrafenib,,,,,chr14_g.105243048G~T,AKT1_c.235C~A,AKT1_Q79K
AKT1,207,Q79K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,The_AKT1_Q79K_mutation_has_been_shown_to_confer_resistance_to_BRAF_inhibitors_(vemurafenib)_in_melanoma_cell_line_M229.,24265152,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,4,accepted,439,2,14,105243048,105243048,G,T,ENST00000407796.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/439,https://civic.genome.wustl.edu/links/variants/169,https://civic.genome.wustl.edu/links/genes/2,,,missense_variant,"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A",14,Vemurafenib,,,,,chr14_g.105243048G~T,AKT1_c.235C~A,AKT1_Q79K
AKT1,207,Q79K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_M229_cell_line_endogenously_expressing_BRAF_V600E_mutation_(a_known_vemurafenib_sensitizing_mutation)_and_overexpressing_AKT1_Q79K_mutation_was_associated_with_resistance_to_vemurafenib_treatment,_as_compared_to_cells_expressing_BRAF_V600E_mutation_and_wildtype_AKT1._Resistance_was_determined_by_assessing_cell_survival.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,,accepted,4498,2,14,105243048,105243048,G,T,ENST00000407796.2,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:46:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/4498,https://civic.genome.wustl.edu/links/variants/169,https://civic.genome.wustl.edu/links/genes/2,,,missense_variant,"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A",14,Vemurafenib,,,,,chr14_g.105243048G~T,AKT1_c.235C~A,AKT1_Q79K
ALK,238,EML4-ALK_AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,"Two_out_of_11_patients_with_an_acquired_crizotinib_resistance_showed_new_ALK_copy-number_gain_(defined_as_more_than_2-fold_increase_in_the_mean_of_the_rearranged_gene_per_cell_in_the_posttreatment_specimen_compared_with_the_pretreatment_specimen),_both_with_>4_fold_increase._One_of_them_also_harbored_a_resistance_mutation_(G1269A).",22235099,PubMed,,"Doebele_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,766,1,2,42396490,42528380,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-02-18_20:41:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/766,https://civic.genome.wustl.edu/links/variants/170,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_amplification,transcript_fusion",,11,Crizotinib,,,,,,,
ALK,238,EML4-ALK_AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,One_patient_with_ALK-rearranged_non-small_cell_lung_cancer_and_an_acquired_resistance_to_crizotinib_showed_new_ALK_amplification_(4.1_fold_increase_compared_to_pre-crizotinib_specimen_as_measured_by_FISH)_and_harbored_an_EGFR_L858R_mutation.,23344087,PubMed,,"Kim_et_al.,_2013,_J_Thorac_Oncol",,2,accepted,767,1,2,42396490,42528380,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-02-18_22:18:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/767,https://civic.genome.wustl.edu/links/variants/170,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_amplification,transcript_fusion",,11,Crizotinib,,,,,,,
ALK,238,EML4-ALK_AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,"Amplification_of_wild-type_EML4-ALK_in_the_non-small_cell_lung_carcinoma_cell_line,_H3122,_caused_resistance_to_crizotinib.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,3,accepted,440,1,2,42396490,42528380,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/440,https://civic.genome.wustl.edu/links/variants/170,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_amplification,transcript_fusion",,11,Crizotinib,,,,,,,
ALK,238,ALK_FUSION_G1202R,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,The_G1202R_mutation_in_the_EML4-ALK_fusion_was_found_to_confer_resistance_to_crizotinib_in_Ba/F3_cells.,22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,4,accepted,441,1,2,29443613,29443613,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/441,https://civic.genome.wustl.edu/links/variants/171,https://civic.genome.wustl.edu/links/genes/1,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg",23.5,Crizotinib,,,,,chr2_g.29443613C~T,ALK_c.3604G~A,ALK_G1202R
ALK,238,ALK_FUSION_G1202R,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,D,Resistance,"Ba/F3_cells_expressing_EML4-ALK_variant_1_with_ALK_G1202R_mutation_were_assessed_for_ceritinib_sensitivity._Crizotinib_was_shown_to_confer_significantly_more_potency_than_ceritinib_(43-fold_decrease_in_IC50)._EML4-ALK_variant_3_NSCLC_cell_line_H2228_was_used_in_SCID_mouse_xenografts_which_were_exposed_to_increasing_crizotinib_up_to_100_mg/kg._Within_40_days_tumors_progressed,_and_progressed_tumors_were_assayed_for_ALK_mutation._Of_80_tumors,_6_had_ALK_mutation_and_3_of_these_were_G1202R._Treatment_of_crizotinib_progressed_tumors_with_ceritinib_resulted_in_tumor_growth_which_did_not_differ_appreciably_from_crizotinib_or_vehicle_treatment_of_these_tumors.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,4,accepted,1345,1,2,29443613,29443613,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",Somatic_Mutation,2016-06-27_23:53:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1345,https://civic.genome.wustl.edu/links/variants/171,https://civic.genome.wustl.edu/links/genes/1,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg",23.5,Ceritinib,,,,,chr2_g.29443613C~T,ALK_c.3604G~A,ALK_G1202R
ALK,238,ALK_FUSION_G1202R,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Resistance,"A_patient_with_ALK-rearranged_lung_adenocarcinoma_responded_to_crizotinib_treatment_and_then_had_relapse._Biopsy_was_taken_within_half_a_month_and_total_DNA_was_extracted_from_the_sample._Exons_20-28,_which_correspond_to_the_tyrosine_kinase_domain_of_ALK,_were_sequenced,_and_ALK_G1202A_was_found._CKIT_focal_amplification_by_FISH_was_also_observed._Tumor_sample_before_crizotinib_treatment_was_not_available_in_this_case.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,3,accepted,1357,1,2,29443613,29443613,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",Somatic_Mutation,2016-06-14_22:53:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1357,https://civic.genome.wustl.edu/links/variants/171,https://civic.genome.wustl.edu/links/genes/1,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg",23.5,Crizotinib,,,,,chr2_g.29443613C~T,ALK_c.3604G~A,ALK_G1202R
ALK,238,ALK_FUSION_G1202R,Cancer,162,,Brigatinib,,Predictive,Supports,D,Resistance,"This_study_compared_drug_responses_in_Ba/F3_cells_expressing_either_EML4-ALK_or_NPM-ALK_fusions,_with_or_without_G1202R_ALK_mutation._Cells_expressing_the_EML4-ALK_variant_3_with_G1202R_ALK_mutation_were_more_resistant_to_brigatinib_treatment_(IC50_325_nM)_than_cells_expressing_wildtype_EML4-ALK_variant_3_(IC50_6_nM)._These_same_experiments_performed_with_the_NPM-ALK_fusion_resulted_in_IC50_of_149_nM_for_G1202R_and_11nM_for_wild_type,_consistent_with_resistance._In_Western_blots,_ablation_of_pALK_with_brigatinib_treatment_above_100_nM_was_seen_in_Ba/F3_cells_expressing_NPM-ALK_wildtype,_but_remained_apparent_at_1000_nM_brigatinib_in_NPM-ALK_G1202R_cells,_despite_dose-dependent_reduction.",25727400,PubMed,,"Fontana_et_al.,_2015,_Cancer_Med",,3,accepted,1351,1,2,29443613,29443613,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",Somatic_Mutation,2016-06-28_21:50:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1351,https://civic.genome.wustl.edu/links/variants/171,https://civic.genome.wustl.edu/links/genes/1,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg",23.5,Brigatinib,,,,,chr2_g.29443613C~T,ALK_c.3604G~A,ALK_G1202R
ALK,238,ALK_FUSION_G1202R,Cancer,162,,Alectinib_(CH5424802),,Predictive,Supports,D,Resistance,"Ba/F3_cell_line_expressing_EML4-ALK_variant_3_with_G1202R_ALK_mutation_was_assessed_for_alectinib_sensitivity_and_IC50_for_survival_of_868_nM_was_reported,_which_was_64.4x_higher_than_the_IC50_reported_for_alectinib_on_Ba/F3_with_EML4-ALK_wild-type._Similar_experiments_using_NPM-ALK_instead_of_EML4-ALK_yielded_survival_IC50_of_549_nM_of_NPM-ALK_G1202R_to_alectinib,_which_was_27.9_times_higher_than_IC50_for_NPM-ALK_wild-type._Western_blots_of_Ba/F3_with_NPM-ALK_wild-type_showed_ablation_of_pALK_levels_above_100_nM_alectinib,_while_pALK_levels_were_essentially_unchanged_up_to_1000_nM_in_NPM-ALK_G1202R_Ba/F3_cells.",25727400,PubMed,,"Fontana_et_al.,_2015,_Cancer_Med",,3,accepted,1350,1,2,29443613,29443613,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1350,https://civic.genome.wustl.edu/links/variants/171,https://civic.genome.wustl.edu/links/genes/1,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg",23.5,Alectinib_(CH5424802),,,,,chr2_g.29443613C~T,ALK_c.3604G~A,ALK_G1202R
ALK,238,ALK_FUSION_G1202R,Non-small_Cell_Lung_Carcinoma,3908,,17-AAG,,Predictive,Supports,D,Sensitivity/Response,"The_G1202R_ALK_mutation_was_found_in_a_crizotinib-resistant_ALK-rearranged_NSCLC,_and_the_mutant_ALK_fusion_was_further_characterized_in_Ba/F3_cells._EML4-ALK_variant_1_with_G1202R_mutation_was_expressed_in_Ba/F3_and_subject_to_17-AAG._IC50_for_cell_number_in_response_to_17-AAG_was_33.4_nM,_in_contrast_to_IC50_for_EML4-ALK_wild-type,_which_was_98.9_nM,_suggesting_sensitization_of_this_variant_to_HSP90_inhibition.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,2,accepted,1352,1,2,29443613,29443613,C,T,ENST00000389048.3,,,,,75,GRCh37,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",Somatic_Mutation,2016-07-10_21:43:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1352,https://civic.genome.wustl.edu/links/variants/171,https://civic.genome.wustl.edu/links/genes/1,"ALK_fusion_with_G1202R_mutation_in_the_ALK_kinase_domain_was_first_identified_in_a_lung_adenocarcinoma_patient_who_had_progressed_after_10_months_of_responding_to_crizotinib._Further_characterization_of_this_variant_verified_crizotinib_resistance_and_additionally_demonstrated_resistance_to_multiple_next_generation_ALK_inhibitors_including_ceritinib,_alectinib_and_brigatinib._Experiments_using_the_HSP90_inhibitor__17-AAG_have_indicated_potential_sensitivity_of_EML4-ALK_G1202R_to_this_drug,_suggesting_this_variant_may_be_an_HSP90_client_protein.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg",23.5,17-AAG,,,,,chr2_g.29443613C~T,ALK_c.3604G~A,ALK_G1202R
ALK,238,EML4-ALK_S1206Y,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,The_S1206Y_mutation_in_the_EML4-ALK_fusion_was_found_to_confer_resistance_to_crizotinib_in_Ba/F3_cells.,22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,4,accepted,443,1,2,29443600,29443600,G,T,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/443,https://civic.genome.wustl.edu/links/variants/172,https://civic.genome.wustl.edu/links/genes/1,,Crizotinib_Resistance,"transcript_fusion,missense_variant","ENST00000389048.3:c.3617C>A,NC_000002.11:g.29443600G>T,NM_004304.4:c.3617C>A,NP_004295.2:p.Ser1206Tyr",6,Crizotinib,,,,,chr2_g.29443600G~T,ALK_c.3617C~A,ALK_S1206Y
ALK,238,EML4-ALK_S1206Y,Cancer,162,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_expressing_the_EML4-ALK_S1206Y_variant_were_treated_with_ceritinib,_and_survival_GI50_value_of_1.5_nM_was_obtained,_which_compares_favorably_with_GI50_of_1.7_for_the_highly_ceritinib_sensitive_EML4-ALK_wild-type_variant_obtained_in_parallel_experiments,_as_well_as_the_GI50_value_of_16_nM_obtained_for_crizotinib_treatment_of_EML4-ALK_wild-type.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,2,accepted,1343,1,2,29443600,29443600,G,T,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1343,https://civic.genome.wustl.edu/links/variants/172,https://civic.genome.wustl.edu/links/genes/1,,Crizotinib_Resistance,"transcript_fusion,missense_variant","ENST00000389048.3:c.3617C>A,NC_000002.11:g.29443600G>T,NM_004304.4:c.3617C>A,NP_004295.2:p.Ser1206Tyr",6,Ceritinib,,,,,chr2_g.29443600G~T,ALK_c.3617C~A,ALK_S1206Y
ALK,238,EML4-ALK_T1151INST,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,"A_lung_adenocarcinoma_patient_responded_to_crizotinib_treatment_for_12_months,_after_which_the_cancer_relapsed_and_sequencing_of_the_ALK_tyrosine_kinase_domain_revealed_a_1151insT_mutation._This_mutation_was_not_found_in_the_pre-crizotinib_biopsy._EML4-ALK_T1151insT_was_expressed_In_Ba/F3_cells_and_an_IC50_of_431.8_nM_was_obtained,_which_was_16_times_higher_than_for_EML4-ALK_wild-type,_indicating_strong_crizotinib_resistance._EML4-ALK_containing_H3122_NSCLC_cells_were_incubated_in_increasing_levels_of_crizotinib_inducing_resistance._The_resulting_cell_line_H3122_CR2_had_IC50_10x_greater_to_crizotinib_than_parental_H3122,_and_was_found_to_contain_1151_insT_mutation._In_western_blots,_pALK_levels_in_H3122_CR2_cells_remained_apparent_under_1000_nM_crizotinib,_whereas_pALK_signal_was_ablated_under_these_conditions_in_parental_H3122_cells.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,4,accepted,444,1,2,29445271,29445272,,CGT,ENST00000389048.3,,,,,75,GRCh37,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",Somatic_Mutation,2016-08-15_20:02:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/444,https://civic.genome.wustl.edu/links/variants/173,https://civic.genome.wustl.edu/links/genes/1,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",,"transcript_fusion,inframe_insertion",NC_000002.11:g.29445271_29445272insCGT,18,Crizotinib,,,,,chr2_g.29445271_29445272insCGT,,
ALK,238,EML4-ALK_T1151INST,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,D,Resistance,"Ba/F3_cells_expressing_EML4-ALK_with_1151_Tins_treated_with_alectinib_had_an_IC50_of_165.7_nM,_16x_higher_than_those_expressing_EML4-ALK_wildtype_variant_1._EML4-ALK_variant_1_expressing_H3122_NSCLC_cell_line_was_cultured_in_increasing_levels_of_crizotinib_to_produce_crizotinib_resistant_cell_lines_CR1,_CR2_and_CR3._H3122_CR2_was_found_to_contain_an_1151_insT_ALK_mutation_and_increased_EML4-ALK_levels._The_H3122_CR2_cell_line_survival_IC50_value_for_alectinib_treatment_was_approximately_20x_higher_than_that_for_H3122_cells.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,3,accepted,1347,1,2,29445271,29445272,,CGT,ENST00000389048.3,,,,,75,GRCh37,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",Somatic_Mutation,2016-07-06_19:41:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1347,https://civic.genome.wustl.edu/links/variants/173,https://civic.genome.wustl.edu/links/genes/1,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",,"transcript_fusion,inframe_insertion",NC_000002.11:g.29445271_29445272insCGT,18,Alectinib_(CH5424802),,,,,chr2_g.29445271_29445272insCGT,,
ALK,238,EML4-ALK_T1151INST,Non-small_Cell_Lung_Carcinoma,3908,,17-AAG,,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_transduced_with_EML4-ALK_1151_insT_were_treated_with_17-AAG_producing_an_IC50_value_of_44.5_nM,_which_was_0.4_times_that_reported_for_EML4-ALK_wildtype_in_Ba/F3,_indicating_possible_increased_dependence_of_EML4-ALK_1151_insT_on_HSP90._17-AAG_also_reduced_survival_of_the_parental_IL3-dependent_Ba/F3_cells_(183.7_nM),_indicating_increased_nonspecific_effects_of_17_AAG_treatment._Crizotinib_resistant_clones_were_produced_from_the_parental_EML4-ALK_variant_1_containing_cell_line_H3122_(CR1,_CR2,_CR3)._H3122_CR2_was_found_to_contain_the_EML4-ALK_InsT_variant._H3122_CR2_and_H3122_cells_were_similarly_sensitized_to_17-AAG_death_with_an_IC50_value_of_approximately_5_nM,_while_control_cells_without_EML4-ALK_had_IC50_values_approximately_10x_higher.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,2,accepted,1349,1,2,29445271,29445272,,CGT,ENST00000389048.3,,,,,75,GRCh37,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",Somatic_Mutation,2016-07-06_19:40:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1349,https://civic.genome.wustl.edu/links/variants/173,https://civic.genome.wustl.edu/links/genes/1,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",,"transcript_fusion,inframe_insertion",NC_000002.11:g.29445271_29445272insCGT,18,17-AAG,,,,,chr2_g.29445271_29445272insCGT,,
ALK,238,EML4-ALK_T1151INST,Non-small_Cell_Lung_Carcinoma,3908,,TAE684,,Predictive,Supports,D,Resistance,"Treatment_of_Ba/F3_cells_expressing_EML4-ALK_1151_insT_with_TAE684_produced_an_IC50_value_(28.3_nM)_20x_higher_cells_expressing_EML4-ALK_wildtype_variant_1._The_crizotinib_resistant_clones_were_produced_from_parental_H3122_cells_(CR1,_CR2,_CR3)._H3122_CR2_was_found_to_contain_the_1151_Tins_variant_as_well_as_elevated_EML4-ALK_expression._H3122_CR2_cells_treated_with_TAE684_produced_IC50_values_20-30_times_that_of_the_parental_H3122_cells._These_results_suggest_possible_variant_resistance_to_the_TAE684-derived_compound_ceritinib.",22277784,PubMed,,"Katayama_et_al.,_2012,_Sci_Transl_Med",,3,accepted,1348,1,2,29445271,29445272,,CGT,ENST00000389048.3,,,,,75,GRCh37,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",Somatic_Mutation,2016-07-06_19:39:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1348,https://civic.genome.wustl.edu/links/variants/173,https://civic.genome.wustl.edu/links/genes/1,"The_ALK_fusion_variant_with_insertion_of_T_at_amino_acid_1151_was_found_in_an_ALK_rearranged_lung_adenocarcinoma_which_had_progressed_after_responding_to_crizotinib_treatment._The_mutation_was_absent_in_tumor_sample_taken_before_crizotinib_treatment._Characterization_of_the_variant_using_cell_lines_expressing_EML4-ALK_with_1151_T_insert_found_the_variant_to_be_highly_crizotinib_resistant,_and_other_work_demonstrated_resistance_to_next_generation_inhibitor_alectinib,_while_resistance_to_tool_compound_TAE684_indicates_potential_resistance_to_the_next_generation_ALK_inhibitor_ceritinib_which_is_derived_from_TAE684._Other_experiments_suggest_theraputic_potential_for_HSP90_inhibitors,_as_EML4-ALK_T1151_Tins_sensitivity_to_17-AAG_has_been_observed.",,"transcript_fusion,inframe_insertion",NC_000002.11:g.29445271_29445272insCGT,18,TAE684,,,,,chr2_g.29445271_29445272insCGT,,
APC,324,MUTATION,Colorectal_Cancer,9256,,G007-LK,,Predictive,Supports,D,Sensitivity/Response,G007-LK_inhibits_in_vivo_tumor_growth_in_a_subset_of_APC-mutant_colorectal_cancers_xenograft_models_but_may_be_limited_by_intestinal_toxicity.,23539443,PubMed,,"Lau_et_al.,_2013,_Cancer_Res.",,4,accepted,446,66,5,112043218,112181936,,,ENST00000457016.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/446,https://civic.genome.wustl.edu/links/variants/174,https://civic.genome.wustl.edu/links/genes/66,,,,,7,G007-LK,,,,,,,
APC,324,MUTATION,Colon_Carcinoma,1520,,JW55,,Predictive,Supports,D,Sensitivity/Response,Canonical_Wnt_signaling_in_colon_carcinoma_cells_with_APC_mutation_was_inhibited_by_JW55_treatment.,22440753,PubMed,,"Waaler_et_al.,_2012,_Cancer_Res.",,3,accepted,445,66,5,112043218,112181936,,,ENST00000457016.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/445,https://civic.genome.wustl.edu/links/variants/174,https://civic.genome.wustl.edu/links/genes/66,,,,,7,JW55,,,,,,,
AR,367,F877L,Prostate_Cancer,10283,,"Enzalutamide,ARN-509",Substitutes,Predictive,Supports,D,Resistance,"Mutations_F876L_in_the_ligand_binding_domain_of_the_androgen_receptor_confered_resistance_to_enzalutamide_and_ARN-509,_causing_these_compounds_to_function_as_partial_agonists_in_two_prostate_cancer_cell_lines.",23779130,PubMed,,"Joseph_et_al.,_2013,_Cancer_Discov",,4,accepted,447,67,X,66943549,66943549,T,C,ENST00000374690.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/447,https://civic.genome.wustl.edu/links/variants/175,https://civic.genome.wustl.edu/links/genes/67,,,missense_variant,"ENST00000374690.3:c.2629T>C,NC_000023.10:g.66943549T>C,NM_000044.4:c.2629T>C,NP_000035.2:p.Phe877Leu",4,Enzalutamide,ARN-509,,,,chrX_g.66943549T~C,AR_c.2629T~C,AR_F877L
AR,367,W742,Prostate_Carcinoma,10286,,Bicalutamide,,Predictive,Supports,D,Resistance,"LNCaP-FGC_cells_with_mutations_at_codon_741_(W741C,_W741L)_were_able_to_use_bicalutamide_as_an_AR_agonist,_promoting_cell_growth_and_increased_prostate-specific_antigen_secretion.",12517791,PubMed,,"Hara_et_al.,_2003,_Cancer_Res.",,4,accepted,448,67,X,66937370,66937372,,,ENST00000374690.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/448,https://civic.genome.wustl.edu/links/variants/176,https://civic.genome.wustl.edu/links/genes/67,,,missense_variant,,4,Bicalutamide,,,,,,,
ATM,472,MUTATION,Hematologic_Cancer,2531,,Olaparib,,Predictive,Supports,D,Sensitivity/Response,"Olaparib_was_found_to_inhibit_cancer_cell_growth_in_ATM_mutant_cell_lines_of_several_blood_cancers_including_Lymphoblastoid_Leukemia,_Mantle_Cell_Lymphoma,_Chronic_Lymphocytic_Leukemia,_and_in_a_murine_xenograft_model_of_Mantle_Cell_Lymphoma.",20739657,PubMed,,"Weston_et_al.,_2010,_Blood",,5,accepted,455,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,Somatic_Mutation,2016-12-01_15:24:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/455,https://civic.genome.wustl.edu/links/variants/178,https://civic.genome.wustl.edu/links/genes/69,,,"loss_of_function_variant,transcription_variant",,86.5,Olaparib,,,,,,,
ATM,472,MUTATION,Glioblastoma_Multiforme,3068,,Temozolomide,,Predictive,Supports,D,Sensitivity/Response,Glioblastoma_cell_lines_were_shown_to_have_increased_sensitivity_to_Temozolomide_when_siRNA-induced_ATM_knockdown_was_applied.,23960094,PubMed,,"Eich_et_al.,_2013,_Mol._Cancer_Ther.",,3,accepted,452,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/452,https://civic.genome.wustl.edu/links/variants/178,https://civic.genome.wustl.edu/links/genes/69,,,"loss_of_function_variant,transcription_variant",,86.5,Temozolomide,,,,,,,
ATM,472,MUTATION,Mantle_Cell_Lymphoma,50746,,Olaparib,,Predictive,Supports,D,Sensitivity/Response,Two_ATM_deficient_mantle_cell_lymphoma_(MCL)_cell_lines_were_more_sensitive_to_PARP-1_inhibition_with_olaparib_or_PJ-34_than_4_other_MCL_cell_lines._shRNA_mediated_ATM_knockdown_in_a_cell_line_increased_sensitivity_to_olaparib._These_results_were_confirmed_in_a_xenograft_model.,20124459,PubMed,,"Williamson_et_al.,_2010,_Mol._Cancer_Ther.",,3,accepted,1907,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_17:38:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1907,https://civic.genome.wustl.edu/links/variants/178,https://civic.genome.wustl.edu/links/genes/69,,,"loss_of_function_variant,transcription_variant",,86.5,Olaparib,,,,,,,
ATM,472,MUTATION,Prostate_Cancer,10283,,Olaparib,,Predictive,Supports,C,Sensitivity/Response,Response_to_olaparib_was_observed_in_4_of_5_with_prostate_cancer_patients_with_ATM_aberrations_(2_germline).,26510020,PubMed,,"Mateo_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,1960,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,Germline_Mutation,2017-04-05_15:38:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/1960,https://civic.genome.wustl.edu/links/variants/178,https://civic.genome.wustl.edu/links/genes/69,,,"loss_of_function_variant,transcription_variant",,86.5,Olaparib,,,,,,,
ATM,472,MUTATION,Melanoma,1909,,Temozolomide,,Predictive,Supports,D,Sensitivity/Response,Melanoma_cell_lines_were_shown_to_have_increased_sensitivity_to_Temozolomide_when_siRNA-induced_ATM_knockdown_was_applied.,23960094,PubMed,,"Eich_et_al.,_2013,_Mol._Cancer_Ther.",,3,accepted,453,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/453,https://civic.genome.wustl.edu/links/variants/178,https://civic.genome.wustl.edu/links/genes/69,,,"loss_of_function_variant,transcription_variant",,86.5,Temozolomide,,,,,,,
ATM,472,UNDEREXPRESSION,Cancer,162,,"KU-0060648,NU7441",Substitutes,Predictive,Supports,D,Sensitivity/Response,ATM-deficient_H1395_and_HT144_cancer_cell_lines_showed_growth_inhibition_when_treated_with_DNA_PKcs_inhibitors_KU-0060648_and_NU7441._These_agents_also_increased_the_lifespan_of_mice_transfused_with_ATM-deficient_lymphoma_cells_when_compared_with_etoposide_or_control.,23761041,PubMed,,"Riabinska_et_al.,_2013,_Sci_Transl_Med",,5,accepted,454,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,Somatic_Mutation,2016-10-10_19:29:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/454,https://civic.genome.wustl.edu/links/variants/179,https://civic.genome.wustl.edu/links/genes/69,,,,,54,KU-0060648,NU7441,,,,,,
ATM,472,UNDEREXPRESSION,Gastric_Adenocarcinoma,3717,,Olaparib,,Predictive,Supports,D,Sensitivity/Response,Low_ATM_protein_expression_led_to_sensitivity_to_PARP_inhibitors_in_TP53_-ve_gastric_cancer_cell_lines_(8_lines_were_used_for_various_aspects_of_this_study).,24841718,PubMed,,"Kubota_et_al.,_2014,_Cell_Cycle",,4,accepted,878,69,11,108093559,108239826,,,ENST00000278616.4,,,,,75,GRCh37,,,2016-02-21_17:47:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/878,https://civic.genome.wustl.edu/links/variants/179,https://civic.genome.wustl.edu/links/genes/69,,,,,54,Olaparib,,,,,,,
AURKA,6790,AMPLIFICATION,Esophagus_Adenocarcinoma,4914,,"Cisplatin,Alisertib",Combination,Predictive,Supports,E,Sensitivity/Response,Antitumour_effect_of_alisertib_treatment_in_esophageal_adenocarcinomas_can_be_intensified_in_combination_with_cisplatin.,22302096,PubMed,,"Sehdev_et_al.,_2012,_Mol._Cancer_Ther.",,3,accepted,456,61,20,54944446,54967393,,,ENST00000395913.3,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/456,https://civic.genome.wustl.edu/links/variants/180,https://civic.genome.wustl.edu/links/genes/61,,,transcript_amplification,,0.75,Cisplatin,Alisertib,,,,,,
AURKA,6790,OVEREXPRESSION,Cervical_Adenocarcinoma,3702,,Paclitaxel,,Predictive,Supports,D,Resistance,"In_the_cervial_andenocarcinoma_cell_line_HeLa,_when_AURK-A_was_overexpressed,_the_cells_were_resistant_to_the_apoptotic_effects_of_Taxol.",12559175,PubMed,,"Anand_et_al.,_2003,_Cancer_Cell",,3,accepted,457,61,20,54944446,54967393,,,ENST00000395913.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/457,https://civic.genome.wustl.edu/links/variants/181,https://civic.genome.wustl.edu/links/genes/61,,,,,38,Paclitaxel,,,,,,,
AURKA,6790,OVEREXPRESSION,Ovarian_Serous_Carcinoma,50933,,PLATINUM,,Predictive,Supports,B,Resistance,A_study_of_41_patients_with_high-grade_ovarian_serous_carcinoma_found_that_high_expression_levels_of_AURKA_correlated_with_poorer_overall_survival_(P = 0.001;_HR_0.14)_and_platinum_therapy_resistance_(P_<_0.001)._Expression_of_AURKA_was_measured_using_immunohistochemical_techniques_on_tumor_samples.,27209210,PubMed,,"Mignogna_et_al.,_2016,_J_Ovarian_Res",,3,accepted,1650,61,20,54944446,54967393,,,ENST00000395913.3,,,,,75,GRCh37,,,2016-09-13_22:51:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1650,https://civic.genome.wustl.edu/links/variants/181,https://civic.genome.wustl.edu/links/genes/61,,,,,38,PLATINUM,,,,,,,
AURKA,6790,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Cisplatin,,Predictive,Supports,B,Resistance,High_levels_of_Aurora-A_expression_(retrospectively_assessed_by_IHC_in_102_NSCLC_patients)_predicted_poorer_overall_survival_and_progression_free_survival_in_a_population_treated_with_surgery_and_cisplatin-based_chemotherapy._In-vitro_data_confirmed_these_results_and_overexpression_or_knockdown_of_AURKA_decreased_or_increased_in-vitro_sensitivity_to_cisplatin.,25082261,PubMed,,"Xu_et_al.,_2014,_J_Transl_Med",,4,accepted,871,61,20,54944446,54967393,,,ENST00000395913.3,,,,,75,GRCh37,,,2016-02-16_19:52:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/871,https://civic.genome.wustl.edu/links/variants/181,https://civic.genome.wustl.edu/links/genes/61,,,,,38,Cisplatin,,,,,,,
BAP1,8314,MUTATION,Uveal_Melanoma,6039,,"LBH-589,Valproic_Acid,Vorinostat_(SAHA),Trichostatin_A_(TSA)",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Somatic_and_germline_BAP1_mutations_are_associated_with_uveal_melanoma._In_this_preclinical_study,_gene_set_enrichment_analysis_revealed_HDAC_inhibitors_as_potential_drugs_in_BAP1_mutant_uveal_melanomas._HDAC_inhibitors_VPA,_TSA,_LBH-589,_and_SAHA_(vorinostat)_were_tested_in-vitro_and_led_to_decreased_proliferation_(all_inhibitors)_decreased_viability_and_cytotoxicity_(TSA,_SAHA,_LBH-589)_in-vitro_and_in-vivo_(VPA)._RNAi_mediated_BAP1_knockdown_increased_sensitivity_to_HDAC_inhibition_(VPA).",22038994,PubMed,,"Landreville_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,1234,70,3,52435029,52444366,,,ENST00000460680.1,,,,,75,GRCh37,"BAP1_is_a_tumor_suppressor_gene,_mutations_in_this_gene_have_been_observed_in_a_number_of_cancers_including_melanoma,_and_renal_cancers._These_mutations_generally_lead_to_loss-of-function_and_mutations_in_the_UHC_domain_of_BAP1_have_been_shown_to_lead_to_structural_instability_and_β-amyloid_aggregation_in_models._Germline_mutations_are_associated_with_an_increased_risk_of_tumorgenesis_and_can_lead_to_the_development_of_""atypical_Spitz_tumours_(ASTs),_cutaneous_melanoma_(CM),_epithelioid_malignant_mesothelioma_(MM)_and_clear_cell_RCC"".",Somatic_Mutation,2016-07-13_23:32:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/1234,https://civic.genome.wustl.edu/links/variants/183,https://civic.genome.wustl.edu/links/genes/70,"BAP1_is_a_tumor_suppressor_gene,_mutations_in_this_gene_have_been_observed_in_a_number_of_cancers_including_melanoma,_and_renal_cancers._These_mutations_generally_lead_to_loss-of-function_and_mutations_in_the_UHC_domain_of_BAP1_have_been_shown_to_lead_to_structural_instability_and_β-amyloid_aggregation_in_models._Germline_mutations_are_associated_with_an_increased_risk_of_tumorgenesis_and_can_lead_to_the_development_of_""atypical_Spitz_tumours_(ASTs),_cutaneous_melanoma_(CM),_epithelioid_malignant_mesothelioma_(MM)_and_clear_cell_RCC"".",,"loss_of_function_variant,protein_altering_variant",,73.5,LBH-589,Valproic_Acid,Vorinostat_(SAHA),Trichostatin_A_(TSA),,,,
BAP1,8314,MUTATION,Malignant_Mesothelioma,1790,,"Vorinostat_(SAHA),Mocetinostat,MC1568",Substitutes,Predictive,Supports,E,Sensitivity/Response,"A_siRNA_screen_identified_BAP1_associated_with_HDAC1_and_HDAC2_expression._HDAC2_or_BAP1_depletion_sensitized_a_mesothelioma_cell_line_(MSTO-211H)_to_HDAC_inhibitors_MC1568,_vorinostat_or_mocetinostat._The_paper_indicates_however,_that_temporary_BAP_knockdown_might_not_adequately_reflect_long-term_BAP1_mutation.",25970771,PubMed,,"Sacco_et_al.,_2015,_Oncotarget",,2,accepted,1235,70,3,52435029,52444366,,,ENST00000460680.1,,,,,75,GRCh37,"BAP1_is_a_tumor_suppressor_gene,_mutations_in_this_gene_have_been_observed_in_a_number_of_cancers_including_melanoma,_and_renal_cancers._These_mutations_generally_lead_to_loss-of-function_and_mutations_in_the_UHC_domain_of_BAP1_have_been_shown_to_lead_to_structural_instability_and_β-amyloid_aggregation_in_models._Germline_mutations_are_associated_with_an_increased_risk_of_tumorgenesis_and_can_lead_to_the_development_of_""atypical_Spitz_tumours_(ASTs),_cutaneous_melanoma_(CM),_epithelioid_malignant_mesothelioma_(MM)_and_clear_cell_RCC"".",Somatic_Mutation,2016-07-01_16:28:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1235,https://civic.genome.wustl.edu/links/variants/183,https://civic.genome.wustl.edu/links/genes/70,"BAP1_is_a_tumor_suppressor_gene,_mutations_in_this_gene_have_been_observed_in_a_number_of_cancers_including_melanoma,_and_renal_cancers._These_mutations_generally_lead_to_loss-of-function_and_mutations_in_the_UHC_domain_of_BAP1_have_been_shown_to_lead_to_structural_instability_and_β-amyloid_aggregation_in_models._Germline_mutations_are_associated_with_an_increased_risk_of_tumorgenesis_and_can_lead_to_the_development_of_""atypical_Spitz_tumours_(ASTs),_cutaneous_melanoma_(CM),_epithelioid_malignant_mesothelioma_(MM)_and_clear_cell_RCC"".",,"loss_of_function_variant,protein_altering_variant",,73.5,Vorinostat_(SAHA),Mocetinostat,MC1568,,,,,
BAP1,8314,MUTATION,Renal_Cell_Carcinoma,4450,,"Everolimus,Sunitinib",Sequential,Predictive,Supports,B,Resistance,"This_study_evaluated_the_effects_of_everolimus_and_sunitinib_on_patients_with_metastatic_renal_cell_carcinoma._A_total_of_220_patients_with_RCC_were_evaluated_for_341_genes_at_540x_coverage._Of_all_220_patients,_19%_of_had_BAP1_mutations._Patients_with_BAP1_mutations_treated_with_first_line_everolimus_followed_by_sunitinib_(N=87_wildtype,_22_mutant)_were_associated_with_shorter_progression_free_survival_(median_[95%_CI]_4.9_[2.9_-_8.1]_vs_10.5_[7.3_-_12.9]_mo;_HR_1.84_[1.1-3.2];_P=0.02)._For_patients_treated_with_sunitinib_followed_by_everolimus_(N=91_wildtype,_20_mutant)_were_associated_with_a_trend_towards_shorter_progression_free_survival_(median_[95%_CI]_8.1_[3.1-11.3]_vs_11.0_[8.3-13.8]_mo;_HR_1.69_[0.9-3.2];_P=0.06).",27751729,PubMed,,"Hsieh_et_al.,_2017,_Eur._Urol.",,4,accepted,5339,70,3,52435029,52444366,,,ENST00000460680.1,,,,,75,GRCh37,"BAP1_is_a_tumor_suppressor_gene,_mutations_in_this_gene_have_been_observed_in_a_number_of_cancers_including_melanoma,_and_renal_cancers._These_mutations_generally_lead_to_loss-of-function_and_mutations_in_the_UHC_domain_of_BAP1_have_been_shown_to_lead_to_structural_instability_and_β-amyloid_aggregation_in_models._Germline_mutations_are_associated_with_an_increased_risk_of_tumorgenesis_and_can_lead_to_the_development_of_""atypical_Spitz_tumours_(ASTs),_cutaneous_melanoma_(CM),_epithelioid_malignant_mesothelioma_(MM)_and_clear_cell_RCC"".",Somatic_Mutation,2017-07-27_18:10:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/5339,https://civic.genome.wustl.edu/links/variants/183,https://civic.genome.wustl.edu/links/genes/70,"BAP1_is_a_tumor_suppressor_gene,_mutations_in_this_gene_have_been_observed_in_a_number_of_cancers_including_melanoma,_and_renal_cancers._These_mutations_generally_lead_to_loss-of-function_and_mutations_in_the_UHC_domain_of_BAP1_have_been_shown_to_lead_to_structural_instability_and_β-amyloid_aggregation_in_models._Germline_mutations_are_associated_with_an_increased_risk_of_tumorgenesis_and_can_lead_to_the_development_of_""atypical_Spitz_tumours_(ASTs),_cutaneous_melanoma_(CM),_epithelioid_malignant_mesothelioma_(MM)_and_clear_cell_RCC"".",,"loss_of_function_variant,protein_altering_variant",,73.5,Everolimus,Sunitinib,,,,,,
BRCA1,672,MUTATION,Ovarian_Carcinoma,4001,,PLATINUM,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_ovarian_carcinomas,_81%_of_tumors_with_germline_BRCA1/2_mutations_were_platinum_sensitive,_whereas_only_60%_of_tumors_with_non-BRCA1/2_mutations_were_platinum_sensitive_(N=47;_N=158;_P=0.01)._Sensitivity_was_defined_by_maintenance_of_complete_response_greater_than_6_months_post_platinum-based_therapy.",24240112,PubMed,,"Pennington_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1529,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2016-07-16_15:14:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1529,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,PLATINUM,,,,,,,
BRCA1,672,MUTATION,Cancer,162,,Olaparib,,Predictive,Supports,A,Sensitivity/Response,"In_this_phase_1_trial,_60_patients_with_advanced_solid_tumors_(ovarian,_breast,_colorectal,_melanoma,_sarcoma,_prostate)_were_treated_with_PARP_inhibitor_olaparib._Durable_antitumor_activity_was_only_observed_in_BRCA1/2_mutation_carriers._19_BRCA_carriers_had_ovarian,_breast,_or_prostate_cancers;_12_of_these_(63%)_had_a_clinical_benefit_from_treatment_with_olaparib:_radiologic_or_tumor-marker_responses_or_meaningful_disease_stabilization_(stable_disease_for_a_period_of_4_months_or_more)._Nine_BRCA_carriers_had_a_response_according_to_RECIST,_with_the_response_sustained_for_more_than_76_weeks_in_one_patient._No_responses_were_seen_in_patients_without_BRCA_mutation.",19553641,PubMed,,"Fong_et_al.,_2009,_N._Engl._J._Med.",,4,accepted,1370,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2016-06-22_19:17:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1370,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Olaparib,,,,,,,
BRCA1,672,MUTATION,Ovarian_Carcinoma,4001,,PLATINUM,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_ovarian_carcinomas,_87%_of_tumors_with_somatic_BRCA1/2_mutations_were_platinum_sensitive,_whereas_only_60%_of_tumors_with_non-BRCA1/2_mutations_were_platinum_sensitive_(N=38;_N=158;_P=0.002)._Sensitivity_to_platinum_was_defined_by_maintenance_of_complete_response_greater_than_6_months_post_platinum-based_therapy.",24240112,PubMed,,"Pennington_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1531,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-16_15:47:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1531,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,PLATINUM,,,,,,,
BRCA1,672,MUTATION,Triple-receptor_Negative_Breast_Cancer,60081,,Olaparib,,Predictive,Supports,B,Resistance,"In_a_study_of_26_patients_with_breast_cancer,_10_patients_were_BRCA-positive_and_16_patients_were_BRCA-negative.__Regardless_of_BRCA_status,_none_showed_objective_response_when_treated_with_olaparib.",21862407,PubMed,,"Gelmon_et_al.,_2011,_Lancet_Oncol.",,3,accepted,1775,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2017-11-02_18:10:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1775,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Olaparib,,,,,,,
BRCA1,672,MUTATION,Breast_Cancer,1612,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"Randomized,_open-label,_phase_3_trial_in_which_olaparib_monotherapy_was_compared_with_standard_therapy_in_patients_with_a_germline_BRCA_mutation_HER2–negative_metastatic_breast_cancer._205_patients_were_assigned_to_receive_olaparib_and_97_were_assigned_to_receive_standard_therapy._Median_progression-free_survival_was_significantly_longer_in_the_olaparib_group_than_in_the_standard-therapy_group_(7.0_months_vs._4.2_months;_hazard_ratio_0.58;_95%CI_0.43_to_0.80;_P<0.001)._A_response_to_treatment_occurred_in_100_of_the_167_patients_who_had_measurable_disease_in_the_olaparib_group_(59.9%;_95%_CI,_52.0_to_67.4)_and_in_19_of_the_66_patients_in_the_standard-therapy_group_(28.8%;_95%_CI,_18.3_to_41.3)._A_complete_response_was_seen_in_9.0%_of_the_patients_who_had_measurable_disease_in_the_olaparib_group_and_in_1.5%_in_the_standard-therapy_group.",28792849,PubMed,,"2017,_N._Engl._J._Med.",,4,accepted,5830,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-06_14:35:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/5830,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Olaparib,,,,,,,
BRCA1,672,MUTATION,Pancreatic_Cancer,1793,,"Cisplatin,Veliparib,Gemcitabine",Combination,Predictive,Supports,B,Sensitivity/Response,In_Phase_I_study_for_pancreatic_cancer_patients_GEM_600_mg/m2_+_CDDP_25_mg/m2_+_Veliparib_20_-_80_mg_twice_daily_showed_response_rate_of__77.8%_(7/9)_and_mOS_of_23.3_months_in_germline_BRCA_mutation-positive_patients_with_stage_IV_disease.,29338080,PubMed,,"O'Reilly_et_al.,_2018,_Cancer",NCT01585805,3,accepted,5932,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-06_14:37:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/5932,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Cisplatin,Veliparib,Gemcitabine,,,,,
BRCA1,672,MUTATION,Pancreatic_Cancer,1793,,Veliparib,,Predictive,Does_Not_Support,B,Sensitivity/Response,Veliparib_400mg_bid_was_administered_to_patients_with_germline_BRCA1/2_mutated_pancreatic_cancer._Sixteen_pts_was_enrolled._All_except_two_pts_(12.5%)_had_previously_been_treated_with_platinum_therapy._No_confirmed_PR_was_observed._One_patient_who_had_received_prior_single-agent_gemcitabine_only_had_an_unconfirmed_PR.,29223478,PubMed,,"Lowery_et_al.,_2018,_Eur._J._Cancer","NCT01585805,NCT02184195",3,accepted,5934,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-06_14:36:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/5934,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Veliparib,,,,,,,
BRCA1,672,MUTATION,Pancreatic_Cancer,1793,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"Twenty-three_patients_with_pancreatic_cancer_havoring_BRCA1/2_germline_mutations_received_olaparib._Eighteen_(78%)_patients_had_a_BRCA2_mutation._All_but_one_had_received_gemcitabine,_and_65%_had_received_prior_platinum._Tumor_response_rate_was_21.7%_and_stable_disease_more_than_8_weeks_was_35%.",25366685,PubMed,,"Kaufman_et_al.,_2015,_J._Clin._Oncol.",,4,accepted,5914,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-06_14:36:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/5914,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Olaparib,,,,,,,
BRCA1,672,MUTATION,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,B,Sensitivity/Response,"A_phase_2_trial_on_patients_with_relapsed,_platinum-sensitive_high_grade_ovarian_carcinoma_(ARIEL2_Part1,_NCT01891344)_was_held_to_assess_PARP_inhibitor_Rucaparib_on_3_genetically_defined_subsets_of_patients._Out_of_40_BRCA_mutant_patients,_10_had_somatic_BRCA1_mutation._Confirmed_objective_response_was_seen_in_79%_of_the_BRCA1_mutant_subgroup,_and_74%_confirmed_objective_response_was_seen_in_the_somatic_BRCA_mutant_subgroup._In_a_BRCA_wild-type_subgroup,_with_low_levels_of_Loss_of_Heterozygosity,_confirmed_objective_response_was_observed_in_10%_of_the_patients.",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,4,accepted,1897,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2017-02-14_20:41:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1897,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Rucaparib,,,,,,,
BRCA1,672,MUTATION,Triple-receptor_Negative_Breast_Cancer,60081,,"Cisplatin,Carboplatin",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_an_evaluation_of_77_patients,_those_who_had_BRCA1/2_germline_mutations_(n=11)_had_an_increase_response_rate_to_cisplatin_when_compared_to_those_without_germline_mutations_(54.5%_versus_19.7%;_P=0.022)_although_progression_free_survival_and_overall_survival_was_not_significantly_different.",25847936,PubMed,,"Isakoff_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,1684,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2016-09-23_19:25:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1684,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Cisplatin,Carboplatin,,,,,,
BRCA1,672,MUTATION,Ovarian_Cancer,2394,,"Olaparib,Cediranib",Combination,Predictive,Supports,B,Sensitivity/Response,"46_women_with_platinum-sensitive,_high-grade,_BRCA1/2+_ovarian_cancer_received_either_olaparib_monotherapy_or_olaparib/cediranib_combination_therapy.__Median_PFS_was_increased_in_combination_therapy_(17.7_months_versus_9.0_months;_HR=0.42;_95%CI_0.23-0.76;_p=0.005);_overall_response_rate_was_increased_in_the_combination_therapy_(79.6%_versus_47.8%;_p=0.002);_and_total_deaths_were_reduced_in_combination_therapy_(6_patients_versus_10_patients).",25218906,PubMed,,"Liu_et_al.,_2014,_Lancet_Oncol.",,3,accepted,1677,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2016-09-23_19:25:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1677,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Olaparib,Cediranib,,,,,,
BRCA1,672,MUTATION,Pancreatic_Cancer,1793,,PLATINUM,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_BRCA1/2_associated_pancreatic_adenocarcinoma_were_evaluated_retrospectively._In_patients_with_stage_3_and_4,_the_median_overall_survival_(mOS)_was_22_months_for_the_platinum_exposed_(n=22),_compared_with_9_months_for_the_non-platinum_(n=21)_treatment_groups_(p<0.039)",25072261,PubMed,,"Golan_et_al.,_2014,_Br._J._Cancer",,4,accepted,5915,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-06_14:36:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/5915,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,PLATINUM,,,,,,,
BRCA1,672,MUTATION,Ovarian_Cancer,2394,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_63_patients_with_ovarian_cancer,_17_patients_had_BRCA1_or_BRCA2_mutations_and_46_patients_had_no_BRCA_mutations.__Of_the_BRCA-positive_patients,_7/17(41%;_95%CI_22-64)_showed_objective_response_to_olaparib_whereas_only_11/46_BRCA-negative_patients_(24%;_95%CI_14-38)_showed_objective_response_to_olaparib.",21862407,PubMed,,"Gelmon_et_al.,_2011,_Lancet_Oncol.",,3,accepted,1772,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Germline_Mutation,2017-01-23_14:46:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1772,https://civic.genome.wustl.edu/links/variants/185,https://civic.genome.wustl.edu/links/genes/6,,,"gene_variant,loss_of_function_variant",,270,Olaparib,,,,,,,
BRCA2,675,MUTATION,Ovarian_Cancer,2394,,"Olaparib,Cediranib",Combination,Predictive,Supports,B,Sensitivity/Response,"46_women_with_platinum-sensitive,_high-grade,_BRCA1/2+_ovarian_cancer_received_either_olaparib_monotherapy_or_olaparib/cediranib_combination_therapy.__Median_PFS_was_increased_in_combination_therapy_(17.7_months_versus_9.0_months;_HR=0.42;_95%CI_0.23-0.76;_p=0.005);_overall_response_rate_was_increased_in_the_combination_therapy_(79.6%_versus_47.8%;_p=0.002);_and_total_deaths_were_reduced_in_combination_therapy_(6_patients_versus_10_patients).",25218906,PubMed,,"Liu_et_al.,_2014,_Lancet_Oncol.",,3,accepted,1678,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2016-09-23_20:15:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1678,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Olaparib,Cediranib,,,,,,
BRCA2,675,MUTATION,Breast_Cancer,1612,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"Randomized,_open-label,_phase_3_trial_in_which_olaparib_monotherapy_was_compared_with_standard_therapy_in_patients_with_a_germline_BRCA_mutation_HER2–negative_metastatic_breast_cancer._205_patients_were_assigned_to_receive_olaparib_and_97_were_assigned_to_receive_standard_therapy._Median_progression-free_survival_was_significantly_longer_in_the_olaparib_group_than_in_the_standard-therapy_group_(7.0_months_vs._4.2_months;_hazard_ratio_0.58;_95%CI_0.43_to_0.80;_P<0.001)._A_response_to_treatment_occurred_in_100_of_the_167_patients_who_had_measurable_disease_in_the_olaparib_group_(59.9%;_95%_CI,_52.0_to_67.4)_and_in_19_of_the_66_patients_in_the_standard-therapy_group_(28.8%;_95%_CI,_18.3_to_41.3)._A_complete_response_was_seen_in_9.0%_of_the_patients_who_had_measurable_disease_in_the_olaparib_group_and_in_1.5%_in_the_standard-therapy_group.",28792849,PubMed,,"2017,_N._Engl._J._Med.",,4,accepted,5831,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-10_18:36:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/5831,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Olaparib,,,,,,,
BRCA2,675,MUTATION,Ovarian_Carcinoma,4001,,PLATINUM,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_ovarian_carcinomas,_87%_of_tumors_with_somatic_BRCA1/2_mutations_were_platinum_sensitive,_whereas_only_60%_of_tumors_with_non-BRCA1/2_mutations_were_platinum_sensitive_(N=38;_N=158;_P=0.002)._Sensitivity_to_platinum_was_defined_by_maintenance_of_complete_response_greater_than_6_months_post_platinum_therapy.",24240112,PubMed,,"Pennington_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1532,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-16_15:13:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1532,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,PLATINUM,,,,,,,
BRCA2,675,MUTATION,Pancreatic_Cancer,1793,,Veliparib,,Predictive,Does_Not_Support,B,Sensitivity/Response,Veliparib_400mg_bid_was_administered_to_patients_with_germline_BRCA1/2_mutated_pancreatic_cancer._Sixteen_pts_was_enrolled._All_except_two_pts_(12.5%)_had_previously_been_treated_with_platinum_therapy._No_confirmed_PR_was_observed._One_patient_who_had_received_prior_single-agent_gemcitabine_only_had_an_unconfirmed_PR.,29223478,PubMed,,"Lowery_et_al.,_2018,_Eur._J._Cancer","NCT01585805,NCT02184195",3,accepted,5935,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-31_18:03:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/5935,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Veliparib,,,,,,,
BRCA2,675,MUTATION,Cancer,162,,Olaparib,,Predictive,Supports,A,Sensitivity/Response,"In_this_phase_1_trial_60_patients_with_advanced_solid_tumors_(ovarian,_breast,_colorectal,_melanoma,_sarcoma,_prostate)_were_treated_with_PARP_inhibitor_olaparib._Durable_antitumor_activity_was_only_observed_in_BRCA1/2_mutation_carriers.19_BRCA_carriers_had_ovarian,_breast,_or_prostate_cancers;_12_of_these_(63%)_had_a_clinical_benefit_from_treatment_with_olaparib:_radiologic_or_tumor-marker_responses_or_meaningful_disease_stabilization_(stable_disease_for_a_period_of_4_months_or_more)._Nine_BRCA_carriers_had_a_response_according_to_RECIST,_with_the_response_sustained_for_more_than_76_weeks_in_one_patient._No_responses_were_seen_in_patients_without_BRCA_mutation.",19553641,PubMed,,"Fong_et_al.,_2009,_N._Engl._J._Med.",,4,accepted,1371,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2016-06-22_19:18:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1371,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Olaparib,,,,,,,
BRCA2,675,MUTATION,Ovarian_Cancer,2394,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_63_patients_with_ovarian_cancer,_17_patients_had_BRCA1_or_BRCA2_mutations_and_46_patients_had_no_BRCA_mutations.__Of_the_BRCA-positive_patients,_7/17(41%;_95%CI_22-64)_showed_objective_response_to_olaparib_whereas_only_11/46_BRCA-negative_patients_(24%;_95%CI_14-38)_showed_objective_response_to_olaparib.",21862407,PubMed,,"Gelmon_et_al.,_2011,_Lancet_Oncol.",,3,accepted,1773,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2017-01-23_15:04:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1773,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Olaparib,,,,,,,
BRCA2,675,MUTATION,Pancreatic_Cancer,1793,,Iniparib,,Predictive,Supports,C,Sensitivity/Response,"Patient_with_germline_BRCA2_mutation_underwent_resection_of_pancreatic_cancer._Around_three_years_later,_tumor_recurrence_was_detected_by_MRI_and_PET-CT_confirmed_it._She_was_treated_with_gemcitabine_plus_iniparib_in_clinical_trial._Excellent_response_to_therapy_was_observed_and_surgery_was_performed_but_no_residual_tumor_tissue_was_detected",21508395,PubMed,,"Fogelman_et_al.,_2011,_Anticancer_Res.",,3,accepted,5936,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2019-01-20_03:49:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/5936,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Iniparib,,,,,,,
BRCA2,675,MUTATION,Pancreatic_Cancer,1793,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"Twenty-three_patients_with_pancreatic_cancer_havoring_BRCA1/2_germline_mutations_received_olaparib._Eighteen_(78%)_patients_had_a_BRCA2_mutation._All_but_one_had_received_gemcitabine,_and_65%_had_received_prior_platinum._Tumor_response_rate_was_21.7%_and_stable_disease_more_than_8_weeks_was_35%.",25366685,PubMed,,"Kaufman_et_al.,_2015,_J._Clin._Oncol.",,4,accepted,5913,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-08_18:56:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/5913,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Olaparib,,,,,,,
BRCA2,675,MUTATION,Pancreatic_Cancer,1793,,PLATINUM,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_BRCA1/2_associated_pancreatic_adenocarcinoma_were_evaluated_retrospectively._In_patients_with_stage_3_and_4,_the_median_overall_survival_(mOS)_was_22_months_for_the_platinum_exposed_(n=22),_compared_with_9_months_for_the_non-platinum_(n=21)_treatment_groups_(p<0.039)",25072261,PubMed,,"Golan_et_al.,_2014,_Br._J._Cancer",,4,accepted,5916,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-10_18:36:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/5916,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,PLATINUM,,,,,,,
BRCA2,675,MUTATION,Triple-receptor_Negative_Breast_Cancer,60081,,"Cisplatin,Carboplatin",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_an_evaluation_of_77_patients,_those_who_had_BRCA1/2_germline_mutations_(n=11)_had_an_increase_response_rate_to_cisplatin_when_compared_to_those_without_germline_mutations_(54.5%_versus_19.7%;_P=0.022)_although_progression_free_survival_and_overall_survival_was_not_significantly_different.",25847936,PubMed,,"Isakoff_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,1685,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2016-09-23_20:15:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1685,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Cisplatin,Carboplatin,,,,,,
BRCA2,675,MUTATION,Ovarian_Carcinoma,4001,,PLATINUM,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_ovarian_carcinomas,_81%_of_tumors_with_germline_BRCA1/2_mutations_were_platinum_sensitive,_whereas_only_60%_of_tumors_with_non-BRCA1/2_mutations_were_platinum_sensitive_(N=47;_N=158;_P=0.01)._Sensitivity_was_defined_by_maintenance_of_complete_response_greater_than_6_months_post_platinum-based_therapy.",24240112,PubMed,,"Pennington_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1530,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2016-07-16_15:11:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1530,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,PLATINUM,,,,,,,
BRCA2,675,MUTATION,Triple-receptor_Negative_Breast_Cancer,60081,,Olaparib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_a_study_of_26_patients_with_breast_cancer,_10_patients_were_BRCA-positive_and_16_patients_were_BRCA-negative.__Regardless_of_BRCA_status,_none_showed_objective_response_when_treated_with_olaparib.",21862407,PubMed,,"Gelmon_et_al.,_2011,_Lancet_Oncol.",,3,accepted,1776,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-18_15:50:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1776,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Olaparib,,,,,,,
BRCA2,675,MUTATION,Pancreatic_Cancer,1793,,"Veliparib,Gemcitabine,Cisplatin",Combination,Predictive,Supports,B,Sensitivity/Response,In_Phase_I_study_for_pancreatic_cancer_patients_GEM_600_mg/m2_+_CDDP_25_mg/m2_+_Veliparib_20_-_80_mg_twice_daily_showed_response_rate_of__77.8%_(7/9)_and_mOS_of_23.3_months_in_germline_BRCA_mutation-positive_patients_with_stage_IV_disease.,29338080,PubMed,,"O'Reilly_et_al.,_2018,_Cancer",NCT01585805,3,accepted,5933,7,13,32889611,32973347,,,ENST00000380152.3,,,,,75,GRCh37,,Germline_Mutation,2018-07-31_18:03:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/5933,https://civic.genome.wustl.edu/links/variants/186,https://civic.genome.wustl.edu/links/genes/7,,,"gene_variant,loss_of_function_variant",,257.5,Veliparib,Gemcitabine,Cisplatin,,,,,
CCNE1,898,AMPLIFICATION,Ovarian_Serous_Cystadenocarcinoma,5746,,"Dinaciclib,MK-2206",Combination,Predictive,Supports,D,Sensitivity/Response,"A_high_throughput_compound_screen_identified_synergistic_combinations_in_CCNE1_amplified_high_grade_serous_ovarian_carcinoma,_including_dinaciclib_and_AKT_inhibitors",27663592,PubMed,,"Au-Yeung_et_al.,_2016,_Clin._Cancer_Res.",,4,accepted,1735,11,19,30302805,30315215,,,ENST00000262643.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_19:33:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1735,https://civic.genome.wustl.edu/links/variants/187,https://civic.genome.wustl.edu/links/genes/11,,,transcript_amplification,,27,Dinaciclib,MK-2206,,,,,,
CCNE1,898,AMPLIFICATION,Estrogen-receptor_Positive_Breast_Cancer,60075,,Palbociclib_(PD0332991),,Predictive,Supports,D,Resistance,"Preclinical_study_in_breast_cancer_cell_lines_treated_with_CDK4/6_inhibitor_palbociclib._Cell_lines_with_acquired_resistance_to_palbociclib_were_developed._Two_palbociclib-resistant_cell_lines_were_derived_through_chronic_exposure_to_1_μmol/L_palbociclib_during_3_to_4_months._Copy_number_profiling_from_exome_sequencing_of_MCF-7_and_MCF-7pR,_confirmed_relative_amplification_of_CCNE1._Silencing_of_CCNE1_or_CDK2_alone_in_MCF-7pR_cells_had_no_effect_on_cell-cycle_arrest,_but_resulted_in_substantially_increased_cell-cycle_arrest_and_reduction_in_cell_growth_in_combination_with_palbociclib.",27020857,PubMed,,"Herrera-Abreu_et_al.,_2016,_Cancer_Res.",,3,accepted,1629,11,19,30302805,30315215,,,ENST00000262643.3,,,,,75,GRCh37,,,2016-11-11_22:07:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1629,https://civic.genome.wustl.edu/links/variants/187,https://civic.genome.wustl.edu/links/genes/11,,,transcript_amplification,,27,Palbociclib_(PD0332991),,,,,,,
DNMT3A,1788,MUTATION,Acute_Myeloid_Leukemia,9119,,Decitabine,,Predictive,Supports,B,Sensitivity/Response,"Among_46_AML_patients_treated_with_decitabine,_the_response_rate_was_75%_(6/8)_among_DNMT3A_mutated_and_34%_(13/38)_among_DNMT3A_wild-type_patients_(P=.008)",22124213,PubMed,,"Metzeler_et_al.,_2012,_Leukemia",,3,accepted,1587,18,2,25455845,25565459,,,ENST00000264709.3,,,,,75,GRCh37,"DNMT3A_mutations_occur_in_a_variety_of_myeloid_malignancies._These_mutations_are_associated_with_adverse_prognosis_in_acute_myeloid_leukemia_(AML),_particularly_in_the_context_of_NPM1_and_FLT3-ITD_mutations,_which_often_co-occur._Early_results_indicate_AML_patients_with_DNMT3A_mutations_may_respond_better_to_decitabine_than_those_with_wild-type._Shorter_survival_has_been_indicated_in_patients_with_T-cell_acute_lymphoblastic_leukemia_and_myelodysplastic_syndrome,_however,_larger_cohorts_are_required_to_verify_this_finding._DNMT3A_mutations_have_been_suggested_as_a_pre-leukemic_lesion_and_found_in_older_individuals_with_clonal_hematopoiesis_but_no_overt_malignancy.",Somatic_Mutation,2016-08-02_15:38:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1587,https://civic.genome.wustl.edu/links/variants/189,https://civic.genome.wustl.edu/links/genes/18,"DNMT3A_mutations_occur_in_a_variety_of_myeloid_malignancies._These_mutations_are_associated_with_adverse_prognosis_in_acute_myeloid_leukemia_(AML),_particularly_in_the_context_of_NPM1_and_FLT3-ITD_mutations,_which_often_co-occur._Early_results_indicate_AML_patients_with_DNMT3A_mutations_may_respond_better_to_decitabine_than_those_with_wild-type._Shorter_survival_has_been_indicated_in_patients_with_T-cell_acute_lymphoblastic_leukemia_and_myelodysplastic_syndrome,_however,_larger_cohorts_are_required_to_verify_this_finding._DNMT3A_mutations_have_been_suggested_as_a_pre-leukemic_lesion_and_found_in_older_individuals_with_clonal_hematopoiesis_but_no_overt_malignancy.",,transcript_variant,,115,Decitabine,,,,,,,
DNMT3A,1788,MUTATION,Cancer,162,,"Pembrolizumab,Nivolumab,Atezolizumab",Substitutes,Predictive,Supports,B,Resistance,"A_subset_of_patients_receiving_PD1/PD-L1_inhibition_appear_to_be_""hyper-progressors,""_with_a_greatly_accelerated_rate_of_tumor_growth_and_clinical_deterioration_compared_to_pre-therapy._The_current_study_investigated_potential_genomic_markers_associated_with_""hyper-progression""._Consecutive_stage_IV_cancer_patients_who_received_immunotherapies_(CTLA-4,_PD-1/PD-L1_inhibitors_or_other_[investigational]_agents)_and_had_their_tumor_evaluated_by_next-generation_sequencing_Amongst_155_patients,_TTF_(time_to_treatment_failure)_<2_months_was_seen_in_4/5_individuals_harbouring_DNMT3A_alteration.",28351930,PubMed,,"Kato_et_al.,_2017,_Clin._Cancer_Res.",,2,accepted,2926,18,2,25455845,25565459,,,ENST00000264709.3,,,,,75,GRCh37,"DNMT3A_mutations_occur_in_a_variety_of_myeloid_malignancies._These_mutations_are_associated_with_adverse_prognosis_in_acute_myeloid_leukemia_(AML),_particularly_in_the_context_of_NPM1_and_FLT3-ITD_mutations,_which_often_co-occur._Early_results_indicate_AML_patients_with_DNMT3A_mutations_may_respond_better_to_decitabine_than_those_with_wild-type._Shorter_survival_has_been_indicated_in_patients_with_T-cell_acute_lymphoblastic_leukemia_and_myelodysplastic_syndrome,_however,_larger_cohorts_are_required_to_verify_this_finding._DNMT3A_mutations_have_been_suggested_as_a_pre-leukemic_lesion_and_found_in_older_individuals_with_clonal_hematopoiesis_but_no_overt_malignancy.",Somatic_Mutation,2017-07-25_20:22:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/2926,https://civic.genome.wustl.edu/links/variants/189,https://civic.genome.wustl.edu/links/genes/18,"DNMT3A_mutations_occur_in_a_variety_of_myeloid_malignancies._These_mutations_are_associated_with_adverse_prognosis_in_acute_myeloid_leukemia_(AML),_particularly_in_the_context_of_NPM1_and_FLT3-ITD_mutations,_which_often_co-occur._Early_results_indicate_AML_patients_with_DNMT3A_mutations_may_respond_better_to_decitabine_than_those_with_wild-type._Shorter_survival_has_been_indicated_in_patients_with_T-cell_acute_lymphoblastic_leukemia_and_myelodysplastic_syndrome,_however,_larger_cohorts_are_required_to_verify_this_finding._DNMT3A_mutations_have_been_suggested_as_a_pre-leukemic_lesion_and_found_in_older_individuals_with_clonal_hematopoiesis_but_no_overt_malignancy.",,transcript_variant,,115,Pembrolizumab,Nivolumab,Atezolizumab,,,,,
EGFR,1956,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,EGFR_Inhibitor,,Predictive,Supports,B,Sensitivity/Response,"A_meta-analysis_of_EGFR_gene_copy_number_as_a_predictive_biomarker_for_patients_receiving_tyrosine_kinase_inhibitor_treatment_was_performed._In_total,_20_(1689_patients,_594_with_increased_gene_copy_number),_10_(822_patients,_290_with_increased_gene_copy_number)_and_5_studies_(294_patients,_129_with_increased_gene_copy_number)_were_analyzed_for_overall_survival_(OS),_progression-free_survival_(PFS)_and_time-to-progression_(TTP)_meta-analyses_respectively._EGFR_amplification_was_associated_with_increased_OS_(HR_=_0.77;_95%_CI_0.66-0.89;_P_=_0.001),_PFS_(HR_=_0.60;_95%_CI_0.46-0.79;_P<0.001)_and_TTP_(HR_=_0.50;_95%_CI_0.28-0.91;_P_=_0.02)._This_effect_was_shown_to_influence_survival_in_predominantly_white_patient_populations_but_not_patients_of_Asian_descent.",20826716,PubMed,,"Dahabreh_et_al.,_2011,_Ann._Oncol.",,4,accepted,948,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-01-29_03:35:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/948,https://civic.genome.wustl.edu/links/variants/190,https://civic.genome.wustl.edu/links/genes/19,,,transcript_amplification,,133,EGFR_Inhibitor,,,,,,,
EGFR,1956,AMPLIFICATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,"87_patients_with_metastatic_colorectal_cancer_treated_with_cetuximab_were_retrospectively_analyzed_for_EGFR_amplifications_by_FISH._In_multivariate_analysis,_EGFR_amplification_predicted_response_and_overall_survival_independent_of_KRAS_status.",18794099,PubMed,,"Personeni_et_al.,_2008,_Clin._Cancer_Res.",,3,accepted,911,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-01-27_00:50:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/911,https://civic.genome.wustl.edu/links/variants/190,https://civic.genome.wustl.edu/links/genes/19,,,transcript_amplification,,133,Cetuximab,,,,,,,
EGFR,1956,AMPLIFICATION,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_this_meta-analysis_(14_studies,_1021_patients),_EGFR_gene_copy_number_(GCN)_was_predictive_of_improved_progression_free_survival_(PFS)_and_overall_survival_(OS)_with_cetuximab_or_panitumumab_regardless_of_KRAS_status._For_the_pooled_analysis,_the_objective_response_rate_(ORR)_was_65.2%_(167/256)_in_patients_with_high_EFGR_GCN,_while_in_patients_with_low_EFGR_GCN,_the_pooled_ORR_was_12.2%_(44/361)._The_odds_ratio_(OR)_was_6.905_(95%_CI:_4.489-10.620;_Z=8.79,_P=0.000)._In_wild_type_KRAS_patients,_the_pooled_OR_was_8.133_(95%_CI:_4.316-15.326;_Z=6.48,_P=0.000).",24653627,PubMed,,"Shen_et_al.,_2014,_Chin._J._Cancer_Res.",,3,accepted,854,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-18_22:50:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/854,https://civic.genome.wustl.edu/links/variants/190,https://civic.genome.wustl.edu/links/genes/19,,,transcript_amplification,,133,Cetuximab,Panitumumab,,,,,,
EGFR,1956,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_290_patients_with_advanced_NSCLC,_177_of_which_were_treated_with_EGFR_TKI_(erlotinib_or_gefitinib)._EGFR_amplification_(Multiplex_ligation-dependent_probe_amplification;_MLPA)_and_Mutation_(PCR)_were_analzed._EGFR_amplification_was_associated_with_EGFR_mutation_but_not_independently_with_patient_benefit_from_EGFR_TKI_(overall_and_progression-free_survival).",26722081,PubMed,,"Fiala_et_al.,_2016,_Anticancer_Res.",,2,accepted,977,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-13_05:10:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/977,https://civic.genome.wustl.edu/links/variants/190,https://civic.genome.wustl.edu/links/genes/19,,,transcript_amplification,,133,Gefitinib,Erlotinib,,,,,,
EGFR,1956,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,"Osimertinib,Rociletinib",Substitutes,Predictive,Supports,D,Resistance,"Evidence_of_wild-type_allele-mediated_resistance,_a_novel_concept_of_acquired_resistance_in_response_to_mutation-selective_inhibitor_therapy_in_cancer_treatment._This_study_reports_that_the_Src-AKT_pathway_contributes_to_acquired_resistance_to_third_generation_EGFR_TKIs._In_addition,_amplification_of_EGFR_wild-type_alleles_but_not_mutant_alleles_was_sufficient_to_confer_acquired_resistance.",28202511,PubMed,,"Nukaga_et_al.,_2017,_Cancer_Res.",,3,accepted,3015,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-05-30_18:38:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/3015,https://civic.genome.wustl.edu/links/variants/190,https://civic.genome.wustl.edu/links/genes/19,,,transcript_amplification,,133,Osimertinib,Rociletinib,,,,,,
EGFR,1956,AMPLIFICATION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"PLATINUM,Cetuximab,5-fluorouracil",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,EGFR_amplification_was_not_a_predictor_of_response_to_cetuximab/5-FU/platinum_in_patients_with_recurrent_or_metastatic_HNSSC_from_the_EXTREME_study.,21048039,PubMed,,"Licitra_et_al.,_2011,_Ann._Oncol.",,4,accepted,691,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-05-31_00:12:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/691,https://civic.genome.wustl.edu/links/variants/190,https://civic.genome.wustl.edu/links/genes/19,,,transcript_amplification,,133,PLATINUM,Cetuximab,5-fluorouracil,,,,,
EGFR,1956,COPY_NUMBER_VARIATION,Non-small_Cell_Lung_Carcinoma,3908,,"Erlotinib,Gefitinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"Among_TKI-treated_patients,_increased_EGFR_gene_copy_number_appears_to_be_associated_with_improved_survival_outcomes.",27664271,PubMed,,"Zhang_et_al.,_2017,_J._Investig._Med.",,4,accepted,5925,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_19:12:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/5925,https://civic.genome.wustl.edu/links/variants/191,https://civic.genome.wustl.edu/links/genes/19,,,copy_number_change,,60,Erlotinib,Gefitinib,,,,,,
EGFR,1956,COPY_NUMBER_VARIATION,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"The_result_of_the_analysis_found_that_EGFR_gene_copy_number_was_associated_with_increased_OS_and_PFS,_supporting_the_idea_that_EGFR_gene_copy_number_is_a_biomarker_for_response_to_EGFR-TKI_therapy_in_patients_with_advanced_NSCLC.",20826716,PubMed,,"Dahabreh_et_al.,_2011,_Ann._Oncol.",,4,accepted,5924,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_19:12:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/5924,https://civic.genome.wustl.edu/links/variants/191,https://civic.genome.wustl.edu/links/genes/19,,,copy_number_change,,60,Gefitinib,Erlotinib,,,,,,
EGFR,1956,OVEREXPRESSION,Esophagus_Squamous_Cell_Carcinoma,3748,,Nimotuzumab,,Predictive,Does_Not_Support,B,Sensitivity/Response,55_tumor_samples_were_analyzed_for_EGFR_expression_using_IHC._The_objective_response_rate_to_anti-EGFR_antibody_nimotuzumab_did_not_differ_significantly_between_EGFR_high-_(18_pts)_and_EGFR_low_to_moderate_groups_(37_pts).,26459251,PubMed,,"Jia_et_al.,_2016,_Clin_Transl_Oncol",,3,accepted,783,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-01-27_00:15:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/783,https://civic.genome.wustl.edu/links/variants/193,https://civic.genome.wustl.edu/links/genes/19,,,,,130,Nimotuzumab,,,,,,,
EGFR,1956,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,EGFR_Inhibitor,,Predictive,Supports,B,Sensitivity/Response,"In_this_prospective_study_in_37_patients_of_whom_34_were_treated_with_different_EGFR_inhibitors_(gefitinib,_erlotinib,_afatinib),_EGFR_mutations_and_a_higher_relative_expression_of_EGFR_in_comparison_to_MET_expression_were_correlated_with_longer_PFS.",26439803,PubMed,,"Park_et_al.,_2015,_Oncotarget",,3,accepted,737,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2015-12-28_18:03:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/737,https://civic.genome.wustl.edu/links/variants/193,https://civic.genome.wustl.edu/links/genes/19,,,,,130,EGFR_Inhibitor,,,,,,,
EGFR,1956,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,EGFR_Inhibitor,,Predictive,Supports,B,Sensitivity/Response,EGFR_overexpression_was_correlated_with_longer_overall_survival_in_patients_with_advanced_NSCLC_treated_with_first_line_chemotherapy_and_cetuximab_than_those_treated_with_first_line_chemotherapy_alone.,22056021,PubMed,,"Pirker_et_al.,_2012,_Lancet_Oncol.",,4,accepted,693,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2015-12-26_21:45:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/693,https://civic.genome.wustl.edu/links/variants/193,https://civic.genome.wustl.edu/links/genes/19,,,,,130,EGFR_Inhibitor,,,,,,,
EGFR,1956,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"82_patients_treated_with_gefitinib_were_retrospectively_analyzed_for_EGFR_mRNA_expression_(rt-PCR_in_64_patients)._Patients_with_high_EGFR_mRNA_expression_(>5.01)_had_43%_response_probability,_whereas_patients_with_low_EGFR_mRNA_expression_had_8%_response_probability_(P_=_0.006)._PFS_but_not_OS_was_also_longer_in_patients_with_high_EGFR_mRNA_expression.",16707605,PubMed,,"Dziadziuszko_et_al.,_2006,_Clin._Cancer_Res.",,3,accepted,954,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-01-27_00:29:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/954,https://civic.genome.wustl.edu/links/variants/193,https://civic.genome.wustl.edu/links/genes/19,,,,,130,Gefitinib,,,,,,,
EGFR,1956,OVEREXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Cetuximab,,Predictive,Does_Not_Support,B,Sensitivity/Response,EGFR_expression_level_was_not_predicitive_of_response_to_cetuximab-containing_first_line_regimens_in_recurrent_or_metastatic_head_and_neck_squamous_cell_carcinoma_and_KRAS-wild_type_colorectal_carcinoma.,23265711,PubMed,,"Licitra_et_al.,_2013,_Eur._J._Cancer",,4,accepted,692,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/692,https://civic.genome.wustl.edu/links/variants/193,https://civic.genome.wustl.edu/links/genes/19,,,,,130,Cetuximab,,,,,,,
KIT,3815,M541L,Chronic_Leukemia,1036,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"In_5_patients_with_KIT_M541L_mutation-positive_chronic_eosinophilic_leukemia_(4_somatic_and_1_germline_mutation),_treatment_with_low_dose_imatinib_resulted_in_complete_and_lasting_remission_with_a_median_follow_up_of_74_months_and_1_patient_relapse_at_50_months.",25015329,PubMed,,"Iurlo_et_al.,_2014,_Oncotarget",,2,accepted,1423,29,4,55593464,55593464,A,C,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2016-07-08_17:47:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1423,https://civic.genome.wustl.edu/links/variants/201,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.1621A>C,NP_000213.1:p.Met541Leu,ENST00000288135.5:c.1621A>C,NC_000004.11:g.55593464A>C",25,Imatinib,,,,,chr4_g.55593464A~C,KIT_c.1621A~C,KIT_M541L
KIT,3815,V560DEL,Thymic_Carcinoma,3284,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_patient_with_thymic_carcinoma,_the_tumor_expressing_an_activating_mutation_in_exon_11_of_KIT_(V560del)_was_sensitive_to_imatinib.",15201427,PubMed,,"Ströbel_et_al.,_2004,_N._Engl._J._Med.",,5,accepted,486,29,4,55593612,55593614,GTT,,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/486,https://civic.genome.wustl.edu/links/variants/202,https://civic.genome.wustl.edu/links/genes/29,,,"amino_acid_deletion,inframe_deletion",NC_000004.11:g.55593612_55593614del,12.5,Imatinib,,,,,chr4_g.55593612_55593614del,,
NRAS,4893,MUTATION,Melanoma,1909,,"Trametinib,Omipalisib_(GSK2126458)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_six_NRAS_mutant_melanoma_cell_lines,_concomitant_use_of_MEK_inhibitor_and_PI3K/mTOR_inhibitor_resulted_in_greater_decrease_in_cell_viability_than_either_alone,_with_the_synergistic_effect_being_marked_in_4/6_cell_lines._MEK_inhibitor_JTP-74057_and_PI3K/mTOR_inhibitor_GSK2126458_together_induced_synergistic_increase_in_apoptotic_Annexin_V+/PI+_cells_in_these_cell_lines._Tumor_xenografts_in_nude_mice_were_established_with_5_of_the_6_cell_lines._Effects_of_single_agent_treatment_with_JTP-74057_or_GSK2126458_ranged_from_minor_inhibition_to_tumor_stasis,_while_dual_inhibitor_treatment_showed_synergistic_effects_in_each_case,_with_marked_tumor_reductions_in_2/5_cases_and_the_authors_report_one_compete_response_in_a_MaMel301_cell_line_xenograft_mouse.",23431193,PubMed,,"Posch_et_al.,_2013,_Proc._Natl._Acad._Sci._U.S.A.",,4,accepted,1429,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-31_15:33:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1429,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Trametinib,Omipalisib_(GSK2126458),,,,,,
NRAS,4893,MUTATION,Skin_Melanoma,8923,,"Ribociclib,Binimetinib",Combination,Predictive,Supports,B,Sensitivity/Response,"Inhibition_of_CDK4_and_6,_regulators_of_the_G1/S_cell_cycle_checkpoint,_arrests_the_cell_cycle_in_the_G1_phase,_suppresses_DNA_synthesis,_and_inhibits_cancer_cell_growth._There_is_an_ongoing_phase_1/2_trial_of_binimetinib_with_the_CDK4/6_inhibitor_ribociclib_(LEE011)_in_mutant_NRAS_melanoma_patients_(NCT01781572)._Early_results_from_the_21_evaluable_patients_were_very_promising,_with_7_patients_achieving_a_partial_response_(33%)_and_11_patients_with_stable_disease_(52%)",26987942,PubMed,,"Vu_et_al.,_2016,_Pharmacol._Res.",,3,accepted,2931,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_19:15:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/2931,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Ribociclib,Binimetinib,,,,,,
NRAS,4893,MUTATION,Melanoma,1909,,"Dabrafenib,Vemurafenib",Substitutes,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_44_relapsed_melanoma_patients_harboring_BRAF_V600E_or_V600K_(known_BRAF_inhibitor_sensitizing_mutations),_MAPK_pathway_reactivation_mechanisms_were_implicated_in_acquired_resistance_to_BRAF_inhibitor_(vemurafenib_or_dabrafenib)_monotherapy._The_following_MAPK_pathway_variants_were_found_in_progressive_tumors_with_patient_matched_baseline_tumors_(some_patients_donated_samples_from_multiple_geographically/temporally_distinct_progressive_tumors):_NRAS_mutations_(G12D,_G12R,_G13R,_Q61K,_Q61R,_Q61L)_in_13/71_(18%)_of_progressive_tumors,_KRAS_mutations_(G12C,_G12R,_Q61H)_in_5/71_(7%)_of_progressive_tumors,_mutant_BRAF_amplification_(2-15_fold_or_4-75_copies)_in_11/57_(19%)_of_progressive_tumors,_mutant_BRAF_alternative_splice_variants_(novel_exon_boundaries_between_1/9,_1/11,_3/9)_in_6/48_(13%)_of_progressive_tumor_RNA.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,6263,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_23:09:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/6263,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Dabrafenib,Vemurafenib,,,,,,
NRAS,4893,MUTATION,Skin_Melanoma,8923,,Binimetinib_(MEK162),,Predictive,Supports,B,Sensitivity/Response,Phase_II_study_in_71_patients_with_NRAS_or_BRAF_V600_mutant_melanoma_treated_with_MEK162._Six_(20%)_of_30_patients_with_NRAS-mutated_melanoma_had_a_partial_response_(three_confirmed).,23414587,PubMed,,"Ascierto_et_al.,_2013,_Lancet_Oncol.",,2,accepted,1472,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_05:03:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1472,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Binimetinib_(MEK162),,,,,,,
NRAS,4893,MUTATION,Cancer,162,,"Metformin,Trametinib",Combination,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_16_NRAS_mutant_cell_lines_(melanoma,_lung_carcinoma,_neuroblastoma_with_various_Q61,_G13,_G12_mutations)._The_combination_of_metformin_and_trametinib_shown_synergistic_effects_in_most_tested_cell_lines_(no_antagonistic_effects_observed)_and_a_melanoma_xenograft_model._Metformin-induced_PI3K_pathway_suppression_was_identified_as_a_potential_mechanism.",25504439,PubMed,,"Vujic_et_al.,_2015,_Oncotarget",,3,accepted,1230,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-20_04:26:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1230,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Metformin,Trametinib,,,,,,
NRAS,4893,MUTATION,Skin_Melanoma,8923,,Binimetinib,,Predictive,Supports,B,Sensitivity/Response,"NEMO_is_an_ongoing,_randomised,_open-label_phase_3_study_of_patients_with_advanced,_unresectable,_AJCC_IIIC/IV_NRAS-mutant_melanoma._402_patients_that_were_previously_untreated_or_progressed_on_or_after_previous_immunotherapy_were_randomised_to_receive_either_binimetinib_(269)_or_dacarbazine_(133)._The_study's_primary_endpoint_was_progression_free_survival._Median_follow-up_was_1.7_months_(IQR_1.4-4.1)._Median_progression-free_survival_was_2.8_months_(95%_CI_2.8-3.6)_in_the_binimetinib_group_and_1.5_months_(1.5-1.7)_in_the_dacarbazine_group,_demonstrating_improved_progression-free_survival_of_binimetinib_compared_with_dacarbazine.",28284557,PubMed,,"Dummer_et_al.,_2017,_Lancet_Oncol.",,5,accepted,2937,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_21:49:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/2937,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Binimetinib,,,,,,,
NRAS,4893,MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"A_cohort_of_patient-derived_xenografts_(PDX)_from_85_patients_with_metastatic_colorectal_cancer_was_created._PDX_were_treated_with_cetuximab_and_mechanisms_of_resistance_investigated._None_of_the_xenografts_harboring_KRAS_(N=18),_NRAS_(N=7)_or_BRAF_(N=3)_mutations_showed_a_response_to_cetuximab_whereas_1_out_of_4_xenografts_with_a_PIK3CA_mutation_responded_to_cetuximab.",22586653,PubMed,,"Bertotti_et_al.,_2011,_Cancer_Discov",,2,accepted,1703,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_22:21:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1703,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Cetuximab,,,,,,,
NRAS,4893,MUTATION,Skin_Melanoma,8923,,Amuvatinib,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_melanoma_cell_lines._Cell_lines_(2-5/assay)_with_NRAS_mutation_were_more_sensitive_to_Amuvatinib_(inhibitor_targets_multiple_tyrosine_kinases)_than_BRAF_mutant_cell_lines_in_growth_inhibition,_tyrosine_phosphorylation_inhibition,_cell_cycle_and_apoptotic_(Annexin_V)_assays.",24950457,PubMed,,"Fedorenko_et_al.,_2014,_Melanoma_Res.",,1,accepted,1476,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-10-25_17:27:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/1476,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Amuvatinib,,,,,,,
NRAS,4893,MUTATION,Melanoma,1909,,RO4987655,,Predictive,Supports,B,Sensitivity/Response,"Phase_I_expansion_and_pharmacodynamic_study_of_the_oral_MEK_inhibitor_RO4987655_(CH4987655)._Among_8_patients_with_NRAS_mutated_melanoma,_4_experienced_SD_or_PR_(1_Patient_received_study_treatment_for_323_days).",24947927,PubMed,,"Zimmer_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,996,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-12_19:31:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/996,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,RO4987655,,,,,,,
NRAS,4893,MUTATION,Melanoma,1909,,Trametinib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Phase_1_trial_in_97_patients_with_melanoma_(81_cutaneous_or_unknown,_16_uveal)._Seven_patients_were_found_to_harbor_an_NRAS_mutation_and_two_of_them_experienced_stable_disease_(one_48_weeks_on_treatment)._Patients_with_concurrent_BRAFV600wt/NRASwt_(n=20)_had_a_trend_of_higher_response_rates_(20%)_than_BRAFV600wt/NRAS-mutant_patients_(n=11;_RR=0%;_p=0.27),_as_well_as_a_trend_of_higher_percentage_of_patients_on_study_at_Week_24_or_at_1_year_(40%_vs._18%_[p=0.26]_and_30%_vs._0%_[p=0.07],_respectively).",22805292,PubMed,,"Falchook_et_al.,_2012,_Lancet_Oncol.",,2,accepted,1227,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:06:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1227,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Trametinib,,,,,,,
NRAS,4893,MUTATION,Skin_Melanoma,8923,,"Trametinib,Docetaxel",Combination,Predictive,Supports,B,Sensitivity/Response,"Phase_1_trial_of_trametinib_and_docetaxel_in_patients_with_advanced_melanoma_lacking_BRAF_V600_mutations._15_patients_were_enrolled_(14_BRAF_wt)._Six_patients_had_a_partial_response,_including_four_out_of_eight_patients_with_NRAS_mutations.",25542057,PubMed,,"Coupe_et_al.,_2015,_Eur._J._Cancer",,2,accepted,1225,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-20_04:13:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1225,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Trametinib,Docetaxel,,,,,,
NRAS,4893,MUTATION,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,A,Resistance,NCCN_guidelines_indicate_colorectal_cancer_patients_with_NRAS_mutations_should_not_be_treated_with_EGFR_inhibitors_cetuximab_or_panitumumab.,28275037,PubMed,,"Benson_et_al.,_2017,_J_Natl_Compr_Canc_Netw",,4,accepted,5344,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:14:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/5344,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Cetuximab,Panitumumab,,,,,,
NRAS,4893,MUTATION,Melanoma,1909,,Binimetinib_(MEK162),,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_7_NRAS_mutant_melanoma_cell_lines,_all_7_were_found_to_be_sensitive_to_the_MEK_inhibitor_MEK162,_whereas_3_of_5_melanoma_cell_lines_that_were_wild_type_for_BRAF_and_NRAS_were_not_sensitive_to_MEK162._In_further_tests_using_two_of_the_seven_NRAS_mutant_cell_lines_(YUDOSO_Q16K/wt_and_YUKIM_Q16R),_colony_forming_capacity_was_reduced_with_increased_MEK162_treatment,_and_MEK162_induced_apoptotic_markers_in_these_cells.",24588908,PubMed,,"Thumar_et_al.,_2014,_Mol._Cancer",,3,accepted,1509,36,1,115247090,115259515,,,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_19:47:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1509,https://civic.genome.wustl.edu/links/variants/208,https://civic.genome.wustl.edu/links/genes/36,,,"gain_of_function_variant,transcript_variant",,208,Binimetinib_(MEK162),,,,,,,
PGR,5241,EXPRESSION,Breast_Cancer,1612,,"Tamoxifen,Exemestane",Substitutes,Predictive,Does_Not_Support,B,,"In_patients_with_breast_cancer,_those_with_low_expression_of_PgR_treated_with_tamoxifen_had_the_same_disease-free_survial_as_those_with_high_expression_of_PgR.",21422407,PubMed,,"Bartlett_et_al.,_2011,_J._Clin._Oncol.",,4,accepted,502,76,11,100900355,101001255,,,ENST00000325455.5,,,,,75,GRCh37,,Somatic_Mutation,2016-01-05_07:56:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/502,https://civic.genome.wustl.edu/links/variants/210,https://civic.genome.wustl.edu/links/genes/76,,,,,70,Tamoxifen,Exemestane,,,,,,
PGR,5241,EXPRESSION,Breast_Cancer,1612,,Tamoxifen,,Predictive,Does_Not_Support,B,,"In_patients_with_ER-Positive_breast_cancer,_expression_of_PgR_does_not_effect_the_outcome_of_treatment_with_tamoxifen.",23280579,PubMed,,"Patani_et_al.,_2013,_Int._J._Cancer",,3,accepted,501,76,11,100900355,101001255,,,ENST00000325455.5,,,,,75,GRCh37,,Somatic_Mutation,2016-01-05_07:56:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/501,https://civic.genome.wustl.edu/links/variants/210,https://civic.genome.wustl.edu/links/genes/76,,,,,70,Tamoxifen,,,,,,,
PIK3CA,5290,AMPLIFICATION,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_PIK3CA_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_induced_to_stably_over-express_PIK3CA_(via_viral_transduction_with_additional_copies_of_wild_type_PIK3CA)_were_significantly_more_resistant_to_vemurafenib_(a_BRAFi)_than_cells_transduced_with_an_empty_vector_(30%_vs_20%_survival,_p_<_.0001)._Though_statistics_were_not_provided,_it_appears_that_amplification_of_wildtype_PIK3CA_confers_less_resistance_than_the_positive_control_variant,_PIK3CA_E545K.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,6275,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_20:27:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/6275,https://civic.genome.wustl.edu/links/variants/212,https://civic.genome.wustl.edu/links/genes/37,,,transcript_amplification,,26,Vemurafenib,,,,,,,
PIK3CA,5290,AMPLIFICATION,Epithelial_Ovarian_Cancer,2152,,Pictilisib,,Predictive,Supports,C,Sensitivity/Response,One_platinum-refractory_epithelial_ovarian_cancer_patient_with_PTEN_loss_and_PIK3CA_amplification_had_a_partial_response_on_treatment_with_PI3K_inhibitor_pictilisib_(GDC-0941)_in_this_phase_1_study._A_total_of_60_patients_with_advanced_solid_tumors_were_enrolled_in_this_study.,25370471,PubMed,,"Sarker_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,756,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/756,https://civic.genome.wustl.edu/links/variants/212,https://civic.genome.wustl.edu/links/genes/37,,,transcript_amplification,,26,Pictilisib,,,,,,,
PIK3CA,5290,AMPLIFICATION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Taselisib_(GDC-0032),,Predictive,Supports,D,Sensitivity/Response,"The_HNSCC_cell_line_LB771_with_PIK3CA_amplification_was_shown_to_have_low_antiproliferative_IC50_for_the_p110beta-sparing_PI3K_inhibitor_taselisib._Under_increasing_taselisib_concentrations,_reduction_in_phospho-Akt_pro-survival_signal_was_apparent,_along_with_increased_levels_of_pro-apoptotic_marker_cleaved_PARP._A_general_tendency_for_taselisib_sensitivity_to_PI3K_activation_(mutation/amplification)_was_also_seen_in_a_panel_of_26_HNSCC_cell_lines",26589432,PubMed,,"Zumsteg_et_al.,_2016,_Clin._Cancer_Res.",,1,accepted,1464,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_18:38:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1464,https://civic.genome.wustl.edu/links/variants/212,https://civic.genome.wustl.edu/links/genes/37,,,transcript_amplification,,26,Taselisib_(GDC-0032),,,,,,,
PIK3CA,5290,AMPLIFICATION,Stomach_Carcinoma,5517,,BYL719_(Alpelisib),,Predictive,Supports,D,Sensitivity/Response,474_cancer_cell_lines_from_the_cancer_cell_line_encyclopedia_were_assessed_for_response_to_the_PI3Kalpha_inhibitor_BYL719_(Alpelisib)._PIK3CA_amplification_was_significanly_associated_with_BYL719_response._A_gastric_cancer_patient_derived_xenograft_(PDX)_was_transplanted_into_two_athymic_mice_and_one_was_treated_with_BYL719._The_untreated_PDX_grew_by_over_100_percent_while_the_BYL719_tumor_was_reduced_by_86_percent.,24608574,PubMed,,"Fritsch_et_al.,_2014,_Mol._Cancer_Ther.",,3,accepted,1403,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-10_21:20:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1403,https://civic.genome.wustl.edu/links/variants/212,https://civic.genome.wustl.edu/links/genes/37,,,transcript_amplification,,26,BYL719_(Alpelisib),,,,,,,
PTEN,5728,DELETION,Prostate_Cancer,10283,,Everolimus,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_II_trial_on_castration-resistant_prostate_cancer_patients,_FISH_detection_of_PTEN_deletion_was_associated_with_increased_progression_free_survival_(p=0.07)_and_with_improved_PSA_response_(p=0.02)_in_response_to_everolimus,_an_mTOR_pathway_inhibitor.",23582881,PubMed,,"Templeton_et_al.,_2013,_Eur._Urol.",,3,accepted,1231,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-21_18:30:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1231,https://civic.genome.wustl.edu/links/variants/213,https://civic.genome.wustl.edu/links/genes/41,,,transcript_ablation,,55,Everolimus,,,,,,,
PTEN,5728,LOSS,Breast_Cancer,1612,,"PP242,Everolimus",Substitutes,Predictive,Does_Not_Support,D,Sensitivity/Response,"In_a_panel_of_31_breast_cancer_cell_lines,_11_had_loss_of_PTEN_function._Cells_were_tested_for_sensitivity_to_mTORC1_inhibitor_everolimus_and_mTORC1/2_inhibitor_PP242,_and_no_significant_correlation_was_found_between_PTEN_status_and_sensitivity_to_mTORC_inhibition.",21358673,PubMed,,"Weigelt_et_al.,_2011,_Oncogene",,3,accepted,1611,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_17:40:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1611,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,PP242,Everolimus,,,,,,
PTEN,5728,LOSS,Endometrial_Cancer,1380,,Temsirolimus,,Predictive,Supports,D,Sensitivity/Response,"A_panel_of_24_endometroid_endometrial_cancer_(EEC)_cell_lines_was_characterized_for_mutations_and_18_cell_lines_were_found_to_have_mutations_in_PTEN_or_absence_of_expression._Cell_lines_were_assessed_for_sensitivity_to_mTORC1_allosteric_inhibitor_temsirolimus,_and_it_was_reported_that_PTEN_loss_had_significant_association_with_temsirolimus_sensitivity._.",23674493,PubMed,,"Weigelt_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1614,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_19:31:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1614,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Temsirolimus,,,,,,,
PTEN,5728,LOSS,Her2-receptor_Positive_Breast_Cancer,60079,,"Trastuzumab,LY294002",Combination,Predictive,Supports,D,Sensitivity/Response,"Knockdown_of_PTEN_in_trastuzumab_sensitive_HER2_breast_cancer_BT474_cells_induced_trastuzumab_resistance._PTEN_null_cells_treated_with_PI3K_inhibitor_LY294002_also_did_not_show_substantial_inhibition,_but_co-treatment_with_trastuzumab_and_LY294002_induced_growth_inhibition_comparable_to_trastuzumab_alone_in_normal_BT474_cells._BT474_mouse_xenograft_tumors_were_injected_with_PTEN_antisense_(AS)_oligonucleotides_and_this_resulted_in_trastuzumab_resitance._Co-treatment_of_PTEN_AS_tumor_mice_with_LY294002_and_trastuzumab_inhibited_tumor_growth_in_comparison_to_PTEN_AS_tumors_treated_with_trastuzumab_or_LY294002_alone.",15324695,PubMed,,"Nagata_et_al.,_2004,_Cancer_Cell",,3,accepted,1455,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-05_16:49:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1455,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,LY294002,,,,,,
PTEN,5728,LOSS,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,B,Resistance,"In_this_study,_81_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._Multivariate_analysis_demonstrated_a_significant_association_between_PTEN_protein_expression_loss_and_lack_of_response_to_panitumumab_or_cetuximab_(P_=_0.0012)._Patients_with_PTEN_non-expressing_tumors_(32/80)_had_shorter_overall_survival,_compared_to_those_with_PTEN_expressing_tumors_(P_=_0.0048),_though_they_had_a_nonsignificant_difference_in_progression_free_survival_(p_=_.0681).__PIK3CA,_PTEN,_and_KRAS_were_evaluated_for_mutations;_PTEN_loss_was_the_only_variant_noted_in_17_of_the_patients_who_experienced_either_stable_disease_or_disease_progression,_while_the_other_patients_experienced_PTEN_loss_in_combination_with_a_KRAS_or_PIK3CA_mutation.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,3,accepted,6315,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2018-11-02_23:40:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/6315,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Panitumumab,Cetuximab,,,,,,
PTEN,5728,LOSS,Stomach_Cancer,10534,,"AZD5363,Docetaxel",Combination,Predictive,Supports,D,Sensitivity/Response,"A_patient_derived_mouse_xenograft_model_was_established_with_gastric_cancer_cells_having_PTEN_loss._The_xenograft_was_resistant_to_monotherapy_with_both_the_pan-Akt_inhibitor_AZD5363,_and_also_to_the_commonly_used_gastric_cancer_chemotheraputic_docetaxel._When_used_in_combination,_AZD5363_and_docetaxel_induced_significant_tumor_growth_inhibition_in_comparison_to_monotherapy_and_vehicle_control.",24088382,PubMed,,"Li_et_al.,_2013,_J_Transl_Med",,1,accepted,1500,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-18_15:22:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1500,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,AZD5363,Docetaxel,,,,,,
PTEN,5728,LOSS,Breast_Cancer,1612,,BYL719_(Alpelisib),,Predictive,Supports,D,Resistance,"A_case_report_described_a_responder_to_PI3K_inhibitor_BYL719_for_a_tumor_with_PIK3CA_E542K_mutation._After_partial_response_for_9.5_months,_resistance_developed._Sequencing_in_this_and_other_patients_as_well_as_preclinical_models_showed_loss_of_PTEN_as_the_probable_mechanism_of_resistance.",25409150,PubMed,,"Juric_et_al.,_2015,_Nature",,4,accepted,716,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/716,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,BYL719_(Alpelisib),,,,,,,
PTEN,5728,LOSS,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_182_metastatic_breast_cancer_patients_of_mixed_HER2_status_treated_with_trastuzumab-based_therapy,_PTEN_loss_(as_measured_by_IHC)_was_associated_with_a_higher_risk_of_death_measured_from_initiation_of_trastuzumab_(HR_=_1.64,_P_=_0.029)_and_diagnosis_of_first_metastasis_(HR_=_1.85,_P_=_0.003).",21594665,PubMed,,"Razis_et_al.,_2011,_Breast_Cancer_Res._Treat.",,2,accepted,2043,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_21:25:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2043,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,,,,,,,
PTEN,5728,LOSS,Pancreatic_Carcinoma,4905,,MK-2206,,Predictive,Supports,C,Sensitivity/Response,"Among_33_patients_treated_with_pan-AKT_inhibitor_MK-2206_in_this_phase_1_study,_one_patient_with_pancreatic_adenocarcinoma_and_PTEN_loss/KRAS_G12D_mutation_experienced_a_decrease_of_approximately_60%_in_cancer_antigen_19-9_levels_and_23%_shrinkage_in_tumor_measurements.",22025163,PubMed,,"Yap_et_al.,_2011,_J._Clin._Oncol.",,2,accepted,938,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/938,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,MK-2206,,,,,,,
PTEN,5728,LOSS,Stomach_Carcinoma,5517,,Chemotherapy,,Predictive,Supports,B,Resistance,"Cancer_and_normal_tissue_samples_were_taken_from_68_gastric_cancer_patients_undergoing_surgery_without_prior_chemotherapy._Tissue_samples_were_divided_into_high_grade_and_low_grade_for_phospho_Akt_(p-Akt)_expression,_and_tested_for_PTEN_LOH_by_sequencing._Patients_with_PTEN_LOH_were_significantly_more_likely_to_have_elevated_p-Akt_(p=0.0081),_and_high_p-Akt_samples_were_significantly_less_sensitive_to_chemotherapy_agents_5-flourouracil,_adriamycin,_mitomycin_and_cis-platinum_in_MTT_assay.",15900596,PubMed,,"Oki_et_al.,_2005,_Int._J._Cancer",,2,accepted,1493,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-05_16:44:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1493,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Chemotherapy,,,,,,,
PTEN,5728,LOSS,Cancer,162,,Everolimus,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_a_single-arm,_open_label_phase_2_trial_in_PIK3CA_amplified/mutated_and/or_PTEN_loss_encompassing_10_patients,_no_objective_responses_were_observed_but_a_stable_disease_response_in_4_patients,_resulting_in_a_median_PFS_of_1.4_months._Everolimus_failed_to_meet_its_enpoint.",28330462,PubMed,,"Kim_et_al.,_2017,_BMC_Cancer",,3,accepted,5840,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,,2017-10-19_16:09:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/5840,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Everolimus,,,,,,,
PTEN,5728,LOSS,Cancer,162,,AZD5363,,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_182_cell_lines_(162_with_PIK3CA_mutation_status_known)_from_solid_and_hematological_tumors,_significant_correlation_was_found_between_AZD5363_(pan-Akt_inhibitor)_sensitivity_and_PIK3CA_mutation_status_(N=33,_p=0.0059)._In_the_subpopulation_free_of_RAS_mutation_(N=19)_the_correlation_was_increased.",22294718,PubMed,,"Davies_et_al.,_2012,_Mol._Cancer_Ther.",,3,accepted,1502,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_21:14:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/1502,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,AZD5363,,,,,,,
PTEN,5728,LOSS,Gastric_Adenocarcinoma,3717,,"Lapatinib,Trastuzumab",Substitutes,Predictive,Supports,B,Resistance,"In_48_patients_with_advanced_gastric_cancer,_retrospectively_analyzed_for_PTEN_expression_using_IHC,_PTEN_loss_was_associated_with_a_shorter_duration_of_response_(median_4.2_vs._6.1_months,_p_=_0.04)_to_HER2-targeted_therapy_(trastuzumab,_N=39;_lapatinib,_N=9)._Response_rates_did_not_differ_between_groups.",25300346,PubMed,,"Zhang_et_al.,_2015,_Oncology",,2,accepted,864,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,,2016-02-22_20:27:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/864,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Lapatinib,Trastuzumab,,,,,,
PTEN,5728,LOSS,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,D,Resistance,"A_large-scale_RNAi_genetic_sereen_in_HER2_overexpressing_breast_cancer_cell_line_BT-474_was_performed_to_discover_genes_whose_loss_induced_trastuzumab_resistance._The_most_prominently_enriched_gene_in_trastuzumab_resistant_populations_was_PTEN._Subsequent_knockdown_of_PTEN_in_BT-474_cells_increased_cell_survival_when_treated_with_trastuzumab,_and_growth_curves_showed_partial_restoration_of_proliferation_in_PTEN_knockdown_BT-474_cells_treated_with_trastuzumab.",17936563,PubMed,,"Berns_et_al.,_2007,_Cancer_Cell",,2,accepted,1383,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_21:04:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1383,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,,,,,,,
PTEN,5728,LOSS,Solid_Tumor,,,"Carboplatin,Paclitaxel,Buparlisib",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"No_objective_responses_were_observed_in_the_PTEN_deficient_cohort._Four_out_of_6_patients_with_stable_disease_(SD)_had_SD_or_better_for_≥6_cycles,_2_of_which_had_PTEN_deficient_tumors._Conclusion_The_addition_of_buparlisib_to_high_dose_carboplatin_and_paclitaxel_was_not_tolerable._The_combination_did_not_reveal_significant_clinical_activity_amongst_a_small_and_heterogenous_group_of_PTEN_deficient_tumors.",28281183,PubMed,,"Smyth_et_al.,_2017,_Invest_New_Drugs",NCT01297452,4,accepted,5957,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2018-02-15_12:59:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/5957,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Carboplatin,Paclitaxel,Buparlisib,,,,,
PTEN,5728,LOSS,Breast_Cancer,1612,,AZD8186,,Predictive,Supports,D,Sensitivity/Response,Breast_and_prostate_cancer_cell_lines_responsive_to_AZD8186_were_enriched_for_PTEN_deficiency.,25398829,PubMed,,"Hancox_et_al.,_2015,_Mol._Cancer_Ther.",,2,accepted,711,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/711,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,AZD8186,,,,,,,
PTEN,5728,LOSS,Cancer,162,,"Buparlisib,Carboplatin,Paclitaxel",Combination,Predictive,Supports,B,Sensitivity/Response,All_three_patients_with_PTEN_loss_had_benefit_from_adding_Buparlisib_to_carboplatin+paclitaxel_therapy_in_a_phase_I_study_in_advanced_solid_cancers.,25672916,PubMed,,"Hyman_et_al.,_2015,_Cancer_Chemother._Pharmacol.",,3,accepted,714,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2015-12-29_17:28:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/714,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Buparlisib,Carboplatin,Paclitaxel,,,,,
PTEN,5728,LOSS,Melanoma,1909,,GSK2141795,,Predictive,Supports,D,Sensitivity/Response,Most_BRAF_mutant_cell_lines_(mostly_V600E)_with_PTEN_mutation_or_loss_of_expression_were_among_those_sensitive_to_inhibition_with_AKT_inhibitor_GSK2141795B.,24735930,PubMed,,"Lassen_et_al.,_2014,_Mol._Cancer",,2,accepted,708,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/708,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,GSK2141795,,,,,,,
PTEN,5728,LOSS,Ovarian_Cancer,2394,,Cisplatin,,Predictive,Supports,D,Resistance,"A_cisplatin_resistant_derivative_of_ovarian_cancer_cell_line_OVCAR-3_was_generated_by_long_term_passage_with_increasing_cisplatin_levels._Western_blot_showed_decreased_PTEN_level_in_the_resistant_cell_line,_and_siRNA_against_PTEN_in_parent_OVCAR-3_cells_induced_cisplatin_resistance.",15790433,PubMed,,"Lee_et_al.,_2005,_Gynecol._Oncol.",,2,accepted,1492,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-05_16:51:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1492,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Cisplatin,,,,,,,
PTEN,5728,LOSS,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_PTEN_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_PTEN_knockdown_cells_(achieved_via_lentiviral_transduction_of_shPTEN)_were_more_resistant_to_vemurafenib_(a_BRAF_inhibitor)_than_cells_expressing_wildtype_PTEN._Lentiviral_mediated_reintroduction_of_PTEN_restored_vemurafenib_sensitivity_in_WM2664,_a_vemurafenib_resistant,_PTEN_non-expressing_and_BRAF_V600D_mutated_human_melanoma_cell_line.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,4,accepted,6271,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_20:44:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/6271,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Vemurafenib,,,,,,,
PTEN,5728,LOSS,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_111_HER2-positive_metastatic_breast_cancer_patients_treated_with_trastuzumab-based_therapy,_PTEN_loss_(as_measured_by_IHC)_was_associated_with_shorter_survival_as_measured_from_initiation_of_trastuzumab_(HR_=_1.92,_P_=_0.017)_and_diagnosis_of_first_metastasis_(HR_=_1.69,_P_=_0.047).",21594665,PubMed,,"Razis_et_al.,_2011,_Breast_Cancer_Res._Treat.",,2,accepted,2035,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2019-01-26_23:08:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/2035,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,,,,,,,
PTEN,5728,LOSS,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,B,Resistance,"PTEN_loss_is_associated_with_loss_of_sensitivity_to_the_HER2-antibody_trastuzumab_in_breast_cancer_in_smaller_trials,_a_phase_III_trial_(NCCTG_N9831)_did_not_show_an_effect_of_PTEN_on_disease-free_survival.",24387334,PubMed,,"Dillon_et_al.,_2014,_Curr_Drug_Targets",,1,accepted,645,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-19_22:49:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/645,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,,,,,,,
PTEN,5728,LOSS,Bladder_Carcinoma,4007,,Everolimus,,Predictive,Supports,B,Resistance,PTEN_loss_is_associated_with_reduced_response_to_mTOR_inhibitors_in_patients_with_bladder_cancer.,23989949,PubMed,,"Seront_et_al.,_2013,_Br._J._Cancer",,4,accepted,644,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2015-11-01_00:47:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/644,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Everolimus,,,,,,,
PTEN,5728,LOSS,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"In_27_patients_with_chemotherapy-naive_or_chemotherapy-refractory_metastatic_colorectal_cancer_who_were_treated_with_cetuximab_and_chemotherapy,_PTEN_loss_was_associated_with_non-response.",21163703,PubMed,,"De_Roock_et_al.,_2011,_Lancet_Oncol.",,3,accepted,506,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2015-10-09_18:40:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/506,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Cetuximab,,,,,,,
PTEN,5728,LOSS,Her2-receptor_Positive_Breast_Cancer,60079,,Everolimus,,Predictive,Supports,B,Sensitivity/Response,"Archival_tumor_samples_from_549_patients_from_the_BOLERO-1_and_-3_trials_were_analyzed_for_alterations_in_the_PI3K_pathway_using_next-generation_sequencing,_immunohistochemistry_(IHC)_and_Sanger_sequencing._In_the_BOLERO_trials,_patients_with_HER2-overexpressing_advanced_breast_cancer_were_treated_with_trastuzumab,_chemotherapy_and_randomized_to_receive_either_everolimus_or_placebo._In_the_pooled_analysis_of_both_trials,_patients_with_PTEN_loss_(as_defined_by_IHC_staining_intensity_and_proportion_of_positive_tumor_cells)_had_a_longer_progression-free_survival_with_everolimus_compared_to_placebo_(HR_0.54_(95%CI_0.31_to_0.96,_P=0.04)_whereas_patients_with_PTEN_normal_status_had_a_hazard_ration_of_1.00_(95%CI_0.8_to_1.26,_P=0.97)._The_same_was_found_when_PI3K_mutations,_PTEN_loss_and_AKT_E17K_mutations_were_combined_and_analyzed_as_hyperactive_PI3K_pathway._Patients_with_PI3K_hyperactive_pathway_had_a_hazard_ratio_of_0.67_(95%CI_0.48_to_0.93,_P=0.02)_compared_to_HR_1.19_(95%CI_0.87_to_1.62,_P=0.28)_in_patients_with_PI3K_normal_pathway._These_trends_were_independently_confirmed_in_both_trials_but_only_pooled_results_showed_consistent_statistical_significance.",27091708,PubMed,,"André_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,1297,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:04:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1297,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Everolimus,,,,,,,
PTEN,5728,LOSS,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Does_Not_Support,B,Resistance,"While_some_reports_indicate_PTEN_loss_is_associated_with_resistance_to_trastuzumab,_in_a_subgroup_of_HER2_breast_cancer_FFPE_samples_from_patients_receiving_trastuzumab_as_later_line_therapy_(second_or_greater_line_therapy),_with_25_PTEN_loss_and_and_25_normal_samples,_no_association_was_seen_between_trastuzumab_response_and_PTEN_status_(p=1.000)_or_overall_survival_and_PTEN_status_(p=0.863).",20813970,PubMed,,"Esteva_et_al.,_2010,_Am._J._Pathol.",,3,accepted,1386,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_18:50:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1386,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,,,,,,,
PTEN,5728,LOSS,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Resistance,"A_subgroup_of_HER2-positive_breast_cancer_patients_that_received_first-line_trastuzumab_treatment_were_assessed_for_PTEN_loss_via_IHC_of_FFPE_samples._46_samples_showed_PTEN_loss_while_41_did_not,_and_PTEN_loss_alone_was_found_to_be_significantly_associated_with_resistance_to_trastuzumab_(p=0.028)_and_shorter_overall_survival_(p=0.008).",20813970,PubMed,,"Esteva_et_al.,_2010,_Am._J._Pathol.",,3,accepted,1385,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_21:05:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1385,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Trastuzumab,,,,,,,
PTEN,5728,LOSS,Prostate_Cancer,10283,,Temsirolimus,,Predictive,Supports,D,Sensitivity/Response,"In_prostate_cancer_xenographs,_PTEN_null_tumors_had_a_significant_decrease_in_cell_size_and_proliferation_when_treated_with_Temsirolimus_(CCI-779).",11504908,PubMed,,"Neshat_et_al.,_2001,_Proc._Natl._Acad._Sci._U.S.A.",,4,accepted,507,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/507,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Temsirolimus,,,,,,,
PTEN,5728,LOSS,Endometrial_Cancer,1380,,"Temsirolimus,Ridaforolimus",Substitutes,Predictive,Does_Not_Support,B,Resistance,"94_endometrial_cancer_samples_of_women_who_had_been_treated_with_single_agent_mTOR_inhibitors_temsirolimus_or_ridaforolimus_were_retrospectively_analyzed._No_predictive_biomarkers_were_identified,_including_PIK3CA_mutations,_KRAS_mutations_or_PTEN_loss.",24166148,PubMed,,"Mackay_et_al.,_2014,_Cancer",,3,accepted,893,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-10_17:07:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/893,https://civic.genome.wustl.edu/links/variants/214,https://civic.genome.wustl.edu/links/genes/41,,,loss_of_function_variant,,268,Temsirolimus,Ridaforolimus,,,,,,
SMAD4,4089,MUTATION,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,B,Resistance,"In_a_retrospective_analysis_of_65_patients_with_metastatic_colorectal_cancer,_SMAD4_mutations_were_more_common_among_patients_with_no_benefit_from_EGFR-inhibition_(cetuximab_or_panitumumab)_(4_patients)_than_with_patients_with_response_to_EGFR_directed_treatment_(1_patient).",26508446,PubMed,,"Lupini_et_al.,_2015,_BMC_Cancer",,2,accepted,719,77,18,48556583,48611409,,,ENST00000342988.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-19_22:48:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/719,https://civic.genome.wustl.edu/links/variants/216,https://civic.genome.wustl.edu/links/genes/77,,,"loss_of_function_variant,transcript_variant",,25,Panitumumab,Cetuximab,,,,,,
TP53,7157,DELETERIOUS_MUTATION,Leukemia,1240,,RG7112,,Predictive,Supports,B,Resistance,"Phase_I_Trial_of_MDM2_inhibitor_RG7112_in_116_patients_with_AML,_ALL,_CML,_CLL,_sCLL_demonstrated_sustained_clinical_improvement_and_induction_of_TP53_target_genes_in_subset_of_patients_with_wild_type_TP53._No_sustained_clinical_improvement_or_induction_of_TP53_target_genes_was_observed_in_patients_with_mutant_TP53.",26459177,PubMed,,"Andreeff_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,2966,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,Somatic_Mutation,2017-05-31_15:15:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/2966,https://civic.genome.wustl.edu/links/variants/221,https://civic.genome.wustl.edu/links/genes/45,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,,,,78,RG7112,,,,,,,
TP53,7157,DELETERIOUS_MUTATION,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,"MDM2_Inhibitor_screen_in_a_panel_of_260_cancer_cell_lines_with_well_characterized_TP53_status_shows_that_only_cancer_cell_lines_with_unaltered_TP53_may_be_sensitive_to_MDM2_Inhibitor_AMGMDS3,_while_those_with_p53_mutations_demonstrated_resistance.",25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,2967,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,Somatic_Mutation,2017-05-10_22:11:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/2967,https://civic.genome.wustl.edu/links/variants/221,https://civic.genome.wustl.edu/links/genes/45,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,,,,78,AMGMDS3,,,,,,,
TP53,7157,DELETERIOUS_MUTATION,Sarcoma,1115,,Pazopanib,,Predictive,Supports,B,Sensitivity/Response,"19_advanced_sarcoma_patients_treated_with_pazopanib_were_retrospectively_assessed_for_mutations_associated_with_response_using_the_Foundation_one_sarcoma/heme_panel._Progression-free_survival_(PFS)_of_patients_with_TP53_mutations_(all_predicted_to_be_loss_of_function)_was_significantly_greater_than_TP53_wild-type_tumors_with_the_median_PFS_of_208_versus_136_days,_respectively_[P_=_0.036,_hazards_ratio_0.38_(95%_confidence_interval_0.09-0.83)].",26646755,PubMed,,"Koehler_et_al.,_2016,_Ann._Oncol.",,2,accepted,1170,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,Somatic_Mutation,2016-06-29_20:03:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1170,https://civic.genome.wustl.edu/links/variants/221,https://civic.genome.wustl.edu/links/genes/45,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,,,,78,Pazopanib,,,,,,,
TP53,7157,DELETERIOUS_MUTATION,Cancer,162,,Nutlin-3a,,Predictive,Supports,D,Resistance,"MDM2_Inhibitor_Nutlin-3a_induced_senescence_in_presence_of_functional_TP53_in_murine_primary_fibroblasts,_oncogenically_transformed_fibroblasts,_and_fibrosarcoma_cell_lines._TP53_mutant_cells_lacking_functional_TP53_were_completely_insensitive_to_the_drug.",17671205,PubMed,,"Efeyan_et_al.,_2007,_Cancer_Res.",,4,accepted,2968,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,Somatic_Mutation,2017-05-11_16:06:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/2968,https://civic.genome.wustl.edu/links/variants/221,https://civic.genome.wustl.edu/links/genes/45,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,,,,78,Nutlin-3a,,,,,,,
TP53,7157,DELETERIOUS_MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Adjuvant_Chemotherapy,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Pooled_analysis_of_TP53_mutations_(exons_5-8)_from_4_randomized_trials_(IALT,_JBR10,_CALGB-9633_and_ANITA)_of_platinum-based_adjuvant_chemotherapy_(ACT)_versus_observation_(OBS)._Patients_with_TP53wt_had_significantly_better_PFS_and_OS_with_ACT_vs._OBS_(p=0.005,_p=0.02,_respectively)_whereas_patients_with_TP53_mutations_did_not_show_significant_differences_in_PFS_and_OS_between_ACT_and_OBS_(p=0.86,_p=0.63).",26899019,PubMed,,"Ma_et_al.,_2016,_J_Thorac_Oncol",,2,accepted,1148,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,Somatic_Mutation,2016-07-26_14:55:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1148,https://civic.genome.wustl.edu/links/variants/221,https://civic.genome.wustl.edu/links/genes/45,Deleterious_mutations_are_mutations_of_TP53_with_prior_characterization_demonstrating_significant_deleterious_effect_on_TP53_protein_function._Inactivating_TP53_mutations_prevent_on_target_activity_and_efficacy_of_MDM2-TP53_interaction_inhibitors.,,,,78,Adjuvant_Chemotherapy,,,,,,,
TP53,7157,MUTATION,Chronic_Lymphocytic_Leukemia,1040,,Alemtuzumab,,Predictive,Supports,B,Sensitivity/Response,"Thirty-six_patients_with_CLL_were_treated_with_alemtuzumab._Partial_or_complete_response_was_achieved_in_6_of_15_patients_with_p53_mutations,_compared_to_4_of_21_without._These_findings_are_not_statistically_significant,_but_the_authors_suggest_that_alemtuzumab_is_an_effective_therapy_for_patients_with_p53_mutations_or_deletions.",14726385,PubMed,,"Lozanski_et_al.,_2004,_Blood",,2,accepted,1481,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_05:02:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1481,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,Alemtuzumab,,,,,,,
TP53,7157,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Docetaxel,,Predictive,Supports,D,Resistance,A_clinical_trial_comparing_selumetinib_and_docetaxel_vs._docetaxel_and_placebo_in_KRAS_mutant_NSCLC_was_recapitulated_in_mice._Tumors_were_induced_in_lung_epithelium_by_nasal_instillation_of_CRE-bearing_adenovirus_in_conditionally_targeted_mice._Kras(G12D)_and_Trp53_knockout_mutant_mice_were_resistant_to_docetaxel_monotherapy_but_sensitive_to_combined_treatment._In_a_small_number_of_human_NSCLC_patients_with_these_genotypes_FDG-PET_signal_intensity_changes_and_pERK_IHC_staining_correlated_with_mouse_data.,22425996,PubMed,,"Chen_et_al.,_2012,_Nature",,3,accepted,1146,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-25_16:56:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1146,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,Docetaxel,,,,,,,
TP53,7157,MUTATION,Stomach_Carcinoma,5517,,EAP_Protocol,,Predictive,Supports,C,Sensitivity/Response,"In_a_study_of_25_patients_with_advanced_gastric_cancer,_mutations_in_TP53_were_identified_in_32%_of_primary_tumors._TP53_mutations_were_associated_with_an_improved_response_to_preoperative_treatment_of_a_modified_EAP_protocol_(combination_of_doxorubicin,_etoposide_and_cisplatin)._Patients_with_mutations_in_TP53_had_an_increased_median_survival_compared_to_patients_with_wildtype_TP53_(18.5mo_vs._10.2mo,_P=0.044).",14514923,PubMed,,"Bataille_et_al.,_2003,_MP,_Mol._Pathol.",,1,accepted,2820,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-13_07:45:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/2820,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,EAP_Protocol,,,,,,,
TP53,7157,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Selumetinib_(AZD6244),Docetaxel",Combination,Predictive,Supports,D,Sensitivity/Response,A_clinical_trial_comparing_selumetinib_and_docetaxel_vs._docetaxel_and_placebo_in_KRAS_mutant_NSCLC_was_recapitulated_in_mice._Tumors_were_induced_in_lung_epithelium_by_nasal_instillation_of_CRE-bearing_adenovirus_in_conditionally_targeted_mice._Kras(G12D)_and_Trp53_knockout_mutant_mice_were_resistant_to_docetaxel_monotherapy_but_sensitive_to_combined_treatment._In_a_small_number_of_human_NSCLC_patients_with_these_genotypes_FDG-PET_signal_intensity_changes_and_pERK_IHC_staining_correlated_with_mouse_data.,22425996,PubMed,,"Chen_et_al.,_2012,_Nature",,3,accepted,1145,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2016-10-10_22:57:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1145,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,Selumetinib_(AZD6244),Docetaxel,,,,,,
TP53,7157,MUTATION,Gastric_Adenocarcinoma,3717,,Chemotherapy,,Predictive,Supports,B,Sensitivity/Response,In_this_meta-analysis_of_13_studies_(564_patients)_p53_positivity_as_defined_by_high_protein_expression_and/or_p53_mutation_was_associated_with_improved_response_to_chemotherapy_(risk_ratio_[RR]_=_0.704;_95%_confidence_intervals_[CI]_=_0.550-0.903;_P_=_0.006).,24740294,PubMed,,"Xu_et_al.,_2014,_PLoS_ONE",,3,accepted,850,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-09_00:03:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/850,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,Chemotherapy,,,,,,,
TP53,7157,MUTATION,Breast_Cancer,1612,,Tamoxifen,,Predictive,Supports,C,Resistance,"In_a_study_202_breast_cancer_patients_undergoing_tamoxifen_treatment,_a_higher_frequency_of_wildtype_TP53_patients_responded_to_treatment_compared_to_those_with_mutations_in_TP53_(66%_wild-type_vs._31%,_odds_ratio_(OR):0.22,_95CI:0.12-0.42,_P<0.0001,_univariate_analysis;_OR:0.29,_95%_CI:0.12-0.42,_P=0.0014,_multivariate_analysis)._The_median_survival_after_start_of_therapy_was_shorter_in_patients_with_mutations_in_TP53_than_for_patients_with_wild-type_TP53_(20mo_vs._29mo,_HR:1.99,95%_CI:1.43-2.75,_P<0.001)._Breast_cancer_patients_with_TP53_mutations_also_had_a_decrease_in_progression-free_survival_(HR:2.61,_95%_CI:1.90-3.6,_P<0.001).",10786679,PubMed,,"Berns_et_al.,_2000,_Cancer_Res.",,1,accepted,2784,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-18_17:24:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2784,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,Tamoxifen,,,,,,,
TP53,7157,MUTATION,Breast_Cancer,1612,,Doxorubicin,,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study,_MMTV-Wnt1_mammary_tumors_with_mutant_TP53_showed_a_better_clinical_response_to_chemotherapy_(doxorubicin)_than_TP53_wild-type_tumors._This_was_mediated_by_wild-type_TP53-induced_cell-arrest_under_chemotherapy_even_in_the_context_of_heterozygous_TP53_point_mutations_or_absence_of_p21._Thus_the_status_of_both_TP53_alleles_should_be_assessed_because_even_one_copy_of_wild-type_TP53_may_contribute_to_poor_response_to_chemotherapy.",22698404,PubMed,,"Jackson_et_al.,_2012,_Cancer_Cell",,4,accepted,851,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_16:07:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/851,https://civic.genome.wustl.edu/links/variants/222,https://civic.genome.wustl.edu/links/genes/45,,,protein_altering_variant,,400,Doxorubicin,,,,,,,
CDK12,51755,LOSS-OF-FUNCTION,Ovarian_Serous_Carcinoma,50933,,Olaparib,,Predictive,Supports,D,Sensitivity/Response,"In_models_of_high-grade_serous_ovarian_cancer_(HGS-OVCa),_CDK12_attenuation_was_sufficient_to_confer_sensitivity_to_PARP1/2_inhibition,_suppression_of_DNA_repair_via_homologous_recombination,_and_reduced_expression_of_BRCA1.",24240700,PubMed,,"Bajrami_et_al.,_2014,_Cancer_Res.",,4,accepted,623,12112,17,37618292,37691399,,,ENST00000447079.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/623,https://civic.genome.wustl.edu/links/variants/236,https://civic.genome.wustl.edu/links/genes/12112,,,loss_of_function_variant,,4,Olaparib,,,,,,,
NT5C2,22978,R367Q,T-cell_Acute_Lymphoblastic_Leukemia,5603,,"6-mercaptopurine,6-thioguanine",Substitutes,Predictive,Supports,D,Resistance,"CCRF-CEM_and_to_a_lesser_extent_CUTLL1_T-ALL_cell_lines_expressing_the_NT5C2_R367Q_mutation_had_increased_resistance_to_6-mercaptopurine_and_6-thioguanine_treatment_than_cells_expressing_wildtype_NT5C2._Consistent_with_this,_isolated_mutant_proteins_also_showed_increased_enzyme_activity_compared_to_wildtype_proteins.",23377281,PubMed,,"Tzoneva_et_al.,_2013,_Nat._Med.",,4,accepted,630,9189,10,104852955,104852955,C,T,ENST00000343289.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/630,https://civic.genome.wustl.edu/links/variants/238,https://civic.genome.wustl.edu/links/genes/9189,,,missense_variant,NC_000010.10:g.104852955C>T,8,6-mercaptopurine,6-thioguanine,,,,chr10_g.104852955C~T,,
NT5C2,22978,R367Q,T-cell_Acute_Lymphoblastic_Leukemia,5603,,"Arabinosylguanine,Nelarabine",Substitutes,Predictive,Does_Not_Support,D,Resistance,"CCRF-CEM_and_CUTLL1_T-ALL_cell_lines_expressing_NT5C2_mutant_proteins_(K359Q,_R367Q_or_D407A)_observed_in_relapsed_T-ALL_patients_showed_no_difference_in_sensitivity_to_nelarabine_or_arabinosylguanine_treatment_when_compared_to_cells_expressing_wildtype_protein_or_vector_alone.",23377281,PubMed,,"Tzoneva_et_al.,_2013,_Nat._Med.",,4,accepted,633,9189,10,104852955,104852955,C,T,ENST00000343289.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/633,https://civic.genome.wustl.edu/links/variants/238,https://civic.genome.wustl.edu/links/genes/9189,,,missense_variant,NC_000010.10:g.104852955C>T,8,Arabinosylguanine,Nelarabine,,,,chr10_g.104852955C~T,,
NT5C2,22978,K359Q,T-cell_Acute_Lymphoblastic_Leukemia,5603,,"Nelarabine,Arabinosylguanine",Substitutes,Predictive,Does_Not_Support,D,Resistance,"CCRF-CEM_and_CUTLL1_T-ALL_cell_lines_expressing_NT5C2_mutant_proteins_(K359Q,_R367Q_or_D407A)_observed_in_relapsed_T-ALL_patients_showed_no_difference_in_sensitivity_to_nelarabine_or_arabinosylguanine_treatment_when_compared_to_cells_expressing_wildtype_protein_or_vector_alone.",23377281,PubMed,,"Tzoneva_et_al.,_2013,_Nat._Med.",,4,accepted,636,9189,10,104852980,104852980,T,G,ENST00000343289.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/636,https://civic.genome.wustl.edu/links/variants/239,https://civic.genome.wustl.edu/links/genes/9189,,,missense_variant,"NC_000010.10:g.104852980T>G,NM_012229.4:c.1075A>C,NP_036361.1:p.Lys359Gln,ENST00000343289.5:c.1075A>C",28,Nelarabine,Arabinosylguanine,,,,chr10_g.104852980T~G,NT5C2_c.1075A~C,NT5C2_K359Q
NT5C2,22978,K359Q,T-cell_Acute_Lymphoblastic_Leukemia,5603,,"6-mercaptopurine,6-thioguanine",Substitutes,Predictive,Supports,D,Resistance,"CCRF-CEM_and_to_a_lesser_extent_CUTLL1_T-ALL_cell_lines_expressing_the_NT5C2_K359Q_mutation_had_increased_resistance_to_6-mercaptopurine_and_6-thioguanine_treatment_than_cells_expressing_wildtype_NT5C2._Consistent_with_this,_isolated_mutant_proteins_also_showed_increased_enzyme_activity_compared_to_wildtype_proteins.",23377281,PubMed,,"Tzoneva_et_al.,_2013,_Nat._Med.",,4,accepted,631,9189,10,104852980,104852980,T,G,ENST00000343289.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/631,https://civic.genome.wustl.edu/links/variants/239,https://civic.genome.wustl.edu/links/genes/9189,,,missense_variant,"NC_000010.10:g.104852980T>G,NM_012229.4:c.1075A>C,NP_036361.1:p.Lys359Gln,ENST00000343289.5:c.1075A>C",28,6-mercaptopurine,6-thioguanine,,,,chr10_g.104852980T~G,NT5C2_c.1075A~C,NT5C2_K359Q
NT5C2,22978,D407A,T-cell_Acute_Lymphoblastic_Leukemia,5603,,"Nelarabine,Arabinosylguanine",Substitutes,Predictive,Does_Not_Support,D,Resistance,"CCRF-CEM_and_CUTLL1_T-ALL_cell_lines_expressing_NT5C2_mutant_proteins_(K359Q,_R367Q_or_D407A)_observed_in_relapsed_T-ALL_patients_showed_no_difference_in_sensitivity_to_nelarabine_or_arabinosylguanine_treatment_when_compared_to_cells_expressing_wildtype_protein_or_vector_alone.",23377281,PubMed,,"Tzoneva_et_al.,_2013,_Nat._Med.",,4,accepted,635,9189,10,104850745,104850745,T,G,ENST00000343289.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/635,https://civic.genome.wustl.edu/links/variants/240,https://civic.genome.wustl.edu/links/genes/9189,,,missense_variant,"NC_000010.10:g.104850745T>G,NM_012229.4:c.1220A>C,NP_036361.1:p.Asp407Ala,ENST00000343289.5:c.1220A>C",8,Nelarabine,Arabinosylguanine,,,,chr10_g.104850745T~G,NT5C2_c.1220A~C,NT5C2_D407A
NT5C2,22978,D407A,T-cell_Acute_Lymphoblastic_Leukemia,5603,,"6-mercaptopurine,6-thioguanine",Substitutes,Predictive,Supports,D,Resistance,"CCRF-CEM_and_to_a_lesser_extent_CUTLL1_T-ALL_cell_lines_expressing_the_NT5C2_D407A_mutation_had_increased_resistance_to_6-mercaptopurine_and_6-thioguanine_treatment_than_cells_expressing_wildtype_NT5C2._Consistent_with_this,_isolated_mutant_proteins_also_showed_increased_enzyme_activity_compared_to_wildtype_protein.",23377281,PubMed,,"Tzoneva_et_al.,_2013,_Nat._Med.",,4,accepted,632,9189,10,104850745,104850745,T,G,ENST00000343289.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/632,https://civic.genome.wustl.edu/links/variants/240,https://civic.genome.wustl.edu/links/genes/9189,,,missense_variant,"NC_000010.10:g.104850745T>G,NM_012229.4:c.1220A>C,NP_036361.1:p.Asp407Ala,ENST00000343289.5:c.1220A>C",8,6-mercaptopurine,6-thioguanine,,,,chr10_g.104850745T~G,NT5C2_c.1220A~C,NT5C2_D407A
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_F317L_was_seen_in_8_imatinib_resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,6978,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2018-12-21_20:01:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/6978,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Imatinib_Mesylate,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_F317L_mutation_was_associated_with_resistance_in_2_μM_imatinib_(2_clones_recovered,_~1%),_5_nM_dasatinib_(6_clones,_~_17%),_and_10_nM_dasatinib_(4_clones,_~7%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6252,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2018-06-27_21:39:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/6252,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Imatinib_Mesylate,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_4_had_F317L_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7045,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2019-01-31_10:30:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/7045,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Imatinib_Mesylate,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase)_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_14_patients_with_F317L_mutations,_1,_2,_and_13_achieved_CCyR,_MCyR,_and_CHR_to_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations._Despite_high_CHR_in_patients_with_the_F317L_variant,_of_the_63_variants_considered,_the_authors_associate_T315I,_F317L,_and_V299L_with_resistance_or_lower_levels_of_response_to_dasatinib_due_to_clinical_resistance_and_low_in_vitro_sensitivity._They_suggest_considering_alternative_treatment_options_for_patients_with_these_three_variants.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,6309,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2018-07-19_21:49:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/6309,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Dasatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_F317L_evaluated,_3/3_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,3,accepted,4381,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2018-07-12_21:49:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/4381,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Bosutinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Reduced_Sensitivity,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_F317L,_4/8_had_a_CHR_and_1/7_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,4382,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2019-02-04_19:04:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/4382,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Bosutinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Resistance,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_F317L_mutation_was__moderately_resistant_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2676,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2017-05-19_16:53:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/2676,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Imatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_F317L_mutation_was_moderately_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2674,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2017-07-25_16:32:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/2674,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Imatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Ponatinib,,Predictive,Supports,B,Sensitivity/Response,Ponatinib_has_shown_to_be_effective_in_patients_with_BCR-ABL_kinase_domain_mutations_like_F317L.,25349473,PubMed,,"Miller_et_al.,_2014,_Biologics",,5,accepted,639,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2015-10-21_20:40:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/639,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Ponatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_F317L_mutation_was_associated_with_resistance_in_2_μM_imatinib_(2_clones_recovered,_~1%),_5_nM_dasatinib_(6_clones,_~_17%),_and_10_nM_dasatinib_(4_clones,_~7%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6270,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2018-07-02_02:38:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/6270,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Dasatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Ponatinib,,Predictive,Supports,D,Sensitivity/Response,Molecular_dynamics_simulations_and_calculated_solvated_interaction_energies_indicate_BCR-ABL_F317L_mutations_are_Ponatinib_sensitive.,24236021,PubMed,,"Tanneeru_et_al.,_2013,_PLoS_ONE",,3,accepted,638,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2016-12-01_15:25:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/638,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Ponatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_were_generated_in_Ba/F3_cell_lines_from_five_independently_derived,_mutagenized_libraries._Dasatinib_resistant_subclones_were_identified_using_﻿50_nM_dasatinib_in_liquid_culture._201_individual_clones_were_identified_representing_10_different_mutations_at_6_different_residues._10_of_these_clones_had_F317L_mutations._To_validate_resistance_to_dasatinib,_a_Ba/F3_cell_line_stably_expressing_the_F317L_mutation_in_the_ABL1_region_of_the_BCR-ABL_fusion_was_generated_and_associated_with_higher_dasatinib_IC50_of_18_nM_vs_1.34_nM_in_wildtype_as_determined_by_dose_response_curves.",15705718,PubMed,,"Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,6215,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2018-06-20_01:43:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/6215,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Dasatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,B,Resistance,BCR-ABL_F317L_has_been_shown_to_confer_resistance_to_dasatinib_in_patients_with_CML.,18818391,PubMed,,"Jabbour_et_al.,_2008,_Blood",,5,accepted,637,4,9,133748288,133748288,T,C,ENST00000318560.5,,,,,75,GRCh37,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Somatic_Mutation,2015-10-21_20:26:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/637,https://civic.genome.wustl.edu/links/variants/241,https://civic.genome.wustl.edu/links/genes/4,"BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.",Imatinib_Resistance,"transcript_fusion,missense_variant","NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C",99.5,Dasatinib,,,,,chr9_g.133748288T~C,ABL1_c.949T~C,ABL1_F317L
ABL1,25,BCR-ABL_F317L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Reduced_Sensitivity,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_F317L,_4/4_had_MaHRs_which_was_higher_than_response_rates_among_wild_type_patients,_and_0/4_had_MCyRs_which_was_lower_than_response_rates_among_wild_type_patients.	17264298	PubMed	NA	Guilhot_et_al.,_2007,_Blood		1	accepted	7030	4	9	133748288	133748288	T	C	ENST00000318560.5		NA	NA		75	GRCh37	BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.	Somatic_Mutation	2019-01-31_10:11:13_UTC	https://civic.genome.wustl.edu/links/evidence_items/7030	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4	BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.	Imatinib_Resistance	transcript_fusion,missense_variant	NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C	99.5
241	ABL1	25	BCR-ABL_F317L	Chronic_Myeloid_Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_F317L_mutation_was__moderately_resistant_to_imatinib_.	15930265	PubMed	NA	O'Hare_et_al.,_2005,_Cancer_Res.		NA	accepted	2680	4	9	133748288	133748288	T	C	ENST00000318560.5		NA	NA		75	GRCh37	BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.	Somatic_Mutation	2018-06-19_19:31:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/2680	https://civic.genome.wustl.edu/links/variants/241	https://civic.genome.wustl.edu/links/genes/4	BCR-ABL_F317L,_like_the_similar_BCR-ABL_T315I_mutation,_is_becoming_a_common_clinical_marker_for_resistance_to_front-line_therapies_in_CML._It_has_been_shown_to_confer_resistance_to_dasatinib,_but_responds_well_to_ponatinib_and_other_second_generation_inhibitors.	Imatinib_Resistance	transcript_fusion,missense_variant	NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C	99.5
242	TP53	7157	DNA_BINDING_DOMAIN_MUTATION	Breast_Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	In_a_study_202_breast_cancer_patients_undergoing_first_line_tamoxifen_treatment,_65_patients_had_mutations_in_TP53._Among_the_p53_wild_type_population_a_66%_response_rate_was_reported,_where_response_was_considered_as_complete_response,_partial_response_or_stable_disease._In_a_patient_subgroup_with_mutations_in_p53_amino_acids_that_directly_interact_with_DNA,_2_of_11_(18%)_of_patients_responded_to_tamoxifen.	10786679	PubMed	NA	Berns_et_al.,_2000,_Cancer_Res.		3	accepted	2783	45	17	7577149	7578443			ENST00000269305.4		NA	NA		75	GRCh37		Somatic_Mutation	2017-08-15_21:22:21_UTC	https://civic.genome.wustl.edu/links/evidence_items/2783	https://civic.genome.wustl.edu/links/variants/242	https://civic.genome.wustl.edu/links/genes/45			DNA_binding_site		35
243	ATM	472	V2288FS*1	Prostate_Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	Treatment_with_the_PARP_inhibitor_olaparib_in_patients_whose_prostate_cancers_were_no_longer_responding_to_standard_treatments_and_who_had_defects_in_DNA-repair_genes_led_to_a_high_response_rate._Overall,_4/6_patients_(3/5_with_no_other_identified_aberrations_in_DNA_repair_genes)_with_several_germline_and_somatic_aberrations_of_ATM_had_a_response._Responders_included_a_single_patient_with_a_somatic_frameshift_mutation_(ATM_V2288fs*1)_predicted_to_result_in_truncation_prior_to_the_PI3K_catalytic_domain_and_other_domains_for_p53_recognition_and_response_to_DNA_damage._No_other_alterations_in_ATM_were_observed;_however,_this_patient_also_had_frameshift_mutations_in_MLH3,_MRE11_and_NBN.	26510020	PubMed	NA	Mateo_et_al.,_2015,_N._Engl._J._Med.		3	accepted	647	69	11	108196840	108196841	TC		ENST00000278616.4		NA	NA		75	GRCh37	A_frameshift_mutation_predicted_to_cause_truncation_before_the_C-terminal_phosphoinositide_3-kinase_(PI3K)_catalytic_domain.	Somatic_Mutation	2016-04-08_15:13:01_UTC	https://civic.genome.wustl.edu/links/evidence_items/647	https://civic.genome.wustl.edu/links/variants/243	https://civic.genome.wustl.edu/links/genes/69	A_frameshift_mutation_predicted_to_cause_truncation_before_the_C-terminal_phosphoinositide_3-kinase_(PI3K)_catalytic_domain.		frameshift_truncation	ENST00000278616.4:c.6863_6864delTC	7.5
244	ATM	472	N2875H	Prostate_Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	Treatment_with_the_PARP_inhibitor_olaparib_in_patients_whose_prostate_cancers_were_no_longer_responding_to_standard_treatments_and_who_had_defects_in_DNA-repair_genes_led_to_a_high_response_rate._Overall,_4/6_patients_(3/5_with_no_other_identified_aberrations_in_DNA_repair_genes)_with_several_germline_and_somatic_aberrations_of_ATM_had_a_response._Responders_included_a_single_patient_with_a_somatic_missense_mutation_(ATM_N2875H)_and_no_other_alterations_in_ATM_or_other_DNA_repair_genes.	26510020	PubMed	NA	Mateo_et_al.,_2015,_N._Engl._J._Med.		3	accepted	648	69	11	108218044	108218044	A	C	ENST00000278616.4		NA	NA		75	GRCh37	A_missense_mutation_within_the_C-terminal_phosphoinositide_3-kinase_(PI3K)_catalytic_domain	Somatic_Mutation	2016-04-08_15:17:02_UTC	https://civic.genome.wustl.edu/links/evidence_items/648	https://civic.genome.wustl.edu/links/variants/244	https://civic.genome.wustl.edu/links/genes/69	A_missense_mutation_within_the_C-terminal_phosphoinositide_3-kinase_(PI3K)_catalytic_domain		missense_variant	ENST00000278616.4:c.8623A>C,NC_000011.9:g.108218044A>C,NM_000051.3:c.8623A>C,NP_000042.3:p.Asn2875His	7.5
245	NF2	4771	Y177FS	Peritoneal_Mesothelioma	1788		Carboplatin,Cisplatin	Substitutes	Predictive	Supports	C	Resistance	A_frameshift_mutation_in_NF2_at_position_Y177_was_found_in_a_patient_who_did_not_respond_to_the_standard_platinum_doublet_chemotherapy_regimen.	25798586	PubMed	NA	Sheffield_et_al.,_2015,_PLoS_ONE		3	accepted	649	3870	22	30051593	30051594		T	ENST00000338641.4		NA	NA		75	GRCh37		Somatic_Mutation	2016-02-17_19:49:55_UTC	https://civic.genome.wustl.edu/links/evidence_items/649	https://civic.genome.wustl.edu/links/variants/245	https://civic.genome.wustl.edu/links/genes/3870			frameshift_elongation	ENST00000338641.4:c.527_528insT,NC_000022.10:g.30051593_30051594insT	7.5
247	PDGFRA	5156	V561A	Gastrointestinal_Stromal_Tumor	9253		Imatinib		Predictive	Supports	D	Sensitivity/Response	293T_cells_stably_transduced_with_PDGFRA_V561A_showed_constitutive_tyrosine_phosphorylation_in_the_absense_of_ligand;_however,_when_treated_with_imatinib,_this_phosphorylation_was_inhibited_similarly_to_that_of_wildtype_PDGFRA,_consistent_with_sensitivity_to_this_inhibitor.	12949711	PubMed	NA	Hirota_et_al.,_2003,_Gastroenterology		3	accepted	652	38	4	55141036	55141036	T	C	ENST00000257290.5		NA	NA		75	GRCh37		Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/652	https://civic.genome.wustl.edu/links/variants/247	https://civic.genome.wustl.edu/links/genes/38			missense_variant	ENST00000257290.5:c.1682T>C,NC_000004.11:g.55141036T>C,NM_006206.5:c.1682T>C,NP_006197.1:p.Val561Ala	3
249	XRCC1	7515	R194W	Non-small_Cell_Lung_Carcinoma	3908		Gemcitabine,Vinorelbine,Docetaxel	Substitutes	Predictive	Supports	B	Sensitivity/Response	The_XRCC1_R194W_variant_was_shown_to_be_correlated_with_increased_chance_of_response_to_platinum-based_chemotherapy_in_Stage_IV_Non-small_Cell_Lung_Carcinoma_(NSCLC)._82_patients_with_Stage_IV_NSCLC_who_had_not_previously_been_treated_with_chemotherapy_were_used_in_this_study.	19157633	PubMed	NA	Sun_et_al.,_2009,_Lung_Cancer		4	accepted	659	6144	19	44057574	44057574	G	A	ENST00000262887.5		NA	NA		75	GRCh37		Germline_Mutation	2015-12-22_15:27:10_UTC	https://civic.genome.wustl.edu/links/evidence_items/659	https://civic.genome.wustl.edu/links/variants/249	https://civic.genome.wustl.edu/links/genes/6144			missense_variant	NC_000019.9:g.44057574G>A	20
250	GSTP1	2950	DELETION	Ovarian_Carcinoma	4001		Cisplatin,Carboplatin,Paclitaxel	Substitutes	Predictive	Supports	D	Sensitivity/Response	Stable_GSTP1_knockdown_in_ovarian_carcinoma_A2780_cell_lines_showed_increased_sensitivity_to_platinum-based_chemotherapy_drugs_carboplatin,_cisplatinum,_carboplatin,_and_paclitaxel._For_each_drug,_3_biological_replicates_were_performed_for_this_study,_and_effectiveness_was_evaluated_using_an_MTT_assay._There_was_not_a_significant_difference_in_sensitivity_to_other_chemotherapy_drugs_such_as_gemcitabine,_topotecan,_and_doxorubicin.	25010864	PubMed	NA	Sawers_et_al.,_2014,_Br._J._Cancer		4	accepted	660	2473	11	67351066	67354131			ENST00000398606.3		NA	NA		75	GRCh37		Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/660	https://civic.genome.wustl.edu/links/variants/250	https://civic.genome.wustl.edu/links/genes/2473			transcript_ablation		4
251	BIRC7	79444	AMPLIFICATION	Colon_Cancer	219		Cisplatin		Predictive	Supports	D	Resistance	Livin_(BIRC7)_overexpression_in_two_colon_cancer_cell_lines_(RKO_and_SW620)_increased_resistance_of_these_cells_to_cisplatin._siRNA_knockdown_of_Livin_rendered_the_cells_more_sensitive_to_cisplatin._The_study_also_further_showed_that_cytoplasmic_Livin_levels_increased_in_four_colon_cancer_cell_lines_(RKO,_SW620,_HCT116,_and_KM12C)_after_cisplatin_treatment_in_a_dose-dependent_manner._This_study_highlighted_Livin_as_a_potential_player_in_colon_cancer_therapy.	23188704	PubMed	NA	Ding_et_al.,_2013,_Tumour_Biol.		4	accepted	661	14842	20	61867235	61871859			ENST00000217169.3		NA	NA		75	GRCh37		Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/661	https://civic.genome.wustl.edu/links/variants/251	https://civic.genome.wustl.edu/links/genes/14842			transcript_amplification		4
252	EGFR	1956	EXON_4_DELETION	Epithelial_Ovarian_Cancer	2152		Cisplatin		Predictive	Supports	D	Resistance	A_variant_of_EGFR_with_exon_4_deletion_(de4_EGFR)_enhanced_the_invasiveness_and_cisplatin_resistance_of_epithelial_ovarian_cancer_cell_lines_(SKOV3,_CAOV3,_ES2)_in_vitro_when_compared_with_wild-type_EGFR._The_three_cell_lines_were_infected_with_lentivirus_for_either_EGFR_or_de4_EGFR,_and_lentivirus-infected_cells_were_used_to_perform_transwell_migration_assays,_invasion_assays,_and_cisplatin_sensitivity_assays.	23764753	PubMed	NA	Zhang_et_al.,_2013,_Carcinogenesis		4	accepted	662	19	7	55214299	55214433			ENST00000275493.2		NA	NA		75	GRCh37		Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/662	https://civic.genome.wustl.edu/links/variants/252	https://civic.genome.wustl.edu/links/genes/19			exon_loss_variant	ENST00000275493.2:c.425_559del	4
254	KRAS	3845	RS61764370	Head_And_Neck_Squamous_Cell_Carcinoma	5520		Cisplatin		Predictive	Supports	B	Resistance	In_the_retrospective_analysis_of_103_HNSSC,_the_TG/GG_rs61764370_variant_was_associated_with_poor_response_to_cisplatin_(log-rank_P_=_0.002).There_seemed_to_be_some_improvement_when_cetuximab_was_added_to_their_platinum-based_regimen_(log-rank_P_=_0.04).	25081901	PubMed	NA	Chung_et_al.,_2014,_Ann._Oncol.		3	accepted	872	30	12	25360224	25360224	A	C	ENST00000311936.3		NA	NA		75	GRCh37	Germline_variant_in_the_3'_UTR_of_KRAS_that_predicts_resistance_to_platinum-based_therapy.	Germline_Polymorphism	2016-02-13_04:02:42_UTC	https://civic.genome.wustl.edu/links/evidence_items/872	https://civic.genome.wustl.edu/links/variants/254	https://civic.genome.wustl.edu/links/genes/30	Germline_variant_in_the_3'_UTR_of_KRAS_that_predicts_resistance_to_platinum-based_therapy.		3_prime_UTR_variant	NM_004985.4:c.*2505T>G,NC_000012.11:g.25360224A>C,ENST00000311936.3:c.*2505T>G	30
254	KRAS	3845	RS61764370	Epithelial_Ovarian_Cancer	2152		Carboplatin,Paclitaxel	Substitutes	Predictive	Supports	B	Resistance	The_functional_variant_rs61764370_in_the_KRAS_gene_3'_UTR_(KRAS-variant)_was_found_to_be_correlated_with_platinum-based_chemotherapy_resistance_in_patients_with_Epithelial_Ovarian_Cancer_(EOC)._291_EOC_patients_without_BRCA_mutations_were_used_in_this_study._Furthermore,_the_researchers_tested_a_KRAS-variant_EOC_cell_line_(BG1)_and_found_it_has_much_greater_platinum-based_chemotherapy_resistance_than_a_non-KRAS-variant_cell_line_(CAOV3).	22139083	PubMed	NA	Ratner_et_al.,_2012,_Oncogene		3	accepted	664	30	12	25360224	25360224	A	C	ENST00000311936.3		NA	NA		75	GRCh37	Germline_variant_in_the_3'_UTR_of_KRAS_that_predicts_resistance_to_platinum-based_therapy.	Germline_Polymorphism	2016-02-13_04:02:23_UTC	https://civic.genome.wustl.edu/links/evidence_items/664	https://civic.genome.wustl.edu/links/variants/254	https://civic.genome.wustl.edu/links/genes/30	Germline_variant_in_the_3'_UTR_of_KRAS_that_predicts_resistance_to_platinum-based_therapy.		3_prime_UTR_variant	NM_004985.4:c.*2505T>G,NC_000012.11:g.25360224A>C,ENST00000311936.3:c.*2505T>G	30
258	MTHFR	4524	A222V	Rectum_Cancer	1993		5-fluorouracil		Predictive	Supports	B	Sensitivity/Response	Patients_with_the_wild_type_(C/C)_MTHFR_gene_are_2.91_times_(95%_CI:_[1.23,_6.89])_more_likely_to_have_a_positive_response_to_neoadjuvant_CRT_and__3.25_times_more_likely_not_to_experience_relapse_(95%_CI:_[1.37,_7.72])_than_patients_with_the_heterozygous__MTHFR_[rs1801133_(C>T)]_mutation_or__the_homzygous_(T/T).	26693073	PubMed	NA	Nikas_et_al.,_2015,_Am_J_Cancer_Res		4	accepted	1757	3672	1	11856378	11856378	G	A	ENST00000376592.1		NA	NA		75	GRCh37		Germline_Polymorphism	2017-07-27_16:19:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/1757	https://civic.genome.wustl.edu/links/variants/258	https://civic.genome.wustl.edu/links/genes/3672			missense_variant	NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A	55
258	MTHFR	4524	A222V	Stomach_Cancer	10534		5-fluorouracil		Predictive	Supports	B	Sensitivity/Response	The_MTHFR_C667T_variant_was_associated_with_significantly_lower_relapse-free_survival_and_overall_survival_in_stomach_cancer_patients_treated_with_5-Fluorouracil-based_therapies._116_Chinese_patients_with_histologically_confirmed_gastric_cancer_were_used_in_this_study,_and_all_patients_had_radical_surgery_before_treatment.	18704422	PubMed	NA	Huang_et_al.,_2009,_Cancer_Chemother._Pharmacol.		3	accepted	669	3672	1	11856378	11856378	G	A	ENST00000376592.1		NA	NA		75	GRCh37		Germline_Mutation	2015-12-21_23:56:32_UTC	https://civic.genome.wustl.edu/links/evidence_items/669	https://civic.genome.wustl.edu/links/variants/258	https://civic.genome.wustl.edu/links/genes/3672			missense_variant	NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A	55
259	GSTP1	2950	I105V	Colorectal_Cancer	9256		FolfoxProtocol		Predictive	Supports	B	Sensitivity/Response	Patients_with_the_GSTP1_I105V_variant_had_greater_response_to_FOLFOX-4_treatment,_longer_progression-free_survival,_and_longer_overall_survival._166_Chinese_patients_with_metastatic_colorectal_carcinoma_who_had_been_treated_with_FOLFOX-4_were_used_in_this_study.	19922504	PubMed	NA	Chen_et_al.,_2010,_Cancer_Sci.		4	accepted	670	2473	11	67352689	67352689	A	G	ENST00000398606.3		NA	NA		75	GRCh37		Germline_Mutation	2015-12-21_23:54:27_UTC	https://civic.genome.wustl.edu/links/evidence_items/670	https://civic.genome.wustl.edu/links/variants/259	https://civic.genome.wustl.edu/links/genes/2473			missense_variant	NM_000852.3:c.313A>G,NP_000843.1:p.Ile105Val,ENST00000398606.3:c.313A>G,NC_000011.9:g.67352689A>G	20
261	XRCC1	7515	Q399R	Cervical_Cancer	4362		Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	The_XRCC1_R399Q_variant_was_correlated_with_increased_response_to_platinum-based_neoadjuvant_chemotherapy_in_patients_with_cervical_cancer._Tumor_samples_from_36_patients_with_Stage_IB_or_IIA_bulky_(greater_than_4_cm_in_size)_cervical_carcinomas_were_used_in_this_study.	16875718	PubMed	NA	Chung_et_al.,_2006,_Gynecol._Oncol.		4	accepted	673	6144	19	44055726	44055726	T	C	ENST00000262887.5		NA	NA		75	GRCh37		Germline_Mutation	2017-05-31_15:35:21_UTC	https://civic.genome.wustl.edu/links/evidence_items/673	https://civic.genome.wustl.edu/links/variants/261	https://civic.genome.wustl.edu/links/genes/6144			missense_variant	NM_006297.2:c.1196A>G,NP_006288.2:p.Gln399Arg,NC_000019.9:g.44055726T>C	40
262	ABCB1	5243	S893T	Ovarian_Cancer	2394		Paclitaxel		Predictive	Supports	B	Sensitivity/Response	The_ABCB1_G2677T/A_(S893T,_rs2032582)_homozygous_variant_was_positively_correlated_with_response_to_paclitaxel_treatment_in_ovarian_cancer_patients._51_epithelial_and_2_fallopian_tube_frozen_tumors_were_analyzed_for_this_study.	16467099	PubMed	NA	Gréen_et_al.,_2006,_Clin._Cancer_Res.		3	accepted	674	4244	7	87160618	87160618	A	T	ENST00000265724.3		NA	NA		75	GRCh37		Germline_Mutation	2015-12-22_15:22:19_UTC	https://civic.genome.wustl.edu/links/evidence_items/674	https://civic.genome.wustl.edu/links/variants/262	https://civic.genome.wustl.edu/links/genes/4244			missense_variant	NM_000927.4:c.2677T>A,NP_000918.2:p.Ser893Thr,NC_000007.13:g.87160618A>T,ENST00000265724.3:c.2677T>A	15
263	ABCB1	5243	I1145I	Non-small_Cell_Lung_Carcinoma	3908		Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	The_mutation_at_codon_3435_(C>T)_correlated_with_a_significantly_higher_response_rate_to_platinum-based_chemotherapy_in_patients_with_advanced_non_small_cell_lung_cancer_(NSCLC).__103_Chinese_patients_with_NSCLC_were_evaluated_in_this_study._However,_there_was_not_a_significant_correlation_between_the_mutation_and_overall_survival.	22296372	PubMed	NA	Yan_et_al.,_2011,_Asian_Pac._J._Cancer_Prev.		2	accepted	675	4244	7	87138645	87138645	A	G	ENST00000265724.3		NA	NA		75	GRCh37		Germline_Mutation	2015-12-22_15:23:27_UTC	https://civic.genome.wustl.edu/links/evidence_items/675	https://civic.genome.wustl.edu/links/variants/263	https://civic.genome.wustl.edu/links/genes/4244			synonymous_variant	NM_000927.4:c.3435T>C,NP_000918.2:p.Ile1145=,NC_000007.13:g.87138645A>G,ENST00000265724.3:c.3435T>C	25
264	ERCC2	2068	K751Q	Non-small_Cell_Lung_Carcinoma	3908		Paclitaxel,Carboplatin	Combination	Predictive	Supports	B	Sensitivity/Response	The_ERCC2_K751Q_variant_is_significantly_correlated_with_increased_response_to_paclitaxel_and_carboplatin_therapies_in_non_small_cell_lung_cancer_(NSCLC)._The_researchers_utilized_data_from_three_previous_clinical_trials_in_Japan_and_the_United_States_with_a_total_of_526_NSCLC_patients.	19470925	PubMed	NA	Gandara_et_al.,_2009,_J._Clin._Oncol.		3	accepted	677	1736	19	45854919	45854919	T	G	ENST00000391945.4		NA	NA		75	GRCh37		Germline_Mutation	2015-12-11_21:16:41_UTC	https://civic.genome.wustl.edu/links/evidence_items/677	https://civic.genome.wustl.edu/links/variants/264	https://civic.genome.wustl.edu/links/genes/1736			missense_variant	NC_000019.9:g.45854919T>G	35
264	ERCC2	2068	K751Q	Osteosarcoma	3347		Cisplatin		Predictive	Supports	B	Resistance	The_ERCC2_K751Q_variant_was_significantly_correlated_with_a_lower_response_to_cisplatin_chemotherapy_in_osteosarcoma_patients_and_shorter_event-free_survival._91_osteosarcoma_patients_with_a_median_age_of_15_years_were_followed_in_this_study.	19434073	PubMed	NA	Caronia_et_al.,_2009,_Pharmacogenomics_J.		4	accepted	676	1736	19	45854919	45854919	T	G	ENST00000391945.4		NA	NA		75	GRCh37		Germline_Mutation	2016-10-02_15:11:45_UTC	https://civic.genome.wustl.edu/links/evidence_items/676	https://civic.genome.wustl.edu/links/variants/264	https://civic.genome.wustl.edu/links/genes/1736			missense_variant	NC_000019.9:g.45854919T>G	35
265	TYMS	7298	5'_TANDEM_REPEAT	Colorectal_Cancer	9256		5-fluorouracil,Irinotecan	Combination	Predictive	Supports	B	Resistance	The_TYMS_5'_3TPR_germline_variant_was_significantly_correlated_with_lower_response_to_irinotecan_plus_5-fluorouracil_treatment_in_colorectal_cancer_patients._149_metastatic_CRC_patients_treated_with_irinotecan/5FU_as_first-line_chemotherapy_were_followed_in_this_study.	20628391	PubMed	NA	Martinez-Balibrea_et_al.,_2010,_Br._J._Cancer		3	accepted	678	5971	18	657604	657742			ENST00000323274.10		NA	NA		75	GRCh37		Germline_Mutation	2015-12-11_21:15:59_UTC	https://civic.genome.wustl.edu/links/evidence_items/678	https://civic.genome.wustl.edu/links/variants/265	https://civic.genome.wustl.edu/links/genes/5971			short_tandem_repeat_variation,5_prime_UTR_variant		15
266	LRP1B	53353	EXON_12–22_DELETION	Ovarian_Cancer	2394		Doxorubicin		Predictive	Supports	D	Resistance	A_minimum_common_region_of_deletion_of_0.19Mb,_encompassing_exons_12–22_of_LRP1B4_was_observed_in_4_patients_exhibiting_acquired_treatment_resistance._Transfection_of_mLRP1B4,_a_fully_functional_minigene_of_LRP1B,_in_IGROV1_and_OVCAR4_ovarian_cell_lines_with_low_expression_of_LRP1B4_increased_sensitivity_to_liposomal_doxorubicin_but_not_doxorubicin._siRNA_knockdown_of_LRP1B4_in_JHOS3_and_Kuramochi_ovarian_cancer_cell_lines_decreased_sensitivity_to_liposomal_doxorubicin_but_not_doxorubicin.	22896685	PubMed	NA	Cowin_et_al.,_2012,_Cancer_Res.		3	accepted	679	12146	2	141665446	141777671			ENST00000389484.3		NA	NA		75	GRCh37		Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/679	https://civic.genome.wustl.edu/links/variants/266	https://civic.genome.wustl.edu/links/genes/12146			exon_loss_variant	ENST00000389484.3:c.1790_3520del	3
267	FGFR1	2260	AMPLIFICATION	Non-small_Cell_Lung_Carcinoma	3908		PD173074		Predictive	Supports	D	Sensitivity/Response	Preclinical_study_showing_FGFR1_amplification_in_NSCLC_and_efficacy_of_FGFR-1_inhibition_in_one_amplified_cell_line.	21666749	PubMed	NA	Dutt_et_al.,_2011,_PLoS_ONE		4	accepted	686	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/686	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158
267	FGFR1	2260	AMPLIFICATION	Breast_Cancer	1612		AZD4547		Predictive	Supports	C	Sensitivity/Response	Activity_of_the_FGFR-selective_inhibitor_AZD4547_in_FGFR1-amplified_breast_cancer_and_FGFR2-amplified_gastroesophageal_cancer_was_analyzed_in_this_study._341_patients_with_advanced_cancer_were_screened_by_FISH,_identifying_FGFR1_amplification_in_18%_of_advanced_HER2-negative_breast_cancers_and_FGFR2_amplification_in_9%_of_advanced_gastroesophageal_cancer._1_patient_had_a_confirmed_response_among_8_patients_treated_with_FGFR1-amplified_breast_cancer._In_a_preclinical_model,_FGFR1_amplification_in_breast_cancer_cell_lines_was_less_pronounced_than_FGFR2-amplifications_in_gastroesophageal_cancers,_which_also_had_a_higher_response_rate_in_the_trial,_indicating_that_high_level_amplification_is_associated_with_response_and_less_common_in_FGFR1-amplified_breast_cancer.	27179038	PubMed	NA	Pearson_et_al.,_2016,_Cancer_Discov		2	accepted	1991	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	N/A	2017-07-20_14:39:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/1991	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158
267	FGFR1	2260	AMPLIFICATION	Breast_Cancer	1612		4-hydroxytamoxifen		Predictive	Supports	D	Resistance	FGFR1-amplified_breast_cancer_cell_lines_show_resistance_to_4-hydroxytamoxifen,_which_is_reversed_by_small_interfering_RNA_silencing_of_FGFR1.	20179196	PubMed	NA	Turner_et_al.,_2010,_Cancer_Res.		3	accepted	1105	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	Somatic_Mutation	2016-02-25_19:23:59_UTC	https://civic.genome.wustl.edu/links/evidence_items/1105	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158
267	FGFR1	2260	AMPLIFICATION	Breast_Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	Dovitinib_was_evaluated_in-vitro,_in_xenograft_and_in_a_phase_2_study._Dovitinib_inhibited_proliferation_in_one_FGFR1-_and_one_FGFR2-amplified_breast_cancer_cell_lines_at_higher_IC50_values_than_in_11_nonamplified_cell_lines._Dovitinib_inhibited_tumor_growth_and_caused_regression_in_both_a_FGFR1-_and_FGFR2-amplified_xenograft_model._81_patients_were_enrolled_in_the_trial_and_treated_with_dovitinib._Unconfirmed_response_or_stable_disease_>6_months_was_observed_in_25%_of_FGFR1-amplified/HR-positive_vs._3%_FGFR1-nonamplified/HR-positive_breast_cancer_patientes._When_FGF3_and_FGFR2_amplifications_were_also_assessed,_a_combined_FGF-pathway_amplified_patient_group_had_a_higher_mean_reduction_in_target_lesion_size_than_patients_with_FGF-non-amplified_tumors.	23658459	PubMed	NA	André_et_al.,_2013,_Clin._Cancer_Res.		2	accepted	1604	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	N/A	2016-09-11_13:26:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/1604	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158
267	FGFR1	2260	AMPLIFICATION	Non-small_Cell_Lung_Carcinoma	3908		Dovitinib		Predictive	Supports	B	Sensitivity/Response	Clinical_trial_studied_the_efficacy_of_Dovitinib_on_26_patients_with_FGFR1_amplifications._Objective_response_for_the_cohort_was_11.5%,_disease_control_rate_was_50%._11.5%_of_patients_exhibited_partial_response,_38.5%_exhibited_stable_disease._Median_PFS_was_2.9_months,_median_OS_was_5_months,_this_trend_was_worse_with_increases_in_FGFR1_amplification_above_average.	27315356	PubMed	NA	Lim_et_al.,_2016,_Cancer		2	accepted	3027	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	Somatic_Mutation	2017-07-25_20:12:41_UTC	https://civic.genome.wustl.edu/links/evidence_items/3027	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158
267	FGFR1	2260	AMPLIFICATION	Bone_Ewing's_Sarcoma	3368		Ponatinib		Predictive	Supports	D	Sensitivity/Response	116_Ewing's_sarcoma_tumor_samples_were_analyzed_in_this_study._2_patient's_samples_underwent_whole_genome_sequencing,_tumor_samples_from_51_patients_underwent_exome_sequencing_and_expression_analysis,_63_samples_underwent_FGFR1_copy_number_analysis,_mRNA_analysis_and_IHC._A_FGFR1_N546K_mutation_was_detected_in_one_patient._Gain_of_the_FGFR1_locus_(qPCR)_was_observed_in_13_of_41_patients_(31.7%)_and_Ewing_sarcoma_cell_lines_(A673,_CADO,_SK-NMC,_SK-ES,_and_VH-64)._FGFR1_was_also_highly_expressed_in_Ewing_sarcoma_(mRNA_and_IHC)_and_correlated_with_copy_number._Retroviral_transduction_of_FGFR1_wild-type_or_the_FGFR1_N546K_mutant_into_NIH3T3_cells_led_to_enhanced_proliferation_especially_for_cells_harboring_the_FGFR1_mutation._ShRNA_mediated_knockdown_of_FGFR1_inhibited_growth_of_Ewing_sarcoma_and_other_cancer_cells_(A549_lung_carcinoma_cell_line_or_leukemia_cell_lines_HL60_and_Kasumi)_with_almost_complete_growth_suppression_only_in_the_Ewing_sarcoma_cell_lines_and_knockdown_of_FGFR1_abrogated_growth_of_cell_lines_in_xenograft._Ponatinib_treatment_inhibited_growth_of_Ewing_sarcoma_cell_lines.	26179511	PubMed	NA	Agelopoulos_et_al.,_2015,_Clin._Cancer_Res.		3	accepted	1247	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4,853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	N/A	2016-07-11_04:11:48_UTC	https://civic.genome.wustl.edu/links/evidence_items/1247	https://civic.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_in-vivo)_evidence_suggests_predictive_value_of_FGFR1_amplification_for_treatment_with_FGFR1-inhibitors._4_of_83_cell_lines_exhibited_FGFR1_amplification,"_and_3_of_these_were_highly_sensitive_to_PD173074._This_sensitivity_was_confirmed_in_a_mouse_xenograft._Clinical_trials_are_currently_ongoing.	21160078	PubMed	NA	Weiss_et_al.",_2010,"_Sci_Transl_Med		5	accepted	680	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	Somatic_Mutation	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/680	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
__n=_21_with_FGFR1_amplification_only)_or_FGFR3_mutation_(n=1)_four_(15.4%)_had_a_reduced_tumor_burden._In_total,"_10_of_32_patients_with_breast_cancer_treated_at_doses_>100mg_had_a_best_response_of_SD.	27870574	PubMed	NA	Nogova_et_al.",_2017,"_J._Clin._Oncol.		2	accepted	1909	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		2017-06-13_16:24:18_UTC	https://civic.genome.wustl.edu/links/evidence_items/1909	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_36_patients_were_treated_at_doses_>100mg_and_disease_control_was_achieved_in_50%_of_patients_(4_PR_and_14_SD)_with_6_patients_receiving_treatment_after_16_weeks.	27870574	PubMed	NA	Nogova_et_al.",_2017,"_J._Clin._Oncol.		3	accepted	1908	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	N/A	2018-02-15_13:12:16_UTC	https://civic.genome.wustl.edu/links/evidence_items/1908	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_2012,"_Mol._Cancer_Ther.		3	accepted	1767	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	Somatic_Mutation	2017-01-24_04:47:11_UTC	https://civic.genome.wustl.edu/links/evidence_items/1767	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_2017,"_J._Clin._Oncol.		2	accepted	1911	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).	N/A	2017-06-13_16:23:53_UTC	https://civic.genome.wustl.edu/links/evidence_items/1911	https://civic.genome.wustl.edu/links/variants/267	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_amplifications_are_the_most_common_aberrations_of_the_FGFR_family_in_cancer._One_study_reports_FGFR1_aberrations_in_3.5%_of_4",853_patients_of_which_most_are_FGFR1_amplifications_(Helsten_et._al.,_2016)._Preclinically,_FGFR1_amplifications_have_also_been_shown_to_confer_sensitivity_to_FGFR1_inhibitors_(Weiss_et._al.,"_2010)._Clinical_studies_are_currently_ongoing_(e.g._NCT01004224).		transcript_amplification		158",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_of_which_14_exhibited_ponatinib_sensitivity._This_sensitivity_was_correlated_with_FGFR1_mRNA_and_protein_expression.	24771645	PubMed	NA	Wynes_et_al.",_2014,"_Clin._Cancer_Res.		4	accepted	681	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).	N/A	2016-02-21_16:09:28_UTC	https://civic.genome.wustl.edu/links/evidence_items/681	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).		N/A		46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_rather_than_copy_number_alterations,"_were_predictive_of_response_to_FGFR_inhibitor_BGJ398_in_cell_lines_and_patient_derived_xenografts.	26015511	PubMed	NA	Göke_et_al.",_2015,"_Clin._Cancer_Res.		3	accepted	799	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).	N/A	2016-02-17_19:50:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/799	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).		N/A		46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_PD173074,BGJ398,"AZD4547	Substitutes	Predictive	Supports	D	Sensitivity/Response	Targeting_of_FGFR1_by_RNA_interference_and_small-molecule_inhibitors_(PD173074",_AZD4547,_BGJ398)_revealed_that_the_requirement_for_FGFR1_signaling_in_STS_cells_is_dictated_by_FGFR1_expression_levels,"_and_identified_the_MAPK-ERK1/2_axis_as_critical_FGFR1_effector_pathway.	27535980	PubMed	NA	Chudasama_et_al.",_2017,"_Clin._Cancer_Res.		3	accepted	2915	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).	Somatic_Mutation	2017-11-19_17:38:34_UTC	https://civic.genome.wustl.edu/links/evidence_items/2915	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).		N/A		46",,,,,,,,,,,,,,,,,,,,,,,,,,,
_2015,"_Anticancer_Res.		2	accepted	800	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).	N/A	2016-02-21_17:44:14_UTC	https://civic.genome.wustl.edu/links/evidence_items/800	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).		N/A		46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Dovitinib_Dilactic_Acid_(TKI258_Dilactic_Acid)	Substitutes	Predictive	Supports	D	Sensitivity/Response	One_urothelial_cell_line_(JMSU1)_with_high_expression_of_FGFR1_was_sensitive_to_treatment_with_FGFR_inhibitors__(SU5402","_TKI258_or_PD173074).	21119661	PubMed	NA	Lamont_et_al.",_2011,"_Br._J._Cancer		2	accepted	801	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).	N/A	2016-02-21_17:44:25_UTC	https://civic.genome.wustl.edu/links/evidence_items/801	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).		N/A		46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_HDC9,_HCT116)_were_analyzed._FGFR1_amplification_(24/454,_assessed_by_FISH)_and/or_activated_pFGFR1_protein_(18/99,"_assessed_by_mRNA_in_situ_hybridization)_was_identified_in_primary_CRC_tissue_samples.	24135816	PubMed	NA	Göke_et_al.",_2013,"_Digestion		2	accepted	896	1885	8	38268656	38325363			ENST00000425967.3		NA	NA		75	GRCh37	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).	N/A	2016-02-21_18:50:39_UTC	https://civic.genome.wustl.edu/links/evidence_items/896	https://civic.genome.wustl.edu/links/variants/268	https://civic.genome.wustl.edu/links/genes/1885	FGFR1_high_expression_has_been_reported_in_11.8%_(178_patients)_of_oral_squamous_cell_carcinoma_patients",_and_was_enriched_in_early_stages_(Freier_et._al.,_2007)._Another_study_reports_FGFR1_expression_in_35%_of_primary_HNSSC_(353_patients)_(Göke_et._al.,_2015)._In_both_studies,_FGFR1_gene_amplification_and_expression_do_not_correlate_well_with_about_35%_of_samples_with_FGFR1_amplification_overexpressing_FGFR1_(Göke_et._al.,_2015)._FGFR1_expression_also_correlated_with_sensitivity_to_FGFR1_inhibitors_in_preclinical_models_of_lung_cancer_(Wynes_et._al.,_2014),_HNSSC_(Göke_et._al.,_2015)_and_urothelial_carcinoma_(Lamont_et._al.,"_2011).		N/A		46",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_but_no_clinical_differences_in_outcome_were_associated_with_the_identity_of_the_5'_partner.	25264305	PubMed	NA	Shaw_et_al.",_2014,"_N._Engl._J._Med.		4	accepted	688	4941	6	117609463	117747018			ENST00000368508.3		NA	NA		75	GRCh37	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).	Somatic_Mutation	2015-12-27_21:58:34_UTC	https://civic.genome.wustl.edu/links/evidence_items/688	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).		transcript_fusion		68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_30_patients_were_evaluated_after_crizotinib_treatment_for_stage_IV_NSCLC_confirmed_for_ROS1_rearrangement._On_crizotinib,"_24_of_the_patients_achieved_objective_responses_including_5_complete_responses._Median_progression_free_survival_was_9.1_months_and_all_patients_had__been_pretreated_with_1_or_more_lines_of_chemotherapy.	25667280	PubMed	NA	Mazières_et_al.",_2015,"_J._Clin._Oncol.		3	accepted	1030	4941	6	117609463	117747018			ENST00000368508.3		NA	NA		75	GRCh37	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).	Somatic_Mutation	2016-02-18_17:13:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/1030	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).		transcript_fusion		68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_an_SDC4-ROS1_rearrangement_was_identified_using_comprehensive_genomic_profiling._The_patient_attained_a_decrease_in_RESIST_target_lesions_by_26.8%_(stable_disease);_however,_the_patient_relapsed_4_months_later._This_patient_also_harbored_a_TP53_mutation,"_MCL1_amplification_and_CDKN2A_deletion.	25922291	PubMed	NA	Le_et_al.",_2015,"_Clin_Lung_Cancer		3	accepted	1690	4941	6	117609463	117747018			ENST00000368508.3		NA	NA		75	GRCh37	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).	Somatic_Mutation	2016-11-04_18:22:42_UTC	https://civic.genome.wustl.edu/links/evidence_items/1690	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).		transcript_fusion		68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_including_patients_with_active_central_nervous_system_(CNS)_disease._Here,_we_summarize_the_overall_safety_and_report_the_antitumor_activity_of_entrectinib_in_a_cohort_of_patients_with_tumors_harboring_NTRK1/2/3,_ROS1,_or_ALK_gene_fusions_Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._Notably,"_a_complete_CNS_response_was_achieved_in_a_patient_with_SQSTM1-NTRK1-rearranged_lung_cancer.	28183697	PubMed	NA	Drilon_et_al.",_2017,"_Cancer_Discov		3	accepted	2951	4941	6	117609463	117747018			ENST00000368508.3		NA	NA		75	GRCh37	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).	Somatic_Mutation	2017-04-14_16:36:35_UTC	https://civic.genome.wustl.edu/links/evidence_items/2951	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).		transcript_fusion		68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_which_does_not_distinguish_ROS1-fusion_partner,_was_used_on_the_tissue_microarray_to_determine_ROS1_fusion_status._2_cases_of_ROS1_fusions_were_found._1_case_was_verified_by_RT-PCR_to_be_a_SLC34A2-ROS1_fusion,_but_this_case_was_also_positive_for_BRAF_V600E.__The_second_case_of_ROS1_fusion_was_of_undetermined_fusion_partner,_where_known_ROS1_fusion_parters_SLC34A2,_CD74_and_SDC4_were_tested._This_case_did_not_have_KRAS_or_BRAF_mutations,"_indicating_that_ROS1_fusion_may_act_in_a_small_subset_of_colorectal_cancer_as_a_driver_targetable_by_crizotinib_or_other_inhibitors.	24296758	PubMed	NA	Aisner_et_al.",_2014,"_Mol._Cancer_Res.		2	accepted	1301	4941	6	117609463	117747018			ENST00000368508.3		NA	NA		75	GRCh37	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).	Somatic_Mutation	2016-05-12_21:54:51_UTC	https://civic.genome.wustl.edu/links/evidence_items/1301	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).		transcript_fusion		68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_never-smoker_patient_with_advanced_NSCLC_with_a_ROS1_rearrangement._The_patient_was_treated_with_crizotinib_with_marked_response_at_1_week_and_resolution_of_the_tumor_confirmed_at_8_and_12_weeks_via_CT-scans._It_was_also_demonstrated_that_crizotinib_inhibits_ROS1_phosphorylation_in_HEK_293_cells_transfected_with_a_CD14-ROS1_fusion_gene,"_and_crizotinib_inhibited_growth_in_the_HCC78_cell_line_containing_a_ROS1_rearrangement_to_a_similar_degree_as_ALK-fusion_positive_cell_lines.	22215748	PubMed	NA	Bergethon_et_al.",_2012,"_J._Clin._Oncol.		3	accepted	1443	4941	6	117609463	117747018			ENST00000368508.3		NA	NA		75	GRCh37	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).	Somatic_Mutation	2016-11-04_18:20:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/1443	https://civic.genome.wustl.edu/links/variants/269	https://civic.genome.wustl.edu/links/genes/4941	ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint",_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,"2014).		transcript_fusion		68",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_stage_IIA)_without_EGFR,_KRAS,_or_BRAF_mutations,"_and_no_ALK_gene_rearrangement._CD72-ROS1_was_identified_in_sequencing_after_progression_on_chemotherapy._Crizotinib_at_250_mg_orally_twice_daily_led_to_resolution_of_metastatic_disease._The_patient_remained_disease-free_for_13_months_when_a_CT-scan_showed_a_relapse_with_two_nodules_in_the_right_lower_lobe._Stereotactic_""",26917690,PubMed,,"Subbiah_et_al.,_2016,_Proc._Natl._Acad._Sci._U.S.A.",,1,accepted,1248,4941,6,117609463,117747018,,,ENST00000368508.3,,,,,75,GRCh37,"ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint,_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,2014).",Somatic_Mutation,2016-06-22_19:28:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1248,https://civic.genome.wustl.edu/links/variants/269,https://civic.genome.wustl.edu/links/genes/4941,"ROS1_is_a_receptor_tyrosine_kinase_that_frequently_forms_gene_fusions_in_several_cancer_types._Approximately_2%_of_NSCLC_patients_harbor_a_ROS1_gene_fusion._Several_fusion_partners_have_been_described_with_a_constant_ROS1-breakpoint,_maintaining_the_kinase_domain_(Solomon_B,_2015)._Following_case-studies_and_retrospective_analyses,_an_expansion_cohort_of_a_phase-1_study_showed_clinical_benefit_of_crizotinib_in_ROS1_rearranged_NSCLC._The_benefit_was_independent_of_the_type_of_ROS1-rearrangement_(Shaw_et._al.,2014).",,transcript_fusion,,68,Dasatinib,,,,,,,,,,,,,,,,
MET,4233,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,A_case-study_of_an_ALK-negative_patient_with_MET_amplification_(MET/CEP7_ratio_>5.0)_who_achieved_a_durable_partial_response_to_MET/ALK-inhibitor_crizotinib.,21623265,PubMed,,"Ou_et_al.,_2011,_J_Thorac_Oncol",,3,accepted,735,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/735,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Colorectal_Cancer,9256,,Anti-EGFR_Monoclonal_Antibody,,Predictive,Supports,D,Resistance,"Functional_studies_show_that_MET_activation_confers_resistance_to_anti-EGFR_therapy_both_in_vitro_and_in_vivo._Notably,_in_patient-derived_colorectal_cancer_xenografts,_MET_amplification_correlated_with_resistance_to_EGFR_blockade,_which_could_be_overcome_by_MET_kinase_inhibitors.",23729478,PubMed,,"Bardelli_et_al.,_2013,_Cancer_Discov",,3,accepted,1971,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2017-03-16_10:13:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1971,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Anti-EGFR_Monoclonal_Antibody,,,,,,,
MET,4233,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_two_patients_with_MET_amplification_(MET:CEP7_ratio_≥5)_and_no_concomitant_MET_exon_14_deletion._A_response_to_crizotinib_was_observed_in_both_cases_suggesting_that_MET_amplification_may_predict_response_to_this_drug_even_in_the_absence_of_MET_exon_14_mutations.,27664533,PubMed,,"Caparica_et_al.,_2017,_J_Thorac_Oncol",,2,accepted,1713,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-11-09_17:44:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1713,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Lung_Squamous_Cell_Carcinoma,3907,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_73_year_old_patient_with_advanced_squamous_cell_carcinoma_of_the_lung_that_tested_negative_for_EGFR,_KRAS_and_PIK3CA_mutations_and_ALK_and_ROS1_rearrangements._c-MET_amplification_was_detected_by_FISH._Crizotinib_led_to_a_partial_response.",24192513,PubMed,,"Schwab_et_al.,_2014,_Lung_Cancer",,2,accepted,890,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_18:48:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/890,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Cancer,162,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_59-year-old_white_female_patient_(60_pack-years)_with_a_CUP-syndrome._Molecular_profiling_identified_both_MET_amplification_(16_copies)_and_a_KRAS_G12V_mutation._The_patient_was_treated_with_crizotinib_and_experienced_a_complete_normalization_of_tumor_metabolic_activity_for_more_than_19_months._Other_identified_aberrations_include_CCND1_amplification_(8_copies),_MYC_amplification_(9_copies)_as_well_as_KRAS_G12V,_TP53_R273L_and_CARD11_N184S.",25232318,PubMed,,"Palma_et_al.,_2014,_Case_Rep_Oncol",,3,accepted,1714,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-11-07_20:33:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1714,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Gastric_Adenocarcinoma,3717,,Onartuzumab,,Predictive,Supports,C,Sensitivity/Response,"A_case-study_describing_a_patient_with_MET_polysomy,_MET_over-expression_and_evidence_of_autocrine_HGF-production_(the_growth_factor_ligand_of_MET)._The_patient_initially_achieved_a_complete_response_on_MET-Inhibitor_MetMAb_(Onartuzumab)_for_2_years_and_mixed_response_after_recurrence_with_resistance_in_some_of_the_newly_developing_metastases.",22389872,PubMed,,"Catenacci_et_al.,_2011,_Cancer_Discov",,3,accepted,689,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/689,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Onartuzumab,,,,,,,
MET,4233,AMPLIFICATION,Glioblastoma_Multiforme,3068,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"A_62_year_old_female_was_diagnosed_with_glioblastoma_(GBM)_WHO_grade_4._Treatment_included_radiation,_temozolomide_and_cediranib._MET_amplification_was_found_by_FISH,_and_ALK_and_MET_inhibitor_crizotinib_treatment_was_started._A_40%_reduction_in_size_of_contrast_enhancing_lesion_was_seen._After_6_months,_progressive_disease_was_seen_and_crizotinib_withdrawn._The_authors_state_this_is_a_first_report_of_response_to_prospective_MET_targeted_therapy_in_GBM.",22162573,PubMed,,"Chi_et_al.,_2012,_J._Clin._Oncol.",,3,accepted,1565,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-08-04_15:17:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1565,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Colorectal_Cancer,9256,,"Cetuximab,Crizotinib",Combination,Predictive,Supports,D,Sensitivity/Response,"Functional_studies_show_that_MET_activation_confers_resistance_to_anti-EGFR_therapy_both_in_vitro_and_in_vivo._Notably,_in_patient-derived_colorectal_cancer_xenografts,_MET_amplification_correlated_with_resistance_to_EGFR_blockade,_which_could_be_overcome_by_MET_kinase_inhibitors.",23729478,PubMed,,"Bardelli_et_al.,_2013,_Cancer_Discov",,3,accepted,1979,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2017-03-20_19:27:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1979,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Cetuximab,Crizotinib,,,,,,
MET,4233,AMPLIFICATION,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_MET_amplification_without_high-level_MET/CEP7_ratio,_MET_exon_14_mutation_or_overexpression_who_achieved_rapid_response_to_crizotinib.",26724472,PubMed,,"Zhang_et_al.,_2016,_J_Thorac_Oncol",,2,accepted,836,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-22_20:31:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/836,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,"2_MET_amplified_NSCLC_cell_lines_(EBC-1_and_H1993),_as_well_as_2_EGFR_mutant_and_2_MET_and_EGFR_wild_type_cell_lines_were_treated_with_ALK_and_MET_inhibitor_crizotinib,_and_the_MET_amplified_cells_had_IC50_100_fold_lower_than_the_non_MET_amplified_cell_lines._Both_crizotinib_treatment_and_siRNA_against_MET_increased_apoptotic_markers_in_MET_amplified_cells_but_not_controls,_indicating_that_crizotinib_targeting_of_amplified_MET_was_inducing_the_apoptotic_effects._Tumors_caused_by_MET_amplified_EBC-1_cells_injected_into_mice_were_significantly_inhibited_with_crizotinib_treatment,_while_tumors_from_non-MET_amplified_cells_showed_no_substantial_effect.",21716144,PubMed,,"Tanizaki_et_al.,_2011,_J_Thorac_Oncol",,4,accepted,1566,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_21:56:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1566,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Resistance,"In_this_study_a_gefitinib-sensitive_cell-line_(HCC827),_acquired_gefitinib_resistance_(HCC827_GR)_by_a_focal_amplification_of_MET.__Resistance_was_conferred_by_the_MET_amplification_driving_ERBB3_(HER3)-dependent_activation_of_PI3K.",17463250,PubMed,,"Engelman_et_al.,_2007,_Science",,4,accepted,733,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/733,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Gefitinib,,,,,,,
MET,4233,AMPLIFICATION,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"In_an_evaluation_of_a_patient_with_crizotinib-sensitive_lung_adenocarcinoma,_an_MET-Amplification_was_identified_using_CGP.__The_patient_attained_a_reduction_in_the_target_lesions_by_38.7%,_and_the_patient_maintained_response_for_at_least_5_months_post-treatment.",25922291,PubMed,,"Le_et_al.,_2015,_Clin_Lung_Cancer",,3,accepted,1692,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_21:48:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1692,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,,,,,,,
MET,4233,AMPLIFICATION,Colorectal_Cancer,9256,,"Crizotinib,Vemurafenib",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_BRAF_V600E_mutant_metastatic_colorectal_cancer._Combined_EGFR_and_BRAF_inhibition_(panitumumab_and_vemurafenib)_showed_an_initial_partial_response_for_4_months._Re-biopsy_at_the_time_of_progression_showed_a_MET_amplification_and_overexpression_(IHC,_ISH)_but_no_secondary_mutations_in_candidate_resistance_genes_(EGFR,_KRAS,_NRAS,_MAP2K1)._MET_amplification_was_also_present_in_a_subset_of_tumor_cells_in_the_pretreatment_sample._MET_amplification_was_also_identified_in_3/17_(18%)_chemonaive_BRAF_V600E_colorectal_cancer_tumor_tissues._Overexpression_of_MET_in_a_BRAF_mutant_CRC_cell_line_(WiDr)_confered_resistance_to_combined_vemurafenib_and_panitumumab._The_addition_of_crizotinib_to_this_combination_restored_sensitivity_in_vitro._The_patient_was_started_on_combined_vemurafenib_and_crizotinib_in_January_2016_and_had_a_metabolic,_clinical_and_tumor_marker_response_that_was_ongoing_at_the_time_of_publication_(06/16)_without_significant_toxicity.",27325282,PubMed,,"Pietrantonio_et_al.,_2016,_Cancer_Discov",,4,accepted,1588,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-08-04_15:16:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1588,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Crizotinib,Vemurafenib,,,,,,
MET,4233,AMPLIFICATION,Lung_Adenocarcinoma,3910,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,C,Resistance,"155_patients_with_lung_adenocarcinomas_underwent_rebiopsy_and_genotyping_(EGFR,_AKT1,_BRAF,_ERBB2,_KRAS,_MEK1,_NRAS,_PIK3CA_and_FISH_for_MET_and_HER2)_after_the_development_of_acquired_resistance_to_EGFR_inhibitors_(gefitinib_or_erlotinib)._MET_amplification_was_seen_in_4_of_75_patients_tested_(no_baseline_samples_available)._One_patient_had_small_cell_transformation_and_MET_amplification,_two_patients_had_EGFR_T790M_mutation_and_MET_amplification.",23470965,PubMed,,"Yu_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1392,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-06-27_23:46:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1392,https://civic.genome.wustl.edu/links/variants/270,https://civic.genome.wustl.edu/links/genes/52,,,transcript_amplification,,81.5,Gefitinib,Erlotinib,,,,,,
CDKN2A,1029,p16_EXPRESSION,Oropharynx_Cancer,8557,,Cetuximab,,Predictive,Does_Not_Support,B,Resistance,This_study_shows_that_benefit_of_EGFR_inhibition_in_addition_to_radiotherapy_was_independent_of_p16/HPV_status._182_patients_were_evaluated.,26712222,PubMed,,"Rosenthal_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,759,14,9,21968055,21974865,,,ENST00000498124.1,,,,,75,GRCh37,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",Somatic_Mutation,2016-02-03_21:18:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/759,https://civic.genome.wustl.edu/links/variants/272,https://civic.genome.wustl.edu/links/genes/14,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,,,180,Cetuximab,,,,,,,
CDKN2A,1029,p16_EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Afatinib,,Predictive,Supports,B,Resistance,"Phase_III_trial_to_compare_afatinib_or_metothrexate_in_recurrent_or_metastatic_head_and_neck_squamous_cell_carcinoma._483_patients_were_randomized_to_either_afatinib_(n=322)_or_methotrexate_(n=161)._285_patients_were_assessed_for_p16_Status_(IHC)._In_the_post-hoc_analysis,_benefit_of_afatinib_compared_with_methotrexate_was_more_pronounced_in_p16-negative_disease_(HR_0·69_[95%_CI_0·50–0·96],_p=0.022)_than_in_p16-positive_disease_(HR_0·95_[CI_0·51–1·75],_p=0.67,_interaction_test_p=0·32).",25892145,PubMed,,"Machiels_et_al.,_2015,_Lancet_Oncol.",,2,accepted,1155,14,9,21968055,21974865,,,ENST00000498124.1,,,,,75,GRCh37,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,2016-05-08_16:06:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1155,https://civic.genome.wustl.edu/links/variants/272,https://civic.genome.wustl.edu/links/genes/14,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,,,180,Afatinib,,,,,,,
CDKN2A,1029,p16_EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Cetuximab,,Predictive,Does_Not_Support,B,Resistance,"In_this_study_response_to_EGFR-inhibition_by_cetuximab_was_independent_of_HPV-status,_represented_by_expression_of_p16_(CDKN2A,_an_established_biomarker_of_HPV_infection)._Expression_of_p16_was_assayed_in_69_HNSCC_patients_by_IHC.",24577089,PubMed,,"Pogorzelski_et_al.,_2014,_Cell_Death_Dis",,4,accepted,697,14,9,21968055,21974865,,,ENST00000498124.1,,,,,75,GRCh37,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",Somatic_Mutation,2016-01-31_16:44:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/697,https://civic.genome.wustl.edu/links/variants/272,https://civic.genome.wustl.edu/links/genes/14,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,,,180,Cetuximab,,,,,,,
CDKN2A,1029,p16_EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Panitumumab,,Predictive,Supports,B,Resistance,"In_this_retrospective_analysis_of_p16_status_as_surrogate_marker_for_HPV_in_the_SPECTRUM_trial,_p16_(CDKN2A)_expression_was_not_associated_with_improved_response_to_EGFR-directed_therapy_(Panitumumab)_in_combination_with_chemotherapy_compared_to_chemotherapy_alone.",23746666,PubMed,,"Vermorken_et_al.,_2013,_Lancet_Oncol.",,3,accepted,696,14,9,21968055,21974865,,,ENST00000498124.1,,,,,75,GRCh37,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",Somatic_Mutation,2015-12-29_18:03:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/696,https://civic.genome.wustl.edu/links/variants/272,https://civic.genome.wustl.edu/links/genes/14,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,,,180,Panitumumab,,,,,,,
CDKN2A,1029,p16_EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,EGFR_Inhibitor,,Predictive,Does_Not_Support,B,Resistance,"In_this_retrospective_analysis_of_the_SPECTRUM_trial,_p16_(CDKN2A)_expression_(and_HPV-infection)_was_not_predictive_of_response_to_EGFR-targeted_therapy_in_combination_with_chemotherapy_(n_=_416_patient_tumors).",24577117,PubMed,,"Vermorken_et_al.,_2014,_Ann._Oncol.",,3,accepted,694,14,9,21968055,21974865,,,ENST00000498124.1,,,,,75,GRCh37,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",Somatic_Mutation,2015-12-28_19:14:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/694,https://civic.genome.wustl.edu/links/variants/272,https://civic.genome.wustl.edu/links/genes/14,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,,,180,EGFR_Inhibitor,,,,,,,
CDKN2A,1029,p16_EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Panitumumab,,Predictive,Supports,B,Sensitivity/Response,p16-negative_patients_(HPV_negative)_have_a_longer_overall_survival_under_panitumumab/chemotherapy_in_comparison_to_chemotherapy_alone.,23746666,PubMed,,"Vermorken_et_al.,_2013,_Lancet_Oncol.",,3,accepted,753,14,9,21968055,21974865,,,ENST00000498124.1,,,,,75,GRCh37,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",Somatic_Mutation,2015-12-29_18:04:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/753,https://civic.genome.wustl.edu/links/variants/272,https://civic.genome.wustl.edu/links/genes/14,"CDKN2A_(p16)_expression_is_a_surrogate_marker_of_HPV_infection_in_oropharyngeal_squamous_cell_carcinoma._CDKN2A_and_p53_are_inactivated_through_HPV_proteins_E6_and_E7_and_therefore_not_altered_in_expression_level_in_HPV-associated_carcinomas._However,_there_is_no_perfect_overlap_between_p16_expression_and_HPV_status_with_some_10-12.5%_of_HPV-negative_tumors_expressing_p16._(Seiwert,_T_JCO,_2014)._p16_positivity_is_a_well-established_positive_prognostic_factor_in_squamous_cell_cancer_of_the_head_and_neck_in_the_primary_and,_as_increasing_evidence_suggests,_recurrent/metastatic_disease_settings._Predictive_information_from_HPV_status_have_not_been_established_to_date._A_lack_of_benefit_from_EGFR-inhibitors_has_been_proposed_by_some_studies._Other_studies_were_not_able_to_reproduce_this_finding.",,,,180,Panitumumab,,,,,,,
RET,5979,KIF5B-RET,Lung_Adenocarcinoma,3910,,"Vandetanib,Everolimus",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_74-year_old_woman_with_EGFR-_and_ALK-negative_lung_adenocarcinoma._FISH_identified_a_deletion_of_5'RET_(FISH,_indicating_RET-gene_rearrangement)_and_genomic_testing_confirmed_a_fusion_of_KIF5B_and_RET._The_patient_was_enrolled_in_a_clinical_trial_with_vandetanib_and_everolimus_(NCT01582191)_with_everolimus_used_to_enhance_brain_accumulation_of_vandetanib._After_two_cycles_of_therapy_a_repeat_MRI_brain_showed_a_decrease_in_the_intracranial_disease_burden_and_PET/CT_showed_systemic_response_as_well.",25982012,PubMed,,"Subbiah_et_al.,_2015,_Lung_Cancer",,2,accepted,1622,42,10,32306071,32345359,,,ENST00000302418.4,10,43609928,43625799,ENST00000355710.3,75,GRCh37,"In_a_study_by_Takeuchi_et._al._a_fusion_screen_was_performed_in_1529_lung_cancer_samples._14_adenocarcinomas_with_KIF5B-RET_and_CCDC6-RET_fusions_were_identified._(Takeuchi_K_et._al.,_2012)",,2016-11-05_22:35:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1622,https://civic.genome.wustl.edu/links/variants/273,https://civic.genome.wustl.edu/links/genes/42,"In_a_study_by_Takeuchi_et._al._a_fusion_screen_was_performed_in_1529_lung_cancer_samples._14_adenocarcinomas_with_KIF5B-RET_and_CCDC6-RET_fusions_were_identified._(Takeuchi_K_et._al.,_2012)",,transcript_fusion,,10,Vandetanib,Everolimus,,,,,,
RET,5979,KIF5B-RET,Lung_Adenocarcinoma,3910,,Vandetanib,,Predictive,Supports,C,Sensitivity/Response,"A_case_study_of_a_patient_with_EGFR,_KRAS,_BRAF,_HER2,_ALK,_ROS1_and_MET_negative_adenocarcinoma_of_the_lung._FISH_analysis_revealed_a_KIF5B-RET_fusion._The_RET_inhibitor_Vandetanib_led_to_remission_in_the_patient.",23584301,PubMed,,"Gautschi_et_al.,_2013,_J_Thorac_Oncol",,2,accepted,698,42,10,32306071,32345359,,,ENST00000302418.4,10,43609928,43625799,ENST00000355710.3,75,GRCh37,"In_a_study_by_Takeuchi_et._al._a_fusion_screen_was_performed_in_1529_lung_cancer_samples._14_adenocarcinomas_with_KIF5B-RET_and_CCDC6-RET_fusions_were_identified._(Takeuchi_K_et._al.,_2012)",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/698,https://civic.genome.wustl.edu/links/variants/273,https://civic.genome.wustl.edu/links/genes/42,"In_a_study_by_Takeuchi_et._al._a_fusion_screen_was_performed_in_1529_lung_cancer_samples._14_adenocarcinomas_with_KIF5B-RET_and_CCDC6-RET_fusions_were_identified._(Takeuchi_K_et._al.,_2012)",,transcript_fusion,,10,Vandetanib,,,,,,,
HRAS,3265,G13D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_Colo-320,_SW48,_and_CaCO2_cell_lines_expressing_HRAS_G13D_mutation_were_associated_with_resistance_to_cetuximab_treatment,_as_compared_to_Colo-320,_SW48,_and_CaCO2_cells_expressing_wild-type_HRAS.",26561417,PubMed,,"Boidot_et_al.,_2016,_Int_J_Colorectal_Dis",,,accepted,3852,2747,11,534285,534285,C,T,ENST00000451590.1,,,,,75,GRCh37,,Somatic_Mutation,2017-06-10_00:20:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/3852,https://civic.genome.wustl.edu/links/variants/274,https://civic.genome.wustl.edu/links/genes/2747,,,missense_variant,"NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A",7.5,Cetuximab,,,,,chr11_g.534285C~T,HRAS_c.38G~A,HRAS_G13D
HRAS,3265,G13D,Colorectal_Cancer,9256,,EGFR_Inhibitor,,Predictive,Supports,C,Resistance,Case_report_of_a_patient_with_metastatic_colorectal_carcinoma_and_a_novel_HRAS_G13D_mutation_showed_resistance_to_treatment_with_panitumumab._In_vitro_models_of_HRAS_G13D_confirmed_resistance_mechanism_in_the_same_study.,26561417,PubMed,,"Boidot_et_al.,_2016,_Int_J_Colorectal_Dis",,3,accepted,699,2747,11,534285,534285,C,T,ENST00000451590.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/699,https://civic.genome.wustl.edu/links/variants/274,https://civic.genome.wustl.edu/links/genes/2747,,,missense_variant,"NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A",7.5,EGFR_Inhibitor,,,,,chr11_g.534285C~T,HRAS_c.38G~A,HRAS_G13D
HRAS,3265,G13D,Skin_Squamous_Cell_Carcinoma,3151,,Vemurafenib,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_23_patients_with_BRAF_V600_mutation_(a_known_vemurafenib_sensitizing_mutation)_that_developed_cutaneous_squamous-cell_carcinoma_upon_treatment_with_vemurafenib_monotherapy,_a_patient_harboring_HRAS_G13D_co-mutation_(n=1)_was_reported_to_be_resistant_to_vemurafenib_treatment.",22256804,PubMed,,"Su_et_al.,_2012,_N._Engl._J._Med.",,,accepted,3851,2747,11,534285,534285,C,T,ENST00000451590.1,,,,,75,GRCh37,,Somatic_Mutation,2017-06-10_13:12:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/3851,https://civic.genome.wustl.edu/links/variants/274,https://civic.genome.wustl.edu/links/genes/2747,,,missense_variant,"NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A",7.5,Vemurafenib,,,,,chr11_g.534285C~T,HRAS_c.38G~A,HRAS_G13D
HRAS,3265,MUTATION,Cancer,162,,"Binimetinib_(MEK162),PD0325901,Everolimus,Selumetinib_(AZD6244),AZD8055",Substitutes,Predictive,Supports,D,Sensitivity/Response,"A_pre-clinical_study_in_10_solid_cancer_cell_lines._HRAS_mutations_(Q61L,_Q61R_and_G12V)_sensitized_cell_lines_toward_MEK_inhibitors_(AZD6244/selumetinib,_MEK162_and_PD0325901)_and_mTOR_inhibitors_(Everolimus_and_AZD8055).",26544513,PubMed,,"Kiessling_et_al.,_2015,_Oncotarget",,3,accepted,700,2747,11,533873,534289,,,ENST00000451590.1,,,,,75,GRCh37,,Somatic_Mutation,2016-07-17_21:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/700,https://civic.genome.wustl.edu/links/variants/275,https://civic.genome.wustl.edu/links/genes/2747,,,coding_transcript_variant,,3,Binimetinib_(MEK162),PD0325901,Everolimus,Selumetinib_(AZD6244),AZD8055,,,
CD274,29126,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Pembrolizumab,,Predictive,Supports,B,Sensitivity/Response,PD-L1_expression_in_at_least_50%_of_tumor_cells_correlated_with_improved_efficacy_of_pembrolizumab.,25891174,PubMed,,"Garon_et_al.,_2015,_N._Engl._J._Med.",NCT01295827,4,accepted,5811,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_18:57:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/5811,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Pembrolizumab,,,,,,,
CD274,29126,EXPRESSION,Melanoma,1909,,"Ipilimumab,Nivolumab",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"A_clinical_trial_of_86_patients_evaluated_concurrent_(n=53)_or_sequential_(n=33)_treatment_of_ipilimumab_(anti-CTLA4)_and_nivolumab_(anti-PD1)._In_the_concurrent_regimen_cohort,_65%_of_patients_showed_clinical_activity_with_no_correlation_between_PD-L1_expression_and_response_(6_of_13_patients_were_PD-L1_positive_versus_9_of_22_patients_were_PD-L1_negative)._In_the_sequential_regimen_cohort,_20%_of_patients_had_an_objective_response_with_a_potential_correlation_between_PD-L1_expression_and_response_(4_of_8_patients_were_PD-L1_positive_versus_1_of_13_patients_were_PD-L1_negative).",23724867,PubMed,,"Wolchok_et_al.,_2013,_N._Engl._J._Med.",,3,accepted,1615,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,Somatic_Mutation,2016-09-10_18:29:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1615,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Ipilimumab,Nivolumab,,,,,,
CD274,29126,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Pembrolizumab,,Predictive,Supports,B,Sensitivity/Response,"This_open-label,_randomized,_phase-3_clinical_trial_compared_pembrolizumab_to_chemotherapy_in_treating_NSCLC_patients_with_PD-L1_expression_on_at_least_50%_of_tumor_cells_and_no_sensitizing_mutation_of_EGFR_or_translocation_of_ALK._Patients_in_the_pembrolizumab_group_exhibited_significantly_better_progression-free_survival_and_overall_survival_compared_to_patients_in_the_chemotherapy_group.",27718847,PubMed,,"Reck_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,1733,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2016-11-07_18:20:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1733,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Pembrolizumab,,,,,,,
CD274,29126,EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Radiation,,Predictive,Supports,B,Resistance,"Radiation-resistant_cell_lines_exhibited_upregulation_and_increased_activation_of_Axl,_PI3_kinase_signalling_as_well_as_increased_expression_of_PD-L1._In_3_cohorts_of_HPV-negative_head_and_neck_squamous_cell_carcinoma_patient_samples_evaluated_with_different_methods_[reverse_phase_protein_array_(N=68),_mRNA_expression_array_(N=97)_or_immunohistochemistry_(N=114),_respectively],_increased_expression_of_PD-L1_was_also_correlated_with_local_failure_following_radiotherapy_as_compared_to_the_PD-L1–low_expression_group_(P_=_0.01,_1.9_×_10−3,_and_9_×_10−4,_respectively).",28476872,PubMed,,"Skinner_et_al.,_2017,_Clin._Cancer_Res.",,4,accepted,3000,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2017-09-09_23:07:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/3000,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Radiation,,,,,,,
CD274,29126,EXPRESSION,Merkel_Cell_Carcinoma,3965,,Pembrolizumab,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Patients_with_Merkel_Cell_Carcinoma_(n=26)_were_enrolled_to_receive_pembrolizumab._Of_these_patients,_25_were_evaluated_for_response_rate_to_pembrolizumab_and_PD-L1_(CD274)_expression.__The_response_rate_to_pembrolizumab_was_56%_(95%CI:_35-76%),_however,_there_was_no_correlation_between_PD-L1_expression_(cutoff_>1%)_on_tumor_cells_or_on_infiltrating_immune_cells_and_clinical_response_to_pembrolizumab_(P=0.61).",27093365,PubMed,,"Nghiem_et_al.,_2016,_N._Engl._J._Med.",,2,accepted,1578,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,Somatic_Mutation,2016-08-02_15:55:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1578,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Pembrolizumab,,,,,,,
CD274,29126,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Atezolizumab,,Predictive,Supports,B,Sensitivity/Response,"Exploratory_biomarker_analysis_from_a_phase-II_randomized_trial_comparing_atezolizumab_(PD-L1)_and_docetaxel_in_previously_treated,_advanced_or_metastatic_non-small_cell_lung_cancer._Baseline_PD-L1_expression_(IHC)_was_assessed_in_tumour_cells_(as_percentage_of_PD-L1-expressing_tumour_cells_TC3≥50%,_TC2≥5%_and_<50%,_TC1≥1%_and_<5%,_and_TC0<1%)_and_tumour-infiltrating_immune_cells_(as_percentage_of_tumour_area:_IC3≥10%,_IC2≥5%_and_<10%,_IC1≥1%_and_<5%,_and_IC0<1%)._Increasing_PD-L1_Expression_was_associated_with_improved_overall_survival_(TC3_or_IC3_HR_0·49_[0·22-1·07;_p=0·068],_TC2/3_or_IC2/3_HR_0·54_[0·33-0·89;_p=0·014],_TC1/2/3_or_IC1/2/3_HR_0·59_[0·40-0·85;_p=0·005],_TC0_and_IC0_HR_1·04_[0·62-1·75;_p=0·871])_but_not_progression_free_survival_or_overall_response_rate.",26970723,PubMed,,"Fehrenbacher_et_al.,_2016,_Lancet",,4,accepted,1172,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2016-03-26_15:41:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1172,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Atezolizumab,,,,,,,
CD274,29126,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Pembrolizumab,Atezolizumab,Nivolumab,Avelumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"Meta-Analysis_of_PD-L1_(CD274)_Expression_Status_in_914_patients_(7_studies)_and_response_to_PD-1/PD-L1_monoclonal_antibodies._Patients_with_PD-L1_positive_tumors_(PD-L1_tumor_cell_staining_≥1%),_had_a_significantly_higher_ORR,_compared_to_patients_with_PD-L1_negative_tumors_(OR:_2.44;_95%_CIs:_1.61-3.68).",26918451,PubMed,,"Passiglia_et_al.,_2016,_Oncotarget",,4,accepted,1167,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2016-06-20_20:51:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1167,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Pembrolizumab,Atezolizumab,Nivolumab,Avelumab,,,,
CD274,29126,EXPRESSION,Cancer,162,,Nivolumab,,Predictive,Supports,B,Sensitivity/Response,"Trial_NCT00730639_tested_monoclonal_antibody_nivolumab_against_the_PD-1_immune_checkpoint_receptor_in_pretreated_patients_with_various_cancer_types._PD-L1_expression_was_tested_in_42_patients_by_ICH_from_tumor_FFPE_biopsies._(18_melanoma,_10_NSCLC,_7_colorectal_cancer,_5_renal_cell_cancer,_2_prostate_cancer)._9_of_25_PD-L1_expressing_patients_showed_objective_response,_and_zero_of_17_PD-L1_negative_patients_showed_objective_response_(p=0.006)._Biopsies_were_optional,_and_therefore_not_fully_randomized.",22658127,PubMed,,"Topalian_et_al.,_2012,_N._Engl._J._Med.",,2,accepted,1517,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-16_15:44:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1517,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Nivolumab,,,,,,,
CD274,29126,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Nivolumab,Pembrolizumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"Based_on_a_meta-analysis_of_20_trials_(1475_patients),_PD-L1_expression_was_associated_with_a_higher_ORR_rate_in_patients_with_NSCLC._Active_drugs_were_Nivolumab_and_Pembrolizumab,_PD-1_receptor_targeting_antibodies.",26086854,PubMed,,"Carbognin_et_al.,_2015,_PLoS_ONE",,4,accepted,743,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2016-02-13_05:27:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/743,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Nivolumab,Pembrolizumab,,,,,,
CD274,29126,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Nivolumab,Pembrolizumab,Atezolizumab,Avelumab,Durvalumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_this_meta-analysis_of_14_studies_with_2857_patients,_the_immunotherapy_response_rate_was_higher_among_PD-L1-positive_patients_(RR:_2.19,_95%_CI:_1.63-2.94)._PD-L1_expression_was_also_related_to_better_progression-free_survival_(HR:_0.69,_95%_CI:_0.57-0.85)_and_better_overall_survival_(HR:_0.77,_95%_CI:_0.67-0.89).",28472902,PubMed,,"Aguiar_et_al.,_2017,_Immunotherapy",,4,accepted,4857,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2017-06-29_15:55:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/4857,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Nivolumab,Pembrolizumab,Atezolizumab,Avelumab,Durvalumab,,,
CD274,29126,EXPRESSION,Melanoma,1909,,"Nivolumab,Pembrolizumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"Based_on_a_meta-analysis_of_20_trials_(1475_patients),_of_which_7_studies_(636_patients)_included_melanoma,_PD-L1_expression_was_associated_with_a_higher_ORR_rate_in_patients_with_melanoma._Active_drugs_were_Nivolumab_and_Pembrolizumab,_PD-1_receptor_targeting_antibodies.",26086854,PubMed,,"Carbognin_et_al.,_2015,_PLoS_ONE",,4,accepted,704,11335,9,5450525,5470547,,,ENST00000381577.3,,,,,75,GRCh37,,,2016-02-13_05:32:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/704,https://civic.genome.wustl.edu/links/variants/276,https://civic.genome.wustl.edu/links/genes/11335,,,,,335,Nivolumab,Pembrolizumab,,,,,,
MTOR,2475,MUTATION,Bladder_Carcinoma,4007,,"Everolimus,Pazopanib",Combination,Predictive,Supports,C,Sensitivity/Response,A_case-study_of_a_patient_with_urothelial_carcinoma_reported_exceptional_response_(14_months)_in_a_phase_1_study_of_Everolimus_and_Pazopanib._Mutations_E2014K_and_E2419K_were_shown_to_be_activating_in-vitro.,24625776,PubMed,,"Wagle_et_al.,_2014,_Cancer_Discov",,3,accepted,705,2073,1,11166592,11322564,,,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/705,https://civic.genome.wustl.edu/links/variants/277,https://civic.genome.wustl.edu/links/genes/2073,,,protein_altering_variant,,22.5,Everolimus,Pazopanib,,,,,,
AKT2,208,EXPRESSION,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,B,Sensitivity/Response,"In_HER2+_metastatic_breast_cancer_treated_with_trastuzumab_(n_=_74_patients),_the_expression_of_AKT2_and_pAkt-Thr308_and/or_pAkt-Ser473_localized_in_nucleus+cytoplasm_was_associated_with_an_improved_time_to_progression_(TTP)_and_overall_survival_(OS)_compared_to_AKT2_negative_tumors_as_measured_by_immunohistochemistry.",22842582,PubMed,,"Grell_et_al.,_2012,_Int._J._Oncol.",,3,accepted,706,254,19,40736224,40791302,,,ENST00000392038.2,,,,,75,GRCh37,,Somatic_Mutation,2018-04-11_12:29:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/706,https://civic.genome.wustl.edu/links/variants/278,https://civic.genome.wustl.edu/links/genes/254,,,,,15,Trastuzumab,,,,,,,
NF2,4771,K159FS*16,Breast_Cancer,1612,,Temsirolimus,,Predictive,Supports,C,Sensitivity/Response,23_patients_were_treated_with_temsirolimus_containing_regimens._1_patient_with_a_complete_response_>3_years_had_a_K159fs*16_mutation_in_NF2._2_patients_were_tested_for_NF2_mutations.,25878190,PubMed,,"Moulder_et_al.,_2015,_Ann._Oncol.",,3,accepted,715,3870,22,30050673,30050675,,,ENST00000338641.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/715,https://civic.genome.wustl.edu/links/variants/279,https://civic.genome.wustl.edu/links/genes/3870,,,frameshift_truncation,,7.5,Temsirolimus,,,,,,,
FBXW7,55294,MUTATION,Cancer,162,,MTOR_Inhibitors,,Predictive,Supports,B,Sensitivity/Response,"418_patients_with_advanced_cancer_were_screened_for_FBXW7_mutations_using_a_multiplex_gene_panel._17_FBXW7_mutations_were_detected_(isolated_mutation_in_2_patients)._Ten_patients_were_treated_with_an_mTOR_inhibitor_with_7_patients_having_stable_disease_as_best_responses_and_a_median_time_to_treatment_failure_of_2.8_months,_two_patients_had_prolonged_stable_disease_of_>16_weeks.",24586741,PubMed,,"Jardim_et_al.,_2014,_PLoS_ONE",,2,accepted,1631,12903,4,153245446,153332714,,,ENST00000281708.4,,,,,75,GRCh37,,Somatic_Mutation,2016-09-11_13:36:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1631,https://civic.genome.wustl.edu/links/variants/281,https://civic.genome.wustl.edu/links/genes/12903,,,"loss_of_function_variant,protein_altering_variant",,20,MTOR_Inhibitors,,,,,,,
FBXW7,55294,MUTATION,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Supports,B,Resistance,65_patients_were_retrospectively_analyzed_for_mutational_profiles_predictive_of_response_to_EGFR-inhibitors_(cetuximab_or_panitumumab)._FBXW7_mutation_was_found_to_be_more_prevalent_in_non-responders_(5_mutations)_than_responders_(1_mutation).,26508446,PubMed,,"Lupini_et_al.,_2015,_BMC_Cancer",,2,accepted,718,12903,4,153245446,153332714,,,ENST00000281708.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-19_22:46:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/718,https://civic.genome.wustl.edu/links/variants/281,https://civic.genome.wustl.edu/links/genes/12903,,,"loss_of_function_variant,protein_altering_variant",,20,Panitumumab,Cetuximab,,,,,,
SMAD4,4089,UNDEREXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Cetuximab,,Predictive,Supports,D,Resistance,"In_this_study,_SMAD4_underexpression_was_associated_with_an_epithelial-to-mesenchymal_transition_and_resistance_to_EGFR-directed_treatment_with_Cetuximab.",26046389,PubMed,,"Cheng_et_al.,_2015,_Cancer_Biol._Ther.",,3,accepted,720,77,18,48556583,48611409,,,ENST00000342988.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/720,https://civic.genome.wustl.edu/links/variants/282,https://civic.genome.wustl.edu/links/genes/77,,,,,3,Cetuximab,,,,,,,
MTOR,2475,H1968Y,Melanoma,1909,,"LY294002,AZD5363",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_a_cell_line_(HEK293T)_with_expression_of_H1968Y_or_P2213S_mTOR_mutations,_LY294002_and_AZD5363_were_more_effective_than_temsirolimus_or_BYL719_in_suppressing_cell_growth.",26490311,PubMed,,"Kong_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,713,2073,1,11188519,11188519,G,A,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/713,https://civic.genome.wustl.edu/links/variants/283,https://civic.genome.wustl.edu/links/genes/2073,,,"gain_of_function_variant,missense_variant","ENST00000361445.4:c.5902C>T,NC_000001.10:g.11188519G>A,NM_004958.3:c.5902C>T,NP_004949.1:p.His1968Tyr",3,LY294002,AZD5363,,,,chr1_g.11188519G~A,MTOR_c.5902C~T,MTOR_H1968Y
MTOR,2475,P2213S,Melanoma,1909,,"LY294002,AZD5363",Combination,Predictive,Supports,D,Sensitivity/Response,"In_a_cell_line_(HEK293T)_with_expression_of_H1968Y_or_P2213S_mTOR_mutations,_LY294002_and_AZD5363_were_more_effective_than_temsirolimus_or_BYL719_in_suppressing_cell_growth.",26490311,PubMed,,"Kong_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,722,2073,1,11184580,11184580,G,A,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/722,https://civic.genome.wustl.edu/links/variants/284,https://civic.genome.wustl.edu/links/genes/2073,,,"gain_of_function_variant,missense_variant","ENST00000361445.4:c.6637C>T,NC_000001.10:g.11184580G>A,NM_004958.3:c.6637C>T,NP_004949.1:p.Pro2213Ser",3,LY294002,AZD5363,,,,chr1_g.11184580G~A,MTOR_c.6637C~T,MTOR_P2213S
BRAF,673,AGK-BRAF,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,A_melanoma_cell_line_with_AGK-BRAF_in-frame_fusion_showed_decreased_sensitivity_towards_Vemurafenib_in_comparison_with_BRAF_mutated_(V600E)_cell_lines.,23890088,PubMed,,"Botton_et_al.,_2013,_Pigment_Cell_Melanoma_Res",,2,accepted,724,5,7,141250989,141255367,,,ENST00000355413.4,7,140434279,140494267,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/724,https://civic.genome.wustl.edu/links/variants/285,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,7,Vemurafenib,,,,,,,
BRAF,673,AGK-BRAF,Melanoma,1909,,Sorafenib,,Predictive,Supports,C,Sensitivity/Response,BRAF_fusion_AGK-BRAF_was_associated_with_decreased_sensitivity_to_vemurafenib_and_increased_sensitivity_to_sorafenib_in-vitro._A_single_patient_with_this_fusion_showed_durable_response_to_sorafenib.,23890088,PubMed,,"Botton_et_al.,_2013,_Pigment_Cell_Melanoma_Res",,2,accepted,723,5,7,141250989,141255367,,,ENST00000355413.4,7,140434279,140494267,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-07-11_04:13:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/723,https://civic.genome.wustl.edu/links/variants/285,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,7,Sorafenib,,,,,,,
BRAF,673,PAPSS1-BRAF,Melanoma,1909,,Trametinib,,Predictive,Supports,D,Sensitivity/Response,"BRAF-fusion_in_""pan-negative""_melanomas_were_identified_in_TCGA_data._Cell-lines_with_a_PAPSS1-BRAF_fusion_were_resistant_to_treatment_with_Vemurafenib_but_sensitive_to_treatment_with_Trametinib._This_fusion_is_believed_to_activate_MAPK_pathway_signaling.",24345920,PubMed,,"Hutchinson_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,726,5,4,108603171,108641608,,,ENST00000265174.4,7,140434279,140487384,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/726,https://civic.genome.wustl.edu/links/variants/286,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,"transcript_fusion,gene_fusion",,6,Trametinib,,,,,,,
BRAF,673,PAPSS1-BRAF,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"BRAF-fusion_in_""pan-negative""_melanomas_were_identified_in_TCGA_data._Cell-lines_with_PAPSS1-BRAF_fusion_were_resistant_to_treatment_with_Vemurafenib.",24345920,PubMed,,"Hutchinson_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,725,5,4,108603171,108641608,,,ENST00000265174.4,7,140434279,140487384,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/725,https://civic.genome.wustl.edu/links/variants/286,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,"transcript_fusion,gene_fusion",,6,Vemurafenib,,,,,,,
BRAF,673,TRIM24-BRAF,Melanoma,1909,,Trametinib,,Predictive,Supports,D,Sensitivity/Response,"A_TRIM24-BRAF_fusion_was_identified_in_a_single_patient_with_metastatic_melanoma_that_was_""pan-negative""_for_driver_mutations._A_cell-line_(293H)_ectopically_expressing_the_TRIM24-BRAF_fusion_was_found_to_be_sensitive_to_the_MEK-inhibitor_Trametinib.",24345920,PubMed,,"Hutchinson_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,727,5,7,138145079,138239711,,,ENST00000343526.4,7,140434279,140487384,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-02-18_22:06:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/727,https://civic.genome.wustl.edu/links/variants/287,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,6,Trametinib,,,,,,,
BRAF,673,TRIM24-BRAF,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,D,Resistance,Foundation_One_NGS_assay_and_targeted_RNAseq_identified_PAPSS1-BRAF_fusion_in_a_melanoma_sample._Further_BRAF_fusions_(TRIM24-BRAF)_were_identified_in_TCGA_and_additional_samples._Ectopic_expression_of_engineered_cDNA_in_293H_cells_showed_that_trametinib_led_to_reduced_ERK1/2_phosphorylation_in_fusion_positive_cells_whereas_vemurafenib_was_not_effective.,24345920,PubMed,,"Hutchinson_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1416,5,7,138145079,138239711,,,ENST00000343526.4,7,140434279,140487384,ENST00000288602.6,75,GRCh37,,,2016-07-10_21:20:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1416,https://civic.genome.wustl.edu/links/variants/287,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,6,Vemurafenib,,,,,,,
BRAF,673,L597R,Skin_Melanoma,8923,,"Vemurafenib,Trametinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_293H_cell_line._Ectopic_expression_of_V600E,_L597R/Q/S,_and_K601E_mutants_elevated_phospho-MEK_and_ERK_levels._Vemurafenib_treatment_of_all_of_the_BRAF_mutant–expressing_cells_led_to_a_decrease_in_phospho-MEK_and_ERK_protein_levels._Treatment_with_MEK_inhibitor_GSK1120212_led_to_a_more_dramatic_decrease_in_phospho-ERK_signaling.",22798288,PubMed,,"Dahlman_et_al.,_2012,_Cancer_Discov",,2,accepted,1458,5,7,140453145,140453145,A,C,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-10-20_04:02:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1458,https://civic.genome.wustl.edu/links/variants/288,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G",12,Vemurafenib,Trametinib,,,,chr7_g.140453145A~C,BRAF_c.1790T~G,BRAF_L597R
BRAF,673,L597R,Melanoma,1909,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,A_case_report_of_a_patient_with_BRAF_L597R_mutation_and_clinical_response_to_BRAF-inhibition_(Vemurafenib)_that_correlated_to_in-vitro_models.,23715574,PubMed,,"Bahadoran_et_al.,_2013,_J._Clin._Oncol.",,4,accepted,728,5,7,140453145,140453145,A,C,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/728,https://civic.genome.wustl.edu/links/variants/288,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G",12,Vemurafenib,,,,,chr7_g.140453145A~C,BRAF_c.1790T~G,BRAF_L597R
ERBB3,2065,OVEREXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,High_expression_of_ERBB3_(her3)_was_associated_with_shorter_overall_survival_(OS)_from_Cetuximab_treatment_in_patients_with_metastatic_colorectal_cancer._Gene_expression_measures_(qRT-PCR)_were_available_for_103_patients.,25520391,PubMed,,"Cushman_et_al.,_2015,_Clin._Cancer_Res.",,4,accepted,729,1733,12,56473645,56497289,,,ENST00000267101.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-02_18:18:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/729,https://civic.genome.wustl.edu/links/variants/289,https://civic.genome.wustl.edu/links/genes/1733,,,,,27,Cetuximab,,,,,,,
ERBB3,2065,OVEREXPRESSION,Cancer,162,,"Gefitinib,CP724714,Selumetinib_(AZD6244)",Substitutes,Predictive,Supports,D,Resistance,Preclinical_study_in_KRAS_mutant_lung_and_colon_cancer_models._A_synthetic_lethal_screen_identified_ERBB3_blockade_to_confer_sensitivity_to_MEK_inhibitors._The_dual_EGFR-ERBB2_(both_forming_heterodimers_with_ERBB3)_inhibitors_afatinib_and_dacomitinib_each_showed_strong_synergy_with_MEK_Inhibition_(trametinib_or_selumetinib)_in_several_KRAS_mutant_cell_lines._MEK_Inhibitors_alone_or_the_combination_with_gefitinib_(EGFRi)_or_CP724714_(ERBB2i)_showed_strong_synergy._Results_were_validated_in-vivo._Basal_ERBB3_expression_was_associated_with_higher_synergy_scores.,24685132,PubMed,,"Sun_et_al.,_2014,_Cell_Rep",,4,accepted,1153,1733,12,56473645,56497289,,,ENST00000267101.3,,,,,75,GRCh37,,,2016-06-23_22:10:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1153,https://civic.genome.wustl.edu/links/variants/289,https://civic.genome.wustl.edu/links/genes/1733,,,,,27,Gefitinib,CP724714,Selumetinib_(AZD6244),,,,,
ERBB3,2065,OVEREXPRESSION,Cancer,162,,"Afatinib,Selumetinib_(AZD6244)",Combination,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_KRAS_mutant_lung_and_colon_cancer_models._A_synthetic_lethal_screen_using_a_total_of_3,530_shRNAs_to_target_518_human_kinases_identified_ERBB3_knockdown_to_confer_sensitivity_of_selumetinib-resistant_H358_cells_(NSCLC_cell_line)_to_the_MEK_inhibitor_selumetinib._The_dual_EGFR-ERBB2_inhibitors_afatinib_and_dacomitinib_each_showed_synergy_with_MEK_Inhibition_via_selumetinib_in_4_KRAS_mutant_cell_lines._Western_blot_evaluation_of_9_NSCLC_and_12_CRC_cell_lines_showed_ERBB3_expression_correlated_with_the_synergy_score_for_combination_afatinib_and_trametinib_treatment._I.e._the_synergy_score_was_low_in_cells_having_low_basal_levels_of_ERBB3_protein_and_high_for_cells_having_high_basal_ERBB3_expression._Using_selumetinib_in_patient-derived_CRC_xenografts_or_trametinib_in_NSCLC_xenografts,_MEK_inhibition_by_selumetinib_or_trametinib_in_combination_with_afatinib_more_effectively_inhibited_increases_in_tumor_volume_than_either_monotherapy.",24685132,PubMed,,"Sun_et_al.,_2014,_Cell_Rep",,3,accepted,1152,1733,12,56473645,56497289,,,ENST00000267101.3,,,,,75,GRCh37,,,2016-03-12_02:21:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1152,https://civic.genome.wustl.edu/links/variants/289,https://civic.genome.wustl.edu/links/genes/1733,,,,,27,Afatinib,Selumetinib_(AZD6244),,,,,,
NT5E,4907,OVEREXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,CD73_high_expression_was_identified_as_a_potential_marker_of_improved_PFS_from_cetuximab_treatment_in_patients_with_metastatic_CRC.,25520391,PubMed,,"Cushman_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,730,3976,6,86159809,86205496,,,ENST00000257770.3,,,,,75,GRCh37,,Somatic_Mutation,2015-12-27_21:40:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/730,https://civic.genome.wustl.edu/links/variants/290,https://civic.genome.wustl.edu/links/genes/3976,,,,,15,Cetuximab,,,,,,,
MYD88,4615,OVEREXPRESSION,Breast_Cancer,1612,,Paclitaxel,,Predictive,Supports,D,Resistance,"In_this_retrospective_analysis_of_211_breast_cancer_tissues,_MYD88_overexpression_was_correlated__with_poor_survival._In-vitro_experiments_showed_a_decrease_in_sensitivity_towards_paclitaxel_in_cell-lines_with_high_MYD88_expression.",26596839,PubMed,,"Xiang_et_al.,_2016,_Tumour_Biol.",,2,accepted,734,3742,3,38179969,38184510,,,ENST00000417037.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/734,https://civic.genome.wustl.edu/links/variants/292,https://civic.genome.wustl.edu/links/genes/3742,,,,,2,Paclitaxel,,,,,,,
PIK3CA,5290,P471L,Merkel_Cell_Carcinoma,3965,,Idelalisib,,Predictive,Supports,C,Sensitivity/Response,A_case_report_of_an_86-year_old_patient_with_metastasized_Merkel_cell_carcinoma_who_achieved_a_complete_clinical_response_under_therapy_with_the_PI3K-inhibitor_Idelalisib.,26466009,PubMed,,"Shiver_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,739,37,3,178928226,178928226,C,T,ENST00000263967.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/739,https://civic.genome.wustl.edu/links/variants/294,https://civic.genome.wustl.edu/links/genes/37,,,missense_variant,"ENST00000263967.3:c.1412C>T,NC_000003.11:g.178928226C>T,NM_006218.3:c.1412C>T,NP_006209.2:p.Pro471Leu",7.5,Idelalisib,,,,,chr3_g.178928226C~T,PIK3CA_c.1412C~T,PIK3CA_P471L
RET,5979,EXPRESSION,Breast_Cancer,1612,,Vandetanib,,Predictive,Supports,D,Sensitivity/Response,"Vandetanib_was_tested_in_4_murine_models_of_patient-derived_xenografts._In_xenografts_with_high_expression_of_EGFR_or_RET,_vandetanib_led_to_tumor_regression,_in_those_without_high_expression,_vandetanib_slowed_tumor_growth.",26686064,PubMed,,"Hatem_et_al.,_2016,_Int._J._Cancer",,2,accepted,740,42,10,43572475,43625799,,,ENST00000355710.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/740,https://civic.genome.wustl.edu/links/variants/295,https://civic.genome.wustl.edu/links/genes/42,,,,,17,Vandetanib,,,,,,,
RIT1,6016,MUTATION,Lung_Adenocarcinoma,3910,,"Selumetinib_(AZD6244),Pictilisib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"RIT1_mutations_were_identified_in_approx._2%_of_lung_adenocarcinomas_(5/87_in_the_""oncogene_negative""_samples_of_TCGA_-_no_RIT1_mutations_were_observed_in_143_samples_with_a_known_driver_mutation)._GDC-0941_impaired_tumor_growth_of_NCI-H2110_(RIT1_M90I_mutated)_xenografts_in_nude_mice._GDC-0941_and_AZD-6244_(selumetinib)_impaired_colony_formation_in-vitro._Combined_PI3K/MEK_inhibition_was_more_effective_than_single_agent_treatment_in-vitro.",24469055,PubMed,,"Berger_et_al.,_2014,_Oncogene",,3,accepted,742,4875,1,155870065,155880706,,,ENST00000368322.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-17_21:10:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/742,https://civic.genome.wustl.edu/links/variants/297,https://civic.genome.wustl.edu/links/genes/4875,,,transcript_variant,,3,Selumetinib_(AZD6244),Pictilisib,,,,,,
MYCN,4613,AMPLIFICATION,Neuroblastoma,769,,CBL0137,,Predictive,Supports,D,Sensitivity/Response,"The_drug_CBL0137_(a_drug_that_interacts_with_SSRP1_aka_FACT)_exhibited_a_synergistic_effect_with_standard_chemotherapy_(cyclophosphamide,_etoposide,_cisplatin,_vincristine,_etc.)_by_blocking_repair_of_DNA_damage_caused_by_genotoxic_drugs,_thus_creating_a_synthetic_lethal_environment_in_MYCN-amplified_neuroblastoma_cells._High_MYCN_expression_was_found_to_sensitize_neuroblastoma_cells_to_CBL0137.",26537256,PubMed,,"Carter_et_al.,_2015,_Sci_Transl_Med",,3,accepted,744,3741,2,16080686,16087129,,,ENST00000281043.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/744,https://civic.genome.wustl.edu/links/variants/298,https://civic.genome.wustl.edu/links/genes/3741,,,transcript_amplification,,43,CBL0137,,,,,,,
SMO,6608,D473H,Brain_Medulloblastoma,60105,,Vismodegib,,Predictive,Supports,C,Resistance,"In_this_case_report,_the_D473H_mutation_was_reported_as_an_acquired_mechanism_of_resistance_to_the_hedgehog_pathway_inhibitor_GDC-0449_(vismodegib).",19726788,PubMed,,"Yauch_et_al.,_2009,_Science",,3,accepted,745,5365,7,128849189,128849189,G,C,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/745,https://civic.genome.wustl.edu/links/variants/299,https://civic.genome.wustl.edu/links/genes/5365,,,missense_variant,"NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C",13.5,Vismodegib,,,,,chr7_g.128849189G~C,SMO_c.1417G~A,SMO_D473H
SMO,6608,D473H,Brain_Medulloblastoma,60105,,Saridegib,,Predictive,Supports,D,Sensitivity/Response,"Saridegib_treatment_induced_tumor_reduction_and_significantly_prolonged_survival_in_a_Shh-driven_mouse_medulloblastoma_model,_and_was_found_to_be_active_in_cells_with_the_D473H_point_mutation.",22550175,PubMed,,"Lee_et_al.,_2012,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,1099,5365,7,128849189,128849189,G,C,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-24_21:37:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1099,https://civic.genome.wustl.edu/links/variants/299,https://civic.genome.wustl.edu/links/genes/5365,,,missense_variant,"NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C",13.5,Saridegib,,,,,chr7_g.128849189G~C,SMO_c.1417G~A,SMO_D473H
SMO,6608,D473H,Basal_Cell_Carcinoma,2513,,Vismodegib,,Predictive,Supports,D,Resistance,"D473_mutations_were_identified_in_5/30_resistant_basal_cell_carcinomas._Crystal_structure_indicated_this_mutation_interacts_with_a_water_molecule_in_the_ligand_binding_pocket,_putatively_altering_its_interaction_with_the_SMO_inhibitor_vismodegib._SMO-/-_mouse_embryonic_fibroblasts_expressing_the_SMO_D473G_mutant_maintained_hedgehog_signaling_in_the_presence_of_the_drug_and_had_IC50_values_>40_fold_higher_than_cells_expressing_wildtype_SMO.",25759020,PubMed,,"Atwood_et_al.,_2015,_Cancer_Cell",,3,accepted,755,5365,7,128849189,128849189,G,C,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/755,https://civic.genome.wustl.edu/links/variants/299,https://civic.genome.wustl.edu/links/genes/5365,,,missense_variant,"NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C",13.5,Vismodegib,,,,,chr7_g.128849189G~C,SMO_c.1417G~A,SMO_D473H
SMO,6608,MUTATION,Basal_Cell_Carcinoma,2513,,"Arsenic_Trioxide,PSI",Substitutes,Predictive,Supports,D,Sensitivity/Response,Basal_cell_carcinomas_with_ligand-binding_pocket_or_constitutively_active_mutations_in_the_SMO_gene_were_sensitive_to_inhibition_of_downstream_hedgehog_signaling_with_PSI_(aPKC-ι/λ/GLI_inhibitor)_or_arsenic_trioxide.,25759020,PubMed,,"Atwood_et_al.,_2015,_Cancer_Cell",,4,accepted,747,5365,7,128828713,128853386,,,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-03_18:59:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/747,https://civic.genome.wustl.edu/links/variants/300,https://civic.genome.wustl.edu/links/genes/5365,,,coding_transcript_variant,,44,Arsenic_Trioxide,PSI,,,,,,
SMO,6608,MUTATION,Cancer,162,,Vismodegib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Twenty-one_patients_had_mutations_in_the_Hedgehog_pathway_(PTCH-1,_n_=_18;_SMO,_n_=_3)._None_of_the_patients_with_SMO_mutations_responded_to_SHH-inhibition_with_vismodegib.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5979,5365,7,128828713,128853386,,,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2018-02-15_23:04:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/5979,https://civic.genome.wustl.edu/links/variants/300,https://civic.genome.wustl.edu/links/genes/5365,,,coding_transcript_variant,,44,Vismodegib,,,,,,,
SMO,6608,MUTATION,Basal_Cell_Carcinoma,2513,,"LDE225,Vismodegib",Sequential,Predictive,Supports,B,Resistance,"Study_explored_the_response_to_the_SMO_inhibitor_sonidegib_(LDE225)_in_a_cohort_of_9_patients_with_advanced_basal_cell_carcinoma__that_exhibited_treatment_resistance_with_vismodegib_(GDC0449)._Sequencing_revealed_that_5_of_these_patients_harbored_SMO_mutations_known_to_confer_resistance_to_the_Smoothened_inhibitors_(D473G,_D473H,_Q477E,_S533N,_W535L)_an_additional_patient_harbored_a_SMO_mutation_of_unknown_consequence_(R168H)._Of_these_patients,_4_with_a_SMO_mutation_displayed_progressive_disease_and_1_stable_disease_for_58_weeks_according_to_RECIST_v1.1_criteria.",26546616,PubMed,,"Danial_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1477,5365,7,128828713,128853386,,,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_05:05:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1477,https://civic.genome.wustl.edu/links/variants/300,https://civic.genome.wustl.edu/links/genes/5365,,,coding_transcript_variant,,44,LDE225,Vismodegib,,,,,,
SMO,6608,MUTATION,Basal_Cell_Carcinoma,2513,,Vismodegib,,Predictive,Supports,B,Resistance,"In_basal_cell_carcinoma,_H231R,_D473G,_W281C_and_Q477E_mutations_conferred_resistance_to_SMO-inhibitor_vismodegib._SMO_mutations_were_identified_in_22_of_44_resistant_basal_cell_carcinomas_in_15_patients.",25759020,PubMed,,"Atwood_et_al.,_2015,_Cancer_Cell",,4,accepted,746,5365,7,128828713,128853386,,,ENST00000249373.3,,,,,75,GRCh37,,Somatic_Mutation,2015-12-29_00:00:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/746,https://civic.genome.wustl.edu/links/variants/300,https://civic.genome.wustl.edu/links/genes/5365,,,coding_transcript_variant,,44,Vismodegib,,,,,,,
PTCH1,5727,MUTATION,Brain_Medulloblastoma,60105,,Vismodegib,,Predictive,Supports,B,Sensitivity/Response,"133_sonic-hedghog_driven_medulloblastomas_were_sequenced_for_alterations_(WGS_or_WES)._60_cases_exhibited_PTCH1_mutations,_most_of_which_were_likely_loss-of-function_(spread_across_the_gene_and_of_types_including:_stop_gain,_splice_site,_frameshift,_etc.)._Functional_models_also_showed_PTCH1_mutant_xenografts_to_be_sensitive_to_SHH_inhibition_with_vismodegib.",24651015,PubMed,,"Kool_et_al.,_2014,_Cancer_Cell",,4,accepted,748,4645,9,98205262,98270943,,,ENST00000331920.6,,,,,75,GRCh37,,Somatic_Mutation,2015-12-29_16:03:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/748,https://civic.genome.wustl.edu/links/variants/301,https://civic.genome.wustl.edu/links/genes/4645,,,"gene_variant,loss_of_function_variant",,25,Vismodegib,,,,,,,
PTCH1,5727,MUTATION,Cancer,162,,Vismodegib,,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Twenty-one_patients_had_mutations_in_the_Hedgehog_pathway_(PTCH-1,_n_=_18;_SMO,_n_=_3)._Three_patients_with_PTCH1_mutations_had_PRs_to_vismodegib_(17%;_unknown_primary_cancer,_n_=_1;_squamous_skin_cancer,_n_=_1;_salivary_gland_cancer,_n_=_1).",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,1,accepted,5978,4645,9,98205262,98270943,,,ENST00000331920.6,,,,,75,GRCh37,,Somatic_Mutation,2018-02-15_23:06:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/5978,https://civic.genome.wustl.edu/links/variants/301,https://civic.genome.wustl.edu/links/genes/4645,,,"gene_variant,loss_of_function_variant",,25,Vismodegib,,,,,,,
PTCH1,5727,LOH,Brain_Medulloblastoma,60105,,Vismodegib,,Predictive,Supports,B,Sensitivity/Response,"Loss-of-heterozygosity_in_SHH-driven_medulloblastoma_was_associated_with_increased_PFS_under_therapy_with_vismodegib_(AKA_HhAntag691,_GDC0449,_GDC-0449)._43_patients_total_were_enrolled_for_this_study.",26169613,PubMed,,"Robinson_et_al.,_2015,_J._Clin._Oncol.",,2,accepted,749,4645,9,98205262,98270943,,,ENST00000331920.6,,,,,75,GRCh37,,Somatic_Mutation,2016-01-27_21:13:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/749,https://civic.genome.wustl.edu/links/variants/302,https://civic.genome.wustl.edu/links/genes/4645,,,loss_of_heterozygosity,,10,Vismodegib,,,,,,,
STK11,6794,UNDEREXPRESSION,Prostate_Cancer,10283,,SB202190,,Predictive,Supports,D,Sensitivity/Response,STK11-deficient_cells_were_sensitive_to_treatment_with_MAPK11_inhibitor_SB202190.,26391455,PubMed,,"Grossi_et_al.,_2015,_Autophagy",,2,accepted,751,5534,19,1205740,1228428,,,ENST00000326873.7,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/751,https://civic.genome.wustl.edu/links/variants/304,https://civic.genome.wustl.edu/links/genes/5534,,,,,2,SB202190,,,,,,,
SYK,6850,OVEREXPRESSION,Ovarian_Cancer,2394,,Paclitaxel,,Predictive,Supports,D,Resistance,Overexpression_and_high_p-SYK/SYK_ratio_were_associated_with_resistance_to_paclitaxel._Inhibition_of_SYK_with_R406_resensitized_cell_lines_to_paclitaxel.,26096845,PubMed,,"Yu_et_al.,_2015,_Cancer_Cell",,3,accepted,752,5572,9,93564069,93660831,,,ENST00000375754.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/752,https://civic.genome.wustl.edu/links/variants/305,https://civic.genome.wustl.edu/links/genes/5572,,,,,3,Paclitaxel,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"The_Phase_III_trial,_TH3RESA_(NCT01419197),_was_performed_in_patients_with_advanced_HER2_breast_cancer_that_was_heavily_pretreated.__Patients_were_required_to_have_prior_exposure_to_trastuzumab_and_lapatinib_as_well_as_a_taxane.__This_patient_population_has_not_seen_many_studies,_responds_poorly_to_late-line_treatment_with_trastuzumab,_and_in_this_study_was_treated_with_trastuzumab_emtansine_(T-DM1,_n=404)_vs._physician's_choice_(usually_trastuzumab_plus_chemotherapy,_n=198).__Results_showed_progression_free_survival_was_6.2_months_in_T-DM1_treatment_vs._3.3_months_under_physician's_choice,_along_with_lower_incidence_of_grade_3_or_worse_events_with_T-DM1.__The_authors_conclude_that_their_findings_in_this_heavily_pretreated_population,_along_with_findings_in_the_EMILIA_trial,_indicate_promise_for_antibody-drug_conjugates.__The_NCI-MATCH_trial_with_further_study_T-DM1_in_the_context_of_HER2_amplification.",24793816,PubMed,,"Krop_et_al.,_2014,_Lancet_Oncol.",,4,accepted,1159,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:12:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1159,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab_Emtansine,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Capecitabine,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_III_trial,_trastuzumab-based_treatment_was_assessed_in_women_with_locally_advanced_or_metastatic_HER2_positive_breast_cancer_who_had_progressed_on_trastuzumab.__Patients_had_12_weeks_or_greater_previous_trastuzumab_treatment_with_time_since_end_of_last_cycle_less_than_6_weeks.__Primary_endpoint_was_time_to_progression.__78_patients_were_assigned_to_each_group,_with_median_time_to_progression_of_5.6_months_in_capecitabine_group_and_8.2_months_in_trastuzumab_plus_capecitabine_group.__The_results_are_in_contrast_to_the_principle_of_change_of_treatment_on_disease_progression,_and_authors_suggest_that_chemotherapy-sensitizing_mechanisms_of_trastuzumab_remain_intact_in_HER2_breast_cancer_cells_with_trastuzumab_progression.",19289619,PubMed,,"von_Minckwitz_et_al.,_2009,_J._Clin._Oncol.",,4,accepted,1133,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:12:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1133,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Capecitabine,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Pancreatic_Cancer,1793,,"Trastuzumab,Pertuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Two_of_nine_patients_(22%)_with_HER2_amplified/overexpressing_pancreatic_cancer_had_a_PR_with_trastuzumab/pertuzumab_combination._Another_patient_had_SD_>_120days.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5985,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2018-02-15_21:55:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/5985,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Pertuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Sensitivity/Response,"A_randomized_clinical_trial_of_469_patients_with_previously_untreated,_HER2-positive,_metastatic_breast_cancer_demonstrated_improved_time_to_disease_progression,_objective_response_rate,_and_duration_of_response_for_patients_who_received_trastuzumab_in_addition_to_chemotherapy_compared_to_chemotherapy_alone.",11248153,PubMed,,"Slamon_et_al.,_2001,_N._Engl._J._Med.",,5,accepted,528,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-01-11_18:47:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/528,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Docetaxel,Trastuzumab,Pertuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"CLEOPATRA_(NCT00567190)_was_a_Phase_III,_randomized_and_double-blind,_placebo-controlled_study_of_808_patients_with_HER2-positive_metastatic_breast_cancer.__Patients_were_HER2-positive_by_IHC3+_or_FISH,_and_patients_who_had_received_prior_hormonal_treatment_or_adjuvant/neo-adjuvant_therapy_with_or_without_trastuzumab_for_longer_than_12_months_before_randomization_were_also_eligible.__The_two_arms_of_the_study_were_trastuzumab_and_docetaxel_with_either_placebo_or_pertuzumab.__Median_PFS_in_the_placebo_arm_was_12.4_months_while_in_the_petuzumab_arm_18.5_months_was_achieved.__Median_OS_in_the_control_arm_was_40.8_months_and_56.5_months_with_pertuzumab.__These_strong_results_make_a_case_for_dual_antibody_blockade_in_first_line_treatments_of_HER2-positive_metastatic_breast_cancer.",25693012,PubMed,,"Swain_et_al.,_2015,_N._Engl._J._Med.",,5,accepted,1077,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_03:58:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1077,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Docetaxel,Trastuzumab,Pertuzumab,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Neratinib,,Predictive,Supports,B,Sensitivity/Response,"In_this_two_arm,_Phase_III_study_(NCT00878709)_of_the_efficacy_of_a_12_month_course_of_the_TKI_neratinib_after_trastuzumab-based_adjuvant_therapy_of_early_stage_HER2-positive_breast_cancer_was_assessed_using_invasive_disease-free_survival_as_primary_endpoint.__HER2_positivity_was_assessed_via_FISH.__At_2_year_follow-up,_70_vs._109_disease-free_survival_events_had_occurred_and_disease-free_survival_rates_were_93.9%_vs._91.6%_(significant)_in_neratinib_vs._placebo_groups_respectively.__Distant_disease-free_survival_and_time_to_distant_recurrence_were_similar_in_both_groups.__These_results_are_an_interesting_contrast_to_results_of_long-term_adjuvant_therapy_with_trastuzumab_(HERA)_which_did_not_show_significant_benefit.",26874901,PubMed,,"Chan_et_al.,_2016,_Lancet_Oncol.",,4,accepted,1113,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_03:59:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1113,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Neratinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"A_phase_II_study_involving_adult_female_patients,_>=18_years,_with_stage_IIIB_or_IV_HER2-positive_(by_IHC_and/or_in_situ_fluorescence)_metastatic_breast_cancer._All_patients_were_previously_treated_with_trastuzumab_and_a_median_of_three_chemotherapy_lines._41_patients_received_50_mg_afatinib_once-daily_until_disease_progression_and_the_primary_endpoint_was_objective_response_rate._4_patients_(10%_of_41_treated;_11%_of_evaluable_patients)_had_partial_response_and_15_patients_(37%_of_41)_had_stable_disease_as_best_response._Thus_a_total_of_19_(46%_of_41)_achieved_clinical_benefit._Median_progression-free_survival_was_15.1_weeks.",22418700,PubMed,,"Lin_et_al.,_2012,_Breast_Cancer_Res._Treat.",,3,accepted,961,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:14:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/961,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"In_a_randomized_phase_II_study,_first_line_treatment_of_HER2-positive_metastatic_breast_cancer_with_trastuzumab_emtansine_(T-DM1)_resulted_in_improved_progression_free_survival_and_fewer_serious_adverse_effects_when_compared_to_treatment_with_combination_trastuzumab_plus_docetaxel_(HT)_(median_follow_up_14_months,_median_PFS_with_T-DM1_14.2_vs_9.2_with_HT).",23382472,PubMed,,"Hurvitz_et_al.,_2013,_J._Clin._Oncol.",,3,accepted,1432,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-07-06_05:01:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1432,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab_Emtansine,,,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"We_identified_142_patients_with_metastatic_colorectal_cancer_whose_tumors_harbored_both_wild-type_exons_2,_3,_and_4_in_KRAS_and_NRAS,_and_wild-type_exon_15_in_BRAF._All_patients_received_cetuximab_after_oxaliplatin,_irinotecan,_and_fluoropyrimidine_failure._HER2_status_was_determined_using_immunohistochemistry_and_silver_in_situ_hybridization_and_correlated_with_cetuximab_efficacy._Of_142_RAS_and_BRAF_wild-type_tumors,_we_observed_7_cases_(4.9%)_of_HER2_amplification_by_SISH._After_a_median_follow-up_of_13.2_months_(range,_1.4-78.1_months),_median_progression-free_survival_(PFS)_was_significantly_different_according_to_HER2_status:_3.1_months_in_patients_with_HER2_amplification_compared_with_5.6_months_in_those_with_non-amplified_HER2_(HR_=_2.73;_95%_CI_=_1.18-6.31;_P_=_0.019)._Overall_survival_(OS)_was_not_significantly_different_between_groups,_although_there_was_a_tendency_towards_shorter_OS_in_patients_with_HER2-amplified_tumors_(HR_=_0.31;_95%_CI_=_0.61-2.82;_10.1_vs._13.5_months;_P_=_0.488).",28223103,PubMed,,"Jeong_et_al.,_2017,_Clin_Colorectal_Cancer",,3,accepted,1993,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2017-06-16_20:15:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1993,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Cetuximab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"The_EMILIA_study_(NCT00829166)_was_a_Phase_II_trial_to_assess_the_efficacy_of_trastuzumab_emtansine_(T-DM1,_n=495)_in_comparison_to_lapatinib_plus_capecitabine_(n=496),_in_treatment_of_advanced_HER2_positive_breast_cancer.__Patients_were_required_to_have_progressed_on_or_after_treatments_involving_trastuzumab_and_a_taxane,_and_no_prior_exposure_to_lapatinib_or_T-DM1.___Primary_endpoints_included_independently_assessed_progression_free_survival_(PFS)_and_safety._PFS_was_9.6_months_in_T-DM1_group_vs._6.4_months_in_lapatinib_plus_capecitabine.__Rates_of_adverse_events_of_grade_3_or_higher_were_greater_with_lapatinib_plus_capecitabine.__These_results,_together_with_other_trials_such_as_TH3RESA_indicate_promise_for_T-DM1_therapy_in_HER2_amplification,_and_this_will_be_further_studied_in_an_arm_of_the_NCI-MATCH_trial.",23020162,PubMed,,"Verma_et_al.,_2012,_N._Engl._J._Med.",,4,accepted,1160,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_03:59:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1160,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab_Emtansine,,,,,,,
ERBB2,2064,AMPLIFICATION,Scrotum_Paget's_Disease,3444,,Trastuzumab,,Predictive,Supports,C,Sensitivity/Response,"A_71-year_old_male_with_metastatic_extramammary_Paget’s_disease_of_the_scrotum_overexpressing_Her2/neu_was_treated_with_trastuzumab,_achieving_a_complete_response._At_12_months,_he_maintains_stable_disease.",25692060,PubMed,,"Barth_et_al.,_2015,_Case_Rep_Oncol_Med",,2,accepted,1693,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-09-23_19:20:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1693,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Trastuzumab,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_phase_II_trial_with_2_arms,_103_patients_with_untreated_stage_IIIB/IV_HER2_positive_NSCLC_were_given_gemcitabine-cisplatin_with_or_without_trastuzumab.__HER2_positivity_was_broadly_defined_as_IHC2+/3+,_positive_by_FISH,_or_increased_circulating_HER2_extracellular_domain.__Significant_differences_between_the_treatment_arms_were_not_observed,_but_in_a_small_subset_of_IHC3+/FISH_positive_patients,_5_of_6_responded_to_trastuzumab_and_had_increased_PFS_of_8.5_months_in_comparison_to_6.1_months_in_the_IHC2+_group.__Although_from_2004,_this_study_remains_cited_in_2016_literature_when_discussing_the_unclear_efficacy_of_trastuzumab_in_wild-type_HER2_overexpressing_NSCLC._The_authors_conclude_that_future_studies_of_trastuzumab_in_HER2_positive_NSCLC_should_focus_on_high_expressing_subjects.",14679114,PubMed,,"Gatzemeier_et_al.,_2004,_Ann._Oncol.",,2,accepted,1041,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1041,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Breast_Cancer,1612,,PP242,,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_31_breast_cancer_cell_lines_with_varied_mutation_backgrounds,_10_cell_lines_harbored_HER2_(ERBB2)_amplification._Sensitivity_to_the_mTORC1/2_inhibitor_PP242_was_assessed,_and_8/10_HER2_positive_cell_lines_were_reported_to_be_sensitive_(IC50_<_1_micro_molar_PP242).__8/21_without_HER2_amplification_were_reported_as_resistant_(IC50_>_1_micro_molar_PP242)._This_pattern_of_HER2_positive_cell_sensitivity_was_not_reported_with_the_rapamycin_analog__mTORC1_inhibitor_everolimus.",21358673,PubMed,,"Weigelt_et_al.,_2011,_Oncogene",,2,accepted,1613,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-11-12_03:13:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1613,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,PP242,,,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"A_cohort_of_patient-derived_xenografts_(PDX)_from_85_patients_with_metastatic_colorectal_cancer_was_created._PDX_were_treated_with_cetuximab_and_mechanisms_of_resistance_investigated._None_of_the_xenografts_harboring_KRAS_(N=18),_NRAS_(N=7)_or_BRAF_(N=3)_mutations_showed_a_response_to_cetuximab_whereas_1_out_of_4_xenografts_with_a_PIK3CA_mutation_responded_to_cetuximab._Among_11_quadruple-negative_samples_with_resistance_to_cetuximab,_HER2_overexpression_and_amplification_(N=3)_and_amplification_(N=1)_were_identified._In_an_independent_second_retrospective_patient_cohort,_3_out_of_17_patients_with_KRAS_wt,_cetuximab_resitant_CRC_were_found_to_harbor_HER2_overexpression_and_amplification._In_this_cohort_no_HER2_overexpression_or_amplification_was_identified_in_14_KRAS_wt_patients_with_response_to_cetuximab.",22586653,PubMed,,"Bertotti_et_al.,_2011,_Cancer_Discov",,4,accepted,1686,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-09-23_15:55:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1686,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Cetuximab,,,,,,,
ERBB2,2064,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Trastuzumab_Emtansine,,Predictive,Supports,D,Sensitivity/Response,"Efficacy_of_trastuzumab_in_HER2_overexpressing_NSCLC_remains_unclear.__In_this_study_using_a_panel_of_NSCLC_HER2_overexpressing_cell_lines,_antiproliferative_effects_of_trastuzumab_emtansine_(T-DM1)_were_observed_in_a_HER2-expression_dependant_manner,_with_strongest_effects_in_Calu-3_(high_expressing)_and_no_effects_in_Calu-6_(low_expressing).__Trastuzumab_did_not_show_notable_effects_on_cell_growth_in_any_tested_cells.__HER2_positivity_in_NSCLC_is_fairly_common_at_2-20%.__A_clinical_trial_(NCT02289833)_is_currently_underway_to_asses_TDM-1_in_HER2_overexpressing_lung_cancer.",24898067,PubMed,,"Cretella_et_al.,_2014,_Mol._Cancer",,4,accepted,1050,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1050,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab_Emtansine,,,,,,,
ERBB2,2064,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Trastuzumab,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_phase_II_trial_a_small_group_of_patients_with_IHC2+_or_IHC3+_HER2_NSCLC,_in_which_primary_platinum-based_therapy_had_failed,_were_given_either_docetaxel_or_trastuzumab_after_which_both_groups_were_given_docetaxel_and_trastuzumab_together.__there_was_one_partial_response_in_the_docetaxel_group_and_none_in_the_trastuzumab_group.__The_authors_report_that_due_to_the_limited_clinical_activity_of_trastuzumab-based_therapy_in_this_cohort,_as_well_as_similar_results_in_other_trastuzumab_studies,_that_targets_other_than_HER2_in_NSCLC_should_be_considered_for_future_study.__This_2004_study_remains_cited_in_2016_literature_in_discussing_the_unclear_efficacy_of_trastuzumab_in_wild-type_HER2_overexpressing_NSCLC,_but_mutant_HER2_in_NSCLC_has_been_further_studied_and_a_picture_of_different_HER2_mutations_being_potentially_responsive_to_specific_targeted_therapies_is_emerging.",14967075,PubMed,,"Lara_et_al.,_2004,_Clin_Lung_Cancer",,3,accepted,1042,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1042,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"This_Phase_II_trial_(LUX-Breast_3_-_NCT01441596)_compared_afatinib,_afatinib_plus_vinorelbine,_or_investigator's_choice_of_treatment.__121_patients_with_HER2_overexpressing_breast_cancer_with_CNS_recurrence_or_regression_who_had_previously_progressed_on_trastuzumab_or_lapatinib_were_assigned_to_3_arms,_with_endpoint_in_the_intention-to-treat_population_being_patient_benefit_at_12_weeks_defined_as_absence_of_CNS_or_extra_CNS_progression,_no_tumor_related_worsening_of_neurological_symptoms_and_no_increase_in_corticosteroid_dose._Benefit_was_seen_in_30%_of_40_patients_assigned_to_afatinib_alone,_34.2%_of_38_assigned_to_afatinib_plus_vinorelbine,_and_41.9%_of_43_assigned_to_investigator's_treatment_choice.__Differences_were_not_statistically_significant,_and_afatanib_patients_experienced_more_adverse_effects.__While_Afatanib_did_show_response_in_HER2_breast_cancer_patients,_it_was_not_better_than_investigator's_treatment_choice_and_the_investigators_state_that_no_further_development_of_afatinib_for_HER2_breast_cancer_will_be_planned.",26596672,PubMed,,"Cortés_et_al.,_2015,_Lancet_Oncol.",,3,accepted,1011,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:15:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1011,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,A66,,Predictive,Supports,D,Sensitivity/Response,"Pharmacologic_(A66;_p110alpha_specific_inhibitor)_or_genetic_(cre-mediated_knockout)_ablation_of_the_p110alpha_PI3K_isoform_reduced_tumor_growth_and_tumor_formation,_respectively,_in_athymic_mice_transplanted_with_cells_transduced_by_MMTV-NeuT_(mammary_specific_overexpression_of_HER2_that_effectively_induces_tumors)._A66_treatment_of_cells_from_MMTV-NeuT_mouse_tumors_resulted_in_decreased_lipid_kinase_activity_and_phospho_Akt_levels.",22802530,PubMed,,"Utermark_et_al.,_2012,_Genes_Dev.",,2,accepted,1381,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-11-03_19:22:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1381,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,A66,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,A,Sensitivity/Response,"HERA_was_a_Phase_III_trial_assessing_application_of_trastuzumab_in_an_extended_adjuvant_setting.__Patients_were_HER2_positive_with_completely_excised_invasive_BC,_node_positive_or_negative,_and_having_undergone_prior_adjuvant_or_neo-adjuvant_chemotherapy.__In_the_3_arm_study_patients_were_given_trastuzumab_courses_of_1_year,_2_years,_or_untreated.__At_the_first_planned_interim_analysis,_trastuzumab_treatment_for_one_year_was_compared_with_observation_alone.__A_significant_difference_in_disease-free_survival_was_seen_with_220_DFS_events_out_of_1693_in_the_observation_arm_versus_127_DFS_events_out_of_1694_in_the_1_year_trastuzumab_arm.__1_year_adjuvant_trastuzumab_is_currently_the_standard_of_care.",16236737,PubMed,,"Piccart-Gebhart_et_al.,_2005,_N._Engl._J._Med.",,4,accepted,1122,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2017-12-04_15:42:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1122,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Sensitivity/Response,"A_randomized_clinical_trial_of_186_patients_with_previously_untreated,_HER2-positive,_metastatic_breast_cancer_demonstrated_improved_overall_survival,_response_rate,_response_duration,_time_to_progression,_and_time_to_treatment_failure_for_patients_who_received_trastuzumab_in_addition_to_chemotherapy_(docetaxel)_compared_to_chemotherapy_alone.",15911866,PubMed,,"Marty_et_al.,_2005,_J._Clin._Oncol.",,5,accepted,529,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-01-11_18:48:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/529,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Trastuzumab,XL147_(Pilaralisib)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_5_trastuzumab_resistant_HER2_overexpressing_breast_cancer_cell_lines,_combination_of_the_pan-PI3K_inhibitor_XL147_and_trastuzumab_treatment_induced_cell_death_to_similar_or_greater_levels_than_XL147_alone._In_three_trastuzumab_resistant_cell_lines_tested,_colony_formation_in_matrigel_was_markedly_inhibited_by_combination_treatment._Apoptotic_markers_were_apparent_with_combination_treatment._In_athymic_mice,_trastuzumab_resistant_cell_line_HR6_was_used_in_tumor_xenografts_and_tumors_were_allowed_to_form._Mice_subsequently_treated_with_trastuzumab_or_XL147_showed_continued_tumor_growth_without_marked_difference_from_control,_while_combination_treatment_essentially_halted_tumor_growth_rate.",23204226,PubMed,,"Chakrabarty_et_al.,_2013,_Cancer_Res.",,4,accepted,1448,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-08-04_04:59:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1448,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,XL147_(Pilaralisib),,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,"Cetuximab,Oxaliplatin,Capecitabine",Combination,Predictive,Does_Not_Support,B,Resistance,"141_patients_were_analyzed_for_ERBB2_(HER2)_positivity_by_FISH_and/or_IHC._Only_6_(4.3%)_were_ERBB2_positive._These_patients_did_not_show_a_difference_in_outcome_after_capecitabine,_oxaliplatin_and_chemoradiotherapy,_with_or_without_cetuximab.",24146218,PubMed,,"Sclafani_et_al.,_2013,_Ann._Oncol.",,1,accepted,895,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-10-06_18:38:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/895,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Cetuximab,Oxaliplatin,Capecitabine,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Lapatinib,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_randomized_open_label_phase_3_study_(NCT00553358),_women_with_HER2_positive_primary_breast_cancer_treated_with_lapatinib_plus_trasuzumab_had_higher_rates_of_pathological_complete_responses_than_seen_in_control_groups_receiving_either_IV_trastuzumab_or_oral_lapatinib_alone_(combination_treatment_pCR_rate_of_51%_vs_29.5%_and_24.7%_for_trastuzumab_and_lapatinib_alone,_respectively).",22257673,PubMed,,"Baselga_et_al.,_2012,_Lancet",,4,accepted,1439,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:13:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/1439,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Lapatinib,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Pictilisib,,Predictive,Supports,D,Sensitivity/Response,"The_HER2/Neu_mammary_tumor_mouse_model_MMTV-NeuT_was_employed_to_demonstrate_dependence_of_HER2_tumor_formation_on_PIK3_p110alpha_isoform._MMTV-NeuT_mice_were_crossed_with_floxed_p110alpha_mice._Diassacociated_tumors_cells_from_these_mice_were_treated_with_Cre_adenovirus_to_delete_p110alpha,_or_GFP_adenovirus,_and_cells_were_transplanted_into_athymic_mice._GFP_treated_cells_formed_new_tumors,_while_p110alpha_deletion_blocked_tumor_formation_indicating_tumor_dependence_on_PI3KA._Next,_MMTV-NeuT_tumors_were_dissociated_and_treated_with_pan-PI3K_inhibitor_GDC-0941._Reduced_lipid_kinase_activity_and_reduced_phospho-Akt_levels_were_seen_in_these_cells._Administration_of_125_mg/kg_GDC-0941_to_athymic_mice_with_transplantation_of_tumor_cells_caused_marked_reduction_of_tumor_cell_volume_in_comparison_to_control_treatment.",22802530,PubMed,,"Utermark_et_al.,_2012,_Genes_Dev.",,3,accepted,1380,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-07-06_20:19:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1380,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Pictilisib,,,,,,,
ERBB2,2064,AMPLIFICATION,Endometrial_Cancer,1380,,Trastuzumab,,Predictive,Does_Not_Support,B,Sensitivity/Response,"This_phase_II_single_arm_study_assessed_trastuzumab_monotherapy_in_HER2_positive_endometrial_cancers_with_tumor_response_as_primary_endpoint.__Participants_had_stage_III,_IV_or_recurrent_HER2_positive_endometrial_cancer.__During_the_trial's_initial_phase,_23_of_132_patients_screened_met_the_criteria_of_IHC2+_or_3+_or_FISH_positivity_for_HER2_status.__In_the_absence_of_results,_the_trial_entered_phase_B,_where_only_patients_with_HER2_amplification_by_FISH_were_admitted.__The_trial_ended_early_due_to_poor_accrual_with_11_of_154_screened_meeting_the_phase_B_criteria._No_major_objective_tumor_responses_were_observed_in_the_study.__28%_of_the_cancers_were_of_the_serous_type_that_had_shown_trastuzumab_response_in_case_studies.__The_investigators_note_that_in_other_HER2_cancers,_such_as_breast_and_gastrointestinal,_trastuzumab_in_combination_with_chemotherapy_has_been_found_most_effective,_and_could_warrant_more_study.__Currently_a_clinical_trial_(NCT01367002)_is_evaluating_carboplatin/paclitaxel_with_or_without_trastuzumab_in_uterine_serous_cancer.",19840887,PubMed,,"Fleming_et_al.,_2010,_Gynecol._Oncol.",,2,accepted,1098,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-02-24_21:06:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1098,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Afatinib,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"Trastuzumab_resistance_is_thought_to_consist_of_multiple_compensatory_mechanisms_involving_ErbB_family_members_such_as_increased_signaling_through_ErbB_family_heterodimers.__The_irreversible_TKI_afatinib_blocks_EGFR,_HER2,_ErbB3_and_ErbB4.__Thus_afatinib_was_studied_in_this_Phase_I_trial_of_trastuzumab-progressed_HER2_positive_metastatic_BC_(MBC)_in_combination_with_continued_trastuzumab_treatment,_where_trastuzumab_is_still_the_perferred_treatment_for_trastuzumab-progressed_MBC.__Objective_response_and_disease_control_rates_were_11%_and_39%.__The_authors_conclude_that_the_clinical_activity_observed_in_this_trial_warrants_further_work_with_afatinib_and_trastuzumab_combination_therapy.",25370464,PubMed,,"Ring_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,1013,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:15:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1013,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Uterine_Corpus_Serous_Adenocarcinoma,5750,,Trastuzumab,,Predictive,Supports,C,Sensitivity/Response,"HER2_expression_in_uterine_serous_papillary_carcinoma_(USPC)_is_thought_to_be_associated_with_poor_prognosis_and_may_act_as_a_targetable_driver_mutation_in_this_cancer.__HER2_overexpression_in_USPC_is_more_common_in_African_American_women.__This_report_covered_2_African_American_patients,_the_first_of_which_presented_high-grade_endometrial_adenocarcinoma_with_IHC3+_HER2-positivity_as_well_as_positivity_by_FISH.__Prior_treatment_involved_surgery_and_chemotherapy.__Treatment_with_pacitaxel/carboplatin_with_trastuzumab_showed_clear_clinical_improvement_assessed_by_CT_scan_and_drop_in_CA-125_levels_from_988_to_7.9_U/mL.__The_second_patient_had_USPC,_and_was_treated_with_surgery_and_radiation.__Trastuzumab_monotheraby_was_then_administered.__After_7_months_of_treatment,_the_patient_showed_no_sign_of_disease_progression_and_CA-125_had_dropped_from_144_to_41_U/mL.__The_investigators_conclude_there_is_promise_in_trastuzumab-based_therapies_in_advanced_endometrial_cancers,_including_USPC.",18555254,PubMed,,"Santin_et_al.,_2008,_Int_J_Gynaecol_Obstet",,4,accepted,1097,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1097,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,B,Sensitivity/Response,Oral_neratinib_showed_objective_response_rates_of_24_and_56%_respectively_in_prior-trastuzumab_and_trastuzumab-naive_cohorts_in_a_Phase_II_trial_with_a_primary_endpoint_of_16-week_progression_free_survival.,20142587,PubMed,,"Burstein_et_al.,_2010,_J._Clin._Oncol.",,3,accepted,761,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/761,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Neratinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Breast_Cancer,1612,,"Lapatinib,Trastuzumab",Combination,Predictive,Supports,D,Sensitivity/Response,"In-vitro_studies_using_ERBB2_over-expressing_breast_cancer_cell_lines_BT474_and_SKBR3_(with_ERBB2_amplification)_showed_apoptosis_under_either_labatinib_or_trastuzumab_treatment.__A_marked_synergistic_apoptotic_effect_under_lapatinib_and_trastuzumab_co-treatment_was_observed_in_BT474_cells,_and_a_milder_synergistic_effect_was_observed_in_SKBR3_cells.",16091755,PubMed,,"Xia_et_al.,_2005,_Oncogene",,3,accepted,1006,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-02-22_02:57:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1006,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Lapatinib,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Pancreatic_Adenocarcinoma,4074,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,"Afatinib_was_growth-inhibitory_for_three_pancreatic_cancer_cell_lines_but_cytotoxic_only_toward_BxPC3_(KRAS_wt)_and_Capan-2_(KRAS_mut)_cells,_both_of_which_express_high_levels_of_EGFR,_ERBB2,_and_ERBB3_receptors._Afatinib_increased_the_radiosensitivity_of_BxPC3_and_Capan-2_cells._In_comparison,_Panc-1_cells_(KRAS_mut)_expressing_low_levels_of_EGFR_family_receptors_were_resistant_to_afatinib-induced_radiosensitization.",26668065,PubMed,,"Huguet_et_al.,_2016,_Target_Oncol",,2,accepted,962,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/962,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Trastuzumab,Afatinib,Lapatinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_this_phase_2_trial,_treatment-naive,_ERBB2-positive_(by_IHC)_breast_cancer_patients_with_stage_IIIA,_B,_C_or_inflammatory_disease_were_randomized_1:1:1_to_afatinib_(n_=_10),_lapatinib_(n_=_8),_or_trastuzumab_(n_=_11)._The_primary_end_point_was_objective_response_rate._Objective_response_was_seen_in_8_afatinib-,_6_lapatinib-,_and_4_trastuzumab-treated_patients._Afatinib_demonstrated_clinical_activity_that_compared_favorably_to_trastuzumab_and_lapatinib_for_neoadjuvant_treatment_of_HER2-positive_breast_cancer.",25537159,PubMed,,"Rimawi_et_al.,_2015,_Clin._Breast_Cancer",,2,accepted,887,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:13:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/887,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Afatinib,Lapatinib,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,B,Resistance,"HER2_amplification_(FISH)_was_assessed_in_170_KRAS_wt_mCRC_patients_treated_with_cetuximab_or_panitumumab._HER2_copy_number_status_was_significantly_correlated_with_respoinse_rate,_PFS_and_OS._Patients_with_amplification_in_all_neoplastic_cells_(4%)_had_worse_outcome_compared_to_patients_without_amplification_(35%,_intermediate_outcome)_or_amplification_in_minor_clones_(61%,_highest_survival_probability)",23348520,PubMed,,"Martin_et_al.,_2013,_Br._J._Cancer",,2,accepted,1688,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-09-23_19:18:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1688,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Cetuximab,Panitumumab,,,,,,
ERBB2,2064,AMPLIFICATION,Gastric_Adenocarcinoma,3717,,Trastuzumab,,Predictive,Supports,B,Sensitivity/Response,"ToGA,_a_Phase_III_study_(NCT01041404)_addressed_use_of_trastuzumab_in_HER2_positive_advanced_gastric_cancer,_where_chemotherapy_using_fluoropyrimidine-based_and_platinum-based_combinations_had_been_common_practice.__Patients_were_given_a_chemotherapy_regime_containing_capecitabine,_flourouracil_and_cisplatin_with_(n=298)_or_without_(n=296)_trastuzumab,_and_had_not_been_previously_treated_for_metastatic_cancer.__Study_endpoint_was_overall_survival,_which_was_significantly_different_in_the_two_populations_(13.8_months_with_chemotherapy_+_trastuzumab_and_11.1_months_for_chemotherapy_alone).__The_authors_conclude_that_trastuzumab_should_be_a_standard_option_for_HER2_positive_advanced_gastric_cancer.",20728210,PubMed,,"Bang_et_al.,_2010,_Lancet",,4,accepted,1022,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-02-15_23:09:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1022,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Gastric_Adenocarcinoma,3717,,Trastuzumab,,Predictive,Supports,A,Sensitivity/Response,"ToGA,_a_Phase_III_study_(NCT01041404)_addressed_use_of_trastuzumab_in_HER2_positive_(overexpression_or_amplification)_advanced_gastric_cancer,_where_chemotherapy_using_fluoropyrimidine-based_and_platinum-based_combinations_had_been_common_practice.__Patients_were_given_a_chemotherapy_regime_containing_capecitabine,_flourouracil_and_cisplatin_with_(n=298)_or_without_(n=296)_trastuzumab,_and_had_not_been_previously_treated_for_metastatic_cancer.__Study_endpoint_was_overall_survival,_which_was_significantly_different_in_the_two_populations_(13.8_months_with_chemotherapy_+_trastuzumab_and_11.1_months_for_chemotherapy_alone).__The_authors_conclude_that_trastuzumab_should_be_a_standard_option_for_HER2_positive_advanced_gastric_cancer.",20728210,PubMed,,"Bang_et_al.,_2010,_Lancet",,4,accepted,1499,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1499,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,,,,,,,
ERBB2,2064,AMPLIFICATION,Salivary_Gland_Carcinoma,50904,,"Pertuzumab,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Four_of_five_patients_with_HER2_amplified/overexpressing_salivary_gland_carcinoma_(80%;_95%_CI,_28%_to_>_99%)_had_responses_(all_PR).",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5984,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2018-02-15_23:00:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/5984,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Pertuzumab,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"With_multiple_mechanisms_of_HER_reprogramming_thought_to_be_behind_trastuzumab_resistance,_including_increased_expression_of_ErbB_members,_afatinib,_which_broadly_and_irreversibly_targets_ErbB_receptors_was_tested_in_a_single_arm_phase_II_trial_on_advanced_stage_HER2_positive_metastatic_breast_cancer._From_41_treated_patients,_10%_had_partial_response,_37%_had_stable_disease_as_best_response_and_46%_achieved_clinical_benefit.__Median_progression_free_survival_(PFS)_was_15.1_weeks_and_median_overall_survival_(OS)_was_61.0_weeks._The_authors_conclude_that_Afatinib_monotherapy_shows_promise_in_treatment_of_metastatic_HER2_positive_breast_cancer_that_has_progressed_under_trastuzumab.",22418700,PubMed,,"Lin_et_al.,_2012,_Breast_Cancer_Res._Treat.",,3,accepted,1010,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:14:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1010,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,"Trastuzumab,Pertuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively.__Thirty_of_114_patients_(26%;_95%_CI,_19%_to_35%)_with_HER2_amplification/overexpression_had_objective_responses_to_treatment_with_trastuzumab_plus_pertuzumab_(two_CR,_28_PR).__Patients_with_HER2-amplified/overexpressing_metastatic_colorectal_cancer_composed_the_largest_tumor-pathway_cohort._In_this_group_of_37_patients_with_refractory_disease_(median,_four_previous_lines_of_therapy),_treatment_with_trastuzumab_plus_pertuzumab_produced_PRs_in_14_patients_(38%;_95%_CI,_23%_to_55%;_Fig_2A)._An_additional_four_patients_had_SD_>_120_days._The_median_DOR_was_11_months_(range,_<_1_to_16+_months;_95%_CI,_2.8_months_to_not_estimable).",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,4,accepted,5981,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2018-02-15_16:18:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/5981,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Pertuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Afatinib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"LUX-Breast_1_is_a_phase_3_trial_(NCT01125566)_which_enrolled_508_patients_with_metastatic_HER2_positive_BC_who_had_progressed_after_adjuvant_or_first-line_trastuzumab._It_was_thought_that_the_wider_range_of_ErbB_family_blocking_and_irreversible_properties_of_afatinib_could_be_beneficial_in_trastuzumab_resistant_cancer_cells,_since_ErbB_family_members_are_thought_to_play_a_role_in_trastuzumab_resistance._Primary_endpoint_was_intention-to-treat_group_PFS._339_patients_were_assigned_to_afatanib_+_vinorelbine_and_169__to_trastuzumab_+_vinorelbine.__Recruitment_was_stopped_prematurely_when_it_was_deemed_unlikely_that_the_increased_PFS_would_be_seen_in_the_afatinib_group._Median_PFS_was_5.5_months_in_the_afatinib_group_and_5.6_months_in_the_trastuzumab_group.__Afatanib_plus_vinorelbine_was_less_well_tolerated_than_trastuzumab_plus_vinorelbine,_and_the_authors_conclude_that_trastuzumab_remains_the_best_choice_for_treatment_of_trastuzumab-progressed_HER2_positive_metastatic_BC.",26822398,PubMed,,"Harbeck_et_al.,_2016,_Lancet_Oncol.",,4,accepted,1012,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:01:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1012,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Capecitabine,Lapatinib",Combination,Predictive,Supports,B,Sensitivity/Response,"This_Phase_III_trial_took_patients_with_locally_advanced_or_metastatic_HER2_(ERBB2)_positive_breast_cancer_that_had_progressed_on_prior_trastuzumab_treatment.__Patients_were_given_capecitabine_(n=161)_or_lapatinib_plus_capecitabine_(n=163)._The_primary_endpoint_of_the_study_was_time_to_progression._Median_time_to_progression_was_4.4_months_in_the_capecitabine_group_and_8.4_months_in_capecitabine_plus_lapatinib_group_(hazard_ratio_was_0.49_;_95%_confidence_interval,_0.34_to_0.71;_P<0.001).__The_results_indicated_that_lapatinib_may_be_useful_in_addressing_the_problem_of_trastuzumab_progression_in_HER2_breast_cancer.",17192538,PubMed,,"Geyer_et_al.,_2006,_N._Engl._J._Med.",,4,accepted,1132,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:00:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1132,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Capecitabine,Lapatinib,,,,,,
ERBB2,2064,AMPLIFICATION,Breast_Cancer,1612,,AKTi-1/2,,Predictive,Supports,D,Sensitivity/Response,Xenografts_established_from_breast_cancer_cell_lines_with_ERBB2_amplification_and_PIK3CA_mutation_(BT474)_or_PIK3CA_mutation_alone_(MCF7)_were_effectively_inhibited_in-vivo_with_an_AKT1/2-inhibitor_(AKTi-1/2;_naphthyridinone).,18725974,PubMed,,"She_et_al.,_2008,_PLoS_ONE",,3,accepted,760,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/760,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,AKTi-1/2,,,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,"Trastuzumab,Lapatinib",Combination,Predictive,Supports,B,Sensitivity/Response,"Phase_2_study_in_27_patients_with_HER2_positive_(IHC,_FISH),_KRAS_wt_metastatic_colorectal_cancer_refractory_to_standard_of_care_received_trastuzumab_and_lapatinib._After_a_median_follow-up_of_94_weeks,_eight_(30%,_95%_CI_14-50)_of_27_patients_had_achieved_an_objective_response,_with_one_patient_(4%,_95%_CI_-3_to_11)_achieving_a_complete_response,_and_seven_(26%,_95%_CI_9-43)_achieving_partial_responses;_12_(44%,_95%_CI_25-63)_patients_had_stable_disease._A_total_of_914_patients_with_KRAS_wt_were_screened_for_this_study,_48_patients_(5%)_were_identified_to_have_HER2-positive_tumors.",27108243,PubMed,,"Sartore-Bianchi_et_al.,_2016,_Lancet_Oncol.",,4,accepted,1689,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-09-23_15:57:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1689,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Lapatinib,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Tgx_221,,Predictive,Does_Not_Support,D,Sensitivity/Response,"Treatment_of_cells_obtained_from_MMTV-NeuT_mouse_mammary_tumors_with_the_p110beta_selective_inhibitor_TGX-221_showed_significant_but_minimal_reductions_in_lipid_kinase_activity_and_negligible_reductions_in_phospho_Akt_levels._In_simmilar_cells_subjected_to_p110alpha_isoform_knockout,_TGX-221_treatment_fully_blocked_Akt_activation,_indicating_that_TGX-221_was_fully_inhibiting_the_p110beta_isoform._Athymic_mice_recieved_MMTV-NeuT_tumor_cell_transplants_and_were_treated_with_TGX-221,_which_resulted_in_significant_but_minimal_reduction_in_tumor_growth_compared_to_controls.",22802530,PubMed,,"Utermark_et_al.,_2012,_Genes_Dev.",,3,accepted,1382,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-07-05_19:47:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1382,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Tgx_221,,,,,,,
ERBB2,2064,AMPLIFICATION,Biliary_Tract_Cancer,4607,,"Pertuzumab,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Two_of_seven_patients_(29%;_95%_CI,_4%_to_71%)_with_biliary_cancer_and_HER2_amplification/overexpression_had_PR,_and_three_had_SD_>_120_days",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5983,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2018-02-15_23:02:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/5983,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Pertuzumab,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Dacomitinib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Phase_2_trial_of_ERBB-inhibitor_dacomitinib_in_stage_IIIB/IV_lung_cancers_with_HER2_mutations_or_amplification._4_patients_with_HER2_amplified_NSCLC_were_enrolled_in_the_trial,_no_one_among_them_had_a_response.",25899785,PubMed,,"Kris_et_al.,_2015,_Ann._Oncol.",,3,accepted,1891,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2017-01-23_15:20:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1891,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Dacomitinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Lung_Small_Cell_Carcinoma,5409,,"Irinotecan,Trastuzumab",Combination,Predictive,Supports,C,Sensitivity/Response,"This_report_details_2_case_studies_in_relapsed_HER2_positive_SCLC.__In_the_first_case,_a_50_pack-year_patient_showed_intense_non-mutant_HER2_expression_by_IHC_without_DNA_amplification,_and_had_undergone_multiple_prior_lines_of_treatment.__With_induction_of_trastuzumab_and_irinotecan_treatment,_tumor_regression_was_observed_with_progression_free_survival_of_4.5_months.__Case_2_involved_a_68_year_old_never-smoker_with_relapsed_SCLC.__Tumor_showed_HER2_positive_SCLC_cells_with_no_amplification_or_mutation.__Third_line_trastuzumab_plus_irinotecan_brought_about_some_symptom_improvement_and_PFS_of_3.5_months.__While_the_efficacy_of_trastuzumab_against_NSCLC_with_elevated_levels_of_wild-type_HER2_expression_remains_unclear,_the_authors_conclude_that_trastuzumab_based_therapy_is_a_promising_strategy_for_chemo-resistant_SCLC.",25601188,PubMed,,"Kinehara_et_al.,_2015,_Lung_Cancer",,4,accepted,1044,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1044,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Irinotecan,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Uterine_Corpus_Endometrial_Carcinoma,50939,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,Eight_uterine_cancer_cell_lines_(four_with_ERBB2_amplification_and_four_without)_were_treated_with_scalar_concentrations_of_afatinib._Primary_chemotherapy-resistant_USC_cell_lines_harbouring_ERBB2_gene_amplification_were_sensitive_to_afatinib_exposure_and_significantly_more_sensitive_than_non-amplified_cell_lines.,25268372,PubMed,,"Schwab_et_al.,_2014,_Br._J._Cancer",,2,accepted,886,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/886,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Afatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Lung_Adenocarcinoma,3910,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,C,Resistance,"155_patients_with_lung_adenocarcinomas_underwent_rebiopsy_and_genotyping_(EGFR,_AKT1,_BRAF,_ERBB2,_KRAS,_MEK1,_NRAS,_PIK3CA_and_FISH_for_MET_and_HER2)_after_the_development_of_acquired_resistance_to_EGFR_inhibitors_(gefitinib_or_erlotinib)._2_of_24_patients_tested_were_found_to_have_HER2_amplification_(but_no_baseline_samples_available_for_analysis)._One_patient_of_which_had_a_metastasis_sample_which_was_reported_to_have_only_HER2_amplification_whereas_another_autopsy_specimen_from_the_same_patient_was_HER2_negative_but_EGFR_T790M_positive.",23470965,PubMed,,"Yu_et_al.,_2013,_Clin._Cancer_Res.",,1,accepted,1393,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-07-07_15:58:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1393,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Gefitinib,Erlotinib,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Trastuzumab,Lapatinib",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"This_Phase_III_trial_compared_the_activity_of_lapatinib_vs._trastuzumab_vs._sequential_trastuzumab_followed_by_lapatinib_vs._lapatinib_plus_trastuzumab_in_an_adjuvant_treatment_setting.__8381_women_were_randomized_to_one_of_four_treatment_arms._Patients_had_HER2_positive_non-metastatic_operable_BC._The_primary_endpoint_was_disease_free_survival.__First_results_report_that_after_median_4.5_year_follow_up,_a_non_significant_16%_improvement_in_DFS_was_seen_in_trastuzumab_+_lapatinib_vs._trastuzumab_alone.__The_results_are_interpreted_as_showing_no_added_benefit_for_labatinib_addition_to_trastuzumab_in_the_adjuvant_treatment_context.__This_trial_is_ongoing_but_not_recruiting_patients_(NCT00490139).",26255196,PubMed,,"Zardavas_et_al.,_2015,_Breast",,4,accepted,1008,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_03:56:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1008,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Lapatinib,,,,,,
ERBB2,2064,AMPLIFICATION,Uterine_Cancer,363,,"Trastuzumab,Pertuzumab",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._None_of_the_7_patients_with_HER2_amplified/overexpressing_uterus_cancer_responded_to_pertuzumab/trastuzumab.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5986,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2018-02-15_21:54:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/5986,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Pertuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Bladder_Carcinoma,4007,,"Trastuzumab,Pertuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Three_of_nine_patients_(33%;_95%_CI,_8%_to_70%)_with_advanced_bladder_cancer_and_HER2_amplification/overexpression_had_responses_(one_CR_ongoing_at_15_months;_two_PR_lasting_1_and_6_months),_and_two_patients_had_SD_>_120_days.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,3,accepted,5982,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2018-02-15_21:51:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/5982,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Pertuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Pertuzumab,Trastuzumab,Docetaxel",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_randomized_phase_3_trial,_HER2_positive_metastatic_breast_cancer_patients_given_first-line_treatment_of_pertuzumab_plus_trastuzumb_plus_docetaxel_experienced_improved_progression_free_survival_(18.5_vs_12.4_months,__P<0.001)_and_increased_objective_response_rate_(80.2%_vs_69.3%,_P=0.001)_than_the_control_group_given_placebo_plus_trastuzumab_plus_docetaxel.",22149875,PubMed,,"Baselga_et_al.,_2012,_N._Engl._J._Med.",,4,accepted,1437,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:13:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1437,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Pertuzumab,Trastuzumab,Docetaxel,,,,,
ERBB2,2064,AMPLIFICATION,Gastric_Adenocarcinoma,3717,,Lapatinib,,Predictive,Supports,B,Sensitivity/Response,"TyTAN,_a_Phase_III_study_in_Asian_patients,_looked_at_addition_of_tyrosine_kinase_inhibitor_lapatinib_to_chemptherapy_in_advanced_HER2_positive_gastric_cancer.__Primary_endpoint_was_Overall_Survival_(OS).__Participants_had_progressed_under_previous_treatment_and_only_a_small_percentage_had_seen_first_line_trastuzumab.__Patients_were_a_mix_of_those_having_undergone_gastrectomy_and_not.__OS_was_not_significantly__different_in_the_ITT_population,_but_certain_subpopulations_showed_significant_differences.__In_the_subset_of_patients_showing_a_stronger_immunohistochemistry_result_for_HER2_(IHC3+),_progression_free_survival_was_significantly_different_at_5.6_months_for_lapatinib_+_pacitaxel_vs._4.2_months_for_pacitaxel_alone.__The_authors_conclude_that_proof_of_concept_for_lapatanib_addition_to_chemotherapy_for_certain_subgroups_is_provided_in_this_study.",24868024,PubMed,,"Satoh_et_al.,_2014,_J._Clin._Oncol.",,3,accepted,1023,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-02-15_23:08:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1023,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Lapatinib,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"In_the_single_arm_Phase_II_study_(TDM4258g)_breast_cancer_patients_who_had_progressed_on_previous_anti-HER2_therapy_were_given_transtuzumab_emtansine_(T-DM1),_a_HER2_monoclonal_antibody_and_antimicrotubule_drug_conjugate._95_trial_participants_with_archival_primary_tumor_were_reassessed_for_HER2_status_(positivity_defined_by_FISH_or_IHC_3+),_and_74_patients_were_confirmed_for_HER2_positivity_and_21_were_normal._Overall_response_rate_was_33.8%_(95%_CI,_23.2%_to_44.9%)_in_patients_with_confirmed_HER2-positive_tumors_and_4.8%_(95%_CI,_1.0%_to_21.8%)_in_HER2_normal_patients._Median_PFS_was_8.2_months_(95%_CI,_4.4_months_to_not_estimable)_in_patients_with_confirmed_HER2-positive_tumors_and_2.6_months_(95%_CI,_1.4_to_3.9_months)_in_HER2_normal_patients.",21172893,PubMed,,"Burris_et_al.,_2011,_J._Clin._Oncol.",,4,accepted,1764,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-12-30_00:39:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1764,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab_Emtansine,,,,,,,
ERBB2,2064,AMPLIFICATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"A_cohort_of_patient-derived_xenografts_(PDX)_from_85_patients_with_metastatic_colorectal_cancer_was_created._PDX_were_treated_with_cetuximab_and_mechanisms_of_resistance_investigated._None_of_the_xenografts_harboring_KRAS_(N=18),_NRAS_(N=7)_or_BRAF_(N=3)_mutations_showed_resistance_whereas_1_out_of_4_xenografts_with_a_PIK3CA_mutation_responded_to_cetuximab._Among_11_quadruple-negative_samples_with_resistance_to_cetuximab,_HER2_overexpression_and_amplification_(N=3)_and_amplification_(N=1)_were_identified._In_an_independent_second_retrospective_cohort,_3_out_of_17_patients_with_KRAS_wt,_cetuximab_resitant_CRC_were_found_to_harbor_HER2_overexpression_and_amplification._In_this_cohort_no_HER2_overexpression_or_amplification_was_identified_in_14_KRAS_wt_patients_with_response_to_cetuximab.",22586653,PubMed,,"Bertotti_et_al.,_2011,_Cancer_Discov",,4,accepted,1687,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1687,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Cetuximab,,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Trastuzumab,Palbociclib_(PD0332991)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_47_breast_cancer_cell_lines,_HER2_overexpressing_cells_were_among_those_more_sensitive_to_CDK4/6_inhibitor_Palbociclib_(PD0332991)._In_the_trastuzumab_sensitive_cell_line_Bt474,_palbociclib_synergized_with_trastuzumab_in_growth_inhibition,_while_in_2_trastuzumab_resistant_cell_lines,_addition_of_trastuzumab_to_palbociclib_treatment_resulted_in_increased_growth_inhibition_over_palbociclib_alone.",19874578,PubMed,,"Finn_et_al.,_2009,_Breast_Cancer_Res.",,2,accepted,1561,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2016-10-06_18:38:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1561,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Trastuzumab,Palbociclib_(PD0332991),,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Lapatinib,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"This_Phase_III_study_(EGF104900)_was_motivated_by_preclinical_and_other_data_demonstrating_synergistic_activity_between_lapatinib_and_trastuzumab_against_HER2_positive_breast_cancer_(BC)_cells.__In_this_study_of_HER2_positive_metastatic_BC_which_had_progressed_on_trastuzumab,_two_arms_were_compared:_lapatinib_vs._lapatinib_+_trastuzumab._Progression_free_survival_(PFS)_was_the_primary_endpoint._For_296_patients,_148_in_each_arm,_median_PFS_of_8.1_weeks_for_lapatinib_and_12.0_for_combination_therapy_was_observed_(P=0.008).__The_authors_conclude_that_in_the_context_of_metastatic_trastuzumab-progressed_HER2_positive_BC,_trastuzumab_with_lapatinib_TKI_addition_is_a_favorable_treatment.",20124187,PubMed,,"Blackwell_et_al.,_2010,_J._Clin._Oncol.",,4,accepted,1009,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_04:00:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1009,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Lapatinib,Trastuzumab,,,,,,
ERBB2,2064,AMPLIFICATION,Her2-receptor_Positive_Breast_Cancer,60079,,"Lapatinib,Trastuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"In_light_of_results_showing_increased_PFS_using_mAB_plus_TKI_in_heavily_pretreated_patients,_the_efficacy_of_trastuzumab_plus_lapatinib_in_a_neoadjuvant_setting_with_untreated_stage_II_or_IIIA_HER2_positive_breast_cancer_was_assessed.__In_this_randomized_3_arm_phase_II_study_(CHER-LOB),_patients_received_(A)_chemotherapy_plus_trastuzumab,_(B)_chemotherapy_plus_lapatinib,_or_(C)_chemotherapy_plus_trastuzumab_and_lapatinib,_with_pathologic_complete_response_(pCR)_as_endpoint.__From_121_patients,_pCR_rates_were_25%_in_arm_A,_26.3%_in_arm_B,_and_46.7%_in_arm_C.__The_authors_conclude_these_results_support_the_superiority_of_dual-HER2_inhibition_in_the_neoadjuvant_context_of_HER2_positive_BC.",22493419,PubMed,,"Guarneri_et_al.,_2012,_J._Clin._Oncol.",,4,accepted,1007,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",Somatic_Mutation,2018-02-18_03:58:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1007,https://civic.genome.wustl.edu/links/variants/306,https://civic.genome.wustl.edu/links/genes/20,"Her2_(ERBB2)_amplifications_are_seen_in_up_to_20%_of_breast_cancers_and_were_associated_with_aggressive_disease_and_poor_prognosis_when_discovered._Trastuzumab_first_found_considerable_success,_and_was_approved_for_treatment,_in_HER2_positive_metastatic_breast_cancer_(MBC)_which_had_progressed_under_chemotherapy.__These_metastatic_cancers_nonetheless_progressed_under_trastuzumab,_and_other_forms_of_therapy_were_studied_for_next_line_treatments,_including_tyrosine_kinase_inhibitors.__Lapatinib,_a_reversible_inhibitor_of_tyrosine_kinase_activity_in_ErbB1_and_ErbB2,_and_afatinib,_an_irreversible_inhibitor_of_all_4_ErbB_forms_were_shown_to_have_activity_in_trastuzumab-progressed_HER2_MBC.__Interestingly_trastuzumab_itself_also_turned_out_to_remain_effective_in_treatment_of_trastuzumab-progressed_HER2_MBC.__The_LUX-Breast_1_trial_compared_a_TKI-based_treatment_(afatinib)_to_a_trastuzumab-based_treatment_of_trastuzumab-progressed_HER2_MBC,_and_the_LUX-Breast_3_trial_addressed_TKI_application_in_the_context_of_HER2_MBC_with_difficult_to_treat_brain_metastases.__In_neither_of_these_cases_was_the_TKI_more_effective,_making_successful_future_replacement_of_trastuzumab-based_therapy_with_a_TKI_in_trastuzumab-progressed_HER2_MBC_seem_unlikely.__Instead,_a_potential_role_for_TKIs_in_this_disease_context_is_revealed_in_preclinical_work_suggesting_synergism_between_TKI_and_trastuzumab_action,_and_clinical_trials_with_lapatinib_or_afatinib_combined_with_trastuzumab_indicate_that_dual_HER2_blockade_may_be_an_effective_therapy.__Dual_antibody_HER2_blockade_with_pertuzumab_instead_of_TKI_in_HER2_MBC_has_also_recently_shown_strong_results_in_the_CLEOPATRA_trial._HER2_overexpression_is_targeted_in_neoadjuvant_breast_cancer_treatment,_and_has_also_been_successfully_targeted_in_gastric_cancer.",,transcript_amplification,,822.5,Lapatinib,Trastuzumab,,,,,,
ALK,238,EML4-ALK_L1152R,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,Case-report_of_a_patient_with_an_acquired_ALK_L1152R_mutation_and_resistance_to_crizotinib_treatment._A_cell_line_model_also_showed_resistance_against_ALK_inhibition.,21791641,PubMed,,"Sasaki_et_al.,_2011,_Cancer_Res.",,4,accepted,763,1,2,29445270,29445270,A,C,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/763,https://civic.genome.wustl.edu/links/variants/307,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3455T>G,NC_000002.11:g.29445270A>C,NM_004304.4:c.3455T>G,NP_004295.2:p.Leu1152Arg",10,Crizotinib,,,,,chr2_g.29445270A~C,ALK_c.3455T~G,ALK_L1152R
ALK,238,EML4-ALK_G1269A,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,11_patients_with_crizotinib-resistant_NSCLC_were_analyzed_for_this_study._Two_harbored_the_G1269A_mutation_that_also_led_to_crizotinib-resistance_in-vitro.,22235099,PubMed,,"Doebele_et_al.,_2012,_Clin._Cancer_Res.",,4,accepted,764,1,2,29432682,29432682,C,G,ENST00000389048.3,,,,,75,GRCh37,The_EML4-ALK_G1269A_mutation_has_been_identified_in_non-small_cell_lung_cancer_patients_resistant_to_crizotinib._Cell_line_data_from_multiple_groups_have_shown_this_mutation_enhances_resistance_to_crizotinib_treatment_in_vitro.,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/764,https://civic.genome.wustl.edu/links/variants/308,https://civic.genome.wustl.edu/links/genes/1,The_EML4-ALK_G1269A_mutation_has_been_identified_in_non-small_cell_lung_cancer_patients_resistant_to_crizotinib._Cell_line_data_from_multiple_groups_have_shown_this_mutation_enhances_resistance_to_crizotinib_treatment_in_vitro.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala",17.5,Crizotinib,,,,,chr2_g.29432682C~G,ALK_c.3806G~C,ALK_G1269A
ALK,238,EML4-ALK_G1269A,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,2_out_of_7_patients_with_an_acquired_resistance_to_crizotinib_had_a_G1269A_mutation._One_of_these_patients_also_harbored_a_L1196M_mutation._In_vitro_follow-up_showed_reduced_crizotinib-induced_ALK_dephosphorylation_(293T)_and_apoptosis_(Ba/F3)_when_EML4-ALK_G1269A_overexpression_was_compared_to_EML4-ALK_overexpression_in_these_cell_lines.,23344087,PubMed,,"Kim_et_al.,_2013,_J_Thorac_Oncol",,3,accepted,765,1,2,29432682,29432682,C,G,ENST00000389048.3,,,,,75,GRCh37,The_EML4-ALK_G1269A_mutation_has_been_identified_in_non-small_cell_lung_cancer_patients_resistant_to_crizotinib._Cell_line_data_from_multiple_groups_have_shown_this_mutation_enhances_resistance_to_crizotinib_treatment_in_vitro.,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/765,https://civic.genome.wustl.edu/links/variants/308,https://civic.genome.wustl.edu/links/genes/1,The_EML4-ALK_G1269A_mutation_has_been_identified_in_non-small_cell_lung_cancer_patients_resistant_to_crizotinib._Cell_line_data_from_multiple_groups_have_shown_this_mutation_enhances_resistance_to_crizotinib_treatment_in_vitro.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala",17.5,Crizotinib,,,,,chr2_g.29432682C~G,ALK_c.3806G~C,ALK_G1269A
ERBB4,2066,MUTATION,Melanoma,1909,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"ERBB4_was_the_most_commonly_mutated_protein_tyrosine_kinase_in_this_study_in_melanoma_(19%_in_79_patients)._Seven_of_the_identified_mutations_in_ERBB4_(E317K,_E452K,_E542K,_R544W,_E563K,_E836K_and_E872K)_were_transforming_and_activating_in-vitro._ERBB4_inhibition_with_shRNA_or_lapatinib_led_to_reduced_cell_growth.",19718025,PubMed,,"Prickett_et_al.,_2009,_Nat._Genet.",,4,accepted,770,1734,2,212295697,212578308,,,ENST00000342788.4,,,,,75,GRCh37,"ERBB4_mutations_have_been_identified_in_melanoma,_lung_adenocarcinoma_and_medulloblastoma._In-vitro_studies_suggest_that_melanoma_cell_lines_harboring_an_ERBB4_mutation_are_sensitive_to_ERBB4_inhibition_with_lapatinib.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/770,https://civic.genome.wustl.edu/links/variants/310,https://civic.genome.wustl.edu/links/genes/1734,"ERBB4_mutations_have_been_identified_in_melanoma,_lung_adenocarcinoma_and_medulloblastoma._In-vitro_studies_suggest_that_melanoma_cell_lines_harboring_an_ERBB4_mutation_are_sensitive_to_ERBB4_inhibition_with_lapatinib.",,"gain_of_function_variant,transcript_variant",,4,Lapatinib,,,,,,,
PIK3CA,5290,MUTATION,Breast_Cancer,1612,,"Epirubicin,5-fluorouracil,Cyclophosphamide,Paclitaxel,Doxorubicin",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"This_study_of_140_patients_with_stage_II-III_breast_cancer_assessed_the_response_of_patients_with_PIK3CA_mutations_to_6_months_of_preoperative_chemotherapy._23/170_patients_had_PIK3CA_mutations._Of_those_patients,_12_received_six_courses_of_5-fluorouracil,_doxorubicin_(or_epirubicin),_and_cyclophosphamide;_this_treatment_group_contained_7_patient_with_E545K_mutations,_1_with_E542K,_and_4_with_H1047R._The_other_11_patients_received_12_weekly_courses_of_paclitaxel_followed_by_four_courses_of_5-fluorouracil,_doxorubicin_(or_epirubicin),_and_cyclophosphamide;_this_treatment_group_contained_1_patient_with_an_E545K_mutation,_1_with_Q546R,_1_with_E542K,_1_with_E542V,_5_with_H1047R,_1_with_G1049R,_and_1_with_H1047T._The_study_did_not_find_evidence_that_PIK3CA_mutations_are_associated_with_preoperative_chemotherapy_sensitivity_in_breast_cancer_treated_with_an_anthracycline_(doxorubicin_or_epirubicin),_5-fluorouracil_and_cyclophosphamide_regardless_of_whether_paclitaxel_was_also_administered._The_lack_of_association_was_true_of_estrogen_receptor_(ER)-positive_and_ER-negative_tumors.",18371219,PubMed,,"Liedtke_et_al.,_2008,_Breast_Cancer_Res.",,3,accepted,6191,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-10_21:59:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/6191,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Epirubicin,5-fluorouracil,Cyclophosphamide,Paclitaxel,Doxorubicin,,,
PIK3CA,5290,MUTATION,Estrogen-receptor_Positive_Breast_Cancer,60075,,Tamoxifen,,Predictive,Does_Not_Support,B,Sensitivity/Response,"This_was_a_Swedish_study_of_270_breast_tumors_removed_from_patients_with_unilateral_operable_breast_cancer,_and_either_lymph_node_metastases_or_a_tumor_diameter_>30mm._PIK3CA_missense_mutations_were_found_in_65/270_(24%)_tumors._Of_these,_36_(55%)_were_in_exon_20—_33_H1047R,_1_Y10121C,_1_G1049R,_and_1_H1047P._The_other_30_were_missense_mutations_in_exon_9—_11_E542K,_18_E545K,_1_Q546P._Within_the_group_of_188_patients_with_ER+_tumors,_PIK3CA_mutation_status_did_not_predict_response_to_tamoxifen.",17575221,PubMed,,"Pérez-Tenorio_et_al.,_2007,_Clin._Cancer_Res.",,3,accepted,6189,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2019-01-20_00:09:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/6189,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Tamoxifen,,,,,,,
PIK3CA,5290,MUTATION,Her2-receptor_Positive_Breast_Cancer,60079,,AZD5363,,Predictive,Supports,D,Sensitivity/Response,"HER2_overexpressing_breast_cancer_cell_lines_with_PIK3CA_mutation_BT474c_(K111N)_and_HCC-1954_(H1047R)_were_used_to_establish_mouse_tumor_xenografts._In_BT474c_xenografts,_three_dosing_schedules_of_AZD5363_caused_significant_tumor_inhibition_(200_mg/kg_twice_daily_>_200_mg/kg_once_daily_>_100_mg/kg_once_daily)._In_HCC-1954_xenografts_two_doses_of_AZD5363_induced_significant_tumor_inhibition_(150_mg/kg_twice_daily_>_75_mg/kg_twice_daily)_while_30_mg/kg_twice_weekly_trastuzumab_was_inactive.",22294718,PubMed,,"Davies_et_al.,_2012,_Mol._Cancer_Ther.",,2,accepted,1504,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-07_21:12:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/1504,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,AZD5363,,,,,,,
PIK3CA,5290,MUTATION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"Taselisib_(GDC-0032),Radiation",Combination,Predictive,Supports,D,Sensitivity/Response,"A_panel_of_26_HNSCC_cell_lines_was_tested_for_efficacy_of_the_p110_alpha,_delta_and_gamma_isoform_inhibitor_taselisib_(GDC-0032)._Cell_lines_with_PIK3CA_mutation_or_amplification_were_the_most_sensitive._Four_HNSCC_cell_lines_with_activating_PIK3CA_alterations_showed_synergistic_cell_death_response_to_the_combination_of_drug_with_radiation_treatment._This_synergism_was_not_apparent_in_4_tested_HNSCC_cell_lines_with_wild-type_PIK3CA_or_PTEN_mutation._Nude_mouse_xenografts_were_established_with_Cal-33_PIK3CA_H1047R_cells._Radiation_and_taselisib_treatments_alone_showed_some_growth_inhibition_in_comparison_to_control,_but_only_the_combined_treatment_led_durable_tumor_regressions.",26589432,PubMed,,"Zumsteg_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,1490,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-08_02:27:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1490,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Taselisib_(GDC-0032),Radiation,,,,,,
PIK3CA,5290,MUTATION,Endometrial_Cancer,1380,,Pictilisib,,Predictive,Supports,D,Sensitivity/Response,"A_panel_of_24_endometrioid_endometrial_cancer_(EEC)_cell_lines_was_characterized_for_a_set_of_mutations_and_sensitivity_to_pan_PI3K_class_I_inhibitor_GDC-0941_(pictilisib)_was_assessed._EEC_cell_lines_with_PIK3CA_mutations_were_significantly_more_sensitive_to_GDC-0941_(Fisher’s_exact_test,_two-tailed,_P=0.038)._Some_of_the_PIK3CA_mutant_cells_contained_PTEN_and_KRAS_mutations,_but_in_these_cells,_these_mutations_did_not_effect_sensitivity.",23674493,PubMed,,"Weigelt_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1616,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-12_03:22:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1616,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Pictilisib,,,,,,,
PIK3CA,5290,MUTATION,Breast_Cancer,1612,,"PP242,Everolimus",Substitutes,Predictive,Supports,D,Sensitivity/Response,A_panel_of_31_breast_cancer_cell_lines_was_tested_for_sensitivity_to_mTORC1_inhibitor_everolimus_and_mTORC1/mTORC2_inhibitor_PP242._Inhibitor_concentrations_for_50%_survival_fraction_(SF50)_were_measured_and_SF50_less_than_one_micro_molar_was_considered_sensitive._PIK3CA_mutant_cell_lines_were_significantly_more_sensitive_to_both_everolimus_and_PP242_than_PIK3CA_wild_type_cell_lines._Apoptotic_indicators_and_cell_cycle_analysis_indicated_that_the_mTOR_inhibitors_induced_G1_arrest_instead_of_apoptosis_in_the_cell_lines.,21358673,PubMed,,"Weigelt_et_al.,_2011,_Oncogene",,3,accepted,1610,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-11_17:32:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1610,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,PP242,Everolimus,,,,,,
PIK3CA,5290,MUTATION,Her2-receptor_Positive_Breast_Cancer,60079,,Everolimus,,Predictive,Supports,B,Sensitivity/Response,"Archival_tumor_samples_from_549_patients_from_the_BOLERO-1_and_-3_trials_were_analyzed_for_alterations_in_the_PI3K_pathway_using_next-generation_sequencing,_immunohistochemistry_(IHC)_and_Sanger_sequencing._In_the_BOLERO_trials,_patients_with_HER2-overexpressing_advanced_breast_cancer_were_treated_with_trastuzumab,_chemotherapy_and_randomized_to_receive_either_everolimus_or_placebo._In_the_pooled_analysis_of_both_trials,_patients_with_PI3K_mutations_had_longer_progression-free_survival_with_everolimus_compared_to_placebo_(HR_0.67_95%CI_0.45_to_1.00,_P=0.05)_whereas_patients_with_PI3K_wild_type_status_did_not_benefit_significantly_(HR_1.1,_95%CI_0.83_to_1.46,_P=0.5)._The_same_was_found_when_PI3K_mutations,_PTEN_loss_and_AKT_E17K_mutations_were_combinedly_analyzed_as_hyperactive_PI3K_pathway._Patients_with_PI3K_hyperactive_pathway_had_a_hazard_ratio_of_0.67_(95%CI_0.48_to_0.93,_P=0.02)_compared_to_HR_1.19_(95%CI_0.87_to_1.62,_P=0.28)_in_patients_with_PI3K_normal_pathway._These_trends_were_independently_confirmed_in_both_trials_but_only_pooled_results_showed_consistent_statistical_significance.",27091708,PubMed,,"André_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,1296,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-05-25_05:58:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1296,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Everolimus,,,,,,,
PIK3CA,5290,MUTATION,Cancer,162,,BYL719_(Alpelisib),,Predictive,Supports,D,Sensitivity/Response,"A_set_of_474_cell_lines_from_the_Cancer_Cell_Line_Encyclopedia_was_tested_for_responsiveness_to_the_PI3Kalpha_specific_inhibitor_BYL719_(Alpelisib)._In_the_PIK3CA_wild_type_subroup_of_cell_lines,_22%_were_assessed_as_responsive,_while_in_the_subgroup_of_cell_lines_with_PIK3CA_mutations,_64%_were_labeled_as_responders._7_patient_derived_xenografts_with_PIK3CA_mutations_(H1047R,_E545K,_M1043I,_C420R,_Q546K)_were_transplanted_into_mice_and_treated_with_BYL719._6/7_mice_responded_with_strong_tumor_growth_inhibition_or_regression,_while_one_(H1047R)_responded_with_weak_growth_inhibition.",24608574,PubMed,,"Fritsch_et_al.,_2014,_Mol._Cancer_Ther.",,4,accepted,1402,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-06-27_23:39:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1402,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,BYL719_(Alpelisib),,,,,,,
PIK3CA,5290,MUTATION,Cancer,162,,"Pictilisib,17-AAG",Substitutes,Predictive,Does_Not_Support,D,Sensitivity/Response,Analysis_of_drug_response_data_from_the_Sanger_center_cell_line_screen._Cell_lines_with_either_PI3K_and/or_PTEN_mutations_did_not_show_a_significant_difference_in_response_to_class_I_PI3K_inhibitor_GDC-0941_(p_=0.07_for_combined_PI3K/PTEN_aberrations_with_a_trend_towards_lower_IC50_for_mutated_cell_lines)._IC50_values_with_HSP90_inhibitor_17-AAG_were_significantly_lower_in_PI3K_and/or_PTEN_mutated_cell_lines_in_the_sanger_cell_line_screening_but_these_results_could_not_be_reproduced_in_the_cancer_cell_line_encyclopedia_screening.,25855885,PubMed,,"Wirtz_et_al.,_2015,_JAMA_Otolaryngol_Head_Neck_Surg",,2,accepted,1358,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-06-27_23:36:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1358,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Pictilisib,17-AAG,,,,,,
PIK3CA,5290,MUTATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_105_HER2-positive_metastic_breast_cancer_patients_treated_with_trastuzumab-based_therapy,_the_presence_of_a_PIK3CA_mutation_(E542K,_E545K,_or_H1047R)_was_associated_with_a_greater_risk_of_progression_(HR_=_2.50,_P_=_0.003,_multivariate_analysis)_compared_to_wildtype_PIK3CA.",21594665,PubMed,,"Razis_et_al.,_2011,_Breast_Cancer_Res._Treat.",,3,accepted,2098,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2019-01-26_22:31:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/2098,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Trastuzumab,,,,,,,
PIK3CA,5290,MUTATION,Stomach_Cancer,10534,,AZD5363,,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_22_gastric_cancer_cell_lines,_4_of_6_cell_lines_having_the_highest_sensitivity_to_AZD5363_contained_a_PIK3CA_mutation_(E542K,_E453K,_E545K)._A_patient_derived_gastric_cancer_xenograft_mouse_model_was_established_with_PIK3CA_H1047R_mutant_cells,_and_treatment_with_AZD5363_induced_significant_tumor_growth_inhibition_in_comparison_to_vehicle_control.",24088382,PubMed,,"Li_et_al.,_2013,_J_Transl_Med",,3,accepted,1501,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-07-11_02:45:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1501,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,AZD5363,,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"A_cohort_of_patient-derived_xenografts_(PDX)_from_85_patients_with_metastatic_colorectal_cancer_was_created._PDX_were_treated_with_cetuximab_and_mechanisms_of_resistance_investigated._None_of_the_xenografts_harboring_KRAS_(N=18),_NRAS_(N=7)_or_BRAF_(N=3)_mutations_showed_a_response_to_cetuximab_and_only_1_out_of_4_xenografts_with_a_PIK3CA_mutation_responded_to_cetuximab.",22586653,PubMed,,"Bertotti_et_al.,_2011,_Cancer_Discov",,1,accepted,1705,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-12_03:24:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1705,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Cetuximab,,,,,,,
PIK3CA,5290,MUTATION,Head_And_Neck_Cancer,11934,,"Pictilisib,17-AAG,Trametinib",Substitutes,Predictive,Does_Not_Support,D,Sensitivity/Response,"6_head_and_neck_cancer_cell_lines_were_tested_for_Response_to_17-AAG,_GDC-0941._Two_of_the_cell_lines_did_not_carry_PIK3CA_mutations._No_clear_difference_was_shown_between_PIK3CA-mutant_and_wild-type_cell_lines_and_there_was_a_trend_towards_increased_resistance._SCC25_cell_line_was_lentivirally_transduced_with_PIK3CA_E545K_or_H1047R_mutation._Engineered_cells,_compared_to_the_parental_cell_line,_showed_decreased_sensitivity_to_17-AAG,_GDC-0941_or_trametinib.",25855885,PubMed,,"Wirtz_et_al.,_2015,_JAMA_Otolaryngol_Head_Neck_Surg",,2,accepted,1364,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-06-27_23:34:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1364,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Pictilisib,17-AAG,Trametinib,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Anti-EGFR_Monoclonal_Antibody,,Predictive,Supports,B,Resistance,"A_meta-analysis_of_8_metastatic_colorectal_cancer_studies_(839_patients)_was_performed._PIK3CA_mutations_were_significantly_associated_with_shorter_PFS_and_OS_following_therapy_with_anti-EGFR_monoclonal_antibodies_(PFS:_8_studies,_839_patients;_HR_=_1.53;_95_%_confidence_interval_(CI)_1.28-1.84;_P_<_0.001;_OS:_5_studies;_587_patients;_HR_=_1.28;_95_%_CI_1.05-1.56;_P_=_0.015).",23435830,PubMed,,"Wu_et_al.,_2013,_J._Cancer_Res._Clin._Oncol.",,4,accepted,915,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-02-14_00:26:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/915,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Anti-EGFR_Monoclonal_Antibody,,,,,,,
PIK3CA,5290,MUTATION,Head_And_Neck_Cancer,11934,,"BEZ235_(NVP-BEZ235,_Dactolisib)",,Predictive,Supports,D,Sensitivity/Response,"Preclinical_analysis_of_the_predicitive_value_of_PIK3CA_mutations_for_mTOR/PI3K_Inhibition_with_BEZ-235._Two_cell_lines_with_PIK3CA_Mutation_(H1047R)_were_more_sensitive_to_BEZ-235_than_two_cell_lines_with_wild-type_PIK3CA_(in-vitro,_results_from_one_cell_line_also_confirmed_in-vivo)._Two_patient-derived_xenografts_with_PIK3CA_mutations_(E110K,_E542K)_showed_sensitivity_to_BEZ-235.",23619167,PubMed,,"Lui_et_al.,_2013,_Cancer_Discov",,3,accepted,1360,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1360,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,BEZ235_(NVP-BEZ235,_Dactolisib),,,,,,
PIK3CA,5290,MUTATION,Cancer,162,,AZD5363,,Predictive,Supports,D,Sensitivity/Response,"Sensitivity_to_pan-Akt_inhibitor_AZD5363_was_assessed_in_a_panel_of_182_cell_lines_(160_with_PTEN_evaluated)_derived_from_solid_and_hematological_tumors._PTEN_loss_of_function_due_to_loss_or_mutation_(N=32)_was_found_to_be_significantly_correlated_with_AZD5363_sensitivity_(p=0.0099),_and_correlation_improved_in_the_subpopulation_free_of_RAS_mutation._Mouse_xenografts_with_786-0_(PTEN-null_renal_cancer)_cells_were_established._75_mg/kg_twice_daily_AZD5363_caused_tumor_growth_inhibition_while_150_mg/kg_twice_daily_induced_moderate_tumor_regression.",22294718,PubMed,,"Davies_et_al.,_2012,_Mol._Cancer_Ther.",,3,accepted,1503,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-07_21:16:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1503,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,AZD5363,,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Bevacizumab,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_clinical_study_of_97_metastatic_colorectal_cancer_patients_who_received_bevacizumab_in_conjunction_with_first-line_chemotherapy_(composed_of_5-fluorouracil_(5-FU)_only,_5-FU_+_oxaliplatin,_5-FU_+_irinotecan,_or_5-FU_+_oxaliplatin_+_irinotecan)._It_assessed_the_relationship_between_PIK3CA_mutation_status_in_primary_tumors_and_response_to_bevacizumab-containing_first_line_chemotherapy,_as_measured_by_PFS._Of_the_97_patients,_83_had_wildtype_PIK3CA_and_14_had_mutations_in_PIK3CA_on_either_exon_9_or_20_(exon_9_mutations:_E542K,_E545K,_E545G,_E545D,_Q546K,_D549N._Exon_20_mutations:_R1023Q,_H1047R,_H1047L,_G1049A)._The_study_found_that_patients_harboring_a_PIK3CA_mutation_were_not_significantly_more_resistant_to_bevacizumab-containing_first-line_chemotherapy_than_patients_with_wildtype_PIK3CA,_as_evidenced_by_a_nonsignificant_difference_in_PFS_between_the_two_groups.",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6300,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-10_22:02:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/6300,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Bevacizumab,,,,,,,
PIK3CA,5290,MUTATION,Cancer,162,,AZD5363,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_37_patients_with_AKT1_(E13K)_mutations,_5_patients_harbored_a_concurrent_PI3K/mTOR_pathway_alteration._The_PFS_of_patients_with_a_concurrent_PI3K/mTOR_pathway_alteration_was_significantly_longer_than_those_without_when_treated_with_AZD-5363_(median_PFS,_not_reached_v_4.3_months,_respectively;_HR,_0.21;_P_=_0.045).",28489509,PubMed,,"Hyman_et_al.,_2017,_J._Clin._Oncol.",,4,accepted,3040,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2017-07-18_19:33:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/3040,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,AZD5363,,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Oxaliplatin,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_clinical_study_of_100_metastatic_colorectal_cancer_patients_who_received_FOLFOX_(oxaliplatin_+_5-fluorouracil_+_folinic_acid)_first-line_therapy_alone_or_with_monoclonal_antibodies_(bevacizumab_or_cetuximab)._It_assessed_the_relationship_between_PIK3CA_mutation_status_in_primary_tumors_and_response_to_oxaliplatin-based_first-line_therapy,_as_measured_by_post_treatment_PFS._Of_100_patients,_81_had_wildtype_PIK3CA_and_19_had_mutations_in_PIK3CA_on_either_exon_9_or_20_(exon_9_mutations:_E542K,_E545K,_E545G,_E545D,_Q546K,_D549N._Exon_20_mutations:_R1023Q,_H1047R,_H1047L,_G1049A)._The_study_found_that_patients_harboring_a_PIK3CA_mutation_were_not_significantly_more_resistant_to_oxaliplatin-based_first-line_therapy_than_patients_with_wildtype_PIK3CA,_as_evidenced_by_a_nonsignificant_difference_in_PFS_between_the_two_groups_(10.7_and_11.7_months,_respectively).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6298,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-12_18:11:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/6298,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Oxaliplatin,,,,,,,
PIK3CA,5290,MUTATION,Breast_Cancer,1612,,"PI3K_Inhibitor,Palbociclib_(PD0332991)",Combination,Predictive,Supports,D,Sensitivity/Response,"Three_PIK3CA_mutant_breast_cancer_cell_lines_were_rendered_resistant_to_PI3K_inhibitors_(BYL719_or_GDC-0941)_by_chronic_exposure._Co-treatment_of_all_three_cell_lines_with_PI3K_inhibitor_and_CDK4/6_inhibitor_palbociclib_resulted_in_synergistic_reductions_in_cell_viability_which_were_not_seen_with_treatment_of_either_compound_alone,_and_resulted_in_similar_suppression_to_viability_as_seen_in_the_respective_PI3K_inhibitor_sensitive_parental_cell_lines.",25002028,PubMed,,"Vora_et_al.,_2014,_Cancer_Cell",,3,accepted,1607,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-08-17_14:42:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1607,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,PI3K_Inhibitor,Palbociclib_(PD0332991),,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,B,Resistance,"Mutational_analysis_of_110_metastatic_colorectal_cancer_patients_was_used_to_examine_objective_tumor_response,_progression_free_survival_(PFS),_and_overall_survival_(OS)_following_treatment_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._In_univariate_analysis,_PIK3CA_mutations_(H1047R_or_E545K)_were_significantly_associated_with_lack_of_response_to_panitumumab_or_cetuximab_(objective_response_rate:_0/15_vs_22/95_for_patients_harboring_PIK3CA_mutated_or_wildtype_tumors,_respectively;_P_=_0.038)._Multivariate_logistic_regression_of_KRAS_mutations,_PIK3CA_mutations_and_PTEN_protein_expression_also_confirmed_an_independent_effect_of_PIK3CA_mutation_on_objective_response_(P_=_0.0337;_OR_=_0.1153;_CI_for_OR:_0.000–0.865)._Patients_with_tumors_harboring_either_PIK3CA_H1047R_or_E545K_mutations_(15/109)_had_decreased_PFS,_compared_to_those_with_wild-type_tumors_(P_=_0.0035),_though_they_had_a_nonsignificant_difference_in_OS._Authors_note_a_trend_in_decreasing_OS_in_patients_with_PIK3CA_mutated_tumors.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,3,accepted,6362,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-06_20:17:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/6362,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Cetuximab,Panitumumab,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_clinical_study_of_44_metastatic_colorectal_cancer_patients_who_received_FOLFIRI_(5-Fluorouacil_+_Folinic_acid_+_irinotecan)_first-line_therapy_alone_or_with_bevacizumab._It_assessed_the_relationship_between_PIK3CA_mutation_status_in_primary_tumors_and_response_to_irinotecan-based_first_line_therapy,_as_measured_by_PFS._Of_the_44_patients,_40_had_wildtype_PIK3CA_and_4_had_mutations_in_PIK3CA_on_either_exon_9_or_20_(exon_9_mutations:_E542K,_E545K,_E545G,_E545D,_Q546K,_D549N._Exon_20_mutations:_R1023Q,_H1047R,_H1047L,_G1049A)._The_study_found_that_patients_harboring_a_PIK3CA_mutation_were_not_significantly_more_resistant_to_irinotecan-based_first-line_therapy_than_patients_with_wildtype_PIK3CA,_as_evidenced_by_a_nonsignificant_difference_in_PFS_between_the_two_groups.",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6299,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-10_22:01:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/6299,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Irinotecan,,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"This_was_a_retrospective_clinical_study_of_92_metastatic_colorectal_cancer_patients_who_received_cetuximab_in_conjunction_with_salvage_chemotherapy_(refractory_to_at_least_one_line_of_treatment)._Salvage_chemotherapy_was_composed_of_5-fluorouracil_(5-FU)_only,_5-FU_+_oxaliplatin,_5-FU_+_irinotecan,_or_5-FU_+_oxaliplatin_+_irinotecan._The_study_assessed_the_relationship_between_PIK3CA_mutation_status_in_primary_tumors_and_response_to_cetuximab-containing_salvage_chemotherapy,_as_measured_by_PFS._Of_the_92_patients,_79_had_wildtype_PIK3CA_and_19_had_mutations_in_PIK3CA_on_either_exon_9_or_20_(exon_9_mutations:_E542K,_E545K,_E545G,_E545D,_Q546K,_D549N._Exon_20_mutations:_R1023Q,_H1047R,_H1047L,_G1049A)._The_study_found_that_patients_harboring_a_PIK3CA_mutation_were_significantly_more_resistant_to_cetuximab-containing_salvage_chemotherapy_than_patients_with_wildtype_PIK3CA_(Median_PFS:_2.5_and_3.9_months,_respectively;_p_=_.014).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6301,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-10_22:02:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/6301,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Cetuximab,,,,,,,
PIK3CA,5290,MUTATION,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,B,Resistance,"In_retrospective_study_of_175_metastatic_breast_cancer_patients_treated_with_trastuzumab-based_therapy,_the_presence_of_a_PIK3CA_mutation_(E542K,_E545K,_or_H1047R)_was_associated_with_a_greater_risk_of_progression_(HR_=_1.86,_P_=_0.014,_multivariate_analysis_)_compared_to_wildtype_PIK3CA.",21594665,PubMed,,"Razis_et_al.,_2011,_Breast_Cancer_Res._Treat.",,3,accepted,2087,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2019-01-26_22:47:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2087,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Trastuzumab,,,,,,,
PIK3CA,5290,MUTATION,Endometrial_Cancer,1380,,"Ridaforolimus,Temsirolimus",Substitutes,Predictive,Does_Not_Support,B,Sensitivity/Response,"94_endometrial_cancer_samples_of_women_who_had_been_treated_with_single_agent_mTOR_inhibitors_temsirolimus_or_ridaforolimus_were_retrospectively_analyzed._No_predictive_biomarkers_were_identified,_including_PIK3CA_mutations_(N=21/73),_KRAS_mutations_(10/73)_or_PTEN_loss.",24166148,PubMed,,"Mackay_et_al.,_2014,_Cancer",,3,accepted,892,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-02-07_04:26:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/892,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Ridaforolimus,Temsirolimus,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Aspirin,,Predictive,Supports,B,Sensitivity/Response,"This_was_a_retrospective_study_of_964_colorectal_cancer_patients_who_participated_in_the_Nurses'_Health_Study_and_the_Health_Professionals_Follow-up_Study._Of_964_patients,_803_patients_had_wildtype_PIK3CA_(aspirin_use:_337/803,_no_aspirin_use:_466/803)__and_161_had_mutated_PIK3CA_(aspirin_use:_66/161,_no_aspirin_use:_95/161)._This_study_found_that—among_patients_with_mutated_PIK3CA_cancer—_regular_use_of_aspirin_following_diagnosis_was_correlated_with_superior_colorectal_cancer_specific_survival_(multivariate_hazard_ratio,_0.18;_95%_CI,_0.06-0.61;_P<0.001)_and_overall_survival_(multivariate_hazard_ratio,_0.54;_95%_CI,_0.31-0.94;_P_=_0.01)._Conversely,_among_patients_with_wild-type_PIK3CA,_regular_use_of_aspirin_after_diagnosis_was_not_significantly_associated_with_colorectal_cancer–specific_survival_or_overall_survival._Among_patients_with_mutated-PIK3CA_tumors,_23_of_90_patients_who_did_not_use_aspirin_after_diagnosis_(26%)_died_within_5_years_after_diagnosis,_whereas_only_2_of_62_regular_users_of_aspirin_after_diagnosis_(3%)_died_within_5_years_after_diagnosis_(P<0.001)._In_contrast,_among_patients_with_wild-type_PIK3CA_tumors,_the_5-year_cumulative_colorectal_cancer–specific_mortality_was_the_same_(15%)_for_users_and_nonusers_of_aspirin_after_diagnosis_(P_=_0.92)._The_authors_conclude_that_PIK3CA_mutation_may_predict_response_to_aspirin_therapy_in_patients_with_newly_diagnosed_colorectal_cancer.",23094721,PubMed,,"Liao_et_al.,_2012,_N._Engl._J._Med.",,3,accepted,6375,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2018-07-11_22:30:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/6375,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Aspirin,,,,,,,
PIK3CA,5290,MUTATION,Colorectal_Cancer,9256,,Cabozantinib,,Predictive,Supports,D,Sensitivity/Response,"20_patient-derived_colorectal_cancer_xenografts_were_treated_with_cabozantinib,_a_c-MET_and_VEGFR2_inhibitor._16_xenografts_showed_sensitivity_(as_defined_by_TGII:_tumor_growth_of_treated_compared_to_control ≤ 20%)._Among_the_genes_tested_for_mutations_(KRAS,_TP53,_PIK3CA,_MET,_VEGFR2,_RET_and_AXL),_PIK3CA_mutations_(4_PDTX)_showed_a_significant_enrichment_in_sensitive_xenografts._PIK3CA_mutations_were_observed_in_4/5_of_the_most_responsive_tumors._Treating_xenografts_derived_from_isogenic_PIK3CA_wildtype_or_mutant_cell_lines_corroborated_this_finding_with_PIK3CA_mutant_xenografts_showing_greater_sensitivity_to_cabozantinib.",25242168,PubMed,,"Song_et_al.,_2015,_Int._J._Cancer",,3,accepted,771,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-02-22_20:32:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/771,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Cabozantinib,,,,,,,
PIK3CA,5290,MUTATION,Breast_Cancer,1612,,"Ribociclib,PI3K_Inhibitor",Combination,Predictive,Supports,D,Sensitivity/Response,"Three_PI3K_mutant_breast_cancer_cell_lines_were_rendered_resistant_to_PI3K_inhibitors_(BYL719_or_GDC-0941),_and_a_panel_of_42_inhibitor_compounds_was_tested_on_the_cells_for_ability_to_resensitize_the_cells_to_PI3K_inhibition._The_CDK4/6_inhibitor_ribociclib_(LEE011)_acted_synergistically_with_PI3K_inhibitor_to_reduce_viability_in_all_three_resistant_cell_lines._In_a_panel_of_12_PIK3CA_mutant_and_10_wild_type_cell_lines,_synergistic_effects_between_P110alpha_inhibitor_BYL719_and_ribociclib_were_significantly_stronger_(weighted_synergy_score_calculation,_ANOVA,_p=0.012)_in_PIK3CA_mutant_cells,_indicating_variant_specific_sensitization._Mouse_xenografts_of_4_different_PIK3CA_mutant_breast_cancer_cells_resistant_to_PI3K_inhibitor_showed_stronger_regression_under_dual_PI3K_inhibitor_and_ribociclib_treatment_than_with_either_treatment_alone.",25002028,PubMed,,"Vora_et_al.,_2014,_Cancer_Cell",,4,accepted,1600,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-11-03_18:35:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1600,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Ribociclib,PI3K_Inhibitor,,,,,,
PIK3CA,5290,MUTATION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Resistance,"The_HER2_overexpressing_breast_cancer_cell_line_BT-474_transduced_with_mutant_PIK3CA_H1047R_demonstrated_essentially_normal_proliferation_under_trastuzumab,_while_control_cells_showed_negligible_proliferation_with_trastuzumab._Sequencing_of_55_HER2_breast_cancer_samples_revealed_25%_PIK3CA_mutation_rate_and_Kaplan_Meier_curves_showed_decreased_time_to_progression_for_mutant_PIK3CA_at_borderline_statistical_significance_(p=0.052)._This_was_potentially_explained_by_presence_of_PTEN_loss_in_wild-type_PIK3CA_sample_and_combining_PTEN_loss_with_PIK3CA_mutation_resulted_in_significant_differences_in_time_to_progression_(p=0.007).",17936563,PubMed,,"Berns_et_al.,_2007,_Cancer_Cell",,2,accepted,1384,37,3,178866311,178957881,,,ENST00000263967.3,,,,,75,GRCh37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1384,https://civic.genome.wustl.edu/links/variants/311,https://civic.genome.wustl.edu/links/genes/37,"PIK3CA_mutations_are_observed_in_many_cancers_among_the_most_prevalent_are_breast_cancer,__colorectal_cancer,_and_head_and_neck_squamous_cell_carcinoma._These_mutations_have_been_observed_in_up_to_40%,_20%,_and_21%_respectively_for_each_of_these_cancer_types_with_mutations_commonly_occurring_within_the_helical_exon_9_and_kinase_domain_of_exon_20._In_breast_cancer_PIK3CA_mutations_have_been_associated_with_better_prognosis,_and_a_greater_survival_outcome,_however_the_PI3K_pathway_is_also_associated_with_increased_drug_resistance_(trastuzumab/lapatinib)._PIK3CA_mutations_in_both_HNSCC_and_CRC_have_been_associated_with_resistance_to_anti-EGFR_therapeutic_agents_and_mutations_in_exon_9_and_20_are_associated_with_a_poorer_prognosis_in_CRC._Interestingly_PIK3CA_mutations_in_HNSCC_have_been_observed_to_be_absent_from_a_number_of_ethnic_groups_including_greek,_german,_and_vietnamese_populations.",,"gain_of_function_variant,transcript_variant",,304,Trastuzumab,,,,,,,
EGFR,1956,VIII,Glioblastoma_Multiforme,3068,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,Expression_of_EGFRvIII_and_PTEN_was_evaluated_in_26_patients_with_glioblastomas_treated_with_erlotinib_or_gefitinib_and_no_EGFR_or_Her2/neu_kinase_domain_mutations._7_patients_responded_to_treatment_while_19_progressed_rapidly._Coexpression_of_EGFRvIII_and_PTEN_was_associated_with_clinical_response_(defined_as_25%_tumor_shrinkage)._These_results_were_confirmed_using_IHC_in_an_independent_cohort_of_33_patients_(8_responders)_treated_with_erlotinib_at_another_institution.,16282176,PubMed,,"Mellinghoff_et_al.,_2005,_N._Engl._J._Med.",,3,accepted,1128,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2016-04-06_16:53:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1128,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,Gefitinib,Erlotinib,,,,,,
EGFR,1956,VIII,Brain_Glioma,60108,,Nimotuzumab,,Predictive,Supports,D,Sensitivity/Response,"Two_human_glioma_cell_lines_(U87MG_or_LNZ308)_overexpressing_either_wild-type_(wt)_EGFR_or_EGFRvIII_were_treated_with_nimotuzumab,_temozolomide,_or_both_in_vitro._Anti-tumor_effects_of_nimotuzumab_were_greater_in_EGFRvIII_in_comparison_to_EGFRwt_(as_measured_by_antitumor_effects,_growth_suppression,_survival_elongation_and_EGFR_and_Akt_phosphorylation)._Combination_of_nimotuzumab_and_temozolomide_further_increased_efficacy.",26778701,PubMed,,"Nitta_et_al.,_2016,_Cancer_Med",,1,accepted,1017,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1017,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,Nimotuzumab,,,,,,,
EGFR,1956,VIII,Malignant_Glioma,3070,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_vIII_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",17177598,PubMed,,"Lee_et_al.,_2006,_PLoS_Med.",,,accepted,4500,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2017-06-15_14:59:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/4500,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,Erlotinib,,,,,,,
EGFR,1956,VIII,Glioblastoma_Multiforme,3068,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_58-year_old_patient_with_disease_progression_after_radiotherapy_and_three_temozolomide_cycles._Afatinib_and_temozolomide_led_to_disease_regression._At_last_assessment_63_treatment_cycles_had_been_completed_and_the_patient_had_survived_for_about_5_years_since_recurrence._Identified_EGFR_aberrations_included_EGFRvIII_positivity,_EGFR_gene_amplification_and_three_somatic_EGFR_mutations.",26423602,PubMed,,"Alshami_et_al.,_2015,_Oncotarget",,2,accepted,773,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/773,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,Afatinib,,,,,,,
EGFR,1956,VIII,Glioblastoma_Multiforme,3068,,Rindopepimut,,Predictive,Supports,B,Sensitivity/Response,"In_a_Phase_II_clinical_trial,_patients_with_Glioblastoma_Multiforme_(GBM),_positive_for_EGFR_VIII_deletion_mutation_(N=65),_were_treated_with_the_Rindopepimut_cancer_vaccine,__and_standard_adjuvant_temozolomide_chemotherapy.__Median_progression_free_survival_(PFS)_was_9.2_months,_and_median_overall_survival_(OS)_was_21.8_months.__A_pivotal,_randomized_Phase_III_trial_is_currently_underway.",25586468,PubMed,,"Schuster_et_al.,_2015,_Neuro-oncology",,3,accepted,971,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2016-02-03_17:18:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/971,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,Rindopepimut,,,,,,,
EGFR,1956,VIII,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"Cetuximab,Docetaxel",Combination,Predictive,Supports,B,Resistance,"47_HNSCC_patients_treated_with_cetuximab/docetaxel_were_retrospectively_analyzed_for_EGFRvIII,_EGFR,_and_AREG_expression_by_IHC._17%_of_cases_expressed_high_levels_of_EGFRvIII._High_vIII_expression_was_associated_with_reduced_disease_control_rate_(DCR)_and_shortened_progression_free_survival_(PFS)_(HR:_3.3,_P_=_0.005)_but_not_with_OS.",21653686,PubMed,,"Tinhofer_et_al.,_2011,_Clin._Cancer_Res.",,2,accepted,848,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2016-02-13_04:37:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/848,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,Cetuximab,Docetaxel,,,,,,
EGFR,1956,VIII,Glioblastoma_Multiforme,3068,,EGFR_Inhibitor,,Predictive,Supports,B,Sensitivity/Response,49_patients_(26_pretreatment_tissues_available_for_analysis)_with_recurrent_glioblastomas_who_were_treated_with_EGFR_TKIs_were_analyzed_in_this_study._Results_were_confirmed_in_an_independent_cohort_of_33_patients._EGFRvIII_and_PTEN_coexpression_were_associated_with_responsiveness_to_EGFR_TKI.,16282176,PubMed,,"Mellinghoff_et_al.,_2005,_N._Engl._J._Med.",,4,accepted,772,19,7,55087058,55223523,,,ENST00000275493.2,,,,,75,GRCh37,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",Somatic_Mutation,2016-02-03_17:26:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/772,https://civic.genome.wustl.edu/links/variants/312,https://civic.genome.wustl.edu/links/genes/19,"The_EGFRvIII_variant_is_an_oncogenic_mutation_that_has_been_reported_in_several_cancers_including_glioblastoma_multiforme,_breast,_lung,_head_and_neck,_ovarian_and_prostate._In_high-grade_gliomas,_EGFRvIII_has_been_reported_in_about_30%_of_cases_with_EGFR_amplification._The_EGFRvIII_mutation_leads_to_deletion_of_the_receptor_ectodomain_exons_2-7._The_presence_of_this_variant_has_been_linked_with_clinical_response_to_EGFR_TKI._(Arteaga_and_Engelmann,_2014)",,disruptive_inframe_deletion,,66,EGFR_Inhibitor,,,,,,,
PTEN,5728,EXPRESSION,Her2-receptor_Positive_Breast_Cancer,60079,,"Everolimus,Fulvestrant",Combination,Predictive,Supports,C,Resistance,"Case_report_of_a_44-year-old_patient_with_recurrent_HER2-positive_breast_cancer._The_primary_tumor_was_HR_positive;_however,_the_metastatic_tumor_was_HR_negative._The_patient_was_resistant_to_classical_chemotherapeutic_agents_and_anti-HER2_treatment._Thus,_the_combination_of_everolimus_and_fulvestrant_was_administered._The_patient_experienced_stable_disease_and_PFS_of_10_months._Genetic_testing_of_pleural_effusion_after_disease_progression_revealed_a_PIK3CA_H1047R_gene_mutation_but_was_positive_for_PTEN_expression_(IHC).",27445490,PubMed,,"Sun_et_al.,_2016,_Onco_Targets_Ther",,1,accepted,1624,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,,2016-11-09_16:12:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1624,https://civic.genome.wustl.edu/links/variants/313,https://civic.genome.wustl.edu/links/genes/41,,,,,54.5,Everolimus,Fulvestrant,,,,,,
PTEN,5728,EXPRESSION,Glioblastoma_Multiforme,3068,,EGFR_Inhibitor,,Predictive,Supports,B,Sensitivity/Response,49_patients_(26_pretreatment_tissues_available_for_analysis)_with_recurrent_glioblastomas_who_were_treated_with_EGFR_TKIs_were_analyzed_in_this_study._Results_were_confirmed_in_an_independent_cohort_of_33_patients._EGFRvIII_and_PTEN_coexpression_were_associated_with_responsiveness_to_EGFR_TKI.,16282176,PubMed,,"Mellinghoff_et_al.,_2005,_N._Engl._J._Med.",,4,accepted,774,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-01-26_23:48:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/774,https://civic.genome.wustl.edu/links/variants/313,https://civic.genome.wustl.edu/links/genes/41,,,,,54.5,EGFR_Inhibitor,,,,,,,
PTEN,5728,EXPRESSION,Glioblastoma_Multiforme,3068,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,Expression_of_EGFRvIII_and_PTEN_was_evaluated_in_26_patients_with_glioblastomas_treated_with_erlotinib_or_gefitinib_and_no_EGFR_or_Her2/neu_kinase_domain_mutations._7_patients_responded_to_treatment_while_19_progressed_rapidly._Coexpression_of_EGFRvIII_and_PTEN_was_associated_with_clinical_response_(defined_as_25%_tumor_shrinkage)._These_results_were_confirmed_using_IHC_in_an_independent_cohort_of_33_patients_(8_responders)_treated_with_erlotinib_at_another_institution.,16282176,PubMed,,"Mellinghoff_et_al.,_2005,_N._Engl._J._Med.",,3,accepted,1129,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,,2016-04-06_16:54:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1129,https://civic.genome.wustl.edu/links/variants/313,https://civic.genome.wustl.edu/links/genes/41,,,,,54.5,Gefitinib,Erlotinib,,,,,,
PTEN,5728,EXPRESSION,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,B,Sensitivity/Response,Trastuzumab_was_more_effective_in_cell_lines_(SKBR3_vs._drug-resistant_SKBR3/R)_and_17_patient_samples_that_exhibit_elevated_PTEN_expression_(by_IHC).,16404430,PubMed,,"Fujita_et_al.,_2006,_Br._J._Cancer",,3,accepted,955,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-07_04:27:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/955,https://civic.genome.wustl.edu/links/variants/313,https://civic.genome.wustl.edu/links/genes/41,,,,,54.5,Trastuzumab,,,,,,,
PTEN,5728,EXPRESSION,Glioblastoma_Multiforme,3068,,Dacomitinib,,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study,_the_EGFR_inhibitor_dacomitinib_had_an_effect_on_cell_viability,_self-renewal_and_proliferation_in_EGFR_amplified_GBM_cells_in-vitro_and_in-vivo_(with_or_without_the_EGFRvIII_mutation)._It_was_less_effective_in_one_cell-line_with_PTEN_deletion.",25939761,PubMed,,"Zahonero_et_al.,_2015,_Mol._Cancer_Ther.",,2,accepted,775,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/775,https://civic.genome.wustl.edu/links/variants/313,https://civic.genome.wustl.edu/links/genes/41,,,,,54.5,Dacomitinib,,,,,,,
NRG1,3084,EXPRESSION,Ovarian_Cancer,2394,,Anti-ERBB3_Agents,,Predictive,Supports,D,Sensitivity/Response,An_NRG1-ERBB3_autocrine_signal-transducing_loop_was_identified_in_a_subset_of_ovarian_cancers_and_cell_lines._Disruption_of_this_loop_led_to_decreased_cell-growth_in-vitro_and_prolonged_survival_in-vivo._An_ERBB3_directed_antibody_(MM-121)_inhibited_tumor-growth_in-vivo.,20227043,PubMed,,"Sheng_et_al.,_2010,_Cancer_Cell",,3,accepted,778,2593,8,31497942,32622294,,,ENST00000523534.1,,,,,75,GRCh37,,,2016-02-20_23:29:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/778,https://civic.genome.wustl.edu/links/variants/314,https://civic.genome.wustl.edu/links/genes/2593,,,,,37,Anti-ERBB3_Agents,,,,,,,
NRG1,3084,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Patritumab,,Predictive,Supports,B,Sensitivity/Response,"In_this_phase-2_study,_215_patients_were_randomized_to_either_erlotinib_and_placebo_or_erlotinib_and_HER3_monoclonal_antibody_patritumab._HRG_(NRG1)_expression_was_retrospectively_defined_as_predictive_biomarker_but_prospectively_assessed_in_102_patients_before_unblinding._NRG1-high_groups_demonstrated_clinical_benefit_from_additional_patritumab_with_hazard_ratios_of_0.37_(P_=_0.0283)_and_0.29_(P_=_0.0027)_in_the_high-_and_low-dose_patritumab_arms,_respectively.",26137564,PubMed,,"Mendell_et_al.,_2015,_EBioMedicine",,4,accepted,813,2593,8,31497942,32622294,,,ENST00000523534.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-14_00:29:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/813,https://civic.genome.wustl.edu/links/variants/314,https://civic.genome.wustl.edu/links/genes/2593,,,,,37,Patritumab,,,,,,,
NRG1,3084,EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"In_non-HER2_amplified_cell_lines,_sensitivity_to_HER2_kinase_inhibitor_lapatinib_was_found_mainly_in_cell-lines_with_elevated_NRG1_expression_and_HER3_activation._This_aberration_was_mainly_identified_in_head_and_neck_cancer_cell_lines.",21840482,PubMed,,"Wilson_et_al.,_2011,_Cancer_Cell",,4,accepted,776,2593,8,31497942,32622294,,,ENST00000523534.1,,,,,75,GRCh37,,,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/776,https://civic.genome.wustl.edu/links/variants/314,https://civic.genome.wustl.edu/links/genes/2593,,,,,37,Lapatinib,,,,,,,
NRG1,3084,EXPRESSION,Cancer,162,,AV-203,,Predictive,Supports,D,Sensitivity/Response,This_screening_study_in_various_tumor_xenografts_identified_NRG1_expression_to_correlate_with_sensivity_to_ERBB3_inhibitory_antibody_AV-203._ERBB3_expression_was_not_predictive_of_response.,25542901,PubMed,,"Meetze_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,861,2593,8,31497942,32622294,,,ENST00000523534.1,,,,,75,GRCh37,,,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/861,https://civic.genome.wustl.edu/links/variants/314,https://civic.genome.wustl.edu/links/genes/2593,,,,,37,AV-203,,,,,,,
NRG1,3084,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Carboplatin,Gemcitabine,Cisplatin,Paclitaxel",Substitutes,Predictive,Supports,D,Sensitivity/Response,In-vivo_studies_of_residual_NSCLC_tumors_(xenografts_of_5_cell_lines)_after_chemotherapy_found_increased_EGFR-family_signaling_and_NRG1_expression._NRG1_inhibition_(YW538.24.71_antibody)_led_to_decreased_tumor_growth_and_enhanced_magnitude_and_response_to_chemotherapy.,23390248,PubMed,,"Hegde_et_al.,_2013,_Sci_Transl_Med",,3,accepted,779,2593,8,31497942,32622294,,,ENST00000523534.1,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/779,https://civic.genome.wustl.edu/links/variants/314,https://civic.genome.wustl.edu/links/genes/2593,,,,,37,Carboplatin,Gemcitabine,Cisplatin,Paclitaxel,,,,
NRG1,3084,EXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,NRG1_upregulation_or_ERBB2_amplification_were_the_main_causes_of_resistance_to_cetuximab_in-vivo_and_in-vitro_in_this_study._Inhibition_of_ERBB2/ERBB3_signaling_restored_cetuximab_sensitivity.,21900593,PubMed,,"Yonesaka_et_al.,_2011,_Sci_Transl_Med",,4,accepted,777,2593,8,31497942,32622294,,,ENST00000523534.1,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/777,https://civic.genome.wustl.edu/links/variants/314,https://civic.genome.wustl.edu/links/genes/2593,,,,,37,Cetuximab,,,,,,,
AREG,374,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,A_cell_line_(DFCI076)_with_EML1-ALK_fusion_and_resistance_mutation_L1152R_showed_no_response_to_ALK_inhibition_with_crizotinib_or_TAE684._There_was_co-dependancy_on_AKT_and_EGFR-signaling_and_inhibition_of_both_pathways_led_to_decreased_cell-growth._Amphiregulin_(AREG)_production_was_identified_as_a_potential_mediator_of_EGFR-activation_(no_other_alterations_detectable)._The_same_mechanism_could_be_reproduced_in_a_cell_line_(H3122)_without_EML1-ALK_mutation_and_resistance_to_crizotinib_that_was_acquired_in-vitro.,21791641,PubMed,,"Sasaki_et_al.,_2011,_Cancer_Res.",,3,accepted,780,389,4,75310851,75320726,,,ENST00000395748.3,,,,,75,GRCh37,,,2016-02-20_23:27:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/780,https://civic.genome.wustl.edu/links/variants/315,https://civic.genome.wustl.edu/links/genes/389,,,,,58,Crizotinib,,,,,,,
AREG,374,EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"Cetuximab,Docetaxel",Combination,Predictive,Supports,B,Resistance,"47_HNSCC_patients_treated_with_cetuximab/docetaxel_were_retrospectively_analyzed_for_EGFRvIII,_EGFR_and_AREG_expression_with_IHC._45%_of_cases_expressed_high_level_of_AREG._High_AREG_expression_in_tumor_cells_was_associated_with_reduced_overall_survival__(hazard_ratio:_2.2,_P_=_0.002)_and_progression_free_survival_(hazard_ratio:_2.2,_P_=_0.016)_compared_to_patients_with_low_AREG_expression_score._AREG_was_an_independent_prognosticator_of_OS_in_multivariate_Cox_analysis._High_EGFRvIII_and_AREG_expression_levels_identified_SCCHN_(squamous_cell_carcinoma,_head_and_neck)_patients_that_were_less_likely_to_benefit_from_combination_treatment_with_cetuximab_and_docetaxel.",21653686,PubMed,,"Tinhofer_et_al.,_2011,_Clin._Cancer_Res.",,2,accepted,846,389,4,75310851,75320726,,,ENST00000395748.3,,,,,75,GRCh37,,,2016-02-20_02:51:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/846,https://civic.genome.wustl.edu/links/variants/315,https://civic.genome.wustl.edu/links/genes/389,,,,,58,Cetuximab,Docetaxel,,,,,,
AREG,374,EXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,"226_cetuximab-treated_patients_with_colorectal_cancer_(CRC)_were_analyzed_for_mRNA_expression_(by_qPCR)_of_EGFR_and_its_ligands_(EGF,_TGFA,_AREG_and_EREG)._High_AREG_mRNA_expression_in_KRAS_wild_type_tumours_was_a_favorable_predictor_in_a_multivariate_analysis_(median_survival_33_vs._15 months,_p=0.0005).___Cetuximab-treated_patients_with_AREG-low_KRAS_wild_type_CRC_had_poor_survival,_similar_to_KRAS_mutated_CRC.",23374602,PubMed,,"Pentheroudakis_et_al.,_2013,_BMC_Cancer",,3,accepted,788,389,4,75310851,75320726,,,ENST00000395748.3,,,,,75,GRCh37,,,2016-02-17_01:16:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/788,https://civic.genome.wustl.edu/links/variants/315,https://civic.genome.wustl.edu/links/genes/389,,,,,58,Cetuximab,,,,,,,
AREG,374,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,B,Resistance,Five_patients_with_acquired_resistance_to_crizotinib_showed_high_concentration_of_amphiregulin_in_malignant_pleural_effusions.,23344087,PubMed,,"Kim_et_al.,_2013,_J_Thorac_Oncol",,2,accepted,781,389,4,75310851,75320726,,,ENST00000395748.3,,,,,75,GRCh37,,,2016-02-08_19:41:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/781,https://civic.genome.wustl.edu/links/variants/315,https://civic.genome.wustl.edu/links/genes/389,,,,,58,Crizotinib,,,,,,,
AREG,374,EXPRESSION,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,B,Sensitivity/Response,"Prospectively_planned_retrospective_biomarker_study_in_archived_tumor_tissue_from_323_patients_from_the_PICCOLO_trial_(panitumumab_plus_irinotecan_in_CRC_patients_with_KRAS_wt)._Tumors_were_classified_as_""high_expressor""_(either_EREG_or_AREG_mRNA_level)_or_""low_expressor""_(neither_EREG_nor_AREG_in_top_tertile).__For_RAS_wild-type_patients_with_high_ligand_expression,_median_PFS_was_8.3_[4.0-11.0]_months_(irinotecan_with_panitumumab)_vs_4.4_[2.8-6.7]_months_(irinotecan_alone);_HR,_0.38_[95%_CI,_0.24-0.61];_P < .001._In_RAS_wild-type_patients_with_low_ligand_expression,_median_PFS_was_3.2_[2.7-8.1]_months_(irinotecan_with_panitumumab)_vs_4.0_[2.7-7.5]_months_(irinotecan);_HR,_0.93_[95%_CI,_0.64-1.37];_P = .73;_interaction_test_results_were_significant_[P = .01])._Results_were_less_clear_for_response_rate_(interaction_P = .17)_and_OS_(interaction_P = .11).",26867820,PubMed,,"Seligmann_et_al.,_2016,_JAMA_Oncol",,4,accepted,1020,389,4,75310851,75320726,,,ENST00000395748.3,,,,,75,GRCh37,,,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1020,https://civic.genome.wustl.edu/links/variants/315,https://civic.genome.wustl.edu/links/genes/389,,,,,58,Panitumumab,,,,,,,
EGFR,1956,G724S,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Sensitivity/Response,"Whole_genome_sequencing_of_a_case_of_colon_carcinoma_revealed_a_G724S_mutation_in_the_EGFR_gene._In-vitro,_this_mutation_was_shown_to_be_oncogenic_and_sensitive_to_Cetuximab,_yet_relatively_insensitive_towards_small_molecules.",24894453,PubMed,,"Cho_et_al.,_2014,_Mol._Cancer",,4,accepted,786,19,7,55241722,55241722,G,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_16:18:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/786,https://civic.genome.wustl.edu/links/variants/317,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2170G>A,NC_000007.13:g.55241722G>A,NM_005228.4:c.2170G>A,NP_005219.2:p.Gly724Ser",4,Cetuximab,,,,,chr7_g.55241722G~A,EGFR_c.2170G~A,EGFR_G724S
EREG,2069,EXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,"226_cetuximab-treated_patients_with_CRC_were_analyzed_for_mRNA_expression_of_EGFR_and_its_ligands._Favorable_predictors_in_a_multivariate_analysis_were_high_AREG_mRNA_in_KRAS_wild_type_tumours,_high_EREG_mRNA_and_low_Ephrin_A2_receptor_mRNA.",23374602,PubMed,,"Pentheroudakis_et_al.,_2013,_BMC_Cancer",,3,accepted,789,1737,4,75230860,75254468,,,ENST00000244869.2,,,,,75,GRCh37,,,2016-02-16_15:02:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/789,https://civic.genome.wustl.edu/links/variants/318,https://civic.genome.wustl.edu/links/genes/1737,,,,,35.5,Cetuximab,,,,,,,
EREG,2069,EXPRESSION,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,B,Sensitivity/Response,"Prospectively_planned_retrospective_biomarker_study_in_archived_tumor_tissue_from_323_patients_from_the_PICCOLO_trial_(panitumumab_plus_irinotecan_in_CRC_patients_with_KRAS_wt)._Tumors_were_classified_as_""high_expressor""_(either_EREG_or_AREG_mRNA_level)_or_""low_expressor""_(neither_EREG_nor_AREG_in_top_tertile)._For_RAS_wild-type_patients_with_high_ligand_expression,_median_PFS_was_8.3_[4.0-11.0]_months_(irinotecan_with_panitumumab)_vs_4.4_[2.8-6.7]_months_(irinotecan_alone);_HR,_0.38_[95%_CI,_0.24-0.61];_P < .001._In_RAS_wild-type_patients_with_low_ligand_expression,_median_PFS_was_3.2_[2.7-8.1]_months_(irinotecan_with_panitumumab)_vs_4.0_[2.7-7.5]_months_(irinotecan);_HR,_0.93_[95%_CI,_0.64-1.37];_P = .73;_interaction_test_results_were_significant_[P = .01])._Results_were_less_clear_for_response_rate_(interaction_P = .17)_and_OS_(interaction_P = .11).",26867820,PubMed,,"Seligmann_et_al.,_2016,_JAMA_Oncol",,4,accepted,1021,1737,4,75230860,75254468,,,ENST00000244869.2,,,,,75,GRCh37,,,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1021,https://civic.genome.wustl.edu/links/variants/318,https://civic.genome.wustl.edu/links/genes/1737,,,,,35.5,Panitumumab,,,,,,,
MAPK1,5594,E322K,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_stage_IVA_HNSCC_with_near-complete_histologic_response_after_13_days_of_neoadjuvant_erlotinib._Whole-exome_sequencing_of_the_pre-treatment_tumor_revealed_a_MAPK1_E322K_mutation_(allelic_fraction_0.13)._In-vitro_studies_in_two_HNSCC_cell_lines_showed_enhanced_EGFR_phosphorylation_and_erlotinib_sensitivity_in_the_mutant_line_compared_with_the_wild-type_line.,26181029,PubMed,,"Van_Allen_et_al.,_2015,_JAMA_Oncol",,4,accepted,791,4532,22,22127164,22127164,C,T,ENST00000215832.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/791,https://civic.genome.wustl.edu/links/variants/320,https://civic.genome.wustl.edu/links/genes/4532,,,"gain_of_function_variant,missense_variant","ENST00000215832.6:c.964G>A,NC_000002.11:g.22127164C>T,NP_002736.3:p.Glu322Lys,NM_002745.4:c.964G>A",10,Erlotinib,,,,,chr22_g.22127164C~T,MAPK1_c.964G~A,MAPK1_E322K
MAPK1,5594,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,WZ4002,,Predictive,Supports,D,Resistance,"Resistance_to_WZ4002_was_induced_in_cell_lines._Amplification_of_MAPK1_or_downregulation_of_ERK-pathway_inhibitors_led_to_resistance_to_EGFR_inhibition_with_WZ4002._Chemical_inhibition_(MEK_inhibition_with_either_CI-1040_or_GSK1120212)_or_shRNA_knockdown_of_MAPK1_resensitized_cells_to_EGFR_inhibition_with_WZ4002_in-vitro._Additionally,_MAPK1_amplification_was_identified_in_1/21_erlotinib-resistant_NSCLC_patients._MAPK1_amplification_was_not_observed_in_the_pretreatment_tumor,_only_the_post-treatment_resistant_tumor_which_lacked_other_more_common_drug-resistance_mechanisms_EGFR_T790M_or_MET_amplification.",22961667,PubMed,,"Ercan_et_al.,_2012,_Cancer_Discov",,4,accepted,792,4532,22,22108789,22221919,,,ENST00000215832.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-18_22:08:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/792,https://civic.genome.wustl.edu/links/variants/321,https://civic.genome.wustl.edu/links/genes/4532,,,transcript_amplification,,4,WZ4002,,,,,,,
KRAS,3845,A146V,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),BEZ235_(NVP-BEZ235,_Dactolisib)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_harboring_NRAS,_KRAS,_BRAF_or_PIK3CA_mutations_and_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._32/40_tumors_harbored_KRAS_mutations_including_2_tumors_with_A146V_mutations_which_achieved_stable_disease_with_combined_therapy_but_progressive_disease_in_either_monotherapy.",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,2209,30,12,25378561,25378561,G,A,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_16:31:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/2209,https://civic.genome.wustl.edu/links/variants/322,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T",8,Selumetinib_(AZD6244),BEZ235_(NVP-BEZ235,_Dactolisib),,,chr12_g.25378561G~A,KRAS_c.437C~T,KRAS_A146V
KRAS,3845,A146V,Non-small_Cell_Lung_Carcinoma,3908,,LY2835219,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_metastatic_lung_adenocarcinoma._Whole_exome_sequencing_of_the_metastatic_tumor_revealed_KRAS_A146V,_STK11_frameshift_deletion_and_ATM_alteration._Preclinical_evidence_led_to_administration_of_CDK4_inhibitor_LY2835219._Specifically,_the_PHIAL_algorithm_nominated_this_variant_as_actionable_on_the_basis_of_a_predicted_synthetic_lethal_relationship_between_activated_KRAS_and_CDK4._The_patient_achieved_stable_disease_and_was_on_treatment_for_16_weeks_which_was_the_patients_best_and_only_clinical_response_to_any_cancer-directed_therapy.",24836576,PubMed,,"Van_Allen_et_al.,_2014,_Nat._Med.",,2,accepted,794,30,12,25378561,25378561,G,A,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-22_20:30:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/794,https://civic.genome.wustl.edu/links/variants/322,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T",8,LY2835219,,,,,chr12_g.25378561G~A,KRAS_c.437C~T,KRAS_A146V
MET,4233,MUTATION,Papillary_Renal_Cell_Carcinoma,4465,,Foretinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_retrospective_analysis_of_74_patients_with_papillary_renal_cell_carcinoma,_treated_with_foretinib,_MET_germline_mutation_was_associated_with_improved_response_rate.__A_response_was_observed_in_5_of_10_(50%)_vs._5_of_57_(8.8%)_patients_with_and_without_germline_MET_mutations,_respectively.",23213094,PubMed,,"Choueiri_et_al.,_2013,_J._Clin._Oncol.",,3,accepted,796,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Germline_Mutation,2016-02-13_05:14:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/796,https://civic.genome.wustl.edu/links/variants/323,https://civic.genome.wustl.edu/links/genes/52,,,"gain_of_function_variant,transcription_variant",,15,Foretinib,,,,,,,
MET,4233,EXON_14_SKIPPING_MUTATION,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,A_single_patient_with_a_MET_c.3028G>A_(splice_donor_site_of_exon_14)_mutation_exhibited_clinical_sensitivity_to_the_c-Met_inhibitor_crizotinib._Exon_14_skipping_was_detected_using_qRT-PCR._Response_to_the_therapy_was_demonstrated_by_comparing_CAT_scans_obtained_before_treatment_to_those_obtained_during_treatment_(at_2_months_of_crizotinib_therapy).,26729443,PubMed,,"Awad_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,1185,52,7,116411903,116412043,,,ENST00000318493.6,,,,,75,GRCh37,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",Somatic_Mutation,2016-03-29_21:14:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1185,https://civic.genome.wustl.edu/links/variants/324,https://civic.genome.wustl.edu/links/genes/52,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",,exon_loss_variant,,33,Crizotinib,,,,,,,
MET,4233,EXON_14_SKIPPING_MUTATION,Lung_Adenocarcinoma,3910,,Capmatinib,,Predictive,Supports,C,Sensitivity/Response,"A_patient_with_MET_c.3028+1G>T_mutation_(METex14)_had_partial_response_(tumor_reduction_of_61%)_after_13_months_capmatinib._MET_gene_copy_number_was_four,_MET_FISH_13.8_copy_number,_and_IHC_3+.",25971938,PubMed,,"Frampton_et_al.,_2015,_Cancer_Discov",,3,accepted,1186,52,7,116411903,116412043,,,ENST00000318493.6,,,,,75,GRCh37,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",Somatic_Mutation,2016-04-06_16:58:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1186,https://civic.genome.wustl.edu/links/variants/324,https://civic.genome.wustl.edu/links/genes/52,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",,exon_loss_variant,,33,Capmatinib,,,,,,,
MET,4233,EXON_14_SKIPPING_MUTATION,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_lung_adenocarcinoma_harboring_a_MET_exon_14_skipping_mutation_and_major_response_to_crizotinib.,26845194,PubMed,,"Shea_et_al.,_2016,_J_Thorac_Oncol",,2,accepted,1651,52,7,116411903,116412043,,,ENST00000318493.6,,,,,75,GRCh37,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",Somatic_Mutation,2016-11-05_22:47:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1651,https://civic.genome.wustl.edu/links/variants/324,https://civic.genome.wustl.edu/links/genes/52,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",,exon_loss_variant,,33,Crizotinib,,,,,,,
MET,4233,EXON_14_SKIPPING_MUTATION,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_never-smoking_metastatic_lung_adenocarcinoma_patient_harboring_a_MET_splice_site_mutation_(c.2887-18_2887-7del12)__treated_with_crizotinib_monotherapy,_was__associated_with_a_response_as_evident_by_the_reduced_size_of_tumors._Prior_to_identification_of_the_MET_splice_site_mutation,_the_patient_was_treated_with_stereotactic_radiotherapy,_palliative_radiation,_and_a_single_cycle_of_pemetrexed;_subsequently,_the_patient_was_treated_with_crizotinib,_but_progressed_at_8_weeks_of_treatment.",25769807,PubMed,,"Jenkins_et_al.,_2015,_Clin_Lung_Cancer",,1,accepted,4786,52,7,116411903,116412043,,,ENST00000318493.6,,,,,75,GRCh37,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",Somatic_Mutation,2017-06-12_15:43:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/4786,https://civic.genome.wustl.edu/links/variants/324,https://civic.genome.wustl.edu/links/genes/52,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",,exon_loss_variant,,33,Crizotinib,,,,,,,
MET,4233,EXON_14_SKIPPING_MUTATION,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,We_now_report_responses_to_the_MET_inhibitors_crizotinib_and_cabozantinib_in_four_patients_with_stage_IV_lung_adenocarcinomas_harboring_mutations_leading_to_MET_exon_14_skipping.,25971939,PubMed,,"Paik_et_al.,_2015,_Cancer_Discov",,3,accepted,797,52,7,116411903,116412043,,,ENST00000318493.6,,,,,75,GRCh37,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/797,https://civic.genome.wustl.edu/links/variants/324,https://civic.genome.wustl.edu/links/genes/52,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",,exon_loss_variant,,33,Crizotinib,,,,,,,
MET,4233,EXON_14_SKIPPING_MUTATION,Cancer,162,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,The_creation_of_a_cell_line_model_(HEK293)_with_MET_exon_14_deletion_(using_the_CRISPR/Cas9_system)_led_to_enhanced_cellular_growth_and_sensitivity_to_the_MET_inhibitor_crizotinib._MET_exon_14_deletion_results_in_an_in-frame_deletion_in_the_MET_protein._Recurrent_splice_site_mutations_that_result_in_exon_14_skipping_have_been_observed_in_~3%_of_all_lung_cancers.,26547802,PubMed,,"Togashi_et_al.,_2015,_Lung_Cancer",,3,accepted,736,52,7,116411903,116412043,,,ENST00000318493.6,,,,,75,GRCh37,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",Somatic_Mutation,2016-02-24_11:44:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/736,https://civic.genome.wustl.edu/links/variants/324,https://civic.genome.wustl.edu/links/genes/52,"Exon_14_mutations_have_been_observed_in_~3%_of_patients_with_NSCLC_(28/933_reported_by_Awad_et_al_J_Clin_Onc_2016),_confirmed_to_cause_exon_skipping_when_available,_and_associated_with_concurrent_MET_amplification._Responses_to_the_c-MET_inhibitor_crizotinib_have_been_reported_in_preclinical_models_and_in_individual_case_reports_as_well_as_a_small-scale_clinical_trial_(17_patients_treated,_Drilon_et_al.,_2016_(suppl;_abstr_108;_ASCO_ID_167889-176))._Larger_studies_are_needed_but_enrollment_of_patients_with_MET_exon_14_skipping_mutation_in_trials_with_MET_inhibitors_or_off-label_treatment_is_encouraged_(Paik_et_al.,_2015_(suppl;_abstr_8021)).",,exon_loss_variant,,33,Crizotinib,,,,,,,
FGFR3,2261,EXPRESSION,Bladder_Carcinoma,4007,,"Dovitinib,SU-5402,PD173074",Substitutes,Predictive,Supports,D,Sensitivity/Response,"The_effects_of_FGFR_inhibitors_(PD173074,_TKI-258_and_SU5402)_in_bladder_carcinoma_cell_lines_were_related_to_FGFR3_(and/or_FGFR1)_expression.",21119661,PubMed,,"Lamont_et_al.,_2011,_Br._J._Cancer",,3,accepted,803,23,4,1795039,1810599,,,ENST00000440486.2,,,,,75,GRCh37,,,2016-02-21_16:30:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/803,https://civic.genome.wustl.edu/links/variants/325,https://civic.genome.wustl.edu/links/genes/23,,,,,3,Dovitinib,SU-5402,PD173074,,,,,
CBLC,23624,EXPRESSION,Cancer,162,,Olaparib,,Predictive,Supports,D,Resistance,"The_E3_ubiquitin_ligase,_CBLC,_was_identified_as_a_candidate_biomarker_for_olaparib_sensitivity_in_a_siRNA_screen_and_further_validated_in-vitro._In_other_words,_expression_of_CBLC_is_predicted_to_confer_resistance_to_olaparib.",25883215,PubMed,,"Frankum_et_al.,_2015,_Oncotarget",,2,accepted,805,9705,19,45281126,45303891,,,ENST00000270279.3,,,,,75,GRCh37,,,2016-02-22_20:35:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/805,https://civic.genome.wustl.edu/links/variants/326,https://civic.genome.wustl.edu/links/genes/9705,,,,,2,Olaparib,,,,,,,
PTPRD,5789,MUTATION,Head_And_Neck_Carcinoma,1542,,JSI-124,,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study,_loss-of-function_of_PTPRD_was_mainly_caused_by_mutation_in_head_and_neck_cancer,_as_identified_in_TCGA_data._PTPRD_mutated_cell-lines_were_more_sensitive_to_STAT3_inhibition_(JSI-124)_than_wild-type_cells._The_authors_generated_several_representative_HNSCC-derived_PTPRD_mutants_by_site-directed_mutagenesis_(S384R,_K1502M,_T1100M_and_L1147F).",26267899,PubMed,,"Peyser_et_al.,_2015,_PLoS_ONE",,3,accepted,807,4692,9,8314246,10033790,,,ENST00000381196.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_16:52:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/807,https://civic.genome.wustl.edu/links/variants/327,https://civic.genome.wustl.edu/links/genes/4692,,,"loss_of_function_variant,transcript_variant",,3,JSI-124,,,,,,,
DEFA1,1667,EXPRESSION,Prostate_Cancer,10283,,Docetaxel,,Predictive,Supports,B,Sensitivity/Response,"Blood_mRNA_levels_of_DEFA1,_DEFA1B_and_DEFA3_were_associated_with_response_to_docetaxel_treatment_in_castration_resistant_prostate_cancer._The_discovery_cohort_consisted_of_6_patients,_results_were_validated_in_10_patients.",26261420,PubMed,,"Kohli_et_al.,_2015,_Onco_Targets_Ther",,2,accepted,808,1428,8,6835172,6837602,,,ENST00000382692.2,,,,,75,GRCh37,,,2016-02-20_02:51:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/808,https://civic.genome.wustl.edu/links/variants/328,https://civic.genome.wustl.edu/links/genes/1428,,,,,10,Docetaxel,,,,,,,
ERCC1,2067,EXPRESSION,Bladder_Carcinoma,4007,,Cisplatin,,Predictive,Does_Not_Support,B,Sensitivity/Response,Immunhistochemistry_of_ERCC1_expression_in_432_patients_revealed_no_correlation_to_response_to_cisplatin_based_chemotherapy._In-vitro_studies_also_did_not_show_any_effects.,26162296,PubMed,,"Klatte_et_al.,_2015,_J._Urol.",,4,accepted,809,1735,19,45916692,45926824,,,ENST00000013807.5,,,,,75,GRCh37,,,2016-02-13_05:40:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/809,https://civic.genome.wustl.edu/links/variants/329,https://civic.genome.wustl.edu/links/genes/1735,,,,,30,Cisplatin,,,,,,,
NOTCH1,4851,AMPLIFICATION,Colorectal_Cancer,9256,,NOTCH1_Antibody,,Predictive,Supports,D,Sensitivity/Response,"NOTCH1_copy-number_gain_in_a_patient-derived_tumor_xenograft_model_of_colorectal_cancer,_was_associated_with_increased_NOTCH1_and_JAG1_activity_and_response_to_a_NOTCH1-targeting_antibody_(PF-06293622).",26152787,PubMed,,"Arcaroli_et_al.,_2016,_Int._J._Cancer",,2,accepted,811,50,9,139388896,139440314,,,ENST00000277541.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_18:43:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/811,https://civic.genome.wustl.edu/links/variants/330,https://civic.genome.wustl.edu/links/genes/50,,,transcript_amplification,,12,NOTCH1_Antibody,,,,,,,
WEE1,7465,RS3910384,Non-small_Cell_Lung_Carcinoma,3908,,"PLATINUM,Gemcitabine",Combination,Predictive,Supports,B,Sensitivity/Response,"The_presence_of_the_WEE1_polymorphism_rs3910384_correlated_with_OS_and_PFS_of_NSCLC_patients_treated_with_platinum-based_chemotherapy._Especially_the_combination_of_two_DNA-damaging_agents_was_associated_with_efficacy._663_patients_were_tested._The_authors_showed_that_rs3910384_is_closely_linked_with_the_putative_functional_WEE1_promoter_at_SNPs_rs6486433,_rs3763869_and_rs3763868.",26057002,PubMed,,"Liu_et_al.,_2015,_Sci_Rep",,3,accepted,814,6104,11,9599943,9599943,A,G,ENST00000450114.2,,,,,75,GRCh37,,Germline_Polymorphism,2016-02-21_22:37:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/814,https://civic.genome.wustl.edu/links/variants/331,https://civic.genome.wustl.edu/links/genes/6104,,,"polymorphic_sequence_variant,intron_variant","NC_000011.9:g.9599943A>G,ENST00000450114.2:c.1141+1133A>G",15,PLATINUM,Gemcitabine,,,,chr11_g.9599943A~G,WEE1_c.1141+1133A~G,
FNTB,2342,RS11623866,Ovarian_Cancer,2394,,Lonafarnib,,Predictive,Supports,B,Resistance,"57_from_105_patients_in_the_AGo-OVAR-15_trial_were_retrospectively_genotyped_for_FNTB_polymorphisms._Resistance_to_lonafarnib-containing_treatment_was_limited_to_patients_with_a_FNTB_rs11623866_(c.-609G > C)_GG_genotype_(HRPFS_6.2,_95%CI = 2.01,_19.41,_P = 0.002;_HROS_9.6,_95%CI = 1.89,_48.54,_P = 0.006).",26033044,PubMed,,"Bachmann_et_al.,_2015,_Br_J_Clin_Pharmacol",,2,accepted,815,1950,14,65453063,65453063,G,C,ENST00000246166.2,,,,,75,GRCh37,,Germline_Polymorphism,2016-02-16_15:13:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/815,https://civic.genome.wustl.edu/links/variants/332,https://civic.genome.wustl.edu/links/genes/1950,,,regulatory_region_variant,NC_000014.8:g.65453063G>C,10,Lonafarnib,,,,,chr14_g.65453063G~C,,
PTPRT,11122,PROMOTER_HYPERMETHYLATION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"Stattic,JSI-124",Substitutes,Predictive,Supports,D,Sensitivity/Response,PTPRT_promoter_hypermethylation_was_associated_with_increased_sensitivity_to_STAT3_inhibition_in_this_preclinical_study_in_HNSCC._The_authors_found_that_PTPRT_promoter_methylation_and_sensitivity_to_Stattic_(a_STAT3_SH2_domain_inhibitor)_or_JSI-124_(a_JAK/STAT3_pathway_inhibitor)_are_significantly_correlated_(P<0.05).,25982282,PubMed,,"Peyser_et_al.,_2016,_Oncogene",,2,accepted,817,8878,,,,,,,,,,,,,,Somatic_Mutation,2016-02-22_02:21:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/817,https://civic.genome.wustl.edu/links/variants/333,https://civic.genome.wustl.edu/links/genes/8878,,,,,2,Stattic,JSI-124,,,,,,
VEGFA,7422,UNDEREXPRESSION,Colorectal_Cancer,9256,,"L-Folinic_Acid,Bevacizumab,Irinotecan,5-fluorouracil",Combination,Predictive,Supports,B,Sensitivity/Response,Decreased_peri-_and_post-therapeutic_expression_of_VEGFA_were_significantly_associated_with_response_to_FOLFIRI_plus_bevacizumab_in_57_patients_with_metastatic_CRC.,25973082,PubMed,,"Tsai_et_al.,_2015,_Int_J_Clin_Exp_Pathol",,2,accepted,818,6071,6,43738444,43752346,,,ENST00000372055.4,,,,,75,GRCh37,,,2016-02-13_05:45:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/818,https://civic.genome.wustl.edu/links/variants/334,https://civic.genome.wustl.edu/links/genes/6071,,,,,10,L-Folinic_Acid,Bevacizumab,Irinotecan,5-fluorouracil,,,,
DNMT1,1786,EXPRESSION,Gastric_Adenocarcinoma,3717,,Cisplatin,,Predictive,Supports,B,Resistance,"High_DNMT1_expression_was_found_in_105/127_(83%)_or_patients_(by_qPCR_assay)._Low_DNMT1_expression_was_associated_with_improved_histopathological_and_clinical_response_and_OS_in_patients_with_gastric_cancer__(P=0.03/P=0.008,_P(log-rank)=0.001,_respectively)._In_one_cisplatin_resistant_cell_line,_DAC_treatment_and_cisplatin_had_a_synergistic_effect.",21458988,PubMed,,"Mutze_et_al.,_2011,_Eur._J._Cancer",,3,accepted,946,1510,19,10244022,10305811,,,ENST00000340748.4,,,,,75,GRCh37,,,2016-02-14_00:37:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/946,https://civic.genome.wustl.edu/links/variants/335,https://civic.genome.wustl.edu/links/genes/1510,,,,,18,Cisplatin,,,,,,,
DNMT1,1786,EXPRESSION,Ovarian_Cancer,2394,,Decitabine,,Predictive,Supports,D,Sensitivity/Response,"DNMT1_expression_(mRNA_expression_from_an_independent_study)_correlated_with_sensitivity_to_decitabine_(ρ,_−0.443,_Pearson_regression_analysis)_in_this_preclinical_study_of_45_solid_tumor_cell_lines._DNMT1_protein_expression_was_also_evaluated_in_two_KRAS-mutant_ovarian_cancer_cell_lines_pre_and_post-decitabine_treatment_showing_downregulation_following_treatment.",25968887,PubMed,,"Stewart_et_al.,_2015,_Cancer_Res.",,3,accepted,819,1510,19,10244022,10305811,,,ENST00000340748.4,,,,,75,GRCh37,,,2016-02-22_20:34:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/819,https://civic.genome.wustl.edu/links/variants/335,https://civic.genome.wustl.edu/links/genes/1510,,,,,18,Decitabine,,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Trametinib,Afatinib",Combination,Predictive,Supports,D,Sensitivity/Response,An_shDNA_Screen_identified_synergy_betwenn_ERBB3_Inhibition_and_MEK_Inhibition_in_KRAS_mutated_cell_lines._Dual_EGFR/ERBB2_Inhibitors_afatinib_and_dacomitinib_and_MEK_Inhibition_was_synergistic_in_colorectal_and_lung_cancer_cell_lines._Induction_of_ERBB3_signalling_was_also_identified_in_a_patient_with_KRAS_mutation_after_MEK_inhibition_with_trametinib.,24685132,PubMed,,"Sun_et_al.,_2014,_Cell_Rep",,4,accepted,991,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/991,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Trametinib,Afatinib,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Trametinib,Afatinib",Combination,Predictive,Supports,D,Sensitivity/Response,An_shDNA_screen_identified_synergy_between_ERBB3_Inhibition_and_MEK_Inhibition_in_KRAS_mutated_cell_lines._Dual_EGFR/ERBB2_Inhibitors_afatinib_and_dacomitinib_and_MEK_Inhibition_was_synergistic_in_colorectal_and_lung_cancer_cell_lines._Induction_of_ERBB3_signalling_was_also_identified_in_a_patient_with_KRAS_mutation_after_MEK_inhibition_with_trametinib.,24685132,PubMed,,"Sun_et_al.,_2014,_Cell_Rep",,2,accepted,992,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/992,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Trametinib,Afatinib,,,,,,
KRAS,3845,MUTATION,Endometrial_Cancer,1380,,"Temsirolimus,Ridaforolimus",Substitutes,Predictive,Does_Not_Support,B,Sensitivity/Response,"94_endometrial_cancer_samples_of_women_who_had_been_treated_with_single_agent_mTOR_inhibitors_temsirolimus_or_ridaforolimus_were_retrospectively_analyzed._Mutations_were_found_in_32_of_73_analyzed_tumors,_10_of_which_were_KRAS_mutations._No_predictive_biomarkers_were_identified,_including_PIK3CA_mutations,_KRAS_mutations_or_PTEN_loss.",24166148,PubMed,,"Mackay_et_al.,_2014,_Cancer",,2,accepted,894,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-13_19:33:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/894,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Temsirolimus,Ridaforolimus,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Dasatinib,Cetuximab",Combination,Predictive,Supports,D,Sensitivity/Response,"Combined_treatment_with_dasatinib_and_cetuximab,_but_not_either_agent_in_monotherapy,_had_an_antitumor_efficacy_in-vitro_and_in_xenografts._These_results_were_based_on_three_KRAS_mutant_cell_lines_(LS180,_LoVo_and_HCT116)_and_two_KRAS_wild-type_cell_lines_(SW48_and_CaCo2).",20956938,PubMed,,"Dunn_et_al.,_2011,_Oncogene",,3,accepted,947,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_16:23:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/947,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Dasatinib,Cetuximab,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,A,Resistance,NCCN_guidelines_indicate_colorectal_cancer_patients_with_KRAS_mutations_should_not_be_treated_with_the_anti-EGFR_therapies_cetuximab_or_panitumumab.,28275037,PubMed,,"Benson_et_al.,_2017,_J_Natl_Compr_Canc_Netw",,5,accepted,5345,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:06:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/5345,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Cetuximab,Panitumumab,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Abemaciclib,,Predictive,Supports,B,Sensitivity/Response,"In_this_multicenter_phase_I_study_of_abemaciclib,_a_total_of_225_patients_were_enrolled:_33_in_dose_escalation_and_192_in_tumor-specific_cohorts._Radiographic_responses_were_achieved_in_previously_treated_patients_with_breast_cancer,_NSCLC,_and_melanoma._The_disease_control_rate_for_the_KRAS-mutant_population_was_55%_(16/29)_compared_to_39%_(13/33)__in_KRAS_wildtype_cohort._Stable_disease_lasting_≥24_weeks_was_achieved_for_31%_(9/29)_with_KRAS-mutant_disease_vs_12%_(4/33)_with_KRAS_wild-type_disease._Median_PFS_was_2.8_months_and_1.9_months_for_the_KRAS-mutant_and_KRAS_wild-type_populations,_respectively.",27217383,PubMed,,"Patnaik_et_al.,_2016,_Cancer_Discov",,3,accepted,4842,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:07:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/4842,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Abemaciclib,,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Nivolumab,Atezolizumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"A_meta-analysis_of_randomized_trials_to_investigate_if_KRAS_mutation_status_affects_survival_benefits_of_immune_checkpoint_inhibition_(ICI)_in_patients_with_advanced_NSCLC._Of_3_eligible_studies_using_either_nivolumab_or_atezolizumab,_138_patients_with_KRAS_mutant_NSCLC_and_371_with_KRAS_wild-type_were_included._ICI_improved_overall_survival_over_that_with_docetaxel_in_KRAS_mutant,_previously-treated_advanced_NSCLC_(hazard_ratio=0.64_[95%_confidence_interval,_0.43-0.96],_P_=_0.03)_but_not_in_those_with_KRAS_wild-type_tumor_(HR_=_0.88_[95%_CI,_0.68-1.13],_P_=_0.30)._These_results_suggest_that_KRAS_mutation_status_may_be_a_potential_biomarker_for_survival_benefits_to_ICIs.",28525386,PubMed,,"Kim_et_al.,_2017,_Oncotarget",,3,accepted,4863,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-06-15_18:58:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/4863,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Nivolumab,Atezolizumab,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"RAF265,Selumetinib_(AZD6244)",Combination,Predictive,Supports,D,Sensitivity/Response,"SiRNA_Screening_in_37_KRAS_Mutant_colorectal_cancer_cell_lines_identified_RAF1_and_MEK_Inhibition_as_synergistic,_whereas_MEK_Inhibition_alone_led_to_quick_resistance_via_upregulation_of_RAF-signalling._This_finding_was_reproduced_two_NSCLC_cell_lines_in_a_second,_independent_shRNA_screen.",25199829,PubMed,,"Lamba_et_al.,_2014,_Cell_Rep",,2,accepted,989,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/989,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,RAF265,Selumetinib_(AZD6244),,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"RAF265,Selumetinib_(AZD6244)",Combination,Predictive,Supports,D,Sensitivity/Response,"SiRNA_Screening_in_37_KRAS_Mutant_colorectal_cancer_cell_lines_identified_RAF1_and_MEK_Inhibition_as_synergistic,_whereas_MEK_Inhibition_alone_led_to_quick_resistance_via_upregulation_of_RAF-signalling._This_finding_could_be_reproduced_in_colorectal_and_lung_cancer_cell_lines_in_a_second,_independent_screen.",25199829,PubMed,,"Lamba_et_al.,_2014,_Cell_Rep",,4,accepted,988,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/988,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,RAF265,Selumetinib_(AZD6244),,,,,,
KRAS,3845,MUTATION,Melanoma,1909,,"Dabrafenib,Vemurafenib",Substitutes,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_44_relapsed_melanoma_patients_harboring_BRAF_V600E_or_V600K_(known_BRAF_inhibitor_sensitizing_mutations),_MAPK_pathway_reactivation_mechanisms_were_implicated_in_acquired_resistance_to_BRAF_inhibitor_(vemurafenib_or_dabrafenib)_monotherapy._The_following_MAPK_pathway_variants_were_found_in_progressive_tumors_with_patient_matched_baseline_tumors_(some_patients_donated_samples_from_multiple_geographically/temporally_distinct_progressive_tumors):_NRAS_mutations_(G12D,_G12R,_G13R,_Q61K,_Q61R,_Q61L)_in_13/71_(18%)_of_progressive_tumors,_KRAS_mutations_(G12C,_G12R,_Q61H)_in_5/71_(7%)_of_progressive_tumors,_mutant_BRAF_amplification_(2-15_fold_or_4-75_copies)_in_11/57_(19%)_of_progressive_tumors,_mutant_BRAF_alternative_splice_variants_(novel_exon_boundaries_between_1/9,_1/11,_3/9)_in_6/48_(13%)_of_progressive_tumor_RNA.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,6264,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_23:07:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/6264,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Dabrafenib,Vemurafenib,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"A_cohort_of_patient-derived_xenografts_(PDX)_from_85_patients_with_metastatic_colorectal_cancer_was_created._PDX_were_treated_with_cetuximab_and_mechanisms_of_resistance_investigated._None_of_the_xenografts_harboring_KRAS_(N=18),_NRAS_(N=7)_or_BRAF_(N=3)_mutations_showed_a_response_to_cetuximab_whereas_1_out_of_4_xenografts_with_a_PIK3CA_mutation_responded_to_cetuximab.",22586653,PubMed,,"Bertotti_et_al.,_2011,_Cancer_Discov",,3,accepted,1702,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_22:15:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1702,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Cetuximab,,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Docetaxel,Selumetinib_(AZD6244)",Combination,Predictive,Supports,B,Sensitivity/Response,"87_patients_with_KRAS_mutant_stage_IIB-IV_NSCLC_after_first_line_therapy_were_randomly_assigned_(1:1)_to_oral_selumetunib_and_docetaxel_or_docetaxel_and_Placebo._Median_OS_was_9·4_months_(6·8-13·6)_in_selumetinib_group_and_5·2_months_(95%_CI_3·8-non-calculable)_in_placebo_group_(hazard_ratio_[HR]_for_death_0·80,_80%_CI_0·56-1·14;_one-sided_p=0·21)._Median_PFS_was_5·3_months_(4·6-6·4)_in_selumetinib_group_and_2·1_months_(95%_CI_1·4-3·7)_in_placebo_group_(HR_for_progression_0·58,_80%_CI_0·42-0·79;_one-sided_p=0·014)._An_objective_response_was_observed_in_16_(37%)_patients_in_the_selumetinib_group_and_none_in_the_placebo_group(p<0·0001).",23200175,PubMed,,"Jänne_et_al.,_2013,_Lancet_Oncol.",,4,accepted,999,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-12_19:32:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/999,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Docetaxel,Selumetinib_(AZD6244),,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,RO4987655,,Predictive,Does_Not_Support,B,,Phase_I_expansion_and_pharmacodynamic_study_of_the_oral_MEK_inhibitor_RO4987655_(CH4987655)._2_PR_and_8_SD_among_18_patients_with_KRAS_Mutant_NSCLC.,24947927,PubMed,,"Zimmer_et_al.,_2014,_Clin._Cancer_Res.",,1,accepted,997,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-11_04:24:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/997,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,RO4987655,,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,BAY_86-9766,,Predictive,Does_Not_Support,C,Sensitivity/Response,"Phase_I_trial_of_the_mitogen-activated_protein_kinase_1/2_inhibitor_BAY_86-9766._4_patients_with_KRAS_+/-_PIK3CA_mutant_colorectal_cancer._3_with_SD,_1_with_PD.",23434733,PubMed,,"Weekes_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1001,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1001,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,BAY_86-9766,,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),Cetuximab",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"A_phase_I_study__to_determine_the_tolerability_and_pharmacokinetics_of_Selumetinib_and_Cetuximab_with_an_expanded_cohort_in_KRAS-mutant_CRC._In_the_KRAS-mutant_CRC_dose_expansion_cohort_14_patients_were_evaluable_for_response._Five_patients_experienced_stable_disease,_nine_had_progressive_disease.__Minimal_anti-tumor_activity_was_observed_in_KRAS-mutant_refractory_metastatic_CRC.",26666244,PubMed,,"Deming_et_al.,_2016,_Invest_New_Drugs",,3,accepted,4866,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:08:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/4866,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Selumetinib_(AZD6244),Cetuximab,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Selumetinib_(AZD6244),Docetaxel",Combination,Predictive,Supports,A,Resistance,"A_phase_3_study_of_selumetinib_and_docetaxel_in_KRAS_mutant,_previously_treated_NSCLC._866_were_enrolled_and_510_randomized._Median_progression-free_survival_was_3.9_months_with_selumetinib + docetaxel_and_2.8_months_with_placebo + docetaxel._Median_overall_survival_was_8.7_months_with_selumetinib + docetaxel_and_7.9_months_with_placebo + docetaxel._Objective_response_rate_was_20.1%_with_selumetinib + docetaxel_and_13.7%_with_placebo + docetaxel.",28492898,PubMed,,"Jänne_et_al.,_2017,_JAMA",,5,accepted,2998,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:06:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/2998,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Selumetinib_(AZD6244),Docetaxel,,,,,,
KRAS,3845,MUTATION,Pancreatic_Adenocarcinoma,4074,,"AZD8186,SCH772984",Combination,Predictive,Supports,D,Sensitivity/Response,"Inhibition_of_ERK_in_11_KRAS_mutant_pancreatic_cancer_cell_lines_with_SCH772984_was_more_effective_than_MEK_Inhibition._Combined_Treatment_with_PI3K_Inhibitor_AZD8186_was_more_effective_than_either_agent_alone._Chemical_library_screen_in_two_cell_lines_also_identified_mTOR,_AKT_Family_Inhibitors_(Temsirolimus,_Everolimus)_to_act_synergistically_with_ERK_Inhibition.",26725216,PubMed,,"Hayes_et_al.,_2016,_Cancer_Cell",,4,accepted,1003,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1003,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,AZD8186,SCH772984,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,Ixazomib,,Predictive,Supports,D,Resistance,"Preclinical_study_in_colorectal_cancer_xenografts._KRAS-G13D_or_KRAS-G12V_mutations_were_introduced_into_KRAS-WT_SW48_cell_line._KRAS_wild-type,_but_not_KRAS_mutant_tumors_were_sensitive_to_proteasome_inhibitor_ixazomib",26709701,PubMed,,"Chattopadhyay_et_al.,_2015,_PLoS_ONE",,1,accepted,1182,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1182,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Ixazomib,,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Trametinib,Docetaxel,Pemetrexed",Combination,Predictive,Supports,B,Sensitivity/Response,"This_phase_I/Ib_two-part_study_evaluated_trametinib_in_combination_with_anticancer_agents_docetaxel_or_pemetrexed_in_NSCLC_with_and_without_KRAS_mutations._Confirmed_partial_response_(PR)_was_observed_in_21%_(10/47)_patients_receiving_trametinib/docetaxel._The_ORR_was_18%_(4_PR_in_22_patients)_in_KRAS_wild-type_versus_24%_(six_PR_in_25_patients)_in_KRAS-mutant_NSCLC._Of_the_42_patients_treated_with_trametinib/pemetrexed,_14%_(6/42)_had_a_PR;_the_ORR_was_17%_(4/23)_in_KRAS-mutated_NSCLC_versus_11%_(2/19)_in_KRAS_wild-type_NSCLC.",27876675,PubMed,,"Gandara_et_al.,_2017,_J_Thorac_Oncol",,3,accepted,4862,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:08:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/4862,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Trametinib,Docetaxel,Pemetrexed,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,RO4987655,,Predictive,Does_Not_Support,B,,Phase_I_expansion_and_pharmacodynamic_study_of_the_oral_MEK_inhibitor_RO4987655_(CH4987655)._All_25_patients_with_KRAS_mutant_colorectal_cancer_experienced_PD.,24947927,PubMed,,"Zimmer_et_al.,_2014,_Clin._Cancer_Res.",,1,accepted,998,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-14_14:23:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/998,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,RO4987655,,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),R1507",Combination,Predictive,Supports,D,Sensitivity/Response,"Preclinial_data_from_KRAS_mutant_colorectal_cancer_cell_lines_show_syngergistic_effect_on_cell_viability_and_apoptosis_in_vitro_and_in_vivo_when_MEK_and_IGF-IR_are_inhibited_concomitantly._In_other_cell_lines,_activation_of_other_RTKs_(such_as_MET)_were_observed_upon_MEK_Inhibition_and_combination_of_RTKi_and_METi_also_showed_synergistic_activity._A_total_of_16_cell_lines_were_used_in_this_study._6_were_KRAS_wild_type,_and_10_harbored_various_KRAS_mutations_(G12C,_G12D,_G12V,_G13D,_and_Q61L)._Additional_data_was_obtained_from_xenografts.",21985784,PubMed,,"Ebi_et_al.,_2011,_J._Clin._Invest.",,3,accepted,1004,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1004,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Selumetinib_(AZD6244),R1507,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Trametinib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_phase_II_trial,_trametinib_or_docetaxel_was_given_to_patients_with_advanced_KRAS-mutant_NSCLC._Median_PFS_was_12_weeks_in_the_trametinib_arm_and_11_weeks_in_the_docetaxel_arm_(HR_1.14;_p_=_0.5197)._Median_OS,_while_the_data_are_immature,_was_8_months_in_the_trametinib_arm_and_was_not_reached_in_the_docetaxel_arm_(HR_0.97;_P_=_0.934)._There_were_10_(12%)_partial_responses_(PRs)_in_the_trametinib_arm_and_5_(12%)_PRs_in_the_docetaxel_arm_(P_=_1.0000)._These_data_suggest_that_trametinib_is_associated_with_similar_PFS_and_response_rates_as_docetaxel.",25722381,PubMed,,"Blumenschein_et_al.,_2015,_Ann._Oncol.",,4,accepted,4867,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-06-26_13:32:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/4867,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Trametinib,,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Selumetinib_(AZD6244),Erlotinib",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,38_KRAS_wild-type_patients_were_randomized_to_erlotinib_or_combination_of_selumetinib_with_erlotinib._41_KRAS_mutant_patients_were_randomized_to_selumetinib_or_the_combination._The_primary_end_points_were_progression-free_survival_(PFS)_for_the_KRAS_wild-type_cohort_and_objective_response_rate_(ORR)_for_the_KRAS_mutant_cohort._Median_PFS_in_the_KRAS_wild-type_arm_was_2.4_months_for_erlotinib_alone_and_2.1_months_for_the_combination._The_ORR_in_the_KRAS_mutant_group_was_0%_for_selumetinib_alone_and_10%_for_the_combination._These_data_suggest_no_difference_in_ORR_or_PFS_with_combination_therapy_of_over_monotherapy_in_KRAS_mutant_and_KRAS_wild-type_advanced_NSCLC.,26802155,PubMed,,"Carter_et_al.,_2016,_Ann._Oncol.",,4,accepted,4868,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-06-29_18:47:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/4868,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Selumetinib_(AZD6244),Erlotinib,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Docetaxel,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_study,_KRAS_was_neither_prognostic_nor_predictive_of_benefit_for_either_docetaxel_or_erlotinib.",26209642,PubMed,,"Rulli_et_al.,_2015,_Ann._Oncol.",,4,accepted,4996,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-06-27_10:23:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/4996,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Docetaxel,,,,,,,
KRAS,3845,MUTATION,Ovarian_Cancer,2394,,Decitabine,,Predictive,Supports,D,Sensitivity/Response,"KRAS_mutation_or_amplification_predicted_sensitivity_to_decitabine_in_ovarian_cancer_cell_lines._The_authors_profiled_the_response_of_45_ovarian,_melanoma,_and_breast_cancer_cell_lines_over_9_days_of_treatment_with_decitabine._4_ovarian_lines_with_KRAS_mutation_were_among_the_most_sensitive_to_decitabine.",25968887,PubMed,,"Stewart_et_al.,_2015,_Cancer_Res.",,3,accepted,820,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_16:24:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/820,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Decitabine,,,,,,,
KRAS,3845,MUTATION,Cancer,162,,AZD5438,,Predictive,Supports,D,Sensitivity/Response,"CDK1_was_identified_in_a_preclinical_siRNA_screen_to_identify_targets_in_KRAS_mutant_tumors._Cell_viability_was_evaluated_following_knockdown_of_834_genes_in_isogenic_LIM1215_colorectal_cancer_cell_lines_harboring_wildtype_(parental),_G12S,_G12D_or_G12V_KRAS._6_targets_identified_by_this_screen_were_evaluated_in_a_second_set_of_isogenic_colorectal_cancer_cell_lines_(SW48)_harboring_wildtype_(parental),_G12S,_G12D,_G12V_or_G13D_KRAS_where_only_CDK1_knockdown_more_profoundly_reduced_survival_in_mutant_cells_compared_to_wildtype._Results_were_validated_in_5_KRAS_mutant_(BRAF_WT)_and_10_KRAS_WT_colorectal_cancer_cell_lines._Chemical_inhibition_of_CDK1_by_AZD5438_in_KRAS_mutant_vs_WT_pancreatic_and_colorectal_cancer_cell_lines_showed_increased_efficacy_in_mutant_cell_lines._Finally,_AZD5438_reduced_tumor_growth_induced_by_SW620_(KRAS_p.G12V)_colorectal_tumour_cells_xenografted_into_immunodeficient_mice.",26881434,PubMed,,"Costa-Cabral_et_al.,_2016,_PLoS_ONE",,3,accepted,1183,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-25_16:58:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1183,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,AZD5438,,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,B,Resistance,"In_the_placebo-controlled_Phase_III_study_SATURN,_using_erlotinib_maintenance_therapy_for_patients_with_advanced_NSCLC_who_were_selected_for_response_or_stable_disease_after_first_line_chemotherapy,_KRAS_mutation_was_assessed._In_the_KRAS_wildtype_group,_erlotinib_showed_a_significant_benefit_for_progression_free_survival_(PFS)_over_placebo_(HR,_0.70;_95%_CI,_0.57_to_0.87,_P<0.001)._No_statistically_significant_improvement_in_PFS_was_seen_with_erlotinib_in_the_KRAS_mutant_group_over_placebo._Significant_difference_in_PFS_between_erlotinib_treated_KRAS_WT_and_MUT_patients_was_not_seen.__Overall,_in_the_intent_to_treat_population_erlotinib_significantly_improved_PFS_over_placebo_(HR,_0.71;_95%_CI,_0.62_to_0.82;_P<0.001).",21969500,PubMed,,"Brugger_et_al.,_2011,_J._Clin._Oncol.",,3,accepted,3895,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:12:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/3895,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Erlotinib,,,,,,,
KRAS,3845,MUTATION,Lung_Adenocarcinoma,3910,,Farnesylthiosalicylic_Acid,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_a_study_of_30_lung_adenocarcinoma_patients_with_documented_KRAS_mutations,_farnesylthiosalicylic_acid_(Salirasib)_mono-therapy_resulted_in_no_partial_responses_and_did_not_improve_overall_survival_rates_compared_to_previously_untreated_patients.",21847063,PubMed,,"Riely_et_al.,_2011,_J_Thorac_Oncol",,3,accepted,1218,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-03_19:11:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1218,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Farnesylthiosalicylic_Acid,,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Trametinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_1_clinical_trial_for_the_use_of_trametinib_for_various_advanced_solid_tumors,_22_out_of_30_NSCLC_patients_harbored_KRAS_mutations._Of_those_22_patients_with_mutant_KRAS,_8_saw_reductions_in_tumor_size_ranging_from_6-52%_including_2_partial_responses.",22805291,PubMed,,"Infante_et_al.,_2012,_Lancet_Oncol.",,2,accepted,1220,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-14_22:32:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1220,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Trametinib,,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"IMO,EGFR_Inhibitor",Combination,Predictive,Supports,D,Sensitivity/Response,TLR9_agonist_immunomodulatory_oligonucleotide_(IMO)_led_to_inhibited_survival_of_LS174T_colorectal_cancer_and_AsPC1_pancreatic_cancer_cell_lines_with_KRAS_mutations.,21890455,PubMed,,"Rosa_et_al.,_2011,_Clin._Cancer_Res.",,2,accepted,943,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-22_20:32:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/943,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,IMO,EGFR_Inhibitor,,,,,,
KRAS,3845,MUTATION,Hepatocellular_Carcinoma,684,,"Refametinib,Sorafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Phase_2_study_in_Asian_patients_with_unresectable_hepatocellular_carcinoma._70_patients_received_refametinib_(BAY_86-9766)_plus_sorafenib_as_study_treatment._A_retrospective_biomarker_analysis_was_performed_in_69_patients_for_KRAS,_NRAS_and_BRAF_mutations_(BEAM_technology)._4_patients_were_identified_to_harbor_RAS_mutations._3_of_whom_still_received_study_treatment_at_the_cutoff_date_used_for_the_final_data_analysis._These_3_patients_had_achieved_confirmed_PR,_with_duration_responses_ranging_from_128_to_382_days._The_fourth_patient_with_a_RAS_mutation_discontinued_study_treatment_after_41_days_on_therapy_due_to_PD._An_overall_of_4_(6_by_modified_RECIST)_patients_achieved_PR.",25294897,PubMed,,"Lim_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,1642,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-09-11_13:37:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1642,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Refametinib,Sorafenib,,,,,,
KRAS,3845,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Docetaxel,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Of_the_275_patients_assessable_for_KRAS_mutation_status,_49_(18%)_were_positive_for_KRAS_mutation._There_were_no_differences_between_treatments_in_OS,_PFS,_or_response_rates_according_to_KRAS_mutation_status,_and_no_evidence_that_KRAS_mutation_is_a_predictive_factor_for_a_differential_survival_effect_between_gefitinib_and_docetaxel.",20038723,PubMed,,"Douillard_et_al.,_2010,_J._Clin._Oncol.",,4,accepted,4997,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-06-27_10:24:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/4997,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Docetaxel,,,,,,,
KRAS,3845,MUTATION,Cancer,162,,Trametinib,,Predictive,Supports,D,Sensitivity/Response,"In_this_screen_of_218_solid_cancer_cell_lines,_KRAS_and_BRAF_mutations_were_predictive_of_response_to_MEK_inhibitor_GSK1120212._40_cell_lines_harbored_a_KRAS_mutation._In_RAF/RAS_mutant_colon_cancer_cell_lines,_co-occurring_PIK3CA/PTEN_mutations_led_to_a_cytostatic_(9/10_cell_lines)_response_rather_than_a_cytotoxic_response_(1/10_cell_lines).",22169769,PubMed,,"Jing_et_al.,_2012,_Mol._Cancer_Ther.",,4,accepted,935,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/935,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Trametinib,,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Bevacizumab,Chemotherapy",Combination,Predictive,Supports,B,Resistance,"Meta-Analysis_of_12_studies_with_2,266_patients_(54_%_were_KRAS_wt)._The_pooled_response_rates_(RR)_for_KRAS_wild-type_(wt)_versus_mutated_(mut)_patients_were_54.8_and_48.3_%,_respectively_(OR_1.42,_P_=_0.02)._Median_PFS_in_KRAS_wild-type_patients_was_significantly_longer_than_in_KRAS_mut_patients_(HR_=_0.85;_95_%_confidence_interval_(CI)_0.74-0.98;_P_=_0.02)._Median_OS_in_wild-type_KRAS_patients_compared_was_significantly_better_than_in_KRAS_mut_patients_(HR_=_0.65;_95_%_CI_0.46-0.92;_P_=_0.01).",23828442,PubMed,,"Petrelli_et_al.,_2013,_Med._Oncol.",,4,accepted,1139,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1139,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Bevacizumab,Chemotherapy,,,,,,
KRAS,3845,MUTATION,Cancer,162,,"GDC-0623,G-573",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_analyzing_the_differential_response_to_MEK_Inhibitors_in_KRAS_and_BRAF_mutant_cancer_cell_lines_and_mouse_xenografts._Efficacy_of_MEK_inhibitors_(GDC-0623_and_G-573)_in_KRAS-driven_tumours_is_mediated_by_a_hydrogen-bond_interaction_with_S212_in_MEK_that_is_critical_for_blocking_MEK_feedback_phosphorylation_by_wild-type_RAF._This_mechanism_was_distinct_from_GDC-0973_which_is_less_potent_in_KRAS_mutant_tumors._Overall,_this_work_indicates_that_MEK_inhibitors_with_this_mechanism_of_action_will_be_most_effective_in_patients_with_both_BRAF_and_KRAS_mutations.",23934108,PubMed,,"Hatzivassiliou_et_al.,_2013,_Nature",,3,accepted,1140,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-22_19:00:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1140,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,GDC-0623,G-573,,,,,,
KRAS,3845,MUTATION,Colorectal_Cancer,9256,,"Binimetinib,Palbociclib",Combination,Predictive,Supports,D,Sensitivity/Response,"A_preclinical_study_to_investigate_the_efficacy_of_Binimetinib,_Palbociclib_and_the_combination_on_KRAS_mutant_colorectal_cancer_cell_lines,_cell_line-derived_and_patient-derived_xenografts.___The_combination_of_MEK_and_CDK4/6_inhibition_inhibited_cancer_cell_growth_and_caused_cell_regression_in_a_synergistic_manner_Combination_therapy_markedly_decreased_levels_of_phosphorylated_ribosomal_protein_S6_both_in_vitro_and_in_vivo_and_decreased_Ki67_staining_in_vivo.",27167191,PubMed,,"Lee_et_al.,_2016,_Oncotarget",,4,accepted,4869,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_18:12:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/4869,https://civic.genome.wustl.edu/links/variants/336,https://civic.genome.wustl.edu/links/genes/30,,,protein_altering_variant,,510,Binimetinib,Palbociclib,,,,,,
PDCD4,27250,EXPRESSION,Lung_Cancer,1324,,Paclitaxel,,Predictive,Supports,B,Sensitivity/Response,PDCD4_expression_was_associated_with_response_to_paclitaxel_in_a_retrospective_analysis_of_77_patients_after_preclinical_validation_and_mechanistic_analysis_of_the_biomarker.,25928036,PubMed,,"Xu_et_al.,_2015,_J._Proteome_Res.",,4,accepted,821,10573,10,112631596,112659763,,,ENST00000393104.2,,,,,75,GRCh37,"A_new_study,_a_retrospective_analysis_of_77_patients,_has_implicated_PDCD4_expression_in_the_sensitivity_to_paclitaxel._However,_this_finding_came_from_a_large_proteome_screen_and_has_not_yet_been_replicated_in_independent_patient_sets.",Somatic_Mutation,2016-01-29_04:19:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/821,https://civic.genome.wustl.edu/links/variants/337,https://civic.genome.wustl.edu/links/genes/10573,"A_new_study,_a_retrospective_analysis_of_77_patients,_has_implicated_PDCD4_expression_in_the_sensitivity_to_paclitaxel._However,_this_finding_came_from_a_large_proteome_screen_and_has_not_yet_been_replicated_in_independent_patient_sets.",,,,20,Paclitaxel,,,,,,,
MGMT,4255,RS16906252,Glioblastoma_Multiforme,3068,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"The_T_allele_of_the_rs16906252_SNP_was_associated_with_MGMT_methylation_and_low_protein_expression._Germline_presence_of_the_T_allele_increased_the_risk_of_glioblastoma_development_(adjusted_odds_ratio,_1.96;_P_=_.013)._Temozolomide_treatment_led_to_better_survival_in_patients_with_the_rs16906252_T_genotype_irrespective_of_methylation_status.",25910840,PubMed,,"Rapkins_et_al.,_2015,_Neuro-oncology",,3,accepted,822,34,10,131265545,131265545,C,T,ENST00000306010.7,,,,,75,GRCh37,,Germline_Polymorphism,2016-02-13_05:49:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/822,https://civic.genome.wustl.edu/links/variants/338,https://civic.genome.wustl.edu/links/genes/34,,,synonymous_variant,NC_000010.10:g.131265545C>T,15,Temozolomide,,,,,chr10_g.131265545C~T,,
TFF3,7033,EXPRESSION,Breast_Cancer,1612,,"Aminoglutethimide,Tamoxifen",Substitutes,Predictive,Supports,B,Sensitivity/Response,"TFF3_expression_was_assessed_by_IHC_in_75_patients,_187_patients_were_identified_for_the_validation_cohort._TFF3_expression_was_associated_with_response_to_endocrine_therapy_(tamoxifen,_aminoglutethimide_or_oophorectomy)_and_outperformed_ER,_PR_and_TFF1_as_biomarkers.",25900183,PubMed,,"May_et_al.,_2015,_Endocr._Relat._Cancer",,3,accepted,823,5737,21,43731777,43735761,,,ENST00000518498.1,,,,,75,GRCh37,,,2016-02-17_01:18:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/823,https://civic.genome.wustl.edu/links/variants/339,https://civic.genome.wustl.edu/links/genes/5737,,,,,15,Aminoglutethimide,Tamoxifen,,,,,,
DKK1,22943,NUCLEAR_EXPRESSION,Colorectal_Cancer,9256,,"Irinotecan,L-Folinic_Acid,5-fluorouracil,Oxaliplatin",Combination,Predictive,Supports,B,Resistance,"Nuclear_expression_of_DICKKOPF-1_was_identified_in_15%_of_699_patients_with_colorectal_cancer_and_was_associated_with_decreased_progression-free_survival_(PFS)_and_overall_survival_(OS)_after_chemotherapy_(FOLFOX,_FOLFIRI,_or_5-FU)_[adjusted_HR,_1.65;_95%_confidence_interval_(CI),_1.23-2.21;_P_=_0.002)].",25788273,PubMed,,"Aguilera_et_al.,_2015,_Oncotarget",,3,accepted,824,9171,10,54074056,54077417,,,ENST00000373970.3,,,,,75,GRCh37,,,2016-02-20_20:11:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/824,https://civic.genome.wustl.edu/links/variants/340,https://civic.genome.wustl.edu/links/genes/9171,,,,,15,Irinotecan,L-Folinic_Acid,5-fluorouracil,Oxaliplatin,,,,
CD44,960,ISOFORM_EXPRESSION,Cancer,162,,RG7356,,Predictive,Supports,D,Sensitivity/Response,"CD44_isoform_expression_(especially_CD44s)_was_identified_to_predict_response_to_CD44_antibody_RG7356_preclinically._Retrospective_evaluation_of_13_patients_from_a_phase_1_study,_treated_with_RG7356,_identified_3_patients_with_CD44s_isoform._2/3_patients_with_CD44s_had_SD_as_best_response._Overall,_5_patients_had_an_OR.",25762343,PubMed,,"Birzele_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,825,855,11,35160728,35251574,,,ENST00000428726.2,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/825,https://civic.genome.wustl.edu/links/variants/341,https://civic.genome.wustl.edu/links/genes/855,,,,,3,RG7356,,,,,,,
EGF,1950,EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Cetuximab,,Predictive,Supports,D,Resistance,3_tongue_cancer_cell_lines_were_used_for_this_study._Addition_of_recombinant_human_EGF_led_to_increased_cetuximab_resistance._EGF_downregulation_suppressed_proliferation_of_cell_lines._Results_for_amphiregulin_and_epiregulin_were_inconclusive.,25677871,PubMed,,"Ansell_et_al.,_2016,_J._Oral_Pathol._Med.",,3,accepted,826,1634,4,110834047,110933422,,,ENST00000265171.5,,,,,75,GRCh37,,,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/826,https://civic.genome.wustl.edu/links/variants/342,https://civic.genome.wustl.edu/links/genes/1634,,,,,3,Cetuximab,,,,,,,
MDM2,4193,EXPRESSION,Malignant_Pleural_Mesothelioma,7474,,"Cisplatin,Pemetrexed",Combination,Predictive,Supports,B,Resistance,"72_patients_with_malignant_pleural_mesothelioma_were_analyzed,_MDM2_immunoexpression_was_assessed_in_65_patients._MDM2_mRNA_and_protein_expression_correlated_with_poor_OS_and_PFS_for_patients_treated_with_cisplatin_and_pemetrexed_(standard_of_care_therapy).",25668009,PubMed,,"Walter_et_al.,_2015,_Br._J._Cancer",,1,accepted,827,3465,12,69201956,69239214,,,ENST00000462284.1,,,,,75,GRCh37,,,2016-03-11_01:49:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/827,https://civic.genome.wustl.edu/links/variants/343,https://civic.genome.wustl.edu/links/genes/3465,,,,,20,Cisplatin,Pemetrexed,,,,,,
HMOX1,3162,EXPRESSION,Renal_Cell_Carcinoma,4450,,"Sunitinib,Sorafenib",Substitutes,Predictive,Supports,B,Resistance,"In_66_patients_with_advanced_renal_cell_carcinoma,_high_expression_of_heme_oxygenase-1_(HO-1)_was_associated_with_poor_overall_response_rate_(2.6%_versus_53.6%,_P<0.01),_clinical_benefit_rate_(47.4%_versus_92.9%,_P<0.01),_shorter_progression-free_survival_(4.4_versus_42_months,_P=0.022)_and_poor_overall_survival_(χ_(2)=4.775,_P=0.029)_in_patients_receiving_sorafenib_or_sunitinib.",26309414,PubMed,,"Zheng_et_al.,_2015,_Onco_Targets_Ther",,3,accepted,829,2657,22,35776828,35790207,,,ENST00000216117.8,,,,,75,GRCh37,,,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/829,https://civic.genome.wustl.edu/links/variants/344,https://civic.genome.wustl.edu/links/genes/2657,,,,,15,Sunitinib,Sorafenib,,,,,,
CASP8,841,EXPRESSION,Bone_Ewing's_Sarcoma,3368,,Conatumumab,,Predictive,Supports,D,Sensitivity/Response,In-vitro_and_in-vivo_sensitivity_to_DR5_antibody_conatumumab_was_correlated_with_expression_of_caspase-8.,26291055,PubMed,,"Kang_et_al.,_2015,_Br._J._Cancer",,3,accepted,831,761,2,202122759,202152434,,,ENST00000358485.4,,,,,75,GRCh37,,,2016-02-21_16:51:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/831,https://civic.genome.wustl.edu/links/variants/346,https://civic.genome.wustl.edu/links/genes/761,,,,,3,Conatumumab,,,,,,,
TYMS,7298,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Pemetrexed,,Predictive,Supports,B,Resistance,"mRNA_levels_of_TYMS,_DHFR_and_GARFT_were_assessed_(rt-PCR)_in_50_patient_samples_of_NSCLC._TYMS_mRNA_levels_were_lower_in_responders_compared_to_non-responders_to_pemetrexed_(1.671_±_0.844_versus_5.978_±_1.895,_p=0.0142).",23060591,PubMed,,"Shimizu_et_al.,_2012,_Anticancer_Res.",,3,accepted,922,5971,18,657604,673578,,,ENST00000323274.10,,,,,75,GRCh37,,,2016-02-13_03:47:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/922,https://civic.genome.wustl.edu/links/variants/347,https://civic.genome.wustl.edu/links/genes/5971,,,,,40,Pemetrexed,,,,,,,
TYMS,7298,EXPRESSION,Gastric_Adenocarcinoma,3717,,Raltitrexed,,Predictive,Supports,B,Resistance,"In_125_gastric_tumors,_plasma_and_tissue_mRNA_levels_of_TYMS_were_lower_in_the_raltitrexed_sensitive_group_compared_to_the_resistant_group_(p_=_0.007_and_0.013,_respectively).",22422354,PubMed,,"Shen_et_al.,_2012,_Int._J._Cancer",,2,accepted,929,5971,18,657604,673578,,,ENST00000323274.10,,,,,75,GRCh37,,,2016-02-22_20:30:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/929,https://civic.genome.wustl.edu/links/variants/347,https://civic.genome.wustl.edu/links/genes/5971,,,,,40,Raltitrexed,,,,,,,
TYMS,7298,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Pemetrexed,,Predictive,Supports,B,Resistance,"mRNA_expression_of_thymidylate_synthase_(TYMS)_in_62_NSCLC_patients_correlated_with_response_rate_to_pemetrexed_mono-_or_combination_therapy._Response_rate_with_low_TYMS_expression_was_0.29_compared_with_0.03_in_patients_with_overexpression_(P_=_0.025)._Patients_with_low_expression_exhibited_a_benefit_in_time_to_progression_(average_TTP_=_56_vs._23_months,_P_=_0.001)_and_in_overall_survival_(average_OS_=_60_vs._25_months,_P_=_0.002).",26502926,PubMed,,"Chamizo_et_al.,_2015,_BMC_Pulm_Med",,3,accepted,832,5971,18,657604,673578,,,ENST00000323274.10,,,,,75,GRCh37,,,2016-02-13_03:47:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/832,https://civic.genome.wustl.edu/links/variants/347,https://civic.genome.wustl.edu/links/genes/5971,,,,,40,Pemetrexed,,,,,,,
PBK,55872,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Resistance,TOPK_(PBK)_silencing_sensitized_lung_cancer_cells_to_gefitinib_in_preclinical_xenograft_models._Over-expression_was_also_associated_with_resistance_in_various_lung_cancer_cell_lines.,26745678,PubMed,,"Li_et_al.,_2016,_Oncotarget",,3,accepted,835,13276,8,27667137,27695612,,,ENST00000301905.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/835,https://civic.genome.wustl.edu/links/variants/348,https://civic.genome.wustl.edu/links/genes/13276,,,,,3,Gefitinib,,,,,,,
SMARCA4,6597,UNDEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Cisplatin,Vinorelbine",Combination,Predictive,Supports,B,Sensitivity/Response,"SMARCA4_expression_was_determined_with_gene_expression_microarray_in_133_patients._Improved_five-year_disease-specific_survival_(DSS)_was_noted_only_in_patients_with_low_SMARCA4_expression_when_treated_with_adjuvant_cisplatin/vinorelbine_(n=36)_(HR=0.1,_95%_CI:_0.0-0.5,_P=0.002_[low];_HR_1.0,_95%_CI:_0.5-2.3,_P=0.92_[high])_compared_to_patients_in_the_observation_arm_(N=30).",26671993,PubMed,,"Bell_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,837,78,19,11071598,11172958,,,ENST00000358026.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-18_18:48:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/837,https://civic.genome.wustl.edu/links/variants/349,https://civic.genome.wustl.edu/links/genes/78,,,,,30,Cisplatin,Vinorelbine,,,,,,
ALK,238,EML4-ALK_C1156Y–L1198F,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_metastatic_ALK-rearranged_NSCLC._After_developing_resistance_to_first_and_second_line_ALK_inhibitors_mediated_by_a_C1156Y_mutation,_the_patient_had_a_partial_response_with_the_third_generation_ALK-inhibitor_lorlatinib._The_patient_progressed_on_lorlatinib_after_8_months,_at_which_point_whole_exome_sequencing_revealed_an_EML4-ALK_C1156Y–L1198F_double_mutation._In_vitro,_the_double_mutation_was_resistant_to_lorlatinib_but_sensitive_to_crizotinib._The_patient_was_started_on_crizotinib_again_and_had_a_clinical_response_that_lasted_for_6_months.",26698910,PubMed,,"Shaw_et_al.,_2016,_N._Engl._J._Med.",,4,accepted,844,1,2,29443625,29445258,,,ENST00000389048.3,,,,,75,GRCh37,EML4-ALK_C1156Y_alone_is_resistant_to_crizotinib_in_non-small_cell_lung_cancer_(NSCLC)_which_has_been_shown_to_be_modulated_(both_increased_sensitivity_and_resistance)_by_additional_ALK_mutations._A_case_report_showed_that_an_NSCLC_harboring_EML4-ALK_C1156Y–L1198F_was_resistant_to_lorlatinib_but_this_second_mutation_re-sensitized_this_tumor_to_crizotinib.,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/844,https://civic.genome.wustl.edu/links/variants/352,https://civic.genome.wustl.edu/links/genes/1,EML4-ALK_C1156Y_alone_is_resistant_to_crizotinib_in_non-small_cell_lung_cancer_(NSCLC)_which_has_been_shown_to_be_modulated_(both_increased_sensitivity_and_resistance)_by_additional_ALK_mutations._A_case_report_showed_that_an_NSCLC_harboring_EML4-ALK_C1156Y–L1198F_was_resistant_to_lorlatinib_but_this_second_mutation_re-sensitized_this_tumor_to_crizotinib.,,"transcript_fusion,missense_variant",,20,Crizotinib,,,,,,,
ALK,238,EML4-ALK_C1156Y–L1198F,Non-small_Cell_Lung_Carcinoma,3908,,Lorlatinib,,Predictive,Supports,C,Resistance,"Case_report_of_a_patient_with_metastatic_ALK-rearranged_NSCLC._After_developing_resistance_to_first_and_second_line_ALK_inhibitors_mediated_by_a_C1156Y_mutation,_the_patient_had_a_partial_response_with_the_third_generation_ALK-inhibitor_lorlatinib._The_patient_progressed_on_lorlatinib_after_8_months,_at_which_point_whole_exome_sequencing_revealed_an_EML4-ALK_C1156Y–L1198F_double_mutation._In_vitro,_the_double_mutation_was_resistant_to_lorlatinib_but_sensitive_to_crizotinib._The_patient_was_started_on_crizotinib_again_and_had_a_clinical_response_that_lasted_for_6_months.",26698910,PubMed,,"Shaw_et_al.,_2016,_N._Engl._J._Med.",,4,accepted,843,1,2,29443625,29445258,,,ENST00000389048.3,,,,,75,GRCh37,EML4-ALK_C1156Y_alone_is_resistant_to_crizotinib_in_non-small_cell_lung_cancer_(NSCLC)_which_has_been_shown_to_be_modulated_(both_increased_sensitivity_and_resistance)_by_additional_ALK_mutations._A_case_report_showed_that_an_NSCLC_harboring_EML4-ALK_C1156Y–L1198F_was_resistant_to_lorlatinib_but_this_second_mutation_re-sensitized_this_tumor_to_crizotinib.,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/843,https://civic.genome.wustl.edu/links/variants/352,https://civic.genome.wustl.edu/links/genes/1,EML4-ALK_C1156Y_alone_is_resistant_to_crizotinib_in_non-small_cell_lung_cancer_(NSCLC)_which_has_been_shown_to_be_modulated_(both_increased_sensitivity_and_resistance)_by_additional_ALK_mutations._A_case_report_showed_that_an_NSCLC_harboring_EML4-ALK_C1156Y–L1198F_was_resistant_to_lorlatinib_but_this_second_mutation_re-sensitized_this_tumor_to_crizotinib.,,"transcript_fusion,missense_variant",,20,Lorlatinib,,,,,,,
EGFR,1956,EXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_refractory_colorectal_cancer_expressing_immunohistochemically_detectable_EGFR_were_randomly_assigned_to_receive_treatment_with_cetuximab_(n=287)_or_receive_supportive_care_alone_(n=285)._Patients_receiving_cetuximab_had_increased_overall_survival_(HR=0.77,_95%CI_0.64-0.92;_p=0.005),_increased_progression-free_survival_(HR=0.68,_95%CI_0.57-0.80;_p<0.001),_and_improved_quality_of_life_at_4_months_measured_by_survey_on_physical_deterioration_(-5.9_vs_-12.5;_p=0.03)_and_global_health_status_(-3.6_vs._-15.2;_p<0.001).",18003960,PubMed,,"Jonker_et_al.,_2007,_N._Engl._J._Med.",,4,accepted,1572,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2016-08-12_13:18:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1572,https://civic.genome.wustl.edu/links/variants/354,https://civic.genome.wustl.edu/links/genes/19,,,,,80,Cetuximab,,,,,,,
EGFR,1956,EXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Sensitivity/Response,"57_patients_with_chemorefractory_colorectal_cancer_expressing_EGFR_(IHC_staining)_were_treated_with_single-agent_cetuximab_in_this_phase_2_study._Five_patients_(9%;_95%_CI,_3%_to_19%)_achieved_a_partial_response._Twenty-one_additional_patients_had_stable_disease_or_minor_responses._The_median_survival_in_these_previously_treated_patients_with_chemotherapy-refractory_colorectal_cancer_was_6.4_months.",14993230,PubMed,,"Saltz_et_al.,_2004,_J._Clin._Oncol.",,1,accepted,1709,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2016-09-27_23:14:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1709,https://civic.genome.wustl.edu/links/variants/354,https://civic.genome.wustl.edu/links/genes/19,,,,,80,Cetuximab,,,,,,,
EGFR,1956,EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"Cetuximab,Docetaxel",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"47_HNSCC_patients_treated_with_cetuximab/docetaxel_were_retrospectively_analyzed_for_EGFRvIII,_EGFR_and_AREG_expression_with_IHC._73_%_of_cases_expressed_high_level_of_EGFRvIII._EGFR_expression_had_no_impact_on_PFS_or_OS.",21653686,PubMed,,"Tinhofer_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,849,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/849,https://civic.genome.wustl.edu/links/variants/354,https://civic.genome.wustl.edu/links/genes/19,,,,,80,Cetuximab,Docetaxel,,,,,,
EGFR,1956,EXPRESSION,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,B,Sensitivity/Response,"463_patients_with_1%_or_more_EGFR_tumor_cell_membrane_staining,_with_metastatic_CRC_progressive_after_standard_chemotherapy_were_randomized_to_panitumumab_plus_best_supportive_care_(BSC,_n_=_231)_or_BSC_alone_(n_=_232)._Panitumumab_significantly_prolonged_PFS_(hazard_ratio_[HR],_0.54;_95%_CI,_0.44_to_0.66,_[P_<_.0001])._Objective_response_rates_favored_panitumumab_over_BSC;_after_a_12-month_minimum_follow-up,_response_rates_were_10%_for_panitumumab_and_0%_for_BSC_(P_<_.0001)._No_difference_was_observed_in_OS_(HR,_1.00;_95%_CI,_0.82_to_1.22),_but_76%_of_BSC_patients_entered_the_cross-over_study.",17470858,PubMed,,"Van_Cutsem_et_al.,_2007,_J._Clin._Oncol.",,2,accepted,1708,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2016-09-27_23:14:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1708,https://civic.genome.wustl.edu/links/variants/354,https://civic.genome.wustl.edu/links/genes/19,,,,,80,Panitumumab,,,,,,,
EGFR,1956,EXPRESSION,Chordoma,3302,,Lapatinib,,Predictive,Supports,B,Sensitivity/Response,"18_advanced_progressing_chordoma_patients_entered_this_study_(median_age:_61_years;_disease_extent:_metastatic_72%_and_locally_advanced_28%)._Epidermal_growth_factor_receptor_(EGFR)_expression_and_activation_were_evaluated_by_immunohistochemistry_and/or_phospho-arrays,_real-time_polimerase_chain_reaction,_fluorescence_immunostaining._Six_(33.3%)_patients_had_PR_and_7_(38.9%)_SD,_as_their_best_Choi_responses,_corresponding_to_RECIST_SD_in_all_cases._Median_PFS_by_Choi_was_6_[interquartile_(IQ)_range_3-8]_months._Median_PFS_by_RECIST_was_8_(IQ_range_4-12)_months,_with_a_22%_CBR._This_phase_II_study_showed_a_modest_antitumor_activity_of_lapatinib_in_chordoma",23559153,PubMed,,"Stacchiotti_et_al.,_2013,_Ann._Oncol.",,3,accepted,1984,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2017-03-24_08:22:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1984,https://civic.genome.wustl.edu/links/variants/354,https://civic.genome.wustl.edu/links/genes/19,,,,,80,Lapatinib,,,,,,,
EGFR,1956,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,Double_blind_Phase_II_clinical_trial_found_an_objective_response_rate_of_18.4%_and_19%_for_two_groups_of_patients_treated_with_250mg/d_and_500mg/d_respectively._The_disease_control_rate_was_found_to_be_54.4%_and_51.4%_for_the_two_groups.,12748244,PubMed,,"Fukuoka_et_al.,_2003,_J._Clin._Oncol.",,3,accepted,4877,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2017-07-20_18:29:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/4877,https://civic.genome.wustl.edu/links/variants/354,https://civic.genome.wustl.edu/links/genes/19,,,,,80,Gefitinib,,,,,,,
CDKN1A,1026,EXPRESSION,Colorectal_Cancer,9256,,5-fluorouracil,,Predictive,Supports,B,Resistance,"112_patients_with_rectal_cancer_who_received_5-FU_based_chemotherapy_and_surgery_were_retrospectively_analyzed_for_expression_of_Ki67,_TS,_BAX,_EpCAM,_p53,_p21,_EGFR,_CD44,_CD133,_CD166,_HIF1α_and_ALDH1._High_pretreatment_p21_(CDKN1A)_expression_was_significantly_associated_with_non-pCR_(p = 0.022)_and_poor_disease_free_survival_(median_DFS_-_low_vs_high_p21:_75.8_vs_58.1_months,_p = 0.002)._Multivariate_analysis_was_also_significant_(p = 0.001,_HR_6.14;_95%_CI_2.03,_18.55).",24708484,PubMed,,"Sim_et_al.,_2014,_BMC_Cancer",,3,accepted,852,913,6,36646487,36655108,,,ENST00000405375.1,,,,,75,GRCh37,,,2016-02-16_14:58:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/852,https://civic.genome.wustl.edu/links/variants/355,https://civic.genome.wustl.edu/links/genes/913,,,,,15,5-fluorouracil,,,,,,,
ALCAM,214,EXPRESSION,Colorectal_Cancer,9256,,5-fluorouracil,,Predictive,Supports,B,Resistance,"112_patients_with_rectal_cancer_who_received_5-FU_based_chemotherapy_and_surgery_were_retrospectively_analyzed_for_expression_of_Ki67,_TS,_BAX,_EpCAM,_p53,_p21,_EGFR,_CD44,_CD133,_CD166,_HIF1α_and_ALDH1._Pretreatment_CD166_(ALCAM)_expression_level_was_associated_with_poor_disease_free_survival_(p = 0.003;_HR_5.61;_95%_CI_1.81,_17.35).",24708484,PubMed,,"Sim_et_al.,_2014,_BMC_Cancer",,3,accepted,853,259,3,105085753,105295744,,,ENST00000306107.5,,,,,75,GRCh37,,,2016-02-14_00:24:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/853,https://civic.genome.wustl.edu/links/variants/356,https://civic.genome.wustl.edu/links/genes/259,,,,,15,5-fluorouracil,,,,,,,
STMN1,3925,EXPRESSION,Endometrial_Carcinoma,2871,,Paclitaxel,,Predictive,Supports,B,Resistance,33_patients_were_retrospectively_analyzed_for_Stathmin_expression_by_IHC._High_protein_expression_was_correlated_with_poor_response_to_paclitaxel_but_not_other_chemotherapy._The_authors_supported_this_conclusion_with_pre-clinical_studies_that_showed_that_knock-down_of_stathmin_improved_sensitivity_to_paclitaxel_in_endometrial_carcinoma_cell_lines_with_both_naturally_higher_and_lower_sensitivity_to_paclitaxel.,24587245,PubMed,,"Werner_et_al.,_2014,_PLoS_ONE",,3,accepted,855,3255,1,26211931,26232957,,,ENST00000426559.2,,,,,75,GRCh37,,,2016-02-14_00:23:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/855,https://civic.genome.wustl.edu/links/variants/357,https://civic.genome.wustl.edu/links/genes/3255,,,,,15,Paclitaxel,,,,,,,
RSF1,51773,AMPLIFICATION,Breast_Cancer,1612,,Tamoxifen,,Predictive,Supports,B,Resistance,"In_retrospective_study,_413_patients_were_assessed_for_RSF1_amplification._28_patients_with_RSF1_amplification_did_not_show_a_benefit_from_adjuvant_tamoxifen_compared_to_placebo_(12_treated_vs_16_placebo)._381_patients_without_amplification_did_show_a_benefit_compared_to_placebo_(187_treated_vs_194_placebo).",24367492,PubMed,,"Keilty_et_al.,_2013,_PLoS_ONE",,2,accepted,857,12121,11,77371041,77532063,,,ENST00000308488.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-20_02:50:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/857,https://civic.genome.wustl.edu/links/variants/358,https://civic.genome.wustl.edu/links/genes/12121,,,transcript_amplification,,10,Tamoxifen,,,,,,,
AR,367,OVEREXPRESSION,Breast_Cancer,1612,,"BEZ235_(NVP-BEZ235,_Dactolisib)",,Predictive,Supports,D,Sensitivity/Response,In-vitro_and_xenograft_studies_of_response_of_breast_cancer_cell_lines_to_PI3K/mTOR_inhibitor_NVP-BEZ235_showed_that_sensitivity_correlated_with_expression_of_the_androgen_receptor_(AR)._Reintroduction_of_AR_expression_resensitized_nonresponsive_AR-negative_cells_to_NVP-BEZ235._A_dihydrotestosterone_(DHT)_and_NVP-BEZ235_combination_achieved_tumor_regression_and_complete_response_in_AR/ER_expressing_tumors_(xenografts).,24356815,PubMed,,"Wang_et_al.,_2014,_Mol._Cancer_Ther.",,3,accepted,859,67,X,66764465,66950461,,,ENST00000374690.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/859,https://civic.genome.wustl.edu/links/variants/359,https://civic.genome.wustl.edu/links/genes/67,,,,,3,BEZ235_(NVP-BEZ235,_Dactolisib),,,,,,
CDKN1B,1027,CYTOPLASMIC_MISLOCALIZATION,Breast_Cancer,1612,,Lapatinib,,Predictive,Supports,D,Resistance,Cytoplasmic_localization_of_p27_(CDKN1B)_leads_to_lapatinib_resistance_in_HER2+_breast_cancer_cell_lines._p27_knockout_resensitiuzed_cells_to_lapatinib.,25587029,PubMed,,"Zhao_et_al.,_2014,_Oncotarget",,3,accepted,860,914,12,12870058,12875305,,,ENST00000228872.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/860,https://civic.genome.wustl.edu/links/variants/360,https://civic.genome.wustl.edu/links/genes/914,,,,,3,Lapatinib,,,,,,,
ERBB3,2065,EXPRESSION,Cancer,162,,AV-203,,Predictive,Does_Not_Support,D,Sensitivity/Response,"The_authors_conducted_an_in_vivo_efficacy_study_of_AV-203_(ERBB3_inhibitory_antibody)_using_a_panel_of_32_xenograft_models_representing_12_human_cancer_types._To_identify_biomarkers_that_can_predict_response_to_AV-203,_the_relationship_between_tumor_growth_inhibition_(TGI)_by_AV-203_and_the_expression_levels_of_ERBB3_and_NRG1_were_evaluated_in_these_tumor_models._ERBB3_expression_was_not_predictive_of_response.",25542901,PubMed,,"Meetze_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,862,1733,12,56473645,56497289,,,ENST00000267101.3,,,,,75,GRCh37,,,2016-02-21_16:31:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/862,https://civic.genome.wustl.edu/links/variants/361,https://civic.genome.wustl.edu/links/genes/1733,,,,,6,AV-203,,,,,,,
ERBB3,2065,EXPRESSION,Pancreatic_Ductal_Adenocarcinoma,3498,,"Pertuzumab,9F7-F11",Combination,Predictive,Supports,D,Sensitivity/Response,In_mice_xenografts_expressing_ERBB3_(HER3)_the_combination_of_ERBB2_(HER2)_and_ERBB3_inhibitors_pertuzumab_and_9F7-F11enhanced_tumor_inhibition_and_the_median_survival_time._Sensitivity_to_single-agent_pertuzumab_might_also_be_increased_through_ERBB3_expression.,25216528,PubMed,,"Thomas_et_al.,_2014,_Oncotarget",,3,accepted,865,1733,12,56473645,56497289,,,ENST00000267101.3,,,,,75,GRCh37,,,2016-02-21_04:47:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/865,https://civic.genome.wustl.edu/links/variants/361,https://civic.genome.wustl.edu/links/genes/1733,,,,,6,Pertuzumab,9F7-F11,,,,,,
AR,367,SPLICE_VARIANT_7,Prostate_Cancer,10283,,"Abiraterone,Enzalutamide",Substitutes,Predictive,Supports,B,Resistance,"Detection_of_AR-V7_in_circulating_tumor_cells_of_62_patients_treated_with_either_enzalitamide_(n=31)_or_arbiraterone_(n=31),_was_correlated_with_lower_PSA_response_rates_and_PSA_PFS_in_men_receiving_enzalutamide_or_abiraterone.",25184630,PubMed,,"Antonarakis_et_al.,_2014,_N._Engl._J._Med.",,3,accepted,863,67,X,66764662,66915917,,,ENST00000504326.1,,,,,75,GRCh37,,,2016-02-08_19:54:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/863,https://civic.genome.wustl.edu/links/variants/362,https://civic.genome.wustl.edu/links/genes/67,,,,,15,Abiraterone,Enzalutamide,,,,,,
UGT1A,7361,EXPRESSION,Colorectal_Cancer,9256,,Ganetespib,,Predictive,Supports,D,Resistance,Colorectal_cancer_cell_lines_were_evaluated_for_response_to_the_HSP90_inhibitor_ganetespib.__Correlating_cell_line-specific_IC50s_with_the_corresponding_gene_expression_patterns_revealed_a_possible_relationship_to_UGT1A_expression._High_UGT1A_expression_was_correlated_with_ganetespib_resistance._Knockdown_of_UGT1A_sensitized_HT29_cells_to_HSP90_inhibition._HCT116_and_SW480_cell_lines_became_resistant_through_UGT1A_overexpression.,25210794,PubMed,,"Landmann_et_al.,_2014,_Cell_Death_Dis",,3,accepted,866,6023,2,234526291,234681956,,,ENST00000373450.4,,,,,75,GRCh37,,,2016-02-22_03:01:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/866,https://civic.genome.wustl.edu/links/variants/363,https://civic.genome.wustl.edu/links/genes/6023,,,,,3,Ganetespib,,,,,,,
ERBB4,2066,NUCLEAR_TRANSLOCATION,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,D,Resistance,HER4_nuclear_translocation_was_identified_as_a_mediator_of_trastuzumab_resistance_in_HER2_positive_breast_cancer_cell_lines._Increased_nuclear_staining_was_also_identified_in_xenograft_and_patient_samples_after_trastuzumab_treatment.,25153719,PubMed,,"Mohd_Nafi_et_al.,_2014,_Oncotarget",,2,accepted,867,1734,2,212240446,213403565,,,ENST00000342788.4,,,,,75,GRCh37,,,2016-02-21_04:48:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/867,https://civic.genome.wustl.edu/links/variants/364,https://civic.genome.wustl.edu/links/genes/1734,,,,,2,Trastuzumab,,,,,,,
ERBB4,2066,EXPRESSION,Breast_Cancer,1612,,Lapatinib,,Predictive,Supports,D,Resistance,"ERBB4_protein_expression_was_identified_in_breast_cancer_cell_lines_with_acquired_lapatinib_resistance._Genetic_ablation_of_ERBB4_(not_ERBB1-3)_led_to_apoptosis_in_trastuzumab-_and_lapatinib_resistant_cells,_probably_through_a_decrease_in_the_PI3K/Akt_pathway.",25590338,PubMed,,"Canfield_et_al.,_2015,_Cell_Cycle",,3,accepted,869,1734,2,212240446,213403565,,,ENST00000342788.4,,,,,75,GRCh37,,,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/869,https://civic.genome.wustl.edu/links/variants/365,https://civic.genome.wustl.edu/links/genes/1734,,,,,5,Lapatinib,,,,,,,
ERBB4,2066,EXPRESSION,Breast_Cancer,1612,,Trastuzumab,,Predictive,Supports,D,Resistance,siRNA_knockdown_of_HER4_or_inhibition_with_neratinib_enhanced_trastuzumab_response_in_breast_cancer_cell_lines.,25153719,PubMed,,"Mohd_Nafi_et_al.,_2014,_Oncotarget",,2,accepted,868,1734,2,212240446,213403565,,,ENST00000342788.4,,,,,75,GRCh37,,,2017-10-12_21:20:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/868,https://civic.genome.wustl.edu/links/variants/365,https://civic.genome.wustl.edu/links/genes/1734,,,,,5,Trastuzumab,,,,,,,
SLFN11,91607,EXPRESSION,Colorectal_Cancer,9256,,SN-38,,Predictive,Supports,D,Sensitivity/Response,"In_this_study,_SLFN11_expression_was_associated_with_sensitivity_to_SN-38_(an_active_metabolite_of_topoisomerase_inhibitor_irinotecan).",25089570,PubMed,,"Tian_et_al.,_2014,_Anticancer_Drugs",,2,accepted,870,16872,17,33677324,33700639,,,ENST00000394566.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/870,https://civic.genome.wustl.edu/links/variants/366,https://civic.genome.wustl.edu/links/genes/16872,,,,,2,SN-38,,,,,,,
RAC1,5879,P29S,Melanoma,1909,,"Dabrafenib,Vemurafenib",Substitutes,Predictive,Supports,D,Resistance,Melanoma_cell_lines_harboring_the_RAC1_P29S_hotspot_mutation_were_shown_to_be_resistant_to_BRAF_inhibition_with_vemurafenib_or_dabrafenib_and_knock-in_or_knock-out_of_this_mutation_decreased_and_increased_sensitivity_to_these_drugs.,25056119,PubMed,,"Watson_et_al.,_2014,_Cancer_Res.",,4,accepted,873,4753,7,6426892,6426892,C,T,ENST00000356142.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-20_23:28:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/873,https://civic.genome.wustl.edu/links/variants/367,https://civic.genome.wustl.edu/links/genes/4753,,,missense_variant,"ENST00000356142.4:c.85C>T,NC_000007.13:g.6426892C>T",4,Dabrafenib,Vemurafenib,,,,chr7_g.6426892C~T,RAC1_c.85C~T,
BIRC5,332,NUCLEAR_EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Taxane,PLATINUM",Combination,Predictive,Supports,B,Sensitivity/Response,Patients_with_nuclear_survivin_(BIRC5)_expression_had_significantly_better_responses_to_taxane-platinum_chemotherapy_than_those_with_low_tumor_N-survivin_expression_(P_<_0.001)_in_a_retrospective_analysis_of_48_patients_with_non-small_cell_lung_cancer.,24961465,PubMed,,"Wu_et_al.,_2014,_Med._Oncol.",,3,accepted,874,355,17,76210267,76221717,,,ENST00000301633.4,,,,,75,GRCh37,,,2016-02-16_14:48:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/874,https://civic.genome.wustl.edu/links/variants/368,https://civic.genome.wustl.edu/links/genes/355,,,,,15,Taxane,PLATINUM,,,,,,
TP53,7157,WILD_TYPE,Esophageal_Carcinoma,1107,,Chemotherapy,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_p53_wild_type_(as_defined_by_low_expression_and/or_wild-type_tp53_gene)_had_a_higher_response_rate_to_chemotherapy-based_treatment_(total_major_response_[MR]:_risk_ratio_[RR]_=_1.09,_95_%_CI_=_1.03-1.16,_P_=_.003;_pathological_MR:_RR_=_1.15,_95_%_CI_=_1.06-1.25,_P_=_.001;_total_complete_response_[CR]:_RR_=_1.08,_95_%_CI_=_1.00-1.17,_P_=_.040)_in_this_meta-analysis_(28_studies,_1497_cases).",23515910,PubMed,,"Zhang_et_al.,_2013,_Ann._Surg._Oncol.",,3,accepted,906,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/906,https://civic.genome.wustl.edu/links/variants/369,https://civic.genome.wustl.edu/links/genes/45,,,wild_type,,68,Chemotherapy,,,,,,,
TP53,7157,WILD_TYPE,Colorectal_Cancer,9256,,"Cetuximab,Capecitabine,Oxaliplatin",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_retrospective_biomarker_analysis_of_the_EXPERT-C_trial,_patients_with_TP53_wild-type_status_had_a_statistically_significant_better_progression_free_survival_(PFS)_(89.3%_vs_65.0%_at_5_years;_hazard_ratio_[HR]_=_0.23;_95%_confidence_interval_[CI]_=_0.07_to_0.78;_two-sided_P_=_.02_by_Cox_regression)_and_overall_survival_(OS)_(92.7%_vs_67.5%_at_5_years;_HR_=_0.16;_95%_CI_=_0.04_to_0.70;_two-sided_P_=_.02_by_Cox_regression)_when_treated_with_Cetuximab_+_CAPOX_(Capecitabine,_Oxaliplatin)_than_in_the_control_arm_without_Cetuximab.",24957073,PubMed,,"Sclafani_et_al.,_2014,_J._Natl._Cancer_Inst.",,3,accepted,875,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,,2016-02-12_23:34:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/875,https://civic.genome.wustl.edu/links/variants/369,https://civic.genome.wustl.edu/links/genes/45,,,wild_type,,68,Cetuximab,Capecitabine,Oxaliplatin,,,,,
TP53,7157,WILD_TYPE,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Sensitivity/Response,MDM2_Inhibitor_screen_in_a_panel_of_260_cancer_cell_lines_with_well_characterized_TP53__status_shows_that_only_cancer_cell_lines_with_unaltered_TP53_may_be_sensitive_to_MDM2_Inhibitor.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,2964,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,,2017-05-10_22:18:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/2964,https://civic.genome.wustl.edu/links/variants/369,https://civic.genome.wustl.edu/links/genes/45,,,wild_type,,68,AMGMDS3,,,,,,,
TP53,7157,WILD_TYPE,Cancer,162,,Nutlin-3a,,Predictive,Supports,D,Sensitivity/Response,"MDM2_Inhibitor_Nutlin-3a_induced_senescence_in_presence_of_functional_TP53_in_murine_primary_fibroblasts,_oncogenically_transformed_fibroblasts,_and_fibrosarcoma_cell_lines._Cells_lacking_functional_TP53_were_completely_insensitive_to_the_drug.",17671205,PubMed,,"Efeyan_et_al.,_2007,_Cancer_Res.",,4,accepted,2963,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,,2017-05-11_15:58:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/2963,https://civic.genome.wustl.edu/links/variants/369,https://civic.genome.wustl.edu/links/genes/45,,,wild_type,,68,Nutlin-3a,,,,,,,
TP53,7157,WILD_TYPE,Leukemia,1240,,RG7112,,Predictive,Supports,B,Sensitivity/Response,"Phase_I_Trial_of_RG7112_in_116_heavily_pretreated_patients_with_AML,_ALL,_CML,_CLL,_sCLL_demonstrated_sustained_clinical_improvement_and_induction_of_TP53_target_genes_in_subset_of_patients_with_wild_type_TP53._96_patients_were_tested_for_TP53_mutation_and_19_cases_of_mutation_were_detected._No_sustained_clinical_improvement_or_induction_of_TP53_target_genes_was_observed_in_patients_with_mutant_TP53.",26459177,PubMed,,"Andreeff_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,2965,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,,2018-10-17_12:27:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/2965,https://civic.genome.wustl.edu/links/variants/369,https://civic.genome.wustl.edu/links/genes/45,,,wild_type,,68,RG7112,,,,,,,
TP53,7157,WILD_TYPE,Non-small_Cell_Lung_Carcinoma,3908,,Adjuvant_Chemotherapy,,Predictive,Supports,B,Sensitivity/Response,"Pooled_analysis_of_TP53_mutations_(exons_5-8)_from_4_randomized_trials_(IALT,_JBR10,_CALGB-9633_and_ANITA,_1209_patients,_median_follow-up_5.5_years)_of_platinum-based_adjuvant_chemotherapy_(ACT)_versus_observation_(OBS)._Patients_with_wild-type_TP53_had_better_outcomes_with_ACT_than_OBS_(HROS=0.77_[0.62-0.95],_p=0.02;_HRDFS=0.75_[0.62-0.92],_p=0.005).",26899019,PubMed,,"Ma_et_al.,_2016,_J_Thorac_Oncol",,3,accepted,1149,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1149,https://civic.genome.wustl.edu/links/variants/369,https://civic.genome.wustl.edu/links/genes/45,,,wild_type,,68,Adjuvant_Chemotherapy,,,,,,,
MRE11,4361,LOSS,Endometrial_Cancer,1380,,BMN-673,,Predictive,Supports,D,Sensitivity/Response,One_endometrial_cell_line_with_decreased_MRE11_expression_caused_by_a_homozygous_poly(T)_mutation_exhibited_increased_sensitivity_to_the_PARP_inhibitor_BMN-673._Loss_of_MRE11_was_identified_in_30.7%_of_endometrial_tumors_(N=521).,24927325,PubMed,,"Koppensteiner_et_al.,_2014,_PLoS_ONE",,2,accepted,876,3586,11,94152895,94227074,,,ENST00000323929.3,,,,,75,GRCh37,,,2016-02-21_17:48:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/876,https://civic.genome.wustl.edu/links/variants/370,https://civic.genome.wustl.edu/links/genes/3586,,,loss_of_function_variant,,2,BMN-673,,,,,,,
TOP1,7150,AMPLIFICATION,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Supports,B,Sensitivity/Response,"FFPE_tumor_samples_from_78_patients_with_colorectal_cancer,_who_had_received_irinotecan_monotherapy_were_analyzed_with_a_FISH_dual-probe._TOP1_gain_was_nonsignificantly_associated_with_objective_response_to_irinotecan_Odds_ratio_(OR):_1.62;_p_=_0.07.",24256029,PubMed,,"Nygård_et_al.,_2014,_Scand._J._Gastroenterol.",,1,accepted,888,5845,20,39657458,39753127,,,ENST00000361337.2,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/888,https://civic.genome.wustl.edu/links/variants/371,https://civic.genome.wustl.edu/links/genes/5845,,,transcript_amplification,,5,Irinotecan,,,,,,,
CDKN1B,1027,EXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,"Cisplatin,5-fluorouracil",Combination,Predictive,Supports,B,Sensitivity/Response,"41_HNSSC_were_analyzed_by_IHC_for_expression_of_EGFR,_p53,_CCND1,_p16,_p21,_p27_(CDKN2B),_p-AKT,_HIF-1a,_Caspase_3_and_BCL2._p27_was_the_only_protein_that_served_as_a_predictive_biomarker_of_response_after_multivariate_analysis_(p=0.025;_n=41_patients).",24239278,PubMed,,"Moreno-Galindo_et_al.,_2014,_Oral_Oncol.",,2,accepted,889,914,12,12870058,12875305,,,ENST00000228872.4,,,,,75,GRCh37,,,2016-02-13_05:34:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/889,https://civic.genome.wustl.edu/links/variants/372,https://civic.genome.wustl.edu/links/genes/914,,,,,10,Cisplatin,5-fluorouracil,,,,,,
AGR2,10551,EXPRESSION,Breast_Cancer,1612,,Tamoxifen,,Predictive,Supports,B,Resistance,"mRNA_expression_of_AGR2_in_61_patients_with_tamoxifen_treated_postmenopausal_breast_cancer_was_determined_by_qRT-PCR_and_was_inversely_associated_with_treatment_response_and_progression_free_survival_(p=_0.0011,_p_=_0.0366_respectively)._AGR2_protein_expression_as_assessed_by_IHC_was_not_significantly_associated_with_treatment_outcome.",24167368,PubMed,,"Hrstka_et_al.,_2013,_Dis._Markers",,1,accepted,891,8407,7,16831435,16844704,,,ENST00000419304.2,,,,,75,GRCh37,,,2016-02-21_17:46:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/891,https://civic.genome.wustl.edu/links/variants/373,https://civic.genome.wustl.edu/links/genes/8407,,,,,5,Tamoxifen,,,,,,,
NAPRT,93100,PROMOTER_HYPERMETHYLATION,Cancer,162,,GNE-617,,Predictive,Supports,D,Sensitivity/Response,Tumor-specific_promoter_hypermethylation_of_NAPRT1_led_to_loss_of_NAPRT1_expression_in_most_tumor_types_sensitive_to_treatment_with_Nampt_inhibitor_GNE-617_and_nicotinic_acid.,24097869,PubMed,,"Shames_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,897,17016,,,,,,,,,,,,,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/897,https://civic.genome.wustl.edu/links/variants/374,https://civic.genome.wustl.edu/links/genes/17016,,,,,3,GNE-617,,,,,,,
EGFR,1956,EXON_18_OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Bevacizumab,Erlotinib",Combination,Predictive,Supports,B,Sensitivity/Response,"Overexpression_of_EGFR_exon_18_(Affymetrix_Human_Exon_1.0_ST)_in_tumor_or_blood_samples_was_associated_with_tumor_shrinkage,_independently_of_EGFR_mutational_status_in_NSCLC_treated_with_bevacizumab_and_erlotinib._76_patients_were_analyzed_for_this_study.",24039832,PubMed,,"Baty_et_al.,_2013,_PLoS_ONE",,2,accepted,898,19,7,55237999,55238735,,,ENST00000344576.2,,,,,75,GRCh37,,,2016-02-22_20:26:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/898,https://civic.genome.wustl.edu/links/variants/375,https://civic.genome.wustl.edu/links/genes/19,,,exon_variant,,10,Bevacizumab,Erlotinib,,,,,,
ZEB1,6935,EXPRESSION,Mantle_Cell_Lymphoma,50746,,"Doxorubicin,Cytarabine,Gemcitabine",Substitutes,Predictive,Supports,D,Resistance,"Downregulation_of_ZEB1_expression_in_mantle_cell_lymphoma_cell_lines_and_mouse_xenografts_led_to_enhanced_sensitivity_towards_treatment_with_doxorubicin,_cytarabin_and_gemcitabine.",24013721,PubMed,,"Sánchez-Tilló_et_al.,_2014,_Cell_Death_Differ.",,2,accepted,899,5649,10,31608101,31818741,,,ENST00000361642.5,,,,,75,GRCh37,,,2016-02-21_17:39:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/899,https://civic.genome.wustl.edu/links/variants/376,https://civic.genome.wustl.edu/links/genes/5649,,,,,5,Doxorubicin,Cytarabine,Gemcitabine,,,,,
ZEB1,6935,EXPRESSION,Mantle_Cell_Lymphoma,50746,,"Salinomycin,Doxorubicin",Combination,Predictive,Supports,D,Sensitivity/Response,"Downregulation_of_ZEB1_expression_in_mantle_cell_lymphoma_cell_lines_and_mouse_xenografts_led_to_enhanced_sensitivity_towards_treatment_with_doxorubicin,_cytarabin_and_gemcitabine._the_combination_of_salinomycin_(downregulating_ZEB1)_and_doxorubicin_was_syngergistic.",24013721,PubMed,,"Sánchez-Tilló_et_al.,_2014,_Cell_Death_Differ.",,3,accepted,900,5649,10,31608101,31818741,,,ENST00000361642.5,,,,,75,GRCh37,,Somatic_Mutation,2017-04-21_18:58:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/900,https://civic.genome.wustl.edu/links/variants/376,https://civic.genome.wustl.edu/links/genes/5649,,,,,5,Salinomycin,Doxorubicin,,,,,,
TIMP1,7076,OVEREXPRESSION,Breast_Cancer,1612,,Paclitaxel,,Predictive,Supports,B,Resistance,High_expression_of_TIMP-1_was_assessed_by_IHC_in_99_primary_breast_cancers_that_had_not_spread_beyond_the_breast_after_6_postoperative_courses_of_paclitaxel-based_chemotherapy._High_TIMP1_levels_were_associated_with_worse_5-year_disease_free_survival_(71.1%)_than_low_levels_(88.5_%;_P_=_0.020)._High_TIMP-1_levels_were_also_associated_with_worse_5-year_overall_survival_(78.9_%)_than_low_levels_(96.7_%;_P_=_0.004).,22544540,PubMed,,"Zhu_et_al.,_2012,_Med._Oncol.",,2,accepted,927,5777,X,47441712,47446188,,,ENST00000218388.4,,,,,75,GRCh37,,,2016-02-20_02:26:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/927,https://civic.genome.wustl.edu/links/variants/377,https://civic.genome.wustl.edu/links/genes/5777,,,,,12,Paclitaxel,,,,,,,
TIMP1,7076,OVEREXPRESSION,Breast_Cancer,1612,,Fulvestrant,,Predictive,Supports,D,Resistance,TIMP1_overexpression_was_associated_with_resistance_to_fulvestrant_in_breast_cancer_cell_lines.,23881388,PubMed,,"Bjerre_et_al.,_2013,_Tumour_Biol.",,2,accepted,901,5777,X,47441712,47446188,,,ENST00000218388.4,,,,,75,GRCh37,,,2016-02-17_23:00:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/901,https://civic.genome.wustl.edu/links/variants/377,https://civic.genome.wustl.edu/links/genes/5777,,,,,12,Fulvestrant,,,,,,,
PTP4A3,11156,OVEREXPRESSION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Sensitivity/Response,"In-vitro_studies_linked_PRL-3_(PP4A3)_expression_to_hyperactivation_and_dependence_on_EGFR_signaling_(through_downregulation_of_PTP1B,_an_inhibitory_phosphatase_of_EGFR)._Retrospective_analysis_of_68_patients_showed_improved_clinical_response_to_the_EGFR_inhibitor_cetuximab_in_tumors_expressing_PRL-3.",23867504,PubMed,,"Al-Aidaroos_et_al.,_2013,_J._Clin._Invest.",,3,accepted,902,8908,8,142402093,142441394,,,ENST00000521578.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/902,https://civic.genome.wustl.edu/links/variants/378,https://civic.genome.wustl.edu/links/genes/8908,,,,,3,Cetuximab,,,,,,,
TYMS,7298,AMPLIFICATION,Lung_Adenocarcinoma,3910,,Pemetrexed,,Predictive,Supports,B,Resistance,TYMS_copy_number_was_lower_in_clinical_samples_responding_to_pemetrexed_in_combination_with_platinum_(n=25)._The_same_was_found_in_17_cell_lines.,23645741,PubMed,,"Kasai_et_al.,_2013,_Anticancer_Res.",,3,accepted,903,5971,18,657604,673578,,,ENST00000323274.10,,,,,75,GRCh37,,Somatic_Mutation,2016-02-09_23:56:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/903,https://civic.genome.wustl.edu/links/variants/379,https://civic.genome.wustl.edu/links/genes/5971,,,transcript_amplification,,15,Pemetrexed,,,,,,,
IGF1R,3480,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,D,Resistance,"Expression_of_IGF1R_in_NSCLC_cell_lines_(n=17)_was_associated_with_resistance_to_EGFR_inhibitor_gefitinib,_however,_knock-in_or_knock-out_of_IGF1R_did_not_affect_gefitinib_sensitivity._IGF1R_expression_was_also_higher_in_patients_with_disease_progression_after_gefitinib_therapy_in_a_clinical_cohort_(n=98).",23619944,PubMed,,"Peled_et_al.,_2013,_Cell_Oncol_(Dordr)",,2,accepted,904,2899,15,99192200,99507759,,,ENST00000268035.6,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/904,https://civic.genome.wustl.edu/links/variants/380,https://civic.genome.wustl.edu/links/genes/2899,,,,,2,Gefitinib,,,,,,,
EPHB4,2050,EXPRESSION,Colorectal_Cancer,9256,,Bevacizumab,,Predictive,Supports,B,Resistance,"EPHB4_expression,_as_assessed_by_quantitative_RT-PCR_in_13_colorectal_cancer_patients_treated_with_bevacizumab,_was_higher_in_non-responders_(p_=_0.048)._No_difference_was_observed_in_a_control_group_without_bevacizumab_treatment._qRT-PCR_results_were_also_shown_to_correlate_with_protein_expression_measured_by_IHC.",23579861,PubMed,,"Guijarro-Muñoz_et_al.,_2013,_Med._Oncol.",,2,accepted,905,1721,7,100400187,100425121,,,ENST00000358173.3,,,,,75,GRCh37,,,2016-02-22_20:28:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/905,https://civic.genome.wustl.edu/links/variants/381,https://civic.genome.wustl.edu/links/genes/1721,,,,,10,Bevacizumab,,,,,,,
TYMS,7298,UNDEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Pemetrexed,,Predictive,Supports,B,Sensitivity/Response,49_tumor_specimens_from_268_NSCLC_patients_treated_with_pemetrexed_were_evaluated_for_expression_of_TYMS_and_DHFR_by_IHC_and_compared_to_treatment_outcomes._Patients_with_low_TS_(≤150)_expression_had_a_longer_median_progression-free_survival_(PFS)_than_those_with_high_TS_(>150)_expression_(4.8_vs._3.4_months;_p=0.01).,21367480,PubMed,,"Chen_et_al.,_2011,_Lung_Cancer",,3,accepted,907,5971,18,657604,673578,,,ENST00000323274.10,,,,,75,GRCh37,,,2016-02-13_03:48:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/907,https://civic.genome.wustl.edu/links/variants/382,https://civic.genome.wustl.edu/links/genes/5971,,,,,20,Pemetrexed,,,,,,,
TYMS,7298,UNDEREXPRESSION,Prostate_Cancer,10283,,Pemetrexed,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_metastatic_prostate_cancer_and_underexpression_of_TYMS_who_showed_a_nonspecified_response_to_pemetrexed_for_at_least_4_months.,24782778,PubMed,,"Russell_et_al.,_2014,_Front_Pharmacol",,2,accepted,908,5971,18,657604,673578,,,ENST00000323274.10,,,,,75,GRCh37,,,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/908,https://civic.genome.wustl.edu/links/variants/382,https://civic.genome.wustl.edu/links/genes/5971,,,,,20,Pemetrexed,,,,,,,
TOP2A,7153,EXPRESSION,Breast_Cancer,1612,,Doxorubicin,,Predictive,Supports,B,Sensitivity/Response,"In_a_retrospective_study,_TOP2A_expression_was_assessed_by_IHC_for_108_breast_cancer_patients_(from_TAX_303_trial)._TOP2A_expression_was_associated_with_a_higher_probability_of_response_in_doxorubicin_treated_but_not_in_docetaxel_treated_breast_cancer_patients.",15486187,PubMed,,"Durbecq_et_al.,_2004,_Mol._Cancer_Ther.",,2,accepted,909,5848,17,38544768,38574202,,,ENST00000423485.1,,,,,75,GRCh37,,,2016-02-18_18:42:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/909,https://civic.genome.wustl.edu/links/variants/383,https://civic.genome.wustl.edu/links/genes/5848,,,,,10,Doxorubicin,,,,,,,
TOP1,7150,EXPRESSION,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Supports,B,Sensitivity/Response,"498_patients_were_retrospectively_analyzed_for_topoisomerase_1_expression_(IHC)._In_the_subgroup_of_patients_treated_with_irinotecan_(38%_of_the_498),_those_patients_expressing_Topoisomerase_I_had_a_better_overall_survival_according_to_multivariate_analysis_(HR_=_0.47,_95%_CI_0.23-0.94,_p_=_0.033).",19775480,PubMed,,"Kostopoulos_et_al.,_2009,_BMC_Cancer",,3,accepted,912,5845,20,39657458,39753127,,,ENST00000361337.2,,,,,75,GRCh37,,,2016-02-20_00:35:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/912,https://civic.genome.wustl.edu/links/variants/384,https://civic.genome.wustl.edu/links/genes/5845,,,,,25,Irinotecan,,,,,,,
TOP1,7150,EXPRESSION,Ovarian_Cancer,2394,,"Carboplatin,Cyclophosphamide,Topotecan",Combination,Predictive,Supports,B,Sensitivity/Response,"Shorter_progression_free_survival_was_observed_in_patients_with_low_expression_(IHC)_of_topoisomerase_1_in_16_patients_with_relapsed_or_persistent_ovarian_or_peritoneal_carcinoma_after_treatment_with_topotecan,_cyclophosphamide_and_carboplatin_followed_by_an_autologous_hematopoietic_stem_cell_transplant.",19648970,PubMed,,"Litzow_et_al.,_2010,_Bone_Marrow_Transplant.",,2,accepted,910,5845,20,39657458,39753127,,,ENST00000361337.2,,,,,75,GRCh37,,,2016-02-24_00:21:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/910,https://civic.genome.wustl.edu/links/variants/384,https://civic.genome.wustl.edu/links/genes/5845,,,,,25,Carboplatin,Cyclophosphamide,Topotecan,,,,,
PRKAA2,5563,T172_PHOSPHORYLATION,Cancer,162,,ACLY_SiRNA,,Predictive,Supports,E,Sensitivity/Response,"Low_levels_of_baseline_p-AMPK_(PRKAA2,_measured_at_Thr172)_were_predictive_of_efficacy_of_ACLY_inhibition_by_siRNA_in_cell_lines_of_various_cancer_histologies.",23506848,PubMed,,"Migita_et_al.,_2013,_Am._J._Pathol.",,2,accepted,913,4503,1,57159476,57159478,,,ENST00000371244.4,,,,,75,GRCh37,,,2016-02-22_20:41:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/913,https://civic.genome.wustl.edu/links/variants/385,https://civic.genome.wustl.edu/links/genes/4503,,,,,0.5,ACLY_SiRNA,,,,,,,
HSPA5,3309,EXPRESSION,Colorectal_Cancer,9256,,5-fluorouracil,,Predictive,Supports,B,Sensitivity/Response,"Expression_of_GRP78_(HSPA5)_in_colorectal_cancer_patients_(n=396,_by_IHC)_showed_improved_benefit_from_adjuvant_chemotherapy_in_stage_III_patients_(52%_vs._28%;_p_=_0.026)._In_vitro,_GRP78_inhibition_reduced_response_to_5-FU.",23456958,PubMed,,"Thornton_et_al.,_2013,_Int._J._Cancer",,4,accepted,914,2778,9,127997132,128003609,,,ENST00000324460.6,,,,,75,GRCh37,,,2016-02-14_00:35:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/914,https://civic.genome.wustl.edu/links/variants/386,https://civic.genome.wustl.edu/links/genes/2778,,,,,20,5-fluorouracil,,,,,,,
EIF4EBP1,1978,PHOSPHORYLATION,Colorectal_Cancer,9256,,"BEZ235_(NVP-BEZ235,_Dactolisib),PP242,WYE354",Substitutes,Predictive,Supports,D,Resistance,"12_CRC_cell_lines_were_evaluated._40%_of_these_were_intrinsically_resistant_to_mTOR_inhibition_with__BEZ235,_PP242_or_WYE354._mTOR_independent_phosphorylation_of_EIF4EBP1_(T37/46)_was_associated_with_resistance_to_mTOR_inhibitors_in_one_analyzed_cell_line_(SW620).",22262166,PubMed,,"Zhang_et_al.,_2012,_Cell_Cycle",,2,accepted,932,1655,8,37888200,37914663,,,ENST00000338825.4,,,,,75,GRCh37,,,2016-02-22_20:36:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/932,https://civic.genome.wustl.edu/links/variants/387,https://civic.genome.wustl.edu/links/genes/1655,,,,,4,BEZ235_(NVP-BEZ235,_Dactolisib),PP242,WYE354,,,,
EIF4EBP1,1978,PHOSPHORYLATION,Gastric_Adenocarcinoma,3717,,Everolimus,,Predictive,Supports,D,Sensitivity/Response,"8_gastric_cancer_cell_lines_were_treated_with_the_MTOR_inhibitor_everolimus._Cell_proliferation_was_effectively_inhibited_in_3_cell_lines_by_everolimus._Phosphorylated_EIF4EBP1_(T37/46,_T70)_levels_were_higher_in_cell_lines_and_xenografts_sensitive_to_everolimus.",23340172,PubMed,,"Nishi_et_al.,_2013,_Cancer_Lett.",,2,accepted,918,1655,8,37888200,37914663,,,ENST00000338825.4,,,,,75,GRCh37,,,2016-02-22_20:38:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/918,https://civic.genome.wustl.edu/links/variants/387,https://civic.genome.wustl.edu/links/genes/1655,,,,,4,Everolimus,,,,,,,
KIT,3815,MUTATION,Gastrointestinal_Stromal_Tumor,9253,,"Pictilisib,Imatinib",Combination,Predictive,Supports,D,Sensitivity/Response,"Human_GISTs_with_different_KIT_mutations_were_grafted_in_136_nude_muce._Mice_were_then_treated_with_control,_imatinib,_GDC-0941,_or_GDC-0941_+_imatinib._The_combination_showed_superior_antitumor_efficacy_that_was_sustained_after_treatment_withdrawal.",23231951,PubMed,,"Floris_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,919,29,4,55524085,55606881,,,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_16:08:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/919,https://civic.genome.wustl.edu/links/variants/388,https://civic.genome.wustl.edu/links/genes/29,,,"gain_of_function_variant,transcript_variant",,17,Pictilisib,Imatinib,,,,,,
KIT,3815,MUTATION,Melanoma,1909,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_II_clinical_trial_of_43_melanoma_patients_harboring_KIT_mutations_or_amplifications,_imatinib_treatment_exhibited_significant_anti-tumor_activity_with_a_median_progression_free_survival_of_3.5_months,_tumor_regression_in_41.9%_of_patients,_and_a_1-year_overall_survival_rate_of_51%._9/10_partial_responses_were_in_patients_with_exon_11_or_13_KIT_mutations.",21690468,PubMed,,"Guo_et_al.,_2011,_J._Clin._Oncol.",,3,accepted,1222,29,4,55524085,55606881,,,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:07:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1222,https://civic.genome.wustl.edu/links/variants/388,https://civic.genome.wustl.edu/links/genes/29,,,"gain_of_function_variant,transcript_variant",,17,Imatinib,,,,,,,
TUBB3,10381,EXPRESSION,Breast_Cancer,1612,,Taxane,,Predictive,Supports,B,Sensitivity/Response,"High_expression_of_betaIII-tubulin,_as_assessed_in_85_breast_cancers_by_IHC,_was_associated_with_better_pathological_response.",23218766,PubMed,,"Wang_et_al.,_2013,_Clin._Breast_Cancer",,2,accepted,921,8262,16,89989687,90002505,,,ENST00000315491.7,,,,,75,GRCh37,,,2016-02-20_21:53:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/921,https://civic.genome.wustl.edu/links/variants/389,https://civic.genome.wustl.edu/links/genes/8262,,,,,12,Taxane,,,,,,,
TUBB3,10381,EXPRESSION,Cancer,162,,Paclitaxel,,Predictive,Supports,D,Resistance,"High_expression_of_class_3_beta-tubulin_led_to_decreased_effect_of_paclitaxel_on_cell_motility_in_HeLa,_MCF-7_and_CHO_cell_lines.",21576762,PubMed,,"Ganguly_et_al.,_2011,_Oncotarget",,2,accepted,920,8262,16,89989687,90002505,,,ENST00000315491.7,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/920,https://civic.genome.wustl.edu/links/variants/389,https://civic.genome.wustl.edu/links/genes/8262,,,,,12,Paclitaxel,,,,,,,
EGFR,1956,Y1092_PHOSPHORYLATION,Non-small_Cell_Lung_Carcinoma,3908,,"Erlotinib,Gefitinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"While_EGFR_mutation_is_a_strong_predictive_factor_for_EGFR_inhibition,_some_patients_with_EGFR_wild-type_also_respond.__The_authors_investigated_whether_phosphorylated_EGFR_could_be_a_potential_predictive_biomarker_in_patients_with_wild-type_EGFR._Phosphorylation_of_Y1068_(assessed_by_IHC)_was_associated_with_improved_progression_free_survival_(PFS)_in_205_patients_with_stage_IIb_and_IV_NSCLC_treated_with_EGFR_tyrosine_kinase_inhibitors_(gefitinib_or_erlotinib)_compared_to_phospho-Y1068_negative_patients_(median_PFS_7.0_months_vs._1.2_months,_P < 0.001)._In_this_group,_92_(44.9%)_were_EGFR_mutant._In_a_subgroup_of_patients_with_wild-type_EGFR,_phospho-Y1068_expression_positive_patients_had_a_significantly_prolonged_PFS_(4.2 months_vs.1.2 months_P < 0.001)_compared_with_those_without_phospho-Y1068_expression.",22901364,PubMed,,"Wang_et_al.,_2012,_J._Exp._Clin._Cancer_Res.",,3,accepted,923,19,7,55272951,55272953,,,ENST00000275493.2,,,,,75,GRCh37,"Although_referred_to_as_Y1068_in_the_literature,_based_on_the_recognition_peptide_described,_this_tyrosine_occurs_at_Y1039_(ENST00000454757.2_v75)_or_Y1092_(ENST00000275493.2_v75).",,2016-02-18_18:32:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/923,https://civic.genome.wustl.edu/links/variants/390,https://civic.genome.wustl.edu/links/genes/19,"Although_referred_to_as_Y1068_in_the_literature,_based_on_the_recognition_peptide_described,_this_tyrosine_occurs_at_Y1039_(ENST00000454757.2_v75)_or_Y1092_(ENST00000275493.2_v75).",,,,15,Erlotinib,Gefitinib,,,,,,
IGF1R,3480,NUCLEAR_EXPRESSION,Sarcoma,1115,,IGF1R_Monoclonal_Antibody,,Predictive,Supports,B,Sensitivity/Response,"IGF-1R_nuclear_immunostaining_(IHC)_was_observed_in_9_out_of_16_samples_of_patients_with_different_sarcomas_(osteosarcoma,_ewing_sarcoma,_liposarcoma,_synovialsarcoma,_desmoplastic_tumor,_rhabdomyosarcoma)._Exclusive_nuclear_immunostaining_was_associated_with_better_progression_free_survival_and_overall_survival_after_therapy_with_IGF1R_antibodies_(R1507,_IMC-A12,_SCH_717454_and_CP-751.871).",22682017,PubMed,,"Asmane_et_al.,_2012,_Eur._J._Cancer",,2,accepted,924,2899,15,99192200,99507759,,,ENST00000268035.6,,,,,75,GRCh37,,,2016-02-20_03:01:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/924,https://civic.genome.wustl.edu/links/variants/391,https://civic.genome.wustl.edu/links/genes/2899,,,,,10,IGF1R_Monoclonal_Antibody,,,,,,,
CFLAR,8837,EXPRESSION,Prostate_Cancer,10283,,Bicalutamide,,Predictive,Supports,D,Resistance,"Expression_of_c-FLIP_(CFLAR)_in_50_prostate_specimens_(assessed_by_IHC)_was_increased_in_castrate-resistant_prostate_cancer._In-vitro,_silencing_of_CFLAR_led_to_sensitization_of_two_cell_lines_to_bicalutamide.",22623731,PubMed,,"McCourt_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,925,7009,2,201980827,202041410,,,ENST00000309955.3,,,,,75,GRCh37,,,2016-02-21_16:27:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/925,https://civic.genome.wustl.edu/links/variants/392,https://civic.genome.wustl.edu/links/genes/7009,,,,,3,Bicalutamide,,,,,,,
PROM1,8842,EXPRESSION,Hepatocellular_Carcinoma,684,,Sorafenib,,Predictive,Supports,B,Resistance,"CD133_(PROM1)_expression_in_39_samples_of_hepatocellular_carcinomas_was_correlated_with_JNK_activity._Both_were_more_highly_expressed_in_patients_not_responding_to_sorafenib._CD133+_cells_(sorted)_were_xenografted_into_mice,_producing_larger,_more_JNK_inhibitor_responsive_tumors_than_CD133-_xenografts.",22596232,PubMed,,"Hagiwara_et_al.,_2012,_Br._J._Cancer",,2,accepted,926,7014,4,15969857,16085324,,,ENST00000510224.1,,,,,75,GRCh37,,,2016-02-21_16:45:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/926,https://civic.genome.wustl.edu/links/variants/393,https://civic.genome.wustl.edu/links/genes/7014,,,,,10,Sorafenib,,,,,,,
FOXP3,50943,EXPRESSION,Breast_Cancer,1612,,Epirubicin,,Predictive,Supports,B,Sensitivity/Response,"1,097_patients_with_breast_cancer_were_evaluated_for_FOXP3_expression_by_IHC._FOXP3_expression_was_found_in_405_tumor_samples_and_associated_with_improved_OS_in_patients_treated_with_anthracycline-based_adjuvant_chemotherapy_(6_cycles_of_'FEC100'_aka_epirubicin_+_cyclophosphamide_+_5-fluorouracil)_but_not_in_patients_treated_with_sequential_anthracycline->taxane_(3_cycles_of_FEC100_followed_by_3_cycles_of_docetaxel)._In-vitro_experiments_confirmed_that_FOXP3_expression_enhance_anthracycline_efficacy._The_in_vitro_data_consisted_of_testing_the_sensitivity_of_various_breast_cancer_cell_lines_to_anthracyclines_after_treatment_with_valproic_acid_(which_increases_FOXP3_expression)._The_authors_observed_that,_while_valproic_acid_has_no_intrinsic_cytotoxic_effect_on_tumor_cells,_it_enhanced_the_cytotoxic_effect_of_epirubicin_specifically_in_cell_lines_where_FOXP3_expression_was_increased.",22431701,PubMed,,"Ladoire_et_al.,_2012,_Ann._Oncol.",,4,accepted,928,11587,X,49106897,49121288,,,ENST00000376207.4,,,,,75,GRCh37,,,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/928,https://civic.genome.wustl.edu/links/variants/394,https://civic.genome.wustl.edu/links/genes/11587,,,,,20,Epirubicin,,,,,,,
RPS6,6194,PHOSPHORYLATION,Gastric_Adenocarcinoma,3717,,Everolimus,,Predictive,Supports,D,Sensitivity/Response,"54_patients_with_advanced_gastric_cancer_were_treated_with_everolimus._Two_patient_responsed_and_potential_biomarkers_were_explored._High_pre-treatment_expression_of_phosphorylated_RPS6_(pS6;_at_Ser240/4)_was_associated_with_higher_disease_control_rate_and_progression_free_survival_(P=0.043,_P=0.001_respectively;_N=28).",22343617,PubMed,,"Yoon_et_al.,_2012,_Br._J._Cancer",,2,accepted,930,5013,9,19376309,19376323,,,ENST00000380394.4,,,,,75,GRCh37,,,2016-02-22_23:46:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/930,https://civic.genome.wustl.edu/links/variants/395,https://civic.genome.wustl.edu/links/genes/5013,,,,,2,Everolimus,,,,,,,
JAK1,3716,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Enzastaurin,,Predictive,Supports,D,Sensitivity/Response,Overexpression_of_JAK1_in_22_lung_cancer_cell_lines_was_associated_with_sensitivity_to_PKC-inhibitor_enzastaurin._Silencing_of_JAK1_(by_small_molecule_JAK_1/2/3_inhibitor)_led_to_resistance.__Overexpression_of_JAK1_(lentiviral_mediated)_led_to_sensitivity_to_enzastaurin.,22333600,PubMed,,"Shimokawa_et_al.,_2012,_Br._J._Cancer",,4,accepted,931,3090,1,65298912,65432187,,,ENST00000342505.4,,,,,75,GRCh37,,,2016-02-21_16:18:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/931,https://civic.genome.wustl.edu/links/variants/396,https://civic.genome.wustl.edu/links/genes/3090,,,,,4,Enzastaurin,,,,,,,
BRCA1,672,EXPRESSION,Malignant_Mesothelioma,1790,,Vinorelbine,,Predictive,Supports,D,Sensitivity/Response,Expression_of_BRCA1_in_6_mesothelioma_cell_lines_was_associated_with_sensitivity_to_vinorelbine_in_functional_studies.,22190288,PubMed,,"Busacca_et_al.,_2012,_J._Pathol.",,2,accepted,933,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,,2016-02-21_16:47:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/933,https://civic.genome.wustl.edu/links/variants/397,https://civic.genome.wustl.edu/links/genes/6,,,,,2,Vinorelbine,,,,,,,
DUSP6,1848,EXPRESSION,Cancer,162,,Trametinib,,Predictive,Supports,D,Sensitivity/Response,Expression_of_DUSP6_was_associated_with_sensitivity_to_MEK_inhibitor_GSK1120212_(Sensitivity:_79%;_specificity:_82%:_P_=_0.0027)_in_218_solid_cancer_cell_lines.,22169769,PubMed,,"Jing_et_al.,_2012,_Mol._Cancer_Ther.",,3,accepted,934,1567,12,89741009,89747048,,,ENST00000279488.7,,,,,75,GRCh37,,,2016-02-20_23:26:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/934,https://civic.genome.wustl.edu/links/variants/398,https://civic.genome.wustl.edu/links/genes/1567,,,,,3,Trametinib,,,,,,,
BRAF,673,MUTATION,Colorectal_Cancer,9256,,Bevacizumab,,Predictive,Supports,B,Resistance,"This_was_a_retrospective_clinical_study_of_97_metastatic_colorectal_cancer_patients_who_received_bevacizumab_in_conjunction_with_first-line_chemotherapy_(composed_of_5-fluorouracil_(5-FU)_only,_5-FU_+_oxaliplatin,_5-FU_+_irinotecan,_or_5-FU_+_oxaliplatin_+_irinotecan)._It_assessed_the_relationship_between_BRAF_mutation_status_in_primary_tumors_and_response_to_bevacizumab-containing_first_line_chemotherapy,_as_measured_by_PFS._Of_the_97_patients,89_had_wildtype_BRAF_and_8_had_mutations_in_BRAF—including_V600E_and_D594K._The_study_found_that_patients_harboring_a_BRAF_mutation_were_significantly_more_resistant_to_bevacizumab-containing_first-line_chemotherapy_than_patients_with_wildtype_BRAF_(Median_PFS:_4.2_and_12.5_months,_respectively;_p_<_.0001).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6305,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-11_22:13:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/6305,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Bevacizumab,,,,,,,
BRAF,673,MUTATION,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Supports,B,Resistance,"This_was_a_retrospective_clinical_study_of_44_metastatic_colorectal_cancer_patients_who_received_FOLFIRI_(5-Fluorouacil_+_Folinic_acid_+_irinotecan)_first-line_therapy_alone_or_with_bevacizumab._It_assessed_the_relationship_between_BRAF_mutation_status_in_primary_tumors_and_response_to_irinotecan-based_first_line_therapy,_as_measured_by_PFS._Of_the_44_patients,_39_had_wildtype_BRAF_and_5_had_mutations_in_BRAF—including_V600E_and_D594K._The_study_found_that_patients_harboring_a_BRAF_mutation_were_significantly_more_resistant_to_irinotecan-based_first-line_therapy_than_patients_with_wildtype_BRAF_(Median_PFS:_3.5_and_12.8_months,_respectively;_p_=_.006).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6304,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-11_22:08:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/6304,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Irinotecan,,,,,,,
BRAF,673,MUTATION,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Does_Not_Support,B,Sensitivity/Response,"A_quantitative_synthesis_was_performed_on_nine_studies_comparing_treatment_of_metastatic_colorectal_cancer_with_cetuximab_or_panitumumab_and_chemotherapy,_versus_chemotherapy_alone,_or_with_other_targeted_inhibitors._It_was_found_that_in_the_patient_subgroup_with_BRAF_mutation_(V600E_in_the_majority_of_cases),_there_were_no_benefits_to_overall_survival,_progression_free_survival,_or_overall_response_rate_with_addition_of_cetuximab_or_panitumumab_to_treatment._This_conclusion_held_in_the_first_line_treatment_as_well_as_general_treatment_setting.",25673558,PubMed,,"Pietrantonio_et_al.,_2015,_Eur._J._Cancer",,3,accepted,1404,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_02:27:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1404,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Cetuximab,Panitumumab,,,,,,
BRAF,673,MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"A_cohort_of_patient-derived_xenografts_(PDX)_from_85_patients_with_metastatic_colorectal_cancer_was_created._PDX_were_treated_with_cetuximab_and_mechanisms_of_resistance_investigated._None_of_the_xenografts_harboring_KRAS_(N=18),_NRAS_(N=7)_or_BRAF_(N=3)_mutations_showed_a_response_to_cetuximab_whereas_1_out_of_4_xenografts_with_a_PIK3CA_mutation_responded_to_cetuximab.",22586653,PubMed,,"Bertotti_et_al.,_2011,_Cancer_Discov",,2,accepted,1704,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_22:24:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1704,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Cetuximab,,,,,,,
BRAF,673,MUTATION,Cancer,162,,Trametinib,,Predictive,Supports,D,Sensitivity/Response,"In_this_screen_of_218_solid_cancer_cell_lines,_BRAF_mutations_were_predictive_of_response_to_the_MEK_inhibitor_GSK1120212._26_of_these_cell_lines_had_the_BRAF_V600E_mutation,_one_cell_line_had_a_G469A_mutation,_one_had_G596R_mutation_and_one_had_an_unspecified_mutation._Also_of_note,_in_RAF/RAS_mutant_colon_cancer_cell_lines,_co-occurring_PIK3CA/PTEN_mutations_led_to_a_cytostatic_response_rather_than_a_cytotoxic_response.",22169769,PubMed,,"Jing_et_al.,_2012,_Mol._Cancer_Ther.",,4,accepted,936,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-18_18:35:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/936,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Trametinib,,,,,,,
BRAF,673,MUTATION,Colorectal_Cancer,9256,,Oxaliplatin,,Predictive,Supports,B,Resistance,"This_was_a_retrospective_clinical_study_of_100_metastatic_colorectal_cancer_patients_who_received_FOLFOX_(oxaliplatin_+_5-fluorouracil_+_folinic_acid)_first-line_therapy_alone_or_with_monoclonal_antibodies_(bevacizumab_or_cetuximab)._It_assessed_the_relationship_between_BRAF_mutation_status_in_primary_tumors_and_response_to_oxaliplatin-based_first-line_therapy,_as_measured_by_post_treatment_PFS._Of_100_patients,_94_had_wildtype_BRAF_and_6_had_mutations_in_BRAF—including_V600E_and_D594K._The_study_found_that_patients_harboring_a_BRAF_mutation_were_significantly_more_resistant_to_oxaliplatin-based_first-line_therapy_than_patients_with_wildtype_BRAF_(Median_PFS:_5.0_and_11._7_months,_respectively;_p_<_.0001).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6303,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-11_21:59:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/6303,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Oxaliplatin,,,,,,,
BRAF,673,MUTATION,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"This_was_a_retrospective_clinical_study_of_92_metastatic_colorectal_cancer_patients_who_received_cetuximab_in_conjunction_with_salvage_chemotherapy_(refractory_to_at_least_one_line_of_treatment)._Salvage_chemotherapy_was_composed_of_5-fluorouracil_(5-FU)_only,_5-FU_+_oxaliplatin,_5-FU_+_irinotecan,_or_5-FU_+_oxaliplatin_+_irinotecan._The_study_assessed_the_relationship_between_BRAF_mutation_status_in_primary_tumors_and_response_to_cetuximab-containing_salvage_chemotherapy,_as_measured_by_PFS._Of_the_92_patients,_83_had_wildtype_BRAF_and_9_had_mutations_in_BRAF—including_V600E_and_D594K._The_study_found_that_patients_harboring_a_BRAF_mutation_were_significantly_more_resistant_to_cetuximab-containing_salvage_chemotherapy_than_patients_with_wildtype_BRAF_(Median_PFS:_2.0_and_3.9,_respectively;_p_=_.0005).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6306,5,7,140453136,140481403,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-11_22:14:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/6306,https://civic.genome.wustl.edu/links/variants/399,https://civic.genome.wustl.edu/links/genes/5,,,"gene_variant,gain_of_function_variant",,136,Cetuximab,,,,,,,
HSPB1,3315,EXPRESSION,Pancreatic_Ductal_Adenocarcinoma,3498,,Gemcitabine,,Predictive,Supports,D,Sensitivity/Response,HSP27_(HSPB1)_expression_in_pancreatic_adenocarcinoma_cell_lines_was_associated_with_sensitivity_to_treatment_with_gemcitabine.,22004109,PubMed,,"Schäfer_et_al.,_2012,_J._Cell._Mol._Med.",,2,accepted,939,2784,7,75931861,75933612,,,ENST00000248553.6,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/939,https://civic.genome.wustl.edu/links/variants/400,https://civic.genome.wustl.edu/links/genes/2784,,,,,2,Gemcitabine,,,,,,,
NQO1,1728,EXPRESSION,Lung_Cancer,1324,,Amrubicin,,Predictive,Supports,D,Resistance,Higher_expression_of_NQO1_was_correlated_with_decreased_cytotoxicity_of_amrubicin_(amrubicinol_is_the_active_metabolite)_in_27_NSCLC_and_SCLC_cell_lines.__siRNA_knockdown_of_NQO1_(in_two_cell_lines)_increased_amrubicinol_cytotoxicity.,21964527,PubMed,,"Takakuwa_et_al.,_2011,_J_Thorac_Oncol",,2,accepted,940,1463,16,69743304,69760854,,,ENST00000320623.5,,,,,75,GRCh37,,,2016-02-21_16:33:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/940,https://civic.genome.wustl.edu/links/variants/401,https://civic.genome.wustl.edu/links/genes/1463,,,,,2,Amrubicin,,,,,,,
NQO1,1728,P187S,Lung_Cancer,1324,,Amrubicin,,Predictive,Supports,D,Sensitivity/Response,"The_presence_of_NQO1_C609T_SNP_(rs1800566)_was_associated_with_decreased_protein_expression_and_higher_amrubicin_sensitivity_in_29_NSCLC_and_SCLC_cell_lines._15_of_these_cell_lines_were_genotyped_for_C609T_(only_3_were_T/T,_and_the_rest_were_C/C_or_C/T)._Cell_lines_with_the_T/T_genotype_had_lower_expression_of_NQ01_and_greater_response_to_amrubicinol.",21964527,PubMed,,"Takakuwa_et_al.,_2011,_J_Thorac_Oncol",,2,accepted,941,1463,16,69745145,69745145,G,A,ENST00000320623.5,,,,,75,GRCh37,,Germline_Polymorphism,2016-02-22_02:52:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/941,https://civic.genome.wustl.edu/links/variants/402,https://civic.genome.wustl.edu/links/genes/1463,,,missense_variant,"NM_000903.2:c.559C>T,NP_000894.1:p.Pro187Ser,NC_000016.9:g.69745145G>A",2,Amrubicin,,,,,chr16_g.69745145G~A,NQO1_c.559C~T,NQO1_P187S
BRCA1,672,UNDEREXPRESSION,Ovarian_Cancer,2394,,"PLATINUM,Taxane",Combination,Predictive,Supports,B,Sensitivity/Response,"Absent/low_expression_of_BRCA1_(IHC)_was_associated_with_improved_response_to_chemotherapy_in_292_patients_with_sporadic_ovarian_cancer_compared_to_patients_with_high_expression_(odds_ratio_2.47:_95%CI_1.10-5.55,_p=0.029).",21920589,PubMed,,"Carser_et_al.,_2011,_Gynecol._Oncol.",,3,accepted,942,6,17,41196312,41277387,,,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2016-01-27_20:06:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/942,https://civic.genome.wustl.edu/links/variants/403,https://civic.genome.wustl.edu/links/genes/6,,,,,15,PLATINUM,Taxane,,,,,,
ABCB1,5243,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Paclitaxel,,Predictive,Supports,D,Resistance,"mRNA_expression_of_ABCB1_in_17_NSCLC_cell_lines_was_associated_with_decreased_response_to_paclitaxel_(correlation_of_mRNA_expression_and_paclitaxel_IC50:_r=0.5322,_P=0.0279).",21883677,PubMed,,"Meng_et_al.,_2011,_Respirology",,2,accepted,944,4244,7,87133175,87342564,,,ENST00000265724.3,,,,,75,GRCh37,,,2016-02-18_19:42:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/944,https://civic.genome.wustl.edu/links/variants/404,https://civic.genome.wustl.edu/links/genes/4244,,,,,2,Paclitaxel,,,,,,,
CXCR4,7852,EXPRESSION,Gastric_Adenocarcinoma,3717,,Docetaxel,,Predictive,Supports,B,Resistance,"CXCR4_expression_as_assessed_by_microarray_analysis,_was_associated_with_resistance_to_docetaxel_in_11_cancer_cell_lines_(R^2_=_0.23,_p_=_0.019)._Expression_levels_(by_qtPCR)_were_also_higher_in_resistant_tumors_among_25_patient_samples.",20651371,PubMed,,"Xie_et_al.,_2010,_Anticancer_Res.",,2,accepted,949,6329,2,136871919,136873813,,,ENST00000409817.1,,,,,75,GRCh37,,,2016-02-20_02:16:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/949,https://civic.genome.wustl.edu/links/variants/405,https://civic.genome.wustl.edu/links/genes/6329,,,,,10,Docetaxel,,,,,,,
MAGEH1,28986,EXPRESSION,Bile_Duct_Adenocarcinoma,4896,,Gemcitabine,,Predictive,Supports,D,Resistance,"10_biliary_tract_carcinoma_cell_lines_were_sorted_based_on_their_gemcitabine_sensitivity._MAGEH1_protein_expression_was_negatively_correlated_with_sensitivity._In_a_clinical_validation_cohort,_MAGEH_protein_expression_was_found_in_4/4_""non-effective""_cases_and_2/5_effective_cases_based_on_RECIST_criteria_after_gemcitabine_treatment.",20088962,PubMed,,"Ojima_et_al.,_2010,_Cancer_Sci.",,2,accepted,950,11261,X,55478538,55479998,,,ENST00000342972.1,,,,,75,GRCh37,,,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/950,https://civic.genome.wustl.edu/links/variants/406,https://civic.genome.wustl.edu/links/genes/11261,,,,,2,Gemcitabine,,,,,,,
ABCC3,8714,AMPLIFICATION,Breast_Cancer,1612,,"Paclitaxel,Monomethyl_Auristatin_E",Substitutes,Predictive,Supports,D,Resistance,44_cell_lines_and_145_patient_samples_were_utilized_in_various_aspects_of_this_study._31_breast_cancer_cell_lines_for_in_vitro_sensitivity_to_paclitaxel_and_Monomethyl_Auristatin_E_(MMAE)._Genome_wide_amplification_was_assessed_by_Affymetrix_SNP_arrays_and_expression_was_assessed_by_Affymetrix_gene_expression_arrays._ABCC3_amplification_(and_expression)_in_ERBB2_(HER2)_amplified_breast_cancer_cell_lines_was_associated_with_resistance_to_paclitaxel_and__MMAE._Three_independently_derived_EVSA-T_cell_lines_overexpressing_ABCC3_were_at_least_20-fold_less_sensitive_to_paclitaxel_and_MMAE_based_on_EC50_values.,18593940,PubMed,,"O'Brien_et_al.,_2008,_Cancer_Res.",,3,accepted,951,6906,17,48712218,48769613,,,ENST00000285238.8,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/951,https://civic.genome.wustl.edu/links/variants/407,https://civic.genome.wustl.edu/links/genes/6906,,,transcript_amplification,,3,Paclitaxel,Monomethyl_Auristatin_E,,,,,,
ABCC10,89845,EXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,Paclitaxel,,Predictive,Supports,D,Resistance,Increased_expression_of_ABCC10_in_17_NSCLC_cell_lines_was_inversely_correlated_with_paclitaxel_sensitivity_(r_=_0.574;_P_<_0.05).,18445659,PubMed,,"Oguri_et_al.,_2008,_Mol._Cancer_Ther.",,3,accepted,952,16656,6,43395292,43418168,,,ENST00000372530.4,,,,,75,GRCh37,,,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/952,https://civic.genome.wustl.edu/links/variants/408,https://civic.genome.wustl.edu/links/genes/16656,,,,,3,Paclitaxel,,,,,,,
ASNS,440,AMPLIFICATION,Ovarian_Cancer,2394,,L-asparaginase,,Predictive,Supports,D,Resistance,ASNS_amplification_and_expression_was_associated_with_resistance_to_L-asparaginase_in_ovarian_cancer_and_leukemia_cell_lines._ASNS_silencing_increased_sensitivity_to_l-ASP_in_2/3_of_ovarian_cancer_cell_lines.,17088436,PubMed,,"Lorenzi_et_al.,_2006,_Mol._Cancer_Ther.",,2,accepted,953,446,7,97481430,97501854,,,ENST00000175506.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/953,https://civic.genome.wustl.edu/links/variants/409,https://civic.genome.wustl.edu/links/genes/446,,,transcript_amplification,,2,L-asparaginase,,,,,,,
POU5F1,5460,EXPRESSION,Colon_Cancer,219,,Oxaliplatin,,Predictive,Supports,D,Resistance,OCT4B1_(POU5F1_splice_variant)_expression_reduced_sensitivity_to_oxaliplatin_(via_P-gp_and_ABCG2_differential_expression)_in_vitro.,26398480,PubMed,,"Wen_et_al.,_2015,_Oncol._Rep.",,2,accepted,958,4419,6,31132120,31138470,,,ENST00000259915.8,,,,,75,GRCh37,,,2016-07-26_14:50:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/958,https://civic.genome.wustl.edu/links/variants/412,https://civic.genome.wustl.edu/links/genes/4419,,,,,2,Oxaliplatin,,,,,,,
ERBB2,2064,KINASE_DOMAIN_MUTATION,Lung_Adenocarcinoma,3910,,Trastuzumab,,Predictive,Supports,C,Sensitivity/Response,"This_was_a_retrospective_study_of_patients_with_advanced_HER2-mutant_NSCLC_who_had_undergone_varied_courses_of_treatment.__All_tumors_were_adenocarcinoma_with_in-frame_HER2_exon_20_insertions.__In_patients_(n=57)_that_had_been_treated_with_trastuzumab_plus_chemotherapy,_an_overall_response_rate_of_75%_and_progression_free_survival_of_5.1_months_were_observed.__No_standard_of_care_currently_exists_for_HER2-mutant_NSCLC.__While_trastuzumab_has_not_shown_clear_benefit_yet_in_wild-type_HER2_overexpressed_NSCLC,_the_authors_conclude_that_further_prospective_studies_should_be_done_with_trastuzumab_plus_chemotherapy_in_advanced_HER2_mutant_NSCLC,_and_that_trastuzumab_plus_chemotherapy_should_be_considered_in_current_treatment_courses_of_this_cancer_type.",26598547,PubMed,,"Mazières_et_al.,_2016,_Ann._Oncol.",,4,accepted,1043,20,17,37879863,37882870,,,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-22_17:41:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1043,https://civic.genome.wustl.edu/links/variants/413,https://civic.genome.wustl.edu/links/genes/20,,,protein_altering_variant,,17.5,Trastuzumab,,,,,,,
ERBB2,2064,KINASE_DOMAIN_MUTATION,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"A_Phase_II_study_for_use_of_Afatinib_in_non-_or_light_smokers_with_lung_adenocarcinoma._Three_patients_with_metastatic_lung_adenocarcinomas_bearing_mutations_in_the_kinase_domain_of_HER2_gene_were_identified_(Y772_A775dup,_G776L,_and_G778_P780dup)._Objective_response_was_observed_in_all_three_of_these_patients.",22325357,PubMed,,"De_Grève_et_al.,_2012,_Lung_Cancer",,3,accepted,959,20,17,37879863,37882870,,,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:49:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/959,https://civic.genome.wustl.edu/links/variants/413,https://civic.genome.wustl.edu/links/genes/20,,,protein_altering_variant,,17.5,Afatinib,,,,,,,
ERBB2,2064,Y772_A775DUP,Non-small_Cell_Lung_Carcinoma,3908,,"Afatinib,Rapamycin_(Sirolimus)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_preclinical_studies_of_transgenic_mice_and_xenografts,_continuous_expression_of_mutant_ERBB2_(M774insAYVM_or_the_equivalent_A775insYVMA)_was_found_to_be_essential_for_tumor_maintenance._Furthermore,_preclinical_in_vivo_studies_assessing_erlotinib,_trastuzumab,_afatinib_(aka_BIBW2992),_and/or_sirolimus_(aka_rapamycin)_revealed_that_the_combination_of_afatinib_and_sirolimus_was_most_effective_in_shrinking_tumors_harboring_this_insertion.",19122144,PubMed,,"Perera_et_al.,_2009,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,960,20,17,37880996,37880997,,TACGTGATGGCT,ENST00000269571.5,,,,,75,GRCh37,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/960,https://civic.genome.wustl.edu/links/variants/414,https://civic.genome.wustl.edu/links/genes/20,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",,inframe_insertion,"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG",36,Afatinib,Rapamycin_(Sirolimus),,,,chr17_g.37880993_37880994insGCTTACGTGATG,ERBB2_c.2314_2325dupTACGTGATGGCT,
ERBB2,2064,Y772_A775DUP,Non-small_Cell_Lung_Carcinoma,3908,,Dacomitinib,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Phase_2_trial_of_ERBB-inhibitor_dacomitinib_in_stage_IIIB/IV_lung_cancers_with_HER2_mutations_or_amplification_(N=30)._Thirteen_tumors_harbored_identical_12_base_pair_exon_20_insertions_[A775_G776insYVMA,_alternative_nomenclature_p.Y772_A775dup(c.2313_2324dup)]._No_partial_responses_were_found_in_this_subgroup_even_though_some_were_on_study_treatment_for_>2_years_and_3_patients_with_other_HER2_mutations_achieved_PRs.",25899785,PubMed,,"Kris_et_al.,_2015,_Ann._Oncol.",,2,accepted,1893,20,17,37880996,37880997,,TACGTGATGGCT,ENST00000269571.5,,,,,75,GRCh37,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",Somatic_Mutation,2018-06-05_21:34:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1893,https://civic.genome.wustl.edu/links/variants/414,https://civic.genome.wustl.edu/links/genes/20,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",,inframe_insertion,"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG",36,Dacomitinib,,,,,chr17_g.37880993_37880994insGCTTACGTGATG,ERBB2_c.2314_2325dupTACGTGATGGCT,
ERBB2,2064,Y772_A775DUP,Lung_Adenocarcinoma,3910,,Trastuzumab_Emtansine,,Predictive,Supports,C,Sensitivity/Response,"A_51-year_old_female_never_smoker_with_stage_IV_lung_adenocarcinoma_carrying_a_HER2_insertion_in_exon_20_(p.A775_G776insYVMA)_by_sequencing_archived_material,_HER2_overexpression_by_IHC_(2+)_and_HER2_amplification_by_in_situ_hybridization_was_treated_with_T-DM1_(trastuzumab_emtansine)._Patient_received_two_cycles_off-label_at_3.6mg/kg_and_was_found_to_have_morphologic_response_of_lung_and_bone_lesions_by_PET_and_CT._TDM-1_therapy_was_ongoing_as_of_publication_April_2015.",25789838,PubMed,,"Weiler_et_al.,_2015,_J_Thorac_Oncol",,3,accepted,1125,20,17,37880996,37880997,,TACGTGATGGCT,ENST00000269571.5,,,,,75,GRCh37,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",Somatic_Mutation,2017-04-03_17:46:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1125,https://civic.genome.wustl.edu/links/variants/414,https://civic.genome.wustl.edu/links/genes/20,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",,inframe_insertion,"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG",36,Trastuzumab_Emtansine,,,,,chr17_g.37880993_37880994insGCTTACGTGATG,ERBB2_c.2314_2325dupTACGTGATGGCT,
ERBB2,2064,Y772_A775DUP,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"A_55_year_old_heavily_pretreated_patient_with_equivocal_HER2_overexpression_(IHC2+_and_no_amplification_in_FISH)_was_found_to_have_the_HER2_YMVA_kinase_domain_insertion.__Afatinib_monotherapy_resulted_in_resolution_of_symptoms_and_10_months_before_progressive_disease.__The_patient_was_subsequently_given_trastuzumab_with_no_response.__The_observed_efficacy_of_afatinib_against_M774insAYVM,_and_studies_reporting_afatinib_activity_against_other_variants_in_the_HER2_kinase_domain,_are_cited_by_the_authors_as_motivation_for_the_arm_of_NCI-MATCH_focusing_on_afatinib_and_activating_HER2_mutations.",26559459,PubMed,,"Li_et_al.,_2015,_Lung_Cancer",,4,accepted,1045,20,17,37880996,37880997,,TACGTGATGGCT,ENST00000269571.5,,,,,75,GRCh37,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",Somatic_Mutation,2016-02-22_17:43:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1045,https://civic.genome.wustl.edu/links/variants/414,https://civic.genome.wustl.edu/links/genes/20,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",,inframe_insertion,"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG",36,Afatinib,,,,,chr17_g.37880993_37880994insGCTTACGTGATG,ERBB2_c.2314_2325dupTACGTGATGGCT,
ERBB2,2064,Y772_A775DUP,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"A_Phase_II_study_for_use_of_Afatinib_in_non-_or_light_smokers_with_lung_adenocarcinoma._Three_patients_with_metastatic_lung_adenocarcinomas_bearing_mutations_in_the_kinase_domain_of_HER2_gene_were_identified_(Y772_A775dup,_G776L,_and_G778_P780dup)._Objective_response_was_observed_in_all_three_of_these_patients._The_patient_with_Y772_A775dup_(Case_1_in_the_paper),_maintained_a_metabolic_complete_response_for_3_months,_ultimately_received_a_total_of_9_months_of_Afatinib,_and_survived_one_year_from_study_entry.",22325357,PubMed,,"De_Grève_et_al.,_2012,_Lung_Cancer",,3,accepted,1888,20,17,37880996,37880997,,TACGTGATGGCT,ENST00000269571.5,,,,,75,GRCh37,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",Somatic_Mutation,2018-06-05_21:34:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1888,https://civic.genome.wustl.edu/links/variants/414,https://civic.genome.wustl.edu/links/genes/20,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",,inframe_insertion,"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG",36,Afatinib,,,,,chr17_g.37880993_37880994insGCTTACGTGATG,ERBB2_c.2314_2325dupTACGTGATGGCT,
ERBB2,2064,Y772_A775DUP,Lung_Carcinoma,3905,,Afatinib,,Predictive,Supports,D,Sensitivity/Response,"Human_HER2_with_YVMA_insertion_was_put_under_a_clara_cell_specific,_rtTA_promoter_system_inducible_via_doxycycline.__Induction_of_mutant_HER2_in_these_mice_drove_rapid_development_of_adenosquamous_lung_tumors,_where_tumor_maintenance_was_dependent_on_continued_YMVA_HER2_induction_by_doxycycline.__Administration_of_afatinib_had_a_stronger_effect_than_erlotinib_or_trastuzumab,_as_measured_by_histology_and_tumor_volume_regression.__Authors_state_that_in_the_case_of_afatinib_vs._trastuzumab,_intracellular_HER2_signaling_may_be_blocked_by_afatanib_but_remain_unaltered_by_trastuzumab.",19122144,PubMed,,"Perera_et_al.,_2009,_Proc._Natl._Acad._Sci._U.S.A.",,4,accepted,1047,20,17,37880996,37880997,,TACGTGATGGCT,ENST00000269571.5,,,,,75,GRCh37,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",Somatic_Mutation,2016-02-22_18:20:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1047,https://civic.genome.wustl.edu/links/variants/414,https://civic.genome.wustl.edu/links/genes/20,"Mutations_in_the_HER2_kinase_domain_occur_at_a_2-4%_frequency_in_lung_adenocarcinomas,_the_majority_of_which_are_in_exon_20_as_in-frame_duplications_or_insertions_in_a_small_8_codon_region_(774-781_or_775-782)._These_are_analogous_to_the_exon_20_alterations_found_in_EGFR_TK_domain._The_M774_insertion,_M774insAYVM,_represents_62.5%_of_all_HER2_kinase_domain_mutations_identified_(when_combined_with_the_A775insYVMA_mutations_as_they_translate_to_the_identical_amino_acid_sequence_changes)._As_demonstrated_in_mouse_models_(Perrera_et_al.,_PNAS_2009)_and_subsequent_clinical_trials_in_human_lung_adenocarcinoma_with_these_insertions,_HER2_YVMA_mutants_predict_response_to_several_targeted_HER2_agonists_such_as_afatinib,_trastuzumab,_neratinib_and_TDM-1_(trastuzumab_emtansine)_as_monotherapy_or_combined_with_specific_chemotherapies.",,inframe_insertion,"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG",36,Afatinib,,,,,chr17_g.37880993_37880994insGCTTACGTGATG,ERBB2_c.2314_2325dupTACGTGATGGCT,
EGFR,1956,C797S,Lung_Adenocarcinoma,3910,,Osimertinib,,Predictive,Supports,C,Resistance,"Case_report_of_a_patient_with_stage_IV_lung_adenocarcinoma_and_a_15–base_pair_deletion_in_EGFR_exon_19._Partial_response_with_erlotinib_was_achieved_for_15_months_after_initial_chemotherapy._After_further_progression,_rebiopsy_additionally_identified_the_EGFR_T790M_mutation_and_the_patient_received_several_cycles_of_chemotherapy_and_targeted_therapy_including_afatinib,_cetuximab,_erlotinib,_AZD9291._She_was_treated_with_AZD9291_for_9_months_until_disease_progression._Repeat_biopsy_detected_EGFRC797S_mutation_additionally_to_both_aforementioned_EGFR_aberrations._In_addition,_PTEN_Y27C_and_CTNNB1_S37F_mutations_were_present_in_all_3_samples,_and_a_TSC2_N486I_was_seen_in_the_third_biopsy_sample_only",26181354,PubMed,,"Yu_et_al.,_2015,_JAMA_Oncol",,1,accepted,1396,19,7,55249091,55249091,T,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-07-07_23:57:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1396,https://civic.genome.wustl.edu/links/variants/415,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2389T>A,NC_000007.13:g.55249091T>A,NM_005228.4:c.2389T>A,NP_005219.2:p.Cys797Ser",17.5,Osimertinib,,,,,chr7_g.55249091T~A,EGFR_c.2389T~A,EGFR_C797S
EGFR,1956,C797S,Non-small_Cell_Lung_Carcinoma,3908,,Osimertinib,,Predictive,Supports,B,Resistance,"An_EGFR_resistance_mutation,_C797S,_was_discovered_by_deep_sequencing_of_cell-free_plasma_DNA_(cfDNA)_from_patients_with_advanced_lung_cancer_whose_tumors_had_developed_resistance_to_osimertinib._Expression_of_this_mutant_EGFR_construct_in_a_cell_line_rendered_it_resistant_to_osimertinib._ddPCR_on_serial_cfDNA_specimens_collected_from_15_osimertinib-treated_subjects_(all_positive_for_T790M_before_treatment)_revealed_6_cases_with_acquired_C797S_mutation.",25939061,PubMed,,"Thress_et_al.,_2015,_Nat._Med.",,3,accepted,964,19,7,55249091,55249091,T,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-13_05:06:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/964,https://civic.genome.wustl.edu/links/variants/415,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2389T>A,NC_000007.13:g.55249091T>A,NM_005228.4:c.2389T>A,NP_005219.2:p.Cys797Ser",17.5,Osimertinib,,,,,chr7_g.55249091T~A,EGFR_c.2389T~A,EGFR_C797S
ERBB2,2064,SERUM_LEVELS,Breast_Cancer,1612,,Lapatinib,,Predictive,Supports,B,Sensitivity/Response,"Serum_and_tissue_levels_of_HER2_(ERBB2)_were_analyzed_in_1,902_breast_cancer_patients_treated_with_lapatinib_or_control._Serum_HER2_(sHER2)_levels_measured_by_ELISA_were_higher_in_patients_with_HER2_amplification_(median_sHER2_levels_were_25.1_ng/mL_in_patients_with_HER2-positive_tumors)._Serum_HER2_levels_were_Independent_predictors_of_lapatinib_progression_free_survival_benefit_(HR_per_10-ng/mL_increase_in_serum_HER2:_lapatinib-containing_therapies,_1.009_v_nonlapatinib-containing_therapies,_1.044;_P_interaction_<_.001)._Tissue_HER2_levels_were_also_predictive,_but_within_this_subgroup,_serum_HER2_still_independently_predicted_lapatinib_PFS_benefit.",26811533,PubMed,,"Lee_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,972,20,17,37856333,37884915,,,ENST00000269571.5,,,,,75,GRCh37,,,2016-02-12_23:22:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/972,https://civic.genome.wustl.edu/links/variants/416,https://civic.genome.wustl.edu/links/genes/20,,,,,35,Lapatinib,,,,,,,
NTRK1,4914,NTRK1_FUSIONS,Cancer,162,,Larotrectinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_Phase_1/2_study_involving_15_pediatric_patients_with_infantile_fibrosarcoma_or_soft_tissue_sarcoma,_8_patients_had_NTRK1_fusions._The_patients_were_administered_Larotrectinib,_and_7_out_of_8_patients_showed_objective_response,_with_2_complete_and_5_partial_responses._The_patient_without_objective_response_had_soft_tissue_sarcoma,_and_showed_stable_disease.",29606586,PubMed,,"Laetsch_et_al.,_2018,_Lancet_Oncol.",NCT02637687,4,accepted,6569,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2018-08-21_18:51:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/6569,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Larotrectinib,,,,,,,
NTRK1,4914,NTRK1_FUSIONS,Cancer,162,,Larotrectinib,,Predictive,Supports,B,Sensitivity/Response,This_was_a_Phase_1/2_study_of_55_patients_from_4_months_to_76_years_old_with_TRK-fusion_positive_tumors_given_NTRK_inhibitor_Larotrectinib._Patients_had_17_unique_NTRK_fusion_types._Patient_overall_response_rate_was_75%_according_to_independent_review_and_80%_according_to_investigator_assessment._Authors_state_that_Larotrectinib_had_durable_anti_tumor_activity_regardless_of_age_or_tumor_type._17/23_patients_with_NTRK1-fusion_showed_maximum_percent_change_in_tumor_size_between_-30%_and_-100%.,29466156,PubMed,,"Drilon_et_al.,_2018,_N._Engl._J._Med.","NCT02576431,NCT02122913,NCT02637687",4,accepted,6567,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2018-08-21_18:42:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/6567,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Larotrectinib,,,,,,,
NTRK1,4914,NTRK1_FUSIONS,Sarcoma,1115,,Larotrectinib_(LOXO-101),,Predictive,Supports,C,Sensitivity/Response,"LOXO-101_is_an_orally_administered_inhibitor_of_the_TRK_kinase_and_is_highly_selective_only_for_the_TRK_family_of_receptors._The_tumor_of_a_41-year-old_woman_with_soft-tissue_sarcoma_metastatic_to_the_lung_was_found_to_harbor_an_LMNA-NTRK1_gene_fusion_encoding_a_functional_LMNA-TRKA_fusion_oncoprotein.__This_patient's_tumors_underwent_rapid_and_substantial_tumor_regression,_with_an_accompanying_improvement_in_pulmonary_dyspnea,_oxygen_saturation,_and_plasma_tumor_markers.",26216294,PubMed,,"Doebele_et_al.,_2015,_Cancer_Discov",,2,accepted,2956,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2018-04-15_14:06:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/2956,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Larotrectinib_(LOXO-101),,,,,,,
NTRK1,4914,NTRK1_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Entrectinib,,Predictive,Supports,C,Sensitivity/Response,1378_cases_of_NSCLC_were_screened._One_patient_(frequency_0.1%)_with_a_NTRK1_gene_rearrangement_(SQSTM1-NTRK1_Fusion)_was_treated_with_entrectinib_in_a_phase_1_study._The_patient_had_resolution_of_prior_dyspnea_and_pain_within_3_weeks._CT_scans_showed_a_partial_response_and_complete_resolution_of_brain_metastases._The_patient_has_continued_treatment_for_over_6_months_with_ongoing_PR.,26565381,PubMed,,"Farago_et_al.,_2015,_J_Thorac_Oncol",,3,accepted,2947,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2018-12-04_17:16:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/2947,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Entrectinib,,,,,,,
NTRK1,4914,NTRK1_FUSIONS,Cancer,162,,Entrectinib,,Predictive,Supports,B,Sensitivity/Response,"in_two_phase_I_studies_in_patients_with_advanced_or_metastatic_solid_tumors,_including_patients_with_active_central_nervous_system_(CNS)_disease._Here,_we_summarize_the_overall_safety_and_report_the_antitumor_activity_of_entrectinib_in_a_cohort_of_patients_with_tumors_harboring_NTRK1/2/3,_ROS1,_or_ALK_gene_fusions_Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._Notably,_a_complete_CNS_response_was_achieved_in_a_patient_with_SQSTM1-NTRK1-rearranged_lung_cancer.",28183697,PubMed,,"Drilon_et_al.,_2017,_Cancer_Discov",,3,accepted,2948,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2017-04-14_16:36:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/2948,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Entrectinib,,,,,,,
NTRK1,4914,NTRK1_FUSIONS,Lung_Adenocarcinoma,3910,,"Lestaurtinib_(CEP-701),Crizotinib,ARRY-470",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Two_patients_were_found_to_harbor_gene_fusions_maintaining_the_kinase_domain_of_NTRK1_(3'_partner),_specifically:_MPRIP-NTRK1_and_CD74-NTRK1.__Both_of_these_fusions_lead_to_constitutive_kinase_activity_and_were_found_to_be_oncogenic._Treatment_of_cells_expressing_NTRK1_fusions_with_inhibitors_of_TRKA_kinase_activity_(ARRY-470,_CEP-701_and,_to_a_lesser_extent,_crizotinib)_inhibited_autophosphorylation_of_TRKA_and_cell_growth.",24162815,PubMed,,"Vaishnavi_et_al.,_2013,_Nat._Med.",,3,accepted,1019,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2016-02-17_19:50:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1019,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Lestaurtinib_(CEP-701),Crizotinib,ARRY-470,,,,,
NTRK1,4914,NTRK1_FUSIONS,Colorectal_Cancer,9256,,Larotrectinib,,Predictive,Supports,D,Sensitivity/Response,"NTRK1_fusions_(one_LMNA-NTRK1_and_two_TPM3-NTRK1)_were_identified_in_2%_of_Korean_colorectal_cancer_patients_(147_patients)._TrkA_(NTRK1)_protein_expression_was_associated_with_presence_of_NTRK1_gene_fusion._These_fusions_were_mutually_exclusive_with_other_oncogenic_drivers_and_showed_in-vitro_sensitivity_to_TrkA_Inhibitor_ARRY470__(Larotrectinib)_(one_cell_line_with_fusion_(KM12),_one_control_cell_line).",26716414,PubMed,,"Park_et_al.,_2016,_Oncotarget",,2,accepted,978,3983,1,156844175,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2018-08-21_19:02:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/978,https://civic.genome.wustl.edu/links/variants/419,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,72.5,Larotrectinib,,,,,,,
IDH1,3417,R132H,Pancreatic_Ductal_Adenocarcinoma,3498,,AG-120,,Predictive,Does_Not_Support,C,Sensitivity/Response,"A_48-year-old_female_was_diagnosed_with_metastatic_pancreatic_ductal_adenocarcinoma_and_subsequently_started_on_standard_of_care_chemotherapy,_during_which_her_hepatic_lesions_progressed._Detailed_molecular_profiling_was_performed_on_a_biopsy_from_a_liver_lesion_that_demonstrated_an_IDH1_mutation,_R132H._The_patient_subsequently_received_a_mutant_IDH1_inhibitor_(AG-120),_but_with_no_response.",27466707,PubMed,,"Brody_et_al.,_2016,_Cancer_Biol._Ther.",,2,accepted,5987,26,2,209113112,209113112,C,T,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2018-02-15_14:20:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/5987,https://civic.genome.wustl.edu/links/variants/420,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His,NC_000002.11:g.209113112C>T,ENST00000415913.1:c.395G>A",9,AG-120,,,,,chr2_g.209113112C~T,IDH1_c.395G~A,IDH1_R132H
IDH1,3417,R132H,Anaplastic_Oligodendroglioma,3181,,AGI-5198,,Predictive,Supports,D,Sensitivity/Response,"In_pre-clinical_studies,_an_IDH1_inhibitor_(AG-5198)_impaired_growth_of_glioma_/_anaplastic_oligodendroglioma_cell_lines_with_IDH1_R132H_mutations.__A_phase_I_clinical_trial_of_the_AG-120_IDH1_inhibitor_in_IDH1_mutant_positive_solid_tumors,_including_glioma_is_currently_underway.",23558169,PubMed,,"Rohle_et_al.,_2013,_Science",,4,accepted,979,26,2,209113112,209113112,C,T,ENST00000415913.1,,,,,75,GRCh37,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/979,https://civic.genome.wustl.edu/links/variants/420,https://civic.genome.wustl.edu/links/genes/26,"IDH1_R132_mutations_have_been_observed_in_a_number_of_cancer_types,_and_appear_to_behave_quite_differently_in_different_environments._In_myelodysplastic_syndromes_and_acute_myeloid_leukemia_(AML),_IDH1_R132_mutations_have_been_shown_to_be_associated_with_worse_outcome_and_shorter_overall_survival._They_have_also_been_linked_to_cytogenetically_normal_AML,_an_intermediate_risk_subtype_of_the_disease._However,_in_glioblastoma_and_astrocytoma,_patients_with_IDH1_mutations_have_shown_better_overall_survival_than_patients_with_wild-type_IDH1._Also_in_contrast_to_AML,_in_glioblastoma,_IDH1_mutations_have_been_associated_with_the_specific_cytogenetic_abnormalities,_1p_and_19q_deletions.",,missense_variant,"NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His,NC_000002.11:g.209113112C>T,ENST00000415913.1:c.395G>A",9,AGI-5198,,,,,chr2_g.209113112C~T,IDH1_c.395G~A,IDH1_R132H
STAG2,10735,UNDEREXPRESSION,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,A375_melanoma_cells_containing_an_inducible_shRNA_for_STAG2_were_grown_as_xenograft_tumors_in_nude_mice._The_mice_in_which_STAG2_was_silenced_had_tumors_that_were_more_sensitive_to_vemurafenib-induced_tumor_shrinkage_than_the_tumors_of_the_control_mice_(P_<_.01).,27500726,PubMed,,"Shen_et_al.,_2016,_Nat._Med.",,4,accepted,1659,8553,X,123095568,123236506,,,ENST00000371157.3,,,,,75,GRCh37,,,2016-11-07_18:53:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1659,https://civic.genome.wustl.edu/links/variants/422,https://civic.genome.wustl.edu/links/genes/8553,,,,,14,Vemurafenib,,,,,,,
HLA-DRA,3122,EXPRESSION,Skin_Melanoma,8923,,"Nivolumab,Pembrolizumab,Atezolizumab",Substitutes,Predictive,Supports,B,Sensitivity/Response,"Melanoma_patients_treated_with_Anti-PD1_or_anti-PD-L1(nivolumab,_pembrolizumab,_MPDL3280A)_therapy_were_analyzed_for_expression_of_HLA-DRA_(the_primary_antigen-presenting_molecule_of_the_MHC-II_pathway)._In_a_discovery_cohort,_30_patients_underwent_IHC_for_HLA-DRA._11/14_(79%)_patients_with_positive_HLA-DR_staining,_had_complete_(n=3)_or_partial_(n=8)_response._6/16_(38%)_HLA-DR_non-expressing_melanomas_responded_to_therapy_(overall_response_rate_79_versus_38%,_Fisher’s_exact_test_P=0.033)._This_finding_was_confirmed_in_a_second_independent_data_set_of_23_melanoma_patients_with_6/8_(75%)_of_HLA-DR(+)_tumours_in_comparison_to_4/15_(27%)_HLA-DR(−)_responding_(Fisher’s_exact_test_P=0.025)._Preclinical_models_confirmed_the_result.",26822383,PubMed,,"Johnson_et_al.,_2016,_Nat_Commun",,3,accepted,985,2622,6,32407619,32412823,,,ENST00000395388.2,,,,,75,GRCh37,,,2016-02-12_23:28:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/985,https://civic.genome.wustl.edu/links/variants/423,https://civic.genome.wustl.edu/links/genes/2622,,,,,15,Nivolumab,Pembrolizumab,Atezolizumab,,,,,
MYD88,4615,L265P,Waldenström's_Macroglobulinemia,,,Ibrutinib,,Predictive,Supports,B,Sensitivity/Response,A_prospective_study_of_ibrutinib_in_63_symptomatic_patients_with_Waldenström's_macroglobulinemia_who_had_received_at_least_one_previous_treatment._The_response_rates_were_highest_among_patients_with_MYD88(L265P)_and_CXCR4(WT)._The_MYD88_L265P_mutation_was_present_in_56_patients_(89%).,25853747,PubMed,,"Treon_et_al.,_2015,_N._Engl._J._Med.",,4,accepted,986,3742,3,38182641,38182641,T,C,ENST00000396334.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-13_05:50:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/986,https://civic.genome.wustl.edu/links/variants/424,https://civic.genome.wustl.edu/links/genes/3742,,,"gain_of_function_variant,missense_variant",NC_000003.11:g.38182641T>C,31,Ibrutinib,,,,,chr3_g.38182641T~C,,
MYD88,4615,L265P,Waldenström's_Macroglobulinemia,,,"IMG-2005-5,IRAK-1/4_Inhibitor",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_a_study_of_30_patients_with_Waldenström’s_macroglobulinemia,_87%_had_MYD88(L265P)_mutations.__Waldenstrom_macroglobulinemia_cells_expressing_MYD88(L265P)_were_treated_with_an_MYD88_homodimerization_inhibitor_or_an_IRAK_1/4_kinase_inhibitor.__The_cells_showed_a_decrease_in_staining_of_NF-kappa-B_p65_phosphorylation.",22931316,PubMed,,"Treon_et_al.,_2012,_N._Engl._J._Med.",,1,accepted,1641,3742,3,38182641,38182641,T,C,ENST00000396334.3,,,,,75,GRCh37,,Somatic_Mutation,2016-09-04_03:24:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1641,https://civic.genome.wustl.edu/links/variants/424,https://civic.genome.wustl.edu/links/genes/3742,,,"gain_of_function_variant,missense_variant",NC_000003.11:g.38182641T>C,31,IMG-2005-5,IRAK-1/4_Inhibitor,,,,chr3_g.38182641T~C,,
KRAS,3845,G12V,Non-small_Cell_Lung_Carcinoma,3908,,"Docetaxel,Selumetinib_(AZD6244)",Combination,Predictive,Supports,B,Sensitivity/Response,"83_patients_from_a_phase_II_trial_(docetaxel_+_placebo_or_selumetinib)_with_KRAS_mutant_tumors_were_retrospectively_assessed_for_differences_in_OS,_PFS,_ORR_and_change_in_tumor_size_at_week_6_according_to_type_of_KRAS_mutation._G12C,_G12D_and_G12V_were_the_most_common_mutations_(46%,_22%,_11%,_respectively)._Patients_with_G12C_or_G12V_mutations_had_a_trend_towards_longer_OS,_PFS_and_ORR_compared_to_other_KRAS_mutations._Changes_in_tumor_size_were_similar_between_groups_with_the_best_responses_in_tumors_with_G12V_mutations._Few_differences_were_observed_between_groups_when_treated_with_docetaxel_+_placebo.",26125448,PubMed,,"Jänne_et_al.,_2015,_Br._J._Cancer",,1,accepted,1143,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2016-10-10_22:55:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1143,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Docetaxel,Selumetinib_(AZD6244),,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Non-small_Cell_Lung_Carcinoma,3908,,PD0332991,,Predictive,Supports,D,Sensitivity/Response,"In_vivo_studies_confirmed_the_activity_of_PD0332991_(CDK4_inhibitor)_on_KRAS_G12V_mutant_tumors._17%_(2/12)_of_mice_treated_with_PD0332991_developed_detectable_lesions,_whereas_75%_of_mice_(3/4)_treated_with_vehicle_developed_lesions_at_the_end_of_the_treatment.",20609353,PubMed,,"Puyol_et_al.,_2010,_Cancer_Cell",,1,accepted,795,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2016-02-17_19:50:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/795,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,PD0332991,,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,__a_SW48_cell_line_expressing_KRAS_G12V_mutation_demonstrated_decreased_sensitivity__to_regorafenib_treatment_(IC50:_241.90_nmol_vs._114.28_nmol,_P<0.01)_compared_to_SW48_cells_expressing_KRAS_wild-type._Resistance_was_determined_by_assessing_cell_viability.",26161928,PubMed,,"Camaj_et_al.,_2015,_Future_Oncol",,,accepted,3924,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2017-07-21_19:18:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/3924,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Regorafenib,,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Colorectal_Cancer,9256,,"Selumetinib_(AZD6244),BEZ235",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_harboring_KRAS,_NRAS,_BRAF,_or_PIK3CA_mutations_and_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._32/40_tumors_harbored_KRAS_mutations_including_8_G12V_mutations_(3_with_PIK3CA_mutations)_where_progressive_disease_occurred_in_only_1_tumor_upon_doublet_treatment_but_6_tumors_in_monotherapy.",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,2001,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2017-07-21_15:56:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/2001,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Selumetinib_(AZD6244),BEZ235,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,Cells_harboring_KRAS_G12V_mutation_were_insensitive_to_cetuximab_treatment_in_isogenic_SW48_cells_and_in_a_mouse_xenograft_model.,20978259,PubMed,,"De_Roock_et_al.,_2010,_JAMA",,4,accepted,136,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2016-09-27_17:34:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/136,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Cetuximab,,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Cancer,162,,Crizotinib,,Predictive,Does_Not_Support,C,Resistance,"Case_report_of_a_59-year-old_white_female_patient_(60_pack-years)_with_a_CUP-syndrome._Molecular_profiling_identified_both_MET_amplification_(16_copies)_and_a_KRAS_G12V_mutation._The_patient_was_treated_with_crizotinib_and_experienced_a_complete_normalization_of_tumor_metabolic_activity_for_more_than_19_months._Other_identified_aberrations_include_CCND1_amplification_(8_copies),_MYC_amplification_(9_copies)_as_well_as_KRAS_G12V,_TP53_R273L_and_CARD11_N184S.",25232318,PubMed,,"Palma_et_al.,_2014,_Case_Rep_Oncol",,2,accepted,1715,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2016-11-07_20:32:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1715,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Crizotinib,,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS,_PIK3CA,_and_PTEN_were_tested_for_mutation;_KRAS_G12V_was_the_only_variant_noted_in_the_primary_rectal_tumor_of_one_patient_who_experienced_disease_progression_(patient_56;_Supplemental_Table_1),_and_the_primary_colon_tumors_of_two_patients_(9,_13;_Supplemental_Table_1)_who_experienced_stable_disease_following_treatment._In_the_larger_cohort,_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,6323,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2018-11-02_22:14:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/6323,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Cetuximab,Panitumumab,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2232,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2017-03-31_02:21:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/2232,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Panitumumab,,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
KRAS,3845,G12V,Lung_Cancer,1324,,Gefitinib,,Predictive,Supports,C,Resistance,"In_recurrent_lung_cancer_patients_treated_with_the_epidermal_growth_factor_receptor_tyrosine_kinase_inhibitor_gefitinib,_patients_with_KRAS_mutations_had_a_lower_frequency_of_partial_response_(PR)_and_stable_disease_(SD)_and_a_higher_rate_of_progressive_disease_(PD)_(PR:0,_SD:1,_PD:15_vs._PR:24,_SD:8,_PD:14;_P=0.0274)_compared_to_wildtype_KRAS_patients._Patients_with_KRAS_mutations_also_had_a_shorter_overall_survival_compared_to_wildtype_KRAS_patients_(HR:2.542,_95%_CI:1.048-6.168,_P=0.0390).",17409929,PubMed,,"Endoh_et_al.,_2006,_J_Thorac_Oncol",,2,accepted,2268,30,12,25398284,25398284,C,A,ENST00000256078.4,,,,,75,GRCh37,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,Somatic_Mutation,2017-05-11_15:29:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/2268,https://civic.genome.wustl.edu/links/variants/425,https://civic.genome.wustl.edu/links/genes/30,KRAS_mutations_are_the_most_common_mutations_in_pancreatic_cancer_occurring_in_>_90%_of_cases._Of_these_the_G12D_activating_mutation_is_the_most_prevalent_and_results_in_a_loss_of_GTPase_activity_which_in_turn_leads_to_a_constitutively_active_form_of_KRAS._This_is_enough_to_cause_pre-cancerous_pancreatic_intraepithelial_lesions,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",43,Gefitinib,,,,,chr12_g.25398284C~A,KRAS_c.35G~T,KRAS_G12V
BRAF,673,WILD_TYPE,Melanoma,1909,,RO4987655,,Predictive,Supports,B,Sensitivity/Response,"Phase_I_expansion_and_pharmacodynamic_study_of_the_oral_MEK_inhibitor_RO4987655._Among_12_patients_with_melanoma_BRAF_wild_type_and_non-NRAS_or_NRAS_unknown_status,_seven_patients_experienced_partial_response_or_stable_disease.",24947927,PubMed,,"Zimmer_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,995,5,7,140434279,140624564,,,ENST00000288602.6,,,,,75,GRCh37,,,2016-02-13_05:43:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/995,https://civic.genome.wustl.edu/links/variants/426,https://civic.genome.wustl.edu/links/genes/5,,,wild_type,,10,RO4987655,,,,,,,
NRAS,4893,Q61K,Skin_Melanoma,8923,,Selumetinib_(AZD6244),,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_melanoma_cell_lines._NRAS_Q61K,_in_addition_to_the_BRAF_V600E_mutation_was_associated_with_resistance_to_vemurafenib_but_sensitivity_to_AZD6244_(selumetinib)_in_vitro_in_the_acquired_resistant_cell_line_M249-AR4_and_in_the_patient-derived_acquired_resistant_cell_line_M376.",22194965,PubMed,,"Atefi_et_al.,_2011,_PLoS_ONE",,2,accepted,1475,36,1,115256530,115256530,G,T,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-14_00:05:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1475,https://civic.genome.wustl.edu/links/variants/427,https://civic.genome.wustl.edu/links/genes/36,,,missense_variant,"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A",12,Selumetinib_(AZD6244),,,,,chr1_g.115256530G~T,NRAS_c.181C~A,NRAS_Q61K
NRAS,4893,Q61K,Colorectal_Cancer,9256,,"BEZ235,Selumetinib_(AZD6244)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_harboring_mutations_in_KRAS,_NRAS,_BRAF,_or_PIK3CA_and_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._NRAS_mutations_were_in_4/40_tumors_(three_Q61K,_one_G12D).",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,2192,36,1,115256530,115256530,G,T,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_16:30:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/2192,https://civic.genome.wustl.edu/links/variants/427,https://civic.genome.wustl.edu/links/genes/36,,,missense_variant,"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A",12,BEZ235,Selumetinib_(AZD6244),,,,chr1_g.115256530G~T,NRAS_c.181C~A,NRAS_Q61K
NRAS,4893,Q61K,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,D,Resistance,"Preclinical_study_in_melanoma_cell_lines._NRAS_Q61K,_in_addition_to_the_BRAF_V600E_mutation_was_associated_with_resistance_to_vemurafenib_but_sensitivity_to_AZD6244_(selumetinib)_in_vitro_in_the_acquired_resistant_cell_line_M249-AR4_and_in_the_patient-derived_acquired_resistant_cell_line_M376.",22194965,PubMed,,"Atefi_et_al.,_2011,_PLoS_ONE",,2,accepted,1474,36,1,115256530,115256530,G,T,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-14_00:05:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1474,https://civic.genome.wustl.edu/links/variants/427,https://civic.genome.wustl.edu/links/genes/36,,,missense_variant,"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A",12,Vemurafenib,,,,,chr1_g.115256530G~T,NRAS_c.181C~A,NRAS_Q61K
NRAS,4893,Q61K,Non-small_Cell_Lung_Carcinoma,3908,,"Trametinib,Selumetinib_(AZD6244)",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Of_the_4,562_patients_with_lung_cancers,_30_showed_NRAS_mutations,_which_corresponded_to_9_different_amino_acid_substitutions._Cell_lines_were_developed_for_6_of_these_mutations_(one_harboring_Q61L,_two_Q61R,_and_three_Q61K_mutations)_and_5/6_were_sensitive_to_MEK_inhibitors_selumetinib_and_trametinib._One_Q61K_line_was_not_sensitive_to_these_inhibitors.",23515407,PubMed,,"Ohashi_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,2907,36,1,115256530,115256530,G,T,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-30_19:32:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/2907,https://civic.genome.wustl.edu/links/variants/427,https://civic.genome.wustl.edu/links/genes/36,,,missense_variant,"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A",12,Trametinib,Selumetinib_(AZD6244),,,,chr1_g.115256530G~T,NRAS_c.181C~A,NRAS_Q61K
NRAS,4893,Q61K,Neuroblastoma,769,,"Everolimus,Binimetinib_(MEK162)",Combination,Predictive,Supports,D,Sensitivity/Response,"In-vitro_study_in_5_neuroblastoma_cell_lines_(2_with_NRAS_Q61K_mutation)._The_combination_of_mTOR_and_MEK_Inhibitors_synergistically_blocked_cell_growth_in_NRAS_mutant_but_not_wild_type_cell_lines._Single_agent_MEK_inhibition_(AZD6244/selumetinib,_MEK162_or_PD0325901)_and_single_agent_mTOR_inhibition_(Everolimus_or_AZD8055)_also_blocked_cell_growth_in_NRAS_mutant_cell_lines,_whereas_single_agent_PI3K_inhibitors_or_MEK_Inhibitors_in_combination_with_PIK3CA/AKT_inhibitors_did_not_show_synergistic_effects.",26821351,PubMed,,"Kiessling_et_al.,_2016,_PLoS_ONE",,3,accepted,1002,36,1,115256530,115256530,G,T,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_23:52:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1002,https://civic.genome.wustl.edu/links/variants/427,https://civic.genome.wustl.edu/links/genes/36,,,missense_variant,"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A",12,Everolimus,Binimetinib_(MEK162),,,,chr1_g.115256530G~T,NRAS_c.181C~A,NRAS_Q61K
MRE11,4361,FRAMESHIFT_MUTATION,Prostate_Cancer,10283,,Olaparib,,Predictive,Supports,B,Sensitivity/Response,"One_patient_in_a_cohort_of_50_patients_with_metastatic_prostate_cancer_had_a_frameshift_mutation_in_the_MRE11,_ATM,_MLH3_and_NBN_genes_and_showed_clinical_response_to_PARP_inhibitor_olaparib_(16_weeks_on_Treatment).",26510020,PubMed,,"Mateo_et_al.,_2015,_N._Engl._J._Med.",,2,accepted,1016,3586,11,94152895,94227074,,,ENST00000323929.3,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1016,https://civic.genome.wustl.edu/links/variants/428,https://civic.genome.wustl.edu/links/genes/3586,,,frameshift_variant,,10,Olaparib,,,,,,,
KIT,3815,EXPRESSION,Endometrial_Cancer,1380,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,Case_Report_of_a_42-year_old_patient_with_low-grade_endometrial_stromal_sarcoma._IHC_was_focally_positive_for_CD117._Imatinib_mesylate_led_to_complete_metabolic_response_(PET-CT).,18607592,PubMed,,"Kalender_et_al.,_2009,_Cancer_Chemother._Pharmacol.",,2,accepted,1024,29,4,55524085,55606881,,,ENST00000288135.5,,,,,75,GRCh37,,,2016-03-16_22:09:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1024,https://civic.genome.wustl.edu/links/variants/429,https://civic.genome.wustl.edu/links/genes/29,,,,,20,Imatinib,,,,,,,
KIT,3815,EXPRESSION,Endometrial_Cancer,1380,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,Case_Report_of_a_41-year_old_patient_with_high-grade_stromal_endometrial_sarcoma_and_a_large_abdominal_and_retroperitoneal_mass_progressing_after_chemotherapy._IHC_for_c-Kit_was_positive_and_treatment_with_imatinib_led_to_an_objective_Response._Surgery_was_performed_and_the_patient_was_free_of_disease_two_years_later.,16487996,PubMed,,"Salvatierra_et_al.,_2006,_Gynecol._Oncol.",,2,accepted,1025,29,4,55524085,55606881,,,ENST00000288135.5,,,,,75,GRCh37,,,2016-02-17_19:49:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1025,https://civic.genome.wustl.edu/links/variants/429,https://civic.genome.wustl.edu/links/genes/29,,,,,20,Imatinib,,,,,,,
KIT,3815,EXPRESSION,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_prospective_phase_III_study_(SWOG_S0033/CALGB_150105)_of_407_patients_with_gastrointestinal_stromal_tumors_(GISTs),_397_patients_were_observed_to_be_CD117-positive_(i.e._KIT-positive)_and_10_patients_were_CD117-negative._Patients_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._When_compared_to_CD117-positive,_GISTs,_CD117-negative_GISTs_did_not_show_significant_difference_in_median_time_to_progression_(18.3_months_vs._20.5_months;_P_=_0.46),_however,_CD-117-negative_GISTs_showed_reduced_overall_survival_relative_to_CD-117-positive_GISTs_(25.8_months_vs._57.1_months;_P=_0.01).",18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,2,accepted,2480,29,4,55524085,55606881,,,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2019-02-08_19:06:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/2480,https://civic.genome.wustl.edu/links/variants/429,https://civic.genome.wustl.edu/links/genes/29,,,,,20,Imatinib,,,,,,,
EPAS1,2034,OVEREXPRESSION,Renal_Cell_Carcinoma,4450,,Pazopanib,,Predictive,Does_Not_Support,B,,"HIF-2A_(EPAS1)_staining_was_conducted_on_66_tumors.__Of_the_66_patients,_25_were_classified_as_responders_and_41_were_classified_as_non-responders.__There_was_no_significant_difference_between_responders_and_non-responders_with_regards_to_overall_response_rate_to_pazopanib_(44%_vs_33%;_P=0.36).",23881929,PubMed,,"Choueiri_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1673,1705,2,46524541,46613836,,,ENST00000263734.3,,,,,75,GRCh37,,Somatic_Mutation,2016-09-23_19:32:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1673,https://civic.genome.wustl.edu/links/variants/435,https://civic.genome.wustl.edu/links/genes/1705,,,,,30,Pazopanib,,,,,,,
VHL,7428,LOSS,Renal_Carcinoma,4451,,Temsirolimus,,Predictive,Supports,D,Sensitivity/Response,Preclinical_studies_linking_the_efficacy_of_mTOR_inhibitor_CCI-779_to_VHL_loss_in_vitro_and_in_mouse_models_of_kidney_cancer._VHL-deficient_tumors_were_more_sensitive_to_mTOR_inhibition_than_VHL-proficient_tumors._Growth_arrest_caused_by_CCI-779_correlated_with_a_block_in_translation_of_HIF1A_mRNA._Expression_of_a_VHL-resistant_HIF1A_cDNA_lacking_the_5'_untranslated_region_rescued_tumor_growth.,16341243,PubMed,,"Thomas_et_al.,_2006,_Nat._Med.",,3,accepted,1035,58,3,10182692,10193904,,,ENST00000256474.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-22_20:32:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1035,https://civic.genome.wustl.edu/links/variants/436,https://civic.genome.wustl.edu/links/genes/58,,,loss_of_function_variant,,23,Temsirolimus,,,,,,,
VHL,7428,LOSS,Renal_Cell_Carcinoma,4450,,VEGF_Inhibition,,Predictive,Supports,B,Resistance,"A_meta-analysis_to_evaluate_the_association_between_the_VHL_alteration_and_clinical_outcomes_in_patients_with_RCC._Six_studies_(total_of_633_patients)_were_included._61,8%_had_a_VHL_mutation._The_meta-analysis_showed_no_association_between_the_VHL_gene_alteration_and_overall_response_rate_or_progression_free_survival._There_was_also_no_correlation_to_overall_survival._VEGFR_inhibition_included:_Sunitinib,_Sorafenib,_Axitinib,_Pazopanib,_Bevacizumab.",28103578,PubMed,,"Kim_et_al.,_2017,_Oncotarget",,4,accepted,4830,58,3,10182692,10193904,,,ENST00000256474.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-09_23:08:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4830,https://civic.genome.wustl.edu/links/variants/436,https://civic.genome.wustl.edu/links/genes/58,,,loss_of_function_variant,,23,VEGF_Inhibition,,,,,,,
FLT3,2322,D835,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,B,Resistance,"13_patients_with_relapsed_or_chemo-refractory_FLT3-ITD+_AML_were_treated_with_sorafenib_(200-400_mg_twice_daily)._12_patients_responded,_but_sorafenib_response_was_lost_in_most_patients_after_72_(range_54-287)_days._Leukemia_initiating_cells_bearing_the_D835_mutation_expanded_during_sorafenib_treatment_and_dominated_during_the_subsequent_clinical_resistance._Results_were_recapitulated_in-vivo.",22368270,PubMed,,"Man_et_al.,_2012,_Blood",,4,accepted,1039,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-02-19_23:15:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1039,https://civic.genome.wustl.edu/links/variants/437,https://civic.genome.wustl.edu/links/genes/24,,,protein_altering_variant,NC_000013.10:g.28592642C>A,46,Sorafenib,,,,,chr13_g.28592642C~A,,
FLT3,2322,D835,Acute_Myeloid_Leukemia,9119,,"Quizartinib_(AC220),Sorafenib",Substitutes,Predictive,Supports,B,Resistance,"In_an_in-vitro_study_using_an_in_vitro_saturation_mutagenesis_assay,_4_residues_with_AC220_(quizartinib)_resistance-conferring_mutations_in_the_kinase_domain_of_FLT3-ITD_were_identified._Mutations_at_three_of_these_amino_acid_positions_conferred_high_degrees_of_in_vitro_AC220_resistance_(based_on_proliferation_and_cell-based_biochemical_assays)._Among_these_residues,_two_within_the_activation_loop_were_found_(D835,_Y842).__Pre-treatment_and_relapse_samples_of_8_patients_(treated_with_AC220)_with_FLT3-ITD+_acute_myeloid_leukemia_were_analyzed._The_activation_loop_mutation_D835Y_was_detected_in_three_cases,_D835V_in_two,_and_D835F_was_identified_in_a_single_patient._Cross-resistance_to_sorafenib_was_identified_in-vitro.",22504184,PubMed,,"Smith_et_al.,_2012,_Nature",,4,accepted,1038,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_23:40:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1038,https://civic.genome.wustl.edu/links/variants/437,https://civic.genome.wustl.edu/links/genes/24,,,protein_altering_variant,NC_000013.10:g.28592642C>A,46,Quizartinib_(AC220),Sorafenib,,,,chr13_g.28592642C~A,,
FLT3,2322,D835,Acute_Myeloid_Leukemia,9119,,SU5614,,Predictive,Supports,D,Resistance,"An_in-vitro_cell-based_screening_approach_generated_FLT3-ITD-expressing_cell_lines_resistant_to_the_FLT3_inhibitors_SU5614,_PKC412,_and_sorafenib._SU5614_resistance_mutations_were_limited_to_exchanges_in_the_second_part_of_the_kinase_domain_(TK2),_with_exchanges_of_D835_predominating_(D835E_were_most_common)._In_clones_that_emerged_at_1,500_nmol/L_SU5614_after_ENU_(mutagen)_treatment,_127_of_179_clones_(71%)_displayed_mutations,_generating_9_different_exchanges_affecting_6_positions_in_the_activation_loop_of_FLT3.",19318574,PubMed,,"von_Bubnoff_et_al.,_2009,_Cancer_Res.",,3,accepted,1037,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-02-22_02:47:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1037,https://civic.genome.wustl.edu/links/variants/437,https://civic.genome.wustl.edu/links/genes/24,,,protein_altering_variant,NC_000013.10:g.28592642C>A,46,SU5614,,,,,chr13_g.28592642C~A,,
FLT3,2322,D835,Acute_Myeloid_Leukemia,9119,,"Quizartinib_(AC220),Ponatinib",Substitutes,Predictive,Supports,D,Resistance,"An_in-vitro_saturation_mutagenesis_screen_of_50_independently_derived_FLT3-ITD_clones_was_performed_to_identify_mutations_that_confer_resistance_to_ponatinib._Mutations_at_3_AL_residues_(D835_[n_=_31],_D839_[n_=_3],_and_Y842_[n_=_16]),_with_varying_degrees_of_resistance_to_ponatinib_were_identified._FLT3_D835_mutations_were_shown_to_confer_resistance_to_the_tyrosine_kinase_inhibitor_AC220_and_ponatinib.__This_was_especially_found_for_D835Y_and_D835V_mutations,_whereas_D835H_mutations_were_found_to_confer_moderate_resistance_to_ponatinib_but_relatively_minimal_resistance_to_AC220.",23430109,PubMed,,"Smith_et_al.,_2013,_Blood",,3,accepted,1036,24,13,28592642,28592642,C,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-02-21_22:23:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1036,https://civic.genome.wustl.edu/links/variants/437,https://civic.genome.wustl.edu/links/genes/24,,,protein_altering_variant,NC_000013.10:g.28592642C>A,46,Quizartinib_(AC220),Ponatinib,,,,chr13_g.28592642C~A,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_the_LUX-LUNG_7_trial,_(NCT01466660)_stage_IIIB_or_IV_NSCLC_patients_with_EGFR_exon_19_deletion,_(n=186)_Leu858Arg_mutation,_(n=132)_or_both_(n=1)_were_divided_into_equal_groups_and_treated_with_first_line_reversible_EGFR_inhibitor_gefitinib_or_irreversible_pan-ErbB_family_inhibitor_afatinib_in_order_to_obtain_a_direct_comparison_of_these_two_approved_first_line_treatments._Significant_difference_was_seen_in_objective_response_with_70%__of_cases_with_afatinib_vs._56%_of_cases_with_gefitinib._Median_progression_free_survival_was_11.0_months_(10.6-12.9)_with_afatinib_and_10.9_months_(9.1-11.5)_with_gefitinib,_HR_0.73_[0.57-0.95]_p=0.017.",27083334,PubMed,,"Park_et_al.,_2016,_Lancet_Oncol.",,4,accepted,1728,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_23:03:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1728,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Afatinib,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2b/3_study_of_585_stage_IIIB-IV_lung_adenocarcinoma_patients_who_had_a_previous_round_of_EGFR-TKI_treatment,_archival_material_was_available_for_141_patients._EGFR_mutational_analysis_revealed_that_96_tumors_had_an_EGFR_mutation,_of_which_76_(79%)_were_positive_for_either_L858R_or_a_deletion_in_exon_19._These_mutations_were_associated_with_improved_progression-free_survival_(median_3.3_months__vs_1.0_month_;_HR:0.51,_95%_CI:0.31-0.85,_P<0.009)_compared_to_placebo_control.",22452896,PubMed,,"Miller_et_al.,_2012,_Lancet_Oncol.",,,accepted,2153,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-11-18_00:31:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/2153,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Afatinib,,,,,,,
EGFR,1956,MUTATION,Lung_Cancer,1324,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_52_patients_with_recurrent_lung_cancer,_27_individuals_had_EGFR_mutation_including_2_point_mutations_in_exon_18_(G719A_and_G1719C),_23_deletions_in_exon_19,_two_insertions_in_exon_19_(I744KIPVAI),_on_mutation_in_exon_20_(S768I),_and_16_point_mutations_in_exon_21_(L858R_and_E709H)._Patients_were_treated_with_the_epidermal_growth_factor_receptor_tyrosine_kinase_inhibitor_gefitinib,_and_tumors_harboring_an_EGFR_mutation_had_an_increased_frequency_of_partial_response_(PR)_and_a_lower_rate_of_progressive_disease_(PD)_(PR:22,_PD:2_vs._PR:2,_PD:17;_P<0.0001)_compared_to_wildtype_EGFR_patients._Patients_with_KRAS_mutations_also_had_a_longer_overall_survival_compared_to_wildtype_EGFR_patients_(HR:2.526,_95%_CI:1.314-4.858,_P=0.0055).",17409929,PubMed,,"Endoh_et_al.,_2006,_J_Thorac_Oncol",,2,accepted,2939,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_19:30:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/2939,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Gefitinib,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_the_placebo-controlled_Phase_III_study_SATURN,_using_erlotinib_maintenance_therapy_for_patients_with_advanced_NSCLC_who_were_selected_for_response_or_stable_disease_after_first_line_chemotherapy,_EGFR_mutation_was_assessed._In_patients_with_EGFR_mutation,_erlotinib_maintenance_reduced_progression_and_death_significantly_with_median_progression_free_survival_(PFS)_of_44.6_vs._13_weeks_over_placebo._Erlotinib_also_significantly_improved_PFS_in_EGFR_wildtype_patients,_but_EGFR_mutant_tumors_treated_with_erlotinib_had_significant_better_PFS_than_EGFR_wildtype._Overall,_in_the_intent_to_treat_population_erlotinib_significantly_improved_PFS_over_placebo_(HR,_0.71;_95%_CI,_0.62_to_0.82;_P<0.001).",21969500,PubMed,,"Brugger_et_al.,_2011,_J._Clin._Oncol.",,4,accepted,4201,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_19:36:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/4201,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Erlotinib,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_3_clinical_trial_of_East_Asian_advanced_pulmonary_adenocarcinoma_patients,_a_subset_of_patients_with_EGFR_mutations_(n=261)_treated_with_gefitinib_were_associated_with_improved_response_(HR:0.48,_95%_CI:0.36-0.64,_P<0.001),_compared_to_carboplatin_plus_paclitaxel_treatment._The_frequency_of_mutation_in_exon_19_deletion_and_L858R_was_53.6%_(140/261)_and_42.5%_(111/261),_respectively.",19692680,PubMed,,"Mok_et_al.,_2009,_N._Engl._J._Med.",,,accepted,2148,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-10-19_19:34:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/2148,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Gefitinib,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_II_trial_for_Bronchioloalveolar_carcinoma_(BAC,_or_in_situ_pulmonary_adenocarcinoma),_EGFR_exons_18-24_were_analyzed_in_7_patients_who_had_shown_a_partial_response_to_Erlotinib,_and_10_patients_who_did_not.__EGFR_mutations_were_seen_in_5/7_responders_but_not_in_any_of_the_non-responders,_which_was_a_significant_result_(p=0.003).",15329413,PubMed,,"Pao_et_al.,_2004,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,3794,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-10-12_21:41:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/3794,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Erlotinib,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_3_clinical_trial_of_non-small_cell_lung_cancer_(NSCLC)_patients,_a_subset_of_patients_with_EGFR_mutations_(n=44)_treated_with_gefitinib_were_associated_with_improved_progression_free_survival_(HR:_0.16,_95%_CI:_0.05-0.49,_P=0.001),_and_a_higher_objective_response_rate_(ORR:_42.1%_vs_21.1%,_p=0.04)_compared_to_patients_treated_with_docetaxel._Of_the_44_patients,_22_had_an_exon_19_deletion,_16_had_an_L858R_mutation,_one_patient_had_an_exon_20_T790M_mutation,_two_had_an_exon_G719A_mutation_and_four_had_other_mutations.",20038723,PubMed,,"Douillard_et_al.,_2010,_J._Clin._Oncol.",,3,accepted,3016,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,,2017-09-08_19:23:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/3016,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Gefitinib,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"This_open_label_Phase_3_Trial_performed_across_36_centers_in_Japan_(WJTOG3405)_assessed_patients_with_postoperative_recurrent_or_stage_IIIB/IV_NSCLC_and_activating_EGFR_mutations_(Exon_19_deletion_and_L858R).__88_patients_were_treated_with_EGFR_inhibitor_gefitinib,_while_89_were_treated_with_cisplatin/docetaxel._Progression_free_survival_was_significantly_longer_with_gefitinib_treatment_with_a_median_of_9.2_months_vs._6.3_with_cisplatin/docetaxel_(HR_0.48;_95%_CI_0.336-0.710;_p<0.0001)._Difference_in_response_to_gefitinib_between_the_two_EGFR_mutation_types_was_not_observed.",20022809,PubMed,,"Mitsudomi_et_al.,_2010,_Lancet_Oncol.",,5,accepted,1937,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_19:21:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1937,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Gefitinib,,,,,,,
EGFR,1956,MUTATION,Peritoneal_Mesothelioma,1788,,CRS/IPHC,,Predictive,Supports,B,Sensitivity/Response,"25_patients_with_metastatic_peritoneal_mesothelioma_were_treated_with_surgical_cytoreduction_consolidated_with_intraperitoneal_hyperthermic_chemotherapy_(CRS/IPHC)._8_of_the_patients_carried_EGFR_mutations_in_the_tyrosine_kinase_domain._Each_mutation_was_not_found_in_100_unrelated_controls._At_study_end_10/18_wildtype_patients_had_died_with_median_survival_of_14_months,_while_2/7_EGFR_mutant_patients_had_died_and_median_survival_was_not_yet_reached._Median_time_to_progression_(TTP)_was_12_months_in_the_wildtype_group_and_in_the_mutant_group_median_TTP_was_not_yet_reached._3_year_progression_free_survival_was_71%_in_the_mutant_group_and_28%_in_the_wildtype_group.",20942962,PubMed,,"Foster_et_al.,_2010,_World_J_Surg_Oncol",,4,accepted,5923,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_19:10:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/5923,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,CRS/IPHC,,,,,,,
EGFR,1956,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,B,Sensitivity/Response,"Mutational_profiling_was_performed_on_EGFR_exons_18-24_from_a_group_of_10_retrospectively_chosen_patients_who_had_shown_partial_response_or_clinical_imporvement_in_response_to_gefitinib,_and_in_8_patients_who_had_not_shown_gefitinib_response._7_of_10_sensitive_patients_had_mutations_in_EGFR,_while_none_of_the_8_gefitinib_refractory_patients_showed_EGFR_mutation_in_these_exons_(p=0.004)",15329413,PubMed,,"Pao_et_al.,_2004,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,2559,19,7,55086794,55279321,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-08_20:08:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/2559,https://civic.genome.wustl.edu/links/variants/442,https://civic.genome.wustl.edu/links/genes/19,,,inframe_variant,,165,Gefitinib,,,,,,,
EGFR,1956,G465R,Colorectal_Cancer,9256,,Sym004,,Predictive,Supports,C,Sensitivity/Response,"An_EGFR_G465R_mutation_(22%_of_mutant_alleles)_was_detected_in_a_biopsy_from_one_patient_which_had_been_previously_treated_with_cetuximab_in_the_analysis_of_15_patients_with_refractory,_metastatic_CRC_after_cetuximab/panitumumab,_prior_to_Sym004_treatment._Subsequent_treatment_of_this_patient_with_Sym004_yielded_disease_stabilization_lasting_15_weeks._In_vitro_analysis_in_colorectal_cancer_cell_line_NIH3T3_with_EGFR_mutations_S492R,_R451C,_K467T,_and_G465R_showed_that_antibody_mixture_Sym004_effectively_bound_to_all_mutants,_whereas_cetuximab_and_panitumumab_did_not_effectively_bind_to_all_mutants._In-vitro,_Sym004_inhibited_growth_of_S492R_and_G465R_EGFR_mutant_cell_lines._In-vivo_analysis_of_S492R_and_G465R_mutant_cell_lines_showed_regression_of_S492R_and_tumor_growth_delay_of_G465R_mutant_cell_lines.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,4,accepted,1057,19,7,55227926,55227926,G,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-23_21:53:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/1057,https://civic.genome.wustl.edu/links/variants/443,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1393G>A,NC_000007.13:g.55227926G>A",20,Sym004,,,,,chr7_g.55227926G~A,EGFR_c.1393G~A,
EGFR,1956,G465R,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,C,Resistance,"An_EGFR_G465R_mutation_(22%_of_mutant_alleles)_was_detected_in_a_biopsy_from_one_patient_which_had_been_previously_treated_with_cetuximab_in_the_analysis_of_15_patients_with_refractory,_metastatic_CRC_after_cetuximab/panitumumab,_prior_to_Sym004_treatment._Treatment_of_this_patient_with_Sym004_yielded_disease_stabilization_lasting_15_weeks._Sym004_is_a_1:1_mixture_of_two_non-overlapping_anti-EGFR_monoclonal_antibodies._In_vitro_analysis_in_the_murine_fibroblast_cell_line_NIH3T3_with_ectopic_expression_of_EGFR_mutations_S492R,_R451C,_K467T,_and_G465R_showed_that_Sym004_effectively_bound_to_all_mutants,_whereas_cetuximab_and_panitumumab_did_not_effectively_bind_to_all_mutants._In-vitro,_Sym004_inhibited_growth_of_S492R_and_G465R_EGFR_mutant_cell_lines._In-vivo_analysis_of_S492R_and_G465R_mutant_cell_lines_showed_regression_of_S492R_and_tumor_growth_delay_of_G465R_mutant_cell_lines._G465R_mutant_cell_lines_were_resistant_to_treatment_with_panitumumab_or_cetuximab_in-vitro.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,4,accepted,1058,19,7,55227926,55227926,G,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-24_17:44:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1058,https://civic.genome.wustl.edu/links/variants/443,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1393G>A,NC_000007.13:g.55227926G>A",20,Cetuximab,Panitumumab,,,,chr7_g.55227926G~A,EGFR_c.1393G~A,
ETS2,2114,RS461155,Non-small_Cell_Lung_Carcinoma,3908,,"Paclitaxel,Cisplatin",Combination,Predictive,Supports,B,Sensitivity/Response,"Eighty_SNPs_in_miRNA_binding_sites_of_cancer_related_genes_selected_from_18,500_miRNA:target_bindings_in_crosslinking,_ligation,_and_sequencing_of_hybrids_(CLASH)_data_were_investigated_in_379_advanced_NSCLC_patients_using_a_sequenom_mass_spectrometry-based_genotype_assay._16_SNPs_were_significantly_associated_with_the_clinical_outcomes_after_chemotherapy_with_paclitaxel-cisplatin:_ETS2_SNP:_OR_=_1.34,_95%_CI_=_1.00–1.81,_P_=_0.05;_aHR_=_0.80,_95%_CI_=_0.69–0.94,_P_=_0.006,_under_additive_model._ETS2_rs461155A>G_was_significantly_associated_with_decreased_ETS2_mRNA_expression_in_both_tumor_and_paired_normal_lung_tissues_(Ptrend_=_4_×_10-7,_and_3_×_10-4,_respectively).",26893365,PubMed,,"Hong_et_al.,_2016,_Oncotarget",,2,accepted,1060,1763,21,40191638,40191638,A,G,ENST00000360214.3,,,,,75,GRCh37,,Germline_Polymorphism,2016-02-23_21:51:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1060,https://civic.genome.wustl.edu/links/variants/445,https://civic.genome.wustl.edu/links/genes/1763,,,synonymous_variant,NC_000021.8:g.40191638A>G,10,Paclitaxel,Cisplatin,,,,chr21_g.40191638A~G,,
EGFR,1956,S492R,Colorectal_Cancer,9256,,"Panitumumab,Sym004",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study_of_cetuximab,_panitumumab_or_sym004_on_various_EGFR_mutations_in_colorectal_cancer._The_S492R_mutation_was_sensitive_to_Sym004_and_panitumumab_treatment_but_resistant_to_cetuximab._Experiments_include_flow_cytometry_binding_assay,_kinase_phosphorylation,_cell_viability,_downstream_signalling.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,4,accepted,1079,19,7,55228009,55228009,C,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-23_19:46:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1079,https://civic.genome.wustl.edu/links/variants/453,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A",23,Panitumumab,Sym004,,,,chr7_g.55228009C~A,EGFR_c.1476C~A,EGFR_S492R
EGFR,1956,S492R,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"In_this_preclinical_study_of_the_effects_of_cetuximab,_panitumumab_or_sym004_on_various_EGFR_mutations_in_colorectal_cancer._The_S492R_mutation_was_sensitive_to_Sym004_and_panitumumab_treatment_but_resistant_to_cetuximab._Experiments_include_flow_cytometry_binding_assay,_kinase_phosphorylation,_cell_viability,_downstream_signalling.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,4,accepted,1080,19,7,55228009,55228009,C,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-03-16_22:09:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/1080,https://civic.genome.wustl.edu/links/variants/453,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A",23,Cetuximab,,,,,chr7_g.55228009C~A,EGFR_c.1476C~A,EGFR_S492R
EGFR,1956,S492R,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,C,Resistance,In-vitro_studies_found_this_mutation_to_confer_resistance_to_cetuximab._2_of_10_patients_studied_also_harbored_EGFR_S492R_and_were_resistant_to_cetuximab_therapy._Panitumumab_was_still_active_in-vitro_and_in_one_patient.,22270724,PubMed,,"Montagut_et_al.,_2012,_Nat._Med.",,4,accepted,717,19,7,55228009,55228009,C,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-08-15_20:02:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/717,https://civic.genome.wustl.edu/links/variants/453,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A",23,Cetuximab,,,,,chr7_g.55228009C~A,EGFR_c.1476C~A,EGFR_S492R
EGFR,1956,S492R,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Sensitivity/Response,"Tumor_sequencing_in_pre-_and_post-therapy_specimens_from_ten_individuals_with_mCRC_who_experienced_disease_progression_after_a_prior_response_to_cetuximab_with_chemotherapy_was_performed._The_S492R_mutation_was_identified_in_two_persons._One_of_them_had_already_died,_the_other_received_treatment_with_panitumumab_and_had_a_partial_response_(50%_tumor_reduction_in_all_liver_lesions)_for_5_months.",22270724,PubMed,,"Montagut_et_al.,_2012,_Nat._Med.",,2,accepted,1078,19,7,55228009,55228009,C,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-23_19:38:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1078,https://civic.genome.wustl.edu/links/variants/453,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A",23,Panitumumab,,,,,chr7_g.55228009C~A,EGFR_c.1476C~A,EGFR_S492R
EGFR,1956,R451C,Colorectal_Cancer,9256,,"Cetuximab,Sym004,Panitumumab",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study_on_the_effects_of_cetuximab,_panitumumab_or_sym004_on_various_EGFR_mutations_in_colorectal_cancer._The_R451C_mutation_showed_moderate_drug-receptor_binding_with_sym004,_cetuximab_and_panitumumab_treatment_and_inhibition_of_EGFR_phosphorylation.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1081,19,7,55227884,55227884,C,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-23_18:43:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1081,https://civic.genome.wustl.edu/links/variants/454,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.1351C>T,NC_000007.13:g.55227884C>T,NM_001346898.1:c.1351C>T,NP_001333827.1:p.Arg451Cys",2,Cetuximab,Sym004,Panitumumab,,,chr7_g.55227884C~T,EGFR_c.1351C~T,EGFR_R451C
EGFR,1956,K467T,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"In_this_preclinical_study_on_the_effects_of_cetuximab,_panitumumab_or_sym004_on_various_EGFR_mutations_in_colorectal_cancer._In_NIH3T3_cells_expressing_EGFR_with_a_K467T_mutation,_Sym004_and_panitumumab_bound_the_mutated_receptor_and_inhibited_EGFR_phosphorylation_in_the_presence_of_ligand_while_cetuximab_neither_bound_to_nor_inhibited_EGFR_phosphorylation_of_the_mutated_receptor.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,1083,19,7,55227933,55227933,A,C,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-10-10_22:40:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1083,https://civic.genome.wustl.edu/links/variants/455,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1400A>C,NC_000007.13:g.55227933A>C",6,Cetuximab,,,,,chr7_g.55227933A~C,EGFR_c.1400A~C,
EGFR,1956,K467T,Colorectal_Cancer,9256,,"Sym004,Panitumumab",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study_on_the_effects_of_cetuximab,_panitumumab_or_sym004_on_various_EGFR_mutations_in_colorectal_cancer._In_NIH3T3_cells_expressing_EGFR_with_a_K467T_mutation,_Sym004_and_panitumumab_bound_the_mutated_receptor_and_inhibited_EGFR_phosphorylation_in_the_presence_of_ligand_while_cetuximab_neither_bound_to_nor_inhibited_EGFR_phosphorylation_of_the_mutated_receptor.",26888827,PubMed,,"Sánchez-Martín_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,1082,19,7,55227933,55227933,A,C,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-10-10_22:39:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/1082,https://civic.genome.wustl.edu/links/variants/455,https://civic.genome.wustl.edu/links/genes/19,,ECD_MUTATION,missense_variant,"ENST00000275493.2:c.1400A>C,NC_000007.13:g.55227933A>C",6,Sym004,Panitumumab,,,,chr7_g.55227933A~C,EGFR_c.1400A~C,
FCGR3A,2214,F212V,Breast_Cancer,1612,,Trastuzumab,,Predictive,Does_Not_Support,B,,1325_HER2-positive_breast_cancer_patients_treated_with_trastuzumab_and_chemotherapy_from_the_N9831_clinical_trial_were_analyzed._There_was_no_statistically_significant_difference_in_disease-free_survival_between_trastuzumab-treated_patients_who_had_the_FCGR3A_158_V/V_high-affinity_genotype_and_patients_without_that_genotype_(V/F_and_F/F).,24989892,PubMed,,"Norton_et_al.,_2014,_Cancer_Immunol_Res",,4,accepted,1087,1844,1,161514542,161514542,A,C,ENST00000367969.3,,,,,75,GRCh37,,Germline_Polymorphism,2017-01-24_22:08:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1087,https://civic.genome.wustl.edu/links/variants/457,https://civic.genome.wustl.edu/links/genes/1844,,,missense_variant,NC_000001.10:g.161514542A>C,35,Trastuzumab,,,,,chr1_g.161514542A~C,,
EGFR,1956,P753S,Skin_Squamous_Cell_Carcinoma,3151,,"Rapamycin_(Sirolimus),Cetuximab",Combination,Predictive,Supports,C,Sensitivity/Response,72-year_old_male_patient_presents_with_SCC_with_a_mutation_profile_consistent_with_UV_exposure._Sequencing_revealed_a_number_of_abnormalities_including_P753S_mutation_in_EGFR._Patient_began_therapy_with_cetuximab_and_sirolimus_and_continued_for_9_months._Disease_burden_was_not_measurable_by_Response_Evaluation_Criteria_in_Solid_Tumors.,24934779,PubMed,,"Ganesan_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,1089,19,7,55242487,55242487,C,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-02-24_00:19:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1089,https://civic.genome.wustl.edu/links/variants/460,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2257C>T,NC_000007.13:g.55242487C>T,NM_005228.4:c.2257C>T,NP_005219.2:p.Pro753Ser",7.5,Rapamycin_(Sirolimus),Cetuximab,,,,chr7_g.55242487C~T,EGFR_c.2257C~T,EGFR_P753S
PML,5371,B2_DOMAIN_MUTATION,Acute_Promyelocytic_Leukemia,60318,,All-trans_Retinoic_Acid,,Predictive,Supports,B,Resistance,Mutations_in_the_B2_domain_of_PML_in_the_PML-RARa_fusion_have_been_shown_to_be_associated_with_resistance_to_standard_ATRA_treatment_in_patients_with_acute_promyelocytic_leukemia.,23670176,PubMed,,"Tomita_et_al.,_2013,_Int._J._Hematol.",,4,accepted,1092,39,15,74315213,74315219,,,ENST00000268058.3,,,,,75,GRCh37,The_B2_domain_in_PML_is_the_binding_site_for_ATRA._Point_mutations_in_this_region_have_been_associated_with_ATRA_resistance_in_patients_with_APL.,Somatic_Mutation,2016-02-25_18:45:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1092,https://civic.genome.wustl.edu/links/variants/461,https://civic.genome.wustl.edu/links/genes/39,The_B2_domain_in_PML_is_the_binding_site_for_ATRA._Point_mutations_in_this_region_have_been_associated_with_ATRA_resistance_in_patients_with_APL.,PML-RARa_B2_Domain,missense_variant,,20,All-trans_Retinoic_Acid,,,,,,,
PML,5371,PML-RARA_A216V,Acute_Promyelocytic_Leukemia,60318,,All-trans_Retinoic_Acid,,Predictive,Supports,C,Resistance,The_mutation_A216V_in_the_B2_domain_of_PML_in_the_PML-RARa_fusion_was_seen_in_a_patient_with_ATRA-resistant_acute_promyelocytic_leukemia.,21613260,PubMed,,"Goto_et_al.,_2011,_Blood",,4,accepted,1093,39,15,74315213,74315213,C,T,ENST00000268058.3,,,,,75,GRCh37,A216V_in_the_B2_domain_of_PML_is_one_of_the_variants_found_in_a_patient_with_ATRA-resistant_APL.,Somatic_Mutation,2016-02-25_18:44:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1093,https://civic.genome.wustl.edu/links/variants/462,https://civic.genome.wustl.edu/links/genes/39,A216V_in_the_B2_domain_of_PML_is_one_of_the_variants_found_in_a_patient_with_ATRA-resistant_APL.,PML-RARa_B2_Domain,missense_variant,NC_000015.9:g.74315213C>T,10,All-trans_Retinoic_Acid,,,,,chr15_g.74315213C~T,,
PML,5371,PML-RARA_L218P,Acute_Promyelocytic_Leukemia,60318,,All-trans_Retinoic_Acid,,Predictive,Supports,C,Resistance,"The_PML_L218P_mutation_in_the_PML-RARa_fusion_was_observed_in_a_patient_with_previously_ATRA-treated,_relapsed_acute_promyelocytic_leukemia_refractory_to_arsenic_trioxide.",21613260,PubMed,,"Goto_et_al.,_2011,_Blood",,3,accepted,1094,39,15,74315219,74315219,T,C,ENST00000268058.3,,,,,75,GRCh37,L218P_in_the_B2_domain_of_PML_is_one_of_the_variants_found_in_a_patient_with_ATRA-resistant_APL.,Somatic_Mutation,2016-08-15_20:03:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1094,https://civic.genome.wustl.edu/links/variants/463,https://civic.genome.wustl.edu/links/genes/39,L218P_in_the_B2_domain_of_PML_is_one_of_the_variants_found_in_a_patient_with_ATRA-resistant_APL.,PML-RARa_B2_Domain,missense_variant,NC_000015.9:g.74315219T>C,7.5,All-trans_Retinoic_Acid,,,,,chr15_g.74315219T~C,,
MET,4233,EXON_14_MUTATION_+_AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"64-year_old_female_(non-smoker)_was_diagnosed_with_NSCLC._A_c.3028_G->A_mutation_was_identified_in_exon_14_resulting_in_exon_14_skipping._Further,_amplification_of_the_MET_gene_was_observed._The_patient_was_given_crizotinib_and_CT_scans_showed_a_positive_response_after_8_weeks_of_treatment.",26729443,PubMed,,"Awad_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,1095,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2016-02-24_17:44:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1095,https://civic.genome.wustl.edu/links/variants/464,https://civic.genome.wustl.edu/links/genes/52,,,"transcript_amplification,exon_loss_variant",,7.5,Crizotinib,,,,,,,
ROS1,6098,CD74-ROS1_G2032R,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,ROS1_kinase_domain_mutations_were_assessed_in_two_patients_with_stage_IIIa/IV_pulmonary_adenocarcinoma_and_a_cell_line._The_ROS1_G2032R_mutation_was_identified_in_a_crizotinib-resistant_tumor_from_one_of_the_patients_harboring_the_CD74–ROS1_fusion._Expression_of_CD74–ROS1_G2032R_in_Ba/F3_cells_conferred_resistance_to_crizotinib_combared_to_CD74–ROS1_(IC50=353.62+/-20.15_vs._2.76+/-0.82).,25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,1254,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-11-04_18:17:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1254,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Crizotinib,,,,,chr6_g.117638347C~T,,
ROS1,6098,CD74-ROS1_G2032R,Non-small_Cell_Lung_Carcinoma,3908,,Foretinib,,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_expressing_CD74–ROS1_G2032R_showed_resistance_to_crizotinib,_compared_with_those_expressing_wild-type_CD74–ROS1_(~128_fold_higher_IC50);_however,_showed_relative_sensitivity_to_foretinib_(only_~6_fold_higher_IC50_than_WT).",25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,1255,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1255,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Foretinib,,,,,chr6_g.117638347C~T,,
ROS1,6098,CD74-ROS1_G2032R,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,Brigatinib,Ceritinib,AZD3463",Substitutes,Predictive,Supports,D,Resistance,"Preclinical_study_analyzing_the_efficacy_of_dual_ROS1/ALK_and_more_specific_ROS1_inhibitors_on_cell_lines_(Ba/F3)_expressing_CD74-ROS1_with_and_without_the_G2032R_mutation._Selective_ROS1_inhibitors_retained_activity_against_the_G2032R_mutation_(cabozatinib,_foretinib),_whereas_dual_ALK/ROS_inhibitors_(crizotinib,_brigatinib,_ceritinib,_AZD3463)_or_ALK-selective_inhibitors_(alectinib)_were_ineffective.",26372962,PubMed,,"Davare_et_al.,_2015,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,1250,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-06-29_21:01:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1250,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Crizotinib,Brigatinib,Ceritinib,AZD3463,,chr6_g.117638347C~T,,
ROS1,6098,CD74-ROS1_G2032R,Non-small_Cell_Lung_Carcinoma,3908,,"Cabozantinib,Foretinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_analyzing_the_efficacy_of_dual_ROS1/ALK_and_more_specific_ROS1_inhibitors_on_cell_lines_(Ba/F3)_expressing_CD74-ROS1_with_and_without_the_G2032R_mutation._Selective_ROS1_inhibitors_retained_activity_against_the_G2032R_mutation_(cabozatinib,_foretinib),_whereas_dual_ALK/ROS_inhibitors_(crizotinib,_brigatinib,_ceritinib,_AZD3463)_or_ALK-selective_inhibitors_(alectinib)_were_ineffective.",26372962,PubMed,,"Davare_et_al.,_2015,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,1249,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-06-29_21:01:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1249,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Cabozantinib,Foretinib,,,,chr6_g.117638347C~T,,
ROS1,6098,CD74-ROS1_G2032R,Non-small_Cell_Lung_Carcinoma,3908,,Cabozantinib,,Predictive,Supports,D,Sensitivity/Response,"Cabozantinib_was_assessed_in_the_CD74-ROS1-mutant_Ba/F3_cells_and_crizotinib-resistant_patient-derived_cancer_cells_(MGH047)_harboring_G2032R-mutated_CD74-ROS1._It_effectively_inhibited_the_survival_of_CD74-ROS1_wild-type_(WT)_and_resistant_mutants_harboring_Ba/F3_and_MGH047_cells._Furthermore,_cabozantinib_could_overcome_all_the_resistance_by_all_newly_identified_secondary_mutations.",25351743,PubMed,,"Katayama_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,1101,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-02-24_18:08:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1101,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Cabozantinib,,,,,chr6_g.117638347C~T,,
ROS1,6098,CD74-ROS1_G2032R,Non-small_Cell_Lung_Carcinoma,3908,,Lorlatinib,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_of_PF-06463922_in_NSCLC_in-vitro,_in-vivo_and_in_enzyme_assays._PF-06463922_showed_inhibition_of_kinase_activity,_cell_viability_and_tumor_growth_in_wild-type,_G2032R_and_L2026M_mutations_in_ROS1.",25733882,PubMed,,"Zou_et_al.,_2015,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,1251,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-05-27_15:26:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1251,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Lorlatinib,,,,,chr6_g.117638347C~T,,
ROS1,6098,CD74-ROS1_G2032R,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Resistance,"Resistance_to_crizotinib_developed_in_a_patient_with_metastatic_lung_adenocarcinoma_harboring_a_CD74-ROS1_rearrangement_who_had_initially_shown_a_dramatic_response_to_treatment._An_acquired_G2032R_mutation_in_the_ROS1_kinase_domain_was_observed_in_the_resistant_tumor,_and_was_found_to_confer_resistance_to_ROS1_kinase_inhibition_through_steric_interference_with_drug_binding.",23724914,PubMed,,"Awad_et_al.,_2013,_N._Engl._J._Med.",,4,accepted,1100,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",Somatic_Mutation,2016-02-25_20:47:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1100,https://civic.genome.wustl.edu/links/variants/465,https://civic.genome.wustl.edu/links/genes/4941,"The_G2032R_missense_mutation_has_been_observed_in_patients_with_crizotinib-resistant_non-small_cell_lung_cancer_harboring_CD74-ROS1_rearrangement._Independent_in_vitro_studies_have_confirmed_that_this_mutation_confers_marked_resistance_to_crizotinib_cells_over_CD74-ROS1_alone._Multiple_groups_have_indicated_CD74-ROS1_G2032R_expressing_cell_lines_are_sensitive_to_both_cabozantinib_and_foretinib_individually_administered_in_vitro._One_group_additionally_showed_this_mutation_conferred_relative_resistance_to_alectinib,_brigatinib,_ceritinib,_and_AZD3463_in_vitro.",,"transcript_fusion,missense_variant",NC_000006.11:g.117638347C>T,31.5,Crizotinib,,,,,chr6_g.117638347C~T,,
FGFR1,2260,ZNF198-FGFR1,Chronic_Myeloproliferative_Disease,2226,,Midostaurin,,Predictive,Supports,C,Sensitivity/Response,"A_t(8;13)(p11;q12)_patient_with_ZNF198-FGFR1-induced_progressive_myeloproliferative_disorder_was_treated_with_PKC412._Radiographic_studies_performed_3_months_after_initiation_of_therapy_revealed_marked_improvement_of_her_cervical,_mediastinal,_and_retroperitoneal_lymphadenopathy,_and_marked_regression_of_splenomegaly_to_normal_size.",15448205,PubMed,,"Chen_et_al.,_2004,_Proc._Natl._Acad._Sci._U.S.A.",,4,accepted,1104,1885,,,,,,,,,,,,,,Somatic_Mutation,2016-02-25_19:34:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1104,https://civic.genome.wustl.edu/links/variants/466,https://civic.genome.wustl.edu/links/genes/1885,,,transcript_fusion,,10,Midostaurin,,,,,,,
KDR,3791,A1065T,Angiosarcoma,1816,,"Sunitinib,Sorafenib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"COS-7_cells_were_transiently_transfected_with_expression_constructs_encoding_cDNAs_for_wild-type_or_A1065T-mutant_KDR._Autophosphorylation_was_observed_on_tyrosine_of_mutant_cells,_but_not_wild-type_cells,_which_were_starved_from_serum_for_6_hours_without_rhVEGF_stimulation._Decreased_phosphorylation_in_mutant_cells_was_noted_after_treatment_with_either_sunitinib_or_sorafenib.",19723655,PubMed,,"Antonescu_et_al.,_2009,_Cancer_Res.",,3,accepted,1106,3153,4,55955969,55955969,C,T,ENST00000263923.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-25_19:38:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1106,https://civic.genome.wustl.edu/links/variants/467,https://civic.genome.wustl.edu/links/genes/3153,,,missense_variant,"NM_002253.2:c.3193G>A,NP_002244.1:p.Ala1065Thr,ENST00000263923.4:c.3193G>A,NC_000004.11:g.55955969C>T",3,Sunitinib,Sorafenib,,,,chr4_g.55955969C~T,KDR_c.3193G~A,KDR_A1065T
KDR,3791,D717V,Angiosarcoma,1816,,"Sunitinib,Sorafenib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"COS-7_cells_were_transiently_transfected_with_expression_constructs_encoding_cDNAs_for_wild-type_or_D717V-mutant_KDR._Autophosphorylation_was_observed_on_tyrosine_of_mutant_cells,_but_not_wild-type_cells,_which_were_starved_from_serum_for_6_hours_without_rhVEGF_stimulation._Decreased_phosphorylation_in_mutant_cells_was_noted_after_treatment_with_either_sunitinib_or_sorafenib.",19723655,PubMed,,"Antonescu_et_al.,_2009,_Cancer_Res.",,3,accepted,1107,3153,4,55968180,55968180,T,A,ENST00000263923.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-25_19:38:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1107,https://civic.genome.wustl.edu/links/variants/468,https://civic.genome.wustl.edu/links/genes/3153,,,missense_variant,"ENST00000263923.4:c.2150A>T,NC_000004.11:g.55968180T>A",3,Sunitinib,Sorafenib,,,,chr4_g.55968180T~A,KDR_c.2150A~T,
TSC2,7249,Q1178*,Thyroid_Carcinoma,3963,,Everolimus,,Predictive,Supports,C,Sensitivity/Response,"The_pretreatment_tumor_contained_a_somatic_nonsense_mutation_(Q1178*)_in_the_tumor-suppressor_gene_TSC2_that_inactivates_the_gene,_allowing_for_activation_of_the_mTOR_pathway_and_resulting_in_sensitivity_to_mTOR_inhibition_by_everolimus._The_patient_received_a_sustained_response_to_everolimus_for_18_months.",25295501,PubMed,,"Wagle_et_al.,_2014,_N._Engl._J._Med.",,5,accepted,1108,47,16,2130300,2130300,C,T,ENST00000219476.3,,,,,75,GRCh37,,Somatic_Mutation,2016-02-25_19:17:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1108,https://civic.genome.wustl.edu/links/variants/469,https://civic.genome.wustl.edu/links/genes/47,,,stop_gained,"NM_000548.4:c.3532C>T,NP_000539.2:p.Gln1178Ter,ENST00000219476.3:c.3532C>T,NC_000016.9:g.2130300C>T",12.5,Everolimus,,,,,chr16_g.2130300C~T,TSC2_c.3532C~T,p.gln1178ter
MTOR,2475,F2108L,Thyroid_Carcinoma,3963,,Everolimus,,Predictive,Supports,C,Resistance,"The_pretreatment_tumor_contained_a_somatic_nonsense_mutation_(Q1178*)_in_the_tumor-suppressor_gene_TSC2_that_inactivates_the_gene,_allowing_for_activation_of_the_mTOR_pathway_and_resulting_in_sensitivity_to_mTOR_inhibition_by_everolimus._The_patient_received_a_sustained_response_to_everolimus_for_18_months,_after_which_time_resistance_developed._The_resistant_tumor_had_a_somatic_mutation_in_MTOR_(F2108L),_that_was_not_detected_in_the_pretreatment_tumor.",25295501,PubMed,,"Wagle_et_al.,_2014,_N._Engl._J._Med.",,5,accepted,1110,2073,1,11187094,11187094,G,T,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-02-25_19:25:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1110,https://civic.genome.wustl.edu/links/variants/470,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6324C>A,NC_000001.10:g.11187094G>T",16.5,Everolimus,,,,,chr1_g.11187094G~T,MTOR_c.6324C~A,
MTOR,2475,F2108L,Breast_Cancer,1612,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Resistance,MCF-7_breast_cancer_cell_line_was_exposed_to_mTOR_inhibitors_AZD8055_or_rapamycin_until_resistance_developed._Deep_sequencing_revealed_an_MTOR_F2108L_mutation_in_rapamycin-resistant_clones_(RR2_cells)._Downstream_signalling_was_independent_of_inhibitor_presence_in_these_clones_and_expression_of_the_mutations_in_MDA-MB-468_cells_led_to_resistance.,27279227,PubMed,,"Rodrik-Outmezguine_et_al.,_2016,_Nature",,4,accepted,1543,2073,1,11187094,11187094,G,T,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-02_19:44:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1543,https://civic.genome.wustl.edu/links/variants/470,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6324C>A,NC_000001.10:g.11187094G>T",16.5,Rapamycin_(Sirolimus),,,,,chr1_g.11187094G~T,MTOR_c.6324C~A,
ALDH1A2,8854,UNDEREXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,All-trans_Retinoic_Acid,,Predictive,Supports,D,Sensitivity/Response,"FaDu_(a_high_ALDH1A2_expression_cell_line)_and_Cal27_(a_low_expression_cell_line)_were_treated_with_all-trans_retinoic_acid_(ATRA),_Adapalene_or_Fenretinide._This_led_to_concentration_dependent_decrease_in_the_survival_fraction_in_both_cell_lines_with_higher_efficacy_in_Cal27_(ED50_≈_1_μM)_as_compared_to_FaDu_cells_(ED_≈_44_μM)._Treatment_with_3_μM_ATRA_sensitized_Cal27_cells_to_irradiation_at_a_dose_of_2_Gy,_but_had_no_or_only_a_minor_effect_on_ALDH1A2-postitive_cells.",26634247,PubMed,,"Seidensaal_et_al.,_2015,_Mol._Cancer",,2,accepted,1115,7024,15,58245622,58358616,,,ENST00000249750.4,,,,,75,GRCh37,,,2016-02-25_20:20:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1115,https://civic.genome.wustl.edu/links/variants/473,https://civic.genome.wustl.edu/links/genes/7024,,,,,2,All-trans_Retinoic_Acid,,,,,,,
KIAA1524,57650,UNDEREXPRESSION,Pancreatic_Ductal_Adenocarcinoma,3498,,Gemcitabine,,Predictive,Supports,D,Sensitivity/Response,"Researchers_studied_the_effect_of_CIP2A_expression_in_relation_to__gemcitabine_sensitivity_via_SW1990_cell_lines._SW1990_cells_with_CIP2A_expression_knocked-down_displayed_lower_IC50_(p=.024),_indicating_a_sensitivity_to_gemcitabine.",26894380,PubMed,,"Xu_et_al.,_2016,_Oncotarget",,3,accepted,1118,13948,3,108268716,108308299,,,ENST00000295746.8,,,,,75,GRCh37,,Somatic_Mutation,2016-02-25_21:45:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1118,https://civic.genome.wustl.edu/links/variants/475,https://civic.genome.wustl.edu/links/genes/13948,,,,,3,Gemcitabine,,,,,,,
KRAS,3845,Q22*,Colon_Mucinous_Adenocarcinoma,3029,,Panitumumab,,Predictive,Supports,C,Resistance,"A_43-year-old_female_was_diagnosed_with_an_adenocarcinoma_of_the_ascending_colon_and_received_6-months_of_adjuvant_chemotherapy._After_5_years_of_completion_of_adjuvant_chemotherapy,_the_disease_relapsed._EGFR_was_assessed_by_immunohistochemistry,_and_the_patient_was_subsequently_treated_with_the_anti-EGFR_monoclonal_antibody_panitumumab._However,_there_was_a_rapid_clinical_worsening,_which_may_possibly_be_attributed_to_a_somatic_mutation_in_KRAS_(Q22*).",19661358,PubMed,,"Palmirotta_et_al.,_2009,_Anticancer_Res.",,2,accepted,1131,30,12,25398255,25398255,G,A,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2016-03-08_17:48:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1131,https://civic.genome.wustl.edu/links/variants/479,https://civic.genome.wustl.edu/links/genes/30,,,stop_gained,"ENST00000256078.4:c.64C>T,NC_000012.11:g.25398255G>A,NM_004985.4:c.64C>T,NP_004976.2:p.Gln22Ter",5,Panitumumab,,,,,chr12_g.25398255G~A,KRAS_c.64C~T,p.gln22ter
DDX43,55510,OVEREXPRESSION,Uveal_Melanoma,6039,,"Selumetinib_(AZD6244),PD0325901,Trametinib",Substitutes,Predictive,Supports,D,Resistance,"MEK_inhibitor-resistant_(selumetinib,_PD0325901,_GSK1129212)_uveal_melanoma_cell_lines_were_created_from_two_GNAQ_Q209L_mutant_cell_lines._Overexpression_of_DDX43_mediated_RAS-induced_selumetinib_resistance_as_demonstrated_by_depletion_of_DDX43_decreasing_RAS_proteins_and_ectopic_expression_of_DDX43_induced_RAS_protein_levels._These_results_were_confirmed_using_biopsies_from_liver_metastases_in_14_patients_with_uveal_melanoma_harboring_GNAQ_or_GNA11_mutations_who_were_treated_on_a_phase_II_study_of_selumetinib._6_patients_with_partial_response_or_stable_disease_for_≥16_weeks,_were_defined_as_“responders”_(R),_8_patients_who_had_disease_progression_before_16_weeks_were_defined_as_“nonresponders”_(NR)._DDX43_Expression_(qPCR)_was_higher_in_nonresponders_(P_=_0.045)._Liver_metastasis_biopsy_samples_(3_R_and_3_NR)_were_immunoblotted_for_DDX43,_pERK_and_RAS_proteins_with_consistent_results.",24899684,PubMed,,"Ambrosini_et_al.,_2014,_Mol._Cancer_Ther.",,4,accepted,1135,13005,6,74104471,74127292,,,ENST00000370336.4,,,,,75,GRCh37,,Somatic_Mutation,2016-10-10_22:50:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1135,https://civic.genome.wustl.edu/links/variants/481,https://civic.genome.wustl.edu/links/genes/13005,,,,,4,Selumetinib_(AZD6244),PD0325901,Trametinib,,,,,
KIT,3815,RS3733542,Acute_Myeloid_Leukemia,9119,,Selumetinib_(AZD6244),,Predictive,Supports,B,Sensitivity/Response,"Patients_with_relapsed/refractory_AML_or_60_years_old_or_more_with_untreated_AML_were_enrolled_on_a_phase_II_study_of_selumetinib_and_analyzed_for_mutations_in_KIT,_NRAS,_KRAS_and_FLT3._KIT_mutation_analysis_(N=41)_revealed_the_presence_of_a_synonymous_SNP_rs3733542_(known_population_frequency_of_20%)_in_exon_18_of_the_KIT_gene_in_six_of_ten_(60%)_patients_assessed_as_having_a_response_or_disease_stabilization_to_selumetinib._In_contrast,_this_SNP_was_detected_in_only_seven_of_31_(23%)_patients_without_a_response_or_disease_stabilization_(P_=_0.027,_Chi-squared_test).",24178622,PubMed,,"Jain_et_al.,_2014,_Clin._Cancer_Res.",,1,accepted,1136,29,4,55602765,55602765,G,C,ENST00000288135.5,,,,,75,GRCh37,,Germline_Polymorphism,2016-06-29_20:21:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1136,https://civic.genome.wustl.edu/links/variants/482,https://civic.genome.wustl.edu/links/genes/29,,,synonymous_variant,"NM_000222.2:c.2586G>C,NP_000213.1:p.Leu862=,ENST00000288135.5:c.2586G>C,NC_000004.11:g.55602765G>C",5,Selumetinib_(AZD6244),,,,,chr4_g.55602765G~C,KIT_c.2586G~C,p.leu862=
TBK1,29110,OVEREXPRESSION,Melanoma,1909,,"Selumetinib_(AZD6244),AZ909",Combination,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_melanoma_cell_lines._TBK1_depletion_(siRNA)_inhibited_migration_and_invasion,_whereas_its_constitutive_overexpression_led_to_an_increase_in_invasion._In_MEK-resistant_NRAS_mutant_melanoma_cell_lines,_TBK1_depletion_or_inhibition_(AZ909)_in_combination_with_MEK_inhibitors_(selumetinib)_promoted_apoptosis_in_3D_culture.",24962318,PubMed,,"Vu_et_al.,_2014,_Mol._Cancer_Res.",,2,accepted,1138,11322,12,64845660,64895888,,,ENST00000331710.5,,,,,75,GRCh37,,,2016-05-12_22:03:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1138,https://civic.genome.wustl.edu/links/variants/483,https://civic.genome.wustl.edu/links/genes/11322,,,,,2,Selumetinib_(AZD6244),AZ909,,,,,,
STK11,6794,LOSS,Peutz-Jeghers_Syndrome,3852,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_a_mouse_model_of_Peutz-Jeghers_syndrome._Heterozygous_Lkb1_(STK11)_knockout_mice_were_generated_and_treated_with_rapamycin_after_the_onset_of_polyposis_at_9_months_of_age._Rapamycin_treatment_significantly_suppressed_polyposis_(p=0.017)_and_pS6_staining_(IHC,_p=0.011).",18281551,PubMed,,"Wei_et_al.,_2008,_Clin._Cancer_Res.",,1,accepted,1618,5534,19,1205740,1228428,,,ENST00000326873.7,,,,,75,GRCh37,,Germline_Mutation,2016-11-03_19:18:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1618,https://civic.genome.wustl.edu/links/variants/485,https://civic.genome.wustl.edu/links/genes/5534,,,loss_of_function_variant,,23,Rapamycin_(Sirolimus),,,,,,,
STK11,6794,LOSS,Non-small_Cell_Lung_Carcinoma,3908,,"Selumetinib_(AZD6244),Docetaxel",Combination,Predictive,Supports,D,Resistance,A_clinical_trial_comparing_selumetinib_and_docetaxel_vs._docetaxel_and_placebo_in_KRAS_mutant_NSCLC_was_recapitulated_in_mice._Tumors_were_induced_in_lung_epithelium_by_nasal_instillation_of_CRE-bearing_adenovirus_in_conditionally_targeted_mice._Kras(G12D)_and_Lkb1_(STK11)_knockout_mutant_mice_showed_only_mild_response_to_combined_treatment_and_very_low_response_rates_to_docetaxel_monotherapy_compared_to_mice_with_Kras(G12D)_alone_or_Kras(G12D)_and_Trp53_knockout._In_a_small_number_of_human_NSCLC_patients_with_these_genotypes_FDG-PET_signal_intensity_changes_and_pERK_IHC_staining_correlated_with_mouse_data.,22425996,PubMed,,"Chen_et_al.,_2012,_Nature",,3,accepted,1144,5534,19,1205740,1228428,,,ENST00000326873.7,,,,,75,GRCh37,,Somatic_Mutation,2016-08-29_09:38:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1144,https://civic.genome.wustl.edu/links/variants/485,https://civic.genome.wustl.edu/links/genes/5534,,,loss_of_function_variant,,23,Selumetinib_(AZD6244),Docetaxel,,,,,,
STK11,6794,LOSS,Non-small_Cell_Lung_Carcinoma,3908,,"Everolimus,Rapamycin_(Sirolimus)",Substitutes,Predictive,Does_Not_Support,D,Sensitivity/Response,Preclinical_study_in_5_NSCLC_cell_lines._Two_LKB1_(STK11)_mutant_cell_lines_had_higher_basal_levels_of_mTOR_activity_(pS6K_and_p4EBP1_levels)_but_were_not_more_sensitive_to_mTOR_inhibitors_(everolimus_or_rapamycin)_than_two_wild_type_cell_lines._Knockdown_of_LKB1_in_one_additional_cell_line_did_not_lead_to_an_increase_in_sensitivity_to_mTOR_inhibitors.,26027660,PubMed,,"Xiao_et_al.,_2015,_Acta_Pharmacol._Sin.",,3,accepted,1620,5534,19,1205740,1228428,,,ENST00000326873.7,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_22:22:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1620,https://civic.genome.wustl.edu/links/variants/485,https://civic.genome.wustl.edu/links/genes/5534,,,loss_of_function_variant,,23,Everolimus,Rapamycin_(Sirolimus),,,,,,
STK11,6794,LOSS,Peutz-Jeghers_Syndrome,3852,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,Treatment_of_mice_with_a_heterozygous_loss_of_Lkb1_(STK11)_with_rapamycin_led_to_reduction_in_polyp_size_(p_<_0.0001)_and_number_of_polyps_(p=0.00022)._pS6_staining_was_also_reduced_after_rapamycin_treatment._Rapamycin_treatment_abolished_FDG-PET_signal_on_imaging.,19541609,PubMed,,"Shackelford_et_al.,_2009,_Proc._Natl._Acad._Sci._U.S.A.",,1,accepted,1619,5534,19,1205740,1228428,,,ENST00000326873.7,,,,,75,GRCh37,,Germline_Mutation,2016-11-07_22:09:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1619,https://civic.genome.wustl.edu/links/variants/485,https://civic.genome.wustl.edu/links/genes/5534,,,loss_of_function_variant,,23,Rapamycin_(Sirolimus),,,,,,,
HAVCR2,84868,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"TIM-3_Inhibitor,PD-1_Inhibitor",Combination,Predictive,Supports,D,Sensitivity/Response,"In_a_preclinical_study_in_an_immunocompetent_mouse_model_of_lung_adenocarcinoma,_upregulation_of_alternative_immune_checkpoints,_notably_T-cell_immunoglobulin_mucin-3_(TIM-3,_aka_HAVCR2)_was_observed_after_progression_under_PD-1_antibody._A_survival_advantage_was_observed_with_the_addition_of_a_TIM-3_blocking_antibody.",26883990,PubMed,,"Koyama_et_al.,_2016,_Nat_Commun",,3,accepted,1151,16394,5,156512843,156536725,,,ENST00000307851.4,,,,,75,GRCh37,,,2016-07-13_23:31:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1151,https://civic.genome.wustl.edu/links/variants/486,https://civic.genome.wustl.edu/links/genes/16394,,,,,10.5,TIM-3_Inhibitor,PD-1_Inhibitor,,,,,,
HAVCR2,84868,OVEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,PD-1_Inhibitor,,Predictive,Supports,C,Resistance,"In_a_preclinical_study_in_an_immunocompetent_mouse_model_of_lung_adenocarcinoma,_upregulation_of_alternative_immune_checkpoints,_notably_T-cell_immunoglobulin_mucin-3_(TIM-3,_aka_HAVCR2)_was_observed_after_progression_under_PD-1_antibody._A_survival_advantage_was_observed_with_the_addition_of_a_TIM-3_blocking_antibody._Two_patients_who_developed_adaptive_resistance_to_anti-PD-1_treatment_also_showed_TIM-3_upregulation_in_blocking_antibody-bound_T_cells_at_treatment_failure.",26883990,PubMed,,"Koyama_et_al.,_2016,_Nat_Commun",,3,accepted,1150,16394,5,156512843,156536725,,,ENST00000307851.4,,,,,75,GRCh37,,,2016-06-14_04:25:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1150,https://civic.genome.wustl.edu/links/variants/486,https://civic.genome.wustl.edu/links/genes/16394,,,,,10.5,PD-1_Inhibitor,,,,,,,
MMP2,4313,SERUM_LEVELS,Brain_Glioma,60108,,Bevacizumab,,Predictive,Supports,B,Sensitivity/Response,"Plasma_levels_of_11_potential_biomarkers_were_tested_at_baseline_and_2_weeks_after_bevacizumab_initiation_in_a_prospective_cohort_of_26_patients_with_recurrent_high-grade_gliomas._Results_were_validated_in_a_separate_retrospective_cohort_(n_=_50)_and_also_tested_in_patients_treated_with_cytotoxic_agents_without_bevacizumab_(n_=_34)._MMP2_level_was_correlated_with_PFS_(hazard_ratio,_3.92;_95%_confidence_interval_[CI]:1.46-10.52;_P_=_.007)_and_OS_(hazard_ratio,_4.62;_95%_CI:_1.58-13.53;_P_=_.005)_in_the_discovery_and_validation_cohorts_but_not_in_patients_treated_without_bevacizumab.",24327581,PubMed,,"Tabouret_et_al.,_2014,_Neuro-oncology",,2,accepted,1158,3549,16,55512883,55540603,,,ENST00000219070.4,,,,,75,GRCh37,,,2016-06-14_04:26:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1158,https://civic.genome.wustl.edu/links/variants/487,https://civic.genome.wustl.edu/links/genes/3549,,,,,25,Bevacizumab,,,,,,,
MMP2,4313,SERUM_LEVELS,Inflammatory_Breast_Carcinoma,6263,,Bevacizumab,,Predictive,Supports,B,Sensitivity/Response,"MMP2_serum_levels_were_assessed_(ELISA)_at_baseline_(b)_and_before_surgery_in_45_available_samples_from_patients_with_inflammatory_breast_cancer_treated_with_bevacizumab-based_neoadjuvant_therapy._High_bMMP2_was_correlated_with_better_disease-free_survival_(DFS,_p=0.001)_and_overall_survival_(OS,_p=0.032)._Correlation_to_DFS_was_also_found_after_multivariate_analysis_(p=0.003,_Hazard_Ratio_[HR]:_0.115)._bMMP2_was_associated_with_relapse_(p=0.002)_and_death_(p=0.049)._During_treatment,_significant_increase_in_MMP2_was_observed_in_100%_of_patients.",26921265,PubMed,,"Tabouret_et_al.,_2016,_Oncotarget",,3,accepted,1156,3549,16,55512883,55540603,,,ENST00000219070.4,,,,,75,GRCh37,,,2016-06-14_04:27:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1156,https://civic.genome.wustl.edu/links/variants/487,https://civic.genome.wustl.edu/links/genes/3549,,,,,25,Bevacizumab,,,,,,,
MMP9,4318,SERUM_LEVELS,Inflammatory_Breast_Carcinoma,6263,,Bevacizumab,,Predictive,Supports,B,Resistance,"MMP9_serum_levels_were_assessed_(ELISA)_at_baseline_(b)_and_before_surgery_in_45_available_samples_from_patients_with_inflammatory_breast_cancer_treated_with_bevacizumab-based_neoadjuvant_therapy._Low_bMMP9_was_correlated_with_better_OS_(p=0.022)_and_non-significantly_associated_with_longer_DFS_(p=0.071)._Correlation_to_DFS_was_also_found_after_multivariate_analysis_(p=0.041,_HR:_3.511)._bMMP9_was_associated_with_death_(p=0.035)._During_treatment,_a_significant_decrease_in_MMP9_levels_(p<0.001)_was_observed_in_87%_of_patients.",26921265,PubMed,,"Tabouret_et_al.,_2016,_Oncotarget",,3,accepted,1157,3553,20,44637547,44645200,,,ENST00000372330.3,,,,,75,GRCh37,,,2016-06-27_00:57:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/1157,https://civic.genome.wustl.edu/links/variants/488,https://civic.genome.wustl.edu/links/genes/3553,,,,,15,Bevacizumab,,,,,,,
HSPH1,10808,NUCLEAR_EXPRESSION,Gastric_Adenocarcinoma,3717,,"Cisplatin,5-fluorouracil",Substitutes,Predictive,Supports,D,Sensitivity/Response,"49_patients_gastric_cancer_patients_treated_with_adjuvant_chemotherapy_were_immunohistochemically_assessed_for_nuclear_HSPH1_(HSP110)_expression._Overall_survival_rate_in_the_high_expression_group_(2+_moderate/3+_strong_staining)_was_significantly_lower_compared_with_the_low_expression_group_(0_no/1+_weak_staining)_(P_=_0.0364)._In_gastric_cancer_cell_lines_(MKN7,_MKN45),_siRNA_mediated_HSP110_knockdown_led_to_a_higher_sensitivity_to_5-FU_and_cisplatin_compared_with_the_parent_and_control_cells_(p_<_0.05).",26943774,PubMed,,"Kimura_et_al.,_2016,_Oncotarget",,1,accepted,1163,8614,13,31710765,31736064,,,ENST00000320027.5,,,,,75,GRCh37,,,2016-05-17_19:37:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1163,https://civic.genome.wustl.edu/links/variants/490,https://civic.genome.wustl.edu/links/genes/8614,,,,,11,Cisplatin,5-fluorouracil,,,,,,
HSPH1,10808,T17_DELETION,Colorectal_Cancer,9256,,"Oxaliplatin,5-fluorouracil",Combination,Predictive,Supports,B,Sensitivity/Response,"329_consecutive_patients_with_stage_II–III_colorectal_tumors_with_MSI_after_surgical_resection_at_tertiary_medical_centers_were_screened_for_HSP110_T(17)_by_PCR._Patients_underwent_adjuvant_chemotherapy_with_5-fluorouracil_and_oxaliplatin._Patients_with_large_HSP110_T(17)_deletions_(≥5_bp;_18_of_77_patients,_23.4%)_had_longer_times_of_relapse-free_survival_than_patients_with_small_or_no_deletions_(≤4_bp;_59_of_77_patients,_76.6%)_in_multivariate_analysis_(hazard_ratio,_0.16;_95%_confidence_interval,_0.012–0.8;_P_=_.03)._A_significant_interaction_between_chemotherapy_and_T17_deletion_was_found_(P_=.009).",24512910,PubMed,,"Collura_et_al.,_2014,_Gastroenterology",,2,accepted,1164,8614,13,31722621,31722637,,,ENST00000320027.5,,,,,75,GRCh37,,Somatic_Mutation,2016-05-10_02:11:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1164,https://civic.genome.wustl.edu/links/variants/491,https://civic.genome.wustl.edu/links/genes/8614,,,short_tandem_repeat_variation,,10,Oxaliplatin,5-fluorouracil,,,,,,
ECSCR,641700,EXPRESSION,Cancer,162,,Antiangiogenic_Therapy,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Biomarkers_for_response_to_antiangiogenic_treatment_were_screened_for_in_hepatocellular_cancer_(n_=_11),_renal_cell_cancer_(n_=_7)_and_non-small_cell_lung_cancer_(n_=_2)._Increased_expression_of_tumor_endothelial_markers:_Robo4_and_ECSCR,_nonsignificantly_correlated_with_prolonged_antiangiogenic_time_to_progression_(ECSCR_high_=_275_days_vs._ECSCR_low_=_92.5_days;_p_=_0.07_and_for_Robo4_high_=_387_days_vs._Robo4_low_=_90.0_days;_p_=_0.08).",26956051,PubMed,,"Pircher_et_al.,_2016,_Oncotarget",,1,accepted,1165,26599,,,,,,,,,,,,,,,2016-11-03_21:48:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1165,https://civic.genome.wustl.edu/links/variants/492,https://civic.genome.wustl.edu/links/genes/26599,,,,,5,Antiangiogenic_Therapy,,,,,,,
ROBO4,54538,EXPRESSION,Cancer,162,,Antiangiogenic_Therapy,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Biomarkers_for_Response_to_antiangiogenic_treatment_were_screened_for_in_hepatocellular_cancer_(n_=_11),_renal_cell_cancer_(n_=_7)_and_non-small_cell_lung_cancer_(n_=_2)._Increased_expression_of_tumor_endothelial_markers:_Robo4_and_ECSCR,_nonsignificantly_correlated_with_prolonged_antiangiogenic_time_to_progression_(ECSCR_high_=_275_days_vs._ECSCR_low_=_92.5_days;_p_=_0.07_and_for_Robo4_high_=_387_days_vs._Robo4_low_=_90.0_days;_p_=_0.08).",26956051,PubMed,,"Pircher_et_al.,_2016,_Oncotarget",,1,accepted,1166,12367,11,124753587,124768177,,,ENST00000306534.3,,,,,75,GRCh37,,,2016-06-27_23:48:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1166,https://civic.genome.wustl.edu/links/variants/493,https://civic.genome.wustl.edu/links/genes/12367,,,,,5,Antiangiogenic_Therapy,,,,,,,
ERBB2,2064,L866M,Colon_Cancer,219,,"Trastuzumab,Lapatinib,Neratinib",Combination,Predictive,Supports,D,Sensitivity/Response,Colon_cancer_patient_derived_xenografts_with_HER2_mutations_are_sensitive_to_HER2_targeted_drugs_and_the_greatest_tumor_reduction_was_seen_with_the_combination_of_a_tyrosine_kinase_inhibitor_with_trastuzumab.,26243863,PubMed,,"Kavuri_et_al.,_2015,_Cancer_Discov",,4,accepted,1178,20,17,37881404,37881404,C,A,ENST00000269571.5,,,,,75,GRCh37,This_mutation_was_shown_to_be_an_activating_mutation_and_conferred_sensitivity_to_a_combination_of_trastuzumab_with_neratinib_or_lapatinib_in_colorectal_cancer_patient-derived_xenografts.,Somatic_Mutation,2016-03-17_22:19:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1178,https://civic.genome.wustl.edu/links/variants/496,https://civic.genome.wustl.edu/links/genes/20,This_mutation_was_shown_to_be_an_activating_mutation_and_conferred_sensitivity_to_a_combination_of_trastuzumab_with_neratinib_or_lapatinib_in_colorectal_cancer_patient-derived_xenografts.,,missense_variant,"ENST00000269571.5:c.2596C>A,NC_000017.10:g.37881404C>A",4,Trastuzumab,Lapatinib,Neratinib,,,chr17_g.37881404C~A,ERBB2_c.2596C~A,
ERBB2,2064,S310F/Y,Colon_Cancer,219,,"Trastuzumab,Neratinib,Lapatinib",Combination,Predictive,Supports,D,Sensitivity/Response,Colon_cancer_patient_derived_xenografts_with_HER2_mutations_are_sensitive_to_HER2_targeted_drugs_and_the_greatest_tumor_reduction_was_seen_with_the_combination_of_a_tyrosine_kinase_inhibitor_with_trastuzumab.,26243863,PubMed,,"Kavuri_et_al.,_2015,_Cancer_Discov",,4,accepted,1179,20,17,37868208,37868208,,,ENST00000269571.5,,,,,75,GRCh37,"ERBB2_S310F/Y_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Greulich_et_al._2012)._This_mutation_was_shown_to_be_an_activating_mutation_(through_hyperphosphorylation)_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_murine_Ba/F3_cells_have_been_shown_to_be_sensitive_to_the_ERBB2_inhibitors_(afatinib,_lapatinib_and_neratinib)._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",Somatic_Mutation,2016-03-17_22:17:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1179,https://civic.genome.wustl.edu/links/variants/497,https://civic.genome.wustl.edu/links/genes/20,"ERBB2_S310F/Y_was_one_of_the_first_ERBB2_variants_to_be_functionally_classified_(Greulich_et_al._2012)._This_mutation_was_shown_to_be_an_activating_mutation_(through_hyperphosphorylation)_in_an_in_vitro_assay._In_the_same_paper,_this_mutation_(along_with_other_ERBB2_activating_mutations)_in_murine_Ba/F3_cells_have_been_shown_to_be_sensitive_to_the_ERBB2_inhibitors_(afatinib,_lapatinib_and_neratinib)._More_recent_evidence_may_show_that_HER2_acitivating_mutations_confer_sensitivity_to_a_host_of_tyrosine_kinase_inhibitors,_which_is_the_topic_of_current_clinical_trials_and_research.",,missense_variant,"ENST00000269571.5:c.929C>T,NC_000017.10:g.37868208C>T",4,Trastuzumab,Neratinib,Lapatinib,,,chr17_g.37868208C~T,ERBB2_c.929C~T,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"This_retrospective_study_of_patients_from_the_PROFILE_1001_and_1005_studies_of_crizotinib_in_advanced_ALK-rearranged_NSCLC_assessed_the_potential_benefit_of_crizotinib_beyond_progressive_disease_(CBPD),_defined_as_continuation_of_crizotinib_for_3_or_more_weeks_after_disease_progression_on_crizotinib._194_patients_who_had_developed_PD_by_data_cutoff_were_studied,_where_120_received_crizotinib_for_a_median_duration_of_19.4_weeks_and_74_discontinued_crizotinib_after_PD._No_gross_imbalances_in_clinicopathologic_features_of_the_two_groups_were_evident.__Significantly_longer_overall_survival_was_observed_in_the_crizotinib_continuing_group_from_time_of_PD_(16.4_vs._3.9_months;_hazard_ratio_0.27,_95%_CI:_0.17–0.42;_P_<_0.0001),_and_from_the_time_of_initial_crizotinib_(29.6_vs._10.8_months;_HR_0.30,_95%_CI:_0.19–0.46;_P_<_0.0001).",24478318,PubMed,,"Ou_et_al.,_2014,_Ann._Oncol.",,4,accepted,1200,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-08-15_19:55:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1200,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,IPI-504,,Predictive,Supports,C,Sensitivity/Response,"In_this_study,_heavily_pretreated_advanced_NSCLC_patients_with_various_molecular_tumor_makeup_were_treated_with_Hsp90_inhibitor_IPI-504_to_assess_overall_response_rate._The_study_did_not_reach_the_targeted_endpoint_of_20%_ORR._However,_of_3/12_patients_found_to_be_ALK-rearranged_via_break_apart_FISH_assay,_2_showed_a_partial_response_and_the_third_stable_disease,_which_was_durable_for_7.2_months._The_authors_note_that_the_break_apart_FISH_assay_used_to_determine_ALK-rearrangement_status_does_not_determine_the_identity_of_the_ALK_fusion_partner_and_the_promising_results_shown_here_may_be_dependent_on_the_nature_of_the_ALK_fusion_partner.",20940188,PubMed,,"Sequist_et_al.,_2010,_J._Clin._Oncol.",,2,accepted,1202,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-11-04_16:51:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1202,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,IPI-504,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,A,Sensitivity/Response,"This_phase_3_trial_named_PROFILE_1014_(NCT01154140)_compared_crizotinib_to_established_chemotherapy_in_first-line_treatment_for_this_disease._The_study_consisted_of_343_patients_with_advanced_or_metastatic_NSCLC_that_tested_positive_for_ALK_rearrangement_via_break-apart_FISH_assay,_and_had_no_prior_systemic_treatment._Patients_were_assigned_in_a_1:1_ratio_to_crizotinib_(N=172)_or_pemetrexed_with_cisplatin_or_carboplatin_(N=171)._Progression_free_survival_was_significantly_longer_with_crizotinib_treatment_than_chemotherapy_(10.9_vs._7.0_months;_hazard_ratio_for_progression_or_death_with_crizotinib,_0.45;_95%_CI,_0.35_to_0.60;P<0.001),_and_objective_response_rate_was_higher_with_crizotinib_treatment_than_chemotherapy_(75%_vs._45%,_P<0.001)._Improvement_in_quality_of_life_was_also_reported.",25470694,PubMed,,"Solomon_et_al.,_2014,_N._Engl._J._Med.",,5,accepted,1199,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-06-22_19:09:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1199,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Pemetrexed,,Predictive,Supports,B,Sensitivity/Response,"Among_95_patients_with_NSCLC_in_this_study,_15_had_an_ALK_translocation._ORR_of_these_patients_compared_to_EGFR_mutated_or_wild-type_tumors_was_superior_(46.7_versus_4.7_versus_16.2%,_p_=_0.001)._TYMS_expression_was_lower_in_ALK-positive_cells.",21642865,PubMed,,"Lee_et_al.,_2011,_J_Thorac_Oncol",,3,accepted,945,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-08-30_16:14:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/945,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Pemetrexed,,,,,,,
ALK,238,ALK_FUSIONS,Vagina_Sarcoma,1901,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Patient_was_34-year-old_woman_with_vaginal_sarcoma,_which_was_excised_with_positive_surgical_margins._Fluorescence_in_situ_hybridization_testing_of_her_tumor_revealed__anaplastic_lymphoma_kinase_gene_rearrangements._A_3-cm_mass_recurred_1_month_later._Treatment_with_crizotinib_resulted_in_complete_regression_of_all_visible_or_palpable_tumor_within_3_weeks.",26942346,PubMed,,"Forde_et_al.,_2016,_Obstet_Gynecol",,2,accepted,6042,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2018-03-20_15:53:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/6042,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Anaplastic_Large_Cell_Lymphoma,50744,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Crizotinib_at_250mg_daily_was_given_to_two_patients_with_relapsed_ALK-rearranged_anaplastic_large_cell_lymphoma_(ALCL)._Patient_one,_26_yrs_old,_had_been_treated_with_the_CHOP-15_chemotherapy_regimen,_then_salvage_chemotherapy_to_prepare_for_autologous_bone_marrow_transplant_but_ultimately_relapsed._After_initiation_of_crizotinib,_PET,_CT_and_bone_marrow_aspirates_showed_complete_remission_of_previous_lesions_at_28_days._At_time_of_publication_the_patient_continued_to_show_persistent_response_at_6_months._A_20_year_old_patient_relapsed_after_one_month_of_CHOP,_and_was_treated_with_further_chemotherapy_and_autologous_bone_marrow_transplantation_resulting_in_partial_response_of_1_month._Crizotinib_was_initialized,_and_after_12_days_PET_scan_showed_complete_regression_of_all_lesions._On_day_60_bone_marrow_aspirates_were_ALK-negative_(pretreatment_evaluation_showed_8%_ALK-positive)._The_authors_conclude_these_two_cases_indicate_sensitivity_to_crizotinib_of_relapsed_ALK-rearranged_ALCL.",21345110,PubMed,,"Gambacorti-Passerini_et_al.,_2011,_N._Engl._J._Med.",,4,accepted,1240,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-11-03_18:32:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1240,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_retrospective_study_comparing_survival_outcomes_in_a_subgroup_of_82_ALK-positive_crizotinib-treated_patients_enrolled_in_a_phase_1_clinical_trial_(NCT00585195),_crizotinib_therapy_was_associated_with_improved_survival._For_the_crizotinib-treated,_ALK-positive_patient_group,_1_year_survival_was_74%_and_2_year_overall_survival_was_54%,_compared_with_72%_and_36%_for_the_control_group_(ALK-positive_crizotinib_naive_patients).",21933749,PubMed,,"Shaw_et_al.,_2011,_Lancet_Oncol.",,3,accepted,1419,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-06-28_20:26:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1419,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_I_trial_(NCT01588028)_in_47_patients,_alectinib_was_assessed_for_its_effectiveness_in_treating_locally_advanced_or_metastatic_ALK-positive_NSCLC_that_had_progressed_or_been_resistant_to_crizotinib_treatment._ALK_rearrangement_was_assessed_via_approved_break_apart_FISH_kit,_and_patients_with_asymptomatic_CNS_metastases_were_also_included._Patients_were_divided_into_different_cohorts_receiving_different_doses_of_alectinib._In_the_600_mg_cohort_(N=13),_there_were_4_confirmed_partial_responses,_3_unconfirmed_partial_responses_and_3_instances_of_stable_disease._Also,_five_of_nine_patients_throughout_the_cohorts_with_measurable_baseline_CNS_lesions_showed_partial_response_to_alectinib._Cerebrospinal_fluid_levels_of_alectinib_increased_linearly_with_blood_alectinib_levels,_indicating_it_effectively_crossed_the_blood-brain_barrier.",25153538,PubMed,,"Gadgeel_et_al.,_2014,_Lancet_Oncol.",,4,accepted,1279,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-06-22_19:06:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1279,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Alectinib_(CH5424802),,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,Brain_neoplasm,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"This_prospective_Phase_III_study_named_Profile_1014_on_NSCLC_ALK-rearranged_patients_assessed_intracranial_disease_control_rate_(IC-DCR)_in_the_subset_of_patients_entering_the_study_with_preexisting_treated_brain_metastasis_(tBM)._IC-DCR_was_significantly_improved_in_the_tBM_group_given_crizotinib_(N=39)_over_chemotherapy_(pemetrexed_+_cisplatin_or_carboplatin;_N=40)_at_12_weeks_(85%_vs._45%,_P<0.001),_and_at_24_weeks_(56%_vs._25%,_P=0.006)._Progression_free_survival_was_also_significantly_improved_with_crizotinib_over_chemotherapy_in_the_tBM_subgroup_(9.0_vs._4.0_months;_HR_0.40;_P<0.001),_where_in_the_intent_to_treat_population_it_was_10.9_vs._7.0_months_(HR_0.45;_P<0.001),_indicating_that_the_difficult_to_treat_BM_population_obtained_benefit_from_crizotinib_at_both_the_brain_and_systemic_level.",27022118,PubMed,,"Solomon_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,1201,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-08-15_19:57:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1201,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,A,Sensitivity/Response,"This_two_arm_Phase_III_study_named_PROFILE_1007_(NCT00932893)_was_performed_to_assess_crizotinib_vs._established_chemotherapy_in_non-small_cell_lung_cancer_patients_positive_for_ALK_rearrangement_(assessed_by_break-apart_FISH)_with_locally_advanced_or_metastatic_disease._347_patients_with_disease_progression_after_one_round_of_platinum-based_chemotherapy_were_randomized_to_receive_crizotinib_(N=173)_or_chemotherapy_(N=174)_consisting_of_pemetrexed_in_pemetrexed-naive_patients_and_docetaxel_for_patients_previously_treated_with_pemetrexed._The_primary_endpoint_-_progression_free_survival_(PFS)_-_was_found_to_be_significantly_better_for_patients_treated_with_crizotinib_(median_7.7_months)_than_with_chemotherapy_(median_3.0_months)_(hazard_ratio_for_disease_progression_or_death_with_crizotinib,_0.49;_95%_CI,_0.37_to_0.64;_P<0.001)._Response_rates_were_65%_for_crizotinib_treatment_and_20%_for_chemotherapy_(P<0.001)._Improvements_in_quality_of_life_were_also_reported.",23724913,PubMed,,"Shaw_et_al.,_2013,_N._Engl._J._Med.",,5,accepted,1198,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-06-22_19:04:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1198,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,A,Sensitivity/Response,"In_this_Phase_II_trial_of_87_patients_(NCT01871805),_alectinib_was_assayed_for_safety_and_efficacy_in_ALK_positive_NSCLC_that_had_progressed_on_crizotinib._Of_69_patients_with_measurable_disease,_35_achieved_objective_response,_with_median_duration_of_response_13.5_months._Of_16_patients_with_measurable_CNS_disease,_four_achieved_CNS_complete_response_and_8_showed_CNS_partial_response._median_duration_of_CNS_response_was_11.1_months._2_deaths_were_observed,_and_1_was_judged_related_to_study_treatment._In_early_2016,_alectinib_was_approved_by_the_FDA_partly_based_on_this_study_for_treatment_of_crizotinib-progressed_ALK_positive_NSCLC",26708155,PubMed,,"Shaw_et_al.,_2016,_Lancet_Oncol.",,5,accepted,1282,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-06-22_19:07:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1282,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Alectinib_(CH5424802),,,,,,,
ALK,238,ALK_FUSIONS,Diffuse_Large_B-cell_Lymphoma,50745,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"A_27_year_old_female_patient_with_advanced-stage_IV,_CD20_negative_diffuse_large_B_cell_lymphoma_(DLBCL)._ALK_rearrangement_was_determined_by_FISH,_but_the_ALK_fusion_partner_was_not_determined_due_to_limited_tissue._The_patient_underwent_treatment_with_CHOP_chemotherapy_regimen_and_radiation_but_did_not_respond._The_patient_progressed_following_salvage_chemotherapy_and_autologous_stem_cell_transplant._Crizotinib_was_then_administered_at_250_mg_twice_daily,_and_LDH_levels_rapidly_dropped_along_with_disappearance_of_palpable_lymphadenopathy,_but_progression_ensued_after_21_days_and_the_patient_died_soon_after._The_authors_attribute_the_short_response_to_crizotinib_to_the_possibility_of_this_tumor_having_an_ALK_fusion_variant_less_responsive_to_ALK_inhibition_and_to_a_high_Ki-67_index_in_the_patient,_and_deem_that_despite_the_brief_response,_crizotinib_shows_promise_in_ALK_rearranged_DLBCL.",24330038,PubMed,,"Wass_et_al.,_2014,_Eur._J._Haematol.",,2,accepted,1264,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-11-04_18:12:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1264,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,B,Sensitivity/Response,"Updated_results_from_ASCEND-1_trial_assessing_safety_and_activity_of_ceritinib_in_ALK_rearranged_locally_advanced_or_metastatic_NSCLC._255_patients_were_enrolled_and_received_at_least_one_dose_of_ceritinib_750_mg/day,_of_whom_246_had_ALK-rearranged_NSCLC_(Median_follow-up:_11.1_months)._Overall_response_rate_was_72%_[95%_CI_61-82]_of_83_ALK_inhibitor-naive_patients_and_56%_[49-64]_of_163_ALK_inhibitor-pretreated_patients._Median_duration_of_response_was_17·0_months_(95%_CI_11.3-non-estimable_[NE])_in_ALK_inhibitor-naive_patients_and_8.3_months_(6.8-9.7)_in_ALK_inhibitor-pretreated_patients._Median_progression-free_survival_was_18.4_months_(95%_CI_11.1-NE)_in_ALK_inhibitor-naive_patients_and_6.9_months_(5.6-8.7)_in_ALK_inhibitor-pretreated_patients._Brain_metastases_control_was_reported_in_79%_[95%_CI_54-94]_of_19_ALK_inhibitor-naive_patients_and_in_65%_[54-76]_of_75_ALK_inhibitor-pretreated_patients.",26973324,PubMed,,"Kim_et_al.,_2016,_Lancet_Oncol.",,4,accepted,1175,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-06-27_16:24:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1175,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Ceritinib,,,,,,,
ALK,238,ALK_FUSIONS,Colorectal_Adenocarcinoma,50861,,Crizotinib,,Predictive,Supports,E,Sensitivity/Response,"26_colorectal_adenocarcinoma_samples_were_run_on_Affymetrix_human_Exon_1.0_arrays_and_a_computational_method_that_assessed_differential_5'_and_3'_gene_expression_for_each_gene_was_used_to_find_potential_rearrangements.__One_sample_showed_potential_rearrangement_and_RT-PCR_demonstrated_an_EML4-ALK_fusion_where_EML4_exon_21_was_fused_to_ALK_exon_13._This_EML4-ALK_variant_is_different_from_those_commonly_found_in_NSCLC._Genomic_PCR_verified_the_existence_of_the_fusion_breakpoint_in_intronic_space,_indicating_that_some_colorectal_adenocarcinoma_may_have_targetable_ALK-fusion_driver_mutations.",19737969,PubMed,,"Lin_et_al.,_2009,_Mol._Cancer_Res.",,1,accepted,1334,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-07-02_02:56:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1334,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,B,Sensitivity/Response,"In_this_initial_report_of_a_single-arm_Phase_I_and_II_study_(JapicCTI-101264)_of_alectinib_(CH5424802),_46_patients_with_advanced_or_metastatic_ALK-rearranged_non_small_cell_lung_cancer_(NSCLC)_were_assessed_for_objective_response_during_phase_II._ALK_positivity_was_assessed_via_IHC_and_verified_with_FISH_or_RT-PCR._Patients_had_received_one_or_more_rounds_of_previous_chemotherapy,_but_no_prior_targeted_therapy_towards_ALK._From_the_46_patients,_41_showed_partial_response,_and_2_showed_complete_response._CNS_metastases_in_three_patients_which_had_not_received_prior_brain_irradiation_showed_response_to_alectinib._Alectinib_was_generally_well_tolerated,_and_the_authors_conclude_that_alectinib_compared_favorably_to_crizotinib_and_could_be_an_effective_and_safe_option_in_ALK-rearranged_NSCLC.",23639470,PubMed,,"Seto_et_al.,_2013,_Lancet_Oncol.",,3,accepted,1272,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-08-15_19:59:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1272,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Alectinib_(CH5424802),,,,,,,
ALK,238,ALK_FUSIONS,Cancer,162,,Entrectinib,,Predictive,Supports,B,Sensitivity/Response,"Two_phase_I_studies_in_patients_with_advanced_or_metastatic_solid_tumors,_including_patients_with_active_central_nervous_system_(CNS)_disease._Here,_we_summarize_the_overall_safety_and_report_the_antitumor_activity_of_entrectinib_in_a_cohort_of_patients_with_tumors_harboring_NTRK1/2/3,_ROS1,_or_ALK_gene_fusions_Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._Notably,_a_complete_CNS_response_was_achieved_in_a_patient_with_SQSTM1-NTRK1-rearranged_lung_cancer.",28183697,PubMed,,"Drilon_et_al.,_2017,_Cancer_Discov",,3,accepted,2952,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2017-04-14_16:36:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/2952,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Entrectinib,,,,,,,
ALK,238,ALK_FUSIONS,Inflammatory_Myofibroblastic_Tumor,50905,,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"As_part_of_a_phase_1_dose-escalation_trial_(NCT00939770),_seven_patients_between_ages_12_months_and_22_years_with_relapsed_or_refractory_inflammatory_myofibroblastic_tumors_with_ALK-rearrangement_were_given_crizotinib._In_six_patients_with_measurable_disease,_responses_included_3_with_partial_response_and_3_with_stable_disease._One_patient_with_evaluable_disease_had_stable_disease_with_treatment_ongoing_at_the_time_of_publication._Crizotinib_was_well_tolerated_in_this_group_of_pediatric_patients.",23598171,PubMed,,"Mossé_et_al.,_2013,_Lancet_Oncol.",,3,accepted,1243,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-08-15_19:59:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1243,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,CH5424802,,Predictive,Supports,C,Sensitivity/Response,"In_this_case_study_of_a_critically_ill_29_year_old_male_nonsmoker_with_advanced_metastatic_ALK-positive_NSCLC,_alectinib_(CH5424802),_was_administered_as_first_line_treatment._Where_most_clinical_trials_only_admit_patients_with_Eastern_Cooperative_Oncology_Performance_status_(PS)_of_0_or_1,_this_patient_had_PS_4_due_to_respiratory_failure,_multiple_bone_metastases_and_complications_from_disseminated_intravascular_coagulation_(DIC)._Administration_of_alectinib_at_300_mg_twice_daily_was_followed_by_marked_improvement_seen_in_tests_associated_with_DIC,_pulmonary_metastasis_and_change_in_PS_from_4_to_0._Further_improvements_after_a_couple_of_months_suggested_a_rapid_complete_response._Alectinib_was_well_tolerated_in_this_first_line_treatment_of_a_critically_ill_ALK-positive_NSCLC_patient.",26938871,PubMed,,"Yoshida_et_al.,_2016,_Anticancer_Drugs",,3,accepted,1273,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-11-03_19:15:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1273,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,CH5424802,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"A_phase-3_clinical_trial_evaluated_347_patients_with_ALK-positive_lung_cancer.__The_study_compared_crizotinib_treatment_(n=173)_with_chemotherapy_treatment_of_either_pemetrexed_or_docetaxel_(n=174).__In_the_crizotinib_arm,_the_response_rate_was_significantly_higher_(65%_vs_20%;_P<0.001),_the_progression-free_survival_was_increased_(7.7_months_vs._3.0_months;_HR=0.49,_95%CI:14_months-26_months;_p<0.001),_however,_there_was_no_significant_improvement_in_overall_survival_(HR=1.02;_95%CI:0.68-1.54;_P=0.54).__Of_the_patients_on_crizotinib_treatment,_global_quality_of_life_was_improved_relative_to_baseline_when_compared_to_chemotherapy_patients_(+5_mean_change,_-5_mean_change;_P<0.001).",26466010,PubMed,,"2015,_N._Engl._J._Med.",,3,accepted,1577,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-10-20_06:25:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1577,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,A,Sensitivity/Response,"In_the_Phase_I_study_PROFILE_1001_(NCT00585195),_a_recommended_crizotinib_dose_of_250_mg_twice_daily_for_28_day_cycles_was_established._Among_1,500_advanced_NSCLC_patients_who_were_screened_for_ALK-rearrangement_using_a_break-apart_FISH_assay,_82_patients_were_eligible_for_crizotinib_treatment.__Overall_response_rate_was_57%,_with_46_partial_responses_and_one_complete_response.__Since_crizotinib_inhibits_MET,_33_patients_with_available_tissue_were_screened_for_MET_amplification_and_were_found_negative,_further_indicating_that_patient_response_was_due_to_ALK_inhibition.__31_patients_were_tested_via_RT-PCR_for_known_EML4-ALK_fusions,_and_13_were_shown_to_have_EML4-ALK_variant_1,_four_cases_had_variant_3,_and_one_instance_of_variants_2,_3b_and_5_were_seen.__9_were_unidentified,_suggesting_other_fusion_partners_in_these_instances.__On_the_basis_of_this_and_a_Phase_II_study,_accelerated_approval_for_crizotinib_in_ALK-positive_advanced_NSCLC_was_granted.",20979469,PubMed,,"Kwak_et_al.,_2010,_N._Engl._J._Med.",,5,accepted,1187,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-04-06_16:50:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1187,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"In_an_evaluation_of_a_patient_with_crizotinib-sensitive_lung_adenocarcinoma,_an_EML4-ALK-E13;A20_rearrangement_was_identified_using_CGP.__The_patient_attained_a_reduction_in_the_target_lesions_by_14.2%,_however,_the_patient_relapsed_17_months_later.",25922291,PubMed,,"Le_et_al.,_2015,_Clin_Lung_Cancer",,3,accepted,1691,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-11-05_21:40:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1691,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Breast_Cancer,1612,,Crizotinib,,Predictive,Supports,E,Sensitivity/Response,"84_breast_cancer_samples_acquired_from_commercial_sources_were_assayed_on_Affymetrix_human_exon_1.0_arrays._A_computational_method_was_used_to_find_potential_gene_fusions_which_assessed_differential_exon_expression_between_the_3'_and_5'_ends_of_each_gene._Two_potential_fusions_were_found_and_assessed_using_RNA_ligase_mediated_rapid_amplifiation_of_cDNA_ends_and_RT-PCR._The_fusions_were_EML4-ALK_variants_1_and_2._Genomic_PCR_identified_fusion_breakpoints,_and_these_differed_from_breakpoints_for_these_EML4-ALK_variants_reported_in_NSCLC.",19737969,PubMed,,"Lin_et_al.,_2009,_Mol._Cancer_Res.",,1,accepted,1335,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2016-07-02_15:33:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1335,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,Brigatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_II_randomized_trial_we_evaluated_two_regimens_of_Brigatinib_in_Crizotinib-refractory_ALK-pos._NSCLC._They_were_randomly_assigned_(1:1)_to_oral_Brigatinib_90_mg_once_daily_(arm_A)_or_180_mg_once_daily_with_a_7-day_lead-in_at_90_mg._Of_222_patients_enrolled_(arm_A:_n_=_112,_arm_B:_n_=_110),_154_(69%)_had_baseline_brain_metastases_and_164_of_222_(74%)_had_received_prior_chemotherapy._investigator-assessed_confirmed_ORR_was_45_(arm_A)_and_54%_(B)._Investigator-assessed_median_PFS_was_9.2_months_(A)_and_12.9_months_(B)._Independent_review_committee-assessed_intracranial_ORR_in_patients_with_measurable_brain_metastases_at_baseline_was_42%_(11/26,_A)_and_67%_(12/18,_B)._Brigatinib_yielded_substantial_whole-body_and_intracranial_responses_as_well_as_robust_PFS;_180_mg_(with_lead-in)_showed_consistently_better_efficacy_than_90_mg,_with_acceptable_safety.",28475456,PubMed,,"Kim_et_al.,_2017,_J._Clin._Oncol.",,4,accepted,4835,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2018-07-10_18:58:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/4835,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Brigatinib,,,,,,,
ALK,238,ALK_FUSIONS,Non-small_Cell_Lung_Carcinoma,3908,,"Alectinib,Crizotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_a_randomized,_open-label_phase_3_trial_303_patients_with_ALK-positive,_previously_untreated_NSCLC_(including_asympt._CNS_disease)_were_randomized_to_reiceive_either_Alectinib_or_Crizotinib._During_a_median_follow-up_of_17.6_months_(crizotinib)_and_18.6_months_(alectinib),_an_event_of_disease_progression/death_occurred_in_41%_(62/152__pt)_in_the_alectinib_group_and_68%_(102/151_patients)_in_the_crizotinib_group._12-month_event-free_survival_rate_68.4%_with_alectinib_vs._48.7%_with_crizotinib._A_total_of_18_patients_(12%)_in_the_alectinib_group_had_an_event_of_CNS_progression,_compared_to_68_patients_(45%)_in_the_crizotinib_group._Response_rates_were_82.9%_(Alectinib)_and_75.5%_(crizotinib).",28586279,PubMed,,"Peters_et_al.,_2017,_N._Engl._J._Med.",,5,accepted,4858,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2017-06-13_01:53:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4858,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Alectinib,Crizotinib,,,,,,
ALK,238,ALK_FUSIONS,Epithelioid_Inflammatory_Myofibroblastic_Sarcoma,80372,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"This_is_a_case_report_of_a__22-year-old_Japanese_man_with_a_pelvic_mesenchymal_neoplasm._Tumor_analysis_include_IHC_and_RT-PCR_led_to_diagnosis_of_epithelioid_inflammatory_myofibroblastic_sarcoma_with_RANBP2-ALK_fusion._Despite_two_surgical_excision_procedures,_local_recurrence_rapidly_occurred,_and_the_tumor_developed_resistance_to_conventional_chemotherapy_with_doxorubicin._Subsequent_administration_of_crizotinib_resulted_in_relief_of_severe_pain_and_durable_tumor_shrinkage_at_least_10_months.",25028698,PubMed,,"Kimbara_et_al.,_2014,_Jpn._J._Clin._Oncol.",,2,accepted,6043,1,2,29415640,29446394,,,ENST00000389048.3,,,,,75,GRCh37,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",Somatic_Mutation,2018-03-19_18:45:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/6043,https://civic.genome.wustl.edu/links/variants/499,https://civic.genome.wustl.edu/links/genes/1,"Following_the_initial_discovery_and_characterization_of_NPM-ALK_fusion_mutation_in_anaplastic_large_cell_lymphoma_(ALCL),_EML4-ALK_fusions_were_found_to_be_driver_mutations_in_a_subset_of_lung_adenocarcinomas._ALK_fusions_bring_the_C-terminal_ALK_kinase_domain_together_with_the_N_terminal_region_of_the_fusion_partner,_and_have_since_been_found_in_a_range_of_cancers_including_inflammatory_myofibroblastic_tumor,_renal_cell_carcinoma,_diffuse_large_B_cell_lymphoma_and_colorectal_cancer.___In_a_Phase_I_trial_for_crizotinib,_a_92%_response_rate_was_seen_in_the_subset_of_patients_with_a_specific_EML4-ALK_variant,_which_was_higher_than_the_57%_rate_in_the_overall_ALK-rearranged_population,_but_the_subpopulation_numbers_were_insufficient_to_correlate_variant_type_with_patient_response.___Due_to_restricted_wild-type_ALK_expression,_and_also_mild_phenotypes_seen_in_ALK_knockout_mice,_ALK_fusions_are_desirable_targets.__ALK_inhibitor_TAE684_was_used_in_initial_characterizations_of_ALK_fusion_cancer_drivers,_and_crizotinib_–_a_small_molecule_ATP-competitor_RTK_inhibitor_which_is_highly_selective_for_ALK_and_MET_-_has_been_approved_as_first_line_therapy_in_ALK-rearranged_NSCLC._____ALK-rearrangement_defines_an_NSCLC_subtype_that_makes_up_3-5%_of_NSCLC_cases,_and_is_characterized_by_higher_proportions_of_younger_patients_and_never_smokers._EML4-ALK_variant_1_is_the_most_common_ALK_fusion_in_NSCLC_and_was_the_first_to_be_discovered_and_demonstrate_cancer_driver_properties_in_vitro_and_in_mouse_models._A_Phase_I_study_of_crizotinib_in_ALK-rearranged_NSCLC_demonstrated_an_increase_in_overall_survival_when_compared_to_standard_chemotherapy._These_and_other_initial_results_prompted_accelerated_approval_for_crizotinib_in_NSCLC.__Continued_clinical_work_demonstrated_benefit_with_crizotinib_over_chemotherapy_in_multi-armed_studies,_and_as_first_line_therapy._Crizotinib_was_also_found_to_remain_beneficial_to_NSCLC_patients_who_had_progressed_on_crizotinib._Additionally,_crizotinib_was_shown_to_increase_intracranial_disease_control_in_brain_metastasis_occurring_from_ALK-rearranged_NSCLC.",ALK_Fusions,transcript_fusion,,470.5,Crizotinib,,,,,,,
ALK,238,EML4-ALK_E20;A20,Cancer,162,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"This_case_study_presented_a_53-year-old_never-smoker_with_a_poorly_differentiated_malignant_neoplasm._Morphology_and_immunohistochemistry_were_unable_to_establish_the_primary_tumor_site._Right_upper_extremity_(RUE),_scalp,_and_multiple_lung_lesions_were_apparent._A_lung_lesion_sample_with_sufficient_material_for_molecular_profiling_was_not_attainable_but_sufficient_material_was_present_from_the_RUE_for_hybrid_capture_genomic_profiling__(FoundationOne_kit_was_used)._EML4-ALK_variant_2_was_found,_and_the_patient_was_started_on_crizotinib._Rapid_symptom_improvement_was_seen._After_1_month,_a_CT_scan_showed_significant_size_reduction_in_lung_tumors,_and_after_5_months_the_patient_was_asymptomatic_with_an_entirely_negative_examination.",25408655,PubMed,,"Chung_et_al.,_2014,_Case_Rep_Oncol",,3,accepted,1245,1,2,42396490,42552694,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",Somatic_Mutation,2016-04-24_17:19:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1245,https://civic.genome.wustl.edu/links/variants/500,https://civic.genome.wustl.edu/links/genes/1,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,16.5,Crizotinib,,,,,,,
ALK,238,EML4-ALK_E20;A20,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,"EML4-ALK_variants_v1_(E13;A20),_v2_(E20;A20),_v3a_(E6;A20)_and_v3b_(E6ins33;A20)_were_expressed_in_Ba/F3_cells_using_retrovirus.__While_all_constructs_rendered_Ba/F3_cells_IL3-independant,_marked_differences_in_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_were_observed,_where_v2_was_most_sensitized_to_growth_inhibition_and_v3a_the_least,_with_v1_and_v3b_intermediate.__While_phospho-ALK_western_blots_indicated_that_the_ALK_inhibitors_acted_similarly_on_both_v2_and_v3a_EML4-ALK_variants,_blots_of_cyclohexamide-treated_cells_showed_that_v2_had_a_shorter_half-life_than_3a_in_the_transduced_cells,_potentially_explaining_increased_v2_sensitivity.__Assays_with_a_panel_of_mutated_EML4-ALK_variants_of_varied_length_suggested_that_longer_EML4-ALK_variants_are_less_stable_in_cells,_although_this_tendency_was_not_observed_across_other_types_of_ALK_fusion.",22912387,PubMed,,"Heuckmann_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,1196,1,2,42396490,42552694,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",Somatic_Mutation,2016-05-23_15:21:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1196,https://civic.genome.wustl.edu/links/variants/500,https://civic.genome.wustl.edu/links/genes/1,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,16.5,Crizotinib,,,,,,,
ALK,238,EML4-ALK_E20;A20,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"In_the_PROFILE_1001_study,_from_31_NSCLC_tumors_positive_for_ALK_fusions_with_sufficient_material_for_RT-PCR_aided_exon_breakpoint_identification,_1_case_of_EML4-ALK_variant_2_(EML4_exon_20_fused_to_ALK_exon_20)_was_found._This_patient_had_adenocarcinoma_and_a_9_pack_year_smoking_history._Crizotinib_treatment_duration_was_over_16_weeks._The_patient_had_multiple_lines_of_prior_treatment_and_showed_a_partial_response_to_first-time_crizotinib_treatment._Overall,_in_the_82_ALK_positive_patients_treated_in_the_study,_46_had_partial_responses_(including_this_patient)_and_1_had_a_complete_response_for_an_overall_response_rate_of_57%.",20979469,PubMed,,"Kwak_et_al.,_2010,_N._Engl._J._Med.",,2,accepted,1189,1,2,42396490,42552694,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-27_16:27:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1189,https://civic.genome.wustl.edu/links/variants/500,https://civic.genome.wustl.edu/links/genes/1,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,16.5,Crizotinib,,,,,,,
ALK,238,EML4-ALK_E20;A20,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,17-DMAG",Combination,Predictive,Supports,D,Sensitivity/Response,"EML4-ALK_fusions_occur_in_2-7%_of_lung_adenocarcinomas._Transduction_of_Ba/F3_cells_with_EML4-ALK_variant_2_(EML4_exon_20_fused_to_ALK_exon_20)_caused_the_cells_to_grow_independently_of_IL3_addition.__EML4-ALK_may_be_a_client_protein_of_Hsp90._Addition_of_Hsp90_inhibitor_17-DMAG_to_the_EML4-ALK_variant_2_cells_induced_cell_death_which_was_rescued_at_lower_17-DMAG_concentrations_by_IL3_addition._This_result_suggests_that_17-DMAG_specifically__targeted_the_EML4-ALK_driver_in_these_cells._Finally,_17-DMAG_and_crizotinib_showed_a_synergistic_effect_in_killing_EML4-ALK_variant_2_cells.",22912387,PubMed,,"Heuckmann_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,1204,1,2,42396490,42552694,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",Somatic_Mutation,2016-05-23_15:16:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1204,https://civic.genome.wustl.edu/links/variants/500,https://civic.genome.wustl.edu/links/genes/1,"EML4-ALK_variant_2_consists_of_a_fusion_of_the_ALK_kinase_domain_(exons_20-29)_with_EML4_exons_1-20._Variant_2_has_cytoplasmic_distribution_and_makes_up_~10%_of_EML4-ALK_fusions_found_in_NSCLC,._Although_the_specific_variant_is_not_consistently_reported,_single_cases_demonstrating_response_to_crizotinib_treatment_in_NSCLC_and_a_differentiated_malignant_neoplasm_of_unknown_origin_have_been_reported._In_vitro,_this_variant_has_shown_greater_sensitivity_to_ALK_inhibition_with_TAE684_and_crizotinib_than_the_EML4-ALK_variants_1_(E13;A20),_3a_(E6;A20)_and_3b_(E6ins33;A20)._The_variant_was_reported_to_be_less_stable_in_cells_than_other_variants,_and_may_be_a_client_protein_of_Hsp90._Along_these_lines_the_variant_has_shown_preclinical_sensitivity_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,16.5,Crizotinib,17-DMAG,,,,,,
ALK,238,EML4-ALK_E2;A20,Renal_Cell_Carcinoma,4450,,,,Predictive,Supports,E,Sensitivity/Response,"Adenocarcinoma_cells_were_detected_via_urinary_cytology_in_a_53_year_old_woman._Cancer_morphology_suggested_papillary_renal_cell_carcinoma_(RCC),_type_2A.__EML4-ALK_variant_5_was_discovered_in_tumor_tissue_using_PCR_with_EML4_and_ALK_specific_primers._The_authors_conclude_that_their_findings_confirm_the_potential_for_ALK_targeting_therapy_in_select_cases_of_RCC.",22252991,PubMed,,"Sugawara_et_al.,_2012,_Cancer",,3,accepted,1266,1,2,42396490,42472827,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-06-28_00:26:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1266,https://civic.genome.wustl.edu/links/variants/501,https://civic.genome.wustl.edu/links/genes/1,,ALK_Fusions,transcript_fusion,,1.75,,,,,,,,
ALK,238,EML4-ALK_E2;A20,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,E,Sensitivity/Response,"Multiplex_RT-PCR_to_detect_in-frame_fusions_of_EML4_to_ALK_was_performed_on_total_RNA_from_253_lung_adenocarcinomas,_and_9_samples_were_found_to_contain_such_fusions,_one_of_which_was_a_novel_fusion_containing_EML4_exon_2_and_exon_20_of_ALK._This_was_called_variant_5._Two_versions_of_this_variant_were_seen:_5a_consisted_of_EML4_exon_2_fused_to_ALK_exon_20_while_5b_contained_a_117bp_intronic_ALK_region_between_the_two_exons._Genomic_PCR_showed_that_EML4-ALK_variant_5_tumor_cells_contained_a_single_EML4-ALK_fusion,_suggesting_5a_and_5b_arise_from_alternate_splicing.__5a_and_5b_showed_in-vitro_kinase_activity_and_transformed_3T3_cells_in_cell_culture._5a_and_5b_transformed_3T3_cells_formed_tumors_when_injected_in_8/8_nude_mice,_but_3T3_transformed_with_ALK_alone_did_not.__These_results_suggest_that_EML4-ALK_variant_5_is_a_driver_mutation_in_lung_adenocarcinoma_targetable_by_ALK_inhibitors_like_crizotinib.",18927303,PubMed,,"Takeuchi_et_al.,_2008,_Clin._Cancer_Res.",,4,accepted,1190,1,2,42396490,42472827,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-06-14_22:22:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1190,https://civic.genome.wustl.edu/links/variants/501,https://civic.genome.wustl.edu/links/genes/1,,ALK_Fusions,transcript_fusion,,1.75,Crizotinib,,,,,,,
KDR,3791,R961W,Colorectal_Adenocarcinoma,50861,,Regorafenib,,Predictive,Supports,C,Sensitivity/Response,"Case_Report_of_a_84-year-old_woman_with_stage_IVb_CRC_after_progression_under_5-fluorouracil_and_bevacizumab._NGS_revealed_a_frameshift_mutation_in_APC,_a_missense_mutation_in_KRAS._Variants_of_uncertain_significance_were:_a_missense_variant_in_ERBB2_and_a_missense_variant_in_KDR_at_amino_acid_961_converting_the_wild_type_residue,_Arginine,_to_Tryptophan_(frequency_28.25%)._Because_of_the_high_frequency_of_the_KDR_(VEGFR2)_mutation,_the_patient_was_considered_a_suitable_candidate_for_a_VEGFR_inhibitor_and_received_regorafenib_monotherapy,_which_is_approved_for_this_situation,_at_80mg_daily_which_was_later_reduced_to_40mg_daily_and_had_CEA_normalization_as_well_as_partial_metabolic_and_radiologic_response._The_patient_remained_almost_asymptomatic_and_without_disease_progression_after_39_weeks.",27004155,PubMed,,"Loaiza-Bonilla_et_al.,_2016,_Cureus",,1,accepted,1191,3153,4,55961059,55961059,G,A,ENST00000263923.4,,,,,75,GRCh37,,Somatic_Mutation,2016-04-08_02:05:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1191,https://civic.genome.wustl.edu/links/variants/502,https://civic.genome.wustl.edu/links/genes/3153,,,missense_variant,"NM_002253.2:c.2881C>T,NP_002244.1:p.Arg961Trp,ENST00000263923.4:c.2881C>T,NC_000004.11:g.55961059G>A",2.5,Regorafenib,,,,,chr4_g.55961059G~A,KDR_c.2881C~T,KDR_R961W
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,TAE684,,Predictive,Does_Not_Support,D,Sensitivity/Response,"Exon-array_and_RT-PCR_was_used_to_screen_a_panel_of_83_NSCLC_cell_lines_for_EML4-ALK_variants._The_cell_lines_NCI-H3122_(containing_EML4-ALK_variant_1)_and_NCI-H2228_(containing_the_EML4_exon_6_and_ALK_exon_20_fusion-variant_3a/3b)_were_identified._TAE684_(0.1uM)_appreciably_inhibited_growth_as_well_as_Akt_and_Erk1/2_phosphorylation_in_variant_1_containing_H3122_cells._However,_incomplete_inhibition_in_3a/3b_containing_H2228_cells_was_observed._H2228_growth_inhibition_by_TAE684_was_more_similar_to_NSCLC_cell_lines_harboring_KRAS_and_EGFR_mutations.",18594010,PubMed,,"Koivunen_et_al.,_2008,_Clin._Cancer_Res.",,2,accepted,1195,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-23_22:57:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1195,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,TAE684,,,,,,,
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"Ceritinib_was_28x_more_potent_(GI50_3.8nM)_than_crizotinib_(GI50_107nM)_at_inhibiting_growth_of__H2228,_an_NSCLC_cell_line_which_harbors_the_EML4-ALK_variant_3a/3b._SCID_mice_xenografted_with_H2228_were_treated_for_14_days_with_crizotinib_(100_mg/kg)_or_ceritinib_(25_or_50_mg/kg)._All_treatments_caused_tumor_regression,_but_tumors_recurred_within_11_days_after_crizotinib_treatment_withdrawal._4/8_mice_treated_with_25_mg/kg_ceritinib_showed_regrowth_after_1_month_treatment_withdrawal._The_remaining_4/8_mice_treated_at_25_mg/kg_ceritinib,_and_all_mice_treated_at_50_mg/kg_ceritinib_maintained_complete_remission_for_four_months._While_100_mg/kg_crizotinib_in_mice_approximates_levels_3-5_times_the_maximal_tolerated_dose_in_humans,_the_authors_state_25_to_50_mg/kg_ceritinib_in_mice_is_predicted_to_approximate_tolerable_doses_in_humans.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,3,accepted,1340,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-28_22:21:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1340,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,Ceritinib,,,,,,,
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_set_of_31_patients_with_NSCLC,_RT-PCR_was_performed_to_test_for_known_EML4-ALK_variants.__Five_patients_tested_positive_for_the_3a/3b_EML4-ALK_variant.__Of_these,_4_had_partial_response_(PR),_and_one_had_disease_progression_(DP),_and_this_was_the_only_DP_in_the_group_of_31.__In_contrast,_of_the_13_testing_positive_for_EML4-ALK_variant_1,_12_showed_PR,_and_1_showed_stable_disease.__These_results_potentially_mirror_findings_in_the_H2228_3a/3b_containing_NSCLC_cell_line_where_some_literature_indicates_it_does_respond_as_strongly_to_ALK_inhibition_as_other_EML4-ALK_NSCLC_cell_lines.",20979469,PubMed,,"Kwak_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,1193,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-28_00:25:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1193,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,Crizotinib,,,,,,,
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Does_Not_Support,D,Sensitivity/Response,"Ba/F3_cells_transduced_with_EML4-ALK_variants_v1_(E13;A20),_v2_(E20;A20),_v3a_(E6;A20)_and_v3b_(E6ins33;A20)_showed_differential_sensitivity_to_both_crizotinib_and_TAE684,_with_variant_3a_(E6;A20)_being_the_least_sensitive._The_authors_suggest_that_the_type/structure_of_ALK_fusion_may_have_some_impact_on_patient_outcome_in_targeted_therapy.",22912387,PubMed,,"Heuckmann_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,1197,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-23_23:12:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1197,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,Crizotinib,,,,,,,
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,"2,4-pyrimidinediamine",,Predictive,Supports,D,Sensitivity/Response,"In_a_cohort_of_75_NSCLC_patients_that_had_tested_positive_for_3_EML4-ALK_rearrangements,_two_individuals_were_identified_via_RT-PCR_with_a_novel_EML4-ALK_translocation_involving_the_first_6_exons_of_EML4_fused_to_the_kinase_domain_of_ALK._Genomic_PCR_resolved_a_single_breakpoint,_but_2_variants_of_the_fusion_were_observed_in_cells._Variant_3a_consisted_of_fusion_at_EML4_exon_6_and_ALK_exon_20,_while_variant_3b_fused_a_33_bp_intronic_EML4_region_between_EML4_exon_6_and_ALK_exon_20.__3a_and_3b_showed_strong_in-vitro_kinase_activity,_transformed_mouse_3T3_cells,_and_3b-transformed_3T3_cells_formed_tumors_in_8/8_nude_mice.__The_ALK_inhibitor_2,4-pyrimidinediamine_inhibited_growth_of_the_3a/b_containing_NCI-H2228_NSCLC_cell_line.__The_results_indicate_that_3a/b_is_a_targetable_driver-mutation_as_other_EML4-ALK_variants.",18593892,PubMed,,"Choi_et_al.,_2008,_Cancer_Res.",,4,accepted,1192,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-28_00:24:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1192,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,2,4-pyrimidinediamine,,,,,,
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,17-DMAG,,Predictive,Does_Not_Support,D,Sensitivity/Response,"Transduction_of_Ba/F3_cells_with_EML4-ALK_variant_3a_caused_the_cells_to_grow_independently_of_IL3_addition.__While_incubation_of_Ba/F3_cells_transduced_with_EML4-ALK_variants_1_and_2_with_Hsp90_inhibitor_17-DMAG_caused_cell_death_that_was_reversible_with_IL3_addition,_Ba/F3_cells_with_variant_3a_were_not_sensitized_to_17-DMAG_induced_death,_suggesting_that_17-DMAG_was_effecting_the_EML4-ALK_driver_of_IL3-independant_proliferation._This_in_turn_suggests_that_variant_3a_may_not_rely_on_Hsp90_for_stability_in_cancer_cells_to_the_extent_of_other_variants.",22912387,PubMed,,"Heuckmann_et_al.,_2012,_Clin._Cancer_Res.",,2,accepted,1205,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-07-02_15:41:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1205,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,17-DMAG,,,,,,,
ALK,238,EML4-ALK_E6;A20,Non-small_Cell_Lung_Carcinoma,3908,,TAE684,,Predictive,Supports,D,Sensitivity/Response,"In_a_panel_of_602_cancer_cell_lines,_3/134_NSCLC_cell_lines_showed_<0.5%_cell_viability_following_treatment_with_the_ALK_inhibitor_TAE684._Of_these,_NCI-H2228_harbored_EML4-ALK_variant_3a/b_(EML4_exon_6_and_ALK_exon_20)._TAE684_inhibited_Akt_and_Erk1/2_phosphorylation_in_H2228_cells_and_appeared_to_induce_a_cytostatic_response.",18451166,PubMed,,"McDermott_et_al.,_2008,_Cancer_Res.",,2,accepted,1194,1,2,42396490,42491871,,,ENST00000318522.5,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",Somatic_Mutation,2016-06-23_22:54:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1194,https://civic.genome.wustl.edu/links/variants/503,https://civic.genome.wustl.edu/links/genes/1,"The_EML4-ALK_variant_3a_consists_of_the_ALK_kinase_domain_fused_to_EML4_exons_1-6,_while_the_3b_variant_has_an_additional_33bp_of_intronic_EML4_sequence_between_EML4_and_ALK_regions._The_two_variants_were_found_to_originate_from_a_single_genomic_rearrangement,_and_3a/3b_is_found_in_~_30%_of_EML4-ALK_positive_NSCLC._Variant_3a_has_cytoplasmic_and_nuclear_distribution._In_vitro,_these_variants_have_shown_sensitivity_to_ALK_inhibitors_TAE684_and_crizotinib_but_less_sensitive_than_other_EML4-ALK_variants._The_H2228_cell_line_contains_3a_and_3b_variants_and_is_described_as_having_cyctostatic_response_to_ALK_inhibition_as_opposed_to_apoptotic._In_a_study_of_31_NSCLC_patients_with_EML4-ALK_rearrangements,_4/5_patients_with_the_3a_variant_showed_a_partial_response_while_1_showed_progressive_disease_(the_only_PD_observed)._In_cells_the_3a_variant_was_reported_to_be_more_stable_than_other_variants,_less_sensitive_to_crizotinib_and_not_to_respond_to_Hsp90_inhibition.",ALK_Fusions,transcript_fusion,,25,TAE684,,,,,,,
TP53,7157,P47S,Cancer,162,,Cisplatin,,Predictive,Supports,E,Resistance,"The_P47S_(rs1800371)_variant_of_TP53_is_observed_in_1.5%_in_African_Americans_and_between_6%_and_8%_in_certain_African_populations_but_has_not_been_detected_in_Caucasian_Americans._This_paper_reports_functional_studies_of_this_variant._Mouse_models_with_this_variant_show_an_increase_in_spontaneous_tumor_formation._16_out_of_20_(80%)_of_S47_homozygous_mice_developed_cancer_between_12_and_18_months_of_age._Cancers_predominantly_included_hepatocellular_carcinoma,_B-cell_lymphoma,_and_histiocytic_sarcoma,_as_well_as_other_tumor_types._In_S47/wild-type_heterozygote_mice_an_increased_cancer_incidence,_with_a_predisposition_for_hepatocellular_carcinoma,_was_also_found._Mouse_embryonic_fibroblasts_and_human_lymphoblastoid_cell_lines_with_S47_mutations_were_significantly_less_sensitive_to_cisplatinum_treatment_compared_to_TP53_wild-type_cells_(apoptosis_and_viability).",27034505,PubMed,,"Jennis_et_al.,_2016,_Genes_Dev.",,2,accepted,1209,45,17,7579548,7579548,G,A,ENST00000269305.4,,,,,75,GRCh37,,Germline_Polymorphism,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1209,https://civic.genome.wustl.edu/links/variants/504,https://civic.genome.wustl.edu/links/genes/45,,,missense_variant,"NM_000546.5:c.139C>T,NP_000537.3:p.Pro47Ser,NC_000017.10:g.7579548G>A",0.5,Cisplatin,,,,,chr17_g.7579548G~A,TP53_c.139C~T,TP53_P47S
GNAQ,2776,MUTATION,Uveal_Melanoma,6039,,"PD0325901,AEB071",Combination,Predictive,Supports,D,Sensitivity/Response,Preclinical_study_in_uveal_melanoma._Increased_PKC_activity_was_found_in_uveal_melanoma_cell_lines_with_GNA11_or_GNAQ_mutations_(n=6)_compared_to_GNA_wt_cell_lines_(n=4)_and_could_be_induced_by_introducing_these_mutations_into_wt_cell_lines._Cell_lines_carrying_GNA_mutations_were_more_sensitive_to_PKC_inhibition_with_AEB071_and_AHT956_in_vitro_and_in_vivo._Combined_inhibition_of_MEK_and_PKC_with_AEB071_and_PD0325901led_to_sustained_MAPK-signalling_blockade_and_induced_apoptosis.,24141786,PubMed,,"Chen_et_al.,_2014,_Oncogene",,4,accepted,1953,2317,9,80331003,80646374,,,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_14:49:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1953,https://civic.genome.wustl.edu/links/variants/505,https://civic.genome.wustl.edu/links/genes/2317,,,,,26,PD0325901,AEB071,,,,,,
GNAQ,2776,MUTATION,Uveal_Melanoma,6039,,Trametinib,,Predictive,Supports,B,Sensitivity/Response,"Phase_1_study_of_trametinib_in_97_patients_with_melanoma_(16_with_uveal_melanoma)._Analysis_in_patients_with_uveal_melanoma_identified_GNAQ_and_GNA11_mutations_in_six_patients,_in_which_three_SD_and_three_PD_were_the_best_responses._One_patient_with_a_GNA11_mutation_identified_by_Illumina_genotyping_stayed_on_study_treatment_for_>40_weeks.",22805292,PubMed,,"Falchook_et_al.,_2012,_Lancet_Oncol.",,2,accepted,1229,2317,9,80331003,80646374,,,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-15_03:05:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1229,https://civic.genome.wustl.edu/links/variants/505,https://civic.genome.wustl.edu/links/genes/2317,,,,,26,Trametinib,,,,,,,
GNAQ,2776,MUTATION,Uveal_Melanoma,6039,,Cabozantinib,,Predictive,Supports,B,Sensitivity/Response,"Patients_with_metastatic_melanoma_(n=77;_48_cutaneous,_23_uveal,_6_mucosal)_were_enrolled_in_a_phase_II_randomised_discontinuation_trial_assessing_cabozantinib._Patients_received_100_mg_cabozantinib_daily_for_12_weeks._Patients_with_stable_disease_(SD;_RECIST;_n=26)_were_randomly_assigned_to_cabozantinib_(n=13)_or_placebo_(n=13)._In_the_uveal_melanoma_cohort,_61%_of_patients_(14/23,_61%)_had_SD_at_week_12._9_patients_had_either_a_GNAQ_(n=5)_or_GNA11_(n=4)_mutation;_only_10_patients_were_analyzed._Patients_with_GNAQ_mutations_remained_on_the_study_treatment_from_1.4-10.3_months._The_median_PFS_for_the_23_patients_with_uveal_melanoma_was_4.8_months_(41%_PFS_at_6_months)_and_median_OS_was_12.6_months._In_the_entire_cohort,_median_overall_PFS_was_3.8_months_(33%_PFS_at_6_months)._After_randomisation,_median_PFS_for_cabozantinib_patients_was_4.1_months_and_2.8_months_for_placebo_(HR_0.59,_p=0.284).",28103611,PubMed,,"Daud_et_al.,_2017,_Br._J._Cancer",,2,accepted,5068,2317,9,80331003,80646374,,,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_15:24:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/5068,https://civic.genome.wustl.edu/links/variants/505,https://civic.genome.wustl.edu/links/genes/2317,,,,,26,Cabozantinib,,,,,,,
GNAQ,2776,MUTATION,Uveal_Melanoma,6039,,JQ1,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_uveal_melanoma_cell_lines._Cell_lines_(n=4)_with_GNAQ_mutation_(92.1,_Omm1.3,_Mel270,_Mel202)_were_more_sensitive_to_BRD4_inhibition_with_JQ1_than_GNAQ/GNA11_wild_type_(n=3)_cell_line._JQ1_also_inhibited_growth_of_a_GNAQ_mutant_cell_line_(92.1)_in_a_mouse_xenograft_model_compared_to_vehicle_(N=5_mice/group).",26397223,PubMed,,"Ambrosini_et_al.,_2015,_Oncotarget",,2,accepted,1210,2317,9,80331003,80646374,,,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:23:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1210,https://civic.genome.wustl.edu/links/variants/505,https://civic.genome.wustl.edu/links/genes/2317,,,,,26,JQ1,,,,,,,
GNA11,2767,MUTATION,Uveal_Melanoma,6039,,JQ1,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_uveal_melanoma_cell_lines._Cell_lines_(n=5)_with_GNAQ_(92.1,_Omm1.3,_Mel270,_Mel202)_or_GNA11_(Omm1)_mutation_were_more_sensitive_to_BRD4_inhibition_with_JQ1_than_GNAQ/11_wild_type_(n=3)_cell_line.",26397223,PubMed,,"Ambrosini_et_al.,_2015,_Oncotarget",,1,accepted,1211,2308,19,3094408,3124002,,,ENST00000078429.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:19:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/1211,https://civic.genome.wustl.edu/links/variants/506,https://civic.genome.wustl.edu/links/genes/2308,,,,,24,JQ1,,,,,,,
GNA11,2767,MUTATION,Uveal_Melanoma,6039,,Cabozantinib,,Predictive,Supports,B,Sensitivity/Response,"A_randomized_phase_II_trial_assessing_the_efficacy_of_Cabozantinib_in_metastatic_melanoma._77_patients_(62%_cutaneous,_30%_uveal,_8%_mucosal)._Patients_received_cabozantinib_100 mg/d_during_a_12-week_lead-in._Patients_with_stable_disease_(SD;_RECIST)_at_week_12_were_randomised_to_cabozantinib_or_placebo._During_lead-in_phase_55%_of_evaluable_patients_showed_reduction_in_target_lesion_size_(59%_uveal_melanoma)._Uveal_melanoma_cohort_included_23_patients,_9_with_GNAQ_(n=5)_and_GNA11_(n=4)_mutations._Responses_were_reported_in_mutational_patients._In_the_uveal_melanoma_cohort,_61%_of_patients_(14/23)_had_SD_at_week_12,_and_no_patient_had_a_PR,_resulting_in_an_overall_disease_control_rate_of_61%._The_median_PFS_for_the_23_patients_with_uveal_melanoma_was_4.8_months.",28103611,PubMed,,"Daud_et_al.,_2017,_Br._J._Cancer",,3,accepted,3049,2308,19,3094408,3124002,,,ENST00000078429.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_16:11:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/3049,https://civic.genome.wustl.edu/links/variants/506,https://civic.genome.wustl.edu/links/genes/2308,,,,,24,Cabozantinib,,,,,,,
GNA11,2767,MUTATION,Uveal_Melanoma,6039,,"PD0325901,AEB071",Combination,Predictive,Supports,D,Sensitivity/Response,Preclinical_study_in_uveal_melanoma._Increased_PKC_activity_was_found_in_uveal_melanoma_cell_lines_with_GNA11_or_GNAQ_mutations_(n=6)_compared_to_GNA_wt_cell_lines_(n=4)_and_could_be_induced_by_introducing_these_mutations_into_wt_cell_lines._Cell_lines_carrying_GNA_mutations_were_more_sensitive_to_PKC_inhibition_with_AEB071_and_AHT956_in_vitro_and_in_vivo._Combined_inhibition_of_MEK_and_PKC_with_AEB071_and_PD0325901led_to_sustained_MAPK-signalling_blockade_and_induced_apoptosis.,24141786,PubMed,,"Chen_et_al.,_2014,_Oncogene",,3,accepted,1952,2308,19,3094408,3124002,,,ENST00000078429.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_16:08:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1952,https://civic.genome.wustl.edu/links/variants/506,https://civic.genome.wustl.edu/links/genes/2308,,,,,24,PD0325901,AEB071,,,,,,
GNA11,2767,MUTATION,Uveal_Melanoma,6039,,Trametinib,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_of_trametinib_in_97_patients_with_melanoma_(16_with_uveal_melanoma)._Analysis_in_patients_with_uveal_melanoma_identified_GNAQ_and_GNA11_mutations_in_six_patients,_in_which_three_SD_and_three_PD_were_the_best_responses._One_patient_with_a_GNA11_mutation_identified_by_Illumina_genotyping_stayed_on_study_treatment_for_>40_weeks.",22805292,PubMed,,"Falchook_et_al.,_2012,_Lancet_Oncol.",,2,accepted,1228,2308,19,3094408,3124002,,,ENST00000078429.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:17:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1228,https://civic.genome.wustl.edu/links/variants/506,https://civic.genome.wustl.edu/links/genes/2308,,,,,24,Trametinib,,,,,,,
GNAQ,2776,Q209,Uveal_Melanoma,6039,,Selumetinib_(AZD6244),,Predictive,Does_Not_Support,B,Sensitivity/Response,"101_patients_with_metastatic_uveal_melanoma_were_randomized_1:1_to_receive_selumetinib_or_chemotherapy._Median_PFS_among_patients_randomized_to_chemotherapy_was_7_weeks_(95%_CI,_4.3-8.4_weeks;_median_treatment_duration,_8_weeks;_interquartile_range_[IQR],_4.3-16_weeks)_vs._15.9_weeks_with_selumetinib_(95%_CI,_8.4-21.1_weeks;_median_treatment_duration,_16.1_weeks;_IQR,_8.1-25.3_weeks)_(hazard_ratio,_0.46;_95%_CI,_0.30-0.71;_P < 0.001)._Most_patients_(80/96_evaluable_harbored_a_mutation_in_exon_5_of_GNAQ_or_GNA11)_but_PFS_benefit_from_Selumetinib_compared_to_chemotherapy_was_greater_in_the_GNAQ_and_GNA11_wild-type_population_(25.9_weeks_[range,_3.7-40.4_weeks]_vs_15.4_weeks_[range,_8.1-16.9_weeks])._However,_PFS_was_still_better_with_Selumetinib_than_chemotherapy_in_the_GNA_mutant_population_(hazard_ratio_0.55,_95%_CI,_0.34-0.87;_P = 0.01)._The_difference_was_explained_by_potential_GNAQ_or_GNA11_mutations_outside_of_exon_5_in_the_GNA_wild-type_population._Another_three_mutations_in_exon_4_were_retrospectively_identified_in_the_wild-type_population_and_one_had_a_major_response.",24938562,PubMed,,"Carvajal_et_al.,_2014,_JAMA",,3,accepted,1213,2317,9,80409487,80409489,,,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1213,https://civic.genome.wustl.edu/links/variants/507,https://civic.genome.wustl.edu/links/genes/2317,,,protein_altering_variant,,20,Selumetinib_(AZD6244),,,,,,,
GNAQ,2776,Q209,Uveal_Melanoma,6039,,BAY_86-9766,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_of_MAPK1/2_inhibitor_BAY_86-9766._53_patients_were_evaluated_for_efficacy,_one_patients_achieved_a_PR_and_11_patients_had_stable_disease._One_ocular_melanoma_patient_with_prolonged_stable_disease,_who_later_went_on_to_complete_28_courses,_was_positive_for_GNAQ_Q209L_and_PTEN_R173S_mutations._The_PTEN_mutation_was_identified_only_in_the_postdose_biopsy_and_not_in_the_predose_biopsy.",23434733,PubMed,,"Weekes_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1233,2317,9,80409487,80409489,,,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2016-04-08_02:12:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1233,https://civic.genome.wustl.edu/links/variants/507,https://civic.genome.wustl.edu/links/genes/2317,,,protein_altering_variant,,20,BAY_86-9766,,,,,,,
PMS2,5395,K706FS*19,Glioblastoma_Multiforme,3068,,Nivolumab,,Predictive,Supports,C,Sensitivity/Response,"Two_siblings_(6_and_3.5_years)_from_nonconsanguineous_parents_were_diagnosed_with_glioblastoma_multiforme._Both_tumors_harbored_TP53_mutations_and_lack_of_MGMT_promoter_hypermethylation_as_poor_prognostic_markers._Germline_homozygous_c.2117delA,_p._Lys706SerfsX19_mutation_in_PMS2,_loss_of_PMS2_staining_in_the_tumor_and_normal_tissue_confirmed_a_diagnosis_of_biallelic_mismatch_repair_deficiency_(bMMRD)._Both_tumors_harbored_driver_mutations_in_POLE_and_were_found_to_harbor_24,680_and_21,919_mutations_per_exome._Neoantigen_load_was_assessed_in_37_bMMRD_patients_and_all_malignant_tumors_had_high_numbers_of_predicted_neoantigens_(7-16x_as_high_as_in_melanoma,_lung_or_other_immunoresponsive_cancers)._Treatment_with_nivolumab_was_begun_and_both_patients_had_radiologic_response._After_9_and_5_months_of_therapy,_respectively,_the_patient_and_her_brother_resumed_normal_schooling_and_daily_activities.",27001570,PubMed,,"Bouffet_et_al.,_2016,_J._Clin._Oncol.",,4,accepted,1214,4371,7,6022512,6022512,,,ENST00000265849.7,,,,,75,GRCh37,,Germline_Mutation,2016-06-17_05:18:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1214,https://civic.genome.wustl.edu/links/variants/508,https://civic.genome.wustl.edu/links/genes/4371,,,minus_1_frameshift_variant,"NM_000535.6:c.2117delA,NP_000526.2:p.Lys706Serfs,NC_000007.13:g.6022512del",10,Nivolumab,,,,,chr7_g.6022512del,PMS2_c.2117delA,p.lys706serfs
KIT,3815,EXON_9_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Reduced_Sensitivity,"This_prospective_study_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_examined_the_relationship_between_KIT_genotype_and_treatment_outcome_for_patients_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105_who_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._Of_33_patients_with_KIT_exon-9_mutant_GISTs,_31_harbored_KIT_A502_Y503_internal_tandom_duplication,_one_harbored_K484_G487del_(KHNG).__Of_the_KIT_exon_9_mutant_patients,_14_were_treated_with_400mg_daily_and_19_were_treated_with_800mg_daily._Patients_with_KIT_exon-9_mutant_GISTs_had_a_significantly_higher_response_rate_when_treated_with_800mg_compared_with_400mg_(CR/PR_17%_vs_67%_for_400mg_and_800mg,_respectively;_OR,_9.05;_p_=_.02)._However,_the_authors_report_that_there_was_not_a_significant_difference_in_time_to_progression_or_overall_survival_between_the_two_dose_groups_for_patients_harboring_KIT_exon-9_mutant_GISTs.",18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,2,accepted,2477,29,4,55592023,55592216,,,ENST00000288135.5,,,,,75,GRCh37,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",Somatic_Mutation,2019-02-08_18:37:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/2477,https://civic.genome.wustl.edu/links/variants/509,https://civic.genome.wustl.edu/links/genes/29,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",,exon_variant,,60,Imatinib,,,,,,,
KIT,3815,EXON_9_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Sunitinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_78_patients_with_gastrointestinal_stromal_tumors_treated_with_sunitinib,_patients_with_Kit_exon_9_mutations_or_wildtype_(lacking_KIT_or_PDGFRA_mutations)_showed_increased_progression_free_survival_and_overall_survival_compared_to_patients_with_Kit_exon_11_mutations.",18955458,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,3,accepted,1424,29,4,55592023,55592216,,,ENST00000288135.5,,,,,75,GRCh37,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",Somatic_Mutation,2016-07-26_14:54:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1424,https://civic.genome.wustl.edu/links/variants/509,https://civic.genome.wustl.edu/links/genes/29,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",,exon_variant,,60,Sunitinib,,,,,,,
KIT,3815,EXON_9_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Sunitinib,,Predictive,Supports,B,Sensitivity/Response,"Primary_tumor_genotyping_of_89_patients_with_metastatic_GIST_given_2nd-line_sunitinib_treatment_after_prior_imatinib_therapy_failure,_revealed_an_improved_response_to_sunitinib_in_patients_with_KIT_exon_9_mutations_or_with_wild-type_KIT_compared_those_with_KIT_exon_11_or_PDGFRA_mutations._1-year_progression_free_survival_rates_for_exon_9_mutants_and_wild_type_were_68%_and_57%,_compared_with_34%_and_15%_for_exon_11_and_PDGFRA_mutants.",22439647,PubMed,,"Rutkowski_et_al.,_2012,_BMC_Cancer",,3,accepted,1223,29,4,55592023,55592216,,,ENST00000288135.5,,,,,75,GRCh37,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",Somatic_Mutation,2016-06-17_05:28:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1223,https://civic.genome.wustl.edu/links/variants/509,https://civic.genome.wustl.edu/links/genes/29,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",,exon_variant,,60,Sunitinib,,,,,,,
KIT,3815,EXON_9_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_III_clinical_trial_comparing_different_doses_of_imatinib_in_GIST_patients,_KIT_exon_9_mutations_were_associated_with_significantly_improved_progression_free_survival_(P=0.0013)_and_a_61%_relative_risk_reduction_in_response_to_the_higher_dose_regimen_(N=31;_800mg/daily)_when_compared_to_the_lower_dose_regimen_(N=27;_400_mg/daily;_HR_0.329;_95%_CI_0.218–0.706)._The_same_dose_dependent_responses_were_not_observed_with_KIT_exon_11_mutations_(N=130_vs_118;_P=0.25;_HR_0.821;_95%_CI_0.585–1.151)_or_with_wild-type_KIT_(N=25_vs_27;_P=0.07;_HR_1.823;_95%_CI_0.938–3.543).",16624552,PubMed,,"Debiec-Rychter_et_al.,_2006,_Eur._J._Cancer",,4,accepted,1221,29,4,55592023,55592216,,,ENST00000288135.5,,,,,75,GRCh37,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",Somatic_Mutation,2016-06-28_00:14:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1221,https://civic.genome.wustl.edu/links/variants/509,https://civic.genome.wustl.edu/links/genes/29,"In_patients_with_gastrointestinal_stromal_tumors_(GIST),_imatinib_has_improved_outcomes_for_patients_with_KIT_mutations._However,_acquired_resistance_to_imatinib_is_common._Patients_harboring_exon_9_KIT_mutations_may_benefit_from_higher_imatinib_doses_(800mg/daily)._Similarly,_imatinib-refractory_tumors_showed_sensitivity_to_sunitinib_treatment._Improved_responses_to_either_treatment_were_not_observed_in_patients_with_exon_11_mutations.",,exon_variant,,60,Imatinib,,,,,,,
PTEN,5728,MUTATION,Endometrial_Carcinoma,2871,,Everolimus,,Predictive,Does_Not_Support,B,Sensitivity/Response,"Tumors_from_35_patients_(12_with_partial_response_or_stable_disease)_with_advanced_endometrial_carcinoma_were_assessed_for_PTEN_mutational_status,_revealing_12_tumors_with_non-identical_PTEN_gene_mutations._No_mutations_found_in_PTEN_were_effective_in_predicting_tumor_response_to_everolimus_treatment._The_clinical_trial_associated_with_this_study_is_NCT00870337.",23238879,PubMed,,"Trédan_et_al.,_2013,_Target_Oncol",,3,accepted,1232,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-04-08_02:47:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1232,https://civic.genome.wustl.edu/links/variants/510,https://civic.genome.wustl.edu/links/genes/41,,,protein_altering_variant,,31,Everolimus,,,,,,,
PTEN,5728,MUTATION,Head_And_Neck_Cancer,11934,,"Pictilisib,17-AAG",Substitutes,Predictive,Does_Not_Support,D,Sensitivity/Response,Analysis_of_drug_response_data_from_the_Sanger_center_cell_line_screen._Cell_lines_with_either_PI3K_and/or_PTEN_mutations_did_not_show_a_significant_difference_in_response_to_the_class_I_PI3K_inhibitor_GDC-0941(p_=0.07_for_combined_PI3K/PTEN_aberrations_with_a_trend_towards_lower_IC50_for_mutated_cell_lines)._IC50_values_with_HSP90_inhibitor_17-AAG_were_significantly_lower_in_PI3K_and/or_PTEN_mutated_cell_lines_in_the_Sanger_cell_line_screening_but_these_results_could_not_be_reproduced_in_the_Broad_cancer_cell_line_encyclopedia_screening.,25855885,PubMed,,"Wirtz_et_al.,_2015,_JAMA_Otolaryngol_Head_Neck_Surg",,2,accepted,1359,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-11_02:19:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1359,https://civic.genome.wustl.edu/links/variants/510,https://civic.genome.wustl.edu/links/genes/41,,,protein_altering_variant,,31,Pictilisib,17-AAG,,,,,,
PTEN,5728,MUTATION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Taselisib_(GDC-0032),,Predictive,Supports,D,Resistance,"In_a_panel_of_26_HNSCC_cell_lines_tested_for_sensitivity_to_taselisib_(an_alpha,_delta_and_gamma_isoform-specific_PI3K_inhibitor)_the_UD-SCC-2_cell_line_with_homozygous_PTEN_deletion_had_considerably_higher_antiproliferative_IC50_than_taselisib_sensitized_cell_lines._Western_blots_of_UD-SCC-3_cells_with_increasing_taselisib_concentration_showed_reduction_of_phospho-Akt_only_at_micro-molar_doses,_in_contrast_to_nano-molar_range_for_sensitized_cells._Slight_induction_of_the_apoptotic_marker_cleaved_PARP_was_only_apparent_at_4_micro-molar_dose._Similar_results_were_reported_with_the_PTEN_mutant_HNSCC_cell_line_UPCI-SCC-90,_and_4_of_the_6_most_taselisib_resistant_cell_lines_had_PTEN_mutation.",26589432,PubMed,,"Zumsteg_et_al.,_2016,_Clin._Cancer_Res.",,3,accepted,1467,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-05_16:35:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1467,https://civic.genome.wustl.edu/links/variants/510,https://civic.genome.wustl.edu/links/genes/41,,,protein_altering_variant,,31,Taselisib_(GDC-0032),,,,,,,
PTEN,5728,MUTATION,Prostate_Cancer,10283,,"Enzalutamide,AZD8186,BYL719_(Alpelisib)",Combination,Predictive,Supports,D,Sensitivity/Response,"Castrated_mice_bearing_androgen-sensitive_human_prostate_adenocarcinomas_(LNCaP_tumors)_were_treated_with_PI3K_inhibitors_(AZD8186,_BYL719)_and_an_androgen_receptor_inhibitor_(MDV3100).__Mice_treated_with_single_therapy_of_either_MDV3100,_BYL719,_or_AZD8186_resulted_in_mild_tumor_growth_inhibition_of_90%,_36%,_and_40%_respectively_(n=5_mice/group).__However,_triple_therapy_of_MDV300,_BYL719,_and_AZD8186_resulted_in_tumor_regression_of_113%_(n=5_mice).",25544636,PubMed,,"Schwartz_et_al.,_2015,_Cancer_Cell",,3,accepted,1522,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-10-25_14:50:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1522,https://civic.genome.wustl.edu/links/variants/510,https://civic.genome.wustl.edu/links/genes/41,,,protein_altering_variant,,31,Enzalutamide,AZD8186,BYL719_(Alpelisib),,,,,
PTEN,5728,MUTATION,Cancer,162,,Ipatasertib,,Predictive,Supports,D,Sensitivity/Response,"IC50_for_the_pan-Akt_inhibitor_ipatasertib_(GDC-0068)_was_determined_over_a_panel_of_100_cancer_cell_lines._Loss_or_mutation_of_PTEN_(e.g._PTEN_deletion,_T319fsX1/Y155C,_etc.)_was_significantly_associated_with_ipatasertib_sensitivity_(p=0.000071)._Non-transformed_human_mammary_epithelial_MCF10A_cells_were_compared_to_an_isogenic_line_with_PTEN_knockout._With_low_or_high_EGF_culture_conditions,_a_4x_or_3.5x_decrease_in_IC50_for_ipatasertib_was_seen_in_PTEN_knockout_cells,_respectively.",23287563,PubMed,,"Lin_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1491,41,10,89622870,89731687,,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-11_02:20:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1491,https://civic.genome.wustl.edu/links/variants/510,https://civic.genome.wustl.edu/links/genes/41,,,protein_altering_variant,,31,Ipatasertib,,,,,,,
FGFR2,2263,MUTATION,Endometrial_Cancer,1380,,Ponatinib,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_endometrial_cancer_cell_lines_(MFE-296,_AN3CA,_MFE-280_and_Ishikawa)._In_cell_proliferation_assays,_the_three_FGFR2_mutant_cell_lines_were_more_sensitive_to_the_pan-FGFR_inhibitor_ponatinib_(AP24534)_than_the_FGFR2_wild_type_cell_line_(Ishikawa)_and_human_embryonic_kidney_cell_line_(HEK293)._Ponatinib_also_inhibited_FGFR2_kinase_activity_and_phosphorylation_(MFE-296_and_MFE-280)_as_well_as_cell_migration_and_invasion_(MFE-296_and_AN3CA)_of_FGFR2_mutated_cancer_cell_lines.",26574622,PubMed,,"Kim_et_al.,_2016,_Cancer_Biol._Ther.",,3,accepted,1236,22,10,123239371,123357917,,,ENST00000457416.2,,,,,75,GRCh37,,Somatic_Mutation,2016-06-23_23:12:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1236,https://civic.genome.wustl.edu/links/variants/511,https://civic.genome.wustl.edu/links/genes/22,,,"gain_of_function_variant,transcript_variant",,8,Ponatinib,,,,,,,
FGFR2,2263,MUTATION,Cholangiocarcinoma,4947,,BGJ-398,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_of_FGFR-inhibitor_BGJ398_in_advanced_cancer_with_FGFR-aberrations._Among_three_patients_with_cholangiocarcinoma_and_FGFR2_aberrations_(2_fusions,_1_mutation),_all_three_had_stable_disease_with_a_reduced_tumor_burden.",27870574,PubMed,,"Nogova_et_al.,_2017,_J._Clin._Oncol.",,2,accepted,1912,22,10,123239371,123357917,,,ENST00000457416.2,,,,,75,GRCh37,,Somatic_Mutation,2017-06-09_23:47:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1912,https://civic.genome.wustl.edu/links/variants/511,https://civic.genome.wustl.edu/links/genes/22,,,"gain_of_function_variant,transcript_variant",,8,BGJ-398,,,,,,,
ALK,238,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_1_clinical_trial_(NCT01283516)_130_patients_with_advanced_cancers_all_harboring_ALK_alterations_were_treated_with_ceritinib.__Of_114_NSCLC_patients_treated_with_at_least_400_mg/daily_ceritinib,_1_had_a_complete_response,_65_had_a_partial_response,_25_had_stable_disease,_12_had_progressive_disease,_and_11_withdrew_from_the_study_early._Ceritinib_dosed_at_400_mg_or_higher_had_similar_results_in_patients_who_had_or_had_not_received_prior_crizotinib_treatment._Overall_response_rate_for_patients_with_prior_crizotinib_treatment_(83_out_of_122)_was_56%_with_median_progression_free_survival_of_6.9_months._For_patients_who_had_no_prior_crizotinib_treatment,_median_progression_free_survival_was_10.4_months.",24670165,PubMed,,"Shaw_et_al.,_2014,_N._Engl._J._Med.",,4,accepted,1237,1,2,29415640,30144432,,,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-28_00:03:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1237,https://civic.genome.wustl.edu/links/variants/512,https://civic.genome.wustl.edu/links/genes/1,,,"gene_variant,gain_of_function_variant",,20,Ceritinib,,,,,,,
ALK,238,NPM-ALK,Anaplastic_Large_Cell_Lymphoma,50744,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,"NPM-ALK_in_anaplastic_large_cell_lymphoma_(ALCL)_was_the_first_ALK-fusion_to_be_discovered_and_characterized.__In_this_study,_targeted_activity_against_NPM-ALK_by_the_ALK_and_MET_inhibitor_crizotinib_was_assessed_in_cell_lines_and_tumor_xenograft_models._Treatment_of_NPM-ALK_positive_ALCL_cell_lines_Karpas299_and_SU-DHL-1_potently_inhibited_growth,_and_this_was_seen_to_occur_at_concentrations_which_also_inhibited_NPM-ALK_phosphorylation_in_these_cells._Administration_of_100mg/kg/d_crizotinib_resulted_in_complete_regression_of_all_tumors,_indicating_that_NPM-ALK_could_be_an_effective_target_for_crizotinib_in_ALCL.",18089725,PubMed,,"Christensen_et_al.,_2007,_Mol._Cancer_Ther.",,5,accepted,1239,1,5,170814120,170818803,,,ENST00000517671.1,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-06-22_19:12:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1239,https://civic.genome.wustl.edu/links/variants/513,https://civic.genome.wustl.edu/links/genes/1,,ALK_Fusions,transcript_fusion,,27,Crizotinib,,,,,,,
ALK,238,NPM-ALK,Cancer,162,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,"In_Ba/F3_cells,_crizotinib_sensitivty_of_the_NPM-ALK_variant_was_compared_to_crizotinib_sensitivity_of_EML4-ALK_variant_3._50%_of_maximal_inhibitory_concentration_for_NPM-ALK_was_42_nM,_which_was_approximately_4x_greater_than_IC50_of_11_nM_obtained_for_EML4-ALK._The_IC50_for_parental_Ba/F3_supplemented_with_IL3_was_2299_nM,_resulting_in_a_fold_difference_of_209.2_for_EML4-ALK_and_55.1_for_NPM-ALK,_indicating_some_reduced_sensitivity_for_NPM-ALK_in_direct_comparison_to_EML4-ALK,_but_substantial_sensitization_to_crizotinib_for_NPM-ALK_in_Ba/F3_cells.",25727400,PubMed,,"Fontana_et_al.,_2015,_Cancer_Med",,2,accepted,1356,1,5,170814120,170818803,,,ENST00000517671.1,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-06-20_21:09:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1356,https://civic.genome.wustl.edu/links/variants/513,https://civic.genome.wustl.edu/links/genes/1,,ALK_Fusions,transcript_fusion,,27,Crizotinib,,,,,,,
ALK,238,NPM-ALK,Anaplastic_Large_Cell_Lymphoma,50744,,Crizotinib,,Predictive,Supports,B,Sensitivity/Response,"In_the_second_part_of_this_Phase_I_study_NCT00939770,_nine_patients_between_the_ages_of_12_months_and_22_years_with_anaplastic_large_cell_lymphoma_(ALCL),_who_were_refractory_to_treatment_and_for_whom_no_further_known_treatments_were_available,_were_treated_with_crizotinib._Six_patients_with_detectable_NPM-ALK_transcript_levels_responded_with_partial_response,_1_with_complete_response,_and_1_with_stable_disease.__Crizotinib_was_well_tolerated_in_these_children.",23598171,PubMed,,"Mossé_et_al.,_2013,_Lancet_Oncol.",,4,accepted,1241,1,5,170814120,170818803,,,ENST00000517671.1,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-06-23_17:59:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1241,https://civic.genome.wustl.edu/links/variants/513,https://civic.genome.wustl.edu/links/genes/1,,ALK_Fusions,transcript_fusion,,27,Crizotinib,,,,,,,
ALK,238,RANBP2-ALK,Inflammatory_Myofibroblastic_Tumor,50905,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"ALK-rearrangements_are_seen_in_50%_of_inflammatory_myofibroblastic_tumor_(IMT)_cases._A_44_year_old_man_was_diagnosed_with_IMT.__He_was_treated_with_surgery_and_catheter_placement_for_administration_of_cisplatin,_doxyrubicin_and_mitomycin_C.__Break-apart_FISH_showed_ALK_rearrangement,_and_immunohistochemical_staining_was_characteristic_of_RANBP2_rearrangement._After_further_chemotherapy_along_with_maintenance_imatinib,_crizotinib_was_started_at_200mg_twice_daily,_and_a_maximal_partial_response_was_achieved_5_months_later,_with_regrowth_occurring_2_months_later._After_further_surgery,_crizotinib_was_restarted_at_250mg_twice_daily_and_almost_2_years_later_the_patient_was_in_complete_radiographic_remission._Another_patient_with_non-ALK_rearranged_IMT_was_administered_crizotinib_in_this_study_but_did_not_respond.",20979472,PubMed,,"Butrynski_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,1244,1,2,109335937,109375004,,,ENST00000283195.6,2,29415640,29446394,ENST00000389048.3,75,GRCh37,,Somatic_Mutation,2016-06-27_23:49:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1244,https://civic.genome.wustl.edu/links/variants/514,https://civic.genome.wustl.edu/links/genes/1,,ALK_Fusions,transcript_fusion,,10,Crizotinib,,,,,,,
FGFR1,2260,N546K,Bone_Ewing's_Sarcoma,3368,,Ponatinib,,Predictive,Supports,E,Sensitivity/Response,"116_Ewing's_sarcoma_tumor_samples_were_analyzed_in_this_study._2_patient's_samples_underwent_whole_genome_sequencing,_tumor_samples_from_51_patients_underwent_exome_sequencing_and_expression_analysis,_63_samples_underwent_FGFR1_copy_number_analysis,_mRNA_analysis_and_IHC._A_FGFR1_N546K_mutation_was_detected_in_one_patient._Gain_of_the_FGFR1_locus_(qPCR)_was_observed_in_13_of_41_patients_(31.7%)_and_Ewing_sarcoma_cell_lines_(A673,_CADO,_SK-NMC,_SK-ES,_and_VH-64)._FGFR1_was_also_highly_expressed_in_Ewing_sarcoma_(mRNA_and_IHC)_and_correlated_with_copy_number._Retroviral_transduction_of_FGFR1_wild-type_or_the_FGFR1_N546K_mutant_into_NIH3T3_cells_led_to_enhanced_proliferation_especially_for_cells_harboring_the_FGFR1_mutation._ShRNA_mediated_knockdown_of_FGFR1_inhibited_growth_of_Ewing_sarcoma_and_other_cancer_cells_(A549_lung_carcinoma_cell_line_or_leukemia_cell_lines_HL60_and_Kasumi)_with_almost_complete_growth_suppression_only_in_the_Ewing_sarcoma_cell_lines_and_knockdown_of_FGFR1_abrogated_growth_of_cell_lines_in_xenograft._Ponatinib_treatment_inhibited_growth_of_Ewing_sarcoma_cell_lines.",26179511,PubMed,,"Agelopoulos_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,1246,1885,8,38274849,38274849,G,T,ENST00000341462.5,,,,,75,GRCh37,,Somatic_Mutation,2016-07-02_15:36:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1246,https://civic.genome.wustl.edu/links/variants/515,https://civic.genome.wustl.edu/links/genes/1885,,,missense_variant,"NM_023110.2:c.1638C>A,NP_075598.2:p.Asn546Lys,ENST00000341462.5:c.1638C>A,NC_000008.10:g.38274849G>T",0.5,Ponatinib,,,,,chr8_g.38274849G~T,FGFR1_c.1638C~A,FGFR1_N546K
ROS1,6098,CD74-ROS1_L2026M,Non-small_Cell_Lung_Carcinoma,3908,,Foretinib,,Predictive,Supports,D,Sensitivity/Response,Ba/F3_cells_expressing_CD74–ROS1_L2026M_mutation_showed_similar_sensitivity_to_foretinib_compared_with_those_expressing_wild-type_CD74–ROS1._This_is_in_contrast_to_the_increased_resistance_to_crizotinib_associated_with_this_mutation_in_the_same_assay.,25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,1258,4941,6,117638365,117638365,G,T,ENST00000368508.3,,,,,75,GRCh37,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1258,https://civic.genome.wustl.edu/links/variants/516,https://civic.genome.wustl.edu/links/genes/4941,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",,"transcript_fusion,missense_variant","NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A",9,Foretinib,,,,,chr6_g.117638365G~T,ROS1_c.6076C~A,
ROS1,6098,CD74-ROS1_L2026M,Non-small_Cell_Lung_Carcinoma,3908,,Lorlatinib,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_of_PF-06463922_in_NSCLC_in-vitro,_in-vivo,_and_in_enzyme_assays._After_establishing_that_the_CD74-ROS1_L2026M_mutation_confers_crizotinib_resistance_in_kinase_activity_and_cell_viability_assays_(in_transduced_BaF3_cells),_response_to_PF-06463922_was_tested.__Wild-type_CD74-ROS1,_CD74-ROS1_G2032R,_and_CD74-ROS1_L2026M_all_showed_sensitivity_to_PF-06463922_in_these_assays.",25733882,PubMed,,"Zou_et_al.,_2015,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,1253,4941,6,117638365,117638365,G,T,ENST00000368508.3,,,,,75,GRCh37,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",Somatic_Mutation,2016-06-28_01:51:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1253,https://civic.genome.wustl.edu/links/variants/516,https://civic.genome.wustl.edu/links/genes/4941,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",,"transcript_fusion,missense_variant","NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A",9,Lorlatinib,,,,,chr6_g.117638365G~T,ROS1_c.6076C~A,
ROS1,6098,CD74-ROS1_L2026M,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,"Preclinical_study_of_PF-06463922_in_NSCLC_in-vitro,_in-vivo_and_in_enzyme_assays._BaF3_cells_expressing_CD74-ROS1_L2026M_were_more_resistant_to_crizotinib_treatment_than_wildtype_CD74-ROS1_in_both_cell_viability_and_ROS1_phosphorylation._Crizotinib_was_also_less_effective_at_inhibiting_kinase_activity_in_ROS1_with_L2026M_mutation_than_wildtype._In_contrast,_PF-06463922_was_effectively_inhibited_the_fusion_harboring_this_mutation_in_these_assays.",25733882,PubMed,,"Zou_et_al.,_2015,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,1252,4941,6,117638365,117638365,G,T,ENST00000368508.3,,,,,75,GRCh37,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",Somatic_Mutation,2016-06-22_19:35:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1252,https://civic.genome.wustl.edu/links/variants/516,https://civic.genome.wustl.edu/links/genes/4941,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",,"transcript_fusion,missense_variant","NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A",9,Crizotinib,,,,,chr6_g.117638365G~T,ROS1_c.6076C~A,
ROS1,6098,CD74-ROS1_L2026M,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,"Ba/F3_cells_expressing_CD74–ROS1_L2026M_mutation_showed_resistance_to_crizotinib_(~10_fold_higher_IC50_value),_compared_with_those_expressing_wild-type_CD74–ROS1;_however,_showed_similar_sensitivity_to_foretinib.",25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,1257,4941,6,117638365,117638365,G,T,ENST00000368508.3,,,,,75,GRCh37,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1257,https://civic.genome.wustl.edu/links/variants/516,https://civic.genome.wustl.edu/links/genes/4941,"The_L2026M_mutation_is_considered_a_gatekeeper_mutation_located_in_the_inhibitor_binding_pocket_of_ROS1_and_corresponding_to_L1196M_in_ALK_and_T790M_in_EGFR._This_mutation_has_not_been_reportedly_observed_in_a_patient_but_inferred_as_a_variant_likely_to_emerge_in_crizotinib-resistant_tumors._In_vitro_kinase_activity,_structural_predictions_and_growth_inhibition_assays_indicate_the_L2026M_mutation_in_the_CD74-ROS1_fusion_provides_crizotinib_resistance._Additional_preclinical_assays_have_indicated_that_crizotinib_resistant_cells_harboring_this_mutation_are_sensitive_to_PF-06463922_and_foretinib.",,"transcript_fusion,missense_variant","NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A",9,Crizotinib,,,,,chr6_g.117638365G~T,ROS1_c.6076C~A,
ROS1,6098,CD74-ROS1_L2155S,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,Foretinib,TAE684",Substitutes,Predictive,Supports,D,Resistance,"The_L2155S_mutation_in_ROS1_was_identified_in_the_HCC78CR1,_-2_and_-3_cell_lines_which_harbor_the_SLC34A2–ROS1_rearrangement_and_in_2_patients_with_NSCLC_with_progressive_disease_following_crizotinib_treatment_and_CD74–ROS1_rearrangment._Crystal_structure_predicted_ROS1_L2155S_mutation_to_be_highly_destabilizating_and_cause_protein_structural_modification._HCC78CR1,_2,_and_3_cells_and_Ba/F3_cells_transfected_with_CD74–ROS1_L2155S,_showed_resistance_to_crizotinib_compared_with_parental_HCC78_and_Ba/F3_cells._In_addition,_these_cell_lines_showed_resistance_to_foretinib,_a_potent_ROS1_inhibitor_that_is_effective_against_ROS1_G2032R-mutant_cells_(16),_and_TAE684,_a_potent_ALK_inhibitor",25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,3,accepted,1256,4941,6,117630062,117630062,A,G,ENST00000368508.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-29_20:26:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1256,https://civic.genome.wustl.edu/links/variants/517,https://civic.genome.wustl.edu/links/genes/4941,,,"transcript_fusion,missense_variant",NC_000006.11:g.117630062A>G,3,Crizotinib,Foretinib,TAE684,,,chr6_g.117630062A~G,,
ROS1,6098,CD74-ROS1_G2101A,Non-small_Cell_Lung_Carcinoma,3908,,Foretinib,,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_expressing_CD74–ROS1_G2101A_showed_resistance_to_crizotinib,_compared_with_those_expressing_wild-type_CD74–ROS1,_and_were_sensitive_to_foretinib.",25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,1260,4941,6,117631376,117631376,C,G,ENST00000368508.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1260,https://civic.genome.wustl.edu/links/variants/518,https://civic.genome.wustl.edu/links/genes/4941,,,"transcript_fusion,missense_variant",NC_000006.11:g.117631376C>G,4,Foretinib,,,,,chr6_g.117631376C~G,,
ROS1,6098,CD74-ROS1_G2101A,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,"Ba/F3_cells_expressing_CD74–ROS1_G2101A_showed_resistance_to_crizotinib,_compared_with_those_expressing_wild-type_CD74–ROS1,_and_were_sensitive_to_foretinib.",25688157,PubMed,,"Song_et_al.,_2015,_Clin._Cancer_Res.",,2,accepted,1259,4941,6,117631376,117631376,C,G,ENST00000368508.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1259,https://civic.genome.wustl.edu/links/variants/518,https://civic.genome.wustl.edu/links/genes/4941,,,"transcript_fusion,missense_variant",NC_000006.11:g.117631376C>G,4,Crizotinib,,,,,chr6_g.117631376C~G,,
FLT3,2322,MUTATION,Acute_Myeloid_Leukemia,9119,,Midostaurin,,Predictive,Supports,A,Sensitivity/Response,Midostaurin_is_FDA-approved_for_the_treatment_of_newly-diagnosed_acute_myeloid_leukemia_patients_harboring_FLT3_mutations.,28546144,PubMed,,"Levis,_2017,_Blood",,3,accepted,5261,24,13,28577411,28674729,,,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_20:08:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/5261,https://civic.genome.wustl.edu/links/variants/519,https://civic.genome.wustl.edu/links/genes/24,,,"gain_of_function_variant,transcript_variant",,40,Midostaurin,,,,,,,
ALK,238,CLTC-ALK,Diffuse_Large_B-cell_Lymphoma,50745,,TAE684,,Predictive,Supports,D,Sensitivity/Response,"A_cell_line_called_LM1_was_established_from_the_bone_marrow_of_a_13_year_old_female_patient_with_relapsed_CLTC-ALK_positive_diffuse_large_B-cell_lymphoma_(DLBCL)._The_patient_had_been_heavily_treated_with_chemotherapy_before_establishment_of_the_cell_line._The_cell_line_maintained_the_tumor_immunophenotype.__SNP_analysis_of_patient_bone_marrow_mononuclear_cells_and_LM1_showed_chromosomal_changes_associated_with_the_cell_line_but_94.7%_of_SNPs_were_identically_called.__ALK_kinase_inhibitor_TAE684_induced_cell_death_in_LM1_cells_at_low_nanomolar_concentrations,_while_it_did_not_significantly_effect_the_ALK-rearrangement_negative_DLBCL_cell_line_Karpas422.__LM1_cells_formed_tumors_in_3/10_SCID_and_9/10_NOD-SCID_mice.__CD30_and_CD138_immmunostaining_were_maintained_between_original_tumor_and_LM1_xenografts._In_mice,_LM1_but_not_Karpas422_xenografts_regressed_with_TAE684_administration,_and_complete_remission_for_13_weeks_was_observed_before_experiment_was_terminated.",21494621,PubMed,,"Cerchietti_et_al.,_2011,_PLoS_ONE",,4,accepted,1261,1,17,57697219,57768072,,,ENST00000269122.3,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_t(2;17)(p23;q23)_translocation_results_in_the_CLTC-ALK_fusion_protein,_the_most_common_ALK_fusion_observed_in_diffuse_large_B_cell_lymphoma_(DLBCL)._ALK-rearranged_DLBCL_is_less_responsive_to_CHOP_chemotherapy._Preclinical_work_indicates_that_CLTC-ALK_DLBCL_is_responsive_to_ALK_inhibition_in_cell_lines_and_mouse_models,_and_two_case_studies_show_short_response_followed_by_progression_when_heavily_pretreated_and_advanced_ALK-positive_DLBCL_is_treated_with_crizotinib_(one_case_CLTC-ALK,_one_case_an_unknown_ALK_fusion).",Somatic_Mutation,2016-06-27_18:45:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1261,https://civic.genome.wustl.edu/links/variants/520,https://civic.genome.wustl.edu/links/genes/1,"The_t(2;17)(p23;q23)_translocation_results_in_the_CLTC-ALK_fusion_protein,_the_most_common_ALK_fusion_observed_in_diffuse_large_B_cell_lymphoma_(DLBCL)._ALK-rearranged_DLBCL_is_less_responsive_to_CHOP_chemotherapy._Preclinical_work_indicates_that_CLTC-ALK_DLBCL_is_responsive_to_ALK_inhibition_in_cell_lines_and_mouse_models,_and_two_case_studies_show_short_response_followed_by_progression_when_heavily_pretreated_and_advanced_ALK-positive_DLBCL_is_treated_with_crizotinib_(one_case_CLTC-ALK,_one_case_an_unknown_ALK_fusion).",ALK_Fusions,transcript_fusion,,19,TAE684,,,,,,,
ALK,238,CLTC-ALK,Diffuse_Large_B-cell_Lymphoma,50745,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"A_21_year_old_male_presented_with_lymphadenopathy_and_a_low_density_mass_in_pancreas._Histopathological_analysis_showed_diffuse_tumor_cell_infiltrate_(CD20/EMA_negative)_with_cytoplasmic_ALK._RT-PCR_indicated_CLTC-ALK_fusion._The_patient_was_diagnosed_with_splenic_ALK_+_diffuse_large_B_cell_lymphoma_(DLBCL),_Stage_III,_Group_A_with_an_IPI_of_3._CHOP-21_chemotherapy_regimen_was_administered_with_improvement_in_abdominal_lymph_nodes_but_worsening_in_retroperitoneal_lymph_nodes_assessed_via_standardized_uptake_values._Subsequent_ICE_chemotherapy_regiment_relieved_some_symptoms_prompting_the_patient_to_refuse_further_treatment_despite_other_indications_of_disease_progression._Therapy_was_reinstated_after_worsening_of_disease._GEMOX_chemotherapy_was_administered_with_dexamethasone_and_250mg_crizotinib_twice_daily_resulting_in_symptom_relief,_decreased_lymphadenopathy_and_LDH_decline._The_disease_then_progressed_and_the_patient_died_2_months_after_crizotinib_initiation._The_authors_conclude_that_partial_response_to_crizotinib_was_observed_and_that_in_future_trials_ALK_rearranged_DLBCL_patients_might_see_increased_benefit_with_earlier_application_of_targeted_therapy_during_the_treatment_course.",26221234,PubMed,,"Li_et_al.,_2015,_Int_J_Clin_Exp_Med",,3,accepted,1265,1,17,57697219,57768072,,,ENST00000269122.3,2,29415640,29446394,ENST00000389048.3,75,GRCh37,"The_t(2;17)(p23;q23)_translocation_results_in_the_CLTC-ALK_fusion_protein,_the_most_common_ALK_fusion_observed_in_diffuse_large_B_cell_lymphoma_(DLBCL)._ALK-rearranged_DLBCL_is_less_responsive_to_CHOP_chemotherapy._Preclinical_work_indicates_that_CLTC-ALK_DLBCL_is_responsive_to_ALK_inhibition_in_cell_lines_and_mouse_models,_and_two_case_studies_show_short_response_followed_by_progression_when_heavily_pretreated_and_advanced_ALK-positive_DLBCL_is_treated_with_crizotinib_(one_case_CLTC-ALK,_one_case_an_unknown_ALK_fusion).",Somatic_Mutation,2016-11-04_18:19:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1265,https://civic.genome.wustl.edu/links/variants/520,https://civic.genome.wustl.edu/links/genes/1,"The_t(2;17)(p23;q23)_translocation_results_in_the_CLTC-ALK_fusion_protein,_the_most_common_ALK_fusion_observed_in_diffuse_large_B_cell_lymphoma_(DLBCL)._ALK-rearranged_DLBCL_is_less_responsive_to_CHOP_chemotherapy._Preclinical_work_indicates_that_CLTC-ALK_DLBCL_is_responsive_to_ALK_inhibition_in_cell_lines_and_mouse_models,_and_two_case_studies_show_short_response_followed_by_progression_when_heavily_pretreated_and_advanced_ALK-positive_DLBCL_is_treated_with_crizotinib_(one_case_CLTC-ALK,_one_case_an_unknown_ALK_fusion).",ALK_Fusions,transcript_fusion,,19,Crizotinib,,,,,,,
BRAF,673,DEL_485-490,Cancer,162,,LY3009120,,Predictive,Supports,D,Sensitivity/Response,"Cells_harboring_in-frame_deletions_in_BRAF_in_the_L485-P490_amino_acid_region_were_found_to_be_sensitive_to_the_RAF_dimer_inhibitor_LY3009120,_but_not_sensitive_to_the_BRAF-selective_inhibitors_vemurafenib_or_dabrafenib._These_deletions_were_observed_in_KRAS_wildtype_pancreatic,_ovarian,_NSCLC,_and_thyroid_cancers._In_three_cell_lines_H2405_(NSCLC_with_L485-P490>Y),_BxPC-3_(pancreatic_with_V487-P492>A),_and_OV-90_(ovarian_with_N486-P490del),_BRAF_deletion–mediated_MAPK_activation_was_found_to_be_sensitive_to_LY3009120_as_evidenced_by_dose-dependent_inhibition_of_phospho-MEK_and_ERK_and_cell_growth_inhibition_with_IC50_values_of_0.04,_0.087,_and_0.007_μmol/L_in_these_three_cell_lines._LY3009120,_but_not_vemurafenib,_also_inhibited_tumor_growth_of_both_H2405_and_BxPC-3_cells_xenografted_into_mice.",26732095,PubMed,,"Chen_et_al.,_2016,_Cancer_Discov",,3,accepted,1267,5,7,140477838,140477855,AGGTGCTGTCACATTCAA,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_21:37:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1267,https://civic.genome.wustl.edu/links/variants/522,https://civic.genome.wustl.edu/links/genes/5,,,inframe_deletion,ENST00000288602.6:c.1453_1470del,3,LY3009120,,,,,,BRAF_c.1453_1470del,
BCL2L11,10018,DELETION_POLYMORPHISM,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,B,Resistance,"DNA_sequencing_was_performed_in_five_Ph+_CML_samples_with_sensitivity_or_resistance_to_imatinib._A_structural_variation_in_BIM2_(BCL2L11)_with_an_identical_2,903-bp_genomic_deletion_was_identified_in_all_three_resistant_samples._2,597_healthy_individuals_were_screened_and_the_deletion_polymorphism_was_identified_in_12.3%_of_East_Asian_Population_but_0%_in_African_or_European_Population._In-vitro,_imatinib-induced_apoptosis_was_reduced_in_cells_harboring_the_BIM_deletion_polymorphism._Two_East_Asian_CML_cohorts_(n=203)_treated_with_imatinib_were_analzed_for_the_polymorphism._Overall_odds_ratio_for_resistant_disease_among_subjects_with_the_deletion_polymorphism_compared_to_those_without_it_was_2.94_(P_=_0.02,_95%_CI_1.17–7.43)._Patients_with_the_polymorphism,_compared_to_those_without,_were_more_likely_to_be_resistant_without_BCR-ABL_mutations_than_resistant_with_BCR-ABL_mutation_or_sensitive_(odds_ratio_=_1.90,_95%_CI_1.08–4.35).",22426421,PubMed,,"Ng_et_al.,_2012,_Nat._Med.",,4,accepted,1280,7953,2,111883195,111886097,,,ENST00000393256.3,,,,,75,GRCh37,,Germline_Polymorphism,2016-06-20_20:50:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1280,https://civic.genome.wustl.edu/links/variants/526,https://civic.genome.wustl.edu/links/genes/7953,,,polymorphic_sequence_variant,,40,Imatinib,,,,,,,
BCL2L11,10018,DELETION_POLYMORPHISM,Non-small_Cell_Lung_Carcinoma,3908,,EGFR_Inhibitor,,Predictive,Supports,B,Resistance,"The_BIM_(BCL2L11)_deletion_polymorphism_was_identified_in_an_EGFR_Mutant_NSCLC_cell_line_with_resistance_to_EGFR-TKI_(HCC2779)._Introduction_of_this_polymorphism_in_a_previously_EGFR-inhibitor_sensitive_cell_line_led_to_TKI-resistance._In_141_NSCLC_patients_with_EGFR_mutations,_the_presence_of_the_polymorphism_(N=26)_was_predictive_of_a_significantly_shorter_PFS_under_treatment_with_EGFR-TKI_(6.6_months_vs._11.9_months,_p_=_0.0027)._Patients_received_either_gefitinib_only_(N=136)_or_erlotinib_only_(N=5).",22426421,PubMed,,"Ng_et_al.,_2012,_Nat._Med.",,4,accepted,1281,7953,2,111883195,111886097,,,ENST00000393256.3,,,,,75,GRCh37,,Germline_Polymorphism,2016-08-15_20:00:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1281,https://civic.genome.wustl.edu/links/variants/526,https://civic.genome.wustl.edu/links/genes/7953,,,polymorphic_sequence_variant,,40,EGFR_Inhibitor,,,,,,,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,The_MGH056-1_cell_line_was_derived_from_a_patient_with_ALK_rearranged_NSCLC_who_had_progressed_on_crizotinib_and_then_on_lower_dose_alectinib_(300_mg_twice_daily)._The_I1171T_ALK_kinase_domain_mutation_was_found_in_this_cell_line_(established_after_alectinib_resistance)._MGH056-1_cells_were_resistant_to_crizotinib_(IC50_236nmol/L;_aproximately_50x_higher_than_for_ceritinib)._About_50_fold_higher_concentration_of_crizotinib_was_required_to_inhibit_Ba/F3_cells_expressing_EML4_ALK_I1171T_than_was_required_for_EML4_ALK_wild-type.,25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1287,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-07-13_18:40:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1287,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,Crizotinib,,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,TAE684,,Predictive,Supports,D,Sensitivity/Response,"The_I1171T_ALK_kinase_domain_mutaion_was_found_in_the_MGH056-1_cell_line_which_was_derived_from_an_ALK_rearranged_NSCLC_patient_who_had_progressed_on_crizotinib_and_then_on_alectinib_given_at_lower_dose_(300mg_twice_daily).__Ectopic_expression_of_EML4-ALK_I1171T_in_Ba/F3_cells_made_these_cells_moderately_resistant_to_crizotinib_and_resistant_to_alectinib._In_contrast,_the_frequently_used_tool_compound_TAE684_was_equally_effective_against_EML4-ALK_wild-type_and_I1171T,_causing_cell_death_at_1000x_lower_concentration_then_in_unaltered_Ba/F3_cells_supplemented_with_IL3.",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1285,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-11-03_18:58:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1285,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,TAE684,,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,C,Resistance,"The_I1171T_mutation_in_ALK_fusions_was_found_in_a_NSCLC_patient_shown_positive_for_ALK_rearrangement_via_break_apart_FISH_assay,_who_progressed_after_8_months_of_crizotinib,_and_then_progressed_again_after_4_months_of_alectinib._The_MGH056-1_cell_line_was_derived_from_this_patient,_and_this_cell_line_was_resistant_to_alectinib._Sequencing_of_MGH056-1_cells_revealed_the_I1171T_mutation_in_ALK._In_cell_culture_studies_Ba/F3_cells_with_EML4-ALK_I1171T_required_more_that_10x_the_concentration_of_alectinib_to_significantly_reduce_viability_that_was_required_for_EML4-ALK_wild-type_expressing_cells._Computer_simulation_studies_indicated_that_the_I1171T_mutation_interfered_with_alectinib_binding_at_the_ALK_active_site.",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,4,accepted,1283,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-11-04_16:33:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1283,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,Alectinib_(CH5424802),,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_expressing_EML4-ALK_variant_3_with_ALK_I1171T_mutation_were_treated_with_ceritinib,_and_survival_IC50_of_2.6_nM_was_observed,_which_compares_favorably_with_highly_ceritinib_sensitive_EML4-ALK_wild-type_variant_1_survival_IC50_of_1.7_nM_reported_from_parallel_experiments._Tumors_from_mice_with_EML4-ALK_variant_3_H2228_NSCLC_cell_xenografts_which_had_progressed_after_approximately_40_days_of_crizotinib_treatment_were_sequenced_for_ALK_mutations._I1171T_was_found_as_one_of_6_ALK_resistance_mutations_from_80_sequenced_tumors._Treatment_of_these_mouse_xenograft_models_with_ceritinib_reduced_tumor_volume_to_zero,_while_in_contrast_tumor_size_increased_with_crizotinib_treatment.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,4,accepted,1344,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1344,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,Ceritinib,,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,C,Resistance,"A_51_year_old_female_never-smoker_was_diagnosed_with_stage_IV_NSCLC_with_liver_metastases._ALK_rearrangement_was_verified_via_FISH._She_was_treated_with_crizotinib_at_250_mg_twice_daily_but_discontinued_due_to_adverse_response._She_then_started_alectinib_at_600_mg_twice_daily_with_partial_response,_but_new_liver_metastases_then_formed_at_5_months._Liver_tumor_biopsy_was_performed_and_was_estimated_to_be_15%_tumor_tissue._Next-generation_sequencing_discovered_an_ALK_I1171N_mutation._The_tumor_was_not_sequenced_prior_to_alectinib_resistance.",25736571,PubMed,,"Ou_et_al.,_2015,_Lung_Cancer",,2,accepted,1367,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-07-10_05:08:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1367,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,Alectinib_(CH5424802),,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,C,Sensitivity/Response,"The_MGH056-1_cell_line_was_derived_from_an_NSCLC_patient_with_ALK-rearrangement_who_had_progressed_on_crizotinib_and_then_on_alectinib._the_cell_line_was_also_resistant_to_crizotinib_and_alectinib,_and_sequencing_of_ALK_from_the_cell_line_revealed_the_I1171T_mutation._Further_testing_of_this_mutation_in_BaF3_cells_revealed_that_cells_expressing_EML4-ALk_with_I1171T_mutation_required_10x_higher_concentration_to_induce_cell_death_than_BaF3_cells_with_wild-type_EML4-ALK._In_contrast,_ceritinib_caused_loss_of_viability_in_EML4-ALK_wild-type_and_I1171T_BaF3_cells_at_comparable_concentrations._Ceritinib_was_also_effective_at_killing_MGH056-1_cells_that_were_resistant_to_alectinib,_and_reduced_Akt_and_ERK_phosphorylation_in_these_cells._Finally,_administration_of_ceritinib_to_the_crizotinib_and_alectinib_resistant_patient_let_to_tumor_regression_and_partial_response_lasting_7_months.",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,4,accepted,1284,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1284,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,Ceritinib,,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,ALK_FUSION_I1171,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,C,Sensitivity/Response,"A_51_year_old_female_never_smoker_was_diagnosed_with_stage_IV_NSCLC_with_liver_metastases,_and_had_adverse_response_to_crizotinib_treatment,_after_which_she_responded_to_alectinib_until_disease_progressed_after_5_months_with_new_liver_metastases._Liver_tumor_biopsy_was_taken_and_estimated_to_be_15%_tumor._Hybrid_capture_next_generation_sequencing_was_performed_and_an_I1171N_mutation_was_found_in_rearranged_ALK,_and_estimated_to_be_in_33%_of_the_tumor_cells._Ceritinib_was_given_at_750_mg_once_daily_but_dose_reduction_to_600_mg_once_daily_was_required_due_to_persistent_nausea._CT_showed_regression_of_liver_lesions_and_primary_lung_lesion_and_ongoing_response_was_seen_at_3_months.",25736571,PubMed,,"Ou_et_al.,_2015,_Lung_Cancer",,3,accepted,1368,1,2,29445213,29445213,A,G,ENST00000389048.3,,,,,75,GRCh37,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,Somatic_Mutation,2016-07-06_19:44:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1368,https://civic.genome.wustl.edu/links/variants/527,https://civic.genome.wustl.edu/links/genes/1,Multiple_case_reports_indicate_that_the_I1171T_missense_mutation_in_ALK-rearranged_non-small_cell_lung_cancer_(NSCLC)_confers_resistance_to_crizotinib_and_alectinib_but_is_sensitive_to_ceritinib_treatment._These_results_have_been_validated_in_vitro._In_vitro_evidence_indicates_this_mutation_interferes_with_alectinib_binding_the_active_site_of_ALK_and_may_explain_the_sensitivity_to_the_structurally_distinct_ALK_inhibitor_ceritinib.,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G",42.5,Ceritinib,,,,,chr2_g.29445213A~G,ALK_c.3512T~C,
ALK,238,EML4-ALK__V1180L,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,D,Resistance,The_alectinib_resistant_cell_line_H3122_CHR-A1_was_generated_by_culturing_of_the_EML4-ALK_(variant_1)_containing_cell_line_H3122_with_increasing_levels_of_alectinib._Molecular_characterization_of_H3122_CHR-A1_revealed_a_V1180L_ALK_kinase_domain_mutation._The_H3122_CHR-A1_cell_line_required_approximately_10_fold_increase_in_crizotinib_concentration_to_induce_similar_levels_of_cell_death_to_H3122._Ectopic_expression_of_EML4-ALK_V1180L_rendered_Ba/F3_cells_moderately_less_susceptible_to_crizotinib_than_ectopic_EML4-ALK.,25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,1288,1,2,29443679,29443679,C,G,ENST00000389048.3,,,,,75,GRCh37,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",Somatic_Mutation,2016-06-22_19:30:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/1288,https://civic.genome.wustl.edu/links/variants/528,https://civic.genome.wustl.edu/links/genes/1,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3538G>C,NC_000002.11:g.29443679C>G,NC_000002.11:G.29443679C>G",13,Crizotinib,,,,,chr2_g.29443679C~G,ALK_c.3538G~C,
ALK,238,EML4-ALK__V1180L,Non-small_Cell_Lung_Carcinoma,3908,,Alectinib_(CH5424802),,Predictive,Supports,D,Resistance,"The_EML4_ALK_variant_1_containing_NSCLC_cell_line_H3122_is_highly_sensitive_to_alectinib,_and_an_alectinib_resistant_derivative_cell_line_H3122_CHR-A1_was_generated_by_incubation_of_H3122_in_increasing_levels_of_alectinib_culminating_in_1_micro-molar,_over_a_course_of_7_months._The_ALK_kinase_domain_mutation_V1180L_was_found_in_these_cells,_and_Ba/F3_cells_expressing_EML4_ALK__V1180L_were_highly_resistant_to_alectinib._Simulations_indicated_that_the_V1180L_mutation_interfered_with_alectinib_binding._The_V1180L_mutation_was_found_to_be_more_resistant_to_alectinib_than_the_I1171T_mutation_found_in_an_ALK-positive_NSCLC_patient_who_developed_alectinib_resistance_on_lower_dose_alectinib__(300mg_twice_daily).",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1286,1,2,29443679,29443679,C,G,ENST00000389048.3,,,,,75,GRCh37,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",Somatic_Mutation,2016-08-28_22:24:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1286,https://civic.genome.wustl.edu/links/variants/528,https://civic.genome.wustl.edu/links/genes/1,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3538G>C,NC_000002.11:g.29443679C>G,NC_000002.11:G.29443679C>G",13,Alectinib_(CH5424802),,,,,chr2_g.29443679C~G,ALK_c.3538G~C,
ALK,238,EML4-ALK__V1180L,Non-small_Cell_Lung_Carcinoma,3908,,Brigatinib,,Predictive,Supports,D,Sensitivity/Response,"ALK_mutation_V1180L_was_found_in_an_H3122_derivative_cell_line_that_had_become_alectinib_resistant_after_being_passaged_in_increasing_levels_of_alectinib._EML4-ALK_V1180L_and_EML4-ALK_wild-type_were_ectopically_expressed_in_Ba/F3_cells,_and_brigatinib_showed_strong_activity_against_both_variants._The_IC50_for_brigatinib_against_EML4-ALK_wild-type_was_0.95,_which_is_about_3x_higher_than_the_IC50_that_was_observed_for_alectinib,_but_about_6x_lower_than_that_for_crizotinib._In_contrast,_the_IC50_for_brigatinib_against_the_alectinib_resistance_variant_EML4-ALK_V1180L_was_0.49,_indicating_increased_sensitivity_to_brigatinib_over_non_mutant_EML4-ALK.",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,2,accepted,1291,1,2,29443679,29443679,C,G,ENST00000389048.3,,,,,75,GRCh37,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1291,https://civic.genome.wustl.edu/links/variants/528,https://civic.genome.wustl.edu/links/genes/1,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3538G>C,NC_000002.11:g.29443679C>G,NC_000002.11:G.29443679C>G",13,Brigatinib,,,,,chr2_g.29443679C~G,ALK_c.3538G~C,
ALK,238,EML4-ALK__V1180L,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"Passaging_of_the_alectinib_sensitive_EML4-ALK_containing_H3122_NSCLC_cell_line_with_increasing_levels_of_alectinib_resulted_in_an_alectinib_resistant_derivative_of_this_cell_line_named_H3122_CHR-A1._A_V1180L_missense_mutation_was_found_in_the_kinase_domain_of_ALK_in_H3122_CHR-A1_cells._Both_H3122_and_H3122_CHR-A1_cells_were_highly_and_equally_sensitive_to_ceritinib_induced_death._In_Ba/F3_cells,_ectopic_expression_of_EML4-ALK_V1180L_rendered_cells_significantly_more_sensitive_to_ceritinib_than_Ba/F3_containing_EML4-ALK_I1171T_mutant_(alectinib_and_crizotinib_resistant)_or_EML4-ALK_wt.",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1289,1,2,29443679,29443679,C,G,ENST00000389048.3,,,,,75,GRCh37,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",Somatic_Mutation,2016-08-07_00:34:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1289,https://civic.genome.wustl.edu/links/variants/528,https://civic.genome.wustl.edu/links/genes/1,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3538G>C,NC_000002.11:g.29443679C>G,NC_000002.11:G.29443679C>G",13,Ceritinib,,,,,chr2_g.29443679C~G,ALK_c.3538G~C,
ALK,238,EML4-ALK__V1180L,Non-small_Cell_Lung_Carcinoma,3908,,TAE684,,Predictive,Supports,D,Sensitivity/Response,"The_V1180L_mutation_in_the_kinase_domain_of_rearranged_ALK_was_found_in_an_alectinib_resistant_cell_line_named_H3122_CHR-A1,_which_was_derived_from_the_alectinib_sensitive_EML4-ALK_variant_1_containing_NSCLC_cell_line_H3122_by_passaging_into_higher_concentrations_of_alectinib._This_cell_line_is_a_model_for_gain_of_alectinib_resistance,_and_also_shows_resistance_to_crizotinib._On_the_other_hand,_the_often_used_tool_ALK_inhibitor_TAE684_was_highly_effective_in_killing_H3122_CHR-A1,_where_H3122_cells_were_only_slightly_more_sensitized_to_TAE684-induced_cell_death._Ectopic_expression_of_EML4-ALK_V1180L_in_Ba/F3_cells_caused_IL3_independent_growth_as_well_as_marked_sensitization_to_TAE684,_to_a_level_greater_than_that_seen_in_EML4-ALK_I1171T_(alectinib_resistance_mutation)_or_EML4-ALK_wt,_and_over_1000x_greater_sensitivity_than_unaltered_Ba/F3_+_IL3.",25228534,PubMed,,"Katayama_et_al.,_2014,_Clin._Cancer_Res.",,3,accepted,1290,1,2,29443679,29443679,C,G,ENST00000389048.3,,,,,75,GRCh37,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",Somatic_Mutation,2016-08-28_22:25:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1290,https://civic.genome.wustl.edu/links/variants/528,https://civic.genome.wustl.edu/links/genes/1,"The_V1180L_missense_mutation_was_identified_in_a_mutagenesis_screen_to_find_mutations_that_conferred_resistance_to_alectinib_in_a_non-small_cell_lung_cancer_cell_line._This_mutation_shows_resistance_to_crizotinib_and_alectinib_but_sensitivity_to_TAE684,_ceritinib_and_more_mild_sensitivity_to_brigatinib._Similar_to_I1171T,_it_resides_in_the_ATP_pocket_of_ALK_and_likely_interferes_with_alectinib_and_crizotinib_binding_as_a_mechanism_of_resistance.",,"transcript_fusion,missense_variant","ENST00000389048.3:c.3538G>C,NC_000002.11:g.29443679C>G,NC_000002.11:G.29443679C>G",13,TAE684,,,,,chr2_g.29443679C~G,ALK_c.3538G~C,
SIRT1,23411,OVEREXPRESSION,Pancreatic_Cancer,1793,,Nicotinamide,,Predictive,Supports,D,Resistance,"In-vitro_study_with_MiaPaCa-2_and_PANC-1_pancreatic_cancer_cell_lines._Inhibition_of_Sirt1_by_increasing_concentrations_of_nicotinamide_led_to_a_decrease_in_viability._Gefitinib_treatment_with_concentrations_of_50_μM_showed_similar_effects_as_observed_for_the_application_of_25_mM_nicotinamide._Combinatory_treatment_with_gefitinib_and_nicotinamide_showed_a_synergistic_effect_on_cell_viability._In_cell_lines_overexpressing_Sirt1,_higher_concentrations_of_nicotinamide_were_required_to_abrogate_increased_cell_viability_mediated_by_Sirt1_overexpression_compared_to_controls.",24088390,PubMed,,"Stenzinger_et_al.,_2013,_BMC_Cancer",,1,accepted,1294,9538,10,69644427,69678147,,,ENST00000212015.6,,,,,75,GRCh37,,,2016-05-04_21:36:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1294,https://civic.genome.wustl.edu/links/variants/529,https://civic.genome.wustl.edu/links/genes/9538,,,,,16,Nicotinamide,,,,,,,
KRAS,3845,G12R,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2264,30,12,25398285,25398285,C,G,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-03-31_02:23:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2264,https://civic.genome.wustl.edu/links/variants/530,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C",24,Panitumumab,,,,,chr12_g.25398285C~G,KRAS_c.34G~C,KRAS_G12R
KRAS,3845,G12R,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_SW48_cell_line_expressing_KRAS_G12R_mutation_demonstrated_decreased_sensitivity__to_regorafenib_treatment_(IC50:_181.77_nmol_vs._114.28_nmol,_P<0.01)_compared_to_SW48_cells_expressing_KRAS_wild-type._Resistance_was_determined_by_assessing_cell_viability.",26161928,PubMed,,"Camaj_et_al.,_2015,_Future_Oncol",,,accepted,3991,30,12,25398285,25398285,C,G,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_19:11:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/3991,https://civic.genome.wustl.edu/links/variants/530,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C",24,Regorafenib,,,,,chr12_g.25398285C~G,KRAS_c.34G~C,KRAS_G12R
KRAS,3845,G12R,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study_to_identify_cetuximab-resistant_clones_following_continuous_drug_treatment,_a_resistant_clone_of_the_Lim1215_colorectal_cancer_cell_line_was_identified_to_have_the_KRAS_G12R_mutation._No_G12R_was_detected_in_the_parental_line_despite_high-resolution_evaluation._Additionally,_endogenously_expressing_KRAS_G12R_(knock-in)_mutation_demonstrated_resistance_to_cetuximab_treatment,_compared_to_Lim1215_parental_cells_expressing_wild-type_KRAS._Resistance_was_determined_by_assessing_cell_viability.",22722830,PubMed,,"Misale_et_al.,_2012,_Nature",,4,accepted,3989,30,12,25398285,25398285,C,G,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_17:06:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/3989,https://civic.genome.wustl.edu/links/variants/530,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C",24,Cetuximab,,,,,chr12_g.25398285C~G,KRAS_c.34G~C,KRAS_G12R
PALB2,79728,BIALLELIC_INACTIVATION,Prostate_Cancer,10283,,Olaparib,,Predictive,Supports,C,Sensitivity/Response,"From_14_prostate_cancer_patients_(88%)_who_had_a_response_to_olaparib,_7_patients_had_BRCA2_loss_(4_with_biallelic_somatic_loss,_and_3_with_germline_mutations),_4_of_5_with_had_ATM_aberrations_and_one_had_a_biallelic_inactivation_of_PALB2_(frameshift_mutation_and_deletion).",26510020,PubMed,,"Mateo_et_al.,_2015,_N._Engl._J._Med.",,3,accepted,1963,15013,16,23614491,23652631,,,ENST00000261584.4,,,,,75,GRCh37,,Somatic_Mutation,2018-09-17_19:43:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1963,https://civic.genome.wustl.edu/links/variants/532,https://civic.genome.wustl.edu/links/genes/15013,,,loss_of_function_variant,,17.5,Olaparib,,,,,,,
PALB2,79728,BIALLELIC_INACTIVATION,Pancreatic_Cancer,1793,,Mitomycin_C,,Predictive,Supports,C,Sensitivity/Response,"In_a_patient_with_gemcitabine-refractory_pancreatic_cancer,_a_tumor-derived_xenograft_was_found_to_be_responsive_to_Mitomycin_C._After_disease_progression,_the_patient_was_started_on_a_regimen_of_mitomycin_C,_and_the_patient_was_shown_to_be_asymptomatic_after_3_years_of_follow-up.",21135251,PubMed,,"Villarroel_et_al.,_2011,_Mol._Cancer_Ther.",,4,accepted,1305,15013,16,23614491,23652631,,,ENST00000261584.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-03_18:34:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1305,https://civic.genome.wustl.edu/links/variants/532,https://civic.genome.wustl.edu/links/genes/15013,,,loss_of_function_variant,,17.5,Mitomycin_C,,,,,,,
FANCC,2176,LOSS-OF-FUNCTION,Pancreatic_Cancer,1793,,"Mitomycin_C,Cisplatin,Chlorambucil,Melphalan,Gemcitabine",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_the_pancreatic_cell_lines_PL11_(FANCC_homozygous_deletion)_and_Hs766T_(FANCG-mutated),_sensitivity_to_DNA_cross-linking_agents_was_observed._PL11_cells_(empty_vector_transduced)_were_more_sensitive_to_mitomycin_C_(MMC),_cisplatin,_chlorambucil,_and_melphalan_than_PL11_cells_transduced_with_a_vector_wildtype_FANCC._Similarly,_mouse_xenografts_of_PL11_cells_(empty_vector)_were_more_sensitive_to_MMC_or_gemcitabine_than_PL11_cells_expressing_a_wildtype_FANCC.",16243825,PubMed,,"van_der_Heijden_et_al.,_2005,_Clin._Cancer_Res.",,3,accepted,1307,1811,9,97861336,98079984,,,ENST00000289081.3,,,,,75,GRCh37,,Unknown,2016-06-27_23:42:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1307,https://civic.genome.wustl.edu/links/variants/534,https://civic.genome.wustl.edu/links/genes/1811,,,loss_of_function_variant,,3,Mitomycin_C,Cisplatin,Chlorambucil,Melphalan,Gemcitabine,,,
PDGFRB,5159,EBF1-PDGFRB,Acute_Lymphocytic_Leukemia,9952,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"A_10-year-old_boy_with_B-cell_acute_lymphoblastic_leukemia_refractory_to_conventional_chemotherapy_and_harboring_an_EBF1-PDGFRB_fusion_responded_to_imatinib_plus_induction_chemotherapy_(vincristine,_daunorubicin,_prednisone,_and_intrathecal_methotrexate)._Complete_remission_was_achieved_with_bone_marrow_MRD_of_0.059%_by_flow_cytometry_and_normal_PDGFRB_by_FISH._Consolidation_therapy_with_cyclophosphamide,_cytarabine,_mercaptopurine,_and_imatinib_followed_and_the_patient_was_still_in_remission_10_months_after_beginning_imatinib.",23835704,PubMed,,"Weston_et_al.,_2013,_J._Clin._Oncol.",,3,accepted,1310,4176,,,,,,,,,,,,,EBF1-PDGFRB_fusions_are_associated_with_Ph-like_acute_lymphoblastic_leukemia_lacking_the_BCR-ABL_fusion._Case_reports_have_shown_positive_responses_to_imatinib_treatment.,Somatic_Mutation,2016-07-01_18:44:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1310,https://civic.genome.wustl.edu/links/variants/535,https://civic.genome.wustl.edu/links/genes/4176,EBF1-PDGFRB_fusions_are_associated_with_Ph-like_acute_lymphoblastic_leukemia_lacking_the_BCR-ABL_fusion._Case_reports_have_shown_positive_responses_to_imatinib_treatment.,,transcript_fusion,,7.5,Imatinib,,,,,,,
MLH1,4292,METHYLATION,Stomach_Carcinoma,5517,,Oxaliplatin,,Predictive,Supports,B,Resistance,The_methylation_status_of_MLH1_was_analyzed_in_a_study_of_53_paraffin-embedded_gastric_cancer_samples._No_association_was_found_between_methylation_status_and_clinical_factors._The_study_showed_that_MLH1_methylation_was_associated_with_resistance_to_treatment_with_oxaliplatin.,24748501,PubMed,,"Li_et_al.,_2015,_Gastric_Cancer",,2,accepted,1315,3532,,,,,,,,,,,,,,Somatic_Mutation,2016-06-23_22:05:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1315,https://civic.genome.wustl.edu/links/variants/538,https://civic.genome.wustl.edu/links/genes/3532,,,,,10,Oxaliplatin,,,,,,,
FLT3,2322,T227M,Renal_Cell_Carcinoma,4450,,Sunitinib,,Predictive,Supports,B,Adverse_Response,"In_219_patients_with_mostly_Renal_Cell_Carcinoma_and_some_Gastrointestinal_Stromal_tumors_given_sunitinib_treatment,_FLT3_T227M_(rs1933437)_was_associated_with_the_development_of_leukopenia._95%_confidence_interval_of_hazard_ratio_of_between_.17_and_.77.",19667267,PubMed,,"van_Erp_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,1317,24,13,28624294,28624294,G,A,ENST00000241453.7,,,,,75,GRCh37,"FLT3_T227M_(rs1933437)_is_a_common_polymorphism_with_a_GMAF_around_.60_based_on_the_Exome_Aggregation_Consortium_(ExAC)_data._Its_role_in_cancer_predisposition_is_still_unknown,_however_it_may_be_associated_with_the_development_of_leukopenia_in_patients_treated_with_sunitinib.",Germline_Polymorphism,2016-05-17_17:47:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1317,https://civic.genome.wustl.edu/links/variants/540,https://civic.genome.wustl.edu/links/genes/24,"FLT3_T227M_(rs1933437)_is_a_common_polymorphism_with_a_GMAF_around_.60_based_on_the_Exome_Aggregation_Consortium_(ExAC)_data._Its_role_in_cancer_predisposition_is_still_unknown,_however_it_may_be_associated_with_the_development_of_leukopenia_in_patients_treated_with_sunitinib.",,"SNP,missense_variant","NM_004119.2:c.680C>T,NP_004110.2:p.Thr227Met,NC_000013.10:g.28624294G>A",15,Sunitinib,,,,,chr13_g.28624294G~A,FLT3_c.680C~T,FLT3_T227M
MTOR,2475,S2215Y,Endometrial_Adenocarcinoma,2870,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,Cell_lines_with_various_putative_activating_mutations_were_tested_for_sensitivity_to_rapamycin._The_cell_line_JHUEM7_with_the_MTOR_mutation_S2215Y_was_hypersensitive_to_rapamycin_treatment_(IC50_of_0.23_nmol/L).,24631838,PubMed,,"Grabiner_et_al.,_2014,_Cancer_Discov",,2,accepted,1319,2073,1,11184573,11184573,G,T,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-29_20:24:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1319,https://civic.genome.wustl.edu/links/variants/542,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6644C>A,NC_000001.10:g.11184573G>T,NM_004958.3:c.6644C>A,NP_004949.1:p.Ser2215Tyr",2,Rapamycin_(Sirolimus),,,,,chr1_g.11184573G~T,MTOR_c.6644C~A,MTOR_S2215Y
MTOR,2475,C1483Y,T-cell_Acute_Lymphoblastic_Leukemia,5603,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,"Cell_lines_with_various_putative_activating_mutations_were_tested_for_sensitivity_to_rapamycin._The_cell_line_MOLT16,_with_MTOR_mutation_C1483Y_was_hypersensitive_to_rapamycin_treatment_(IC50_of_0.75_nmol/L).",24631838,PubMed,,"Grabiner_et_al.,_2014,_Cancer_Discov",,2,accepted,1320,2073,1,11217230,11217230,C,T,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-24_20:56:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1320,https://civic.genome.wustl.edu/links/variants/543,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.4448G>A,NC_000001.10:g.11217230C>T,NM_004958.3:c.4448G>A,NP_004949.1:p.Cys1483Tyr",2,Rapamycin_(Sirolimus),,,,,chr1_g.11217230C~T,MTOR_c.4448G~A,MTOR_C1483Y
MTOR,2475,E1799K,Clear_Cell_Renal_Cell_Carcinoma,4467,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,"Cell_lines_with_various_putative_activating_mutations_were_tested_for_sensitivity_to_rapamycin._The_cell_line_SNU349,_with_MTOR_mutation_E1799K_was_hypersensitive_to_rapamycin_treatment_(IC50_of_0.19_nmol/L).",24631838,PubMed,,"Grabiner_et_al.,_2014,_Cancer_Discov",,2,accepted,1321,2073,1,11190804,11190804,C,T,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_15:24:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1321,https://civic.genome.wustl.edu/links/variants/544,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"NM_004958.3:c.5395G>A,NP_004949.1:p.Glu1799Lys,NC_000001.10:g.11190804C>T,ENST00000361445.4:c.5395G>A",2,Rapamycin_(Sirolimus),,,,,chr1_g.11190804C~T,MTOR_c.5395G~A,MTOR_E1799K
FGFR2,2263,N550K,Endometrial_Cancer,1380,,PD173074,,Predictive,Supports,D,Sensitivity/Response,"The_endometrial_cancer_cell_lines,_AN3CA_and_MFE296,_which_carry_the_N550K_FGFR2_mutation,_were_found_to_be_sensitive_to_FGFR_inhibition_with_PD174074_(10_to_40x_more_sensitive_than_cell_lines_with_wild_type_FGFR2.).",18757403,PubMed,,"Byron_et_al.,_2008,_Cancer_Res.",,3,accepted,1322,22,10,123258034,123258034,A,T,ENST00000457416.2,,,,,75,GRCh37,,Somatic_Mutation,2016-06-29_20:23:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1322,https://civic.genome.wustl.edu/links/variants/545,https://civic.genome.wustl.edu/links/genes/22,,,"gain_of_function_variant,missense_variant","NM_022970.3:c.1650T>A,NP_075259.4:p.Asn550Lys,ENST00000457416.2:c.1650T>A,NC_000010.10:g.123258034A>T",3,PD173074,,,,,chr10_g.123258034A~T,FGFR2_c.1650T~A,FGFR2_N550K
RB1,5925,OVEREXPRESSION,Pancreatic_Adenocarcinoma,4074,,"5-fluorouracil,Doxorubicin,Mitomycin_C,Gemcitabine",Substitutes,Predictive,Supports,D,Resistance,"In_Capan-1_cell_lines_engineered_to_reduce_pRB_expression_(by_transfection_with_p16),_resensitization_to_chemotherapy-induced_apoptosis_was_observed._The_effect_was_asserted_to_be_specific_to_pRB_depletion_because,_in_two_separate_cell_lines,_also_transfected_with_p16,_that_retained_high_pRB_expression,_chemotherapy_resistance_was_still_observed.",11792751,PubMed,,"Plath_et_al.,_2002,_J._Natl._Cancer_Inst.",,2,accepted,1324,4795,13,48877911,49056122,,,ENST00000267163.4,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_15:26:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1324,https://civic.genome.wustl.edu/links/variants/547,https://civic.genome.wustl.edu/links/genes/4795,,,,,2,5-fluorouracil,Doxorubicin,Mitomycin_C,Gemcitabine,,,,
PPP1R15A,23645,RS557806,Colorectal_Cancer,9256,,"Bevacizumab,FOLFIRI_Regimen",Combination,Predictive,Supports,B,Sensitivity/Response,"Exome_and_RNA_sequencing_was_performed_in_tumor_and_matched_normal_tissue_of_19_patients_with_metastatic_colorectal_cancer_treated_with_chemotherapy_and_bevacizumab._The_variant_PPP1R15A_(rs557806)_showed_the_most_significant_association_(P_=_0.000401)_with_FOLFIRI-bevacizumab-driven_tumor_inhibition_rate_in_exome_sequencing_data_and_the_highest_correlation_(r_=_0.74)_with_the_drug_responses_in_RNA_sequencing_data._Patients_who_were_homozygous_for_the_reference_alleles_(GG)_of_PPP1R15A_rs557806_exhibited_greater_disease_control_rates_and_a_tendency_toward_greater_overall_response_rate_than_those_with_homozygous_or_heterozygous_substitution_alleles_(GC_and_CC;_P_=_0.027_and_0.073)_when_treated_with_bevacizumab-containing_regimens._PPP1R15A_rs557806_nonsignificantly_correlated_with_DCR_in_multivariate_analysis_(P_=_0.054)._In_HCT116_xenograft_tumors,_tumor_growth_IR_with_FRB_was_25_%_in_mock_cells,_24_%_in_clones_with_reference_alleles_(G_alleles)_of_PPP1R15A_rs557806,_and_17_%_in_clones_with_substitution_alleles_(C_alleles)_of_PPP1R15A_rs557806_(P_=_0.004,_day_13)._FDG-PET_imaging_on_day_7_showed_FDG_uptake_(mean_SUV_max)_of_0.219_and_0.500_in_HCT116_xenografts_expressing_the_reference_allele_(G)_and_substitution_allele_(C)_of_PPP1R15A_rs557806,_respectively_(P_=_0.032).",27177629,PubMed,,"Roh_et_al.,_2016,_J._Cancer_Res._Clin._Oncol.",,1,accepted,1325,9722,19,49377242,49377242,G,C,ENST00000200453.5,,,,,75,GRCh37,,Germline_Polymorphism,2016-06-23_21:12:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1325,https://civic.genome.wustl.edu/links/variants/548,https://civic.genome.wustl.edu/links/genes/9722,,,"polymorphic_sequence_variant,missense_variant","NM_014330.3:c.752G>C,NP_055145.3:p.Arg251Pro,ENST00000200453.5:c.752G>C,NC_000019.9:g.49377242G>C",5,Bevacizumab,FOLFIRI_Regimen,,,,chr19_g.49377242G~C,PPP1R15A_c.752G~C,PPP1R15A_R251P
ALK,238,F1245C,Neuroblastoma,769,,Crizotinib,,Predictive,Supports,C,Resistance,A_participant_in_Children's_Oncology_Group_(COG)_study_AVDL0912_with_measurable_neuroblastoma_mutated_at_ALK_F1245C_was_administered_crizotinib_at_100mg_twice_daily.__The_patient_showed_progressive_disease_as_best_response_after_two_28-day_cycles_on_crizotinib.,23598171,PubMed,,"Mossé_et_al.,_2013,_Lancet_Oncol.",,3,accepted,1333,1,2,29436859,29436859,A,C,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_20:27:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1333,https://civic.genome.wustl.edu/links/variants/549,https://civic.genome.wustl.edu/links/genes/1,,,missense_variant,"NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G",10.5,Crizotinib,,,,,chr2_g.29436859A~C,ALK_c.3734T~G,ALK_F1245C
ALK,238,F1245C,Neuroblastoma,769,,Lorlatinib,,Predictive,Supports,D,Sensitivity/Response,"Patient_derived_xenografts_of_neuroblastoma_Felix_cells_with_F1245C_ALK_mutation_in_CB17_SCID_mice_showed_growth_inhibition_with_crizotinib_treatment_over_control,_and_mice_had_improved_duration_of_event-free_survival_(EFS)_with_crizotinib_treatment_over_vehicle,_but_EFS_with_crizotinib_went_down_to_0%_by_six_weeks.__In_contrast,_PF-06463922_treatment_induced_complete_tumor_regression_and_EFS_rate_of_100%_at_six_weeks.__PF-06463922_inhibited_viability_in_Felix_cells_at_37x_efficacy_over_crizotinib,_with_IC50_values_of_21.8_+/-_0.4_and_814.0_+/-_119_respectively.__PF-06463922_was_well_tolerated_in_the_animal_models.",26554404,PubMed,,"Infarinato_et_al.,_2016,_Cancer_Discov",,3,accepted,1330,1,2,29436859,29436859,A,C,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_19:58:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1330,https://civic.genome.wustl.edu/links/variants/549,https://civic.genome.wustl.edu/links/genes/1,,,missense_variant,"NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G",10.5,Lorlatinib,,,,,chr2_g.29436859A~C,ALK_c.3734T~G,ALK_F1245C
ALK,238,DEL4-11,Neuroblastoma,769,,Brigatinib,,Predictive,Supports,D,Sensitivity/Response,"The_MYCN_amplification_positive_relapsed_neuroblastoma-derived_cell_line_CLB-BAR_contains_the_driver_ALK_DEL_11-14_mutation,_which_removes_extracellular_domain_exons_4_through_11._Brigatinib_treatment_of_CLB-BAR_cells_reduced_MYCN_protein_levels_and_ALK_phosphorylation_(Y1604)_similar_to_crizotnib._Brigatinib_reduced_CLB-BAR_cellular_proliferation_more_effectively_than_crizotinib_(IC50_75.2_vs_186.4nM)._CLB-BAR_xenografts_in_BalbC/NUDE_mice_responded_to_brigatinib_with_reduced_tumor_volume_and_weight_(N=8/group)_as_well_as_reduced_ALK_phosphorylation_and_MYCN_levels_compared_to_untreated_controls._Release_of_brigatinib_administration_at_day_15_resulted_in_tumor_growth_(N=2).",27049722,PubMed,,"Siaw_et_al.,_2016,_Oncotarget",,3,accepted,1336,1,2,29497965,29754982,,,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-17_21:41:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1336,https://civic.genome.wustl.edu/links/variants/550,https://civic.genome.wustl.edu/links/genes/1,,,inframe_deletion,,3,Brigatinib,,,,,,,
ALK,238,ALK_FUSION_F1245C,Cancer,162,,Crizotinib,,Predictive,Supports,D,Resistance,"A_Ba/F3_cell_line_expressing_EML4-ALK_variant_1_was_created,_and_then_exposed_to_the_DNA_modifying_agent_ENU._Cells_were_subsequently_cultured_in_96_well_plates_at_increasing_concentrations_of_crizotinib_(250,_500,_720,_1000,_1440_and_2000_nM)._Cell_growth_occurred_in_all_wells_at_250_nM,_and_was_absent_at_2000_nM._From_500_through_1440_nM_there_were_progressively_fewer_resistant_clones_present._422_mutations_representing_16_different_sites_were_identified._EML4-ALK_F1245C_was_found_at_500_nM_crizotinib,_and_was_among_the_10_most_frequently_observed_mutations._Ba/F3_cells_with_unaltered_EML4-ALK_had_crizotinib_IC50_values_for_viability_of_132_+/-_45_nM._EML4-ALK_F1245C_clones_from_the_selection_assay_had_IC50_viability_value_of_425_+/-_100_nM,_while_Ba/F3_cells_expressing_reintroduced_EML4-ALK_F1245C_had_IC50_value_of_269_+/-_194_nM.",22034911,PubMed,,"Zhang_et_al.,_2011,_Chem_Biol_Drug_Des",,2,accepted,1337,1,2,29436859,29436859,A,C,ENST00000389048.3,,,,,75,GRCh37,"In_neuroblastoma,_F1245_is_one_of_three_hotspot_ALK_mutations_found_at_a_high_frequency._In_a_case_study,_a_pretreated_non-small_cell_lung_cancer_(NSCLC)_patient_with_EML4-ALK_F1245C_mutation_responded_well_to_ceritinib_after_slow_disease_progression_during_crizotinib_treatment._Crizotinib_resistance_was_attributed_to_the_F1245C_mutation,_although_the_ALK-rearrangement_was_not_sequenced_prior_to_crizotinib_treatment._The_patient's_slow_onset_of_disease_progression_during_crizotinib_treatment_mirrors_preclinical_findings_that_indicate_ALK-fusion_with_F1245C_has_moderate_resistance_to_crizotinib_compared_to_the_fusion_alone.",Somatic_Mutation,2016-06-22_19:29:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1337,https://civic.genome.wustl.edu/links/variants/551,https://civic.genome.wustl.edu/links/genes/1,"In_neuroblastoma,_F1245_is_one_of_three_hotspot_ALK_mutations_found_at_a_high_frequency._In_a_case_study,_a_pretreated_non-small_cell_lung_cancer_(NSCLC)_patient_with_EML4-ALK_F1245C_mutation_responded_well_to_ceritinib_after_slow_disease_progression_during_crizotinib_treatment._Crizotinib_resistance_was_attributed_to_the_F1245C_mutation,_although_the_ALK-rearrangement_was_not_sequenced_prior_to_crizotinib_treatment._The_patient's_slow_onset_of_disease_progression_during_crizotinib_treatment_mirrors_preclinical_findings_that_indicate_ALK-fusion_with_F1245C_has_moderate_resistance_to_crizotinib_compared_to_the_fusion_alone.",,"transcript_fusion,missense_variant","NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G",14.5,Crizotinib,,,,,chr2_g.29436859A~C,ALK_c.3734T~G,ALK_F1245C
ALK,238,ALK_FUSION_F1245C,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,"A_52_year_old_with_a_non-smoking_history_was_diagnosed_with_stage_IV_NSCLC-adenocarcinoma_and_treated_with_chemotherapy.__Upon_disease_progression,_the_initial_diagnostic_biopsy_tested_positive_for_ALK-rearrangement_using_break_apart_FISH,_but_the_ALK_fusion_was_not_sequenced_for_mutations._Break-apart_signal_was_positive_in_66%_of_tumor_cells._Crizotinib_was_initiated_and_a_sustained_near_complete_response_for_27_months_was_observed,_after_which_an_FDG-avid_cervical_lymph_node_appeared_along_with_pleural_effusions_and_pleural_nodules._A_pleural_nodule_was_biopsied_and_profiled_using_hybrid-capture_next_generation_sequencing,_and_revealed_EML4-ALK_variant_3_with_F1245C_mutation_at_mutant_allele_frequency_of_2%_and_tumor_purity_of_13%._Crizotinib_was_maintained_for_8_additional_months_due_to_low_tumor_burden_and_slow_progression.",26775591,PubMed,,"Kodityal_et_al.,_2016,_Lung_Cancer",,2,accepted,1339,1,2,29436859,29436859,A,C,ENST00000389048.3,,,,,75,GRCh37,"In_neuroblastoma,_F1245_is_one_of_three_hotspot_ALK_mutations_found_at_a_high_frequency._In_a_case_study,_a_pretreated_non-small_cell_lung_cancer_(NSCLC)_patient_with_EML4-ALK_F1245C_mutation_responded_well_to_ceritinib_after_slow_disease_progression_during_crizotinib_treatment._Crizotinib_resistance_was_attributed_to_the_F1245C_mutation,_although_the_ALK-rearrangement_was_not_sequenced_prior_to_crizotinib_treatment._The_patient's_slow_onset_of_disease_progression_during_crizotinib_treatment_mirrors_preclinical_findings_that_indicate_ALK-fusion_with_F1245C_has_moderate_resistance_to_crizotinib_compared_to_the_fusion_alone.",Somatic_Mutation,2016-06-07_03:29:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1339,https://civic.genome.wustl.edu/links/variants/551,https://civic.genome.wustl.edu/links/genes/1,"In_neuroblastoma,_F1245_is_one_of_three_hotspot_ALK_mutations_found_at_a_high_frequency._In_a_case_study,_a_pretreated_non-small_cell_lung_cancer_(NSCLC)_patient_with_EML4-ALK_F1245C_mutation_responded_well_to_ceritinib_after_slow_disease_progression_during_crizotinib_treatment._Crizotinib_resistance_was_attributed_to_the_F1245C_mutation,_although_the_ALK-rearrangement_was_not_sequenced_prior_to_crizotinib_treatment._The_patient's_slow_onset_of_disease_progression_during_crizotinib_treatment_mirrors_preclinical_findings_that_indicate_ALK-fusion_with_F1245C_has_moderate_resistance_to_crizotinib_compared_to_the_fusion_alone.",,"transcript_fusion,missense_variant","NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G",14.5,Crizotinib,,,,,chr2_g.29436859A~C,ALK_c.3734T~G,ALK_F1245C
ALK,238,ALK_FUSION_F1245C,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,C,Sensitivity/Response,"A_52_year_old_male_never_smoker_was_diagnosed_with_stage_IV_NSCLC_adenocarcinoma_and_was_treated_with_chemotherapy_with_eventual_disease_progression._He_tested_positive_for_ALK_rearrangement_via_break_apart_FISH_assay,_and_started_crizotinib_with_near_complete_response_for_27_months._Progression_then_occurred_and_biopsy_of_a_pleural_nodule_was_performed_with_hybrid-capture_NGS._EML4-ALK_variant_3_with_F1245C_mutation_was_found_with_allele_frequency_of_2%_and_tumor_purity_13%._Due_to_slow_progression_and_low_tumor_burden_crizotinib_was_maintained_for_additional_8_months,_and_then_he_was_transitioned_onto_ceritinib_at_750_mg_daily._After_3_months_ceritinib,_complete_radiographic_response_was_seen_and_the_patient_was_without_evidence_of_disease_at_6_months._Dose_was_reduced_to_600_mg_ceritinib_daily_due_to_gastrointestinal_side_effects.",26775591,PubMed,,"Kodityal_et_al.,_2016,_Lung_Cancer",,3,accepted,1338,1,2,29436859,29436859,A,C,ENST00000389048.3,,,,,75,GRCh37,"In_neuroblastoma,_F1245_is_one_of_three_hotspot_ALK_mutations_found_at_a_high_frequency._In_a_case_study,_a_pretreated_non-small_cell_lung_cancer_(NSCLC)_patient_with_EML4-ALK_F1245C_mutation_responded_well_to_ceritinib_after_slow_disease_progression_during_crizotinib_treatment._Crizotinib_resistance_was_attributed_to_the_F1245C_mutation,_although_the_ALK-rearrangement_was_not_sequenced_prior_to_crizotinib_treatment._The_patient's_slow_onset_of_disease_progression_during_crizotinib_treatment_mirrors_preclinical_findings_that_indicate_ALK-fusion_with_F1245C_has_moderate_resistance_to_crizotinib_compared_to_the_fusion_alone.",Somatic_Mutation,2016-06-07_03:29:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1338,https://civic.genome.wustl.edu/links/variants/551,https://civic.genome.wustl.edu/links/genes/1,"In_neuroblastoma,_F1245_is_one_of_three_hotspot_ALK_mutations_found_at_a_high_frequency._In_a_case_study,_a_pretreated_non-small_cell_lung_cancer_(NSCLC)_patient_with_EML4-ALK_F1245C_mutation_responded_well_to_ceritinib_after_slow_disease_progression_during_crizotinib_treatment._Crizotinib_resistance_was_attributed_to_the_F1245C_mutation,_although_the_ALK-rearrangement_was_not_sequenced_prior_to_crizotinib_treatment._The_patient's_slow_onset_of_disease_progression_during_crizotinib_treatment_mirrors_preclinical_findings_that_indicate_ALK-fusion_with_F1245C_has_moderate_resistance_to_crizotinib_compared_to_the_fusion_alone.",,"transcript_fusion,missense_variant","NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G",14.5,Ceritinib,,,,,chr2_g.29436859A~C,ALK_c.3734T~G,ALK_F1245C
ALK,238,ALK_FUSION_G1269A,Cancer,162,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"EML4-ALK_with_G1269A_mutation_was_tested_for_sensitivity_to_ceritinib_via_transduction_into_Ba/F3_cells_and_generation_of_survival_curves_varying_ceritinib_concentration._IC50_of_33_nM_was_seen,_which_was_1.5_times_the_IC50_for_EML4-ALK_wild-type,_indicating_sensitivity_of_the_G1269A_mutation_to_ceritinib_in_the_context_of_EML4-ALK._The_mutation_was_also_tested_for_ceritinib_sensitivity_in_the_context_of_NPM-ALK,_where_IC50_values_were_reported_of_19_nM_and_20_nM_for_mutant_and_wild-type_versions,_respectively,_also_indicating_sensitivity._In_western_blots,__Y1604_pALK_levels_for_wild-type_NPM-ALK_were_ablated_at_100_nM,_while_at_100_nM_residual_pALK_levels_were_seen_in_G1269A_blotting,_with_ablation_of_signal_at_and_above_300_nM,_which_differed_somewhat_from_the_equivalent_IC50_values_reported_for_mutant_and_wild-type_in_the_NPM-ALK_background,_but_still_agrees_with_sensitivity_to_ceritinib_for_this_mutation.",25727400,PubMed,,"Fontana_et_al.,_2015,_Cancer_Med",,2,accepted,1355,1,2,29432682,29432682,C,G,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_22:14:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1355,https://civic.genome.wustl.edu/links/variants/552,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala",10,Ceritinib,,,,,chr2_g.29432682C~G,ALK_c.3806G~C,ALK_G1269A
ALK,238,ALK_FUSION_G1269A,Non-small_Cell_Lung_Carcinoma,3908,,Ceritinib,,Predictive,Supports,D,Sensitivity/Response,"The_NSCLC_cell_line_MGH021-4,_harboring_SQSTM1-ALK_G1269A,_was_6_times_more_sensitive_to_ceritinib_(80nM_GI50)_than_crizotinib_(500_nM)_in_proliferation_assays_and_caused_notable_reductions_in_phospho-ALK_and_phospho-AKT_(detected_by_Western_blot)_at_concentrations_10_fold_lower_than_crizotinib._GI50_values_were_similar_in_Ba/F3_cells_expressing_either_EML4-ALK_wild-type_or_EML4-ALK_G1269A_(1.6nM_and_2.2nM,_respectively)._In_contrast,_crizotinib_treatment_of_Ba/F3_with_EML4-ALK_G1269A_had_survival_GI50_of_130nM.",24675041,PubMed,,"Friboulet_et_al.,_2014,_Cancer_Discov",,3,accepted,1342,1,2,29432682,29432682,C,G,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-06_01:00:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1342,https://civic.genome.wustl.edu/links/variants/552,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala",10,Ceritinib,,,,,chr2_g.29432682C~G,ALK_c.3806G~C,ALK_G1269A
ALK,238,ALK_FUSION_G1269A,Cancer,162,,Brigatinib,,Predictive,Supports,D,Sensitivity/Response,"EML4-ALK_with_ALK_G1269A_has_been_seen_in_crizotinib_resistant_NSCLC,_and_this_mutation_was_tested_for_Brigatinib_sensitivity_via_ectopic_expression_in_Ba/F3_cells,_where_half_maximal_inhibitory_concentration_of_9_nM_was_seen,_which_was_1.5_times_the_IC50_of_EML4-ALK_wild-type_to_brigatinib._NPM-ALK_G1269A_was_also_tested_for_brigatinib_sensitivity,_and_IC50_values_of_11_nM_were_reported_for_both_NPM-ALK_G1269A_and_NPM-ALK_wild-type._In_western_blotting,_brigatinib_at_and_above_100_nM_ablated_pALK_signal_(Y_1604),_indicating_sensitivity_of_this_variant_to_brigatinib_together_with_the_other_results.",25727400,PubMed,,"Fontana_et_al.,_2015,_Cancer_Med",,2,accepted,1353,1,2,29432682,29432682,C,G,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-10_21:38:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1353,https://civic.genome.wustl.edu/links/variants/552,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala",10,Brigatinib,,,,,chr2_g.29432682C~G,ALK_c.3806G~C,ALK_G1269A
ALK,238,ALK_FUSION_G1269A,Cancer,162,,Alectinib_(CH5424802),,Predictive,Supports,D,Resistance,"EML4-ALK_with_ALK_G1269A_mutation_was_tested_for_sensitivity_to_alectinib_using_Ba/F3_cells._In_Ba/F3_cells_with_ectopic_EML4-ALK_variant_1_G1269A,_IC50_of_84_nM_was_reported_with_alectinib,_which_was_a_6_fold_increase_over_IC50_for_EML4-ALK_wild-type._The_authors_considered_a_fold_difference_of_4_to_10_between_the_alectinib-sensitized_wild-type_and_mutant_variant_to_indicate_a_resistant_mutant_variant._In_the_background_of_the_NPM-ALK_fusion,_IC50_for_G1269A_mutation_was_104_nM,_which_was_5.3_fold_that_reported_for_NPM-ALK_wild-type._Western_blots_of_alectinib_treated_NPM-ALK_G1269A_were_performed_and_reduced_pALK_Y1604_was_seen_at_300_nM_alectinib,_and_no_pALK_at_1000_nM._In_contrast_pALK_signal_was_ablated_at_and_above_100_nM_in_NPM-ALK_wild-type.",25727400,PubMed,,"Fontana_et_al.,_2015,_Cancer_Med",,3,accepted,1354,1,2,29432682,29432682,C,G,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-10_21:40:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1354,https://civic.genome.wustl.edu/links/variants/552,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala",10,Alectinib_(CH5424802),,,,,chr2_g.29432682C~G,ALK_c.3806G~C,ALK_G1269A
CDK4,1019,AMPLIFICATION,Liposarcoma,3382,,PD0332991,,Predictive,Supports,B,Sensitivity/Response,"In_a_phase_2_clinical_trial,_NCT01209598,_30_patients_with_CDK4-amplified_and_RB-expressing_well_differentiated_and_dedifferentiated_liposarcomas_(WDLS/DDLS)_were_treated_with_a_selective_CDK_4/6_inhibitor,_PD0332991._Treatment_with_PD0332991_was_associated_with_favorable_progression_free_survival_rates_(66%_PFS_rate,_primary_end_point_being_greater_than_40%)_suggesting_that_CDK4_amplification_is_predictive_of_sensitivity_to_CDK4_inhibitor_therapy.",23569312,PubMed,,"Dickson_et_al.,_2013,_J._Clin._Oncol.",,3,accepted,1366,13,12,58141510,58146304,,,ENST00000257904.6,,,,,75,GRCh37,,Somatic_Mutation,2016-06-18_04:03:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1366,https://civic.genome.wustl.edu/links/variants/553,https://civic.genome.wustl.edu/links/genes/13,,,transcript_amplification,,30,PD0332991,,,,,,,
CDK4,1019,AMPLIFICATION,Liposarcoma,3382,,Palbociclib,,Predictive,Supports,B,Sensitivity/Response,"More_than_90%_of_well-differentiated_or_dedifferentiated_liposarcomas_(WD/DDLS)_have_CDK4_amplification.__A_prior_phase_2_study_demonstrated_that_treatment_with_palbociclib_(200_mg/d_for_14_days_every_21_days)_resulted_in_clinical_benefit_in_WD/DDLS_but_moderate_hematologic_toxic_effects._In_this_phase_2,_nonrandomized,_open-label_clinical_trial_conducted_at_the_Memorial_Sloan_Kettering_Cancer_Center,_60_patients_18_years_and_older_with_advanced_WD/DDLS_and_measurable_disease_by_RECIST_1.1_were_enrolled_from_December_2011_to_January_2014_and_followed_to_March_2015._Patients_received_oral_palbociclib_at_new_dose_scheme,_125_mg/d_for_21_days_in_28-day_cycles._Progression-free_survival_at_12_weeks_was_57.2%_and_overall_median_PFS_was_17.9_weeks._There_was_1_complete_response._Toxic_effects_were_primarily_hematologic_and_included_neutropenia_(grade_3,_n = 20_[33%];_grade_4,_n = 2_[3%])_but_no_neutropenic_fever.__Compared_to_other_dose_scheme_in_PMID_23569312_with_200mg/d:_12week_PFS_66%,_overall_median_PFS_18_weeks.",27124835,PubMed,,"Dickson_et_al.,_2016,_JAMA_Oncol",,3,accepted,4841,13,12,58141510,58146304,,,ENST00000257904.6,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_16:22:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/4841,https://civic.genome.wustl.edu/links/variants/553,https://civic.genome.wustl.edu/links/genes/13,,,transcript_amplification,,30,Palbociclib,,,,,,,
CDKN2A,1029,LOSS,Ovarian_Cancer,2394,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_of_the_effects_of_PD-0332991_on_proliferation,_cell-cycle,_apoptosis,_and_Rb_phosphorylation_in_a_panel_of_40_human_ovarian_cancer_cell_lines._Concentration-dependent_antiproliferative_effects_of_PD-0332991_were_seen_in_all_ovarian_cancer_cell_lines,_but_varied_significantly_between_individual_lines._Rb-proficient_cell_lines_with_low_p16_expression_were_significantly_more_sensitive_to_PD-0332991_(as_defined_by_IC50_<_mean)_in_mRNA_expression_(Agilent),_protein_level_(Western_Blot)_and_copy_number_(Array_CGH)_analyses.",21278246,PubMed,,"Konecny_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,1377,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_20:02:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1377,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Palbociclib_(PD0332991),,,,,,,
CDKN2A,1029,LOSS,Her2-receptor_Negative_Breast_Cancer,60080,,"Palbociclib_(PD0332991),Letrozole",Combination,Predictive,Supports,C,Sensitivity/Response,"A_patient_with_metastatic_ER-positive,_her2-negative_breast_cancer_with_CDKN2A_loss_experienced_a_short-lived_(~3-month)_clinical_response_to_palbociclib_when_given_in_combination_with_letrozole.",26715889,PubMed,,"Gao_et_al.,_2015,_Curr_Oncol",,3,accepted,1765,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Somatic_Mutation,2017-01-24_04:20:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1765,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Palbociclib_(PD0332991),Letrozole,,,,,,
CDKN2A,1029,LOSS,Skin_Melanoma,8923,,Flavopiridol,,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_9_melanoma_cell_lines._Three_cell_lines_did_not_have_CDKN2A_(p16)_mutations_and_showed_expression_of_the_protein_on_western_blot_analysis._Two_of_the_other_six_cell_lines_had_stop_codons_leading_to_a_truncated_protein,_and_three_had_missense_mutations_with_evidence_of_protein_expression_on_western_blot_(two_cell_lines_with_a_P114L_mutation_and_one_with_an_E88K_mutation)._Mean_IC50s_of_flavopiridol_were_significantly_lower_in_cell_lines_with_a_mutated_or_non-expressed_p16_(p16-)_(mean_50%_inhibitory_concentration_[IC(50)]_=_12.5_nM),_than_in_cell_lines_with_intact_p16_(p16+)_(mean_IC(50)_=_25_nM).",12777976,PubMed,,"Robinson_et_al.,_2003,_Melanoma_Res.",,2,accepted,1372,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_20:06:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1372,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Flavopiridol,,,,,,,
CDKN2A,1029,LOSS,Dermatofibrosarcoma_Protuberans,3507,,Palbociclib,,Predictive,Supports,D,Sensitivity/Response,"An_imatinib-resistant_cell_line,_DFSP105,_was_established_from_a_dermatofibrosarcoma_protuberans_which_had_progressed_to_a_high-grade_fibrosarcomatous_DFSP._The_disease-associated_PDGFB-COL1A1_fusion_was_consistent_with_the_most_common_form,_a_supernumerary_ring_chromosome._Genetic_characterization_of_the_cell_line_with_a_SNP_array_identified_a_homozygous_CDKN2A/B_deletion._Treatment_of_this_cell_line_with_CDK4/6_inhibitor_palbociclib_led_to_growth_inhibition_and_reduced_RB1_phosphorylation_in_vitro_and_in-vivo.",25852058,PubMed,,"Eilers_et_al.,_2015,_Mol._Cancer_Ther.",,2,accepted,1881,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Unknown,2017-01-30_23:02:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/1881,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Palbociclib,,,,,,,
CDKN2A,1029,LOSS,Skin_Melanoma,8923,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"In_a_cohort_of_143_patients_with_primary_invasive_melanoma_hemizygous_or_homozygous_loss_of_CDKN2A_was_observed_(FISH)_in_56%_of_cases._PD0332991_efficacy_(proliferation_assay)_was_assessed_in_a_panel_of_47_melanoma_cell_lines._Loss_of_functional_p16INK4A_(CDKN2A)_due_to_gene_deletion_(49%_of_cells),_methylation_(4%_of_cells),_or_mutation_(19%_of_cells)_was_the_most_prevalent_alteration_occurring_in_71%_of_cell_lines,_and_significantly_correlated_with_PD0332991_sensitivity_(Fisher's_exact_test_P_<_0.02).",24495407,PubMed,,"Young_et_al.,_2014,_Pigment_Cell_Melanoma_Res",,3,accepted,1375,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_20:02:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1375,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Palbociclib_(PD0332991),,,,,,,
CDKN2A,1029,LOSS,Renal_Cell_Carcinoma,4450,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_of_CDK4/6_inhibitor_PD-0332991_in_28_renal_carcinoma_cell_lines_(25_malignant_RCC_and_three_non-malignant,_transformed_cell_lines_derived_from_kidney_epithelium)._Both_p15_and_p16_loss_(CGH)_were_tested_for_association_with_response_to_PD-0332991_using_Fisher's_exact_test._Cell_lines_with_p16_and_p15_losses_were_significantly_more_likely_to_be_classified_as_responders_(defined_by_pharmacokinetic_data-based_concentration_of_<=400nM)_to_PD-0332991_(p=0.027,_relative_risk_(RR)=2.06_and_p=0.047,_RR=1.71,_respectively)._Four_cell_lines_had_homozygous_deletions_of_CDKN2A_but_not_CDKN2B,_and_three_of_these_lines_were_classified_as_being_sensitive_to_PD-0332991._There_were_no_cell_lines_with_only_CDKN2B_deletion.",23898052,PubMed,,"Logan_et_al.,_2013,_Anticancer_Res.",,3,accepted,1373,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_20:03:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1373,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Palbociclib_(PD0332991),,,,,,,
CDKN2A,1029,LOSS,Ewing_Sarcoma,3369,,"Palbociclib,Linsitinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"A_patient-derived_xenograft_(PDX)_from_a_patient_with_cyclin-dependent_kinase_inhibitor_2A/B_(CDKN2A/B)_loss_and_FUS-ERG_fusion_positive_Ewing's_sarcoma_was_created._The_PDX_was_treated_in_four_cohorts_(each_N=6)_with_control,_doxorubicin,_CDK4/6_inhibitor_palbociclib_or_IGF-1R_inhibitor_linsitinib._Both_linsitinib_and_palbociclib_cohorts_were_significantly_more_effective_than_control_and_doxorubicin._Doxorubicin_was_part_of_the_patient's_treatment_(Neoadjuvant_chemotherapy_with_DOX,_vincristine,_and_cyclophosphamide)_and_was_noted_by_authors_as_failing_to_control_tumor_growth.",27286459,PubMed,,"Murakami_et_al.,_2016,_Oncotarget",,2,accepted,1879,14,9,21967752,21994623,,,ENST00000579755.1,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_20:39:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1879,https://civic.genome.wustl.edu/links/variants/554,https://civic.genome.wustl.edu/links/genes/14,,,loss_of_function_variant,,22.5,Palbociclib,Linsitinib,,,,,,
CDKN2B,1030,LOSS,Renal_Cell_Carcinoma,4450,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_of_CDK4/6_inhibitor_PD-0332991_in_28_renal_carcinoma_cell_lines_(25_malignant_RCC_and_three_non-malignant,_transformed_cell_lines_derived_from_kidney_epithelium)._Both_p15_and_p16_loss_(CGH)_were_tested_for_association_with_response_to_PD-0332991_using_Fisher's_exact_test._Cell_lines_with_p16_and_p15_losses_were_significantly_more_likely_to_be_classified_as_responders_(defined_by_pharmacokinetic_data-based_concentration_of_<=400nM)_to_PD-0332991_(p=0.027,_relative_risk_(RR)=2.06_and_p=0.047,_RR=1.71,_respectively)._Four_cell_lines_had_homozygous_deletions_of_CDKN2A_but_not_CDKN2B,_and_three_of_these_lines_were_classified_as_being_sensitive_to_PD-0332991._There_were_no_cell_lines_with_only_CDKN2B_deletion.",23898052,PubMed,,"Logan_et_al.,_2013,_Anticancer_Res.",,3,accepted,1374,916,9,22002902,22009362,,,ENST00000276925.6,,,,,75,GRCh37,,Somatic_Mutation,2016-07-06_20:09:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1374,https://civic.genome.wustl.edu/links/variants/555,https://civic.genome.wustl.edu/links/genes/916,,,transcript_ablation,,5,Palbociclib_(PD0332991),,,,,,,
CDKN2B,1030,LOSS,Ewing_Sarcoma,3369,,"Palbociclib,Linsitinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"A_patient-derived_xenograft_(PDX)_from_a_patient_with_cyclin-dependent_kinase_inhibitor_2A/B_(CDKN2A/B)_loss_and_FUS-ERG_fusion_positive_Ewing's_sarcoma_was_created._The_PDX_was_treated_in_four_cohorts_(each_N=6)_with_control,_doxorubicin,_CDK4/6_inhibitor_palbociclib_or_IGF-1R_inhibitor_linsitinib._Both_linsitinib_and_palbociclib_cohorts_were_significantly_more_effective_than_control_and_doxorubicin._Doxorubicin_was_part_of_the_patient's_treatment_(Neoadjuvant_chemotherapy_with_DOX,_vincristine,_and_cyclophosphamide)_and_was_noted_by_authors_as_failing_to_control_tumor_growth.",27286459,PubMed,,"Murakami_et_al.,_2016,_Oncotarget",,2,accepted,1880,916,9,22002902,22009362,,,ENST00000276925.6,,,,,75,GRCh37,,Somatic_Mutation,2017-02-07_17:53:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1880,https://civic.genome.wustl.edu/links/variants/555,https://civic.genome.wustl.edu/links/genes/916,,,transcript_ablation,,5,Palbociclib,Linsitinib,,,,,,
CDK4,1019,R24C,Skin_Melanoma,8923,,Palbociclib_(PD0332991),,Predictive,Supports,D,Sensitivity/Response,"In_a_cohort_of_143_patients_with_primary_invasive_melanoma,_copy-number_gain_of_CDK4_was_observed_(FISH)_in_37%_of_cases._PD0332991_efficacy_(proliferation_assay)_was_assessed_in_a_panel_of_47_melanoma_cell_lines._Four_cell_lines_had_an_R24C_activating_mutation_in_CDK4,_three_of_these_were_sensitive_to_PD0332991_(palbociclib).",24495407,PubMed,,"Young_et_al.,_2014,_Pigment_Cell_Melanoma_Res",,1,accepted,1376,13,12,58145431,58145431,G,A,ENST00000257904.6,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_21:10:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1376,https://civic.genome.wustl.edu/links/variants/556,https://civic.genome.wustl.edu/links/genes/13,,,missense_variant,"NM_000075.3:c.70C>T,NP_000066.1:p.Arg24Cys,ENST00000257904.6:c.70C>T,NC_000012.11:g.58145431G>A",1,Palbociclib_(PD0332991),,,,,chr12_g.58145431G~A,CDK4_c.70C~T,CDK4_R24C
GNA11,2767,Q209,Uveal_Melanoma,6039,,Selumetinib_(AZD6244),,Predictive,Does_Not_Support,B,Sensitivity/Response,"101_patients_with_metastatic_uveal_melanoma_were_randomized_1:1_to_receive_selumetinib_or_chemotherapy._Median_PFS_among_patients_randomized_to_chemotherapy_was_7_weeks_(95%_CI,_4.3-8.4_weeks;_median_treatment_duration,_8_weeks;_interquartile_range_[IQR],_4.3-16_weeks)_vs._15.9_weeks_with_selumetinib_(95%_CI,_8.4-21.1_weeks;_median_treatment_duration,_16.1_weeks;_IQR,_8.1-25.3_weeks)_(hazard_ratio,_0.46;_95%_CI,_0.30-0.71;_P < 0.001)._Most_patients_(80/96_evaluable_harbored_a_mutation_in_exon_5_of_GNAQ_or_GNA11)_but_PFS_benefit_from_Selumetinib_compared_to_chemotherapy_was_greater_in_the_GNAQ_and_GNA11_wild-type_population_(25.9_weeks_[range,_3.7-40.4_weeks]_vs_15.4_weeks_[range,_8.1-16.9_weeks])._However,_PFS_was_still_better_with_Selumetinib_than_chemotherapy_in_the_GNA_mutant_population_(hazard_ratio_0.55,_95%_CI,_0.34-0.87;_P = 0.01)._The_difference_was_explained_by_potential_GNAQ_or_GNA11_mutations_outside_of_exon_5_in_the_GNA_wild-type_population._Another_three_mutations_in_exon_4_were_retrospectively_identified_in_the_wild-type_population_and_one_had_a_major_response.",24938562,PubMed,,"Carvajal_et_al.,_2014,_JAMA",,3,accepted,1212,2308,19,3118942,3118942,,,ENST00000078429.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1212,https://civic.genome.wustl.edu/links/variants/558,https://civic.genome.wustl.edu/links/genes/2308,,,missense_variant,,15,Selumetinib_(AZD6244),,,,,,,
CALR,811,EXON_9_FRAMESHIFT,Chronic_Myeloproliferative_Disease,2226,,Pegylated_IFN-alpha-2a,,Predictive,Supports,B,Sensitivity/Response,"Study_explored_the_hematologic_and_molecular_responses_in_a_cohort_of_31_patients_presenting_with_thrombocythemia_and_CALR_exon_9_frameshift_mutations._All_31_patients_exhibited_a_hematologic_response_at_the_time_of_followup_(European_LeukemiaNet_criteria)._In_regards_to_molecular_response,_before_treatment_the_CALR_mutant_allele_displayed_a_median_frequency_of_41%_across_the_cohort,_during_treatment_a_significant_decrease_was_observed_in_comparison_to_controls_treated_with_hydroxyurea_and_aspirin.",26486786,PubMed,,"Verger_et_al.,_2015,_Blood",,4,accepted,1482,732,19,13054527,13054727,,,ENST00000316448.5,,,,,75,GRCh37,"Exon_9_insertions_and_deletions_have_become_part_of_the_WHO_diagnostic_criteria_for_essential_thrombocythemia_(ET)_and_primary_myelofibrosis_(PMF)_(Arber_et_al,_2016)._These_mutations_are_typically_heterozygous_and_in_the_absence_of_JAK2_and_MPL_mutations._Approximately_80%_of_observed_mutations_are_type_1_(p.L367fs*46),_the_result_of_a_52 bp_deletion,_or_type_2_(p.K385fs*47),_the_result_of_a_5-bp_TTGTC_insertion,_and_studies_have_suggested_phenotypic_and_prognostic_differences_between_them._In_PMF_patients,_CALR_exon_9_mutations_have_been_associated_with_improved_median_survival.",Somatic_Mutation,2017-04-12_20:42:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1482,https://civic.genome.wustl.edu/links/variants/559,https://civic.genome.wustl.edu/links/genes/732,"Exon_9_insertions_and_deletions_have_become_part_of_the_WHO_diagnostic_criteria_for_essential_thrombocythemia_(ET)_and_primary_myelofibrosis_(PMF)_(Arber_et_al,_2016)._These_mutations_are_typically_heterozygous_and_in_the_absence_of_JAK2_and_MPL_mutations._Approximately_80%_of_observed_mutations_are_type_1_(p.L367fs*46),_the_result_of_a_52 bp_deletion,_or_type_2_(p.K385fs*47),_the_result_of_a_5-bp_TTGTC_insertion,_and_studies_have_suggested_phenotypic_and_prognostic_differences_between_them._In_PMF_patients,_CALR_exon_9_mutations_have_been_associated_with_improved_median_survival.",,exon_variant,,80,Pegylated_IFN-alpha-2a,,,,,,,
EGFR,1956,S768I,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Resistance,"In_stage_IV_lung_adenocarcinoma_patients_(n=2)_harboring_EGFR_S768I_mutation,_EGFR_S768I_was_associated_with_progressive_disease_after_1_month_of_erlotinib_monotherapy;_the_patient_was_previously_treated_with_standard_chemotherapy.",22895145,PubMed,,"Lund-Iversen_et_al.,_2012,_J_Thorac_Oncol",,,accepted,4273,19,7,55249005,55249005,G,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-08-17_16:14:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/4273,https://civic.genome.wustl.edu/links/variants/562,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile",17.5,Erlotinib,,,,,chr7_g.55249005G~T,EGFR_c.2303G~T,EGFR_S768I
EGFR,1956,S768I,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"S768I_mutations_in_exon_20_of_the_EGFR_gene_are_rare_and_are_typically_seen_in_conjunction_with_sensitizing_EGFR_mutations._Because_of_this_mutation's_rarity_and_the_variability_of_responses_of_treated_cases,_its_exact_prognostic_and_predictive_role_is_not_fully_understood._In_our_experience,_S768I_mutations_in_isolation_do_not_necessarily_confer_sensitivity_to_erlotinib,_but_in_conjunction_with_sensitizing_EGFR_mutations,_S768I_mutations_do_not_restrict_efficacy.",27211795,PubMed,,"Leventakos_et_al.,_2016,_J_Thorac_Oncol",,2,accepted,2906,19,7,55249005,55249005,G,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-05-23_13:43:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/2906,https://civic.genome.wustl.edu/links/variants/562,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile",17.5,Erlotinib,,,,,chr7_g.55249005G~T,EGFR_c.2303G~T,EGFR_S768I
EGFR,1956,S768I,Lung_Adenocarcinoma,3910,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_an_81-year_old_man_with_lung_adenocarcinoma_and_EGFR_S768I_mutation._The_patient_then_received_chemotheraoy_(vinorelbine)_and_showed_stable_disease._Gefitinib_was_administered_when_disease_progression_was_noted_4_months_later_and_the_patient_was_followed-up_without_signs_of_disease_progression_for_461_days.,20522446,PubMed,,"Masago_et_al.,_2010,_Jpn._J._Clin._Oncol.",,2,accepted,1395,19,7,55249005,55249005,G,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-07-07_23:51:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1395,https://civic.genome.wustl.edu/links/variants/562,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile",17.5,Gefitinib,,,,,chr7_g.55249005G~T,EGFR_c.2303G~T,EGFR_S768I
EGFR,1956,S768I,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,A_patient_with_metastatic_lung_adenocarcinoma_was_found_to_harbor_EGFR_T790M_and_S768I_mutations_when_acquired_resistance_developed_after_8_years_of_erlotinib_treatment._Analysis_of_original_tumor_samples_from_2001_and_2003_were_found_to_also_harbor_the_S768I_(but_not_T790M)_mutation._Three-dimensional_visualization_showed_the_768_position_to_be_outside_of_the_erlotinib_binding_position.,25521405,PubMed,,"Hellmann_et_al.,_2014,_J_Thorac_Oncol",,3,accepted,1394,19,7,55249005,55249005,G,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2016-07-10_21:22:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1394,https://civic.genome.wustl.edu/links/variants/562,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile",17.5,Erlotinib,,,,,chr7_g.55249005G~T,EGFR_c.2303G~T,EGFR_S768I
EGFR,1956,S768I,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_S768I_demonstrated_reduced_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_S768I_and_EGFR_L858R_expressing_cells_were_250_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4274,19,7,55249005,55249005,G,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-16_11:31:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/4274,https://civic.genome.wustl.edu/links/variants/562,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile",17.5,Erlotinib,,,,,chr7_g.55249005G~T,EGFR_c.2303G~T,EGFR_S768I
BRAF,673,V600K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"In_the_Phase_III_study_of_vemurafenib_versus_dacarbazine_BRIM-3_(NCT01006980)_in_metastatic_melanoma,_57_patients_were_confirmed_to_have_V600K_mutation._In_this_subgroup_of_treatment-naive_patients,_significant_differences_were_seen_in_overall_survival_(14.5_months_with_vemurafenib_vs._7.6_months_with_dacarbazine),_as_well_as_median_progression_free_survival_(5.9_months_with_vemurafenib_vs._1.7_months_with_dacarbazine).",24508103,PubMed,,"McArthur_et_al.,_2014,_Lancet_Oncol.",,4,accepted,1399,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_23:40:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1399,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Vemurafenib,,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Sensitivity/Response,"In_a_retrospective_study_of_300_stage_IV_melanoma_patients,_patients_with_BRAF_V600K_mutation_(n=18)_were_associated_with_a_5.6%_(1/18)_complete_response,_a_22.2%_(4/18)_partial_response_and_stable_disease_in_44.4%_(8/18)_of_cases;_however,_27.8%_(5/18)_of_patients_harboring_BRAF_V600K_experienced_progressive_disease_and_patients_with_BRAF_V600E_mutation_achieved_a_more_impressive_clinical_benefit,_as_compared_to_patients_with_BRAF_V600K_mutation_(P=0.016).",25524477,PubMed,,"Ugurel_et_al.,_2015,_Ann._Oncol.",,,accepted,4180,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:19:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/4180,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Vemurafenib,,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Skin_Melanoma,8923,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_a_clinical_trial_(NCT01597908)_of_704_metastatic_melanoma_patients,_patients_harboring_a_BRAF_V600K_mutation_and_treated_with_vemurafenib_(n=34)_were_associated_with_a_44%_response_rate,_as_compared_to_a_65%_response_rate_in_V600E_mutation_positive_patients_treated_with_dabrafenib_and_trametinib_combination_therapy_(n=34).",25399551,PubMed,,"Robert_et_al.,_2015,_N._Engl._J._Med.",NCT01597908,3,accepted,4181,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:05:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/4181,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Dabrafenib,Trametinib,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Melanoma,1909,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Adjuvant_dual_treatment_with_BRAF_inhibitor_dabrafenib_and_MEK_inhibitor_trametinib_was_administered_to_patients_with_stage_III_resected_melenoma_with_V600E_or_V600K_mutation_in_this_stage_III_trial_(COMBO-AD,_NCT01682083)._78_(9%)_patients_had_V600K,_and_were_administered_dabrafenib_and_trametinib_or_placebo_for_12_months._In_subsequent_analysis,_relapse_or_death_occurred_in_16/41_patients_(39%)_in_the_treatment_group_and_19/37_patients_(51%)_in_the_placebo_group_for_a_95%_CI_Hazard_Ratio_of_0.54_(0.27-1.06).",28891408,PubMed,,"Long_et_al.,_2017,_N._Engl._J._Med.",NCT01682083,4,accepted,6179,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:05:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/6179,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Trametinib,Dabrafenib,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Melanoma,1909,,Dabrafenib,,Predictive,Supports,B,Sensitivity/Response,"Patients_were_treated_with_a_specific_RAF_inhibitor_(dabrafenib),_which_improved_overall_survival_of_patients_with_BRAF_mutations_(P<0.003),_compared_to_non-treated_patients_with_BRAF_mutations._Patients_having_BRAF_mutations_were_associated_with_reduced_overall_survival_(11.1_mo_vs._46.1_mo_for_wild-type,_P=0.006)._BRAF_mutations_were_more_frequent_in_tumors_with_superficially_spreading_histological_sub-type_(43%__vs._19%_,_P<0.001)_compared_to_BRAF_wild-type_tumors.",21343559,PubMed,,"Long_et_al.,_2011,_J._Clin._Oncol.",,,accepted,2505,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:17:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/2505,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Dabrafenib,,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Melanoma,1909,,"Trametinib,Dabrafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"In_this_Phase_III_trial_(coBRIM,_NCT01689519)_of_495_V600_mutant_melanoma_patients,_56_had_V600K_mutation._32_patients_were_treated_with_vemurafenib_and_placebo,_and_24_were_treated_with_vemurafenib_and_cobimetinib_and_tested_for_progression_free_survival._17_of_32_monotherapy_group_patients_had_an_event_with_median_progression_free_survival_of_5.3_months._In_the_combination_group_4_of_24_patients_had_an_event_with_median_progression-free_survival_not_met,_however,_when_in_combination_with_other_V600_mutations_median_progression-free_survival_was_9.9_months_with_combination_treatment._Median_time_to_followup_for_the_whole_cohort_was_7.3_months._Hazard_Ratio_for_progression_or_death_was_0.27_(0.09-0.81).",25265494,PubMed,,"Larkin_et_al.,_2014,_N._Engl._J._Med.",,4,accepted,6965,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-11-08_16:57:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/6965,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Trametinib,Dabrafenib,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,C,Sensitivity/Response,"A_53_year_old_male_presented_with_a_scalp_lesion_which_was_incompletely_excised._Metastases_were_seen_in_lymph_node_biopsy_and_subsequently_in_CT._BRAF_inhibitor_vemurafenib_was_then_administered_at_960_mg_twice_daily_and_later_at_720_mg_twice_daily_and_reduction_in_metastases_was_observed._After_2_years_complete_radiological_response_was_seen,_while_treatment_was_discontinued_due_to_cardiomyopathy._12_months_after_stopping_vemurafenib_patient_did_not_show_evidence_of_metastatic_melanoma.",26989536,PubMed,,"Sahadudheen_et_al.,_2016,_Case_Rep_Oncol_Med",,3,accepted,1400,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-06-27_23:29:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1400,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Vemurafenib,,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
BRAF,673,V600K,Melanoma,1909,,Trametinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_study_of_322_advanced_melanoma_patients_with_BRAF-V600E_or_BRAF-V600K_mutations,_treatment_with_trametinib_was_associated_with_improved_progression-free_survival_(4.8mo_vs._1.5mo,_<0.001)_compared_to_chemotherapy_control_group._Additionally,_treatment_with_trametinib_was_associated_with_increased_6-month_overall_survival_(HR:0.54,_95%_CI:0.32-0.92,_P=0.01).",22663011,PubMed,,"Flaherty_et_al.,_2012,_N._Engl._J._Med.",,,accepted,2506,5,7,140453136,140453137,AC,TT,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:18:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/2506,https://civic.genome.wustl.edu/links/variants/563,https://civic.genome.wustl.edu/links/genes/5,,Other_V600's,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",82.5,Trametinib,,,,,chr7_g.140453136_140453137delinsTT,BRAF_c.1798_1799delGTinsAA,BRAF_V600K
SF3B1,23451,K700E,Breast_Cancer,1612,,Spliceostatin_A,,Predictive,Supports,D,Sensitivity/Response,"Mutations_in_SF3B1_were_identified_in_21/936_ER_positive_vs._1/289_ER_negative_breast_cancers._Mutation_was_recurrent_(K700E_in_74%_or_K666Q_or_K666E_in_another_9%_of_tumors)._Treatment_of_two_SF3B1_mutant_cell_lines_(pancreatic_and_endometrial_with_K700_and_K666_mutation,_respectively)_and_six_wild-type_controls_showed_that_mutant_cell_lines_were_significantly_more_sensitive_to_spliceostatin_A_(SF3b_complex_inhibitor).",25424858,PubMed,,"Maguire_et_al.,_2015,_J._Pathol.",,2,accepted,1417,44,2,198266834,198266834,T,C,ENST00000335508.6,,,,,75,GRCh37,,Somatic_Mutation,2016-07-13_18:40:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1417,https://civic.genome.wustl.edu/links/variants/565,https://civic.genome.wustl.edu/links/genes/44,,HEAT_domain_mutation,missense_variant,"NM_012433.3:c.2098A>G,NP_036565.2:p.Lys700Glu,ENST00000335508.6:c.2098A>G,NC_000002.11:g.198266834T>C",2,Spliceostatin_A,,,,,chr2_g.198266834T~C,SF3B1_c.2098A~G,SF3B1_K700E
PDGFRB,5159,PDGFRB_FUSIONS,Chronic_Myeloproliferative_Disease,2226,,Imatinib,,Predictive,Supports,A,Sensitivity/Response,"Twelve_patients_with_BCR-ABL-negative_chronic_myeloproliferative_disease_and_reciprocal_translocations_involving_PDGFRB_received_imatinib_for_a_median_of_47_months_(range,_0.1-60_months)._Eleven_had_prompt_responses,_10_had_complete_resolution_of_cytogenetic_abnormalities_and_decrease_or_disappearance_of_fusion_transcripts_as_measured_by_reverse_transcriptase-polymerase_chain_reaction_(RT-PCR)._Updates_were_sought_from_8_further_patients_previously_described_in_the_literature;_prompt_responses_were_described_in_7_and_persist_in_6.",16960151,PubMed,,"David_et_al.,_2007,_Blood",,4,accepted,1498,4176,,,,,,,,,,,,,,Somatic_Mutation,2017-01-05_19:09:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/1498,https://civic.genome.wustl.edu/links/variants/568,https://civic.genome.wustl.edu/links/genes/4176,,,transcript_fusion,,140,Imatinib,,,,,,,
IDH2,3418,MUTATION,Acute_Myeloid_Leukemia,9119,,Enasidenib_(AG-221),,Predictive,Supports,D,Sensitivity/Response,"Mutations_in_IDH1_or_IDH2_are_identified_in_approximately_20%_of_patients_with_AML.This_study_report_the_discovery_and_characterization_of_AG-221,_orally_available,_selective,_potent_inhibitor_of_the_mutant_IDH2_enzyme._AG-221_suppressed_oncometobolite_2HG_production_and_induced_cellular_differentiation_in_primary_human_IDH2_mutated_AML_cells_in_vivo_and_in_xenograft_mouse_models,_providing_a_statistically_significant_benefit_in_an_aggressive_IDH2_R140Q-mutant_AML_xenograft_mouse_model._Clinical_trials_are_ongoing.",28193778,PubMed,,"Yen_et_al.,_2017,_Cancer_Discov",,4,accepted,4833,27,15,90626277,90645736,,,ENST00000330062.3,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_21:22:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/4833,https://civic.genome.wustl.edu/links/variants/570,https://civic.genome.wustl.edu/links/genes/27,,,protein_altering_variant,,54,Enasidenib_(AG-221),,,,,,,
IDH2,3418,MUTATION,Acute_Myeloid_Leukemia,9119,,Enasidenib,,Predictive,Supports,B,Sensitivity/Response,"A_first-in-human_phase_1/2_trial_assessing_the_pharmacology,_safety_and_activity_of_Enasidenib_in_IDH2-mutant_myeloid_hematoblastosis_patients._In_the_AML_subgroup_(n=176)_of_included_patients_(n=239)_the_overall_response_rate_was_40.3%,_with_median_response_duration_of_5.8_months._Responses_were_associated_with_cellular_differentiation_and_maturation,_typically_without_evidence_of_aplasia._Median_overall_survival_among_relapsed/refractory_patients_was_9.3_months,_and_for_the_34_patients_(19.3%)_with_complete_response_was_19.7_months.",28588020,PubMed,,"Stein_et_al.,_2017,_Blood",,4,accepted,5069,27,15,90626277,90645736,,,ENST00000330062.3,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_21:21:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/5069,https://civic.genome.wustl.edu/links/variants/570,https://civic.genome.wustl.edu/links/genes/27,,,protein_altering_variant,,54,Enasidenib,,,,,,,
MTOR,2475,E2014K_+_E2419K,Urothelial_Carcinoma,2671,,"Pazopanib,Everolimus",Combination,Predictive,Supports,C,Sensitivity/Response,"A_phase_1_clinical_trial_identified_a_patient_with_chemotherapy-refractory_urothelial_carcinoma_who_had_complete_radiographic_response_lasting_14_months_after_combined_everolimus_and_pazopanib_treatment._This_patient_was_exome_sequenced_and_two_mutations_co-occurring_in_MTOR_were_identified._Expression_of_these_mutations_in_HEK293T_cells_demonstrated_these_were_activating_mutations._The_authors_propose_that_these_two_activating_mutations_are_the_reason_for_the_dramatic_response_to_mTOR_inhibition_and_considered_them_as_""biologically_plausible""_to_confer_sensitivity_to_everolimus.",24625776,PubMed,,"Wagle_et_al.,_2014,_Cancer_Discov",,2,accepted,1438,2073,1,11174420,11187857,,,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-08-22_19:43:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1438,https://civic.genome.wustl.edu/links/variants/572,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,,5,Pazopanib,Everolimus,,,,,,
RICTOR,253260,AMPLIFICATION,Lung_Adenocarcinoma,3910,,"Cc-223,MLN0128",Substitutes,Predictive,Supports,C,Sensitivity/Response,Study_describes_an_18_year_old_never_smoker_patient_presenting_with_lung_adenocarcinoma._A_genomic_profiling_assay_(FoundationOne)_revealed_a_7-copy_amplification_of_RICTOR_as_the_only_somatic_alteration._RICTOR_amplification_was_confirmed_via_FISH_and_IHC._On_two_separate_treatments_with_dual_mTOR1/2_inhibitors_patient_exhibited_stable_disease_for_more_than_18_months.,26370156,PubMed,,"Cheng_et_al.,_2015,_Cancer_Discov",,2,accepted,1440,20480,5,38938021,39074510,,,ENST00000357387.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_21:41:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1440,https://civic.genome.wustl.edu/links/variants/573,https://civic.genome.wustl.edu/links/genes/20480,,,transcript_amplification,,5,Cc-223,MLN0128,,,,,,
PDGFRA,5156,FIP1L1-PDGFRA,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Imatinib,,Predictive,Supports,B,Sensitivity/Response,A_cohort_of_seven_male_patients_with_myeloproliferative_hypereosinophilic_syndrome_and_elevated_serum_tryptase_levels_were_enrolled_in_a_study_of_imatinib_mesylate_therapy._All_seven_patients_demonstrated_improvement_in_clinical_symptoms_and_resolution_of_laboratory_abnormalities_and_bone_marrow_pathology_in_response_to_treatment._Complete_molecular_remission_of_FIP1L1-PDGFRA_was_observed_in_5_of_6_patients_tested_post-therapy.,14504092,PubMed,,"Klion_et_al.,_2004,_Blood",,4,accepted,1441,38,4,54243812,54294350,,,ENST00000337488.6,4,55141008,55164414,ENST00000257290.5,75,GRCh37,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",Somatic_Mutation,2017-04-11_20:55:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1441,https://civic.genome.wustl.edu/links/variants/574,https://civic.genome.wustl.edu/links/genes/38,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",,transcript_fusion,,60.5,Imatinib,,,,,,,
PDGFRA,5156,FIP1L1-PDGFRA,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Ponatinib,,Predictive,Supports,D,Sensitivity/Response,"In_a_FIP1L1-PDGFRA_positive_eosinophil_cell_line_growth-inhibitory_effects_were_seen_with_all_PDGFR-blocking_agents,_(ponatinib,_sorafenib,_masitinib,_nilotinib,_dasatinib,_sunitinib,_midostaurin)_with_ponatinib_found_to_be_the_most_potent_compound.",24407160,PubMed,,"Sadovnik_et_al.,_2014,_Exp._Hematol.",,3,accepted,1777,38,4,54243812,54294350,,,ENST00000337488.6,4,55141008,55164414,ENST00000257290.5,75,GRCh37,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",,2017-01-23_18:26:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1777,https://civic.genome.wustl.edu/links/variants/574,https://civic.genome.wustl.edu/links/genes/38,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",,transcript_fusion,,60.5,Ponatinib,,,,,,,
PDGFRA,5156,FIP1L1-PDGFRA,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Imatinib,,Predictive,Supports,A,Sensitivity/Response,"Of_eleven_patients_prospectively_accrued_with_hypereosinophilic_syndrome,_nine_had_favorable_responses_to_imatinib_that_lasted_>3_months_post-treatment._Of_these_nine_patients,_five_were_found_to_have_a_FIP1L1-PDGFRA_fusion.",12660384,PubMed,,"Cools_et_al.,_2003,_N._Engl._J._Med.",,3,accepted,1445,38,4,54243812,54294350,,,ENST00000337488.6,4,55141008,55164414,ENST00000257290.5,75,GRCh37,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",Somatic_Mutation,2017-04-11_20:54:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1445,https://civic.genome.wustl.edu/links/variants/574,https://civic.genome.wustl.edu/links/genes/38,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",,transcript_fusion,,60.5,Imatinib,,,,,,,
PDGFRA,5156,FIP1L1-PDGFRA,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"A_patient_with_monoblastic_myeloid_sarcoma_harbouring_a_PCR_confirmed_FIP1L1-PDGFRA_rearrangement_was_treated_with_imatinib_monotherapy._The_patient_demonstrated_a_durable_response_(10_wks)_while_on_therapy_which_was_reversed_when_the_patient_discontinued_treatment._Imatinib_therapy_was_subsequently_restarted,_with_peripheral_blood_and_BM_analyses_returning_to_normal_after_4_weeks.",24456122,PubMed,,"Srinivas_et_al.,_2014,_Br._J._Haematol.",,3,accepted,1774,38,4,54243812,54294350,,,ENST00000337488.6,4,55141008,55164414,ENST00000257290.5,75,GRCh37,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",Somatic_Mutation,2017-04-13_03:14:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1774,https://civic.genome.wustl.edu/links/variants/574,https://civic.genome.wustl.edu/links/genes/38,"Prospective_trials_of_patients_with_hypereosinophilic_syndrome_harboring_the_FIP1L1-PDGFRA_fusion_identified_marked_response_to_imatinib_treatment_(Gotlib_and_Cool,_Leukemia_2008)._Imatinib_is_FDA_approved_for_the_treatment_of_&quot;adult_patients_with_hypereosinophilic_syndrome_(HES)_and/or_chronic_eosinophilic_leukemia_(CEL)_who_have_the_FIP1L1-PDGFRα_fusion_kinase&quot;_(NDA021588).",,transcript_fusion,,60.5,Imatinib,,,,,,,
ROS1,6098,TFG-ROS1,Inflammatory_Myofibroblastic_Tumor,50905,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_pediatric_patient_with_treatment-refactory_inflammatory_myofibroblastic_tumor_negative_for_ALK_expression_and_rearrangement._Next_generation_sequencing_of_the_patient_revealed_a_TFG-ROS1_fusion._CT_scans_after_3_cycles_of_crizotinib_treatment_showed_a_reduction_of_the_tumor_mass_which_continued_to_decrease_at_the_time_of_publication_after_4_months_of_crizonitib_treatment.,24875859,PubMed,,"Lovly_et_al.,_2014,_Cancer_Discov",,3,accepted,1444,4941,3,100428269,100447702,,,ENST00000240851.4,6,117609463,117642557,ENST00000368508.3,75,GRCh37,,Somatic_Mutation,2016-08-19_18:19:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1444,https://civic.genome.wustl.edu/links/variants/576,https://civic.genome.wustl.edu/links/genes/4941,,,transcript_fusion,,7.5,Crizotinib,,,,,,,
PDGFRA,5156,FIP1L1-PDGFRA_T674I,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Ponatinib,,Predictive,Supports,D,Sensitivity/Response,"Ba/F3_cells_expressing_two_clinically_relevant,_imatinib-resistant,_mutant_forms_of_FIP1L1-PDGFRA,_namely_T674I_and_D842V_were_tested_for_growth_inhibition_by_8_PDGFR-blocking_TKIs._Strong_inhibitory_effects_on_both_mutants_were_seen_only_with_ponatinib.",24407160,PubMed,,"Sadovnik_et_al.,_2014,_Exp._Hematol.",,3,accepted,1779,38,4,55144547,55144547,C,T,ENST00000257290.5,,,,,75,GRCh37,A_case_study_of_relapsed_myeloproliferative_hypereosinophilic_syndrome_suggests_that_a_T674I_mutation_in_the_PDGFRA_split_kinase_domain_of_FIP1L1-PDGFRA_fusions_may_confer_resistance_to_imatinib.,Somatic_Mutation,2017-01-30_23:04:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1779,https://civic.genome.wustl.edu/links/variants/577,https://civic.genome.wustl.edu/links/genes/38,A_case_study_of_relapsed_myeloproliferative_hypereosinophilic_syndrome_suggests_that_a_T674I_mutation_in_the_PDGFRA_split_kinase_domain_of_FIP1L1-PDGFRA_fusions_may_confer_resistance_to_imatinib.,,"transcript_fusion,missense_variant","NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile",15.5,Ponatinib,,,,,chr4_g.55144547C~T,PDGFRA_c.2021C~T,PDGFRA_T674I
PDGFRA,5156,FIP1L1-PDGFRA_T674I,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Imatinib,,Predictive,Supports,C,Resistance,"One_patient_with_FIP1L1/PDGFRA-positive_CEL_was_identified_as_developing_secondary_resistance_to_imatinib._A_PDGFRA_T674I_mutation_was_identified_in_the_tyrosine_kinase_domain._Salvage_therapy_with_nilotinib_and_sorafenib_each_failed_in_this_patient,_who_was_eventually_transplanted_with_an_HLA-matched_sibling_donor.",21818111,PubMed,,"Metzgeroth_et_al.,_2012,_Leukemia",,3,accepted,7020,38,4,55144547,55144547,C,T,ENST00000257290.5,,,,,75,GRCh37,A_case_study_of_relapsed_myeloproliferative_hypereosinophilic_syndrome_suggests_that_a_T674I_mutation_in_the_PDGFRA_split_kinase_domain_of_FIP1L1-PDGFRA_fusions_may_confer_resistance_to_imatinib.,Somatic_Mutation,2018-12-28_16:03:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/7020,https://civic.genome.wustl.edu/links/variants/577,https://civic.genome.wustl.edu/links/genes/38,A_case_study_of_relapsed_myeloproliferative_hypereosinophilic_syndrome_suggests_that_a_T674I_mutation_in_the_PDGFRA_split_kinase_domain_of_FIP1L1-PDGFRA_fusions_may_confer_resistance_to_imatinib.,,"transcript_fusion,missense_variant","NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile",15.5,Imatinib,,,,,chr4_g.55144547C~T,PDGFRA_c.2021C~T,PDGFRA_T674I
PDGFRA,5156,FIP1L1-PDGFRA_T674I,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Imatinib,,Predictive,Supports,C,Resistance,"A_patient_treated_with_imatinib_for_a_FIP1L1-PDGFRA_mutation_relapsed_during_treatment._A_T674I_mutation_in_the_PDGFRA_split_kinase_domain_was_hypothesized_to_confer_resistance,_due_to_the_strong_evidence_of_this_fusion_in_driving_myeloproliferative_hypereosinophilic_syndrome_and_the_contextual_similarity_to_T315I_mutations_in_BCR-ABL.",12660384,PubMed,,"Cools_et_al.,_2003,_N._Engl._J._Med.",,2,accepted,1446,38,4,55144547,55144547,C,T,ENST00000257290.5,,,,,75,GRCh37,A_case_study_of_relapsed_myeloproliferative_hypereosinophilic_syndrome_suggests_that_a_T674I_mutation_in_the_PDGFRA_split_kinase_domain_of_FIP1L1-PDGFRA_fusions_may_confer_resistance_to_imatinib.,Somatic_Mutation,2017-04-11_20:55:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/1446,https://civic.genome.wustl.edu/links/variants/577,https://civic.genome.wustl.edu/links/genes/38,A_case_study_of_relapsed_myeloproliferative_hypereosinophilic_syndrome_suggests_that_a_T674I_mutation_in_the_PDGFRA_split_kinase_domain_of_FIP1L1-PDGFRA_fusions_may_confer_resistance_to_imatinib.,,"transcript_fusion,missense_variant","NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile",15.5,Imatinib,,,,,chr4_g.55144547C~T,PDGFRA_c.2021C~T,PDGFRA_T674I
BIRC5,332,OVEREXPRESSION,Her2-receptor_Positive_Breast_Cancer,60079,,Trastuzumab,,Predictive,Supports,B,Resistance,"13_HER2_breast_cancer_patients_were_treated_with_trastuzumab_and_then_trastuzumab_+_docetaxel_prior_to_surgery._Pretreatment_biopsies_and_post-treatment_surgical_samples_were_obtained,_and_microarray_performed._5_of_13_patients_responded_to_treatment,_and_pretreatment_biopsies_from_non-responders_showed_significantly_higher_survivin_(BIRC5)_mRNA_(p=0.026)_levels_than_responders._In_HER2_positive,_trastuzumab-sensitive_BT474_cells,_overexpression_of_survivin_blunted_sensitivity_to_trastuzumab._In_HER2_positive_trastuzumab-resistant_breast_cancer_cell_lines,_knockdown_of_survivin_with_RNAi_or_with_YM155_induced_growth_inhibition_and_apoptosis.",23204226,PubMed,,"Chakrabarty_et_al.,_2013,_Cancer_Res.",,4,accepted,1449,355,17,76210267,76221717,,,ENST00000301633.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-01_15:31:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/1449,https://civic.genome.wustl.edu/links/variants/578,https://civic.genome.wustl.edu/links/genes/355,,,,,20,Trastuzumab,,,,,,,
BRAF,673,D594A,Skin_Melanoma,8923,,"MEK_Inhibitor,Sorafenib",Substitutes,Predictive,Supports,E,Sensitivity/Response,"Preclinical_study_in_melanoma_cell_lines._Inactivity_of_BRAF_as_mediated_by_specific_mutation_(D594A,_D594V_or_K483M)_or_selective_pharmacological_inhibition_leads_to_MEK_hyperactivation_through_CRAF_binding_in_NRAS_mutant_D04_cells._Either_pan-RAF_(e.g._sorafenib_in_the_abscence_of_CRAF_T421N_gatekeeper_mutation)_or_MEK_inhibitors_(e.g.,_trametinib)_could_instead_block_ERK_pathway_hyperactivation_in_RAS_mutated_cancers.",20141835,PubMed,,"Heidorn_et_al.,_2010,_Cell",,3,accepted,1454,5,7,140453154,140453154,T,G,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-09-12_10:41:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1454,https://civic.genome.wustl.edu/links/variants/579,https://civic.genome.wustl.edu/links/genes/5,,Kinase_Dead_BRAF_Mutation,missense_variant,"ENST00000288602.6:c.1781A>C,NC_000007.13:g.140453154T>G,NM_004333.4:c.1781A>C,NP_004324.2:p.Asp594Ala",0.75,MEK_Inhibitor,Sorafenib,,,,chr7_g.140453154T~G,BRAF_c.1781A~C,BRAF_D594A
BRAF,673,D594V,Skin_Melanoma,8923,,"Sorafenib,Trametinib",Substitutes,Predictive,Supports,E,Sensitivity/Response,"Preclinical_study_in_melanoma_cell_lines._Inactivity_of_BRAF_as_mediated_by_specific_mutation_(D594A,_D594V_or_K483M)_or_selective_pharmacological_inhibition_leads_to_MEK_hyperactivation_through_CRAF_binding_in_NRAS_mutant_D04_cells._Either_pan-RAF_(e.g._sorafenib_in_the_abscence_of_CRAF_T421N_gatekeeper_mutation)_or_MEK_inhibitors_could_instead_block_ERK_pathway_hyperactivation_in_RAS_mutated_cancers.",20141835,PubMed,,"Heidorn_et_al.,_2010,_Cell",,3,accepted,1456,5,7,140453154,140453154,T,A,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_22:42:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1456,https://civic.genome.wustl.edu/links/variants/580,https://civic.genome.wustl.edu/links/genes/5,,Kinase_Dead_BRAF_Mutation,missense_variant,"NM_004333.4:c.1781A>T,NP_004324.2:p.Asp594Val,NC_000007.13:g.140453154T>A,ENST00000288602.6:c.1781A>T",0.75,Sorafenib,Trametinib,,,,chr7_g.140453154T~A,BRAF_c.1781A~T,BRAF_D594V
BRAF,673,K483M,Skin_Melanoma,8923,,"Sorafenib,MEK_Inhibitor",Substitutes,Predictive,Supports,E,Sensitivity/Response,"Preclinical_study_in_melanoma_cell_lines._Inactivity_of_BRAF_as_mediated_by_specific_mutation_(D594A,_D594V_or_K483M)_or_selective_pharmacological_inhibition_leads_to_MEK_hyperactivation_through_CRAF_binding_in_NRAS_mutant_D04_cells._Either_pan-RAF_(e.g._sorafenib_in_the_abscence_of_CRAF_T421N_gatekeeper_mutation)_or_MEK_inhibitors_(e.g.,_trametinib)_could_instead_block_ERK_pathway_hyperactivation_in_RAS_mutated_cancers.",20141835,PubMed,,"Heidorn_et_al.,_2010,_Cell",,3,accepted,1457,5,7,140477859,140477860,TT,CA,ENST00000288602.6,,,,,75,GRCh37,The_K483M_variant_is_a_kinase_dead_loss-of-function_variant_in_the_catalytic_site_of_BRAF._This_engineered_variant_is_often_used_as_a_control_when_evaluating_other_BRAF_variants.,Somatic_Mutation,2016-09-12_10:41:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1457,https://civic.genome.wustl.edu/links/variants/581,https://civic.genome.wustl.edu/links/genes/5,The_K483M_variant_is_a_kinase_dead_loss-of-function_variant_in_the_catalytic_site_of_BRAF._This_engineered_variant_is_often_used_as_a_control_when_evaluating_other_BRAF_variants.,Kinase_Dead_BRAF_Mutation,"loss_of_function_variant,missense_variant","NC_000007.13:g.140477859_140477860delinsCA,ENST00000288602.6:c.1448_1449delinsTG",0.75,Sorafenib,MEK_Inhibitor,,,,chr7_g.140477859_140477860delinsCA,BRAF_c.1448_1449delinsTG,
BRAF,673,L597S,Skin_Melanoma,8923,,TAK-733,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_69_year_old_patient_with_metastatic_melanoma_treated_with_MEK_inhibitor_TAK-733_in_a_clinical_trial._A_partial_radiographic_response_with_a_decrease_of_31%_in_the_sum_of_maximum_diameters_of_target_metastatic_lesions_in_the_liver_and_spleen_was_noted_after_2_cycles_of_therapy_and_remained_progression_free_at_more_than_24_weeks._Follow-up_sequencing_analysis_of_DNA_from_the_patient's_tumor_revealed_a_somatic_BRAF_L597S_mutation.,22798288,PubMed,,"Dahlman_et_al.,_2012,_Cancer_Discov",,3,accepted,1460,5,7,140453145,140453146,AG,GA,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2017-02-14_21:47:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1460,https://civic.genome.wustl.edu/links/variants/582,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NC_000007.13:g.140453145_140453146delinsGA,NM_004333.4:c.1789_1790delCTinsTC,NP_004324.2:p.Leu597Ser,ENST00000288602.6:c.1789_1790delCTinsTC",9.5,TAK-733,,,,,chr7_g.140453145_140453146delinsGA,BRAF_c.1789_1790delCTinsTC,BRAF_L597S
BRAF,673,L597S,Skin_Melanoma,8923,,"Vemurafenib,Trametinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_293H_cell_line._Ectopic_expression_of_V600E,_L597R/Q/S,_and_K601E_mutants_elevated_phospho-MEK_and_ERK_levels._Vemurafenib_treatment_of_all_of_the_BRAF_mutant–expressing_cells_led_to_a_decrease_in_phospho-MEK_and_ERK_protein_levels._Treatment_with_MEK_inhibitor_GSK1120212_led_to_a_more_dramatic_decrease_in_phospho-ERK_signaling.",22798288,PubMed,,"Dahlman_et_al.,_2012,_Cancer_Discov",,2,accepted,1459,5,7,140453145,140453146,AG,GA,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-07-18_15:24:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1459,https://civic.genome.wustl.edu/links/variants/582,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NC_000007.13:g.140453145_140453146delinsGA,NM_004333.4:c.1789_1790delCTinsTC,NP_004324.2:p.Leu597Ser,ENST00000288602.6:c.1789_1790delCTinsTC",9.5,Vemurafenib,Trametinib,,,,chr7_g.140453145_140453146delinsGA,BRAF_c.1789_1790delCTinsTC,BRAF_L597S
BRAF,673,L597Q,Skin_Melanoma,8923,,Trametinib,,Predictive,Supports,C,Sensitivity/Response,Case_study_report_including_one_patient_with_L597Q_mutation-positive_metastatic_melanoma_(M1b_disease)_treated_with_the_MEK_inhibitor_trametinib._The_L597Q_patient_achieved_a_RECIST_partial_response_and_showed_maximum_tumor_shrinkage_of_33%_with_trametinib_as_the_first-line_treatment_and_had_a_partial_response_for_6.2_months.,24933606,PubMed,,"Bowyer_et_al.,_2014,_Melanoma_Res.",,3,accepted,4905,5,7,140453145,140453145,A,T,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-03-20_15:48:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/4905,https://civic.genome.wustl.edu/links/variants/583,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A",14.5,Trametinib,,,,,chr7_g.140453145A~T,BRAF_c.1790T~A,BRAF_L597Q
BRAF,673,L597Q,Skin_Melanoma,8923,,"Vemurafenib,Trametinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_293H_cell_line._Ectopic_expression_of_V600E,_L597R/Q/S,_and_K601E_mutants_elevated_phospho-MEK_and_ERK_levels._Vemurafenib_treatment_of_all_of_the_BRAF_mutant–expressing_cells_led_to_a_decrease_in_phospho-MEK_and_ERK_protein_levels._Treatment_with_MEK_inhibitor_GSK1120212_led_to_a_more_dramatic_decrease_in_phospho-ERK_signaling.",22798288,PubMed,,"Dahlman_et_al.,_2012,_Cancer_Discov",,2,accepted,1461,5,7,140453145,140453145,A,T,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-10-20_04:03:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1461,https://civic.genome.wustl.edu/links/variants/583,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A",14.5,Vemurafenib,Trametinib,,,,chr7_g.140453145A~T,BRAF_c.1790T~A,BRAF_L597Q
BRAF,673,L597Q,Cancer,162,,Vemurafenib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,_and_MACF1-_and_WASFL-BRAF_fusion.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5971,5,7,140453145,140453145,A,T,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-02-16_11:22:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/5971,https://civic.genome.wustl.edu/links/variants/583,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A",14.5,Vemurafenib,,,,,chr7_g.140453145A~T,BRAF_c.1790T~A,BRAF_L597Q
BRAF,673,K601E,Skin_Melanoma,8923,,"Trametinib,Vemurafenib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_293H_cell_line._Ectopic_expression_of_V600E,_L597R/Q/S,_and_K601E_mutants_elevated_phospho-MEK_and_ERK_levels._Vemurafenib_treatment_of_all_of_the_BRAF_mutant–expressing_cells_led_to_a_decrease_in_phospho-MEK_and_ERK_protein_levels._Treatment_with_MEK_inhibitor_GSK1120212_led_to_a_more_dramatic_decrease_in_phospho-ERK_signaling.",22798288,PubMed,,"Dahlman_et_al.,_2012,_Cancer_Discov",,3,accepted,1462,5,7,140453134,140453134,T,C,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-10-20_04:03:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1462,https://civic.genome.wustl.edu/links/variants/584,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1801A>G,NP_004324.2:p.Lys601Glu,NC_000007.13:g.140453134T>C,ENST00000288602.6:c.1801A>G",3,Trametinib,Vemurafenib,,,,chr7_g.140453134T~C,BRAF_c.1801A~G,BRAF_K601E
BRAF,673,L597V,Skin_Melanoma,8923,,Trametinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_phase_1_study_in_advanced_melanoma_patients._97_patients_with_melanoma_were_enrolled_and_treated_with_trametinib._One_patient_with_a_BRAF_Leu597Val_had_a_confirmed_partial_response_with_60%_tumour_reduction_and_received_study_treatment_for_more_than_2_years.,22805292,PubMed,,"Falchook_et_al.,_2012,_Lancet_Oncol.",,3,accepted,1463,5,7,140453146,140453146,G,C,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-07-19_19:34:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1463,https://civic.genome.wustl.edu/links/variants/585,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1789C>G,NP_004324.2:p.Leu597Val,NC_000007.13:g.140453146G>C,ENST00000288602.6:c.1789C>G",7.5,Trametinib,,,,,chr7_g.140453146G~C,BRAF_c.1789C~G,BRAF_L597V
KIT,3815,AMPLIFICATION,Mucosal_Melanoma,50929,,Imatinib,,Predictive,Supports,B,Resistance,"Phase_2_trial_in_metastatic_mucosal,_acral_or_chronically_sun-damaged_melanoma._Twenty-five_patients_were_enrolled_(24_evaluable)._Eight_patients_(33%)_had_tumors_with_KIT_mutations,_11_(46%)_with_KIT_amplifications,_and_five_(21%)_with_both._Median_follow-up_was_10.6_months._Best_overall_response_rate_was_statistically_significantly_different_by_mutation_status:_7_of_13_or_54%_KIT_mutated_v_0%_KIT_amplified_only.",23775962,PubMed,,"Hodi_et_al.,_2013,_J._Clin._Oncol.",,3,accepted,1466,29,4,55524085,55606881,,,ENST00000288135.5,,,,,75,GRCh37,,,2016-07-06_05:02:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1466,https://civic.genome.wustl.edu/links/variants/586,https://civic.genome.wustl.edu/links/genes/29,,,transcript_amplification,,15,Imatinib,,,,,,,
NF1,4763,MUTATION,Plexiform_Neurofibroma,5151,,Selumetinib_(AZD6244),,Predictive,Supports,B,Sensitivity/Response,"Treatment_with_selumetinib_(NCT01362803)_resulted_in_confirmed_partial,_long_term_responses_in_17_of_the_24_children_with_NF1_associated_plexiform_fibromas_(71%)_and_decreases_from_baseline_in_neurofibroma_volume_in_12_of_18_mice_(67%).",28029918,PubMed,,"Dombi_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,1958,3867,17,29421945,29704695,,,ENST00000358273.4,,,,,75,GRCh37,,Germline_Mutation,2017-07-25_19:31:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1958,https://civic.genome.wustl.edu/links/variants/587,https://civic.genome.wustl.edu/links/genes/3867,,,"loss_of_function_variant,protein_altering_variant",,32,Selumetinib_(AZD6244),,,,,,,
NF1,4763,MUTATION,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,C,Resistance,"NF1_was_identified_in_an_unbiased_RNAi_screen_as_mediator_of_resistance_to_BRAF_inhibition_in_BRAF_mutant_melanoma._Knockdown_of_NF1_led_to_PLX4720_resistance_in-vitro._MEK_inhibition_with_AZD6244_(selumetinib)_had_some_efficacy_but_was_also_less_active_than_in_NF1_proficient_cells.__4_patients_with_mutant_alleles_of_NF1_were_identified_among_patients_relapsed_after_vemurafenib._Of_these,_one_was_a_nonsense_mutation_(p.R2450*)_present_in_both_pretreatment_and_postrelapse_biopsies._The_patient_had_a_progression-free_survival_(PFS)_of_about_10_weeks._The_other_NF1_mutations_were_silent_events_(patient_15,_c.135T>C,_patient_45_c.4023G>A,_and_patient_50_c3018C>T)_located_within_candidate_splicing_motifs._Patients_15_and_50_exhibited_response_rates_of_relatively_short_duration_(10_and_12_weeks,_respectively)_and_the_mutations_were_observed_in_both_the_pretreatment_and_postrelapse_biopsies._Patient_45_experienced_a_PFS_of_5_months,_and_the_NF1_mutation_was_only_present_in_the_postrelapse_biopsy_indicative_of_acquired_resistance.",23288408,PubMed,,"Whittaker_et_al.,_2013,_Cancer_Discov",,4,accepted,1470,3867,17,29421945,29704695,,,ENST00000358273.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-17_20:57:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1470,https://civic.genome.wustl.edu/links/variants/587,https://civic.genome.wustl.edu/links/genes/3867,,,"loss_of_function_variant,protein_altering_variant",,32,Vemurafenib,,,,,,,
NF1,4763,MUTATION,Skin_Melanoma,8923,,"PD0325901,Rapamycin_(Sirolimus)",Combination,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_of_mouse_melanoma_both_in-vitro_and_in-vivo._Braf/Nf1-mutant_melanomas_were_less_sensitive_to_vemurafenib_than_the_MEK_inhibitor_PD0325901._mTOR_inhibition_with_rapamycin_had_a_more_pronounced_effect_than_GDC-0941_on_mouse_melanoma,_but_synergized_with_PD0325901(but_not_vemurafenib)_to_promote_tumor_regression.",23171796,PubMed,,"Maertens_et_al.,_2013,_Cancer_Discov",,3,accepted,1469,3867,17,29421945,29704695,,,ENST00000358273.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_18:39:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1469,https://civic.genome.wustl.edu/links/variants/587,https://civic.genome.wustl.edu/links/genes/3867,,,"loss_of_function_variant,protein_altering_variant",,32,PD0325901,Rapamycin_(Sirolimus),,,,,,
NF1,4763,MUTATION,Skin_Melanoma,8923,,"VTX-11e,AZ628",Substitutes,Predictive,Supports,D,Sensitivity/Response,"NF1_was_identified_in_an_unbiased_RNAi_screen_as_mediator_of_resistance_to_BRAF_inhibition_in_BRAF_mutant_melanoma._BRAF_V600E/NF1_mutant_cell_lines_were_sensitive_to_ERK_inhibition_with_VTX-11e,_modest_resistance_was_observed_against_RAF_inhibitor_AZ628._Combined_PLX4720_and_AZD6244_(selumetinib)_achieved_greater_efficacy_than_either_agent_alone_but_NF1_knockdown_was_still_associated_with_residual_resistance_to_combined_RAF/MEK_inhibition_in_vitro.",23288408,PubMed,,"Whittaker_et_al.,_2013,_Cancer_Discov",,2,accepted,1471,3867,17,29421945,29704695,,,ENST00000358273.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-26_15:02:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1471,https://civic.genome.wustl.edu/links/variants/587,https://civic.genome.wustl.edu/links/genes/3867,,,"loss_of_function_variant,protein_altering_variant",,32,VTX-11e,AZ628,,,,,,
NF1,4763,MUTATION,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,D,Resistance,"Preclinical_study_of_mouse_melanoma_in-vitro_and_in-vivo._In-vitro_treament_of_Braf-mutant_melanomas_were_10-fold_more_sensitive_to_vermurafenib_(PLX4032)_treatment_than_Braf/Nf1-mutant_melanomas._In_vivo_treatment_of_mice_with_Braf/Nf1-mutant_allografts_showed_less_sensitivity_to_vemurafenib_(PLX4032)_than_the_MEK_inhibitor,_PD0325901.",23171796,PubMed,,"Maertens_et_al.,_2013,_Cancer_Discov",,2,accepted,1468,3867,17,29421945,29704695,,,ENST00000358273.4,,,,,75,GRCh37,,Somatic_Mutation,2016-10-22_14:44:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1468,https://civic.genome.wustl.edu/links/variants/587,https://civic.genome.wustl.edu/links/genes/3867,,,"loss_of_function_variant,protein_altering_variant",,32,Vemurafenib,,,,,,,
ALK,238,HIP1-ALK_I1171N,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,Alectinib_(CH5424802)",Sequential,Predictive,Supports,C,Resistance,Case_study_describes_a_female_(age_58)_never-smoker_presenting_with_stage_IV_NSCLC_with_an_ALK_rearrangement_(confirmed_by_fish)._Patient_was_treated_with_crizotinib_(partial_response)_and_alectinib_(complete_response)._Liver_metastasis_was_noted_after_12_months_with_sequencing_revealing_a_HIP1-ALK_fusion_with_a_I1171N_variant.,25393796,PubMed,,"Ou_et_al.,_2014,_J_Thorac_Oncol",,2,accepted,1483,1,2,29445213,29445213,A,T,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2017-05-31_15:32:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1483,https://civic.genome.wustl.edu/links/variants/588,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>A,NC_000002.11:g.29445213A>T,NM_004304.4:c.3512T>A,NP_004295.2:p.Ile1171Asn",5,Crizotinib,Alectinib_(CH5424802),,,,chr2_g.29445213A~T,ALK_c.3512T~A,ALK_I1171N
ALK,238,EML4-ALK_I1171S,Non-small_Cell_Lung_Carcinoma,3908,,"Crizotinib,Alectinib_(CH5424802)",Sequential,Predictive,Supports,C,Resistance,Case_study_describes_a_caucasian_male_(age_38)_never_smoker_presenting_with_stage_IV_non-small_cell_lung_cancer_with_an_ALK_rearrangement._Patient_was_given_crizotinib_and_exhibited_a_partial_response_after_5_months_with_brain_metastasis_occurring_at_21_months._Patient_then_received_alectinib_and_exhibited_partial_response_however_liver_metastasis_presented_after_12_months_on_alectinib._Sequencing_of_this_liver_metastasis_revealed_an_EML4-ALK_fusion_with_an_I1171S_variant_at_a_variant_frequency_of_36%_(tumor_purity_estimated_as_70%).,25393796,PubMed,,"Ou_et_al.,_2014,_J_Thorac_Oncol",,2,accepted,1484,1,2,29445213,29445213,A,C,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-08-04_05:39:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1484,https://civic.genome.wustl.edu/links/variants/589,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant","ENST00000389048.3:c.3512T>G,NC_000002.11:g.29445213A>C",5,Crizotinib,Alectinib_(CH5424802),,,,chr2_g.29445213A~C,ALK_c.3512T~G,
RAF1,5894,AMPLIFICATION,Skin_Melanoma,8923,,"Carboplatin,Paclitaxel,Sorafenib",Combination,Predictive,Supports,B,Sensitivity/Response,"Retrospective_analysis_of_somatic_mutations_and_copy_number_changes_in_119_patients_treated_with_carboplatin,_paclitaxel,_±_sorafenib_(CPS)_in_the_E2603_trial._CPS_therapy_was_associated_with_improved_progression-free_survival_(PFS)_compared_with_CP_in_patients_with_tumors_that_were_positive_for_RAF1_gene_copy_gains_(HR_=_0.372;_P_=_0.025).",26307133,PubMed,,"Wilson_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1496,4767,3,12625100,12705725,,,ENST00000251849.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-10_21:44:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1496,https://civic.genome.wustl.edu/links/variants/591,https://civic.genome.wustl.edu/links/genes/4767,,,transcript_amplification,,10,Carboplatin,Paclitaxel,Sorafenib,,,,,
KRAS,3845,AMPLIFICATION,Skin_Melanoma,8923,,"Sorafenib,Carboplatin,Docetaxel",Combination,Predictive,Supports,B,Sensitivity/Response,"Retrospective_analysis_of_somatic_mutations_and_copy_number_changes_in_119_patients_treated_with_carboplatin,_paclitaxel,_±_sorafenib_(CPS)_in_the_E2603_trial._CPS_therapy_was_associated_with_improved_overall_survival_compared_with_CP_in_patients_with_tumors_positive_for_KRAS_gene_copy_gains_(HR_=_0.25;_P_=_0.035).",26307133,PubMed,,"Wilson_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1497,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,,2016-07-10_21:42:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1497,https://civic.genome.wustl.edu/links/variants/592,https://civic.genome.wustl.edu/links/genes/30,,,transcript_amplification,,27,Sorafenib,Carboplatin,Docetaxel,,,,,
KRAS,3845,AMPLIFICATION,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,In_vitro_studies_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_KRAS_and_BRAF_V600E_(a_known_BRAF_sensitizing_mutation)_found_that_cells_induced_to_stably_over-express_wildtype_KRAS4a_or_KRAS4b_(via_viral_transduction_with_additional_copies_of_KRAS4a_or_KRAS4b)_were_more_resistant_to_vemurafenib_(a_BRAFi)_than_cells_transduced_with_empty_vectors._Resistance_was_determined_by_assessing_cell_survival.,24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,6317,30,12,25362365,25403737,,,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_20:21:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/6317,https://civic.genome.wustl.edu/links/variants/592,https://civic.genome.wustl.edu/links/genes/30,,,transcript_amplification,,27,Vemurafenib,,,,,,,
RET,5979,OVEREXPRESSION,Papillary_Adenocarcinoma,3112,,Sunitinib,,Predictive,Supports,C,Sensitivity/Response,"A_78-year-old_man_presented_with_oral_papillary_adenocarcinoma_and_lung_metastases_that_were_refractory_to_standard_treatment.__Tumor_sequencing_showed_increased_MAPK_activity_due_to_RET_over-expression_and_PTEN_deletion,_therefore_sunitinib_(RET_inhibitor)_was_initiated.__After_28_days_post-administration,_the_lung_metastases_decreased_in_size_by_22%_(28mm_to_21mm)_and_no_new_metastatic_lesions_had_appeared.__After_4_months,_the_patient_grew_resistant_to_treatment.",20696054,PubMed,,"Jones_et_al.,_2010,_Genome_Biol.",,3,accepted,1518,42,10,43572475,43625799,,,ENST00000355710.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-19_19:39:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1518,https://civic.genome.wustl.edu/links/variants/597,https://civic.genome.wustl.edu/links/genes/42,,,,,7.5,Sunitinib,,,,,,,
CTLA4,1493,CTLA4-CD28,Sezary's_Disease,8541,,Ipilimumab,,Predictive,Supports,C,Sensitivity/Response,"A_67-year-old_Caucasian_female_with_stage_IVA_Sezary_syndrome_presented_refractory_to_traditional_therapy_and_was_enrolled_in_a_whole_genome_study_trial._Sequencing_revealed_a_CTLA4-CD28_fusion_protein_such_that_the_inhibitory_CTLA4_receptor_activated_a_stimulatory_CD28_intracellular_domain_that_promoted_proliferation._The_patient_was_treated_with_iplimumab,_a_CTLA4_receptor_inhibitor,_and_after_10_days,_there_was_a_reduction_in_erythema_and_ulceration_by_50%,_a_reduction_in_tumor_size_by_75%,_and_overall_improved_quality_of_life._However,_during_the_sixth_week_of_therapy,_the_patient_rapidly_developed_skin_tumors_and_died_3_months_later.",25802883,PubMed,,"Sekulic_et_al.,_2015,_Mol_Genet_Genomic_Med",,2,accepted,1520,1285,2,204732509,204736210,,,ENST00000302823.3,2,204599507,204603635,ENST00000324106.8,75,GRCh37,"A_survey_of_115_T-cell_lymphoma_samples_of_diverse_subtypes_identified_this_fusion_in_26_of_45_cases_of_angioimmunoblastic_T-cell_lymphomas_(58%),_nine_of_39_peripheral_T-cell_lymphomas,_not_otherwise_specified_(23%),_and_nine_of_31_extranodal_NK/T_cell_lymphomas_(29%).",Somatic_Mutation,2016-08-19_18:49:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1520,https://civic.genome.wustl.edu/links/variants/599,https://civic.genome.wustl.edu/links/genes/1285,"A_survey_of_115_T-cell_lymphoma_samples_of_diverse_subtypes_identified_this_fusion_in_26_of_45_cases_of_angioimmunoblastic_T-cell_lymphomas_(58%),_nine_of_39_peripheral_T-cell_lymphomas,_not_otherwise_specified_(23%),_and_nine_of_31_extranodal_NK/T_cell_lymphomas_(29%).",,transcript_fusion,,5,Ipilimumab,,,,,,,
AR,367,MUTATION,Prostate_Cancer,10283,,"Bicalutamide,Flutamide,Cyproterone_Acetate,Nilutamide",Substitutes,Predictive,Supports,B,Resistance,"In_a_study_of_150_patients_with_metastatic_castration_resistant_prostate_cancer_(mCRPC),_71.3%_of_cases_(n=107)_harbored_androgen_receptor_(AR)_pathway_aberrations.___Within_the_AR_mutation_cohort,_78_patients_had_AR_amplification_mutations,_16_patients_had_AR_missense_mutations,_and_13_patients_had_mutations_in_ZBTB16,_NCOR1,_FOXA1,_and_SPOP,_which_are_all_AR_regulators_or_downstream_effectors.__All_AR_mutations_were_exclusive_to_mCRPC_neoplasms_and_were_not_found_in_primary_prostate_cancer.",26000489,PubMed,,"Robinson_et_al.,_2015,_Cell",,4,accepted,1521,67,X,66764465,66950461,,,ENST00000374690.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-17_21:26:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1521,https://civic.genome.wustl.edu/links/variants/600,https://civic.genome.wustl.edu/links/genes/67,,,transcript_variant,,20,Bicalutamide,Flutamide,Cyproterone_Acetate,Nilutamide,,,,
NOTCH1,4851,LOSS-OF-FUNCTION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,LGK974,,Predictive,Supports,D,Sensitivity/Response,"In_an_evaluation_of_96_head_and_neck_squamous_cell_carcinoma_(HNSCC)_cell_lines,_31_were_responsive_to_LGK974_(PORCN_inhibitor)._Of_40_cell_lines_(25_responsive,_15_non-responsive)_that_were_exome_sequenced,_6_cell_lines_had_NOTCH1_loss-of-function_mutations_(N-terminal_frameshift/nonsense)_and_5/6_cell_lines_that_had_NOTCH1_mutations_were_susceptible_to_LGK974_(PORCN_inhibitor).",24277854,PubMed,,"Liu_et_al.,_2013,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,1525,50,9,139388896,139440314,,,ENST00000277541.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_21:15:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1525,https://civic.genome.wustl.edu/links/variants/601,https://civic.genome.wustl.edu/links/genes/50,,,loss_of_function_variant,,2,LGK974,,,,,,,
CDK6,1021,OVEREXPRESSION,Estrogen-receptor_Positive_Breast_Cancer,60075,,Fulvestrant,,Predictive,Supports,B,Resistance,"In_two_cohorts_(n=45_and_n=46)_of_ER+_breast_cancer_patients_who_had_received_fulvestrant,_CDK6_overexpression_correlated_with_shorter_median_time_to_progression_in_both_cohorts_(2.5_vs._8.2_months_and_3.4_vs._8.9_months_for_CDK6_overexpression_vs._normal_expression)._CDK6_expression_did_not_correlate_with_other_lines_of_treatment_(N=68,_tamoxifen_or_endocrine_therapy)._Four_fulvestrant-resistant_cell_lines_were_derived_from_estrogen_responsive_and_fulvestrant_sensitive_parental_breast_cancer_cell_line_MCF-7/SO.5._Gene_expression_profiling_showed_upregulation_of_CDK6_in_the_fulvestrant_resistant_derivatives._Knockdown_of_CDK6_in_these_derivative_cells_resulted_in_fulvestrant_sensitivity.",27252418,PubMed,,"Alves_et_al.,_2016,_Clin._Cancer_Res.",,4,accepted,1526,12,7,92234235,92463231,,,ENST00000265734.4,,,,,75,GRCh37,,,2016-08-22_22:39:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1526,https://civic.genome.wustl.edu/links/variants/602,https://civic.genome.wustl.edu/links/genes/12,,,,,22,Fulvestrant,,,,,,,
CDK6,1021,OVEREXPRESSION,Estrogen-receptor_Positive_Breast_Cancer,60075,,"Palbociclib_(PD0332991),Fulvestrant",Combination,Predictive,Supports,D,Sensitivity/Response,"Four_fulvestrant_(estrogen_receptor_degrader)_resistant_cell_lines_were_derived_from_parent_fulvestrant_sensitive_ER+_MCF-7/SO.5_breast_cancer_cell_line._Derivative_cell_lines_showed_some_sensitivity_to_CDK4/6_inhibitor_palbociclib,_and_increased_growth_inhibition_when_treated_with_fulvestrant_and_palbociclib_together.",27252418,PubMed,,"Alves_et_al.,_2016,_Clin._Cancer_Res.",,2,accepted,1527,12,7,92234235,92463231,,,ENST00000265734.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-12_15:17:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1527,https://civic.genome.wustl.edu/links/variants/602,https://civic.genome.wustl.edu/links/genes/12,,,,,22,Palbociclib_(PD0332991),Fulvestrant,,,,,,
FLT3,2322,OVEREXPRESSION,Adult_B-Lymphoblastic_Leukemia,60592,,Sunitinib,,Predictive,Supports,C,Sensitivity/Response,"A_25-year-old_Caucasian_male_presented_with_a_second_relapse_of_B-ALL._RNA_sequencing_revealed_FLT3_overexpression_(also_confirmed_by_IHC)._The_patient_was_treated_with_22_days_of_sunitinib,_permitting_the_patient_to_undergo_a_bone_marrow_transplant._A_bone_marrow_biopsy_showed_complete_clearance_by_variant_allele_frequency_and_the_patient_remains_in_remission_4-years_post_matched-unrelated_donor_allograft.",27181063,PubMed,,"Griffith_et_al.,_2016,_Exp._Hematol.",,3,accepted,1528,24,13,28577411,28674729,,,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-09-05_22:16:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/1528,https://civic.genome.wustl.edu/links/variants/603,https://civic.genome.wustl.edu/links/genes/24,,,,,7.5,Sunitinib,,,,,,,
GNAQ,2776,Q209P,Skin_Melanoma,8923,,PLX4720,,Predictive,Supports,D,Resistance,"Cells_were_derived_from_a_26-year_old_patient_with_vemurafenib_resistant_BRAF-mutated_(V600E)_cutaneous_melanoma_(designated_20_092_cells)._Five_of_his_metastases_evaluated_using_whole_genome_sequencing_contained_a_GNAQ_(Q209P)_mutation._20_092_cells_were_insensitive_to_BRAF_inhibition_(PLX4720)_in_both_proliferation_assays_and_evaluation_of_pERK_compared_to_BRAF_V600E_mutated,_GNAQ_wild-type_A375P_cells._Using_GNAQ_(Q209P)_siRNA_in_22_092_cells,_ERK_activity_was_suppressed_and_cell_sensitivity_to_PLX4720_was_increased.",24504448,PubMed,,"Turajlic_et_al.,_2014,_Ann._Oncol.",,3,accepted,1537,2317,9,80409488,80409488,T,G,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_16:22:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1537,https://civic.genome.wustl.edu/links/variants/604,https://civic.genome.wustl.edu/links/genes/2317,,,missense_variant,"NC_000009.11:g.80409488T>G,NM_002072.4:c.626A>C,NP_002063.2:p.Gln209Pro,ENST00000286548.4:c.626A>C",8,PLX4720,,,,,chr9_g.80409488T~G,GNAQ_c.626A~C,GNAQ_Q209P
GNAQ,2776,Q209P,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,C,Resistance,A_26-year_old_patient_presented_with_vemurafenib_resistant_BRAF-mutated_(V600E)_cutaneous_melanoma._Five_of_his_metastases_were_evaluated_using_whole_genome_sequencing._A_GNAQ_(Q209P)_mutation_was_identified_as_unanimously_present_in_all_five_tumors.,24504448,PubMed,,"Turajlic_et_al.,_2014,_Ann._Oncol.",,2,accepted,1533,2317,9,80409488,80409488,T,G,ENST00000286548.4,,,,,75,GRCh37,,Somatic_Mutation,2016-07-20_18:36:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1533,https://civic.genome.wustl.edu/links/variants/604,https://civic.genome.wustl.edu/links/genes/2317,,,missense_variant,"NC_000009.11:g.80409488T>G,NM_002072.4:c.626A>C,NP_002063.2:p.Gln209Pro,ENST00000286548.4:c.626A>C",8,Vemurafenib,,,,,chr9_g.80409488T~G,GNAQ_c.626A~C,GNAQ_Q209P
PTEN,5728,V317FS,Skin_Melanoma,8923,,"MK-2206,PD184352",Combination,Predictive,Supports,D,Sensitivity/Response,"A_26-year_old_patient_presented_with_vemurafenib_resistant_BRAF_V600E-mutated_cutaneous_melanoma._Five_metastases_were_evaluated_using_whole_genome_sequencing_and_a_4-bp_deletion_in_PTEN_(frameshift_mutation_at_V317)_was_identified_as_unanimously_present_in_all_five_tumors_and_a_pre-treatment_biopsy._The_other_copy_of_PTEN_was_lost_with_a_chromosome-wide_loss_of_chr_10._Subsequently,_a_patient-derived_tumor_cell_line_(designated_22_092)_was_suspended_in_a_solution_of_PD18352/MK2206_combination_therapy_and_cell_growth_inhibition_confirmed_tumor_sensitivity_to_MEK/AKT_inhibitors_compared_to_the_BRAF_V600E-containing_A375P_cell_line._ERK_inhibitor_resistance_was_demonstrated_as_a_result_of_a_GNAQ_Q209P_mutation_also_identified_in_the_patient._This_cell_line_showed_overexpression_of_AKT_and_no_expression_of_PTEN.",24504448,PubMed,,"Turajlic_et_al.,_2014,_Ann._Oncol.",,3,accepted,1534,41,10,89720799,89720802,TACT,,ENST00000371953.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_22:42:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1534,https://civic.genome.wustl.edu/links/variants/605,https://civic.genome.wustl.edu/links/genes/41,,,frameshift_variant,"ENST00000371953.3:c.950_953delTACT,NC_000010.10:g.89720799_89720802del",3,MK-2206,PD184352,,,,chr10_g.89720799_89720802del,PTEN_c.950_953delTACT,
RB1,5925,LOSS-OF-FUNCTION,Glioblastoma_Multiforme,3068,,Palbociclib_(PD0332991),,Predictive,Supports,D,Resistance,"A_panel_of_21_glioblastoma_cell_lines_harboring_various_mutations_was_treated_with_palbociclib._16_of_the_cell_lines_with_intact_Rb_showed_decreased_proliferation_(bromodeoxyuridine_incorporation,_BrdU_flow_cytometry)_and_growth_arrest_characteristic_of_senescence,_while_the_5_cell_lines_that_did_not_show_a_palbociclib_response_had_homozygous_deletion_of_Rb._Rb_positive_and_palbociclib_responsive_GBM_cell_line_U87MG_was_treated_with_shRNA_against_Rb._shRb_treated_cells_showed_restoration_of_cell_proliferation_(BrdU_incorporation)_under_palbociclib_treatment,_indicating_resistance.",20354191,PubMed,,"Michaud_et_al.,_2010,_Cancer_Res.",,3,accepted,1595,4795,13,48877911,49056122,,,ENST00000267163.4,,,,,75,GRCh37,,Somatic_Mutation,2016-08-23_06:58:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/1595,https://civic.genome.wustl.edu/links/variants/606,https://civic.genome.wustl.edu/links/genes/4795,,,loss_of_function_variant,,6,Palbociclib_(PD0332991),,,,,,,
RB1,5925,LOSS-OF-FUNCTION,Breast_Cancer,1612,,Palbociclib_(PD0332991),,Predictive,Supports,D,Resistance,"In_3_ER_positive_and_2_ER_negative_breast_cancer_cell_lines_with_intact_Rb,_significant_growth_inhibition,_as_measured_by_BrdU_incorporation,_was_seen_with_incubation_in_CDK4/6_inhibitor_palbociclib_(PD-0332991)._In_contrast,_two_ER_negative_cell_lines_lacking_detectable_Rb_were_fully_resistant_to_palbociclib._Knockdown_of_Rb_in_3_of_the_tested_Rb_positive_cell_lines_led_to_moderate_palbociclib_resistance_in_short_term_incubation_experiments.__In_longer_term_(15_day)_palbociclib_incubations_of_ER_negative_MDA-MB-231_cells_and_ER_positive_MCF-7_cells,_significant_resistance_to_palbociclib_was_seen_in_Rb_knockdown_conditions_while_wild-type_Rb_cells_maintained_sensitivity.",20473330,PubMed,,"Dean_et_al.,_2010,_Oncogene",,3,accepted,1535,4795,13,48877911,49056122,,,ENST00000267163.4,,,,,75,GRCh37,,Somatic_Mutation,2016-08-23_06:58:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/1535,https://civic.genome.wustl.edu/links/variants/606,https://civic.genome.wustl.edu/links/genes/4795,,,loss_of_function_variant,,6,Palbociclib_(PD0332991),,,,,,,
ESR1,2099,OVEREXPRESSION,Breast_Cancer,1612,,"Palbociclib_(PD0332991),Letrozole",Combination,Predictive,Supports,B,Sensitivity/Response,"A_phase_2_clinical_trial_evaluated_165_patients_with_oestrogen_receptor_positive_and_HER2-negative_breast_cancer_such_that_84_patients_received_combination_therapy_of_palbociclib_plus_letrozole_and_81_patients_received_letrozole_alone._The_combination_therapy_arm_had_higher_median_duration_of_progression-free_survival_when_compared_to_the_letrozole_only_group_(20.2_months_vs._10.2_months;_p<0.0004)._A_subcategory_of_patients_taking_combination_therapy,_who_lacked_mutations_in_p16_or_CCND1_(n=34),_had_an_even_higher_median_free_survival_of_26.1_months.__Noticeable_side_effects_in_the_combination_therapy_group_included_neutropenia_(54%)_leucopenia_(19%),_fatigue_(4%)_back_pain_(2%),_diarrhea_(2%)_and_pulmonary_embolism_(4%).",25524798,PubMed,,"Finn_et_al.,_2015,_Lancet_Oncol.",,4,accepted,1541,21,6,152128686,152424406,,,ENST00000206249.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-16_15:07:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1541,https://civic.genome.wustl.edu/links/variants/607,https://civic.genome.wustl.edu/links/genes/21,,,,,20,Palbociclib_(PD0332991),Letrozole,,,,,,
ALK,238,EML4-ALK_C1156Y–L1196M,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,A_28_year_old_patient_with_T4N3M1_stage_lung_adenocarcinoma_harboring_an_EML4-ALK_variant_1_fusion_was_treated_with_crizotinib_after_failing_conventional_therapy._The_patient_achieved_a_partial_response_but_progressed_after_5_months_of_treatment._Molecular_analysis_at_this_time_identified_two_missense_mutations_in_ALK_C1156Y_and_L1196M._Ba/F3_cells_expressing_EML4-ALK_L1196M_or_EML4-ALK_C1156Y_were_more_resistant_to_crizontinib_treatment_than_those_expressing_EML4-ALK_wildtype.,20979473,PubMed,,"Choi_et_al.,_2010,_N._Engl._J._Med.",,4,accepted,236,1,2,29443631,29445258,,,ENST00000389048.3,,,,,75,GRCh37,,Somatic_Mutation,2016-07-15_04:22:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/236,https://civic.genome.wustl.edu/links/variants/608,https://civic.genome.wustl.edu/links/genes/1,,,"transcript_fusion,missense_variant",,10,Crizotinib,,,,,,,
MTOR,2475,M2327I,Breast_Cancer,1612,,"RapaLink-1,Rapamycin_(Sirolimus)",Substitutes,Predictive,Does_Not_Support,D,Resistance,MCF-7_breast_cancer_cell_line_was_exposed_to_mTOR_inhibitor_AZD8055_until_resistance_developed._Deep_sequencing_revealed_an_MTOR_M2327I_mutation_in_the_AZD8055-resistant_clone._These_cells_remained_sensitive_to_rapamycin_and_RapaLink-1_in_vitro_and_in_mouse_xenografts._Expression_of_the_mutation_in_MDA-MB-468_cells_led_to_AZD8055_resistance_and_these_cells_were_also_rapamycin_and_RapaLink-1_sensitive.,27279227,PubMed,,"Rodrik-Outmezguine_et_al.,_2016,_Nature",,3,accepted,1545,2073,1,11177096,11177096,C,A,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_21:55:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1545,https://civic.genome.wustl.edu/links/variants/609,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6981G>T,NC_000001.10:g.11177096C>A",7,RapaLink-1,Rapamycin_(Sirolimus),,,,chr1_g.11177096C~A,MTOR_c.6981G~T,
MTOR,2475,M2327I,Breast_Cancer,1612,,AZD8055,,Predictive,Supports,D,Resistance,MCF-7_breast_cancer_cell_line_was_exposed_to_mTOR_inhibitor_AZD8055_until_resistance_developed._Deep_sequencing_revealed_an_MTOR_M2327I_mutation_in_the_AZD8055-resistant_clone._Downstream_signalling_was_independent_of_inhibitor_presence_in_these_clones_and_expression_of_the_mutation_in_MDA-MB-468_cells_led_to_resistance._Tumor_volume_grew_more_rapidly_in_mice_with_xenografts_of_M2327I_mTOR_mutant_MCF7_cells_treated_with_AZD8055_than_rapamycin_or_RapaLink-1_treatment.,27279227,PubMed,,"Rodrik-Outmezguine_et_al.,_2016,_Nature",,4,accepted,1544,2073,1,11177096,11177096,C,A,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-02_19:44:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/1544,https://civic.genome.wustl.edu/links/variants/609,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6981G>T,NC_000001.10:g.11177096C>A",7,AZD8055,,,,,chr1_g.11177096C~A,MTOR_c.6981G~T,
MTOR,2475,A2034V,Breast_Cancer,1612,,"AZD8055,RapaLink-1",Substitutes,Predictive,Does_Not_Support,D,Resistance,MCF-7_breast_cancer_cell_line_was_exposed_to_mTOR_inhibitor_rapamycin_until_resistance_developed._Deep_sequencing_revealed_an_MTOR_A2034V_mutation_in_the_resistant_clone_(RR1)._Downstream_signalling_was_independent_of_inhibitor_presence_in_these_clones_and_expression_of_the_mutation_in_MDA-MB-468_cells_led_to_resistance_to_rapamycin_but_maintained_sensistivity_to_AZD8055._A_novel_mTOR_inhibitor_RapaLink-1_was_designed_and_showed_efficacy_in_A2034V_mTOR_mutant_cell_lines_in-vivo_and_in-vitro._AZD8055_also_retained_efficacy_in_these_clones_in_xenograft.,27279227,PubMed,,"Rodrik-Outmezguine_et_al.,_2016,_Nature",,4,accepted,1548,2073,1,11187796,11187796,G,A,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_18:42:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1548,https://civic.genome.wustl.edu/links/variants/610,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6101C>T,NC_000001.10:g.11187796G>A",8,AZD8055,RapaLink-1,,,,chr1_g.11187796G~A,MTOR_c.6101C~T,
MTOR,2475,A2034V,Breast_Cancer,1612,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Resistance,MCF-7_breast_cancer_cell_line_was_exposed_to_mTOR_inhibitor_rapamycin_until_resistance_developed._Deep_sequencing_revealed_an_MTOR_A2034V_mutation_in_the_resistant_clone._Downstream_signalling_was_independent_of_inhibitor_presence_in_these_clones_and_expression_of_the_mutation_in_MDA-MB-468_cells_led_to_resistance._Xenografts_of_these_cells_were_more_resistant_to_rapamycin_than_AZD8055_or_RapaLink-1_treatment.,27279227,PubMed,,"Rodrik-Outmezguine_et_al.,_2016,_Nature",,4,accepted,1547,2073,1,11187796,11187796,G,A,ENST00000361445.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-02_19:45:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1547,https://civic.genome.wustl.edu/links/variants/610,https://civic.genome.wustl.edu/links/genes/2073,,,missense_variant,"ENST00000361445.4:c.6101C>T,NC_000001.10:g.11187796G>A",8,Rapamycin_(Sirolimus),,,,,chr1_g.11187796G~A,MTOR_c.6101C~T,
BRAF,673,D594G,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_53,_KRAS_exon_2_wild-type,_metastatic_colorectal_cancer_patients,_patients_harboring_BRAF_G466A_(n=1),_G469A_(n=2),_D594G_(n=1),_or_V600E_(n=2)_mutations_were_reported_to_be_non-responders_to_cetuximab_in_combination_with_irinotecan,_(BRAF_mutation_positive:_responders_vs._non-responders_=_0_vs._6;_BRAF_wild-type:_responders_vs._non-responders_30_vs._17;_P=0.004),_as_compared_to_patients_with_wild-type_BRAF.",26989027,PubMed,,"Hsu_et_al.,_2016,_Oncotarget",,,accepted,4472,5,7,140453154,140453154,T,C,ENST00000288602.6,,,,,75,GRCh37,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,Somatic_Mutation,2018-02-16_12:48:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/4472,https://civic.genome.wustl.edu/links/variants/611,https://civic.genome.wustl.edu/links/genes/5,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,,missense_variant,"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G",23.5,Cetuximab,,,,,chr7_g.140453154T~C,BRAF_c.1781A~G,BRAF_D594G
BRAF,673,D594G,Skin_Melanoma,8923,,U0126,,Predictive,Supports,D,Resistance,"In_this_preclinical_study,_melanoma_cell_lines_harboring_the_kinase-dead_G469E-_and_D594G_mutations_were_identified._These_cell_lines_were_resitant_to_MEK-Inhibition_but_underwent_apoptosis_after_shRNA-mediated_CRAF_knowdown_or_Treatment_with_the_pan-RAF_Inhibitor_sorafenib.",18794803,PubMed,,"Smalley_et_al.,_2009,_Oncogene",,3,accepted,6002,5,7,140453154,140453154,T,C,ENST00000288602.6,,,,,75,GRCh37,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,,2018-07-24_15:35:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/6002,https://civic.genome.wustl.edu/links/variants/611,https://civic.genome.wustl.edu/links/genes/5,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,,missense_variant,"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G",23.5,U0126,,,,,chr7_g.140453154T~C,BRAF_c.1781A~G,BRAF_D594G
BRAF,673,D594G,Colorectal_Cancer,9256,,"Panitumumab,Cetuximab",Substitutes,Predictive,Does_Not_Support,C,Resistance,Two_patients_with_stage_IV_BRAF_(D594G)_mutations_received_anti-EGFR_antibody_therapy_(cetuximab_and_panitumumab)._The_first_patient_was_on_FOLFOX_plus_bevacizumab_and_showed_no_signs_of_progression_for_10_months._No_response_was_observed_after_cetuximab_was_given_as_a_third_line_therapy._The_second_patient_received_panitumumab_with_FOLFOX_and_showed_no_signs_of_progression_for_8_months_with_reduction_of_the_size_of_metastases.,27404270,PubMed,,"Amaki-Takao_et_al.,_2016,_Oncology",,1,accepted,1554,5,7,140453154,140453154,T,C,ENST00000288602.6,,,,,75,GRCh37,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,Somatic_Mutation,2016-07-16_21:26:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1554,https://civic.genome.wustl.edu/links/variants/611,https://civic.genome.wustl.edu/links/genes/5,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,,missense_variant,"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G",23.5,Panitumumab,Cetuximab,,,,chr7_g.140453154T~C,BRAF_c.1781A~G,BRAF_D594G
BRAF,673,D594G,Skin_Melanoma,8923,,Sorafenib,,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study,_melanoma_cell_lines_harboring_the_kinase-dead_G469E-_and_D594G_mutations_were_identified._These_cell_lines_were_resitant_to_MEK-Inhibition_but_underwent_apoptosis_after_shRNA-mediated_CRAF_knowdown_or_Treatment_with_the_pan-RAF_Inhibitor_sorafenib.",18794803,PubMed,,"Smalley_et_al.,_2009,_Oncogene",,3,accepted,6001,5,7,140453154,140453154,T,C,ENST00000288602.6,,,,,75,GRCh37,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,Somatic_Mutation,2018-07-24_15:33:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/6001,https://civic.genome.wustl.edu/links/variants/611,https://civic.genome.wustl.edu/links/genes/5,This_BRAF_mutation_has_a_markedly_reduced_kinase_activity_and_leads_to_paradoxical_MEK-pathway_activation_via_CRAF_binding.,,missense_variant,"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G",23.5,Sorafenib,,,,,chr7_g.140453154T~C,BRAF_c.1781A~G,BRAF_D594G
FLT3,2322,D835H,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,C,Resistance,"Three_children_with_relapsed_or_refractory_FLT3-ITD-positive_AML_were_treated_with_sorafenib._FLT3_mutations_were_assessed_before_treatment_and_at_the_time_of_resistance._During_the_initiation_of_the_treatment,_all_three_patients_had_undetectable_levels_of_FLT3_(D835H)_mutations,_however,_after_resistance_developed,_the_mutation_frequency_rose_to_33.1%,_35.7%,_and_11.0%_in_the_three_patients._Ba/F3_cells_expressing_FLT3_mutants_were_resistant_to_sorafenib-dependent_inhibition_of_cell_viability",23969938,PubMed,,"Baker_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1556,24,13,28592642,28592642,C,G,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-08-28_04:50:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1556,https://civic.genome.wustl.edu/links/variants/612,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,ENST00000241453.7:c.2503G>C,NC_000013.10:g.28592642C>G",7.5,Sorafenib,,,,,chr13_g.28592642C~G,FLT3_c.2503G~C,FLT3_D835H
FLT3,2322,D835H/Y,Acute_Myeloid_Leukemia,9119,,Sorafenib,,Predictive,Supports,D,Resistance,Mouse_Ba/F3_cells_with_FLT3_mutations_were_evaluated_for_sorafenib_resistance.__Cells_with_single_FLT3_(D835H/Y)_mutants_were_resistant_to_sorafenib_(IC50_81_nm/210_nM)_whereas_cells_with_FLT3_(ITD)_mutants_were_not_resistant_to_sorafenib_(IC50_1.1_nM).__Cells_with_double_mutants_(ITD-D835H/Y_or_ITD_F691L)_were_highly_resistant_to_sorafenib_(IC50_460-3300_nM).,23969938,PubMed,,"Baker_et_al.,_2013,_Clin._Cancer_Res.",,1,accepted,1557,24,13,28592642,28592642,C,G/A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2016-07-21_19:57:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1557,https://civic.genome.wustl.edu/links/variants/613,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,NM_004119.2:c.2503G>T,NP_004110.2:p.Asp835Tyr,ENST00000241453.7:c.2503G>C,ENST00000241453.7:c.2503G>T",1,Sorafenib,,,,,,FLT3_c.2503G~T,FLT3_D835Y
JAK1,3716,Q503*,Skin_Melanoma,8923,,Pembrolizumab,,Predictive,Supports,C,Resistance,"Paired_tumor_samples_were_analyzed_from_four_patients_with_metastatic_melanoma_and_initial_response_with_a_subsequent_relapse_under_pembrolizumab_(PD-1_checkpoint_inhibitor)_therapy._Baseline_biopsies_were_obtained_before_therapy_initiation_with_pembrolizumab_(before_prior_vemurafenib_treatment_in_patient_1)._A_JAK1_Q503*_mutation_was_observed_at_the_time_of_relapse_in_patient_1._This_mutation_was_one_of_3_new_homozygous_mutations_in_this_patient_(53_new_mutations_total)_and_the_tumor_was_described_to_be_genetically_similar_to_the_pre-treatment_tumor._CRIPR-Cas9_mediated_modelling_of_the_JAK1_mutation_in_a_melanoma_cell_line_led_to_a_loss_of_response_to_interferon_alpha,_beta_and_gamma.",27433843,PubMed,,"Zaretsky_et_al.,_2016,_N._Engl._J._Med.",,4,accepted,1567,3090,1,65321333,65321333,G,A,ENST00000342505.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_21:27:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1567,https://civic.genome.wustl.edu/links/variants/614,https://civic.genome.wustl.edu/links/genes/3090,,,stop_gained,"NC_000001.10:g.65321333G>A,ENST00000342505.4:c.1507C>T",10,Pembrolizumab,,,,,chr1_g.65321333G~A,JAK1_c.1507C~T,
JAK2,3717,Exon_12_splice_site_insertion,Skin_Melanoma,8923,,Pembrolizumab,,Predictive,Supports,C,Resistance,Paired_tumor_samples_were_analyzed_from_four_patients_with_metastatic_melanoma_and_initial_response_with_a_subsequent_relapse_under_pembrolizumab_(PD-1_checkpoint_inhibitor)_therapy._Baseline_biopsies_were_obtained_before_therapy_initiation_with_pembrolizumab._A_JAK2_F547_splice_site_mutation_was_observed_at_the_time_of_relapse_in_patient_2._RNA_sequencing_revealed_an_in-frame_stop_codon_after_exon_12._The_JAK2_mutation_was_the_only_homozygous_mutation_(allele_frequency_>85%)_of_76_new_nonsynonymous_mutations_in_patient_2._Cell_line_modelling_of_baseline_and_relapse_JAK2_mutational_status_revealed_a_loss_of_response_to_interferon_gamma_and__loss_of_JAK2_protein._This_loss_of_response_was_also_modeled_in_another_cell_line.,27433843,PubMed,,"Zaretsky_et_al.,_2016,_N._Engl._J._Med.",,4,accepted,1568,28,9,5070053,5070054,,G,ENST00000381652.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_21:31:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1568,https://civic.genome.wustl.edu/links/variants/615,https://civic.genome.wustl.edu/links/genes/28,,,,NC_000009.11:g.5070053_5070054insG,10,Pembrolizumab,,,,,chr9_g.5070053_5070054insG,,
B2M,567,S14FS,Skin_Melanoma,8923,,Pembrolizumab,,Predictive,Supports,C,Resistance,Paired_tumor_samples_were_analyzed_from_four_patients_with_metastatic_melanoma_and_initial_response_with_a_subsequent_relapse_under_pembrolizumab_(PD-1_checkpoint_inhibitor)_therapy._Baseline_biopsies_were_obtained_before_therapy_initiation_with_pembrolizumab._A_B2M_frame-shift_deletion_in_exon_1_was_identified_as_the_only_new_homozygous_mutation_among_24_new_relapse-specific_mutations._Immunohistochemistry_revealed_loss_of_MHC1_outer-membrane_localization.,27433843,PubMed,,"Zaretsky_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,1569,537,15,45003786,45003789,TCTT,,ENST00000558401.1,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_22:04:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1569,https://civic.genome.wustl.edu/links/variants/616,https://civic.genome.wustl.edu/links/genes/537,,,frameshift_truncation,"ENST00000558401.1:c.42_45delTCTT,NC_000015.9:g.45003786_45003789del",7.5,Pembrolizumab,,,,,chr15_g.45003786_45003789del,B2M_c.42_45delTCTT,
BRAF,673,PPFIBP2-BRAF,Skin_Melanoma,8923,,Trametinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_47year_old_female_patient_with_metastatic_melanoma_(BRAF,_NRAS,_KIT_negative)._A_PPFIBP2-BRAF_fusion_was_identified_from_DNA_from_a_brain_metastasis_(inton_3_of_PPFIBP2_fused_to_intron_10_of_BRAF)._Trametinib_was_introduced_and_anemia_and_ECOG_status_improved._Imaging_revealed_a_90%_decrease_in_extracranial_and_19%_decrease_in_intracranial_metastases_with_no_new_metastases_and_no_progressing_sites_at_6_weeks._Trametinib_was_stopped_and_pembrolizumab_introduced_at_this_time._Progressive_disease_was_noted_after_5_cycles_of_pembrolizumab_but_re-introduction_of_trametinib_did_not_show_an_effect.",26072686,PubMed,,"Menzies_et_al.,_2015,_Pigment_Cell_Melanoma_Res",,2,accepted,1570,5,11,7535001,7586998,,,ENST00000299492.4,7,140434279,140481493,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-11-04_18:35:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1570,https://civic.genome.wustl.edu/links/variants/617,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,5,Trametinib,,,,,,,
BRAF,673,KIAA1549-BRAF,Sarcoma,1115,,"Sorafenib,Bevacizumab,Temsirolimus",Combination,Predictive,Supports,C,Sensitivity/Response,"A_patient_with_a_malignant_spindle_cell_tumor_of_the_chest_wall_treated_as_a_soft_tissue_sarcoma_was_identified_to_harbor_a_KIAA1549-BRAF_fusion._This_patient_responded_to_treatment_with_the_pan-kinase_inhibitor_sorafenib_in_combination_with_bevacizumab_and_temsirolimus,_achieving_stable_disease_after_2_cycles_extending_into_11_cycles_at_which_time_she_expired_due_to_co-morbidities_(acute_myocardial_infarction,_hypotension)._Of_note,_sequencing_of_236_cancer-related_genes_identified_CDKN2A_A68fs*51,_SUFU_E283fs*3,_MAP3K1_N325fs*3_and_homozygous_deletion_of_PTEN_as_well.",24422672,PubMed,,"Subbiah_et_al.,_2014,_J_Hematol_Oncol",,2,accepted,1664,5,7,138545885,138666064,,,ENST00000440172.1,7,140434279,140487384,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2017-02-07_05:21:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1664,https://civic.genome.wustl.edu/links/variants/618,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,7.5,Sorafenib,Bevacizumab,Temsirolimus,,,,,
BRAF,673,KIAA1549-BRAF,Skin_Melanoma,8923,,Trametinib,,Predictive,Supports,C,Sensitivity/Response,"A_65_yr_old_male_patient_with_metastatic_acral_lentiginous_melanoma_(BRAF,_NRAS,_KIT_negative)_was_found_to_harbor_a_KIAA1549-BRAF_(intron_15-intron_8)_fusion_in_a_subcutaneous_metastasis_sample_after_disease_progression._Trametinib_was_started_and_fatigue_and_ECOG_status_improved_but_imaging_revealed_slight_disease_progression_after_2_weeks_(15_sites_measurable,_9_stable,_6_progressive)._No_new_metastases_were_identified._The_patient_was_switched_to_pembrolizumab_and_major_disease_progression_was_noted.",26072686,PubMed,,"Menzies_et_al.,_2015,_Pigment_Cell_Melanoma_Res",,1,accepted,1571,5,7,138545885,138666064,,,ENST00000440172.1,7,140434279,140487384,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-11-03_19:19:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1571,https://civic.genome.wustl.edu/links/variants/618,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,7.5,Trametinib,,,,,,,
PTGS2,5743,OVEREXPRESSION,Colorectal_Cancer,9256,,Aspirin,,Predictive,Supports,B,Sensitivity/Response,"Mail-in_surveys_conducted_every_two_years_since_1980_evaluated_82,911_woman_and_47,363_men_for_regular_aspirin_use.__In_this_cohort,_aspirin_use_was_associated_with_a_lower_relative_risk_of_colorectal_cancer_(RR=0.73;_95%_CI_0.69-0.87;_p<0.001).__Immunohistochemical_analysis_was_employed_on_a_subset_of_636_cases_to_evaluate_COX2_overexpression.__Of_these_tumors,_67%_had_moderate_or_strong_COX2_expression_and_33%_had_weak_or_absent_COX-2_expression.__In_tumors_with_COX-2_overexpression,_regular_aspirin_use_conferred_significant_risk_reduction_of_colorectal_cancer_(RR=0.64;_95%CI_0.52-0.78)_however,_in_tumors_with_reduced_COX2_expression,_aspirin_use_had_no_influence_on_colorectal_cancer_incidence_(RR=0.96,_95%CI_0.73-1.26).",17522398,PubMed,,"Chan_et_al.,_2007,_N._Engl._J._Med.",,3,accepted,1573,4659,1,186640923,186649559,,,ENST00000367468.5,,,,,75,GRCh37,,Somatic_Mutation,2016-08-17_18:50:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1573,https://civic.genome.wustl.edu/links/variants/619,https://civic.genome.wustl.edu/links/genes/4659,,,,,15,Aspirin,,,,,,,
MET,4233,OVEREXPRESSION,Uveal_Melanoma,6039,,"Trametinib,Selumetinib_(AZD6244)",Substitutes,Predictive,Supports,D,Resistance,"In_this_study_the_authors_screened_for_growth_factors_that_elicited_resistance_in_newly_characterized_metastatic_uveal_melanoma_cell_lines_to_clinical-grade_MEK_inhibitors,_trametinib_and_selumetinib,_showing_that_neuregulin_1_(NRG1)_and_hepatocyte_growth_factor_(HGF)_provide_resistance_to_MEK_inhibition._Trametinib_enhances_the_responsiveness_to_NRG1_and_sustained_HGF-mediated_activation_of_AKT._Targeting_ERBB3_and_cMET_could_overcome_resistance_to_trametinib.",25952648,PubMed,,"Cheng_et_al.,_2015,_Cancer_Res.",,3,accepted,3038,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,Somatic_Mutation,2017-10-21_23:09:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/3038,https://civic.genome.wustl.edu/links/variants/621,https://civic.genome.wustl.edu/links/genes/52,,,,,64,Trametinib,Selumetinib_(AZD6244),,,,,,
MET,4233,OVEREXPRESSION,Stomach_Carcinoma,5517,,Rilotumumab,,Predictive,Does_Not_Support,B,Sensitivity/Response,"In_this_randomised,_double-blind,_placebo-controlled_phase_3_trial,_609_patients_with_MET+_(expression_of_at_least_1+_intensity_on_25%_or_more_tumor_cells)_gastric_cancer_or_gastroesophageal_adenocarcinoma_were_randomized_to_chemotherapy_(epirubicin,_cisplatin,_capecitabine)_with_placebo_or_MET_inhibitor_rilotumumab._Study_treatment_was_stopped_early_because_of_a_higher_number_of_deaths_in_the_rilotumumab_arm._Median_overall_survival_was_8·8_months_(95%_CI_7·7-10·2)_in_the_rilotumumab_group_compared_with_10·7_months_(9·6-12·4)_in_the_placebo_group_(stratified_hazard_ratio_1·34,_95%_CI_1·10-1·63;_p=0·003).",28958504,PubMed,,"Catenacci_et_al.,_2017,_Lancet_Oncol.",,5,accepted,5835,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2017-10-21_23:08:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/5835,https://civic.genome.wustl.edu/links/variants/621,https://civic.genome.wustl.edu/links/genes/52,,,,,64,Rilotumumab,,,,,,,
MET,4233,OVEREXPRESSION,Uveal_Melanoma,6039,,Crizotinib,,Predictive,Supports,D,Sensitivity/Response,"c-MET_and_ligand_HGF_were_expressed_by_6_uveal_melanoma_cell_lines_in-vitro._GNA-mutant_cell_lines_(n=3)_showed_stronger_expression_of_ligand_and_receptor_as_well_as_more_receptor_phosphorylation._SiRNA_mediated_MET-knockdown_reduced_cell_migration_but_not_cell_growth._Crizotinib_treatment_led_to_a_decrease_in_cell_growth_and_migration._At_25_nmol/L_of_crizotinib,_only_the_migration_of_G-protein_mutant_cells_lines_and_not_G-protein_wild_type_cell_lines_was_decreased._Crizotinib_did_not_lead_to_a_reduction_in_tumor_volume_of_two_cell_lines_in_vivo_but_reduced_the_formation_of_macrometastases_(luciferase_activity,_p=0.03).",24140933,PubMed,,"Surriga_et_al.,_2013,_Mol._Cancer_Ther.",,1,accepted,1583,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-11-11_17:08:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1583,https://civic.genome.wustl.edu/links/variants/621,https://civic.genome.wustl.edu/links/genes/52,,,,,64,Crizotinib,,,,,,,
MET,4233,OVEREXPRESSION,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Supports,B,Resistance,"Whole_exome_sequencing,_transcriptome_and_methylome_alterations_in_48_melanoma_samples_with_acquired_resistance_to_BRAFi_+/-_MEKi_therapy_compared_to_patient-matched_baseline_melanoma_tissues_were_analyzed._39%_of_resistant_melanomas_were_not_accounted_for_by_any_validated_mutational_mechanism._c-MET_was_overexpressed_in_21_of_48_(44%)_resistant_samples._Methylome_analysis_revealed_three_CpG_clusters_(C1–3)_with_differential_methylation_to_be_negatively_correlated_with_differential_c-MET_mRNA_expression._In_nearly_all_(90%)_pairwise_comparisons_of_tumors_and_cell_lines,_differential_c-MET_mRNA_expression_could_be_accounted_for_by_at_least_one_differential_CpG_cluster_methylation_(Δβ_≥_10%_and_FDR_adjusted_p_≤_0.05)._In_contrast,_only_48%_displayed_a_concordant_differential_expression_pattern_of_at_least_one_c-MET_transcription_factor._In_an_independent_study,_c-MET_was_overexpressed_in_8_of_35_(23%)_MAPKi-resistant_tumors_from_7_of_26_(27%)_patients._In_two_human_BRAF_V600E_mutant_cell_lines,_BRAFi_treatment_led_to_progressive_methylation-expression_changes_akin_to_observations_across_MAPKi-sensitive_versus_resistant_tumors.",26359985,PubMed,,"Hugo_et_al.,_2015,_Cell",,4,accepted,1581,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-08-18_11:15:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1581,https://civic.genome.wustl.edu/links/variants/621,https://civic.genome.wustl.edu/links/genes/52,,,,,64,Vemurafenib,,,,,,,
MET,4233,OVEREXPRESSION,Skin_Melanoma,8923,,Vemurafenib,,Predictive,Does_Not_Support,B,Resistance,"FFPE_tumours_from_patients_enrolled_in_the_BRIM2_(n_=_59)_and_BRIM3_(n_=_150)_trials_of_vemurafenib_in_advanced_BRAF_mutant_(V600E/K)_melanoma_were_analyzed_for_MET_expression_(IHC)._Pretreatment_MET_expression_was_frequent_at_the_≥1_+_cutoff_(BRIM3,_31%;_BRIM2,_49%),_but_relatively_infrequent_at_the_≥2_+_cutoff_(BRIM3,_9%;_BRIM2,_19%)._Retrospective_subset_analyses_showed_that,_irrespective_of_the_cutoff_used_or_the_treatment_arm,_MET_expression_did_not_show_prognostic_significance,_in_terms_of_objective_response_rate,_progression-free_survival,_or_overall_survival.",23802768,PubMed,,"Jubb_et_al.,_2013,_Histopathology",,3,accepted,1584,52,7,116312459,116436396,,,ENST00000318493.6,,,,,75,GRCh37,,,2016-08-17_18:51:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1584,https://civic.genome.wustl.edu/links/variants/621,https://civic.genome.wustl.edu/links/genes/52,,,,,64,Vemurafenib,,,,,,,
RAD23B,5887,EXPRESSION,Sarcoma,1115,,Vorinostat_(SAHA),,Predictive,Supports,D,Sensitivity/Response,"Western_blot_analyses_were_performed_for_HR23b_(RAD23B)_expression_sarcoma_cell_lines_after_treatment_with_vorinostat,_belinostat,_mocetinostat_and_entinostat._All_HDACi_were_able_to_regulate_proliferation_and_apoptosis_in_vitro._Sensitivity_to_vorinostat_correlated_significantly_with_HR23b_protein_expression._IHC_in_523_patient_samples_revealed_high_HR23b_expression_in_12.5%_of_sarcomas_(among_them_malignant_peripheral_nerve_sheath_tumours,_pleomorphic_liposarcomas,_leiomyosarcomas,_dedifferentiated_liposarcomas,_synovial_sarcomas_and_angiosarcomas)_and_23.2%_of_GIST.",27499916,PubMed,,"Angelika_Ihle_et_al.,_2016,_J_Pathol_Clin_Res",,2,accepted,1597,4760,9,110045560,110094475,,,ENST00000358015.3,,,,,75,GRCh37,,,2016-11-11_17:17:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1597,https://civic.genome.wustl.edu/links/variants/625,https://civic.genome.wustl.edu/links/genes/4760,,,,,2,Vorinostat_(SAHA),,,,,,,
RET,5979,CCDC6-RET,Non-small_Cell_Lung_Carcinoma,3908,,Nintedanib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_60-year_old_woman_with_lung_adenocarcinoma._After_negative_testing_for_EGFR_mutations_and_ALK_translocations_and_failure_of_platinum-based_chemotherapy_she_was_enrolled_on_a_nintedanib-docetaxel_trial._Docetaxel_was_discontinued_after_22_cycles_because_of_edema_and_fatigue._A_total_of_48_treatment_cycles_(26_cycles_of_nintedanib_alone)_was_administered_over_33_months_before_documentation_of_disease_progression_in_March_2013._Genomic_testing_revealed_a_CCDC6-RET_fusion_but_no_other_actionable_mutations_(confirmed_by_FISH).,26787234,PubMed,,"Takeda_et_al.,_2016,_Ann._Oncol.",,2,accepted,1601,42,,,,,,,,,,,,,,Somatic_Mutation,2016-11-06_00:34:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1601,https://civic.genome.wustl.edu/links/variants/626,https://civic.genome.wustl.edu/links/genes/42,,,transcript_fusion,,5,Nintedanib,,,,,,,
MAP2K1,5604,C121S,Melanoma,1909,,Vemurafenib,,Predictive,Supports,C,Resistance,A_patient_with_BRAF-mutant_melanoma_relapsed_after_treatment_with_PLX4032_(vemurafenib)._The_MAP2K1_C121S_mutation_was_identified_as_a_relapse-specific_variant_and_was_undetectable_in_the_pre-treatment_tumor._In_vitro_experiments_showed_that_the_C121S_mutation_increased_kinase_activity_and_conferred_resistance_to_PLX4032.,21383288,PubMed,,"Wagle_et_al.,_2011,_J._Clin._Oncol.",,4,accepted,1602,31,15,66729154,66729154,G,C,ENST00000307102.5,,,,,75,GRCh37,,Somatic_Mutation,2016-08-19_18:25:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/1602,https://civic.genome.wustl.edu/links/variants/627,https://civic.genome.wustl.edu/links/genes/31,,,missense_variant,"ENST00000307102.5:c.362G>C,NC_000015.9:g.66729154G>C,NM_002755.3:c.362G>C,NP_002746.1:p.Cys121Ser",10,Vemurafenib,,,,,chr15_g.66729154G~C,MAP2K1_c.362G~C,MAP2K1_C121S
FGFR3,2261,S249C,Urothelial_Carcinoma,2671,,Pazopanib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_67_year_old_woman_with_high-grade_papillary_urothelial_carcinoma._The_patient_underwent_chemotherapy_and_palliative_cystectomy_followed_by_tumor_progression_and_pulmonary_lesion_enlargement._Genomic_profiling_of_the_cystectomy_specimen_identified_FGFR3,_CCND1_and_FGF19_amplification_as_well_as_an_FGFR3_S249C_mutation_(allele_frequency_58%)._Pazopanib_was_initiated_on_the_basis_of_these_findings_and_a_partial_response_was_achieved_for_>6_months.",25766722,PubMed,,"Palma_et_al.,_2015,_Eur._Urol.",,2,accepted,1603,23,4,1803568,1803568,C,G,ENST00000340107.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_20:32:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1603,https://civic.genome.wustl.edu/links/variants/628,https://civic.genome.wustl.edu/links/genes/23,,,missense_variant,NC_000004.11:g.1803568C>G,5,Pazopanib,,,,,chr4_g.1803568C~G,,
FGFR2,2263,AMPLIFICATION,Stomach_Carcinoma,5517,,AZD4547,,Predictive,Supports,B,Sensitivity/Response,"Nine_patients_with_FGFR2-amplified_gastroesophageal_cancer_were_treated_with_AZD4547.__Of_these_9_patients,_3_showed_confirmed_responses_to_AZD4547._Median_progression-free_survival_was_6.6_months_(range=6.2-10.5)._Two_additional_patients_had_a_response_in_day_15_using_FDG-PET_but_were_not_considered_complete_responders_by_RECIST_criteria._High-level_FGFR2-amplified_(arbitrarily_defined_as_FISH-ratio_>_5)_cancers_had_a_higher_likelihood_of_response_and_were_associated_with_a_substantially_higher_expression_of_both_FGFR2_mRNA_and_FGFR2_protein_(IHC)._In_vitro_and_in_PDX_models,_FGFR2-amplified_cell_lines_were_sensitive_to_FGFR_inhibition._Further_preclinical_analyses_suggested,_that_FGFR2_amplification_mainly_signals_via_the_PI3K_pathway.",27179038,PubMed,,"Pearson_et_al.,_2016,_Cancer_Discov",,3,accepted,1990,22,10,123239371,123357917,,,ENST00000457416.2,,,,,75,GRCh37,,,2017-07-27_20:12:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1990,https://civic.genome.wustl.edu/links/variants/629,https://civic.genome.wustl.edu/links/genes/22,,,transcript_amplification,,25,AZD4547,,,,,,,
FGFR2,2263,AMPLIFICATION,Breast_Cancer,1612,,Dovitinib,,Predictive,Supports,B,Sensitivity/Response,"Dovitinib_was_evaluated_in-vitro,_in_xenograft_and_in_a_phase_2_study._Dovitinib_inhibited_proliferation_in_one_FGFR1-_and_one_FGFR2-amplified_breast_cancer_cell_lines_at_higher_IC50_values_than_in_11_nonamplified_cell_lines._Dovitinib_inhibited_tumor_growth_and_caused_regression_in_both_a_FGFR1-_and_FGFR2-amplified_xenograft_model._81_patients_were_enrolled_in_the_trial_and_treated_with_dovitinib._2_patients_were_reported_to_harbor_FGFR2_amplifications_and_both_had_a_reduction_in_tumor_size_of_18.5_and_28.2%,_respectively._When_FGFR1,_FGF3_and_FGFR2_amplifications_were_combined,_a_combined_FGF-pathway_amplified_patient_group_had_a_higher_mean_reduction_in_target_lesion_size_than_patients_with_FGF-non-amplified_tumors.",23658459,PubMed,,"André_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1605,22,10,123239371,123357917,,,ENST00000457416.2,,,,,75,GRCh37,,,2016-09-11_13:26:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/1605,https://civic.genome.wustl.edu/links/variants/629,https://civic.genome.wustl.edu/links/genes/22,,,transcript_amplification,,25,Dovitinib,,,,,,,
FGF3,2248,AMPLIFICATION,Breast_Cancer,1612,,Dovitinib,,Predictive,Supports,B,Sensitivity/Response,"81_patients_were_enrolled_in_a_clinical_trial_with_the_FGFR_inhibitor_dovitinib._Four_of_these_patients_had_FGF3_amplifications_(qPCR)_and_showed_tumor_reductions_of_100%,_30.8%,_23.0%,_and_7.5%,_respectively._3_of_these_4_patients_also_had_FGFR1_amplifications_(≥6_copies_by_qPCR)_and_the_fourth_presented_with_FGFR1-gene_gain_(3.4_copies_of_FGFR1_by_qPCR_and_SISH_negative).",23658459,PubMed,,"André_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1606,1873,11,69624992,69633792,,,ENST00000334134.2,,,,,75,GRCh37,,,2016-09-11_13:28:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1606,https://civic.genome.wustl.edu/links/variants/630,https://civic.genome.wustl.edu/links/genes/1873,,,transcript_amplification,,10,Dovitinib,,,,,,,
VHL,7428,R200W_(c.598C>T),Chuvash_Polycythemia,60474,Polycythemia,Ruxolitinib,,Predictive,Supports,C,Sensitivity/Response,Homozygous_VHL_R200W_mutations_result_in_a_rare_congenital_polycythemia_known_as_Chuvash_polycythemia._Treatment_of_3_patients_with_this_disease_with_the_JAK1/2_inhibitor_ruxolitinib_led_to_symptomatic_and_hematologic_improvements_in_all_patients_through_21-78_weeks_of_treatment.,27518686,PubMed,,"Zhou_et_al.,_2016,_N._Engl._J._Med.",,4,accepted,1608,58,3,10191605,10191605,C,T,ENST00000256474.2,,,,,75,GRCh37,,Germline_Mutation,2016-08-22_15:44:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1608,https://civic.genome.wustl.edu/links/variants/631,https://civic.genome.wustl.edu/links/genes/58,,,missense_variant,"NM_000551.3:c.598C>T,NP_000542.1:p.Arg200Trp,ENST00000256474.2:c.598C>T,NC_000003.11:g.10191605C>T",10,Ruxolitinib,,,,,chr3_g.10191605C~T,VHL_c.598C~T,VHL_R200W
RB1,5925,PHOSPHORYLATION,Breast_Cancer,1612,,Alpelisib_(NVP-BYL719),,Predictive,Supports,B,Resistance,"The_p110alpha-specific_PI3K_inhibitor_BYL719_was_used_on_a_panel_of_five_PI3K_inhibitor_sensitive_and_five_resistant_breast_cancer_cell_lines._Sensitive_cells_(IC50<400nM)_showed_reduced_phospho-Rb_(p-Rb)_western_blot_levels_in_response_to_BYL719_treatment,_while_resistant_cell_lines_(IC50>800nM)_showed_significantly_less_reduction_in_p-Rb_after_BYL719._Paired_biopsies_before_and_after_treatment_were_taken_from_a_set_of_eight_patients_classified_as_either_responder_or_non-responder_to_BYL719._Responder_samples_showed_significantly_reduced_p-Rb_staining_after_treatment_in_comparison_to_non-responder_biopsies._In_biopsies_taken_from_a_group_of_three_responders_who_progressed,_p-Rb_levels_were_increased_after_progression.",25002028,PubMed,,"Vora_et_al.,_2014,_Cancer_Cell",,3,accepted,1609,4795,13,48877911,49056122,,,ENST00000267163.4,,,,,75,GRCh37,,,2016-09-10_18:27:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1609,https://civic.genome.wustl.edu/links/variants/632,https://civic.genome.wustl.edu/links/genes/4795,,,,,15,Alpelisib_(NVP-BYL719),,,,,,,
PIK3R1,5295,MUTATION,Breast_Cancer,1612,,PP242,,Predictive,Supports,D,Sensitivity/Response,"Sensitivity_to_mTORC1/2_inhibitor_PP242_was_assessed_in_a_panel_of_breast_cancer_cell_lines_with_various_mutation_backgrounds._PTEN_and_PIK3CA_mutations_were_heavily_represented_in_the_panel._However,_a_PTEN_and_PIK3CA_wild_type_cell_line_'HS578T'_was_found_to_harbor_a_mutation_in_the_PI3K_regulatory_protein_PIK3R1._Like_PIK3CA_mutant_cell_lines,_the_PIK3R1_mutant_HS578T_line_was_also_determined_to_be_sensitive_to_PP242._Approximately_70%_of_PIK3CA_wild_type_lines_were_not_sensitive_to_PP242._This_suggests_that_mutations_in_the_PI3K_holoenzyme_may_be_targetable_by_mTORC1/2_inhibition.",21358673,PubMed,,"Weigelt_et_al.,_2011,_Oncogene",,2,accepted,1612,4289,5,67511548,67597649,,,ENST00000521381.1,,,,,75,GRCh37,,Somatic_Mutation,2016-11-08_02:38:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/1612,https://civic.genome.wustl.edu/links/variants/633,https://civic.genome.wustl.edu/links/genes/4289,,,"gain_of_function_variant,missense_variant",,2,PP242,,,,,,,
STK11,6794,D194E,Pancreatic_Cancer,1793,,Everolimus,,Predictive,Supports,C,Sensitivity/Response,Case_study_of_a_46-year_old_male_patient_with_Peutz-Jeghers_Syndrome_and_pancreatic_cancer._A_germline_STK11_D194E_mutation_was_identified_with_LOH_in_the_tumor_sample._phospho-S6_ribosomal_protein_staining_was_observed_in_the_tumor_indicating_mTOR_pathway_activation._Everolimus_treatement_led_to_partial_response_(but_no_change_in_phospho-S6_ribosomal_protein_staining)_for_9_months.,21189378,PubMed,,"Klümpen_et_al.,_2011,_J._Clin._Oncol.",,2,accepted,1617,5534,19,1220489,1220489,C,A,ENST00000326873.7,,,,,75,GRCh37,,Germline_Mutation,2016-11-06_00:48:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1617,https://civic.genome.wustl.edu/links/variants/634,https://civic.genome.wustl.edu/links/genes/5534,,,"loss_of_heterozygosity,missense_variant","NM_000455.4:c.582C>A,NP_000446.1:p.Asp194Glu,ENST00000326873.7:c.582C>A,NC_000019.9:g.1220489C>A",5,Everolimus,,,,,chr19_g.1220489C~A,STK11_c.582C~A,STK11_D194E
AKT2,208,AMPLIFICATION,Lung_Adenocarcinoma,3910,,"Vandetanib,Everolimus",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_74-year_old_woman_with_EGFR-_and_ALK-negative_lung_adenocarcinoma._FISH_identified_a_deletion_of_5'RET_(FISH,_indicating_RET-gene_rearrangement)_and_genomic_testing_confirmed_a_fusion_of_KIF5B_and_RET,_as_well_as_an_AKT2_gene_amplification._The_patient_was_enrolled_in_a_clinical_trial_with_vandetanib_and_everolimus_(NCT01582191)_with_everolimus_used_to_enhance_brain_accumulation_of_vandetanib._After_two_cycles_of_therapy_a_repeat_MRI_brain_showed_a_decrease_in_the_intracranial_disease_burden_and_PET/CT_showed_systemic_response_as_well.",25982012,PubMed,,"Subbiah_et_al.,_2015,_Lung_Cancer",,1,accepted,1621,254,19,40736224,40791302,,,ENST00000392038.2,,,,,75,GRCh37,,,2016-11-07_18:51:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1621,https://civic.genome.wustl.edu/links/variants/635,https://civic.genome.wustl.edu/links/genes/254,,,transcript_amplification,,2.5,Vandetanib,Everolimus,,,,,,
PTEN,5728,R130*,Thyroid_Cancer,1781,,"Perifosine,Temsirolimus",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Preclinical_study_in_thyroid_cancer_cell_lines._6_cell_lines_with_alterations_of_the_PI3K/Akt_pathway_were_more_sensitive_to_Akt_inhibitor_perifosine_or_MTOR_inhibitor_temsirolimus_than_5_cell_lines_without_genetic_alterations_in_the_PI3K/Akt_pathway._Among_the_alterations,_one_cell_line_harbored_a_PTEN_allele_deletion_and_R130*_mutation._This_cell_line_harbored_the_lowest_IC50_values_to_both_perifosine_and_temsirolimus_and_also_showed_increased_apoptosis_with_perifosine_in_a_xenograft_model.",19706758,PubMed,,"Liu_et_al.,_2009,_Cancer_Res.",,2,accepted,1627,41,10,89692904,89692904,C,T,ENST00000371953.3,,,,,75,GRCh37,,,2016-11-11_19:40:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/1627,https://civic.genome.wustl.edu/links/variants/636,https://civic.genome.wustl.edu/links/genes/41,,,stop_gained,"NM_000314.6:c.388C>T,NP_000305.3:p.Arg130Ter,ENST00000371953.3:c.388C>T,NC_000010.10:g.89692904C>T",2,Perifosine,Temsirolimus,,,,chr10_g.89692904C~T,PTEN_c.388C~T,p.arg130ter
FBXW7,55294,LOSS-OF-FUNCTION,Cancer,162,,Rapamycin_(Sirolimus),,Predictive,Supports,D,Sensitivity/Response,"FBXW7_was_shown_to_target_mTOR_for_ubiquitination_and_degradation.__A_reciprocal_relationship_between_FBXW7_or_PTEN_loss_was_identified_in_breast_cancer_tumors_and_cell_lines_(mutual_exclusivity_of_these_two_events).__In_total_only_4_out_of_450_tumor_and_cell_line_samples_had_concomitant_loss_of_both_genes_(p=4.9x10^-7)._Cell_lines_(n=5)_with_FBXW7_mutations_or_deletions_were_significantly_sensitive_to_rapamycin_and_downregulation_of_FBXW7_(shRNA)_increased_the_sensitivity_to_rapamycin._In_summary,_this_evidence_suggests_that_FBXW7_may_be_a_biomarker_for_cancers_sensitivity_to_inhibitors_of_the_mTOR_pathway.",18787170,PubMed,,"Mao_et_al.,_2008,_Science",,4,accepted,1632,12903,4,153242410,153457253,,,ENST00000281708.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_20:19:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1632,https://civic.genome.wustl.edu/links/variants/637,https://civic.genome.wustl.edu/links/genes/12903,,,loss_of_function_variant,,4.5,Rapamycin_(Sirolimus),,,,,,,
FBXW7,55294,LOSS-OF-FUNCTION,Renal_Cell_Carcinoma,4450,,Everolimus,,Predictive,Supports,E,Sensitivity/Response,mTOR_protein_levels_were_found_to_underly_a_circadian_24-hour_rhythm_regulated_by_time-dependent_Fbxw7-mediated_ubiquitination._Survival_rates_of_tumor-bearing_mice_with_everolimus_showed_time-dependency_consistent_with_mTOR_protein_levels._It_could_be_hypothesized_that_FBXW7_loss_leads_to_an_increase_in_mTOR_protein_levels_independent_of_circadian_regulation_and_higher_sensitivity_to_mTOR_inhibitors.,24253377,PubMed,,"Okazaki_et_al.,_2014,_Cancer_Res.",,2,accepted,1628,12903,4,153242410,153457253,,,ENST00000281708.4,,,,,75,GRCh37,,,2016-11-11_20:18:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1628,https://civic.genome.wustl.edu/links/variants/637,https://civic.genome.wustl.edu/links/genes/12903,,,loss_of_function_variant,,4.5,Everolimus,,,,,,,
RB1,5925,M695FS*26,Estrogen-receptor_Positive_Breast_Cancer,60075,,Palbociclib_(PD0332991),,Predictive,Supports,D,Resistance,"Preclinical_study_in_breast_cancer_cell_lines_treated_with_CDK4/6_inhibitor_palbociclib._Palbociclib-resistant_xenografts_from_one_cell_line_(PDX244)_were_developed_in-vivo._In_resistant_xenografts,_western_blot_analysis_showed_a_decrease_of_pRb_protein_levels_in_4_of_7_CDK4/6-acquired_resistant_tumors_and_a_sustained_expression_of_the_E2F_target_cyclin_E2,_in_contrast_to_CDK4/6_inhibitor-sensitive_PDX244._Genomic_characterization_of_PDX244LR1_showed_the_acquisition_of_an_RB1_frameshift_mutation_(RB1_p.M695fs*26).",27020857,PubMed,,"Herrera-Abreu_et_al.,_2016,_Cancer_Res.",,2,accepted,1630,4795,13,49033946,49033947,,A,ENST00000267163.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-07_20:23:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1630,https://civic.genome.wustl.edu/links/variants/638,https://civic.genome.wustl.edu/links/genes/4795,,,frameshift_truncation,"ENST00000267163.4:c.2083_2084insA,NC_000013.10:g.49033946_49033947insA",2,Palbociclib_(PD0332991),,,,,chr13_g.49033946_49033947insA,RB1_c.2083_2084insA,
JUN,3725,OVEREXPRESSION,Colorectal_Adenocarcinoma,50861,,Irbesartan,,Predictive,Supports,C,Sensitivity/Response,"A_67-year-old_female_presents_with_recurrent_metastatic_colonic_adenocarcinoma.__Immunohistochemical_and_genetic_workup_showed_overexpression_of_c-JUN_and_FOS,_which_presumably_signals_through_the_RAAS_pathway._The_patient_was_treated_with_irbesartan_and_after_5_weeks_of_therapy,_the_CEA_value_decreased_from_18_to_3.1_and_there_was_radiological_resolution_of_the_disease.__Her_10_month_CEA_was_1.4.",27022066,PubMed,,"Jones_et_al.,_2016,_Ann._Oncol.",,2,accepted,1633,3094,1,59246465,59249785,,,ENST00000371222.2,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_22:28:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1633,https://civic.genome.wustl.edu/links/variants/639,https://civic.genome.wustl.edu/links/genes/3094,,,,,5,Irbesartan,,,,,,,
FOS,2353,OVEREXPRESSION,Colon_Adenocarcinoma,234,,Irbesartan,,Predictive,Supports,C,Sensitivity/Response,"A_67-year-old_female_presents_with_recurrent_metastatic_colonic_adenocarcinoma.__Immunohistochemical_and_genetic_workup_showed_overexpression_of_c-JUN_and_FOS,_which_presumably_signals_through_the_RAAS_pathway._The_patient_was_treated_with_Irbesartan_and_after_5_weeks_of_therapy,_the_CEA_value_decreased_from_18_to_3.1_and_there_was_radiological_resolution_of_the_disease.__Her_10_month_CEA_was_1.4.",27022066,PubMed,,"Jones_et_al.,_2016,_Ann._Oncol.",,2,accepted,1634,1955,14,75745477,75748933,,,ENST00000303562.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_23:31:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1634,https://civic.genome.wustl.edu/links/variants/640,https://civic.genome.wustl.edu/links/genes/1955,,,,,5,Irbesartan,,,,,,,
IDH1,3417,MUTATION,Brain_Glioma,60108,,Olaparib,,Predictive,Supports,D,Sensitivity/Response,"Mutations_in_isocitrate_dehydrogenase_1_and_2,_which_result_in_overproduction_of_2-hydroxyglutarate_(2HG)._2HG_is_considered_to_be_an_oncometabolite,_or_a_metabolite_that_promotes_carcinogenesis,_and_inhibitors_of_mutant_isocitrate_dehydrogenase_are_in_development_to_target_this_process._The_authors_discovered_that_2HG_overproduction_impairs_homologous_recombination_used_in_DNA_repair_and_sensitizes_cancer_cells_to_treatment_with_PARP_inhibitors,_another_class_of_cancer_drugs_that_are_already_in_clinical_use.",28148839,PubMed,,"Sulkowski_et_al.,_2017,_Sci_Transl_Med",,3,accepted,2933,26,2,209101803,209116275,,,ENST00000415913.1,,,,,75,GRCh37,,Somatic_Mutation,2017-05-11_15:31:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/2933,https://civic.genome.wustl.edu/links/variants/645,https://civic.genome.wustl.edu/links/genes/26,,,transcript_variant,,18,Olaparib,,,,,,,
SMAD4,4089,DELETION,Colorectal_Cancer,9256,,5-fluorouracil,,Predictive,Supports,B,Resistance,"A_retrospective_study_with_202_colorectal_cancer_patients_found_that_SMAD4_deletion_was_associated_with_worse_outcomes_during_5-fluorouracil_treatment._The_hazard_ratio_for_disease-free_survival_was_2.89_times_greater_for_patients_with_SMAD4_deletion_as_compared_to_those__with_normal_SMAD4_diploidy_(P_=_.045).__For_overall_survival,_the_hazard_ratio_was_3.23_times_greater_for_SMAD4_deletion_(P_=_.056).",12237773,PubMed,,"Boulay_et_al.,_2002,_Br._J._Cancer",,3,accepted,1644,77,18,48556583,48611409,,,ENST00000342988.3,,,,,75,GRCh37,,,2016-09-10_18:30:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1644,https://civic.genome.wustl.edu/links/variants/646,https://civic.genome.wustl.edu/links/genes/77,,,transcript_ablation,,15,5-fluorouracil,,,,,,,
ATRX,546,UNDEREXPRESSION,Astrocytoma,3069,,"Temozolomide,Procarbazine,Lomustine,Vincristine",Substitutes,Predictive,Supports,B,,"A_retrospective_tumor_sample_study_found_that_the_loss_of_ATRX_expression_(less_than_10%_of_nuclei)_in_IDH-mutant_astrocytomas_treated_with_temozolomide_or_a_combination_of_procarbazine,_lomustine_and_vincristine_was_associated_with_a_greater_time_to_treatment_failure_(55.6_months_vs._31.8_months;_P_=_.0168)_and_a_greater_progression-free_survival_(37.1_months_vs._18.1_months;_P_=_.038).",23904111,PubMed,,"Wiestler_et_al.,_2013,_Acta_Neuropathol.",,3,accepted,1647,525,X,76760356,77041702,,,ENST00000373344.5,,,,,75,GRCh37,,,2016-09-11_13:02:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1647,https://civic.genome.wustl.edu/links/variants/648,https://civic.genome.wustl.edu/links/genes/525,,,,,19,Temozolomide,Procarbazine,Lomustine,Vincristine,,,,
MET,4233,D1228N,Non-small_Cell_Lung_Carcinoma,3908,,Crizotinib,,Predictive,Supports,C,Resistance,Case_report_of_a_patient_with_NSCLC_harboring_a_MET_exon_14_skipping_mutation_and_initial_response_to_crizotinib._A_second_biopsy_at_the_time_of_progression_revealed_an_acquired_MET_D1228N_mutation.,27343442,PubMed,,"Heist_et_al.,_2016,_J_Thorac_Oncol",,2,accepted,1652,52,7,116423407,116423407,G,A,ENST00000397752.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_23:27:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1652,https://civic.genome.wustl.edu/links/variants/649,https://civic.genome.wustl.edu/links/genes/52,,,missense_variant,"NM_001127500.2:c.3736G>A,NP_001120972.1:p.Asp1246Asn,NC_000007.13:g.116423407G>A,ENST00000397752.3:c.3682G>A",5,Crizotinib,,,,,chr7_g.116423407G~A,MET_c.3682G~A,MET_D1246N
GAS6,2621,EXPRESSION,Prostate_Cancer,10283,,Docetaxel,,Predictive,Supports,D,Resistance,"Prostate_Cancer_(PCa)_cell_lines_were_either_cultured_alone,_co-cultured_with_osteoblasts_expressing_GAS6,_or_cultured_in_the_presence_of_media_with_GAS6_to_examine_their_response_to_therapy_with_docetaxel._Docetaxel_efficiently_induced_apoptosis_in_the_cells_cultured_without_any_GAS6,_but_it_was_not_able_to_do_so_in_the_cells_that_were_in_media_with_GAS6_present_or_that_were_co-cultured_with_osteoblasts_expressing_GAS6._PCa_cells_in_the_presence_of_GAS6_were_found_to_be_in_G1_phase_for_a_greater_duration_which_may_help_explain_the_increased_resistance_to_docetaxel.",27153245,PubMed,,"Lee_et_al.,_2016,_J._Cell._Biochem.",,3,accepted,1656,2186,13,114523524,114567046,,,ENST00000357389.3,,,,,75,GRCh37,,,2016-09-16_19:30:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1656,https://civic.genome.wustl.edu/links/variants/652,https://civic.genome.wustl.edu/links/genes/2186,,,,,23,Docetaxel,,,,,,,
STAG3,10734,UNDEREXPRESSION,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,A375_melanoma_cells_containing_an_inducible_shRNA_for_STAG3_were_grown_as_xenograft_tumors_in_nude_mice._The_mice_in_which_STAG3_was_silenced_had_tumors_that_were_more_sensitive_to_vemurafenib-induced_tumor_shrinkage_than_the_tumors_of_the_control_mice_(P_<_.01).,27500726,PubMed,,"Shen_et_al.,_2016,_Nat._Med.",,4,accepted,1660,8552,7,99775186,99812003,,,ENST00000426455.1,,,,,75,GRCh37,,,2016-11-07_20:22:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1660,https://civic.genome.wustl.edu/links/variants/654,https://civic.genome.wustl.edu/links/genes/8552,,,,,4,Vemurafenib,,,,,,,
MAP2K1,5604,Q56_V60del,Ovarian_Serous_Carcinoma,50933,,Selumetinib_(AZD6244),,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_51-year_old_patient_with_recurrent_low-grade_serous_ovarian_cancer._Selumetinib_treatment_in_a_phase-II_trial_led_to_a_complete_and_durable_response_>_5_years._Sequencing_(MSK-IMPACT_Panel)_was_performed_on_the_patients_tumor_and_germline_and_identified_a_15-bp_in-frame_deletion_of_MAP2K1_(8.3%_of_tumor_reads_but_0%_in_germline)._In-silico_modelling_suggested_loss_of_negative_feedback_on_kinase_activity_from_this_deletion.In-vitro_expression_of_the_MEK1_Q56_V60_deletion_as_well_as_the_previously_characterized_MEK1_F53L_mutation_in_293H_cells_resulted_in_elevated_levels_of_phosphorylated_ERK_and_phosphorylated_ribosomal_protein_S6_kinase_as_compared_with_wild-type_MEK1_as_well_as_increased_colony_formation_and_tumor_growth_in-vivo._Selumetinib_treatment_of_MEK1-transfected_cells_confirmed_retained_sensitivity_to_MEK_inhibition_and_inhibition_of_colony_formation.,26324360,PubMed,,"Grisham_et_al.,_2015,_J._Clin._Oncol.",,4,accepted,1661,31,15,66727449,66727463,CCAGAAGCAGAAGGT,,ENST00000307102.5,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_21:38:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/1661,https://civic.genome.wustl.edu/links/variants/655,https://civic.genome.wustl.edu/links/genes/31,,,inframe_deletion,"ENST00000307102.5:c.165_179del,NC_000015.9:g.66727449_66727463del",10,Selumetinib_(AZD6244),,,,,chr15_g.66727449_66727463del,MAP2K1_c.165_179del,
BRAF,673,BRAF-CUL1,Ovarian_Serous_Carcinoma,50933,,MEK_Inhibitor,,Predictive,Supports,C,Sensitivity/Response,"One_patient_with_low-grade_serous_ovarian_cancer_had_an_in-frame_fusion_between_the_BRAF_kinase_domain_and_CUL1_identified_by_panel_sequencing_(MSK-IMPACT),_with_expression_confirmed_by_whole-transcriptome_sequencing._This_patient_with_metastatic_disease_after_treatment_with_carboplatin_and_paclitaxel,_was_enrolled_onto_a_study_of_paclitaxel_in_combination_with_an_oral_MEK_inhibitor_and_achieved_a_CR._She_continued_to_receive_therapy_for_7_months,_until_discontinuation_because_of_the_development_of_pneumonitis._At_publication,_sustained_CR_had_lasted_>_18_months.",26324360,PubMed,,"Grisham_et_al.,_2015,_J._Clin._Oncol.",,2,accepted,1662,5,7,140434279,140487384,,,ENST00000288602.6,7,148395737,148457588,ENST00000602748.1,75,GRCh37,,Somatic_Mutation,2016-10-22_14:43:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1662,https://civic.genome.wustl.edu/links/variants/656,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,5,MEK_Inhibitor,,,,,,,
BRAF,673,ZKSCAN1-BRAF,Melanoma,1909,,Trametinib,,Predictive,Supports,C,Sensitivity/Response,"Analysis_of_BRAF_fusions_in_20,573_tumors,_across_12_distinct_tumor_types._BRAF_fusions_were_identified_in_55_(0.3%)_patients_and_enriched_in_spitzoid_melanoma,_pilocytic_astrocytomas,_pancreatic_acinar_and_papillary_thyroid_cancers._Clinical_data_were_available_for_two_patients._Among_them_one_46-year_old_woman_with_spitzoid_melanoma_that__harbored__a_ZKSCAN1-BRAF_fusion_responded_to_treatment_with_the_MEK_inhibitor_trametinib._Subcutaneous__tumor__nodules__exhibited__clinical_responses_within_14_days_of_therapy,_and_her_dominant_bulky_right_lung_metastases_showed_significant_response_by_Day_45._Subsequent_robotic-assisted_lobectomy_was_able_to_remove_the_previously_unresectable_tumor_with_clean_surgical_margins.",26314551,PubMed,,"Ross_et_al.,_2016,_Int._J._Cancer",,3,accepted,1663,5,7,99613222,99627575,,,ENST00000426572.1,7,140434279,140482957,ENST00000288602.6,75,GRCh37,,Somatic_Mutation,2016-11-05_22:15:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1663,https://civic.genome.wustl.edu/links/variants/657,https://civic.genome.wustl.edu/links/genes/5,,BRAF_Fusions,transcript_fusion,,7.5,Trametinib,,,,,,,
BRAF,673,L505H,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"Using_a_mutation_screen_in_the_BRAFV600E_melanoma_cell_line_A375,_the_L505H_variant_was_identified_as_conferring_resistance_to_vemurafenib._Analysis_of_the_mutation_in_T293_cell_lines_found_that_the_L505H_mutant_alone_or_with_V600e_had_greater_kinase_activity_and_increased_the_levels_of_phospho-MEK._Finally,_transduction_of_Ba/F3_cells_with_BRAF_V600E/L505H_IL3_independent_proliferation.",24112705,PubMed,,"Wagenaar_et_al.,_2014,_Pigment_Cell_Melanoma_Res",,4,accepted,1668,5,7,140477794,140477794,A,T,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-03_18:57:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1668,https://civic.genome.wustl.edu/links/variants/658,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"ENST00000288602.6:c.1514T>A,NC_000007.13:g.140477794A>T,NM_004333.4:c.1514T>A,NP_004324.2:p.Leu505His",19,Vemurafenib,,,,,chr7_g.140477794A~T,BRAF_c.1514T~A,BRAF_L505H
BRAF,673,L505H,Melanoma,1909,,Vemurafenib,,Predictive,Supports,B,Resistance,"In_this_study,_the_investigators_followed_10_patients_treated_with_vemurafenib,_and_then_they_collected_biopsies_of_lesions_that_progressed._In_one_of_these_patients,_they_identified_the_L505H_mutation.",25515853,PubMed,,"Hoogstraat_et_al.,_2015,_Pigment_Cell_Melanoma_Res",,3,accepted,1669,5,7,140477794,140477794,A,T,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-09-23_20:24:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1669,https://civic.genome.wustl.edu/links/variants/658,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"ENST00000288602.6:c.1514T>A,NC_000007.13:g.140477794A>T,NM_004333.4:c.1514T>A,NP_004324.2:p.Leu505His",19,Vemurafenib,,,,,chr7_g.140477794A~T,BRAF_c.1514T~A,BRAF_L505H
NF2,4771,MUTATION,Acoustic_Neuroma,12689,,Everolimus,,Predictive,Supports,B,,"Ten_patients_with_Neurofibromatosis_2_were_enrolled_for_treatment_with_Everolimus.__At_12_months,_no_patients_had_reduction_in_tumor_volume_>20%,_however,_five_patients_had_stable_disease_with_a_reduction_in_annual_growth_rate_from_67%_growth/year_to_0.5%_growth/year.__Growth_of_tumors_ensued_after_discontinuation_of_Everolimus.",25567352,PubMed,,"Goutagny_et_al.,_2015,_J._Neurooncol.",,3,accepted,1671,3870,22,29999547,30094587,,,ENST00000338641.4,,,,,75,GRCh37,,Germline_Mutation,2016-09-23_20:25:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1671,https://civic.genome.wustl.edu/links/variants/659,https://civic.genome.wustl.edu/links/genes/3870,,,transcript_variant,,15,Everolimus,,,,,,,
HIF1A,3091,EXPRESSION,Renal_Cell_Carcinoma,4450,,Pazopanib,,Predictive,Does_Not_Support,B,,Immunohistochemical_staining_was_performed_on_65_patients_for_HIF1A_such_that_23_were_considered_responders_and_42_were_considered_non-responders.__There_was_no_difference_between_the_two_groups_with_regards_to_overall_response_rate_to_pazopanib.__There_was_no_difference_between_the_two_groups_with_regards_to_progression_free_survival.,23881929,PubMed,,"Choueiri_et_al.,_2013,_Clin._Cancer_Res.",,2,accepted,1674,2596,14,62164340,62214489,,,ENST00000539097.1,,,,,75,GRCh37,,,2017-01-23_15:49:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1674,https://civic.genome.wustl.edu/links/variants/660,https://civic.genome.wustl.edu/links/genes/2596,,,,,10,Pazopanib,,,,,,,
ERBB2,2064,MUTATION,Bladder_Carcinoma,4007,,PLATINUM,,Predictive,Supports,C,Sensitivity/Response,"In_patients_with_muscle-invasive_bladder_chancer,_a_cohort_of_complete_responders_to_platinum_chemotherapy_(n=38)_and_non-responders_to_platinum_chemotherapy_(n=33)_were_evaluated_for_178_cancer-associated_genes._Of_the_complete_responders,_24%_had_an_ERBB2_missense_mutations_and_no_non-responders_had_ERBB2_mutations_(p=0.003).",25636205,PubMed,,"Groenendijk_et_al.,_2016,_Eur._Urol.",,3,accepted,1694,20,17,37868196,37881332,,,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_22:16:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1694,https://civic.genome.wustl.edu/links/variants/666,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,,37.5,PLATINUM,,,,,,,
ERBB2,2064,MUTATION,Non-small_Cell_Lung_Carcinoma,3908,,"Trastuzumab,Pertuzumab",Combination,Predictive,Supports,B,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Among_thirty-six_patients_that_received_treatment_with_trastuzumab_plus_pertuzumab_because_of_a_HER2_mutation_(without_amplification/overexpression)_four_patients_(11%;_95%_CI,_3%_to_26%)_had_objective_responses.__Fourteen_of_the_36_patients_with_HER2-mutated_tumors_had_NSCLC_(adenocarcinoma,_n_=_13;_adenosquamous,_n_=_1);_in_this_group,_three_patients_(21%;_95%_CI,_5%_to_51%)_had_PR_and_three_had_SD_>_120_days._Only_one_of_the_other_22_patients_with_HER2-mutated_tumors_responded_to_treatment_with_pertuzumab_plus_trastuzumab_(biliary_cancer).",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5980,20,17,37868196,37881332,,,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2018-02-15_23:03:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/5980,https://civic.genome.wustl.edu/links/variants/666,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,,37.5,Trastuzumab,Pertuzumab,,,,,,
ERBB2,2064,MUTATION,Breast_Cancer,1612,,Neratinib,,Predictive,Supports,B,Sensitivity/Response,"16_patients_with_HER2-mutated_metastatic_breast_cancer_were_treated_with_neratinib_monotherapy._Of_these_16_patients,_14_had_known-activating_mutations_and_2_had_mutations_of_unknown_significance._Five_of_the_16_patients_achieved_clinical_benefit_including_1_complete_response_(6%),_1_partial_response_(6%)_and_3_with_stable_disease_>24_weeks_(19%)._Clinical_benefit_was_observed_across_different_HER2_mutations_including_L755S,_V777_G778_insGSP,_P780_Y781_insGSP,_V842I,_S310F,_and_L869R.",28679771,PubMed,,"Ma_et_al.,_2017,_Clin._Cancer_Res.",,4,accepted,5338,20,17,37868196,37881332,,,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_18:54:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/5338,https://civic.genome.wustl.edu/links/variants/666,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,,37.5,Neratinib,,,,,,,
MYCL,4610,EXPRESSION,Multiple_Myeloma,9538,,"I-BET151,JQ1",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Four_myeloma_cell_lines_were_treated_with_two_different_BET_inhibitors_(I-BET151_or_JQ1)._Proliferation_of_three_cell_lines_(KMS11,_RPMI8226_and_MM1S)_but_not_U266_(only_partial_inhibition)_was_strongly_inhibited_by_the_BET_inhibitors._Microarray_analysis_showed_a_downregulation_of_MYC-dependent_genes_after_treatment._qRT-PCR_showed_that_MYCL1_but_not_c-MYC_and_MYCN_was_expressed_in_U266_cells_and_I-BET151_induced_downregulation_of_MYCL1._In_contrast,_c-MYC_but_not_MYCL_was_expressed_in_the_other_cell_lines_and_I-BET151_induced_downregulation_of_c-MYC.",27276402,PubMed,,"Suzuki_et_al.,_2016,_Anticancer_Drugs",,1,accepted,1706,3738,1,40361098,40367685,,,ENST00000397332.2,,,,,75,GRCh37,,,2016-11-09_22:18:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/1706,https://civic.genome.wustl.edu/links/variants/670,https://civic.genome.wustl.edu/links/genes/3738,,,,,1,I-BET151,JQ1,,,,,,
HGF,3082,EXPRESSION,Glioblastoma_Multiforme,3068,,SGX523,,Predictive,Supports,D,Sensitivity/Response,Three_metastatic_glioblastoma_cell_lines_were_compared_with_their_parental_cell_lines_with_regard_to_differential_gene_expression._HGF_signalling_was_among_the_top_pathways_identified._Exogenous_HFG_led_to_an_increase_in_MET_activity_(except_in_one_cell_line_with_high_endogenous_HGF_levels)_which_was_abrogated_by_MET_inhibitor_SGX523._Three_HGF_autocrine_cell_lines_were_grown_in_mice_and_showed_significantly_increased_sensitivity_to_SGX523_than_three_non-HGF_autocrine_cell_lines_(P<0.05).,22203985,PubMed,,"Xie_et_al.,_2012,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,1707,2591,7,81328322,81399514,,,ENST00000222390.5,,,,,75,GRCh37,,,2016-11-12_03:42:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1707,https://civic.genome.wustl.edu/links/variants/671,https://civic.genome.wustl.edu/links/genes/2591,,,,,2,SGX523,,,,,,,
SOX10,6663,LOSS,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,FACS-assisted_shRNA_genetic_screen_identified_SOX10_as_a_determinant_of_vemurafenib_resistance._Suppression_of_SOX10_in_melanoma_cells_confers_resistance_to_BRAF_and_MEK_inhibitors_through_activation_of_TGF-β_signalling_and_upregulation_of_EGFR_and_PDGFRB._EGFR_expression_or_exposure_to_TGF-β_becomes_beneficial_for_proliferation_of_melanoma_cells_in_the_presence_of_BRAF_or_MEK_inhibitors._Melanoma_cells_with_low_SOX10_and_consequently_high_EGFR_expression_are_enriched_in_the_presence_of_vemurafenib._This_study_finds_evidence_for_SOX10_loss_(N=2)_and/or_activation_of_TGF-β_signalling_(N=2)_in_4_of_the_6_EGFR-positive_drug-resistant_melanoma_patient_samples.,24670642,PubMed,,"Sun_et_al.,_2014,_Nature",,4,accepted,1710,5418,22,38368307,38380544,,,ENST00000396884.2,,,,,75,GRCh37,,,2016-09-28_15:53:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1710,https://civic.genome.wustl.edu/links/variants/672,https://civic.genome.wustl.edu/links/genes/5418,,,loss_of_function_variant,,4,Vemurafenib,,,,,,,
FGF2,2247,EXPRESSION,Acute_Myeloid_Leukemia,9119,,Quizartinib_(AC220),,Predictive,Supports,D,Resistance,"AML_MOLM14_cells_were_cocultured_with_FLT3_inhibitor_AC220_(10_nM)_and_selected_proteins_expressed_in_the_bone_marrow_microenvironment._FL_and_FGF2_were_the_only_proteins_that_increased_viability_>2_standard_deviations._FGFR_inhibitor_PD173074_(and_FGFR1_siRNA)_was_able_to_attenuate_the_protective_effect_of_FGF2.__Removing_FL_or_FGF2_from_ligand-dependent_resistant_cultures_transiently_restored_sensitivity_to_AC220,_but_accelerated_acquisition_of_secondary_resistance_mutations._10_FLT3-ITD_AML_patients_treated_with_AC220_developed_increased_FGF2_expression_(IHC)_in_marrow_stromal_cells,_which_peaked_prior_to_overt_clinical_relapse_and_detection_of_resistance_mutations",27671675,PubMed,,"Traer_et_al.,_2016,_Cancer_Res.",,4,accepted,1711,1872,4,123747863,123819391,,,ENST00000264498.3,,,,,75,GRCh37,,,2016-11-09_21:00:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/1711,https://civic.genome.wustl.edu/links/variants/673,https://civic.genome.wustl.edu/links/genes/1872,,,,,4,Quizartinib_(AC220),,,,,,,
ERRFI1,54206,E384*,Cholangiocarcinoma,4947,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"An_ERRFI1_(E384X)_was_detected_in_a_patient_with_metastatic,_recurrent/refractory_cholangiocarcinoma_(allelic_fraction_11%)_without_any_mutations_or_amplifications_in_other_EGFR_signaling_members_such_as_EGFR_and_BRAF._The_patient_was_treated_with_erlotinib_150_mg_orally/daily._After_3_months,_RECIST_v1.1_partial_response_evidenced_by_a_decrease_of_58%_in_the_sum_of_largest_diameters_was_observed.",24550739,PubMed,,"Borad_et_al.,_2014,_PLoS_Genet.",,2,accepted,1724,12271,1,8073509,8073509,C,A,ENST00000377482.5,,,,,75,GRCh37,,Somatic_Mutation,2016-11-05_23:29:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1724,https://civic.genome.wustl.edu/links/variants/691,https://civic.genome.wustl.edu/links/genes/12271,,,"stop_gained,loss_of_function_variant",NC_000001.10:g.8073509C>A,5,Erlotinib,,,,,chr1_g.8073509C~A,,
ESR1,2099,S463P,Estrogen-receptor_Positive_Breast_Cancer,60075,,Aromatase_Inhibitor,,Predictive,Supports,D,Resistance,ESR1_S463P_variants_were_observed_after_extensive_treatment_with_hormonal_therapy_(aromatase_inhibition)._Expression_of_the_S463P_mutant_was_found_to_induce_modest_activity_in_the_absence_of_hormone._This_mutation_displayed_elevated_levels_of_Ser118_phosphorylation_compared_to_wild-type_ERα_and_appeared_to_possess_estrogen-independent_activity.,24185512,PubMed,,"Toy_et_al.,_2013,_Nat._Genet.",,2,accepted,1727,21,6,152415537,152415537,T,C,ENST00000440973.1,,,,,75,GRCh37,,Somatic_Mutation,2016-11-12_14:53:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/1727,https://civic.genome.wustl.edu/links/variants/692,https://civic.genome.wustl.edu/links/genes/21,,,missense_variant,"ENST00000440973.1:c.1387T>C,NC_000006.11:g.152415537T>C",2,Aromatase_Inhibitor,,,,,chr6_g.152415537T~C,ESR1_c.1387T~C,
SGK1,6446,OVEREXPRESSION,Breast_Cancer,1612,,Alpelisib_(NVP-BYL719),,Predictive,Supports,B,Resistance,"A_group_of_18_breast_cancer_patients_were_treated_with_PI3Kalpha_inhibitor_alpelisib_plus_an_aromatase_inhbitor_(NCT01870505)._3_out_of_3_patients_expressing_high_tumor_SGK1_mRNA_had_disease_progression_as_best_response_with_median_progression_free_survival_(PFS)_of_56_days,_while_15_patients_classified_with_low_to_medium_SGK1_mRNA_had_median_PFS_111_days_with_4/15_having_disease_progression_as_best_response.",27451907,PubMed,,"Castel_et_al.,_2016,_Cancer_Cell",,3,accepted,1730,5225,6,134490384,134639196,,,ENST00000367858.5,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_23:21:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/1730,https://civic.genome.wustl.edu/links/variants/693,https://civic.genome.wustl.edu/links/genes/5225,,,,,24,Alpelisib_(NVP-BYL719),,,,,,,
SGK1,6446,OVEREXPRESSION,Breast_Cancer,1612,,"BYL719_(Alpelisib),SGK1-Inh",Combination,Predictive,Supports,D,Sensitivity/Response,"The_alpelisib_(PI3Kalpha_inhibitor)_resistant_breast_cancer_cell_line_HCC1954_was_treated_with_alpelsisb_alone_or_in_combination_with_the_SGK1_kinase_inhibitor_SGK1-Inh._Addition_of_SGK1_reduced_viability_over_alpelisib_alone,_and_phospho-S6K_as_well_as_phospho-4EBP1_levels_decreased_with_combination_treatment._HCC1954_xenografts_showed_increased_tumor_volume_with_treatment_of_alpelisib_or_SGK1-Inh_alone,_but_only_combination_treatment_resulted_in_lack_of_volume_increase_and_decreased_phospho-S6K_levels_in_tumors_by_IHC.",27451907,PubMed,,"Castel_et_al.,_2016,_Cancer_Cell",,4,accepted,1731,5225,6,134490384,134639196,,,ENST00000367858.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-31_15:27:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1731,https://civic.genome.wustl.edu/links/variants/693,https://civic.genome.wustl.edu/links/genes/5225,,,,,24,BYL719_(Alpelisib),SGK1-Inh,,,,,,
SGK1,6446,OVEREXPRESSION,Breast_Cancer,1612,,Alpelisib_(NVP-BYL719),,Predictive,Supports,D,Resistance,SGK1_mRNA_expression_was_elevated_in_five_breast_cancer_cell_lines_which_were_resistant_to_PI3Kalpha_inhibitor_alpelisib_in_comparison_to_five_sensitive_cell_lines._Western_blots_showed_clear_elevation_of_protein_levels_in_3/5_resistant_cell_lines._Ectopic_SGK1_expression_in_sensitive_MDA-MB-361_cells_resulted_in_alpelisib_resistance_and_preservation_of_phopho-S6K_and_phospho-4EBP_with_alpelisib_treatment._Knockdown_of_SGK1_in_resistant_HCC1954_cells_increased_alpelisib_sensitivity_and_reduced_p-S6K_and_p-4EBP_levels_with_alpelisib_treatment._Promoter_methylation_at_SGK1_was_increased_in_sensitive_cells_compared_to_alpelisib_resistant_cell_lines.,27451907,PubMed,,"Castel_et_al.,_2016,_Cancer_Cell",,5,accepted,1729,5225,6,134490384,134639196,,,ENST00000367858.5,,,,,75,GRCh37,,Somatic_Mutation,2016-11-04_23:21:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1729,https://civic.genome.wustl.edu/links/variants/693,https://civic.genome.wustl.edu/links/genes/5225,,,,,24,Alpelisib_(NVP-BYL719),,,,,,,
BRAF,673,G596C,Non-small_Cell_Lung_Carcinoma,3908,,"Dabrafenib,Trametinib",Combination,Predictive,Supports,D,Sensitivity/Response,"non-V600_BRAF_mutations_can_be_sensitive_to_clinically_relevant_doses_of_Dabrafenib_and_Trametinib_in_HEK293T_cells,_in_lung_epithelial_cellular_model_(BEAS-2B)_and_in_human_cancer_cell_lines_harboring_non-V600_BRAF_mutations",27577079,PubMed,,"Noeparast_et_al.,_2016,_Oncotarget",,,accepted,1738,5,7,140453149,140453149,C,A,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-08_21:37:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1738,https://civic.genome.wustl.edu/links/variants/694,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1786G>T,NP_004324.2:p.Gly596Cys,NC_000007.13:g.140453149C>A,ENST00000288602.6:c.1786G>T",0,Dabrafenib,Trametinib,,,,chr7_g.140453149C~A,BRAF_c.1786G~T,BRAF_G596C
SMARCB1,6598,UNDEREXPRESSION,Synovial_Sarcoma,5485,,EPZ-6438,,Predictive,Supports,D,Sensitivity/Response,"Treatment_with_tazemetostat_,_a_small-molecule_inhibitor_of_EZH2,_results_in_concentration-dependent_cell_growth_inhibition_and_cell_death_specifically_in_SS18-SSX-positive,_SMARCB1-deficient_synovial_sarcomas.",27391784,PubMed,,"Kawano_et_al.,_2016,_PLoS_ONE",,2,accepted,1739,5356,22,24129150,24176703,,,ENST00000344921.6,,,,,75,GRCh37,,,2016-11-15_16:47:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1739,https://civic.genome.wustl.edu/links/variants/695,https://civic.genome.wustl.edu/links/genes/5356,,,,,2,EPZ-6438,,,,,,,
SMARCB1,6598,DELETION,Rhabdoid_Cancer,3672,,EPZ-6438,,Predictive,Supports,D,Sensitivity/Response,EPZ-6438_(Tazemetostat)_induces_apoptosis_and_differentiation_specifically_in_SMARCB1-deleted_malignant_rhabdoid_tumors_(MRT)_cells._This_study_compared_in_vitro_EPZ-6438_treatment_of_four_SMARCB1-deleted_MRT_cell_lines_to_three_control_(wild-type)_cell_lines._These_data_demonstrate_the_dependency_of_SMARCB1_mutant_MRTs_on_EZH2_enzymatic_activity_and_suggest_treatment_of_these_genetically_defined_cancers_with_EZH2_inhibitors.,23620515,PubMed,,"Knutson_et_al.,_2013,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,1740,5356,22,24129150,24176703,,,ENST00000344921.6,,,,,75,GRCh37,,Somatic_Mutation,2016-11-12_15:53:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/1740,https://civic.genome.wustl.edu/links/variants/696,https://civic.genome.wustl.edu/links/genes/5356,,,transcript_ablation,,3,EPZ-6438,,,,,,,
NF2,4771,LOSS,Thyroid_Carcinoma,3963,,Selumetinib_(AZD6244),,Predictive,Supports,D,Sensitivity/Response,"NF2_loss_promotes_oncogenic_RAS-signaling_via_YAP-dependent_transactivation_of_RAS_and_sensitizes_to_MEK_inhibition._The_authors_demonstrate_this_in_(A)_isogenic_lines_derived_from_C643_cells_(HRASG13R,_NF2-WT)_modified_to_stably_express_shNF2,_(B)_in_set_of_7_RAS-mutant_thyroid_cancer_cell_lines_that_differ_in_their_NF2_expression_levels,_and_(C)_in_a_Hras-G12V/Nf2-null_mouse_model.",26359368,PubMed,,"Garcia-Rendueles_et_al.,_2015,_Cancer_Discov",,4,accepted,1742,3870,22,29999547,30094587,,,ENST00000338641.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-12_14:57:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1742,https://civic.genome.wustl.edu/links/variants/697,https://civic.genome.wustl.edu/links/genes/3870,,,loss_of_function_variant,,4,Selumetinib_(AZD6244),,,,,,,
NF1,4763,LOSS,Malignant_Peripheral_Nerve_Sheath_Tumor,5940,,JQ1_Compound,,Predictive,Supports,D,Sensitivity/Response,"BRD4_inhibition_supressess_growth_and_tumorigenesis_of_NF1-/-,_TP53-/-_MPNST_cells_in_mouse_xenografts",24373973,PubMed,,"Patel_et_al.,_2014,_Cell_Rep",,3,accepted,1743,3867,17,29421945,29704695,,,ENST00000358273.4,,,,,75,GRCh37,,Somatic_Mutation,2016-11-11_22:58:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1743,https://civic.genome.wustl.edu/links/variants/698,https://civic.genome.wustl.edu/links/genes/3867,,,loss_of_function_variant,,3,JQ1_Compound,,,,,,,
ERBB3,2065,V104M,Urothelial_Carcinoma,2671,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_this_phase_II_trial,_patients_with_metastatic_platinum-refractory_urothelial_carcinoma_(UC)_received_afatinib_(40_mg/day)._Among_the_21_tumors,_five_of_six_patients_(83.3%)_with_ERBB2_(HER2)_and/or_ERBB3_alterations_achieved_3-month_progression-free_survival_(PFS3)_versus_none_of_15_patients_without_alterations_(P_<_.001)._Three_of_three_patients_with_ERBB3_somatic_mutations_(G284R,_V104M,_and_R103G)_achieved_PFS3.",27044931,PubMed,,"Choudhury_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,1746,1733,12,56478854,56478854,G,A,ENST00000267101.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-27_22:43:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/1746,https://civic.genome.wustl.edu/links/variants/701,https://civic.genome.wustl.edu/links/genes/1733,,,missense_variant,NC_000012.11:g.56478854G>A,15,Afatinib,,,,,chr12_g.56478854G~A,,
ERBB3,2065,R103G,Urothelial_Carcinoma,2671,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_this_phase_II_trial,_patients_with_metastatic_platinum-refractory_urothelial_carcinoma_(UC)_received_afatinib_(40_mg/day)._Among_the_21_tumors,_five_of_six_patients_(83.3%)_with_ERBB2_(HER2)_and/or_ERBB3_alterations_achieved_3-month_progression-free_survival_(PFS3)_versus_none_of_15_patients_without_alterations_(P_<_.001)._Three_of_three_patients_with_ERBB3_somatic_mutations_(G284R,_V104M,_and_R103G)_achieved_PFS3.",27044931,PubMed,,"Choudhury_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,1747,1733,12,56478851,56478851,C,G,ENST00000267101.3,,,,,75,GRCh37,,Somatic_Mutation,2016-12-01_15:27:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/1747,https://civic.genome.wustl.edu/links/variants/702,https://civic.genome.wustl.edu/links/genes/1733,,,missense_variant,NC_000012.11:g.56478851C>G,15,Afatinib,,,,,chr12_g.56478851C~G,,
ERBB3,2065,G284R,Urothelial_Carcinoma,2671,,Afatinib,,Predictive,Supports,B,Sensitivity/Response,"In_this_phase_II_trial,_patients_with_metastatic_platinum-refractory_urothelial_carcinoma_(UC)_received_afatinib_(40_mg/day)._Among_the_21_tumors,_five_of_six_patients_(83.3%)_with_ERBB2_(HER2)_and/or_ERBB3_alterations_achieved_3-month_progression-free_survival_(PFS3)_versus_none_of_15_patients_without_alterations_(P_<_.001)._Three_of_three_patients_with_ERBB3_somatic_mutations_(G284R,_V104M,_and_R103G)_achieved_PFS3.",27044931,PubMed,,"Choudhury_et_al.,_2016,_J._Clin._Oncol.",,3,accepted,1748,1733,12,56481922,56481922,G,A,ENST00000267101.3,,,,,75,GRCh37,,Somatic_Mutation,2016-11-27_22:40:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/1748,https://civic.genome.wustl.edu/links/variants/703,https://civic.genome.wustl.edu/links/genes/1733,,,missense_variant,NC_000012.11:g.56481922G>A,15,Afatinib,,,,,chr12_g.56481922G~A,,
EGFR,1956,D761Y,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,C,Resistance,D761Y_as_a_secondary_mutation_was_reported_to_be_associated_with_resistance_to_gefitinib_and_erlotinib_in_NSCLC_cells_that_contain_the_L858R-EGFR_mutation._This_mutation_combination_was_observed_in_a_single_patient_with_lung_cancer_and_specifically_in_a_metastatic_brain_lesion_following_gefitinib_treatment._Functional_validation_of_its_role_in_drug_sensitivity_was_examined_in_cell_lines_(293T_and_Ba/F3_cells).,17085664,PubMed,,"Balak_et_al.,_2006,_Clin._Cancer_Res.",,3,accepted,1763,19,7,55242511,55242511,G,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-02-06_22:44:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/1763,https://civic.genome.wustl.edu/links/variants/712,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2281G>T,NM_005228.4:c.2281G>T,NP_005219.2:p.Asp761Tyr,NC_000007.13:g.55242511G>T",7.5,Gefitinib,Erlotinib,,,,chr7_g.55242511G~T,EGFR_c.2281G~T,EGFR_D761Y
CRBN,51185,MUTATION,Multiple_Myeloma,9538,,"Lenalidomide,Pomalidomide",Substitutes,Predictive,Supports,C,Resistance,"A_37_year_old,_heavily_pretreated_(including_thalidomide_and_lenalidomide)_patient_with_IgG-kappa_multiple_myeloma_was_sequenced_following_extramedullary_relapse._A_high_number_of_alterations_were_observed_including_38_rearrangements,_35_translocations,_4_indels,_and_271_nonsynonymous_point_mutations._Two_mutations_altering_CRBN_(Q99*_and_R283K),_a_gene_previously_described_as_being_necessary_for_immunomodulatory_drug_response,_were_observed_and_thought_to_be_responsible_for_resistance_to_the_pomalidomide_and_dexamethasone_treatment_she_received_but_failed_to_respond_to_following_sequencing.",23480694,PubMed,,"Egan_et_al.,_2013,_Br._J._Haematol.",,3,accepted,1766,11761,3,3191695,3221394,,,ENST00000231948.4,,,,,75,GRCh37,,Somatic_Mutation,2017-08-31_16:54:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/1766,https://civic.genome.wustl.edu/links/variants/713,https://civic.genome.wustl.edu/links/genes/11761,,,,,7.5,Lenalidomide,Pomalidomide,,,,,,
PDGFRA,5156,AMPLIFICATION,Non-small_Cell_Lung_Carcinoma,3908,,Sunitinib,,Predictive,Supports,D,Sensitivity/Response,"In_the_sunitinib-sensitive_adenosquamous_NSCLC_cell_line,_PDGFRA_expression_was_associated_with_focal_PFGRA_gene_amplification,_which_was_similarly_detected_in_a_small_fraction_of_squamous_cell_NSCLC_primary_tumor_specimens._Moreover,_in_this_NSCLC_cell_line,_focal_amplification_of_the_gene_encoding_the_PDGFR_ligand_PDGFC_was_also_detected.",19366796,PubMed,,"McDermott_et_al.,_2009,_Cancer_Res.",,3,accepted,1771,38,4,55095264,55164414,,,ENST00000257290.5,,,,,75,GRCh37,,Somatic_Mutation,2017-06-29_20:55:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1771,https://civic.genome.wustl.edu/links/variants/716,https://civic.genome.wustl.edu/links/genes/38,,,transcript_amplification,,3,Sunitinib,,,,,,,
EGFR,1956,G719,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Sensitivity/Response,"EGFR_G719_mutations_have_been_associated_with_increased_sensitivity_to_first_generation_EGFR_tyrosine_kinase_inhibitors,_including_erlotinib_and_gefitinib._In_a_study_of_patients_treated_with_erlotinib_or_gefitinib,_a_subset_of_patients_with_EGFR_mutation_at_codons_G719_or_L861_(n=30)_was_associated_with_improved_response_rate_(47.5%_vs_16.5%,_P<0.001)_median_progression_free_survival_(5.0_vs_2.0_months,_P<0.001),_and_overall_survival_(15.0_vs._10.4_months,_P_=0.030),_compared_to_patients_with_wild-type_EGFR_(n=272).",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,4189,19,7,55241707,55241708,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-07-06_18:22:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/4189,https://civic.genome.wustl.edu/links/variants/718,https://civic.genome.wustl.edu/links/genes/19,,,protein_altering_variant,,25,Gefitinib,Erlotinib,,,,,,
EGFR,1956,G719,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,B,Sensitivity/Response,"In_a_meta-analysis_of_7_clinical_trials_of_erlotinib,_10/24_patients_with_Exon_18_mutations_harbored_a_G719_variant._These_variants_were_associated_with_improved_progression-free_and_overall_survival._No_statistical_analysis_was_reported_for_this_variant_and_PFS_or_OS,_citing_small_sample_size_across_the_studies.",26773740,PubMed,,"Klughammer_et_al.,_2016,_J_Thorac_Oncol",,2,accepted,1780,19,7,55241707,55241708,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-06-22_21:44:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/1780,https://civic.genome.wustl.edu/links/variants/718,https://civic.genome.wustl.edu/links/genes/19,,,protein_altering_variant,,25,Erlotinib,,,,,,,
BRD4,23476,BRD4-NUTM1,NUT_Midline_Carcinoma,60463,,JQ1,,Predictive,Supports,D,Sensitivity/Response,Treatment_of_the_patient-derived_797_NMC_cell_line_for_48_hours_with_JQ1_(500_nM)__provoked_terminal_differentiation_which_was_accompanied_by_growth_arrest_and_sustained_inhibition_of_proliferation.__Non-BRD4-dependent_cell_lines_including_a_squamous_carcinoma_cell_line_(TE10)_failed_to_exhibit_differentiation_effects_when_treated_with_JQ1.,20871596,PubMed,,"Filippakopoulos_et_al.,_2010,_Nature",,3,accepted,1781,9588,,,,,,,,,,,,,,Somatic_Mutation,2017-01-24_04:51:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1781,https://civic.genome.wustl.edu/links/variants/719,https://civic.genome.wustl.edu/links/genes/9588,,,,,3,JQ1,,,,,,,
EGFR,1956,S720,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Resistance,"Efficacy_of_erlotinib_treatment_was_evaluated_by_meta-analysis_of_results_from_seven_trials_and_literature_review._Two_patients_with_p.S270P,_and_one_patient_with_p.S720F_were_observed_to_have_poor_survival_outcomes.",26773740,PubMed,,"Klughammer_et_al.,_2016,_J_Thorac_Oncol",,3,accepted,1782,19,7,55241710,55241711,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-01-23_15:48:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1782,https://civic.genome.wustl.edu/links/variants/720,https://civic.genome.wustl.edu/links/genes/19,,,protein_altering_variant,,7.5,Erlotinib,,,,,,,
EGFR,1956,K757R,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_meta-analysis_of_7_clinical_trials_evaluating_the_efficacy_of_erlotinib,_one_patient_was_described_with_the_exon_19_mutation_K757R_from_the_MERIT_study._Progression-free_(250_days)_and_overall_(435_days)_survival_suggested_sensitivity_in_this_patient._Literature_analysis_did_not_identify_additional_reports_of_patients_harboring_this_mutation.",26773740,PubMed,,"Klughammer_et_al.,_2016,_J_Thorac_Oncol",,3,accepted,1786,19,7,55242500,55242500,A,G,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_22:14:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1786,https://civic.genome.wustl.edu/links/variants/723,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2270A>G,NC_000007.13:g.55242500A>G",7.5,Erlotinib,,,,,chr7_g.55242500A~G,EGFR_c.2270A~G,
EGFR,1956,E746G,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_meta-analysis_of_7_clinical_trials_evaluating_the_efficacy_of_erlotinib,_one_patient_was_described_with_the_exon_19_mutation_E746G_from_the_BeTa_study._Progression-free_(415_days)_and_overall_(462_days)_survival_suggested_sensitivity_in_this_patient._No_statistical_analysis_was_reported_for_this_variant_and_PFS_or_OS,_citing_small_sample_size_across_the_studies.",26773740,PubMed,,"Klughammer_et_al.,_2016,_J_Thorac_Oncol",,1,accepted,1787,19,7,55242467,55242467,A,G,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-05-18_17:22:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/1787,https://civic.genome.wustl.edu/links/variants/724,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2237A>G,NC_000007.13:g.55242467A>G",2.5,Erlotinib,,,,,chr7_g.55242467A~G,EGFR_c.2237A~G,
EGFR,1956,EXON_20_INSERTION,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,B,Resistance,"In_retrospective_analysis_of_trials,_afatinib_conferred_limited_clinical_benefit_to_patients_with_EGFR_exon_20_insertion_mutations_(N=23)._Only_2_patients_had_objective_responses.",26051236,PubMed,,"Yang_et_al.,_2015,_Lancet_Oncol.",,3,accepted,1809,19,7,55248991,55249022,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-02-23_19:38:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1809,https://civic.genome.wustl.edu/links/variants/726,https://civic.genome.wustl.edu/links/genes/19,,,inframe_insertion,,15,Afatinib,,,,,,,
EGFR,1956,EXON_20_INSERTION,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Resistance,"In_stage_IV_lung_adenocarcinoma_patients_(n=2)_harboring_EGFR_inframe_exon_20_insertion_mutation,_EGFR_exon_20_insertion_was_associated_with_progressive_disease_after_1_and_3_months_of_erlotinib_monotherapy,_respectively;_both_patients_were_previously_treated_with_standard_chemotherapy.",22895145,PubMed,,"Lund-Iversen_et_al.,_2012,_J_Thorac_Oncol",,,accepted,4650,19,7,55248991,55249022,,,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-08-17_15:45:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/4650,https://civic.genome.wustl.edu/links/variants/726,https://civic.genome.wustl.edu/links/genes/19,,,inframe_insertion,,15,Erlotinib,,,,,,,
UGT1A1,54658,UGT1A1*28,Cancer,162,,Belinostat,,Predictive,Supports,A,Adverse_Response,The_FDA_approved_package_insert_for_Belinostat_recommends_dose_adjustment_for_UGT1A1*28_allele_homozygotes.,26313268,PubMed,,"Goey_et_al.,_2016,_J_Clin_Pharmacol",,5,accepted,1792,12422,2,234668881,234668882,,TATATATATATATA,ENST00000305208.5,,,,,75,GRCh37,,Germline_Polymorphism,2016-12-02_22:10:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1792,https://civic.genome.wustl.edu/links/variants/729,https://civic.genome.wustl.edu/links/genes/12422,,,microsatellite,NC_000002.11:g.234668881_234668882TA[7],50,Belinostat,,,,,chr2_g.234668881_234668882TA[7],,
UGT1A1,54658,UGT1A1*60,Cancer,162,,Belinostat,,Predictive,Supports,B,Adverse_Response,"In_a_phase_1_trial_belinostat_(400-800mg/m2/24h)_was_administered_to_25_patients_in_combination_with_cisplatin_and_etoposide._Endpoints_were_associations_between_genotype_of_UGT1A1_and_pharmacokinetics,_toxicities_and_proteine_lysine_acetylation._Belinostat_AUC_and_half-life_was_significantly_increased_in_UGT1A1*60_carriers,_and_they_were_at_greater_risk_for_thrombocytopenia.",26313268,PubMed,,"Goey_et_al.,_2016,_J_Clin_Pharmacol",,4,accepted,1795,12422,,,,,,,,,,,,,,Germline_Polymorphism,2017-02-16_19:34:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1795,https://civic.genome.wustl.edu/links/variants/732,https://civic.genome.wustl.edu/links/genes/12422,,,microsatellite,,20,Belinostat,,,,,,,
EGFR,1956,V769_770insASV,Lung_Adenocarcinoma,3910,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"Although_EGFR_exon_20_insertions_may_confer_reduced_sensitivity_to_erlotinib,_patients_with_this_particular_mutation_appeared_to_benefit_from_therapy.",26773740,PubMed,,"Klughammer_et_al.,_2016,_J_Thorac_Oncol",,3,accepted,1799,19,7,55249009,55249010,,GCCAGCGTG,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-02-21_16:29:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/1799,https://civic.genome.wustl.edu/links/variants/736,https://civic.genome.wustl.edu/links/genes/19,,,direct_tandem_duplication,NM_005228.4:c.2300_2308dupCCAGCGTGG,7.5,Erlotinib,,,,,,EGFR_c.2300_2308dupCCAGCGTGG,
DPYD,1806,DPYD*2A_HOMOZYGOSITY,Cancer,162,,"5-FU,Tegafur,Capecitabine",Substitutes,Predictive,Supports,A,Adverse_Response,"The_Clinical_Pharmacogenomics_Implementation_Consortium_Guidelines_for_DPYD_genotype_and_5-FU_dosing_does_not_recommend_the_use_of_5-FU_or_capecitabine_in_patients_with_homozygous_DPYD*2A,_*13_or_rs67376798_and_the_FDA_drug_labels_warn_to_use_precautions_in_this_patient_population.",23988873,PubMed,,"Caudle_et_al.,_2013,_Clin._Pharmacol._Ther.",,5,accepted,1800,1526,1,97915614,97915614,C,T,ENST00000370192.3,,,,,75,GRCh37,,Germline_Polymorphism,2016-12-02_22:01:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1800,https://civic.genome.wustl.edu/links/variants/737,https://civic.genome.wustl.edu/links/genes/1526,,,splice_donor_variant,"NC_000001.10:g.97915614C>T,NM_000110.3:c.1905+1G>A,ENST00000370192.3:c.1905+1G>A",50,5-FU,Tegafur,Capecitabine,,,chr1_g.97915614C~T,DPYD_c.1905+1G~A,
DPYD,1806,DPYD*13_HOMOZYGOSITY,Cancer,162,,"5-FU,Capecitabine,Tegafur",Substitutes,Predictive,Supports,A,Adverse_Response,"The_Clinical_Pharmacogenomics_Implementation_Consortium_Guidelines_for_DPYD_genotype_and_5-FU_dosing_does_not_recommend_the_use_of_5-FU_or_capecitabine_in_patients_with_homozygous_DPYD*2A,_*13_or_rs67376798_and_the_FDA_drug_labels_warn_to_use_precautions_in_this_patient_population.",23988873,PubMed,,"Caudle_et_al.,_2013,_Clin._Pharmacol._Ther.",,5,accepted,1801,1526,1,97981343,97981343,A,C,ENST00000370192.3,,,,,75,GRCh37,,Germline_Polymorphism,2016-12-02_22:01:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/1801,https://civic.genome.wustl.edu/links/variants/738,https://civic.genome.wustl.edu/links/genes/1526,,,missense_variant,"NM_000110.3:c.1679T>G,NP_000101.2:p.Ile560Ser,ENST00000370192.3:c.1679T>G,NC_000001.10:g.97981343A>C",50,5-FU,Capecitabine,Tegafur,,,chr1_g.97981343A~C,DPYD_c.1679T~G,DPYD_I560S
DPYD,1806,RS67376798_HOMOZYGOSITY,Cancer,162,,"5-FU,Capecitabine,Tegafur",Substitutes,Predictive,Supports,A,Adverse_Response,"The_Clinical_Pharmacogenomics_Implementation_Consortium_Guidelines_for_DPYD_genotype_and_5-FU_dosing_does_not_recommend_the_use_of_5-FU_or_capecitabine_in_patients_with_homozygous_DPYD*2A,_*13_or_rs67376798_and_the_FDA_drug_labels_warn_to_use_precautions_in_this_patient_population.",23988873,PubMed,,"Caudle_et_al.,_2013,_Clin._Pharmacol._Ther.",,5,accepted,1803,1526,,,,,,,,,,,,,,Germline_Polymorphism,2016-12-02_22:01:54_UTC,https://civic.genome.wustl.edu/links/evidence_items/1803,https://civic.genome.wustl.edu/links/variants/740,https://civic.genome.wustl.edu/links/genes/1526,,,polymorphic_sequence_variant,,50,5-FU,Capecitabine,Tegafur,,,,,
PDGFRA,5156,TNKS2-PDGFRA,"Myeloid_And_Lymphoid_Neoplasms_With_Eosinophilia_And_Abnormalities_Of_PDGFRA,_PDGFRB,_And_FGFR1",80164,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,A_patient_harbouring_a_novel_TNKS2–PDGFRA_fusion_in_a_myeloid_neoplasm_with_eosinophilia_demonstrated_a_dramatic_and_durable_response_upon_treatment_with_Imatinib_mono_therapy.,25658984,PubMed,,"Chalmers_et_al.,_2015,_Blood_Cancer_J",,3,accepted,1838,38,10,93558069,93619405,,,ENST00000371627.4,4,55141008,55164414,ENST00000257290.5,75,GRCh37,,Somatic_Mutation,2017-01-24_04:56:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/1838,https://civic.genome.wustl.edu/links/variants/774,https://civic.genome.wustl.edu/links/genes/38,,,transcript_fusion,,7.5,Imatinib,,,,,,,
SLCO1B1,10599,RS4149056,Cancer,162,,Methotrexate,,Predictive,Supports,B,Adverse_Response,499_children_from_ALL_trials_treated_with_methotrexate_were_genotyped_for_8_SNPs_in_5_genes._The_SLCO1B1_rs4149056_variant_was_significantly_associated_with_MTX_AUC0-48h_and_as_such_associated_with_increased_toxicity.,23652803,PubMed,,"Radtke_et_al.,_2013,_Blood",,3,accepted,1841,8450,12,21331549,21331549,T,C,ENST00000256958.2,,,,,75,GRCh37,,Germline_Polymorphism,2017-01-23_15:07:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1841,https://civic.genome.wustl.edu/links/variants/777,https://civic.genome.wustl.edu/links/genes/8450,,,"polymorphic_sequence_variant,missense_variant",NC_000012.11:g.21331549T>C,15,Methotrexate,,,,,chr12_g.21331549T~C,,
SLCO1B1,10599,N130D,Cancer,162,,Methotrexate,,Predictive,Supports,B,Adverse_Response,499_children_from_ALL_trials_treated_with_methotrexate_were_genotyped_for_8_SNPs_in_5_genes._The_SLCO1B1_RS2306283_variant_was_significantly_associated_with_MTX_AUC0-48h_and_as_such_associated_with_increased_toxicity.,23652803,PubMed,,"Radtke_et_al.,_2013,_Blood",,3,accepted,1842,8450,12,21329738,21329738,A,G,ENST00000256958.2,,,,,75,GRCh37,,Germline_Polymorphism,2017-01-23_15:07:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1842,https://civic.genome.wustl.edu/links/variants/778,https://civic.genome.wustl.edu/links/genes/8450,,,missense_variant,NC_000012.11:g.21329738A>G,15,Methotrexate,,,,,chr12_g.21329738A~G,,
TYMS,7298,RS34743033,Cancer,162,,Methotrexate,,Predictive,Supports,B,Adverse_Response,"499_children_from_ALL_trials_treated_with_methotrexate_were_genotyped_for_8_SNPs_in_5_genes._The_TYMS_rs34743033_tandem_repeat_polymorphism_was_the_only_significant_predictor_of_stomatitis_in_a_multiple_regression_model_considering_sex,_age,_MRD_class,_WBC,_MTX_AUC0-48h,_and_genotypes_as_independent_variables_(B_=_−0.48;_95%_CI,_−0.84,_−0.12;_R2_=_0.018;_P_=_.009)",23652803,PubMed,,"Radtke_et_al.,_2013,_Blood",,3,accepted,1843,5971,18,657646,657646,C,T,ENST00000323274.10,,,,,75,,,Germline_Polymorphism,2017-01-23_16:34:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1843,https://civic.genome.wustl.edu/links/variants/779,https://civic.genome.wustl.edu/links/genes/5971,,,,,15,Methotrexate,,,,,,,
ERBB3,2065,V855A,Non-small_Cell_Lung_Carcinoma,3908,,"Afatinib,Pertuzumab",Substitutes,Predictive,Supports,D,Sensitivity/Response,Case_report_on_a_novel_V855A_mutation_located_in_exon_21_of_the_HER3_tyrosine_kinase_domain_and_found_in_the_tumor_specimen_of_an_adolescent_patient_with_a_chemotherapy-resistant_advanced_NSCLC._Protein_alignments_indicated_this_mutation_was_analogous_to_EGFR-L858R_and_BRAF-L597V._Co-expression_of_wildtype_HER2_and_HER3-V855A_in_Ba/F3_cells_led_to_sensitivity_to_afatinib_and_pertuzumab.,26689995,PubMed,,"Umelo_et_al.,_2016,_Oncotarget",,2,accepted,1845,1733,12,56491672,56491672,T,C,ENST000000267101.3,,,,,75,GRCh37,,Somatic_Mutation,2017-02-06_22:37:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/1845,https://civic.genome.wustl.edu/links/variants/781,https://civic.genome.wustl.edu/links/genes/1733,,,missense_variant,NC_000012.11:g.56491672T>C,2,Afatinib,Pertuzumab,,,,chr12_g.56491672T~C,,
FGFR2,2263,FGFR2-BICC1,Urothelial_Carcinoma,2671,,JNJ-42756493,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_of_pan-FGFR_inhibitor_JNJ-42756493_in_patients_with_solid_tumors._No_responses_were_seen_36_patients_without_known_FGFR_pathway_aberrations._Among_23_patients_with_FGFR_pathway_aberrations,_4_partial_responses_as_well_as_16_with_stable_disease_were_seen._In_patients_with_FGFR2-BICC1_fusions,_1_patient_with_urothelial_cancer_harboring_FGFR2-BICC1/FGFR2-CASP7_fusions_had_a_PR.",26324363,PubMed,,"Tabernero_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,1917,22,10,123239371,123357917,,,ENST00000457416.2,10,60461834,60591195,ENST00000373886.3,75,GRCh37,,,2017-05-03_16:14:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1917,https://civic.genome.wustl.edu/links/variants/782,https://civic.genome.wustl.edu/links/genes/22,,,transcript_fusion,,38,JNJ-42756493,,,,,,,
FGFR2,2263,FGFR2-BICC1,Cholangiocarcinoma,4947,,"PD173074,BGJ398",Substitutes,Predictive,Supports,D,Sensitivity/Response,Expression_of_the_FGFR2-BICC1_fusion_kinase_in_NIH3T3_cells_demonstrated_transforming_ability_that_was_effectively_suppressed_with_the_fibroblast_growth_factor_receptor_(FGFR)_kinase_inhibitors_BGJ398_and_PD173074.,24122810,PubMed,,"Arai_et_al.,_2014,_Hepatology",,3,accepted,1851,22,10,123239371,123357917,,,ENST00000457416.2,10,60461834,60591195,ENST00000373886.3,75,GRCh37,,Somatic_Mutation,2017-05-31_15:24:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/1851,https://civic.genome.wustl.edu/links/variants/782,https://civic.genome.wustl.edu/links/genes/22,,,transcript_fusion,,38,PD173074,BGJ398,,,,,,
FGFR2,2263,FGFR2-BICC1,Endometrial_Cancer,1380,,JNJ-42756493,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_of_pan-FGFR_inhibitor_JNJ-42756493_in_patients_with_solid_tumors._No_responses_were_seen_36_patients_without_FGFR_pathway_aberrations._Among_23_patients_with_FGFR_pathway_aberrations,_4_partial_responses_as_well_as_16_with_stable_disease_were_seen._A_patient_with_endometrial_cancer_with_synchronous_FGFR3-TACC3_and_FGFR2-BICC1/FGFR2-OFD1_fusions_had_a_PR.",26324363,PubMed,,"Tabernero_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,1920,22,10,123239371,123357917,,,ENST00000457416.2,10,60461834,60591195,ENST00000373886.3,75,GRCh37,,Somatic_Mutation,2017-03-13_08:33:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/1920,https://civic.genome.wustl.edu/links/variants/782,https://civic.genome.wustl.edu/links/genes/22,,,transcript_fusion,,38,JNJ-42756493,,,,,,,
FGFR2,2263,FGFR2-AHCYL1,Cholangiocarcinoma,4947,,"BGJ398,PD173074",Substitutes,Predictive,Supports,D,Sensitivity/Response,Expression_of_the_FGFR2-AHCYL1_fusion_kinase_in_NIH3T3_cells_demonstrated_transforming_ability_that_was_effectively_suppressed_with_the_fibroblast_growth_factor_receptor_(FGFR)_kinase_inhibitors_BGJ398_and_PD173074.,24122810,PubMed,,"Arai_et_al.,_2014,_Hepatology",,3,accepted,1853,22,10,123239371,123357917,,,ENST00000457416.2,1,110554984,110566357,ENST00000369799.5,75,GRCh37,,Somatic_Mutation,2017-05-31_15:23:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1853,https://civic.genome.wustl.edu/links/variants/783,https://civic.genome.wustl.edu/links/genes/22,,,transcript_fusion,,23,BGJ398,PD173074,,,,,,
PTPRD,5789,V253I,Bone_Ewing's_Sarcoma,3368,,"Cixutumumab,R1507",Substitutes,Predictive,Supports,C,Sensitivity/Response,"Report_of_complete_response_to_IGF1-R_antibody,_with_or_without_mTOR_inhibitor_tensirolimus_in_2/3_Ewing_Sarcoma_patients_with_germline_PTPRD_mutations_(V253I_and_W775*,_R995C)._The_third_patient_had_stable_disease_(T781A_mutant)._Four_wildtype_patients_had_stable_or_progressive_disease.",23800680,PubMed,,"Jiang_et_al.,_2013,_Oncotarget",,4,accepted,1856,4692,9,8521481,8521481,C,T,ENST00000381196.4,,,,,75,GRCh37,,Germline_Mutation,2017-02-23_19:40:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/1856,https://civic.genome.wustl.edu/links/variants/792,https://civic.genome.wustl.edu/links/genes/4692,,,missense_variant,"NM_002839.3:c.757G>A,NP_002830.1:p.Val253Ile,NC_000009.11:g.8521481C>T",10,Cixutumumab,R1507,,,,chr9_g.8521481C~T,PTPRD_c.757G~A,PTPRD_V253I
RRM1,6240,OVEREXPRESSION,Pancreatic_Cancer,1793,,Gemcitabine,,Predictive,Supports,D,Resistance,The_mRNA_expression_level_of_RRM1_was_analyzed_by_RT-PCR_in_3_human_pancreatic_cancer_cell_lines_cultured_in_incrementally_increased_concentrations_of_gemcitabine._Expression_levels_of_RRM1_progressively_increased_during_the_development_of_gemcitabine_resistance.,17224927,PubMed,,"Nakano_et_al.,_2007,_Br._J._Cancer",,2,accepted,1859,5051,11,4116039,4160106,,,ENST00000300738.5,,,,,75,GRCh37,,,2017-02-06_23:05:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/1859,https://civic.genome.wustl.edu/links/variants/795,https://civic.genome.wustl.edu/links/genes/5051,,,,,2,Gemcitabine,,,,,,,
RRM2,6241,OVEREXPRESSION,Pancreatic_Cancer,1793,,Gemcitabine,,Predictive,Supports,D,Resistance,The_mRNA_expression_level_of_RRM2_was_analyzed_by_RT-PCR_in_3_human_pancreatic_cancer_cell_lines__cultured_in_incrementally_increased_concentrations_of_gemcitabine._Expression_levels_of_RRM2_progressively_increased_during_the_development_of_gemcitabine_resistance.,17224927,PubMed,,"Nakano_et_al.,_2007,_Br._J._Cancer",,2,accepted,1860,5052,2,10262455,10271545,,,ENST00000360566.2,,,,,75,GRCh37,,,2017-05-31_15:22:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1860,https://civic.genome.wustl.edu/links/variants/796,https://civic.genome.wustl.edu/links/genes/5052,,,,,2,Gemcitabine,,,,,,,
POLE,5426,MUTATION,Endometrial_Cancer,1380,,Pembrolizumab,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_endometrial_cancer_and_exceptional_response_to_pembrolizumab_(maintained_at_14_months)._POLE_mutations_V411L_(exonuclease_domain)_and_R114*_were_identified_in_the_primary_tumor_as_well_as_a_resected_lymph_node_metastasis._The_tumor_harbored_a_high_mutational_load_as_assessed_by_panel_sequencing._Analysis_of_TCGA_RNA-seq_data_revealed_an_association_between_POLE_mutations_and_high_immune_marker_expression.,27159395,PubMed,,"Mehnert_et_al.,_2016,_J._Clin._Invest.",,3,accepted,1862,4386,12,133202900,133256623,,,ENST00000320574.5,,,,,75,GRCh37,,Somatic_Mutation,2017-02-17_08:37:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1862,https://civic.genome.wustl.edu/links/variants/797,https://civic.genome.wustl.edu/links/genes/4386,,,gene_variant,,15,Pembrolizumab,,,,,,,
POLE,5426,MUTATION,Glioblastoma_Multiforme,3068,,Pembrolizumab,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_glioblastoma_multiforme_and_POLE_germline_mutation._The_patient_was_treated_with_pembrolizumab_and_lymphocyte_infiltration_was_noted_after_resection_of_a_spinal_metastasis._An_objective_radiographic_response_was_noted_in_the_intracranial_lesion._A_high_neoantigen_load_was_identified.,27683556,PubMed,,"Johanns_et_al.,_2016,_Cancer_Discov",,3,accepted,1861,4386,12,133202900,133256623,,,ENST00000320574.5,,,,,75,GRCh37,,Germline_Mutation,2017-01-24_22:21:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/1861,https://civic.genome.wustl.edu/links/variants/797,https://civic.genome.wustl.edu/links/genes/4386,,,gene_variant,,15,Pembrolizumab,,,,,,,
MET,4233,D1228V,Non-small_Cell_Lung_Carcinoma,3908,,Savolitinib,,Predictive,Supports,C,Resistance,"Case_report_of_a_patient_with_lung_adenocarcinoma_harboring_both_a_mutation_in_EGFR_and_an_amplification_of_MET._After_progression_on_erlotinib_the_patient_was_treated_with_combined_type_I_MET_(savolitinib)_and_EGFR_(osimertinib)_inhibition_and_responded._When_resistance_developed,_a_new_MET_kinase_domain_mutation,_D1228V,_was_detected._Drug_binding_predictions_and_in_vitro_studies_demonstrated_that_the_D1228V_mutation_induces_resistance_to_type_I_but_not_type_II_MET_TKIs._The_patient_was_treated_with_erlotinib_(EGFR_TKI)_combined_with_cabozantinib,_a_type_II_MET_inhibitor,_and_had_a_response_which_continued_at_the_time_of_report_(5_months).",27694386,PubMed,,"Bahcall_et_al.,_2016,_Cancer_Discov",,4,accepted,1865,52,7,116423408,116423408,A,T,ENST00000397752.3,,,,,75,GRCh37,,Somatic_Mutation,2017-02-13_13:27:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1865,https://civic.genome.wustl.edu/links/variants/798,https://civic.genome.wustl.edu/links/genes/52,,,missense_variant,"ENST00000397752.3:c.3683A>T,NC_000007.13:g.116423408A>T",20,Savolitinib,,,,,chr7_g.116423408A~T,MET_c.3683A~T,
MET,4233,D1228V,Non-small_Cell_Lung_Carcinoma,3908,,Cabozantinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_with_lung_adenocarcinoma_harboring_both_a_mutation_in_EGFR_and_an_amplification_of_MET._After_progression_on_erlotinib_the_patient_was_treated_with_combined_type_I_MET_(savolitinib)_and_EGFR_(osimertinib)_inhibition_and_responded._When_resistance_developed,_a_new_MET_kinase_domain_mutation,_D1228V,_was_detected._Drug_binding_predictions_and_in_vitro_studies_demonstrated_that_the_D1228V_mutation_induces_resistance_to_type_I_but_not_type_II_MET_TKIs._The_patient_was_treated_with_erlotinib_(EGFR_TKI)_combined_with_cabozantinib,_a_type_II_MET_inhibitor,_and_had_a_response_which_continued_at_the_time_of_report_(5_months).",27694386,PubMed,,"Bahcall_et_al.,_2016,_Cancer_Discov",,4,accepted,1864,52,7,116423408,116423408,A,T,ENST00000397752.3,,,,,75,GRCh37,,Somatic_Mutation,2017-02-13_13:27:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1864,https://civic.genome.wustl.edu/links/variants/798,https://civic.genome.wustl.edu/links/genes/52,,,missense_variant,"ENST00000397752.3:c.3683A>T,NC_000007.13:g.116423408A>T",20,Cabozantinib,,,,,chr7_g.116423408A~T,MET_c.3683A~T,
RB1,5925,MUTATION,Lung_Small_Cell_Carcinoma,5409,,Chemotherapy,,Predictive,Supports,B,Sensitivity/Response,"Study_evaluated_a_total_of_50_small_cell_lung_cancer_patients_with_extensive_stage_disease._Multivariate_analysis_identified_RB1_as_a_factor_in_predicting_response_to_first-line_chemotherapy_(odds_ratio_5.58_compared_to_WT,_p=.038)._Kaplan-Meier_survival_analysis_revealed_patients_with_RB1_mutations_exhibited_better_overall_survival_(p_=_.04,_11.7_versus_9.1_months,_CI_=_1.1-28.2).",26802149,PubMed,,"Dowlati_et_al.,_2016,_Ann._Oncol.",,2,accepted,1866,4795,13,48877911,49056122,,,ENST00000267163.4,,,,,75,GRCh37,,Somatic_Mutation,2017-02-06_17:41:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1866,https://civic.genome.wustl.edu/links/variants/799,https://civic.genome.wustl.edu/links/genes/4795,,,gene_variant,,10,Chemotherapy,,,,,,,
NTRK1,4914,SQSTM1-NTRK1,Non-small_Cell_Lung_Carcinoma,3908,,Entrectinib,,Predictive,Supports,C,Sensitivity/Response,"In_1378_cases_of_NSCLC_screened_for_NTRK1_rearrangements,_2_were_identified_(frequency_0.1%)._One_patient_with_SQSTM1-NTRK1_was_treated_with_entrectinib_in_a_phase_1_study._The_patient_had_resolution_of_prior_dyspnea_and_pain_within_3_weeks._CT_scans_showed_a_partial_response_and_complete_resolution_of_brain_metastases._The_patient_has_continued_treatment_for_over_6_months_with_ongoing_PR.",26565381,PubMed,,"Farago_et_al.,_2015,_J_Thorac_Oncol",,3,accepted,1868,3983,,,,,,,,,,,,,,Somatic_Mutation,2017-04-14_16:51:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1868,https://civic.genome.wustl.edu/links/variants/800,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,22.5,Entrectinib,,,,,,,
NTRK1,4914,SQSTM1-NTRK1,Non-small_Cell_Lung_Carcinoma,3908,,Entrectinib,,Predictive,Supports,C,Sensitivity/Response,"Two_phase_I_studies_in_patients_with_advanced_or_metastatic_solid_tumors,_including_patients_with_active_central_nervous_system_(CNS)_disease._Here,_we_summarize_the_overall_safety_and_report_the_antitumor_activity_of_entrectinib_in_a_cohort_of_patients_with_tumors_harboring_NTRK1/2/3,_ROS1,_or_ALK_gene_fusions_Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._Notably,_a_complete_CNS_response_was_achieved_in_a_patient_with_SQSTM1-NTRK1-rearranged_lung_cancer.",28183697,PubMed,,"Drilon_et_al.,_2017,_Cancer_Discov",,3,accepted,2950,3983,,,,,,,,,,,,,,Somatic_Mutation,2017-04-14_16:37:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/2950,https://civic.genome.wustl.edu/links/variants/800,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,22.5,Entrectinib,,,,,,,
NTRK1,4914,SQSTM1-NTRK1,Pediatric_Fibrosarcoma,3520,,Larotrectinib,,Predictive,Supports,C,Sensitivity/Response,"One_patient_with_infantile_fibrosarcoma_and_a_NTRK1-SQSTM1_fusion_was_treated_with_larotrectinib_and_exhibited_a_partial_response._Treatment_was_done_within_a_multicentre,_open-label,_phase_1/2_study_and_enrolled_infants,_children,_and_adolescents_aged_1_month_to_21_years_with_locally_advanced_or_metastatic_solid_tumours_or_CNS_tumours_that_had_relapsed,_progressed,_or_were_non-responsive_to_available_therapies_regardless_of_TRK_fusion_Status._In_total,_24_patients_(n=17_with_tumours_harbouring_TRK_fusions,_n=7_without_a_documented_TRK_fusion)_were_enrolled._Among_the_fusion-positive_patients,_eight_(47%)_had_infantile_fibrosarcoma,_seven_(41%)_had_other_soft_tissue_sarcomas,_and_two_(12%)_had_papillary_thyroid_cancer._14_(93%)_of_15_patients_with_TRK_fusion-positive_cancers_achieved_an_objective_response;_the_remaining_patient_had_tumour_regression_that_did_not_meet_the_criteria_for_objective_response._None_of_the_seven_patients_with_TRK_fusion-negative_cancers_had_an_objective_response.",29606586,PubMed,,"Laetsch_et_al.,_2018,_Lancet_Oncol.",NCT02637687,3,accepted,6103,3983,,,,,,,,,,,,,,,2018-08-21_18:28:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/6103,https://civic.genome.wustl.edu/links/variants/800,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,22.5,Larotrectinib,,,,,,,
NTRK3,4916,ETV6-NTRK3,Salivary_Gland_Carcinoma,50904,,Entrectinib,,Predictive,Supports,C,Sensitivity/Response,Case_report_of_a_patient_with_mammary_analogue_secretory_carcinoma_(MASC)_harboring_an_ETV6-NTRK3_fusion._The_patient_was_treated_with_entrectinib_and_exhibited_a_partial_response_for_7_months_followed_by_disease_progression.,26884591,PubMed,,"Drilon_et_al.,_2016,_Ann._Oncol.",,3,accepted,1869,3985,12,11802788,12022903,,,ENST00000396373.4,15,88483984,88418230,ENST00000394480.2,75,GRCh37,,Somatic_Mutation,2017-01-31_22:35:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/1869,https://civic.genome.wustl.edu/links/variants/801,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,59,Entrectinib,,,,,,,
NTRK3,4916,ETV6-NTRK3,Salivary_Gland_Carcinoma,50904,,Crizotinib,,Predictive,Does_Not_Support,C,Sensitivity/Response,Case_report_of_a_patient_with_mammary_analogue_secretory_carcinoma_(MASC)_harboring_an_ETV6-NTRK3_fusion._The_patient_was_treated_with_crizotinib_and_had_stable_disease_but_disease_progression_after_18_weeks._The_patient_was_subsequently_treated_with_entrectinib_and_exhibited_a_partial_response_for_7_months_followed_by_disease_progression.,26884591,PubMed,,"Drilon_et_al.,_2016,_Ann._Oncol.",,2,accepted,1870,3985,12,11802788,12022903,,,ENST00000396373.4,15,88483984,88418230,ENST00000394480.2,75,GRCh37,,Somatic_Mutation,2017-01-30_23:03:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1870,https://civic.genome.wustl.edu/links/variants/801,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,59,Crizotinib,,,,,,,
NTRK3,4916,ETV6-NTRK3,Pediatric_B-lymphoblastic_Leukemia,,,"Larotrectinib,PLX7486",Substitutes,Predictive,Supports,D,Sensitivity/Response,"In_this_manuscript,_the_authors_describe_the_first_genetically_engineered_mouse_model_of_ETV6-NTRK3_ALL_and_report_remarkable_efficacy_of_TRK_inhibitors,_which_induce_complete_suppression_of_leukemic_cell_proliferation_when_administered_as_a_monotherapy._They_also_show_in_vivo_efficacy_of_TRK_inhibition_in_a_PDX_model_of_ETV6-NTRK3_ALL._TRK-targeting_compounds_including_PLX7486_and_larotrectinib_are_predicted_to_show_efficacy_in_B-ALL_with_ETV6-NTRK3_fusion_which_accounts_for_approximately_1%_of_Ph-like_B-ALL.",29880614,PubMed,,"Roberts_et_al.,_2018,_Blood",,4,accepted,6930,3985,12,11802788,12022903,,,ENST00000396373.4,15,88483984,88418230,ENST00000394480.2,75,GRCh37,,Somatic_Mutation,2018-10-17_12:36:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/6930,https://civic.genome.wustl.edu/links/variants/801,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,59,Larotrectinib,PLX7486,,,,,,
NTRK3,4916,ETV6-NTRK3,Pediatric_Fibrosarcoma,3520,,Larotrectinib,,Predictive,Supports,B,Sensitivity/Response,"Four_out_of_six_patients_with_infantile_fibrosarcoma_and_a_NTRK3-ETV6_fusion_had_a_partial_response,_the_remaining_two_had_a_complete_response_with_larotrectinib._Treatment_was_done_within_a_multicentre,_open-label,_phase_1/2_study_and_enrolled_infants,_children,_and_adolescents_aged_1_month_to_21_years_with_locally_advanced_or_metastatic_solid_tumours_or_CNS_tumours_that_had_relapsed,_progressed,_or_were_non-responsive_to_available_therapies_regardless_of_TRK_fusion_Status._In_total,_24_patients_(n=17_with_tumours_harbouring_TRK_fusions,_n=7_without_a_documented_TRK_fusion)_were_enrolled._Among_the_fusion-positive_patients,_eight_(47%)_had_infantile_fibrosarcoma,_seven_(41%)_had_other_soft_tissue_sarcomas,_and_two_(12%)_had_papillary_thyroid_cancer._14_(93%)_of_15_patients_with_TRK_fusion-positive_cancers_achieved_an_objective_response;_the_remaining_patient_had_tumour_regression_that_did_not_meet_the_criteria_for_objective_response._None_of_the_seven_patients_with_TRK_fusion-negative_cancers_had_an_objective_response.",29606586,PubMed,,"Laetsch_et_al.,_2018,_Lancet_Oncol.",NCT02637687,4,accepted,6099,3985,12,11802788,12022903,,,ENST00000396373.4,15,88483984,88418230,ENST00000394480.2,75,GRCh37,,,2018-08-21_18:28:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/6099,https://civic.genome.wustl.edu/links/variants/801,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,59,Larotrectinib,,,,,,,
NTRK3,4916,ETV6-NTRK3,Breast_Secretory_Carcinoma,4922,,"LOXO-101,Larotrectinib",Substitutes,Predictive,Supports,C,Sensitivity/Response,"Shukla_et_al_report_on_a_remarkable_case_study_of_a_14_year_old_pediatric_patient_with_refractory_secretory_breast_carcinoma_first_presenting_as_a_fibroadenoma_at_8_yo._Over_the_next_years,_she_experienced_recurrence,_multiple_rounds_of_chemotherapy_and_metastasis_--_until_her_case_was_presented_at_a_virtual_multidisciplinary_tumor_board_organized_by_the_Global_Cancer_Institute_which_recommended_testing_for_ETV6-NTRK3_fusion._This_fusion_was_confirmed_by_RNA-seq,_targeted_DNA_and_WGS_sequencing_as_well_as_immunohistochemistry_staining_with_a_TRK_antibody._The_patient_was_treated_with_LOXO-101_(larotrectinib)_in_a_single_patient_use_protocol._Within_two_months,_she_experienced_near_complete_resolution_of_a_10.4_×_8.5_cm_fungating_chest_mass_with_multiple_satellite_lesions_(See_Figure_2)._The_authors_note_that_TERT_promoter_mutation_and_a_reciprocal_inversion_including_CDKN2A_were_also_identified,_but_given_what_is_known_about_LOXO-101_and_ETV6-NTRK3,_they__infer_ETV6-NTRK3_fusion_as_the_primary_mitogenic_driver_in_this_patient.",29623306,PubMed,,"Shukla_et_al.,_2017,_JCO_Precis_Oncol",,3,accepted,6475,3985,12,11802788,12022903,,,ENST00000396373.4,15,88483984,88418230,ENST00000394480.2,75,GRCh37,,Somatic_Mutation,2018-08-21_15:25:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/6475,https://civic.genome.wustl.edu/links/variants/801,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,59,LOXO-101,Larotrectinib,,,,,,
NTRK3,4916,ETV6-NTRK3_G623R,Breast_Cancer,1612,,Entrectinib,,Predictive,Supports,C,Resistance,Case_report_of_a_patient_with_mammary_analogue_secretory_carcinoma_(MASC)_harboring_an_etv6-ntrk3_fusion._The_patient_was_treated_with_entrectinib_and_exhibited_a_partial_response_for_7_months_followed_by_disease_progression.__A_NTRK3_exon_16_G623R_(c.1867G>A)_mutation_was_identified_in_the_progressive_tumor._Cell_line_and_structural_models_revealed_that_this_mutation_conferred_relative_resistance_to_entrectinib.,26884591,PubMed,,"Drilon_et_al.,_2016,_Ann._Oncol.",,4,accepted,1874,3985,15,88476265,88476265,C,T,ENST00000394480.2,,,,,75,GRCh37,,Somatic_Mutation,2017-01-22_20:33:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1874,https://civic.genome.wustl.edu/links/variants/805,https://civic.genome.wustl.edu/links/genes/3985,,,"transcript_fusion,missense_variant","NC_000015.9:g.88476265C>T,ENST00000394480.2:c.1867G>A",10,Entrectinib,,,,,chr15_g.88476265C~T,NTRK3_c.1867G~A,
MSH2,4436,LOSS,Urothelial_Carcinoma,2671,,"MEDI0680,MEDI4736",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_45-year_old_woman_of_Japanese_descent_with_recurrent_urothelial_carcinoma._The_patient_was_identified_to_harbor_mutations_in_MSH2_(A913fs*2,_E226*,_E580*)_and_in_MSH6_(R361H)_by_panel_sequencing_as_well_as_loss_of_expression_of_these_genes_as_confirmed_by_IHC._Testing_also_revealed_a_high_mutational_load_as_well_as_2+_PD-L1_expression_in_80%_of_the_cells.__The_patient_was_treated_with_anti-PD-L1_inhibitor_MEDI4736_and_MEDI0680_in_a_phase_1_trial_and_had_a_complete_remission_within_2_months_of_treatment_that_was_ongoing_after_11_months.",26674132,PubMed,,"Castro_et_al.,_2015,_J_Immunother_Cancer",,3,accepted,1877,3628,2,47630108,47710367,,,ENST00000233146.2,,,,,75,GRCh37,,Somatic_Mutation,2017-02-08_03:48:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1877,https://civic.genome.wustl.edu/links/variants/808,https://civic.genome.wustl.edu/links/genes/3628,,,loss_of_function_variant,,7.5,MEDI0680,MEDI4736,,,,,,
MSH6,2956,LOSS,Urothelial_Carcinoma,2671,,"MEDI4736,MEDI0680",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_45-year_old_woman_of_Japanese_descent_with_recurrent_urothelial_carcinoma._The_patient_was_identified_to_harbor_mutations_in_MSH2_(A913fs*2,_E226*,_E580*)_and_in_MSH6_(R361H)_by_panel_sequencing_as_well_as_loss_of_expression_of_these_genes_as_confirmed_by_IHC._Testing_also_revealed_a_high_mutational_load_as_well_as_2+_PD-L1_expression_in_80%_of_the_cells._The_patient_was_treated_with_anti-PD-L1_inhibitor_MEDI4736_and_MEDI0680_in_a_phase_1_trial_and_had_a_complete_remission_within_2_months_of_treatment_that_was_ongoing_after_11_months.",26674132,PubMed,,"Castro_et_al.,_2015,_J_Immunother_Cancer",,3,accepted,1878,2478,2,48010221,48037240,,,ENST00000234420.5,,,,,75,GRCh37,,,2017-02-08_03:44:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/1878,https://civic.genome.wustl.edu/links/variants/809,https://civic.genome.wustl.edu/links/genes/2478,,,loss_of_function_variant,,7.5,MEDI4736,MEDI0680,,,,,,
ERBB2,2064,G776L,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"A_Phase_II_study_for_use_of_Afatinib_in_non-_or_light_smokers_with_lung_adenocarcinoma._Three_patients_with_metastatic_lung_adenocarcinomas_bearing_mutations_in_the_kinase_domain_of_HER2_gene_were_identified_(Y772_A775dup,_G776L,_and_G778_P780dup)._Objective_response_was_observed_in_all_three_of_these_patients._The_patient_with_G776L_(Case_2_in_the_paper)_achieved_a_partial_response_after_two_months_of_afatinib_(50_mg/day)._The_time_to_progression_of_this_single_agent_was_four_months._The_patient_was_also_noted_to_have_a_EGFR_kinase_domain_(exon_21:_p.Ala859Thr)_mutation.",22325357,PubMed,,"De_Grève_et_al.,_2012,_Lung_Cancer",,3,accepted,1889,20,17,37880997,37880998,GG,CT,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-02-07_18:07:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/1889,https://civic.genome.wustl.edu/links/variants/816,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,ENST00000269571.5:c.2326_2327delinsCT,7.5,Afatinib,,,,,,ERBB2_c.2326_2327delinsCT,
ERBB2,2064,G778_P780DUP,Non-small_Cell_Lung_Carcinoma,3908,,Dacomitinib,,Predictive,Supports,C,Sensitivity/Response,"Phase_2_trial_of_ERBB-inhibitor_dacomitinib_in_stage_IIIB/IV_lung_cancers_with_HER2_mutations_or_amplification._Two_patients_were_identified_with_identical_HER2_p.G778_P780dup_mutations_(p._P780_Y781insGSP,_c._2339_2340ins_GGCTCCCCA)_and_no_amplification._Both_had_a_confirmed_partial_response_lasting_11_and_14_months._Only_3/30_patients_on_this_trial_had_a_partial_response_(no_complete_responses).",25899785,PubMed,,"Kris_et_al.,_2015,_Ann._Oncol.",,3,accepted,1892,20,17,37881011,37881012,,GGCTCCCCA,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-02-06_17:16:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1892,https://civic.genome.wustl.edu/links/variants/817,https://civic.genome.wustl.edu/links/genes/20,,,inframe_insertion,NM_004448.3:c.2332_2340dupGGCTCCCCA,15,Dacomitinib,,,,,,ERBB2_c.2332_2340dupGGCTCCCCA,
ERBB2,2064,G778_P780DUP,Lung_Adenocarcinoma,3910,,Afatinib,,Predictive,Supports,C,Sensitivity/Response,"A_Phase_II_study_for_use_of_Afatinib_in_non-_or_light_smokers_with_lung_adenocarcinoma._Three_patients_with_metastatic_lung_adenocarcinomas_bearing_mutations_in_the_kinase_domain_of_HER2_gene_were_identified_(Y772_A775dup,_G776L,_and_G778_P780dup)._Objective_response_was_observed_in_all_three_of_these_patients._The_patient_with_G778_P780dup_(Case_3_in_the_paper),_had_a_rapid_clinical_and_symptomatic_response_to_Afatinib_and_stable_disease_which_lasted_for_3_months._Progressive_disease_at_4_months_led_to_the_addition_of_paclitaxel,_resulting_in_partial_response._Total_Afatinib_treatment_was_15_months_(11_in_combination)_at_which_time_the_patient_developed_a_brain_metastasis_but_no_other_progressive_disease.",22325357,PubMed,,"De_Grève_et_al.,_2012,_Lung_Cancer",,3,accepted,1890,20,17,37881011,37881012,,GGCTCCCCA,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-02-06_22:29:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/1890,https://civic.genome.wustl.edu/links/variants/817,https://civic.genome.wustl.edu/links/genes/20,,,inframe_insertion,NM_004448.3:c.2332_2340dupGGCTCCCCA,15,Afatinib,,,,,,ERBB2_c.2332_2340dupGGCTCCCCA,
ERBB2,2064,M774DELINSWLV,Non-small_Cell_Lung_Carcinoma,3908,,Dacomitinib,,Predictive,Supports,C,Sensitivity/Response,"Phase_2_trial_of_ERBB-inhibitor_dacomitinib_in_stage_IIIB/IV_lung_cancers_with_HER2_mutations_or_amplification_(N=30)._One_patient_was_found_to_harbor_a_unique_Exon_20_indel_(p._M774delinsWLV,_c.2320A>TGGCT_GG;_p._M774delinsWLV,_c.2320delins_TGGCTGG)_and_was_among_the_three_patients_that_had_a_partial_response.",25899785,PubMed,,"Kris_et_al.,_2015,_Ann._Oncol.",,3,accepted,1894,20,17,37880991,37880991,A,TGGCTGG,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-02-07_18:08:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1894,https://civic.genome.wustl.edu/links/variants/818,https://civic.genome.wustl.edu/links/genes/20,,,inframe_indel,,7.5,Dacomitinib,,,,,,,
PTPRB,5787,LOSS-OF-FUNCTION,Angiosarcoma,1816,,Sunitinib,,Predictive,Supports,D,Sensitivity/Response,"The_endothelial_phosphatase_PTPRB,_a_negative_regulator_of_vascular_growth_factor_tyrosine_kinases,_harbored_truncating_mutations_in_10_of_39_angiosarcomas_(26%)_which_correlated_with_MYC_amplifications._In_HUVEC_cell_line_model,_silencing_of_PTPRB__induced_features_of_angiogenesis_which_were_abolished_in_the_presence_of_sunitinib_or_vatalinib,_inhibitors_of_VEGFR.",24633157,PubMed,,"Behjati_et_al.,_2014,_Nat._Genet.",,3,accepted,1895,4690,12,70910630,71031220,,,ENST00000334414.6,,,,,75,GRCh37,,Somatic_Mutation,2017-01-13_17:03:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/1895,https://civic.genome.wustl.edu/links/variants/819,https://civic.genome.wustl.edu/links/genes/4690,,,loss_of_function_variant,,3,Sunitinib,,,,,,,
HLA-C,3107,COPY-NEUTRAL_LOSS_OF_HETEROZYGOSITY,Colorectal_Cancer,9256,,Adoptive_T-cell_Transfer,,Predictive,Supports,C,Resistance,"A_patient_with_metastatic_colorectal_cancer_was_enrolled_in_a_phase_2_clinical_trial_(NCT01174121)._24_cultures_of_tumor-infiltrating_lymphocytes_were_expanded_from_3_lung_metastasis_resections._After_cultures_were_tested_for_reactivity,_the_patient_was_infused_with_1.48_x_10^11_tumor-infiltrating_lymphocytes_(75%_CD8+_T_cells)_that_were_specifically_reactive_to_KRAS_G12D_and_HLA-C*08:02._A_single_lesion_that_progressed_after_9_months_still_expressed_the_KRAS_G12D_mutation._Whole-exome_analysis_revealed_copy-neutral_loss_of_heterozygosity_at_chromosome_6,_encoding_the_HLA_locus_and_resulting_in_loss_of_the_targeted_HLA-C*08:02_allele.",27959684,PubMed,,"Tran_et_al.,_2016,_N._Engl._J._Med.",,3,accepted,1899,2608,,,,,,,,,,,,,,Somatic_Mutation,2017-02-06_22:35:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1899,https://civic.genome.wustl.edu/links/variants/821,https://civic.genome.wustl.edu/links/genes/2608,,,,,7.5,Adoptive_T-cell_Transfer,,,,,,,
JAK1,3716,S703I,Hepatocellular_Carcinoma,684,,Ruxolitinib,,Predictive,Supports,D,Sensitivity/Response,A_JAK1_S703I_mutation_was_found_to_activate_the_JAK-STAT_signaling_pathway_in_vitro_and_in_vivo_in_hepatocellular_carcinoma._Ruxolitinib_causes_the_suppression_of_JAK-STAT_signaling_pathway_in_PDX_models_bearing_JAK1_S703I_mutation_and_delays_tumor_progression.,26701727,PubMed,,"Yang_et_al.,_2016,_Oncotarget",,4,accepted,1900,3090,1,65311203,65311203,C,A,ENST00000342505.4,,,,,75,GRCh37,,Somatic_Mutation,2017-02-02_21:56:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1900,https://civic.genome.wustl.edu/links/variants/822,https://civic.genome.wustl.edu/links/genes/3090,,,missense_variant,"ENST00000342505.4:c.2108G>T,NC_000001.10:g.65311203C>A",4,Ruxolitinib,,,,,chr1_g.65311203C~A,JAK1_c.2108G~T,
ARAF,369,S490T,Colorectal_Cancer,9256,,"Vemurafenib,Irinotecan,Cetuximab",Combination,Predictive,Supports,C,Resistance,"Phase_1b_study_of_vemurafenib,_cetuximab_and_irinotecan_in_19_BRAF_V600E_mutant_colorectal_cancer_patients._cfDNA_panel_sequencing_was_performed_in_10_patients_after_disease_progression._One_patient_had_an_acquired_ARAF_S490T_mutation_that_was_not_identified_before_treatment_initiation.",27729313,PubMed,,"Hong_et_al.,_2016,_Cancer_Discov",,1,accepted,1905,3,X,47429340,47429340,T,A,ENST00000377045.4,,,,,75,GRCh37,,Somatic_Mutation,2017-08-31_19:47:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/1905,https://civic.genome.wustl.edu/links/variants/825,https://civic.genome.wustl.edu/links/genes/3,,,missense_variant,,2.5,Vemurafenib,Irinotecan,Cetuximab,,,,,
GNAS,2778,R201C,Colorectal_Cancer,9256,,"Vemurafenib,Cetuximab,Irinotecan",Combination,Predictive,Supports,C,Resistance,"Phase_1b_study_of_vemurafenib,_cetuximab_and_irinotecan_in_19_BRAF_V600E_mutant_colorectal_cancer_patients._cfDNA_panel_sequencing_was_performed_in_10_patients_after_disease_progression._One_patient_acquired_a_novel_GNAS1_R201C_mutation_at_disease_progression.",27729313,PubMed,,"Hong_et_al.,_2016,_Cancer_Discov",,2,accepted,1906,2319,20,57484420,57484420,C,T,ENST00000371085.3,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_14:51:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/1906,https://civic.genome.wustl.edu/links/variants/826,https://civic.genome.wustl.edu/links/genes/2319,,,missense_variant,"NM_000516.5:c.601C>T,NP_000507.1:p.Arg201Cys,NC_000020.10:g.57484420C>T,ENST00000371085.3:c.601C>T",5,Vemurafenib,Cetuximab,Irinotecan,,,chr20_g.57484420C~T,GNAS_c.601C~T,GNAS_R201C
FGFR3,2261,MUTATION,Bladder_Carcinoma,4007,,BGJ-398,,Predictive,Supports,B,Sensitivity/Response,"Phase_1_study_of_FGFR-inhibitor_BGJ398_in_advanced_cancer_with_FGFR-aberrations._In_the_subgroup_of_eight_patients_with_FGFR3-mutated_bladder/urothelial_cancer_treated_at_doses_≥_100_mg,_the_disease_control_rate_(SD_+_PR)_was_75%._3_patients_achieved_PRs_and_3_patients_had_SD._Of_the_six_patients_with_disease_control,_the_time_on_treatment_ranged_from_15.1_to_≥_101_weeks,_with_one_ongoing_at_data_cutoff.",27870574,PubMed,,"Nogova_et_al.,_2017,_J._Clin._Oncol.",,3,accepted,1910,23,,,,,,,,,,,,,,Somatic_Mutation,2017-06-13_16:20:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/1910,https://civic.genome.wustl.edu/links/variants/827,https://civic.genome.wustl.edu/links/genes/23,,,,,15,BGJ-398,,,,,,,
FGFR2,2263,FUSION,Cholangiocarcinoma,4947,,BGJ-398,,Predictive,Supports,C,Sensitivity/Response,"Phase_1_study_of_FGFR-inhibitor_BGJ398_in_advanced_cancer_with_FGFR-aberrations._Among_three_patients_with_cholangiocarcinoma_and_FGFR2_aberrations_(2_fusions,_1_mutation),_all_three_had_stable_disease_with_a_reduced_tumor_burden.",27870574,PubMed,,"Nogova_et_al.,_2017,_J._Clin._Oncol.",,2,accepted,1913,22,,,,,,,,,,,,,,Somatic_Mutation,2017-05-03_16:15:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/1913,https://civic.genome.wustl.edu/links/variants/828,https://civic.genome.wustl.edu/links/genes/22,,,,,20,BGJ-398,,,,,,,
FGFR2,2263,FUSION,Cancer,162,,JNJ-42756493,,Predictive,Supports,B,Sensitivity/Response,"Phase_1_study_of_pan-FGFR_inhibitor_JNJ-42756493_in_patients_with_solid_tumors._No_responses_were_seen_36_patients_without_FGFR_pathway_aberrations._Among_23_patients_with_FGFR_pathway_aberrations,_4_partial_responses_as_well_as_16_with_stable_disease_were_seen._In_patients_with_FGFR2_fusions,_1_patient_with_urothelial_cancer_had_a_PR_harbored_FGFR2-BICC1/FGFR2-CASP7_fusions,_a_patient_with_endometrial_cancer_and_synchronous_FGFR3-TACC3_and_FGFR2-BICC1/FGFR2-OFD1_fusions_had_a_PR,_and_tumor_shrinkage_was_observed_in_a_patient_with_adrenal_carcinoma_and_FGFR3-TACC3/FGFR2-CCDC6_fusions.",26324363,PubMed,,"Tabernero_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,1918,22,,,,,,,,,,,,,,Somatic_Mutation,2017-06-15_19:07:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1918,https://civic.genome.wustl.edu/links/variants/828,https://civic.genome.wustl.edu/links/genes/22,,,,,20,JNJ-42756493,,,,,,,
FGFR3,2261,FGFR3-TACC3,Cancer,162,,JNJ-42756493,,Predictive,Supports,B,Sensitivity/Response,"Phase_1_study_of_pan-FGFR_inhibitor_JNJ-42756493_in_patients_with_solid_tumors._No_responses_were_seen_36_patients_without_FGFR_pathway_aberrations._Among_23_patients_with_FGFR_pathway_aberrations,_5_partial_responses_(PR)_and_16_with_stable_disease_were_seen._In_patients_harboring_FGFR3-TACC3,_there_were_2_urothelial_cancer_patients_with_PRs,_1_endometrial_cancer_patient_with_PR_(also_had_FGFR2-BICC1/FGFR2-OFD1_fusions),_and_tumor_shrinkage_in_a_patient_with_adrenal_carcinoma_(also_had_FGFR2-CCDC6_fusion).",26324363,PubMed,,"Tabernero_et_al.,_2015,_J._Clin._Oncol.",,3,accepted,1919,23,,,,,,,,,,,,,,,2017-06-08_19:12:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/1919,https://civic.genome.wustl.edu/links/variants/830,https://civic.genome.wustl.edu/links/genes/23,,,,,15,JNJ-42756493,,,,,,,
ALK,238,ALTERNATIVE_TRANSCRIPT_(ATI),Skin_Melanoma,8923,,Crizotinib,,Predictive,Supports,C,Sensitivity/Response,"Expression_of_an_alternative_ALK_transcript_(ATI),_encompassing_exons_20–29_preceded_by_~400_base_pairs_(bp)_of_intron_19,_but_not_exons_1–19_was_identified_in_three_samples_of_thyroid_cancer_and_melanoma._In_TCGA_samples,_ALK_ATI_was_expressed_in_approx._11%_of_melanoma_samples._Functional_activity_of_ALK_ATI_was_shown_in-vitro._In_vivo_studies_confirmed_oncogenic_activity_of_ALK_ATI_similar_to_other_ALK_mutations_or_fusions_and_sensitivity_to_crizotinib._A_patient_with_metastatic_melanoma_and_ALK_ATI_expression_but_no_MET_or_ALK_aberrations_identified_with_FISH_and_a_341-gene_panel_sequencing__was_treated_with_crizotinib_and_had_symptomatic_improvement_and_tumor_shrinkage_within_6_weeks_of_therapy",26444240,PubMed,,"Wiesner_et_al.,_2015,_Nature",,4,accepted,1936,1,,,,,,,,,,,,,This_novel_ALK_transcript_(alternative_isoform)_initiates_from_a_de_novo_alternative_transcription_initiation_(ATI)_site_in_ALK_intron_19.,,2017-06-15_19:16:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/1936,https://civic.genome.wustl.edu/links/variants/839,https://civic.genome.wustl.edu/links/genes/1,This_novel_ALK_transcript_(alternative_isoform)_initiates_from_a_de_novo_alternative_transcription_initiation_(ATI)_site_in_ALK_intron_19.,,,,10,Crizotinib,,,,,,,
PDGFRA,5156,P577S,Melanoma,1909,,"Imatinib,Crenolanib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Five_PDGFRA_Mutations_(P577S,_V658A,_R841K,_H845Y,_and_G853D)__resulted_in_strong_autophosphorylation_of_PDGFRA._Crenolanib_showed_higher_potency_than_imatinib_in_inhibiting_the_kinase_activity_of_PDGFRA._Except_for_the__imatinib-resistant_V658A_mutation,_all_the_other_mutations_were_sensitive_to_both_imatinib_and_crenolanib.",24132921,PubMed,,"Dai_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1974,38,4,55141083,55141083,C,T,ENST00000257290.5,,,,,75,GRCh37,,Somatic_Mutation,2017-03-16_10:12:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/1974,https://civic.genome.wustl.edu/links/variants/862,https://civic.genome.wustl.edu/links/genes/38,,,missense_variant,"NM_006206.4:c.1729C>T,NP_006197.1:p.Pro577Ser,NC_000004.11:g.55141083C>T,ENST00000257290.5:c.1729C>T",3,Imatinib,Crenolanib,,,,chr4_g.55141083C~T,PDGFRA_c.1729C~T,PDGFRA_P577S
PDGFRA,5156,R841K,Melanoma,1909,,"Imatinib,Crenolanib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Five_PDGFRA_Mutations_(P577S,_V658A,_R841K,_H845Y,_and_G853D)_resulted_in_strong_autophosphorylation_of_PDGFRA._Crenolanib_showed_higher_potency_than_imatinib_in_inhibiting_the_kinase_activity_of_PDGFRA._Except_for_the_imatinib-resistant_V658A_mutation,_all_the_other_mutations_were_sensitive_to_both_imatinib_and_crenolanib.",24132921,PubMed,,"Dai_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1975,38,4,55152090,55152090,G,A,ENST00000257290.5,,,,,75,GRCh37,,,2017-03-16_10:11:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/1975,https://civic.genome.wustl.edu/links/variants/863,https://civic.genome.wustl.edu/links/genes/38,,,missense_variant,"NM_006206.4:c.2522G>A,NP_006197.1:p.Arg841Lys,NC_000004.11:g.55152090G>A,ENST00000257290.5:c.2522G>A",3,Imatinib,Crenolanib,,,,chr4_g.55152090G~A,PDGFRA_c.2522G~A,PDGFRA_R841K
PDGFRA,5156,H845Y,Melanoma,1909,,"Crenolanib,Imatinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Five_PDGFRA_Mutations_(P577S,_V658A,_R841K,_H845Y,_and_G853D)_resulted_in_strong_autophosphorylation_of_PDGFRA._Crenolanib_showed_higher_potency_than_imatinib_in_inhibiting_the_kinase_activity_of_PDGFRA._Except_for_the_imatinib-resistant_V658A_mutation,_all_the_other_mutations_were_sensitive_to_both_imatinib_and_crenolanib.",24132921,PubMed,,"Dai_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1976,38,4,55152101,55152101,C,T,ENST00000257290.5,,,,,75,GRCh37,,Somatic_Mutation,2017-03-16_10:03:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/1976,https://civic.genome.wustl.edu/links/variants/864,https://civic.genome.wustl.edu/links/genes/38,,,missense_variant,"NM_006206.4:c.2533C>T,NP_006197.1:p.His845Tyr,NC_000004.11:g.55152101C>T,ENST00000257290.5:c.2533C>T",3,Crenolanib,Imatinib,,,,chr4_g.55152101C~T,PDGFRA_c.2533C~T,PDGFRA_H845Y
PDGFRA,5156,G853D,Melanoma,1909,,"Crenolanib,Imatinib",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Five_PDGFRA_Mutations_(P577S,_V658A,_R841K,_H845Y,_and_G853D)_resulted_in_strong_autophosphorylation_of_PDGFRA._Crenolanib_showed_higher_potency_than_imatinib_in_inhibiting_the_kinase_activity_of_PDGFRA._Except_for_the_imatinib-resistant_V658A_mutation,_all_the_other_mutations_were_sensitive_to_both_imatinib_and_crenolanib.",24132921,PubMed,,"Dai_et_al.,_2013,_Clin._Cancer_Res.",,3,accepted,1977,38,4,55152126,55152126,G,A,ENST00000257290.5,,,,,75,GRCh37,,Somatic_Mutation,2017-03-16_10:11:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/1977,https://civic.genome.wustl.edu/links/variants/865,https://civic.genome.wustl.edu/links/genes/38,,,missense_variant,"NM_006206.4:c.2558G>A,NP_006197.1:p.Gly853Asp,NC_000004.11:g.55152126G>A,ENST00000257290.5:c.2558G>A",3,Crenolanib,Imatinib,,,,chr4_g.55152126G~A,PDGFRA_c.2558G~A,PDGFRA_G853D
MTAP,4507,DELETION,Breast_Cancer,1612,,5-Fluoropyrimidine,,Predictive,Supports,D,Sensitivity/Response,"MTAP_and_CDKN2A_gene_(RT-qPCR)_and_protein_(western-blotting)_expresison_as_well_as_promoter_methylation_status__was_analyzed_in_breast_cancer_patients_and_seven_breast_cancer_cell_lines._Knockdown_of_MTAP_in_one_cell_line_increased_sensitivity_to_inhibitors_of_de_novo_adenine_synthesis_(5-FU,_AZA_and_MTX),_mainly_5-FU.",26751376,PubMed,,"de_Oliveira_et_al.,_2016,_PLoS_ONE",,1,accepted,1980,3659,,,,,,,,,,,,,,Somatic_Mutation,2017-06-29_18:54:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/1980,https://civic.genome.wustl.edu/links/variants/867,https://civic.genome.wustl.edu/links/genes/3659,,,,,1,5-Fluoropyrimidine,,,,,,,
VPS37A,137492,UNDEREXPRESSION,Ovarian_Cancer,2394,,Cetuximab,,Predictive,Supports,D,Resistance,Vps37A-deficient_ovarian_cancer_cells_become_irresponsive_to_inhibition_by_the_therapeutic_antibody_cetuximab_in-vitro.,22016507,PubMed,,"Wittinger_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,1981,18353,8,17104080,17155533,,,ENST00000324849.4,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_21:29:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/1981,https://civic.genome.wustl.edu/links/variants/868,https://civic.genome.wustl.edu/links/genes/18353,,,,,3,Cetuximab,,,,,,,
BTK,695,T316A,Chronic_Lymphocytic_Leukemia,1040,,Ibrutinib,,Predictive,Supports,C,Resistance,"Case_report_of_a_patient_with_CLL_and_Richter-transformed_relapse_under_ibrutinib_(after_an_initial_partial_response_for_10_months)._Sequencing_of_sequential_samples_of_this_patient_revealed_a_novel_BTK_T316_mutation_at_relapse_(allele_frequency_of_75%)._Characterization_of_this_mutation_showed_that_is_was_located_on_the_SH2_domain,_not_associated_with_Ibrutinib_binding._Introduction_of_this_mutation_in_an_Ibrutinib-sensitive_lymphoma_cell_line_showed_resistance_comparable_to_the_known_C481_resistance_mutations,_which_was_also_confirmed_by_absence_of_downstream_signaling.",27626698,PubMed,,"Sharma_et_al.,_2016,_Oncotarget",,4,accepted,1985,65,X,100613633,100613633,T,C,ENST00000308731.7,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_14:38:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/1985,https://civic.genome.wustl.edu/links/variants/870,https://civic.genome.wustl.edu/links/genes/65,,,missense_variant,"ENST00000308731.7:c.946T>C,NM_000061.2:c.946T>C,NC_000023.10:g.100613633T>C",10,Ibrutinib,,,,,chrX_g.100613633T~C,BTK_c.946T~C,
ERBB2,2064,T862A,Stomach_Carcinoma,5517,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"Cell_proliferation_analysis_showed_that_the_ERBB2-H878Y_mutant_had_the_highest_sensitivity_against_lapatinib_among_all_mutations_tested._Another_mutation,_ERBB2-V777L_also_remained_sensitive_to_lapatinib_with_a_cellular_IC50_value_similar_to_that_of_wild_type_ERBB2._Remaining_mutations_showed_a_shift_towards_significant_higher_cellular_IC50_values_compared_to_the_wild_type_receptor._Since_levels_of_up_to_1_µM_of_lapatinib_may_be_achieved_in_patients,_ERBB2-V773A,_ERBB2-T862A_and_ERBB2-N857S_mutations_might_respond_to_higher_doses_of_lapatinib._In_contrast,_ERBB2-L755S,_ERBB2-L755P_and_ERBB2-T798M_caused_strong_lapatinib_resistance.",22046346,PubMed,,"Kancha_et_al.,_2011,_PLoS_ONE",,3,accepted,1986,20,17,37881392,37881392,A,G,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-15_19:35:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/1986,https://civic.genome.wustl.edu/links/variants/871,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,"ENST00000269571.5:c.2584A>G,NC_000017.10:g.37881392A>G",3,Lapatinib,,,,,chr17_g.37881392A~G,ERBB2_c.2584A~G,
ERBB2,2064,V773A,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"Cell_proliferation_analysis_showed_that_the_ERBB2-H878Y_mutant_had_the_highest_sensitivity_against_lapatinib_among_all_mutations_tested._Another_mutation,_ERBB2-V777L_also_remained_sensitive_to_lapatinib_with_a_cellular_IC50_value_similar_to_that_of_wild_type_ERBB2._Remaining_mutations_showed_a_shift_towards_significant_higher_cellular_IC50_values_compared_to_the_wild_type_receptor._Since_levels_of_up_to_1_µM_of_lapatinib_may_be_achieved_in_patients,_ERBB2-V773A,_ERBB2-T862A_and_ERBB2-N857S_mutations_might_respond_to_higher_doses_of_lapatinib._In_contrast,_ERBB2-L755S,_ERBB2-L755P_and_ERBB2-T798M_caused_strong_lapatinib_resistance.",22046346,PubMed,,"Kancha_et_al.,_2011,_PLoS_ONE",,3,accepted,1987,20,17,37880989,37880989,T,C,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-15_19:18:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/1987,https://civic.genome.wustl.edu/links/variants/872,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,"ENST00000269571.5:c.2318T>C,NC_000017.10:g.37880989T>C",3,Lapatinib,,,,,chr17_g.37880989T~C,ERBB2_c.2318T~C,
ERBB2,2064,N857S,Ovarian_Cancer,2394,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"Cell_proliferation_analysis_showed_that_the_ERBB2-H878Y_mutant_had_the_highest_sensitivity_against_lapatinib_among_all_mutations_tested._Another_mutation,_ERBB2-V777L_also_remained_sensitive_to_lapatinib_with_a_cellular_IC50_value_similar_to_that_of_wild_type_ERBB2._Remaining_mutations_showed_a_shift_towards_significant_higher_cellular_IC50_values_compared_to_the_wild_type_receptor._Since_levels_of_up_to_1_µM_of_lapatinib_may_be_achieved_in_patients,_ERBB2-V773A,_ERBB2-T862A_and_ERBB2-N857S_mutations_might_respond_to_higher_doses_of_lapatinib._In_contrast,_ERBB2-L755S,_ERBB2-L755P_and_ERBB2-T798M_caused_strong_lapatinib_resistance.",22046346,PubMed,,"Kancha_et_al.,_2011,_PLoS_ONE",,3,accepted,1988,20,17,37881378,37881378,A,G,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-15_19:30:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/1988,https://civic.genome.wustl.edu/links/variants/873,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,"NC_000017.10:g.37881378A>G,NP_004439.2:p.Asn857Ser,NM_004448.3:c.2570A>G,ENST00000269571.5:c.2570A>G",3,Lapatinib,,,,,chr17_g.37881378A~G,ERBB2_c.2570A~G,ERBB2_N857S
ERBB2,2064,H878Y,Hepatocellular_Carcinoma,684,,Lapatinib,,Predictive,Supports,D,Sensitivity/Response,"Cell_proliferation_analysis_showed_that_the_ERBB2-H878Y_mutant_had_the_highest_sensitivity_against_lapatinib_among_all_mutations_tested._Another_mutation,_ERBB2-V777L_also_remained_sensitive_to_lapatinib_with_a_cellular_IC50_value_similar_to_that_of_wild_type_ERBB2._Remaining_mutations_showed_a_shift_towards_significant_higher_cellular_IC50_values_compared_to_the_wild_type_receptor._Since_levels_of_up_to_1_µM_of_lapatinib_may_be_achieved_in_patients,_ERBB2-V773A,_ERBB2-T862A_and_ERBB2-N857S_mutations_might_respond_to_higher_doses_of_lapatinib._In_contrast,_ERBB2-L755S,_ERBB2-L755P_and_ERBB2-T798M_caused_strong_lapatinib_resistance.",22046346,PubMed,,"Kancha_et_al.,_2011,_PLoS_ONE",,3,accepted,1989,20,17,37881440,37881440,C,T,ENST00000269571.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-15_19:24:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/1989,https://civic.genome.wustl.edu/links/variants/874,https://civic.genome.wustl.edu/links/genes/20,,,missense_variant,"ENST00000269571.5:c.2632C>T,NC_000017.10:g.37881440C>T",3,Lapatinib,,,,,chr17_g.37881440C~T,ERBB2_c.2632C~T,
ERBB2,2064,OVEREXPRESSION,Pancreatic_Cancer,1793,,"Trastuzumab,Capecitibine",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,"This_is_Phase_II_trial_of_Trastuzumab_and_capecitabine_as_first_line_treatment_in_patients_with_IHC_3+_HER2_expressing_advanced_pancreatic_cancer_or_cancer_with_HER2_gene_amplification_of_stage_IVB._Total_207_patients_could_be_assessed_for_HER2_expression._From_the_23_patient_with_IHC_3+_HER2_expression_or_IHC_2+_and_HER2_gene_amplification,_17_patients_were_included_in_the_study_and_could_be_assessed_for_response_to_the_treatment._Contrary_to_breast_and_gastric_cancer,_only_7_out_of_11_(64%)_patients_with_IHC_3+_HER2_expression_showed_gene_amplification._PFS_rate_at_12_weeks_was_estimated_as_23.5%._Median_PFS_was_65_days._Median_OS_was_6.9_months._Authors_concluded_not_to_recommend_further_evaluation_of_anti-HER2_treatment_in_patients_with_metastatic_pancreatic_cancer.",22374460,PubMed,,"Harder_et_al.,_2012,_Br._J._Cancer",,4,accepted,5955,20,,,,,,,,,,,,,,Somatic_Mutation,2018-02-13_20:12:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/5955,https://civic.genome.wustl.edu/links/variants/875,https://civic.genome.wustl.edu/links/genes/20,,,,,77.5,Trastuzumab,Capecitibine,,,,,,
ERBB2,2064,OVEREXPRESSION,Salivary_Gland_Cancer,8850,,"Capecitabin,Zoledronic_Acid,Trastuzumab",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_a_58_year_old_man_with_multiple_bone_metastases_after_local_therapy_of_a_carcinoma_ex_pleomorphic_adenoma_one_year_earlier._The_original_tumor_tested_strongly_positive_for_HER2/neu_by_immunohistochemistry._The_patient_was_treated_with_trastuzumab,_capecitabine,_and_zoledronic_acid._He_experienced_total_resolution_of_symptoms_and_repeat_FDG-PET_scan_after_three_cycles_revealed_interval_disease_resolution._Continued_treatment_resulted_in_maintenance_of_disease_control_for_over_2_years.",20504363,PubMed,,"Sharon_et_al.,_2010,_Head_Neck_Oncol",,3,accepted,6171,20,,,,,,,,,,,,,,,2018-07-12_18:45:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/6171,https://civic.genome.wustl.edu/links/variants/875,https://civic.genome.wustl.edu/links/genes/20,,,,,77.5,Capecitabin,Zoledronic_Acid,Trastuzumab,,,,,
ERBB2,2064,OVEREXPRESSION,Pancreatic_Cancer,1793,,"Trastuzumab,Gemcitabine",Combination,Predictive,Does_Not_Support,B,Sensitivity/Response,Patients_with_metastatic_pancreatic_cancer_with_IHC_2+/3+_HER2_received_gemcitabine_and_Trastuzumab_combination._Screening_logs_demonstrated_the_rate_of_HER2_overexpression_was_16%._Thirty-four_patients_were_enrolled._Thirty_patients_(88%)_had_pancreatic_cancers_with_2+_overexpression_and_4_patients_(12%)_had_3+_overexpression._Confirmed_partial_responses_were_observed_in_2_of_32_patients_(6%)._The_median_survival_for_all_34_patients_was_7_months.,15581051,PubMed,,"Safran_et_al.,_2004,_Cancer_Invest.",,4,accepted,5956,20,,,,,,,,,,,,,,Somatic_Mutation,2018-07-12_18:45:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/5956,https://civic.genome.wustl.edu/links/variants/875,https://civic.genome.wustl.edu/links/genes/20,,,,,77.5,Trastuzumab,Gemcitabine,,,,,,
ERBB2,2064,OVEREXPRESSION,Her2-receptor_Positive_Breast_Cancer,60079,,Ado-trastuzumab_Emtansine,,Predictive,Supports,B,Sensitivity/Response,"Trastuzumab_emtansine_has_its_indication_for_patients_with_HER2-positive_metastatic_breast_cancer_after_therapy_with_Trastuzumab_and_Taxane,_approval_based_on_PFS_and_preliminary_OS_data._EMILIA_was_a_randomised_open-label,_phase_III_study_for_patients_with_HER2-positive,_unresectable,_locally_advanced,_or_metastatic_breast_cancer_previously_treated_with_Trastuzumab_and_a_Taxane,_randomized_1:1_to_Trastuzumab-emtansine_or_Capecitabine_plus_Lapatinib._991_patients_were_enrolled._Median_OS_was_29.9m_vs._25.9m._Fewer_grade_3_or_worse_AE_occurred_with_trastuzumab_emtansine_than_with_capecitabine_plus_lapatinib_control_treatment.",28526536,PubMed,,"Diéras_et_al.,_2017,_Lancet_Oncol.",,4,accepted,4840,20,,,,,,,,,,,,,,Somatic_Mutation,2017-10-23_19:35:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/4840,https://civic.genome.wustl.edu/links/variants/875,https://civic.genome.wustl.edu/links/genes/20,,,,,77.5,Ado-trastuzumab_Emtansine,,,,,,,
ERBB2,2064,OVEREXPRESSION,Salivary_Gland_Cancer,8850,,"Trastuzumab,Paclitaxel",Combination,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_61-year-old_caucasian_male_with_a_renal_mass_and_subsequent_liver_metastases._Histopathological_examination_of_the_liver_led_to_the_diagnosis_of_metastastic_adenocarcinoma_of_the_salivary_Gland,_which_had_been_diagnosed_and_treated_in_the_Patient_20_years_earlier._IHC_revealed_Her2/neu,_3+._The_patient_was_treated_successfully_with_trastuzumab/paclitaxel_with_near-complete_response_as_measured_by_PET-CT_scans_for_more_than_a_year.",23826550,PubMed,,"Firwana_et_al.,_2012,_Avicenna_J_Med",,2,accepted,6170,20,,,,,,,,,,,,,,,2018-07-18_15:44:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/6170,https://civic.genome.wustl.edu/links/variants/875,https://civic.genome.wustl.edu/links/genes/20,,,,,77.5,Trastuzumab,Paclitaxel,,,,,,
ERBB2,2064,OVEREXPRESSION,Head_And_Neck_Squamous_Cell_Carcinoma,5520,,Lapatinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_60-year_old_patient_with_p16_positive_tumor_of_the_tonsil_with_lung_metastases_after_primary_radiochemotherapy._The_metastases_were_analyzed_using_a_commercial_molecular_analysis_and_overexpression_of_HER2_was_identified_(IHC,_95%_of_cells,_with_high_intensity_3+_staining)_which_was_confirmed_on_RNA-level._The_patient_was_treated_with_single-agent_lapatinib._A_locally_recurrent_tumor_was_excised_(and_found_HER2-negative)_and_the_patient_continued_on_lapatinib_(for_2_years)_as_well_as_5_cycles_5-FU_and_irinotecan._All_lung_metastases_decreased_in_size_within_3_months_of_lapatinib_mono_therapy_initiation._The_patient_remains_free_of_local_or_distant_disease_5_years_after_starting_lapatinib.",28061634,PubMed,,"Seim_et_al.,_2017,_Ann._Otol._Rhinol._Laryngol.",,2,accepted,1992,20,,,,,,,,,,,,,,Somatic_Mutation,2017-05-15_19:00:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/1992,https://civic.genome.wustl.edu/links/variants/875,https://civic.genome.wustl.edu/links/genes/20,,,,,77.5,Lapatinib,,,,,,,
GNAS,2778,T393C,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,B,Resistance,"The_disease_control_rate_of_patients_with_GNAS1_T393C_CC_genotype_was_lower_than_that_of_patients_with_variant_genotype_(TT_or_CT)_(46.2%_vs_73.8%,_P=0.039)._Univariate_analysis_identified_gender,_smoking_history,_histology_and_GNAS1_T393C_polymorphism_as_predictive_marker_of_PFS_(P=0.04,_P<0.001,_P<0.001_and_P=0.005)._Multivariate_analysis_of_factors,_including_smoking_history,_performance_status_score,_histology,_GNAS1_T393C_polymorphism_demonstrated_that_GNAS1_T393C_polymorphism_was_correlated_independently_with_PFS_(P=0.007)._The_data_suggests_the_role_of_GNAS1_T393C_CC_genotype_as_a_poor_predictive_marker_both_of_DCR_and_PFS_in_advanced_NSCLC_patients_treated_with_tyrosine_kinase_inhibitor.",24758907,PubMed,,"Hong_et_al.,_2014,_Zhongguo_Fei_Ai_Za_Zhi",,2,accepted,1995,2319,20,57428713,57428713,T,C,ENST00000371100,,,,,75,GRCh37,,Germline_Polymorphism,2017-05-11_15:46:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/1995,https://civic.genome.wustl.edu/links/variants/877,https://civic.genome.wustl.edu/links/genes/2319,,,missense_variant,,165,Gefitinib,Erlotinib,,,,,,
GNAS,2778,T393C,Esophageal_Cancer,5041,,"Cisplatin,5-fluorouracil",Combination,Predictive,Supports,B,Resistance,"Overall,_63%_of_the_patients_in_the_T-allele_group_(TT_+_CT),_i.e_with_the_T393C_genotype,_were_minor_responders_with_more_than_10%_residual_vital_tumor_cells_in_resection_specimens,_whereas_T(-)_genotypes_(CC)_showed_a_major_histopathological_response_with_less_than_10%_residual_vital_tumor_cells_in_80%.",19274060,PubMed,,"Alakus_et_al.,_2009,_Pharmacogenomics_J.",,4,accepted,2895,2319,20,57428713,57428713,T,C,ENST00000371100,,,,,75,GRCh37,,Germline_Polymorphism,2017-04-03_19:30:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2895,https://civic.genome.wustl.edu/links/variants/877,https://civic.genome.wustl.edu/links/genes/2319,,,missense_variant,,165,Cisplatin,5-fluorouracil,,,,,,
NRAS,4893,G12D,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_148_treatment_naive_metastatic_colorectal_cancer_patients,_patients_with_RAS_mutations_(n=10),_including_KRAS_A146T,_KRAS_G13D,_NRAS_G12D_and_NRAS_Q179*,_treated_with_FOLFOX4_plus_cetuximab_were_associated_with_decreased_overall_survival_(16.3mo_vs._28.5mo,_HR:0.43,_95%_CI:0.20-0.89,_P=0.020)_and_decreased_progression_free_survival_(7.2mo_vs._9.7mo,_HR:0.56,_95%_CI:0.27-1.16,_P=0.11),_as_compared_to_patients_with_wild-type_KRAS_and_NRAS.",25666295,PubMed,,"Kaczirek_et_al.,_2015,_Clin_Colorectal_Cancer",,,accepted,3693,36,1,115258747,115258747,C,T,ENST00000369535.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-20_15:51:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/3693,https://civic.genome.wustl.edu/links/variants/878,https://civic.genome.wustl.edu/links/genes/36,,,missense_variant,"NM_002524.4:c.35G>A,NP_002515.1:p.Gly12Asp,NC_000001.10:g.115258747C>T,ENST00000369535.4:c.35G>A",0,Cetuximab,,,,,chr1_g.115258747C~T,NRAS_c.35G~A,NRAS_G12D
TP53,7157,G245S,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_G245S_loss_of_function_mutation_is_present_in_3_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,4883,45,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2018-04-30_23:41:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/4883,https://civic.genome.wustl.edu/links/variants/879,https://civic.genome.wustl.edu/links/genes/45,,,,,4,AMGMDS3,,,,,,,
IDH1,3417,R132L,Malignant_Glioma,3070,,Bevacizumab,,Predictive,Supports,B,Sensitivity/Response,"In_a_clinical_study_of_63_recurrent_glioma_patients,_patients_treated_with_bevacizumab_monotherapy_(n=11)_and_harboring_IDH1_codon_132_mutation_were_associated_with_improved_progression_free_survival_(3.23_months_vs._1.37_months,_p=0.05),_as_compared_to_patients_with_wild-type_IDH1.",22199315,PubMed,,"Lv_et_al.,_2011,_Anticancer_Res.",,2,accepted,2020,26,2,209113112,209113112,C,A,ENST00000415913.1,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_19:55:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/2020,https://civic.genome.wustl.edu/links/variants/880,https://civic.genome.wustl.edu/links/genes/26,,,missense_variant,"NM_001282386.1:c.395G>T,NP_001269315.1:p.Arg132Leu,NC_000002.11:g.209113112C>A,ENST00000415913.1:c.395G>T",10,Bevacizumab,,,,,chr2_g.209113112C~A,IDH1_c.395G~T,IDH1_R132L
PIK3CA,5290,E545G,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_PIK3CA_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_virally_induced_to_stably_over-express_PIK3CA_E545G_were_significantly_more_resistant_to_BRAF_inhibition_by_vemurafenib_than_cells_transduced_with_an_empty_vector_(50%_vs_20%_survival_at_the_highest_concentration,_p_<_.0001)._Though_statistics_were_not_provided,_E545G_appears_to_confer_similar_levels_of_resistance_to_vemurafenib_as_the_positive_control_variant,_PIK3CA_E545K.",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,3724,37,3,178936092,178936092,A,G,ENST00000263967.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_20:24:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/3724,https://civic.genome.wustl.edu/links/variants/883,https://civic.genome.wustl.edu/links/genes/37,,,missense_variant,"NM_006218.3:c.1634A>G,NP_006209.2:p.Glu545Gly,NC_000003.11:g.178936092A>G,ENST00000263967.3:c.1634A>G",2,Vemurafenib,,,,,chr3_g.178936092A~G,PIK3CA_c.1634A~G,PIK3CA_E545G
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_7_had_F359V_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7043,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:29:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/7043,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Imatinib_Mesylate,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3__cell_line_stably_expressing_the_F359V_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_nilotinib_treatment_(IC50:_5.16-fold),_as_compared_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,2170,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:39:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2170,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Nilotinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_F359V_mutation_was_associated_with_resistance_in_2_μM_imatinib_(3_clones_recovered,_~2%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6256,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-27_21:47:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/6256,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Imatinib_Mesylate,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Reduced_Sensitivity,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_F359V,_5/7_had_MaHRs_which_was_comparable_to_response_rates_among_wild_type_patients,_and_1/7_had_MCyRs_which_which_was_lower_than_response_rates_among_wild_type_patients.",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,3817,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:06:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/3817,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Dasatinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_F359V,_0/2_had_a_CHR_and_1/2_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,3816,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:49:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/3816,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Bosutinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase)_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Of_the_27_with_F359V_mutations,_14,_17,_and_25_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,3819,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:12:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/3819,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Dasatinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_F359V_mutation_was_moderately_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2167,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:35:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/2167,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Imatinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,"Imatinib_Mesylate,Nilotinib",Substitutes,Predictive,Supports,C,Resistance,"In_this_open-label,_phase_II_registration_trial,_patients_that_were_imatinib-resistant_or_intolerant_underwent_nilotinib_monotherapy._Within_12_months_of_nilotinib_therapy,_there_was_no_significant_difference_in_response_to_nilotinib_treatment_between_patients_with_mutations_in_the_Abl1_kinase_domain_versus_without._However,_the_authors_identify_Y253H,_E255K/V,_and_F359C/V_variants_as_resistant_as_they_had_an_IC50_of_>150nM._In_patients_with_F359C_and/or_F359V_mutations_prior_to_nilotinib_treatment,_complete_hematological_responses_were_achieved_in_3_of_10_patients,_a_major_cytogenetic_response_in_1_of_11_patients,_a_complete_cytogenetic_response_in_0_of_11_patients,_and_major_molecular_response_in_0_of_10_patients._After_a_median_follow-up_of_15.5_months,_9_of_11_patients_with_this_mutation_progressed_or_died._The_F359C_mutation_was_present_in_1_patient_at_baseline_and_newly_emerged_in_1_patient_at_progression._The_F359V_mutation_was_present_in_4_patients_at_baseline_and_newly_emerged_in_1_patient_at_progression.",19652056,PubMed,,"Hughes_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,6970,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-11-05_22:44:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/6970,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Imatinib_Mesylate,Nilotinib,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Resistance,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_F359V_mutation_was__moderately_resistant_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2169,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-19_16:42:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/2169,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Imatinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_C475V_was_seen_in_one_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,6995,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_21:20:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/6995,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Imatinib_Mesylate,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
ABL1,25,BCR-ABL_F359V,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_F359V_evaluated,_6/6_had_complete_hematologic_responses_and_4/7_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,2,accepted,3815,4,9,133748414,133748414,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:57:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/3815,https://civic.genome.wustl.edu/links/variants/892,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",44.5,Bosutinib,,,,,chr9_g.133748414T~G,ABL1_c.1075T~G,ABL1_F359V
KRAS,3845,A146P,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,B,Resistance,"In_irinotecan-resistant_metastatic_colorectal_cancer_patients_who_had_been_treated_with_cetuximab_and_irinotecan,_KRAS_mutations_in_codon_61_or_146_were_associated_with_shorter_progression-free_survival_compared_to_wildtype_KRAS_(3.8mo_vs._5.1mo,_HR:0.46,_95%_CI:0.11-0.88,_P=0.028)._In_BRAF_wildtype_patients,_KRAS_mutations_in_codon_61_or_146_were_associated_with_reduced_response_rate_(0%_vs._37%,_P=0.047)_and_reduced_progression-free_survival_compared_to_wildtype_KRAS_patients_(3.8mo_vs._5.3mo,_HR:0.45,_95%_CI:0.10-0.85,_P=0.023).",19603018,PubMed,,"Loupakis_et_al.,_2009,_Br._J._Cancer",,3,accepted,2225,30,12,25378562,25378562,C,G,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-09-06_20:22:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/2225,https://civic.genome.wustl.edu/links/variants/905,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.436G>C,NP_004976.2:p.Ala146Pro,NC_000012.11:g.25378562C>G,ENST00000256078.4:c.436G>C",15,Cetuximab,,,,,chr12_g.25378562C~G,KRAS_c.436G~C,KRAS_A146P
KRAS,3845,A146T,Colorectal_Cancer,9256,,"BEZ235,Selumetinib_(AZD6244)",Combination,Predictive,Supports,D,Sensitivity/Response,"In_28_out_of_40_(70%)_metastatic_colorectal_cancer_tumors_implanted_into_mice,_the_therapeutic_combination_of_the_MEK_inhibitor_AZD6244_and_the_PI3K/mTor_inhibitor_BEZ235_resulted_in_disease_stabilization._Mean_tumor_growth_was_lower_in_the_tumors_treated_with_AZD6244+_BEZ235_(+77%_vs._+267%,_P=1E-6)_compared_to_AZD6244_alone_and_(+77%_vs._+222%,_P=0.0014)_BEZ235_alone._32/40_tumors_harbored_KRAS_mutations_including_2_A146T_tumors_(1_also_harboring_PIK3CA_E545K)_which_both_showed_disease_stabilization_during_doublet_therapy_but_progression_on_either_single_agent.",22392911,PubMed,,"Migliardi_et_al.,_2012,_Clin._Cancer_Res.",,3,accepted,2206,30,12,25378562,25378562,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_16:32:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/2206,https://civic.genome.wustl.edu/links/variants/906,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A",21,BEZ235,Selumetinib_(AZD6244),,,,chr12_g.25378562C~T,KRAS_c.436G~A,KRAS_A146T
KRAS,3845,A146T,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,D,Resistance,"Preclinical_data_supporting_resistance_of_Exon_4_mutations,_in_particular_A146T,_to_cetuximab_and_sensitivity_to_PD0325901._This_study_involved_treatment_of_mice_bearing_A146T_KRAS_xenografts_treated_with_PD0325901_or_cetuximab.",20570890,PubMed,,"Janakiraman_et_al.,_2010,_Cancer_Res.",,3,accepted,2943,30,12,25378562,25378562,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_16:33:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2943,https://civic.genome.wustl.edu/links/variants/906,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A",21,Cetuximab,,,,,chr12_g.25378562C~T,KRAS_c.436G~A,KRAS_A146T
KRAS,3845,A146T,Colorectal_Cancer,9256,,"FOLFOX4,Cetuximab",Combination,Predictive,Supports,B,Resistance,"In_a_retrospective_study_of_148_treatment_naive_metastatic_colorectal_cancer_patients,_patients_with_RAS_mutations_and_wildtype_BRAF_(n=10),_including_A146T_(N=3),_G15D_(N=1),_and_V152M/NRAS_V160A,_treated_with_FOLFOX4_plus_cetuximab_were_associated_with_decreased_overall_survival_(16.3mo_vs._28.5mo,_HR:0.43,_95%_CI:0.20-0.89,_P=0.020)_and_decreased_progression_free_survival_(7.2mo_vs._9.7mo,_HR:0.56,_95%_CI:0.27-1.16,_P=0.11),_as_compared_to_patients_with_wild-type_KRAS,_NRAS_and_BRAF.",25666295,PubMed,,"Kaczirek_et_al.,_2015,_Clin_Colorectal_Cancer",,3,accepted,3858,30,12,25378562,25378562,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_16:34:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/3858,https://civic.genome.wustl.edu/links/variants/906,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A",21,FOLFOX4,Cetuximab,,,,chr12_g.25378562C~T,KRAS_c.436G~A,KRAS_A146T
KRAS,3845,Q61H,Colorectal_Cancer,9256,,Cetuximab,,Predictive,Supports,C,Resistance,"In_a_colorectal_cancer_patient_with_a_KRAS_Q61H_mutation,_KRAS_Q61H_was_reported_to_be_refractory_to_cetuximab_treatment._The_patient_was_treated_with_cetuximab_and_irinotecan_for_18_months,_had_a_partial_response_to_therapy_and_then_experienced_progressive_disease_with_a_re-biopsy_of_the_tumor_identifying_a_KRAS_Q61H_mutation.",22722830,PubMed,,"Misale_et_al.,_2012,_Nature",,,accepted,3862,30,12,25380275,25380275,T,G,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_16:34:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/3862,https://civic.genome.wustl.edu/links/variants/907,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.183A>C,NP_004976.2:p.Gln61His,NC_000012.11:g.25380275T>G,ENST00000256078.4:c.183A>C",0,Cetuximab,,,,,chr12_g.25380275T~G,KRAS_c.183A~C,KRAS_Q61H
KRAS,3845,G12S,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",11050000,PubMed,,"Rowley_et_al.,_2000,_Blood",,2,accepted,2277,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_11:23:36_UTC,https://civic.genome.wustl.edu/links/evidence_items/2277,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Melphalan,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Colorectal_Cancer,9256,,Panitumumab,,Predictive,Supports,C,Resistance,"In_a_retrospective_study_of_427_metastatic_colorectal_patients,_KRAS_mutations_were_observed_in_43%_of_the_tumor_samples._Patients_with_mutations_in_codon_12_or_13_of_KRAS_were_associated_with_reduced_response_to_panitumumab_compared_to_wildtype_KRAS_(HR:0.99,_95%_CI:0.73-1.36_vs._HR:0.45,_95%_CI:0.34-0.59;_P<0.0001)._Additionally,_patients_with_KRAS_mutations_showed_no_significant_improvement_between_treatment_with_panitumumab_and_best_supportive_care_alone_(PFS:_7.4_wk_vs_7.3_wk).",18316791,PubMed,,"Amado_et_al.,_2008,_J._Clin._Oncol.",,,accepted,2269,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-03-31_01:51:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/2269,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Panitumumab,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,B,Resistance,"In_a_study_of_patients_receiving_melphalan-based_therapy,_those_with_KRAS_codon_12_mutations_were_less_likely_to_have_a_positive_response_than_those_with_wildtype_KRAS_(26.9%_vs._58.3%,_P=0.015).",19284554,PubMed,,"Greco_et_al.,_2009,_J._Exp._Clin._Cancer_Res.",,,accepted,2274,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-03-31_01:57:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/2274,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Melphalan,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Lung_Cancer,1324,,Gefitinib,,Predictive,Supports,B,Resistance,"In_recurrent_lung_cancer_patients_treated_with_the_epidermal_growth_factor_receptor_tyrosine_kinase_inhibitor_gefitinib,_patients_with_KRAS_mutations_had_a_lower_frequency_of_partial_response_(PR)_and_stable_disease_(SD)_and_a_higher_rate_of_progressive_disease_(PD)_(PR:0,_SD:1,_PD:15_vs._PR:24,_SD:8,_PD:14;_P=0.0274)_compared_to_wildtype_KRAS_patients._Patients_with_KRAS_mutations_also_had_a_shorter_overall_survival_compared_to_wildtype_KRAS_patients_(HR:2.542,_95%_CI:1.048-6.168,_P=0.0390).",17409929,PubMed,,"Endoh_et_al.,_2006,_J_Thorac_Oncol",,2,accepted,2273,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-04-11_18:55:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2273,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Gefitinib,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",12483530,PubMed,,"Rowley_et_al.,_2002,_Oncogene",,2,accepted,2278,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_11:24:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/2278,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Melphalan,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Multiple_Myeloma,9538,,Melphalan,,Predictive,Supports,D,Resistance,"In_in_vitro_experiments,_myeloma_cell_lines_expressing_activating_NRAS_and_KRAS_mutations_are_less_sensitive_to_the_apoptosis-inducing_effects_of_dexamethasone,_doxorubicin,_and_melphalan_in_comparison_to_cells_with_wildtype_RAS.",16497971,PubMed,,"Hoang_et_al.,_2006,_Blood",,2,accepted,2279,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_11:24:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2279,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Melphalan,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Colorectal_Cancer,9256,,Regorafenib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_SW48_cell_line_expressing_KRAS_G12S_mutation_demonstrated_decreased_sensitivity__to_regorafenib_treatment_(IC50:_264.23_nmol_vs._114.28_nmol,_P<0.01)_compared_to_SW48_cells_expressing_KRAS_wild-type._Resistance_was_determined_by_assessing_cell_viability.",26161928,PubMed,,"Camaj_et_al.,_2015,_Future_Oncol",,,accepted,4012,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2017-07-21_19:00:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/4012,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Regorafenib,,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
KRAS,3845,G12S,Colorectal_Cancer,9256,,"Cetuximab,Panitumumab",Substitutes,Predictive,Supports,C,Resistance,"In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS_PIK3CA_and_PTEN_were_tested_for_mutation;_KRAS_G12S_was_the_only_variant_noted_in_the_primary_tumor_of_one_patient_who_experienced_disease_progression_following_treatment_(colon_tumor_of_patient_20;_Supplemental_Table_1)._In_the_larger_cohort,_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.",19223544,PubMed,,"Sartore-Bianchi_et_al.,_2009,_Cancer_Res.",,2,accepted,6314,30,12,25398285,25398285,C,T,ENST00000256078.4,,,,,75,GRCh37,,Somatic_Mutation,2018-11-02_22:02:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/6314,https://civic.genome.wustl.edu/links/variants/913,https://civic.genome.wustl.edu/links/genes/30,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",23.5,Cetuximab,Panitumumab,,,,chr12_g.25398285C~T,KRAS_c.34G~A,KRAS_G12S
TP53,7157,R273L,Ovarian_Cancer,2394,,"Cisplatin,Carboplatin",Substitutes,Predictive,Supports,C,Resistance,"Ovarian_cancer_patients_with_TP53_missense_mutations_were_refractory_to_platinum-based_chemotherapy_(66%_vs._34%_in_wildtype,_P=0.008)_and_had_a_shorter_time_to_disease_progression_(n=54,_P=0.037)._A_study_of_ovarian_carcinoma_patients_(n=178)_reported_a_reduced_overall_survival_(HR:1.59,_95%_CI:1.09-2.33,_P=0.014)_for_patients_with_mutations_in_TP53.",11595686,PubMed,,"Reles_et_al.,_2001,_Clin._Cancer_Res.",,,accepted,2286,45,17,7577120,7577120,C,A,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-08_13:10:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/2286,https://civic.genome.wustl.edu/links/variants/918,https://civic.genome.wustl.edu/links/genes/45,,,missense_variant,"NM_000546.5:c.818G>T,NP_000537.3:p.Arg273Leu,NC_000017.10:g.7577120C>A,ENST00000269305.4:c.818G>T",0,Cisplatin,Carboplatin,,,,chr17_g.7577120C~A,TP53_c.818G~T,TP53_R273L
TP53,7157,Y220C,Stomach_Carcinoma,5517,,EAP_Protocol,,Predictive,Supports,C,Sensitivity/Response,"In_a_study_of_25_patients_with_advanced_gastric_cancer,_mutations_in_TP53_were_identified_in_32%_of_primary_tumors._TP53_mutations_were_associated_with_an_improved_response_to_preoperative_treatment_of_a_modified_EAP_protocol_(combination_of_doxorubicin,_etoposide_and_cisplatin)._Patients_with_mutations_in_TP53_had_an_increased_median_survival_compared_to_patients_with_wildtype_TP53_(18.5mo_vs._10.2mo,_P=0.044).",14514923,PubMed,,"Bataille_et_al.,_2003,_MP,_Mol._Pathol.",,,accepted,2306,45,17,7578190,7578190,T,C,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-15_07:33:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/2306,https://civic.genome.wustl.edu/links/variants/922,https://civic.genome.wustl.edu/links/genes/45,,,missense_variant,"NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G",4,EAP_Protocol,,,,,chr17_g.7578190T~C,TP53_c.659A~G,TP53_Y220C
TP53,7157,Y220C,Cancer,162,,AMGMDS3,,Predictive,Supports,D,Resistance,Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_Y220C_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.,25730903,PubMed,,"Saiki_et_al.,_2015,_Oncotarget",,4,accepted,4884,45,17,7578190,7578190,T,C,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2018-04-30_23:41:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4884,https://civic.genome.wustl.edu/links/variants/922,https://civic.genome.wustl.edu/links/genes/45,,,missense_variant,"NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G",4,AMGMDS3,,,,,chr17_g.7578190T~C,TP53_c.659A~G,TP53_Y220C
IDH1,3417,R132S,Malignant_Glioma,3070,,Bevacizumab,,Predictive,Supports,B,Sensitivity/Response,"In_a_clinical_study_of_63_recurrent_glioma_patients,_patients_treated_with_bevacizumab_monotherapy_(n=11)_and_harboring_IDH1_codon_132_mutation_were_associated_with_improved_progression_free_survival_(3.23_months_vs._1.37_months,_p=0.05),_as_compared_to_patients_with_wild-type_IDH1.",22199315,PubMed,,"Lv_et_al.,_2011,_Anticancer_Res.",,2,accepted,2339,26,2,209113113,209113113,G,T,ENST00000415913.1,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_19:55:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/2339,https://civic.genome.wustl.edu/links/variants/928,https://civic.genome.wustl.edu/links/genes/26,,,missense_variant,"NM_001282386.1:c.394C>A,NP_001269315.1:p.Arg132Ser,NC_000002.11:g.209113113G>T,ENST00000415913.1:c.394C>A",10,Bevacizumab,,,,,chr2_g.209113113G~T,IDH1_c.394C~A,IDH1_R132S
PDGFRA,5156,V561D,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"This_case_study_examines_one_patient_from_a_larger_cohort_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105._Patients_in_this_cohort_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._This_patient's_GIST_harbored_PDGFRA_exon_12_V561D._The_patient_was_treated_with_800mg_of_imatinib_per_day,_and_had_not_progressed_or_died_as_of_31_months_of_follow_up_(vs_median_TTP_of_12.8_months_for_WT).",18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,1,accepted,2474,38,4,55141036,55141036,T,A,ENST00000257290.5,,,,,75,GRCh37,,Somatic_Mutation,2019-02-08_18:32:29_UTC,https://civic.genome.wustl.edu/links/evidence_items/2474,https://civic.genome.wustl.edu/links/variants/941,https://civic.genome.wustl.edu/links/genes/38,,,missense_variant,"NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A",2.5,Imatinib,,,,,chr4_g.55141036T~A,PDGFRA_c.1682T~A,PDGFRA_V561D
KIT,3815,V559D,Cancer,162,,"SU11248,MLN518,BMS-354825,Imatinib,PD-180970",Substitutes,Predictive,Supports,D,Sensitivity/Response,"KIT(V559D)_were_expressed_in_HEK-293_cells_(in_vitro)._Imatinib,_BMS-354825,_PD-180970,_MLN-518,_and_SU-11248_bind_variant_V559D_with_high_affinity_(Kd_=<_20_nM),_and_inhibit_KIT_autophosphorylation._Despite_similar_binding_affinities,_the_cellular_activity_of_BMS-354825_was_>10-fold_greater_than_that_of_SU-11248_or_PD-180970,_and_the_authors_hypothesize_that_additional_pharmaceutical_properties_may_contribute_to_the_greater_cellular_potency.",16046538,PubMed,,"Carter_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,2,accepted,3029,29,4,55593610,55593610,T,A,,,,,,,GRCh37,,Somatic_Mutation,2017-07-10_15:51:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/3029,https://civic.genome.wustl.edu/links/variants/968,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,,9.5,SU11248,MLN518,BMS-354825,Imatinib,PD-180970,,,
KIT,3815,V559D,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,Patient_with_c-kit-positive_mesenchymal_tumor_in_descending_part_of_the_duodenum._The_patient_has_received_400mg_Imatinib_daily_for_10_years._He_responded_well_to_therapy_(Karnofsky_index_90%)._V559D_is_a_positive_predictor_of_imatinib_response_with_long_term_usage.,22114577,PubMed,,"Cameron_et_al.,_2011,_Case_Rep_Oncol",,3,accepted,3028,29,4,55593610,55593610,T,A,,,,,,,GRCh37,,Somatic_Mutation,2017-07-28_01:11:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/3028,https://civic.genome.wustl.edu/links/variants/968,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,,9.5,Imatinib,,,,,,,
KIT,3815,D816H,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._D816H_was_observed_as_a_secondary_KIT_mutation_in_two_patients_with_secondary_imatinib_resistance._The_mutation_was_shown_to_occur_at_a_hotspot_(D816)_of_previously_reported_secondary_KIT_mutations_in_imatinib_resistant_GISTs._When_co-expressed_with_V560D_(imatinib_sensitive)_in_vitro_D816H_showed_""extreme""_imatinib_resistance._It_was_also_highly_resistant_in_isolation.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2923,29,4,55599320,55599320,G,C,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:45:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/2923,https://civic.genome.wustl.edu/links/variants/983,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.2446G>C,NP_000213.1:p.Asp816His,NC_000004.11:g.55599320G>C,ENST00000288135.5:c.2446G>C",7.5,Imatinib,,,,,chr4_g.55599320G~C,KIT_c.2446G~C,KIT_D816H
KIT,3815,D820Y,Melanoma,1909,,Imatinib,,Predictive,Supports,C,Resistance,"FFPE_tumor_specimens_from_295_melanoma_patients_were_screened_for_KIT_amplification_and_mutation._Of_these,_51_patients_had_variants_in_KIT_and_28_of_these_were_treated_with_imatinib_mesylate_at_400_mg_orally,_twice_daily_with_25_patients_eligible_for_response_evaluation._None_of_the_patients_had_mutations_in_BRAF,_NRAS,_or_GNAQ._Two_patients_achieved_a_durable_complete_response,_two_achieved_a_durable_partial_response,_and_5_achieved_stable_disease_>12_weeks_with_a_median_survival_of_46.3_weeks._One_patient_harboring_a_somatic_D820Y_mutation_at_roughly_50%_variant_allele_frequency_(1:1_with_wild_type)_displayed_Imatinib_mesylate–resistance_and_disease_progression,_which_is_consistent_with_resistant_mechanisms_described_in_Gastro-Intestinal_Stromal_Tumors.",21642685,PubMed,,"Carvajal_et_al.,_2011,_JAMA",,3,accepted,2886,29,4,55599332,55599332,G,T,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-11_15:03:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/2886,https://civic.genome.wustl.edu/links/variants/986,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T",12.5,Imatinib,,,,,chr4_g.55599332G~T,KIT_c.2458G~T,KIT_D820Y
KIT,3815,Y823D,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._Y823D_was_observed_as_a_secondary_KIT_mutation_in_five_patients_with_secondary_imatinib_resistance._The_mutation_was_shown_to_occur_at_a_hotspot_(Y823)_of_previously_reported_secondary_KIT_mutations_in_imatinib_resistant_GISTs._When_co-expressed_with_V560D_(imatinib_sensitive)_in_vitro_Y823D_showed_""extreme""_imatinib_resistance.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2919,29,4,55599341,55599341,T,G,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:47:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/2919,https://civic.genome.wustl.edu/links/variants/989,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.2467T>G,NP_000213.1:p.Tyr823Asp,NC_000004.11:g.55599341T>G,ENST00000288135.5:c.2467T>G",7.5,Imatinib,,,,,chr4_g.55599341T~G,KIT_c.2467T~G,KIT_Y823D
BRAF,673,G469A,Cancer,162,,Vemurafenib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,_and_MACF1-_and_WASFL-BRAF_fusion.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5965,5,7,140481402,140481402,C,G,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2018-02-16_11:20:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/5965,https://civic.genome.wustl.edu/links/variants/992,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,"NM_004333.4:c.1406G>C,NP_004324.2:p.Gly469Ala,NC_000007.13:g.140481402C>G,ENST00000288602.6:c.1406G>C",5,Vemurafenib,,,,,chr7_g.140481402C~G,BRAF_c.1406G~C,BRAF_G469A
BRAF,673,G469E,Skin_Melanoma,8923,,Sorafenib,,Predictive,Supports,D,Sensitivity/Response,"In_this_preclinical_study,_melanoma_cell_lines_harboring_the_kinase-dead_G469E-_and_D594G_mutations_were_identified._These_cell_lines_were_resitant_to_MEK-Inhibition_but_underwent_apoptosis_after_shRNA-mediated_CRAF_knowdown_or_Treatment_with_the_pan-RAF_Inhibitor_sorafenib.",18794803,PubMed,,"Smalley_et_al.,_2009,_Oncogene",,3,accepted,6003,5,7,140481402,140481402,C,T,,,,,,,GRCh37,,Somatic_Mutation,2018-07-24_15:33:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/6003,https://civic.genome.wustl.edu/links/variants/993,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,,6,Sorafenib,,,,,,,
BRAF,673,G469E,Skin_Melanoma,8923,,U0126,,Predictive,Supports,D,,"In_this_preclinical_study,_melanoma_cell_lines_harboring_the_kinase-dead_G469E-_and_D594G_mutations_were_identified._These_cell_lines_were_resitant_to_MEK-Inhibition_(U0126)_but_underwent_apoptosis_after_shRNA-mediated_CRAF_knowdown_or_treatment_with_the_pan-RAF_inhibitor_sorafenib.",18794803,PubMed,,"Smalley_et_al.,_2009,_Oncogene",,3,accepted,6004,5,7,140481402,140481402,C,T,,,,,,,GRCh37,,Somatic_Mutation,2018-07-24_15:35:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/6004,https://civic.genome.wustl.edu/links/variants/993,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,,6,U0126,,,,,,,
EGFR,1956,R108K,Malignant_Glioma,3070,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_R108K_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",17177598,PubMed,,"Lee_et_al.,_2006,_PLoS_Med.",,,accepted,4186,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-06-15_22:41:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/4186,https://civic.genome.wustl.edu/links/variants/994,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,T263P,Malignant_Glioma,3070,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_T263P_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",17177598,PubMed,,"Lee_et_al.,_2006,_PLoS_Med.",,,accepted,4187,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-06-15_22:39:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/4187,https://civic.genome.wustl.edu/links/variants/995,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,A289V,Malignant_Glioma,3070,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_A289V_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_EGFR_wild-type._Variant_function_was_assessed_by_EGFR_auto-phosphorylation._Sensitivity_was_assessed_by_cell_viability_assay_using_stable_transfection_of_each_variant_and_increasing_concentrations_of_erlotinib_(0–10_uM).",17177598,PubMed,,"Lee_et_al.,_2006,_PLoS_Med.",,3,accepted,4188,19,7,55221822,55221822,C,T,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-08-25_01:11:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/4188,https://civic.genome.wustl.edu/links/variants/996,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"NM_005228.4:c.866C>T,NP_005219.2:p.Ala289Val,NC_000007.13:g.55221822C>T,ENST00000275493.2:c.866C>T",3,Erlotinib,,,,,chr7_g.55221822C~T,EGFR_c.866C~T,EGFR_A289V
EGFR,1956,G719A,Non-small_Cell_Lung_Carcinoma,3908,,"Erlotinib,Gefitinib",Substitutes,Predictive,Does_Not_Support,C,Sensitivity/Response,"In_a_large_retrospective_study,_EGFR_exons_18-21_were_assessed_using_direct_sequencing_in_753_French_NSCLC_cases._Clinical_details_and_patient_outcomes_were_taken,_including_whether_the_first_generation_TKIs_erlotinib_or_gefitinib_were_administered._One_patient_was_found_to_have_a_G719A_mutation,_was_administered_a_TKI,_and_an_NSCLC_progression_was_observed.",23749122,PubMed,,"Locatelli-Sanchez_et_al.,_2013,_Lung",,2,accepted,6181,19,7,55241708,55241708,G,C,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2018-05-31_19:52:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/6181,https://civic.genome.wustl.edu/links/variants/999,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"NM_005228.4:c.2156G>C,NP_005219.2:p.Gly719Ala,NC_000007.13:g.55241708G>C,ENST00000275493.2:c.2156G>C",5,Erlotinib,Gefitinib,,,,chr7_g.55241708G~C,EGFR_c.2156G~C,EGFR_G719A
EGFR,1956,G719A,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_study_of_297_non-small_cell_lung_cancer_patients,_15%_of_the_analyzed_tumors_had__EGFR_mutations_including_deletions_in_exon_19_(n=22),_L858R_(n=16)_and_G719A_(n=2)._Patients_with_EGFR_mutations_treated_with_gefitinib_were_associated_with_improved_response_rates_(42.1%_vs._6.6%,_P=0.04)_compared_to_wildtype_EGFR_patients.",20038723,PubMed,,"Douillard_et_al.,_2010,_J._Clin._Oncol.",,,accepted,2508,19,7,55241708,55241708,G,C,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-05-18_15:21:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/2508,https://civic.genome.wustl.edu/links/variants/999,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"NM_005228.4:c.2156G>C,NP_005219.2:p.Gly719Ala,NC_000007.13:g.55241708G>C,ENST00000275493.2:c.2156G>C",5,Gefitinib,,,,,chr7_g.55241708G~C,EGFR_c.2156G~C,EGFR_G719A
EGFR,1956,V742A,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_V742A_demonstrated_increased_sensitivity_to_erlotinib_treatment_comparable_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_V742A_and_EGFR_L858R_expressing_cells_were_21_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4197,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-09-16_11:38:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/4197,https://civic.genome.wustl.edu/links/variants/1001,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,L747_P753delinsS,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_L747_P753>S_demonstrated_increased_sensitivity_to_erlotinib_treatment_comparable_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_L747_P753>S_and_EGFR_L858R_expressing_cells_were_5_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4266,19,7,55242470,55242487,,,,,,,,,GRCh37,,Somatic_Mutation,2017-09-16_11:34:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/4266,https://civic.genome.wustl.edu/links/variants/1012,https://civic.genome.wustl.edu/links/genes/19,,,inframe_deletion,,0,Erlotinib,,,,,,,
EGFR,1956,R831H,Malignant_Mesothelioma,1790,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_COS-7_cell_line_expressing_EGFR_R831H_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",20942962,PubMed,,"Foster_et_al.,_2010,_World_J_Surg_Oncol",,,accepted,4279,19,7,55259434,55259434,G,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2018-01-18_23:34:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/4279,https://civic.genome.wustl.edu/links/variants/1017,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,"ENST00000275493.2:c.2492G>A,NC_000007.13:g.55259434G>A",0,Erlotinib,,,,,chr7_g.55259434G~A,EGFR_c.2492G~A,
EGFR,1956,L838V,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_L838V_demonstrated_reduced_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_L838V_and_EGFR_L858R_expressing_cells_were_160_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4280,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-09-16_11:05:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/4280,https://civic.genome.wustl.edu/links/variants/1018,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,L861Q,Malignant_Glioma,3070,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_L861Q_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",17177598,PubMed,,"Lee_et_al.,_2006,_PLoS_Med.",,,accepted,4299,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-06-15_22:23:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/4299,https://civic.genome.wustl.edu/links/variants/1020,https://civic.genome.wustl.edu/links/genes/19,,,,,7.5,Erlotinib,,,,,,,
EGFR,1956,L861Q,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_study,_a_group_of_6_participants,_5_with_stage_IV_and_one_with_stage_IIIB_lung_adenocarcinoma,_were_sequenced_at_EGFR_exons_18_to_21._All_patients_had_L861Q_mutation_and_were_treated_with_the_1st_generation_TKI_gefitinib._4_patients_had_partial_response_with_progression_free_survival_(PFS)_of_4.3,_19.3,_10.0,_8.7_months;_overall_survival_(OS)_of_4.3,_34.9,_15.7,_15.7_months;_and_all_4_were_alive_at_study_end._One_patient_had_stable_disease,_PFS_6.5_months,_OS_15.2_months,_and_was_not_alive_at_study_end._One_patient_had_progressive_disease_as_response,_with_PFS_of_2.8_months,_OS_of_10.7_months,_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,_2.0_and_10.4_wild_type.",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,3802,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-07-06_21:48:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/3802,https://civic.genome.wustl.edu/links/variants/1020,https://civic.genome.wustl.edu/links/genes/19,,,,,7.5,Gefitinib,,,,,,,
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_M244V_mutation_was__sensitive_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2638,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-19_16:44:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/2638,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Imatinib,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_M244V_evaluated,_2/2_had_complete_hematologic_responses_and_2/3_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,2,accepted,4307,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:36:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/4307,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Bosutinib,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_46_patients_with_M244V_mutations,__20,_27,_and_45_achieved_a_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4302,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:10:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/4302,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Dasatinib,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_M244V_evaluated,_3/3_had_CHR_and_2/3_had_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,2,accepted,4308,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:47:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/4308,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Bosutinib,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_5_had_M244V_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7042,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:29:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/7042,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Imatinib_Mesylate,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_M244V_was_seen_in_3_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,2,accepted,6994,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_20:42:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/6994,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Imatinib_Mesylate,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_M244V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_M244V_mutation_was_associated_with_resistance_in_2_μM_imatinib_(1_clone_recovered,_0.71%)._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6242,4,9,133738330,133738330,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-27_21:13:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/6242,https://civic.genome.wustl.edu/links/variants/1021,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G",34.5,Imatinib_Mesylate,,,,,chr9_g.133738330A~G,ABL1_c.730A~G,ABL1_M244V
ABL1,25,BCR-ABL_L248V,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_L248V_mutation_was_moderately_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2641,4,9,133738342,133738342,C,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:34:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/2641,https://civic.genome.wustl.edu/links/variants/1022,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G",28.5,Imatinib,,,,,chr9_g.133738342C~G,ABL1_c.742C~G,ABL1_L248V
ABL1,25,BCR-ABL_L248V,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_15_patients_with_L248V_mutations,_6,_10,_and_15_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,6308,4,9,133738342,133738342,C,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:58:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/6308,https://civic.genome.wustl.edu/links/variants/1022,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G",28.5,Dasatinib,,,,,chr9_g.133738342C~G,ABL1_c.742C~G,ABL1_L248V
ABL1,25,BCR-ABL_L248V,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_L248V_evaluated,_3/3_had_complete_hematologic_responses_and_2/3_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,2,accepted,4310,4,9,133738342,133738342,C,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:38:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/4310,https://civic.genome.wustl.edu/links/variants/1022,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G",28.5,Bosutinib,,,,,chr9_g.133738342C~G,ABL1_c.742C~G,ABL1_L248V
ABL1,25,BCR-ABL_L248V,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._61_clones_grew_in_a_combination_of_400_nM_imatinib_and_50_nM_nilotinib._Of_these,_19_were_sequenced_and_2_(~11%)_were_found_to_have_L248V_mutations.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6236,4,9,133738342,133738342,C,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_00:51:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/6236,https://civic.genome.wustl.edu/links/variants/1022,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G",28.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133738342C~G,ABL1_c.742C~G,ABL1_L248V
ABL1,25,BCR-ABL_L248V,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_3_had_L248V_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7044,4,9,133738342,133738342,C,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:30:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/7044,https://civic.genome.wustl.edu/links/variants/1022,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G",28.5,Imatinib_Mesylate,,,,,chr9_g.133738342C~G,ABL1_c.742C~G,ABL1_L248V
ABL1,25,BCR-ABL_L248V,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate,Dasatinib",Substitutes,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib_to_identify_resistance_mutations._The_L248V_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_2_μM_imatinib_(3_clones_recovered,_~2%_of_viable_clones_in_this_treatment),_50nM_nilotinib_(1_clone,_~2%),_and_5nM_dasatinib_(3_clones,_~9%)._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,2644,4,9,133738342,133738342,C,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-10-08_22:26:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/2644,https://civic.genome.wustl.edu/links/variants/1022,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G",28.5,Nilotinib,Imatinib_Mesylate,Dasatinib,,,chr9_g.133738342C~G,ABL1_c.742C~G,ABL1_L248V
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,B,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_9_had_G250E_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7041,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:28:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/7041,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Imatinib_Mesylate,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_G250E_mutation_was_associated_with_resistance_in_2_μM_imatinib_(3_clone_recovered,_~2%),_4_μM_imatinib_(1_clone_recovered,_~0.74%),_and_50_nM_nilotinib_(5_clone,_~11%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6267,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_02:31:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/6267,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Nilotinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Resistance,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_G250E_mutation_was__resistant_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2647,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-19_16:45:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/2647,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Imatinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_G250E_evaluated,_1/1_had_a_complete_hematologic_response_and_2/2_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,2,accepted,4313,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:38:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/4313,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Bosutinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Of_60_patients_with_G250E_mutations,_20,_29,_and_56_achieved_a_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4316,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:13:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/4316,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Dasatinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Reduced_Sensitivity,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_G250E,_3/6_had_a_CHR_and_0/5_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,2,accepted,4314,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:46:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/4314,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Bosutinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_G250E_mutation_was_associated_with_resistance_in_2_μM_imatinib_(3_clone_recovered,_~2%),_4_μM_imatinib_(1_clone_recovered,_~0.74%),_and_50_nM_nilotinib_(5_clone,_~11%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6244,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-27_21:18:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/6244,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Imatinib_Mesylate,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3_cell_line_stably_expressing_the_G250E_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_nilotinib_treatment_(IC50:_4.56-fold),_as_compared_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2648,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:40:02_UTC,https://civic.genome.wustl.edu/links/evidence_items/2648,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Nilotinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_G250E_mutation_was_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,2645,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:34:57_UTC,https://civic.genome.wustl.edu/links/evidence_items/2645,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Imatinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Reduced_Sensitivity,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_G250E,_6/9_had_MaHRs_which_was_comparable_to_response_rates_among_wild_type_patients,_and_1/9_had_MCyRs_which_was_lower_than_response_rates_among_wild_type_patients.",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,4318,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:02:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/4318,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Dasatinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,BCR-ABL_G250E,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_G250E_was_seen_in_6_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,6993,4,9,133738349,133738349,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_20:41:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/6993,https://civic.genome.wustl.edu/links/variants/1023,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A",49,Imatinib,,,,,chr9_g.133738349G~A,ABL1_c.749G~A,ABL1_G250E
ABL1,25,Q252H,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_Q252H_mutation_was_associated_with_resistance_to_4_μM_and_16_μM_imatinib_(4_clones_[~3%]_and_1_clone_[~3%]_recovered,_respectively)_as_well_as_10_nM_dasatinib_(1_clone_[~2%])._No_clones_recovered_at_2_μM/8_μM_imatinib_or_5_nM_dasatinib._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6274,4,9,133738356,133738356,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_02:35:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/6274,https://civic.genome.wustl.edu/links/variants/1024,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C",15.5,Dasatinib,,,,,chr9_g.133738356G~C,ABL1_c.756G~C,ABL1_Q252H
ABL1,25,Q252H,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_were_generated_in_Ba/F3_cell_lines_from_five_independently_derived,_mutagenized_libraries._Dasatinib_resistant_subclones_were_identified_using_﻿50_nM_dasatinib_in_liquid_culture._201_individual_clones_were_identified_representing_10_different_mutations_at_6_different_residues._1_of_these_clones_had_an_Q252H_mutation.",15705718,PubMed,,"Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,1,accepted,6219,4,9,133738356,133738356,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-20_01:46:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/6219,https://civic.genome.wustl.edu/links/variants/1024,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C",15.5,Dasatinib,,,,,chr9_g.133738356G~C,ABL1_c.756G~C,ABL1_Q252H
ABL1,25,Q252H,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_Q252H_mutation_was_associated_with_resistance_to_4_μM_and_16_μM_imatinib_(4_clones_[~3%]_and_1_clone_[~3%]_recovered,_respectively)_as_well_as_10_nM_dasatinib_(1_clone_[~2%])._No_clones_recovered_at_2_μM/8_μM_imatinib_or_5_nM_dasatinib._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6245,4,9,133738356,133738356,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_02:34:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/6245,https://civic.genome.wustl.edu/links/variants/1024,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C",15.5,Imatinib_Mesylate,,,,,chr9_g.133738356G~C,ABL1_c.756G~C,ABL1_Q252H
ABL1,25,Q252H,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Sensitivity/Response,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_Q252H_mutation_was_sensitive_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,2650,4,9,133738356,133738356,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:34:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/2650,https://civic.genome.wustl.edu/links/variants/1024,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C",15.5,Imatinib,,,,,chr9_g.133738356G~C,ABL1_c.756G~C,ABL1_Q252H
ABL1,25,Q252H,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,C,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Of_6_patients_with__Q252H_mutations,_1,_1,_and_3_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations._The_authors_identify_Q252H_as_one_of_4_variants_with_a_low_CCyR_but_advise_caution_when_interpreting_these_results_due_to_low_sample_size.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4327,4,9,133738356,133738356,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:20:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/4327,https://civic.genome.wustl.edu/links/variants/1024,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C",15.5,Dasatinib,,,,,chr9_g.133738356G~C,ABL1_c.756G~C,ABL1_Q252H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Substitutes,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib_to_identify_resistance_mutations._The_Y253H_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_50nM_nilotinib_(14_clones_recovered,_~30%_of_viable_clones_in_this_treatment),_500nM_nilotinib_(50_clones,_~63%),_and_16_nM_imatinib_(16_clones;_~48%)._Resistant_clones_were_also_found_at_2,_4,_and_8_μM_imatinib._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,3,accepted,2654,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-10-08_22:22:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/2654,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._61_clones_grew_in_a_combination_of_400_nM_imatinib_and_50_nM_nilotinib._Of_these,_19_were_sequenced_and_5_(~26%)_were_found_to_have_Y253H_mutations.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6237,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_00:54:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/6237,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_23_patients_with_the_Y253H_mutation,_14,_15,_and_20_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4335,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:23:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/4335,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Dasatinib,,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Substitutes,Predictive,Supports,C,Resistance,"In_this_open-label,_phase_II_registration_trial,_patients_that_were_imatinib_resistant_or_intolerant_underwent_nilotinib_monotherapy._Within_12_months_of_nilotinib_therapy,_there_was_no_significant_difference_in_response_to_nilotinib_treatment_between_patients_with_mutations_in_the_Abl1_kinase_domain_versus_without._However,_the_authors_identify_Y253H,_E255K/V,_and_F359C/V_variants_as_resistant_as_they_had_an_IC50_of_>150_nM._In_patients_with_Y253H_mutations_prior_to_nilotinib_treatment,_complete_hematologic_response_was_achieved_in_0_of_6_patients,_major_cytogenetic_response_in_1_of_8_patients,_complete_cytogenetic_response_in_0_of_8_patients,_and_major_molecular_response_in_0_of_7_patients._After_median_follow-up_of_15.5_months,_3_of_8_patients_with_this_mutation_progressed_or_died._The_Y253H_mutation_was_present_in_two_patients_at_baseline_and_newly_emerged_in_two_patients_at_progression.",19652056,PubMed,,"Hughes_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,6200,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-11-05_22:44:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/6200,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_Y253H_was_seen_in_6_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,6992,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_20:40:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/6992,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Imatinib_Mesylate,,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,B,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_6_had_Y253H_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7040,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:28:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/7040,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Imatinib_Mesylate,,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_Y253H_evaluated,_5/6_had_CHR_and_4/6_had_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,4332,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:44:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/4332,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Bosutinib,,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,BCR-ABL_Y253H,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_Y253H_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,2,accepted,4331,4,9,133738357,133738357,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:41:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/4331,https://civic.genome.wustl.edu/links/variants/1025,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C",52.5,Bosutinib,,,,,chr9_g.133738357T~C,ABL1_c.757T~C,ABL1_Y253H
ABL1,25,Y253F,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Resistance,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_Y253F_mutation_was__moderately_resistant_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2657,4,9,133738358,133738358,A,T,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-19_16:49:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2657,https://civic.genome.wustl.edu/links/variants/1026,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T",4.5,Imatinib,,,,,chr9_g.133738358A~T,ABL1_c.758A~T,ABL1_Y253F
ABL1,25,Y253F,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_Y253F_evaluated,_1/1_had_a_complete_hematologic_response_and_0/1_had_a_major_cytogenetic_response.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,1,accepted,4340,4,9,133738358,133738358,A,T,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:07:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/4340,https://civic.genome.wustl.edu/links/variants/1026,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T",4.5,Bosutinib,,,,,chr9_g.133738358A~T,ABL1_c.758A~T,ABL1_Y253F
ABL1,25,Y253F,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_Y253F_mutation_was_moderately_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2655,4,9,133738358,133738358,A,T,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:34:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/2655,https://civic.genome.wustl.edu/links/variants/1026,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T",4.5,Imatinib,,,,,chr9_g.133738358A~T,ABL1_c.758A~T,ABL1_Y253F
ABL1,25,BCR-ABL_D276G,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,C,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_8_patients_with_D276G_mutations,_3,_4,_and_7_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4359,4,9,133747520,133747520,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:26:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/4359,https://civic.genome.wustl.edu/links/variants/1027,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G",16,Dasatinib,,,,,chr9_g.133747520A~G,ABL1_c.827A~G,ABL1_D276G
ABL1,25,BCR-ABL_D276G,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_D276G_mutation_was_associated_with_resistance_in_2_μM_imatinib_(1_clone_recovered,_~0.71%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6246,4,9,133747520,133747520,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-27_21:20:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/6246,https://civic.genome.wustl.edu/links/variants/1027,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G",16,Imatinib_Mesylate,,,,,chr9_g.133747520A~G,ABL1_c.827A~G,ABL1_D276G
ABL1,25,BCR-ABL_D276G,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,D,Resistance,"A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_D276G_mutation_was_moderately_resistant_to_imatinib.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2663,4,9,133747520,133747520,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:34:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/2663,https://civic.genome.wustl.edu/links/variants/1027,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G",16,Imatinib,,,,,chr9_g.133747520A~G,ABL1_c.827A~G,ABL1_D276G
ABL1,25,BCR-ABL_D276G,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_D276G_evaluated,_1/1_had_a_complete_hematologic_responses_and_0/1_had_a_major_cytogenetic_response.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,1,accepted,4357,4,9,133747520,133747520,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:09:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/4357,https://civic.genome.wustl.edu/links/variants/1027,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G",16,Bosutinib,,,,,chr9_g.133747520A~G,ABL1_c.827A~G,ABL1_D276G
ABL1,25,BCR-ABL_D276G,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3__cell_line_stably_expressing_the_D276G_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_sensitivity_to_nilotinib_treatment_(IC50:_2.00-fold),_as_compared_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,2666,4,9,133747520,133747520,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:39:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/2666,https://civic.genome.wustl.edu/links/variants/1027,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G",16,Nilotinib,,,,,chr9_g.133747520A~G,ABL1_c.827A~G,ABL1_D276G
ABL1,25,BCR-ABL_M351T,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_M351T_mutation_was_associated_with_resistance_in_2_μM_imatinib_(1_clone_recovered,_~0.71%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6254,4,9,133748391,133748391,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-27_21:42:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/6254,https://civic.genome.wustl.edu/links/variants/1029,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C",38,Imatinib_Mesylate,,,,,chr9_g.133748391T~C,ABL1_c.1052T~C,ABL1_M351T
ABL1,25,BCR-ABL_M351T,Chronic_Myeloid_Leukemia,8552,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_M351T_mutation_was__sensitive_to_imatinib_.",15930265,PubMed,,"O'Hare_et_al.,_2005,_Cancer_Res.",,,accepted,2684,4,9,133748391,133748391,T,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-22_02:13:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/2684,https://civic.genome.wustl.edu/links/variants/1029,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C",38,Imatinib,,,,,chr9_g.133748391T~C,ABL1_c.1052T~C,ABL1_M351T
ABL1,25,BCR-ABL_M351T,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Reduced_Sensitivity,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_M351T,_3/6_had_MaHRs_which_was_comparable_to_response_rates_among_wild_type_patients,_and_1/6_had_MCyRs_which_was_lower_than_response_rates_among_wild_type_patients.	17264298	PubMed	NA	Guilhot_et_al.,_2007,_Blood		1	accepted	4397	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-31_09:58:09_UTC	https://civic.genome.wustl.edu/links/evidence_items/4397	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1029	ABL1	25	BCR-ABL_M351T	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced_Sensitivity	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_M351T,_1/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4394	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:40:58_UTC	https://civic.genome.wustl.edu/links/evidence_items/4394	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1029	ABL1	25	BCR-ABL_M351T	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_6_had_M351T_mutations	17264298	PubMed	NA	Guilhot_et_al.,_2007,_Blood		1	accepted	7037	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-31_10:20:36_UTC	https://civic.genome.wustl.edu/links/evidence_items/7037	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1029	ABL1	25	BCR-ABL_M351T	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_M351T_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6989	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:30:24_UTC	https://civic.genome.wustl.edu/links/evidence_items/6989	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1029	ABL1	25	BCR-ABL_M351T	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	B	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_54_patients_with_M351T_mutations,_25,_28,_and_51_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		4	accepted	4396	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:30:20_UTC	https://civic.genome.wustl.edu/links/evidence_items/4396	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1029	ABL1	25	BCR-ABL_M351T	Chronic_Myeloid_Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In_an_in_vitro_study,_Ba/F3_cell_line_stably_expressing_the_M351T_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_gene_fusion_was_associated_with_sensitivity_to_nilotinib_treatment_(IC50:_0.44-fold),_comparable_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.	19075254	PubMed	NA	Redaelli_et_al.,_2009,_J._Clin._Oncol.		3	accepted	2685	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-25_16:39:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/2685	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1029	ABL1	25	BCR-ABL_M351T	Chronic_Myeloid_Leukemia	8552		Imatinib		Predictive	Supports	D	Sensitivity/Response	A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_M351T_mutation_was_sensitive_to_imatinib.	19075254	PubMed	NA	Redaelli_et_al.,_2009,_J._Clin._Oncol.		3	accepted	2682	4	9	133748391	133748391	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-25_16:33:39_UTC	https://civic.genome.wustl.edu/links/evidence_items/2682	https://civic.genome.wustl.edu/links/variants/1029	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	38
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	A_panel_of_18_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_H396R_mutation_was_resistant_to_imatinib.	19075254	PubMed	NA	Redaelli_et_al.,_2009,_J._Clin._Oncol.		2	accepted	2687	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-25_16:33:25_UTC	https://civic.genome.wustl.edu/links/evidence_items/2687	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	In_two_cell-based_studies,_a_panel_of_either_18_or_16_mutations_representing_85%_of_known_mutations_seen_in_imatinib_CML_patents_were_used_to_evaluate_the_effectiveness_of_drug_binding._All_mutations_were_compared_with_non-mutated_BCR-ABL_protein_and_were_grouped_according_to_their_anti-proliferative_activity._Mutant_cell_lines_that_exhibited_a_greater_than_4-fold_increase_in_IC50_value_were_considered_resistant_to_drug,_2-4_fold_increase_in_IC50_were_moderately_resistant_and_less_than_2-fold_change_in_IC50_was_sensitive_to_drug_treatment._The_H396R_mutation_was__resistant_to_imatinib_.	15930265	PubMed	NA	O'Hare_et_al.,_2005,_Cancer_Res.		NA	accepted	2689	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2017-05-22_02:15:19_UTC	https://civic.genome.wustl.edu/links/evidence_items/2689	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_H396R_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6988	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:29:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/6988	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	B	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_33_patients_with_H396R_mutations,_13,_17,_and_30_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		3	accepted	4413	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:34:21_UTC	https://civic.genome.wustl.edu/links/evidence_items/4413	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_H396R_evaluated,_1/1_had_a_complete_hematologic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		1	accepted	4411	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_22:03:33_UTC	https://civic.genome.wustl.edu/links/evidence_items/4411	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_H396R,_0/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4410	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:39:39_UTC	https://civic.genome.wustl.edu/links/evidence_items/4410	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1030	ABL1	25	BCR-ABL_H396R	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_H396R_mutation_was_associated_with_resistance_in_2_μM_imatinib_(1_clone_recovered,_~0.71%)_and_4_μM_imatinib_(1_clone,_~0.74%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	6258	4	9	133750356	133750356	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-02_02:41:03_UTC	https://civic.genome.wustl.edu/links/evidence_items/6258	https://civic.genome.wustl.edu/links/variants/1030	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	26.5
1066	TP53	7157	M237I	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_M237I_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4885	45		NA	NA					NA	NA		NA	GRCh37			2018-04-30_23:29:19_UTC	https://civic.genome.wustl.edu/links/evidence_items/4885	https://civic.genome.wustl.edu/links/variants/1066	https://civic.genome.wustl.edu/links/genes/45					4
1068	TP53	7157	Y234C	Ovarian_Cancer	2394		Cisplatin,Carboplatin	Substitutes	Predictive	Supports	C	Resistance	Ovarian_cancer_patients_with_TP53_missense_mutations_were_refractory_to_platinum-based_chemotherapy_(66%_vs._34%_in_wildtype,_P=0.008)_and_had_a_shorter_time_to_disease_progression_(n=54,_P=0.037)._A_study_of_ovarian_carcinoma_patients_(n=178)_reported_a_reduced_overall_survival_(HR:1.59,_95%_CI:1.09-2.33,_P=0.014)_for_patients_with_mutations_in_TP53.	11595686	PubMed	NA	Reles_et_al.,_2001,_Clin._Cancer_Res.		NA	accepted	2745	45	17	7577580	7577580	T	C	ENST00000269305.4		NA	NA		75	GRCh37		Somatic_Mutation	2017-05-08_13:06:09_UTC	https://civic.genome.wustl.edu/links/evidence_items/2745	https://civic.genome.wustl.edu/links/variants/1068	https://civic.genome.wustl.edu/links/genes/45			missense_variant	NM_000546.5:c.701A>G,NP_000537.3:p.Tyr234Cys,NC_000017.10:g.7577580T>C,ENST00000269305.4:c.701A>G	0
1092	TP53	7157	V157F	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_V157F_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4887	45	17	7578461	7578461	C	A	ENST00000269305.4		NA	NA		75	GRCh37		Somatic_Mutation	2018-04-30_23:56:09_UTC	https://civic.genome.wustl.edu/links/evidence_items/4887	https://civic.genome.wustl.edu/links/variants/1092	https://civic.genome.wustl.edu/links/genes/45			missense_variant	NM_000546.5:c.469G>T,NP_000537.3:p.Val157Phe,NC_000017.10:g.7578461C>A,ENST00000269305.4:c.469G>T	4
1106	BRAF	673	G464V	Cancer	162		Vemurafenib		Predictive	Does_Not_Support	C	Sensitivity/Response	The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.,_2018,_J._Clin._Oncol.	NCT02091141	2	accepted	5964	5	7	140481417	140481417	C	A	ENST00000288602.6		NA	NA		75	GRCh37		Somatic_Mutation	2018-02-16_11:13:00_UTC	https://civic.genome.wustl.edu/links/evidence_items/5964	https://civic.genome.wustl.edu/links/variants/1106	https://civic.genome.wustl.edu/links/genes/5			missense_variant	NM_004333.4:c.1391G>T,NP_004324.2:p.Gly464Val,NC_000007.13:g.140481417C>A,ENST00000288602.6:c.1391G>T	5
1108	TP53	7157	R282L	Stomach_Carcinoma	5517		EAP_Protocol		Predictive	Supports	C	Sensitivity/Response	In_a_study_of_25_patients_with_advanced_gastric_cancer,_mutations_in_TP53_were_identified_in_32%_of_primary_tumors._TP53_mutations_were_associated_with_an_improved_response_to_preoperative_treatment_of_a_modified_EAP_protocol_(combination_of_doxorubicin,_etoposide_and_cisplatin)._Patients_with_mutations_in_TP53_had_an_increased_median_survival_compared_to_patients_with_wildtype_TP53_(18.5mo_vs._10.2mo,_P=0.044).	14514923	PubMed	NA	Bataille_et_al.,_2003,_MP,_Mol._Pathol.		NA	accepted	2818	45	17	7577093	7577093	C	A	ENST00000269305.4		NA	NA		75	GRCh37		Somatic_Mutation	2017-05-15_07:28:14_UTC	https://civic.genome.wustl.edu/links/evidence_items/2818	https://civic.genome.wustl.edu/links/variants/1108	https://civic.genome.wustl.edu/links/genes/45			missense_variant	NM_000546.5:c.845G>T,NP_000537.3:p.Arg282Leu,NC_000017.10:g.7577093C>A,ENST00000269305.4:c.845G>T	0
1109	TP53	7157	R213P	Stomach_Carcinoma	5517		EAP_Protocol		Predictive	Supports	C	Sensitivity/Response	In_a_study_of_25_patients_with_advanced_gastric_cancer,_mutations_in_TP53_were_identified_in_32%_of_primary_tumors._TP53_mutations_were_associated_with_an_improved_response_to_preoperative_treatment_of_a_modified_EAP_protocol_(combination_of_doxorubicin,_etoposide_and_cisplatin)._Patients_with_mutations_in_TP53_had_an_increased_median_survival_compared_to_patients_with_wildtype_TP53_(18.5mo_vs._10.2mo,_P=0.044).	14514923	PubMed	NA	Bataille_et_al.,_2003,_MP,_Mol._Pathol.		NA	accepted	2819	45	17	7578211	7578211	C	G	ENST00000269305.4		NA	NA		75	GRCh37		Somatic_Mutation	2017-05-15_07:16:14_UTC	https://civic.genome.wustl.edu/links/evidence_items/2819	https://civic.genome.wustl.edu/links/variants/1109	https://civic.genome.wustl.edu/links/genes/45			missense_variant	NM_000546.5:c.638G>C,NP_000537.3:p.Arg213Pro,NC_000017.10:g.7578211C>G,ENST00000269305.4:c.638G>C	0
1152	ABL1	25	BCR-ABL_F486S	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_F486S_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6987	4	9	133755488	133755488	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:28:06_UTC	https://civic.genome.wustl.edu/links/evidence_items/6987	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4			transcript_fusion,missense_variant	ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser	23
1152	ABL1	25	BCR-ABL_F486S	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_F486S,_0/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4440	4	9	133755488	133755488	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:25:05_UTC	https://civic.genome.wustl.edu/links/evidence_items/4440	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4			transcript_fusion,missense_variant	ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser	23
1152	ABL1	25	BCR-ABL_F486S	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	B	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_13_patients_with_F486S_mutations,_5,_6,_and_12_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		3	accepted	4571	4	9	133755488	133755488	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_22:07:42_UTC	https://civic.genome.wustl.edu/links/evidence_items/4571	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4			transcript_fusion,missense_variant	ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser	23
1152	ABL1	25	BCR-ABL_F486S	Chronic_Myeloid_Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	In_an_in_vitro_study,_a_Ba/F3_cell_line_stably_expressing_the_F486S_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_sensitivity_to_nilotinib_treatment_(IC50:_1.85-fold),_comparable_to_Ba/F3_cells_expressing_BCR-ABL_fusion_protein._Sensitivity_was_determined_by_assessing_cell_proliferation.	19075254	PubMed	NA	Redaelli_et_al.,_2009,_J._Clin._Oncol.		3	accepted	2829	4	9	133755488	133755488	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-25_16:38:59_UTC	https://civic.genome.wustl.edu/links/evidence_items/2829	https://civic.genome.wustl.edu/links/variants/1152	https://civic.genome.wustl.edu/links/genes/4			transcript_fusion,missense_variant	ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser	23
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_E255V_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4443	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:43:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/4443	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_E255V_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6986	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:25:31_UTC	https://civic.genome.wustl.edu/links/evidence_items/6986	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced_Sensitivity	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_E255V,_1/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4444	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:38:50_UTC	https://civic.genome.wustl.edu/links/evidence_items/4444	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate,Nilotinib	Substitutes	Predictive	Supports	D	Resistance	In_an_in_vitro_study,_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib_to_identify_resistance_mutations._The_E255V_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_identified_and_associated_with_resistance_to_imatinib_(1_clone,_0.43%_of_viable_clones_in_this_treatment,_recovered_in_4_μM_but_none_at_2,_8,_or_16_μM)_and_nilotinib_(1_clone,_1.25%,_recovered_at_500nM_but_none_at_50,_2000_or_5000nM)._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	2851	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-10-08_22:10:49_UTC	https://civic.genome.wustl.edu/links/evidence_items/2851	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_a_Ba/F3__cell_line_stably_expressing_the_E255V_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_nilotinib_treatment_(IC50:_10.31-fold),_as_compared_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein._Sensitivity_was_determined_by_assessing_cell_proliferation.	19075254	PubMed	NA	Redaelli_et_al.,_2009,_J._Clin._Oncol.		3	accepted	2850	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-25_16:35:50_UTC	https://civic.genome.wustl.edu/links/evidence_items/2850	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate,Nilotinib	Substitutes	Predictive	Supports	C	Resistance	In_this_open-label,_phase_II_registration_trial,_patients_that_were_imatinib_resistant_or_intolerant_underwent_nilotinib_monotherapy._Within_12_months_of_nilotinib_therapy,_there_was_no_significant_difference_in_response_to_nilotinib_treatment_between_patients_with_mutations_in_the_Abl1_kinase_domain_versus_without._However,_the_authors_identify_Y253H,_E255K/V,_and_F359C/V_variants_as_resistant_as_they_had_an_IC50_greater_than_150_nM._In_patients_with_E255K_and/or_E255V_mutations_prior_to_nilotinib_treatment,_complete_hematological_responses_were_achieved_in_5_of_7_patients,_major_cytogenetic_responses_in_3_of_7_patients,_complete_cytogenetic_responses_in_0_of_7_patients,_and_a_major_molecular_response_in_1_of_7_patients._After_a_median_follow-up_of_15.5_months,_6_of_7_patients_with_this_mutation_progressed_or_died._The_E255K_mutation_was_present_in_6_patients_at_baseline_and_newly_emerged_in_4_patients_at_progression._The_E255V_mutation_was_present_in_0_patients_at_baseline_and_newly_emerged_in_3_patients_at_progression.	19652056	PubMed	NA	Hughes_et_al.,_2009,_J._Clin._Oncol.		3	accepted	6971	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-11-05_22:45:12_UTC	https://civic.genome.wustl.edu/links/evidence_items/6971	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1173	ABL1	25	BCR-ABL_E255V	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	B	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_11_patients_with_E255V_mutations,_4,_4,_and_9_achieved_a_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		3	accepted	4447	4	9	133738364	133738364	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:36:12_UTC	https://civic.genome.wustl.edu/links/evidence_items/4447	https://civic.genome.wustl.edu/links/variants/1173	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	37.5
1181	EGFR	1956	R776C	Non-small_Cell_Lung_Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_R776C_demonstrated_increased_sensitivity_to_erlotinib_treatment_comparable_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_respectively.	19147750	PubMed	NA	Kancha_et_al.",_2009,"_Clin._Cancer_Res.		NA	accepted	4468	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2017-09-16_10:56:35_UTC	https://civic.genome.wustl.edu/links/evidence_items/4468	https://civic.genome.wustl.edu/links/variants/1181	https://civic.genome.wustl.edu/links/genes/19					0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib._The_E292V_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_identified_and_associated_with_resistance_to_nilotinib_treatment_(1_clone_recovered_at_50nM)._In_a_review_of_20_publications,"_this_mutation_was_not_previously_described_in_imatinib_resistant_patients.	16772610	PubMed	NA	Bradeen_et_al.",_2006,"_Blood		2	accepted	2853	4	9	133747568	133747568	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-10-08_22:12:58_UTC	https://civic.genome.wustl.edu/links/evidence_items/2853	https://civic.genome.wustl.edu/links/variants/1183	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.875A>T",NC_000009.11:g.133747568A>T,NM_005157.5:c.875A>T,"NP_005148.2:p.Glu292Val	2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Nilotinib	Substitutes	Predictive	Supports	C	Resistance	In_this_open-label",_phase_II_registration_trial,_patients_that_were_imatinib_resistant_or_intolerant_underwent_nilotinib_monotherapy._Within_12_months_of_nilotinib_therapy,_there_was_no_significant_difference_in_response_to_nilotinib_treatment_between_patients_with_mutations_in_the_Abl1_kinase_domain_versus_without._However,_the_authors_identify_Y253H,_E255K/V,_and_F359C/V_variants_as_resistant_as_they_had_an_IC50_of_>150nM._In_patients_with_F359C_and/or_F359V_mutations_prior_to_nilotinib_treatment,_complete_hematological_responses_were_achieved_in_3_of_10_patients,_a_major_cytogenetic_response_in_1_of_11_patients,_a_complete_cytogenetic_response_in_0_of_11_patients,_and_major_molecular_response_in_0_of_10_patients._After_a_median_follow-up_of_15.5_months,"_9_of_11_patients_with_this_mutation_progressed_or_died._The_F359C_mutation_was_present_in_1_patient_at_baseline_and_newly_emerged_in_1_patient_at_progression._The_F359V_mutation_was_present_in_4_patients_at_baseline_and_newly_emerged_in_1_patient_at_progression.	19652056	PubMed	NA	Hughes_et_al.",_2009,"_J._Clin._Oncol.		3	accepted	6233	4	9	133748415	133748415	T	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-11-05_22:44:39_UTC	https://civic.genome.wustl.edu/links/evidence_items/6233	https://civic.genome.wustl.edu/links/variants/1184	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1076T>G",NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,"ENST00000318560.5:c.1076T>G	31.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_F359C,"_2/2_had_MaHRs_and_2/2_had_MCyRs_which_were_comparable_to_response_rates_among_wild_type_patients.""",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,2,accepted,4481,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_09:55:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/4481,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Dasatinib,,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C,,,,,,,,,,,
ABL1,25,BCR-ABL_F359C,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_2_had_F359C_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7035,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:18:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/7035,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Imatinib_Mesylate,,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C
ABL1,25,BCR-ABL_F359C,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_F359C_was_seen_in_two_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,6985,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_20:24:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/6985,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Imatinib_Mesylate,,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C
ABL1,25,BCR-ABL_F359C,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._61_clones_grew_in_a_combination_of_400_nM_imatinib_and_50_nM_nilotinib._Of_these,_19_were_sequenced_and_7_(~37%)_were_found_to_have_F359C_mutations.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6239,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_02:23:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/6239,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C
ABL1,25,BCR-ABL_F359C,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,C,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_5_patients_with_F359C_mutations,_3,_3,_and_4_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,4482,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:37:49_UTC,https://civic.genome.wustl.edu/links/evidence_items/4482,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Dasatinib,,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C
ABL1,25,BCR-ABL_F359C,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_F359C,_2/2_had_a_CHR_and_1/2_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,4480,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:36:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/4480,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Bosutinib,,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C
ABL1,25,BCR-ABL_F359C,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Substitutes,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib_to_identify_resistance_mutations._The_F359C_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_to_50nM_nilotinib_(6_clones_recovered,_~13%_of_viable_clones_in_this_treatment)_and_2_μM_imatinib_(6_clones,_~4%)._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,2854,4,9,133748415,133748415,T,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-10-08_22:18:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/2854,https://civic.genome.wustl.edu/links/variants/1184,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G",31.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133748415T~G,ABL1_c.1076T~G,ABL1_F359C
BRAF,673,N581S,Cancer,162,,Vemurafenib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,_and_MACF1-_and_WASFL-BRAF_fusion.",29320312,PubMed,,"Hainsworth_et_al.,_2018,_J._Clin._Oncol.",NCT02091141,2,accepted,5967,5,7,140453193,140453193,T,C,,,,,,,GRCh37,,Somatic_Mutation,2018-02-16_11:21:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/5967,https://civic.genome.wustl.edu/links/variants/1186,https://civic.genome.wustl.edu/links/genes/5,,,missense_variant,,5,Vemurafenib,,,,,,,
EGFR,1956,A864T,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_A864T_demonstrated_increased_sensitivity_to_erlotinib_treatment_comparable_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_A864T_and_EGFR_L858R_expressing_cells_were_49_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4495,19,7,55259532,55259532,G,A,ENST00000275493.2,,,,,75,GRCh37,,Somatic_Mutation,2017-09-15_00:32:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/4495,https://civic.genome.wustl.edu/links/variants/1187,https://civic.genome.wustl.edu/links/genes/19,,,missense_variant,ENST00000275493.2:c.2590G>A,0,Erlotinib,,,,,,EGFR_c.2590G~A,
EGFR,1956,N826S,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_N826S_demonstrated_reduced_sensitivity_to_erlotinib_treatment,_compared_to_Ba/F3_cells_expressing_a_known_sensitizing_mutation_(EGFR_L858R)._Sensitivity_was_determined_by_assessing_cell_proliferation,_the_IC50_of_erlotinib_for_EGFR_N826S_and_EGFR_L858R_expressing_cells_were_505_nmol/L_and_6_nmol/L,_respectively.",19147750,PubMed,,"Kancha_et_al.,_2009,_Clin._Cancer_Res.",,,accepted,4496,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-09-14_22:50:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/4496,https://civic.genome.wustl.edu/links/variants/1188,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
AKT3,10000,E17K,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_AKT3_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_virally_induced_to_stably_over-express_AKT3_E17K_were_significantly_more_resistant_to_BRAF_inhibition_via_vemurafenib_than_cells_transduced_with_empty_vectors_(40%_vs_20%_survival,_p_=_.0033).",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,3,accepted,4521,7936,1,243859016,243859016,C,T,ENST00000366539.1,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_20:06:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/4521,https://civic.genome.wustl.edu/links/variants/1227,https://civic.genome.wustl.edu/links/genes/7936,,,missense_variant,"NM_001206729.1:c.49G>A,NP_001193658.1:p.Glu17Lys,NC_000001.10:g.243859016C>T,ENST00000366539.1:c.49G>A",3,Vemurafenib,,,,,chr1_g.243859016C~T,AKT3_c.49G~A,AKT3_E17K
ABL1,25,L384M,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_a_majority_of_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response,_major_cytogenetic_response,_complete_cytogenetic_response_(CCyR),_and_major_molecular_response._However,_out_of_2_patients_with_the_L384M_mutation,_0_achieved_CCyR_with_dasatinib_monotherapy._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,1,accepted,4527,4,9,133750319,133750319,C,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:59:30_UTC,https://civic.genome.wustl.edu/links/evidence_items/4527,https://civic.genome.wustl.edu/links/variants/1230,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met",3.5,Dasatinib,,,,,chr9_g.133750319C~A,ABL1_c.1150C~A,ABL1_L384M
ABL1,25,L384M,Chronic_Myeloid_Leukemia,8552,,"Nilotinib,Imatinib_Mesylate",Substitutes,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib_to_identify_resistance_mutations._The_L384M_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_resistance_in_50nM_nilotinib_(1_clone_recovered,_~2%_of_viable_clones_in_this_treatment)_and_2_μM_imatinib_(1_clone,_~0.7%)._L384M_was_one_of_3_novel_mutations_that_were_not_identified_in_imatinib_resistant_patients_from_a_review_of_20_publications.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,1,accepted,2861,4,9,133750319,133750319,C,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-10-08_22:00:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2861,https://civic.genome.wustl.edu/links/variants/1230,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met",3.5,Nilotinib,Imatinib_Mesylate,,,,chr9_g.133750319C~A,ABL1_c.1150C~A,ABL1_L384M
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_were_generated_in_Ba/F3_cell_lines_from_five_independently_derived,_mutagenized_libraries._Dasatinib_resistant_subclones_were_identified_using_﻿50_nM_dasatinib_in_liquid_culture._201_individual_clones_were_identified_representing_10_different_mutations_at_6_different_residues._1_of_these_clones_had_an_V299L_mutation._To_validate_resistance_to_dasatinib,_a_Ba/F3_cell_line_stably_expressing_the_V299L_mutation_in_the_ABL1_region_of_the_BCR-ABL_fusion_was_generated_and_associated_with_higher_dasatinib_IC50_of_18_nM_vs_1.34_nM_in_wildtype_as_determined_by_dose_response_curves.",15705718,PubMed,,"Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.",,3,accepted,6216,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-20_01:01:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/6216,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Dasatinib,,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Reduced_Sensitivity,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_V299L,_1/2_had_a_CHR_and_0/2_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,4538,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:33:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/4538,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Bosutinib,,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_stably_expressing_the_V299L_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_sensitivity_to_nilotinib_treatment_(IC50:_1.34-fold),_comparable_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,2862,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:36:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/2862,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Nilotinib,,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,B,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_V299L_was_seen_in_two_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,6982,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_20:20:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/6982,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Imatinib_Mesylate,,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,C,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response,_major_cytogenetic_response,_complete_cytogenetic_response_(CCyR),_and_major_molecular_response._There_was_1_patient_with_a_V299L_mutation_who_did_not_achieved_CCyR_with_dasatinib_monotherapy._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations._Of_the_63_variants_considered,_the_authors_associate_T315I,_F317L,_and_V299L_with_resistance_to_dasatinib_or_lower_levels_of_response_due_to_clinical_resistance_and_low_in_vitro_sensitivity._They_suggest_considering_alternative_treatment_options_for_patients_with_these_variants.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,1,accepted,4540,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_21:45:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/4540,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Dasatinib,,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_V299L_mutation_was_associated_with_resistance_in_10_nM_dasatinib_(3_clone_recovered,_~5%)._No_clones_were_recovered_in_5_nM_dasatinib._In_a_review_of_20_publications,_this_mutation_was_described_in_imatinib_resistant_patients.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6247,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-06-27_21:21:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/6247,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Dasatinib,,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,BCR-ABL_V299L,Chronic_Myeloid_Leukemia,8552,,"Imatinib_Mesylate,Dasatinib",Combination,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._Of_the_11_clones_that_grew_in_a_combination_of_400_nM_imatinib_and_10_nM_dasatinib,_1_(9%)_was_found_to_have_a_V299L_mutation.",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,6241,4,9,133747588,133747588,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-02_02:27:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/6241,https://civic.genome.wustl.edu/links/variants/1231,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",20,Imatinib_Mesylate,Dasatinib,,,,chr9_g.133747588G~C,ABL1_c.895G~C,ABL1_V299L
ABL1,25,L387F,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_L387F_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,6981,4,9,133750330,133750330,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-14_19:20:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/6981,https://civic.genome.wustl.edu/links/variants/1232,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe",7,Imatinib_Mesylate,,,,,chr9_g.133750330G~C,ABL1_c.1161G~C,ABL1_L387F
ABL1,25,L387F,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Supports,C,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_L387F,_1/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,1,accepted,4552,4,9,133750330,133750330,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-12-21_19:30:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/4552,https://civic.genome.wustl.edu/links/variants/1232,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe",7,Bosutinib,,,,,chr9_g.133750330G~C,ABL1_c.1161G~C,ABL1_L387F
ABL1,25,L387F,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3-p210BCR-ABL1_cell_line_was_ENU-mutated_and_exposed_to_graded_concentrations_of_imatinib,_nilotinib_or_dasatinib._The_L387F_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_identified_and_associated_with_resistance_to_nilotinib_treatment_(1_clone_recovered_at_50nM).",16772610,PubMed,,"Bradeen_et_al.,_2006,_Blood",,2,accepted,2863,4,9,133750330,133750330,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-10-08_22:01:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/2863,https://civic.genome.wustl.edu/links/variants/1232,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe",7,Nilotinib,,,,,chr9_g.133750330G~C,ABL1_c.1161G~C,ABL1_L387F
ABL1,25,BCR-ABL_G398R,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3__cell_line_stably_expressing_the_G398R_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_fusion_protein_was_associated_with_sensitivity_to_dasatinib_treatment_(IC50:_1.27nM_vs._IC50:_1.83nM),_comparable_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,2,accepted,4561,4,9,133750361,133750361,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_22:27:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/4561,https://civic.genome.wustl.edu/links/variants/1233,https://civic.genome.wustl.edu/links/genes/4,,,"transcript_fusion,missense_variant","ENST00000318560.5:c.1192G>C,NC_000009.11:g.133750361G>C,NM_005157.5:c.1192G>C,NP_005148.2:p.Gly398Arg",5,Dasatinib,,,,,chr9_g.133750361G~C,ABL1_c.1192G~C,ABL1_G398R
ABL1,25,BCR-ABL_G398R,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_Ba/F3_cell_line_stably_expressing_the_G398R_mutation_in_the_ABL1_portion_of_the_BCR-ABL1_gene_fusion_was_associated_with_sensitivity_to_nilotinib_treatment_(IC50:_0.49-fold),_comparable_to_Ba/F3_cells_expressing_BCR-ABL1_fusion_protein_(reported_to_be_sensitizing_to_nilotinib)._Sensitivity_was_determined_by_assessing_cell_proliferation.",19075254,PubMed,,"Redaelli_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,2864,4,9,133750361,133750361,G,C,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-25_16:36:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/2864,https://civic.genome.wustl.edu/links/variants/1233,https://civic.genome.wustl.edu/links/genes/4,,,"transcript_fusion,missense_variant","ENST00000318560.5:c.1192G>C,NC_000009.11:g.133750361G>C,NM_005157.5:c.1192G>C,NP_005148.2:p.Gly398Arg",5,Nilotinib,,,,,chr9_g.133750361G~C,ABL1_c.1192G~C,ABL1_G398R
BRCA1,672,M1V,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2868,6,17,41276113,41276113,T,C,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:32:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/2868,https://civic.genome.wustl.edu/links/variants/1236,https://civic.genome.wustl.edu/links/genes/6,,,start_lost,"NM_007294.3:c.1A>G,NP_009225.1:p.Met1Val,NC_000017.10:g.41276113T>C,ENST00000471181.2:c.1A>G",0,Rucaparib,,,,,chr17_g.41276113T~C,BRCA1_c.1A~G,BRCA1_M1V
BRCA1,672,M1I,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2869,6,17,41276111,41276111,C,A,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:33:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/2869,https://civic.genome.wustl.edu/links/variants/1237,https://civic.genome.wustl.edu/links/genes/6,,,start_lost,"NM_007294.3:c.3G>T,NP_009225.1:p.Met1Ile,NC_000017.10:g.41276111C>A,ENST00000471181.2:c.3G>T",0,Rucaparib,,,,,chr17_g.41276111C~A,BRCA1_c.3G~T,BRCA1_M1I
BRCA1,672,C61G,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2870,6,17,41258504,41258504,A,C,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:41:03_UTC,https://civic.genome.wustl.edu/links/evidence_items/2870,https://civic.genome.wustl.edu/links/variants/1238,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"NM_007294.3:c.181T>G,NP_009225.1:p.Cys61Gly,NC_000017.10:g.41258504A>C,ENST00000471181.2:c.181T>G",0,Rucaparib,,,,,chr17_g.41258504A~C,BRCA1_c.181T~G,BRCA1_C61G
BRCA1,672,C64Y,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2871,6,17,41258494,41258494,C,T,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:41:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/2871,https://civic.genome.wustl.edu/links/variants/1239,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"NM_007294.3:c.191G>A,NP_009225.1:p.Cys64Tyr,NC_000017.10:g.41258494C>T,ENST00000471181.2:c.191G>A",0,Rucaparib,,,,,chr17_g.41258494C~T,BRCA1_c.191G~A,BRCA1_C64Y
BRCA1,672,R71G,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2872,6,17,41258474,41258474,T,C,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:34:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/2872,https://civic.genome.wustl.edu/links/variants/1240,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"NM_007294.3:c.211A>G,NP_009225.1:p.Arg71Gly,NC_000017.10:g.41258474T>C,ENST00000471181.2:c.211A>G",0,Rucaparib,,,,,chr17_g.41258474T~C,BRCA1_c.211A~G,BRCA1_R71G
BRCA1,672,R71K,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2873,6,17,41258473,41258473,C,T,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:35:31_UTC,https://civic.genome.wustl.edu/links/evidence_items/2873,https://civic.genome.wustl.edu/links/variants/1241,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"NM_007294.3:c.212G>A,NP_009225.1:p.Arg71Lys,NC_000017.10:g.41258473C>T,ENST00000471181.2:c.212G>A",0,Rucaparib,,,,,chr17_g.41258473C~T,BRCA1_c.212G~A,BRCA1_R71K
BRCA1,672,R1495M,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2874,6,17,41228505,41228505,C,A,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:35:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2874,https://civic.genome.wustl.edu/links/variants/1242,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"ENST00000357654.3:c.4484G>T,NM_007294.3:c.4484G>T,NP_009225.1:p.Arg1495Met,NC_000017.10:g.41228505C>A",0,Rucaparib,,,,,chr17_g.41228505C~A,BRCA1_c.4484G~T,BRCA1_R1495M
BRCA1,672,E1559K,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2875,6,17,41226348,41226348,C,T,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:33:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/2875,https://civic.genome.wustl.edu/links/variants/1243,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"NM_007294.3:c.4675G>A,NP_009225.1:p.Glu1559Lys,NC_000017.10:g.41226348C>T,ENST00000357654.3:c.4675G>A",0,Rucaparib,,,,,chr17_g.41226348C~T,BRCA1_c.4675G~A,BRCA1_E1559K
BRCA1,672,D1692N,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2876,6,17,41219625,41219625,C,T,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:33:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/2876,https://civic.genome.wustl.edu/links/variants/1244,https://civic.genome.wustl.edu/links/genes/6,,,missense_variant,"NM_007294.3:c.5074G>A,NP_009225.1:p.Asp1692Asn,NC_000017.10:g.41219625C>T,ENST00000357654.3:c.5074G>A",0,Rucaparib,,,,,chr17_g.41219625C~T,BRCA1_c.5074G~A,BRCA1_D1692N
BRCA1,672,R1443*,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2877,6,17,41234451,41234451,G,A,ENST00000471181.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:35:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/2877,https://civic.genome.wustl.edu/links/variants/1245,https://civic.genome.wustl.edu/links/genes/6,,,stop_gained,"NM_007294.3:c.4327C>T,NP_009225.1:p.Arg1443Ter,NC_000017.10:g.41234451G>A,ENST00000471181.2:c.4327C>T",0,Rucaparib,,,,,chr17_g.41234451G~A,BRCA1_c.4327C~T,p.arg1443ter
BRCA1,672,Q1467*,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2878,6,17,41228590,41228590,G,A,ENST00000357654.3,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:39:37_UTC,https://civic.genome.wustl.edu/links/evidence_items/2878,https://civic.genome.wustl.edu/links/variants/1246,https://civic.genome.wustl.edu/links/genes/6,,,stop_gained,"NM_007294.3:c.4399C>T,NP_009225.1:p.Gln1467Ter,NC_000017.10:g.41228590G>A,ENST00000357654.3:c.4399C>T",0,Rucaparib,,,,,chr17_g.41228590G~A,BRCA1_c.4399C~T,p.gln1467ter
BRCA2,675,M1R,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2879,7,13,32890599,32890599,T,G,ENST00000544455.1,,,,,,GRCh37,,Somatic_Mutation,2018-07-06_14:57:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/2879,https://civic.genome.wustl.edu/links/variants/1247,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,"NM_000059.3:c.2T>G,NC_000013.10:g.32890599T>G,NP_000050.2:p.Met1Arg,ENST00000544455.1:c.2T>G",0,Rucaparib,,,,,chr13_g.32890599T~G,BRCA2_c.2T~G,BRCA2_M1R
BRCA2,675,M1I,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2880,7,13,32890600,32890600,G,T,ENST00000544455.1,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:58:59_UTC,https://civic.genome.wustl.edu/links/evidence_items/2880,https://civic.genome.wustl.edu/links/variants/1248,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,"NC_000013.10:g.32890600G>T,NM_000059.3:c.3G>T,NP_000050.2:p.Met1Ile,ENST00000544455.1:c.3G>T",0,Rucaparib,,,,,chr13_g.32890600G~T,BRCA2_c.3G~T,BRCA2_M1I
BRCA2,675,V159M,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2881,7,13,32900287,32900287,G,A,ENST00000544455.1,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_15:00:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/2881,https://civic.genome.wustl.edu/links/variants/1249,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,"ENST00000544455.1:c.475G>A,NM_000059.3:c.475G>A,NP_000050.2:p.Val159Met,NC_000013.10:g.32900287G>A",0,Rucaparib,,,,,chr13_g.32900287G~A,BRCA2_c.475G~A,BRCA2_V159M
BRCA2,675,V211L,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2882,7,13,32900751,32900751,G,C,,,,,,,GRCh37,,Somatic_Mutation,2018-07-06_15:01:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/2882,https://civic.genome.wustl.edu/links/variants/1250,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,NC_000013.10:g.32900751G>C,0,Rucaparib,,,,,chr13_g.32900751G~C,,
BRCA2,675,V211I,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2883,7,13,32900751,32900751,G,A,,,,,,,GRCh37,,Somatic_Mutation,2018-07-06_15:01:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2883,https://civic.genome.wustl.edu/links/variants/1251,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,NC_000013.10:g.32900751G>A,0,Rucaparib,,,,,chr13_g.32900751G~A,,
BRCA2,675,R2336P,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2884,7,13,32921033,32921033,G,C,ENST00000544455.1,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_15:03:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/2884,https://civic.genome.wustl.edu/links/variants/1252,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,"NM_000059.3:c.7007G>C,NP_000050.2:p.Arg2336Pro,NC_000013.10:g.32921033G>C,ENST00000544455.1:c.7007G>C",0,Rucaparib,,,,,chr13_g.32921033G~C,BRCA2_c.7007G~C,BRCA2_R2336P
BRCA2,675,R2336H,Ovarian_Cancer,2394,,Rucaparib,,Predictive,Supports,C,Sensitivity/Response,"In_a_phase_2_study_of_206_recurrent,_platinum-sensitive,_high-grade_ovarian_cancer_patients,_patients_with_germline_or_somatic_BRCA1_or_BRCA2_mutation_(n=40)_were_associated_with_improved_progression_free_survival_(HR_0.27,_95%_CI:_0.16-0.44,_p<0.0001)__as_compared_to_BRCA1/2_wild-type,_loss_of_heterozygosity_low_patients_(n=71)_treated_with_rucaparib_monotherapy;_further,_BRCA1/2_mutation_patients_achieved_a_longer_median_duration_of_response_(9.2_months,_95%_CI:_6.4-12.9,_p=0.013_vs._5.6_months,_95%_CI:_4.6-8.5).",27908594,PubMed,,"Swisher_et_al.,_2017,_Lancet_Oncol.",,,accepted,2885,7,13,32921033,32921033,G,A,ENST00000544455.1,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_15:00:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2885,https://civic.genome.wustl.edu/links/variants/1253,https://civic.genome.wustl.edu/links/genes/7,,,missense_variant,"NM_000059.3:c.7007G>A,NP_000050.2:p.Arg2336His,ENST00000544455.1:c.7007G>A,NC_000013.10:g.32921033G>A",0,Rucaparib,,,,,chr13_g.32921033G~A,BRCA2_c.7007G~A,BRCA2_R2336H
MGMT,4255,UNDEREXPRESSION,Neuroendocrine_Tumor,169,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"Among_those_patients_who_received_temozolomide-based_therapy_in_this_study,_the_median_progression-free_survival_for_patients_whose_tumors_showed_intact_MGMT_expression_was_9.3_months_compared_with_19.2_months_for_patients_with_MGMT-deficient_tumors_(P_=_0.11)._The_median_overall_survival_for_patients_whose_tumors_showed_intact_MGMT_expression_was_19.1_months;_the_median_overall_survival_for_patients_with_MGMT_deficient_tumors_was_not_reached.",19118063,PubMed,,"Kulke_et_al.,_2009,_Clin._Cancer_Res.",,2,accepted,2904,34,10,131265448,131566271,,,ENST00000306010.7,,,,,75,GRCh37,,,2017-04-03_19:23:39_UTC,https://civic.genome.wustl.edu/links/evidence_items/2904,https://civic.genome.wustl.edu/links/variants/1255,https://civic.genome.wustl.edu/links/genes/34,,,,,65,Temozolomide,,,,,,,
MGMT,4255,UNDEREXPRESSION,Malignant_Glioma,3070,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"This_study_showed_that_low_MGMT_mRNA_expression_was_strongly_predictive_for_prolonged_time_to_progression,_treatment_response,_and_length_of_survival_in_univariate_and_multivariate_models_(p<0.0001)._The_degree_of_MGMT_mRNA_expression_was_highly_correlated_with_the_MGMT_promoter_methylation_status_(p<0.0001);_however,_discordant_findings_were_seen_in_12_glioblastoma_patients._Patients_with_methylated_tumors_with_high_MGMT_mRNA_expression_(N_=_6)_did_significantly_worse_than_those_with_low_transcriptional_activity_(p<0.01)._Conversely,_unmethylated_tumors_with_low_MGMT_mRNA_expression_(N_=_6)_did_better_than_their_counterparts.",21365007,PubMed,,"Kreth_et_al.,_2011,_PLoS_ONE",,3,accepted,2901,34,10,131265448,131566271,,,ENST00000306010.7,,,,,75,GRCh37,,,2017-04-03_19:26:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/2901,https://civic.genome.wustl.edu/links/variants/1255,https://civic.genome.wustl.edu/links/genes/34,,,,,65,Temozolomide,,,,,,,
MGMT,4255,UNDEREXPRESSION,Oligodendroglioma,3181,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"In_this_study,_loss_of_chromosome_1p_and_low_MGMT_protein_expression_were_associated_with_objective_response_(P_<_.003_and_P_<_.04,_respectively)._However,_only_54%_of_the_study_group_had_evaluation_of_1p/19q_status,_and_MGMT_protein_expression_was_studied_in_only_33%._Therefore,_the_association_between_1p_deletion_and_low_MGMT_protein_expression_was_statistically_significant_when_evaluated_further_and_verified_in_the_extended_group_of_31_patients_with_low-grade_oligodendrogliomas.",16541434,PubMed,,"Levin_et_al.,_2006,_Cancer",,2,accepted,2902,34,10,131265448,131566271,,,ENST00000306010.7,,,,,75,GRCh37,,,2017-04-03_19:26:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/2902,https://civic.genome.wustl.edu/links/variants/1255,https://civic.genome.wustl.edu/links/genes/34,,,,,65,Temozolomide,,,,,,,
MGMT,4255,UNDEREXPRESSION,Glioblastoma_Multiforme,3068,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"In_this_study,_patients_with_low_MGMT_expression,_compared_with_patients_with_high_MGMT_expression,_had_a_significantly_higher_response_rate_(55%_v_7%,_respectively;_P_=_.004)_and_improved_PFS_(median,_5.5_v_1.9_months,_respectively;_P_=_.009)_and_OS_(median,_16_v_5_months,_respectively;_P_=_.003)._Among_patients_with_MGMT_data_available_for_analysis,_radiotherapy_was_started_and_completed_in_91%_of_patients_with_low_MGMT_expression._In_contrast,_among_patients_with_high_MGMT_expression,_only_64%_started_radiotherapy,_and_43%_completed_it._These_results_suggest_that_neoadjuvant_chemotherapy_may_be_feasible_for_inoperable_glioblastoma_patients_expressing_low_levels_of_MGMT_without_compromising_subsequent_treatment_with_radiotherapy,_whereas_patients_with_high_MGMT_expression_are_less_likely_to_respond_and_more_likely_to_experience_progression_before_or_during_radiotherapy.",17442989,PubMed,,"Chinot_et_al.,_2007,_J._Clin._Oncol.",,3,accepted,2899,34,10,131265448,131566271,,,ENST00000306010.7,,,,,75,GRCh37,,,2017-04-03_19:27:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/2899,https://civic.genome.wustl.edu/links/variants/1255,https://civic.genome.wustl.edu/links/genes/34,,,,,65,Temozolomide,,,,,,,
MGMT,4255,UNDEREXPRESSION,Glioblastoma_Multiforme,3068,,Temozolomide,,Predictive,Supports,B,Sensitivity/Response,"In_41_glioblastomas_treated_with_temozolomide_(TMZ)_therapy_(MGMT-immunopositive:_n_=_22,_negative:_n_=_19),_both_progression_free_survival_and_overall_survival_were_significantly_better_in_MGMT-immunonegative_glioblastomas._(PFS:_P_=_0.0015,_OS:_P_=_0.0384).",21331613,PubMed,,"Watanabe_et_al.,_2011,_Brain_Tumor_Pathol",,3,accepted,2903,34,10,131265448,131566271,,,ENST00000306010.7,,,,,75,GRCh37,,,2017-04-03_19:27:13_UTC,https://civic.genome.wustl.edu/links/evidence_items/2903,https://civic.genome.wustl.edu/links/variants/1255,https://civic.genome.wustl.edu/links/genes/34,,,,,65,Temozolomide,,,,,,,
RRM1,6240,UNDEREXPRESSION,Pancreatic_Cancer,1793,,Gemcitabine,,Predictive,Supports,B,Sensitivity/Response,"In_this_study,_human_pancreatic_carcinoma_cell_line_MiaPaCa2,_which_is_a_gemcitabine-sensitive_cell_line,_was_used_for_the_establishment_of_chemoresistant_cells_MiaPaCa2-RG._Analysis_for_identifying_genetic_alterations_relating_to_gemcitabine_resistance_revealed_that_RRM1_was_the_most_upregulated_gene_with_a_4.5_fold_expression._RRM1-speciﬁc_RNAi_transfection_significantly_reduced_the_gemcitabine_chemoresistance_of_MiaPaCa2-RG_to_the_same_level_as_that_of_gemcitabine_sensitive_MiaPaCa2._Moreover,_gemcitabine_response_of_MiaPaCa2_also_became_more_sensitive.__Next,_patients_with_pancreatic_cancer_were_recruited_and_18_tissue_samples_were_taken._The_patients_with_a_low_RRM1_expression_had_a_significantly_better_outcome_after_gemcitabine_treatment_than_those_patients_with_high_RRM1_expression_(P=0.016).",17131328,PubMed,,"Nakahira_et_al.,_2007,_Int._J._Cancer",,3,accepted,5508,5051,11,4116039,4160106,,,ENST00000300738.5,,,,,75,GRCh37,,,2017-09-09_23:01:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/5508,https://civic.genome.wustl.edu/links/variants/1257,https://civic.genome.wustl.edu/links/genes/5051,,,,,85,Gemcitabine,,,,,,,
RRM1,6240,UNDEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Paclitaxel,Vinorelbine,Gemcitabine",Substitutes,Predictive,Supports,B,Sensitivity/Response,"The_study_began_with_a_total_of_443_patients_that_were_randomly_assigned_to_either_regimen_A_(Paclitaxel_and_cisplatin_with_gemcitabine)_or_regimen_B_(_cisplatin_and_vinorelbine)._Of_those_patients,_261_had_tissue_available_for_RRM1_evaluation.__In_regimen_B,_survival_increased_significantly_in_patients_with_low_RRM1_expression_as_compared_to_those_with_a_high_expression_(P=0.046)._However,_in_regimen_A,_the_increase_in_survival_for_patients_with_low_RRM1_expression_as_opposed_to_those_with_a_high_RRM1_expression_was_not_as_significant_(P=0.366).",23038758,PubMed,,"Vilmar_et_al.,_2013,_Ann._Oncol.",,3,accepted,5599,5051,11,4116039,4160106,,,ENST00000300738.5,,,,,75,GRCh37,,Unknown,2017-09-09_23:01:45_UTC,https://civic.genome.wustl.edu/links/evidence_items/5599,https://civic.genome.wustl.edu/links/variants/1257,https://civic.genome.wustl.edu/links/genes/5051,,,,,85,Paclitaxel,Vinorelbine,Gemcitabine,,,,,
RRM1,6240,UNDEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Gemcitabine,Cisplatin",Combination,Predictive,Supports,B,Sensitivity/Response,"In_the_personalized_therapy_group_of_this_study,_patients_received_chemotherapy_based_on_RRM-1_IHC_expression_levels,_whereas_the_standard_therapy_group_received_non-customized_chemotherapy._There_were_statistically_significant_improvements_between_the_personalized_therapy_group_versus_the_standard_therapy_group_in_disease_control_rate_(82.9%_vs_55.3%,_P=0.004),_and_progression-free_survival_(median:_5.5_months_vs_3.0_months,_P=0.005)._Besides,_the_overall_survival_had_a_tendency_to_become_more_prolonged_(median:_16.0_months_vs_12.4_months,_P=0.286).",24595080,PubMed,,"Nie_et_al.,_2013,_Cancer_Biomark",,4,accepted,2905,5051,11,4116039,4160106,,,ENST00000300738.5,,,,,75,GRCh37,,,2017-04-03_19:22:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/2905,https://civic.genome.wustl.edu/links/variants/1257,https://civic.genome.wustl.edu/links/genes/5051,,,,,85,Gemcitabine,Cisplatin,,,,,,
RRM1,6240,UNDEREXPRESSION,Pancreatic_Cancer,1793,,Gemcitabine,,Predictive,Supports,B,Sensitivity/Response,"There_were_68_patients_enrolled_in_this_study,_28_of_which_were_treated_with_gemcitabine.__Of_those_28,_14_patients_had_a_low_RRM1_expression_and_14_had_a_high_RRM1_expression._Only_the_patients_with_low_RRM1_expression_received_a_significant_benefit_from_gemcitabine_(p=0.0010)_whereas_the_benefit_for_those_with_a_high_RRM1_expression_was_not_significantly_better_(p=0.3309).__The_study_also_tested_the_role_of_ERCC1_expression_and_its_correlation_to_RRM1_expression._It_was_found_that_patients_with_a_combined_high_RRM1_and_ERCC1_expression_had_good_prognosis_with_the_highest_survival_rate_(P=0.0127).",19543324,PubMed,,"Akita_et_al.,_2009,_Oncogene",,3,accepted,5506,5051,11,4116039,4160106,,,ENST00000300738.5,,,,,75,GRCh37,,,2017-07-28_18:30:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/5506,https://civic.genome.wustl.edu/links/variants/1257,https://civic.genome.wustl.edu/links/genes/5051,,,,,85,Gemcitabine,,,,,,,
RRM1,6240,UNDEREXPRESSION,Non-small_Cell_Lung_Carcinoma,3908,,"Gemcitabine,Docetaxel,Vinorelbine",Substitutes,Predictive,Supports,B,Sensitivity/Response,"In_this_study,_229_tumors_were_analyzed_for_RRM1_expression._This_resulted_in_146_that_were_negative_for_RRM1_expression_and_83_that_were_positive._These_tumors_were_studied_for_a_relationship_between_RRM1_expression_and_chemotherapy_regimens,_gemcitabine,_docetaxel_and_carboplatin,_and_vinorelbine_and_carboplatin._In_the_patients_receiving_gemcitabine_treatment,_the_progression-free_survival_of_RRM1-negative_patients_was_significantly_higher_than_that_of_RRM1-positive_patients_(8.8_months_vs._7.6_months,_P_=_0.01)._The_patients_that_were_positive_for_RRM1_expression,_had_a_better_response_to_docetaxel_or_vinorelbine_treatment_than_gemcitabine_(P=0.047_and_P=0.047)._However,_there_were_no_differences_of_response_to_docetaxel_and_vinorelbine_in_regards_to_RRM1_expression.",24647522,PubMed,,"Dong_et_al.,_2014,_PLoS_ONE",,4,accepted,5530,5051,11,4116039,4160106,,,ENST00000300738.5,,,,,75,GRCh37,,,2017-09-09_23:01:24_UTC,https://civic.genome.wustl.edu/links/evidence_items/5530,https://civic.genome.wustl.edu/links/variants/1257,https://civic.genome.wustl.edu/links/genes/5051,,,,,85,Gemcitabine,Docetaxel,Vinorelbine,,,,,
KIT,3815,N822K,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._N822K_was_observed_as_a_secondary_KIT_mutation_in_two_patients_with_secondary_imatinib_resistance_and_one_patient_with_primary_resistance,_and_also_as_a_primary_mutation_in_a_patient_with_primary_resistance._The_mutation_was_shown_to_occur_at_a_hotspot_(N822)_of_previously_reported_secondary_KIT_mutations_in_imatinib_resistant_GISTs._When_co-expressed_with_V560D_(imatinib_sensitive)_in_vitro_N822K_showed_moderate_imatinib_resistance.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2918,29,4,55599340,55599340,T,A,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:55:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/2918,https://civic.genome.wustl.edu/links/variants/1263,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A",7.5,Imatinib,,,,,chr4_g.55599340T~A,KIT_c.2466T~A,KIT_N822K
KIT,3815,C809G,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._C809G_was_observed_as_a_secondary_KIT_mutation_in_one_patient_with_secondary_imatinib_resistance._In_vitro,_C809G_showed_imatinib_resistance_both_in_isolation_and_when_coexpressed_with_K642E_+_N822H_(the_primary_KIT_mutations,_found_on_the_same_allele,_for_this_patient).",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2920,29,4,55599299,55599299,T,G,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:44:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/2920,https://civic.genome.wustl.edu/links/variants/1264,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"ENST00000288135.5:c.2425T>G,NC_000004.11:g.55599299T>G",7.5,Imatinib,,,,,chr4_g.55599299T~G,KIT_c.2425T~G,
KIT,3815,D820A,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._D820A_was_observed_as_a_secondary_KIT_mutation_in_one_patient_with_secondary_imatinib_resistance._The_mutation_was_shown_to_occur_at_a_hotspot_(D820)_of_previously_reported_secondary_KIT_mutations_in_imatinib_resistant_GISTs._A_cell_line_derived_from_a_separate_patient_with_the_same_primary_(V560D)_and_secondary_(D820A)_mutations_showed_moderately_increased_resistance_to_imatinib_compared_to_reports_for_GIST_lines_with_primary_exon_11_KIT_mutations_alone.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2921,29,4,55599333,55599333,A,C,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:39:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/2921,https://civic.genome.wustl.edu/links/variants/1265,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"ENST00000288135.5:c.2459A>C,NC_000004.11:g.55599333A>C",7.5,Imatinib,,,,,chr4_g.55599333A~C,KIT_c.2459A~C,
KIT,3815,D820G,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._D820G_was_observed_as_a_secondary_KIT_mutation_in_two_patients_with_secondary_imatinib_resistance._The_mutation_was_shown_to_occur_at_a_hotspot_(D820)_of_previously_reported_secondary_KIT_mutations_in_imatinib_resistant_GISTs._When_co-expressed_with_V560D_(imatinib_sensitive)_in_vitro_D820G_showed_""extreme""_imatinib_resistance.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2922,29,4,55599333,55599333,A,G,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:46:46_UTC,https://civic.genome.wustl.edu/links/evidence_items/2922,https://civic.genome.wustl.edu/links/variants/1266,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.2459A>G,NP_000213.1:p.Asp820Gly,NC_000004.11:g.55599333A>G,ENST00000288135.5:c.2459A>G",7.5,Imatinib,,,,,chr4_g.55599333A~G,KIT_c.2459A~G,KIT_D820G
KIT,3815,T670I,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Resistance,"147_patients_with_advanced,_unresectable_GISTs_were_enrolled_onto_a_randomized,_phase_II_clinical_study_of_imatinib_(CSTI571-B2222)._Specimens_from_43_pretreatment_and/or_imatinib-resistant_tumors_were_analyzed_to_identify_molecular_correlates_of_imatinib_resistance._T670I_was_observed_as_a_secondary_KIT_mutation_in_one_patient_with_secondary_imatinib_resistance._The_mutation_was_shown_to_occur_at_a_hotspot_(T670)_of_previously_reported_secondary_KIT_mutations_in_imatinib_resistant_GISTs._When_co-expressed_with_V560D_(imatinib_sensitive)_in_vitro_T670I_showed_""extreme""_imatinib_resistance._It_also_showed_resistance_in_isolation.",16954519,PubMed,,"Heinrich_et_al.,_2006,_J._Clin._Oncol.",,3,accepted,2924,29,4,55595519,55595519,C,T,ENST00000288135.5,,,,,75,GRCh37,,Somatic_Mutation,2017-07-27_15:34:52_UTC,https://civic.genome.wustl.edu/links/evidence_items/2924,https://civic.genome.wustl.edu/links/variants/1267,https://civic.genome.wustl.edu/links/genes/29,,,missense_variant,"NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T",7.5,Imatinib,,,,,chr4_g.55595519C~T,KIT_c.2009C~T,KIT_T670I
BRAF,673,AMPLIFICATION,Colorectal_Cancer,9256,,"Dabrafenib,Panitumumab",Combination,Predictive,Supports,C,Resistance,"Paired_pre-treatment_and_post-progression_tumor_biopsies_from_BRAF-mutant_CRC_patients_treated_with_RAF_inhibitor_combinations_were_analyzed._Alterations_in_MAPK_pathway_genes_were_found_in_resistant_tumors_not_present_in_matched_pre-treatment_tumors,_including_KRAS_amplification,_BRAF_amplification,_and_a_MEK1_mutation.",25673644,PubMed,,"Ahronian_et_al.,_2015,_Cancer_Discov",,3,accepted,2929,5,7,140434279,140624564,,,ENST00000288602.6,,,,,75,GRCh37,,Somatic_Mutation,2017-04-25_21:33:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/2929,https://civic.genome.wustl.edu/links/variants/1269,https://civic.genome.wustl.edu/links/genes/5,,,transcript_amplification,,7.5,Dabrafenib,Panitumumab,,,,,,
ROS1,6098,G2032R,Lung_Adenocarcinoma,3910,,Crizotinib,,Predictive,Supports,C,Resistance,"Resistance_to_crizotinib_developed_in_a_patient_with_metastatic_lung_adenocarcinoma_harboring_a_CD74-ROS1_rearrangement_who_had_initially_shown_a_dramatic_response_to_treatment._A_biopsy_of_a_resistant_tumor_showed_an_acquired_G2032R_mutation_in_the_ROS1_kinase_domain._Although_this_mutation_does_not_lie_at_the_gatekeeper_residue,_it_confers_resistance_to_ROS1_kinase_inhibition_through_steric_interference_with_drug_binding._The_same_resistance_mutation_was_observed_at_all_the_metastatic_sites_that_were_examined_at_autopsy,_suggesting_that_this_mutation_was_an_early_event_in_the_clonal_evolution_of_resistance.",23724914,PubMed,,"Awad_et_al.,_2013,_N._Engl._J._Med.",,1,accepted,2934,4941,6,117638347,117638347,C,T,ENST00000368508.3,,,,,75,GRCh37,,Somatic_Mutation,2017-05-18_20:12:20_UTC,https://civic.genome.wustl.edu/links/evidence_items/2934,https://civic.genome.wustl.edu/links/variants/1271,https://civic.genome.wustl.edu/links/genes/4941,,,missense_variant,"NC_000006.11:g.117638347C>T,NM_002944.2:c.6094G>A,NP_002935.2:p.Gly2032Arg,ENST00000368508.3:c.6094G>A",2.5,Crizotinib,,,,,chr6_g.117638347C~T,ROS1_c.6094G~A,ROS1_G2032R
MAP2K1,5604,K57N,Lung_Adenocarcinoma,3910,,Selumetinib_(AZD6244),,Predictive,Supports,D,Sensitivity/Response,"Mutational_profiling_of_a_large_cohort_of_lung_adenocarcinomas__identified_in_2_of_207_primary_lung_tumors_a_somatic_activating_mutation_in_exon_2_of_MEK1_(i.e.,_mitogen-activated_protein_kinase_kinase_1_or_MAP2K1)_that_substitutes_asparagine_for_lysine_at_amino_acid_57_(K57N)_in_the_nonkinase_portion_of_the_kinase._Neither_of_these_two_tumors_harbored_known_mutations_in_other_genes_encoding_components_of_the_EGFR_signaling_pathway_(i.e.,_EGFR,_HER2,_KRAS,_PIK3CA,_and_BRAF)._Expression_of_mutant,_but_not_wild-type,_MEK1_leads_to_constitutive_activity_of_extracellular_signal-regulated_kinase_(ERK)-1/2_in_human_293T_cells_and_to_growth_factor-independent_proliferation_of_murine_Ba/F3_cells._A_selective_MEK_inhibitor,_AZD6244,_inhibits_mutant-induced_ERK_activity_in_293T_cells_and_growth_of_mutant-bearing_Ba/F3_cells.",18632602,PubMed,,"Marks_et_al.,_2008,_Cancer_Res.",,2,accepted,2936,31,15,66727455,66727455,G,T,ENST00000307102.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-18_20:06:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/2936,https://civic.genome.wustl.edu/links/variants/1272,https://civic.genome.wustl.edu/links/genes/31,,,missense_variant,"NM_002755.3:c.171G>T,NP_002746.1:p.Lys57Asn,NC_000015.9:g.66727455G>T,ENST00000307102.5:c.171G>T,NG_008305.1:g.53245G>T",9.5,Selumetinib_(AZD6244),,,,,chr15_g.53245G~T,MAP2K1_c.171G~T,MAP2K1_K57N
NTRK3,4916,NTRK3_FUSIONS,Cancer,162,,Larotrectinib,,Predictive,Supports,B,Sensitivity/Response,This_was_a_Phase_1/2_study_of_55_patients_from_4_months_to_76_years_old_with_TRK-fusion_positive_tumors_given_NTRK_inhibitor_Larotrectinib._Patients_had_17_unique_NTRK_fusion_types._Patient_overall_response_rate_was_75%_according_to_independent_review_and_80%_according_to_investigator_assessment._Authors_state_that_Larotrectinib_had_durable_anti_tumor_activity_regardless_of_age_or_tumor_type._26/27_patients_with_NTRK3-fusion_showed_maximum_percent_change_in_tumor_size_between_-30%_and_-100%.,29466156,PubMed,,"Drilon_et_al.,_2018,_N._Engl._J._Med.","NCT02576431,NCT02122913,NCT02637687",4,accepted,6568,3985,,,,,,,,,,,,,,Somatic_Mutation,2018-08-21_18:43:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/6568,https://civic.genome.wustl.edu/links/variants/1277,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,35,Larotrectinib,,,,,,,
NTRK3,4916,NTRK3_FUSIONS,Cancer,162,,Entrectinib,,Predictive,Supports,B,Sensitivity/Response,"in_two_phase_I_studies_in_patients_with_advanced_or_metastatic_solid_tumors,_including_patients_with_active_central_nervous_system_(CNS)_disease._Here,_we_summarize_the_overall_safety_and_report_the_antitumor_activity_of_entrectinib_in_a_cohort_of_patients_with_tumors_harboring_NTRK1/2/3,_ROS1,_or_ALK_gene_fusions_Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._Notably,_a_complete_CNS_response_was_achieved_in_a_patient_with_SQSTM1-NTRK1-rearranged_lung_cancer.",28183697,PubMed,,"Drilon_et_al.,_2017,_Cancer_Discov",,3,accepted,2949,3985,,,,,,,,,,,,,,Somatic_Mutation,2017-04-14_16:36:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/2949,https://civic.genome.wustl.edu/links/variants/1277,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_fusion,,35,Entrectinib,,,,,,,
NTRK1,4914,LMNA-NTRK1,Sarcoma,1115,,Larotrectinib_(LOXO-101),,Predictive,Supports,C,Sensitivity/Response,"LOXO-101_is_an_orally_administered_inhibitor_of_the_TRK_kinase_and_is_highly_selective_only_for_the_TRK_family_of_receptors._The_tumor_of_a_41-year-old_woman_with_soft-tissue_sarcoma_metastatic_to_the_lung_was_found_to_harbor_an_LMNA-NTRK1_gene_fusion_encoding_a_functional_LMNA-TRKA_fusion_oncoprotein.__This_patient's_tumors_underwent_rapid_and_substantial_tumor_regression,_with_an_accompanying_improvement_in_pulmonary_dyspnea,_oxygen_saturation,_and_plasma_tumor_markers.",26216294,PubMed,,"Doebele_et_al.,_2015,_Cancer_Discov",,2,accepted,2955,3983,1,156084498,156108548,,,ENST00000368300.4,1,156844363,156851434,ENST00000524377.1,75,GRCh37,,Somatic_Mutation,2017-04-17_20:39:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/2955,https://civic.genome.wustl.edu/links/variants/1278,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,20,Larotrectinib_(LOXO-101),,,,,,,
NTRK1,4914,LMNA-NTRK1,Colorectal_Adenocarcinoma,50861,,Entrectinib,,Predictive,Supports,C,Sensitivity/Response,"A_gene_fusion_between_exon_10_of_NTRK1_and_exon_11_of_the_LMNA_genes_was_observed_in_a_patient_with_metastatic_colorectal_cancer_after_therapy_with_first-line_FOLFOX,_second-line_FOLFIRI/cetuximab,_and_third-line_irinotecan._The_patient_treated_in_a_clinical_trial_with_pan-TRK_kinase_inhibitor_entrectinib._Treatment_was_well_tolerated_and_led_to_a_partial_response_(PR)_with_30%_tumor_shrinkage_of_multiple_liver_metastases._Clinical_response_lasted_4_months.",26546295,PubMed,,"Russo_et_al.,_2016,_Cancer_Discov",,3,accepted,2960,3983,1,156084498,156108548,,,ENST00000368300.4,1,156844363,156851434,ENST00000524377.1,75,GRCh37,,,2017-08-31_17:21:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/2960,https://civic.genome.wustl.edu/links/variants/1278,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,20,Entrectinib,,,,,,,
NTRK1,4914,LMNA-NTRK1,Sarcoma,1115,,Larotrectinib,,Predictive,Supports,C,Sensitivity/Response,"One_Patient_with_soft_tissue_sarcoma_and_a_NTRK1-LMNA_fusion_had_a_partial_response_with_larotrectinib._Treatment_was_done_within_a_multicentre,_open-label,_phase_1/2_study_and_enrolled_infants,_children,_and_adolescents_aged_1_month_to_21_years_with_locally_advanced_or_metastatic_solid_tumours_or_CNS_tumours_that_had_relapsed,_progressed,_or_were_non-responsive_to_available_therapies_regardless_of_TRK_fusion_Status._In_total,_24_patients_(n=17_with_tumours_harbouring_TRK_fusions,_n=7_without_a_documented_TRK_fusion)_were_enrolled._Among_the_fusion-positive_patients,_eight_(47%)_had_infantile_fibrosarcoma,_seven_(41%)_had_other_soft_tissue_sarcomas,_and_two_(12%)_had_papillary_thyroid_cancer._14_(93%)_of_15_patients_with_TRK_fusion-positive_cancers_achieved_an_objective_response;_the_remaining_patient_had_tumour_regression_that_did_not_meet_the_criteria_for_objective_response._None_of_the_seven_patients_with_TRK_fusion-negative_cancers_had_an_objective_response.",29606586,PubMed,,"Laetsch_et_al.,_2018,_Lancet_Oncol.",NCT02637687,3,accepted,6100,3983,1,156084498,156108548,,,ENST00000368300.4,1,156844363,156851434,ENST00000524377.1,75,GRCh37,,,2018-08-21_18:29:07_UTC,https://civic.genome.wustl.edu/links/evidence_items/6100,https://civic.genome.wustl.edu/links/variants/1278,https://civic.genome.wustl.edu/links/genes/3983,,NTRK1_Fusions,transcript_fusion,,20,Larotrectinib,,,,,,,
NTRK1,4914,AMPLIFICATION,Cancer,162,,Entrectinib,,Predictive,Supports,B,Resistance,"Entrectinib,_a_potent_oral_inhibitor_of_the_tyrosine_kinases_TRKA/B/C,_ROS1,_and_ALK,_was_evaluated_in_two_phase_I_studies_in_patients_with_advanced_or_metastatic_solid_tumors,_including_CNS_disease._Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._No_objective_responses_(per_RECIST_v1.1;_ref._38)_were_observed_in_patients_whose_tumors_did_not_harbor_gene_fusions_involving_NTRK1/2/3,_ROS1,_or_ALK,_with_the_exception_of_1_patient_with_an_ALKF1245V_mutant_neuroblastoma.",28183697,PubMed,,"Drilon_et_al.,_2017,_Cancer_Discov",,4,accepted,2958,3983,1,156830686,156851434,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2018-04-11_12:42:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/2958,https://civic.genome.wustl.edu/links/variants/1280,https://civic.genome.wustl.edu/links/genes/3983,,,transcript_amplification,,20,Entrectinib,,,,,,,
NTRK3,4916,AMPLIFICATION,Cancer,162,,Entrectinib,,Predictive,Supports,B,Resistance,"Entrectinib,_a_potent_oral_inhibitor_of_the_tyrosine_kinases_TRKA/B/C,_ROS1,_and_ALK,_was_evaluated_in_two_phase_I_studies_in_patients_with_advanced_or_metastatic_solid_tumors,_including_CNS_disease._Responses_were_observed_in_non-small_cell_lung_cancer,_colorectal_cancer,_mammary_analogue_secretory_carcinoma,_melanoma,_and_renal_cell_carcinoma,_as_early_as_4_weeks_after_starting_treatment_and_lasting_as_long_as_>2_years._No_objective_responses_(per_RECIST_v1.1;_ref._38)_were_observed_in_patients_whose_tumors_did_not_harbor_gene_fusions_involving_NTRK1/2/3,_ROS1,_or_ALK,_with_the_exception_of_1_patient_with_an_ALKF1245V_mutant_neuroblastoma.",28183697,PubMed,,"Drilon_et_al.,_2017,_Cancer_Discov",,4,accepted,2959,3985,15,88418230,88799978,,,ENST00000394480.2,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_18:50:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/2959,https://civic.genome.wustl.edu/links/variants/1281,https://civic.genome.wustl.edu/links/genes/3985,,,transcript_amplification,,20,Entrectinib,,,,,,,
NTRK1,4914,LMNA-NTRK1_G595R_AND_G667C,Colorectal_Adenocarcinoma,50861,,Entrectinib,,Predictive,Supports,C,Resistance,"A_gene_fusion_between_exon_10_of_NTRK1_and_exon_11_of_the_LMNA_genes_was_observed_in_a_patient_with_metastatic_colorectal_cancer_after_therapy_with_first-line_FOLFOX,_second-line_FOLFIRI/cetuximab,_and_third-line_irinotecan._The_patient_treated_in_a_clinical_trial_with_pan-TRK_kinase_inhibitor_entrectinib._Treatment_was_well_tolerated_and_led_to_a_partial_response_(PR)_with_30%_tumor_shrinkage_of_multiple_liver_metastases._Clinical_response_lasted_4_months._Longitudinal_analysis_of_ctDNA_in_plasma_samples_revealed_a_p.G595R-_and_p.G667C_mutation_in_NTRK1_that_were_absent_before_treatment_initiation_but__emerged_4_weeks_upon_initiation_of_treatment_with_entrectinib._These_mutations_were_also_validated_using_xenograft,_in_vitro_and_3D-modeling.",26546295,PubMed,,"Russo_et_al.,_2016,_Cancer_Discov",,4,accepted,2961,3983,1,156846342,156849107,,,ENST00000524377.1,,,,,75,GRCh37,,Somatic_Mutation,2017-08-31_17:27:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/2961,https://civic.genome.wustl.edu/links/variants/1282,https://civic.genome.wustl.edu/links/genes/3983,,,missense_variant,,10,Entrectinib,,,,,,,
CTNNB1,1499,S45F,Desmoid_Fibromatosis,,,Meloxicam,,Predictive,Does_Not_Support,C,Sensitivity/Response,"Of_the_33_patients_with_desmoid_fibromatosis_treated_with_meloxicam,_a_COX-2_selective_inhibitor,_one_showed_complete_remission_(CR),_7_partial_remission_(PR),_12_stable_disease_(SD),_and_13_progressive_disease_(PD)._The_following_3_point_mutations_were_identified_in_21_of_the_33_cases_(64%):_T41A_(16_cases),_S45F_(4_cases)_and_S45P_(one_case)._All_four_cases_with_S45F_mutation_exhibited_strong_nuclear_expression_of_β-catenin._S45F_mutation_was_significantly_associated_with_a_poor_response_(all_cases;_PD)_(p_=_0.017)",24788118,PubMed,,"Hamada_et_al.,_2014,_PLoS_ONE",,2,accepted,6049,1290,3,41266137,41266137,C,T,ENST00000349496.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-10_18:28:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/6049,https://civic.genome.wustl.edu/links/variants/1286,https://civic.genome.wustl.edu/links/genes/1290,,,missense_variant,"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T",60,Meloxicam,,,,,chr3_g.41266137C~T,CTNNB1_c.134C~T,CTNNB1_S45F
ARID1A,8289,LOSS-OF-FUNCTION,Ovarian_Clear_Cell_Carcinoma,50934,,GSK126,,Predictive,Supports,D,Sensitivity/Response,"Inhibition_of_the_EZH2_methyltransferase_acts_in_a_synthetic_lethal_manner_in_ARID1A_mutated_ovarian_cancer_cells._ARID1A_mutational_status_correlates_with_response_to_the_EZH2_inhibitor._Significantly,_EZH2_inhibition_causes_regression_of_ARID1A_mutated_ovarian_tumors_in_vivo.",25686104,PubMed,,"Bitler_et_al.,_2015,_Nat._Med.",,4,accepted,2983,6559,,,,,,,,,,,,,,Somatic_Mutation,2018-07-06_20:29:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/2983,https://civic.genome.wustl.edu/links/variants/1293,https://civic.genome.wustl.edu/links/genes/6559,,,,,7,GSK126,,,,,,,
ARID1A,8289,LOSS-OF-FUNCTION,Ovarian_Clear_Cell_Carcinoma,50934,,Dasatinib,,Predictive,Supports,D,Sensitivity/Response,"High-throughput__drug_screens_in_OCCC_tumor_cell_model_identified_synthetic_lethal_(SL)_interaction_between_the_kinase_inhibitor_dasatinib_and_ARID1A_mutation._Imposing_ARID1A_deficiency_upon_a_variety_of_human_or_mouse_cells_induced_dasatinib_sensitivity,_both_in_vitro_and_in_vivo.",27364904,PubMed,,"Miller_et_al.,_2016,_Mol._Cancer_Ther.",,3,accepted,2982,6559,,,,,,,,,,,,,,Somatic_Mutation,2018-07-06_20:29:40_UTC,https://civic.genome.wustl.edu/links/evidence_items/2982,https://civic.genome.wustl.edu/links/variants/1293,https://civic.genome.wustl.edu/links/genes/6559,,,,,7,Dasatinib,,,,,,,
CTNNB1,1499,ACTIVATING_MUTATION,Melanoma,1909,,"CTLA-4_Antibody,PD-L1_Antibody",Substitutes,Predictive,Supports,D,Resistance,Activation_of_melanoma-cell-intrinsic_WNT/β-catenin_signalling_pathway_contributes_to_a_lack_of_T-cell_infiltration_in_melanoma._Molecular_analysis_of_human_metastatic_melanoma_samples_revealed_a_correlation_between_activation_of_the_WNT/β-catenin_signalling_pathway_and_absence_of_a_T-cell_gene_expression_signature._In_autochthonous_mouse_melanoma_models_active_β-catenin_signalling_results_in_T-cell_exclusion_and_resistance_to_anti-PD-L1/anti-CTLA-4_monoclonal_antibody_therapy.,25970248,PubMed,,"Spranger_et_al.,_2015,_Nature",,4,accepted,2988,1290,3,41240930,41281936,,,ENST00000349496.5,,,,,75,GRCh37,,Somatic_Mutation,2017-05-30_18:06:43_UTC,https://civic.genome.wustl.edu/links/evidence_items/2988,https://civic.genome.wustl.edu/links/variants/1296,https://civic.genome.wustl.edu/links/genes/1290,,,"gain_of_function_variant,transcript_variant",,4,CTLA-4_Antibody,PD-L1_Antibody,,,,,,
MERTK,10461,OVEREXPRESSION,Melanoma,1909,,UNC1062,,Predictive,Supports,D,Sensitivity/Response,"Highest_MERTK_expression_was_observed_in_metastatic_melanomas,_followed_by_primary_melanomas,_and_lowest_in_benign_nevi._Over_half_of_melanoma_cell_lines_overexpressed_MERTK_compared_with_normal_human_melanocytes;_however,_overexpression_did_not_correlate_with_mutations_in_BRAF_or_RAS._MERTK_inhibition_via_shRNA_reduced_MERTK-mediated_downstream_signaling,_reduced_colony_formation_by_up_to_59%,_and_diminished_tumor_volume_by_60%_in_a_human_melanoma_murine_xenograft_model._Treatment_of_melanoma_cells_with_UNC1062,_a_novel_MERTK-selective_small-molecule_tyrosine_kinase_inhibitor,_reduced_activation_of_MERTK-mediated_downstream_signaling,_induced_apoptosis_in_culture,_reduced_colony_formation_in_soft_agar,_and_inhibited_invasion_of_melanoma_cells.",23585477,PubMed,,"Schlegel_et_al.,_2013,_J._Clin._Invest.",,3,accepted,2991,8331,2,112656056,112787138,,,ENST00000295408.4,,,,,75,GRCh37,,Somatic_Mutation,2017-05-03_16:17:14_UTC,https://civic.genome.wustl.edu/links/evidence_items/2991,https://civic.genome.wustl.edu/links/variants/1299,https://civic.genome.wustl.edu/links/genes/8331,,,,,3,UNC1062,,,,,,,
AKT3,10000,OVEREXPRESSION,Breast_Cancer,1612,,MK-2206,,Predictive,Supports,D,Resistance,Upregulation_of_AKT3_due_to_epigenetic_reprogramming_may_confer_acquired_resistance_to_AKT_inhibitor_(MK2206)_in_breast_cancer_preclinical_model.,27297869,PubMed,,"Stottrup_et_al.,_2016,_Mol._Cancer_Ther.",,4,accepted,1922,7936,,,,,,,,,,,,,,,2017-05-13_18:18:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/1922,https://civic.genome.wustl.edu/links/variants/1301,https://civic.genome.wustl.edu/links/genes/7936,,,,,7,MK-2206,,,,,,,
AKT3,10000,OVEREXPRESSION,Triple-receptor_Negative_Breast_Cancer,60081,,AKT3_Inhibitor,,Predictive,Supports,E,Sensitivity/Response,"AKT3_was_found_to_be_preferentially_required_for_the_proliferation_and_tumor_growth_of_TNBC._It_was_found_to_be_upregulated_in_a_set_of_TNBC_cell_lines_compared_to_other_breast_cancer_types._Depletion_of_AKT3_in_TNBC_sensitizes_cells_to_the_pan-Akt_inhibitor_GSK690693._It_was_found_that_depletion_of_Akt3_potentially_inhibits_the_growth_of_TNBC_cell_lines_in_three-dimensional_(3D)_spheroid_cultures_and_in_mouse_xenograft_models,_which_imply_that_therapeutic_targeting_of_AKT3_may_provide_a_new_treatment_option_for_TNBCs.",24335962,PubMed,,"Chin_et_al.,_2014,_Cancer_Res.",,4,accepted,1923,7936,,,,,,,,,,,,,,,2017-05-13_18:17:44_UTC,https://civic.genome.wustl.edu/links/evidence_items/1923,https://civic.genome.wustl.edu/links/variants/1301,https://civic.genome.wustl.edu/links/genes/7936,,,,,7,AKT3_Inhibitor,,,,,,,
AKT3,10000,OVEREXPRESSION,Melanoma,1909,,Vemurafenib,,Predictive,Supports,D,Resistance,"An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_AKT3_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_induced_to_stably_over-express_AKT3_(via_viral_transduction_of_additional_copies_of_wild_type_AKT3)_were_significantly_more_resistant_to_BRAF_inhibition_by_vemurafenib_than_cells_transduced_with_empty_vectors_(30%_vs_20%_survival,_p_=_.0064).",24265155,PubMed,,"Shi_et_al.,_2014,_Cancer_Discov",,2,accepted,6261,7936,,,,,,,,,,,,,,Somatic_Mutation,2018-07-19_20:08:47_UTC,https://civic.genome.wustl.edu/links/evidence_items/6261,https://civic.genome.wustl.edu/links/variants/1301,https://civic.genome.wustl.edu/links/genes/7936,,,,,7,Vemurafenib,,,,,,,
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,SU11248,,Predictive,Does_Not_Support,D,Sensitivity/Response,Murine_Ba/F3_cells_with_FLT3_D835V_mutation_were_assessed_as_not_sensitive_to_SU11248.(IC50_=_110nm),15304385,PubMed,,"Yee_et_al.,_2004,_Blood",,3,accepted,3008,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-06-16_15:26:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/3008,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,SU11248,,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,Sunitinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_retrospective_study_of_15_acute_myeloid_leukemia_patients,_the_patients_with_FLT3_D835_mutation_(n=2)_were_associated_with_improved_response_to_sunitinib_treatment_(2/2_vs._2/7)_compared_to_FLT3_wild-type_patients._The_FLT3_D835_mutation_positive_patients_were_treated_with_sunitinib_after_failure_of_standard_chemotherapy._After_4wk_of_sunitinib_therapy,_one_patient_showed_morphological_response_and_the_other_patient_showed_partial_response_to_sunitinib_therapy.",15459012,PubMed,,"Fiedler_et_al.,_2005,_Blood",,,accepted,4022,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-06-15_20:25:09_UTC,https://civic.genome.wustl.edu/links/evidence_items/4022,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,Sunitinib,,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,"SU11248,Daunorubicin",Combination,Predictive,Supports,D,Sensitivity/Response,"SU11248_+_Daunorubicin_has_a_synergic_effect_on_Murine_Ba/F3_cells_with_FLT3_D835V_mutation._(Combination_Index_=_0.82_for_ED50,_Combination_Index_=_0.72_for_ED75,_Combination_Index_=_0.64_for_ED90)",15304385,PubMed,,"Yee_et_al.,_2004,_Blood",,2,accepted,3010,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-06-16_15:28:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/3010,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,SU11248,Daunorubicin,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,"SU11248,Cytarabine",Combination,Predictive,Supports,D,Sensitivity/Response,"SU11248_+_Cytarabin_has_a_synergic_effect_on_Murine_Ba/F3_cells_with_FLT3_D835V_mutation_(Combination_Index_=_0.59_for_ED50,_Combination_Index_=_0.71_for_ED75,_Combination_Index_=_0.82_for_ED90)",15304385,PubMed,,"Yee_et_al.,_2004,_Blood",,2,accepted,3009,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-06-16_15:31:16_UTC,https://civic.genome.wustl.edu/links/evidence_items/3009,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,SU11248,Cytarabine,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,"AS602868,AG1296",Substitutes,Predictive,Supports,D,Sensitivity/Response,"Murine_Ba/F3_cells_with_FLT3_D835V_mutation_were_assessed_as_sensitive_to_both_AS602868_and_AG1296.(IC50_=_1.85uM_and_IC50_=_4.55uM,_respectively)",17330097,PubMed,,"Griessinger_et_al.,_2007,_Leukemia",,3,accepted,3034,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2018-04-30_18:49:51_UTC,https://civic.genome.wustl.edu/links/evidence_items/3034,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,AS602868,AG1296,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,MLN518,,Predictive,Supports,D,Resistance,Murine_Ba/F3_cells_with_FLT3-D835V_mutations_were_evaluated_as_non-responsive_to_MLN518._Cells_with_single_FLT3_(D835V)_mutants_were_resistant_to_MLN518(IC50_>_10uM)_whereas_cells_with_FLT3_(ITD)_mutants_were_not_resistant_to_MLN518_(IC50_0.55uM).,15256420,PubMed,,"Clark_et_al.,_2004,_Blood",,3,accepted,3007,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-06-16_15:21:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/3007,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,MLN518,,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
FLT3,2322,D835V,Acute_Myeloid_Leukemia,9119,,Quizartinib,,Predictive,Does_Not_Support,D,Sensitivity/Response,"Murine_Ba/F3_cell_line_has_a_restrictive_sensitivity_to_Quizartinib(AC220),_a_second_generation_class_II_tyrosine_kinase_inhibitor._(IC50_for_proliferation_=_172nM,_IC50_for_induction_of_apoptosis_=_888nM)",23497317,PubMed,,"Kampa-Schittenhelm_et_al.,_2013,_Mol._Cancer",,5,accepted,3012,24,13,28592641,28592641,T,A,ENST00000241453.7,,,,,75,GRCh37,,Somatic_Mutation,2017-06-16_15:32:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/3012,https://civic.genome.wustl.edu/links/variants/1302,https://civic.genome.wustl.edu/links/genes/24,,,missense_variant,"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A",18,Quizartinib,,,,,chr13_g.28592641T~A,FLT3_c.2504A~T,FLT3_D835V
MYC,4609,OVEREXPRESSION,Lung_Small_Cell_Carcinoma,5409,,"Prexasertib,Olaparib,Cisplatin",Combination,Predictive,Supports,D,Sensitivity/Response,"A_preclinical_study_to_evaluate_the_efficacy_of_targeting_the_overexpressed_CHEK1_cell_cycle_chekpoint_kinase,_including_both_miRNA_and_Prexasertib-induced_inhibition._Both_in_vitro_and_in_vivo,_Prexasertib_had_strong_single_agent_efficacy_and_augmented_the_effect_of_Olaparib_or_Cisplatin_in_either_combination,_including_platinum-resistant_models._CHEK1_and_MYC_overexpression_were_predictors_of_response.",28490518,PubMed,,"Sen_et_al.,_2017,_Cancer_Res.",,4,accepted,3003,3737,,,,,,,,,,,,,,Somatic_Mutation,2017-12-18_20:28:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/3003,https://civic.genome.wustl.edu/links/variants/1303,https://civic.genome.wustl.edu/links/genes/3737,,,,,9,Prexasertib,Olaparib,Cisplatin,,,,,
MYC,4609,OVEREXPRESSION,Multiple_Myeloma,9538,,JQ-1,,Predictive,Supports,D,Sensitivity/Response,"BET_inhibition_by_JQ1_downregulates_MYC_transcription,_followed_by_genome-wide_downregulation_of_Myc-dependent_target_genes._In_experimental_models_of_multiple_myeloma,_a_Myc-dependent_hematologic_malignancy,_JQ1_produces_a_potent_antiproliferative_effect_associated_with_cell-cycle_arrest_and_cellular_senescence.",21889194,PubMed,,"Delmore_et_al.,_2011,_Cell",,5,accepted,5505,3737,,,,,,,,,,,,,,Somatic_Mutation,2017-12-18_20:39:08_UTC,https://civic.genome.wustl.edu/links/evidence_items/5505,https://civic.genome.wustl.edu/links/variants/1303,https://civic.genome.wustl.edu/links/genes/3737,,,,,9,JQ-1,,,,,,,
TP53,7157,OVEREXPRESSION,Stomach_Cancer,10534,,"Cisplatin,Etoposide,Mitomycin",Combination,Predictive,Supports,B,,"In_a_Phase_II_trial_of_25_patients_with_metastaic_gastric_cancer,_patients_received_preoperative_high_dose_chemotherapy_(HDCT)_consisting_of_etoposide,_cisplatin_and_mitomycin._Patients_with_greater_than_50%_regression_in_response_to_HDCT_received_surgery._TP53_overexpression_was_assayed_by_immunohistochemistry._14_patients_showed_p53_overexpression,_and_12_of_these_qualified_for_resection._Overall_survival_in_patients_with_p53_overexpression_was_17.3_months_in_contrast_to_patients_with_negative_p53_immunohistochemistry,_where_it_was_7.2_months_(p=0.0003).",14514923,PubMed,,"Bataille_et_al.,_2003,_MP,_Mol._Pathol.",,4,accepted,2799,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:56:11_UTC,https://civic.genome.wustl.edu/links/evidence_items/2799,https://civic.genome.wustl.edu/links/variants/1306,https://civic.genome.wustl.edu/links/genes/45,,,,,50,Cisplatin,Etoposide,Mitomycin,,,,,
TP53,7157,OVEREXPRESSION,Ovarian_Cancer,2394,,"Cisplatin,Carboplatin",Substitutes,Predictive,Supports,B,Resistance,"In_a_study_involving_patients_with_invasive_ovarian_carcinoma_who_had_undergone_surgery,_a_subset_of_73_patients_were_classified_via_response_to_platinum-based_chemotherapy_as_sensitive_or_resistant/refractory_and_tested_for_p53_overexpression_(>10%_postive_stained_nuclei)._78%_of_p53_negative_patients_were_classified_as_sensitive,_in_compariston_to_39%_of_p53_positive_patients_(p=0.001).",11595686,PubMed,,"Reles_et_al.,_2001,_Clin._Cancer_Res.",,3,accepted,3013,45,17,7571720,7590856,,,ENST00000269305.4,,,,,75,GRCh37,,Somatic_Mutation,2018-07-06_14:55:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/3013,https://civic.genome.wustl.edu/links/variants/1306,https://civic.genome.wustl.edu/links/genes/45,,,,,50,Cisplatin,Carboplatin,,,,,,
TP53,7157,ALTERATION,Ovarian_Cancer,2394,,"Cisplatin,Carboplatin",Substitutes,Predictive,Supports,B,Resistance,"In_a_group_of_patients_with_invasive_ovarian_carcinoma_who_had_undergone_surgery,_a_subset_of_74_patients_treated_with_platinum_based_chemotherapy_were_assessed_for__p53_alteration_(p53_mutation_or_p53_overexpression_by_immunostaining_>10%_positive)._Significant_decreased_time_to_progression_(p=0.037)_was_seen_in_the_subset_of__patients_with_p53_alteration_(n=54)_in_comparison_to_the_group_with_normatl_p53_(n=20)",11595686,PubMed,,"Reles_et_al.,_2001,_Clin._Cancer_Res.",,4,accepted,2771,45,,,,,,,,,,,,,P53_ALTERATION_is_a_bucket_type_variant_used_in_studies_which_is_constructed_by_combining_all_cases_of_p53_mutation_together_with_p53_overexpression._This_includes_cases_which_have_p53_mutation_or_overexpression_alone_or_as_well_as_cases_where_both_occur_in_combination.,Somatic_Mutation,2017-09-08_22:17:18_UTC,https://civic.genome.wustl.edu/links/evidence_items/2771,https://civic.genome.wustl.edu/links/variants/1307,https://civic.genome.wustl.edu/links/genes/45,P53_ALTERATION_is_a_bucket_type_variant_used_in_studies_which_is_constructed_by_combining_all_cases_of_p53_mutation_together_with_p53_overexpression._This_includes_cases_which_have_p53_mutation_or_overexpression_alone_or_as_well_as_cases_where_both_occur_in_combination.,,,,40,Cisplatin,Carboplatin,,,,,,
GNAS,2778,R201H,Follicular_Thyroid_Carcinoma,3962,,Radioactive_Iodine,,Predictive,Supports,C,Sensitivity/Response,"A_79_year_old_patient_with_prior_history_of_graves'_disease_presented_with_follicular_thyroid_carcinoma._Two_mutations_NRAS_p.Q61K_and_GNAS_p.R201H_were_detected._The_thyroid_cancer_manifested_as_a_13.5_cm_mass._There_were_minimal_lung,_humerus_and_T9_spine_metastases,_and_exhibited_a_very_good_response_to_the_radioactive_iodine_treatment_after_he_had_underwent_total_thyroidectomy_and_bilateral_neck_dissection._They_also_screened_other_23_fatal_cases_and_revealed_that_none_of_them_had_GNAS_p.R201H_mutation._But_two_of_them_had_NRAS_p.Q61K_mutation.",26788326,PubMed,,"Lu_et_al.,_2016,_Endocrinol_Diabetes_Metab_Case_Rep",,2,accepted,3045,2319,,,,,,,,,,,,,,Somatic_Mutation,2017-07-20_14:59:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/3045,https://civic.genome.wustl.edu/links/variants/1319,https://civic.genome.wustl.edu/links/genes/2319,,,,,5,Radioactive_Iodine,,,,,,,
EGFR,1956,G719D,Non-small_Cell_Lung_Carcinoma,3908,,"Gefitinib,Erlotinib",Substitutes,Predictive,Supports,C,Sensitivity/Response,"In_a_study,_2_participants_with_stage_IV_lung_adenocarcinoma_were_sequenced_at_EGFR_exons_18_to_21._Both_patients_were_found_to_have_G719D_mutation_and_were_treated_with_the_1st_generation_TKIs_gefitinib_or_erlotinib._The_first_patient_(M,_81,_smoker)_was_treated_with_gefitinib_and_had_a_partial_response,_progression_free_survival_(PFS)_of_21.7_months,_overall_survival_(OS)_of_22.5_months_and_was_alive_at_study_end._The_second_patient_(M,_76,_smoker)_was_treated_with_erlotinib_and_had_stable_disease_as_response,_PFS_of_2.6_months,_OS_of_2.6_months_and_was_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,_2.0_and_10.4_wild_type.",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,4210,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-07-06_21:54:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/4210,https://civic.genome.wustl.edu/links/variants/1420,https://civic.genome.wustl.edu/links/genes/19,,,,,7.5,Gefitinib,Erlotinib,,,,,,
EGFR,1956,D770_N771insSVD,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_D770_N771insSVD_demonstrated_reduced_sensitivity_to_erlotinib_treatment_(IC50=3.187�M),_comparable_to_Ba/F3_cells_expressing_EGFR_L858R_and_T790M_co-mutation_(T790M_is_a_known_resistant_mutation_to_1st_and_2nd_generation_EGFR_tyrosine_kinase_inhibitors;_IC50=4.155�M)._Resistance_was_determined_by_assessing_cell_proliferation,_EGFR,_AKT_and_ERK_phosphorylation.",24353160,PubMed,,"Yasuda_et_al.,_2013,_Sci_Transl_Med",,,accepted,4275,19,7,55249013,55249014,,GCGTGGACA,,,,,,,GRCh37,,Somatic_Mutation,2018-02-11_10:47:15_UTC,https://civic.genome.wustl.edu/links/evidence_items/4275,https://civic.genome.wustl.edu/links/variants/1445,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,H773_V774insH,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,D,Resistance,"In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_H773_V774insH_demonstrated_reduced_sensitivity_to_erlotinib_treatment_(IC50=3.902�M),_comparable_to_Ba/F3_cells_expressing_EGFR_L858R_and_T790M_co-mutation_(T790M_is_a_known_resistant_mutation_to_1st_and_2nd_generation_EGFR_tyrosine_kinase_inhibitors;_IC50=4.155�M)._Resistance_was_determined_by_assessing_cell_proliferation,_EGFR,_AKT_and_ERK_phosphorylation.",24353160,PubMed,,"Yasuda_et_al.,_2013,_Sci_Transl_Med",,,accepted,4276,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2018-02-11_11:11:05_UTC,https://civic.genome.wustl.edu/links/evidence_items/4276,https://civic.genome.wustl.edu/links/variants/1446,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,L838P,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_study,_1_participant_with_stage_IV_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_L838P_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(F,_66,_nonsmoker)_had_a_partial_response,_progression_free_survival_(PFS)_of_15.2_months,_overall_survival_(OS)_of_29.3_months_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,_2.0_and_10.4_wild_type.",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,4252,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-07-06_22:31:55_UTC,https://civic.genome.wustl.edu/links/evidence_items/4252,https://civic.genome.wustl.edu/links/variants/1457,https://civic.genome.wustl.edu/links/genes/19,,,,,7.5,Gefitinib,,,,,,,
EGFR,1956,T847I,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"In_a_study,_1_participant_with_stage_IIIB_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_T847I_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(M,_77,_smoker)_progressive_disease_as_response,_progression_free_survival_(PFS)_of_1.1_months,_overall_survival_(OS)_of_1.1_months_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,_2.0_and_10.4_wild_type.",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,2,accepted,4260,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-07-06_22:38:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/4260,https://civic.genome.wustl.edu/links/variants/1463,https://civic.genome.wustl.edu/links/genes/19,,,,,5,Gefitinib,,,,,,,
EGFR,1956,V851I,Non-small_Cell_Lung_Carcinoma,3908,,Erlotinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_study_of_1261_non-small_cell_lung_cancer_patients,_49.8%_of_the_analyzed_tumors_had_EGFR_mutations_including_deletions_in_exon_19_(n=258),_L858R_(n=260),_T790M_(n=6)_and_insertions_or_duplications_in_exon_20_(n=25)._Patients_with_EGFR_deletions_in_exon_19_or_L858R_mutations_were_associated_with_an_improved_response_to_erlotinib_or_gefitinib_with_partial_or_complete_response_(74.1%_vs._16.5%,_P<0.001)_when_compared_to_wildtype_EGFR_patients._Additionally,_tumors_with_EGFR_mutations_in_L858R_or_deletions_in_exon_19_were_associated_with_increased_overall_survival_(19.6mo_vs._10.4mo)_compared_to_wildtype_(all_patients_were_treated_with_either_erlotinib_or_gefitinib).",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,,accepted,4264,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-07-06_22:40:33_UTC,https://civic.genome.wustl.edu/links/evidence_items/4264,https://civic.genome.wustl.edu/links/variants/1466,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
EGFR,1956,L861R,Non-small_Cell_Lung_Carcinoma,3908,,Gefitinib,,Predictive,Supports,C,Sensitivity/Response,"In_a_study,_1_participant_with_stage_IV_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_L861R_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(M,_83,_nonsmoker)_had_a_partial_response,_progression_free_survival_(PFS)_of_37.5_months,_overall_survival_(OS)_of_53.3_months_and_was_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,_2.0_and_10.4_wild_type.",21531810,PubMed,,"Wu_et_al.,_2011,_Clin._Cancer_Res.",,3,accepted,4669,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2017-07-06_22:45:42_UTC,https://civic.genome.wustl.edu/links/evidence_items/4669,https://civic.genome.wustl.edu/links/variants/1477,https://civic.genome.wustl.edu/links/genes/19,,,,,7.5,Gefitinib,,,,,,,
EGFR,1956,E868G,Malignant_Mesothelioma,1790,,Erlotinib,,Predictive,Supports,D,Sensitivity/Response,"In_an_in_vitro_study,_a_COS-7_cell_line_expressing_EGFR_E868G_demonstrated_increased_sensitivity_to_erlotinib_treatment,_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.",20942962,PubMed,,"Foster_et_al.,_2010,_World_J_Surg_Oncol",,,accepted,4301,19,,,,,,,,,,,,GRCh37,,Somatic_Mutation,2018-01-18_23:34:00_UTC,https://civic.genome.wustl.edu/links/evidence_items/4301,https://civic.genome.wustl.edu/links/variants/1482,https://civic.genome.wustl.edu/links/genes/19,,,,,0,Erlotinib,,,,,,,
ABL1,25,BCR-ABL_E355G,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_E355G_evaluated,_2/2_had_complete_hematologic_responses_and_1/2_had_major_cytogenetic_responses.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,1,accepted,4400,4,9,133748403,133748403,A,G,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-12_21:52:26_UTC,https://civic.genome.wustl.edu/links/evidence_items/4400,https://civic.genome.wustl.edu/links/variants/1487,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G",19.5,Bosutinib,,,,,chr9_g.133748403A~G,ABL1_c.1064A~G,ABL1_E355G
ABL1,25,BCR-ABL_E355G,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_E355G,_2/4_had_MaHRs_and_2/4_had_MCyRs_which_were_comparable_to_response_rates_among_wild_type.	17264298	PubMed	NA	Guilhot_et_al.,_2007,_Blood		1	accepted	4402	4	9	133748403	133748403	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-31_09:56:55_UTC	https://civic.genome.wustl.edu/links/evidence_items/4402	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G	19.5
1487	ABL1	25	BCR-ABL_E355G	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_E355G_mutation_was_associated_with_resistance_in_2_μM_imatinib_(1_clone_recovered,_~0.71%)._In_a_review_of_20_publications,_this_mutation_was_previously_described_in_imatinib_resistant_patients.	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	6255	4	9	133748403	133748403	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-06-27_21:44:57_UTC	https://civic.genome.wustl.edu/links/evidence_items/6255	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G	19.5
1487	ABL1	25	BCR-ABL_E355G	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_4_had_E355G_mutations	17264298	PubMed	NA	Guilhot_et_al.,_2007,_Blood		1	accepted	7036	4	9	133748403	133748403	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-31_10:19:35_UTC	https://civic.genome.wustl.edu/links/evidence_items/7036	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G	19.5
1487	ABL1	25	BCR-ABL_E355G	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	B	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_19_patients_with_E355G_mutations,_4,_9,_and_17_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		2	accepted	4403	4	9	133748403	133748403	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_22:01:49_UTC	https://civic.genome.wustl.edu/links/evidence_items/4403	https://civic.genome.wustl.edu/links/variants/1487	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G	19.5
1488	ABL1	25	BCR-ABL_L387M	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	C	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_5_patients_with_L387M_mutations,_4,_4,_and_5_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		3	accepted	4406	4	9	133750328	133750328	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:32:24_UTC	https://civic.genome.wustl.edu/links/evidence_items/4406	https://civic.genome.wustl.edu/links/variants/1488	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1159T>A	7.5
1506	ABL1	25	L298V	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_L298V_evaluated,_1/1_had_a_complete_hematologic_response_and_0/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		1	accepted	4475	4	9	133747585	133747585	C	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:10:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/4475	https://civic.genome.wustl.edu/links/variants/1506	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.892C>G	2.5
1507	ABL1	25	BCR-ABL_F311I	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_F311I_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4478	4	9	133748270	133748270	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:46:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/4478	https://civic.genome.wustl.edu/links/variants/1507	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.931T>A,NC_000009.11:g.133748270T>A,NM_005157.5:c.931T>A,NP_005148.2:p.Phe311Ile	5
1509	ABL1	25	BCR-ABL_E453Q	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_E453Q_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4486	4	9	133753888	133753888	G	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_22:07:49_UTC	https://civic.genome.wustl.edu/links/evidence_items/4486	https://civic.genome.wustl.edu/links/variants/1509	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1357G>C,NC_000009.11:g.133753888G>C,NM_005157.5:c.1357G>C,NP_005148.2:p.Glu453Gln	5
1510	ARID1A	8289	Q456X	Ovarian_Clear_Cell_Carcinoma	50934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In_an_in_vitro_study,_a_HCT116_cell_line_expressing_ARID1A_Q456*_mutation_demonstrated_increased_sensitivity_to_dasatinib_treatment,_compared_to_HCT116_cells_expressing_wild-type_ARID1A._Sensitivity_was_determined_by_assessing_cell_survival.	27364904	PubMed	NA	Miller_et_al.,_2016,_Mol._Cancer_Ther.		NA	accepted	4487	6559		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-07-06_20:39:53_UTC	https://civic.genome.wustl.edu/links/evidence_items/4487	https://civic.genome.wustl.edu/links/variants/1510	https://civic.genome.wustl.edu/links/genes/6559					0
1513	EGFR	1956	H773_V774insNPH	Lung_Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In_a_lung_adenocarcinoma_patient_harboring_EGFR_H773_V774insNPH_mutation,_EGFR_H773_V774insNPH_was_associated_with_progressive_disease_in_response_to_erlotinib_monotherapy.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4493	19	7	55249012	55249013		AACCCCCAC			NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-08_23:49:28_UTC	https://civic.genome.wustl.edu/links/evidence_items/4493	https://civic.genome.wustl.edu/links/variants/1513	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0
1514	EGFR	1956	D770_N771insGL	Lung_Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In_a_study_of_19_non-small_cell_lung_carcinoma_patients_with_EGFR_exon_20_insertion_mutation_and_treated_with_erlotinib_monotherapy,_patients_with_EGFR_D770_N771insGL_mutation_(n=3)_experienced_progressive_disease.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4494	19	7	55249012	55249013		GGGTTA	ENST00000275493.2		NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-08_23:47:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/4494	https://civic.genome.wustl.edu/links/variants/1514	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0
1515	EGFR	1956	A763_Y764insFQEA	Non-small_Cell_Lung_Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	In_an_in_vitro_study,_Ba/F3_and_BID007_cell_lines_expressing_EGFR_A763_Y764insFQEA_demonstrated_increased_sensitivity_to_erlotinib_treatment_(IC50=0.048�M_and_0.082�M,_respectively),_comparable_to_Ba/F3_and_NCI-H3255_cells_expressing_EGFR_L858R_(a_known_sensitizing_mutation_to_EGFR_tyrosine_kinase_inhibitors;_IC50=0.006�M_and_0.068�M,_respectively)._Sensitivity_was_determined_by_assessing_cell_proliferation,_EGFR,_AKT_and_ERK_phosphorylation,_levels_of_BIM_(a_marker_of_EGFR_TKI-induced_cell_killing)_and_cell_viability.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4497	19	7	55248992	55248993		TCCAGGAAGCCT	ENST00000275493.2		NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-11_11:29:18_UTC	https://civic.genome.wustl.edu/links/evidence_items/4497	https://civic.genome.wustl.edu/links/variants/1515	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0
1517	KRAS	3845	G13V	Colorectal_Cancer	9256		Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	In_this_study,_a_large_cohort_of_metastatic_colorectal_cancer_patients_were_treated_with_anti-epidermal_growth_factor_receptor_monoclonal_antibodies_(cetuximab_or_panitumumab)._KRAS_PIK3CA_and_PTEN_were_tested_for_mutation;_KRAS_G13V_was_the_only_variant_noted_in_the_primary_colon_tumor_of_one_patient_who_experienced_disease_progression_(Patient_4;_Supplemental_Table_1)_following_treatment._In_the_larger_cohort,_patients_with_tumors_harboring_any_KRAS_mutation_had_significantly_decreased_incidence_of_objective_response_than_patients_with_wtKRAS_tumors._Authors_noted_that_patients_with_tumors_harboring_KRAS_mutations_tended_to_have_decreased_PFS_and_OS_compared_to_those_with_wild-type_tumors_though_the_differences_were_not_statistically_significant.	19223544	PubMed	NA	Sartore-Bianchi_et_al.,_2009,_Cancer_Res.		2	accepted	6312	30	12	25398280	25398281	GC	AA	ENST00000256078.4		NA	NA		75	GRCh37		Somatic_Mutation	2018-11-02_22:00:24_UTC	https://civic.genome.wustl.edu/links/evidence_items/6312	https://civic.genome.wustl.edu/links/variants/1517	https://civic.genome.wustl.edu/links/genes/30			missense_variant	NC_000012.11:g.25398280_25398281delinsAA,ENST00000256078.4:c.38_39delinsTT,NM_004985.4:c.38_39delinsTT,NP_004976.2:p.Gly13Val	5
1523	ABL1	25	BCR-ABL_F359I	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_F359I_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4530	4	9	133748414	133748414	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:56:10_UTC	https://civic.genome.wustl.edu/links/evidence_items/4530	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A	27.5
1523	ABL1	25	BCR-ABL_F359I	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_F359I_was_seen_in_two_imatinib-resistant_patients_that_were_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6984	4	9	133748414	133748414	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:23:12_UTC	https://civic.genome.wustl.edu/links/evidence_items/6984	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A	27.5
1523	ABL1	25	BCR-ABL_F359I	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	B	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_12_patients_with_F359I_mutations,_7,_10,_and_12_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		3	accepted	4532	4	9	133748414	133748414	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:38:33_UTC	https://civic.genome.wustl.edu/links/evidence_items/4532	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A	27.5
1523	ABL1	25	BCR-ABL_F359I	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_F359I_evaluated,_2/2_had_CHR_and_2/2_had_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		2	accepted	4531	4	9	133748414	133748414	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:35:51_UTC	https://civic.genome.wustl.edu/links/evidence_items/4531	https://civic.genome.wustl.edu/links/variants/1523	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A	27.5
1525	ABL1	25	BCR-ABL_F317V	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_F317V_mutation_was_associated_with_resistance_in_5_nM_dasatinib_(1_clone_recovered,__~_3%)_and_25_nM_dasatinib_(1_clone,_~3%)._No_clones_were_recovered_at_10_nM_dasatinib.	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	6253	4	9	133748288	133748288	T	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-06-27_21:41:27_UTC	https://civic.genome.wustl.edu/links/evidence_items/6253	https://civic.genome.wustl.edu/links/variants/1525	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.949T>G,NP_005148.2:p.Phe317Val,NC_000009.11:g.133748288T>G,ENST00000318560.5:c.949T>G	5
1525	ABL1	25	BCR-ABL_F317V	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_were_generated_in_Ba/F3_cell_lines_from_five_independently_derived,_mutagenized_libraries._Dasatinib_resistant_subclones_were_identified_using_﻿50_nM_dasatinib_in_liquid_culture._201_individual_clones_were_identified_representing_10_different_mutations_at_6_different_residues._83_of_these_clones_had_F317V_mutations._To_validate_resistance_to_dasatinib,_a_Ba/F3_cell_line_stably_expressing_the_F317V_mutation_in_the_ABL1_region_of_the_BCR-ABL_fusion_was_generated_and_associated_with_higher_dasatinib_IC50_of_53_nM_vs_1.34_nM_in_wildtype_as_determined_by_dose_response_curves.	15705718	PubMed	NA	Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.		3	accepted	6208	4	9	133748288	133748288	T	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-06-20_01:42:42_UTC	https://civic.genome.wustl.edu/links/evidence_items/6208	https://civic.genome.wustl.edu/links/variants/1525	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.949T>G,NP_005148.2:p.Phe317Val,NC_000009.11:g.133748288T>G,ENST00000318560.5:c.949T>G	5
1526	ABL1	25	E279K	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Does_Not_Support	C	Resistance	This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_8_patients_with_E279K_mutations,_5,_5,_and_8_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.	19779040	PubMed	NA	Müller_et_al.,_2009,_Blood		3	accepted	4543	4	9	133747528	133747528	G	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:52:30_UTC	https://civic.genome.wustl.edu/links/evidence_items/4543	https://civic.genome.wustl.edu/links/variants/1526	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.835G>A,NC_000009.11:g.133747528G>A,NM_005157.5:c.835G>A,NP_005148.2:p.Glu279Lys	7.5
1527	ABL1	25	Q300R	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_Q300R,_1/1_had_a_CHR_and_1/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4545	4	9	133747592	133747592	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:34:56_UTC	https://civic.genome.wustl.edu/links/evidence_items/4545	https://civic.genome.wustl.edu/links/variants/1527	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.899A>G	5
1527	ABL1	25	Q300R	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_Q300R_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6983	4	9	133747592	133747592	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:22:11_UTC	https://civic.genome.wustl.edu/links/evidence_items/6983	https://civic.genome.wustl.edu/links/variants/1527	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.899A>G	5
1528	ABL1	25	BCR-ABL_F311L	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_F311L_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4546	4	9	133748270	133748270	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:48:16_UTC	https://civic.genome.wustl.edu/links/evidence_items/4546	https://civic.genome.wustl.edu/links/variants/1528	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.931T>C,NP_005148.2:p.Phe311Leu,NC_000009.11:g.133748270T>C,ENST00000318560.5:c.931T>C	7
1528	ABL1	25	BCR-ABL_F311L	Chronic_Myeloid_Leukemia	8552		Nilotinib,Imatinib_Mesylate	Combination	Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._61_clones_grew_in_a_combination_of_400_nM_imatinib_and_50_nM_nilotinib._Of_these,_19_were_sequenced_and_1_(~5%)_was_found_to_have_an_F311L_mutation.	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	6238	4	9	133748270	133748270	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-02_02:19:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/6238	https://civic.genome.wustl.edu/links/variants/1528	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.931T>C,NP_005148.2:p.Phe311Leu,NC_000009.11:g.133748270T>C,ENST00000318560.5:c.931T>C	7
1529	ABL1	25	BCR-ABL_N331S	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_N331S_evaluated,_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		1	accepted	4549	4	9	133748331	133748331	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:50:14_UTC	https://civic.genome.wustl.edu/links/evidence_items/4549	https://civic.genome.wustl.edu/links/variants/1529	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.992A>G	2.5
1530	ABL1	25	BCR-ABL_L364P	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_L364P_evaluated,_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		1	accepted	4551	4	9	133750260	133750260	T	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:58:07_UTC	https://civic.genome.wustl.edu/links/evidence_items/4551	https://civic.genome.wustl.edu/links/variants/1530	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1091T>C	2.5
1531	ABL1	25	BCR-ABL_H396P	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_H396P_evaluated,_1/1_had_a_complete_hematologic_response_and_2/2_had_major_cytogenetic_responses.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4554	4	9	133750356	133750356	A	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_21:59:42_UTC	https://civic.genome.wustl.edu/links/evidence_items/4554	https://civic.genome.wustl.edu/links/variants/1531	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro	7
1531	ABL1	25	BCR-ABL_H396P	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._61_clones_grew_in_a_combination_of_400_nM_imatinib_and_50_nM_nilotinib._Of_these,_19_were_sequenced_and_1_(~5%)_was_found_to_have_an_H396P_mutation.	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	6240	4	9	133750356	133750356	A	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-02_02:25:11_UTC	https://civic.genome.wustl.edu/links/evidence_items/6240	https://civic.genome.wustl.edu/links/variants/1531	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro	7
1532	ABL1	25	D421G	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_D421G_evaluated,_1/1_had_a_complete_hematologic_response_and_0/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		1	accepted	4559	4	9	133750431	133750431	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_21:10:55_UTC	https://civic.genome.wustl.edu/links/evidence_items/4559	https://civic.genome.wustl.edu/links/variants/1532	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1262A>G,NC_000009.11:g.133750431A>G,NM_005157.5:c.1262A>G,NP_005148.2:p.Asp421Gly	2.5
1534	ABL1	25	BCR-ABL_E450V	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_E450V_evaluated,_1/1_had_a_complete_hematologic_response_and_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		2	accepted	4563	4	9	133753880	133753880	A	T	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_22:04:23_UTC	https://civic.genome.wustl.edu/links/evidence_items/4563	https://civic.genome.wustl.edu/links/variants/1534	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1349A>T,NC_000009.11:g.133753880A>T,NM_005157.5:c.1349A>T,NP_005148.2:p.Glu450Val	5
1535	ABL1	25	BCR-ABL_E453K	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_E453K_evaluated,_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.,_2011,_Blood		1	accepted	4565	4	9	133753888	133753888	G	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_22:05:15_UTC	https://civic.genome.wustl.edu/links/evidence_items/4565	https://civic.genome.wustl.edu/links/variants/1535	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1357G>A,NC_000009.11:g.133753888G>A,NM_005157.5:c.1357G>A,NP_005148.2:p.Glu453Lys	2.5
1536	ABL1	25	E453A	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_E453A,_1/1_had_a_CHR_and_0/0_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4567	4	9	133753889	133753889	A	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:21:16_UTC	https://civic.genome.wustl.edu/links/evidence_items/4567	https://civic.genome.wustl.edu/links/variants/1536	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1358A>C,NC_000009.11:g.133753889A>C,NM_005157.5:c.1358A>C,NP_005148.2:p.Glu453Ala	5
1536	ABL1	25	E453A	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_E453A_was_seen_in_a_single_imatinib-resistant_pati",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.",_2012,"_Blood		1	accepted	6980	4	9	133753889	133753889	A	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_20:19:44_UTC	https://civic.genome.wustl.edu/links/evidence_items/6980	https://civic.genome.wustl.edu/links/variants/1536	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1358A>C",NC_000009.11:g.133753889A>C,NM_005157.5:c.1358A>C,"NP_005148.2:p.Glu453Ala	5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I._Of_patients_with_P480A_evaluated,"_1/1_had_a_major_cytogenetic_response.	21865346	PubMed	NA	Cortes_et_al.",_2011,"_Blood		1	accepted	4568	4	9	133755469	133755469	C	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-12_22:08:34_UTC	https://civic.genome.wustl.edu/links/evidence_items/4568	https://civic.genome.wustl.edu/links/variants/1537	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1438C>G	2.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_SNU-251_cell_line_expressing_BRCA1_W1815X_mutation_demonstrated_increased_sensitivity_to_olaparib_treatment_with_long-term_exposure,"_compared_to_ovarian_cell_lines_expressing_BRCA1_wild-type._Sensitivity_was_determined_by_assessing_cytotoxicity_and_doubling_time.	23415752	PubMed	NA	Stordal_et_al.",_2013,"_Mol_Oncol		NA	accepted	4623	6	17	41199682	41199682	C	T			NA	NA		NA	GRCh37		Somatic_Mutation	2018-07-06_14:38:48_UTC	https://civic.genome.wustl.edu/links/evidence_items/4623	https://civic.genome.wustl.edu/links/variants/1555	https://civic.genome.wustl.edu/links/genes/6			stop_gained		0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_EGFR_D770_N771insGT_was_associated_with_lack_of_response_to_treatment_with_erlotinib_monotherapy.	23371856	PubMed	NA	Arcila_et_al.",_2013,"_Mol._Cancer_Ther.		NA	accepted	4643	19	7	55249012	55249013		GGCACA	ENST00000275493.2		NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-11_07:14:35_UTC	https://civic.genome.wustl.edu/links/evidence_items/4643	https://civic.genome.wustl.edu/links/variants/1566	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_the_patient_was_treated_with_acitretin,"_but_did_not_achieve_any_response.	26822128	PubMed	NA	Khamaysi_et_al.",_2016,"_Br._J._Dermatol.		NA	accepted	4654	5365	7	128846398	128846398	C	T	ENST00000249373.3		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-20_15:22:44_UTC	https://civic.genome.wustl.edu/links/evidence_items/4654	https://civic.genome.wustl.edu/links/variants/1570	https://civic.genome.wustl.edu/links/genes/5365			missense_variant	NM_005631.4:c.1234C>T",NP_005622.1:p.Leu412Phe,NC_000007.13:g.128846398C>T,"ENST00000249373.3:c.1234C>T	0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_mouse_embryonic_fibroblasts_(MEFs),_null_for_the_Smo_mouse_gene_expressing_SMO_L412F_mutation,"_demonstrated_resistance_to_vismodegib_treatment_(IC50:_>320_nmol/L_vs._8.23_nmol/L)_compared_to_MEFs_expressing_wild-type_SMO._Resistance_was_determined_by_assessing_GLI1_mRNA_expression_levels.	25759020	PubMed	NA	Atwood_et_al.",_2015,"_Cancer_Cell		NA	accepted	4653	5365	7	128846398	128846398	C	T	ENST00000249373.3		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-20_16:00:58_UTC	https://civic.genome.wustl.edu/links/evidence_items/4653	https://civic.genome.wustl.edu/links/variants/1570	https://civic.genome.wustl.edu/links/genes/5365			missense_variant	NM_005631.4:c.1234C>T",NP_005622.1:p.Leu412Phe,NC_000007.13:g.128846398C>T,"ENST00000249373.3:c.1234C>T	0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_COS-7_cell_line_expressing_EGFR_W731L_demonstrated_increased_sensitivity_to_erlotinib_treatment,"_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.	20942962	PubMed	NA	Foster_et_al.",_2010,"_World_J_Surg_Oncol		NA	accepted	4655	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-01-18_23:33:33_UTC	https://civic.genome.wustl.edu/links/evidence_items/4655	https://civic.genome.wustl.edu/links/variants/1571	https://civic.genome.wustl.edu/links/genes/19					0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_COS-7_cell_line_expressing_EGFR_E734Q_demonstrated_increased_sensitivity_to_erlotinib_treatment,"_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.	20942962	PubMed	NA	Foster_et_al.",_2010,"_World_J_Surg_Oncol		NA	accepted	4656	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-01-18_23:32:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/4656	https://civic.genome.wustl.edu/links/variants/1572	https://civic.genome.wustl.edu/links/genes/19			missense_variant		0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_COS-7_cell_line_expressing_EGFR_T785A_demonstrated_increased_sensitivity_to_erlotinib_treatment,"_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.	20942962	PubMed	NA	Foster_et_al.",_2010,"_World_J_Surg_Oncol		NA	accepted	4657	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-01-18_23:32:25_UTC	https://civic.genome.wustl.edu/links/evidence_items/4657	https://civic.genome.wustl.edu/links/variants/1573	https://civic.genome.wustl.edu/links/genes/19					0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_COS-7_cell_line_expressing_EGFR_C797Y_demonstrated_increased_sensitivity_to_erlotinib_treatment,"_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.	20942962	PubMed	NA	Foster_et_al.",_2010,"_World_J_Surg_Oncol		NA	accepted	4658	19	7	55249092	55249092	G	A	ENST00000275493.2		NA	NA		75	GRCh37		Somatic_Mutation	2018-01-18_23:32:06_UTC	https://civic.genome.wustl.edu/links/evidence_items/4658	https://civic.genome.wustl.edu/links/variants/1574	https://civic.genome.wustl.edu/links/genes/19			missense_variant	ENST00000275493.2:c.2390G>A	0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_COS-7_cell_line_expressing_EGFR_Y801H_demonstrated_increased_sensitivity_to_erlotinib_treatment,"_compared_to_COS-7_cells_expressing_EGFR_wild-type._Sensitivity_was_determined_by_assessing_EGFR_auto-phosphorylation.	20942962	PubMed	NA	Foster_et_al.",_2010,"_World_J_Surg_Oncol		NA	accepted	4659	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-01-18_23:31:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/4659	https://civic.genome.wustl.edu/links/variants/1575	https://civic.genome.wustl.edu/links/genes/19					0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_patients_with_EGFR_A767_V769dupASV_mutation_(n=3)_experienced_progressive_disease.	24353160	PubMed	NA	Yasuda_et_al.",_2013,"_Sci_Transl_Med		NA	accepted	4665	19	7	55249000	55249001		GCCAGCGTG	ENST00000275493.2		NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-02_20:52:02_UTC	https://civic.genome.wustl.edu/links/evidence_items/4665	https://civic.genome.wustl.edu/links/variants/1579	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_V379I_mutation_was_associated_with_resistance_in_2_μM_imatinib_(2_clones_recovered,_~1%)._In_a_review_of_20_publications,"_this_mutation_was_previously_described_in_imatinib_resistant_patients.	16772610	PubMed	NA	Bradeen_et_al.",_2006,"_Blood		2	accepted	6257	4	9	133750304	133750304	G	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-02_02:39:52_UTC	https://civic.genome.wustl.edu/links/evidence_items/6257	https://civic.genome.wustl.edu/links/variants/1609	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1135G>A",NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,"NP_005148.2:p.Val379Ile	7",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_V379I,"_3/4_had_MaHRs_and_2/4_had_MCyRs_which_were_comparable_to_response_rates_among_wild_type_patients.""",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,4704,4,9,133750304,133750304,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_09:53:41_UTC,https://civic.genome.wustl.edu/links/evidence_items/4704,https://civic.genome.wustl.edu/links/variants/1609,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile",7,Dasatinib,,,,,chr9_g.133750304G~A,ABL1_c.1135G~A,ABL1_V379I,,,,,,,,,,,
ABL1,25,BCR-ABL_V379I,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_4_had_V379I_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7033,4,9,133750304,133750304,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:15:10_UTC,https://civic.genome.wustl.edu/links/evidence_items/7033,https://civic.genome.wustl.edu/links/variants/1609,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile",7,Imatinib_Mesylate,,,,,chr9_g.133750304G~A,ABL1_c.1135G~A,ABL1_V379I
ABL1,25,BCR-ABL_A397P,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_2_had_A397P_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7034,4,9,133750358,133750358,G,C,ENST00000318560.5,,,,,75,GRCh37,,,2019-01-31_10:18:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/7034,https://civic.genome.wustl.edu/links/variants/1612,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,"ENST00000318560.5:c.1189G>C,NC_000009.11:g.133750358G>C,NM_005157.5:c.1189G>C,NP_005148.2:p.Ala397Pro",5,Imatinib_Mesylate,,,,,chr9_g.133750358G~C,ABL1_c.1189G~C,ABL1_A397P
ABL1,25,BCR-ABL_A397P,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,C,Resistance,"In_this_phase_II_multinational_study,_patients_with_accelerated_phase_CML_and_BCR-ABL_fusions_were_treated_with_dasatinib_monotherapy._Response_rate_among_60_imatinib-resistant_patients_with_BCR-ABL_mutations_did_not_differ_from_the_rate_of_the_total_population_of_100_imatinib-resistant_or_-intolerant_patients._44_(73%)_of_60_BCR-ABL_mutant_patients_achieved_major_hematologic_responses_(MaHRs)_and_18_(30%)_of_60_achieved_major_cytogenetic_responses_(MCyRs)._Of_patients_with_A397P,__2/2_had_MaHRs_and_1/2_had_MCyRs_which_were_comparable_to_response_rates_among_wild_type_patients.	17264298	PubMed	NA	Guilhot_et_al.,_2007,_Blood		1	accepted	4710	4	9	133750358	133750358	G	C	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-31_09:54:36_UTC	https://civic.genome.wustl.edu/links/evidence_items/4710	https://civic.genome.wustl.edu/links/variants/1612	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1189G>C,NC_000009.11:g.133750358G>C,NM_005157.5:c.1189G>C,NP_005148.2:p.Ala397Pro	5
1625	ABL1	25	BCR-ABL_F317I	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_were_introduced_into_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_in_Ba/F3_cells_using_N-ethyl-N-nitrosourea_mutagenesis._Resulting_clones_were_grown_in_a_range_of_tyrosine_kinase_inhibitor_concentrations_to_identify_resistance_mutations._The_F317I_mutation_was_associated_with_resistance_in_5_nM_dasatinib_(2_clone_recovered,_~_6%)_and_10_nM_dasatinib_(10_clones,_~18%).	16772610	PubMed	NA	Bradeen_et_al.,_2006,_Blood		2	accepted	6251	4	9	133748288	133748288	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-06-27_21:31:10_UTC	https://civic.genome.wustl.edu/links/evidence_items/6251	https://civic.genome.wustl.edu/links/variants/1625	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.949T>A,NP_005148.2:p.Phe317Ile,NC_000009.11:g.133748288T>A,ENST00000318560.5:c.949T>A	3
1625	ABL1	25	BCR-ABL_F317I	Chronic_Myeloid_Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_stochastic_mutations_in_the_ABL1_region_of_a_stably_expressed_p210_BCR-ABL_fusion_were_generated_in_Ba/F3_cell_lines_from_five_independently_derived,_mutagenized_libraries._Dasatinib_resistant_subclones_were_identified_using_﻿50_nM_dasatinib_in_liquid_culture._201_individual_clones_were_identified_representing_10_different_mutations_at_6_different_residues._1_of_these_clones_had_an_F317I_mutation.	15705718	PubMed	NA	Burgess_et_al.,_2005,_Proc._Natl._Acad._Sci._U.S.A.		1	accepted	6217	4	9	133748288	133748288	T	A	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-06-20_01:47:58_UTC	https://civic.genome.wustl.edu/links/evidence_items/6217	https://civic.genome.wustl.edu/links/variants/1625	https://civic.genome.wustl.edu/links/genes/4			missense_variant	NM_005157.5:c.949T>A,NP_005148.2:p.Phe317Ile,NC_000009.11:g.133748288T>A,ENST00000318560.5:c.949T>A	3
1627	BRAF	673	G596R	Cancer	162		Vemurafenib		Predictive	Does_Not_Support	C	Sensitivity/Response	The_phase_2a_MyPathway_study_assigned_patients_with_HER2,_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.,_2018,_J._Clin._Oncol.	NCT02091141	2	accepted	5969	5	7	140453149	140453149	C	G	ENST00000288602.6		NA	NA		75	GRCh37		Somatic_Mutation	2018-02-16_11:22:07_UTC	https://civic.genome.wustl.edu/links/evidence_items/5969	https://civic.genome.wustl.edu/links/variants/1627	https://civic.genome.wustl.edu/links/genes/5			missense_variant	NM_004333.4:c.1786G>C,NP_004324.2:p.Gly596Arg,NC_000007.13:g.140453149C>G,ENST00000288602.6:c.1786G>C	5
1639	ABL1	25	C475V	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_C475V,_1/1_had_a_CHR_and_1/1_had_a_MCyR._9_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4768	4	9	133753954	133753955	TG	GT			NA	NA		NA	GRCh37		Somatic_Mutation	2018-11-16_21:33:44_UTC	https://civic.genome.wustl.edu/links/evidence_items/4768	https://civic.genome.wustl.edu/links/variants/1639	https://civic.genome.wustl.edu/links/genes/4			splice_donor_variant		5
1639	ABL1	25	C475V	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_C475V_was_seen_in_a_single_imatinib_resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6977	4	9	133753954	133753955	TG	GT			NA	NA		NA	GRCh37		Somatic_Mutation	2018-11-16_21:44:26_UTC	https://civic.genome.wustl.edu/links/evidence_items/6977	https://civic.genome.wustl.edu/links/variants/1639	https://civic.genome.wustl.edu/links/genes/4			splice_donor_variant		5
1640	ABL1	25	N336S	Chronic_Myeloid_Leukemia	8552		Imatinib_Mesylate		Predictive	Supports	C	Resistance	In_a_study_of_39_chronic_phase_CML_patients_with_BCR-ABL_variants,_N336S_was_seen_in_a_single_imatinib-resistant_patient_that_was_also_resistant_or_intolerant_to_dasatinib_and/or_nilotinib_treatment._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occurring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	6979	4	9	133748346	133748346	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2019-01-14_19:18:23_UTC	https://civic.genome.wustl.edu/links/evidence_items/6979	https://civic.genome.wustl.edu/links/variants/1640	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1007A>G	5
1640	ABL1	25	N336S	Chronic_Myeloid_Leukemia	8552		Bosutinib		Predictive	Does_Not_Support	C	Resistance	This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)_were_comparable_for_patients_with_Abl1_mutation_versus_without._Of_patients_with_N336S,_1/1_had_a_CHR_and_0/1_had_a_MCyR._Nine_patients_in_this_study_had_multiple_kinase_domain_mutations,_but_it_was_not_indicated_when_mutations_were_co-occuring.	22371878	PubMed	NA	Khoury_et_al.,_2012,_Blood		1	accepted	4769	4	9	133748346	133748346	A	G	ENST00000318560.5		NA	NA		75	GRCh37		Somatic_Mutation	2018-12-21_19:19:53_UTC	https://civic.genome.wustl.edu/links/evidence_items/4769	https://civic.genome.wustl.edu/links/variants/1640	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000318560.5:c.1007A>G	5
1647	POLD1	5424	C284Y	Lung_Adenocarcinoma	3910		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	In_a_retrospective_study_of_34_non-small_cell_lung_cancer_patients,_a_lung_adenocarcinoma_patient_with_POLD1_deleterious_(as_determined_by_Polyphen_or_SIFT)_C284Y_mutation_and_a_high_nonsynonymous_mutation_burden,_treated_with_pembrolizumab_monotherapy,_was_associated_with_a_durable_clinical_benefit;_POLD1_deleterious_mutation_was_not_identified_in_any_patients_who_did_not_experience_a_durable_clinical_benefit.	25765070	PubMed	NA	Rizvi_et_al.,_2015,_Science		NA	accepted	4776	4384		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-04-16_14:09:51_UTC	https://civic.genome.wustl.edu/links/evidence_items/4776	https://civic.genome.wustl.edu/links/variants/1647	https://civic.genome.wustl.edu/links/genes/4384					0
1648	POLD1	5424	E374K	Non-small_Cell_Lung_Carcinoma	3908		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	In_a_retrospective_study_of_34_non-small_cell_lung_cancer_patients,_a_patient,_who_never_smoked,_with_POLD1_deleterious_E374K_mutation_(as_determined_by_Polyphen_or_SIFT)_and_a_high_nonsynonymous_mutation_burden,_treated_with_pembrolizumab_monotherapy,_was_associated_with_a_durable_clinical_benefit;_POLD1_deleterious_mutation_was_not_identified_in_patients_who_did_not_experience_a_durable_clinical_benefit.	25765070	PubMed	NA	Rizvi_et_al.,_2015,_Science		NA	accepted	4777	4384		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-04-16_14:12:40_UTC	https://civic.genome.wustl.edu/links/evidence_items/4777	https://civic.genome.wustl.edu/links/variants/1648	https://civic.genome.wustl.edu/links/genes/4384					0
1652	PIK3R2	5296	N561D	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An_in_vitro_study_of_WM2664_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_PIK3R2_and_BRAF_V600D_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_virally_induced_to_stably_over-express_PIK3R2_N561D_were_significantly_more_resistant_to_vemurafenib_(a_BRAF_inhibitor)_than_cells_transduced_with_an_empty_vector_(40%_vs_0%_survival_at_the_highest_concentration,_p_<_.0001).	24265155	PubMed	NA	Shi_et_al.,_2014,_Cancer_Discov		3	accepted	4783	4290		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-07-19_20:31:18_UTC	https://civic.genome.wustl.edu/links/evidence_items/4783	https://civic.genome.wustl.edu/links/variants/1652	https://civic.genome.wustl.edu/links/genes/4290					3
1653	PIK3CA	5290	D350G	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	An_in_vitro_study_of_M229_(a_human_melanoma_cell_line)_endogenously_expressing_wildtype_PIK3CA_and_BRAF_V600E_(a_known_BRAF_inhibitor_sensitizing_mutation)_found_that_cells_virally_induced_to_stably_over-express_PIK3CA_D350G_were_significantly_more_resistant_to_BRAF_inhibition_by_vemurafenib__than_cells_transduced_with_empty_vectors_(40%_vs_20%_survival_at_the_highest_concentration,_p=.0148)._Though_statistics_were_not_provided,_D350G_appears_to_confer_less_resistance_to_vemurafenib_than_the_positive_control_variant,_PIK3CA_E545K.	24265155	PubMed	NA	Shi_et_al.,_2014,_Cancer_Discov		2	accepted	4784	37	3	178921567	178921567	A	G	ENST00000263967.3		NA	NA		75	GRCh37		Somatic_Mutation	2018-07-19_20:22:57_UTC	https://civic.genome.wustl.edu/links/evidence_items/4784	https://civic.genome.wustl.edu/links/variants/1653	https://civic.genome.wustl.edu/links/genes/37			missense_variant	ENST00000263967.3:c.1049A>G,NC_000003.11:g.178921567A>G,NM_006218.2:c.1049A>G,NP_006209.2:p.Asp350Gly	2
1654	NRAS	4893	Q179X	Colorectal_Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	In_a_retrospective_study_of_148_treatment_naive_metastatic_colorectal_cancer_patients,_patients_with_RAS_mutations_(n=10),_including_KRAS_A146T,_KRAS_G13D,_NRAS_G12D_and_NRAS_Q179*,_treated_with_FOLFOX4_plus_cetuximab_were_associated_with_decreased_overall_survival_(16.3mo_vs._28.5mo,_HR:0.43,_95%_CI:0.20-0.89,_P=0.020)_and_decreased_progression_free_survival_(7.2mo_vs._9.7mo,_HR:0.56,_95%_CI:0.27-1.16,_P=0.11),_as_compared_to_patients_with_wild-type_KRAS_and_NRAS.	25666295	PubMed	NA	Kaczirek_et_al.,_2015,_Clin_Colorectal_Cancer		NA	accepted	4785	36		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2017-07-20_15:58:23_UTC	https://civic.genome.wustl.edu/links/evidence_items/4785	https://civic.genome.wustl.edu/links/variants/1654	https://civic.genome.wustl.edu/links/genes/36					0
1656	ABL1	25	R351W	Non-small_Cell_Lung_Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In_this_in_vitro_study,_the_H1915_non-small_cell_lung_cancer_cell_line_(homozygous_for_a_R351W_mutation)_was_shown_to_be_susceptible_to_dasatinib._This_line_showed_a_significant_reduction_in_colony_formation_(P_<_0.001)_and_MTT_assay,_which_tests_for_NADH_activity_(P_=_1.09_x_10^5),_with_dasatinib_vs_vehicle_treatment._There_was_no_significant_difference_in_a_lung_cancer_cell_line_without_a_known_driver_(H2126)_nor_in_an_immortalized_bronchial_epithelial_line_(Beas-2B)_with_either_drug_treatment_in_colony_forming_and_MTT_assays._Additionally,_reduction_in_cell_viability_upon_kinase_inhibitor_treatment_could_be_rescued_with_tetracycline-induced_overexpression_of_resistant_ABL1-T315I_(P_<_0.001)_confirming_the_genetic_dependency_of_this_cell_line_on_ABL1._Moreover,_a_significant_increased_in_cytotoxicity_was_noted_with_siRNA_facilitated_depletion_of_ABL1_(P_<_0.005)_with_no_significant_change_in_H2126_or_Beas-2B_lines_supporting_ABL1_as_the_primary_drug_target.	26758680	PubMed	NA	Testoni_et_al.,_2016,_EMBO_Mol_Med		4	accepted	4787	4	9	133748333	133748333	C	T	ENST00000372348.2		NA	NA		75	GRCh37		Somatic_Mutation	2018-11-05_23:08:35_UTC	https://civic.genome.wustl.edu/links/evidence_items/4787	https://civic.genome.wustl.edu/links/variants/1656	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000372348.2:c.1051C>T	9
1656	ABL1	25	R351W	Non-small_Cell_Lung_Carcinoma	3908		Imatinib		Predictive	Supports	D	Sensitivity/Response	In_this_in_vitro_study,_the_H1915_non-small_cell_lung_cancer_cell_line_(homozygous_for_a_R351W_mutation)_was_shown_to_be_susceptible_to_imatinib._This_line_showed_a_significant_reduction_in_colony_formation_(P_=_0.0004)_and_MTT_assay,_which_tests_for_NADH_activity_(P_<_0.001),_with_imatinib_vs_vehicle_treatment._There_was_no_significant_difference_in_a_lung_cancer_cell_line_without_a_known_driver_(H2126)_nor_in_an_immortalized_bronchial_epithelial_line_(Beas-2B)_with_either_drug_treatment_in_colony_forming_and_MTT_assays._Additionally,_reduction_in_cell_viability_upon_kinase_inhibitor_treatment_was_rescued_with_tetracycline-induced_overexpression_of_resistant_ABL1-T315I_(P_<_0.001)_confirming_the_genetic_dependency_of_this_cell_line_on_ABL1._Moreover,_siRNA_facilitated_depletion_of_ABL1_expression_resulted_in_significantly_increased_cytotoxicity_(P_<_0.004)_with_no_significant_change_in_H2126_or_Beas-2B_lines_for_2/3_siRNAs_supporting_ABL1_as_the_primary_drug_target._Significant_tumor_reduction_was_observed_in_murine_NSCLC_xenografts_of_the_H1915_cell_line_treated_with_imatinib_compared_to_vehicle_treatment_(P_=_0.0016)._No_change_in_tumor_growth_was_observed_in_xenografts_of_the_H650_cell_line_containing_a_wildtype_ABL1_locus._In_both_in_vitro_and_in_vivo_experiments,_doxycycline-inducible_expression_of_drug-resistant_ABL1-T315I_rescued_imatinib-mediated_inhibitory_effects_supporting_the_specificity_of_drug_responses.	26758680	PubMed	NA	Testoni_et_al.,_2016,_EMBO_Mol_Med		5	accepted	6376	4	9	133748333	133748333	C	T	ENST00000372348.2		NA	NA		75	GRCh37		Somatic_Mutation	2018-11-05_23:10:28_UTC	https://civic.genome.wustl.edu/links/evidence_items/6376	https://civic.genome.wustl.edu/links/variants/1656	https://civic.genome.wustl.edu/links/genes/4			missense_variant	ENST00000372348.2:c.1051C>T	9
1657	ABL1	25	G340L	Non-small_Cell_Lung_Carcinoma	3908		Imatinib_Mesylate,Dasatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	In_this_in_vitro_study,_the_H2110_non-small_cell_lung_cancer_cell_line_(heterozygous_for_a_G340L_mutation)_was_shown_to_be_susceptible_to_imatinib_and_dasatinib_monotherapies._This_line_showed_a_significant_reduction_in_colony_formation_(P_=_0.0001)_and_MTT_assay,_which_tests_for_NADH_activity_(P_<_0.001),_with_imatinib_vs_vehicle_treatment._A_significant_reduction_in_colony_formation_(P_<_0.001)_with_dasatinib_treatment_vs_vehicle_was_also_observed._There_was_no_significant_difference_in_a_lung_cancer_cell_line_without_a_known_driver_(H2126)_nor_in_an_immortalized_bronchial_epithelial_line_(Beas-2B)_with_either_drug_treatment_in_colony_forming_and_MTT_assays._Moreover,_a_significant_increase_in_cytotoxicity_was_noted_with_siRNA_facilitated_depletion_of_ABL1_(P_<_0.001)_with_no_significant_change_in_H2126_or_Beas-2B_lines_supporting_ABL1_as_the_primary_drug_target.	26758680	PubMed	NA	Testoni_et_al.,_2016,_EMBO_Mol_Med		3	accepted	4788	4	9	133748300	133748301	GG	CT			NA	NA		NA	GRCh37		Somatic_Mutation	2018-07-23_21:38:00_UTC	https://civic.genome.wustl.edu/links/evidence_items/4788	https://civic.genome.wustl.edu/links/variants/1657	https://civic.genome.wustl.edu/links/genes/4			coding_sequence_variant		3
1664	EGFR	1956	M766_A767insAI	Non-small_Cell_Lung_Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_M766_A767insAI_demonstrated_reduced_sensitivity_to_erlotinib_treatment_(IC50=3.403�M),_comparable_to_Ba/F3_cells_expressing_EGFR_L858R_and_T790M_co-mutation_(T790M_is_a_known_resistant_mutation_to_1st_and_2nd_generation_EGFR_tyrosine_kinase_inhibitors;_IC50=4.155�M)._Resistance_was_determined_by_assessing_cell_proliferation,_EGFR,_AKT_and_ERK_phosphorylation.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4799	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-11_10:43:49_UTC	https://civic.genome.wustl.edu/links/evidence_items/4799	https://civic.genome.wustl.edu/links/variants/1664	https://civic.genome.wustl.edu/links/genes/19					0
1665	EGFR	1956	Y764_V765insHH	Non-small_Cell_Lung_Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	In_an_in_vitro_study,_a_Ba/F3_cell_line_expressing_EGFR_Y764_V765insHH_demonstrated_reduced_sensitivity_to_erlotinib_treatment_(IC50=3.845�M),_comparable_to_Ba/F3_cells_expressing_EGFR_L858R_and_T790M_co-mutation_(T790M_is_a_known_resistant_mutation_to_1st_and_2nd_generations_EGFR_tyrosine_kinase_inhibitors;_IC50=4.155�M)._Resistance_was_determined_by_assessing_cell_proliferation,_EGFR,_AKT_and_ERK_phosphorylation.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4800	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-11_10:35:51_UTC	https://civic.genome.wustl.edu/links/evidence_items/4800	https://civic.genome.wustl.edu/links/variants/1665	https://civic.genome.wustl.edu/links/genes/19					0
1666	EGFR	1956	D770_N771insGY	Lung_Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In_a_study_of_19_non-small_cell_lung_carcinoma_patients_with_EGFR_exon_20_insertion_mutation_and_treated_with_erlotinib_monotherapy,_patients_with_EGFR_delD770insGY_mutation_(n=2)_experienced_progressive_disease.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4801	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-08_23:47:00_UTC	https://civic.genome.wustl.edu/links/evidence_items/4801	https://civic.genome.wustl.edu/links/variants/1666	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0
1667	EGFR	1956	P772_H773insYNP	Non-small_Cell_Lung_Carcinoma	3908		Erlotinib		Predictive	Supports	C	Resistance	In_a_non-small_cell_lung_cancer_patient_harboring_EGFR_P772_H773insYNP_mutation,_EGFR_P772_H773insYNP_was_associated_with_progressive_disease_in_response_to_erlotinib_monotherapy.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4802	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-08_23:45:43_UTC	https://civic.genome.wustl.edu/links/evidence_items/4802	https://civic.genome.wustl.edu/links/variants/1667	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0
1668	EGFR	1956	P772_V774insPHV	Lung_Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	In_a_lung_adenocarcinoma_patient_harboring_EGFR_P772_V774insPHV_mutation,_EGFR_P772_V774insPHV_was_associated_with_progressive_disease_in_response_to_erlotinib_monotherapy.	24353160	PubMed	NA	Yasuda_et_al.,_2013,_Sci_Transl_Med		NA	accepted	4803	19		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-02-08_23:46:02_UTC	https://civic.genome.wustl.edu/links/evidence_items/4803	https://civic.genome.wustl.edu/links/variants/1668	https://civic.genome.wustl.edu/links/genes/19			inframe_insertion		0
1681	JAK2	3717	F547_SPLICE_SITE_MUTATION	Melanoma	1909		Pembrolizumab		Predictive	Supports	C	Resistance	In_a_retrospective_study_of_four_relapsed,_malignant_melanoma_patients,_JAK2_(c.1641+2T>G)_F547_splice_site_mutation_was_associated_with_acquired_resistance_to_pembrolizumab_monotherapy_in_one_patient.	27433843	PubMed	NA	Zaretsky_et_al.,_2016,_N._Engl._J._Med.		NA	accepted	4825	28	9	5070054	5070054	T	G			NA	NA		NA	GRCh37		Somatic_Mutation	2017-07-25_19:41:09_UTC	https://civic.genome.wustl.edu/links/evidence_items/4825	https://civic.genome.wustl.edu/links/variants/1681	https://civic.genome.wustl.edu/links/genes/28			splice_donor_variant		0
1682	ARID1A	8289	P1175FS*5	Ovarian_Clear_Cell_Carcinoma	50934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In_an_in_vitro_study,_a_HCH1_cell_line_expressing_ARID1A_P1175fs*5_mutation_demonstrated_increased_sensitivity_to_dasatinib_treatment,_compared_to_ES2,_KK_and_RMG-1_cells_expressing_wild-type_ARID1A._Sensitivity_was_determined_by_assessing_cell_survival.	27364904	PubMed	NA	Miller_et_al.,_2016,_Mol._Cancer_Ther.		NA	accepted	4826	6559		NA	NA					NA	NA		NA	GRCh37		Somatic_Mutation	2018-07-06_20:39:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/4826	https://civic.genome.wustl.edu/links/variants/1682	https://civic.genome.wustl.edu/links/genes/6559					0
1687	RET	5979	FUSION	Non-small_Cell_Lung_Carcinoma	3908		Vandetanib		Predictive	Supports	B	Sensitivity/Response	We_aimed_to_assess_the_efficacy_and_safety_of_vandetanib_in_patients_with_advanced_RET-rearranged_NSCLC._In_this_open-label,_multicentre,_phase_2_trial_(LURET),_patients_with_advanced_RET-rearranged_NSCLC_continuously_received_300_mg_of_oral_vandetanib_daily._1536_patients_with_EGFR_mutation-negative_NSCLC_were_screened,,_34_were_RET-positive_(2%),_19_were_enrolled_and_17_patients_were_eligible_for_primary_analysis.___9_patients_(53%)_achieved_and_objective_response,_in_the_intention_to_treat_population_of_19_patients,_9_patients_(47%_achieved_an_OR._At_data_cutoff,_median_PFS_was_4,7_months._The_results_define_RET_rearrangement_as_a_new_molecular_subgroup_of_NSCLC_suitable_for_targeted_therapy.	27825616	PubMed	NA	Yoh_et_al.,_2017,_Lancet_Respir_Med		3	accepted	4849	42		NA	NA					NA	NA		NA			Somatic_Mutation	2018-10-11_08:59:37_UTC	https://civic.genome.wustl.edu/links/evidence_items/4849	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42					60
1687	RET	5979	FUSION	Non-small_Cell_Lung_Carcinoma	3908		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	RET_rearrangements_are_found_in_1-2%_of_non-small-cell_lung_cancers._Cabozantinib_is_a_multikinase_inhibitor_with_activity_against_RET_that_produced_a_10%_overall_response_in_unselected_patients_with_lung_cancers._An_open-label,_two-stage,_single-centre,_phase_2,_single-arm_trial_in_the_USA_in_metastatic/unresectable_lung_cancer_harbouring_RET_rearrangement._26_Patients_were_given_60_mg_of_cabozantinib_orally_per_day._The_primary_objective_was_overall_response,_25_patients_assessable._KIF5B-RET_was_the_predominant_fusion_in_16_(62%)_patients._With_confirmed_PR_seen_in_7/25_(28%)_response-assessable_patients._The_reported_activity_of_cabozantinib_in_patients_with_RET-rearranged_lung_cancers_defines_RET_rearrangements_as_actionable_drivers_in_patients_with_lung_cancers	27825636	PubMed	NA	Drilon_et_al.,_2016,_Lancet_Oncol.		3	accepted	4847	42		NA	NA					NA	NA		NA			Somatic_Mutation	2018-10-11_09:03:09_UTC	https://civic.genome.wustl.edu/links/evidence_items/4847	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42					60
1687	RET	5979	FUSION	Non-small_Cell_Lung_Carcinoma	3908		Vandetanib		Predictive	Supports	B	Sensitivity/Response	RET_rearrangements_involving_RET_are_found_in_about_1%_of_NSCLC_and_define_a_unique_molecular_subset.__This_study_was_a_multi-center,_open-label,_phase_II_clinical_trial_to_examine_the_safety_and_efficacy_of_Vandetanib_(300_mg/d)_in_RET_positive_NSCLC_patients_(confirmed_by_FISH),_Primary_endpoint_was_the_objective_response_rate._18_patients_were_enrolled,_the_majority_were_a_heavily_pretreated_population._Among_the_17_evaluable_patients,_three_had_a_partial_response_(ORR = 18%)_and_eight_had_a_stable_disease_(DCR = 65%)._Among_these_patients,_the_PR_or_SD_was_durable_for_more_than_6_months_in_8_patients._Vandetanib_also_showed_a_PFS_of_4.5_months,_and_an_OS_of_11.6_months_during_a_median_follow-up_duration_of_14_months.	27803005	PubMed	NA	Lee_et_al.,_2017,_Ann._Oncol.		3	accepted	4848	42		NA	NA					NA	NA		NA			Somatic_Mutation	2018-10-11_09:14:36_UTC	https://civic.genome.wustl.edu/links/evidence_items/4848	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42					60
1687	RET	5979	FUSION	Non-small_Cell_Lung_Carcinoma	3908		Alectinib		Predictive	Supports	B	Sensitivity/Response	Alectinib_is_an_anaplastic_lymphoma_kinase_tyrosine_kinase_inhibitor_(TKI)_that_also_has_anti-RET_activity_in_vitro._The_clinical_activity_of_alectinib_in_patients_with_RET-rearranged_NSCLC_has_not_yet_been_reported._4_patients_with_metastatic_RET-rearranged_NSCLC_were_identified._3_of_4_had_received_prior_RET_TKIs,_including_cabozantinib_and_experimental_RET_inhibitors._We_observed_two_(50%)_objective_radiographic_responses_after_treatment_with_alectinib_(one_confirmed_and_one_unconfirmed),_with_durations_of_therapy_of_6_months_and_more_than_5_months_(treatment_ongoing)._Notably,_one_of_these_two_patients_had_his_dose_of_alectinib_escalated_to_900_mg_twice_daily_and_had_clinical_improvement_in_central_nervous_system_metastases._In_addition,_one_patient_(25%)_experienced_a_best_response_of_stable_disease_lasting_approximately_6_weeks._A_fourth_patient_who_was_RET_TKI-naive_had_primary_progression_while_receiving_alectinib.	27544060	PubMed	NA	Lin_et_al.,_2016,_J_Thorac_Oncol		3	accepted	4850	42		NA	NA					NA	NA		NA			Somatic_Mutation	2018-10-11_09:00:55_UTC	https://civic.genome.wustl.edu/links/evidence_items/4850	https://civic.genome.wustl.edu/links/variants/1687	https://civic.genome.wustl.edu/links/genes/42					60
1693	CHEK1	1111	OVEREXPRESSION	Lung_Small_Cell_Carcinoma	5409		Prexasertib,Olaparib,Cisplatin	Combination	Predictive	Supports	D	Sensitivity/Response	A_preclinical_study_to_evaluate_the_efficacy_of_targeting_the_overexpressed_CHEK1_cell_cycle_chekpoint_kinase,_including_both_miRNA_and_Prexasertib-induced_inhibition._Both_in_vitro_and_in_vivo,_Prexasertib_had_strong_single_agent_efficacy_and_augmented_the_effect_of_Olaparib_or_Cisplatin_in_either_combination,_including_platinum-resistant_models._CHEK1_and_MYC_overexpression_were_predictors_of_response.	28490518	PubMed	NA	Sen_et_al.,_2017,_Cancer_Res.		4	accepted	4874	981		NA	NA					NA	NA		NA			N/A	2017-12-18_20:29:46_UTC	https://civic.genome.wustl.edu/links/evidence_items/4874	https://civic.genome.wustl.edu/links/variants/1693	https://civic.genome.wustl.edu/links/genes/981					4
1695	TP53	7157	R158H	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R158H_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4886	45		NA	NA					NA	NA		NA			Somatic_Mutation	2018-04-30_23:56:54_UTC	https://civic.genome.wustl.edu/links/evidence_items/4886	https://civic.genome.wustl.edu/links/variants/1695	https://civic.genome.wustl.edu/links/genes/45					4
1696	TP53	7157	R249S	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R249S_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4888	45		NA	NA					NA	NA		NA			Somatic_Mutation	2018-04-30_23:28:59_UTC	https://civic.genome.wustl.edu/links/evidence_items/4888	https://civic.genome.wustl.edu/links/variants/1696	https://civic.genome.wustl.edu/links/genes/45					4
1697	TP53	7157	R280K	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R280K_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4889	45		NA	NA					NA	NA		NA			Somatic_Mutation	2018-04-30_23:28:26_UTC	https://civic.genome.wustl.edu/links/evidence_items/4889	https://civic.genome.wustl.edu/links/variants/1697	https://civic.genome.wustl.edu/links/genes/45					4
1698	TP53	7157	R280T	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R280T_loss_of_function_mutation_is_present_in_1_cell_line_and_it_is_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4890	45		NA	NA					NA	NA		NA			Somatic_Mutation	2018-04-30_23:23:25_UTC	https://civic.genome.wustl.edu/links/evidence_items/4890	https://civic.genome.wustl.edu/links/variants/1698	https://civic.genome.wustl.edu/links/genes/45					4
1699	TP53	7157	R158L	Cancer	162		AMGMDS3		Predictive	Supports	D	Resistance	Subset_of_58_cancer_cell_lines_with_unaltered_TP53_is_sensitive_to_MDM2_Inhibitor_AMGMDS3._None_of_115_cancer_cell_lines_with_TP53_mutation_and_absence_of_WT_allele_are_sensitive_to_MDM2_Inhibitor._TP53_R158L_loss_of_function_mutation_is_present_in_2_cell_lines_and_all_are_insensitive_to_MDM2_Inhibitor_AMGMDS3.	25730903	PubMed	NA	Saiki_et_al.,_2015,_Oncotarget		4	accepted	4891	45		NA	NA					NA	NA		NA			Somatic_Mutation	2018-04-30_23:16:00_UTC	https://civic.genome.wustl.edu/links/evidence_items/4891	https://civic.genome.wustl.edu/links/variants/1699	https://civic.genome.wustl.edu/links/genes/45					4
1765	EGFR	1956	Gain-of-function	Non-small_Cell_Lung_Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	Study_found_Somatic_EGFR_mutations_localized_to_exons_19,21_in_8/9_patients_who_exhibited_a_response_to_Gefitinib_treatment._Of_these_mutations_7/8_were_localized_near_the_ATP_cleft_Gefitinib_targets._No_EGFR_mutations_were_observed_in_7_patients_with_no_response_to_Gefitinib._An_expansion_cohort_independent_of_the_Gefitinib_study_showed_2/25_patients_harbored_EGFR_mutations._A_second_expansion_independent_of_Gefitinib_consisting_of_95_tumors_and_108_cell_lines_showed_no_mutations_in_exons_19,21.	15118073	PubMed	NA	Lynch_et_al.,_2004,_N._Engl._J._Med.		4	accepted	4931	19		NA	NA					NA	NA		NA			Somatic_Mutation	2018-07-10_18:49:03_UTC	https://civic.genome.wustl.edu/links/evidence_items/4931	https://civic.genome.wustl.edu/links/variants/1765	https://civic.genome.wustl.edu/links/genes/19					20
1854	EGFR	1956	Ex19_del_L858R	Non-small_Cell_Lung_Carcinoma	3908		Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In_a_study_of_1261_non-small_cell_lung_cancer_patients,_49.8%_of_the_analyzed_tumors_had_EGFR_mutations_including_deletions_in_exon_19_(n=258),_L858R_(n=260),_T790M_(n=6)_and_insertions_or_duplications_in_exon_20_(n=25)._Patients_with_EGFR_deletions_in_exon_19_or_L858R_mutations_were_associated_with_an_improved_response_to_erlotinib_or_gefitinib_with_partial_or_complete_response_(74.1%_vs._16.5%,_P<0.001)_when_compared_to_wildtype_EGFR_patients._Additionally,_tumors_with_EGFR_mutations_in_L858R_or_deletions_in_exon_19_were_associated_with_increased_overall_survival_(19.6mo_vs._10.4mo)_compared_to_wildtype_(all_patients_were_treated_with_either_erlotinib_or_gefitinib)._From_61_patients_with_uncommon_EGFR_mutations_of_unknown_clinical_significance,_47.5%_were_responders_in_contrast_to_the_74.1%_responders_in_the_exon_19_deleti",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_2011,"_Clin._Cancer_Res.		4	accepted	4759	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_20:26:47_UTC	https://civic.genome.wustl.edu/links/evidence_items/4759	https://civic.genome.wustl.edu/links/variants/1854	https://civic.genome.wustl.edu/links/genes/19			missense_variant","inframe_deletion		50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_95%_CI:_0.05-0.75,"_P=0.017)_as_compared_to_treatment_(n=18)_with_pemtrexed/platinum_alone.__In_the_subgroup_of_patients_without_EGFR_mutation_(defined_as_all_patients_without_the_specific_EGFR_exon_19_deletion_or_L858R_mutation)_a_difference_in_median_PFS_was_not_seen_between_the_chemotherapy_versus_chemotherapy_with_gefitinib_treatment_groups.	24755888	PubMed	NA	Yu_et_al.",_2014,"_Cancer_Biol._Ther.		4	accepted	2156	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-10-02_20:42:41_UTC	https://civic.genome.wustl.edu/links/evidence_items/2156	https://civic.genome.wustl.edu/links/variants/1854	https://civic.genome.wustl.edu/links/genes/19			missense_variant","inframe_deletion		50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_and_improved_progression-free_survival_was_reported_in_the_erlotinib_treated_cohort_as_compared_to_the_cohort_that_was_treated_with_standard_chemotherapy_(9.7mo_vs._5.2mo,_HR:0.37,_95%CI:0.25-0.54,_P<0.0001,_univariate_analysis;_HR:0.35,_95%CI:0.23-0.52,_P<0.0001,"_multivariate_analysis).	22285168	PubMed	NA	Rosell_et_al.",_2012,"_Lancet_Oncol.		4	accepted	3791	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-08-04_14:30:13_UTC	https://civic.genome.wustl.edu/links/evidence_items/3791	https://civic.genome.wustl.edu/links/variants/1854	https://civic.genome.wustl.edu/links/genes/19			missense_variant","inframe_deletion		50",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	In_a_cohort_of_NSCLC_patients_treated_with_tyrosine_kinase_inhibitors_erlotinib_or_gefitinib",_61_patients_with_uncommon_mutations_of_unknown_clinical_significance_(UMUCS)_in_EGFR_exons_18-21_responded_at_a_rate_of_47.5%_(primarily_G719_and_L861,_N=30/61)._This_was_significantly_greater_(p<0.001)_than_a_response_rate_of_16.5%_in_EGFR_wild_type_patients_but_significantly_smaller_(p<0.001)_than_a_74.1%_response_in_EGFR_mutant_patients_with_canonical_exon_19_deletion_or_L858R_mutation._Uncommon_mutations_also_had_greater_median_PFS_(5.0_vs._2.0_months,_P_<_0.001)_and_median_overall_survival_(15.0_vs._10.4_months,"_P_=_0.030)_than_in_patients_with_the_wild-type_EGFR.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		4	accepted	4755	19		NA	NA					NA	NA		NA		Rare_exon_18-21_mutations_in_EGFR_consist_of_all_EGFR_mutations_excluding_sensitizing_L858R_substitutions_and_exon_19_deletions","_as_well_as_resistance_mutation_T790M.	Somatic_Mutation	2017-07-20_15:35:36_UTC	https://civic.genome.wustl.edu/links/evidence_items/4755	https://civic.genome.wustl.edu/links/variants/1863	https://civic.genome.wustl.edu/links/genes/19	Rare_exon_18-21_mutations_in_EGFR_consist_of_all_EGFR_mutations_excluding_sensitizing_L858R_substitutions_and_exon_19_deletions","_as_well_as_resistance_mutation_T790M.		exon_variant		30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Erlotinib	Substitutes	Predictive	Does_Not_Support	B	Sensitivity/Response	In_a_cohort_of_NSCLC_patients_tested_for_mutation_in_EGFR_exons_18-21_a_subset_had_uncommon_mutations_of_unknown_clinical_significance_(UMUCS)._The_most_commonly_occurring_UMUCS_were_G719_and_L861_mutations._Among_patients_that_had_UMUCS_but_not_G719_or_L861",_the_response_rate_to_tyrosine_kinase_inhibitors_erlotinib_or_gefitinib,_progression_free_survival,_and_overall_survival_were_20%,_1.6_month_and_11.1_months,_which_was_similar_for_wild_type_EGFR_(16.5%,_2.0_months_and_10.4_months),_which_contrasted_to_higher_response_for_more_commonly_occurring_G719_and_L861_mutations_(53.3%_and_60.0%,"_respectively).	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		2	accepted	4762	19		NA	NA					NA	NA		NA		Rare_exon_18-21_mutations_in_EGFR_consist_of_all_EGFR_mutations_excluding_sensitizing_L858R_substitutions_and_exon_19_deletions","_as_well_as_resistance_mutation_T790M.	Somatic_Mutation	2017-07-20_15:35:46_UTC	https://civic.genome.wustl.edu/links/evidence_items/4762	https://civic.genome.wustl.edu/links/variants/1863	https://civic.genome.wustl.edu/links/genes/19	Rare_exon_18-21_mutations_in_EGFR_consist_of_all_EGFR_mutations_excluding_sensitizing_L858R_substitutions_and_exon_19_deletions","_as_well_as_resistance_mutation_T790M.		exon_variant		30",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	EGFR_L861_mutations_have_been_associated_with_increased_sensitivity_to_first_generation_EGFR_tyrosine_kinase_inhibitors",_including_erlotinib_and_gefitinib._In_a_study_of_patients_treated_with_erlotinib_or_gefitinib,_a_subset_of_patients_with_EGFR_mutation_at_codons_G719_or_L861_(n=30)_was_associated_with_improved_response_rate_(47.5%_vs_16.5%,_P<0.001)_median_progression_free_survival_(5.0_vs_2.0_months,_P<0.001),_and_overall_survival_(15.0_vs._10.4_months,_P_=0.030),"_compared_to_patients_with_wild-type_EGFR_(n=272).	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		3	accepted	4298	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_18:11:13_UTC	https://civic.genome.wustl.edu/links/evidence_items/4298	https://civic.genome.wustl.edu/links/variants/1866	https://civic.genome.wustl.edu/links/genes/19					15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_2_participants_with_stage_IV_adenocarcinoma_were_sequenced_at_EGFR_exons_18_to_21.__Both_patients_were_found_to_have_L747P_mutation_and_were_treated_with_the_1st_generation_TKIs_gefitinib_or_erlotinib._The_first_patient_(M,_62,_nonsmoker)_was_treated_with_gefitinib_and_had_progressive_disease,_progression_free_survival_(PFS)_of_1.0_months,_overall_survival_(OS)_of_7.7_months_and_was_not_alive_at_study_end._The_second_patient_(M,_39,_nonsmoker)_was_treated_with_erlotinib_and_had_progressive_disease_as_response,_PFS_of_2.3_months,_OS_of_7.2_months_and_was_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		2	accepted	4220	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_22:55:33_UTC	https://civic.genome.wustl.edu/links/evidence_items/4220	https://civic.genome.wustl.edu/links/variants/1891	https://civic.genome.wustl.edu/links/genes/19					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_1_participant_with_stage_IV_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_V774A_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(F,_51,_nonsmoker)_had_a_partial_response,_progression_free_survival_(PFS)_of_6.9_months,_overall_survival_(OS)_of_29.7_months_and_was_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		3	accepted	4226	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_22:40:50_UTC	https://civic.genome.wustl.edu/links/evidence_items/4226	https://civic.genome.wustl.edu/links/variants/1892	https://civic.genome.wustl.edu/links/genes/19					7.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_1_participant_with_stage_IV_squamous_cell_lung_carcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_V774M_mutation,_and_was_treated_with_the_1st_generation_TKI_erlotinib._The_patient_(M,_80,_smoker)_had_progressive_disease_as_response,_progression_free_survival_(PFS)_of_1.6_months,_overall_survival_(OS)_of_6.7_months_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		2	accepted	4231	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_22:41:56_UTC	https://civic.genome.wustl.edu/links/evidence_items/4231	https://civic.genome.wustl.edu/links/variants/1894	https://civic.genome.wustl.edu/links/genes/19					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_1_participant_with_stage_IIIB_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_K806E_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(M,_77,_nonsmoker)_had_progressive_disease_as_response,_progression_free_survival_(PFS)_of_1.6_months,_overall_survival_(OS)_of_28.1_months_and_was_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		2	accepted	4239	19	7	55249118	55249118	A	G	ENST00000275493.2		NA	NA		75	GRCh37		Somatic_Mutation	2017-07-06_21:59:56_UTC	https://civic.genome.wustl.edu/links/evidence_items/4239	https://civic.genome.wustl.edu/links/variants/1895	https://civic.genome.wustl.edu/links/genes/19			missense_variant	ENST00000275493.2:c.2416A>G	5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_1_participant_with_stage_IV_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_N826Y_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(F,_46,_nonsmoker)_had_progressive_disease_as_response,_progression_free_survival_(PFS)_of_3.3_months,_overall_survival_(OS)_of_13.9_months_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		2	accepted	4244	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_22:37:30_UTC	https://civic.genome.wustl.edu/links/evidence_items/4244	https://civic.genome.wustl.edu/links/variants/1896	https://civic.genome.wustl.edu/links/genes/19					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_1_participant_with_stage_IIIB_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_V834I_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(F,_79,_nonsmoker)_had_a_partial_response,_progression_free_survival_(PFS)_of_5.0_months,_overall_survival_(OS)_of_15.0_months_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		3	accepted	4248	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_22:45:46_UTC	https://civic.genome.wustl.edu/links/evidence_items/4248	https://civic.genome.wustl.edu/links/variants/1897	https://civic.genome.wustl.edu/links/genes/19					7.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_1_participant_with_stage_IV_lung_adenocarcinoma_was_sequenced_at_EGFR_exons_18_to_21_and_was_found_to_have_N842S_mutation,_and_was_treated_with_the_1st_generation_TKI_gefitinib._The_patient_(F,_73,_nonsmoker)_progressive_disease_as_response,_progression_free_survival_(PFS)_of_0.9_months,_overall_survival_(OS)_of_9.7_months_and_was_not_alive_at_study_end._As_a_whole,_patients_with_uncommon_EGFR_mutations_had_a_response_rate_of_47.5%,_which_was_between_common_(del19_and_L858R)_at_74.1%,_and_wild_type_EGFR_at_16.5%._Median_PFS_and_OS_(months)_for_the_three_groups:_5.0_and_15.0_uncommon,_8.5_and_19.6_common,"_2.0_and_10.4_wild_type.	21531810	PubMed	NA	Wu_et_al.",_2011,"_Clin._Cancer_Res.		2	accepted	4256	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-07-06_22:36:46_UTC	https://civic.genome.wustl.edu/links/evidence_items/4256	https://civic.genome.wustl.edu/links/variants/1899	https://civic.genome.wustl.edu/links/genes/19					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Irinotecan	Combination	Predictive	Supports	C	Sensitivity/Response	The_publication_describes_a_patient_with_a_somatic_RAD50_L1237F_mutation_in_combination_with_LOH_and_a_TP53_A161T_mutation_that_showed_a_complete_response_to_a_combination_treatment_with_Irinotecan_and_the_CHK1_inhibitor_AZD7762.	24934408	PubMed	NA	Al-Ahmadie_et_al.",_2014,"_Cancer_Discov		4	accepted	5829	8032		NA	NA					NA	NA		NA			Somatic_Mutation	2017-09-21_18:58:43_UTC	https://civic.genome.wustl.edu/links/evidence_items/5829	https://civic.genome.wustl.edu/links/variants/2168	https://civic.genome.wustl.edu/links/genes/8032					10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_a_subset_of_patients_with_EGFR_mutations_(n=261)_treated_with_gefitinib_were_associated_with_improved_response_(HR:0.48,_95%_CI:0.36-0.64,_P<0.001),_compared_to_carboplatin_plus_paclitaxel_treatment._The_frequency_of_mutation_in_exon_19_deletion_and_L858R_was_53.6%_(140/261)_and_42.5%_(111/261),"_respectively.	19692680	PubMed	NA	Mok_et_al.",_2009,"_N._Engl._J._Med.		NA	accepted	2512	19		NA	NA					NA	NA		NA			Somatic_Mutation	2017-10-19_19:34:54_UTC	https://civic.genome.wustl.edu/links/evidence_items/2512	https://civic.genome.wustl.edu/links/variants/2174	https://civic.genome.wustl.edu/links/genes/19					0",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_prioritizing_a_therapeutic_strategie_targeting_the_HER-family_of_growth_factor_receptors_with_afatinib._This_patient_was_treated_with_the_pan_HER-family_kinase_inhibitor_afatinib_and_displayed_significant_and_durable_response_to_treatment.	28950338	PubMed	NA	Jones_et_al.",_2017,"_Ann._Oncol.		3	accepted	5858	2593		NA	NA					NA	NA		NA			Somatic_Mutation	2018-07-19_10:36:18_UTC	https://civic.genome.wustl.edu/links/evidence_items/5858	https://civic.genome.wustl.edu/links/variants/2178	https://civic.genome.wustl.edu/links/genes/2593		NRG1_gene_fusions			7.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_prioritizing_therapeutic_strategies_targeting_the_HER-family_of_growth_factor_receptors._This_patient_was_treated_with_the_pan_HER-family_kinase_inhibitor_afatinib_and_displayed_a_significant_and_durable_response_to_treatment.	28950338	PubMed	NA	Jones_et_al.",_2017,"_Ann._Oncol.		3	accepted	5859	2593		NA	NA					NA	NA		NA				2018-07-19_10:36:27_UTC	https://civic.genome.wustl.edu/links/evidence_items/5859	https://civic.genome.wustl.edu/links/variants/2179	https://civic.genome.wustl.edu/links/genes/2593		NRG1_gene_fusions			7.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_eight_showed_tumor_response_(18.8%)_and_thirty-six_showed_tumor_shrinkage_(75%).	29182496	PubMed	NA	Javle_et_al.",_2017,"_J._Clin._Oncol.		4	accepted	5908	22		NA	NA					NA	NA		NA			Somatic_Mutation	2018-07-12_18:35:57_UTC	https://civic.genome.wustl.edu/links/evidence_items/5908	https://civic.genome.wustl.edu/links/variants/2202	https://civic.genome.wustl.edu/links/genes/22					20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_but_one_tumor_showed_a_23%_reduction_in__size._Water_fall_plot_of_this_article_showed_5_patients_with_stable_disease.	29182496	PubMed	NA	Javle_et_al.",_2017,"_J._Clin._Oncol.		4	accepted	5912	22		NA	NA					NA	NA		NA			Somatic_Mutation	2018-07-12_18:36:04_UTC	https://civic.genome.wustl.edu/links/evidence_items/5912	https://civic.genome.wustl.edu/links/variants/2206	https://civic.genome.wustl.edu/links/genes/22					20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"GDC-0980	Combination	Predictive	Supports	D	Sensitivity/Response	Novel_alternative_splice_isoform_of_BAP1_(BAP1Δ)_that_misses_part_of_the_catalytic_domain_showed_reduced_deubiquitinating_activity_compared_with_full-length_BAP1._MPM_cell_lines_expressing_more_than_20%_of_BAP1Δ_are_more_sensitive_to_olaparib_(a_PARP1_inhibitor)","_and_this_sensitivity_is_enhanced_when_olaparib_treatment_is_combined_with_GDC0980_(a_dual_PI3K-mTOR_inhibitor).	28389374	PubMed	NA	Parrotta_et_al.",_2017,"_J_Thorac_Oncol		3	accepted	5929	70		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-15_13:05:52_UTC	https://civic.genome.wustl.edu/links/evidence_items/5929	https://civic.genome.wustl.edu/links/variants/2211	https://civic.genome.wustl.edu/links/genes/70					3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_BARD1β,_results_in_a_more_malignant_phenotype_with_decreased_RAD51_foci_formation,_reduced_BRCA1_E3_ubiquitin_ligase_activity,"_and_decreased_nuclear_BRCA1_protein_localization._BARD1β_sensitizes_colon_cancer_cells_to_poly_ADP_ribose_polymerase_1_(PARP-1)_inhibition_even_in_a_BRCA1_WT_background.	27197561	PubMed	NA	Ozden_et_al.",_2016,"_Sci_Rep		3	accepted	5953	549		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-15_13:11:21_UTC	https://civic.genome.wustl.edu/links/evidence_items/5953	https://civic.genome.wustl.edu/links/variants/2219	https://civic.genome.wustl.edu/links/genes/549					3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"_and_her_response_has_been_stable_on_follow-up.	24687827	PubMed	NA	Godbert_et_al.",_2015,"_J._Clin._Oncol.		3	accepted	5954	1		NA	NA					NA	NA		NA			Somatic_Mutation	2019-02-10_00:38:20_UTC	https://civic.genome.wustl.edu/links/evidence_items/5954	https://civic.genome.wustl.edu/links/variants/2220	https://civic.genome.wustl.edu/links/genes/1					7.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5966	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-16_11:20:52_UTC	https://civic.genome.wustl.edu/links/evidence_items/5966	https://civic.genome.wustl.edu/links/variants/2221	https://civic.genome.wustl.edu/links/genes/5					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5968	5	7	140481411	140481411	C	A	ENST00000288602.6		NA	NA		75	GRCh37		Somatic_Mutation	2018-02-16_11:21:52_UTC	https://civic.genome.wustl.edu/links/evidence_items/5968	https://civic.genome.wustl.edu/links/variants/2222	https://civic.genome.wustl.edu/links/genes/5			missense_variant	NC_000007.13:g.140481411C>A",NM_004333.4:c.1397G>T,NP_004324.2:p.Gly466Val,"ENST00000288602.6:c.1397G>T	5",,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5970	5	7	140453118	140453118	C	T	ENST00000288602.6		NA	NA		75	GRCh37		Somatic_Mutation	2018-02-16_11:22:21_UTC	https://civic.genome.wustl.edu/links/evidence_items/5970	https://civic.genome.wustl.edu/links/variants/2223	https://civic.genome.wustl.edu/links/genes/5			missense_variant		5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5972	5	7	140434507	140434507	G	T	ENST00000288602.6		NA	NA		75	GRCh37		Somatic_Mutation	2018-02-16_11:24:30_UTC	https://civic.genome.wustl.edu/links/evidence_items/5972	https://civic.genome.wustl.edu/links/variants/2224	https://civic.genome.wustl.edu/links/genes/5			missense_variant	ENST00000288602.6:c.2193G>T	5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	In_a_retrospective_study_of_44_relapsed_melanoma_patients_harboring_BRAF_V600E_or_V600K_(known_BRAF_inhibitor_sensitizing_mutations)",_MAPK_pathway_reactivation_mechanisms_were_implicated_in_acquired_resistance_to_BRAF_inhibitor_(vemurafenib_or_dabrafenib)_monotherapy._The_following_MAPK_pathway_variants_were_found_in_progressive_tumors_with_patient_matched_baseline_tumors_(some_patients_donated_samples_from_multiple_geographically/temporally_distinct_progressive_tumors):_NRAS_mutations_(G12D,_G12R,_G13R,_Q61K,_Q61R,_Q61L)_in_13/71_(18%)_of_progressive_tumors,_KRAS_mutations_(G12C,_G12R,_Q61H)_in_5/71_(7%)_of_progressive_tumors,_mutant_BRAF_amplification_(2-15_fold_or_4-75_copies)_in_11/57_(19%)_of_progressive_tumors,_mutant_BRAF_alternative_splice_variants_(novel_exon_boundaries_between_1/9,_1/11,"_3/9)_in_6/48_(13%)_of_progressive_tumor_RNA.	24265155	PubMed	NA	Shi_et_al.",_2014,"_Cancer_Discov		3	accepted	6401	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-07-19_23:10:50_UTC	https://civic.genome.wustl.edu/links/evidence_items/6401	https://civic.genome.wustl.edu/links/variants/2225	https://civic.genome.wustl.edu/links/genes/5					20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5973	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-16_11:23:21_UTC	https://civic.genome.wustl.edu/links/evidence_items/5973	https://civic.genome.wustl.edu/links/variants/2225	https://civic.genome.wustl.edu/links/genes/5					20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively_Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5974	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-16_00:05:12_UTC	https://civic.genome.wustl.edu/links/evidence_items/5974	https://civic.genome.wustl.edu/links/variants/2226	https://civic.genome.wustl.edu/links/genes/5					20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	In_a_retrospective_study_of_44_relapsed_melanoma_patients_harboring_BRAF_V600E_or_V600K_(known_BRAF_inhibitor_sensitizing_mutations)",_MAPK_pathway_reactivation_mechanisms_were_implicated_in_acquired_resistance_to_BRAF_inhibitor_(vemurafenib_or_dabrafenib)_monotherapy._The_following_MAPK_pathway_variants_were_found_in_progressive_tumors_with_patient_matched_baseline_tumors_(some_patients_donated_samples_from_multiple_geographically/temporally_distinct_progressive_tumors):_NRAS_mutations_(G12D,_G12R,_G13R,_Q61K,_Q61R,_Q61L)_in_13/71_(18%)_of_progressive_tumors,_KRAS_mutations_(G12C,_G12R,_Q61H)_in_5/71_(7%)_of_progressive_tumors,_mutant_BRAF_amplification_(2-15_fold_or_4-75_copies)_in_11/57_(19%)_of_progressive_tumors,_mutant_BRAF_alternative_splice_variants_(novel_exon_boundaries_between_1/9,_1/11,"_3/9)_in_6/48_(13%)_of_progressive_tumor_RNA.	24265155	PubMed	NA	Shi_et_al.",_2014,"_Cancer_Discov		3	accepted	6400	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-07-19_23:10:17_UTC	https://civic.genome.wustl.edu/links/evidence_items/6400	https://civic.genome.wustl.edu/links/variants/2226	https://civic.genome.wustl.edu/links/genes/5					20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively_Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5975	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-16_00:04:13_UTC	https://civic.genome.wustl.edu/links/evidence_items/5975	https://civic.genome.wustl.edu/links/variants/2227	https://civic.genome.wustl.edu/links/genes/5					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._Of_26_patients_with_BRAF_V600E_mutations,_objective_responses_were_seen_in_12_patients_(46%;_95%_CI,_27%_to_67%)._Only_one_of_23_patients_(4%;_95%_CI,_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-BRAF_fusion)._Nonresponding_BRAF_mutations_included:_K601E_(n_=_6),_G464V_(n_=_2),_G469A_(n_=_2),_G496A_(n_=_2),_N581S_(n_=_2),_and_one_each_for_G466V,_G596R,_G606E,_L597Q,_P731T,_intron_9_rearrangement,_intron_10_rearrangement,"_and_MACF1-_and_WASFL-BRAF_fusion.	29320312	PubMed	NA	Hainsworth_et_al.",_2018,"_J._Clin._Oncol.	NCT02091141	2	accepted	5976	5		NA	NA					NA	NA		NA			Somatic_Mutation	2018-02-16_11:23:02_UTC	https://civic.genome.wustl.edu/links/evidence_items/5976	https://civic.genome.wustl.edu/links/variants/2228	https://civic.genome.wustl.edu/links/genes/5					5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
_EGFR,_BRAF_or_SHH_alterations_to_treatment_with_pertuzumab_plus_trastuzumab,_erlotinib,_vemurafenib,_or_vismodegib,_respectively._One_of_23_patients_(4%;_95%_CI,"_0%_to_22%)_with_other_non-V600_BRAF_mutations_had_a_PR_(pancreas_cancer_with_a_CUX1-""",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7031,4,9,133753906,133753906,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:12:38_UTC,https://civic.genome.wustl.edu/links/evidence_items/7031,https://civic.genome.wustl.edu/links/variants/2370,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,ENST00000318560.5:c.1375G>A,20,Dasatinib,,,,,,ABL1_c.1375G~A,,,,,,,
ABL1,25,BCR-ABL_E459K,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_patients_with_and_without_ABL1_mutation_had_comparable_complete_hematologic_response_(CHR),_major_cytogenetic_response_(MCyR),_complete_cytogenetic_response_(CCyR),_and_major_molecular_response_(MMR)._Out_of_12_patients_with_the_E459K_mutations,_4,_6,_and_11_achieved_CCyR,_MCyR,_and_CHR_with_dasatinib_monotherapy,_respectively._Analyses_by_variant_included_patients_with_multiple_kinase_domain_mutations.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,6310,4,9,133753906,133753906,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2018-07-19_22:03:23_UTC,https://civic.genome.wustl.edu/links/evidence_items/6310,https://civic.genome.wustl.edu/links/variants/2370,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,ENST00000318560.5:c.1375G>A,20,Dasatinib,,,,,,ABL1_c.1375G~A,
ABL1,25,BCR-ABL_E459K,Chronic_Myeloid_Leukemia,8552,,Imatinib_Mesylate,,Predictive,Supports,C,Resistance,"In_a_phase_II_study_of_60_imatinib-resistant_patients_with_BCR-ABL_mutations,_3_had_E459K_mutations",17264298,PubMed,,"Guilhot_et_al.,_2007,_Blood",,1,accepted,7046,4,9,133753906,133753906,G,A,ENST00000318560.5,,,,,75,GRCh37,,Somatic_Mutation,2019-01-31_10:31:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/7046,https://civic.genome.wustl.edu/links/variants/2370,https://civic.genome.wustl.edu/links/genes/4,,,missense_variant,ENST00000318560.5:c.1375G>A,20,Imatinib_Mesylate,,,,,,ABL1_c.1375G~A,
ABL1,25,TKD_MUTATION,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,B,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Among_115_patients_with_mutational_analysis_at_baseline,_subsets_were_evaluated_for_complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)._Both_were_comparable_for_patients_with_Abl1_mutation_versus_without_[CHR_=_33/34_vs._27/27;_MCyR_=_41/59_(69%)_vs._19/35_(54%)]._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,3,accepted,6335,4,,,,,,,,,,,,,,Somatic_Mutation,2018-07-12_21:30:27_UTC,https://civic.genome.wustl.edu/links/evidence_items/6335,https://civic.genome.wustl.edu/links/variants/2371,https://civic.genome.wustl.edu/links/genes/4,,,,,60,Bosutinib,,,,,,,
ABL1,25,TKD_MUTATION,Chronic_Myeloid_Leukemia,8552,,Nilotinib,,Predictive,Does_Not_Support,B,Resistance,"In_this_open-label,_phase_II_registration_trial,_patients_that_were_imatinib_resistant_(n_=_192)_or_intolerant_(n_=_89)_underwent_nilotinib_monotherapy._Prior_to_nilotinib_treatment,_105_and_9_patients_with_baseline_BCR-ABL_mutations_were_imatinib_resistant_and_intolerant,_respectively._Within_12_months_of_therapy,_among_patients_with_baseline_mutations,_complete_hematologic_response_was_achieved_in_57_(71%)_of_80_[vs._35_(80%)_of_80_Abl1_wildtype_patients,_P_=_.393],_major_cytogenetic_response_in_49_of_100_[vs._52_(60%)_of_87,_P_=_.145],_complete_cytogenetic_response_in_32_of_100_[vs._35_(40%)_of_87,_P_=_.285],_and_major_molecular_response_in_19_(22%)_of_87_[vs._22_(29%)_of_76,_P_=_.366]._These_data_shows_no_significant_difference_in_nilotinib_efficacy_between_patients_with_baseline_mutations_in_the_Abl1_kinase_domain_versus_without._The_authors_observe_clinical_efficacy_of_nilotinib_for_many_of_the_29_variants_found_and_identify_only_Y253H,_E255K/V,_and_F359C/V_as_resistance_conferring_variants_with_IC50_greater_than_150_nM._Individuals_with_T315I_variants_(3%_of_total_population)_were_excluded.",19652056,PubMed,,"Hughes_et_al.,_2009,_J._Clin._Oncol.",,3,accepted,6342,4,,,,,,,,,,,,,,Somatic_Mutation,2018-11-05_22:51:04_UTC,https://civic.genome.wustl.edu/links/evidence_items/6342,https://civic.genome.wustl.edu/links/variants/2371,https://civic.genome.wustl.edu/links/genes/4,,,,,60,Nilotinib,,,,,,,
ABL1,25,TKD_MUTATION,Chronic_Myeloid_Leukemia,8552,,Dasatinib,,Predictive,Does_Not_Support,B,Resistance,"This_is_a_retrospective_study_of_imatinib-resistant_(n_=_805)_or_-intolerant_(n_=_238),_chronic_myeloid_leukemia_(chronic-phase),_patients_with_mutations_in_the_BCR-ABL_gene_fusion_kinase_domain_from_the_START-C,_START-R,_and_CA180-034_trials._With_dasatinib_monotherapy,_imatinib-resistant_patients_with_and_without_ABL1_mutation__had_comparable_complete_hematologic_response_[CHR=_90%_(345/384)_vs._93%_(390/421)],_major_cytogenetic_response_[MCyR=_56%_(211/384)_vs._58%_(243/421)],_complete_cytogenetic_response_[CCyR=_43%_(164/384)_vs._47%_(196/421)],_and_major_molecular_response_[MMR=_31%_(115/367)_vs._36%_(145/404)]._Of_the_63_imatinib-resistant_variants_observed_(see_comment),_the_authors_associate_T315I,_F317L,_and_V299L_with_resistance_to_dasatinib_or_lower_levels_of_response_due_to_clinical_resistance_and_low_in_vitro_sensitivity._However,_F317L_does_have_a_high_CHR._They_suggest_considering_alternative_treatment_options_for_patients_with_these_three_variants.",19779040,PubMed,,"Müller_et_al.,_2009,_Blood",,3,accepted,6311,4,,,,,,,,,,,,,,Somatic_Mutation,2018-07-12_21:00:34_UTC,https://civic.genome.wustl.edu/links/evidence_items/6311,https://civic.genome.wustl.edu/links/variants/2371,https://civic.genome.wustl.edu/links/genes/4,,,,,60,Dasatinib,,,,,,,
ABL1,25,TKD_MUTATION,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Among_39_patients_with_mutational_analysis_at_baseline,_subsets_were_evaluated_for_complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)._Both_were_comparable_for_patients_with_Abl1_mutation_versus_without_[CHR_=_26/39_(67%)_vs._34/44_(77%);_MCyR_=_11/35_(31%)_vs._15/43_(35%)]._The_authors_observe_responses_with_bosutanib_monotherapy_across_many_BCR-ABL_mutations_with_the_notable_exception_of_T315I.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,6996,4,,,,,,,,,,,,,,Somatic_Mutation,2018-12-21_19:56:19_UTC,https://civic.genome.wustl.edu/links/evidence_items/6996,https://civic.genome.wustl.edu/links/variants/2371,https://civic.genome.wustl.edu/links/genes/4,,,,,60,Bosutinib,,,,,,,
ABL1,25,P-Loop_Mutation,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,B,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Among_115_patients_with_mutational_analysis_at_baseline,_subsets_were_evaluated_for_complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)._Both_were_comparable_for_patients_with_P-loop_mutations_versus_patients_without_Abl1_mutations_[_CHR_=_9/9_vs._27/27;_MCyR_=_7/10_vs._19/35_(54%)]._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,3,accepted,6336,4,,,,,,,,,,,,,,Somatic_Mutation,2018-07-12_21:31:56_UTC,https://civic.genome.wustl.edu/links/evidence_items/6336,https://civic.genome.wustl.edu/links/variants/2375,https://civic.genome.wustl.edu/links/genes/4,,,,,25,Bosutinib,,,,,,,
ABL1,25,P-Loop_Mutation,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Among_39_patients_with_mutational_analysis_at_baseline,_subsets_were_evaluated_for_complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)._Both_were_comparable_for_patients_with_P-loop_mutations_versus_patients_without_Abl1_mutations_[_CHR_=_9/14_(64%)_vs._34/44_(77%);_MCyR_=_4/13_(31%)_vs._15/43_(35%)]._The_authors_observe_responses_with_bosutanib_monotherapy_across_many_BCR-ABL_mutations_with_the_notable_exception_of_T315I.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,2,accepted,6997,4,,,,,,,,,,,,,,Somatic_Mutation,2018-12-21_19:53:01_UTC,https://civic.genome.wustl.edu/links/evidence_items/6997,https://civic.genome.wustl.edu/links/variants/2375,https://civic.genome.wustl.edu/links/genes/4,,,,,25,Bosutinib,,,,,,,
ABL1,25,Non-P-Loop_Mutation,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,B,Resistance,"In_this_retrospective_study,_imatinib-resistant_or_-intolerant_patients,_with_chronic_phase_CML_and_BCR-ABL_fusions,_were_treated_with_bosutanib_monotherapy._Among_115_patients_with_mutational_analysis_at_baseline,_subsets_were_evaluated_for_complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)._Both_were_comparable_for_patients_with_non-P-loop_mutations_versus_patient_without_Abl1_mutations_[_CHR_=_22/23_(96%)_vs._27/27;_MCyR_=_26/39_(67%)_vs._19/35_(54%)]._The_authors_conclude_that_bosutanib_is_effective_across_all_BCR-ABL_mutations_observed_except_T315I.",21865346,PubMed,,"Cortes_et_al.,_2011,_Blood",,3,accepted,6337,4,,,,,,,,,,,,,,Somatic_Mutation,2018-07-12_21:32:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/6337,https://civic.genome.wustl.edu/links/variants/2376,https://civic.genome.wustl.edu/links/genes/4,,,,,30,Bosutinib,,,,,,,
ABL1,25,Non-P-Loop_Mutation,Chronic_Myeloid_Leukemia,8552,,Bosutinib,,Predictive,Does_Not_Support,B,Resistance,"This_was_a_retrospective_study_of_dasatinib_and/or_nilotinib-resistant_or_-intolerant_patients_pretreated_with_imatinib_aimed_at_evaluating_the_efficacy_of_bosutanib_monotherapy._All_patients_had_chronic_phase_CML_and_BCR-ABL_fusions._Among_39_patients_with_mutational_analysis_at_baseline,_subsets_were_evaluated_for_complete_hematologic_response_(CHR)_and_major_cytogenetic_response_(MCyR)._Both_were_comparable_for_patients_with_non-P-loop_mutations_versus_patient_without_Abl1_mutations_[_CHR_=_18/29_(62%)_vs._34/44_(77%);_MCyR_=_9/26_(35%)_vs._15/43_(35%)]._The_authors_observe_responses_with_bosutanib_monotherapy_across_many_BCR-ABL_mutations_with_the_notable_exception_of_T315I.",22371878,PubMed,,"Khoury_et_al.,_2012,_Blood",,3,accepted,6998,4,,,,,,,,,,,,,,Somatic_Mutation,2018-12-21_19:54:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/6998,https://civic.genome.wustl.edu/links/variants/2376,https://civic.genome.wustl.edu/links/genes/4,,,,,30,Bosutinib,,,,,,,
CSF3R,1441,T618I,Chronic_Neutrophilic_Leukemia,80187,,Ruxolitinib,,Predictive,Supports,D,Sensitivity/Response,Demonstrates_that_activating_mutations_in_CSF3R_are_sufficient_to_drive_a_myeloproliferative_disorder_resembling_aCML_and_CNL_that_is_sensitive_to_pharmacologic_JAK_inhibition.,24081659,PubMed,,"Fleischman_et_al.,_2013,_Blood",,4,accepted,6380,1239,,,,,,,,,,,,,,Somatic_Mutation,2018-07-13_13:56:17_UTC,https://civic.genome.wustl.edu/links/evidence_items/6380,https://civic.genome.wustl.edu/links/variants/2387,https://civic.genome.wustl.edu/links/genes/1239,,,,,14,Ruxolitinib,,,,,,,
CSF3R,1441,T618I,Chronic_Neutrophilic_Leukemia,80187,,Ruxolitinib,,Predictive,Supports,C,Sensitivity/Response,"Case_report_of_a_patient_treated_with_ruxolitinib,_an_FDA-approved_JAK1/2_inhibitor,_which_resulted_in_dramatic_improvement_of_his_blood_counts._He_also_had_significant_reduction_of_spleen_volume_and_constitutional_symptoms.",25180155,PubMed,,"Dao_et_al.,_2014,_Leuk_Res_Rep",NCT02092324,4,accepted,6381,1239,,,,,,,,,,,,,,Somatic_Mutation,2018-07-13_13:56:22_UTC,https://civic.genome.wustl.edu/links/evidence_items/6381,https://civic.genome.wustl.edu/links/variants/2387,https://civic.genome.wustl.edu/links/genes/1239,,,,,14,Ruxolitinib,,,,,,,
NTRK1,4914,NTRK1-TRIM63,Melanoma,1909,Melanoma,Larotrectinib,,Predictive,Supports,E,Sensitivity/Response,"In_this_study_we_report_that_nonspitzoid_metastasizing_melanomas_of_adults_may_also_harbor_NTRK_fusions_and_that_NTRK_expression_can_be_immunohistochemically_detected_in_these_tumors._Of_751_melanomas_analyzed_by_next-generation_sequencing,_4_metastatic_melanomas_were_identified_with_NTRK_fusions,_3_involving_NTRK1_(TRIM63,_DDR2,_and_GON4L),_1_involving_NTRK2_(TRAF2)._All_tumors_were_cytologically_characterized_by_the_presence_of_large_epithelioid_melanocytes_and_were_immunoreactive_with_anti-Trk_antibody._The_NTRK1-TRIM63_fusion_occurred_in_a_63_yo_man_with_a_nodular_melanoma_with_the_primary_tumor_on_the_shin_and_skin_and_lymph_node_metastases._No_known_melanoma_drivers_were_identified_as_co-occurring_in_this_patient._Thus,_the_presence_of_an_NTRK_family_fusion_in_nonspitzoid_metastasizing_melanomas_of_adults_may_provide_a_therapeutic_opportunity_for_NTRK_inhibitors_such_as_larotrectinib_in_a_small_subset_of_patients_with_metastatic_melanoma.",29683819,PubMed,,"Lezcano_et_al.,_2018,_Am._J._Surg._Pathol.",,2,accepted,6392,3983,,,,,,,,,,,,,,Somatic_Mutation,2018-08-20_21:50:21_UTC,https://civic.genome.wustl.edu/links/evidence_items/6392,https://civic.genome.wustl.edu/links/variants/2393,https://civic.genome.wustl.edu/links/genes/3983,,,,,0.5,Larotrectinib,,,,,,,
NTRK1,4914,NTRK1-DDR2,Melanoma,1909,Melanoma,Larotrectinib,,Predictive,Supports,E,Sensitivity/Response,"In_this_study_we_report_that_nonspitzoid_metastasizing_melanomas_of_adults_may_also_harbor_NTRK_fusions_and_that_NTRK_expression_can_be_immunohistochemically_detected_in_these_tumors._Of_751_melanomas_analyzed_by_next-generation_sequencing,_4_metastatic_melanomas_were_identified_with_NTRK_fusions,_3_involving_NTRK1_(TRIM63,_DDR2,_and_GON4L),_1_involving_NTRK2_(TRAF2)._All_tumors_were_cytologically_characterized_by_the_presence_of_large_epithelioid_melanocytes_and_were_immunoreactive_with_anti-Trk_antibody._The_NTRK1-DDR2_fusion_occurred_in_a_55_yo_woman_with_a_nodular_melanoma._Her_primary_tumor_was_umbilical_with_a_metastasis_to_the_colon._NF1_truncation_and_RAC1_p295_were_identified_as_co-occurring_melanoma_drivers_in_this_patient._Thus,_the_presence_of_an_NTRK_family_fusion_in_nonspitzoid_metastasizing_melanomas_of_adults_may_provide_a_therapeutic_opportunity_for_NTRK_inhibitors_such_as_larotrectinib_in_a_small_subset_of_patients_with_metastatic_melanoma.",29683819,PubMed,,"Lezcano_et_al.,_2018,_Am._J._Surg._Pathol.",,2,accepted,6393,3983,,,,,,,,,,,,,,Somatic_Mutation,2018-08-20_21:41:35_UTC,https://civic.genome.wustl.edu/links/evidence_items/6393,https://civic.genome.wustl.edu/links/variants/2394,https://civic.genome.wustl.edu/links/genes/3983,,,,,0.5,Larotrectinib,,,,,,,
NTRK1,4914,NTRK1-GON4L,Melanoma,1909,,Larotrectinib,,Predictive,Supports,E,Sensitivity/Response,"In_this_study_we_report_that_nonspitzoid_metastasizing_melanomas_of_adults_may_also_harbor_NTRK_fusions_and_that_NTRK_expression_can_be_immunohistochemically_detected_in_these_tumors._Of_751_melanomas_analyzed_by_next-generation_sequencing,_4_metastatic_melanomas_were_identified_with_NTRK_fusions,_3_involving_NTRK1_(TRIM63,_DDR2,_and_GON4L),_1_involving_NTRK2_(TRAF2)._All_tumors_were_cytologically_characterized_by_the_presence_of_large_epithelioid_melanocytes_and_were_immunoreactive_with_anti-Trk_antibody._The_NTRK1-GON4L_fusion_occurred_in_a_36_yo_woman_with_a_nodular_melanoma._Her_primary_tumor_was_on_her_back_with_a_metastasis_to_the_duodenum._NRAS_Q61L_was_identified_as_a_co-occurring_melanoma_driver_in_this_patient._Thus,_the_presence_of_an_NTRK_family_fusion_in_nonspitzoid_metastasizing_melanomas_of_adults_may_provide_a_therapeutic_opportunity_for_NTRK_inhibitors_such_as_larotrectinib_in_a_small_subset_of_patients_with_metastatic_melanoma.",29683819,PubMed,,"Lezcano_et_al.,_2018,_Am._J._Surg._Pathol.",,2,accepted,6394,3983,,,,,,,,,,,,,,Somatic_Mutation,2018-08-20_21:57:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/6394,https://civic.genome.wustl.edu/links/variants/2395,https://civic.genome.wustl.edu/links/genes/3983,,,,,0.5,Larotrectinib,,,,,,,
NTRK2,4915,ETV6-NTRK2,Hematologic_Cancer,2531,Hematological_neoplasm,Larotrectinib,,Predictive,Supports,C,Sensitivity/Response,"Rearrangements_involving_the_neurotrophic_receptor_kinase_genes_(NTRK1,_NTRK2,_and_NTRK3;_hereafter_referred_to_as_TRK)_produce_oncogenic_fusions_in_a_wide_variety_of_cancers_in_adults_and_children._Although_TRK_fusions_occur_in_<1%_of_all_solid_tumors,_inhibition_of_TRK_results_in_profound_therapeutic_responses_resulting_in_breakthrough_FDA-approval_of_the_TRK_inhibitor_larotrectinib_for_adult_and_pediatric_solid_tumor_patients_regardless_of_histology._In_contrast_to_solid_tumors,_the_frequency_of_TRK_fusions_and_clinical_effects_of_targeting_TRK_in_hematologic_malignancies_is_unknown._Here,_through_an_evaluation_for_TRK_fusions_across_>_7,000_patients_with_hematologic_malignancies,_we_identified_TRK_fusions_in_acute_lymphoblastic_leukemia_(ALL),_acute_myeloid_leukemia_(AML),_histiocytosis,_multiple_myeloma_and_dendritic_cell_neoplasms._Although_TRK_fusions_occurred_in_only_0.1%_of_patients_(8_out_of_7,311_patients),_they_conferred_responsiveness_to_TRK_inhibition_in_vitro_and_in_vivo_in_a_patient-derived_xenograft_and_a_corresponding_AML_patient_with_ETV6-NTRK2_fusion._These_data_identify_that_despite_their_individual_rarity,_collectively_TRK_fusions_are_present_in_a_wide_variety_of_hematologic_malignancies_and_predict_clinically_significant_therapeutic_responses_to_TRK_inhibition.",29920189,PubMed,,"Taylor_et_al.,_2018,_J._Clin._Invest.",,3,accepted,6396,3984,,,,,,,,,,,,,,Somatic_Mutation,2018-10-17_12:45:53_UTC,https://civic.genome.wustl.edu/links/evidence_items/6396,https://civic.genome.wustl.edu/links/variants/2396,https://civic.genome.wustl.edu/links/genes/3984,,,,,7.5,Larotrectinib,,,,,,,
BRAF,673,D594K,Colorectal_Cancer,9256,,Oxaliplatin,,Predictive,Supports,B,Resistance,"Of_100_metastatic_colorectal_cancer_patients_treated_with_oxaliplatin-based_first-line_therapy,_the_6_patients_with_either_BRAF_V600E_or_D594K_had_reduced_progression-free_survival_compared_to_94_patients_with_wildtype_BRAF_(5.0mo_vs._11.7mo,_HR:6.4,_95%CI:2.6-15.6,_P<0.0001).",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6403,5,,,,,,,,,,,,,,Somatic_Mutation,2018-07-19_23:01:48_UTC,https://civic.genome.wustl.edu/links/evidence_items/6403,https://civic.genome.wustl.edu/links/variants/2398,https://civic.genome.wustl.edu/links/genes/5,,,,,30,Oxaliplatin,,,,,,,
BRAF,673,D594K,Colorectal_Cancer,9256,,Irinotecan,,Predictive,Supports,B,Resistance,"The_presence_of_BRAF_V600E_or_D594K_was_associated_with_reduced_progression-free_survival_in_5_patients_with_metastatic_colorectal_cancer_treated_with_irinotecan-based_first_line_therapy_(3.5mo_vs._12.8mo,_HR:4.1,_95%CI:1.5-11.3,_P=0.006)_when_compared_to_39_patients_with_wildtype_BRAF.",19603024,PubMed,,"Souglakos_et_al.,_2009,_Br._J._Cancer",,3,accepted,6402,5,,,,,,,,,,,,,,Somatic_Mutation,2018-07-19_22:55:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/6402,https://civic.genome.wustl.edu/links/variants/2398,https://civic.genome.wustl.edu/links/genes/5,,,,,30,Irinotecan,,,,,,,
NTRK3,4916,ETV6-NTRK3_FUSION,Congenital_Fibrosarcoma,8418,,LOXO-101,,Predictive,Supports,C,Sensitivity/Response,"Nagasubramanian_et_al_reports_on_a_case_of_refractory_infantile_fibrosarcoma_(IFS)_with_constitutive_activation_of_the_tropomyosin‐related_kinase_(TRK)_signaling_pathway_from_an_ETS_variant_gene_6–neurotrophin_3_receptor_gene_(ETV6–NTRK3)_gene_fusion._The_patient_was_diagnosed_with_IFS_at_6_months_of_age._At_16_months_the_patient_enrolled_in_a_pediatric_Phase_1_trial_of_LOXO‐101,_an_experimental,_highly_selective_inhibitor_of_TRK._The_patient_experienced_a_rapid,_radiographic_response,_demonstrating_the_potential_for_LOXO‐101_to_provide_benefit_for_IFS_harboring_NTRK_gene_fusions.",27093299,PubMed,,"Nagasubramanian_et_al.,_2016,_Pediatr_Blood_Cancer",,2,accepted,6473,3985,,,,,,,,,,,,,,Somatic_Mutation,2018-08-21_15:30:32_UTC,https://civic.genome.wustl.edu/links/evidence_items/6473,https://civic.genome.wustl.edu/links/variants/2422,https://civic.genome.wustl.edu/links/genes/3985,,,,,5,LOXO-101,,,,,,,
JAK2,3717,JAK2_F694L,Pediatric_B-cell_Acute_Lymphoblastic_Leukemia,,Acute_lymphoblastic_leukemia,Ruxolitinib,,Predictive,Supports,C,Sensitivity/Response,"A_17-year-old_Native_American_female_with_B-ALL_had_persistent_MRD_at_the_end_of_induction._In_addition_to_a_complex_karyotype,_sequencing_revealed_a_novel_F694L_mutation_in_JAK2,_a_p.Cys119_Ile121delinsTrpGlyLeu_in_IKZF1,_and_a_IGH-CRLF2_translocation,_all_consistent_with_BCR-ABL1_like_B-ALL._In_addition_to_conventional_cytotoxic_therapy,_the_patient_was_started_on_40_mg/m2/day_ruxolitinib_TKI_BID_for_2_weeks_on,_2_weeks_off,_and_MRD_diminished_to_<0.01%_prior_to_allogeneic_transplant._The_patient_was_in_remission_with_100%_engraftment_from_a_full_match_sibling_at_day_100_post-transplant.",27860260,PubMed,,"Mayfield_et_al.,_2017,_Pediatr_Blood_Cancer",,2,accepted,7021,28,,,,,,,,,,,,,,Somatic_Mutation,2018-12-28_16:18:06_UTC,https://civic.genome.wustl.edu/links/evidence_items/7021,https://civic.genome.wustl.edu/links/variants/2587,https://civic.genome.wustl.edu/links/genes/28,,,,,5,Ruxolitinib,,,,,,,
PIK3CA,5290,WILD_TYPE,Colorectal_Cancer,9256,,Aspirin,,Predictive,Does_Not_Support,B,Sensitivity/Response,"This_was_a_retrospective_study_of_964_colorectal_cancer_patients_who_participated_in_the_Nurses'_Health_Study_and_the_Health_Professionals_Follow-up_Study._Of_964_patients,_803_patients_had_wildtype_PIK3CA_(aspirin_use:_337/803,_no_aspirin_use:_466/803)_and_161_had_mutated_PIK3CA_(aspirin_use:_66/161,_no_aspirin_use:_95/161)._Among_patients_with_wild-type_PIK3CA,_regular_use_of_aspirin_after_diagnosis_was_not_significantly_associated_with_increased_survival._The_5-year_cumulative_colorectal_cancer_specific_mortality_was_the_same_(15%)_for_users_and_nonusers_of_aspirin_after_diagnosis_(P_=_0.92).",23094721,PubMed,,"Liao_et_al.,_2012,_N._Engl._J._Med.",,3,accepted,2038,37,,,,,,,,,,,,,,Somatic_Mutation,2019-01-19_23:55:28_UTC,https://civic.genome.wustl.edu/links/evidence_items/2038,https://civic.genome.wustl.edu/links/variants/2590,https://civic.genome.wustl.edu/links/genes/37,,,,,15,Aspirin,,,,,,,
KIT,3815,T417_D419delinsY,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,This_patient_was_part_of_a_larger_cohort_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105_who_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._This_patient's_GIST_had_a_KIT_exon_8_deletion/insertion_TYD417-419Y._This_patient_represents_the_first_reported_sporadic_GIST_with_a_KIT_exon_8_mutation_as_germline_DNA_from_surrounding_normal_tissue_was_was_KIT_wildtype._The_patient_had_an_unconfirmed_partial_response_to_400mg_daily_imatinib_(TTP_8.1_months)_and_a_censored_OS_of_59.3_months.,18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,2,accepted,2417,29,,,,,,,,,,,,,,Somatic_Mutation,2019-02-08_17:40:25_UTC,https://civic.genome.wustl.edu/links/evidence_items/2417,https://civic.genome.wustl.edu/links/variants/2620,https://civic.genome.wustl.edu/links/genes/29,,,,,5,Imatinib,,,,,,,
KIT,3815,F506_F508DUP,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Does_Not_Support,C,Sensitivity/Response,This_patient_was_part_of_a_larger_cohort_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105._Patients_in_the_study_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._This_patient's_GIST_harbored_a_tandem_reduplication_of_KIT_codons_506_to_508_(FAF)_after_F508_(F506_F508dup)._The_patient's_response_to_imatinib_was_not_assessed_but_the_TTP_was_10.6_months.,18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,1,accepted,2441,29,,,,,,,,,,,,,,Somatic_Mutation,2019-02-08_17:45:58_UTC,https://civic.genome.wustl.edu/links/evidence_items/2441,https://civic.genome.wustl.edu/links/variants/2621,https://civic.genome.wustl.edu/links/genes/29,,,,,2.5,Imatinib,,,,,,,
KIT,3815,K484_G487DEL,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Supports,C,Sensitivity/Response,"This_patient_was_from_a_larger_cohort_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105._Patients_in_the_study_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._This_patient's_GIST_harbored_a_homozygous_deletion_of_KIT_codons_484_to_487_(KHNG;_K484_G487del).__The_patient's_response_to_imatinib_was_not_assessed,_and_the_TTP_was_46.9_months.",18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,1,accepted,2465,29,,,,,,,,,,,,,,Somatic_Mutation,2019-02-08_17:50:50_UTC,https://civic.genome.wustl.edu/links/evidence_items/2465,https://civic.genome.wustl.edu/links/variants/2622,https://civic.genome.wustl.edu/links/genes/29,,,,,2.5,Imatinib,,,,,,,
PDGFRA,5156,EXON_18_MUTATION,Gastrointestinal_Stromal_Tumor,9253,,Imatinib,,Predictive,Does_Not_Support,C,Sensitivity/Response,"These_four_patients_were_part_of_a_larger_cohort_of_397_patients_with_incurable_(i.e._metastatic_or_unresectable)_CD117-positive_Gastrointestinal_stromal_tumors_(GISTs)_enrolled_in_the_North_American_phase_III_study_SWOG_S0033/CALGB_150105_who_were_treated_with_either_400mg_or_800mg_of_imatinib_per_day._All_four_patients'_GISTs_harbored_PDGFRA_exon_18_mutatations_(one_I843_S847delinsM,_three_D842_H845del)._The_overall_survival_was_more_than_12_months_for_all_four_of_these_patients_(mean_40.8_months),_which_is_comparable_to_patients_with_WT_PDGFRA_(49.0months).",18955451,PubMed,,"Heinrich_et_al.,_2008,_J._Clin._Oncol.",,1,accepted,2486,38,,,,,,,,,,,,,,Somatic_Mutation,2019-02-08_18:22:12_UTC,https://civic.genome.wustl.edu/links/evidence_items/2486,https://civic.genome.wustl.edu/links/variants/2623,https://civic.genome.wustl.edu/links/genes/38,,,,,2.5,Imatinib,,,,,,,
